PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Westermaier, T; Jauss, A; Eriskat, J; Kunze, E; Roosen, K				Westermaier, Thomas; Jauss, Alina; Eriskat, Joerg; Kunze, Ekkehard; Roosen, Klaus			The Temporal Profile of Cerebral Blood Flow and Tissue Metabolites Indicates Sustained Metabolic Depression After Experimental Subarachnoid Hemorrhage in Rats	NEUROSURGERY			English	Article						Cerebral blood flow and oxidative metabolism; Microdialysis; Subarachnoid hemorrhage; Vasospasm	PYRUVATE-DEHYDROGENASE; PERFUSION-PRESSURE; ENERGY-METABOLISM; OXYGEN-METABOLISM; TIME-COURSE; ISCHEMIA; BRAIN; MICRODIALYSIS; VASOSPASM; MODELS	BACKGROUND: Derangement of cerebral metabolism occurs after various insults such as ischemia, traumatic brain injury, and subarachnoid hemorrhage (SAH). OBJECTIVE: To investigate the course of cerebral blood flow and metabolic parameters in the first hours after experimental SAH. METHODS: Sixteen Sprague-Dawley rats were subjected to SAH using the endovascular filament model or served as controls (8 rats in each group). Local cerebral blood flow and intracranial pressure were measured continuously. Microdialysis samples were acquired in 30-minute intervals for 6 hours after SAH. Concentrations of glucose, lactate, pyruvate, and glutamate were determined. RESULTS: After induction of SAH, cerebral perfusion pressure and local cerebral blood flow sharply decreased. The decrease in local cerebral blood flow exceeded the decrease in cerebral perfusion pressure throughout the observation period. Glutamate concentrations in microdialysis samples increased sixfold and recovered to baseline levels. Lactate concentrations immediately increased after SAH, recovered incompletely, and remained above the levels of control animals until the end of the sampling period. Pyruvate concentrations showed a delayed increase starting 2 hours after SAH. CONCLUSION: The course of cerebral blood flow after SAH resembles global ischemia followed by a continuous low-flow state caused by a sudden decrease in cerebral perfusion pressure and acute vasoconstriction. The courses of lactate and pyruvate concentrations indicate a persistently deranged aerobic metabolism.	[Westermaier, Thomas; Jauss, Alina; Eriskat, Joerg; Kunze, Ekkehard; Roosen, Klaus] Univ Wurzburg, Dept Neurosurg, D-97080 Wurzburg, Germany	Westermaier, T (corresponding author), Univ Wurzburg, Dept Neurosurg, Josef Schneider Str 11, D-97080 Wurzburg, Germany.	Westermaier.T@nch.uni-wuerzburg.de	Westermaier, Thomas/AAE-2701-2019; Kunze, Ekkehard/AAE-6926-2019				Audebert HJ, 2005, DEUT MED WOCHENSCHR, V130, P2495, DOI 10.1055/s-2005-918593; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; BEDERSON JB, 1995, STROKE, V26, P1086, DOI 10.1161/01.STR.26.6.1086; Bianchi MC, 2003, AM J NEURORADIOL, V24, P1958; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; CARPENTER DA, 1991, J CEREBR BLOOD F MET, V11, P837, DOI 10.1038/jcbfm.1991.143; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; CHOPP M, 1988, STROKE, V19, P1383, DOI 10.1161/01.STR.19.11.1383; CORBETT RJT, 1990, J NEUROCHEM, V54, P1208, DOI 10.1111/j.1471-4159.1990.tb01950.x; DELGADO TJ, 1985, STROKE, V16, P595, DOI 10.1161/01.STR.16.4.595; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; HEISS WD, 1992, STROKE, V23, P1668, DOI 10.1161/01.STR.23.11.1668; HOFFMAN TL, 1994, J NEUROSURG, V81, P567, DOI 10.3171/jns.1994.81.4.0567; JACKOWSKI A, 1990, J CEREBR BLOOD F MET, V10, P835, DOI 10.1038/jcbfm.1990.140; JAKOBSEN M, 1990, ACTA NEUROL SCAND, V82, P174, DOI 10.1111/j.1600-0404.1990.tb04485.x; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; Karaszewski B, 2009, BRAIN, V132, P955, DOI 10.1093/brain/awp010; LIN BW, 1995, STROKE, V26, P1634, DOI 10.1161/01.STR.26.9.1634; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; MARTIN WRW, 1984, ACTA NEUROCHIR, V70, P3, DOI 10.1007/BF01406037; Miyazaki T, 2006, SURG NEUROL, V65, P360, DOI 10.1016/j.surneu.2005.10.025; Paxinos G., 2005, RAT BRAIN STEREOTAXI; PEERLESS SJ, 1982, STROKE, V13, P473, DOI 10.1161/01.STR.13.4.473; Pluta RM, 2009, NEUROL RES, V31, P151, DOI 10.1179/174313209X393564; Prunell GF, 2003, NEUROSURGERY, V52, P165, DOI 10.1097/00006123-200301000-00022; Prunell GF, 2004, NEUROSURGERY, V54, P426, DOI 10.1227/01.NEU.0000103670.09687.7A; Robertson CS, 1998, NEUROL RES, V20, pS91; Sarrafzadeh A, 2005, J NEURORADIOLOGY, V32, P348, DOI 10.1016/S0150-9861(05)83168-2; SARRAFZADEH AS, 2005, ACTA NEUROCHIR SUPP, P9589; Sato M, 2006, ACTA NEUROCHIR, V148, P623, DOI 10.1007/s00701-005-0717-x; Schwartz AY, 2000, J NEUROSCI METH, V96, P161, DOI 10.1016/S0165-0270(00)00156-4; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Staub F, 2000, NEUROSURGERY, V47, P1106, DOI 10.1097/00006123-200011000-00016; SUGI T, 1975, STROKE, V6, P715, DOI 10.1161/01.STR.6.6.715; SVENDGAARD NA, 1985, STROKE, V16, P602, DOI 10.1161/01.STR.16.4.602; VEELKEN JA, 1995, STROKE, V26, P1279, DOI 10.1161/01.STR.26.7.1279; VILLA RF, 1983, NEUROCHEM RES, V8, P269, DOI 10.1007/BF00963926; VOLDBY B, 1985, J NEUROSURG, V62, P48, DOI 10.3171/jns.1985.62.1.0048; Westermaier T, 2009, J CEREBR BLOOD F MET, V29, P771, DOI 10.1038/jcbfm.2008.169; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003	41	20	20	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2011	68	1					223	229		10.1227/NEU.0b013e3181fe23c1			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	694IE	WOS:000285288200063	21099709				2021-06-18	
J	Kaufman, NA; Beare, JE; Tan, AA; Vitek, MP; McKenna, SE; Hoane, MR				Kaufman, Nicholas A.; Beare, Jason E.; Tan, Arlene A.; Vitek, Michael P.; McKenna, Suzanne E.; Hoane, Michael R.			COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Therapy; Recovery of function; Amnesia; Treatment; FPI	TRAUMATIC BRAIN-INJURY; SYSTEM INFLAMMATORY RESPONSE; CLOSED-HEAD INJURY; NICOTINAMIDE TREATMENT; FUNCTIONAL RECOVERY; INTRACEREBRAL HEMORRHAGE; MICROGLIAL ACTIVATION; MIMETIC PEPTIDES; CONTUSION INJURY; APOE GENOTYPE	COG1410, a small, novel ApoE-mimetic peptide derived from the receptor binding region of apolipoprotein E (ApoE), has been classified as anti-inflammatory in nature and improves motor, sensorimotor, and cognitive dysfunction following cortical contusion injury (CCI). In order to further examine COG1410's preclinical efficacy on cognitive recovery, the present study evaluated COG1410 following moderate fluid percussion injury (FPI). Animals were prepared with a moderate, unilateral FPI over the hippocampus. Following FPI, animals received a regimen of five doses of COG1410 or vehicle at 2 and 4 h (1.0 mg/kg, i.v.) followed by additional doses administered 24, 48, and 72 h (1.0 mg/kg, i.p.). Prior to injury, animals were trained for 4 days (4 trials/day) in the Morris water maze (MWM) and then tested for retrograde amnesia on post-FPI day 11 and then on a working memory task on day 18. Testing for motor dysfunction on the tapered balanced beam began on day 2 post-FPI. Administration of this regimen of COG1410 significantly improved retention of memory in the retrograde amnesia test compared to vehicle post-FPI. However. COG1410 did not significantly improve acquisition of working memory in the MWM. Motor dysfunction on the tapered beam post-FPI was improved in the COG1410-treated group compared to vehicle treatment. Cortical lesion analysis revealed that the COG1410-treated animals demonstrated significantly less tissue loss compared to vehicle-treated animals. The results of this study suggest that COG1410 significantly limited the behavioral dysfunction and tissue loss associated with FPI and demonstrated continued preclinical efficacy for TBI. (C) 2010 Elsevier B.V. All rights reserved.	[Kaufman, Nicholas A.; Beare, Jason E.; Tan, Arlene A.; Hoane, Michael R.] So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA; [Vitek, Michael P.; McKenna, Suzanne E.] Cognosci Inc, Res Triangle Pk, NC USA; [Vitek, Michael P.] Duke Univ, Med Ctr, Dept Med, Div Neurol, Durham, NC 27710 USA; [Vitek, Michael P.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Ctr Integrat Res Cognit & Neural Sci, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu	; Beare, Jason/D-2870-2016	Vitek, Michael/0000-0001-8140-8048; Hoane, Michael/0000-0001-7779-2657; Beare, Jason/0000-0003-3988-1223	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R44NS048689, R44AG020473]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS048689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R44AG020473] Funding Source: NIH RePORTER	Funding provided by Cognosci Inc. grants R44NS048689 and R44AG020473 from the NIH. Special thanks to Andrea Quigley, Keith Gregory, and Sarah Heck for technical assistance. Cognosci, Inc. has filed for patent protection for COG1410.	Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Ferguson S, 2010, NEUROSCIENCE, V168, P811, DOI 10.1016/j.neuroscience.2010.01.031; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; James ML, 2009, J STROKE CEREBROVASC, V18, P144, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.012; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; McDonagh DL, 2010, ANESTHESIOLOGY, V112, P852, DOI 10.1097/ALN.0b013e3181d31fd7; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Wang H, 2009, ANAESTH INTENS CARE, V37, P38, DOI 10.1177/0310057X0903700111; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Woodlee M.T., 2005, BEHAV LAB RAT HDB TE, P129	47	20	24	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	DEC 10	2010	214	2					395	401		10.1016/j.bbr.2010.06.017			7	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	643SJ	WOS:000281318700030	20600347	Green Accepted			2021-06-18	
J	Ciapetti, M; Circelli, A; Zagli, G; Migliaccio, ML; Spina, R; Alessi, A; Acquafresca, M; Bartolini, M; Peris, A				Ciapetti, Marco; Circelli, Alessandro; Zagli, Giovanni; Migliaccio, Maria Luisa; Spina, Rosario; Alessi, Alessandro; Acquafresca, Manlio; Bartolini, Marco; Peris, Adriano			Diagnosis of carotid arterial injury in major trauma using a modification of Memphis criteria	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article							BLUNT CEREBROVASCULAR INJURIES; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CT ANGIOGRAPHY; ASSOCIATION; OUTCOMES	Background: Incidence of Blunt Cerebrovascular Injuries (BCVI) after head injury has been reported as 0.5-1% of all admissions for blunt trauma, with a high stroke and mortality rate. The purpose of this study is to evaluate if a modification of Memphis criteria could improve the rate of BCVI diagnosis. Methods: Trauma patients consecutively admitted to Intensive Care Unit (ICU) from Jan 2008 to Oct 2009 were considered for the study. Memphis criteria comprehend: basilar skull fracture with involvement of the carotid canal, cervical spine fracture, neurological exam not explained by brain imaging, Horner's syndrome, LeFort II-III fractures, and neck soft tissue injury. As single criteria modification, we included all patients with petrous bone fracture, even without carotid canal involvement. In all patients at risk of BCVI, 64-slice angio-CT-scans was performed. Results: During the study period, 266 patients were admitted to the ICU for blunt major trauma. Among them, 162 presented traumatic brain injury or cervical spine fracture. In accordance with the proposed modified-Memphis criteria, 53 patients showed risk factors for BCVI compared to 45 using the original Memphis criteria. Among the 53 patients, 6 resulted as having carotid lesions (2.2% of all blunt major traumas; one patient more than when using Memphis criteria). Anticoagulant therapy with low molecular weight heparin was administered in all patients. No stroke or hemorrhagic complications occurred. Clinical examination at 6-months showed no central neurological deficit. Conclusion: A modification of a single criteria of Memphis screening protocol might permit the identification of a higher percentage of BCVI. Limited by sample size, this study needs to be validated.	[Ciapetti, Marco; Zagli, Giovanni; Migliaccio, Maria Luisa; Spina, Rosario; Peris, Adriano] Careggi Teaching Hosp, Emergency Dept, Anesthesia & Intens Care Unit, I-50139 Florence, Italy; [Circelli, Alessandro] Univ Florence, I-50139 Florence, Italy; [Alessi, Alessandro] Careggi Teaching Hosp, Dept Vasc Surg, I-50139 Florence, Italy; [Acquafresca, Manlio; Bartolini, Marco] Careggi Teaching Hosp, Dept Diagnost Imaging, I-50139 Florence, Italy	Zagli, G (corresponding author), Careggi Teaching Hosp, Emergency Dept, Anesthesia & Intens Care Unit, Largo Brambilla 3, I-50139 Florence, Italy.	giovanni.zagli@unifi.it		Bartolini, Marco/0000-0003-2518-6369			Berne JD, 2004, J TRAUMA, V57, P11, DOI 10.1097/01.TA.0000135499.70048.C7; Berne JD, 2001, J AM COLL SURGEONS, V192, P314, DOI 10.1016/S1072-7515(01)00772-4; BERNE JD, 2009, J VASC SURG, V30, P30; Berne JD, 2009, J TRAUMA, V67, P1333, DOI 10.1097/TA.0b013e31818888c7; Biffl WL, 2009, J TRAUMA, V67, P1150, DOI 10.1097/TA.0b013e3181c1c1d6; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Cothren CC, 2003, J TRAUMA, V55, P811, DOI 10.1097/01.TA.0000092700.92587.32; CRISSEY MM, 1974, SURGERY, V75, P543; Eastman AL, 2009, J TRAUMA, V67, P551, DOI 10.1097/TA.0b013e3181b84408; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Mutze S, 2005, RADIOLOGY, V237, P884, DOI 10.1148/radiol.2373042189; Rogers FB, 1999, J TRAUMA, V46, P380, DOI 10.1097/00005373-199903000-00005; Schneidereit NP, 2006, J TRAUMA, V60, P209, DOI 10.1097/01.ta.0000195651.60080.2c; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Stuhlfaut JW, 2005, AM J ROENTGENOL, V185, P1063, DOI 10.2214/AJR.04.1217; Utter GH, 2006, J AM COLL SURGEONS, V203, P838, DOI 10.1016/j.jamcollsurg.2006.08.003; YAMADA S, 1967, J TRAUM, V7, P333, DOI 10.1097/00005373-196705000-00001	21	20	20	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	NOV 22	2010	18								61	10.1186/1757-7241-18-61			5	Emergency Medicine	Emergency Medicine	691PE	WOS:000285092500001	21092211	DOAJ Gold, Green Published			2021-06-18	
J	Berry, C; Ley, EJ; Mirocha, J; Salim, A				Berry, Cherisse; Ley, Eric J.; Mirocha, James; Salim, Ali			Race Affects Mortality After Moderate to Severe Traumatic Brain Injury	JOURNAL OF SURGICAL RESEARCH			English	Article; Proceedings Paper	5th Annual Academic Surgical Congress	FEB 03-05, 2010	San Antonio, TX	Assoc Acad Surg (AAS), Soc Univ Surg (SUS)		traumatic brain injury; outcome; mortality; race; insurance	INSURANCE STATUS; RACIAL DISPARITIES; EMERGENCY-DEPARTMENT; CARE; OUTCOMES; HEALTH; IMPACT; RISK	Background. Traumatic brain injury (TB!) is the most common cause of death and disability in trauma patients, affecting over 1 million Americans per year. Minorities are at disproportionate risk for TBI, and they account for nearly half of all brain injury hospitalizations. Little is known regarding racial disparities in TBI patients. The objective of this study was to investigate the association of race on mortality in patients with moderate to severe isolated TBI. Methods. The Los Angeles County Trauma System database, consisting of admissions from five Level I and eight Level II trauma centers, was queried for all patients with isolated moderate to severe TBI admitted between 1998 and 2005. Demographics and mortality were compared between races: Asian, African American, Hispanic, White, and Other. Multivariate logistic regression was used to determine the relationship between race and mortality. Results. A total of 17,977 (23.8% female, 76.2% male) severe TBI patients were evaluated. Of this study population, 7.1% were Asian, 13.5% were African American, 42.3% were Hispanic, 32.5% were White, and 4.7% where classified as Other. Overall, Asians (adjusted Odds Ratio [AOR] 1.4; 95% CI: 1.14-1.71, P = 0.001) had a significantly higher risk in mortality when compared with Whites. Surprisingly, neither African Americans (AOR 1.02; 95% CI: 0.87-1.2, P = 0.82), nor Hispanics (AOR 1.00; 95% CI: 0.89-1.13, P > 0.9) were at increased risk of death compared to their White counterparts. Conclusion. This data supports the hypothesis that race may play a role in mortality in moderate to severe TBI. However, only Asians were at higher risk for death. (C) 2010 Elsevier Inc. All rights reserved.	[Berry, Cherisse; Ley, Eric J.; Mirocha, James; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Berry, Cherisse/AAO-5701-2020				Arthur M, 2008, MED CARE, V46, P192, DOI 10.1097/MLR.0b013e31815b9d8e; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P293, DOI 10.1093/phr/118.4.293; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Institute of Medicine, 2002, UN TREATM WHAT HEALT; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Rosen H, 2009, ARCH SURG-CHICAGO, V144, P1006, DOI 10.1001/archsurg.2009.195; Sabharwal S, 2007, J PEDIATR ORTHOPED, V27, P690, DOI 10.1097/BPO.0b013e3181425653; Salim A, 2010, J TRAUMA, V68, P211, DOI 10.1097/TA.0b013e3181a0e659; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Sorani MD, 2009, J TRAUMA, V67, P75, DOI 10.1097/TA.0b013e31818234e8; Wall SP, 2005, ACAD EMERG MED, V12, P862, DOI 10.1197/j.aem.2005.05.003; Wallace LS, 2007, J SURG RES, V140, P208, DOI 10.1016/j.jss.2007.01.029; White FA, 2007, J EMERG MED, V32, P159, DOI 10.1016/j.jemermed.2006.05.043; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979	21	20	20	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2010	163	2					303	308		10.1016/j.jss.2010.03.018			6	Surgery	Surgery	653SB	WOS:000282115900024	20605614				2021-06-18	
J	Dooley, JJ; Beauchamp, M; Anderson, VA				Dooley, Julian J.; Beauchamp, Miriam; Anderson, Vicki A.			The Measurement of Sociomoral Reasoning in Adolescents With Traumatic Brain Injury: A Pilot Investigation	BRAIN IMPAIRMENT			English	Article						traumatic brain injury; moral reasoning; aggression		Moral reasoning skills are crucial for appropriate and adaptive social functioning. Impairments in moral reasoning have been associated with aggressive and violent behaviours. Traditional measures of moral reasoning may provide limited insight into daily behavioural functioning as these measures are dependent on several higher order cognitive skills and, as such, may be limited in their utility with certain clinical populations. In Study 1, new measures of sociomoral reasoning and maturity, the So-Moral and So-Mature, were described. Further, the psychometric properties of the So-Moral and So-Mature were investigated in a sample of 50 adolescents aged 11 to 19 (mean age = 14.5, SD = 2.6 years, 25 male). Preliminary support was found for the validity and reliability of both tasks. In Study 2, the clinical applicability of the So-Moral and So-Mature were examined in a sample 25 adolescents with traumatic brain injury (TBI; mean age = 13.8, SD = 2.3 years, 15 male). Response trends suggested that adolescents with TBI generated less developmentally mature responses to sociomoral dilemmas and those with more severe injuries performed most poorly. The sociomoral reasoning tasks described promote participant's emotional involvement and investment as well as being appropriate for use with clinical populations.	[Dooley, Julian J.] Edith Cowan Univ, Child Hlth Promot Res Ctr, Mt Lawley, WA 6050, Australia; [Beauchamp, Miriam] Univ Montreal, Montreal, PQ H3C 3J7, Canada; [Anderson, Vicki A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki A.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Anderson, Vicki A.] Univ Melbourne, Melbourne, Vic 3010, Australia	Dooley, JJ (corresponding author), Edith Cowan Univ, Child Hlth Promot Res Ctr, 2 Bradford St, Mt Lawley, WA 6050, Australia.	j.dooley@ecu.edu.au					Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Beauchamp M., 2010, PRINCIPLES PRACTICE, P315, DOI 10.1017/CBO9780511674815.024; Bigler E. D., 1997, CHILDHOOD TRAUMATIC, P7; Borg JS, 2006, J COGNITIVE NEUROSCI, V18, P803, DOI 10.1162/jocn.2006.18.5.803; BRYANT BK, 1982, CHILD DEV, V53, P413, DOI 10.1111/j.1467-8624.1982.tb01331.x; Couper E, 2002, BRAIN IMPAIR, V3, P105, DOI DOI 10.1375/BRIM.3.2.105; de Castro BO, 2002, CHILD DEV, V73, P916, DOI 10.1111/1467-8624.00447; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Eslinger PJ, 2009, J CLIN EXP NEUROPSYC, V31, P158, DOI 10.1080/13803390802298064; Eslinger PJ, 2004, BRAIN COGNITION, V55, P84, DOI 10.1016/s0278-2626(03)00281-1; Gibbs J. C., 1992, MORAL MATURITY MEASU; Greene JD, 2004, NEURON, V44, P389, DOI 10.1016/j.neuron.2004.09.027; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Haidt J, 2001, PSYCHOL REV, V108, P814, DOI 10.1037//0033-295X.108.4.814; Harenski CL, 2006, NEUROIMAGE, V30, P313, DOI 10.1016/j.neuroimage.2005.09.034; KOHLBERG L, 1974, AM J MENT DEF, V79, P142; KOHLBERG L, 1972, PRISON J, V51, P3; Kohlberg L., 1958, THESIS U CHICAGO; Kohlberg Lawrence., 1981, ESSAYS MORAL DEV, V1; Little TD, 2003, MERRILL PALMER QUART, V49, P343, DOI 10.1353/mpq.2003.0014; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; Mikhail J, 2007, TRENDS COGN SCI, V11, P143, DOI 10.1016/j.tics.2006.12.007; Moll J, 2005, COGN BEHAV NEUROL, V18, P68, DOI 10.1097/01.wnn.0000152236.46475.a7; Moll J, 2002, NEUROIMAGE, V16, P696, DOI 10.1006/nimg.2002.1118; Moll J, 2002, J NEUROSCI, V22, P2730, DOI 10.1523/JNEUROSCI.22-07-02730.2002; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Oliveira-Souza R., 2000, NEUROLOGY S3, V54, P252; Piaget J, 1965, MORAL JUDGMENT CHILD; Pujol J, 2008, HUM BRAIN MAPP, V29, P910, DOI 10.1002/hbm.20436; Roberts J.R., 1990, J ABNORMAL CHILD PSY, V18, P231; Stams GJ, 2006, J ABNORM CHILD PSYCH, V34, P697, DOI 10.1007/s10802-006-9056-5; TEASDALE G, 1974, LANCET, V2, P81; THOMSON JJ, 1985, YALE LAW J, V94, P1395, DOI 10.2307/796133; Wall S., CLIN CHILD IN PRESS; Wechsler D., 1999, MANUAL WASI	37	20	20	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646			BRAIN IMPAIR	Brain Impair.	SEP	2010	11	2			SI		152	161		10.1375/brim.11.2.152			10	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	V24IS	WOS:000208404700006					2021-06-18	
J	Ekmark-Lewen, S; Lewen, A; Meyerson, BJ; Hillered, L				Ekmark-Lewen, Sara; Lewen, Anders; Meyerson, Bengt J.; Hillered, Lars			The Multivariate Concentric Square Field Test Reveals Behavioral Profiles of Risk Taking, Exploration, and Cognitive Impairment in Mice Subjected to Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognition; functional outcome; mouse; Multivariate Concentric Square Field Test; traumatic brain injury	WATER MAZE PERFORMANCE; CORTICAL IMPACT MODEL; MUS-MUSCULUS-MUSCULUS; 2 LABORATORY STRAINS; MOTOR DEFICITS; RATS; MOUSE; RESPONSES; STRATEGIES; OUTCOMES	There is a need for more efficient tests to evaluate functional outcome following experimental traumatic brain injury (TBI), reflecting deficits in cognitive, sensory, and motor functions that are seen in TBI patients. The Multivariate Concentric Square Field (TM) (MCSF) test is a relatively new behavioral model that measures exploration, risk taking, risk assessment, and shelter seeking, all of which are evolutionarily-conserved strategies for survival. The multivariate design enables scoring of different functional domains in a single test situation, with a free choice of optional environmental settings. Furthermore, repeated trials permits cognitive effects to be measured. In the present study, 11 anesthetized C57BL6 mice received controlled cortical injury (CCI) (0.5mm and 3.3 m/sec) over the right parietal cerebral cortex or sham surgery (n - 12). Naive mice (n 12) not subjected to any surgical procedure were also included. The animals were evaluated in the MCSF test at 2 and 7 days post-surgery, and behavioral profiles were analyzed. The results revealed differences in risk taking and explorative behavior between the sham animals and the animals subjected to trauma. Animals subjected to trauma were characterized by taking more risks and had a higher level of exploration activity, but they sought less shelter. Repeated exposure to the MCSF caused a general decrease in activity in the naive and sham group, while a more specific behavioral impairment was seen in injured mice, suggesting cognitive dysfunction. We submit that the MCSF test is a useful complementary tool for functional outcome evaluation in experimental TBI.	[Ekmark-Lewen, Sara; Lewen, Anders; Hillered, Lars] Uppsala Univ, Dept Neurosci, Univ Uppsala Hosp, SE-75185 Uppsala, Sweden; [Meyerson, Bengt J.] Uppsala Univ, Biomed Ctr, Dept Neurosci, Div Pharmacol, SE-75185 Uppsala, Sweden	Ekmark-Lewen, S (corresponding author), Uppsala Univ, Dept Neurosci, Univ Uppsala Hosp, SE-75185 Uppsala, Sweden.	Sara.Ekmark-Lewen@neuro.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Hillered, Lars/0000-0002-2808-9292	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; Swedish Brain Foundation; Ahlen Foundation; Uppsala University Hospital	This work was supported by grants from the Swedish Medical Research Council, the Swedish Brain Foundation, the Ahlen Foundation, and Uppsala University Hospital.	Alsio J, 2009, GENES BRAIN BEHAV, V8, P193, DOI 10.1111/j.1601-183X.2008.00464.x; Augustsson H, 2004, PHYSIOL BEHAV, V81, P685, DOI 10.1016/j.physbeh.2004.03.014; Augustsson H, 2005, PHYSIOL BEHAV, V84, P265, DOI 10.1016/j.physbeh.2004.12.002; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; CLAUSEN F, 2001, 31 ANN M SOC NEUR SA; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eriksson L., 2006, MULTI MEGAVARIATE 1; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Israelsson C, 2006, J NEUROSCI RES, V84, P47, DOI 10.1002/jnr.20856; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Karlsson O, 2009, TOXICOL SCI, V112, P185, DOI 10.1093/toxsci/kfp196; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marques JM, 2008, PHYSIOL BEHAV, V93, P139, DOI 10.1016/j.physbeh.2007.08.006; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Meyerson BJ, 2006, BEHAV BRAIN RES, V168, P100, DOI 10.1016/j.bbr.2005.10.020; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Rodgers RJ, 1997, NEUROSCI BIOBEHAV R, V21, P801, DOI 10.1016/S0149-7634(96)00058-9; Roman E, 2007, BEHAV BRAIN RES, V183, P195, DOI 10.1016/j.bbr.2007.06.009; Roman E, 2006, HORM BEHAV, V50, P736, DOI 10.1016/j.yhbeh.2006.06.016; Roman E, 2009, BEHAV BRAIN RES, V205, P249, DOI 10.1016/j.bbr.2009.08.020; Roos MW, 2003, BRAIN RES, V961, P15, DOI 10.1016/S0006-8993(02)03829-5; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002	44	20	20	2	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1643	1655		10.1089/neu.2009.0953			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500011	20578827				2021-06-18	
J	Jin, H; Wang, SM; Hou, LJ; Pan, CG; Li, B; Wang, H; Yu, MK; Lu, YC				Jin, Hai; Wang, Sumin; Hou, Lijun; Pan, Chengguang; Li, Bo; Wang, Hui; Yu, Mingkun; Lu, Yicheng			Clinical treatment of traumatic brain injury complicated by cranial nerve injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic brain injury; Cranial nerve injury; Diagnosis; Surgical treatment	OPTIC NEUROPATHY; DECOMPRESSION; DYSFUNCTION; DIAGNOSIS	Objective: To discuss the epidemiology, diagnosis and surgical treatment of cranial nerve injury following traumatic brain injury (TBI) for the sake of raising the clinical treatment of this special category of TBI. Patients and methods: A retrospective analysis was made of 312 patients with cranial nerve injury among 3417 TBI patients, who were admitted for treatment in this hospital. Results: A total of 312 patients (9.1%) involving either a single nerve or multiple nerves among the 12 pairs of cranial nerves were observed. The extent of nerve injury varied and involved the olfactory nerve (66 cases), optic nerve (78 cases), oculomotor nerve (56 cases), trochlear nerve (8 cases), trigeminal nerve (4 cases), abducent nerve (12 cases), facial nerve (48 cases), acoustic nerve (10 cases), glossopharyngeal nerve (8 cases), vagus nerve (6 cases), accessory nerve (10 cases) and hypoglossal nerve (6 cases). Imaging examination revealed skull fracture in 217 cases, complicated brain contusion in 232 cases, epidural haematoma in 194 cases, subarachnoid haemorrhage in 32 cases, nasal cerebrospinal fluid (CSF) leakage in 76 cases and ear CSF leakage in 8 cases. Of the 312 patients, 46 patients died; the mortality rate associated with low cranial nerve injury was as high as 73.3%. Among the 266 surviving patients, 199 patients received conservative therapy and 67 patients received surgical therapy; the curative rates among these two groups were 61.3% (122 patients) and 86.6% (58 patients), respectively. Conclusion: TBI-complicated cranial nerve injury is subject to a high incidence rate, a high mortality rate and a high disability rate. Our findings suggest that the chance of recovery may be increased in cases where injuries are amenable to surgical decompression. It is necessary to study all 12 pairs of cranial nerves systematically. Clinically, it is necessary to standardise surgical indications, operation timing, surgical approaches and methods for the treatment of TBI-complicated cranial nerve injury. (C) 2010 Elsevier Ltd. All rights reserved.	[Jin, Hai; Hou, Lijun; Pan, Chengguang; Li, Bo; Wang, Hui; Yu, Mingkun; Lu, Yicheng] Second Mil Med Univ, Changzheng Hosp, Shanghai Neurosurg Inst, Dept Neurosurg, Shanghai 200003, Peoples R China; [Wang, Sumin] Second Mil Med Univ, Changhai Hosp, Dept Otolaryngol, Shanghai 200003, Peoples R China	Hou, LJ (corresponding author), Second Mil Med Univ, Changzheng Hosp, Shanghai Neurosurg Inst, Dept Neurosurg, 415 Fengyang Rd, Shanghai 200003, Peoples R China.	lhou@partners.org					Acheson JF, 2004, EYE, V18, P1169, DOI 10.1038/sj.eye.6701559; AHMED B, 2006, BR J ORAL MAXILLOFAC, V44, P313; Blomqvist EH, 2004, RHINOLOGY, V42, P189; Carta A, 2006, EUR J OPHTHALMOL, V16, P847; Cheng YS, 2008, CHINESE MED J-PEKING, V121, P276, DOI 10.1097/00029330-200802010-00020; ENRIQUE U, 1996, J NEUROSURG, V84, P522; Exadaktylos AK, 2005, J TRAUMA, V58, P336, DOI 10.1097/01.TA.0000141874.73520.A6; Kennelly KD, 2006, NEUROLOGIST, V12, P188, DOI 10.1097/01.nrl.0000215784.76741.9e; Leung DYL, 2006, J TRAUMA, V60, P685, DOI 10.1097/01.ta.0000205919.68089.c0; Milbrandt K, 2005, CAN MED ASSOC J, V172, P632, DOI 10.1503/cmaj.1041089; Mine S, 1999, ACTA NEUROCHIR, V141, P27, DOI 10.1007/s007010050262; Ohlsson M, 2007, EXP BRAIN RES, V179, P121, DOI 10.1007/s00221-006-0775-1; Sandford AA, 2006, INT J PEDIATR OTORHI, V70, P1015, DOI 10.1016/j.ijporl.2005.10.013; Shahzadi S, 2007, SURG NEUROL, V68, P464, DOI 10.1016/j.surneu.2006.10.064; SONG WX, 2002, OPHTHALMOLOGY, V11, P286; Wang DH, 2008, ORL-J OTO-RHIN-LARYN, V70, P130, DOI 10.1159/000114537; Wu N, 2008, J INT MED RES, V36, P883, DOI 10.1177/147323000803600503; Zapala Jan, 2005, Klin Oczna, V107, P263	18	20	24	1	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2010	41	9					918	923		10.1016/j.injury.2010.03.007			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	634SL	WOS:000280605500008	20399426				2021-06-18	
J	Sveen, U; Bautz-Holter, E; Sandvik, L; Alvsaker, K; Roe, C				Sveen, Unni; Bautz-Holter, Erik; Sandvik, Leiv; Alvsaker, Kristin; Roe, Cecilie			Relationship between competency in activities, injury severity, and post-concussion symptoms after traumatic brain injury	SCANDINAVIAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						Activities of daily living; competency; functioning; instrumental ADL; post-concussion symptoms; traumatic brain injury	MINOR HEAD-INJURY; QUALITY-OF-LIFE; SYSTEMATIC BIAS; RATING-SCALE; FOLLOW-UP; MILD; SATISFACTION; RECOVERY; OUTCOMES; CLASSIFICATION	Objective: To determine to what extent injury severity and post-concussion symptoms after 3 months predict ability in activities 12 months after traumatic brain injury (TBI) and assess the frequency of problems in daily activities. Methods: A one-year cohort of 63 persons with mild to severe TBI was assessed on admission, after three and 12 months. Injury severity was assessed using the Glasgow Coma Scale, Abbreviated Injury Scale for the head and Injury Severity Score. Post-concussion symptoms were reported using the Rivermead Post Concussion Symptoms Questionnaire after three months. The Patient Competency Rating Scale (PCRS), a self-rating scale of ability in activities, was applied 12 months post-injury. The PCRS consists of the domains interpersonal/emotional and cognitive competency, and instrumental ADL. Multiple backward regression models were performed with the three subscales of PCRS as dependent variables. Results: Activity problems at 12 months were related to perceived cognitive and interpersonal/emotional competency. Post-concussion symptoms reported at three-month follow-up were main predictors of cognitive and interpersonal/emotional competency at 12 months. Injury severity predicted only cognitive competency. Conclusion: Symptoms evolving after the trauma seem to be the strongest predictor of perceived ability in activities in this population. This underlines the need for follow-up after TBI to identify persons at risk of developing long-term activity limitations.	[Sveen, Unni; Bautz-Holter, Erik; Alvsaker, Kristin; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway; [Sveen, Unni] Univ Oslo, Dept Geriatr Med, Oslo Univ Hosp, Oslo, Norway; [Sveen, Unni] Oslo Univ Coll, Oslo, Norway; [Sandvik, Leiv] Oslo Univ Hosp, Clin Res Ctr, N-0407 Oslo, Norway	Sveen, U (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	unni.sveen@uus.no			Norwegian Foundation for Health and Rehabilitation	The authors would like to thank all the participants in this study, Liv Brathen, Cathrine Advocaat, Malin Mongs, and Inger Seip for helpful assistance with the registrations, and Terje Sprenger for stimulating discussions. They would also like to thank the staff at the Neurosurgical Department for their support during the inclusion period, and Susan Schanche for skilful help with the English language. The Norwegian Foundation for Health and Rehabilitation provided a grant for the study.	[Anonymous], 2009, OXFORD DICT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; Hurley Robin A., 2002, Curr Treat Options Neurol, V4, P59, DOI 10.1007/s11940-002-0005-5; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; Johansson U, 2003, BRAIN INJURY, V17, P991, DOI 10.1080/0269905031000110508; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; NAKASERICHARDSO.R, 2006, J NEUROL NEUROS 1218; Novack TA, 2000, BRAIN INJURY, V14, P987; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2005, ACT NEUR S, V93, P39; ROE C, 2009, DISABIL REH IN PRESS; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stilwell P, 1999, NEUROPSYCHOL REHABIL, V9, P277, DOI 10.1080/096020199389374; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sundstrom Terje, 2005, Tidsskr Nor Laegeforen, V125, P1310; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Toschlog EA, 2003, AM SURGEON, V69, P491; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	45	20	21	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1103-8128	1651-2014		SCAND J OCCUP THER	Scand. J. Occup. Ther.	SEP	2010	17	3					225	232		10.3109/11038120903171295			8	Rehabilitation	Rehabilitation	672EQ	WOS:000283566200006	20302448				2021-06-18	
J	Georgoff, P; Meghan, S; Mirza, K; Stein, SC				Georgoff, Patrick; Meghan, Sudha; Mirza, Kasim; Stein, Sherman C.			Geographic Variation in Outcomes from Severe Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Epidemiology; Mortality; Outcomes; Traumatic brain injury	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; MULTIMODALITY EVOKED-POTENTIALS; SAN-DIEGO-COUNTY; COMPUTERIZED-TOMOGRAPHY; INTRACRANIAL-PRESSURE; EARLY PREDICTION; PROGNOSTIC VALUE; INTENSIVE-CARE; SUBARACHNOID HEMORRHAGE	BACKGROUND: Recent reports have documented a wide range of outcomes after treatment of severe traumatic brain injury at trauma centers throughout the world. METHODS: In an effort to test the contribution of geography to treatment outcome, we compared case series published from 1975 to 2009. Trauma centers were divided into those from the United States, other developed countries, and the developing world. We pooled data on mortality rates using meta-analytic techniques, and corrected for temporal trends and other covariates using meta-regression. RESULTS: Our search yielded 231 case series, totaling more than 121,000 cases. There was a decrease in mortality over time in all three geographic locales. The small advantage the United States had versus other high and moderate income countries tended to decrease over time, whereas low income countries reported significantly greater mortality, and their rates decreased more slowly over time. CONCLUSIONS: Low income countries have the highest mortality rates in treating patients with severe closed traumatic brain injury. The lower intensity of treatment appears to be the largest contributor to the discrepancy, and other possible causes are discussed.	[Georgoff, Patrick; Meghan, Sudha; Mirza, Kasim; Stein, Sherman C.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Stein, SC (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.	sherman.stein@uphs.upenn.edu					Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; ANDERSON DW, 1983, PUBLIC HEALTH REP, V98, P475; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Athiappan S., 1993, Annals Academy of Medicine Singapore, V22, P452; Auer L, 1979, Acta Neurochir Suppl (Wien), V28, P171; Baguley I, 2000, BRAIN INJURY, V14, P505; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Benzer A, 1995, Anasthesiol Intensivmed Notfallmed Schmerzther, V30, P231, DOI 10.1055/s-2007-996481; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRAAKMAN R, 1992, ACTA NEUROCHIR, V116, P161, DOI 10.1007/BF01540870; BRAIN TRAUM FD, 2000, J NEUROTRAUM, V17, P563; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Brain Trauma Foundation, 1995, GUID MAN SEV HEAD IN; BRICOLO A, 1977, J NEUROSURG, V47, P680, DOI 10.3171/jns.1977.47.5.0680; BROWNE LA, 1977, IRISH MED J, V70, P197; BUCHMANN B, 1992, J TRAUMA, V32, P459, DOI 10.1097/00005373-199204000-00009; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; BULLIET M, 2005, NY POST, P3; Carter BG, 2005, INTENS CARE MED, V31, P765, DOI 10.1007/s00134-005-2633-1; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Cremer OL, 2008, EUR J ANAESTH, V25, P87, DOI 10.1017/S0265021507003237; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Douglas IS, 2005, LANCET, V365, P212; Dunn LT, 2000, BRIT J NEUROSURG, V14, P219; EDDY VA, 1995, AM SURGEON, V61, P24; EDNA TH, 1983, ACTA NEUROCHIR, V69, P15, DOI 10.1007/BF02055848; Eftekhar Behzad, 2005, BMC Med Inform Decis Mak, V5, P3; Einarson TR, 1997, CLIN THER, V19, P559, DOI 10.1016/S0149-2918(97)80140-3; Eker C, 2000, BRAIN INJURY, V14, P605; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; ELGINDI S, 2001, REV ESPANOLA NEUROPS, V3, P3; Enderson BL, 2007, J TRAUMA, V62, P33; Engberg AW, 2004, ACTA NEUROL SCAND, V110, P281, DOI 10.1111/j.1600-0404.2004.00323.x; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; ESPERSEN JO, 1982, ACTA NEUROCHIR, V65, P81, DOI 10.1007/BF01405444; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2004, ACT NEUR S, V89, P101; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FELDMAN Z, 1991, LANCET, V337, P1451, DOI 10.1016/0140-6736(91)93137-X; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; GALBRAITH S, 1977, SCOT MED J, V22, P129, DOI 10.1177/003693307702200208; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GIBSON RM, 1989, LANCET, V2, P369; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Goosen J, 2003, INJURY, V34, P704, DOI 10.1016/S0020-1383(03)00153-0; GORDON E, 1995, J NEUROSURG ANESTH, V7, P235, DOI 10.1097/00008506-199510000-00001; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Gujral IB, 2006, BRAIN INJURY, V20, P283, DOI 10.1080/02699050500488058; Habbema J D, 1979, Acta Neurochir Suppl (Wien), V28, P158; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Harris OA, 2008, J NEUROSURG, V109, P433, DOI 10.3171/JNS/2008/109/9/0433; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; HEIDEN JS, 1983, PHYS THER, V63, P1946, DOI 10.1093/ptj/63.12.1946; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hofman K, 2005, AM J PUBLIC HEALTH, V95, P13, DOI 10.2105/AJPH.2004.039354; HOLLIDAY PO, 1982, NEUROSURGERY, V10, P25, DOI 10.1227/00006123-198201000-00005; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hsiao KY, 2008, EMERG MED J, V25, P670, DOI 10.1136/emj.2007.053405; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 1979, Int Anesthesiol Clin, V17, P133, DOI 10.1097/00004311-197917020-00006; JENNETT B, 1976, LANCET, V1, P1031; JENNETT B, 1975, CIBA F SYMP, V34, P3; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jin PHPFK, 2008, J NEUROTRAUM, V25, P1003, DOI 10.1089/neu.2007.0463; Joshipura MK, 2008, WORLD J SURG, V32, P1613, DOI 10.1007/s00268-008-9634-5; Joshipura MK, 2003, INJURY, V34, P686, DOI 10.1016/S0020-1383(03)00163-3; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KAGAN RJ, 1994, AM SURGEON, V60, P394; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; Kim Y, 2000, J TRAUMA, V48, P280, DOI 10.1097/00005373-200002000-00014; KING JT, 1995, J NEUROSURG, V83, P403, DOI 10.3171/jns.1995.83.3.0403; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KLEIN DG, 1999, NURS CLIN N AM, V11, P209; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Kraus J F, 2000, Neurosurg Focus, V8, pe5; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Lane PL, 2000, CAN J SURG, V43, P442; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Lee A, 2003, INJURY, V34, P815, DOI 10.1016/S0020-1383(02)00395-9; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; Lobato R D, 1979, Acta Neurochir Suppl (Wien), V28, P70; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; Lu J, 2005, ACT NEUR S, V95, P281; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; McConnell KJ, 2005, HEALTH SERV RES, V40, P435, DOI 10.1111/j.1475-6773.2005.0u367.x; McSwain NE, 2004, J TRAUMA, V57, P8; Miller J D, 1979, Acta Neurochir Suppl (Wien), V28, P86; MILLER JD, 1992, BRIT J SURG, V79, P60, DOI 10.1002/bjs.1800790122; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Minardi J, 2009, MT SINAI J MED, V76, P138, DOI 10.1002/msj.20105; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray CJL, 1996, GLOBAL BURDEN DIS CO; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; MURRAY GD, 1986, STAT MED, V5, P103, DOI 10.1002/sim.4780050202; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nathens A B, 2001, Adv Surg, V35, P61; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; Nordstrom C H, 1989, Brain Inj, V3, P267, DOI 10.3109/02699058909029640; Nordstrom C H, 1989, Brain Inj, V3, P247, DOI 10.3109/02699058909029639; Oakley PA, 2004, INJURY, V35, P379, DOI 10.1016/S0020-1383(03)00096-2; Odebode TO, 2008, NIGER J CLIN PRACT, V11, P265; Ogungbo B, 2004, J AM COLL SURGEONS, V198, P852, DOI 10.1016/j.jamcollsurg.2004.02.003; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; PAZZAGLIA P, 1975, J NEUROL NEUROSUR PS, V38, P149, DOI 10.1136/jnnp.38.2.149; Peden M., 2004, WORLD REPORT ROAD TR; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; Pillai SV, 2003, NEUROL INDIA, V51, P345; Price D J, 1979, Acta Neurochir Suppl (Wien), V28, P179; Pryor JP, 2003, J TRAUMA, V55, P442; Raja IA, 2001, WORLD J SURG, V25, P1230; Ramesh VG, 2008, J CLIN NEUROSCI, V15, P1110, DOI 10.1016/j.jocn.2007.08.033; Razzak JA, 2002, B WORLD HEALTH ORGAN, V80, P900; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; Richard K E, 1979, Acta Neurochir Suppl (Wien), V28, P66; RIMEL RW, 1981, RESUSCITATION, V9, P75, DOI 10.1016/0300-9572(81)90036-8; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Rudnik A, 1992, Acta Neurochir Suppl (Wien), V55, P33; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Sauerland S, 2004, LANCET, V364, P1291, DOI 10.1016/S0140-6736(04)17202-4; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; Servadei F, 2000, NEUROSURGERY, V46, P70; Shavelle R, 2000, J Insur Med, V32, P163; Siddiqui Arshad A, 2004, J Coll Physicians Surg Pak, V14, P173; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stocchetti N, 2001, Eur J Emerg Med, V8, P215, DOI 10.1097/00063110-200109000-00009; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Stranjalis G, 2008, J TRAUMA, V65, P789, DOI 10.1097/TA.0b013e3181469e26; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Sundbarg G, 1989, Brain Inj, V3, P283, DOI 10.3109/02699058909029641; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Sutton AJ., 2000, METHODS METAANALYSIS; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teoh LSG, 2000, INTENS CARE MED, V26, P157, DOI 10.1007/s001340050039; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Tsementzis S A, 1979, Acta Neurochir Suppl (Wien), V28, P78; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Valadka AB, 2000, J TRAUMA, V49, P1, DOI 10.1097/00005373-200007000-00001; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; Winchell RJ, 1998, J TRAUMA, V45, P104; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	248	20	21	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	AUG-SEP	2010	74	2-3					331	345		10.1016/j.wneu.2010.03.025			15	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	792WM	WOS:000292781100037	21492567				2021-06-18	
J	Griffen, JA; Hanks, RA; Meachen, SJ				Griffen, Julie A.; Hanks, Robin A.; Meachen, Sarah-Jane			The Reliability and Validity of the Community Integration Measure in Persons With Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						community integration; brain injury; reliability; validity; rehabilitation	PARTICIPATION; SATISFACTION	Objective: To investigate the psychometric properties of the Community Integration Measure (CIM), a scale that assesses self-perceived quality of community integration, among persons with traumatic brain injury (TB I). Method: Persons (N = 279) with TBI completed the CIM, as well as other measures of community integration and quality of life, and were followed up to 15 years postinjury. Results: The CIM was found to be a reliable instrument with adequate internal consistency. Validity was demonstrated in its relationship to other measures of community integration and life satisfaction. Utility was evident in its prediction of perceived social support. Conclusion: Results suggest that the CIM is an adequate measure of community integration for persons with histories of TBI of up to 15 years.	[Griffen, Julie A.; Meachen, Sarah-Jane] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Hanks, Robin A.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48202 USA	Griffen, JA (corresponding author), Wayne State Univ, Dept Psychol, 5057 Woodward Ave,7th Floor, Detroit, MI 48202 USA.	jgriffen@wayne.edu					Bodenheimer CF, 2004, ARCH PHYS MED REHAB, V85, pS23, DOI 10.1016/j.apmr.2004.03.009; Brown M, 2006, PARTICIPATION OBJECT; Cutrona CE., 1987, ADV PERSONAL RELATIO, V1, P37; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; GLASS TA, 1992, SOC SCI MED, V34, P1249, DOI 10.1016/0277-9536(92)90317-J; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McGrew K. S., 1994, CHALLENGES SERVICE S, P65; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; Ostir GV, 2005, AGING CLIN EXP RES, V17, P35, DOI 10.1007/BF03337718; Reistetter TA, 2005, NEUROREHABILITATION, V20, P139; Salter K, 2008, BRAIN INJURY, V22, P820, DOI 10.1080/02699050802425428; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; Ware J.E., 1998, SF 12 SCORE SF 12 PH, V2; Whiteneck G. G., 1997, ASSESSING MED REHABI, P91; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Zabora J, 2001, PSYCHOSOMATICS, V42, P241, DOI 10.1176/appi.psy.42.3.241	20	20	20	0	5	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2010	55	3					292	297		10.1037/a0020503			6	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	642ND	WOS:000281220800010	20804273				2021-06-18	
J	Ho, KM; Burrell, M; Rao, S				Ho, Kwok M.; Burrell, Maxine; Rao, Sudhakar			Extracranial injuries are important in determining mortality of neurotrauma	CRITICAL CARE MEDICINE			English	Article						hypoxia; injury severity; outcome; prognosis; prediction; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERITY SCORE; HEAD-INJURY; SURVIVAL; LINKAGE	Objective: This study aimed to assess the significance of extracranial injuries, as measured by Injury Severity Score, on 6-mo and 9-yr mortality of neurotrauma. Design: Retrospective linked data cohort study. Setting: A major neurotrauma center in Western Australia. Patients: Six hundred eighty-three adult neurotrauma patients. Measurements and Main Results: Data were first used to validate the largest published international neurotrauma "extended" mortality prognostic model, in which extracranial injuries are considered significant if the patient has hypoxemia or hypotension on admission. Logistic and Cox regression, incorporating bootstrap techniques to adjust for overfitting, were used to assess the significance of Injury Severity Score in determining 6-mo and 9-yr mortality, respectively. Among a total of 683 patients admitted between 1994 and 2002, 636 (93.1%) had extracranial injuries. The international neurotrauma "extended" mortality prognostic model was poorly calibrated and underestimated the observed mortality (slope and intercept of the calibration curve were 2.14 and 0.35, respectively) when applied to our patients. Incorporating Injury Severity Score into the model improved its calibration. Injury Severity Score accounted for 11% of the variability and was the third most important factor after Marshall computed tomographic grading (17.8%) and pupil reactivity (14.5%) in determining 6-mo mortality. There was a notable increase in mortality between 6-mo (19.2%) and 24-mo follow-up (25.8%). Injury Severity Score remained important and accounted for 9.2% of the variability in determining 9-yr mortality after the injury. Conclusions: Hypotension and hypoxemia on admission were inadequate markers of extracranial injuries; incorporating more comprehensive extracranial injury assessment by the Injury Severity Score to the standard neurologic prognostic factors improved the accuracy of predictions on mortality after neurotrauma. (Crit Care Med 2010; 38:1562-1568)	[Ho, Kwok M.] Royal Perth Hosp, Dept Intens Care Med, Perth, WA, Australia; [Burrell, Maxine; Rao, Sudhakar] Royal Perth Hosp, Trauma Serv, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia	Ho, KM (corresponding author), Royal Perth Hosp, Dept Intens Care Med, Perth, WA, Australia.	kwok.ho@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004	BUPA; Medical Research Foundation of Royal Perth Hospital	The BUPA and Medical Research Foundation of Royal Perth Hospital funded the data linkage process involved in this study. No funding was received from the National Institutes of Health, Wellcome Trust, HHMI, or others.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brenneman FD, 1997, J TRAUMA, V42, P773, DOI 10.1097/00005373-199705000-00003; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Harrell Frank E., 2001, REGRESSION MODELING; Ho KM, 2007, J CLIN EPIDEMIOL, V60, P746, DOI 10.1016/j.jclinepi.2006.10.017; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; LI G, 2009, CHEST           1016; Meier U, 2006, ACTA NEUROCHIR SUPPL, V96, P373; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Perel P, 2007, J EVAL CLIN PRACT, V13, P464, DOI 10.1111/j.1365-2753.2006.00713.x; Probst C, 2009, J TRAUMA, V66, P1212, DOI 10.1097/TA.0b013e318197b97c; Robinson WP, 2005, J TRAUMA, V58, P437, DOI 10.1097/01.TA.0000153935.18997.14; Roozenbeek B, 2009, J NEUROTRAUM, V26, P1069, DOI 10.1089/neu.2008.0569; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Williams TA, 2006, ANAESTH INTENS CARE, V34, P307, DOI 10.1177/0310057X0603400316	22	20	20	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	2010	38	7					1562	1568		10.1097/CCM.0b013e3181e2ccd8			7	Critical Care Medicine	General & Internal Medicine	612RL	WOS:000278920000008	20526198				2021-06-18	
J	Darwish, RS; Amiridze, NS				Darwish, Ribal S.; Amiridze, Nana S.			Detectable Levels of Cytochrome c and Activated Caspase-9 in Cerebrospinal Fluid after Human Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Activated caspase-9; Cytochrome c; Traumatic brain injury	SEVERE HEAD-INJURY; UP-REGULATION; APOPTOSIS; INVOLVEMENT; CHILDREN; INFANTS; RELEASE; DEATH	The intrinsic pathway of apoptosis has been proposed as one mechanism of cell death after traumatic brain injury (TBI). This study tested the hypothesis that cytochrome c and activated caspase-9 are released into the cerebrospinal fluid (CSF) after severe TBI and that their presence correlates with mitochondrial injury and severity of neurologic outcome. Nine adult patients with severe TBI (GCS a parts per thousand currency sign 8) underwent placement of intraventricular catheters for monitoring and management of intracranial pressure. CSF was sampled at catheter insertion (2-26 h after injury) and at intervals of 24, 48, and 72 h thereafter. Control samples were obtained from patients undergoing spinal anesthesia (ASA1). CSF levels of cytochrome c and activated caspase-9 were measured using ELISA. Cytochrome c was detected in 18 (51.4%) samples, in the range of 0.08-5 ng/ml; mean value for cytochrome c was 0.44 ng/ml (SD +/- A 0.632). Activated caspase-9 was detected in 10 samples (28.6%); mean value was 0.28 ng/ml (SD +/- A 0.39). R (s) between cytochrome c and Glasgow outcome score (GOS) was -0.25 (P = 0.14), and between GOS and activated caspase-9 was -0.35 (P = 0.04). R calculated based on linear regression of activated caspase-9 and cytochrome c concentrations was 0.18. Control CSF samples had no detectable levels of either marker (detection level for cytochrome c was 0.08 ng/ml and 0.20 for activated caspase-9). We concluded that activated caspase-9 and cytochrome c are present in the CSF of patients with severe TBI. Activated caspase-9 shows weak correlation with poor neurologic outcome.	[Darwish, Ribal S.] Univ Maryland, Med Ctr, Dept Anesthesiol, Crit Care Med Div, Baltimore, MD 21201 USA; [Amiridze, Nana S.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA	Darwish, RS (corresponding author), Univ Maryland, Med Ctr, Dept Anesthesiol, Crit Care Med Div, 22 S Greene St, Baltimore, MD 21201 USA.	Rdarwish@anes.umm.edu; Namiridze@umm.edu		Darwish, Ribal/0000-0003-0727-0401			Bayir H, 2003, J CEREBR BLOOD F MET, V23, P51, DOI 10.1097/01.WCB.0000040399.30600.E3; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; DARWISH R, 2004, ANN M AM ASS NEUR SU; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Li YZ, 1999, MOL MED, V5, P232, DOI 10.1007/BF03402120; Qiu JH, 2002, J NEUROSCI, V22, P3504; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Uzan M, 2006, ACTA NEUROCHIR, V148, P1157, DOI 10.1007/s00701-006-0887-1; Wright KM, 2007, CELL DEATH DIFFER, V14, P625, DOI 10.1038/sj.cdd.4402024; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	18	20	22	1	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	JUN	2010	12	3					337	341		10.1007/s12028-009-9328-3			5	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	590RJ	WOS:000277244700004	20087688				2021-06-18	
J	Dorsi, MJ; Hsu, W; Belzberg, AJ				Dorsi, Michael J.; Hsu, Wesley; Belzberg, Allan J.			Epidemiology of brachial plexus injury in the pediatric multitrauma population in the United States Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						brachial plexus injury; trauma; prevalence; nerve injury; National Pediatric Trauma Registry	BROWN-SEQUARD-SYNDROME; SUBCLAVIAN PSEUDOANEURYSM; CLAVICULAR FRACTURE; LESIONS; TRAUMA; COMPLICATIONS; PARALYSIS; AVULSION; CHILDREN; REPAIR	Object. The aim of this study was to estimate the prevalence of brachial plexus injury (BPI) in pediatric multitrauma patients. Methods. The National Pediatric Trauma Registry was queried using the ICD-9 code 953.4, injury to brachial plexus, to identify cases of BPI. The patient demographics, mechanism of trauma, and associated ICD-9 diagnoses were analyzed. Results. Brachial plexus injuries were identified in 113 (0.1%) of the 103,434 injured children entered in the registry between April 1, 1985, and March 31, 2002. Sixty-nine patients (61%) were male. Injuries were most often caused by motor vehicle accidents involving passengers (36 cases [32%]) or pedestrians (19 cases [17%]). Head injuries were diagnosed in 47% of children and included concussion in 27%, intracranial bleeds in 21%, and skull fractures in 14%. Upper-extremity vascular injury occurred in 16%. The most common musculoskeletal injuries were fractures of the humerus (16%), ribs (16%), clavicle (13%), and scapula (11%). Spinal fractures occurred in 12% of patients, and spinal cord injury occurred in 4%. The Injury Severity Score ranged from 1 to 75, with a mean score of 10, and 6 patients (5%) died as a result of injuries sustained during a traumatic event. Conclusions. Brachial plexus injuries occur in 0.1% of pediatric multitrauma patients. Motor vehicle accidents and pedestrians struck by a motor vehicle are the most common reasons for BPIs in this population. Common associated injuries include head injuries, upper-extremity vascular injuries, and fractures of the spine, humerus, ribs, scapula, and clavicle. (DOI: 10.3171/2010.3.PEDS09538)	[Dorsi, Michael J.; Hsu, Wesley; Belzberg, Allan J.] Johns Hopkins Med Inst, Dept Neurosurg, Baltimore, MD 21205 USA	Dorsi, MJ (corresponding author), Univ Calif Los Angeles, 635 Charles E Young Dr S,NRB 404, Los Angeles, CA 90095 USA.	mdorsi@jhmi.edu					ALNOT JY, 1986, CHIRURGIE, V112, P674; AYCOCK TM, 1971, SOUTHERN MED J, V64, P1165, DOI 10.1097/00007611-197110000-00002; Battiston B, 2006, MICROSURG, V26, P311, DOI 10.1002/micr.20244; Birch R, 1998, SURG DISORDERS PERIP, P157; Boome R, 2000, GROWING HAND DIAGNOS, P653; Brown KR, 2001, ANN VASC SURG, V15, P43, DOI 10.1007/BF02693799; BRUNELLI GA, 1995, MICROSURG, V16, P17, DOI 10.1002/micr.1920160107; D'Aubigne M, 1967, Rev Chir Orthop Reparatrice Appar Mot, V53, P23; Diamond S, 2003, AM SURGEON, V69, P848; DUMONTIER C, 1990, Annales de Chirurgie de la Main et du Membre Superieur, V9, P351, DOI 10.1016/S0753-9053(05)80508-3; El-Gammal TA, 2003, MICROSURG, V23, P14, DOI 10.1002/micr.10084; Fields CE, 2002, SURG CLIN N AM, V82, P105, DOI 10.1016/S0039-6109(03)00143-9; Fletcher I, 1969, HAND, V1, P129; Gilbert A, 2006, MICROSURG, V26, P334, DOI 10.1002/micr.20248; HANSKY B, 1993, EUR J CARDIO-THORAC, V7, P497, DOI 10.1016/1010-7940(93)90281-F; HOULDEN DA, 1992, J TRAUMA, V33, P244, DOI 10.1097/00005373-199208000-00014; HOWARD FM, 1965, J BONE JOINT SURG AM, VA 47, P1335, DOI 10.2106/00004623-196547070-00005; KAY SP, 1986, CLIN ORTHOP RELAT R, P219; Kim DH, 2003, J NEUROSURG, V98, P1005, DOI 10.3171/jns.2003.98.5.1005; Kitsis CK, 2003, INJURY, V34, P69, DOI 10.1016/S0020-1383(02)00169-9; MANSKE DJ, 1985, J BONE JOINT SURG AM, V67A, P1367, DOI 10.2106/00004623-198567090-00010; McGowin J F, 1989, J Spinal Disord, V2, P104; Midha R, 1997, NEUROSURGERY, V40, P1182, DOI 10.1097/00006123-199706000-00014; Nordin L, 2009, J BONE JOINT SURG BR, V91B, P88, DOI 10.1302/0301-620X.91B1.21668; Rigault P, 1969, Rev Chir Orthop Reparatrice Appar Mot, V55, P125; Stephen AB, 1997, INJURY, V28, P557, DOI 10.1016/S0020-1383(97)83474-2; Watanabe K, 2005, J TRAUMA, V58, P1073, DOI 10.1097/01.TA.0000087649.78376.1B	27	20	20	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUN	2010	5	6					573	577		10.3171/2010.3.PEDS09538			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	600YF	WOS:000278024200007	20515329				2021-06-18	
J	Moines, LESM; Allen, DN; Puente, AE; Neblina, C				Moines, Liza E. San Miguel; Allen, Daniel N.; Puente, Antonio E.; Neblina, Cris			Validity of the WISC-IV Spanish for a Clinically Referred Sample of Hispanic Children	PSYCHOLOGICAL ASSESSMENT			English	Article						WISC-IV Spanish; Hispanic children; learning disabilities; ADHD; Puerto Rican children	TRAUMATIC BRAIN-INJURY; HIGH-FUNCTIONING AUTISM; CRITERION VALIDITY; INTELLIGENCE SCALE; ADOLESCENTS; PROFILES; EDITION	The Wechsler Intelligence Scale for Children (WISC) is the most commonly used intelligence test for children. Five years ago, a Spanish version of the WISC-IV was published (WISC-IV Spanish: Wechsler. 2005). hut a limited amount of published information is available regarding its utility when assessing clinical samples. The current study included 107 children who were Spanish speaking and of Puerto Rican descent that had been administered the WISC-IV Spanish. They were subdivided into a clinical sample of 35 children with diagnoses of various forms of brain dysfunction (primarily learning disability. attention-deficit/hyperactivity disorder, and epilepsy) and a comparison group made up of 72 normal children who were part of the WISC-IV Spanish version standardization sample. Comparisons between these groups and the standardization sample were performed for the WISC-IV Spanish index and subtest scores. Results indicated that the clinical sample performed worse than the comparison samples on the Working Memory and Processing Speed Indexes, although findings varied to some extent depending on whether the clinical group was compared with the normal comparison group or the standardization sample. These findings provide support for the criterion validity of the WISC-IV Spanish when it is used to assess a clinically referred sample with brain dysfunction.	[Moines, Liza E. San Miguel] Univ Puerto Rico, Sch Med, Neurol Sect, Child Neurol Program, San Juan, PR 00936 USA; [Allen, Daniel N.; Neblina, Cris] Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA; [Puente, Antonio E.] Univ N Carolina, Dept Psychol, Wilmington, NC USA	Moines, LESM (corresponding author), Univ Puerto Rico, Sch Med, Neurol Sect, Child Neurol Program, Med Sci Campus, San Juan, PR 00936 USA.	lsanmiguel@rcm.upr.edu		Allen, Daniel/0000-0003-4868-2242			Allen DN, 2010, PSYCHOL ASSESSMENT, V22, P57, DOI 10.1037/a0016056; Allen DN, 2009, CHILD NEUROPSYCHOL, V15, P543, DOI 10.1080/09297040902748234; *AM ED RES ORG AM, 1999, STAND ED PSYCH TEST; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ARDILA A, 1992, NEUROPSYCHOLOGICAL E; Braden J. P., 2007, J PSYCHOEDUCATIONAL, V25, P292, DOI [10.1177/0734282907302955, DOI 10.1177/0734282907302955]; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Goldstein G, 2008, NEUROPSYCHOLOGY, V22, P301, DOI 10.1037/0894-4105.22.3.301; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Matarazzo JD, 1972, WECHSLERS MEASUREMEN; Mayes Susan Dickerson, 2006, J Atten Disord, V9, P486, DOI 10.1177/1087054705283616; PUENTE AE, 1998, WISC 3 CLIN USE INTE, P227; RAIFORD SE, 2008, 4 PEARS ASS; Renteria L, 2008, CLIN NEUROPSYCHOL, V22, P455, DOI 10.1080/13854040701336428; Siegel DJ, 1996, J AUTISM DEV DISORD, V26, P389, DOI 10.1007/BF02172825; SOLANTO M, 2008, J ABNORMAL CHILD PSY, V36, P129; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2005, WECHSLER INTELLIGENC; Wechsler D., 1991, WECHSLER INTELLIGENC; Weiss L.G., 2006, WISC 4 ADV CLIN INTE; WEISS LG, 2008, 6 PEARS ASS	27	20	21	0	16	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590			PSYCHOL ASSESSMENT	Psychol. Assess.	JUN	2010	22	2					465	469		10.1037/a0018895			5	Psychology, Clinical	Psychology	609OF	WOS:000278665600026	20528073				2021-06-18	
J	Wilde, EA; McCauley, SR; Kelly, TM; Weyand, AM; Pedroza, C; Levin, HS; Clifton, GL; Schnelle, KP; Shah, MV; Moretti, P				Wilde, Elisabeth A.; McCauley, Stephen R.; Kelly, Tara M.; Weyand, Annie M.; Pedroza, Claudia; Levin, Harvey S.; Clifton, Guy L.; Schnelle, Kathleen P.; Shah, Monika V.; Moretti, Paolo			The Neurological Outcome Scale for Traumatic Brain Injury (NOS-TBI): I. Construct Validity	JOURNAL OF NEUROTRAUMA			English	Article						Neurological Outcome Scale for Traumatic Brain Injury; outcome; traumatic brain injury; validity	HEALTH STROKE SCALE; CLINICAL-TRIALS; RELIABILITY; VOLUME	The Neurological Outcome Scale for Traumatic Brain Injury (NOS-TBI) is a measure adapted from the National Institutes of Health Stroke Scale (NIHSS), and is intended to capture essential neurological deficits impacting individuals with traumatic brain injury (TBI) (see Wilde et al., 2010). In the present study we evaluate the measure's construct validity via comparison with a quantified neurological examination performed by a neurologist. Spearman rank-order correlation between the NOS-TBI and the neurological examination was rho = 0.76, p<0.0001, suggesting a high degree of correspondence (construct validity) between these two measures of neurological function. Additionally, items from the NOS-TBI compared favorably to the neurological examination items, with correlations ranging from 0.60 to 0.99 (all p<0.0001). On formal neurological examination, some degree of neurological impairment was observed in every participant in this cohort of individuals undergoing rehabilitation for TBI, and on the NOS-TBI neurological impairment was evident in all but one participant. This study documents the presence of measurable neurological sequelae in a sample of patients with TBI in a post-acute rehabilitation setting, underscoring the need for formal measurement of the frequency and severity of neurological deficits in this population. The results suggest that the NOS-TBI is a valid measure of neurological functioning in patients with TBI.	[Wilde, Elisabeth A.] Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Kelly, Tara M.; Levin, Harvey S.; Clifton, Guy L.; Schnelle, Kathleen P.; Shah, Monika V.] Univ Texas Houston Med Sch, Houston, TX USA; [McCauley, Stephen R.; Moretti, Paolo] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Pedroza, Claudia] Univ Texas Med Sch Houston, Ctr Clin Res & Evidence Based Med, Houston, TX USA; [Moretti, Paolo] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Wilde, EA (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	ewilde@bcm.edu		Pedroza, Claudia/0000-0003-4235-1282	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 43353]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS043353] Funding Source: NIH RePORTER	We would like to extend our gratitude to the participants and their families, whose cooperation and patience helped make this study possible. This study was supported in part by grant NS 43353 from the National Institutes of Health/National Institute of Neurological Disorders and Stroke, to Guy L. Clifton, Principal Investigator. The information in this manuscript and the manuscript itself has never been published either electronically or in print. None of the authors have any financial or other relationships that could be construed as a conflict of interest with respect to the content of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Anastasi A, 1997, PSYCHOL TESTING, V7th; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Derex L, 2004, J NEUROL SCI, V225, P3, DOI 10.1016/j.jns.2004.05.020; DOlhaberriague L, 1996, STROKE, V27, P2331, DOI 10.1161/01.STR.27.12.2331; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Lyden P, 2004, ARCH NEUROL-CHICAGO, V61, P1677, DOI 10.1001/archneur.61.11.1677; LYDEN PD, 1991, STROKE, V22, P1345, DOI 10.1161/01.STR.22.11.1345; Lyden PD, 2001, STROKE, V32, P1310, DOI 10.1161/01.STR.32.6.1310; MCCAULEY SR, 2010, J NEUROTRAUMA, V27; Meyer MA, 1998, STROKE, V29, P1480, DOI 10.1161/01.STR.29.7.1480; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; *SAS I INC, 2008, STAT AN SOFTW WIND; Saver JL, 1999, STROKE, V30, P293, DOI 10.1161/01.STR.30.2.293; Schiemanck SK, 2005, NEUROREHAB NEURAL RE, V19, P133, DOI 10.1177/154596830501900207; TEASDALE G, 1974, LANCET, V2, P81; Wilde EA, 2010, J NEUROTRAUM, V27, P975, DOI 10.1089/neu.2009.1193; Young FB, 2005, STROKE, V36, P2187, DOI 10.1161/01.STR.0000181089.41324.70	18	20	20	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					983	989		10.1089/neu.2009.1194			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300002	20210594	Green Published			2021-06-18	
J	Armstead, WM; Kiessling, JW; Kofke, WA; Vavilala, MS				Armstead, William M.; Kiessling, J. Willis; Kofke, W. Andrew; Vavilala, Monica S.			SNP improves cerebral hemodynamics during normotension but fails to prevent sex dependent impaired cerebral autoregulation during hypotension after brain injury	BRAIN RESEARCH			English	Article						Brain injury; Cerebral circulation; Newborn; Autoregulation; Signal transduction	BLOOD-FLOW; CHILDREN; AGE; METABOLISM	Traumatic brain injury (TBI is a leading cause of morbidity in children and boys are disproportionately represented. Hypotension is common and worsens outcome after TBI. Previous studies show that adrenomedullin, a cerebrovasodilator, prevented sex dependent impairment of autoregulation during hypotension after piglet fluid percussion brain injury (FPI). We hypothesized that this concept was generalizable and that administration of another vasodilator, sodium nitroprusside (SNP), may equally improve CBF and cerebral autoregulation in a sex dependent manner after FPI. SNP produced equivalent percent cerebrovasodilation in male and female piglets. Reductions in pial artery diameter, cortical CBF, and cerebral perfusion pressure (CPP) concomitant with elevated intracranial pressure (ICP) after FPI were greater in male compared to female piglets during normotension which was blunted by SNP. During hypotension, pial artery dilation (PAD) was impaired more in the male than the female after FPI. However, SNP did not improve hypotensive PAD after FPI in females and paradoxically caused vasoconstriction in males. SNP did not prevent reductions in CBF, CPP or autoregulatory index during combined hypotension and FPI in either sex. SNP aggravated ERK MAPK upregulation after FPI. These data indicate that despite prevention of reductions in CBF after FPI, SNP does not prevent impairment of autoregulation during hypotension after FPI. These data suggest that therapies directed at a purely hemodynamic increase in CPP will fail to improve outcome during combined TBI and hypotension. (C) 2010 Elsevier B.V. All rights reserved.	[Armstead, William M.; Kiessling, J. Willis; Kofke, W. Andrew] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Armstead, William M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol Pediat & Neurol Surg, Seattle, WA 98195 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD57355]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD057355] Funding Source: NIH RePORTER	This research was funded by a grant from the National Institutes of Health, HD57355 (WMA).	Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Armstead WM, 2007, J CEREBR BLOOD F MET, V27, P1702, DOI 10.1038/sj.jcbfm.9600473; Armstead WM, 2010, J NEUROTRAUM, V27, P391, DOI 10.1089/neu.2009.1094; Armstead WM, 2009, J CEREBR BLOOD F MET, V29, P524, DOI 10.1038/jcbfm.2008.142; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Joshi S, 2003, ANESTHESIOLOGY, V98, P412, DOI 10.1097/00000542-200302000-00022; Laher I, 2001, J CEREBR BLOOD F MET, V21, P887, DOI 10.1097/00004647-200108000-00001; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Newacheck PW, 2004, PEDIATRICS, V114, P79, DOI 10.1542/peds.114.1.79; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	20	20	22	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 12	2010	1330						142	150		10.1016/j.brainres.2010.03.024			9	Neurosciences	Neurosciences & Neurology	599FP	WOS:000277896800014	20298682	Green Accepted			2021-06-18	
J	Bian, XX; Yuan, XS; Qi, CP				Bian, Xiao-xing; Yuan, Xue-song; Qi, Chuan-ping			Effect of Recombinant Human Erythropoietin on Serum S100B Protein and Interleukin-6 Levels After Traumatic Brain Injury in the Rat	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						erythropoietin; traumatic brain injury; S100B protein; interleukin-6	NEONATAL HYPOXIA/ISCHEMIA; HEAD TRAUMA; NEUROPROTECTION; NEUROGENESIS; CYTOKINE; RECEPTOR; EDEMA	Erythropoietin (EPO) has a neuroprotective effect in the animal model of ischemia/hypoxia, but the mechanisms underlying the EPO effect in traumatic brain injury (TBI) are not well understood. This study examined the potential neuroprotective mechanisms of recombinant human EPO (rhEPO) in rats after TBI. Sixty healthy adult male Sprague-Dawley rats were randomly divided into 5 groups: 1000 U/kg rhEPO-treated, 3000 U/kg rhEPO-treated, 5000 U/kg rhEPO-treated, citicoline, and normal saline (control) groups. The TBI model was based on the modified Feeney's free falling model. Serum samples were collected at 6 hours, 24 hours, 3 days, 5 days, and 7 days after trauma. The serum S100B protein and interleukin-6 (IL-6) levels were measured after treatment in each group with double antibody sandwich enzyme-linked immunosorbent assay. Both serum S100B protein and IL-6 levels were significantly lower in 3000 U/kg rhEPO-treated and 5000 U/kg rhEPO-treated groups (p < 0.001). The decrease in serum S100B protein level was correlated with the dosage of rhEPO. Medium doses of rhEPO achieved the optimum decreases in the serum IL-6 level. Therefore, inhibition of the composition and secretion of S100B protein and IL-6 levels by EPO might be one of the mechanisms involved in decreasing inflammatory reaction in the brain, and may be responsible for the neuroprotective effect after TBI.	[Bian, Xiao-xing; Yuan, Xue-song] Jiangsu Univ, Affiliated Wujin Hosp, Dept Neurosurg, Changzhou 213002, Jiangsu, Peoples R China; [Qi, Chuan-ping] Jiangsu Univ, Affiliated Wujin Hosp, Dept Ctr Lab, Changzhou 213002, Jiangsu, Peoples R China	Bian, XX (corresponding author), Jiangsu Univ, Affiliated Wujin Hosp, Dept Neurosurg, Changzhou 213002, Jiangsu, Peoples R China.	cedar.y@163.com					Chen Da-qing, 2005, Chin J Traumatol, V8, P245; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hartley CE, 2008, J NEUROSURG, V109, P708, DOI 10.3171/JNS/2008/109/10/0708; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Keller M, 2006, NEUROBIOL DIS, V24, P357, DOI 10.1016/j.nbd.2006.07.007; King CE, 2007, EXP NEUROL, V205, P48, DOI 10.1016/j.expneurol.2007.01.017; Lima JE, 2006, BRAZ J MED BIOL RES, V39, P129, DOI 10.1590/S0100-879X2006000100015; Liu RQ, 2006, J NEUROCHEM, V96, P1101, DOI 10.1111/j.1471-4159.2005.03597.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Okutan O, 2008, SURG NEUROL, V70, P498, DOI 10.1016/j.surneu.2007.07.061; Ozisik K, 2006, TRANSPLANT P, V38, P2784, DOI 10.1016/j.transproceed.2006.08.100; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Ozturk E, 2008, PROG NEURO-PSYCHOPH, V32, P81, DOI 10.1016/j.pnpbp.2007.07.016; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Straume-Naesheim TM, 2008, NEUROSURGERY, V62, P1297, DOI 10.1227/01.neu.0000333301.34189.3d; Sun Y, 2005, STROKE, V36, P1672, DOI 10.1161/01.STR.0000173406.04891.8c; Toth C, 2008, NEUROSCIENCE, V154, P767, DOI 10.1016/j.neuroscience.2008.03.052; van der Kooij MA, 2008, BRAIN RES REV, V59, P22, DOI 10.1016/j.brainresrev.2008.04.007; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	29	20	23	0	2	JAPAN NEUROSURGICAL SOC	TOKYO	5-25-16 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105	1349-8029		NEUROL MED-CHIR	Neurol. Med.-Chir.	MAY	2010	50	5					361	365		10.2176/nmc.50.361			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	596QX	WOS:000277701300003	20505289	Bronze			2021-06-18	
J	Demakis, GJ; Rimland, CA				Demakis, George J.; Rimland, Casey A.			Untreated Mild Traumatic Brain Injury in a Young Adult Population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Brain injury; Neuropsychology; Treatment; Young adult	UNITED-STATES; EPIDEMIOLOGY	The current study was conducted to determine (a) the demographic and injury characteristics of individuals who did not receive treatment for mild brain injury and (b) the reasons these individuals do not receive or seek treatment. In a large sample of undergraduate students initially surveyed via an on-line questionnaire (n = 1,853), 35% of those who responded to a subsequent survey acknowledged that they had experienced at least one mild traumatic brain injury (TBI) for which they were not treated. Compared with those who were treated for each TBI, those who were untreated were more likely to be men and were less likely to report persisting symptoms 3 months after the injury. There were no differences in demographics or injury characteristics (e.g., length of time unconscious) between groups. Of those with an untreated TBI, the most common reasons for not seeking treatment were that the symptoms resolved quickly and that they were neither bothersome nor disruptive. Findings are discussed in terms of research on recovery from mild TBI.	[Demakis, George J.; Rimland, Casey A.] Univ N Carolina, Dept Psychol, Charlotte, NC 28223 USA	Demakis, GJ (corresponding author), Univ N Carolina, Dept Psychol, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	gdemakis@uncc.edu		Rimland, Casey/0000-0002-5187-6921			Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Wang PS, 2005, ARCH GEN PSYCHIAT, V62, P629, DOI 10.1001/archpsyc.62.6.629	13	20	20	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2010	25	3					191	196		10.1093/arclin/acq004			6	Psychology, Clinical; Psychology	Psychology	587MC	WOS:000276995600004	20197295	Bronze			2021-06-18	
J	Fang, R; Dorlac, GR; Allan, PF; Dorlac, WC				Fang, Raymond; Dorlac, Gina R.; Allan, Patrick F.; Dorlac, Warren C.			Intercontinental aeromedical evacuation of patients with traumatic brain injuries during Operations Iraqi Freedom and Enduring Freedom	NEUROSURGICAL FOCUS			English	Article						critical care; traumatic brain injury; military medicine; war; wounds and injuries	PROPOFOL INFUSION SYNDROME	Traumatic brain injury contributes significantly to military combat morbidity and mortality. No longer maintaining comprehensive medical care facilities throughout the world, the US military developed a worldwide trauma care system making the patient the moving part of the system. Life-saving interventions are performed early, and essential care is delivered at forward locations. Patients then proceed successively through increasingly capable levels of care culminating with arrival in the US. Proper patient selection and thorough mission preparation are crucial to the safe and successful intercontinental aeromedical evacuation of critical brain-injured patients during Operations Iraqi Freedom and Enduring Freedom. (DOI: 10.3171/2010.2.FOCUS1043)	[Fang, Raymond] Landstuhl Reg Med Ctr, Div Surg, APO, AE 09180 USA; [Dorlac, Gina R.; Dorlac, Warren C.] Univ Cincinnati, USAF, Ctr Sustainment Trauma & Readiness Skills, Cincinnati, OH 45221 USA	Fang, R (corresponding author), Landstuhl Reg Med Ctr, Div Surg, 402 Box 506, APO, AE 09180 USA.	Raymond.Fang@amedd.army.mil					Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Beninati W, 2008, CRIT CARE MED, V36, pS370, DOI 10.1097/CCM.0b013e31817e3143; CAMPION EM, 2010, J SURG RES, V158, P214; Carlton PK, 2008, CRIT CARE MED, V36, pS255, DOI 10.1097/CCM.0b013e31817da609; GOODMAN MD, 2009, J SURG RES; Grant GA, 2007, J TRAUMA, V62, pS100, DOI 10.1097/TA.0b013e318065b42c; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; *PUBL AFF OFF AIR, 2008, C17 US AIR FORC PUBL; Rosen DJ, 2007, J TRAUMA, V63, P443, DOI 10.1097/TA.0b013e31809fe910; *US DEP DEF, 2004, EM WAR SURG 3 US REV, P5; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x	11	20	22	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	MAY	2010	28	5							E11	10.3171/2010.2.FOCUS1043			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	589ZU	WOS:000277193600011	20568927				2021-06-18	
J	Fitzharris, M; Bowman, D; Ludlow, K				Fitzharris, Michael; Bowman, Diana; Ludlow, Karinne			Factors associated with return-to-work and health outcomes among survivors of road crashes in Victoria	AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH			English	Article						accidents; disability; pain; quality of life; wounds; injuries; compensation	SPINAL-CORD-INJURY; TRAUMATIC BRAIN INJURY; COMPENSATION; DETERMINANTS; DISABILITY; EMPLOYMENT; PREDICTION; SEVERITY; ACCIDENT; LIFE	Objective: To explore the relationships between injury, disability, work role and return-to-work outcomes following admission to hospital as a consequence of injury sustained in a road crash Design and setting: Prospective cohort study of patients admitted to an adult trauma centre and two metropolitan teaching hospitals in Victoria, Australia Participants were interviewed in hospital, 2.5 and eight months post-discharge Participants: Participants were 60 employed and healthy adults aged 18 to 59 years admitted to hospital in the period February 2004 to March 2005 Results: Despite differences in health between the lower extremity fracture and non-fracture groups eight months post-crash the proportions having returned to work was approximately 90% Of those returning to work, 44% did so in a different role After adjustment for baseline parameters, lower extremity injuries were associated with a slower rate of return to work (HR. 0 31, 95%CI 0 16-0 58) as was holding a manual occupation (HR 0 16, 95 %CI 0 09-0 57) There were marked differences in physical health between and within the injury groups at both follow-up periods Conclusions: These results demonstrate that both injury type and severity and the nature of ones occupation have a considerable influence on the rate and pattern of return to work following injury Further, persisting disability has a direct influence on the likelihood of returning to work The implications of these findings and the types of data required to measure outcome post-injury are discussed	[Fitzharris, Michael; Bowman, Diana] Monash Univ, Accid Res Ctr, Clayton, Vic 3800, Australia; [Bowman, Diana] Univ Melbourne, Melbourne Sch Populat Hlth, Melbourne, Vic 3010, Australia; [Ludlow, Karinne] Monash Univ, Fac Law, Clayton, Vic 3800, Australia	Fitzharris, M (corresponding author), Monash Univ, Accid Res Ctr, Clayton, Vic 3800, Australia.			Fitzharris, Michael/0000-0002-3691-6868; Ludlow, Karinne/0000-0002-3179-1349	MUARC Foundation; Monash UniversityMonash University; MUARC Doctoral Students Research Fund (DSRF)	The data collected here was done so as part of the first author's PhD candidature at Monash University under the supervision of Professor Brian Fildes, Dr Judith Charlton and Professor Claes Tingvall During this time Michael Fitzharns was a Research Fellow in the Department of Trauma Surgery, The Alfred. the National Trauma Research Institute and the Department of Emergency Medicine, Southern Health The authors gratefully acknowledge the significant contribution of each participant as well as that of the treating nursing and medical staff of the hospitals involved The authors wish to thank Professor Thomas Kossmann, Professor Johannes Wenzel and Dr Pam Rosenganen for supporting the study Thanks also to Louise Nuzgemeyer RN, Manager, Trauma Registry, The Alfred. Michelle Sratze RN & Claire Sage RN. Trauma Care-Coordinators, The Alfred, and Metz Lindsay RN, Southern Health, for vital support without which this research would not be possible Michael Fitzharns acknowledges the financial contribution of the MUARC Foundation and Monash University for providing stipend funding and the MUARC Doctoral Students Research Fund (DSRF) for supporting this research activity The views expiessed are those of the authors and do not necessarily represent those of Monash University, the Accident Research Centre, the MUARC Foundation, Alfred Health or Southern Health.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; [Anonymous], 1998, ABBR INJ SCAL AIS 19; *AUSTR BUR STAT, 1997, 12200 AUSTR BUR STAT; Australian Bureau of Statistics, 1995, 43990 AUSTR BUR STAT; Babor TF., 2001, AUDIT ALCOHOL USE DI, V2nd; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; Bryant R.A., 2000, ACUTE STRESS DISORDE; *BUR TRANSP EC, 2000, ROAD CRUSH COSTS AUS; BUTLER RJ, 1995, IND LABOR RELAT REV, V48, P452, DOI 10.2307/2524774; Cassidy JD, 2000, NEW ENGL J MED, V342, P1179, DOI 10.1056/NEJM200004203421606; Fitzharris Michael, 2007, Traffic Inj Prev, V8, P309, DOI 10.1080/15389580701216533; Gabbe BJ, 2007, MED J AUSTRALIA, V187, P14, DOI 10.5694/j.1326-5377.2007.tb01108.x; Harris I, 2005, JAMA-J AM MED ASSOC, V293, P1644, DOI 10.1001/jama.293.13.1644; Holtslag HR, 2007, CLIN REHABIL, V21, P373, DOI 10.1177/0269215507072084; Krause JS, 1999, ARCH PHYS MED REHAB, V80, P1492; Krause N, 2001, AM J IND MED, V40, P464, DOI 10.1002/ajim.1116; Leduc BE, 2002, DISABIL REHABIL, V24, P196, DOI 10.1080/09638280110067603; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; Matthews LR, 2005, INT J PSYCHOL, V40, P339, DOI 10.1080/00207590444000320; Matthews LR, 2005, BEHAV RES THER, V43, P475, DOI 10.1016/j.brat.2004.03.008; Mayou R, 2002, PSYCHOL MED, V32, P671, DOI 10.1017/S0033291702005470; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; MORRIS JA, 1991, J TRAUMA, V31, P827, DOI 10.1097/00005373-199106000-00014; *NAT CTR CLASS HLT, 2000, ICD10AM NCCH; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Ponsford J., 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Read KM, 2004, J TRAUMA, V57, P815, DOI 10.1097/01.TA.0000136289.15303.44; Siegel S., 1988, NONPARAMETRIC STAT B; *STAT CORP, 2003, STATA STAT SOFTW COM; TEASDALE G, 1974, LANCET, V2, P81; Vittinghoff E, 2005, STAT BIOL HEALTH, pVII; Ware JE., 2001, SF 36 PHYS MENTAL HL, V2; World Health Organization ( WHO ), 2002, COMM LANG FUNCT DIS; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Yasuda S, 2002, NEUROREHABILITATION, V17, P177	41	20	20	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1326-0200	1753-6405		AUST NZ J PUBL HEAL	Aust. N. Z. Publ. Health	APR	2010	34	2					153	159		10.1111/j.1753-6405.2010.00500.x			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	586WE	WOS:000276944800010	23331359	Bronze			2021-06-18	
J	Huang, RQ; Cheng, HL; Zhao, XD; Dai, W; Zhuang, Z; Wu, Y; Liu, Y; Shi, JX				Huang, Ren-qiang; Cheng, Hui-lin; Zhao, Xu-dong; Dai, Wei; Zhuang, Zong; Wu, Yi; Liu, Yong; Shi, Ji-xin			Preliminary study on the effect of trauma-induced secondary cellular hypoxia in brain injury	NEUROSCIENCE LETTERS			English	Article						Trauma brain injury; Hypoxia; Cerebral cortex; Sprague-Dawley rat	GROWTH-FACTOR-BETA; FOCAL CEREBRAL-ISCHEMIA; INDUCIBLE FACTOR-1; RAT-BRAIN; EXPRESSION; TISSUE; HOMEOSTASIS; INDUCTION; NEURONS; CELLS	Secondary cerebral hypoxia has recently been shown to play an important role in the outcome of patients suffering from traumatic brain injury (TBI). However, the precise mechanisms underlying secondary cerebral hypoxia are complex and interrelated. In this study, we investigate the effect of hypoxia within a rat model of trauma-induced late cerebral cortex injury. Using the hypoxia marker pimonidazole, we verified and isolated areas of the cortex that had suffered hypoxic damage. Using subsequent reverse-transcriptase PCR analyses, we found that the expressions of both transforming growth factor beta 1 (TGF-beta 1) and hypoxia-inducible factor-1 alpha (HIF-1 alpha) increased significantly under hypoxic conditions induced by TBI compared with uninjured control animals. In addition, the maximum mRNA expression of TGF-beta 1 and HIF-1 alpha was found at 3 days and 12 h after TBI, respectively. Our data suggest that secondary cerebral hypoxia injury involves various cytokines including TGF-beta 1 and HIF-1 alpha. Furthermore, upon immunohistochemical analysis, both TGF-beta 1 and HIF-1 alpha expression were almost localized in the same types of cells by using immunohistochemical study. These results may have important implications in the understanding of trauma-induced secondary cerebral hypoxia injury. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Huang, Ren-qiang; Cheng, Hui-lin; Shi, Ji-xin] Second Mil Med Univ Shanghai, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China; [Cheng, Hui-lin; Zhao, Xu-dong; Dai, Wei; Zhuang, Zong; Wu, Yi; Shi, Ji-xin] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu Prov, Peoples R China; [Liu, Yong] Kyoto Univ, Inst Res Reactor, Particle Radiat Oncol Res Ctr, Osaka 59004, Japan	Shi, JX (corresponding author), Second Mil Med Univ Shanghai, Jinling Hosp, Sch Med, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	aboo2710@163.com; jxshi@yahoo.cn					Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Durante W, 2001, CIRCULATION, V103, P1121, DOI 10.1161/01.CIR.103.8.1121; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ghafar MA, 2002, LAB INVEST, V82, P903, DOI 10.1097/01.LAB.0000021135.87203.92; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kim ES, 1998, MOL BRAIN RES, V62, P122, DOI 10.1016/S0169-328X(98)00217-4; KLEMPT ND, 1992, MOL BRAIN RES, V13, P93, DOI 10.1016/0169-328X(92)90048-G; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Liu Y, 2009, J RADIAT RES, V50, P233, DOI 10.1269/jrr.08112; Marmarou A, 2005, ACT NEUR S, V95, P277; Martin C, 1998, AM J OBSTET GYNECOL, V178, P527, DOI 10.1016/S0002-9378(98)70433-8; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; Mazzeo AT, 2007, J NEUROL SCI, V261, P1, DOI 10.1016/j.jns.2007.04.026; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; Raleigh JA, 1998, INT J RADIAT ONCOL, V42, P727, DOI 10.1016/S0360-3016(98)00329-0; ROBERTS JT, 1986, BRIT J RADIOL, V59, P107, DOI 10.1259/0007-1285-59-698-107; Ruocco A, 1999, J CEREBR BLOOD F MET, V19, P1345, DOI 10.1097/00004647-199912000-00008; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Vincent KA, 2000, CIRCULATION, V102, P2255; WANG XK, 1995, BRAIN RES BULL, V36, P607, DOI 10.1016/0361-9230(94)00243-T; Westbury CB, 2007, BRIT J RADIOL, V80, P934, DOI 10.1259/bjr/25046649; Zhu Y, 2002, J NEUROSCI, V22, P3898, DOI 10.1523/JNEUROSCI.22-10-03898.2002	27	20	22	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAR 31	2010	473	1					22	27		10.1016/j.neulet.2010.02.011			6	Neurosciences	Neurosciences & Neurology	588MN	WOS:000277074500005	20152885				2021-06-18	
J	Peltier, J; Verclytte, S; Delmaire, C; Deramond, H; Pruvo, JP; Le Gars, D; Godefroy, O				Peltier, Johann; Verclytte, Sebastien; Delmaire, Christine; Deramond, Herve; Pruvo, Jean-Pierre; Le Gars, Daniel; Godefroy, Olivier			Microsurgical anatomy of the ventral callosal radiations: new destination, correlations with diffusion tensor imaging fiber-tracking, and clinical relevance	JOURNAL OF NEUROSURGERY			English	Article						corpus callosum; white matter; fiber dissection technique; anatomy; MR imaging	HUMAN CORPUS-CALLOSUM; CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL EVALUATION; SIGNAL INTENSITY; SCHIZOPHRENIA; 3RD-VENTRICLE; ABNORMALITIES; CONNECTIONS; CALLOSOTOMY; ANTERIOR	Object. In the current literature, there is a lack of a detailed map of the origin, course, and connections of the ventral callosal radiations of the human brain. Methods. The authors used an older dissection technique based on a freezing process as well as diffusion tensor imaging to investigate this area of the human brain. Results. The authors demonstrated interconnections between areas 11, 12, and 25 for the callosal radiations of the trunk and rostrum of the corpus callosum; between areas 9, 10, and 32 for the genu; and between areas 6, 8, and 9 for the ventral third of the body. The authors identified new ventral callosal connections crossing the rostrum between both temporal poles and coursing within the temporal stem, and they named these connections the "callosal radiations of Peltier." They found that the breadth of the callosal radiations slightly increases along their course from the rostrum to the first third of the body of the corpus callosum. Conclusions. The fiber dissection and diffusion tensor imaging techniques are complementary not only in their application to the study of the commissural system in the human brain, but also in their practical use for diagnosis and surgical planning. Further investigations, neurocognitive tests, and other contributions will permit elucidation of the functional relevance of the newly identified callosal radiations in patients with disease involving the ventral corpus callosum. (DOI: 10.3171/2009.6.JNS081712)	[Peltier, Johann; Le Gars, Daniel] Univ Picardy Jules Verne, Lab Anat & Organogenesis, Amiens, France; [Verclytte, Sebastien; Delmaire, Christine; Pruvo, Jean-Pierre; Godefroy, Olivier] Lille Univ Hosp, Dept Neuroradiol, Lille, France; [Peltier, Johann] Univ Picardy Jules Verne, CNRS, UMR 8160, Lab Funct Neurosci & Pathol, Amiens, France; [Deramond, Herve] Amiens Univ Hosp, Dept Neuroradiol, F-80054 Amiens 1, France	Peltier, J (corresponding author), Amiens Univ Hosp, Dept Neurosurg, Victor Pauchet Pl, F-80054 Amiens 1, France.	peltier.johann@chu-amiens.fr	Godefroy, Olivier/D-6117-2012	Godefroy, Olivier/0000-0001-6789-6620			ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Arguin M, 2000, NEUROPSYCHOLOGIA, V38, P283, DOI 10.1016/S0028-3932(99)00077-9; BENTIN S, 1984, NEUROPSYCHOLOGIA, V22, P601, DOI 10.1016/0028-3932(84)90024-1; Boussaoud D, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-67; Brambilla P, 2004, J NEUROL NEUROSUR PS, V75, P221; Carr DB, 1998, SYNAPSE, V29, P193; CASTROCALDAS A, 1989, NEUROSURGERY, V25, P442, DOI 10.1227/00006123-198909000-00020; CLARK CR, 1989, BRAIN, V112, P165, DOI 10.1093/brain/112.1.165; DAVID AS, 1994, BEHAV BRAIN RES, V64, P203, DOI 10.1016/0166-4328(94)90132-5; Debierre C. M., 1907, CERVEAU MOELLE EPINI; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; DERIBET RM, 1957, ANATOMIE SCHEMATIQUE; DIMOND SJ, 1977, BRAIN, V100, P543, DOI 10.1093/brain/100.3.543; Duffau H, 2004, J NEUROSURG, V100, P431, DOI 10.3171/jns.2004.100.3.0431; EGAAS B, 1995, ARCH NEUROL-CHICAGO, V52, P794, DOI 10.1001/archneur.1995.00540320070014; Foong J, 2000, J NEUROL NEUROSUR PS, V68, P242, DOI 10.1136/jnnp.68.2.242; Friedman MA, 2003, NEUROSURGERY, V52, P791, DOI 10.1227/01.NEU.0000053367.94965.6B; Giedd JN, 1999, PROG NEURO-PSYCHOPH, V23, P571; HABIB M, 1994, REV NEUROPSYCHOL, V4, P69; Hutter B O, 1997, J Neurosurg Sci, V41, P123; JEEVES MA, 1979, J NEUROL NEUROSUR PS, V42, P134, DOI 10.1136/jnnp.42.2.134; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; KAWAGUCHI Y, 1992, EXP BRAIN RES, V88, P33, DOI 10.1007/BF02259126; Keshavan MS, 2002, J NEUROL NEUROSUR PS, V72, P757, DOI 10.1136/jnnp.72.6.757; Klingler J, 1935, SCHWEIZ ARCH NEUROL, V36, P247; Lassonde M, 1997, J Neurosurg Sci, V41, P67; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Mac Master FP, 1999, PROG NEURO-PSYCHOPH, V23, P601; Mazza M, 2004, BRAIN COGNITION, V55, P525, DOI 10.1016/j.bandc.2004.03.005; Paturet G., 1964, TRAITE ANATOMIE HUMA, VIV; PETERSON BS, 1994, PSYCHIAT RES, V55, P86; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; RAINE A, 1990, ARCH GEN PSYCHIAT, V47, P1060; Rhoton AL, 2007, NEUROSURGERY, V61, P1, DOI 10.1227/01.NEU.0000280027.92382.2B; Rumsey JM, 1996, BIOL PSYCHIAT, V39, P769, DOI 10.1016/0006-3223(95)00225-1; SAPPEY PC, 1877, TRAITE ANATOMIE DESC, V3; Suwanwela NC, 2002, J NEUROL NEUROSUR PS, V72, P533; TESTUT L, 1948, TRAITE ANATOMIE HUMA, V1; Velut S, 1998, NEUROCHIRURGIE, V44, P17; Winkler PA, 1997, NEUROSURGERY, V40, P973, DOI 10.1097/00006123-199705000-00020; Winkler PA, 1999, NEUROSURGERY, V45, P309, DOI 10.1097/00006123-199908000-00023; Wong TT, 2006, CHILD NERV SYST, V22, P999, DOI 10.1007/s00381-006-0133-4; Yang Y, 2008, SURG NEUROL, V70, P252, DOI 10.1016/j.surneu.2007.06.076	43	20	20	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2010	112	3					512	519		10.3171/2009.6.JNS081712			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	562IQ	WOS:000275043900007	19612974				2021-06-18	
J	Newberry, A; Sherwood, P; Hricik, A; Bradley, S; Kuo, J; Crago, E; Hoffman, LA; Given, BA				Newberry, Alyssa; Sherwood, Paula; Hricik, Allison; Bradley, Sarah; Kuo, Jein; Crago, Elizabeth; Hoffman, Leslie A.; Given, Barbara A.			Understanding Recruitment and Retention in Neurological Research	JOURNAL OF NEUROSCIENCE NURSING			English	Article							COGNITIVE STATUS EXAMINATION; MENTAL-STATE-EXAMINATION; CAREGIVERS; CANCER; CHALLENGES; STRATEGIES; SURVIVORS; CAPACITY	Cognitive deficits in participants and the abrupt and traumatic way in which many neurological conditions present are two examples of the unique challenges in recruiting and retaining participants with neurological injury for research studies. The purpose of this investigation was to identify obstacles to recruitment and retention in three ongoing research studies. These Studies involve persons with neurological disorders across the continuum of care, from those newly diagnosed and with emergent presentation to those with more established chronic neurological conditions. For this analysis, we evaluated the effectiveness of the strategies employed to improve participation rates. The first study was a project funded by the National Institutes of Health designed to identify biomarkers of vasospasm in persons (n = 496) with aneurysmal subarachnoid hemorrhage who presented to the neurovascular intensive care unit (National Institute of Nursing Research, RO1 NR004339). The purpose of the second study was to examine biobehavioral interactions in family caregivers (n = 59) of persons with a primary malignant brain tumor recruited in the community setting. The third project involved recruiting persons (n = 1,019) within an outpatient neurosurgical center to participate in a research registry. To determine differential effectiveness of strategies, consent and attrition rates were calculated at serial points over time in three studies, and recruitment and retention strategies were compared. Sentinel time points in participants' disease trajectories played a key role in determining whether those who were approached to participate gave consent and were retained, particularly in the Studies involving persons with aneurysmal subarachnoid hemorrhage (consent = 85%; retention = 89%) and persons with primary malignant brain tumors and their caregivers (consent = 68%; retention = 83%). In addition, several specific recruiter and interviewer training techniques were associated with higher recruitment and retention. Targeted strategies to improve participation rates are vital for neuroscience nurses involved in any aspect of clinical research, including those Who Conduct Studies, assist with data collection, and recruit potential participants.	[Newberry, Alyssa; Sherwood, Paula; Hricik, Allison; Bradley, Sarah; Kuo, Jein; Crago, Elizabeth; Hoffman, Leslie A.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA; [Given, Barbara A.] Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA	Newberry, A (corresponding author), Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA.	agn8@pitt.edu			 [R01 CA 118711001];  [R01 NR004339-06]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA118711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004339, R01NR011044] Funding Source: NIH RePORTER	The authors acknowledge the following Studies: "Mind-Body Interactions in Neuro-Oncology Caregiving" (Sherwood, principal investigator; Grant R01 CA 118711001) and "The Role of 20-Hete on Vasospasm-Induced Ischemia After SAH" (Hoffman, principal investigator; Grant R01 NR004339-06).	Adams J, 1997, CONTROL CLIN TRIALS, V18, P14, DOI 10.1016/S0197-2456(96)00132-8; Aitken Leanne, 2003, Int J Nurs Pract, V9, P338, DOI 10.1046/j.1440-172X.2003.00449.x; Connell CM, 2001, ALZ DIS ASSOC DIS, V15, P137, DOI 10.1097/00002093-200107000-00005; Dancy BL, 2004, NURS OUTLOOK, V52, P234, DOI 10.1016/j.outlook.2004.04.012; Dilworth-Anderson P, 2005, ALZ DIS ASSOC DIS, V19, P256, DOI 10.1097/01.wad.0000190803.11340.66; Given Barbara, 2002, Oncol Nurs Forum, V29, P949, DOI 10.1188/02.ONF.949-956; GIVEN BP, 1993, FAMILY HOME CARE CAN; GIVEN BP, 1998, FAMILY HOME CARE CAN; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Kim SYH, 2006, BEHAV SCI LAW, V24, P469, DOI 10.1002/bsl.702; Krupp W, 2000, ACTA NEUROCHIR, V142, P233, DOI 10.1007/s007010050030; Murphy MR, 2007, RES NURS HEALTH, V30, P347, DOI 10.1002/nur.20186; Northouse LL, 2006, RES NURS HEALTH, V29, P199, DOI 10.1002/nur.20128; Ott CD, 2006, CANCER NURS, V29, P21, DOI 10.1097/00002820-200601000-00004; Ransom S, 2006, RES NURS HEALTH, V29, P190, DOI 10.1002/nur.20129; Sadler GR, 2007, CONTEMP CLIN TRIALS, V28, P423, DOI 10.1016/j.cct.2006.11.006; Roper BL, 1996, NEUROPSY NEUROPSY BE, V9, P54; SCHWAMM LH, 1987, ANN INTERN MED, V107, P486, DOI 10.7326/0003-4819-107-4-486; Smith SD, 2008, TOP STROKE REHABIL, V15, P593, DOI 10.1310/tsr1506-593; Sullivan-Bolyai S, 2007, WESTERN J NURS RES, V29, P486, DOI 10.1177/0193945907299658; Tansey CM, 2007, INTENS CARE MED, V33, P2051, DOI 10.1007/s00134-007-0817-6; Thompson EE, 1996, J CONSULT CLIN PSYCH, V64, P861, DOI 10.1037/0022-006X.64.5.861	22	20	20	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	FEB	2010	42	1					47	57		10.1097/JNN.0b013e3181c1fdd9			11	Clinical Neurology; Nursing	Neurosciences & Neurology; Nursing	552RQ	WOS:000274311500007	20187349	Green Accepted			2021-06-18	
J	Chen, AS; McEwen, ML; Sun, SX; Ravikumar, R; Springer, JE				Chen, Anshu; McEwen, Melanie L.; Sun, Shixin; Ravikumar, Rangaswamyrao; Springer, Joe E.			Proteomic and Phosphoproteomic Analyses of the Soluble Fraction following Acute Spinal Cord Contusion in Rats	JOURNAL OF NEUROTRAUMA			English	Article						contusion; phosphoproteome; proteome; spinal cord injury; 2-DE	CASPASE-3 APOPTOTIC CASCADE; HEAT-SHOCK PROTEINS; GENE-EXPRESSION; COMPRESSION TRAUMA; SURROGATE MARKERS; ALPHA-CRYSTALLIN; TIME COURSE; CELL-DEATH; INJURY; BRAIN	Traumatic spinal cord injury (SCI) causes marked neuropathological changes in the spinal cord, resulting in limited functional recovery. Currently, there are no effective treatments, and the mechanisms underlying these neuropathological changes are not completely understood. In this study, two-dimensional gel electrophoresis coupled with mass spectrometry was used to investigate injury-related changes in the abundance (SYPRO Ruby stain) and phosphorylation (Pro-Q Diamond stain) of proteins from the soluble fraction of the lesion epicenter at 24 h following SCI. Over 1500 SYPRO Ruby-stained spots and 100 Pro-Q Diamond-stained spots were examined. We identified 26 unique proteins within 38 gel spots that differentially changed in abundance, phosphorylation, or both in response to SCI. Protein redundancies among the gel spots were likely due to differences in proteolysis, post-translational modifications, and the existence of isoforms. The proteins affected were blood-related proteins, heat-shock proteins, glycolytic enzymes, antioxidants, and proteins that function in cell structure, cell signaling, DNA damage, and protein degradation. These protein changes post injury may suggest additional avenues of investigation into the underlying molecular mechanisms responsible for the pathophysiological consequences of SCI.	[Chen, Anshu; McEwen, Melanie L.; Springer, Joe E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Chen, Anshu; McEwen, Melanie L.; Ravikumar, Rangaswamyrao; Springer, Joe E.] Univ Kentucky, Dept Phys Med & Rehabil, Lexington, KY 40536 USA; [Chen, Anshu; McEwen, Melanie L.; Ravikumar, Rangaswamyrao; Springer, Joe E.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Sun, Shixin] Appl Biosyst Inc, Framingham, MA USA	Springer, JE (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B469 BBSRB,741 S Limestone, Lexington, KY 40536 USA.	jspring@uky.edu			PHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NS46380]; Craig H. Neilsen Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046380] Funding Source: NIH RePORTER	The authors would like to thank Anne Stanley and Dr. Bruce A. Stanley in the Proteomics/Mass Spectrometry Core Facility at Pennsylvania State University College of Medicine for helping with the protein identification. This work was supported by PHS grant NS46380 (J.E.S.), an endowment from the Cardinal Hill Rehabilitation Hospital (J.E.S.), and a grant from the Craig H. Neilsen Foundation (M. L. M.).	Aimone JB, 2004, EXP NEUROL, V189, P204, DOI 10.1016/j.expneurol.2004.05.042; ANDERSON DK, 1980, J NEUROSURG, V53, P375, DOI 10.3171/jns.1980.53.3.0375; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Brown IR, 2007, ANN NY ACAD SCI, V1113, P147, DOI 10.1196/annals.1391.032; Cao F, 2008, J CLIN NEUROSCI, V15, P541, DOI 10.1016/j.jocn.2007.05.014; Cao QL, 2005, EXP NEUROL, V191, pS3, DOI 10.1016/j.expneurol.2004.08.026; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; Cox B, 2005, METHODS, V35, P303, DOI 10.1016/j.ymeth.2004.08.021; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Ding QX, 2006, PROTEOMICS, V6, P505, DOI 10.1002/pmic.200500296; Fagan A, 2007, PROTEOMICS, V7, P2162, DOI 10.1002/pmic.200600898; Fialho E, 2005, ARCH BIOCHEM BIOPHYS, V436, P246, DOI 10.1016/j.abb.2005.01.005; Ganea E, 2001, CURR PROTEIN PEPT SC, V2, P205, DOI 10.2174/1389203013381107; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Grant P, 2000, J NEUROCYTOL, V29, P843, DOI 10.1023/A:1010999509251; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; GUTIERREZ JA, 1995, BIOCHEM J, V305, P197, DOI 10.1042/bj3050197; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Hwan AY, 2006, BIOCHEM BIOPH RES CO, V348, P560, DOI 10.1016/j.bbrc.2006.07.105; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Kaji A, 2007, EMERG MED CLIN N AM, V25, P735, DOI 10.1016/j.emc.2007.06.012; Kang SK, 2006, PROTEOMICS, V6, P2797, DOI 10.1002/pmic.200500621; Kislinger T, 2006, CELL, V125, P173, DOI 10.1016/j.cell.2006.01.044; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Ling X, 2007, J NEUROSCI RES, V85, P2175, DOI 10.1002/jnr.21362; Liu QL, 2007, CELL, V131, P106, DOI 10.1016/j.cell.2007.08.039; Liu XZ, 1997, J NEUROSCI, V17, P5395; Loy DN, 2005, NEUROSURGERY, V56, P391, DOI 10.1227/01.NEU.0000148906.83616.D2; Lucas JH, 1998, J NEUROPATH EXP NEUR, V57, P937, DOI 10.1097/00005072-199810000-00006; Maikos JT, 2007, J NEUROTRAUM, V24, P492, DOI 10.1089/neu.2006.0149; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McClellan AJ, 2007, CELL, V131, P121, DOI 10.1016/j.cell.2007.07.036; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; McEwen ML, 2005, J HISTOCHEM CYTOCHEM, V53, P809, DOI 10.1369/jhc.4A6467.2005; Nishimura RN, 2005, MUSCLE NERVE, V32, P693, DOI 10.1002/mus.20373; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOBLE LJ, 1987, BRAIN RES, V424, P177, DOI 10.1016/0006-8993(87)91208-X; NOBLE LJ, 1988, EXP NEUROL, V99, P567, DOI 10.1016/0014-4886(88)90173-2; NORDBY HK, 1982, ACTA NEUROCHIR, V65, P93, DOI 10.1007/BF01405445; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Pawson T, 2005, TRENDS BIOCHEM SCI, V30, P286, DOI 10.1016/j.tibs.2005.04.013; Power JHT, 2008, ACTA NEUROPATHOL, V115, P611, DOI 10.1007/s00401-008-0373-3; Ravikumar R, 2007, J NEUROTRAUM, V24, P1618, DOI 10.1089/neu.2007.0329; Robinson MB, 2005, J NEUROSCI, V25, P9735, DOI 10.1523/JNEUROSCI.1912-05.2005; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schoonheim PJ, 2007, PLANT PHYSIOL, V143, P670, DOI 10.1104/pp.106.090159; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 1997, J NEUROCHEM, V68, P2469; Springer JE, 2000, J NEUROSCI, V20, P7246; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Taylor SW, 2003, TRENDS BIOTECHNOL, V21, P82, DOI 10.1016/S0167-7799(02)00037-9; Tsai MC, 2008, MOL CELL PROTEOMICS, V7, P1668, DOI 10.1074/mcp.M800076-MCP200; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang LH, 1996, J NEUROSCI, V16, P6197; Wu XF, 2005, J NEUROCHEM, V93, P943, DOI 10.1111/j.1471-4159.2005.03078.x; Wuermser LA, 2007, ARCH PHYS MED REHAB, V88, pS55, DOI 10.1016/j.apmr.2006.12.002; Yan XD, 2009, J NEUROTRAUM, V26, P179, DOI 10.1089/NEU.2008.0533; Yates DM, 2009, EUR J CELL BIOL, V88, P193, DOI 10.1016/j.ejcb.2008.11.004; Yates JR, 2005, NAT REV MOL CELL BIO, V6, P702, DOI 10.1038/nrm1711; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459	72	20	21	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					263	274		10.1089/neu.2009.1051			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200023	19691422	Green Published			2021-06-18	
J	Dong, XQ; Yang, SB; Zhu, FL; Lv, QW; Zhang, GH; Huang, HB				Dong, Xiao-Qiao; Yang, Song-Bin; Zhu, Fang-Long; Lv, Qing-Wei; Zhang, Guo-Hai; Huang, Hang-Bin			Resistin is associated with mortality in patients with traumatic brain injury	CRITICAL CARE			English	Article							ADIPOKINE GENE-EXPRESSION; HEAD-INJURY; IN-VITRO; MACROPHAGES; ALPHA	Introduction: Recently, we reported that high levels of resistin are present in the peripheral blood of patients with intracerebral hemorrhage and are associated with a poor outcome. However, not much is known regarding the change in plasma resistin and its relation with mortality after traumatic brain injury (TBI). Thus, we sought to investigate change in plasma resistin level after TBI and to evaluate its relation with disease outcome. Methods: Fifty healthy controls and 94 patients with acute severe TBI were included. Plasma samples were obtained on admission and at days 1, 2, 3, 5 and 7 after TBI. Its concentration was measured by enzyme-linked immunosorbent assay. Results: Twenty-six patients (27.7%) died from TBI within 1 month. After TBI, plasma resistin level in patients increased during the 6-hour period immediately after TBI, peaked within 24 hours, plateaued at day 2, decreased gradually thereafter and was substantially higher than that in healthy controls during the 7-day period. A forward stepwise logistic regression selected plasma resistin level (odds ratio, 1.107; 95% confidence interval, 1.014-1.208; P = 0.023) as an independent predictor for 1-month mortality of patients. A multivariate linear regression showed that plasma resistin level was negatively associated with Glasgow Coma Scale score (t = -6.567, P < 0.001). A receiver operating characteristic curve identified plasma resistin cutoff level (30.8 ng/mL) that predicted 1-month mortality with the optimal sensitivity (84.6%) and specificity (75.0%) values (area under curve, 0.854; 95% confidence interval, 0.766-0.918; P < 0.001). Conclusions: Increased plasma resistin level is found and associated with Glasgow Coma Scale score and mortality after TBI.	[Dong, Xiao-Qiao] First Hangzhou Municipal Peoples Hosp, Dept Neurosurg, Hangzhou 310000, Zhejiang, Peoples R China; [Yang, Song-Bin; Zhu, Fang-Long; Lv, Qing-Wei; Zhang, Guo-Hai; Huang, Hang-Bin] Shengzhou Peoples Hosp, Dept Neurosurg, Shenzhou 312400, Peoples R China	Dong, XQ (corresponding author), First Hangzhou Municipal Peoples Hosp, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310000, Zhejiang, Peoples R China.	dxqhyy@163.com					Bokarewa M, 2005, J IMMUNOL, V174, P5789, DOI 10.4049/jimmunol.174.9.5789; Brown R, 2008, NEUROSCI LETT, V432, P73, DOI 10.1016/j.neulet.2007.12.008; Dong XQ, 2010, J CRIT CARE, V25, P243, DOI 10.1016/j.jcrc.2009.09.008; Efstathiou SP, 2007, CLIN CHIM ACTA, V378, P78, DOI 10.1016/j.cca.2006.10.023; Fasshauer M, 2001, BIOCHEM BIOPH RES CO, V288, P1027, DOI 10.1006/bbrc.2001.5874; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kaser S, 2003, BIOCHEM BIOPH RES CO, V309, P286, DOI 10.1016/j.bbrc.2003.07.003; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Lu SC, 2002, FEBS LETT, V530, P158, DOI 10.1016/S0014-5793(02)03450-6; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Pang SS, 2006, CELL MOL IMMUNOL, V3, P29; Patel L, 2003, BIOCHEM BIOPH RES CO, V300, P472, DOI 10.1016/S0006-291X(02)02841-3; Reilly MP, 2005, CIRCULATION, V111, P932, DOI 10.1161/01.CIR.0000155620.10387.43; Silswal N, 2005, BIOCHEM BIOPH RES CO, V334, P1092, DOI 10.1016/j.bbrc.2005.06.202; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Wiesner G, 2006, NEUROREPORT, V17, P1195, DOI 10.1097/01.wnr.0000224776.12647.ba; Wilkinson M, 2007, NEUROENDOCRINOLOGY, V86, P191, DOI 10.1159/000108635	21	20	20	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X			CRIT CARE	Crit. Care		2010	14	5							R190	10.1186/cc9307			5	Critical Care Medicine	General & Internal Medicine	685AN	WOS:000284596500029	21029428	DOAJ Gold, Green Published			2021-06-18	
S	Kabadi, SV; Maher, TJ		Andrews, RJ; Slikker, W; Trembly, B; Patterson, TA		Kabadi, Shruti V.; Maher, Timothy J.			Posttreatment with uridine and melatonin following traumatic brain injury reduces edema in various brain regions in rats	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	9th International Conference on Neuroprotective Agents	SEP 07-11, 2008	Marine Biol Lab, Woods Hole, MA		Marine Biol Lab	uridine; melatonin; edema; traumatic brain injury (TBI)	CEREBRAL-ARTERY OCCLUSION; CDP-CHOLINE; ANTIOXIDANT ENZYMES; NEURONAL DEATH; STROKE MODEL; HEAD TRAUMA; DAMAGE; CITICOLINE; ISCHEMIA; VOLUME	Traumatic brain injury (TBI) is a major health problem and a significant cause of death, disability, and neurobehavioral deficits. We investigated the effect of posttreatment with uridine and melatonin, separate and in combination, on edema in various brain regions following TBI via lateral fluid percussion. Uridine (16 and 32 mg/kg, i.p.) and melatonin (200 mg/kg, i.p.), individually reduced edema in impacted striatum versus TBI. Combination treatment of uridine (32) and melatonin (200) decreased edema in impacted as well as non-impacted hippocampus (75.7 +/- 0.5% and 75.4 +/- 0.3%) and striatum (69.7 +/- 1.2% and 72.6 +/- 0.5%) respectively, as compared to the group that received vehicle following TBI. Combination of uridine (16) and melatonin (200) attenuated edema levels in impacted hippocampus (76.6 +/- 0.4%) and striatum (71.7 +/- 0.5% and 74 +/- 0.3%, respectively). Combination of uridine and melatonin may be a possible treatment strategy for the damage caused by TBI and its neuroprotective potential needs to be evaluated further.	[Kabadi, Shruti V.; Maher, Timothy J.] Massachusetts Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Boston, MA 02115 USA	Maher, TJ (corresponding author), Massachusetts Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, 179 Longwood Ave, Boston, MA 02115 USA.	Timothy.Maher@mcphs.edu					Alvarez XA, 1997, METHOD FIND EXP CLIN, V19, P201; Antolin I, 1996, FASEB J, V10, P882; Baranova AI, 2006, J NEUROTRAUM, V23, P1233, DOI 10.1089/neu.2006.23.1233; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cansev M, 2005, BRAIN RES, V1058, P101, DOI 10.1016/j.brainres.2005.07.054; Cansev M, 2006, BRAIN RES REV, V52, P389, DOI 10.1016/j.brainresrev.2006.05.001; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; Connolly GP, 1999, TRENDS PHARMACOL SCI, V20, P218, DOI 10.1016/S0165-6147(99)01298-5; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1992, J NEUROTRAUMA, V9, P475; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; FARABEGOLI C, 1988, ACTA PHYSIOL SCAND, V132, P209, DOI 10.1111/j.1748-1716.1988.tb08319.x; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Gupta YK, 2002, CAN J PHYSIOL PHARM, V80, P210, DOI 10.1139/Y02-052; Hardeland R, 2005, ENDOCRINE, V27, P119, DOI 10.1385/ENDO:27:2:119; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Jayakumar AR, 2008, J BIOL CHEM, V283, P33874, DOI 10.1074/jbc.M804016200; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kong XY, 2008, CELL MOL NEUROBIOL, V28, P569, DOI 10.1007/s10571-007-9212-7; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Lopez-Burillo S, 2003, J PINEAL RES, V34, P269, DOI 10.1034/j.1600-079X.2003.00041.x; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; Mor M, 2004, J PINEAL RES, V36, P95, DOI 10.1046/j.1600-079X.2003.00102.x; MYERS CS, 1995, PHARMACOL BIOCHEM BE, V52, P749, DOI 10.1016/0091-3057(95)00169-W; Norenberg MD, 2007, METAB BRAIN DIS, V22, P219, DOI 10.1007/s11011-007-9062-5; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Pei Z, 2002, J PINEAL RES, V32, P168, DOI 10.1034/j.1600-079x.2002.1o847.x; Pei Z, 2003, STROKE, V34, P770, DOI 10.1161/01.STR.0000057460.14810.3E; PETERS GJ, 1987, CANCER CHEMOTH PHARM, V20, P101, DOI 10.1007/BF00253962; Plataras C, 2003, Z NATURFORSCH C, V58, P277; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Richardson UI, 2003, BRAIN RES, V971, P161, DOI 10.1016/S0006-8993(03)02333-3; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Schabitz WR, 1999, STROKE, V30, P427, DOI 10.1161/01.STR.30.2.427; Sinha K, 2001, EUR J PHARMACOL, V428, P185, DOI 10.1016/S0014-2999(01)01253-5; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Winiarska K, 2006, J PINEAL RES, V40, P168, DOI 10.1111/j.1600-079X.2005.00295.x; Wurtman RJ, 2000, BIOCHEM PHARMACOL, V60, P989, DOI 10.1016/S0006-2952(00)00436-6	56	20	21	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-777-1	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1199						105	113		10.1111/j.1749-6632.2009.05352.x			9	Multidisciplinary Sciences; Neurosciences	Science & Technology - Other Topics; Neurosciences & Neurology	BRJ59	WOS:000282838900012	20633115				2021-06-18	
J	Nehrt, A; Hamann, K; Ouyang, H; Shi, RY				Nehrt, Ashley; Hamann, Kristin; Ouyang, Hui; Shi, Riyi			Polyethylene Glycol Enhances Axolemmal Resealing following Transection in Cultured Cells and in Ex Vivo Spinal Cord	JOURNAL OF NEUROTRAUMA			English	Article						gap potential; guinea pig; membrane potential; membrane surface tension; membrane tension; plasma membrane; spinal cord white matter; sucrose gap recording; surfactant; white matter	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC HYPOTHERMIA; MEMBRANE-PERMEABILITY; NERVE MEMBRANES; IN-VITRO; CUT END; AXONS; REPAIR; CONTUSION; INVOLVEMENT	The integrity of the neuronal membrane is critical for its function as well as survival, and ineffective repair of damaged membranes may be one of the key factors underlying the neuronal degeneration and overall functional loss that occurs after spinal cord injury and traumatic brain injury. Previously, we showed that polyethylene glycol ( PEG) can reseal axonal membranes following compression in isolated guinea pig spinal cord white matter. We now report that 10 mM PEG can also significantly enhance membrane resealing following transection in the clinically relevant conditions of low extracellular Ca2+ and low temperature. Such beneficial effects were demonstrated both functionally, through membrane potential measured by double sucrose gap apparatus, and anatomically, through horseradish peroxidase and tetramethyl rhodamine dextran dye exclusion assays. We further noted that axons with small diameters preferentially benefited from PEG-mediated axolemmal resealing. Using atomic force microscopy, we further showed that PEG can effectively reduce neuronal membrane surface tension. We hypothesize that PEG may promote axolemmal resealing by increasing membrane line tension and reducing membrane tension, thus creating conditions more favorable to membrane resealing. In summary, these studies suggest that PEG is effective under the clinically relevant conditions of low Ca2+ and temperature, and thus has the potential to be used in combination with other more established interventions in spinal cord and traumatic brain injury.	[Nehrt, Ashley; Hamann, Kristin; Ouyang, Hui; Shi, Riyi] Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Med, W Lafayette, IN 47907 USA; [Ouyang, Hui; Shi, Riyi] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA	Shi, RY (corresponding author), Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Med, 408 S Univ St, W Lafayette, IN 47907 USA.	riyi@purdue.edu			State of Indiana; Purdue University Neuroscience program	We thank Phyllis Zickmund and Gary Leung for their excellent technical support. We also thank Todd Rickett for proofreading and Dr. Richard Borgens for his support and encouragement. This study was supported by funding from the State of Indiana. Ashley Nehrt was supported by the funding provided by Purdue University Neuroscience program.	Borgens RB, 2000, FASEB J, V14, P27; BORGENS RB, 1980, P NATL ACAD SCI-BIOL, V77, P1209, DOI 10.1073/pnas.77.2.1209; Casas CE, 2005, J NEUROSURG-SPINE, V2, P308, DOI 10.3171/spi.2005.2.3.0308; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2009, J NEUROTRAUM, V26, P393, DOI 10.1089/neu.2008.0556; Dai JW, 1998, J NEUROSCI, V18, P6681; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Dine CJ, 2009, EMERG MED CLIN N AM, V27, P137, DOI 10.1016/j.emc.2008.07.003; Eddleman CS, 1997, P NATL ACAD SCI USA, V94, P4745, DOI 10.1073/pnas.94.9.4745; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Golakani MH, 2019, J NEUROTRAUM, V36, P3410, DOI 10.1089/neu.2019.6421; HAYES KC, 1993, PARAPLEGIA, V31, P730, DOI 10.1038/sc.1993.115; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Hui OY, 2008, J NEUROTRAUM, V25, P19, DOI 10.1089/neu.2007.0340; Jensen JM, 2003, J NEUROPHYSIOL, V90, P2334, DOI 10.1152/jn.00868.2002; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KRAUSE TL, 1994, J NEUROSCI, V14, P6638; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lo TP, 2009, J COMP NEUROL, V514, P433, DOI 10.1002/cne.22014; LUCAS JH, 1994, J NEUROTRAUM, V11, P35, DOI 10.1089/neu.1994.11.35; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Peasley MA, 2002, AM J PHYSIOL-CELL PH, V283, pC980, DOI 10.1152/ajpcell.00591.2001; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Raucher D, 1999, BIOPHYS J, V77, P1992, DOI 10.1016/S0006-3495(99)77040-2; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Robertson CL, 2000, CRIT CARE MED, V28, P3218, DOI 10.1097/00003246-200009000-00017; SCHLAEPFER WW, 1974, BRAIN RES, V69, P203, DOI 10.1016/0006-8993(74)90002-X; Sheetz MP, 2001, NAT REV MOL CELL BIO, V2, P392, DOI 10.1038/35073095; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2001, J NEUROCYTOL, V30, P829, DOI 10.1023/A:1019645505848; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; Shi RY, 2004, J NEUROCYTOL, V33, P203, DOI 10.1023/B:NEUR.0000030695.76840.19; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Simon CM, 2009, J NEUROTRAUM, V26, P563, DOI 10.1089/neu.2008.0523; SPIRA ME, 1993, J NEUROBIOL, V24, P300, DOI 10.1002/neu.480240304; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; Togo T, 1999, J CELL SCI, V112, P719; Westergren H, 2000, ACTA NEUROCHIR, V142, P567, DOI 10.1007/s007010050471; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Wieloch T, 2001, IUBMB LIFE, V52, P247, DOI 10.1080/15216540152846064; Winckler B, 1999, NATURE, V397, P698, DOI 10.1038/17806; Wingrave JM, 2003, J NEUROSCI RES, V73, P95, DOI 10.1002/jnr.10607; XIE XY, 1991, J NEUROSCI, V11, P3257; YAWO H, 1983, SCIENCE, V222, P1351, DOI 10.1126/science.6658457; YAWO H, 1985, J NEUROSCI, V5, P1626; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; Yu ZW, 1998, MOL MEMBR BIOL, V15, P59, DOI 10.3109/09687689809027519	65	20	21	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					151	161		10.1089/neu.2009.0993			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200013	19691421				2021-06-18	
J	Noe, E; Ferri, J; Colomer, C; Moliner, B; Chirivella, J				Noe, E.; Ferri, J.; Colomer, C.; Moliner, B.; Chirivella, J.			APOE genotype and verbal memory recovery during and after emergence from post-traumatic amnesia	BRAIN INJURY			English	Article						APOE; post-traumatic amnesia; traumatic brain injury; rehabilitation; memory	TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E POLYMORPHISM; HEAD-INJURY; ASSOCIATION; EPSILON-4; COGNITION; MODERATE; SCALE	Objective: To determine if APOE genotype is linked to memory function after moderate-severe traumatic brain injury (TBI). Methods: Eighty-two patients in post-traumatic amnesia (PTA) and 107 patients who had emerged from PTA were selected from 239 consecutive patients admitted to the facility. Verbal memory assessments, including the Spanish version of the California Verbal Learning Test and the Working-Memory Index of the WAIS-III, were conducted immediately after PTA resolution or during the first week after admission for patients who were out of PTA. Both groups were reassessed 6 months after inclusion in a multidisciplinary rehabilitation programme. Results: Patients with the APOE-epsilon 4 allele (n = 17 in the PTA group and n = 9 in the out of PTA group) entered rehabilitation at a more impaired level, but made remarkable progress during follow-up. Fifty-five patients from the initial sample emerged from PTA during the follow-up period. Age, GOAT at admission and chronicity, but not APOE genotype or initial trauma severity, were significant predictors of emergence from PTA. Conclusions: APOE genotype seems to be associated with the trajectory of cognitive recovery after TBI, but does not play a determinant role in the efficacy of memory rehabilitation in this population.	[Noe, E.; Ferri, J.; Colomer, C.; Moliner, B.; Chirivella, J.] Hosp Valencia Mar, Serv Dano Cerebral Hosp NISA, FIVAN, Valencia 46011, Spain	Noe, E (corresponding author), Hosp Valencia Mar, Serv Dano Cerebral Hosp NISA, FIVAN, C Rio Tajo N 1, Valencia 46011, Spain.	enoe@comv.es		Noe Sebastian, Enrique/0000-0002-2547-8727			Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; BENEDET MJ, 1999, TEST APRENDIZAJE VER; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Jiang Y, 2007, J NEUROTRAUM, V24, P1802, DOI 10.1089/neu.2007.0299; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Mueller SG, 2008, NEUROIMAGE, V42, P42, DOI 10.1016/j.neuroimage.2008.04.174; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Ponsford J, 2007, NEUROLOGY, V68, P619, DOI 10.1212/01.wnl.0000254609.04330.9d; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; SANEDA D L, 1992, Brain Injury, V6, P167, DOI 10.3109/02699059209029655; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Tate RL, 2001, J HEAD TRAUMA REHAB, V16, P525, DOI 10.1097/00001199-200112000-00002; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WECHSLER D, 1999, ESCALA INTELIGENCIA, V3; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460	30	20	21	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	6					886	892		10.3109/02699051003724952			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	620MT	WOS:000279504700011	20377344				2021-06-18	
J	Nyakale, NE; Clauss, RP; Nel, W; Sathekge, M				Nyakale, Nozipho E.; Clauss, Ralf P.; Nel, Wally; Sathekge, Mike			Clinical and brain SPECT scan response to zolpidem in patients after brain damage	ARZNEIMITTELFORSCHUNG-DRUG RESEARCH			English	Article						CAS 82626-48-0; Clinical rating scale; SPECT; Stroke; Traumatic brain injury; Zolpidem	TRANSIENT IMPROVEMENT; PERFUSION; AROUSAL; STATE; INJURY; BABOON	Previous reports document transient improvements after daily zolpidem (CAS 82626-48-0) in patients with brain damage. This multi-patient study evaluates the response to zolpidem in neurologically disabled patients, using (99m)TcHMPAO brain SPECT scans and clinical rating scales. Method: 23 of 41 consecutive adult patients, at least 6 months after brain damage were identified as neurologically disabled patients by scoring less than 100/100 on the Barthel Index. Causes of their brain damage included stroke (n = 12), traumatic brain injury (n = 7), anaphylaxis (n = 2), drugs overdose (n = 1) and birth injury (n = 1). The selected 23 patients had a baseline (99m)TcHMPAO brain SPECT scan before starting daily zolpidem therapy and a second within two weeks of therapy, performed 1 h after 10 mg oral zolpidem. Scans were designated as improved when at least two of three assessors detected improvement after zolpidem. The rest were designated non improved. After four months daily zolpidem therapy, patients were rated on the Tinetti Falls Efficacy Scale (TFES) before and after zolpidem. The TFES ratings were compared using a Wilcoxon non parametric signed rank test. Scan improvers were compared with non improvers, using a two sample t test with unequal variance. Results: Mean overall improvement after zolpidem on TFES was 11.3%, from 73.4/100 to 62.1/100 (p = 0.0001). 10/23 (43%) patients improved on SPECT scan after zolpidem. Their mean TFES improvement was 19.4% (+/- 16.75) compared with 5.08% (+/- 5.17) in 13/23 non improvers (p = 0.0081). Conclusion: This prospective study adds further evidence to previous reports of zolpidem efficacy in patients with established brain damage.	[Clauss, Ralf P.] Royal Surrey Cty Hosp, Dept Nucl Med, Guildford GU2 7XX, Surrey, England; [Nyakale, Nozipho E.; Sathekge, Mike] Univ Pretoria, Dept Nucl Med, ZA-0002 Pretoria, South Africa; [Nel, Wally] Pollock Pk Med Ctr, Springs, South Africa	Clauss, RP (corresponding author), Royal Surrey Cty Hosp, Dept Nucl Med, Guildford GU2 7XX, Surrey, England.	rclauss@royalsurrey.nhs.uk	Sathekge, Mike/AAJ-6466-2020	Sathekge, Mike/0000-0002-2806-0625			BANDURA A, 1982, AM PSYCHOL, V37, P122, DOI 10.1037/0003-066X.37.2.122; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss R, 2004, NEW ENGL J MED, V351, P511, DOI 10.1056/NEJM200407293510522; Clauss RP, 2000, S AFR MED J, V90, P68; Clauss RP, 2002, ARZNEIMITTELFORSCH, V52, P740; Clauss RP, 2001, ARZNEIMITTEL-FORSCH, V51, P619; CLAUSS RP, 2005, 9 EUR FED NEUR SOC C; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; Cohen SI, 2008, AM J PHYS MED REHAB, V87, P229, DOI 10.1097/PHM.0b013e318161971b; FRISTON KJ, 1965, HUM BRAIN MAPP, V2, P165; HALL SD, 2008, NATURE P; Harrison TS, 2005, CNS DRUGS, V19, P65; MAHONEY F I, 1965, Md State Med J, V14, P61; Sanger DJ, 1999, PHARMACOL BIOCHEM BE, V64, P269, DOI 10.1016/S0091-3057(99)00081-7; SANGER DJ, 1986, PSYCHOPHARMACOLOGY, V89, P317; Shadan FF, 2004, SOUTH MED J, V97, P791, DOI 10.1097/00007611-200408000-00025; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Slomka PJ, 2001, COMPUT MED IMAG GRAP, V25, P153, DOI 10.1016/S0895-6111(00)00044-6; TINETTI ME, 1990, J GERONTOL, V45, pP239, DOI 10.1093/geronj/45.6.P239; Van Laere K, 2001, EUR J NUCL MED, V28, P90, DOI 10.1007/s002590000407; Van Laere KJ, 2002, J NUCL MED, V43, P458	22	20	21	0	3	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0004-4172	1616-7066		ARZNEIMITTELFORSCH	Arzneimittelforschung-Drug Res.		2010	60	4					177	181					5	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	591XU	WOS:000277339600003	20486466				2021-06-18	
J	Redpath, SJ; Williams, WH; Hanna, D; Linden, MA; Yates, P; Harris, A				Redpath, S. J.; Williams, W. H.; Hanna, D.; Linden, M. A.; Yates, P.; Harris, A.			Healthcare professionals' attitudes towards traumatic brain injury (TBI): The influence of profession, experience, aetiology and blame on prejudice towards survivors of brain injury	BRAIN INJURY			English	Article						Attitudes; traumatic brain injury; healthcare professionals; prejudice; helping behaviour	AUTOBIOGRAPHICAL MEMORY; STAFFS PERCEPTIONS; PERCEIVED STIGMA; ATTRIBUTIONS; PERSONALITY; PREDICTORS; SEVERITY; EMOTION; NURSES	Primary objective: To investigate the attitudes of healthcare professionals towards individuals with traumatic brain injury (TBI) and their relationship to intended healthcare behaviour. Research design: An independent groups design utilized four independent variables; aetiology, group, blame and gender to explore attitudes towards survivors of brain injury. The dependent variables were measured using the Prejudicial Evaluation and Social Interaction Scale (PESIS) and Helping Behaviour Scale (HBS). Methods and procedures: A hypothetical vignette based methodology was used. Four hundred and sixty participants (131 trainee nurses, 94 qualified nurses, 174 trainee doctors, 61 qualified doctors) were randomly allocated to one of six possible conditions. Main outcomes and results: Regardless of aetiology, if an individual is to blame for their injury, qualified healthcare professionals have more prejudicial attitudes than those entering the profession. There is a significant negative relationship between prejudice and helping behaviour for qualified healthcare professionals. Conclusions: Increased prejudicial attitudes of qualified staff are related to a decrease in intended helping behaviour, which has the potential to impact negatively on an individual's recovery post-injury.	[Redpath, S. J.] Abertawe Bro Morgannwg Univ Hlth Board, Cymru, Wales; [Williams, W. H.] Univ Exeter, Sch Psychol, Exeter, Devon, England; [Hanna, D.] Queens Univ Belfast, Sch Psychol, Belfast BT7 1NN, Antrim, North Ireland; [Linden, M. A.] Queens Univ Belfast, Nursing & Midwifery Res Unit, Belfast BT7 1NN, Antrim, North Ireland; [Yates, P.; Harris, A.] Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England	Redpath, SJ (corresponding author), Morriston Hosp, Dept Neuropsychol, Swansea SA6 6NL, W Glam, Wales.	simon.redpath@abm-tr.wales.nhs.uk	Linden, Mark/L-7754-2019	Linden, Mark/0000-0002-3832-4102; williams, huw/0000-0003-0670-2620; Hanna, Donncha/0000-0003-3382-4842	Economic and Social Research Council (ESRC)UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [res 062 23 0135]; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/E002692/1] Funding Source: researchfish	W. H. Williams was supported by a grant from Economic and Social Research Council (ESRC) res 062 23 0135.	Bessell AL, 2008, J INT NEUROPSYCH SOC, V14, P63, DOI 10.1017/S1355617708080065; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Corrigan PW, 1999, AM PSYCHOL, V54, P765, DOI 10.1037/0003-066X.54.9.765; Doyal Len, 2006, Int J Surg, V4, P146, DOI 10.1016/j.ijsu.2006.06.023; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; FRANKS JA, 2002, BRIT J CLIN GOVERNAN, V7, P34; George D., 2003, SPSS WINDOWS STEP ST, V4th; Hair J.F., 1995, MULTIVARIATE DATA AN, V4th ed.; Haslam S.A., 2001, PSYCHOL ORG SOCIAL I; HOPCUTT B, 2008, NATL SERVICE FRAMEWO; Jahoda A, 2005, J INTELL DISABIL RES, V49, P544, DOI 10.1111/j.1365-2788.2005.00693.x; KELLY JA, 1987, J MED EDUC, V62, P549; Linden MA, 2007, ARCH CLIN NEUROPSYCH, V22, P665, DOI 10.1016/j.acn.2007.04.009; Linden MA, 2005, BRAIN INJURY, V19, P1011, DOI 10.1080/02699050500110314; Mackay N, 2005, BRIT J CLIN PSYCHOL, V44, P255, DOI 10.1348/014466505X29620; MANCHESTER D, 2006, BRAIN INJURY, V20, P1029; Markham D, 2003, BRIT J CLIN PSYCHOL, V42, P243, DOI 10.1348/01446650360703366; McClure J, 2008, BRAIN INJURY, V22, P639, DOI 10.1080/02699050802255585; McClure J, 2006, BRAIN INJURY, V20, P1029, DOI 10.1080/02699050600909870; McKinlay A, 2001, J ADV NURS, V34, P107, DOI 10.1046/j.1365-2648.2001.3411728.x; McManus IC, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-29; Perlick DA, 2001, PSYCHIAT SERV, V52, P1613, DOI 10.1176/appi.ps.52.12.1613; Perlick DA, 2001, PSYCHIAT SERV, V52, P1627, DOI 10.1176/appi.ps.52.12.1627; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Redpath SJ, 2004, BRAIN INJURY, V18, P861, DOI 10.1080/02699050410001671838; REDPATH SJ, 2008, THESIS QUEENS U BELF; Sirey JA, 2001, PSYCHIAT SERV, V52, P1615, DOI 10.1176/appi.ps.52.12.1615; Stewart D, 1999, J ADV NURS, V30, P740, DOI 10.1046/j.1365-2648.1999.01140.x; Weigel L, 2006, BRIT J CLIN PSYCHOL, V45, P205, DOI 10.1348/014466505X67510; WEINER B, 1985, PSYCHOL REV, V92, P548, DOI 10.1037/0033-295X.92.4.548; Weiner B., 1986, ATTRIBUTION THEORY M; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1080/09602010244000444, 10.1016/S0960-9822(02)01374-X]; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; WRIGHT SG, 2005, NURSING STAND, V19, P46	35	20	20	1	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	6					802	811		10.3109/02699051003709623			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	620MT	WOS:000279504700002	20455671				2021-06-18	
J	Semrud-Clikeman, M				Semrud-Clikeman, Margaret			Pediatric Traumatic Brain Injury: Rehabilitation and Transition to Home and School	APPLIED NEUROPSYCHOLOGY			English	Article						children; rehabilitation; TBI; treatment	COGNITIVE REHABILITATION; HEAD-INJURY; FAMILY INTERVENTION; YOUNG-CHILDREN; BEHAVIOR; TBI; RECOMMENDATIONS; RECOVERY; OUTCOMES; DAMAGE	The purpose of this review is to provide a summary of the empirical research on rehabilitation in pediatric traumatic brain injury (TBI). Studies of the effectiveness of interventions with children with TBI are hampered by difficulty with combining subjects with various levels of TBI, problems with random assignment to treatment groups, and varying age levels at injury. While these are areas of concern, there are emerging studies that indicate both applied behavioral analysis (ABA) and positive behavioral interventions are helpful to many children. For some children, ABA is not successful, and a shift to positive behavioral interventions has been found to be helpful. Transitions to home and school can be difficult particularly if there are family issues that predated the injury. This review provides additional information for the pediatric neuropsychologist to assist with transition to school and home. Studies utilizing the Internet for family interventions have revealed promising results. This review suggests that additional studies as to the efficacy of interventions following TBI are needed particularly to evaluate outcomes after initial recovery and at follow-up. In addition, this review suggests that an important role for pediatric neuropsychologists is to provide support for schools and families through therapy and inservices for school personnel on TBI.	[Semrud-Clikeman, Margaret] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA; [Semrud-Clikeman, Margaret] Michigan State Univ, Dept Psychiat, E Lansing, MI 48824 USA	Semrud-Clikeman, M (corresponding author), Michigan State Univ, Dept Psychol, 321 A W Fee Hall, E Lansing, MI 48824 USA.	semrudcl@msu.edu	Berger, Emily/N-7268-2017	Berger, Emily/0000-0001-5550-807X			ALLEN K, 1994, REHABIL PSYCHOL, V39, P30; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Arroyos-Jurado E, 2000, J SCHOOL PSYCHOL, V38, P571, DOI 10.1016/S0022-4405(00)00053-4; BERGLAND MM, 1996, ACQUIRED BRAIN INJUR, P17; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CARTER RR, 1985, COGNITIVE REHABILITA, V3, P14; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CICERONE KD, 2009, NEUROPSYCHOLOGY, V23, P20; COHEN SB, 1996, ACQUIRED BRAIN INJUR, P126; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Conoley JC, 1996, J LEARN DISABIL-US, V29, P662, DOI 10.1177/002221949602900610; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DEPOMPEI R, 1993, STAFF DEV CLIN INTER, P229; Ellison PAT., 2009, CHILD NEUROPSYCHOLOG; Feeney TJ, 2008, J POSIT BEHAV INTERV, V10, P115, DOI 10.1177/1098300707312540; Fyffe CE, 2004, J APPL BEHAV ANAL, V37, P401, DOI 10.1901/jaba.2004.37-401; Jutai Jeffrey W, 2003, Top Stroke Rehabil, V10, P77; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 2004, NEUROPSYCHOL ASSESSM; Lincoln NB, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002842; MAEGDEN J, 2007, PEDIATRIC NEUROPSYCH; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; MILLER L, 1993, AM J FAM THER, V21, P111, DOI 10.1080/01926189308250910; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rosen CD, 1986, HEAD TRAUMA ED REINT; Saxe R, 2004, ANNU REV PSYCHOL, V55, P87, DOI 10.1146/annurev.psych.55.090902.142044; Semrud-Clikeman M., 2005, HDB SCH NEUROPSYCHOL, P425; SEMRUDCLIKEMAN M, 2001, TRAUMATIC BRAIN INJU; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Vanderploeg RD, 2006, J HEAD TRAUMA REHAB, V21, P179, DOI 10.1097/00001199-200603000-00010; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wilson B. A., 2005, EFFECTIVENESS REHABI, P143; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Ylvisaker Mark, 1993, Seminars in Speech and Language, V14, P74, DOI 10.1055/s-2008-1064160; ZENICUS A, 1989, BRAIN INJURY, V3, P67	49	20	20	0	24	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2010	17	2					116	122	PII 922181819	10.1080/09084281003708985			7	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	596CX	WOS:000277662800007	20467952				2021-06-18	
J	Young, AE				Young, Amanda E.			Employment maintenance and the factors that impact it after vocational rehabilitation and return to work	DISABILITY AND REHABILITATION			English	Article						Return to work; rehabilitation; participation barriers and facilitators	LOW-BACK-PAIN; TRAUMATIC BRAIN-INJURY; MUSCULOSKELETAL DISORDERS; RECOVERY EXPECTATIONS; OCCUPATIONAL INJURY; SICKNESS ABSENCE; DISABILITY; HEALTH; RECURRENCE; EPISODES	Purpose. To determine post-return-to-work disability and functioning amongst occupationally injured workers and to test the extent to which demographic and other variables relate to employment maintenance. In addition, the project sought to document what workers believe determined their work continuation. Method. Semi-structured in-depth interviews were conducted to inquire about participant's (N=150) post-vocational rehabilitation return-to-work experiences. Results were interpreted using the health and health-related domains from the International Classification of Functioning, Disability and Health. Results. Although most participants were working at the time of interview, almost all were experiencing functional-or activity-based restrictions. Factors differentiating those employed from those not, were largely contextual and included relationships with supervisors, economic climate, and working conditions. Conclusions. The findings stress the importance of considering environmental strains when planning return to work and indicate ways to assist workers to achieve return-to-work success.	Ctr Disabiilty Res, Liberty Mutual Res Inst Safety, Hopkinton, MA 01748 USA	Young, AE (corresponding author), Ctr Disabiilty Res, Liberty Mutual Res Inst Safety, 71 Frankland Rd, Hopkinton, MA 01748 USA.	amandae.young@libertymutual.com	Young, Amanda/H-8851-2016	Young, Amanda/0000-0002-7288-3469			ABENHAIM L, 1988, BRIT J IND MED, V45, P829; American Association for Public Opinion Research, 2008, STAND DEF FIN DISP C, V5th; Baril R, 2003, SOC SCI MED, V57, P2101, DOI 10.1016/S0277-9536(03)00131-X; Burdorf A, 2006, OCCUP ENVIRON MED, V63, P522, DOI 10.1136/oem.2005.019745; Campbell Research and Consulting, 2000, NAT RET TO WORK MON; Cole DC, 2002, CAN MED ASSOC J, V166, P749; Concha-Barrientos M, 2005, AM J IND MED, V48, P470, DOI 10.1002/ajim.20226; Duggan CH, 2008, DISABIL REHABIL, V30, P978, DOI 10.1080/09638280701797549; Gross DP, 2005, J OCCUP ENVIRON MED, V47, P428, DOI 10.1097/01.jom.0000158706.96994.a5; Gross DP, 2004, SPINE, V29, P920, DOI 10.1097/00007632-200404150-00020; Kenny D, 1998, AUST J REHAB COUNSEL, V4, P97; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; Lotters F, 2005, SCAND J WORK ENV HEA, V31, P367; Lotters F, 2005, SPINE, V30, P1086; Lysaght RM, 2008, WORK, V30, P255; MURPHY G, 2001, RETURN WORK FOLLOWIN; Nieuwenhuijsen K, 2004, OCCUP ENVIRON MED, V61, P817, DOI 10.1136/oem.2003.009688; *OFF MAN BUDG, 1987, STAND IND CLASS SIC; *OFF NAT STAT, 2000, STAND OCC CLASS 2000; ROSSIGNOL M, 1992, SPINE, V17, P1043, DOI 10.1097/00007632-199209000-00006; Schonherr MC, 2004, SPINAL CORD, V42, P177, DOI 10.1038/sj.sc.3101581; Schultz IZ, 2005, HANDBOOK OF COMPLEX OCCUPATIONAL DISABILITY CLAIMS: EARLY RISK IDENTIFICATIONS, INTERVENTION, AND PREVENTION, P523; Shaw WS, 2003, J OCCUP REHABIL, V13, P129, DOI 10.1023/A:1024997000505; Stamm T, 2007, CURR OPIN RHEUMATOL, V19, P184, DOI 10.1097/BOR.0b013e3280148e64; Subramanian A, 2006, J OCCUP REHABIL, V16, P123, DOI 10.1007/s10926-005-9012-1; Sundar V, 2008, DISABIL REHABIL, V30, P955, DOI 10.1080/09638280701800285; Tsaousides T, 2008, REHABIL PSYCHOL, V53, P456, DOI 10.1037/a0012579; U. S. Department of Labor Bureau of Labor Statistics, 1992, OCC INJ ILLN CLASS M; Vercillo A, 2008, JOB RETENTION SUCCES; Wasiak R, 2006, SPINE, V31, P219, DOI 10.1097/01.brs.0000194774.85971.df; Wasiak R, 2004, J OCCUP ENVIRON MED, V46, P68, DOI 10.1097/01.jom.0000105987.32375.3d; Wasiak R, 2007, J OCCUP REHABIL, V17, P766, DOI 10.1007/s10926-007-9101-4; Westmorland Muriel G, 2004, Work, V23, P31; World Health Organization ( WHO ), 2002, COMM LANG FUNCT DIS; Young AE, 2005, J OCCUP REHABIL, V15, P557, DOI 10.1007/s10926-005-8034-z; Young AE, 2002, J OCCUP REHABIL, V12, P175, DOI 10.1023/A:1016894628429; Young AE, 2009, DISABIL REHABIL, V31, P2013, DOI 10.3109/09638280902887412; 1997, BLS HDB METHODS	38	20	20	0	11	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.		2010	32	20					1621	1632		10.3109/09638281003611029			12	Rehabilitation	Rehabilitation	660RQ	WOS:000282661800001	20158373				2021-06-18	
J	Folkersma, H; Boellaard, R; Vandertop, WP; Kloet, RW; Lubberink, M; Lammertsma, AA; van Berckel, BNM				Folkersma, Hedy; Boellaard, Ronald; Vandertop, W. Peter; Kloet, Reina W.; Lubberink, Mark; Lammertsma, Adriaan A.; van Berckel, Bart N. M.			Reference Tissue Models and Blood-Brain Barrier Disruption: Lessons from (R)-[C-11]PK11195 in Traumatic Brain Injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						blood-brain barrier; craniocerebral trauma; (R)-[C-11]PK11195; humans; positron emission tomography	POSITRON-EMISSION-TOMOGRAPHY; ACTIVATED MICROGLIA; MULTIPLE-SCLEROSIS; IN-VIVO; IMAGE REGISTRATION; PET	(R)-[C-11]PK11195 is a tracer for activated microglia. The purpose of this study was to assess the validity of the simplified reference tissue model for analyzing (R)-[C-11]PK11195 studies in traumatic brain injury (TBI), where blood-brain barrier disruptions are likely. Methods: Dynamic (R)-[C-11]PK11195 scans were acquired at 3 time points after TBI. Plasma input-derived binding potential (BPNDPI), volume of distribution (V-T) and K-1/k(2), and simplified reference tissue model-derived binding potential (BPNDSRTM) were obtained. Simulations were performed to assess the effect of varying K-1/k(2). Results: Early after TBI, an increase in V-T, but not in BPNDPI, was found. Early K-1/k(2) correlated with V-T and BPNDSRTM but not with BPNDPI. One and 6 mo after TBI, BPNDSRTM correlated with BPNDPI. Conclusion: Early after TBI, (R)-[C-11]PK11195 studies should be analyzed using plasma input models.	[Folkersma, Hedy; Vandertop, W. Peter] Vrije Univ Amsterdam, Neurosurg Ctr Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlands; [Boellaard, Ronald; Kloet, Reina W.; Lubberink, Mark; Lammertsma, Adriaan A.; van Berckel, Bart N. M.] Vrije Univ Amsterdam, Dept Nucl Med & PET Res, Med Ctr, NL-1081 HV Amsterdam, Netherlands	Folkersma, H (corresponding author), Vrije Univ Amsterdam, Neurosurg Ctr Amsterdam, Med Ctr, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	hedy.folkersma@vumc.nl	Vandertop, William P./K-9288-2018	Boellaard, Ronald/0000-0002-0313-5686; Lammertsma, Adriaan/0000-0003-1237-2891	Dutch Brain Foundation [9F01.21]; Netherlands Organisation for Scientific ResearchNetherlands Organization for Scientific Research (NWO) [016.066.09]	We thank the patients, their families, and the control subjects for volunteering for this study, and the personnel of the BV Cyclotron VU and staff of the Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, for production of (R)-[<SUP>11</SUP>C]PK11195 and technical assistance. This work was made possible by research grant 9F01.21 from the Dutch Brain Foundation and NWO VIDI grant 016.066.09 from the Netherlands Organisation for Scientific Research.	Banati RB, 1999, NEUROLOGY, V53, P2199, DOI 10.1212/WNL.53.9.2199; Banati RB, 2000, BRAIN, V123, P2321, DOI 10.1093/brain/123.11.2321; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Debruyne JC, 2003, EUR J NEUROL, V10, P257, DOI 10.1046/j.1468-1331.2003.00571.x; Defrise M, 1997, IEEE T MED IMAGING, V16, P145, DOI 10.1109/42.563660; Gerhard A, 2005, NEUROIMAGE, V24, P591, DOI 10.1016/j.neuroimage.2004.09.034; Gerhard A, 2003, NEUROLOGY, V61, P686, DOI 10.1212/01.WNL.0000078192.95645.E6; Greuter HNJM, 2005, NUCL MED BIOL, V32, P307, DOI 10.1016/j.nucmedbio.2004.12.005; GROOM GN, 1995, J NUCL MED, V36, P2207; Kropholler MA, 2005, J CEREBR BLOOD F MET, V25, P842, DOI 10.1038/sj.jcbfm.9600092; Kropholler MA, 2006, J CEREBR BLOOD F MET, V26, P1431, DOI 10.1038/sj.jcbfm.9600289; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Maes F, 1997, IEEE T MED IMAGING, V16, P187, DOI 10.1109/42.563664; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; Versijpt J, 2005, MULT SCLER J, V11, P127, DOI 10.1191/1352458505ms1140oa; West J, 1997, J COMPUT ASSIST TOMO, V21, P554, DOI 10.1097/00004728-199707000-00007	16	20	20	0	4	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	DEC	2009	50	12					1975	1979		10.2967/jnumed.109.067512			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	529YM	WOS:000272555300014	19910429	Bronze			2021-06-18	
J	Shen, YX; Fan, ZH; Zhao, JG; Zhang, P				Shen, Yi-Xin; Fan, Zhi-Hai; Zhao, Jia-Guo; Zhang, Peng			The application of platelet-rich plasma may be a novel treatment for central nervous system diseases	MEDICAL HYPOTHESES			English	Article							EPIDERMAL-GROWTH-FACTOR; SPINAL-CORD-INJURY; IN-VITRO; FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; DEGENERATIVE DISEASES; DOPAMINERGIC-NEURONS; FUNCTIONAL RECOVERY; STEM-CELLS; RECEPTOR	As a potential biological product, platelet-rich plasma (PRP) has been widely utilized in the areas of oral and maxillofacial reconstruction, bone and soft tissue restoration and wound healing. A recent study reported that the application of PRP on interrupted sciatic nerve could promote remyelinization of peripheral nerve. This renovated a notion that the application of PRP might extend to the nervous system. Most central nervous system (CNS) diseases have a series of common pathological changes in the later period of diseases which induce neurons and glia apoptosis and aggravate neurological dysfunction. It has been demonstrated that the potent restorative function of PRP is mainly based on neurotrophic capacity of preparation rich in growth factors (PRGFs) and scaffolding effect of platelet-rich gel (PRG), all of which could be certified to ameliorate the pathological process of CNS diseases. In view of this, we propose a hypothesis that the application of PRP and its derivatives might provide a novel therapeutic approach for CNS diseases, especially for traumatic brain or spinal cord injury, autoimmune diseases and neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. (C) 2009 Elsevier Ltd. All rights reserved.	[Shen, Yi-Xin; Fan, Zhi-Hai; Zhang, Peng] Soochow Univ, Affiliated Hosp 2, Dept Orthopaed, Suzhou 215004, Jiangsu, Peoples R China; [Zhao, Jia-Guo] Tianjin Hosp, Dept Orthopaed, Tianjin 300211, Peoples R China; [Zhao, Jia-Guo] China Med Univ, Shengjing Hosp, Dept Orthopaed, Shenyang 110004, Liaoning, Peoples R China	Zhao, JG (corresponding author), Tianjin Hosp, Dept Orthopaed, Tianjin 300211, Peoples R China.	pcrole@foxmail.com; tyb0423@yahoo.com.cn					Anitua E, 2007, BIOMATERIALS, V28, P4551, DOI 10.1016/j.biomaterials.2007.06.037; Bielecki TM, 2007, J BONE JOINT SURG BR, V89B, P417, DOI 10.1302/0301-620X.89B3.18491; Bogaert E, 2006, MUSCLE NERVE, V34, P391, DOI 10.1002/mus.20609; Carmeliet P, 2002, SEMIN CELL DEV BIOL, V13, P39, DOI 10.1006/scdb.2001.0290; CHENG B, 1995, J NEUROSCI, V15, P7095; Egawa-Tsuzuki T, 2004, EXP NEUROL, V186, P89, DOI 10.1016/j.expneurol.2003.11.001; Ehrenfest DMD, 2009, TRENDS BIOTECHNOL, V27, P158, DOI 10.1016/j.tibtech.2008.11.009; Eppley BL, 2006, PLAST RECONSTR SURG, V118, p147E, DOI 10.1097/01.prs.0000239606.92676.cf; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Froestl W, 2000, Pharm Acta Helv, V74, P247, DOI 10.1016/S0031-6865(99)00035-7; Gris P, 2007, GLIA, V55, P1145, DOI 10.1002/glia.20537; HEFTI F, 1994, J NEUROBIOL, V25, P1418, DOI 10.1002/neu.480251109; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kocaoemer A, 2007, STEM CELLS, V25, P1270, DOI 10.1634/stemcells.2006-0627; Kojima A, 2002, J NEUROTRAUM, V19, P223, DOI 10.1089/08977150252806974; Kwon YK, 2002, J BIOCHEM MOL BIOL, V35, P87; Lippa CF, 1995, NEURODEGENERATION, V4, P425, DOI 10.1006/neur.1995.0051; MAIESE K, 1995, J CEREBR BLOOD F MET, V15, P440, DOI 10.1038/jcbfm.1995.55; Mattson MP, 2006, ANTIOXID REDOX SIGN, V8, P1997, DOI 10.1089/ars.2006.8.1997; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; Mehta S, 2008, J ORTHOP TRAUMA, V22, P433, DOI 10.1097/BOT.0b013e31817e793f; Nakao Y, 2001, J THORAC CARDIOV SUR, V122, P136, DOI 10.1067/mtc.2001.114101; NIKKHAH G, 1993, EXP BRAIN RES, V92, P516; Ozdinler PH, 2006, NAT NEUROSCI, V9, P1371, DOI 10.1038/nn1789; Park SK, 2001, DEV NEUROSCI-BASEL, V23, P327, DOI 10.1159/000048716; Peng H, 1998, J CEREBR BLOOD F MET, V18, P349, DOI 10.1097/00004647-199804000-00002; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Roussa E, 2006, STEM CELLS, V24, P2120, DOI 10.1634/stemcells.2005-0514; Sariguney Y, 2008, J RECONSTR MICROSURG, V24, P159, DOI 10.1055/s-2008-1076752; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Schmidt CE, 2003, ANNU REV BIOMED ENG, V5, P293, DOI 10.1146/annurev.bioeng.5.011303.120731; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P95, DOI 10.1196/annals.1403.007; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Stoll G, 2004, BRAIN PATHOL, V14, P51, DOI 10.1111/j.1750-3639.2004.tb00497.x; Tirassa P, 2003, J NEUROSCI RES, V72, P557, DOI 10.1002/jnr.10614; Valenzuela CF, 1996, J BIOL CHEM, V271, P16151, DOI 10.1074/jbc.271.27.16151; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Wang JM, 2000, BRAIN RES, V859, P381, DOI 10.1016/S0006-8993(00)02008-4; Wang K, 2004, NEUROSCI LETT, V364, P154, DOI 10.1016/j.neulet.2004.04.086; Weibrich G, 2002, J CRANIO MAXILL SURG, V30, P97, DOI 10.1054/jcms.2002.0285; WERNER MH, 1988, J HISTOCHEM CYTOCHEM, V36, P81, DOI 10.1177/36.1.3275713; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrotniak Maciej, 2007, Ortop Traumatol Rehabil, V9, P227; WYSSCORAY T, 1995, AM J PATHOL, V147, P53	46	20	22	0	10	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	DEC	2009	73	6					1038	1040		10.1016/j.mehy.2009.05.021			3	Medicine, Research & Experimental	Research & Experimental Medicine	534UN	WOS:000272923000043	19767153				2021-06-18	
J	Vaccari, JPD; Marcillo, A; Nonner, D; Dietrich, WD; Keane, RW				Vaccari, Juan Pablo de Rivero; Marcillo, Alex; Nonner, Doris; Dietrich, W. Dalton; Keane, Robert W.			Neuroprotective effects of bone morphogenetic protein 7 (BMP7) treatment after spinal cord injury	NEUROSCIENCE LETTERS			English	Article						Bone morphogenetic protein 7; Spinal cord injury; Glutamate excitotoxicity; MAPK signaling	TRAUMATIC BRAIN-INJURY; INTRACISTERNAL OSTEOGENIC PROTEIN-1; FUNCTIONAL RECOVERY; NEUROTROPHIC FACTOR; SIGNALING PATHWAYS; CORTICAL-NEURONS; CROSS-TALK; STROKE; KINASE; NMDA	Bone morphogenetic protein 7 (BMP7) has been shown to ameliorate reduced dendritic growth induced by glutamate excitotoxicity in neuronal tissue cultures and/or provide an enhancement of functional recovery in central nervous system (CNS) injury. BMP7 expression is modulated by spinal cord injury (SCI), but the molecular mechanisms involved in neuroprotection have not been clearly defined. Here, we show that BMP7 treatment of rats subjected to mild cervical SCI significantly increased the pro-survival mitogen-activated protein kinase-38 (MAPK-38) pathway and levels of N-methyl-D-aspartate receptor I (NMDAR-1) resulting in a significant increase in neuronal sparing in the ventral horn of the spinal cord. Moreover, BMP7 was neuroprotective against glutamate-mediated excitotoxicity in cultured cortical neurons. These studies show that BMP7 administration may be used as a therapeutic strategy to reduce the damaging excitotoxic effects following SCI. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Nonner, Doris; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Vaccari, Juan Pablo de Rivero; Marcillo, Alex; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Vaccari, Juan Pablo de Rivero; Marcillo, Alex; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA	Keane, RW (corresponding author), Univ Miami, Miller Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave, Miami, FL 33136 USA.	rkeane@miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834	Department of DefenseUnited States Department of Defense [USAMRMC X81XWH-05-1-0001]	This work was supported by Department of Defense grant: USAMRMC X81XWH-05-1-0001. We thank David Molnar and Dr. Juan Carlos de Rivero Vaccari for technical assistance.	BENARDETE EA, 2009, BRAIN RES; BRAMLETT HD, 2005, INT J NEUROPROT NEUR, V1, P165; Brown KM, 2004, DEV BRAIN RES, V152, P61, DOI 10.1016/j.devbrainres.2004.06.001; Chang CF, 2003, STROKE, V34, P558, DOI 10.1161/01.STR.0000051507.64423.00; Charytoniuk DA, 2000, NEUROSCIENCE, V100, P33, DOI 10.1016/S0306-4522(00)00246-3; Chaverneff F, 2009, J NEUROCHEM, V109, P733, DOI 10.1111/j.1471-4159.2009.05990.x; Chou J, 2006, J NEUROL SCI, V240, P21, DOI 10.1016/j.jns.2005.08.015; Cox S, 2004, BRAIN RES, V1010, P55, DOI 10.1016/j.brainres.2004.02.068; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Enzmann GU, 2005, EXP NEUROL, V195, P293, DOI 10.1016/j.expneurol.2005.04.021; Esquenazi S, 2002, EXP NEUROL, V176, P41, DOI 10.1006/exnr.2002.7906; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gazzerro E, 2007, CURR OPIN PHARMACOL, V7, P325, DOI 10.1016/j.coph.2007.01.003; Haddad JJ, 2005, PROG NEUROBIOL, V77, P252, DOI 10.1016/j.pneurobio.2005.10.008; Haghighi SS, 2000, SPINAL CORD, V38, P733, DOI 10.1038/sj.sc.3101074; Harvey BK, 2005, PHARMACOL THERAPEUT, V105, P113, DOI 10.1016/j.pharmthera.2004.09.003; Hu MC, 2004, J BIOL CHEM, V279, P12051, DOI 10.1074/jbc.M310526200; JANTAS D, 2009, NEUROCHEM RES; Kawamata T, 1998, NEUROREPORT, V9, P1441, DOI 10.1097/00001756-199805110-00035; KAWAMOTO JC, 1986, BRAIN RES, V384, P84, DOI 10.1016/0006-8993(86)91222-9; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lewen A, 1997, NEUROREPORT, V8, P475, DOI 10.1097/00001756-199701200-00020; McAdoo DJ, 1997, J NEUROTRAUM, V14, P507, DOI 10.1089/neu.1997.14.507; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; Nicole O, 2001, J NEUROSCI, V21, P3024, DOI 10.1523/JNEUROSCI.21-09-03024.2001; Nonner D, 2001, J NEUROCHEM, V77, P691, DOI 10.1046/j.1471-4159.2001.00273.x; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Ren JM, 2000, NEUROPHARMACOLOGY, V39, P860, DOI 10.1016/S0028-3908(99)00261-0; Repici M, 2009, NEUROSCIENCE, V159, P94, DOI 10.1016/j.neuroscience.2008.11.049; Ryu BR, 1999, J NEUROBIOL, V39, P536, DOI 10.1002/(SICI)1097-4695(19990615)39:4<536::AID-NEU7>3.3.CO;2-A; Setoguchi T, 2001, BRAIN RES, V921, P219, DOI 10.1016/S0006-8993(01)03123-7; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; Timmer J, 2005, DEV BIOL, V285, P1, DOI 10.1016/j.ydbio.2005.05.039; Zwijsen A, 2003, FEBS LETT, V546, P133, DOI 10.1016/S0014-5793(03)00566-0	35	20	21	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 20	2009	465	3					226	229		10.1016/j.neulet.2009.09.013			4	Neurosciences	Neurosciences & Neurology	510CY	WOS:000271066800006	19765637				2021-06-18	
J	Alexander, T; Fuller, G; Hargovan, P; Clarke, DL; Muckart, DJ; Thomson, SR				Alexander, T.; Fuller, G.; Hargovan, P.; Clarke, D. L.; Muckart, D. J.; Thomson, S. R.			An audit of the quality of care of traumatic brain injury at a busy regional hospital in South Africa	SOUTH AFRICAN JOURNAL OF SURGERY			English	Article							HEAD-INJURIES; MANAGEMENT; EMERGENCY; ACCIDENT	Access to care by a dedicated neurosurgical unit is limited in the developing world, and the vast majority of patients who sustain a head injury are managed by general surgeons. Prevention of secondary brain injury is paramount. While the principles of management are relatively straightforward, delivering this care may be difficult. This audit looks at the spectrum of head injuries presenting to a busy regional hospital and attempts to measure the quality of care offered to these patients. Patients and methods. The audit includes three separate sections. The first is a prospective audit of all patients with a traumatic brain injury presenting to the Accident and Emergency (AE) department at Edendale Hospital, Pietermaritzburg, over a 2-month period, The next two sub-audits consist of a random review of referral letters and AE clerking notes to assess the quality of care received by these patients. A total of 25 referral letters and 28 AE inpatient notes were randomly chosen for review and compared with agreed standardised markers for quality of care. Results. Over the 2 months October and November 2007, 150 patients with a head injury were seen in the AE department. Of these 117 were male. A total of 76 were discharged home after investigation with a head injury warning chart, 49 were admitted to the general wards, 11 were admitted to the surgical intensive care unit, 10 were referred to the neurosurgical centre in Durban, and 4 died in the AE department. Of the 10 who needed advanced neurosurgical care, 3 required urgent burr-holes before referral. One of these patients died. All the remaining 9 patients who were transferred to the neurosurgery unit survived. The referral letters and AE clerking notes revealed major deficits. Conclusion. Traumatic brain injury is a common problem. Only a small subset of patients require specialised neurosurgical care. Although many patients with intracranial injury can tolerate the delay associated with transfer, some cases are acute and urgent intervention by non-neurosurgeons is needed. Prevention of secondary brain injury is poorly understood and not prioritised. This situation needs to be improved. The introduction of formalised standard referral and management sheets may help to improve care.	[Alexander, T.; Fuller, G.; Hargovan, P.] Edendale Hosp, Dept Accid & Emergency, Pietermaritzburg, South Africa; [Clarke, D. L.; Muckart, D. J.; Thomson, S. R.] Univ KwaZulu Natal, Dept Gen Surg, Durban, South Africa	Alexander, T (corresponding author), Edendale Hosp, Dept Accid & Emergency, Pietermaritzburg, South Africa.			Clarke, Damian/0000-0002-8467-1455			Chesnut RM, 2007, SURG CLIN N AM, V87, P119, DOI 10.1016/j.suc.2006.09.018; Cohn SM, 2007, J TRAUMA, V62, P951, DOI 10.1097/01.ta.0000260131.79063.50; FISHER RB, 1990, BRIT MED J, V300, P1560, DOI 10.1136/bmj.300.6739.1560; Guha A, 2004, POSTGRAD MED J, V80, P650, DOI 10.1136/pgmj.2004.019570; Harrington DT, 2005, ANN SURG, V241, P961, DOI 10.1097/01.sla.0000164178.62726.f1; Harris OA, 2008, J NEUROSURG, V109, P433, DOI 10.3171/JNS/2008/109/9/0433; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JACOBSON S, 1993, J TRAUMA, V35, P491, DOI 10.1097/00005373-199309000-00032; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Myburgh J A, 1999, Crit Care Resusc, V1, P55; Nadvi SS, 1997, S AFR MED J, V87, P1669; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; O'Connor AE, 2001, NEW ZEAL MED J, V114, P443; Pitts LH, 1998, J TRAUMA, V44, P989; Rinker CF, 1998, J TRAUMA, V44, P984, DOI 10.1097/00005373-199806000-00009; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; Thomson R, 1994, Qual Health Care, V3, P86, DOI 10.1136/qshc.3.2.86; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004; WALLACE SA, 1994, J ACCID EMERG MED, V11, P33; Zulu BMW, 2007, INJURY, V38, P576, DOI 10.1016/j.injury.2007.01.002	21	20	22	0	4	SA MEDICAL ASSOC	PRETORIA	BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3, PRETORIA, 0002, SOUTH AFRICA	0038-2361	2078-5151		S AFR J SURG	South Afr. J. Surg.	NOV	2009	47	4					120	+					6	Surgery	Surgery	547DK	WOS:000273865600004	20141069				2021-06-18	
J	Bagiella, E				Bagiella, Emilia			Clinical Trials in Rehabilitation: Single or Multiple Outcomes?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Clinical trials as topic; Rehabilitation	END-POINTS	Bagiella E. Clinical trials in rehabilitation: single or multiple outcomes? Arch Phys Med Rebabil 2009;90 (11 Suppl 1):S17-21. In clinical trials, the choice of the primary outcome affects the study design, the sample size calculations, the data analysis, and the interpretation of the study results. Most importantly, it may determine the future of the intervention being studied. In several clinical and rehabilitation settings, a single primary outcome measure is often not sufficient to reflect the effect of an intervention because attention is focused on multiple aspects of patients' recovery. In stroke and traumatic brain injuries trials, for example, functional recovery is as important as cognitive recovery. Thus, a trial with a functional scale alone as the primary outcome would not be informative a out the effectiveness of the intervention on cognitive functions. From the methodologic point of view, the choice of multiple primary outcomes presents several challenges, including selecting a measure, among several, to be used for sample size calculations; dealing with multiple comparisons; and interpreting the results. In this article, we discuss a global test procedure that allows investigators to use several binary measures as primary outcomes in a clinical trial. This procedure offers an efficient solution under very reasonable assumptions, avoids loss of power caused by multiple comparisons, has greater statistical power than any single outcome measure, and is easily interpreted and of direct clinical interest.	Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA	Bagiella, E (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, 722 W 168th St, New York, NY 10032 USA.	eb51@columbia.edu					Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Fleiss J., 1986, DESIGN ANAL CLIN EXP; Hardin J.W., 2003, GEN ESTIMATING EQUAT; MEIER P, 1975, BIOMETRICS, V31, P511, DOI 10.2307/2529434; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; Pocock SJ, 1997, CONTROL CLIN TRIALS, V18, P530, DOI 10.1016/S0197-2456(97)00008-1; POCOCK SJ, 1997, CONTROL CLIN TRIALS, V18, P546; Rao CR., 1999, LINEAR MODELS LEAST; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tilley BC, 1999, ARTHRITIS RHEUM, V42, P1879, DOI 10.1002/1529-0131(199909)42:9<1879::AID-ANR12>3.0.CO;2-1; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136	13	20	20	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2009	90	11		1			S17	S21		10.1016/j.apmr.2009.08.133			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	520XE	WOS:000271882100004	19892070				2021-06-18	
J	Ishibe, N; Pordarczyk, RC; Fulco, C				Ishibe, Naoko; Pordarczyk, Renee C.; Fulco, Carolyn			Overview of the Institute of Medicine's Committee Search Strategy and Review Process for Gulf War and Health: Long-term Consequences of Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; outcomes; traumatic brain injury		Objectives: To exam I ne the strength of the peer-reviewed literature on the evidence for an association between traumatic brain injury (TBI) and long-term health outcomes using the association categories established and used by previous Institute of Medicine Committees on Gulf War and Health. The health effects that were evaluated were neurologic, cognitive, social functioning, psychiatric, and other (eg, brain tumor, mortality) outcomes. Participants: Not applicable. Design: A comprehensive search using Medline and PsycINFO databases and a critical review of the peer-reviewed literature on human TBI published between 1960 and 2008. Primary Measures: Not applicable. Results: A total of 14 302 citations were identified, of which 1933 were reviewed for further scientific merit; of these, 152 studies met the inclusion/exclusion criteria that form the basis for the findings and recommendations contained, in this topical issue. Conclusion: Based on this review, the committee concluded that there was sufficient evidence of a causal relationship for 3 health outcomes with TBI, sufficient evidence of an association for 13 outcomes, limited/suggestive evidence of an association for 10 outcomes, and inadequate/insufficient evidence to determine whether an association exists for 10 outcomes.	[Ishibe, Naoko] Natl Acad, Inst Med, Board Hlth Select Populat, Washington, DC 20001 USA	Ishibe, N (corresponding author), Natl Acad, Inst Med, Board Hlth Select Populat, 500 5th St NW, Washington, DC 20001 USA.	nishibe@nas.edu			US Department of Veterans AffairsUS Department of Veterans Affairs; National Academies	This study was supported by a contract from the US Department of Veterans Affairs to the Institute of Medicine, the National Academies. We thank Dr George Rutberford for his technical assistance. We also thank Ms Deepali Patel for her assistance with the original literature searches and organizational expertise.	Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; HILL AB, 1965, P ROY SOC MED, V49, P175; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; 2009, GULF WAR HLTH, V7; 2000, GULF WAR HLTH, V1	8	20	20	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2009	24	6					424	429		10.1097/HTR.0b013e3181c13426			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	528VW	WOS:000272476100002	19940675				2021-06-18	
J	Avraham, Y; Grigoriadis, NC; Magen, I; Poutahidis, T; Vorobiav, L; Zolotarev, O; Ilan, Y; Mechoulam, R; Berry, EM				Avraham, Y.; Grigoriadis, N. C.; Magen, I.; Poutahidis, T.; Vorobiav, L.; Zolotarev, O.; Ilan, Y.; Mechoulam, R.; Berry, E. M.			Capsaicin affects brain function in a model of hepatic encephalopathy associated with fulminant hepatic failure in mice	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						hepatic encephalopathy; fulminant hepatic failure; capsaicin; cannabinoids; thioacetamide; TRPV1 receptors; astrogliosis; catecholamines; serotonin; cognition	CANNABINOID RECEPTOR AGONIST; CLOSED-HEAD INJURY; LIVER-DISEASE; CB2 RECEPTORS; MOUSE-BRAIN; ENDOCANNABINOIDS; ASTROGLIOSIS; SYSTEM; 2-AG; EXPRESSION	Background and purpose: Hepatic encephalopathy is a neuropsychiatric syndrome caused by liver failure. In view of the effects of cannabinoids in a thioacetamide-induced model of hepatic encephalopathy and liver disease and the beneficial effect of capsaicin (a TRPV1 agonist) in liver disease, we assumed that capsaicin may also affect hepatic encephalopathy. Experimental approach: Fulminant hepatic failure was induced in mice by thioacetamide and 24 h later, the animals were injected with one of the following compound(s): 2-arachidonoylglycerol (CB1, CB2 and TRPV1 receptor agonist); HU308 (CB2 receptor agonist), SR141716A (CB1 receptor antagonist); SR141716A+2-arachidonoylglycerol; SR144528 (CB2 receptor antagonist); capsaicin; and capsazepine (TRPV1 receptor agonist and antagonist respectively). Their neurological effects were evaluated on the basis of activity in the open field, cognitive function in an eight-arm maze and a neurological severity score. The mice were killed 3 or 14 days after thioacetamide administration. 2-arachidonoylglycerol and 5-hydroxytryptamine (5-HT) levels were determined by gas chromatography-mass spectrometry and high-performance liquid chromatography with electrochemical detection, respectively. Results: Capsaicin had a neuroprotective effect in this animal model as shown by the neurological score, activity and cognitive function. The effect of capsaicin was blocked by capsazepine. Thioacetamide induced astrogliosis in the hippocampus and the cerebellum and raised brain 5-hydroxytryptamine levels, which were decreased by capsaicin, SR141716A and HU-308. Thioacetamide lowered brain 2-arachidonoylglycerol levels, an effect reversed by capsaicin. Conclusions: Capsaicin improved both liver and brain dysfunction caused by thioacetamide, suggesting that both the endocannabinoid and the vanilloid systems play important roles in hepatic encephalopathy. Modulation of these systems may have therapeutic value.	[Avraham, Y.; Magen, I.; Vorobiav, L.; Zolotarev, O.; Berry, E. M.] Hadassah Hebrew Univ, Dept Metab & Human Nutr, Braun Sch Publ Hlth, Sch Med, IL-91120 Jerusalem, Israel; [Grigoriadis, N. C.] Aristotle Univ Thessaloniki, Dept Neurol, AHEPA Univ Hosp, GR-54006 Thessaloniki, Greece; [Poutahidis, T.] Aristotle Univ Thessaloniki, Dept Pathol, Sch Vet Med, GR-54006 Thessaloniki, Greece; [Ilan, Y.] Hadassah Univ Hosp, Liver Unit, IL-91120 Jerusalem, Israel; [Mechoulam, R.] Hebrew Univ Jerusalem, Dept Med Chem & Nat Prod, Fac Med, Jerusalem, Israel	Avraham, Y (corresponding author), Hadassah Hebrew Univ, Dept Metab & Human Nutr, Braun Sch Publ Hlth, Sch Med, IL-91120 Jerusalem, Israel.	yosefa@md.huji.ac.il		Magen, Iddo/0000-0002-3011-3175	Israel Science FoundationIsrael Science Foundation	We would like to thank the Israel Science Foundation for the support of the study.	Ahboucha S, 2007, METAB BRAIN DIS, V22, P291, DOI 10.1007/s11011-007-9065-2; Alexander SPH, 2008, BRIT J PHARMACOL, V153, pS1, DOI 10.1038/sj.bjp.0707746; Archer VE, 2002, MED HYPOTHESES, V59, P450, DOI 10.1016/S0306-9877(02)00152-4; Avraham Y, 2006, NEUROBIOL DIS, V21, P237, DOI 10.1016/j.nbd.2005.07.008; Avraham Y, 1996, BRAIN RES, V732, P133, DOI 10.1016/0006-8993(96)00514-8; Avraham Y, 2008, AM J GASTROENTEROL, V103, P3047, DOI 10.1111/j.1572-0241.2008.02155.x; Avraham Y, 2008, PROSTAG LEUKOTR ESS, V79, P35, DOI 10.1016/j.plefa.2008.07.003; BALASINGAM V, 1994, J NEUROSCI, V14, P846; Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953; Benito C, 2003, J NEUROSCI, V23, P11136; BLUNDELL JE, 1992, AM J CLIN NUTR, V55, P155, DOI 10.1093/ajcn/55.1.155s; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Dagon Y, 2007, FASEB J, V21, P2431, DOI 10.1096/fj.06-7705com; Di Marzo V, 1998, FEBS LETT, V436, P449, DOI 10.1016/S0014-5793(98)01175-2; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Fernandez-Martinez A, 2004, J HEPATOL, V40, P963, DOI 10.1016/j.jhep.2004.02.019; Fioravanti B, 2008, J NEUROSCI, V28, P11593, DOI 10.1523/JNEUROSCI.3322-08.2008; FITZ GJ, 2002, SLEISENGER FORDTRANS, P1543; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; Gabbay E, 2005, LIVER INT, V25, P921, DOI 10.1111/j.1478-3231.2005.01180.x; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Haider S, 2004, POL J PHARMACOL, V56, P73; Hanus L, 2003, BRAIN RES, V983, P144, DOI 10.1016/S0006-8993(03)03046-4; Herber DL, 2006, GLIA, V53, P382, DOI 10.1002/glia.20272; Izzo AA, 2008, GUT, V57, P1140, DOI 10.1136/gut.2008.148791; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Kim CS, 2003, CELL SIGNAL, V15, P299, DOI 10.1016/S0898-6568(02)00086-4; Kunos G, 2006, NAT MED, V12, P607, DOI 10.1038/nm0606-608; Lee JS, 2004, ARCH PHARM RES, V27, P1147, DOI 10.1007/BF02975121; Lee WS, 2005, J PEDIATR GASTR NUTR, V40, P575, DOI 10.1097/01.MPG.0000158524.30294.E2; Li Y, 2003, GUT, V52, P293, DOI 10.1136/gut.52.2.293; Lotersztajn S, 2008, BRIT J PHARMACOL, V153, P286, DOI 10.1038/sj.bjp.0707511; Lu IJ, 2005, J APPL PHYSIOL, V98, P1646, DOI 10.1152/japplphysiol.01133.2004; Magen I, 2008, CURR PHARM DESIGN, V14, P2362, DOI 10.2174/138161208785740063; Mechoulam R, 2007, MOL NEUROBIOL, V36, P68, DOI 10.1007/s12035-007-8008-6; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Morgan MY, 2007, METAB BRAIN DIS, V22, P389, DOI 10.1007/s11011-007-9060-7; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; PICK CG, 1983, INT J NEUROSCI, V21, P63, DOI 10.3109/00207458308986121; Rohl C, 2007, BRAIN RES, V1129, P43, DOI 10.1016/j.brainres.2006.10.057; Shawcross D, 2005, LANCET, V365, P431, DOI 10.1016/S0140-6736(05)17832-5; Teixeira-Clerc F, 2008, PATHOL BIOL, V56, P36, DOI 10.1016/j.patbio.2007.01.001; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Varga K, 1998, FASEB J, V12, P1035; ZIMMERMANN C, 1989, HEPATOLOGY, V9, P594, DOI 10.1002/hep.1840090414	48	20	22	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	OCT	2009	158	3					896	906		10.1111/j.1476-5381.2009.00368.x			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	507CB	WOS:000270826600024	19764982	Bronze, Green Published			2021-06-18	
J	Wright, MJ; Woo, E; Schmitter-Edgecombe, M; Hinkin, CH; Miller, EN; Gooding, AL				Wright, Matthew J.; Woo, Ellen; Schmitter-Edgecombe, Maureen; Hinkin, Charles H.; Miller, Eric N.; Gooding, Amanda L.			The Item-Specific Deficit Approach to evaluating verbal memory dysfunction: Rationale, psychometrics, and application	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Memory; Psychometrics; Brain injury; Traumatic brain injury; Human immunodeficiency virus	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; HIV-ASSOCIATED DEMENTIA; TEMPORAL-LOBE EPILEPSY; CLOSED-HEAD INJURY; EPISODIC MEMORY; PARKINSONS-DISEASE; LEARNING TEST; LONG-TERM; RETRIEVAL DEFICITS	In the current study, we introduce the Item-Specific Deficit Approach (ISDA), a novel method for characterizing memory process deficits in list-learning data. To meet this objective, we applied the ISDA to California Verbal Learning Test (CVLT) data collected from a sample of 132 participants (53 healthy participants and 79 neurologically compromised participants). Overall, the ISDA indices measuring encoding, consolidation, and retrieval deficits demonstrated advantages over some traditional indices and indicated acceptable reliability and validity. Currently, the ISDA is intended for experimental use, although further research may support its utility for characterizing memory impairments in clinical assessments.	[Wright, Matthew J.; Woo, Ellen; Hinkin, Charles H.; Miller, Eric N.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA; [Woo, Ellen] Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Los Angeles, CA USA; [Schmitter-Edgecombe, Maureen] Washington State Univ, Pullman, WA 99164 USA; [Hinkin, Charles H.; Gooding, Amanda L.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; [Miller, Eric N.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA	Wright, MJ (corresponding author), Harbor UCLA Med Ctr, 1000 W Carson St,D-2 Annex,5,Box 495, Torrance, CA 90509 USA.	mwright@labiomed.org		Miller, Eric/0000-0002-0650-714X	Marchionne Memorial Doctoral Fellowship (Washington State University); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R03 HD35838, R01 NS47690, R01 MH585522, T32 MH019535]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD035838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019535, R01MH058552] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047690] Funding Source: NIH RePORTER	Special thanks go to Anna Curren and for her assistance. This work was supported by a Marchionne Memorial Doctoral Fellowship (Washington State University) as well as National Institutes of Health funding (R03 HD35838, R01 NS47690, R01 MH585522, and T32 MH019535). Profitable use of the item-specific deficit approach (ISDA) is under the protection of U.S. Patent No. 60/862,837.	AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; Aggleton JP, 2006, TRENDS COGN SCI, V10, P455, DOI 10.1016/j.tics.2006.08.003; Alessio A, 2004, EPILEPSY BEHAV, V5, P22, DOI 10.1016/j.yebeh.2003.10.010; ANASTASI A, 1988, PSYCHOL TESTING, P109; Ariza M, 2006, BRAIN INJURY, V20, P1053, DOI 10.1080/02699050600909862; Beatty WW, 2003, ARCH CLIN NEUROPSYCH, V18, P509, DOI 10.1016/S0887-6177(02)00148-8; Bernard F, 2001, NEUROREPORT, V12, P1737, DOI 10.1097/00001756-200106130-00044; Bor D, 2004, EUR J NEUROSCI, V19, P3365, DOI 10.1111/j.1460-9568.2004.03438.x; Buckner RL, 1999, NAT NEUROSCI, V2, P311, DOI 10.1038/7221; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; Carey CL, 2004, J CLIN EXP NEUROPSYC, V26, P307, DOI 10.1080/13803390490510031; Cohen R, 2006, CLIN NEUROPSYCHOLOGY, P572; CRONBACH LJ, 1984, ESSENTIALS PSYCHOL T, P158; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 2000, CALIFORNIA VERBAL LE, V2; DELIS DC, 1995, ASSESSMENT, V2, P151, DOI DOI 10.1177/107319119500200205; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Dolan RJ, 1999, HIPPOCAMPUS, V9, P25, DOI 10.1002/(SICI)1098-1063(1999)9:1<25::AID-HIPO3>3.3.CO;2-W; ELLIS HC, 1983, FUNDAMENTALS HUMAN M, P84; ERBER JT, 1985, EXP AGING RES, V11, P101, DOI 10.1080/03610738508259288; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Faglioni P, 2000, NEUROPSYCHOLOGY, V14, P456, DOI 10.1037//0894-4105.14.3.456; Fernandez G, 1998, J NEUROSCI, V18, P1841; Fuster JM, 2000, INT J PSYCHOPHYSIOL, V35, P155, DOI 10.1016/S0167-8760(99)00050-1; GEISELMAN RE, 1982, J EXP PSYCHOL GEN, V111, P109, DOI 10.1037/0096-3445.111.1.109; GIMRANOV RF, 2005, HUM PHYSIOL+, V31, P398; Greicius MD, 2003, HIPPOCAMPUS, V13, P164, DOI 10.1002/hipo.10064; Habib R, 2003, TRENDS COGN SCI, V7, P241, DOI 10.1016/S1364-6613(03)00110-4; Heaton R K, 1995, J Int Neuropsychol Soc, V1, P231; Howe M. L., 1988, COGNITIVE DEV ADULTH, P39, DOI 10.1007/978-1-4612-3852-2_2; Jefferies E, 2004, J MEM LANG, V51, P623, DOI 10.1016/j.jml.2004.07.005; Karlsgodt KH, 2005, NEUROIMAGE, V25, P1224, DOI 10.1016/j.neuroimage.2005.01.038; KEHOE J, 1995, PRACTICAL ASSESSMENT, V10; KLINE TJB, 2005, PSYCHOL TESTING PRAC, P167; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A, P414; Manly JJ, 2004, APPL NEUROPSYCHOL, V11, P37, DOI 10.1207/s15324826an1101_5; Manly JJ, 2002, J INT NEUROPSYCH SOC, V8, P341, DOI 10.1017/S1355617702813157; NIELSENBOHLMAN L, 1994, NEUROREPORT, V5, P1517, DOI 10.1097/00001756-199407000-00027; Norman MA, 2000, J CLIN EXP NEUROPSYC, V22, P80, DOI 10.1076/1380-3395(200002)22:1;1-8;FT080; Nyberg L, 2002, COGNITIVE BRAIN RES, V13, P281, DOI 10.1016/S0926-6410(02)00052-6; Nyberg L, 1996, PSYCHON B REV, V3, P135, DOI 10.3758/BF03212412; PEAVY G, 1994, J CLIN EXP NEUROPSYC, V16, P508, DOI 10.1080/01688639408402662; Pedhazur E., 1991, MEASUREMENT DESIGN A, P81; POSTMAN L, 1971, EXPT PSYCHOL; RIEFER DM, 1991, B PSYCHONOMIC SOC, V29, P415; Rund BR, 1999, ACTA PSYCHIAT SCAND, V100, P85, DOI 10.1111/j.1600-0447.1999.tb10829.x; Scott JC, 2006, NEUROPSYCHOLOGIA, V44, P1336, DOI 10.1016/j.neuropsychologia.2006.01.008; SPILICH GJ, 1982, EXPT AGING RES, V8, P45; SQUIRE LR, 1994, INT REV NEUROBIOL, V37, P243; Squire LR, 1998, HIPPOCAMPUS, V8, P205, DOI 10.1002/(SICI)1098-1063(1998)8:3<205::AID-HIPO3>3.3.CO;2-8; SQUIRE LR, 1980, NEUROPSYCHOLOGIA, V18, P368; Stip E, 2007, CLIN NEUROPHARMACOL, V30, P218, DOI 10.1097/WNF.0B013E318059BE76; Strange BA, 2002, J NEUROSCI, V22, P523, DOI 10.1523/JNEUROSCI.22-02-00523.2002; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G; TULVING E, 1973, PSYCHOL REV, V80, P352, DOI 10.1037/h0020071; Tulving E, 1997, CURR OPIN NEUROBIOL, V7, P209, DOI 10.1016/S0959-4388(97)80009-8; TULVING E, 1968, J EXP PSYCHOL, V77, P593, DOI 10.1037/h0026069; URBINA S, 2004, ESSENTIALS PSYCHOL T, P117; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Vingerhoets G, 2006, EPILEPSY BEHAV, V8, P422, DOI 10.1016/j.yebeh.2005.11.013; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; White DA, 1997, J CLIN EXP NEUROPSYC, V19, P357, DOI 10.1080/01688639708403864; Whitehead A, 2004, INT J GERIATR PSYCH, V19, P624, DOI 10.1002/gps.1133; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Wilde MC, 1995, J CLIN EXP NEUROPSYC, V17, P849, DOI 10.1080/01688639508402434; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]	68	20	20	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	2009	31	7					790	802		10.1080/13803390802508918			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	500AS	WOS:000270270000002	19142773	Green Accepted			2021-06-18	
J	Greve, KW; Curtis, KL; Bianchini, KJ; Ord, JS				Greve, Kevin W.; Curtis, Kelly L.; Bianchini, Kevin J.; Ord, Jonathan S.			Are the Original and Second Edition of the California Verbal Learning Test Equally Accurate in Detecting Malingering?	ASSESSMENT			English	Article						California Verbal Learning Test; memory; malingering; traumatic brain injury; chronic pain; assessment	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; DIGIT RECOGNITION TEST; NEUROCOGNITIVE DYSFUNCTION; CLASSIFICATION ACCURACY; SPECIFICITY; INDICATORS; SENSITIVITY; MMPI-2	This two-part study sought to determine the equivalence of the California Verbal Learning Tests (CVLT-1 and CVLT-2) in the detection of malingering in traumatic brain injury (TB1) and chronic pain. Part 1 compared a variety of scores from the two versions in carefully matched patient groups. Part 2 used criterion groups (known-groups) methodology to examine the relative rates of false positive (FP) errors across the two versions. Participants were 442 TBI (CVLT-1 = 3 10; CVLT-2 = 132) and 378 chronic pain patients (CVLT-1 = 250; CVLT-2 = 128). Overall, the CVLT-2 was more difficult than the CVLT-1, with the chronic pain patients showing larger version effects than the TBI patients. The two versions of the CVLT were equally accurate in detecting malingering in TBI and chronic pain. However, they were not interchangeable. The use of CVLT-1 cutoffs with the CVLT-2 may result in an increased risk of FP error. Appropriate cutoff adjustment in clinical practice is recommended.	[Greve, Kevin W.; Bianchini, Kevin J.] Univ New Orleans, Jefferson Neurobehav Grp, Los Angeles, CA USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; BINDER LM, 1993, PORTLAND DIGIT RECOG; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 2000, CALIFORNIA VERBAL LE; Doane BM, 2005, CLIN NEUROPSYCHOL, V19, P99, DOI 10.1080/13854040490524100; Donders J, 2007, BRAIN INJURY, V21, P319, DOI 10.1080/02699050701253129; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P816, DOI 10.1080/13854040500346610; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; MILLIS SR, 2007, J INT NEUROPSYCH SOC, V13, P193; MILLIS SR, 1997, CVLT ASSESSMENT FINA; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1997, WAIS 3 ADM SCORING M	32	20	21	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911			ASSESSMENT	Assessment	SEP	2009	16	3					237	248		10.1177/1073191108326227			12	Psychology, Clinical	Psychology	482YS	WOS:000268927400002	19098280				2021-06-18	
J	Atighechi, S; Salari, H; Baradarantar, MH; Jafari, R; Karimi, G; Mirjali, M				Atighechi, Saeid; Salari, Hadi; Baradarantar, Mohammad Hossein; Jafari, Rozita; Karimi, Ghasem; Mirjali, Mehdi			A comparative study of brain perfusion single-photon emission computed tomography and magnetic resonance imaging in patients with post-traumatic anosmia	AMERICAN JOURNAL OF RHINOLOGY & ALLERGY			English	Article						Anosmia; frontal lobe; head injury; MRI; 99mtc-ethyl-cysteinate-dimer; olfactory bulb; SPECT	CLOSED HEAD-INJURY; OLFACTORY FUNCTION; COMPARING SPECT; SMELL; DYSFUNCTION; TASTE; MRI	Background: Loss of smell is a problem that can occur in up to 30% of patients with head trauna. The olfactory function investigation methods so far in use have mostly relied on subjective responses given by patients. Recently, some studies have used magnetic resonance imaging (MRI) and single-photon emission computed tomography (SPECT) to evaluate patients with post-traumatic anosmia. The present study seeks to detect post-traumatic anosmia and the areas in the brain that are related to olfactory impairment by using SPECT and MRI as imaging techniques. Methods: The study was conducted on 21 patients suffering from head injury and consequently anosmia as defined by an olfactory identification test. Two control groups (traumatic normosmic and nontraumatic healthy individuals) were selected. Brain MRI, qualitative and semiquantitative SPECT with 99mtc-ethyl-cysteinate-dimer were taken from all the patients. Then the brain SPECT and MRI were compared with each other. Results: Semi-quantitative assessment of the brain perfusion SPECT revealed frontal, left parietal, and left temporal hypoperfusion as compared with the two control groups. Eighty-five percent of the anosmic patients had abnormal brain MRI. Regarding the MRI, the main abnormality proved to be in the anterior inferior region of the frontal lobes and olfactory bulbs. Conclusions: The findings of this study suggest that damage to the frontal lobes and olfactory bulbs as shown in the brain MRI and hypoperfusion in the frontal, left parietal, and left temporal lobes in the semiquantitative SPECT corresponds to post-traumatic anosmia. Further neurophysiological and imaging studies are definitely needed to set the idea completely. (Am J Rhinol Allergy 23, 409-412, 2009; doi: 10.2500/ajra.2009.23.3345)	[Atighechi, Saeid; Baradarantar, Mohammad Hossein; Jafari, Rozita; Karimi, Ghasem] Yazd Univ Med Sci, Shahid Sadughi Hosp, Dept Otolaryngol, Shahid Ghandi 8915887857, Yazd, Iran; [Mirjali, Mehdi] Forens Med Org Yazd, Yazd, Iran	Atighechi, S (corresponding author), Yazd Univ Med Sci, Shahid Sadughi Hosp, Dept Otolaryngol, Shahid Ghandi 8915887857, Yazd, Iran.	atighechi@ssu.ac.ir	karimi, ghasem/Q-3127-2018; atighechi, saeid/F-6352-2017	atighechi, saeid/0000-0002-9330-5342; karimi, ghasem/0000-0001-9400-3488			CAIN WS, 1988, LARYNGOSCOPE, V98, P83; CAIN WS, 1983, AM J OTOLARYNG, V4, P252, DOI 10.1016/S0196-0709(83)80068-4; Di Nardo W, 2000, AM J RHINOL, V14, P57, DOI 10.2500/105065800781602984; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; Eftekhari M, 2006, AM J RHINOL, V20, P577, DOI 10.2500/ajr.2006.20.2906; Eibenstein A, 2005, NEUROL SCI, V26, P147, DOI 10.1007/s10072-005-0452-3; HENDRIKS A P J, 1988, Rhinology (Utrecht), V26, P229; HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P467; Liu Jian-Feng, 2008, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V43, P198; Mann NM, 2004, OTOLARYNG CLIN N AM, V37, P289, DOI 10.1016/S0030-6665(03)00157-9; Mann NM, 2006, CLIN NUCL MED, V31, P458, DOI 10.1097/01.rlu.0000227010.72925.6d; MOTT AE, 1991, MED CLIN N AM, V75, P1321, DOI 10.1016/S0025-7125(16)30391-1; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Nik H, 2007, BRIT J HOSP MED, V68, P237, DOI 10.12968/hmed.2007.68.5.23328; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Scott A E, 1989, Ear Nose Throat J, V68, P297; Summer D, 1976, HDB CLIN NEUROLOGY, P235; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; Varney NR, 1998, J HEAD TRAUMA REHAB, V13, P63; Yousem DM, 2001, SEMIN ULTRASOUND CT, V22, P456, DOI 10.1016/S0887-2171(01)90001-0	21	20	21	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1945-8924	1945-8932		AM J RHINOL ALLERGY	Am. J. Rhinol. Allergy	JUL-AUG	2009	23	4					409	412		10.2500/ajra.2009.23.3345			4	Otorhinolaryngology	Otorhinolaryngology	481HC	WOS:000268797300009	19671257				2021-06-18	
J	O'Phelan, KH; Park, D; Efird, JT; Johnson, K; Albano, M; Beniga, J; Green, DM; Chang, CWJ				O'Phelan, Kristine H.; Park, Dalnam; Efird, Jimmy T.; Johnson, Katherine; Albano, Melanie; Beniga, Juliet; Green, Deborah M.; Chang, Cherylee W. J.			Patterns of Increased Intracranial Pressure After Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article; Proceedings Paper	5th Annual Meeting of the Neurocritical-Care-Society	NOV 01, 2007	Las Vegas, NV	Neurocrit Care Soc		Intracranial pressure; Traumatic brain injury; Intracranial hypertension	HYPERTONIC SALINE; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; MANNITOL; RESUSCITATION; EDEMA	Secondary brain injury due to increased intracranial pressure (ICP) contributes to post-traumatic morbidity and mortality. Although it is often taught that increased ICP begins early after traumatic brain injury, some patients develop increased ICP after the first 3 days post-injury. We examined our data to describe temporal patterns of increased ICP. This is a retrospective review of prospectively collected physiologic and demographic data. Seventy-seven patients were included. We identified four patterns of increased ICP: beginning within 72 h (early), beginning after 72 h (late), early increases with resolution, and then a second rise after 72 h (bimodal), and continuously increased ICP. Late increases in ICP occur in 17% of this cohort. Peak day of swelling was day 7 for the "late" rise group and day 4 for the other patients with increased ICP. Forty-four percent of patients showed enlargement of cerebral contusions on follow-up imaging at 24 h post-injury. Late rises in ICP were not rare in this cohort. This is clinically relevant as it may impact decisions about ICP monitor removal. Differences between groups in age, CT patterns of injury, fluid therapy, osmotic use, and fever were not statistically significant.	Neuroscience Inst, Queens Med Ctr, Honolulu, HI 96813 USA; [O'Phelan, Kristine H.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [O'Phelan, Kristine H.; Park, Dalnam; Johnson, Katherine; Albano, Melanie; Beniga, Juliet; Green, Deborah M.; Chang, Cherylee W. J.] Queens Med Ctr, Inst Neurosci, Honolulu, HI 96813 USA; [O'Phelan, Kristine H.; Green, Deborah M.; Chang, Cherylee W. J.] Univ Hawaii, Dept Med, John A Burns Sch Med, Honolulu, HI 96813 USA; [O'Phelan, Kristine H.; Green, Deborah M.; Chang, Cherylee W. J.] Univ Hawaii, Dept Surg, John A Burns Sch Med, Honolulu, HI 96813 USA; [Efird, Jimmy T.] Cincinnati Childrens Hosp, Div Pediat Gen & Thorac Surg, Cincinnati, OH 45229 USA	O'Phelan, KH (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, 1120 NW 14th St,CRB 1358, Miami, FL 33136 USA.	kophelan@med.miami.edu	Chang, Cherylee/ABG-2080-2020	Green-LaRoche, MD, Deborah/0000-0001-8158-0788			ADAMS JH, 1992, HEAD INJURY GREENFIE; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS91; BUXTON RL, 1970, LANCET, V2, P498; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; DOSTAL PCV, 1998, CRIT CARE, V2; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Kohta M, 2007, J CLIN NEUROSCI, V14, P167, DOI 10.1016/j.jocn.2006.01.042; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Madigan MC, 2008, J TRAUMA, V64, P280, DOI 10.1097/TA.0b013e3181622bb6; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155	24	20	20	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2009	10	3					280	286		10.1007/s12028-008-9183-7			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	449KG	WOS:000266328900005	19165634				2021-06-18	
J	Scales, DC; Riva-Cambrin, J; Le, TL; Pinto, R; Cook, DJ; Granton, JT				Scales, Damon C.; Riva-Cambrin, Jay; Le, Thao Lan; Pinto, Ruxandra; Cook, Deborah J.; Granton, John T.		Canadian Critical Care Trials Grp	Prophylaxis against venous thromboembolism in neurointensive care patients: Survey of Canadian practice	JOURNAL OF CRITICAL CARE			English	Article						Critical care; Neurosurgery; Venous thromboembolism; Venous thrombosis; Anticoagulants; Intracranial hemorrhage; Survey	DEEP-VEIN THROMBOSIS; TRAUMATIC BRAIN-INJURY; NEUROSURGICAL PATIENTS; SUBARACHNOID HEMORRHAGE; COMPRESSION STOCKINGS; RESPONSE RATES; MAJOR TRAUMA; DOUBLE-BLIND; PREVENTION; ENOXAPARIN	Purpose: Although anticoagulant thromboprophylaxis reduces the incidence of venous thromboembolism in critically ill patients, it may increase the risk of devastating bleeding complications in neurosurgical patients. For this population, anticoagulant thromboprophylaxis remains controversial and randomized controlled studies are sparse. Our goal was to establish sufficient clinical equipoise to facilitate future research in this area. Materials and Methods: We conducted a survey of Canadian neurosurgeons and neurointensivists to better understand current practice. We developed a novel self-administered questionnaire on anticoagulant thromboprophylaxis for different neurosurgical subgroups using illustrative clinical scenarios. The instrument was evaluated for clinical sensibility by 20 nurses, neurosurgeons, and intensivists and then mailed to Canadian neurosurgeons (Canadian Neurosurgery Society) and intensivists (Canadian Critical Care Society). Results: The response rate after 3 mailings was 50% for neurosurgeons (66/132) and 49% for intensivists (94/193). Most respondents reported use of anticoagulant thromboprophylaxis for neurosurgical patients, although the timing varied considerably. Use of anticoagulant thromboprophylaxis (ever) ranged from 60% for traumatic intracranial hemorrhage after decompressive craniotomy to 90% for traumatic spinal injury. The responses were comparable between specialties. Conclusions: Most Canadian physicians reported using anticoagulant thromboprophylaxis after neurosurgery, although practice patterns differed as to when and for whom. Future research should quantify the benefits and risks in relation to the time of initiation in different neurosurgical subgroups. Our results suggest there is equipoise regarding the use of anticoagulation thromboprophylaxis in neurosurgical patients. Therefore randomized controlled trials are justifiable and needed to guide clinicians. (C) 2009 Elsevier Inc. All rights reserved.	[Scales, Damon C.; Pinto, Ruxandra; Granton, John T.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Scales, Damon C.] Univ Toronto, Interdepartmental Div Crit Care Med, Toronto, ON M5B 1W8, Canada; [Scales, Damon C.] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; [Riva-Cambrin, Jay] Primary Childrens Med Ctr, Dept Neurosurg, Salt Lake City, UT 84113 USA; [Riva-Cambrin, Jay] Univ Utah, Salt Lake City, UT 84112 USA; [Le, Thao Lan] George Mason Univ, Fairfax, VA 22030 USA; [Cook, Deborah J.] St Josephs Healthcare, Hamilton, ON L8N 4A6, Canada; [Cook, Deborah J.] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada; [Cook, Deborah J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; [Granton, John T.] Univ Hlth Network, Dept Med, Toronto, ON M5G 2C4, Canada; [Granton, John T.] Univ Hlth Network, Dept Crit Care, Toronto, ON M5G 2C4, Canada	Scales, DC (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada.	damon.scales@utoronto.ca		Le, Thao Lan/0000-0003-3299-7450			Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; *AM ASS NEUR SURG, GUID MAN SEV HEAD IN; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Attia J, 2001, ARCH INTERN MED, V161, P1268, DOI 10.1001/archinte.161.10.1268; *CAMBR U, 1982, JUDGM UNC HEUR BIAS; CERRATO D, 1978, J NEUROSURG, V49, P378, DOI 10.3171/jns.1978.49.3.0378; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; Danish SF, 2005, NEUROSURGERY, V56, P1286, DOI 10.1227/01.NEU.0000159882.11635.EA; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Hammond FM, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199802000-00007; JOFFE SN, 1975, J NEUROSURG, V42, P201, DOI 10.3171/jns.1975.42.2.0201; Kellerman SE, 2001, AM J PREV MED, V20, P61, DOI 10.1016/S0749-3797(00)00258-0; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; SAWAYA R, 1992, J NEURO-ONCOL, V14, P119; Siironen J, 2003, J NEUROSURG, V99, P953, DOI 10.3171/jns.2003.99.6.0953; VALLADARES JB, 1980, NEUROSURGERY, V6, P138, DOI 10.1227/00006123-198002000-00004; Wurm G, 2004, CLIN NEUROL NEUROSUR, V106, P97, DOI 10.1016/j.clineuro.2004.01.006	21	20	20	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441			J CRIT CARE	J. Crit. Care	JUN	2009	24	2					176	184		10.1016/j.jcrc.2009.03.010			9	Critical Care Medicine	General & Internal Medicine	458CR	WOS:000266991700004	19501306				2021-06-18	
J	Chung, RS; Leung, YK; Butler, CW; Chen, Y; Eaton, ED; Pankhurst, MW; West, AK; Guillemin, GJ				Chung, R. S.; Leung, Y. K.; Butler, C. W.; Chen, Y.; Eaton, E. D.; Pankhurst, M. W.; West, A. K.; Guillemin, G. J.			Metallothionein Treatment Attenuates Microglial Activation and Expression of Neurotoxic Quinolinic Acid Following Traumatic Brain Injury	NEUROTOXICITY RESEARCH			English	Article						Traumatic brain injury; Neuroinflammation; Neuron-glia interactions	KYNURENINE PATHWAY; DISEASE; CNS; METABOLISM; CELLS; BETA; PROTECT; FAMILY; ZINC	The kynurenine pathway has been implicated as a major component of the neuroinflammatory response to brain injury and neurodegeneration. We found that the neurotoxic kynurenine pathway intermediate quinolinic acid (QUIN) is rapidly expressed, within 24 h, by reactive microglia following traumatic injury to the rodent neocortex. Furthermore, administration of the astrocytic protein metallothionein attenuated this neuroinflammatory response by reducing microglial activation (by approximately 30%) and QUIN expression. The suppressive effect of MT was confirmed upon cultured cortical microglia, with 1 mu g/ml MT almost completely blocking interferon-gamma induced activation of microglia and QUIN expression. These results demonstrate the neuroimmunomodulatory properties of MT, which may have therapeutic applications for the treatment of traumatic brain injury.	[Chung, R. S.; Leung, Y. K.; Butler, C. W.; Eaton, E. D.; Pankhurst, M. W.; West, A. K.] Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Hobart, Tas 7001, Australia; [Chen, Y.; Guillemin, G. J.] Univ New S Wales, Ctr Immunol, Sydney, NSW 2052, Australia	Chung, RS (corresponding author), Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Private Bag 58, Hobart, Tas 7001, Australia.	rschung@utas.edu.au; g.guillemin@cfi.unsw.edu.au	Pankhurst, Michael/F-2585-2017; Chung, Roger/ABF-8395-2020; Guillemin, Gilles J/C-3878-2015	Pankhurst, Michael/0000-0002-0976-5742; Guillemin, Gilles J/0000-0001-8105-4470; Chung, Roger/0000-0002-9286-947X	Australian Research CouncilAustralian Research Council [DP0556630, LP0774820, DP0984673]; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [490025, 544913]	This work was supported by research grants from the Australian Research Council (DP0556630; LP0774820) and National Health and Medical Research Council (ID# 490025, 544913). RSC holds an Australian Research Council ARF Fellowship (DP0984673).	Ambjorn M, 2008, J NEUROCHEM, V104, P21, DOI 10.1111/j.1471-4159.2007.05036.x; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Christofides J, 2006, J NEUROCHEM, V97, P1078, DOI 10.1111/j.1471-4159.2006.03807.x; Chung RS, 2008, J NEUROCHEM, V104, P14, DOI 10.1111/j.1171-4159.2007.05026.x; Chung RS, 2007, CELL MOL LIFE SCI, V64, P2716, DOI 10.1007/s00018-007-7267-8; Chung RS, 2008, J BIOL CHEM, V283, P15349, DOI 10.1074/jbc.M708446200; Chung RS, 2004, CELL MOL LIFE SCI, V61, P1238, DOI 10.1007/s00018-004-4026-y; Chung RS, 2003, J NEUROSCI, V23, P3336; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Floden AM, 2006, J NEUROSCI, V26, P4644, DOI 10.1523/JNEUROSCI.4822-05.2006; FOSTER AC, 1984, NEUROSCI LETT, V48, P273, DOI 10.1016/0304-3940(84)90050-8; Garcao P, 2006, J NEUROSCI RES, V84, P182, DOI 10.1002/jnr.20870; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Guillemin GJ, 2007, J NEUROSCI, V27, P12884, DOI 10.1523/JNEUROSCI.4101-07.2007; Guillemin GJ, 2005, NEUROPATH APPL NEURO, V31, P395, DOI 10.1111/j.1365-2990.2005.00655.x; Guillemin GJ, 2001, J NEUROCHEM, V78, P842, DOI 10.1046/j.1471-4159.2001.00498.x; Guillemin GJ, 2003, ADV EXP MED BIOL, V527, P105; Hartai Z, 2005, ACTA NEUROL SCAND, V112, P93, DOI 10.1111/j.1600-0404.2005.00442.x; Heyes MP, 1996, ADV EXP MED BIOL, V398, P125; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Jhamandas KH, 2000, NEUROTOX RES, V2, P139, DOI 10.1007/BF03033790; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kukacka J, 2006, NEUROENDOCRINOL LETT, V27, P116; Laporte V, 2004, J LEUKOCYTE BIOL, V76, P451, DOI 10.1189/jlb.1203620; Mackay GM, 2006, EUR J NEUROL, V13, P30, DOI 10.1111/j.1468-1331.2006.01220.x; Penkowa M, 2002, J COMP NEUROL, V444, P174, DOI 10.1002/cne.10149; Penkowa M, 1999, J NEUROSCI, V19, P2535; Platten M, 2005, SCIENCE, V310, P850, DOI 10.1126/science.1117634; Ruddick Jon P., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000068; Smythe GA, 2002, ANAL BIOCHEM, V301, P21, DOI 10.1006/abio.2001.5490; West AK, 2004, REV NEUROSCIENCE, V15, P157; Yin XY, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-21; YOUN J, 1995, J TOXICOL ENV HEALTH, V45, P397, DOI 10.1080/15287399509532004; Youn J, 1999, TOXICOL SCI, V52, P199, DOI 10.1093/toxsci/52.2.199	35	20	20	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428			NEUROTOX RES	Neurotox. Res.	MAY	2009	15	4					381	389		10.1007/s12640-009-9044-y			9	Neurosciences	Neurosciences & Neurology	428HG	WOS:000264838000009	19384571				2021-06-18	
J	Singhi, SC; Tiwari, L				Singhi, Sunit C.; Tiwari, Lokesh			Management of intracranial hypertension	INDIAN JOURNAL OF PEDIATRICS			English	Article						Intracranial pressure; Children; Traumatic brain injury; Cerebral perfusion pressure; Hyperosmolar therapy	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; EARLY DECOMPRESSIVE CRANIECTOMY; NERVOUS-SYSTEM INFECTIONS; INTRA-CRANICAL PRESSURE; CONTROLLED-TRIAL; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; HYPERTONIC SALINE; RANDOMIZED-TRIAL	Raised intracranial pressure (ICP) is a life threatening condition that is common to many neurological and non-neurological illnesses. Unless recognized and treated early it may cause secondary brain injury due to reduced cerebral perfusion pressure (CPP), and progress to brain herniation and death. Management of raised ICP includes care of airway, ventilation and oxygenation, adequate sedation and analgesia, neutral neck position, head end elevation by 20A degrees-30A degrees, and short-term hyperventilation (to achieve PCO(2) 32-35 mm Hg) and hyperosmolar therapy (mannitol or hypertonic saline) in critically raised ICP. Barbiturate coma, moderate hypothermia and surgical decompression may be helpful in refractory cases. Therapies aimed directly at keeping ICP < 20 mmHg have resulted in improved survival and neurological outcome. Emerging evidence suggests that cerebral perfusion pressure targeted therapy may offer better outcome than ICP targeted therapies.	[Singhi, Sunit C.; Tiwari, Lokesh] Postgrad Inst Med Educ & Res, Adv Pediat Ctr, Dept Pediat, Pediat Emergency & Intens Care Units, Chandigarh 160012, India	Singhi, SC (corresponding author), Postgrad Inst Med Educ & Res, Adv Pediat Ctr, Dept Pediat, Pediat Emergency & Intens Care Units, Chandigarh 160012, India.	sunit.singhi@gmail.com	Tiwari, Lokesh/I-5965-2019	Tiwari, Lokesh/0000-0002-2231-0152			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS34; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS49; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS40; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; ADLESON PD, 2003, PCCM, V4, P531; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Bader MK, 2005, AACN ADV CRIT CARE, V16, P526, DOI 10.1097/00044067-200510000-00009; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Biousse V, 2003, AM J OPHTHALMOL, V135, P437, DOI 10.1016/S0002-9394(02)02062-7; Caricato A, 2005, J TRAUMA, V58, P571, DOI 10.1097/01.TA.0000152806.19198.DB; Cheung A, 2005, NEUROCRIT CARE, V3, P216, DOI 10.1385/NCC:3:3:216; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Czosnyka M, 1996, NEUROSURGERY, V38, P219, DOI 10.1097/00006123-199601000-00053; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Edwards P, 2005, LANCET, V365, P1957; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GOPINATH SP, 1995, NEUROSURGERY, V36, P1137, DOI 10.1227/00006123-199506000-00011; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kaal ECA, 2004, CURR OPIN ONCOL, V16, P593, DOI 10.1097/01.cco.0000142076.52721.b3; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; KISHORE PRS, 1981, AM J ROENTGENOL, V137, P829, DOI 10.2214/ajr.137.4.829; Knapp JM, 2005, AACN ADV CRIT CARE, V16, P199, DOI 10.1097/00044067-200504000-00011; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Lindvall P, 2004, CLIN INFECT DIS, V38, P384, DOI 10.1086/380970; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Marchuk G, 2005, CAN J NEUROL SCI, V32, pS22; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; REBAUD P, 1988, INTENS CARE MED, V14, P522, DOI 10.1007/BF00263524; Roth P, 2000, Crit Care Nurs Q, V23, P14; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Schramm WM, 1998, ANESTH ANALG, V86, P123, DOI 10.1097/00000539-199801000-00025; Shetty R, 2008, J CHILD NEUROL, V23, P192, DOI 10.1177/0883073807308716; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Valentin A, 2003, CRIT CARE MED, V31, P1539, DOI 10.1097/01.CCM.0000065270.53951.9E; WELCH K, 1980, J NEUROSURG, V52, P693, DOI 10.3171/jns.1980.52.5.0693; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725	57	20	20	0	6	ALL INDIA INST MEDICAL SCIENCES	NEW DELHI	ANSARI NAGAR, NEW DELHI 110 029, INDIA	0019-5456			INDIAN J PEDIATR	Indian J. Pediatr.	MAY	2009	76	5					519	529		10.1007/s12098-009-0137-7			11	Pediatrics	Pediatrics	449LM	WOS:000266332100011	19466385				2021-06-18	
J	Wagshul, ME; Kelly, EJ; Yu, HJ; Garlick, B; Zimmerman, T; Egnor, MR				Wagshul, Mark E.; Kelly, Erin J.; Yu, Hui Jing; Garlick, Barbara; Zimmerman, Tom; Egnor, Michael R.			Resonant and notch behavior in intracranial pressure dynamics	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article; Proceedings Paper	50th Meeting of the Society-for-Research-into-Hydrocephalus-and-Spina-Bifida	AUG 30-SEP 02, 2006-2008	Cambridge, ENGLAND	Soc Res Hydrocephalus & Spina Bifida		intracranial pressure; compliance; notch filter; resonance; transfer function; pulse pressure; pulsatility	CEREBROSPINAL-FLUID FLOW; CSF PULSE-WAVE; HEAD-INJURED PATIENTS; CEREBRAL BLOOD-FLOW; PHASE-CONTRAST MR; SYSTEMS-ANALYSIS; HYDROCEPHALUS PATIENTS; MATHEMATICAL-MODEL; STROKE VOLUME; FORM ANALYSIS	Object. The intracranial pulse pressure is often increased when neuropathology is present, particularly in cases of increased intracranial pressure (ICP) such as occurs in hydrocephalus. This pulse pressure is assumed to originate from arterial blood pressure oscillations enterin g the cranium; the fact that there is a coupling between the arterial blood pressure and the ICP is undisputed. In this study, the nature of this coupling and how it changes under conditions of increased ICP are investigated. Methods. In 12 normal dogs, intracarotid and parenchymal pulse pressure were measured and their coupling was characterized using amplitude and phase transfer function analysis. Mean intracranial ICP was manipulated via infusions of isotonic saline into the spinal subarachnoid space, and changes in transfer function were monitored. Results. Under normal conditions, the ICP wave led the arterial wave, and there was a minimum in the pulse pressure amplitude near the frequency of the heart rate. Under conditions of decreased intracranial compliance, the ICP wave began to lag behind the arterial wave and increased significantly in amplitude. Most interestingly, in many animals the Pulse pressure exhibited a minimum in amplitude at a mean pressure that coincided with the transition from a leading to lagging ICP wave. Conclusions. This transfer function behavior is characteristic of a resonant notch system. This may represent a component of the intracranial Windkessel mechanism, which protects the microvasculature from arterial pulsatility. The impairment of this resonant notch system may play a role in the altered pulse pressure in conditions such as hydrocephalus and traumatic brain swelling. New models of intracranial dynamics are needed for understanding the frequency-sensitive behavior elucidated in these studies and could open a path for development of new therapies that are geared toward addressing the pulsation dysfunction in pathological conditions, such as hydrocephalus and traumatic brain injury, affecting ICP and flow dynamics. (DOI: 10.3171/2009.1.PEDS08109)	[Wagshul, Mark E.] SUNY Stony Brook, Hlth Sci Ctr, Dept Radiol, Stony Brook, NY 11794 USA; [Wagshul, Mark E.; Egnor, Michael R.] SUNY Stony Brook, Dept Neurosurg, Stony Brook, NY 11794 USA; [Wagshul, Mark E.; Yu, Hui Jing] SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; [Kelly, Erin J.] Toshiba Amer Med Syst, Div MR Imaging, Tustin, CA USA; [Garlick, Barbara] SUNY Stony Brook, Dept Surg, Stony Brook, NY 11794 USA	Wagshul, ME (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Radiol, L4-109 Stony Brook, Stony Brook, NY 11794 USA.	mark.wagshul@stonybrook.edu	Yu, Hui Jing/A-1619-2013	Yu, Hui Jing/0000-0003-0662-9670			Alperin NJ, 2000, RADIOLOGY, V217, P877, DOI 10.1148/radiology.217.3.r00dc42877; Bakker SLM, 2002, ACTA NEUROL SCAND, V106, P123, DOI 10.1034/j.1600-0404.2002.01329.x; Bateman GA, 2005, NEURORADIOLOGY, V47, P741, DOI 10.1007/s00234-005-1418-0; Bateman GA, 2003, NEURORADIOLOGY, V45, P65, DOI 10.1007/s00234-002-0901-0; Bergsneider M, 1998, ACT NEUR S, V71, P266; Bilfinger TV, 2000, ANN THORAC SURG, V69, P480, DOI 10.1016/S0003-4975(99)01083-8; BRADLEY WG, 1986, RADIOLOGY, V159, P611, DOI 10.1148/radiology.159.3.3704142; Bradley WG, 1996, RADIOLOGY, V198, P523, DOI 10.1148/radiology.198.2.8596861; Bradley WG, 2002, MAYO CLIN PROC, V77, P507, DOI 10.4065/77.6.507; Chopp M, 1980, Biomed Sci Instrum, V16, P149; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; de Marco G, 2004, J COMPUT ASSIST TOMO, V28, P247, DOI 10.1097/00004728-200403000-00015; Dixon GR, 2002, MAYO CLIN PROC, V77, P509, DOI 10.4065/77.6.509; Egeler-Peerdeman SM, 1998, ACT NEUR S, V71, P340; Egnor M, 2003, PEDIATR NEUROSURG, V38, P273, DOI 10.1159/000069826; Egnor M, 2002, PEDIATR NEUROSURG, V36, P281, DOI 10.1159/000063533; Egnor M, 2001, PEDIATR NEUROSURG, V35, P284, DOI 10.1159/000050440; Eide PK, 2007, PEDIATR NEUROSURG, V43, P472, DOI 10.1159/000108790; Eide PK, 2006, ACTA NEUROCHIR, V148, P1151, DOI 10.1007/s00701-006-0896-0; Eide PK, 2006, MED ENG PHYS, V28, P579, DOI 10.1016/j.medengphy.2005.09.008; Eide PK, 2006, ACTA NEUROCHIR, V148, P21, DOI 10.1007/s00701-005-0654-8; Eide PK, 2005, PEDIATR NEUROSURG, V41, P122, DOI 10.1159/000085868; FOLTZ EL, 1981, SURG NEUROL, V15, P283, DOI 10.1016/S0090-3019(81)80009-2; FOLTZ EL, 1984, INTRACRANIAL PRESSUR, V6, P337; Foss T, 2007, DEMENT GERIATR COGN, V23, P47, DOI 10.1159/000096683; FRIDEN HG, 1983, NEUROSURGERY, V13, P351, DOI 10.1227/00006123-198310000-00002; GREITZ D, 1993, ACTA RADIOL, V34, P1; Greitz D, 2004, NEUROSURG REV, V27, P145, DOI 10.1007/s10143-004-0326-9; Henry-Feugeas MC, 2001, INVEST RADIOL, V36, P146, DOI 10.1097/00004424-200103000-00003; HIRAI O, 1984, SURG NEUROL, V21, P67, DOI 10.1016/0090-3019(84)90404-X; Horowitz P., 1989, ART ELECT; Kahlon B, 2007, NEUROSURGERY, V60, P124, DOI 10.1227/01.NEU.0000249208.04344.A3; KASUGA Y, 1987, J NEUROSURG, V66, P907, DOI 10.3171/jns.1987.66.6.0907; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; Kim DS, 1999, CHILD NERV SYST, V15, P461, DOI 10.1007/s003810050440; Kim J, 2007, AM J NEURORADIOL, V28, P983; Klinge P, 2005, NEUROSURGERY, V57, P40, DOI 10.1227/01.NEU.0000168187.01077.2F; Lang EW, 2003, J NEUROSURG, V98, P214, DOI 10.3171/jns.2003.98.1.0214; Lewis SB, 1998, CLIN EXP PHARMACOL P, V25, P947, DOI 10.1111/j.1440-1681.1998.tb02350.x; LIN ES, 1991, BRIT J ANAESTH, V66, P476, DOI 10.1093/bja/66.4.476; Luetmer PH, 2002, NEUROSURGERY, V50, P534, DOI 10.1097/00006123-200203000-00020; MATSUMOTO T, 1994, CHILD NERV SYST, V10, P91, DOI 10.1007/BF00302770; Miyati T, 2003, EUR RADIOL, V13, P1019, DOI 10.1007/s00330-002-1697-3; MUNROE J, 1783, OBSERVATIONS STRUCTU; NITTA M, 1982, NEUROCHIRURGIA, V25, P186; Peters T.M, 1998, FOURIER TRANSFORM BI; PIPER IR, 1993, NEUROSURGERY, V32, P805, DOI 10.1227/00006123-199305000-00014; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; PORTNOY HD, 1985, CHILD NERV SYST, V1, P248, DOI 10.1007/BF00272020; PORTNOY HD, 1982, J NEUROSURG, V56, P666, DOI 10.3171/jns.1982.56.5.0666; PORTNOY HD, 1981, NEUROSURGERY, V9, P14, DOI 10.1227/00006123-198107000-00004; PORTNOY HD, 1986, CHILD NERV SYST, V2, P107, DOI 10.1007/BF00270834; PORTNOY HD, 1986, INTRACRANIAL PRESSUR, V6, P256; QUENCER RM, 1990, NEURORADIOLOGY, V32, P371, DOI 10.1007/BF00588471; Ramirez RW, 1985, FFT FUNDAMENTALS CON; ROBERTSON CS, 1989, J NEUROSURG, V71, P673, DOI 10.3171/jns.1989.71.5.0673; SAGAWA K, 1990, J MOL CELL CARDIOL, V22, P253, DOI 10.1016/0022-2828(90)91459-K; SHAPIRO K, 1980, ANN NEUROL, V7, P508, DOI 10.1002/ana.410070603; SKLAR FH, 1977, J NEUROSURG, V47, P670, DOI 10.3171/jns.1977.47.5.0670; SKLAR FH, 1984, INTRACRANIAL PRESSUR, V6, P323; Tenti G, 2002, PEDIATR NEUROSURG, V37, P221, DOI 10.1159/000065400; URSINO M, 1991, IEEE T BIO-MED ENG, V38, P795, DOI 10.1109/10.83592; URSINO M, 1988, ANN BIOMED ENG, V16, P379, DOI 10.1007/BF02364625; Ursino M, 1997, J APPL PHYSIOL, V82, P1256; WHITE DN, 1979, J NEUROL SCI, V42, P11, DOI 10.1016/0022-510X(79)90150-3; Zou R, 2008, J NEUROS-PEDIATR, V2, P83, DOI 10.3171/PED/2008/2/7/083	66	20	20	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	MAY	2009	3	5					354	364		10.3171/2009.1.PEDS08109			11	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	437QJ	WOS:000265501700004	19409013				2021-06-18	
J	Wei, YT; Sun, XD; Xia, X; Cui, FZ; He, Y; Liu, BF; Xu, QY				Wei, Yue-Teng; Sun, Xiao-Dan; Xia, Xue; Cui, Fu-Zhai; He, Yu; Liu, Bing-Fang; Xu, Qun-Yuan			Hyaluronic Acid Hydrogel Modified with Nogo-66 Receptor Antibody and Poly(L-Lysine) Enhancement of Adherence and Survival of Primary Hippocampal Neurons	JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS			English	Article						hyaluronic acid; hydrogel; antiNgR; poly(L-lysine); cell attachment; tissue engineering; biomaterial; bioengineering; central nervous system injuries; repairing CNS injuries; modified hyaluronic acid hydrogels	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; IN-VITRO; AXONAL REGENERATION; POLYETHYLENE-GLYCOL; NERVE REGENERATION; DELIVERY-SYSTEM; CULTURE; RAT; ATTACHMENT	Hyaluronic acid (HA) hydrogel was modified with poly(L-lysine) (PLL) and Nogo-66 Receptor antibody (antiNgR) to enhance the repair of central nervous system (CNS) injuries. The immobilization of PLL was characterized by X-ray photoelectron spectroscopy (XPS) and the immobilization of antiNgR was studied by immunofluorescence. The cytocompatibility of this modified hydrogel was analyzed by culturing primary hippocampal neurons. The quantity and morphology of the neurons were influenced by different modifications; the primary hippocampal neurons cultured with modified HA hydrogel exhibited multipolar and bipolar morphology were compared with unmodified hydrogel cultures. The number of neurons obtained by culturing with HA hydrogel modified with both PLL and antiNgR was almost twice the number of neurons cultured with HA modified with only PLL or antiNgR. This phenomenon was attributed to the collaborative effect of PLL and antiNgR on the neurons. The characteristics of this new hydrogel system, including pore structure, water absorption, hydrolysis degradation did not change much when compared with the hydrogel modified with PLL or antiNgR, respectively. It is expected that this modified HA hydrogel has potential as a CNS tissue engineering material.	[Wei, Yue-Teng; Sun, Xiao-Dan; Xia, Xue; Cui, Fu-Zhai] Tsinghua Univ, Adv Mat Lab, Dept Mat Sci & Engn, Beijing 100084, Peoples R China; [He, Yu; Liu, Bing-Fang; Xu, Qun-Yuan] Capital Med Univ, Beijing Inst Neurosci, Beijing Ctr Neural Regenerat & Repairing, Key Lab Neurodegenerat Dis,Minist Educ, Beijing 100069, Peoples R China	Cui, FZ (corresponding author), Tsinghua Univ, Adv Mat Lab, Dept Mat Sci & Engn, Beijing 100084, Peoples R China.	cuifz@mail.tsinghua.edu.cn	Wei, Yueteng/B-4653-2012; liu, bingfang/J-9615-2013		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [50573044, 30670656]; National Basic Research Program of ChinaNational Basic Research Program of China [2005CB623905, 2007CB947704]; National Natural Science Foundation of BeijingBeijing Natural Science Foundation [705001]; Beijing Scientific Committee [20005187040311]; Foundation of Analysis and Testing in Tsinghua University	Yue-Teng Wei and Yu He contributed equally to this work. This work was supported by National Natural Science Foundation of China (Grant No. 50573044, 30670656), National Basic Research Program of China (Grant No. 2005CB623905, 2007CB947704), National Natural Science Foundation of Beijing (Grant No. 705001), Beijing Scientific Committee (Grant No. 20005187040311) and Foundation of Analysis and Testing in Tsinghua University.	Baptiste D, 2007, J NEUROTRAUM, V24, P1285; Borgens RB, 1999, NEUROSCIENCE, V91, P251, DOI 10.1016/S0306-4522(98)00584-3; Brittis PA, 2001, NEURON, V30, P11, DOI 10.1016/S0896-6273(01)00258-6; Cai J, 2007, J BIOMED MATER RES A, V83A, P512, DOI 10.1002/jbm.a.31296; CARBONETTO S, 1983, J NEUROSCI, V3, P2324; Evans MS, 1998, J NEUROSCI METH, V79, P37, DOI 10.1016/S0165-0270(97)00159-3; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210; Hadlock T, 1999, LARYNGOSCOPE, V109, P1412, DOI 10.1097/00005537-199909000-00010; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; Hou S, 2006, NEUROSCIENCE, V137, P519, DOI 10.1016/j.neuroscience.2005.09.029; Hou SP, 2005, J NEUROSCI METH, V148, P60, DOI 10.1016/j.jneumeth.2005.04.016; Hu M, 2000, TISSUE ENG, V6, P585, DOI 10.1089/10763270050199532; Joosten EAJ, 2004, J NEUROSCI RES, V77, P127, DOI 10.1002/jnr.20088; Lin ASP, 2003, BIOMATERIALS, V24, P481, DOI 10.1016/S0142-9612(02)00361-7; Miralles G, 2001, J BIOMED MATER RES, V57, P268, DOI 10.1002/1097-4636(200111)57:2<268::AID-JBM1167>3.0.CO;2-L; Oerther S, 2000, BIOPOLYMERS, V54, P273, DOI 10.1002/1097-0282(20001005)54:4<273::AID-BIP40>3.3.CO;2-9; Park SN, 2002, BIOMATERIALS, V23, P1205, DOI 10.1016/S0142-9612(01)00235-6; SECKEL BR, 1995, J NEUROSCI RES, V40, P318, DOI 10.1002/jnr.490400305; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; Tian WM, 2005, J CONTROL RELEASE, V102, P13, DOI 10.1016/j.jconrel.2004.09.025; YAVIN E, 1974, J CELL BIOL, V62, P540, DOI 10.1083/jcb.62.2.540; YONG VW, 1988, DEV NEUROSCI-BASEL, V10, P222, DOI 10.1159/000111972; Zhang T, 2007, J BIOACT COMPAT POL, V22, P19, DOI 10.1177/0883911506074025	25	20	20	3	28	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0883-9115	1530-8030		J BIOACT COMPAT POL	J. Bioact. Compat. Polym.	MAY	2009	24	3					205	219		10.1177/0883911509102266			15	Biotechnology & Applied Microbiology; Materials Science, Biomaterials; Polymer Science	Biotechnology & Applied Microbiology; Materials Science; Polymer Science	443OF	WOS:000265918900001					2021-06-18	
J	Stuehmer, C; Blum, KS; Kokemueller, H; Tavassol, F; Bormann, KH; Gellrich, NC; Rucker, M				Stuehmer, Constantin; Blum, Katrin S.; Kokemueller, Horst; Tavassol, Frank; Bormann, Kai Hendrik; Gellrich, Nils-Claudius; Ruecker, Martin			Influence of Different Types of Guns, Projectiles, and Propellants on Patterns of Injury to the Viscerocranium	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							WOUNDS; HEAD; SHOTGUN	Purpose: Gunshot injuries to the Oral and craniomaxillofacial region vary with the type of gun used. Computed tomography (CT) is the standard diagnostic tool for assessing tissue damage in patients with gunshot injuries. Cone-beam computed tomography (CBCT) is a new imaging technique that has recently become available for clinical diagnosis. The objective of this study was to characterize injury patterns with a focus on gun types and identify the imaging modality that is best suited to assessing injuries caused by different gun types. Patients and Methods: We present the cases of 14 patients who sustained gunshot injuries to the viscerocranium during the past 10 years. The injuries were caused by 8 basic combinations of handguns or long guns with soft lead core projectiles, partial or full metal-jacketed bullets, and different propellants. Diagnosis was based on clinical and radiological findings (including CT and CBCT). Results: We found a direct correlation between the gun/projectile combination on the one hand and the diameter of the wound track, tissue contamination, and tissue destruction on the other. Entrance and exit Wounds are indicative of certain gun/projectile combinations. High-density projectiles cause severe artifacts in CT, unlike CBCT, making it difficult to evaluate anatomic structures in close proximity to the projectile. Conclusions: Every gun/projectile combination is associated with a typical pattern of injury. Even in the absence of the offending projectile, it is thus possible to narrow clown the likely gun and/or projectile. In the diagnostic imaging of injuries caused by high-density projectiles, CBCT is more suitable than CT. (C) 2009 American Association of Oral and Maxillofacial Surgeons	[Stuehmer, Constantin; Kokemueller, Horst; Tavassol, Frank; Bormann, Kai Hendrik; Gellrich, Nils-Claudius; Ruecker, Martin] Hannover Med Sch, Ctr Dent Oral & Orthodont Surg, Dept Oral & Maxillofacial Surg, D-30625 Hannover, Germany; [Blum, Katrin S.] Hannover Med Sch, Dept Diagnost Radiol, D-30625 Hannover, Germany	Stuehmer, C (corresponding author), Hannover Med Sch, Ctr Dent Oral & Orthodont Surg, Dept Oral & Maxillofacial Surg, Carl Neuberg Str 1, D-30625 Hannover, Germany.	constuehmer@web.de					Betz P, 1997, FORENSIC SCI INT, V86, P155, DOI 10.1016/S0379-0738(97)02121-X; Bowyer GW, 1996, J TRAUMA, V40, pS159, DOI 10.1097/00005373-199603001-00035; HARRUFF RC, 1995, J FORENSIC SCI, V40, P801; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; Obajimi M O, 2004, West Afr J Med, V23, P58; Pohlenz P, 2007, ORAL SURG ORAL MED O, V103, P412, DOI 10.1016/j.tripleo.2006.05.008; Rothschild MA, 2000, INT J LEGAL MED, V113, P349; Salzano A, 2000, Radiol Med, V99, P26; Scialpi M, 1995, Radiol Med, V89, P485; STIERNBERG CM, 1992, ARCH OTOLARYNGOL, V118, P592; Vayvada H, 2005, J CRANIOFAC SURG, V16, P794, DOI 10.1097/01.scs.0000180014.06352.65; Verleisdonk E J M M, 2002, Ned Tijdschr Geneeskd, V146, P1271	12	20	23	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	APR	2009	67	4					775	781		10.1016/j.joms.2008.08.036			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	427VZ	WOS:000264808500010	19304034				2021-06-18	
J	Relyea-Chew, A; Hollingworth, W; Chan, L; Comstock, BA; Overstreet, KA; Jarvik, JG				Relyea-Chew, Annemarie; Hollingworth, William; Chan, Leighton; Comstock, Bryan A.; Overstreet, Karen A.; Jarvik, Jeffrey G.			Personal Bankruptcy After Traumatic Brain or Spinal Cord Injury: The Role of Medical Debt	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Health care costs; Insurance, health; Rehabilitation; Spinal cord injuries	HEALTH PLAN; INSURANCE; DECISION; COVERAGE; RISK	Objective: To estimate the prevalence of medical debt among traumatic brain injury (TBI) and spinal cord injury (SCI) patients who discharged their debts through bankruptcy. Design: A cross-sectional comparison of bankruptcy filings of injured versus randomly selected bankruptcy petitioners. Setting: Patients hospitalized with SCI or TBI (1996-2002) and personal bankruptcy petitioners (2001-2004) in western Washington State. Participants: Subjects (N = 186) who filed for bankruptcy, comprised of 93 patients with previous SCI or TBI and 93 randomly selected bankruptcy petitioners. Interventions: Not applicable. Main Outcome Measures: Medical and nonmedical debt, assets, income, expenses, and employment recorded in the bankruptcy petition. Results: Five percent of randomly selected petitioners and 26% of petitioners with TBI or SCI had substantial medical debt (debt that accounted for more than 20% of all unsecured debts). SCI and TB I petitioners had fewer assets and were more likely to be receiving government income assistance at the time of bankruptcy than controls. SCI and TBI patients with a higher blood alcohol content at injury were more likely to have substantial medical debts (odds ratio=2.70; 95% confidence interval, 1.04-7.00). Conclusions: Medical debt plays an important role in some bankruptcies after TBI or SCI. We discuss policy options for reducing financial distress after serious injury.	[Hollingworth, William] Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; [Relyea-Chew, Annemarie; Jarvik, Jeffrey G.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA; [Comstock, Bryan A.] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Jarvik, Jeffrey G.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; [Jarvik, Jeffrey G.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Comstock, Bryan A.; Jarvik, Jeffrey G.] Univ Washington, Ctr Cost & Outcomes Res, Seattle, WA 98195 USA; [Relyea-Chew, Annemarie] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Chan, Leighton] NIH, Ctr Clin, Dept Rehabil Med, Bethesda, MD 20892 USA; [Overstreet, Karen A.] Western Dist Washington, US Bankruptey Court, Seattle, WA USA	Hollingworth, W (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.	william.hollingworth@bristol.ac.uk	Jarvik, Jeffrey/AAL-4292-2021	Hollingworth, William/0000-0002-0840-6254	Royalty Research Fund of the University of WashingtonUniversity of Washington; intramural research program of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Supported by the Royalty Research Fund of the University of Washington and the intramural research program of the National Institutes of Health.	[Anonymous], BANKR STAT; BAKER WA, 1976, INORG CHIM ACTA, V16, P5, DOI 10.1016/S0020-1693(00)91684-0; Carlson MJ, 2006, ANN FAM MED, V4, P391, DOI 10.1370/afm.573; Cook J, 1998, JAMA-J AM MED ASSOC, V279, P822; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Domowitz I, 1999, J FINANC, V54, P403, DOI 10.1111/0022-1082.00110; Dranove D, 2006, HEALTH AFFAIR, V25, pW74, DOI 10.1377/hlthaff.25.w74; Fay S, 2002, AM ECON REV, V92, P706, DOI 10.1257/00028280260136327; *FED RES STAT REL, CONS CRED; Gabel J, 2003, HEALTH AFFAIR, V22, P117, DOI 10.1377/hlthaff.22.5.117; GILMER T, 2005, HLTH AFF MILLW S JAN; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HIMMELSTEIN DU, 2005, HLTH AFF MILLW S JAN; HOLAHAN J, 2002, HLTH AFF MILLWOOD S, pW187; Hollingworth W, 2007, MED CARE, V45, P702, DOI 10.1097/MLR.0b013e318041f765; *HOUS COMM FIN I I, 2004, 2014 HB HOUS COMM FI; Jensen S, 2005, AM BANKRUPT LAW J, V79, P485; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Kreutzer JS, 2007, NEUROREHABILITATION, V22, P53; Martin MJ, 2005, J TRAUMA, V59, P860, DOI 10.1097/01.ta.0000187964.47703.e9; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Meade MA, 2004, ARCH PHYS MED REHAB, V85, P1782, DOI 10.1016/j.apmr.2004.05.001; Moore L, 2006, J TRAUMA, V60, P1238, DOI 10.1097/01.ta.0000195593.60245.80; *NAT AC PR I MED, 2004, COMM CONS UN INS AM; Rivara FP, 2000, J TRAUMA, V48, P115, DOI 10.1097/00005373-200001000-00019; Singleton Michael, 2004, Traffic Inj Prev, V5, P144, DOI 10.1080/713903941; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Sullivan T., 2000, FRAGILE MIDDLE CLASS; Wharam JF, 2007, JAMA-J AM MED ASSOC, V297, P1093, DOI 10.1001/jama.297.10.1093; Woolhandler S, 2003, JAMA-J AM MED ASSOC, V290, P798; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5	31	20	20	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2009	90	3					413	419		10.1016/j.apmr.2008.07.031			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	421YW	WOS:000264395200007	19254605	Green Accepted, Green Published			2021-06-18	
J	Carlson, NE; Brenner, LA; Wierman, ME; Harrison-Felix, C; Morey, C; Gallagher, S; Ripley, D				Carlson, N. E.; Brenner, L. A.; Wierman, M. E.; Harrison-Felix, C.; Morey, C.; Gallagher, S.; Ripley, D.			Hypogonadism on admission to acute rehabilitation is correlated with lower functional status at admission and discharge	BRAIN INJURY			English	Article						Endocrine dysfunction; physical function; testosterone; traumatic brain injury	TRAUMATIC BRAIN-INJURY; TESTOSTERONE REPLACEMENT; SEX-HORMONES; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; COGNITIVE FUNCTION; INFECTED MEN; HYPOPITUITARISM; PERFORMANCE; STRENGTH	Primary objective: To investigate the association between hormone levels and functional status during acute TBI rehabilitation. Research design: Retrospective cohort study of 43 men with moderate-to-severe TBI admitted to an acute rehabilitation unit during a 1 year period. Methods and procedures: Labs were drawn on admission, including total and free testosterone (T), prolactin, adrenocorticotropin hormone (ACTH), cortisol, thyroid stimulating hormone (TSH), free thyroxine (fT4) and insulin-like growth factor (IGF-1). Functional Independence Measure (FIM) scores were obtained at admission and discharge. Main outcome and results: Associations between admission hormone levels and the main outcomes, admission and discharge FIM scores, were assessed using linear regression. Lower total and free T-levels at admission were associated with lower total FIM scores at admission (p 0.038) and discharge (p 0.046). Higher cortisol levels at admission were significantly associated with lower admission (p = 0.012) and discharge (p = 0.036) scores on the cognitive-FIM. Prolactin, TSH, fT4 and IGF-1 were not correlated with functional status. Conclusions: In men, lower total and free T-levels at admission to acute rehabilitation correlate with lower admission and discharge FIM scores. These data support the need for studies to investigate the impact of physiological testosterone therapy on outcomes during and post-rehabilitation.	[Carlson, N. E.] Univ Colorado Denver, Dept Biostat & Informat, Aurora, CO 80045 USA; [Brenner, L. A.] VA VISN 19 Mental Illness Res Educ & Clin Ctr, Denver, CO USA; [Brenner, L. A.; Harrison-Felix, C.; Morey, C.; Ripley, D.] Craig Hosp, Rocky Mt Reg Traumat Brain Injury Syst, Englewood, CO USA; [Wierman, M. E.] Univ Colorado, Dept Psychiat, Denver, CO USA; [Brenner, L. A.] Univ Colorado, Dept Neurol, Denver, CO USA; [Brenner, L. A.; Harrison-Felix, C.] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO USA; [Wierman, M. E.] Univ Colorado, Sch Med, Dept Med, Denver, CO USA; [Wierman, M. E.] Denver VA Med Ctr, Res Serv, Denver, CO USA; [Gallagher, S.] Childrens Hosp, Denver, CO 80218 USA	Carlson, NE (corresponding author), Univ Colorado Denver, Dept Biostat & Informat, 17000 E 17th PL,MS C245, Aurora, CO 80045 USA.	nichole.carlson@ucdenver.edu	Brenner, Lisa A./AAG-2442-2019	Ripley, David/0000-0002-5349-1830			Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bhasin S, 1998, J CLIN ENDOCR METAB, V83, P3155, DOI 10.1210/jc.83.9.3155; Bhasin S, 2000, JAMA-J AM MED ASSOC, V283, P763, DOI 10.1001/jama.283.6.763; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; CLARK JDA, 1992, CLIN ENDOCRINOL, V36, P481, DOI 10.1111/j.1365-2265.1992.tb02249.x; Clark MJ, 2008, AM J PHYS MED REHAB, V87, P281, DOI 10.1097/PHM.0b013e318168bbec; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Eskelinen Seija I, 2007, Endocr Pract, V13, P743; Ferin M, 1999, J CLIN ENDOCR METAB, V84, P1768, DOI 10.1210/jc.84.6.1768; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Grinspoon S, 2000, ANN INTERN MED, V133, P348, DOI 10.7326/0003-4819-133-5-200009050-00010; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEE SC, 1994, BRAIN INJURY, V8, P571; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mateo JM, 2008, NEUROBIOL LEARN MEM, V89, P582, DOI 10.1016/j.nlm.2007.11.002; Moffat SD, 2002, J CLIN ENDOCR METAB, V87, P5001, DOI 10.1210/jc.2002-020419; Mohamad MJ, 2007, NEUROENDOCRINOL LETT, V28, P182; Molitch ME, 2001, ENDOCRIN METAB CLIN, V30, P585, DOI 10.1016/S0889-8529(05)70203-6; O'Connor DB, 2001, NEUROPSYCHOLOGIA, V39, P1385, DOI 10.1016/S0028-3932(01)00067-7; Okun MS, 2002, ARCH NEUROL-CHICAGO, V59, P1750, DOI 10.1001/archneur.59.11.1750; Ottenbacher KJ, 2006, J AM GERIATR SOC, V54, P1666, DOI 10.1111/j.1532-5415.2006.00938.x; Page ST, 2005, J CLIN ENDOCR METAB, V90, P1502, DOI 10.1210/jc.2004-1933; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; REICHLIN S, 1992, WILLIAMS TXB ENDOCRI, P174; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS579; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Stanworth RD, 2008, CLIN INTERV AGING, V3, P25; *STAT U NEW YORK B, 1997, UN DAT SYST MED REH; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Storer TW, 2003, J CLIN ENDOCR METAB, V88, P1478, DOI 10.1210/jc.2002-021231; TEASDALE G, 1974, LANCET, V2, P81; Traumatic Brain Injury Model Systems National Data Center, 2007, TRAUM BRAIN INJ MOD; Wolf OT, 2002, HORM BEHAV, V41, P259, DOI 10.1006/hbeh.2002.1770; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; Yaffe K, 2002, J AM GERIATR SOC, V50, P707, DOI 10.1046/j.1532-5415.2002.50166.x; Yaffe K, 2000, LANCET, V356, P708, DOI 10.1016/S0140-6736(00)02628-3; Young TP, 2007, BRAIN INJURY, V21, P645, DOI 10.1080/02699050701210426	47	20	20	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	4					336	344	PII 909972518	10.1080/02699050902788535			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	425MY	WOS:000264643000008	19330595				2021-06-18	
J	de Andrade, AF; Paiva, WS; de Amorim, RLO; Figueiredo, EG; Neto, ER; Teixeira, MJ				de Andrade, Almir Ferreira; Paiva, Wellingson Silva; Oliveira de Amorim, Robson Luis; Figueiredo, Eberval Gadelha; Rusafa Neto, Eloy; Teixeira, Manoel Jacobsen			THE PATHOPHYSIOLOGICAL MECHANISMS FOLLOWING TRAUMATIC BRAIN INJURY	REVISTA DA ASSOCIACAO MEDICA BRASILEIRA			Portuguese	Article						Trauma; Brain injuries; Physiopathology; Review	SEVERE HEAD-INJURY; CEREBRAL-BLOOD-FLOW; PLATEAU WAVES; APOPTOSIS; HEMATOMA; METABOLISM; HUMANS; DAMAGE; EDEMA	Traumatic brain injury is the main cause of death and disability in children and adults in Western Countries. The definitive brain injury is a consequence of pathophysiological mechanisms that begin at the moment of an accident and may extend for days or weeks. Traumatic brain injury may be classified as diffuse or focal. These two mechanisms are commonly associated in a patient, however one is generally predominant. Therefore knowledge of the pathophysiological mechanisms or brain injury in head trauma is important to establish the therapeutic, clinical and surgical measures. In this paper the authors present a critical review of the literature on the pathophysiological principles of traumatic brain injury. [Rev Assoc Med Bras 2009; 55(1): 75-81]	[de Andrade, Almir Ferreira; Paiva, Wellingson Silva; Oliveira de Amorim, Robson Luis; Figueiredo, Eberval Gadelha; Rusafa Neto, Eloy; Teixeira, Manoel Jacobsen] Univ Sao Paulo, Fac Med, Hosp Clin, Div Neurocirurgia, Sao Paulo, Brazil	Paiva, WS (corresponding author), Rua Dr Ovidio Pires Campos 171,Apto 511, BR-05403010 Sao Paulo, Brazil.	wellingsonpaiva@yahoo.com.br	Figueiredo, Eberval Gadelha/H-3488-2012; Teixeira, Manoel J/E-3110-2012; Paiva, Wellingson S/G-5517-2013; Amorim, Robson/AAK-1368-2021; Figueiredo, Eberval G/E-2071-2016	Paiva, Wellingson S/0000-0002-5165-7040; Amorim, Robson/0000-0003-2391-7519; 			Adekoya N, 2004, PUBLIC HEALTH REP, V119, P486, DOI 10.1016/j.phr.2004.07.006; Aldrich EF, 1996, NEUROLOGICAL SURG, P1719; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; BAYKANER K, 1988, SURG NEUROL, V30, P339, DOI 10.1016/0090-3019(88)90195-4; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; Bor-Seng-Shu Edson, 2004, Neurosurg Focus, V16, pECP1; Bruno V, 2001, J CEREBR BLOOD F MET, V21, P1013, DOI 10.1097/00004647-200109000-00001; Cameron PA, 2004, J TRAUMA, V56, P890, DOI 10.1097/01.TA.0000053398.40463.51; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; Engberg AW, 2004, ACTA NEUROL SCAND, V110, P281, DOI 10.1111/j.1600-0404.2004.00323.x; Firsching R, 2001, WORLD J SURG, V25, P1221; FRANCEL P, 1996, NEUROLOGICAL SURG, P1595; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Goodman JC, 1999, TRAUMATIC BRAIN INJU, P143; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kelly DF, 1996, NEUROTRAUMA, P71; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kraus JF, 1993, HEAD INJURY, P1; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Maragos WF, 2004, J NEUROCHEM, V91, P257, DOI 10.1111/j.1471-4159.2004.02736.x; Marmarou A, 2003, ACT NEUR S, V86, P7; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; McCrory P, 2001, BRIT J SPORT MED, V35, P380, DOI 10.1136/bjsm.35.6.380; McCrory PR, 2001, NEUROLOGY, V57, P2283, DOI 10.1212/WNL.57.12.2283; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Meixensberger J, 2001, NEUROL RES, V23, P801, DOI 10.1179/016164101101199379; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; MILLER JD, 1987, TRAUMATIC BRAIN EDEM, P99; MILLER JD, 1993, TRAUMATIC BRAIN SWEL, P331; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Nau R, 2002, BRAIN PATHOL, V12, P329; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SAFAR P, 1997, TXB NEUROANESTHESIA, P557; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Sawauchi S, 2007, NEUROL SURG TOKYO, V35, P665; Teasdale G, 1996, NEUROLOGICAL SURG, P1533; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; Wilson JX, 2002, J NEUROSURG ANESTH, V14, P66, DOI 10.1097/00008506-200201000-00014	50	20	22	0	6	ASSOC MEDICA BRASILEIRA	SAO PAULO	RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL	0104-4230			REV ASSOC MED BRAS	Rev. Assoc. Med. Bras.		2009	55	1					75	81		10.1590/S0104-42302009000100020			7	Medicine, General & Internal	General & Internal Medicine	442GO	WOS:000265829800019	19360283	DOAJ Gold			2021-06-18	
J	Greiffenstein, M				Greiffenstein, Manfred F.			Clinical Myths of Forensic Neuropsychology	CLINICAL NEUROPSYCHOLOGIST			English	Article						Myths; Neuropsychology; Forensic; Clinical folklore	TRAUMATIC BRAIN-INJURY; REPEATED ADMINISTRATIONS; BATTERY; VALIDITY; MEMORY	Clinical myths and lore are unfounded beliefs that still influence practice decisions. I examine the validity of six beliefs commonly encountered in forensic neuropsychology practice: the admissibility of test batteries; avoidance of practice effects; forewarning insures good effort; average deficits in bright persons; 15% chronic impairment in mild brain injury; and examiner bias causing malingering. I show these beliefs are invalid because of material misunderstandings of case law and literature, falsification by empirical findings, and lack of authoritative sources. The benefits, costs, and persistence of clinical myths are discussed.	Psychol Syst Inc, Royal Oak, MI 48073 USA	Greiffenstein, M (corresponding author), Psychol Syst Inc, 32121 Woodward,Suite 201, Royal Oak, MI 48073 USA.	mfgreiff@comcast.net					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Buss D.M., 2005, HDB EVOLUTIONARY PSY; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CHAPMAN LJ, 1969, J ABNORM PSYCHOL, V74, P271, DOI 10.1037/h0027592; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Diaz-Asper CM, 2004, J INT NEUROPSYCH SOC, V10, P82; Dodrill CB, 1997, CLIN NEUROPSYCHOL, V11, P1, DOI 10.1080/13854049708407025; DODRILL CB, 1975, J NERV MENT DIS, V161, P185, DOI 10.1097/00005053-197509000-00006; FOX DD, 1995, J CLIN PSYCHOL, V51, P42, DOI 10.1002/1097-4679(199501)51:1<42::AID-JCLP2270510108>3.0.CO;2-Z; Galbraith K, 1958, AFFLUENT SOC; Greiffenstein M. F., 2008, TXB CLIN NEUROPSYCHO, P905; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HORTON AM, 1992, PERCEPT MOTOR SKILL, V75, P257, DOI 10.2466/PMS.75.4.257-258; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Johnson JL, 1997, ARCH CLIN NEUROPSYCH, V12, P231, DOI 10.1016/S0887-6177(96)00040-6; Johnson JL, 1998, PERCEPT MOTOR SKILL, V87, P152, DOI 10.2466/pms.1998.87.1.152; KAUFMAN AS, 1994, ENCY HUMAN INTELLIGE, V2, P828; KOLATA G, 2006, NY TIMES        1122; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McCaffrey RJ, 1995, NEUROPSYCHOL REV, V5, P203, DOI 10.1007/BF02214762; MCCREA M, 2007, NEW EVIDENCE BASE DI; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; McNally R, 2005, AM J PSYCHOL, V118, P152; Melton G. B., 1997, PSYCHOL EVALUATIONS; MITRUSHINA M, 1991, J CLIN PSYCHOL, V47, P790, DOI 10.1002/1097-4679(199111)47:6<790::AID-JCLP2270470610>3.0.CO;2-C; Morgan JE, 2008, TXB CLIN NEUROPSYCHO; NISBETT RICHARD E., 1980, HUMAN INFERENCE STRA; Paauw D S, 1999, J Am Board Fam Pract, V12, P143; Posthuma A., 2002, AM J FORENSIC PSYCH, V20, P21; PUTNAM SH, 1992, PSYCHOL ASSESSMENT, V4, P312; Reed JE, 1996, BEHAV SCI LAW, V14, P315, DOI 10.1002/(SICI)1099-0798(199622)14:3<315::AID-BSL242>3.0.CO;2-X; Reitan RM, 1996, ARCH CLIN NEUROPSYCH, V11, P573, DOI 10.1016/0887-6177(95)00037-2; REITAN RM, 2002, J FORENSIC NEUROPSYC, V3, P275; ROGERS R, 1983, J PSYCHIAT LAW, V11, P443; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Russell EW, 2007, ARCH CLIN NEUROPSYCH, V22, P787, DOI 10.1016/j.acn.2007.06.006; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Shatz M W, 1981, J Clin Neuropsychol, V3, P171, DOI 10.1080/01688638108403123; Storm J, 2000, PSYCHOL ASSESSMENT, V12, P158, DOI 10.1037/1040-3590.12.2.158; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Suhr JA, 2002, ARCH CLIN NEUROPSYCH, V17, P69, DOI 10.1016/S0887-6177(00)00102-5; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P325, DOI 10.1080/13854040600760488; Theisen ME, 1998, ASSESSMENT, V5, P85, DOI 10.1177/107319119800500110; VANDERPLOEG RD, 1994, CLIN GUIDE NEUROPSYC, P1; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2441, DOI 10.1001/jama.296.20.2441; Wong J. L., 1998, INT J REHABILITATION, V4, P153; WORTMAN CB, 1989, J CONSULT CLIN PSYCH, V57, P349, DOI 10.1037/0022-006X.57.3.349; Youngjohn JR, 1999, ARCH CLIN NEUROPSYCH, V14, P511, DOI 10.1016/S0887-6177(98)00049-3	52	20	21	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	2					286	296	PII 793945250	10.1080/13854040802104873			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	399LS	WOS:000262802000007	18609338				2021-06-18	
J	Kilov, AM; Togher, L; Grant, S				Kilov, Andrea M.; Togher, Leanne; Grant, Susan			Problem solving with friends: Discourse participation and performance of individuals with and without traumatic brain injury	APHASIOLOGY			English	Article							QUALITY-OF-LIFE; COMMUNICATION ACTIVITIES; PEOPLE; SATISFACTION; IMPAIRMENT; SKILLS	Background: Traumatic brain injury (TBI) is a leading cause of hospitalisation and disability worldwide. There is general consensus in the literature reporting poor communication and social outcomes for individuals with TBI. While the literature is extensive in describing cognitive communication difficulties manifesting in the discourse of individuals with TBI, it does not include genres that represent everyday interactions. Furthermore, there are very few studies in the literature that explore interactions of individuals with TBI and their friends, even though it is common for individuals with TBI to lose friends within the first year of their injury. Aims: To explore discourse participation and performance of individuals with and without TBI in a shared problem-solving task with their friends. Methods Procedures: Ten participants with severe TBI were matched with ten control participants for sex, age, and education. Participants problem-solved names and functions of unfamiliar objects with their friends. The resulting discourse was transcribed, divided into moves, and analysed for its generic structure potential (GSP) within a systemic functional linguistics approach. The number of moves contributed by each participant (participation) and frequencies of moves assigned to generic structural elements (performance) were tallied and then statistically analysed. Results Outcomes: There was no significant difference in discourse participation and performance between participants with and without TBI. Individuals with and without TBI mostly talked about the task, gave thesis propositions, offered the possible function of the object, and gave rationales for their decisions. These may be obligatory (not optional) elements of problem-solving discourse. Individuals without TBI used significantly more tangential and unrelated talk, which may be indicative of more frequent and successful attempts to engage in social chat, even in a goal-driven activity. Conclusions: Competent discourse participation and performance is possible for individuals with TBI when they engage in meaningful interactions with friends. Problem solving may be a useful therapy genre for maximising communication outcomes of individuals with TBI, as it encourages the involvement of friends and elicits social chat as well as other creative language options.	[Kilov, Andrea M.; Togher, Leanne; Grant, Susan] Univ Sydney, Lidcombe, NSW 2141, Australia	Kilov, AM (corresponding author), Univ Sydney, Cumberland Campus C42,75 E St, Lidcombe, NSW 2141, Australia.	a_kilov@hotmail.com	Togher, Leanne/AAC-7083-2019	Togher, Leanne/0000-0002-4518-6748			Adamovich B. B., 1992, SCALES COGNITIVE ABI; Bloom R. L., 1994, DISCOURSE ANAL APPL; Bonduelle M, 1995, HUM REPROD, V10, P3327, DOI 10.1093/oxfordjournals.humrep.a135914; Butt D., 2000, USING FUNCTIONAL GRA; Cherney L.R., 1998, ANAL DISCOURSE COMMU; COELHO C, 1995, DISCOURSE ANAL APPL, P95; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Cools C, 1998, INT J REHABIL RES, V21, P323, DOI 10.1097/00004356-199809000-00007; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Davidson B, 2003, APHASIOLOGY, V17, P243, DOI 10.1080/729255457; Eggins S., 1997, ANAL CASUAL CONVERSA; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gangoiti L., 2004, REHABILITATION, V38, P313; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; HALLIDAY MAK, 1995, DISCOURSE SOC SYSTEM; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hemmeter ML, 2000, TOP EARLY CHILD SPEC, V20, P56, DOI 10.1177/027112140002000110; Hwang B, 2000, J AUTISM DEV DISORD, V30, P331, DOI 10.1023/A:1005579317085; JENNETT B, 1977, INTRO NEUROSURGERY; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; KAZDIN AE, 1992, METHODOLOGICAL ISSUE; Kendall E, 1997, J HEAD TRAUMA REHAB, V12, P68, DOI 10.1097/00001199-199706000-00007; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Larkins BM, 2004, BRAIN INJURY, V18, P691, DOI 10.1080/02699050310001617389; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; Marshall RC, 2003, BRAIN INJURY, V17, P589, DOI 10.1080/0269905031000088496; Martin J.R., 1984, CHILDREN WRITING REA, P21; McCluskey AE, 2000, BRAIN INJURY, V14, P943, DOI 10.1080/02699050050191896; MCDONALD S, 1999, COMMUNICATION DISORD, P338; Nolte J, 1998, HUMAN BRAIN INTRO IT; Paterson J., 2002, REHABILITATION NURSI, V27, P13, DOI [10.1002/j.2048-7940.2002.tb01973.x, DOI 10.1002/J.2048-7940.2002.TB01973.X]; Poynton C., 1985, LANGUAGE GENDER MAKI; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Rosenthal M., 1999, REHABILITATION ADULT; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; SNOW P, 1999, 22 ANN BRAIN IMP C S; Snow PC, 2000, BRAIN INJURY, V14, P397; Stubbs M., 1983, DISCOURSE ANAL SOCIO; Tannen Deborah, 2005, CONVERSATIONAL STYLE; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; TOGHER L, 1998, THESIS U SYDNEY AUST; Warren L, 1996, J REHABIL RES DEV, V33, P404; *WHO, 2001, ICF INT CLASS FUNCT	50	20	20	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology		2009	23	5					584	605	PII 794611250	10.1080/02687030701855382			22	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	427RC	WOS:000264795400004					2021-06-18	
J	Kuipers, P; Foster, M; Smith, S; Fleming, J				Kuipers, Pim; Foster, Michele; Smith, Sharon; Fleming, Jennifer			Using ICF-Environment factors to enhance the continuum of outpatient ABI rehabilitation: An exploratory study	DISABILITY AND REHABILITATION			English	Article						Acquired Brain Injury; outpatient rehabilitation; ICF Environment factors	TRAUMATIC BRAIN-INJURY; HEALTH; EXPERIENCES; DISCHARGE; FAMILIES; OUTCOMES; NEEDS; MODEL; CARE; HOME	Purpose. This study utilized the Environment dimension of the ICF, to explore needs of outpatients and their family members in the context of system and professional needs in an outpatient rehabilitation unit. Method. A two-phase qualitative exploration comprised structured workshops with outpatient rehabilitation unit professional staff and semi-structured interviews on two occasions with 18 outpatients and their significant others. Data was thematically analysed and categorized according to ICF Environment dimensions. Results. The study found that the ICF Environment dimension was a worthwhile area for research, beneficial for outpatient professionals, relevant to patient and family members' concerns, and useful for conceptualizing intervention. The study found that key foci for outpatient assistance at the Environment level should include: psychosocial support and relationships; information transfer and communication in transition to outpatient rehabilitation; and subsequent connection with community, vocational and support services. Conclusion. Research using the ICF Environment dimension provides a practical means of connecting some of the features of a community-oriented approach with hospital or centre-based outpatient rehabilitation.	[Kuipers, Pim] Univ Queensland, CONROD, Brisbane, Qld, Australia; [Kuipers, Pim] Flinders Univ S Australia, Ctr Remote Hlth, Brisbane, Qld, Australia; [Kuipers, Pim] Charles Darwin Univ, Brisbane, Qld, Australia; [Foster, Michele] Univ Queensland, Sch Social Work & Appl Human Sci, Brisbane, Qld, Australia; [Smith, Sharon] Princess Alexandra Hosp, ABIOS, Brisbane, Qld 4102, Australia; [Fleming, Jennifer] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia		pim.kuipers@flinders.edu.au	Fleming, Jennifer M/B-4436-2011	Kuipers, Pim/0000-0003-0340-2286			Anderson C, 2002, PHARMACOECONOMICS, V20, P537, DOI 10.2165/00019053-200220080-00004; Barnes MP, 2001, J REHABIL MED, V33, P244; Bay Esther, 2006, Res Theory Nurs Pract, V20, P141; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; DOIG E, 2007, HLTH CARE POLICY PRA; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Koskinen S, 2007, J REHABIL MED, V39, P467, DOI 10.2340/16501977-0077; Lefebvre H, 2005, BRAIN INJURY, V19, P585, DOI 10.1080/02699050400025026; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; Mayo NE, 2000, STROKE, V31, P1016, DOI 10.1161/01.STR.31.5.1016; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Rice-Oxley M, 1999, CLIN REHABIL, V13, P7, DOI 10.1191/026921599668051623; Stier-Jarmer M, 2005, DISABIL REHABIL, V27, P389, DOI 10.1080/09638280400014022; Stucki G, 2005, DISABIL REHABIL, V27, P349, DOI 10.1080/09638280400013941; Von Koch L, 1998, DISABIL REHABIL, V20, P367, DOI 10.3109/09638289809166095; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; World Health Organization, INT CLASS FUNCT DIS; 2004, QSR QUALITATATIVE SO	22	20	20	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2009	31	2					144	151	PII 792733278	10.1080/01674820701817938			8	Rehabilitation	Rehabilitation	402IR	WOS:000263007900010	18608394				2021-06-18	
J	Schneiders, AG; Sullivan, SJ; McCrory, PR; Gray, A; Maruthayanar, S; Singh, P; Ranhotigammage, P; Van der Salm, R				Schneiders, A. G.; Sullivan, S. J.; McCrory, P. R.; Gray, A.; Maruthayanar, S.; Singh, P.; Ranhotigammage, P.; Van der Salm, R.			The effect of exercise on motor performance tasks used in the neurological assessment of sports-related concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							ERROR SCORING SYSTEM; POSTURAL STABILITY; RUGBY UNION; BALANCE; RELIABILITY; AGREEMENT; EXERTION; PLAYERS; ELICITS; FATIGUE	Sports-related concussion is assessed using both cognitive and motor performance tasks. There is limited understanding of how exercise affects these measures. The purpose of this study was to investigate the effect of moderate-intensity exercise on three selected measures of motor performance. A repeated measures design was used to compare baseline motor performance scores with post-exercise scores with an exercise intervention modelled on the physiological demands of a team sport. 30 physically active subjects performed timed motor performance tasks: Finger-to-Nose (FTN), Tandem Gait (TG) and Single Leg Stance (SLS). The tasks were administered twice pre-exercise and twice post-exercise. FTN, TG and SLS demonstrated high test-retest reliability (ICC values >0.8). 15 minutes of moderate-intensity exercise caused a significant improvement in FTN (T2 = 2.66 (SD 0.38), T3 = 2.49 (0.32); p<0.001) and TG (T2 = 13.08 (2.84), T3 = 12.23 (2.22); p = 0.001), but not in SLS (T2 = 5.94 (4.99), T3 = 5.91 (5.54); p = 0.507). Improvement in the performance of motor tasks after exercise has implications for the immediate assessment of sports-related concussion, given that measures of motor performance are utilised in concussion assessment instruments.	[Schneiders, A. G.] Univ Otago, Sch Physiotherapy, Ctr Physiotherapy Res, Dunedin 9054, New Zealand; [McCrory, P. R.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Gray, A.] Univ Otago, Dept Prevent & Social Med, Dunedin 9054, New Zealand	Schneiders, AG (corresponding author), Univ Otago, Sch Physiotherapy, Ctr Physiotherapy Res, POB 56, Dunedin 9054, New Zealand.	tony.schneiders@otago.ac.nz	McCrory, Paul/Q-8688-2019; Gray, Andrew Robert/L-9161-2015; Schneiders, Anthony/F-4212-2015	Gray, Andrew Robert/0000-0003-4299-2194; Schneiders, Anthony/0000-0002-1583-3879; McCrory, Paul/0000-0003-4850-0568			[Anonymous], 1999, SAS STAT V8 SOFTW US; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Deutsch MU, 1998, J SPORT SCI, V16, P561, DOI 10.1080/026404198366524; Duthie G, 2003, SPORTS MED, V33, P973, DOI 10.2165/00007256-200333130-00003; DWYER GB, 2005, ACSMS HLTH RELATED P, P162; Hopkins WG, 2000, SPORTS MED, V30, P1, DOI 10.2165/00007256-200030010-00001; JOHNSTON K, 1998, CAN J NEUROL SCI, V25, pS98; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kingma H, 2006, CURR OPIN NEUROL, V19, P21, DOI 10.1097/01.wco.0000199021.48538.d9; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Nardone A, 1997, ELECTROMYOGR MOTOR C, V105, P309, DOI 10.1016/S0924-980X(97)00040-4; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Stolze H, 2002, J NEUROL NEUROSUR PS, V73, P310, DOI 10.1136/jnnp.73.3.310; Susco TM, 2004, J ATHL TRAINING, V39, P241; SWAINE BR, 1993, PHYS THER, V73, P71, DOI 10.1093/ptj/73.2.71; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Warren J, 2006, PHYS THER SPORT, V7, P185, DOI 10.1016/j.ptsp.2006.06.002; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	20	20	20	1	13	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	DEC	2008	42	12					1011	1013		10.1136/bjsm.2007.041665			3	Sport Sciences	Sport Sciences	385SI	WOS:000261833500022	18308895				2021-06-18	
J	Russeler, J; Brett, A; Klaue, U; Sailer, M; Munte, TF				Ruesseler, Jascha; Brett, Alexandra; Klaue, Ulrike; Sailer, Michael; Muente, Thomas F.			The effect of coaching on the simulated malingering of memory impairment	BMC NEUROLOGY			English	Article							SYMPTOM VALIDITY TESTS; VERBAL-LEARNING TEST; FORENSIC NEUROPSYCHOLOGY; EXPANDED VERSION; HEAD-INJURY; EXAGGERATION; PERFORMANCE; VALIDATION; ATTORNEYS; DEFICITS/	Background: Detecting malingering or exaggeration of impairments in brain function after traumatic brain injury is of increasing importance in neuropsychological assessment. Lawyers involved in brain injury litigation cases routinely coach their clients how to approach neuropsychological testing to their advantage. Thus, it is important to know how robust assessment methods are with respect to symptom malingering or exaggeration. Methods: The influence of different coaching methods on the simulated malingering of memory impairments is investigated in neurologically healthy participants using the Short-Term-Memory Test from the Bremer Symptom-Validierung (STM-BSV). Cut-offs were derived from patients with mild to severe traumatic brain injury. For comparison purposes, the German adaptation of the Rey Auditory Verbal Learning Test (AVLT), and the Rey 15 Items Test (FIT) were additionally administered. Four groups of neurologically healthy subjects were instructed to (1) perform as best as they can, (2) simulate brain injury, (3) simulate brain injury and received additional information about the sequelae of head trauma, (4) simulate brain injury and received additional information on how to avoid detection. Furthermore, a group of patients with mild to severe closed head injury performed the tests with best effort. Results: The nave simulator and the symptom coached groups were the easiest to detect, whereas the symptom plus test coached group was the hardest to detect. The AVLT and the FIT were not suited to detect simulators (sensitivities from 0% to 50.8% at 75% specificity) whereas the STM-BSV detected simulators with 67% - 88% sensitivity at a specificity of 73%. However, the STM-BSV was not robust to coaching. Conclusion: The present investigation shows that symptom validity testing as implemented in the BSV-STM is one clinically useful element in the detection of memory malingering. However, clinicians have to be aware that coaching influences performance in the test.	[Ruesseler, Jascha; Brett, Alexandra; Klaue, Ulrike; Muente, Thomas F.] Otto von Guericke Univ, Dept Psychol 2, Neuropsychol Unit, Magdeburg, Germany; [Ruesseler, Jascha; Muente, Thomas F.] Ctr Behav Brain Sci, Magdeburg, Germany; [Klaue, Ulrike; Sailer, Michael] Median Klin NRZ, Magdeburg, Germany; [Sailer, Michael] Otto von Guericke Univ, Klin Neurol 2, Magdeburg, Germany; [Ruesseler, Jascha] Inst Psychol 2, Abt Neuropsychol, D-39016 Magdeburg, Germany	Russeler, J (corresponding author), Otto von Guericke Univ, Dept Psychol 2, Neuropsychol Unit, Magdeburg, Germany.	jascha.ruesseler@nat.uni-magdeburg.de; alexandra.brett@ovgu.de; ulrike.klaue@web.de; michael.sailer@med.ovgu.de; thomas.muente@med.ovgu.de	Munte, Thomas/C-2077-2014	Russeler, Jascha/0000-0002-5053-5914	Research of JR and TFM; German Research Foundation (DFG)German Research Foundation (DFG)	We thank Susanne Ploetz, Maria Zinke, and Kerstin Patzwald for help in data acquisition and the Median Klinik NRZ Magdeburg for support in assessing the patients. Research of JR and TFM is financially supported by various grants from the German Research Foundation (DFG).	Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; Bauer L, 2006, ARCH CLIN NEUROPSYCH, V21, P121, DOI 10.1016/j.acn.2005.06.010; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; BOONE KB, 2007, ASSESSMENT MALINGERE, P27; Brennan AM, 2006, APPL NEUROPSYCHOL, V13, P1, DOI 10.1207/s15324826an1301_1; BRICKENKAMP R, 2002, TEST D2; Essig SM, 2001, ARCH CLIN NEUROPSYCH, V16, P271, DOI 10.1016/S0887-6177(99)00065-7; Glassmire DM, 2003, J CLIN EXP NEUROPSYC, V25, P465, DOI 10.1076/jcen.25.4.465.13875; Gouvier W. D., 1988, ARCH CLIN NEUROPSYCH, V3, P331; Green P., 2003, GREENS WORD MEMORY T; Haines ME, 2001, CLIN NEUROPSYCHOL, V15, P171, DOI 10.1076/clin.15.2.171.1891; Heilbronner RL, 2004, CLIN NEUROPSYCHOL, V18, P312, DOI 10.1080/13854040490501574; Heilbrun K, 1990, BEHAVIORAL SCI LAW, V8, P45; Helmstaedter C., 2001, VERBALER LERN MERKFA; Heubrock D., 2000, TESTBATTERIE FORENSI; Hilsabeck RC, 2001, ARCH CLIN NEUROPSYCH, V16, P669, DOI 10.1016/S0887-6177(00)00077-9; JAGER AO, 1997, BERLINER INTELLIGENZ; Langeluddecke PM, 2005, J CLIN EXP NEUROPSYC, V27, P576, DOI 10.1080/13803390490918372; Larrabee G. J., 2007, ASSESSMENT MALINGERE, P14; Larrabee G. J., 2007, ASSESSMENT MALINGERE, P80; Lynch W, 2004, J HEAD TRAUMA REHAB, V19, P277, DOI 10.1097/00001199-200405000-00008; Merten T, 2005, ARCH CLIN NEUROPSYCH, V20, P719, DOI 10.1016/j.acn.2005.04.004; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Suhr J, 2004, J CLIN EXP NEUROPSYC, V26, P416, DOI 10.1080/13803390490510121; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr J. A., 2007, ASSESSMENT MALINGERE; SUHR JA, 2007, ASSESSMENT MALINGERE, P287; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; WETTER MW, 1995, PROF PSYCHOL-RES PR, V26, P474, DOI 10.1037/0735-7028.26.5.474; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; Zimmermann P., 2002, TESTBATTERIE AUFMERK	41	20	20	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	OCT 7	2008	8								37	10.1186/1471-2377-8-37			14	Clinical Neurology	Neurosciences & Neurology	363GU	WOS:000260256600001	18838010	DOAJ Gold, Green Published			2021-06-18	
J	Pickering, C; Hagglund, M; Szmydynger-Chodobska, J; Marques, F; Palha, JA; Waller, L; Chodobski, A; Fredriksson, R; Lagerstrom, MC; Schioth, HB				Pickering, Chris; Hagglund, Maria; Szmydynger-Chodobska, Joanna; Marques, Fernanda; Palha, Joana A.; Waller, Linn; Chodobski, Adam; Fredriksson, Robert; Lagerstrom, Malin C.; Schioth, Helgi B.			The Adhesion GPCR GPR125 is specifically expressed in the choroid plexus and is upregulated following brain injury	BMC NEUROSCIENCE			English	Article							PROTEIN-COUPLED RECEPTORS; GENOME; GENERATION; EVOLUTION; BINDING; FAMILY; CELLS; GENE	Background: GPR125 belongs to the family of Adhesion G protein-coupled receptors (GPCRs). A single copy of GPR125 was found in many vertebrate genomes. We also identified a Drosophila sequence, DmCG15744, which shares a common ancestor with the entire Group III of Adhesion GPCRs, and also contains Ig, LRR and HBD domains which were observed in mammalian GPR125. Results: We found specific expression of GPR125 in cells of the choroid plexus using in situ hybridization and protein-specific antibodies and combined in situ/immunohistochemistry co-localization using cytokeratin, a marker specific for epithelial cells. Induction of inflammation by LPS did not change GPR125 expression. However, GPR125 expression was transiently increased ( almost 2-fold) at 4 h after traumatic brain injury (TBI) followed by a decrease ( approximately 4-fold) from 2 days onwards in the choroid plexus as well as increased expression ( 2-fold) in the hippocampus that was delayed until 1 day after injury. Conclusion: These findings suggest that GPR125 plays a functional role in choroidal and hippocampal response to injury.	[Pickering, Chris; Lagerstrom, Malin C.] Uppsala Univ, Dept Neurosci, BMC, Div Dev Genet, SE-75124 Uppsala, Sweden; [Szmydynger-Chodobska, Joanna; Chodobski, Adam] Brown Univ, Warren Alpert Med Sch, Dept Clin Neurosci, Providence, RI 02903 USA; [Marques, Fernanda; Palha, Joana A.] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Hlth Sci, P-4710057 Braga, Portugal	Pickering, C (corresponding author), Uppsala Univ, Dept Neurosci, BMC, Div Dev Genet, Box 593, SE-75124 Uppsala, Sweden.	chris.pickering@neuro.uu.se; maria.hagglund@neuro.uu.se; joanna_szmydynger-chodobska@brown.edu; fmarques@ecsaude.uminho.pt; japalha@ecsaude.uminho.pt; Linn.Waller.2968@student.uu.se; adam_chodobski@brown.edu; robert.fredriksson@neuro.uu.se; malin.lagerstrom@neuro.uu.se; helgi.schioth@neuro.uu.se	Marques, Fernanda/D-4238-2012; Palha, Joana Almeida/C-2745-2009; Schioth, Helgi/AAQ-7239-2020; Fredriksson, Robert/AAH-3921-2019	Marques, Fernanda/0000-0002-3612-1870; Palha, Joana Almeida/0000-0002-8866-368X; Fredriksson, Robert/0000-0002-2810-3226; Pickering, Chris/0000-0002-6630-7852	Hjarnfonden (Brain Research Foundation); Swedish Research Foundation; Novo NordiskNovo Nordisk; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-49479]; FEDER/Portuguese Foundation for Science and TechnologyPortuguese Foundation for Science and TechnologyEuropean Commission [POCTI/SAU-NEU/56618/2004]; FCTPortuguese Foundation for Science and TechnologyEuropean Commission; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049479] Funding Source: NIH RePORTER	The authors wish to thank Anders Hellstrom and Julie Sarri for technical assistance. ML was supported by Hjarnfonden (Brain Research Foundation). Studies were supported by grants from the Swedish Research Foundation and Novo Nordisk to HBS and TBI studies were supported by grant NS-49479 from the NIH to AC. JAP studies were supported by grant POCTI/SAU-NEU/56618/2004 from FEDER/Portuguese Foundation for Science and Technology (FCT). FM has a PhD fellowship from FCT.	Bjarnadottir TK, 2004, GENOMICS, V84, P23, DOI 10.1016/j.ygeno.2003.12.004; BROCKLEHURST G, 1979, ANN ROY COLL SURG, V61, P349; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Chodobski A, 2001, MICROSC RES TECHNIQ, V52, P65; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Emerich DF, 2005, BIOESSAYS, V27, P262, DOI 10.1002/bies.20193; Endo H, 1998, BRAIN RES, V793, P297, DOI 10.1016/S0006-8993(98)00042-0; Engelhardt B, 2006, J NEURAL TRANSM, V113, P477, DOI 10.1007/s00702-005-0409-y; Engelhardt B, 2001, MICROSC RES TECHNIQ, V52, P112, DOI 10.1002/1097-0029(20010101)52:1<112::AID-JEMT13>3.0.CO;2-5; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Ferrand-Drake M, 1999, NEUROSCIENCE, V93, P537, DOI 10.1016/S0306-4522(99)00181-5; Fredriksson R, 2005, ANN NY ACAD SCI, V1040, P89, DOI 10.1196/annals.1327.011; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Fridmanis D, 2007, MOL PHYLOGENET EVOL, V43, P864, DOI 10.1016/j.ympev.2006.11.007; Gard AL, 2004, NEUROSCIENCE, V127, P43, DOI 10.1016/j.neuroscience.2004.03.065; Harmar AJ, 2001, GENOME BIOL, V2; Jain RK, 2001, ADV DRUG DELIVER REV, V46, P149, DOI 10.1016/S0169-409X(00)00131-9; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Klabunde T, 2002, CHEMBIOCHEM, V3, P929, DOI 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO;2-5; Kudo S, 2007, ONCOL REP, V18, P785; Kwakkenbos MJ, 2006, FASEB J, V20, P2582, DOI 10.1096/fj.06-6500fje; Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518; Lagerstrom MC, 2007, J NEUROCHEM, V100, P1129, DOI 10.1111/j.1471-4159.2006.04281.x; Lagerstrom MC, 2006, PLOS COMPUT BIOL, V2, P493, DOI 10.1371/journal.pcbi.0020054; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Marques F, 2007, NEUROSCIENCE, V144, P424, DOI 10.1016/j.neuroscience.2006.09.029; Nordstrom KJV, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-9; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; Pierre K, 2000, NEUROSCIENCE, V100, P617, DOI 10.1016/S0306-4522(00)00294-3; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Seandel M, 2007, NATURE, V449, P346, DOI 10.1038/nature06129; Serot JM, 2003, FRONT BIOSCI-LANDMRK, V8, pS515, DOI 10.2741/1085; Serot JM, 2000, ACTA NEUROPATHOL, V99, P105, DOI 10.1007/PL00007412; Sousa JC, 2007, NEUROBIOL AGING, V28, P713, DOI 10.1016/j.neurobiolaging.2006.03.015; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Vakonakis I, 2008, STRUCTURE, V16, P944, DOI 10.1016/j.str.2008.02.020; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495	43	20	20	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	OCT 3	2008	9								97	10.1186/1471-2202-9-97			14	Neurosciences	Neurosciences & Neurology	363HD	WOS:000260257500001	18834514	DOAJ Gold, Green Published			2021-06-18	
J	Hartings, JA; Gugliotta, M; Gilman, C; Strong, AJ; Tortella, FC; Bullock, MR				Hartings, Jed A.; Gugliotta, Marinella; Gilman, Charlotte; Strong, Anthony J.; Tortella, Frank C.; Bullock, M. Ross			Repetitive cortical spreading depolarizations in a case of severe brain trauma	NEUROLOGICAL RESEARCH			English	Article						Spreading cortical depression; seizure; traumatic brain injury; microdialysis; electroencephalography; critical care	FOCAL CEREBRAL-ISCHEMIA; PERIINFARCT DEPOLARIZATIONS; ARTERY OCCLUSION; BLOOD-FLOW; REGIONAL CHANGES; DEPRESSION; INJURY; GLUCOSE; HYPOTHERMIA; MICRODIALYSIS	Objective and importance: Cortical spreading depolarizations (CSD) are waves of mass tissue depolarization that mediate progressive development of cortical infarction in animal models and occur in similar to 50% of patients with acute brain injury. Here we performed multi-modal cerebral monitoring to investigate pathologies associated with CSD occurrence in a case of severe traumatic brain injury. Clinical presentation: A 20 years old male suffering severe traumatic brain injury from a fall had extensive frontal subdural and intraparenchymal hemorrhage with mass effect. Craniectomy was performed for hematoma evacuation and decompression. Intervention: During surgery, a subdural electrocorticography (ECoG) electrode strip, along with microdialysis and PtiO2 probes, was placed beside injured cortex for CSD monitoring. Within 13-81 hours post-injury, 34 CSD occurred. CSD incidence increased during spontaneous hyperthermia and decreased during induced normothermia. Periods of CSD activity were also associated with low brain glucose (<0.10 mmol/l), elevated glutamate (>40 mmol/l) and lactate/pyruvate (>40), and PtiO2<10 mmHg. CSD caused progressive deterioration of ECoG activity only in regions with infarction at follow-up on day 27. Conclusion: Repetitive mass tissue depolarizations accompanied a negative course of hemorrhagic lesion progression in the presence of ischemic conditions after traumatic brain injury. Whether as cause or effect, CSD may represent an inherent component of progressive metabolic failure leading to tissue death, and temperature appears to be an important factor influencing their occurrence. Continuous ECoG is a valuable tool for monitoring subclinical events such as CSD and seizures and for translational research in acute brain injury mechanisms and therapeutics. [Neurol Res 2008; 30: 876-882]	[Hartings, Jed A.; Tortella, Frank C.] Walter Reed Army Inst Res, Div Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Gugliotta, Marinella; Gilman, Charlotte; Bullock, M. Ross] Virginia Commonwealth Univ, Div Neurosurg, Richmond, VA USA; [Strong, Anthony J.] Kings Coll Hosp London, Dept Neurosurg, London, England	Hartings, JA (corresponding author), Walter Reed Army Inst Res, Div Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	jed.hartings@na.amedd.army.mil		Hartings, Jed/0000-0001-8583-3471	US Department of DefenseUnited States Department of Defense	This work was supported by US Department of Defense funding. The views of the authors do not purport or reflect the position of the Department of the Army or the Department of Defense (para 4-3, AR 360-5).	Alkan T, 2001, NEUROSURG QUART, V11, P96, DOI 10.1097/00013414-200106000-00003; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BACK T, 1994, J CEREBR BLOOD F MET, V14, P12, DOI 10.1038/jcbfm.1994.3; Bhatia R, 2006, NEUROSURGERY, V58, P313, DOI 10.1227/01.NEU.0000208963.42378.83; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; CHEN Q, 1993, J CEREBR BLOOD F MET, V13, P389, DOI 10.1038/jcbfm.1993.52; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CSIBA L, 1985, BRAIN RES, V336, P167, DOI 10.1016/0006-8993(85)90430-5; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gyngell ML, 1995, NMR BIOMED, V8, P206, DOI 10.1002/nbm.1940080505; Hartings JA, 2005, J NEUROTRAUM, V22, P1201; Hartings JA, 2006, J CEREBR BLOOD F MET, V26, P696, DOI 10.1038/sj.jcbfm.9600223; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; Menna G, 2000, J NEUROPHYSIOL, V83, P1338; MIES G, 1984, EXP NEUROL, V84, P249, DOI 10.1016/0014-4886(84)90222-X; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; Ohta K, 2001, STROKE, V32, P535, DOI 10.1161/01.STR.32.2.535; Otori T, 2003, J CEREBR BLOOD F MET, V23, P43, DOI 10.1097/01.WCB.0000035180.38851.38; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Shin HK, 2006, J CEREBR BLOOD F MET, V26, P1018, DOI 10.1038/sj.jcbfm.9600252; Soukup J, 2002, NEUROL RES, V24, P161, DOI 10.1179/016164102101199710; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2000, STROKE, V31, P214, DOI 10.1161/01.STR.31.1.214; Strong AJ, 2007, BRAIN, V130, P995, DOI 10.1093/brain/awl392; Takano K, 1996, ANN NEUROL, V39, P308, DOI 10.1002/ana.410390307; Trabold R, 2006, J NEUROTRAUM, V23, P760; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Yamamoto T, 2002, NEUROL RES, V24, P789, DOI 10.1179/016164102101200906	42	20	20	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	OCT	2008	30	8					876	882		10.1179/174313208X309739			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	358FG	WOS:000259901900015	18534057				2021-06-18	
J	Bolliet, C; Bohn, MC; Spector, M				Bolliet, Catherine; Bohn, Martha C.; Spector, Myron			Non-viral delivery of the gene for glial cell line-derived neurotrophic factor to mesenchymal stem cells in vitro via a collagen scaffold	TISSUE ENGINEERING PART C-METHODS			English	Article							TRAUMATIC BRAIN-INJURY; MARROW STROMAL CELLS; FUNCTIONAL RECOVERY; PARKINSONS-DISEASE; NEURAL STEM; ADULT-RAT; GDNF; NEURONS; TRANSFECTION; NERVE	Recent advances in tissue engineering that combine an extracellular matrix-like scaffold with therapeutic molecules, cells, DNA encoding therapeutic proteins, or a combination of the three hold promise for treating defects in the brain resulting from a penetrating injury or tumor resection. The purpose of this study was to investigate a porous sponge-like collagen scaffold for non-viral delivery of a plasmid encoding for glial cell line-derived neurotrophic factor (pGDNF) to rat marrow stromal stem cells (also referred to as mesenchymal stem cells, MSCs). The effects of the following parameters on GDNF synthesis in the three-dimensional (313) constructs were evaluated and compared with results in monolayer culture: initial plasmid load (2-50 mu g pGDNF), ratio of a lipid transfection reagent to plasmid (5: 10), culture environment during the transfection (static and dynamic), and cell density. The level of gene expression in the collagen scaffolds achieved therapeutic levels that had previously been found to support survival of dopaminergic and trigeminal neurons in vitro. For the highest loading of plasmid (50 mu g), the level of GDNF protein remained six to seven times above the control level after 2 weeks, a significant difference. Cell density in the scaffold was of importance for an early increase in GDNF production, with accumulated GDNF being approximately 60% greater after 9 days of culture when scaffolds were initially seeded with 2 million rat MSCs compared to 500,000 cells. Application of orbital shaking during the 4 h of transfection had a positive effect on the production of GDNF on 3D constructs but not of the same magnitude as reported in monolayer studies. Overall, these results demonstrate that the combination of tissue engineering and non-viral transfection of MSCs for the over-expression of GDNF is a promising approach for the long-term production of GDNF and probably for neurotrophic factors in general.	[Bolliet, Catherine; Spector, Myron] Harvard Univ, Sch Med, Brigham & Womens Hosp, Vet Affairs Boston Healthcare Syst, Boston, MA 02130 USA; [Bolliet, Catherine; Spector, Myron] MIT, Cambridge, MA 02139 USA; [Bohn, Martha C.] Northwestern Univ, Childrens Mem Res Ctr, Chicago, IL 60611 USA	Spector, M (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Vet Affairs Boston Healthcare Syst, 150 S Huntington Ave,MS 151, Boston, MA 02130 USA.	mspector@rics.bwh.harvard.edu		Spector, Myron/0000-0003-3328-4858	Office of Research and Development, Rehabilitation Research and Development Service, Department of Veterans AffairsUS Department of Veterans Affairs	This material is based upon work supported by the Office of Research and Development, Rehabilitation Research and Development Service, Department of Veterans Affairs. M. Spector is a Veterans Affairs Research Career Scientist.	Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; Berry M, 2001, MOL CELL NEUROSCI, V17, P706, DOI 10.1006/mcne.2001.0975; Bjorklund A, 2000, BRAIN RES, V886, P82, DOI 10.1016/S0006-8993(00)02915-2; Capito RM, 2007, GENE THER, V14, P721, DOI 10.1038/sj.gt.3302918; Carro E, 2003, MOL NEUROBIOL, V27, P153, DOI 10.1385/MN:27:2:153; Chamberlain LJ, 2000, J NEUROSCI RES, V60, P666, DOI 10.1002/(SICI)1097-4547(20000601)60:5<666::AID-JNR12>3.3.CO;2-S; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Chevallay B, 2000, MED BIOL ENG COMPUT, V38, P211, DOI 10.1007/BF02344779; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; Clarkson ED, 1997, CELL TISSUE RES, V289, P207, DOI 10.1007/s004410050867; Cui FZ, 2003, J BIOACT COMPAT POL, V18, P413, DOI 10.1177/0883911503040470; Duvshani-Eshet M, 2007, MOL CANCER THER, V6, P2371, DOI 10.1158/1535-7163.MCT-07-0019; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Ericson C, 2002, EXP NEUROL, V173, P22, DOI 10.1006/exnr.2001.7829; Feril LB, 2006, CANCER SCI, V97, P1111, DOI 10.1111/j.1349-7006.2006.00286.x; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; HARVEY AR, 1994, RESTOR NEUROL NEUROS, V6, P221, DOI 10.3233/RNN-1994-6306; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Kameda M, 2007, EUR J NEUROSCI, V26, P1462, DOI 10.1111/j.1460-9568.2007.05776.x; Kinner B, 2002, EXP CELL RES, V278, P72, DOI 10.1006/excr.2002.5561; Kordower JH, 1997, EXP NEUROL, V144, P41, DOI 10.1006/exnr.1996.6386; Kurozumi K, 2005, MOL THER, V11, P96, DOI 10.1016/j.ymthe.2004.09.020; Kurozumi K, 2004, MOL THER, V9, P189, DOI 10.1016/j.ymthe.2003.10.012; Li S, 2000, GENE THER, V7, P31, DOI 10.1038/sj.gt.3301110; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Ma W, 2004, EXP NEUROL, V190, P276, DOI 10.1016/j.expneurol.2003.10.016; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Maswood N, 2002, NEUROBIOL AGING, V23, P881, DOI 10.1016/S0197-4580(02)00022-2; Murata R, 2007, OSTEOARTHR CARTILAGE, V15, P1275, DOI 10.1016/j.joca.2007.04.001; Palmer TD, 1999, J NEUROSCI, V19, P8487; Peister A, 2004, GENE THER, V11, P224, DOI 10.1038/sj.gt.3302163; Price TJ, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-4; Samuel RE, 2002, HUM GENE THER, V13, P791, DOI 10.1089/10430340252898975; SHEN RY, 1994, P NATL ACAD SCI USA, V91, P8920, DOI 10.1073/pnas.91.19.8920; Shoichet MS, 2000, ADV DRUG DELIVER REV, V42, P81, DOI 10.1016/S0169-409X(00)00055-7; Tai MH, 2003, EXP NEUROL, V183, P508, DOI 10.1016/S0014-4886(03)00130-4; Tresco PA, 2000, PROG BRAIN RES, V128, P349; Villoslada P, 2004, PROG BRAIN RES, V146, P403; Wei YT, 2007, BIOMED MATER, V2, pS142, DOI 10.1088/1748-6041/2/3/S11; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Xie YB, 2001, TISSUE ENG, V7, P585, DOI 10.1089/107632701753213200; YANNAS IV, 1980, J BIOMED MATER RES, V14, P65, DOI 10.1002/jbm.820140108	43	20	20	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3384	1937-3392		TISSUE ENG PART C-ME	Tissue Eng. Part C-Methods	SEP	2008	14	3					207	219		10.1089/ten.tec.2008.0168			13	Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical; Materials Science, Biomaterials	Cell Biology; Engineering; Materials Science	354AT	WOS:000259612000005	18721070				2021-06-18	
J	Fink, EL; Lai, YC; Zhang, XP; Janesko-Feldman, K; Adelson, PD; Szabo, C; Berger, RP; Sarnaik, AA; Kochanek, PM; Clark, RSB				Fink, Ericka L.; Lai, Yichen; Zhang, Xiaopeng; Janesko-Feldman, Keri; Adelson, P. David; Szabo, Csaba; Berger, Rachel P.; Sarnaik, Ajit A.; Kochanek, Patrick M.; Clark, Robert S. B.			Quantification of poly(ADP-ribose)-modified proteins in cerebrospinal fluid from infants and children after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						ADP-ribosyltransferase; biomarker; enzyme-linked immunosorbent assay; head injury; poly(ADP-ribose) polymerase; poly(ADP-ribose) synthetase	APOPTOSIS-INDUCING FACTOR; PROGRAMMED CELL-DEATH; POLYMERASE INHIBITORS; NAD(+) DEPLETION; ADP-RIBOSYLATION; GENE DISRUPTION; MICE; ISCHEMIA; ACTIVATION; EXPRESSION	Poly-ADP-ribosylation (PAR) of proteins by poly(ADP-ribose) polymerases (PARP) occurs after experimental traumatic brain injury (TBI) and modulates neurologic outcome. Several promising pharmacological PARP inhibitors have been developed for use in humans, but there is currently no clinically relevant means of monitoring treatment effects. We therefore used an enzyme-linked immunosorbent assay to measure PAR-modified proteins in cerebrospinal fluid (CSF). Cerebrospinal fluid samples from 17 pediatric TBI patients and 15 controls were plated overnight and then incubated with polyclonal antibody against PAR. Histone-1, a PARP substrate, was incubated with active PARP, NAD, and nicked DNA, and served as the standard. Both peak and mean CSF PAR-modified proteins were increased in TBI patients versus controls. Peak CSF PAR-modified protein levels occurred on day 1 and levels remained increased on day 2 after TBI. Increases in peak CSF PAR-modified protein concentrations were independently associated with age and male sex, but not initial Glasgow Coma Scale score, Glasgow outcome score, or mechanism of injury. The increase in PAR-modified proteins in CSF after TBI may be because of increased PARP activation, decreased PAR degradation, or both. As PAR-modified protein concentration correlated with age and male sex, developmental and sex-dependent roles for PARP after TBI are implicated.	[Fink, Ericka L.; Lai, Yichen; Zhang, Xiaopeng; Janesko-Feldman, Keri; Sarnaik, Ajit A.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Fink, Ericka L.; Lai, Yichen; Zhang, Xiaopeng; Janesko-Feldman, Keri; Sarnaik, Ajit A.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; [Fink, Ericka L.; Berger, Rachel P.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; [Adelson, P. David] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Szabo, Csaba] Univ Med & Dent New Jersey, Dept Surg, Newark, NJ 07103 USA	Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Adelson, David/W-2083-2019; Szabo, Csaba/D-1882-2013; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Fink, Ericka/0000-0002-3683-4571; Lai, Yi-Chen/0000-0002-9450-5506	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS38620, P50 NS30318]; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD4068, K12 HD04734, RO1 HD04596896, RO1 GM060915]; Children's Hospital of Pittsburgh; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686, K12HD047349] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045968] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM060915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P01NS030318, R01NS038620] Funding Source: NIH RePORTER	Supported by NINDS RO1 NS38620 and P50 NS30318, NICHD T32 HD40686, K12 HD047349 and RO1 HD045968, RO1 GM060915, and the Children's Hospital of Pittsburgh.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; de la Lastra CA, 2007, CURR PHARM DESIGN, V13, P933; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Chevanne M, 2007, REJUV RES, V10, P191, DOI 10.1089/rej.2006.0514; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Cosi C, 1996, BRAIN RES, V729, P264, DOI 10.1016/S0006-8993(96)00571-9; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; GRUBE K, 1992, P NATL ACAD SCI USA, V89, P11759, DOI 10.1073/pnas.89.24.11759; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hagberg H, 2004, J NEUROCHEM, V90, P1068, DOI 10.1111/j.1471-4159.2004.02547.x; Halmosi R, 2001, MOL PHARMACOL, V59, P1497; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; Lai Y, 2008, J NEUROCHEM, V104, P1700, DOI 10.1111/j.1471-4159.2007.05114.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; LAPLACA MC, 1998, J NEUROTRAUM, V15, P878; Love S, 1999, BRAIN, V122, P247, DOI 10.1093/brain/122.2.247; Mabley JG, 2005, J PHARMACOL EXP THER, V315, P812, DOI 10.1124/jpet.105.090480; Martin SS, 2005, INT J DEV NEUROSCI, V23, P673, DOI 10.1016/j.ijdevneu.2005.08.002; MESSRIPOUR M, 1994, J NEUROCHEM, V62, P502; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SHAMBAUGH GE, 1988, NEUROCHEM RES, V13, P973, DOI 10.1007/BF00970771; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.bi.54.070185.000445; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	31	20	20	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2008	28	9					1523	1529		10.1038/jcbfm.2008.52			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	341LQ	WOS:000258716400001	18506195	Green Accepted, Bronze			2021-06-18	
J	Mangus, BE; Shen, LY; Helmer, SD; Maher, J; Smith, RS				Mangus, Barry E.; Shen, Luke Y.; Helmer, Stephen D.; Maher, Janae; Smith, R. Stephen			Taser and Taser associated injuries: A case series	AMERICAN SURGEON			English	Article							OCULAR INJURY	Taser devices were introduced in 1974 and are increasingly used by law enforcement agencies. Taser use theoretically reduces the risk of injury and death by decreasing the use of lethal force. We report a spectrum of injuries sustained by four patients subdued with Taser devices. Injuries identified in our review included: 1) a basilar skull fracture, right subarachnoid hemorrhage, and left-sided epidural hemorrhage necessitating craniotomy; 2) a concussion, facial laceration, comminuted nasal fracture, and orbital floor fracture; 3) penetration of the outer table and cortex of the cranium by a Taser probe with seizure-like activity reported by the officer when the Taser was activated; and 4) a forehead hematoma and laceration. The Taser operator's manual states that these devices are designed to incapacitate a target from a safe distance without causing death or permanent injury. However, individuals may be exposed to the potential for significant injury. These devices represent a new mechanism for potential injury. Trauma surgeons and law enforcement agencies should be aware of the potential danger of significant head injuries as a result of loss of neuromuscular control.	[Mangus, Barry E.; Shen, Luke Y.; Helmer, Stephen D.; Maher, Janae; Smith, R. Stephen] Univ Kansas, Sch Med, Dept Surg, Wichita, KS 67214 USA; [Smith, R. Stephen] Via Christi Reg Med Ctr, Div Trauma, Wichita, KS USA	Smith, RS (corresponding author), Roanoke Mem Hosp, Dept Surg, 1906 Belleview Ave, Roanoke, VA 24014 USA.	rssmith@carifon.com		Helmer, Stephen/0000-0002-8760-7950			Chen SL, 2006, CLIN EXP OPHTHALMOL, V34, P378, DOI 10.1111/j.1442-9071.2006.01228.x; Jenkinson Emma, 2006, J Clin Forensic Med, V13, P229, DOI 10.1016/j.jcfm.2005.11.006; KORNBLUM RN, 1991, J FORENSIC SCI, V36, P434; Maier A., 2005, HUMAN EFFECTIVENES 1; Ng W, 2005, AM J OPHTHALMOL, V139, P713, DOI 10.1016/j.ajo.2004.11.039; ORDOG GJ, 1987, ANN EMERG MED, V16, P73, DOI 10.1016/S0196-0644(87)80292-5; *TASER INT, GEN INF; TUTTLE S, 2007, TASER ELECT CONTROL; TASER ELECT DEVICE D	9	20	20	0	1	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	SEP	2008	74	9					862	865					4	Surgery	Surgery	344NC	WOS:000258933400020	18807679				2021-06-18	
J	Stravitz, RT; Lee, WM; Kramer, AH; Kramer, DJ; Hynan, L; Blei, AT				Stravitz, R. Todd; Lee, William M.; Kramer, Andreas H.; Kramer, David J.; Hynan, Linda; Blei, Andres T.			Therapeutic hypothermia for acute liver failure: Toward a randomized, controlled trial in patients with advanced hepatic encephalopathy	NEUROCRITICAL CARE			English	Article; Proceedings Paper	5th Annual Meeting of the Neurocritical-Care-Society	NOV 01, 2007	Las Vegas, NV	Neurocrit Care Soc		cerebral edema; hypothermia; acute liver failure	UNCONTROLLED INTRACRANIAL HYPERTENSION; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; ARTERIAL AMMONIA; BODY-TEMPERATURE; CEREBRAL EDEMA; CARDIAC-ARREST; PRESSURE	Acute liver failure (ALF), the abrupt loss of liver function in a patient without previous liver disease, remains a highly mortal condition. Patients with ALF often succumb to their liver injury after the development of cerebral edema, resulting in intracranial hypertension and brain herniation. While the management of cerebral edema in ALF always includes the administration of osmotically active agents, osmotherapy often reduces intracranial pressure (ICP) insufficiently, such that herniation may be delayed but not prevented. Therapeutic hypothermia, the intentional reduction of body core temperature, has been increasingly used to treat cerebral edema in patients with traumatic and hypoxic brain injury. Data in animal models of ALF also suggest that hypothermia is effective in the prevention and treatment of cerebral edema, and case reports in humans have suggested that hypothermia is an effective bridge to orthotopic liver transplantation. A randomized, controlled trial comparing the management of ALF patients under normothermic and hypothermic conditions is a logical extension of these preliminary observations. Herein, we consider the many difficulties which will be encountered in the design of such a trial in patients with ALF at high risk of developing cerebral edema.	[Stravitz, R. Todd] Virginia Commonwealth Univ, Hume Lee Transplant Ctr, Sect Hepatol, Richmond, VA 23298 USA; [Lee, William M.; Hynan, Linda] Univ Texas Dallas, SW Med Ctr, Dallas, TX USA; [Kramer, Andreas H.] Univ Calgary, Calgary, AB, Canada; [Kramer, David J.] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; [Blei, Andres T.] Northwestern Univ, Chicago, IL USA	Stravitz, RT (corresponding author), Virginia Commonwealth Univ, Hume Lee Transplant Ctr, Sect Hepatol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	rstravit@hsc.vcu.edu	Hynan, Linda S/P-6473-2016	Hynan, Linda/0000-0002-4642-7769	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01 DK058369] Funding Source: Medline		Axelrod YK, 2006, CRIT CARE CLIN, V22, P767, DOI 10.1016/j.ccc.2006.06.001; Bernal W, 2003, SEMIN LIVER DIS, V23, P227; Bernal W, 2007, HEPATOLOGY, V46, P1844, DOI 10.1002/hep.21838; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BLEI AT, 1993, LANCET, V341, P157, DOI 10.1016/0140-6736(93)90016-A; Caldwell SH, 2006, HEPATOLOGY, V44, P1039, DOI 10.1002/hep.21303; CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; Clemmesen JO, 1997, HEPATOLOGY, V26, P1423; Clemmesen JO, 1999, HEPATOLOGY, V29, P648, DOI 10.1002/hep.510290309; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Cordoba J, 1999, GASTROENTEROLOGY, V116, P686, DOI 10.1016/S0016-5085(99)70191-5; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; FORBES A, 1989, HEPATOLOGY, V10, P306, DOI 10.1002/hep.1840100309; HANID MA, 1980, GUT, V21, P866, DOI 10.1136/gut.21.10.866; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jalan R, 2004, GASTROENTEROLOGY, V127, P1338, DOI 10.1053/j.gastro.2004.08.005; Jalan R, 2003, TRANSPLANTATION, V75, P2034, DOI 10.1097/01.TP.0000066240.42113.FF; Jalan R, 2003, SEMIN LIVER DIS, V23, P271; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; Jalan R, 2001, HEPATOLOGY, V34, P50, DOI 10.1053/jhep.2001.25386; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Lee WM, 2003, SEMIN LIVER DIS, V23, P217; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Munoz SJ, 2005, GASTROENTEROLOGY, V128, P1143, DOI 10.1053/j.gastro.2005.02.048; MUNOZ SJ, 1993, TRANSPLANTATION, V55, P1071, DOI 10.1097/00007890-199305000-00025; Murphy N, 2004, HEPATOLOGY, V39, P464, DOI 10.1002/hep.20056; OGRADY JG, 1993, LANCET, V342, P273; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; PEREIRA LMMB, 1992, GUT, V33, P98, DOI 10.1136/gut.33.1.98; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Rolando N, 2000, HEPATOLOGY, V32, P734, DOI 10.1053/jhep.2000.17687; Rose C, 2000, HEPATOLOGY, V31, P872, DOI 10.1053/he.2000.5923; Schiodt FV, 2006, LIVER TRANSPLANT, V12, P1776, DOI 10.1002/lt.20886; Schmidt LE, 2007, HEPATOLOGY, V45, P789, DOI 10.1002/hep.21503; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Stravitz RT, 2007, CRIT CARE MED, V35, P2498, DOI 10.1097/01.CCM.0000287592.94554.5F; Tofteng F, 2004, J CEREBR BLOOD F MET, V24, P798, DOI 10.1097/01.WCB.0000125648.03213.1D; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; Trey C, 1970, Prog Liver Dis, V3, P282; Vaquero J, 2005, LIVER TRANSPLANT, V11, P1581, DOI 10.1002/lt.20625; Vaquero J, 2005, J CLIN GASTROENTEROL, V39, pS147, DOI 10.1097/01.mcg.0000155515.94843.55; Vaquero J, 2003, GASTROENTEROLOGY, V125, P755, DOI 10.1016/S0016-5085(03)01051-5; Vaquero J, 2007, NAT CLIN PRACT GASTR, V4, P528, DOI 10.1038/ncpgasthep0927; Vaquero J, 2007, GASTROENTEROLOGY, V132, P372, DOI 10.1053/j.gastro.2006.11.025; WARE AJ, 1971, GASTROENTEROLOGY, V61, P877; WILLIAMS R, 1994, HEPATOLOGY, V20, pS5, DOI 10.1016/0270-9139(94)90265-8; Williams R, 1996, SEMIN LIVER DIS, V16, P343, DOI 10.1055/s-2007-1007247	52	20	20	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2008	9	1					90	96		10.1007/s12028-008-9090-y			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	340PM	WOS:000258657500013	18389180				2021-06-18	
J	McKinlay, J; Chapman, G; Elliot, S; Mallick, A				McKinlay, J.; Chapman, G.; Elliot, S.; Mallick, A.			Pre-emptive Novalung-assisted carbon dioxide removal in a patient with chest, head and abdominal injury	ANAESTHESIA			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; BRAIN-INJURY	A young man sustained traumatic lung, head and abdominal injuries. Despite mechanical ventilation, deteriorating respiratory function resulted in severe hypoxia and hypercapnia, with high P(a)CO(2) compounding an already raised intracranial pressure (ICP). The Novalung was pre-emptively used without anticoagulation, prior to laparotomy, to remove carbon dioxide and to allow for cerebral and lung protective strategies. This facilitated control of ICP thereby limited possible secondary brain injury.	[McKinlay, J.; Chapman, G.; Elliot, S.; Mallick, A.] Gen Infirm, Dept Anaesthet, Leeds LS1 3EX, W Yorkshire, England	Mallick, A (corresponding author), Gen Infirm, Dept Anaesthet, D Floor Jubilee Bldg,Great George St, Leeds LS1 3EX, W Yorkshire, England.	abhiram.mallick@leedsth.nhs.uk					Bein T, 2005, J TRAUMA, V58, P1294, DOI 10.1097/01.TA.0000173275.06947.5C; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Mallick A, 2007, ANAESTHESIA, V62, P72, DOI 10.1111/j.1365-2044.2006.04863.X; Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X	7	20	20	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0003-2409			ANAESTHESIA	Anaesthesia	JUL	2008	63	7					767	770		10.1111/j.1365-2044.2008.05484.x			4	Anesthesiology	Anesthesiology	311XE	WOS:000256632900014	18582263	Bronze			2021-06-18	
J	Mitra, B; Cameron, PA; Gabbe, BJ; Rosenfeld, JV; Kavar, B				Mitra, Biswadev; Cameron, Peter A.; Gabbe, Belinda J.; Rosenfeld, Jeffrey V.; Kavar, Bhadrakant			Management and hospital outcome of the severely head injured elderly patient	ANZ JOURNAL OF SURGERY			English	Article						craniocerebral trauma; elderly; emergency; neurosurgery	TRAUMATIC BRAIN-INJURY; PROGNOSTIC-FACTORS; INTRACRANIAL HEMATOMAS; MORTALITY; AGE; COMA; ANTICOAGULATION; CLASSIFICATION; TOMOGRAPHY; SEVERITY	Introduction: Severe traumatic head injury in the elderly has been associated with poor outcomes. However, there is currently no consensus to direct management in these patients. This study outlines the demographics, injury characteristics, management and outcome of the elderly trauma patients with severe head injury across a defined population. Materials and Methods: A retrospective review of all elderly patients (age > 64 years) with a Glasgow Coma Scale (GCS) score of 8 or less, and confirmed intracranial pathology or fractured skull, was undertaken over a period of 40 months from July 2001 to September 2005. Data on patient demographics, injury cause, presenting clinical features and interventions were collected. In-hospital mortality was used as the primary outcome. Results: There were 96 patients who met the inclusion criteria. One-third of the patients were managed palliatively, one-third supportively without surgery and another third underwent surgery. Overall mortality was 70.8% (n = 68). Older age and brainstem injuries were identified as independent predictors of mortality. Mortality was reported in all patients aged 85 years or older. Conclusions: Although overall outcomes were poor, careful consideration should be given to active treatment as favourable outcomes were possible even in the presence of extremely low GCS scores. Prediction of outcome on the basis of age and anatomical diagnoses may help in this decision-making.	[Mitra, Biswadev; Cameron, Peter A.] Alfred Hosp, Emergency & Trauma Ctr, Melbourne, Vic 3004, Australia; [Cameron, Peter A.; Rosenfeld, Jeffrey V.] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Mitra, Biswadev; Cameron, Peter A.; Gabbe, Belinda J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg & Surg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Neurosurg & Surg, Melbourne, Vic 3004, Australia; [Kavar, Bhadrakant] Royal Melbourne Hosp, Dept Neurosurg, Melbourne, Vic, Australia	Mitra, B (corresponding author), Alfred Hosp, Emergency & Trauma Ctr, Commercial Rd, Melbourne, Vic 3004, Australia.	b.mitra@alfred.org.au	Mitra, Biswadev/AAC-3724-2019; Rosenfeld, Jeffrey V/B-7249-2011	Mitra, Biswadev/0000-0002-0508-2450; Cameron, Peter/0000-0002-1443-557X; Gabbe, Belinda/0000-0001-7096-7688			*AUSTR BUR STAT, 2004, CAUS DEATH; *AUSTR BUR STAT, 2005, POP AG SEX AUSTR EL; *AUSTR BUR STAT, 2005, ABBR INJ SCAL AIS 20; Australian Bureau of Statistics, 2006, YB AUSTR 2006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baltas I, 1998, J Neurosurg Sci, V42, P85; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; Cameron PA, 2004, ANZ J SURG, V74, P424, DOI 10.1111/j.1445-1433.2004.03029.x; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; JAMJOOM A, 1992, BRIT J NEUROSURG, V6, P27, DOI 10.3109/02688699209002898; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Rosenfeld JV, 2005, LANCET, V366, P1509, DOI 10.1016/S0140-6736(05)67609-X; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tornetta P, 1999, J TRAUMA, V46, P702, DOI 10.1097/00005373-199904000-00024; Ushewokunze S, 2004, BRIT J NEUROSURG, V18, P604, DOI 10.1080/02688690400022763; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591	34	20	22	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1445-1433			ANZ J SURG	ANZ J. Surg.	JUL	2008	78	7					588	592		10.1111/j.1445-2197.2008.04579.x			5	Surgery	Surgery	314WV	WOS:000256840800018	18593416				2021-06-18	
J	Skandsen, T; Lund, TI; Fredriksli, O; Vik, A				Skandsen, Toril; Lund, Tom Ivar; Fredriksli, Oddrun; Vik, Anne			Global outcome, productivity and epilepsy 3-8 years after severe head injury. The impact of injury severity	CLINICAL REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; LATE POSTTRAUMATIC SEIZURES; FOLLOW-UP; STRUCTURED INTERVIEWS; PROSPECTIVE COHORT; YOUNG-PEOPLE; SCALE; DISABILITY; RECOVERY; MODERATE	Objective: To assess long-term outcome in survivors after severe head injury and relate outcome to injury severity. Design: Follow-up 3-8 years post injury in a retrospectively collected sample. Setting: A neurosurgical department in a regional trauma centre. Subjects: Of 146 individuals admitted, 135 were actively treated. Twenty-four per cent of these died within six months. Ninety-three of the 94 (aged 1-88 years) who survived more than three years were included in the follow-up. They were separated into groups based on their level of consciousness at four weeks post injury: oriented (n=39), confused (n=22) or in a minimally conscious/vegetative state (MCS/VS) (n=26) and not possible to assess (n=6). Outcome measures: Glasgow Outcome Scale Extended (GOSE), participation in work/education (productivity) and posttraumatic epilepsy. Results: GOSE scores were: vegetative state: 3%, severe disability: 28% (22% lower level, 6% upper level), moderate disability: 39% (22% lower level, 17% upper level) and good recovery: 27% (10% lower level, 17% upper level). Productivity was 34% (aged 7-64 years). The three severity groups had different GOSE scores (P < 0.001) and different proportion of productive individuals (P < 0.001). Twenty-three per cent experienced posttraumatic epilepsy and this was significantly associated with the highest injury severity (P < 0.001) and intracranial surgery (P=0.01). Conclusions: Being independent in daily life but unable to work was the typical long-term outcome. Stratifying the patients based on consciousness at four weeks we found different outcomes. Among oriented patients, almost all regained independency, whereas in the most severe group, poor outcomes and posttraumatic epilepsy was common.	[Skandsen, Toril] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, N-7006 Trondheim, Norway; [Skandsen, Toril] Norwegian Univ Sci & Technol, Dept Neurosci, Trondheim, Norway; [Lund, Tom Ivar] Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, Trondheim, Norway; [Fredriksli, Oddrun] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, Trondheim, Norway	Skandsen, T (corresponding author), Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, N-7006 Trondheim, Norway.	toril.skandsen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338			Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; CRERNER OL, 2007, J TRAUMA, V61, P1484; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; GROSWASSER Z, 1990, J NEUROSURG, V72, P81, DOI 10.3171/jns.1990.72.1.0081; HAGEN C, 1972, LERELS EMOTIONAL COG; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Malec JF, 2005, REHABILITATION TRAUM, P176; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; MOEN KG, 2005, EUR J EMERG IN PRESS; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	42	20	21	0	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	JUL	2008	22	7					653	662		10.1177/0269215508089067			10	Rehabilitation	Rehabilitation	329YZ	WOS:000257907800009	18586817				2021-06-18	
J	Zaaroor, M; Soustiel, JF; Brenner, B; Bar-Lavie, Y; Martinowitz, U; Levi, L				Zaaroor, M.; Soustiel, J. F.; Brenner, B.; Bar-Lavie, Y.; Martinowitz, U.; Levi, L.			Administration off label of recombinant factor-VIIa (rFVIIa) to patients with blunt or penetrating brain injury without coagulopathy	ACTA NEUROCHIRURGICA			English	Article						brain contusion; brain injury-penetrating; recombinant factor-VIIa	ACTIVATED FACTOR-VII; HEAD TRAUMA; HEMORRHAGE; DEFICIENCY; VASOSPASM; IX	Traumatic brain contusions may increase in size over time or may develop at a delay after injury. This may lead to neurological deterioration, long term morbidity or even death. Coagulation disorders after injury can contribute to progression of haemorrhage. Recombinant activated factor VII (rFVIIa) was used in 12 patients with a severe head injury who had no systemic coagulopathy but who were considered to be at risk of progression of their intracranial lesion. Twelve consecutive patients suffering from life-threatening acute head injuries from blunt (3 cases) and penetrating mechanisms were given with rFVIIa, either to prevent the expected development of brain contusion or to assist in bleeding control during surgery. In 11 patients, rFVIIa was given by the attending neurosurgeon. Two of the patients died of their severe penetrating injuries one of whom had severe vasospasm 2 days after administration of rFVIIa. The other 11 patients did not appear to suffer any treatment-related adverse effects. When the drug was given prophylactically to prevent brain resection (6 cases) or to limit the need for widening resection (5 cases), marked control was achieved in seven cases, and a lesser effect was observed in the other 4 cases. We conclude that, in a small and highly individually selected series of patients with severe head injury, the administration of rFVIIa did not lead to adverse effects. Although the majority of patients were considered to be at high risk of progression of their lesions, this occurred in only one. The early use of rFVIIa in head injured patients without systemic coagulopathy may reduce the occurrence of enlargement of contusions, the requirement of further operation, and adverse outcome. Prospective randomised controlled studies are required to investigate this.	[Zaaroor, M.; Soustiel, J. F.; Brenner, B.; Levi, L.] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; [Bar-Lavie, Y.] Ramban Med Ctr, Dept Intens Care, IL-31096 Haifa, Israel; [Martinowitz, U.] Tel Hashomer Med Ctr, Natl Haemophilia Ctr, Tel Hashomer, Israel; [Zaaroor, M.; Soustiel, J. F.; Brenner, B.; Levi, L.] Ramban Med Ctr, Dept Neurosurg, Thrombosis & Haemostasis Unit, IL-31096 Haifa, Israel	Levi, L (corresponding author), Ramban Med Ctr, Dept Neurosurg, Thrombosis & Haemostasis Unit, POB 9602, IL-31096 Haifa, Israel.	llevi@rambam.health.gov.il					BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; Gerlach R, 2002, J NEUROSURG, V96, P946, DOI 10.3171/jns.2002.96.5.0946; Hoffman M, 1998, BLOOD COAGUL FIBRIN, V9, pS61; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Kluger Y, 2007, CRIT CARE, V11, DOI 10.1186/cc6092; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Morenski JD, 2003, J NEUROSURG, V98, P611, DOI 10.3171/jns.2003.98.3.0611; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Scharrer I, 1999, HAEMOPHILIA, V5, P253; Soustiel JF, 2004, SURG NEUROL, V62, P201, DOI 10.1016/j.surneu.2003.10.037; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Wong WY, 2000, HAEMOPHILIA, V6, P50	16	20	22	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	JUL	2008	150	7					663	668		10.1007/s00701-008-1593-y			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	322HP	WOS:000257366100005	18473114				2021-06-18	
J	Vazquez, JF; Clement, HW; Sommer, O; Schulz, E; van Calker, D				Vazquez, Juan Francisco; Clement, Hans-Willi; Sommer, Olaf; Schulz, Eberhard; van Calker, Dietrich			Local stimulation of the adenosine A(2B) receptors induces an increased release of IL-6 in mouse striatum: an in vivo microdialysis study	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocyte; brain; cytokine; purine	CENTRAL-NERVOUS-SYSTEM; INTERLEUKIN-6 IL-6; CEREBRAL-ISCHEMIA; CYTOKINE ACTIONS; MESSENGER-RNA; RAT-BRAIN; EXPRESSION; ASTROCYTES; PROTEIN; CELLS	Both adenosine and interleukin-6 (IL-6) have been implicated in the pathophysiology of, e.g., epileptic seizures, traumatic brain injury, and affective disorders. Stimulation of adenosine A(2B) receptors on astrocytes in vitro leads to the increased synthesis and secretion of IL-6. We investigated whether or not activation of adenosine receptors evokes an increase of IL-6 release also in vivo. 5'-N-ethylcarboxamidoadenosine, a non-specific adenosine-agonist or vehicle was administered into the striatum of freely moving mice by reverse microdialysis. A statistical significant increase of the IL-6 concentration in the perfusate was detected already 60 min after 5'-N-ethylcarboxamidoadenosine administration. IL-6 increased progressively and reached a maximum after 240 min. This effect appears to be mediated through adenosine A(2B) receptors since it was counteracted by the specific A(2B) receptor antagonist MRS1706 but not by the specific A(1) receptor antagonist DPCPX. We conclude that adenosine via activation of A(2B) receptors evokes IL-6 release also in vivo.	[van Calker, Dietrich] Univ Freiburg, Dept Psychiat & Psychotherapy, Freiburg, Germany; [Vazquez, Juan Francisco; Clement, Hans-Willi; Schulz, Eberhard] Univ Freiburg, Dept Child & Adolescent Psychiat, Freiburg, Germany; [Sommer, Olaf] Univ Freiburg, Dept Gen & Digest Surg, Freiburg, Germany	van Calker, D (corresponding author), Univ Freiburg Klinikum, Abt Psychiat & Psychotherapie, Hauptstr 5, D-79104 Freiburg, Germany.	dietrich.calker@uniklinik-freiburg.de	Vazquez-Costa, Juan F/D-4393-2015	Vazquez-Costa, Juan F/0000-0002-3043-7938			Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Balschun D, 2004, FASEB J, V18, P1788, DOI 10.1096/fj.04-1625fje; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Biber K, 2001, NEUROPSYCHOPHARMACOL, V24, P86, DOI 10.1016/S0893-133X(00)00169-X; BIBER K, 2007, IN PRESS NEUROPSYCHO; Calker D, 2005, NEUROCHEM RES, V30, P1205, DOI 10.1007/s11064-005-8792-1; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; Choi YH, 1999, PHYSIOL BEHAV, V67, P587, DOI 10.1016/S0031-9384(99)00110-9; Clapp-Lilly KL, 1999, J NEUROSCI METH, V90, P129, DOI 10.1016/S0165-0270(99)00064-3; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Fiebich BL, 2005, NEUROCHEM INT, V46, P501, DOI 10.1016/j.neuint.2004.11.009; Fiebich BL, 1996, J NEUROCHEM, V66, P1426; Fredholm BB, 2005, INT REV NEUROBIOL, V63, P191, DOI 10.1016/S0074-7742(05)63007-3; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Herrmann O, 2003, J CEREBR BLOOD F MET, V23, P406, DOI 10.1097/01.WCB.0000055177.50448.FA; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Huang CC, 2001, REV NEUROSCIENCE, V12, P51; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Juttler E, 2002, NEUROSCIENTIST, V8, P268, DOI 10.1177/1073858402008003012; Kim YC, 2000, J MED CHEM, V43, P1165, DOI 10.1021/jm990421v; Michel PP, 1999, J NEUROCHEM, V72, P2074, DOI 10.1046/j.1471-4159.1999.0722074.x; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pizzi M, 2004, MOL CELL NEUROSCI, V25, P301, DOI 10.1016/j.mcn.2003.10.022; Rosi S, 2003, J NEUROCHEM, V86, P220, DOI 10.1046/j.1471-4159.2003.01825.x; Sallmann S, 2000, J NEUROSCI, V20, P8637; Schwaninger M, 2000, GLIA, V31, P51, DOI 10.1002/(SICI)1098-1136(200007)31:1<51::AID-GLIA50>3.0.CO;2-M; Schwaninger M, 1997, J NEUROCHEM, V69, P1145; Sjogren S, 2002, BRIT J DERMATOL, V146, P375, DOI 10.1046/j.1365-2133.2002.04621.x; Stevens B, 2002, NEURON, V36, P855, DOI 10.1016/S0896-6273(02)01067-X; Suzuki S, 2000, NEUROREPORT, V11, P2565, DOI 10.1097/00001756-200008030-00043; Taga T, 2005, CLIN REV ALLERG IMMU, V28, P249, DOI 10.1385/CRIAI:28:3:249; Tawfik HE, 2005, AM J PHYSIOL-HEART C, V288, pH1411, DOI 10.1152/ajpheart.00684.2004; Trincavelli ML, 2004, J NEUROCHEM, V91, P1180, DOI 10.1111/j.1471-4159.2004.02793.x; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	38	20	20	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2008	105	3					904	909		10.1111/j.1471-4159.2007.05191.x			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	290RF	WOS:000255139200030	18088370	Bronze			2021-06-18	
J	Coster, WJ; Haley, SM; Ni, P; Dumas, HM; Fragala-Pinkham, MA				Coster, Wendy J.; Haley, Stephen M.; Ni, Pengsheng; Dumas, Helene M.; Fragala-Pinkham, Maria A.			Assessing self-care and social function using a computer adaptive testing version of the pediatric evaluation of disability inventory	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						outcome assessment (health care); pediatrics; rehabilitation	ITEM RESPONSE THEORY; TRAUMATIC BRAIN INJURY; INPATIENT REHABILITATION; CHILDREN; MOBILITY; OUTCOMES; YOUTH; PEDI; LIKELIHOOD; SCALES	Objective: To examine score agreement, validity, precision, and response burden of a prototype computer adaptive testing (CAT) version of the self-care and social function scales of the Pediatric Evaluation of Disability Inventory compared with the full-length version of these scales. Design: Computer simulation analysis of cross-sectional and longitudinal retrospective data; cross-sectional prospective study. Setting: Pediatric rehabilitation hospital, including inpatient acute rehabilitation, day school program, outpatient clinics; community-based day care, preschool, and children's homes. Participants: Children with disabilities (n=469) and 412 children with no disabilities (analytic sample); 38 children with disabilities and 35 children without disabilities (cross-validation sample). Interventions: Not applicable. Main Outcome Measures: Summary scores from prototype CAT applications of each scale using 15-, 10-, and 5-item stopping rules; scores from the full-length self-care and social function scales; time (in seconds) to complete assessments an respondent ratings of burden. Results: Scores from both computer simulations and field administration of the prototype CATs were highly consistent with scores from full-length administration (r range, .94-99). Using computer simulation of retrospective data, discriminant validity, and sensitivity to change of the CATs closely approximated that of the full-length scales, especially when the 15- and 10-item stopping rules were applied. In the cross-validation study the time to administer both CATs was 4 minutes, compared with over 16 minutes to complete the full-length scales. Conclusions: Self-care and social function score estimates from CAT administration are highly comparable with those obtained from full-length scale administration, with small losses in validity and precision and substantial decreases in administration time.	[Coster, Wendy J.] Boston Univ, Sargent Coll, Dept Occupat Therapy & Rehabil Counseling, Boston, MA 02215 USA; [Haley, Stephen M.] Boston Univ, Sch Publ Hlth, Hlth & Disabil Res Inst, Boston, MA USA; [Dumas, Helene M.; Fragala-Pinkham, Maria A.] Franciscan Hosp Children, Res Ctr Children Special Hlth Care Needs, Boston, MA USA	Coster, WJ (corresponding author), Boston Univ, Sargent Coll, Dept Occupat Therapy & Rehabil Counseling, 635 Commonwealth Ave, Boston, MA 02215 USA.	wjcoster@bu.edu	Fragala-Pinkham, Maria/AAY-4354-2020	Ni, Pengsheng/0000-0003-1774-2185	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43HD042388, R41HD052318, K02HD045354] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R41 HD052318, R43 HD042388, K02 HD045354, R43 HD42388-01, R41 HD052318-01A1, K02 HD45354-01A1] Funding Source: Medline		ANDRICH D, 1998, RASCH MODELS MEASURE; Beauducel A, 2006, STRUCT EQU MODELING, V13, P186, DOI 10.1207/s15328007sem1302_2; BUTLER C, 1995, DEV MED CHILD NEUROL, V37, P753; Dijkers MP, 2003, ARCH PHYS MED REHAB, V84, P384, DOI 10.1053/apmr.2003.50006; Dumas H M, 2001, Pediatr Rehabil, V4, P177, DOI 10.1080/13638490210121720; Dumas HM, 2002, AM J PHYS MED REHAB, V81, P661, DOI 10.1097/00002060-200209000-00005; Dumas HM, 2001, BRAIN INJURY, V15, P891, DOI 10.1080/02699050110065691; DUMAS HM, 2001, PHYS OCCUP THER PEDI, V21, P17; Embretson S.E., 2013, ITEM RESPONSE THEORY; Engelbert RHH, 1997, PEDIAT PHYS THER, V9, P18; FELDMAN AB, 1990, PHYS THER, V70, P602, DOI 10.1093/ptj/70.10.602; Fischer GH, 1995, RASCH MODELS FDN REC; Fragala MA, 2002, BRAIN INJURY, V16, P149, DOI 10.1080/02699050110103328; Haley S. M., 1993, PHYS MED REH CLIN N, V4, P529; Haley SM, 2005, ARCH PHYS MED REHAB, V86, P932, DOI 10.1016/j.apmr.2004.10.032; Haley SM, 2001, PHYS THER, V81, P1425, DOI 10.1093/ptj/81.8.1425; HALEY SM, 1992, PEDIAT EVALUATION DI; Hambleton R. K., 1991, FUNDAMENTALS ITEM RE; HARIHARAN S, 1990, J EDUC MEAS, V27, P361; Hays RD, 2000, MED CARE, V38, P28; Iyer LV, 2003, PHYS THER, V83, P888, DOI 10.1093/ptj/83.10.888; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Ketelaar M, 2001, PHYS THER, V81, P1534, DOI 10.1093/ptj/81.9.1534; Kothari DH, 2003, PHYS THER, V83, P776, DOI 10.1093/ptj/83.9.776; Lollar DJ, 2000, ARCH PHYS MED REHAB, V81, pS46, DOI 10.1053/apmr.2000.20624; Ludlow L H, 2000, J Outcome Meas, V4, P482; Ludlow LH, 1996, EDUC PSYCHOL MEAS, V56, P122, DOI 10.1177/0013164496056001008; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MISLEVY RJ, 1986, J EDUC STAT, V11, P3, DOI 10.3102/10769986011001003; Msall ME, 2002, PEDIATRICS, V109, P317, DOI 10.1542/peds.109.2.317; Muthen B.O., 1998, MPLUS USERS GUIDE; Nichols D.S., 1996, PEDIATR PHYS THER, V8, DOI [https://doi.org/10.1097/00001577-199600810-00004, DOI 10.1097/00001577-199600810-00004]; Nordmark E, 2000, DEV MED CHILD NEUROL, V42, P245, DOI 10.1017/S0012162200000426; Norrlin S, 2003, ACTA PAEDIATR, V92, P204; Ostensjo S, 2003, DEV MED CHILD NEUROL, V45, P603, DOI 10.1017/S0012162203001105; Revicki DA, 1997, QUAL LIFE RES, V6, P595, DOI 10.1023/A:1018420418455; TJUR T, 1982, SCAND J STAT, V9, P23; Tsai PY, 2002, CHILD NERV SYST, V18, P48, DOI 10.1007/s00381-001-0531-6; van der Linden W.J., 1997, HDB MODERN ITEM RESP; Wainer H, 2000, COMPUTERIZED ADAPTIV; Ware JE, 2000, MED CARE, V38, P73; WARM TA, 1989, PSYCHOMETRIKA, V54, P427, DOI 10.1007/BF02294627; Wright FV, 1993, CAN J REHABIL, V7, P41; Wu M, 1998, CONQUEST COMPUTER SO	45	20	21	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2008	89	4					622	629		10.1016/j.apmr.2007.09.053			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	289IG	WOS:000255047600005	18373991	Green Accepted			2021-06-18	
J	Liu, WP; Jiang, XD; Fu, XF; Cui, SJ; Du, MX; Cai, YQ; Xu, RX				Liu, Wenpeng; Jiang, Xiaodan; Fu, Xiafei; Cui, Shaojie; Du, Mouxuan; Cai, Yingqian; Xu, Ruxiang			Bone marrow stromal cells can be delivered to the site of traumatic brain injury via intrathecal transplantation in rabbits	NEUROSCIENCE LETTERS			English	Article						bone marrow stromal cells; traumatic brain injury; transplantation; green fluorescent protein	NEURAL PRECURSOR CELLS; FUNCTIONAL RECOVERY; SPINAL-CORD; GENE-TRANSFER; STEM-CELLS; RAT-BRAIN; MIGRATION; THERAPY; REPAIR	Recent studies suggest that bone marrow stromal cells (BMSCs) are promising grafts for treatment of traumatic brain injury (TBI). Neural precursor cells (NPCs) have been detected in the site of cervical cord injury following intrathecal injection by lumbar puncture. So, this study is designed to determine whether BMSCs (after intrathecal administration by lumbar puncture) could also migrate to the TBI site. The cells were cultured in vitro and transfected with adenovirus green fluorescent protein (Ad-GFP), and then transplanted intrathecally or intravenously into an autologous rabbit model of TBI. The labeled, grafted cells were identified in the injured cerebral tissue using fluorescence microscopy. Results showed that the intrathecal protocol was more efficient than the intravenous one. And motor dysfunction was improved after autologous transplantation of BMSCs. This study suggests another attractive minimally invasive option for treating TBI. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Liu, Wenpeng; Jiang, Xiaodan; Du, Mouxuan; Cai, Yingqian; Xu, Ruxiang] So Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou, Peoples R China; [Fu, Xiafei] So Med Univ, Zhujiang Hosp, Dept Obstet & Gynecol, Guangzhou, Peoples R China; [Cui, Shaojie] 306 Hosp Peoples Liberat Army, Dept Neurosurg, Beijing, Peoples R China	Xu, RX (corresponding author), So Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou, Peoples R China.	zhanghuimeng1688@sina.com; 1wp88899@hotmail.com					Aarum J, 2003, P NATL ACAD SCI USA, V100, P15983, DOI 10.1073/pnas.2237050100; Bakshi A, 2006, J NEUROTRAUM, V23, P55, DOI 10.1089/neu.2006.23.55; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fukunaga A, 2003, ACTA NEUROCHIR, V145, P473, DOI 10.1007/s00701-003-0038-x; Ji JF, 2004, NEUROSCI LETT, V355, P236, DOI 10.1016/j.neulet.2003.11.024; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jin KL, 2005, NEUROBIOL DIS, V18, P366, DOI 10.1016/j.nbd.2004.10.010; Kretz A, 2003, MOL THER, V7, P659, DOI 10.1016/S1525-0016(03)00062-5; Kruger GM, 2002, CELL, V110, P399, DOI 10.1016/S0092-8674(02)00899-1; Lacza Z, 2003, BRAIN RES PROTOC, V11, P145, DOI 10.1016/S1385-299X(03)00039-4; Lepore AC, 2005, BRAIN RES, V1045, P206, DOI 10.1016/j.brainres.2005.03.050; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Miyaguchi K, 2000, BRAIN RES BULL, V51, P195, DOI 10.1016/S0361-9230(99)00217-8; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rao MS, 2000, PROG BRAIN RES, V128, P273; Seledtsov VI, 2005, BIOMED PHARMACOTHER, V59, P415, DOI 10.1016/j.biopha.2005.01.012; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; STEVE SWH, 2002, EXP NEUROL, V177, P360; Swanger SA, 2005, CELL TRANSPLANT, V14, P775, DOI 10.3727/000000005783982594	24	20	23	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 28	2008	434	2					160	164		10.1016/j.neulet.2007.12.067			5	Neurosciences	Neurosciences & Neurology	288EC	WOS:000254968000002	18325665				2021-06-18	
J	Elliott, MB; Jallo, JJ; Tuma, RF				Elliott, Melanie B.; Jallo, Jack J.; Tuma, Ronald F.			An investigation of cerebral edema and injury volume assessments for controlled cortical impact injury	JOURNAL OF NEUROSCIENCE METHODS			English	Article						controlled cortical impact; CCI injury; traumatic brain injury; cerebral edema; injury volume; triphenyltetrazolium chloride	TRAUMATIC BRAIN-INJURY; RATS; CONTUSION; ISCHEMIA; MODEL	Using the controlled cortical impact (CCI) model, our laboratory compared edema in contralateral and ipsilateral regions to help clarify conflicting reports of contralateral edema and for enhanced assessment and interpretation of CCI injury pathophysiology. This investigation examined regional edema in response to graded injury severities over time with regards to tissue damage. Prior to injury rats were anesthetized with ketamine and xylazine (1:1). CCI injury parameters were set at 4.0 m/s and 120 to 130 ms. Rats were randomized to receive moderate or severe injuries set at 2.0 and 3.0 mm depths, respectively. Cerebral edema and injury volume were examined separately following euthanasia with pentobarbital. Cerebral edema was measured using the wet-dry weight technique at 24 or 48 It after injury. Sham animals underwent all surgical procedures except the impact injury. Injury volume was quantified using 2,3,5-triphenyltetrazolium chloride staining at 24 h or 7 days after injury. The results of this investigation confirm that cerebral edema is absent in the uninjured, contralateral hemisphere after moderate and severe CCI injury. There were regional differences in cerebral edema formation in the hemisphere ipsilateral to injury that were dependent on injury severity and the length of time after injury. Tissue damage was reduced over 7 days following moderate CCI injury. Conclusions: (1) the absence of edema in the contralateral hemisphere allows it to serve as a valid control for edema formation, (2) misrepresenting injury volume because of edema continues to be a problem for evaluating CCI injury and treatment efficacy, and (3) reduced injury volume over 7 days following CCI injury suggests tissue recovery after initial dysfunction. (c) 2007 Elsevier B.V. All rights reserved.	[Elliott, Melanie B.] Temple Univ, Dept Phys Therapy, Philadelphia, PA 19140 USA; [Jallo, Jack J.] Temple Univ, Sch Med, Dept Neurosurg, Philadelphia, PA 19140 USA; [Tuma, Ronald F.] Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA	Elliott, MB (corresponding author), Temple Univ, Dept Phys Therapy, 3307 N Broad St, Philadelphia, PA 19140 USA.	mdion@temple.edu; jack.jallo@teinple.edu; ronald.tuma@teniple.edu		Jallo, Jack/0000-0002-5512-1729			BARONE FC, 1991, BRAIN RES BULL, V26, P285, DOI 10.1016/0361-9230(91)90240-K; Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Davis A E, 2000, Crit Care Nurs Q, V23, P1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Drummond JC, 1998, ANESTHESIOLOGY, V88, P993, DOI 10.1097/00000542-199804000-00020; Elliott MB, 2007, J NEUROTRAUM, V24, P195, DOI 10.1089/neu.2006.0094; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Okuno S, 2001, NEUROL RES, V23, P657, DOI 10.1179/016164101101198983; Onal MZ, 1997, STROKE, V28, P1060, DOI 10.1161/01.STR.28.5.1060; Stroop R, 1998, ACT NEUR S, V71, P303; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Thomale UW, 2004, J NEUROTRAUM, V21, P1737; Unterberg AW, 1997, ACT NEUR S, V70, P106; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	20	20	22	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 15	2008	168	2					320	324		10.1016/j.jneumeth.2007.10.019			5	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	271YK	WOS:000253824400005	18076998				2021-06-18	
J	Cornielje, H; Velema, JP; Finkenfluge, H				Cornielje, Huib; Velema, Johan P.; Finkenfluge, Harry			Community based rehabilitation programmes: monitoring and evaluation in order to measure results	LEPROSY REVIEW			English	Article							TRAUMATIC BRAIN-INJURY; CLASSIFICATION; PROJECTS	Although community Based Rehabilitation has now formally existed for almost 30 years, few papers have been written about the results of this approach. The authors hope to contribute With this paper towards methodologies that will help to Measure results of community Based Rehabilitation programmes. The importance of establishing - prior to the development of Community Based Rehabilitation - an extensive baseline has not been extensively covered as the importance of it is almost self-evident: vel the lack of baseline data often severely hampers the possibility of being able to measure the effects of Community Based Rehabilitation. The article places considerable importance on management information systems and monitoring, since it is believed that evaluation will greatly benefit from both the existence of baseline data as well as a well-developed and well-implemented information system. The present article emphasises the need for participatory processes in the development of baseline data and information systems. Four key areas for measuring CBR are highlighted: people, power, public society and partnerships. Finally, a tool is presented in order to evaluate (or monitoring and evaluation) systematically.	[Cornielje, Huib] Enablement, NL-2402 PX Alphen Aan Den Rijn, Netherlands; [Velema, Johan P.] Leprosy Mission Int, Evaluat & Monitoring Network, NL-7301 BD Apeldoorn, Netherlands; [Finkenfluge, Harry] Erasmus MC Univ Med Ctr Rotterdam, Inst Hlth Policy & Management, NL-3000 DR Rotterdam, Netherlands	Cornielje, H (corresponding author), Enablement, Langenhorst 36, NL-2402 PX Alphen Aan Den Rijn, Netherlands.	h.cornielje@enablement.nl					BOYCE W, 2000, ASIA PACIFIC DISABIL, V11, P69; BOYCE W, 2001, ASIA PACIFIC DISABIL, V12, P3; Cornielje H, 2002, LEPROSY REV, V73, P47; Cornielje H, 2000, LEPROSY REV, V71, P472; CORNIELJE H, 1999, RES INFORM REHABILIT; Evans PJ, 2001, SOC SCI MED, V53, P333, DOI 10.1016/S0277-9536(00)00321-X; Finkenflugel H, 2005, INT J REHABIL RES, V28, P187, DOI 10.1097/00004356-200509000-00001; Finkenflugel H, 2008, DISABIL REHABIL, V30, P348, DOI 10.1080/09638280701257288; Khasnabis C, 2008, LEPROSY REV, V79, P17; Kusek J.Z., 2004, 10 STEPS RESULTS BAS; MCLAREN P, 1998, INDICATORS DISABILIT; Powell BA, 2002, DISASTERS, V26, P175, DOI 10.1111/1467-7717.00199; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Thomas M, 2008, LEPROSY REV, V79, P10; Thomas MJ, 2003, LEPROSY REV, V74, P175; Velema JP, 2008, LEPROSY REV, V79, P65; Velema JP, 2008, DISABIL REHABIL, V30, P396, DOI 10.1080/09638280701256272; Velema JP, 2003, DISABIL REHABIL, V25, P1252, DOI 10.1080/09638280310001599970; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WHO, 1997, WHOQOL MEAS QUAL LIF; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; Wirz S, 2002, INT J REHABIL RES, V25, P163, DOI 10.1097/00004356-200209000-00001	22	20	20	0	3	LEPRA	COLCHESTER	28 MIDDLEBOROUGH, COLCHESTER CO1 1TG, ESSEX, ENGLAND	0305-7518	2162-8807		LEPROSY REV	Lepr. Rev.	MAR	2008	79	1					36	49					14	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	341LD	WOS:000258715100006	18540236				2021-06-18	
J	dela Cruz, GG; Knapik, JJ; Birk, MG				dela Cruz, Georgia G.; Knapik, Joseph J.; Birk, Marcella G.			Evaluation of mouthguards for the prevention of orofacial injuries during United States Army basic military training	DENTAL TRAUMATOLOGY			English	Article							DENTAL INJURIES; MOUTH PROTECTORS; CONCUSSIONS; WEAR	Beginning in January 2000, all individuals participating in basic military training at Fort Leonard Wood, Missouri, were issued boil-and-bite mouthguards. From January 2000 to March 2001, trainees were required to wear mouthguards only for a single activity, pugil stick training. After March 2001, mouthguards were required for four activities including pugil stick training, unarmed combat, rifle/bayonet training, and the confidence/obstacle course. Dentists systematically tracked trainees who reported to the dental clinic with orofacial injuries during three periods: January 2000-March 2001 (phase 1), April-September 2001 (phase 2) and September 2002-June 2003 (phase 3). Orofacial injury rates were 3.35, 1.89 and 1.91 cases/10 000 person-years in phases 1, 2 and 3, respectively. The overall risk of an orofacial injury was 1.76 (95% confidence interval = 1.03-3.02) times higher in phase 1 compared with the combined phases 2 and 3 (P = 0.006). Thus, orofacial injury rates were lower when mouthguards were required for four training activities as opposed to one training activity. Mouthguards are now required at all five Army basic training sites when trainees are performing any of the four training activities.	[dela Cruz, Georgia G.; Knapik, Joseph J.; Birk, Marcella G.] USA, Ctr Hlth Promot & Prevent Med, Aberdeen Proving Ground, MD 21010 USA	dela Cruz, GG (corresponding author), USA, Ctr Hlth Promot & Prevent Med, LTC dela Cruz,5158 Blackhawk Rd, Aberdeen Proving Ground, MD 21010 USA.	georgia.delacruz@us.army.mil					ADAMS JR, 2004, RULES INTERPRETATION; ALEXANDER D, 1995, IOWA DENT J, V40, P41; [Anonymous], 2004, J AM DENT ASSOC, V135, P1061; [Anonymous], 1964, J AM DENT ASSOC, V68, P430; Barbic D, 2005, CLIN J SPORT MED, V15, P294, DOI 10.1097/01.jsm.0000171883.74056.21; Blignaut J B, 1987, Br J Sports Med, V21, P5; *BUR DENT HLTH ED, 1963, J AM DENT ASSOC, V66, P539; CARLOS TA, 1938, ORAL HYG, V28, P1580; Chapman P J, 1985, Br J Sports Med, V19, P34; COHEN A, 1958, J Am Dent Assoc, V56, P863; Cohen A, 1961, B NAT ASS SECONDARY, V45, P145; Cohen A, 1962, PENN DENT J, V29, P6; de Wet F A, 1981, J Dent Assoc S Afr, V36, P249; DUFFY PJ, 2005, ICE HOCKEY RULES INT; Dunbar D, 1962, J MASS DENT SOC, V11, P34; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; GARFIELD S, 1969, TREATISE TEETH RELAT; HEINTZ WD, 1968, J AM DENT ASSOC, V77, P632; HEINTZ WD, 1975, PHYSICIAN SPORTSMED, V3, P61; HUGHSTON JC, 1980, AM J SPORT MED, V8, P61, DOI 10.1177/036354658000800201; Jacobs WH, 1938, ORAL HYGIENE, V28, P1148; *JOINT COMM MOUTH, 1960, REP JOINT COMM MOUTH; Kahn H. A., 1989, STAT METHODS EPIDEMI; KATZ RV, 1979, COMMUNITY DENT ORAL, V7, P30, DOI 10.1111/j.1600-0528.1979.tb01182.x; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; MAESTRELLODEMOYA MG, 1989, J DENT CHILD, V56, P36; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; MCNUTT T, 1989, Pediatric Dentistry, V11, P209; MOON DG, 1961, J AM DENT ASSOC, V62, P568, DOI 10.14219/jada.archive.1961.0104; Morton J G, 1979, N Z Dent J, V75, P151; POWERS J M, 1984, Journal of the American Dental Association, V109, P84; Quarrie KL, 2005, BRIT J SPORT MED, V39, P650, DOI 10.1136/bjsm.2004.016022; REED RV, 1994, BRIT DENT J, V176, P478, DOI 10.1038/sj.bdj.4808485; Schoen G, 1956, B NASSAU COUNTY DENT, V30, P12; STEVENS OO, 1963, J AM DENT ASSOC, V67, P521, DOI 10.14219/jada.archive.1963.0330; STOKES ANS, 1987, ENDOD DENT TRAUMATOL, V3, P255; Upson N, 1985, Br J Sports Med, V19, P89; WATTS G, 1954, J AM DENT ASSOC, V49, P7, DOI 10.14219/jada.archive.1954.0132; WINTERS CW, 2005, LACROSSE MENS RULES; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x	40	20	22	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	FEB	2008	24	1					86	90		10.1111/j.1600-9657.2006.00500.x			5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	242PV	WOS:000251738700018	18173673				2021-06-18	
J	Shein, NA; Grigoriadis, N; Alexandrovich, AG; Simeonidou, C; Spandou, E; Tsenter, J; Yatsiv, I; Horowitz, M; Shohami, E				Shein, Na'ama A.; Grigoriadis, Nikolaos; Alexandrovich, Alexander G.; Simeonidou, Constantina; Spandou, Evangelia; Tsenter, Jeanna; Yatsiv, Ido; Horowitz, Michal; Shohami, Esther			Differential neuroprotective properties of endogenous and exogenous erythropoietin in a mouse model of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral edema; closed head injury; heat acclimation	CLOSED-HEAD INJURY; RECOMBINANT-HUMAN-ERYTHROPOIETIN; FLUORO-JADE-B; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; CROSS-TOLERANCE; ACCLIMATION INCREASES; COGNITIVE DEFICITS; NERVOUS-SYSTEM; MICE	Both heat acclimation (HA) and post-injury treatment with recombinant human erythropoietin (Epo, rhEpo, exogenous Epo) are neuroprotective against traumatic brain injury (TBI). Our previous data demonstrated that HA-induced neuroprotection includes improved functional recovery and reduced cerebral edema formation. Additionally, in earlier Western-blot analyses, we found that HA mice display increased expression of the specific erythropoietin receptor (EpoR) and of hypoxia-inducible factor-1 alpha (HIF-1 alpha), the inducible subunit of the transcription factor, which regulates Epo gene expression, but not of Epo itself. In light of this, the aim of the current study was threefold: (1) to assess Epo expression in the trauma area and hippocampus following HA, rhEpo administration, or combined HA-rhEpo treatment, using immunohistochemical methods that offer enhanced anatomical resolution; (2) to examine the effects of endogenous and exogenous Epo on edema formation in normothermic (NT) mice; and (3) to evaluate the effects of exogenous Epo administration on neuroprotective outcome measures in HA animals. HA induced enhanced expression of endogenous Epo in the trauma area and the hippocampus. Treatment with anti-Epo antibody given to NT mice increased edema formation, whereas rhEpo induced no beneficial effect. Cognitive performance testing and immunohistochemical findings reinforced HA and rhEpo as separate protective interventions but showed no advantage to combining the two strategies. We therefore suggest that HA-induced neuroprotection is shaped by pre-existing mediators but cannot be modified by post-injury treatment aimed at increasing the levels of neuroprotective agents.	[Shein, Na'ama A.; Alexandrovich, Alexander G.; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-92220 Jerusalem, Israel; [Shein, Na'ama A.; Horowitz, Michal] Hebrew Univ Jerusalem, Dept Physiol, IL-92220 Jerusalem, Israel; [Grigoriadis, Nikolaos] AHEPA Univ, Dept Neurol, Thessaloniki, Greece; [Simeonidou, Constantina; Spandou, Evangelia] AHEPA Univ, Dept Physiol, Thessaloniki, Greece; Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece; [Tsenter, Jeanna] Hadassah Med Ctr, Rehabil Ctr, IL-91120 Jerusalem, Israel; [Yatsiv, Ido] Hadassah Med Ctr, Pediat Crit Care Unit, IL-91120 Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-92220 Jerusalem, Israel.	esty@cc.huji.ac.il					Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Arieli Y, 2003, BRAIN RES, V962, P15, DOI 10.1016/S0006-8993(02)03681-8; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Horowitz M, 2004, J APPL PHYSIOL, V97, P1496, DOI 10.1152/japplphysiol.00306.2004; Horowitz M, 2002, COMP BIOCHEM PHYS A, V131, P475, DOI 10.1016/S1095-6433(01)00500-1; HOROWITZ M, 1985, COMP BIOCHEM PHYS A, V80, P57, DOI 10.1016/0300-9629(85)90678-4; Horowitz M, 1999, AM J PHYSIOL-REG I, V277, pR47; HOROWITZ M, 1994, TEMPERATURE OSMOREGU, P87; Horowitz M, 2007, PROG BRAIN RES, V162, P373, DOI 10.1016/S0079-6123(06)62018-9; Kumral A, 2003, BIOL NEONATE, V83, P224, DOI 10.1159/000068926; LEVI E, 1993, J APPL PHYSIOL, V75, P833; Maloyan A, 2005, PHYSIOL GENOMICS, V23, P79, DOI 10.1152/physiolgenomics.00279.2004; Maloyan A, 1999, AM J PHYSIOL-REG I, V276, pR1506; Meier U, 2005, ACT NEUR S, V95, P55; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reinert M, 2000, Neurosurg Focus, V8, pe10; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; Simic G, 2000, EXP NEUROL, V165, P12, DOI 10.1006/exnr.2000.7448; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Stockmann C, 2006, CLIN EXP PHARMACOL P, V33, P968, DOI 10.1111/j.1440-1681.2006.04474.x; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	48	20	20	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2008	25	2					112	123		10.1089/neu.2007.0358			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266RZ	WOS:000253456000004	18260794				2021-06-18	
J	Conte, V; Raghupathi, R; Watson, DJ; Fujimoto, S; Royo, NC; Marklund, N; Stocchetti, N; McIntosh, TK				Conte, Valeria; Raghupathi, Ramesh; Watson, Deborah J.; Fujimoto, Scott; Royo, Nicolas C.; Marklund, Niklas; Stocchetti, Nino; McIntosh, Tracy K.			TrkB gene transfer does not alter hippocampal neuronal loss and cognitive deficits following traumatic brain injury in mice	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						adeno-associated virus; cell death; cognition; in vivo gene therapy; neurotrophins	P75 NEUROTROPHIN RECEPTOR; NEONATAL HYPOXIA-ISCHEMIA; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT BRAIN; CHOLINERGIC NEURONS; CORTICAL CONTUSION; DOWN-REGULATION; MESSENGER-RNA; FULL-LENGTH	Purpose: The ability of brain-derived neurotrophic factor (BDNF) to attenuate secondary damage and influence behavioral outcome after experimental traumatic brain injury (TBI) remains controversial. Because TBI can result in decreased expression of the trkB receptor, thereby preventing BDNF from exerting potential neuroprotective effects, the contribution of both BDNF and its receptor trkB to hippocampal neuronal loss and cognitive dysfunction were evaluated. Methods: Full-length trkB was overexpressed in the left hippocampus of adult C57BI/6 mice using recombinant adeno-associated virus serotype 2/5 (rAAV 2/5). EGFP (enhanced green fluorescent protein) expression was present at two weeks after AAV-EGFP injection and remained sustained up to four weeks after the injection. At 2 weeks following gene transduction, mice were subjected to parasagittal controlled cortical impact (CCI) brain injury, followed by either BDNF or PBS infusion into the hippocampus. Results: No differences were observed in learning ability at two weeks post-injury or in motor function from 48 hours to two weeks among treatment groups. The number of surviving pyramidal neurons in the CA2-CA3 region of the hippocampus was also not different among treatment groups. Conclusions: These data suggest that neither overexpression of trkB, BNDF infusion or their combination affects neuronal survival or behavioral outcome following experimental TBI in mice.	[Raghupathi, Ramesh] Drexel Univ, Dept Neurobiol & Anat, Coll Med, Philadelphia, PA 19129 USA; [Conte, Valeria; Watson, Deborah J.; Fujimoto, Scott; Royo, Nicolas C.; Marklund, Niklas; McIntosh, Tracy K.] Univ Penn, Traumat Brain Injury Lab, Dept Neurosurg, Philadelphia, PA 19104 USA; [Conte, Valeria; Fujimoto, Scott; Royo, Nicolas C.; Marklund, Niklas; McIntosh, Tracy K.] Vet Adm Med Ctr, Philadelphia, PA 19104 USA; [Conte, Valeria; Stocchetti, Nino] Univ Milan, Neurosurg Intens Care Unit, Dept Anesthesia & Crit Care Med,IRCCS, Osped Maggiore Policlin,Mangiagallie Regina Elena, Milan, Italy	Raghupathi, R (corresponding author), Drexel Univ, Dept Neurobiol & Anat, Coll Med, 2900 Queen Lane, Philadelphia, PA 19129 USA.	Rramesh@drexelmed.edu	Stocchetti, Nino/O-7444-2017	Stocchetti, Nino/0000-0003-3250-6834; Marklund, Niklas/0000-0002-9797-5626	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK47757, P30 DK047757] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS041561, R01 NS040978-07, NS41561, P50 NS008803, NS 08803, R01 NS040978, NS 40978] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK047757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, R01NS041561, P50NS008803, P01NS008803] Funding Source: NIH RePORTER		Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Andsberg G, 2002, NEUROBIOL DIS, V9, P187, DOI 10.1006/nbdi.2001.0456; Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; BELLUARDO N, 1995, NEUROSCI LETT, V196, P1, DOI 10.1016/0304-3940(95)11819-I; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Chamberlin NL, 1998, BRAIN RES, V793, P169, DOI 10.1016/S0006-8993(98)00169-3; Cheng L, 2002, J NEUROSCI, V22, P3977, DOI 10.1523/JNEUROSCI.22-10-03977.2002; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Endres M, 2000, J CEREBR BLOOD F MET, V20, P139, DOI 10.1097/00004647-200001000-00018; FAN G, 2004, NAT NEUROSCI, V3, P350; Frank L, 1997, EXP NEUROL, V145, P62, DOI 10.1006/exnr.1997.6440; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Haapasalo A, 2001, BIOCHEM BIOPH RES CO, V280, P1352, DOI 10.1006/bbrc.2001.4296; Han BH, 2000, NEUROBIOL DIS, V7, P38; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kalb R, 2005, TRENDS NEUROSCI, V28, P5, DOI 10.1016/j.tins.2004.11.003; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kiprianova I, 1999, EXP NEUROL, V159, P511, DOI 10.1006/exnr.1999.7109; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Knusel B, 1997, NEUROSCIENCE, V78, P851, DOI 10.1016/S0306-4522(96)00616-1; KNUSEL B, 1992, J NEUROSCI, V12, P4391; Kokaia Z, 1998, NEUROSCIENCE, V84, P1113, DOI 10.1016/S0306-4522(97)00579-4; Kryl D, 1999, J NEUROSCI, V19, P5823, DOI 10.1523/JNEUROSCI.19-14-05823.1999; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Li YX, 1998, P NATL ACAD SCI USA, V95, P10884, DOI 10.1073/pnas.95.18.10884; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McKeon RJ, 1997, EXP NEUROL, V148, P558, DOI 10.1006/exnr.1997.6698; Miller FD, 2001, NEURON, V32, P767, DOI 10.1016/S0896-6273(01)00529-3; Minichiello L, 1998, NEURON, V21, P335, DOI 10.1016/S0896-6273(00)80543-7; MORSE JK, 1993, J NEUROSCI, V13, P4146; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; MURAI H, 1995, J NEUROTRAUM, V12, P964; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Passini MA, 2002, J NEUROSCI, V22, P6437; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Schabitz WR, 2004, STROKE, V35, P992, DOI 10.1161/01.STR.0000119754.85848.0D; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sommerfeld MT, 2000, J BIOL CHEM, V275, P8982, DOI 10.1074/jbc.275.12.8982; Tanaka T, 1997, J NEUROSCI, V17, P2959; Troy CM, 2002, J BIOL CHEM, V277, P34295, DOI 10.1074/jbc.M205167200; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Yan Q, 1997, J COMP NEUROL, V378, P135; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6	65	20	21	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2008	26	1					45	56					12	Neurosciences	Neurosciences & Neurology	306GQ	WOS:000256236700004	18431005				2021-06-18	
J	Davis, LM; Rho, JM; Sullivan, PG				Davis, Laurie M.; Rho, Jong M.; Sullivan, Patrick G.			UCP-mediated free fatty acid uncoupling of isolated cortical mitochondria from fasted animals: Correlations to dietary modulations	EPILEPSIA			English	Article						Calorie reduction; Fasting; Free fatty acids; Mitochondria; Reactive oxygen species; Trauma; Ketogenic diet	OXIDATIVE STRESS; BRAIN	Uncoupling proteins (UCP) translocate protons from the mitochondrial intermembrane space to the matrix, thereby "uncoupling" electron transport from the production of ATP. It has been shown that these proteins are highly expressed in animals maintained on the ketogenic diet (KD). Although the exact mechanism remains unclear, it is known that these proteins are activated within a protective antireactive oxygen species (ROS) mechanism by free fatty acids (FFA). In our current studies, mitochondrial samples were probed for the presence of UCP2, which is the most ubiquitously expressed UCP isoform. We found that both traumatic brain injury and fasting upregulated the expression of UCP2, with a synergistic upregulation in fasted injured animals. We then used mitochondria from fasted naive animals to screen a number of FFA for their activation of uncoupling as well as their ability to reduce ROS. We found that arachidonic acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), palmitoleic acid, myristic acid, and butyric acid increased mitochondrial uncoupling when added after oligomycin. These FFA, along with oleic acid, also reduced ROS in mitochondria incubated with oligomycin. In order to correlate our data to KD and fasting, both of which have been shown to be neuroprotective after neurologic insult, we determined the serum levels of FFA in KD and fasted animals using gas chromatography/mass spectroscopy. We also determined brain and cerebrospinal fluid (CSF) FFA levels from fasted animals.	[Davis, Laurie M.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Davis, Laurie M.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY USA; [Rho, Jong M.] Barrow Neurol Inst, Phoenix, AZ 85013 USA; [Rho, Jong M.] St Josephs Hosp, Phoenix, AZ USA	Sullivan, PG (corresponding author), 741 S Limestone,375 BBSRB, Lexington, KY 40536 USA.	patsullivan@uky.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS48191]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191] Funding Source: NIH RePORTER	This work has been supported by NIH grant NS48191 to P. G. Sullivan.	Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; Echtay KS, 2005, BIOFACTORS, V24, P119, DOI 10.1002/biof.5520240114; Kiec-Wilk B, 2005, J PHYSIOL PHARMACOL, V56, P149; LANE N, 2006, POWER SEX SUICIDE MI; Liang LP, 2004, FREE RADICAL BIO MED, V36, P542, DOI 10.1016/j.freeradbiomed.2003.11.029; Nicholls D. G., 2002, BIOENERGETICS, V3; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Patel M, 2003, NEUROSCIENCE, V118, P431, DOI 10.1016/S0306-4522(02)00979-X; Sleven H, 2006, NEUROCHEM INT, V48, P75, DOI 10.1016/j.neuint.2005.10.002; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543	12	20	22	0	5	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0013-9580			EPILEPSIA	Epilepsia		2008	49			8			117	119		10.1111/j.1528-1167.2008.01854.x			3	Clinical Neurology	Neurosciences & Neurology	374QW	WOS:000261059800035	19049607	Bronze, Green Accepted			2021-06-18	
J	Hessen, E; Anderson, V; Nestvold, K				Hessen, Erik; Anderson, Vicki; Nestvold, Knut			MMPI-2 profiles 23 years after paediatric mild traumatic brain injury	BRAIN INJURY			English	Article						long-term TBI outcome; mild paediatric head injury; mTBI; MMPI-2; post-concussive syndrome	MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; CHILDREN; ADOLESCENTS; CLASSIFICATION; SCALE	Primary objective: Research suggest that post-concussive syndrome after mild traumatic brain injury (mTBI) is more common than chronic cognitive impairment. The aim of this study was to investigate very long-term outcome of subjective complaints after paediatric mTBI. Research design: The study was a follow-up 23 years after a prospective head injury study at a general hospital in Norway. Methods and procedures: Forty-one patients were assessed with the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) 23 years after sustaining mTBI as children. Main outcomes and results: A good overall outcome was found with scores close to the normative mean, average length of education and normal employment rate. However, the children that sustained complicated mTBI showed slightly more pathological scores, typical for mild post-concussive syndrome. The most important predictors of poor outcome were skull fracture and a combination of post-traumatic amnesia 30 minutes and EEG pathology within 24 hours after TBI. No influence of pre- and post-injury risk factors on current MMPI-2 profiles was evident. Conclusions: The results give support for the notion of potentially differential impact of uncomplicated vs complicated mTBI. The findings suggest that children and adolescents sustaining complicated mTBI may be at risk of developing subtle chronic symptoms typical of post-concussive syndrome.	[Hessen, Erik; Nestvold, Knut] Akershus Univ Hosp, Dept Neurol, Oslo, Norway; [Anderson, Vicki] Univ Melbourne, Melbourne, Vic, Australia; [Hessen, Erik] Univ Oslo, Dept Psychol, Cognit Dev Res Unit, N-0316 Oslo, Norway	Hessen, E (corresponding author), Akershus Univ Hosp, Dept Neurol, N-1478 Lorenskog, Norway.	erik.hessen@nevropsykologi.no					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; BUTCHER JN, 2004, MMPI 2; Chervinsky AB, 1998, ARCH CLIN NEUROPSYCH, V13, P433, DOI 10.1016/S0887-6177(97)00016-4; CROWE L, UNPUB PEDIATRICS; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, NEUROBEHAVIORAL RECO, P229; DOLAN RJ, 1994, PSYCHOL MED, V24, P849, DOI 10.1017/S0033291700028944; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; GEENE RL, 2000, MMPI 2 INTERPRETIVE; Greene, 2000, MMPI 2 INTERPRETIVE; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; *HOU COMM SEL COMM, 2001, 3 REP HEAD INJ REH; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; JENNETT B, 1975, LANCET, V1, P480; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRAUS JF, 1989, PSYCHIAT MED, V7, P11; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MACK JL, 1979, MMPI CLIN RES TRENDS, P53; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Miller L, 1996, J COGNITIVE REHABILI, V14, P8; Mittenberg W., 1997, CLIN NEUROPSYCHOL, V11, P305; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; *STAT SENTR, 2001, STAT NORW; Tellier A, 1999, BRAIN INJURY, V13, P463; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Warriner EM, 2003, J CLIN EXP NEUROPSYC, V25, P904, DOI 10.1076/jcen.25.7.904.16494; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	51	20	20	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	1					39	50		10.1080/02699050701846179			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	250QF	WOS:000252314400006	18183508				2021-06-18	
B	Karger, B		Tsokos, M		Karger, Bernd			Forensic Ballistics	FORENSIC PATHOLOGY REVIEWS, VOL 5	Forensic Pathology Reviews		English	Article; Book Chapter						Backspatter; Capability to act; Cross sectional area; Deformation; Deposits on bullets; DNA-analysis; Energy deposit; Fragmentation; Gunshots to the head; Incapacitation; Intermediate target; Transfer of trace evidence; Wound ballistics	CLOSE-RANGE SHOTS; CRANIOCEREBRAL MISSILE INJURIES; HIGH-VELOCITY BULLETS; GUNSHOT WOUNDS; TRACE EVIDENCE; TRAJECTORY RECONSTRUCTION; PENETRATING GUNSHOTS; AUTOPSY FINDINGS; SURVIVAL-TIME; SPENT BULLETS	Forensic ballistics is the application of ballistics for forensic purposes. The basis is formed by wound ballistics. Two main mechanisms of injury are differentiated: the crush-mechanism resulting in the permanent cavity and the stretch-mechanism resulting in the temporary cavity. The missile-tissue interactions such as yawing, deformation, fragmentation, and bone contact are explained here and it is shown why the energy deposit or the missile velocity are not the sole or primary factors in determining the severity of a wound. The special wound ballistics of the head including indirect ("remote'') injuries in the brain and skull are discussed. Incapacitation is a necessarily occuring inability to perform complex movements and is therefore based on physiological effects independent of psychological mechanisms such as pain or surprise. Immediate incapacitation can only be caused by direct disruption of brain tissue and thus by penetrating gunshots to the head. Ballistic parameters and intracranial trajectories where sustained capability to act is possible are discussed. Rapid incapacitation is produced by massive blood loss via acute cerebral hypoxemia and subsequent unconsciousness. Targets of rapid incapacitation are the heart, aorta, and the truncus of the pulmonary artery. In cases of considerable ballistic injury to the lungs, liver, kidneys, spleen, large arteries or central veins, the latent period until incapacitation will be in the range of one or several minutes (delayed incapacitation). This potential for physical activity is not always exhausted due to psychological factors. Backspatter is biological material propelled retrogradely out of the entrance wound towards the firearm/the hand of the person shooting. Blood and tissue particles are accelerated by the subcutaneous gas effect, temporary cavitation, and tail splashing. Backspatter therefore is common in close-range gunshots to the head where blood and tissue can travel for several meters. The number of bloodstains can vary greatly and the stains are located in a semicircle of almost 1808 in front of the entrance wound. Characteristic for backspatter are small or tiny droplet or splashing stains with the elongated shapes roughly aiming at the entrance wound. Magnification and appropriate lightning are necessary for investigating backspatter. DNA-analysis of stains can establish a clear link between a person or object and a clearly defined gunshot. Contact of a bullet with an intermediate target can alter the trajectory and stability of the bullet. Contact with fragile materials such as concrete, glass, asphalt, or gypsum-board regularly results in abundant deposits on the bullet, which can be visualized by SEM ( scanning electron microscopy) and determined by X-ray microanalysis. Ductile materials such as wood and car body parts only transfer scarce deposits to the bullet which can be indicative of the intermediate target. This important trace evidence is not eliminated by subsequent perforation of tissue. Individualisation of deposits on FMJ bullets after perforation of a human body can be successfully carried out by PCR-typing of STRs and mitochondrial DNA. In cases of gunfights, this makes it possible to determine who was killed or injured by which bullet. The person shooting can be identified by additional comparison of rifling marks. Cellular material is recovered by swabbing the bullet, which should be protected against contamination and loss of material.	Univ Munster, Inst Legal Med, Munster, Germany	Karger, B (corresponding author), Univ Munster, Inst Legal Med, Munster, Germany.	karger@uni-muenster.de					ALBREHT M, 1979, ACTA CHIR SCAND, P185; ALLEN IV, 1982, INJURY, V14, P183, DOI 10.1016/0020-1383(82)90057-2; AMATO JJ, 1974, AM J SURG, V127, P454, DOI 10.1016/0002-9610(74)90296-7; BERLIN R, 1978, ACTA CHIR SCAND, V144, P213; Berlin R, 1976, Acta Chir Scand Suppl, V459, P1; BERLIN R, 1977, ACTA CHIR SCAND, P5; Betz P, 1995, FORENSIC SCI INT, V76, P47, DOI 10.1016/0379-0738(95)01793-3; BEYER JC, 1962, WOUND BALLISTICS, P135; Black AN, 1941, BRIT MED J, V1941, P872, DOI 10.1136/bmj.2.4224.872; BOWEN TE, 1988, 2 US REVISION EMERGE, P13; Boyer CN, 2005, J TRAUMA, V59, P1463, DOI 10.1097/01.ta.0000195526.27014.c5; BRATZKE H, 1985, Archiv fuer Kriminologie, V175, P31; Bruning A., 1934, DTSCH Z GESAMTE GERI, V23, P71, DOI [10.1007/BF01771912, DOI 10.1007/BF01771912]; BURNETT BR, 1991, J FORENSIC SCI, V36, P1745; BUTLER EG, 1945, J NEUROSURG, V2, P358, DOI 10.3171/jns.1945.2.4.0358; Callender GR, 1935, MIL SURG, V77, P177; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; CLEMEDSON CJ, 1973, Z RECHTSMED, V73, P103, DOI 10.1007/BF01882332; COOPER GJ, 1990, BRIT J SURG, V77, P606, DOI 10.1002/bjs.1800770604; CROCKARD HA, 1977, J NEUROSURG, V46, P784, DOI 10.3171/jns.1977.46.6.0784; CROCKARD HA, 1977, J NEUROSURG, V46, P776, DOI 10.3171/jns.1977.46.6.0776; Di Maio VJM., 1985, GUNSHOT WOUNDS PRACT; DiMaio V J, 1977, J Forensic Sci, V22, P132; DiMaio V.J.M., 1974, FBI LAW ENFORCE B, V43, P3; DIMAIO VJM, 1987, J FORENSIC SCI, V32, P38; DITTMANN W, 1986, WEHRMED MONATSSCHR, V33, P3; DZIEMIAN A J, 1961, J Trauma, V1, P341; Fackler M. L., 1991, WOUND BALLISTICS REV, V1, P38; FACKLER ML, 1984, J TRAUMA, V24, P35, DOI 10.1097/00005373-198401000-00005; FACKLER ML, 1985, J TRAUMA, V25, P522, DOI 10.1097/00005373-198506000-00009; FACKLER ML, 1988, J TRAUMA, V28, pS21, DOI 10.1097/00005373-198801001-00007; FACKLER ML, 1988, JAMA-J AM MED ASSOC, V259, P2730, DOI 10.1001/jama.259.18.2730; FACKLER ML, 1984, J TRAUMA, V24, P263, DOI 10.1097/00005373-198403000-00014; Fackler ML, 1989, INT DEFENSE REV, P59; Fackler ML, 1992, WOUND BALLISTICS REV, V1, P32; FINNIE JW, 1993, J COMP PATHOL, V108, P93, DOI 10.1016/S0021-9975(08)80231-9; FRAENCKEL P, 1924, ARCH KRIMINOL, V76, P314; FREYTAG E, 1963, ARCH PATHOL, V76, P215; Fryc O, 1979, Beitr Gerichtl Med, V37, P389; GERBER AM, 1972, J NEUROSURG, V36, P43, DOI 10.3171/jns.1972.36.1.0043; Goldsmith W, 1999, INT J IMPACT ENG, V22, P95, DOI 10.1016/S0734-743X(98)00031-1; Goroncy C, 1924, DTSCH Z GERICHTL MED, V4, P145; HABBE D, 1989, AM J FOREN MED PATH, V10, P335, DOI 10.1097/00000433-198912000-00012; HARVEY EN, 1947, SURGERY, V21, P218; Harvey EN, 1945, WAR MED, V8, P91; HENN R, 1969, ARCH KRIMINOL, V143, P188; HERBICH J, 1955, BEITR GERICHTL MED, V20, P22; HOPKINSON DAW, 1963, P ROY SOC MED, V56, P461, DOI 10.1177/003591576305600606; HUDSON P, 1981, AM J FOREN MED PATH, V2, P239, DOI 10.1097/00000433-198109000-00009; INTRONA F, 1989, AM J FOREN MED PATH, V10, P275, DOI 10.1097/00000433-198912000-00001; JASON A, 1991, WOUND BALLISTICS REV, V1, P8; Jussila J, 2005, INJURY, V36, P282, DOI 10.1016/j.injury.2004.09.010; KARGER B, 1995, INT J LEGAL MED, V108, P117, DOI 10.1007/BF01844822; Karger B, 1996, INT J LEGAL MED, V109, P147, DOI 10.1007/BF01369676; Karger B, 1997, INT J LEGAL MED, V110, P101, DOI 10.1007/s004140050041; KARGER B, 1995, INT J LEGAL MED, V108, P53, DOI 10.1007/BF01369905; Karger B, 1996, INT J LEGAL MED, V109, P66, DOI 10.1007/BF01355519; Karger B, 2002, AM J FOREN MED PATH, V23, P211, DOI 10.1097/00000433-200209000-00001; Karger B, 1997, INT J LEGAL MED, V110, P188, DOI 10.1007/s004140050065; Karger B, 2001, INT J LEGAL MED, V115, P16, DOI 10.1007/s004140000202; Karger B, 1996, INT J LEGAL MED, V108, P177, DOI 10.1007/BF01369787; Karger B, 2001, INT J LEGAL MED, V114, P343, DOI 10.1007/s004140000203; Karger B, 1997, INT J LEGAL MED, V110, P27; Karger B, 1998, INT J LEGAL MED, V111, P314, DOI 10.1007/s004140050178; Karger B, 1997, INT J LEGAL MED, V110, P323, DOI 10.1007/s004140050096; KARGER B, 2003, HDB RECHTSMEDIZIN, V1, P593; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KIRKPATRICK JB, 1978, J NEUROSURG, V49, P185, DOI 10.3171/jns.1978.49.2.0185; KLAGES U, 1975, Z RECHTSMED, V76, P307, DOI 10.1007/BF02114691; KLAUE R, 1949, DTSCH Z NERVENHEILKD, V161, P167; Knight B., 1977, FORENSIC MED, P510; KNUDSEN PJT, 1993, INT J LEGAL MED, V106, P61, DOI 10.1007/BF01225042; KNUDSEN PJT, 1993, INT J LEGAL MED, V106, P15, DOI 10.1007/BF01225018; KOCHER T, 1895, LEHRE SCHUSSWUNDEN D; Kolsky H., 1980, BALLISTIC MAT PENETR, P185; Konig H G, 1989, Beitr Gerichtl Med, V47, P247; KRAULAND W, 1952, ACTA NEUROCHIR, V2, P233; KRAUSS M, 1957, Mil Med, V121, P221; LAMPRECHT K, 1959, ARCH KRIMINOL, V97, P128; LEVY V, 1988, AM J FOREN MED PATH, V9, P215, DOI 10.1097/00000433-198809000-00007; LINDSEY D, 1980, J TRAUMA, V20, P1068, DOI 10.1097/00005373-198012000-00012; LORENZ R, 1948, DTSCH Z GERICHTL MED, V39, P435; MacDonell HL., 1982, BLOODSTAIN PATTERN I, P16; MARSH TO, 1989, J FORENSIC SCI, V34, P491; MAXEINER H, 1986, MED RECHT, P317; METTER D, 1983, Z RECHTSMED, V90, P167, DOI 10.1007/BF02116227; MISSLIWETZ J, 1990, Archiv fuer Kriminologie, V185, P129; NAEGELI O, 1984, VJSCHR GERICHTL MED, V40, P231; Newgard K, 1992, WOUND BALLISTICS REV, V1, P12; NICHOLS CA, 1991, AM J CLIN PATHOL, V95, P660, DOI 10.1093/ajcp/95.5.660; NICHOLS CA, 1990, AM J FOREN MED PATH, V11, P17, DOI 10.1097/00000433-199003000-00003; PAYR E, 1922, HDB ARZTLICHEN ERFAH, P285; PENG L, 1990, J TRAUMA S, V6, P187; Petersohn F, 1967, Dtsch Z Gesamte Gerichtl Med, V59, P259, DOI 10.1007/BF00576905; PETRACO N, 1990, J FORENSIC SCI, V35, P1284; PEX JO, 1987, J FORENSIC SCI, V32, P1587; RAGSDALE BD, 1984, MIL MED, V149, P301; RAGSDALE BD, 1988, J TRAUMA, V28, pS109, DOI 10.1097/00005373-198801001-00024; ROBENS W, 1982, ACTA CHIR SCAND, P223; SCEPANOVIC D, 1982, ACTA CHIR SCAND, P29; Scott R, 1983, Clin Lab Med, V3, P273; SELLIER K, 1971, Z RECHTSMED, V69, P217; SELLIER K, 1982, SCHUSSWAFFEN SCHUSSW, V1; SELLIER K, 1994, WOUND BALLISTICS SCI, P144; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; SIGHTS WP, 1969, J NEUROSURG, V31, P25, DOI 10.3171/jns.1969.31.1.0025; SMITH OC, 1987, J FORENSIC SCI, V32, P1416; SMITH S, 1943, POLICE J, V16, P108; Spatz H, 1941, ZBL NEUROCHIR, V6, P162; Spitz W. U., 1961, J FORENSIC SCI, V6, P290; STEPHENS BG, 1983, J FORENSIC SCI, V28, P437; STONE IC, 1992, AM J FOREN MED PATH, V13, P275, DOI 10.1097/00000433-199212000-00001; STURDIVAN L, 1969, 1447 BALL RES LAB; SUNESON A, 1988, J TRAUMA, V28, pS197, DOI 10.1097/00005373-198801001-00041; TIKKA S, 1988, ANN MED MILIT FENN, V62, P17; Verhoff MA, 2003, INT J LEGAL MED, V117, P229, DOI 10.1007/s00414-003-0383-6; VONHOFFMANN VER, 1898, LEHRBUCH GERICHTLICH, P389; WAGNER H J, 1963, Dtsch Z Gesamte Gerichtl Med, V54, P258, DOI 10.1007/BF00574419; Walcher K., 1929, DTSCH Z GES GERICHTL, V13, P313; WATKINS FP, 1988, J TRAUMA, V28, pS40, DOI 10.1097/00005373-198801001-00011; Weimann W., 1931, Dtsch.Z.Gerichtl.Med., V17, P92; Werkgartner A., 1924, BEITR GERICHTL MED, V6, P148; Zhang JY, 2005, J NEUROTRAUM, V22, P1335, DOI 10.1089/neu.2005.22.1335; Zwingli M, 1941, ARCH KRIMINOL, V108, P1	124	20	20	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA			978-1-59745-110-9; 978-1-58829-832-4	FORENSIC PATHOL REV			2008	5						139	172		10.1007/978-1-59745-110-9_9	10.1007/978-1-59745-110-9		34	Medicine, Legal	Legal Medicine	BLX81	WOS:000271343500009					2021-06-18	
J	Ownsworth, TL; Turpin, M; Andrew, B; Fleming, J				Ownsworth, Tamara L.; Turpin, Merrill; Andrew, Brooke; Fleming, Jennifer			Participant perspectives on an individualised self-awareness intervention following stroke: A qualitative case study	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; THALAMIC HEMORRHAGE; REHABILITATION; DEFICITS; PEOPLE; SCALE	Most research investigating the efficacy of neurorehabilitation has focused upon pre- versus post-intervention functioning, which is important for evidence-based practice but overlooks the therapeutic process. Therefore, this qualitative study aimed to investigate a participant's perspective of experiences in therapy throughout an awareness rehabilitation intervention. The participant (CP), a young male with awareness deficits following a right thalamic stroke, had repeatedly attempted to return to work and experienced recurrent periods of depression associated with his employment difficulties. Throughout a 12-session rehabilitation intervention, which targeted self-awareness and self-regulation skills, CP provided interview feedback concerning his experiences of different therapy exercises. The key themes emerging from the data regarding CP's perspectives included: understanding benchmarks and the value of feedback, learning through practical exercises, and individualising therapy. In collaboration with a disability employment support service, CP achieved paid durable employment. This study highlights the importance of considering participants' perspectives of the therapeutic process to assist in the design and evaluation of awareness rehabilitation interventions.	[Ownsworth, Tamara L.] Griffith Univ, Sch Psychol, Mt Gravatt, Qld 4122, Australia; [Ownsworth, Tamara L.] Griffith Univ, Appl Cognit Neurosci Res Ctr, Mt Gravatt, Qld 4122, Australia; [Turpin, Merrill; Andrew, Brooke; Fleming, Jennifer] Univ Queensland, Div Occupat Therapy, St Lucia, Qld, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia	Ownsworth, TL (corresponding author), Griffith Univ, Sch Psychol, Mt Gravatt Campus, Nathan, Qld 4111, Australia.	t.ownsworth@griffith.edu.au	Turpin, Merrill/F-8749-2010; Fleming, Jennifer M/B-4436-2011	Turpin, Merrill/0000-0001-7946-0883; Ownsworth, Tamara/0000-0003-1835-7094			BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BOGOUSSLAVSKY J, 1994, EUR NEUROL, V34, P306, DOI 10.1159/000117068; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; Dirette D, 2002, BRAIN INJURY, V16, P861, DOI 10.1080/02699050210131902; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Fleming JM, 1996, BRAIN INJURY, V10, P1; Gilchrist VJ, 1999, DOING QUALITATIVE RE; Kristensen OS, 2004, BRAIN INJURY, V18, P1049, DOI 10.1080/02699050410001672279; KUMRAL E, 1995, STROKE, V26, P964, DOI 10.1161/01.STR.26.6.964; Langer K.G., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [https://doi.org/10.1080/09602019208401395, DOI 10.1080/09602019208401395]; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Liebson E, 2000, J NEUROL NEUROSUR PS, V68, P107, DOI 10.1136/jnnp.68.1.107; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; McKenna K., 2006, CLIENT ED PARTNERSHI, P1; Morris RG., 2004, COGN NEUROPSYCHOL, P275; Myers P.S., 1999, RIGHT HEMISPHERE DAM; O'Callaghan C, 2006, NEUROPSYCHOL REHABIL, V16, P579, DOI 10.1080/09602010500368834; Ownsworth T, 2006, REHABIL PSYCHOL, V51, P50, DOI 10.1037/0090-5550.51.1.50; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T., 2005, NEUROPSYCHOANALYSIS, V7, P83; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; RUDDLE JA, 2005, J COGNITIVE REHABILI, V23, P12; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Toglia J, 2000, NEUROREHABILITATION, V15, P57; TRZEPAC PT, 1993, PSYCHIAT MENTAL STAT; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wilson BA, 2000, INT HDB NEUROPSYCHOL, P231; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640; Yin R. K., 2008, CASE STUDY RES DESIG, V4th	38	20	20	1	15	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	5-6					692	712		10.1080/09602010701595136			21	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	360PQ	WOS:000260070200014	17926196				2021-06-18	
J	Wortzel, HS; Filley, CM; Anderson, CA; Oster, T; Ardnilegas, DB				Wortzel, Hal S.; Filley, Christopher M.; Anderson, C. Alan; Oster, Timothy; Ardnilegas, David B.			Forensic applications of cerebral single photon emission computed tomography in mild traumatic brain injury	JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW			English	Article							MINOR HEAD-INJURY; OBSESSIVE-COMPULSIVE PATIENTS; BLOOD-FLOW; TECHNETIUM-99M-HMPAO SPECT; PSYCHIATRIC-ILLNESS; SLEEP; CONCUSSION; NEUROLOGY; PERFUSION; SYMPTOMS	Traumatic brain injury (TBI) is a substantial source of mortality and morbidity world wide. Although most such injuries are relatively mild, accurate diagnosis and prognostication after mild TBI are challenging. These problems are complicated further when considered in medicolegal contexts, particularly civil litigation. Cerebral single photon emission computed tomography (SPECT) may contribute to the evaluation and treatment of persons with mild TBI. Cerebral SPECT is relatively sensitive to the metabolic changes produced by TBI. However, such changes are not specific to this condition, and their presence on cerebral SPECT imaging does not confirm a diagnosis of mild TBI. Conversely, the absence of abnormalities on cerebral SPECT imaging does not exclude a diagnosis of mild TBI, although such findings may be of prognostic value. The literature does not demonstrate consistent relationships between SPECT images and neuropsychological testing or neuropsychiatric symptoms. Using the rules of evidence shaped by Doubert v. Merrell Dow Pharmaceuticals, Inc., and its progeny to analyze the suitability of SPECT for forensic purposes, we suggest that expert testimony regarding SPECT findings should be admissible only as evidence to support clinical history, neuropsychological test results, and structural brain imaging findings and not as stand-alone diagnostic data.	[Wortzel, Hal S.] Univ Colorado, Sch Med, Dept Psychiat, Neurobehav Disorders Program, Denver, CO 80262 USA; [Filley, Christopher M.; Anderson, C. Alan] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA; [Filley, Christopher M.; Anderson, C. Alan] Denver VA, Denver, CO USA	Wortzel, HS (corresponding author), Univ Colorado, Sch Med, Dept Psychiat, Neurobehav Disorders Program, CPH Room 2508,4200 E 9th Ave,C268-25, Denver, CO 80262 USA.	hal.worrzel@uchsc.edu					*AM C REH MED, 1993, J HEAD INJURY REHABI, V8, P6; ANDERSON KE, 2005, TXB TRAUMATIC BRAIN, P107; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; ARCINIEGAS DB, 2005, TXB TRAUMATIC BRAIN, P135; ASENBAUM S, 1995, J NUCL MED, V36, P1150; Audenaert Kurt, 2003, Med Sci Monit, V9, pMT112; Barkai G, 2004, PSYCHIAT RES-NEUROIM, V132, P279, DOI 10.1016/j.pscychresns.2004.09.004; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Camargo EE, 2001, J NUCL MED, V42, P611; Davalos Deana B, 2002, Appl Neuropsychol, V9, P92, DOI 10.1207/S15324826AN0902_4; Deb S, 1999, AM J PSYCHIAT, V156, P374; DEVOUS MD, 1992, J CLIN PSYCHIAT, V53, P13; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DOUGHERTY DD, 2004, ESSENTIALS NEUROIMAG, P75; GOLDSTEIN R, 2003, PRINCIPLES PRACTICE, P789; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hicks JW, 2003, PRINCIPLES PRACTICE, P850; HOEHNSARIC R, 1991, AM J PSYCHIAT, V148, P1243; HOLMAN BL, 1991, J NUCL MED, V32, P1206; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 2005, TXB TRAUMATIC BRAIN, P3; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MACHLIN SR, 1991, AM J PSYCHIAT, V148, P1240; Masdeu J C, 1994, J Neuroimaging, V4, P177; MAYBERG HS, 1996, SEMIN CLIN NEUROPSYC, V1, P195; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Mirza M, 1998, ACTA NEUROL BELG, V98, P190; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; MOUNTZ JM, 1995, ARTHRITIS RHEUM, V38, P926, DOI 10.1002/art.1780380708; Nakabeppu Y, 2001, ANN NUCL MED, V15, P459, DOI 10.1007/BF02988354; Reeves D, 2003, J AM ACAD PSYCHIATRY, V31, P89; ROPER SN, 1991, J NUCL MED, V32, P1684; ROSEN J, 2007, NY TIMES MAGAZI 0311, P48; SAMSON K, 2007, NEUROLOGY TODAY 0403, P1; Shirakawa S, 2002, PSYCHIAT CLIN NEUROS, V56, P291, DOI 10.1046/j.1440-1819.2002.00961.x; Smith MT, 2002, SLEEP, V25, P325; *SOC NUCL MED, 2002, SOC NUCL MED PROC GU, P113; TEASDALE G, 1974, LANCET, V2, P81; Thurman DA, 1999, TRAUMATIC BRAIN INJU, P1; VANHEERTUM RL, 1991, SEMIN NUCL MED, V21, P24, DOI 10.1016/S0001-2998(05)80077-7; Wilson J, 1996, J NUCL MED, V37, P1256; WOODS SW, 1992, J CLIN PSYCHIAT, V53, P20	52	20	21	0	2	AMER ACAD PSYCHIATRY & LAW	BLOOMFIELD	ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA	1093-6793			J AM ACAD PSYCHIATRY	J. Am. Acad. Psychiatry Law		2008	36	3					310	322					13	Law; Psychiatry	Government & Law; Psychiatry	356EZ	WOS:000259762800007	18802178				2021-06-18	
J	Gobbel, GT; Bonfield, C; Carson-Walter, EB; Adelson, PD				Gobbel, G. T.; Bonfield, C.; Carson-Walter, E. B.; Adelson, P. D.			Diffuse alterations in synaptic protein expression following focal traumatic brain injury in the immature rat	CHILDS NERVOUS SYSTEM			English	Article						pediatric; rat; NeuN; synaptophysin; traumatic brain injury	HEAD-INJURY; SYNAPTOPHYSIN IMMUNOREACTIVITY; NERVOUS-SYSTEM; SYNAPTOGENESIS; NEUN; QUANTIFICATION; IDENTIFICATION; LOCALIZATION; GLYCOPROTEIN; HIPPOCAMPUS	Introduction The mechanisms responsible for cognitive decline after traumatic brain injury (TBI) in pediatric patients are poorly understood. The present study examined the potential role of synaptic alterations in this process by using an animal model of immature head injury to define the impact of TBI on expression of the synaptic protein, synaptophysin. Materials and methods After craniotomy, TBI was induced in postnatal day 17 (PND17) rats using controlled cortical impact delivered to the left hemisphere. NeuN, a neuronal marker, and synaptophysin expression were examined 1 day, 1 week, and 1 month after injury by immunohistochemistry and immunoblotting. Results There were significant decreases in both NeuN and synaptophysin after 1 day and 1 week but not 1 month after injury within the hippocampus and neocortex adjacent to the impact site compared to sham-injured controls. The decrease in synaptophysin and NeuN was also noted in the contralateral hippocampus by 1 day after injury and in the contralateral neocortex by 1 week, indicating that changes in protein expression were not solely localized to the injury site but occurred in more distant regions as well. Discussion In conclusion, the decrease and recovery in synaptophysin parallel the cognitive changes that occur after experimental TBI in the PND17 rat, which suggests that changes in this protein may contribute to cognitive declines after injury. The results also suggest that, in spite of the focal nature of the impact, diffuse alterations in protein expression can occur after immature TBI and may contribute to the subsequent cognitive dysfunction.	Univ Pittsburgh, Dept Neurol Surg, UPMC Presbyterian, Pittsburgh, PA 15213 USA	Adelson, PD (corresponding author), Univ Pittsburgh, Dept Neurol Surg, UPMC Presbyterian, Suite B-400,200 Lothrop St, Pittsburgh, PA 15213 USA.	gobbleg@upmc.edu; bonfield.christopher@medstudent.pitt.edu; David.Adelson@chp.edu	Adelson, David/W-2083-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042298] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS42298-01] Funding Source: Medline		Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; ANDREWS RJ, 1991, STROKE, V22, P943, DOI 10.1161/01.STR.22.7.943; BAYER SA, 1993, NEUROTOXICOLOGY, V14, P83; BAYER SA, 1980, J COMP NEUROL, V190, P115, DOI 10.1002/cne.901900108; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BOURGEOIS JP, 1994, CEREB CORTEX, V4, P78, DOI 10.1093/cercor/4.1.78; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; Calhoun ME, 1998, NEUROBIOL AGING, V19, P599, DOI 10.1016/S0197-4580(98)00098-0; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; CHEN KS, 1995, NEUROSCIENCE, V68, P19, DOI 10.1016/0306-4522(95)00099-5; Deweer B, 2001, BEHAV BRAIN RES, V127, P209, DOI 10.1016/S0166-4328(01)00366-7; FLETCHER EJ, 1995, RECEPTOR CHANNEL, V3, P21; Hagberg H, 1997, ACTA PAEDIATR, V86, P85; Hunter SF, 1997, BRAIN, V120, P2071, DOI 10.1093/brain/120.11.2071; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Iwasaki N, 1997, NEURORADIOLOGY, V39, P841, DOI 10.1007/s002340050517; JACOBSONM, 1991, DEV NEUROBIOL, P223; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KRAUS JF, 1987, PEDIATRICS, V79, P501; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Lind D, 2005, J NEUROSCI RES, V79, P295, DOI 10.1002/jnr.20354; Liu HX, 2005, MOL BRAIN RES, V139, P169, DOI 10.1016/j.molbrainres.2005.05.014; LOHMANN SM, 1978, P NATL ACAD SCI USA, V75, P4037, DOI 10.1073/pnas.75.8.4037; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; McPhail LT, 2004, EXP NEUROL, V185, P182, DOI 10.1016/j.expneurol.2003.10.001; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; RAKIC P, 1986, SCIENCE, V232, P232, DOI 10.1126/science.3952506; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Smith M.L., 1989, HDB NEUROPSYCHOLOGY, P91; Smith TD, 2000, J NEUROSCI, V20, P6587, DOI 10.1523/JNEUROSCI.20-17-06587.2000; Stevenson K. L., 2000, Journal of Neurotrauma, V17, P944; TRAN MP, 2001, J NEUROTRAUM, V18, P1141; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; UYLINGS HBM, 1990, PROG BRAIN RES, V85, P31; VOIGT T, 1993, J COMP NEUROL, V330, P48, DOI 10.1002/cne.903300105; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9	41	20	20	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	OCT	2007	23	10					1171	1179		10.1007/s00381-007-0345-2			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	208CO	WOS:000249297600013	17457592				2021-06-18	
J	Kuo, JR; Lin, KC; Lu, CL; Lin, HJ; Wang, CC; Chang, CH				Kuo, J.-R.; Lin, K.-C.; Lu, C.-L.; Lin, H.-J.; Wang, C.-C.; Chang, C. H.			Correlation of a high D-dimer level with poor outcome in traumatic intracranial hemorrhage	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						D-dimer level; outcome; traumatic and non-traumatic ICH	BRAIN-INJURY; HEAD-INJURY; COMA; COAGULOPATHY; FIBRIN; SCALE	The correlations between D-dimer and Glasgow Coma Scale (GCS), pupillary light reflex, distance of midline shift on brain computed tomography (CT), and Glasgow Outcome Score (GOS) in patients with trauma/non-trauma intracranial hemorrhage (ICH) are not consistent in studies. Ninety-eight traumatic and 59 non-traumatic ICH patients were studied. Pre-existing venous thrombosis, recent surgery, drug use (aspirin or coumadin), or malignancy, were excluded. D-dimer level was estimated within hours after acute insult, and statistical analyses were used for comparisons between groups. Traumatic ICH patients had higher D-dimer levels than controls (2984 vs. 256 mu g/l; P = 0.001). The GCS, midline shift on brain CT, pupillary reflex, and GOS at 3 months were significantly correlated with high D-dimer value in traumatic patients (individual P < 0.001), but not in the non-traumatic group. Using receiver-operating characteristic curve (ROC), the cutoff point was 1496 mu g/l, with sensitivity and specificity of 100% and 83%, respectively. D-dimer >= 1496 mu g/l predicted a poor outcome [adjusted odds ratio (OR) 14.44, 95% CI 1.16-179.27; P = 0.038]. A high D-dimer level is associated with a poor outcome in patients with traumatic ICH. It can be used in addition to neurological assessment to predict the outcome.	Chi Mei Med Ctr, Dept Neurol, Yung Kung City 710, Tainan, Taiwan; Chi Mei Med Ctr, Dept Neurosurg, Yung Kung City 710, Tainan, Taiwan; Chi Mei Med Ctr, Clin Res Inst, Yung Kung City 710, Tainan, Taiwan; Chi Mei Med Ctr, Dept Emergency Med, Yung Kung City 710, Tainan, Taiwan	Lin, KC (corresponding author), Chi Mei Med Ctr, Dept Neurol, 901 Chung Hwa Rd, Yung Kung City 710, Tainan, Taiwan.	gaujang@mail2000.com.tw		Lu, Chin-Li/0000-0002-0818-4823			Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bayir A, 2006, NEUROL INDIA, V54, P363, DOI 10.4103/0028-3886.28106; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; Cenic A, 2005, CAN J NEUROL SCI, V32, P501, DOI 10.1017/S0317167100004510; CHAN KH, 1990, J NEUROSURG, V72, P189, DOI 10.3171/jns.1990.72.2.0189; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; Delgado P, 2006, NEUROLOGY, V67, P94, DOI 10.1212/01.wnl.0000223349.97278.e0; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fujii Y, 2001, STROKE, V32, P883, DOI 10.1161/01.STR.32.4.883; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; JENNETT B, 1975, LANCET, V1, P480; Juvela S, 2006, STROKE, V37, P1451, DOI 10.1161/01.STR.0000221710.55467.33; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Pathak A, 2005, Neurol India, V53, P178; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; Ungerstedt JS, 2003, J NEUROSURG ANESTH, V15, P13, DOI 10.1097/00008506-200301000-00003; ZWEIG MH, 1993, CLIN CHEM, V39, P561	22	20	26	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	OCT	2007	14	10					1073	1078		10.1111/j.1468-1331.2007.01908.x			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	213IU	WOS:000249660900007	17880559				2021-06-18	
J	Hoffmann, O; Mahrhofer, C; Rueter, N; Freyer, D; Bert, B; Fink, H; Weber, JR				Hoffmann, Olaf; Mahrhofer, Cordula; Rueter, Nina; Freyer, Dorette; Bert, Bettina; Fink, Heldrun; Weber, Joerg R.			Pneumococcal cell wall-induced meningitis impairs adult hippocampal neurogenesis	INFECTION AND IMMUNITY			English	Article							NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; DENTATE GYRUS; BACTERIAL-MENINGITIS; STREPTOCOCCUS-PNEUMONIAE; NEGATIVE REGULATOR; BINDING-PROTEIN; MESSENGER-RNA; PROLIFERATION; EXPRESSION	Bacterial meningitis is a major infectious cause of neuronal degeneration in the hippocampus. Neurogenesis, a continuous process in the adult hippocampus, could ameliorate such loss. Yet the high rate of sequelae from meningitis suggests that this repair mechanism is inefficient. Here we used a mouse model of nonreplicative bacterial meningitis to determine the impact of transient intracranial inflammation on adult neurogenesis. Experimental meningitis resulted in a net loss of neurons, diminished volume, and impaired neurogenesis in the dentate gyrus for weeks following recovery from the insult. Inducible nitric oxide synthase (NOS) immunoreactivity was prominent in microglia in nonproliferating areas of the dentate gyrus and hilus region after meningitis induction. Treatment with the specific NOS inhibitor N6-(1-iminoethyl)-L-lysine restored neurogenesis in experimental meningitis. These data suggest that local central nervous system inflammation in and of itself suppresses adult neurogenesis by affecting both proliferation and neuronal differentiation. Repair of cognitive dysfunction following meningitis could be improved by intervention to interrupt these actively suppressive effects.	Charite Univmed Berlin, Dept Cell Biol, Ctr Anat, D-10117 Berlin, Germany; Charite Univmed Berlin, Dept Neurol, Ctr Anat, D-10117 Berlin, Germany; Free Univ Berlin, Inst Pharmacol & Toxicol Vet Med, Berlin, Germany	Weber, JR (corresponding author), Charite Univmed Berlin, Dept Cell Biol, Ctr Anat, Schumannstr 20-21, D-10117 Berlin, Germany.	joerg.weber@charite.de		Bert, Bettina/0000-0002-8202-9290			Bert B, 2005, NEUROBIOL LEARN MEM, V84, P57, DOI 10.1016/j.nlm.2005.03.005; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; BOHR V, 1984, ARCH NEUROL-CHICAGO, V41, P1045, DOI 10.1001/archneur.1984.04050210043012; Boje KMK, 1996, BRAIN RES, V720, P75, DOI 10.1016/0006-8993(96)00142-4; BOJE KMK, 1995, EUR J PHARMACOL, V272, P297, DOI 10.1016/0014-2999(94)00715-J; Braun JS, 2002, J CLIN INVEST, V109, P19; Burns KA, 2005, EUR J NEUROSCI, V21, P803, DOI 10.1111/j.1460-9568.2005.03907.x; Champlin DT, 2000, DEVELOPMENT, V127, P3543; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DiGirolamo G, 2003, BRIT J PHARMACOL, V139, P1164, DOI 10.1038/sj.bjp.0705315; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; Filippov V, 2003, MOL CELL NEUROSCI, V23, P373, DOI 10.1016/S1044-7431(03)00060-5; FISCHER H, 1984, J BACTERIOL, V157, P507, DOI 10.1128/JB.157.2.507-513.1984; GARCIABUSTOS JF, 1987, J BIOL CHEM, V262, P15400; Gerber J, 2003, J NEUROSCI RES, V73, P441, DOI 10.1002/jnr.10682; Gibbs SM, 2003, MOL NEUROBIOL, V27, P107, DOI 10.1385/MN:27:2:107; Grandgirard D, 2007, DEV NEUROSCI-BASEL, V29, P134, DOI 10.1159/000096218; Hoffmann O, 2002, J CEREBR BLOOD F MET, V22, P988, DOI 10.1097/00004647-200208000-00010; Iosif RE, 2006, J NEUROSCI, V26, P9703, DOI 10.1523/JNEUROSCI.2723-06.2006; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Leib SL, 1998, J INFECT DIS, V177, P692, DOI 10.1086/514226; Li N, 2004, DRUG METAB DISPOS, V32, P1265, DOI 10.1124/dmd.32.11.1265; Liu JL, 1998, J NEUROSCI, V18, P7768; Mitchell L, 2004, J INFECT DIS, V190, P2039, DOI 10.1086/425520; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nau R, 1999, J NEUROPATH EXP NEUR, V58, P265, DOI 10.1097/00005072-199903000-00006; Packer MA, 2003, P NATL ACAD SCI USA, V100, P9566, DOI 10.1073/pnas.1633579100; Parent JM, 1997, J NEUROSCI, V17, P3727; Peunova N, 2001, J NEUROSCI, V21, P8809, DOI 10.1523/JNEUROSCI.21-22-08809.2001; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Reilly CM, 2002, KIDNEY INT, V61, P839, DOI 10.1046/j.1523-1755.2002.00230.x; SCHELD WM, 1980, J CLIN INVEST, V66, P243, DOI 10.1172/JCI109850; Schneider O, 1999, NEUROLOGY, V53, P1584, DOI 10.1212/WNL.53.7.1584; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Suzuki Y, 1999, J CEREBR BLOOD F MET, V19, P1175, DOI 10.1097/00004647-199911000-00001; TAUBER MG, 1985, J INFECT DIS, V151, P528, DOI 10.1093/infdis/151.3.528; Tauber SC, 2005, J NEUROPATH EXP NEUR, V64, P806, DOI 10.1097/01.jnen.0000178853.21799.88; TOMASZ A, 1981, REV INFECT DIS, V3, P190; TOUMANEN E, 1985, J INFECT DIS, V151, P859; TUOMANEN E, 1985, J INFECT DIS, V151, P535, DOI 10.1093/infdis/151.3.535; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vermeire K, 2000, J LEUKOCYTE BIOL, V68, P119; VOITS M, 1995, J NEUROSCI METH, V57, P101, DOI 10.1016/0165-0270(94)00143-5; Weber JR, 2003, IMMUNITY, V19, P269, DOI 10.1016/S1074-7613(03)00205-X; Winkler F, 2001, J INFECT DIS, V183, P1749, DOI 10.1086/320730; Yoshimura A, 1999, J IMMUNOL, V163, P1; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	57	20	21	0	4	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0019-9567			INFECT IMMUN	Infect. Immun.	SEP	2007	75	9					4289	4297		10.1128/IAI.01679-06			9	Immunology; Infectious Diseases	Immunology; Infectious Diseases	205RG	WOS:000249131700012	17591796	Green Published, Bronze			2021-06-18	
J	Qiu, Y; He, YX; Wang, B; Zhu, F; Wang, WJ				Qiu, Yong; He, Yong Xiong; Wang, Bin; Zhu, Feng; Wang, Wei Jun			The anatomical relationship between the aorta and the thoracic vertebral bodies and its importance in the placement of the screw in thoracoscopic correction of Scoliosis	EUROPEAN SPINE JOURNAL			English	Article						aorta; thoracic vertebrae; anatomy; thoracoscopy; scoliosis	ADOLESCENT IDIOPATHIC SCOLIOSIS; ANTERIOR SPINAL-FUSION; FALSE ANEURYSM; INSTRUMENTATION; DEFORMITY; POSITION; SURGERY; TOMOGRAPHY; INJURY	Thoracoscopically-assisted anterior spinal instrumentation is being used widely to treat adolescent idiopathic scoliosis (AIS). Recent studies have showed that screws placed thoracoscopically could counter the aorta or entrance into the spinal canal. There are a few studies defining the anatomic landmarks to identify the relationship between the aorta and the thoracic vertebral body using quantitative measurement for the sake of safe placement of thoracoscopic vertebral screw in anterior correction for AIS. The CT scanning from T4 to T12 in 64 control subjects and 30 AIS patients from mainland China were analyzed manually. Parameters to be measured included the angle for safety screw placement (alpha), the angle of the aorta relative to the vertebral body (beta), the distance from the line between the left and the right rib heads to the anterior wall of the vertebral canal (a), the distance from the left rib head to posterior wall of the aorta (b), the vertebral body transverse diameter (c) and vertebral rotation (gamma). No significant differences were found between the groups with respect to age or sex. Compared with the control group, alpha angle from T7 to T10, beta angle from T5 to T10 and b value at T9, T10 were significantly lower in the scoliotic group. The a value was significantly lower in the scoliotic group. The c value showed no significant difference between the two groups. In conclusion, to place the thoracoscopic vertebral screw safely, at the cephalad thoracic spine (T4-T6), the maximum ventral excursion angle should decrease gradually from 20 degrees to 5 degrees, the entry-point of the screw should be close to the rib head. For apical vertebrae (T7-T9), the maximum ventral excursion angle increased gradually from 5 degrees to 12 degrees. At the caudal thoracic spine (T10-T12), the maximum ventral excursion angle increased, the entry-point should shift 3-5 mm ventrally.	Nanjing Univ, Drum Tower Hosp, Sch Med, Dept Spine Surg, Nanjing 210008, Peoples R China	Qiu, Y (corresponding author), Nanjing Univ, Drum Tower Hosp, Sch Med, Dept Spine Surg, No 321 Zhongsham Rd, Nanjing 210008, Peoples R China.	scoliosis2002@sina.com	Wang, Weijun/A-1438-2016	Wang, Weijun/0000-0001-7191-5548			Ahat E, 1996, INJURY, V27, P225, DOI 10.1016/0020-1383(95)00212-X; Arlet V, 2000, EUR SPINE J, V9, pS17, DOI 10.1007/s005860000186; BAKER JK, 1993, SPINE, V18, P2227, DOI 10.1097/00007632-199311000-00014; Bullmann V, 2005, SPINE, V30, P2078, DOI 10.1097/01.brs.0000179083.84421.64; Choi JB, 2001, J TRAUMA, V50, P140, DOI 10.1097/00005373-200101000-00029; DUNN HK, 1986, ORTHOP CLIN N AM, V17, P113; Ebara S, 2000, SPINE, V25, P876, DOI 10.1097/00007632-200004010-00018; Huitema GC, 2006, SPINE, V31, P1734, DOI 10.1097/01.brs.0000224178.04578.03; Husted DS, 2003, SPINE, V28, P2324, DOI 10.1097/01.BRS.0000085361.32600.63; KRISMER M, 1992, SPINE, V17, P263; Kuklo TR, 2005, J SPINAL DISORD TECH, V18, pS58, DOI 10.1097/01.bsd.0000123424.12852.75; Liljenqvist UR, 2002, J BONE JOINT SURG AM, V84A, P359, DOI 10.2106/00004623-200203000-00005; Maruyama T, 2004, SPINE, V29, P2067, DOI 10.1097/01.brs.0000138409.14577.f0; MATSUZAKI H, 1993, SPINE, V18, P2327, DOI 10.1097/00007632-199311000-00033; Newton PO, 2000, SPINE, V25, P1028, DOI 10.1097/00007632-200004150-00019; Newton PO, 2005, SPINE, V30, P392, DOI 10.1097/01.brs.0000153404.62017.75; Niemeyer T, 2000, EUR SPINE J, V9, P499, DOI 10.1007/s005860000181; Ohnishi T, 2001, J NEUROSURG, V95, P253, DOI 10.3171/spi.2001.95.2.0253; Parent S, 2002, SPINE, V27, P2305, DOI 10.1097/00007632-200211010-00002; Picetti G, 1998, ORTHOPEDICS, V21, P1285; Picetti GD, 2002, NEUROSURGERY, V51, P978, DOI 10.1097/00006123-200210000-00023; Sevastik B, 1996, SURG RADIOL ANAT, V18, P51, DOI 10.1007/BF03207763; Sucato DJ, 2004, SPINE, V29, P554, DOI 10.1097/01.BRS.0000106495.91477.92; Sucato DJ, 2003, J BONE JOINT SURG AM, V85A, P1461, DOI 10.2106/00004623-200308000-00006; WOOLSEY RM, 1986, SURG NEUROL, V25, P267, DOI 10.1016/0090-3019(86)90237-5; Zhang H, 2006, SPINE, V31, P183, DOI 10.1097/01.brs.0000194842.15232.4a	26	20	24	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0940-6719	1432-0932		EUR SPINE J	Eur. Spine J.	SEP	2007	16	9					1367	1372		10.1007/s00586-007-0338-6			6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	209QX	WOS:000249404200011	17410383	Green Published			2021-06-18	
J	Wu, XH; Yang, SH; Duan, DY; Cheng, HH; Bao, YT; Zhang, YK				Wu, Xing-Huo; Yang, Shu-Hua; Duan, De-Yu; Cheng, Heng-Hui; Bao, Yu-Ting; Zhang, Yukun			Anti-apoptotic effect of insulin in the control of cell death and neurologic deficit after acute spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; insulin; neurological deficit; spinal cord injury (SCI)	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE; VASCULAR MECHANISMS; NERVOUS-SYSTEM; GROWTH-FACTOR; UP-REGULATION; EXPRESSION; CASPASE-3; INFLAMMATION; ANTAGONIST	Recent studies confirmed that the new cell survival signal pathway of Insulin-PI3K-Akt exerted cyto-protective actions involving anti-apoptosis. This study was undertaken to investigate the potential neuroprotective effects of insulin in the pathogenesis of spinal cord injury (SCI) and evaluate its therapeutic effects in adult rats. SCI was produced by extradural compression using modified Allen's stall with damage energy of 40 g-cm force. One group of rats was subjected to SCI in combination with the administration of recombinant human insulin dissolved in 50% glucose solution at the dose of 1 IU / kg center dot day, for 7 days. At the same time, another group of rats was subjected to SCI in combination with the administration of an equal volume of sterile saline solution. Functional recovery was evaluated using open-field walking, inclined plane tests, and motor evoked potentials (MEPs) during the first 14 days post-trauma. Levels of protein for B-cell lymphoma/leukemia-2 gene (Bcl-2), Caspase-3, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) were quantified in the injured spinal cord by Western blot analysis. Neuronal apoptosis was detected by TUNEL, and spinal cord blood flow (SCBF) was measured by laser-Doppler flowmetry (LDF). Ultimately, the data established the effectiveness of insulin treatment in improving neurologic recovery, increasing the expression of anti-apoptotic bcl-2 proteins, inhibiting caspase-3 expression decreasing neuronal apoptosis, reducing the expression of proinflammatory cytokines iNOS and COX-2, and ameliorating microcirculation of injured spinal cord after moderate contusive SCI in rats. In sum, this study reported the beneficial effects of insulin in the treatment of SCI, with the suggestion that insulin should be considered as a potential therapeutic agent.	Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan, Peoples R China; Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pathol, Wuhan, Peoples R China; Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Ultrasonic Diagnost, Wuhan, Peoples R China	Yang, SH (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan, Peoples R China.	shuhua196@yahoo.com.cn					Adachi K, 2005, NEUROSCI RES, V52, P295, DOI 10.1016/j.neures.2005.03.002; AUTHES DL, 1996, NEUROSURGERY, V39, P804; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BLIGHT AR, 1991, J NEUROL SCI, V106, P158, DOI 10.1016/0022-510X(91)90253-4; BOBERTSON GS, BRAIN PATHOL, V10, P283; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; David CA, 2002, J BIOMOL SCREEN, V7, P259, DOI 10.1177/108705710200700309; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P265, DOI 10.1097/00002826-200109000-00003; Gao F, 2002, CIRCULATION, V105, P1497, DOI 10.1161/01.CIR.0000012529.00367.0F; Garcia-Alias G, 2003, J NEUROTRAUM, V20, P501, DOI 10.1089/089771503765355568; Gerozissis K, 2003, CELL MOL NEUROBIOL, V23, P873, DOI 10.1023/A:1025021529347; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; Guizar-Sahagun G, 2005, NEUROSCIENCE, V130, P639, DOI 10.1016/j.neuroscience.2004.09.056; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hulsebosch CE, 2000, J NEUROTRAUM, V17, P1205, DOI 10.1089/neu.2000.17.1205; Jonassen AK, 2000, J MOL CELL CARDIOL, V32, P757, DOI 10.1006/jmcc.2000.1118; KIERNAN JA, 1990, TRENDS PHARMACOL SCI, V11, P316, DOI 10.1016/0165-6147(90)90233-X; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li SX, 2006, TOXICOLOGY, V217, P46, DOI 10.1016/j.tox.2005.08.018; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Meirer R, 2001, J RECONSTR MICROSURG, V17, P625, DOI 10.1055/s-2001-18818; MUHL H, 1994, BRIT J PHARMACOL, V112, P128; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; PETER VW, 2003, SPINE, V28, P941; Popovich PG, 2003, TRENDS PHARMACOL SCI, V24, P13, DOI 10.1016/S0165-6147(02)00006-8; Qiu JX, 2001, J NEUROTRAUM, V18, P1267, DOI 10.1089/089771501317095304; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Sharma HS, 2000, AMINO ACIDS, V19, P351, DOI 10.1007/s007260070066; Siddle K, 2001, BIOCHEM SOC T, V29, P513, DOI 10.1042/BST0290513; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Winkler T, 2000, ACTA NEUROCHIR SUPPL, V76, P291; WOZNIAK M, 1993, NEUROCHEM INT, V22, P1, DOI 10.1016/0197-0186(93)90062-A; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; WRATHALL JR, 1992, J NEUROTRAUM, V9, pS129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhao WQ, 2001, MOL CELL ENDOCRINOL, V177, P125, DOI 10.1016/S0303-7207(01)00455-5	43	20	27	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2007	24	9					1502	1512		10.1089/neu.2006.0228			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	214ZT	WOS:000249777600008	17892411				2021-06-18	
J	Maier, B; Lehnert, M; Laurer, HL; Marzi, I				Maier, Bernd; Lehnert, Mark; Laurer, Helmut L.; Marzi, Ingo			Biphasic elevation in cerebrospinal fluid and plasma concentrations of endothelin 1 after traumatic brain injury in human patients	SHOCK			English	Article						endothelin 1; microcirculatory disorder; subarachnoid hemorrhage; traumatic brain injury	EXPERIMENTAL SUBARACHNOID HEMORRHAGE; SUPEROXIDE GENERATION; CEREBRAL VASOSPASM; HEAD-INJURY; DYSFUNCTION; IMPAIRMENT; EXPRESSION; ARTERY	Severe traumatic brain injury (TBI) is characterized by a high mortality and poor outcome. The pathomechanisms involved are cytokine-mediated proinflammatory and anti-inflammatory reactions and significant cerebral microcirculatory disorders. The role of endothelin 1 (ET-1), a very potent vasoconstrictive peptide, in the deterioration of cerebral perfusion after trauma is still unclear. The presented study investigated the changes in ET-1 in the cerebrospinal fluid (CSF) and plasma after TBI in humans, with special regard to the presence of subarachnoid hemorrhage (SAH) and clinical outcome. Twenty patients with TBI were consecutively enrolled into the study, 10 patients without SAH (TBI group) and 10 patients with SAH (TBI-H group). Paired samples of plasma and CSF were collected for 10 days after trauma. Analysis of the ET-1 concentrations showed that TBI is associated with initially increased ET-1 values in plasma (TBI, day 1; TBI-H, days 2-3) and significantly increased (P < 0.05, vs. control) CSF concentrations (TBI, days 1-2; TBI-H, days 1-3) in the first days after trauma. In the further time course, ET-1 values declined in both groups, reaching reference values in plasma. The CSF values remained significantly (P < 0.05 vs. control) elevated. Both groups showed a second peak on the beginning of the second week after trauma in plasma and CSF Whereas plasma concentrations failed to reach significance, CSF values showed a significant peak on day 7 in both groups. The TBI-H patients had significantly (P < 0.05) higher values in the secondary peak compared with patients of the TBI group. The kinetics of traumatic SAH-dependent ET-1 needs to be assessed in further investigations.	Univ Frankfurt, Sch Med, Dept Trauma Hand & Reconstruct Surg, D-60590 Frankfurt, Germany	Maier, B (corresponding author), Univ Frankfurt, Sch Med, Dept Trauma Hand & Reconstruct Surg, D-60590 Frankfurt, Germany.	bernd.maier@trauma.uni-frankfurt.de					Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Armstead WM, 2004, CURR PHARM DESIGN, V10, P2185, DOI 10.2174/1381612043384178; Armstead WM, 2001, PEPTIDES, V22, P39, DOI 10.1016/S0196-9781(00)00354-5; Armstead WM, 2001, J NEUROTRAUM, V18, P1039, DOI 10.1089/08977150152693737; ASANO T, 1989, BIOCHEM BIOPH RES CO, V159, P1345, DOI 10.1016/0006-291X(89)92258-4; BEUTH W, 2001, NEUROL NEUROCHIR S5, V35, P5125; CARDOSO ER, 1985, ACTA NEUROCHIR, V76, P140, DOI 10.1007/BF01418477; CLOZEL M, 1993, LIFE SCI, V52, P825, DOI 10.1016/0024-3205(93)90081-D; Grasso G, 2004, BRAIN RES REV, V44, P49, DOI 10.1016/j.brainresrev.2003.10.003; IDE K, 1989, Neurological Research, V11, P101; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kasemsri T, 1997, AM J PHYSIOL-HEART C, V273, pH2639; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Lampl Y, 1997, STROKE, V28, P1951, DOI 10.1161/01.STR.28.10.1951; LYSKO PG, 1995, DEV BRAIN RES, V88, P96, DOI 10.1016/0165-3806(95)00087-T; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MCKENZIE AL, 1995, J NEUROTRAUM, V12, P257, DOI 10.1089/neu.1995.12.257; Onoda K, 1996, J NEUROSURG, V85, P846, DOI 10.3171/jns.1996.85.5.0846; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zuccarello M, 1996, STROKE, V27, P1896, DOI 10.1161/01.STR.27.10.1896	25	20	22	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	JUN	2007	27	6					610	614		10.1097/shk.0b013e31802f9eaf			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	173FS	WOS:000246859500004	17505299				2021-06-18	
J	Monnerie, H; Le Roux, PD				Monnerie, Hubert; Le Roux, Peter D.			Reduced dendrite growth and altered glutamic acid decarboxylase (GAD) 65-and 67-kDa isoform protein expression from mouse cortical GABAergic neurons following excitotoxic injury in vitro	EXPERIMENTAL NEUROLOGY			English	Article						GABA; neuron; dendrites; cerebral cortex; glutamate; excitotoxicity	MICROTUBULE-ASSOCIATED PROTEIN-2; GAMMA-AMINOBUTYRIC-ACID; TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; MESSENGER-RNA; HIPPOCAMPAL-NEURONS; NMDA RECEPTORS; INDUCED NEURODEGENERATION; REGIONAL DIFFERENCES; PYRAMIDAL NEURONS	The vulnerability of brain cells to neurologic insults varies greatly, depending on their neuronal subpopulation. However, cells surviving pathological insults such as ischemia or brain trauma may undergo structural changes, e.g., altered process growth, that could compromise brain function. In this study, we examined the effect of glutamate excitotoxicity on dendrite growth from surviving cortical GABAergic neurons in vitro. Glutamate exposure did not affect GABAergic neuron viability, however, it significantly reduced dendrite growth from GABAergic neurons. This effect was blocked by the AMPA receptor antagonists NBQX and CFM-2, and mimicked by AMPA, but not NMDA. Glutamate excitotoxicity also caused an NMDA receptor-mediated decrease in the GABA synthesizing enzyme glutamic acid decarboxylase (GAD65/67) immunoreactivity from GABAergic neurons, measured using immunocytochemical and Western blot techniques. GAD is necessary for GABA synthesis; however, reduction of GABA by 3-mercaptopropionic acid (3-MPA), which inhibits GABA synthesis, did not alter dendrite growth. These results suggest that GABAergic cortical neurons are relatively resistant to excitotoxic-induced cell death, but they can display morphological and biochemical alterations which may impair their function. (c) 2007 Elsevier Inc. All rights reserved.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19107 USA	Le Roux, PD (corresponding author), Univ Penn, Dept Neurosurg, 330 S 9th St,4th Floor, Philadelphia, PA 19107 USA.	lerouxp@uphs.upenn.edu					Asada H, 1997, P NATL ACAD SCI USA, V94, P6496, DOI 10.1073/pnas.94.12.6496; Bering R, 1997, EXP BRAIN RES, V115, P423, DOI 10.1007/PL00005712; BRUNO V, 1995, EUR J NEUROSCI, V7, P1906, DOI 10.1111/j.1460-9568.1995.tb00712.x; Bywood PT, 2000, NEUROSCI LETT, V280, P5, DOI 10.1016/S0304-3940(99)00990-8; Bywood PT, 2000, EXP NEUROL, V161, P306, DOI 10.1006/exnr.1999.7259; Centonze D, 2001, PROG NEUROBIOL, V63, P687, DOI 10.1016/S0301-0082(00)00037-X; Chimirri A, 1997, J MED CHEM, V40, P1258, DOI 10.1021/jm960506l; CHOI DW, 1987, J NEUROSCI, V7, P357; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAVENPORT CJ, 1990, EPILEPSY RES, V5, P28, DOI 10.1016/0920-1211(90)90063-2; Engel D, 2001, J PHYSIOL-LONDON, V535, P473, DOI 10.1111/j.1469-7793.2001.00473.x; Frahm C, 2004, NEUROSCIENCE, V127, P341, DOI 10.1016/j.neuroscience.2004.05.027; Giorgi S, 1997, NEUROSCIENCE, V80, P793, DOI 10.1016/S0306-4522(97)00114-0; HADDAD GG, 1993, PROG NEUROBIOL, V40, P277, DOI 10.1016/0301-0082(93)90014-J; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hasbani MJ, 2000, NEUROSCIENTIST, V6, P110, DOI 10.1177/107385840000600208; HENG JE, 1995, NEUROREPORT, V6, P1890, DOI 10.1097/00001756-199510020-00016; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Holgado A, 2000, J NEUROBIOL, V43, P121, DOI 10.1002/(SICI)1097-4695(200005)43:2<121::AID-NEU2>3.0.CO;2-P; Huang PP, 1999, NEUROSURGERY, V45, P1413, DOI 10.1097/00006123-199912000-00029; Kingston AE, 1999, EUR J PHARMACOL, V377, P155, DOI 10.1016/S0014-2999(99)00397-0; Kinney JW, 2006, J NEUROSCI, V26, P1604, DOI 10.1523/JNEUROSCI.4722-05.2006; Laferriere NB, 1999, NEUROL RES, V21, P524, DOI 10.1080/01616412.1999.11740969; Le Roux P, 1999, EXP NEUROL, V160, P151, DOI 10.1006/exnr.1999.7194; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; LEROUX PD, 1995, J NEUROBIOL, V27, P97, DOI 10.1002/neu.480270110; LEROUX PD, 1994, J NEUROSCI, V14, P4639; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Li GL, 2000, APMIS, V108, P98; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Manor D, 1996, NEUROCHEM RES, V21, P1031, DOI 10.1007/BF02532413; Martone ME, 2000, HIPPOCAMPUS, V10, P610, DOI 10.1002/1098-1063(2000)10:5<610::AID-HIPO12>3.3.CO;2-5; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MELDRUM BS, 1994, NEUROLOGY, V44, P14; Metzger F, 1998, J NEUROSCI, V18, P1735; Monnerie H, 2003, J NEUROSCI RES, V74, P688, DOI 10.1002/jnr.10797; Monnerie H, 2003, NEUROSCI LETT, V345, P182, DOI 10.1016/S0304-3940(03)00526-3; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Murphy DD, 1998, J NEUROSCI, V18, P2550; NAJLERAHIM A, 1992, EXP NEUROL, V118, P352, DOI 10.1016/0014-4886(92)90193-T; NAJLERAHIM A, 1992, EXP BRAIN RES, V90, P332; Neder L, 2002, CELL MOL NEUROBIOL, V22, P689, DOI 10.1023/A:1021852907068; NETOPILOVA M, 1995, EPILEPSY RES, V20, P179, DOI 10.1016/0920-1211(94)00068-8; Netopilova M, 1997, NEUROSCI LETT, V226, P68, DOI 10.1016/S0304-3940(97)00241-3; NITSCH C, 1989, NEUROSCI LETT, V105, P263, DOI 10.1016/0304-3940(89)90631-9; OBENAUS A, 1993, J NEUROSCI, V13, P4470; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Patz S, 2003, EUR J NEUROSCI, V18, P1, DOI 10.1046/j.1460-9568.2003.02702.x; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29; RIBAK CE, 1979, SCIENCE, V205, P211, DOI 10.1126/science.109922; RIMVALL K, 1992, J NEUROCHEM, V58, P158, DOI 10.1111/j.1471-4159.1992.tb09291.x; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SEGAL M, 1995, TRENDS NEUROSCI, V18, P468, DOI 10.1016/0166-2236(95)92765-I; Shetty AK, 2001, EXP NEUROL, V169, P276, DOI 10.1006/exnr.2001.7668; Shetty AK, 2000, J NEUROSCI, V20, P8788; SIMON RP, 1984, J CEREBR BLOOD F MET, V4, P350, DOI 10.1038/jcbfm.1984.52; Sinor AD, 2000, NEUROSCI LETT, V290, P213, DOI 10.1016/S0304-3940(00)01361-6; Soghomonian JJ, 1998, TRENDS PHARMACOL SCI, V19, P500, DOI 10.1016/S0165-6147(98)01270-X; Swann JW, 2000, HIPPOCAMPUS, V10, P617, DOI 10.1002/1098-1063(2000)10:5<617::AID-HIPO13>3.0.CO;2-R; TECOMA ES, 1989, NEUROLOGY, V39, P676, DOI 10.1212/WNL.39.5.676; Torrey EF, 2005, BIOL PSYCHIAT, V57, P252, DOI 10.1016/j.biopsych.2004.10.019; Wilson MT, 1998, J NEUROSCI RES, V52, P599, DOI 10.1002/(SICI)1097-4547(19980601)52:5<599::AID-JNR12>3.0.CO;2-Y; Yin H z, 1994, Neurobiol Dis, V1, P43, DOI 10.1006/nbdi.1994.0006	66	20	20	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2007	205	2					367	382		10.1016/j.expneurol.2007.02.007			16	Neurosciences	Neurosciences & Neurology	176TQ	WOS:000247108200008	17433299				2021-06-18	
J	van Landeghem, FKH; Weiss, T; Oehmichen, M; von Deimling, A				van Landeghem, Frank K. H.; Weiss, Thorsten; Oehmichen, Manfred; von Deimling, Andreas			Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans	ACTA NEUROPATHOLOGICA			English	Article						astrocyte; human; oligodendrocyte; PACAP27; PACAP38; traumatic brain injury	GLUTAMATE TRANSPORTER PROTEINS; VASOACTIVE-INTESTINAL-PEPTIDE; CEREBELLAR GRANULE NEURONS; CULTURED RAT ASTROCYTES; POLYPEPTIDE PACAP; CORTICAL-NEURONS; NERVOUS-SYSTEM; REACTIVE ASTROCYTES; BASAL FOREBRAIN; UP-REGULATION	The pituitary adenylate cyclase-activating peptide (PACAP) is involved in many processes of the developing and mature central nervous system, such as proliferation, differentiation, apoptosis, neurotransmission, inflammation and neuroprotection. Alternative posttranslational processing of PACAP results in two biologically active, amidated 27- and 38-amino acid peptides termed PACAP27 and PACAP38. In the present study, we examined whether traumatic brain injury ( TBI) affects cellular immunopositivity for PACAP27 and PACAP38. Patients ( n = 55) were classified into three groups dependent on their survival time ( under 24 h, between 24 h and 7 days and between 7 days and 99 days postinjury). PACAP27 and PACAP38 were expressed by neurons and glial cells in normal human neocortex ( n = 10). Following TBI, the total number of PACAP27- and PACAP38- positive cells was significantly decreased for a prolonged survival period within the traumatized neocortex. In the pericontusional cortex, the number of cells expressing PACAP27 and PACAP38 was significantly increased at all survival times examined. Triple immunofluorescence examinations revealed a significant increase in the absolute numbers of GFAP-positive reactive astrocytes as well as a decrease in the CNP-positive oligodendrocytes, each coexpressing PACAP27 or PACAP38 in the contusional and pericontusional cortex. We hypothesize that the increase of glial PACAP immunoreactivity may be interpreted as part of a complex endogenous neuroprotective response in the pericontusional regions, but the precise role of PACAP following TBI is yet to be determined.	Charite Univ Med Berlin, CVK, Inst Neuropathol, D-13353 Berlin, Germany; Univ Klinikum Schleswig Holstein, Inst Med Legale, D-23562 Lubeck, Germany; Univ Klinikum Heidelberg, Dept Neuropathol, Fak Med, D-69120 Heidelberg, Germany	van Landeghem, FKH (corresponding author), Charite Univ Med Berlin, CVK, Inst Neuropathol, Charite Campus Virchow Klinikum,Augustenburger Pl, D-13353 Berlin, Germany.	frank.van_landeghem@charite.de	von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X			ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; Aronica E, 2003, EUR J NEUROSCI, V17, P2106, DOI 10.1046/j.1460-9568.2003.02657.x; Ashur-Fabian O, 1997, J MOL NEUROSCI, V9, P211, DOI 10.1007/BF02800503; Chen WH, 2005, NEUROSCI LETT, V384, P117, DOI 10.1016/j.neulet.2005.04.070; Dai XD, 2003, J NEUROSCI, V23, P5846; Dai XD, 2001, GLIA, V34, P234, DOI 10.1002/glia.1057; Dejda A, 2005, PHARMACOL REP, V57, P307; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; Figiel M, 2000, J NEUROSCI, V20, P3596; Ganea D, 2002, CRIT REV ORAL BIOL M, V13, P229, DOI 10.1177/154411130201300303; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Grimaldi M, 1999, EUR J NEUROSCI, V11, P2767, DOI 10.1046/j.1460-9568.1999.00693.x; Grimaldi M, 2000, ANN NY ACAD SCI, V921, P312; Jaworski DM, 2000, CELL TISSUE RES, V300, P219, DOI 10.1007/s004410000184; Joo KM, 2004, J COMP NEUROL, V476, P388, DOI 10.1002/cne.20231; Kimura H, 2004, REGUL PEPTIDES, V123, P135, DOI 10.1016/j.regpep.2004.04.020; Kimura H, 2003, LARYNGOSCOPE, V113, P1000, DOI 10.1097/00005537-200306000-00016; Larsen JO, 1997, MOL BRAIN RES, V46, P109, DOI 10.1016/S0169-328X(96)00279-3; Lee M, 2001, J NEUROSCI, V21, P3849, DOI 10.1523/JNEUROSCI.21-11-03849.2001; Masmoudi O, 2003, FASEB J, V17, P17, DOI 10.1096/fj.02-0317com; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; Moller K, 1997, BRAIN RES, V775, P166, DOI 10.1016/S0006-8993(97)00923-2; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; Oehmichen M, 2003, J NEUROTRAUM, V20, P87, DOI 10.1089/08977150360517218; Oehmichen M, 2006, FORENSIC NEUROPATHOL; PALKOVITS M, 1995, BRAIN RES, V699, P116, DOI 10.1016/0006-8993(95)00869-R; Privat Alain, 1995, P3; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Reglodi D, 2004, REGUL PEPTIDES, V123, P85, DOI 10.1016/j.regpep.2004.05.016; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Schluter K, 2002, EUR J NEUROSCI, V16, P836, DOI 10.1046/j.1460-9568.2002.02130.x; Shioda S, 2006, ANN NY ACAD SCI, V1070, P550, DOI 10.1196/annals.1317.080; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Suzuki R, 2003, MOL BRAIN RES, V115, P10, DOI 10.1016/S0169-328X(03)00172-4; Tamas A, 2006, J NEUROTRAUM, V23, P686, DOI 10.1089/neu.2006.23.686; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C; Tatsuno I, 1996, ANN NY ACAD SCI, V805, P613; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/S0006-8993(96)00716-0; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2003, J NEUROSCI RES, V72, P303, DOI 10.1002/jnr.10530; Vaudry D, 2002, EUR J NEUROSCI, V15, P1451, DOI 10.1046/j.1460-9568.2002.01981.x; Vaudry D, 2002, P NATL ACAD SCI USA, V99, P6398, DOI 10.1073/pnas.082112699; Vermeiren C, 2005, J NEUROCHEM, V94, P405, DOI 10.1111/j.1471-4159.2005.03216.x; Waschek JA, 2002, DEV NEUROSCI-BASEL, V24, P14, DOI 10.1159/000064942; Zhang YZ, 1996, NEUROSCIENCE, V74, P1099, DOI 10.1016/S0306-4522(96)00168-6; Zhou CJ, 2002, CURR PROTEIN PEPT SC, V3, P423, DOI 10.2174/1389203023380576; Zhou XR, 1999, J NEUROSCI RES, V57, P953, DOI 10.1002/(SICI)1097-4547(19990915)57:6<953::AID-JNR21>3.3.CO;2-I	53	20	20	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2007	113	6					683	693		10.1007/s00401-007-0208-7			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	171IO	WOS:000246729600007	17431645				2021-06-18	
J	Batista, CEA; Chugani, HT; Juhasz, C; Behen, ME; Shankaran, S				Batista, Carlos E. A.; Chugani, Harry T.; Juhasz, Csaba; Behen, Michael E.; Shankaran, Seetha			Transient hypertnetabolism of the basal ganglia following perinatal hypoxia	PEDIATRIC NEUROLOGY			English	Article							POSITRON EMISSION TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; CEREBRAL-PALSY; ISCHEMIC ENCEPHALOPATHY; ASPHYXIA; GLUTAMATE/GLUTAMINE	Positron emission tomography can tie used to evaluate brain function following perinatal hypoxia. This case report demonstrates transient hypermetabolism in the basal ganglia detected by glucose metabolism positron emission tomography study in a newborn who suffered hypoxic-ischemic encephalopathy and developed dystonic cerebral palsy later. A scan repeated at 4 years of age showed severe hypometabolism in the lentiform nuclei and thalami. Transient hypermetabolism in the basal ganglia following perinatal hypoxia may be related to excitotoxic damage causing permanent neurological symptoms in the form of dystonic cerebral palsy. Thus, positron emission tomography can help predict this form of cerebral palsy in neonates. (C) 2007 by Elsevier Inc. All rights reserved.	Wayne State Univ, Div Pediat Neurol, PET Ctr, Childrens Hosp Michigan, Detroit, MI 48201 USA; Wayne State Univ, Carman & Ann Adams Dept Pediat, Detroit, MI 48201 USA; Wayne State Univ, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Dept Radiol, Detroit, MI 48201 USA	Chugani, HT (corresponding author), Wayne State Univ, Div Pediat Neurol, PET Ctr, Childrens Hosp Michigan, 3901 Beaubien Blvd, Detroit, MI 48201 USA.	hchugani@pet.wayne.edu	Juhasz, Csaba/P-3665-2019; Batista, Carlos Eduardo/G-1857-2010	Batista, Carlos/0000-0003-1299-9934			Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; BARKOVICH AJ, 1995, AM J NEURORADIOL, V16, P427; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BLENNOW M, 1995, ACTA PAEDIATR, V84, P1289, DOI 10.1111/j.1651-2227.1995.tb13551.x; COLAMARIA V, 1988, BRAIN DEV-JPN, V10, P57, DOI 10.1016/S0387-7604(88)80049-4; HASEGAWA M, 1992, BRAIN DEV-JPN, V14, P1; Johnston MV, 2005, BRAIN PATHOL, V15, P234; KERRIGAN JF, 1991, PEDIATR NEUROL, V7, P415, DOI 10.1016/0887-8994(91)90024-F; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; NELSON KB, 1988, J PEDIATR-US, V112, P572, DOI 10.1016/S0022-3476(88)80169-0; Perlman JM, 1997, PEDIATRICS, V99, P851, DOI 10.1542/peds.99.6.851; Pu YL, 2000, AM J NEURORADIOL, V21, P203; Rutherford M, 2006, PEDIATR RADIOL, V36, P582, DOI 10.1007/s00247-006-0164-8; SHEWMON DA, 1981, ANN NEUROL, V9, P358, DOI 10.1002/ana.410090408; Shulman RG, 2004, TRENDS NEUROSCI, V27, P489, DOI 10.1016/j.tins.2004.06.005; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	16	20	22	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994			PEDIATR NEUROL	Pediatr. Neurol.	MAY	2007	36	5					330	333		10.1016/j.pediatrneurol.2007.01.004			4	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	172SM	WOS:000246824400008	17509466				2021-06-18	
J	Zulu, BMW; Mulaudzi, TV; Madiba, TE; Muckart, DJJ				Zulu, B. M. W.; Mulaudzi, T. V.; Madiba, T. E.; Muckart, D. J. J.			Outcome of head injuries in general surgical units with an off-site neurosurgical service	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article; Proceedings Paper	24th Biennal Congress of the Association-of-Surgeons-of-South-Africa	AUG 23, 2004	Cape Town, SOUTH AFRICA	Assoc Surg S Africa		head injury; neurosurgical unit; general surgical unit	BRAIN INJURY; TRAUMA; COMA; MORTALITY; SEVERITY; SCORE	Introduction: In order to cope with bed shortages in the only neurosurgical unit (NSU) in KwaZulu-Natal, it has become necessary to manage head injured patients in a general surgical unit (GSU) at the referral hospitals in consultation with the NSU. This study was undertaken to assess the outcome of patients with head injuries managed in a GSU in consultation with a regional NSU. Patients and methods: A prospective pilot study was carried out in a single surgical unit over an 18-month period (July 1997-December 1998), followed by a larger prospective study over a 6-month period (January-June 2001). All patients with head injuries severe enough to warrant admission to hospital (GCS <= 15 or 15 with localising signs) were included. Results: The pilot study comprised 86 patients and the subsequent study comprised 230 patients, giving a total of 316 patients in the whole study. The mean age was 31 12 years. Following consultation with the NSU, 265 (84%) patients were managed in the GSU and 51 (16%) required transfer to the NSU. Forty-one patients died giving a mortality rate of 13%. Twenty eight of the 42 patients with GCS <= 8 died (67%) compared to 13 out of 274 with GCS > 8 (5%) (p < 0.0001). Eleven of the 51 patients destined to the NSU died (22%) compared to 30 of 265 in the GSU (11%) (p = 0.046). The average hospital stay was 10 +/- 18 days. Forty surviving patients (17%) from the GSU and 20 from the NSU (51%) were discharged with neurological sequelae (p < 0.001). Conclusion: Head trauma is associated with high morbidity and mortality. Nonsurgical treatment of traumatic brain injury at the referral hospital by the GSU is acceptable practice. Outcome is determined primarily by the GCS on presentation. NSU patients had a significantly higher mortality rate. A delay before surgery did not seem to affect outcome. (c) 2007 Elsevier Ltd. All rights reserved.	Univ KwaZulu Natal, Dept Surg, ZA-4013 Congella, South Africa; King Edward VIII Hosp, Durban, South Africa	Madiba, TE (corresponding author), Univ KwaZulu Natal, Dept Surg, Private Bag 7, ZA-4013 Congella, South Africa.	madiba@ukzn.ac.za	Madiba, T E/N-6069-2013; Madiba, T E/ABI-8313-2020	Madiba, T E/0000-0002-0155-9143; Madiba, T E/0000-0002-0155-9143			Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; BECKMANN V, 2004, INTENS CARE MED, V30, P1508; BOTO GR, 2006, J NEUROL NEUROSUR PS, V1, P1; Campbell NC, 1997, BRIT J SURG, V84, P1737, DOI 10.1046/j.1365-2168.1997.02819.x; COOKE RS, 1995, INJURY, V26, P395, DOI 10.1016/0020-1383(95)00003-R; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENTLEMAN D, 1993, BRIT MED J, V307, P547, DOI 10.1136/bmj.307.6903.547; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Jithoo R, 2003, J TELEMED TELECARE, V9, P63, DOI 10.1258/135763303321327894; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; MUCKART DJJ, 1995, S AFR MED J, V85, P1172; MUCKART DJJ, 1991, S AFR MED J, V79, P93; Nadvi SS, 1997, S AFR MED J, V87, P1669; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; RaeGrant AD, 1996, J TRAUMA, V40, P401, DOI 10.1097/00005373-199603000-00013; TEASDALE G, 1974, LANCET, V2, P81; Warren J, 2004, CRIT CARE MED, V32, P256, DOI 10.1097/01.CCM.0000104917.39204.0A	21	20	20	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAY	2007	38	5					576	583		10.1016/j.injury.2007.01.002			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	176AO	WOS:000247055300010	17472793				2021-06-18	
J	Henzler, D; Cooper, DJ; Tremayne, AB; Rossaint, R; Higgins, A				Henzler, Dietrich; Cooper, D. James; Tremayne, Ann B.; Rossaint, Rolf; Higgins, Alisa			Early modifiable factors associated with fatal outcome in patients with severe traumatic brain injury: A case control study	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; craniocerebral trauma; fatal outcome; intracranial pressure; multiple trauma; hypotension	ROAD TRAFFIC FATALITIES; MODERATE HYPOTHERMIA; OCCULT HYPOPERFUSION; MAJOR TRAUMA; MANAGEMENT; POLYTRAUMA; AUSTRALIA; VICTORIA; CARE; MORTALITY	Objective. Survival of patients with severe traumatic brain injury may be improved by minimizing secondary brain injury. We aimed to identify potentially modifiable contributors to secondary brain injury that may persist and adversely affect patient outcome. Design: Retrospective case control study. Nonsurviving patients with traumatic brain injury were selected and matched 1:1 for age, Glasgow Coma Scale score, Abbreviated Injury Scale: Head (AIS(HEAD)), Revised Trauma Score, and Injury Severity Score with survivors. Potentially modifiable contributors to secondary brain injury were examined and compared in both groups. Setting. A level I trauma center in Melbourne, Australia. Patients: Patients with traumatic brain injury caused by blunt trauma with an AIS(HEAD) >= 4 were identified from a prospective intensive care database. Interventions: None. Measurements and Main Results. Between January 1, 1999, and July 30, 2000, 74 patients, including 37 nonsurvivors, were identified. By design, the groups were well matched for injury severity and baseline conditions. In nonsurvivors, mean arterial pressure was similar to that of survivors at hospital arrival but was lower at 4 hrs after arrival (71 +/- 16 vs. 80 +/- 15 mm Hg, p =.016). A mean arterial pressure <= 65 mm Hg during this 4-hr period was associated with a four-fold increase in the odds of nonsurvival (95% confidence interval, 1.25-12.8). Intracranial pressure monitoring and intensive care unit admission tended to be initiated later in nonsurvivors, potentially delaying recognition and management of inadequate cerebral perfusion pressure. In nonsurvivors, hypothermia did not normalize during the first 24 hrs after injury. Conclusions: In patients with severe traumatic brain injury, lower blood pressure in the first 4 hrs after admission was associated with mortality and may have increased the rate of secondary brain injury. Outcomes of patients with severe traumatic brain injury may potentially be improved by early targeting of the higher mean arterial pressure observed in survivors (mean arterial pressure 80 mm Hg), which may facilitate improved cerebral perfusion. Slower initiation of intracranial pressure monitoring and of intensive care unit admission may also have adversely affected outcomes, whereas persistent hypothermia was associated with nonsurvival.	Univ Hosp Aachen, Dept Anesthesiol, Aachen, Germany; Monash Univ, Alfred Hosp, ICU, Dept Surg, Melbourne, Vic 3181, Australia; Monash Univ, Alfred Hosp, ICU, Dept Med, Melbourne, Vic 3181, Australia; Monash Univ, ANZIC RC, Dept Epidemiol & Prevent Med, Dept Med, Melbourne, Vic 3181, Australia	Cooper, DJ (corresponding author), Univ Hosp Aachen, Dept Anesthesiol, Aachen, Germany.	j.cooper@alfred.org.au	Higgins, Alisa/AAM-8088-2020; Cooper, D. James/G-7961-2013	Higgins, Alisa/0000-0001-8295-7559; Cooper, D. James/0000-0002-5872-9051; Henzler, Dietrich/0000-0001-5511-6885			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baltas I, 1998, J Neurosurg Sci, V42, P85; Blow O, 1999, J TRAUMA, V47, P964, DOI 10.1097/00005373-199911000-00028; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; Claridge JA, 2000, J TRAUMA, V48, P8, DOI 10.1097/00005373-200001000-00003; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLLICOTT PE, 1980, JAMA-J AM MED ASSOC, V243, P1156; Cooper DJ, 1998, J TRAUMA, V45, P772, DOI 10.1097/00005373-199810000-00027; Copes W. S., 1990, P 33 ANN M ASS ADV A, P205; Dereeper E, 1998, RESUSCITATION, V36, P15, DOI 10.1016/S0300-9572(97)00080-4; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Henzler D, 2001, Crit Care Resusc, V3, P153; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Krettek C, 1998, LANGENBECK ARCH SURG, V383, P220, DOI 10.1007/s004230050122; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McDermott FT, 1997, J TRAUMA, V43, P831, DOI 10.1097/00005373-199711000-00016; McDermott FT, 2001, BRIT J SURG, V88, P1099, DOI 10.1046/j.0007-1323.2001.01835.x; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Mikhail J, 1999, AACN Clin Issues, V10, P85, DOI 10.1097/00044067-199902000-00008; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; Rose S, 1998, LANGENBECK ARCH SURG, V383, P199, DOI 10.1007/s004230050119; Segers MJM, 1998, UNFALLCHIRURG, V101, P742, DOI 10.1007/s001130050332; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012	29	20	21	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	APR	2007	35	4					1027	1031		10.1097/01.CCM.0000259526.45894.08			5	Critical Care Medicine	General & Internal Medicine	151PJ	WOS:000245302400004	17334255				2021-06-18	
J	Kremer, S; Oppenheim, C; Schmitt, E; Dietemann, JL				Kremer, S.; Oppenheim, C.; Schmitt, E.; Dietemann, J-L			Diffusion MRI: Technique and clinical applications	JOURNAL DE RADIOLOGIE			French	Article						diffusion MRI; brain; stroke; tumor	CREUTZFELDT-JAKOB-DISEASE; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; REVERSIBLE ENCEPHALOPATHY SYNDROME; CLOSED-HEAD INJURY; IMAGING FINDINGS; WATER DIFFUSION; AXONAL INJURY; WEIGHTED MRI; BRAIN-TUMORS; COEFFICIENT	Diffusion MRI gives information that is not available with conventional MRI examinations. It can provide early diagnosis of stroke and helps in diagnosing cerebral lymphoma, cerebral bacterial abscess, and epidermoid cyst. It helps distinguish between vasogenic, edema and cytotoxic edema and has prognostic value. Acquisition is fast and should be performed in all neuroradiological examinations.	CHU Strasbourg, Serv Radiol 2, F-67098 Strasbourg, France; Hop St Anne, Serv Neuroradiol, F-75014 Paris, France; CHU Nancy, Serv Neuroradiol, F-54000 Nancy, France	Kremer, S (corresponding author), CHU Strasbourg, Serv Radiol 2, Ave Moliere, F-67098 Strasbourg, France.	stephane.kremer@chru-strasbourg.fr	Oppenheim, Catherine/N-1635-2018	Oppenheim, Catherine/0000-0003-3410-0862			Ahn KJ, 2004, NEURORADIOLOGY, V46, P978, DOI 10.1007/s00234-004-1276-1; Bammer R, 2003, EUR J RADIOL, V45, P169, DOI 10.1016/S0720-048X(02)00303-0; Briellmann RS, 2005, EPILEPSIA, V46, P760, DOI 10.1111/j.1528-1167.2005.47604.x; Chen S, 2001, AM J NEURORADIOL, V22, P1089; Chong-Han CH, 2003, AM J ROENTGENOL, V181, P1711, DOI 10.2214/ajr.181.6.1811711; Chua GC, 2002, CLIN RADIOL, V57, P800, DOI 10.1053/crad.2002.0977; Cole AJ, 2004, EPILEPSIA, V45, P72, DOI 10.1111/j.0013-9580.2004.04014.x; Collie DA, 2003, AM J NEURORADIOL, V24, P1560; Cosnard G, 2003, J NEURORADIOLOGY, V30, P146; Covarrubias DJ, 2002, AM J NEURORADIOL, V23, P1038; Dubrulle F, 2006, RADIOLOGY, V238, P604, DOI 10.1148/radiol.2381041649; Ducreux D, 2002, J NEURORADIOLOGY, V29, P39; Ducreux D, 2001, AM J NEURORADIOL, V22, P261; Filippi M, 2000, ARCH NEUROL-CHICAGO, V57, P1017, DOI 10.1001/archneur.57.7.1017; Hakyemez B, 2005, EUR J RADIOL, V54, P214, DOI 10.1016/j.ejrad.2004.06.018; Heiner L, 2003, EUR J RADIOL, V45, P195, DOI 10.1016/S0720-048X(02)00306-6; Helenius J, 2002, AM J NEURORADIOL, V23, P194; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Kamal AK, 2003, AM J NEURORADIOL, V24, P895; Lamy C, 2006, EUR RADIOL, V16, P1090, DOI 10.1007/s00330-005-0049-5; Lamy C, 2004, J NEUROIMAGING, V14, P89, DOI 10.1177/1051228403258161; Leuthardt EC, 2002, SURG NEUROL, V58, P395, DOI 10.1016/S0090-3019(02)00929-1; Lovblad KO, 2006, EUR RADIOL, V16, P1253, DOI 10.1007/s00330-005-0103-3; Morita N, 2002, NEURORADIOLOGY, V44, P907, DOI 10.1007/s00234-002-0860-5; Mukherjee P, 2001, RADIOLOGY, V219, P756, DOI 10.1148/radiology.219.3.r01jn48756; Oppenheim C, 2005, J RADIOL, V86, P1069, DOI 10.1016/S0221-0363(05)81495-7; Oppenheim C, 2004, J NEUROL NEUROSUR PS, V75, P1066, DOI 10.1136/jnnp.2003.020172; Oppenheim C, 2001, STROKE, V32, P2486, DOI 10.1161/hs1101.098331; Pasco A, 2006, EUR RADIOL, V16, P1501, DOI 10.1007/s00330-005-0086-0; Purroy F, 2004, STROKE, V35, P2313, DOI 10.1161/01.STR.0000141703.21173.91; Rees J, 2003, CURR OPIN NEUROL, V16, P643, DOI 10.1097/00019052-200312000-00001; Roberts TPL, 2003, EUR J RADIOL, V45, P185, DOI 10.1016/S0720-048X(02)00305-4; Rovira A, 2002, AM J NEURORADIOL, V23, P989; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; Silvera S, 2005, AM J NEURORADIOL, V26, P236; Stadnik TW, 2001, AM J NEURORADIOL, V22, P969; Tung GA, 2001, AM J ROENTGENOL, V177, P709, DOI 10.2214/ajr.177.3.1770709; Yamasaki F, 2005, RADIOLOGY, V235, P985, DOI 10.1148/radiol.2353031338; Young GS, 2005, AM J NEURORADIOL, V26, P1551	40	20	23	0	1	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0221-0363			J RADIOL	J. Radiol.	MAR	2007	88	3	2				428	443		10.1016/S0221-0363(07)89845-3			16	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	162DE	WOS:000246066200002	17457256				2021-06-18	
J	Bay, E; Hagerty, BM; Williams, RA				Bay, Esther; Hagerty, Bonnie M.; Williams, Reg A.			Depressive symptomatology after mild-to-moderate traumatic brain injury: A comparison of three measures	ARCHIVES OF PSYCHIATRIC NURSING			English	Article							NEUROBEHAVIORAL FUNCTIONING INVENTORY; HEAD-INJURY; MOOD; DISABILITY; STRESS	Measurement of posttraumatic brain injury depression is problematic. Disagreement exists about the best screening measure, and symptoms of brain injury often overlap those of depression. In an outpatient sample of 75 persons, we compared aspects of Criterion A of the Diagnostic and Statistical Manual of Mental Disorders-Fourth Revision, Text Revision (2000), with three depression subscales: the Neurobehavioral Functioning (NFI-D), Profile of Moods State (POMS-D), and Center for Epidemiologic Studies (CES-D). Nearly 40% of this outpatient sample had significant levels of depressive symptoms. All measures were internally consistent, reliable, and highly correlated. For persons with mild-to-moderate traumatic brain injury, the CES-D was the best screening instrument because of its ease in administration, sensitivity in detecting probable major depressive disorders, its established categories of severity, and its comprehensiveness. Further effort in the establishment of depression severity categories using the NFI-D is needed. (c) 2007 Elsevier Inc. All rights reserved.	MI State Univ, Coll Nursing, Howell, MI 48843 USA; Univ Michigan, Sch Nursing, Dept Psychiat, Ann Arbor, MI 48109 USA	Bay, E (corresponding author), MI State Univ, Coll Nursing, 4375 Sundance Crossing, Howell, MI 48843 USA.						Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; BAY E, 2001, DISS ABSTR INT; Bay Esther, 2005, J Neurosci Nurs, V37, P4; Bay Esther, 2004, Res Theory Nurs Pract, V18, P213, DOI 10.1891/088971804780957108; BRESLAU N, 1986, ARCH GEN PSYCHIAT, V43, P309; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Davidson RJ, 2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Devins GM, 1985, TEST CRITIQUES, P144; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; EATON W, 2004, CTR EPIDEMIOLOGIC ST, V3; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jean-Bay E, 2000, J Neurosci Nurs, V32, P169; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; MCNAIR DM, 1964, J ABNORM SOC PSYCH, V69, P620, DOI 10.1037/h0040902; MCNAIR DM, 2002, PROFILE MOOD STATES; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Nemeroff CB, 1998, SCI AM, V278, P42, DOI 10.1038/scientificamerican0698-42; NOLENHOEKSEMA S, 1987, PSYCHOL BULL, V101, P259, DOI 10.1037/0033-2909.101.2.259; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGNATO G, 1991, AWARENESS DEFICIT AF, P10; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sheline YI, 1998, NEUROSCIENTIST, V4, P331, DOI 10.1177/107385849800400514; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Smarr KL., 2003, ARTHRITIS CARE RES, V49, pS134, DOI [10.1002/art.11410, DOI 10.1002/ART.11410]; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wilhelm K, 2004, PSYCHOSOMATICS, V45, P461, DOI 10.1176/appi.psy.45.6.461; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Willis G.B., 1999, QUESTION APPRAISAL S	48	20	21	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9417	1532-8228		ARCH PSYCHIAT NURS	Arch. Psychiatr. Nurs.	FEB	2007	21	1					2	11		10.1016/j.apnu.2006.07.005			10	Nursing; Psychiatry	Nursing; Psychiatry	134HS	WOS:000244074700002	17258103				2021-06-18	
J	Chesnut, RM				Chesnut, Randall M.			Care of central nervous system injuries	SURGICAL CLINICS OF NORTH AMERICA			English	Article							CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; POSTTRAUMATIC INTRACRANIAL HYPERTENSION; ARTERIOVENOUS OXYGEN DIFFERENCE; 7.5-PERCENT SODIUM-CHLORIDE; BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; COMPUTED-TOMOGRAPHY; HYPERTONIC SALINE	The primary method of improving outcome from traumatic brain injury is through avoiding secondary insults to the injured brain. Although surgery is important, most management is critical care. Evidence-based guidelines continue to be developed to assist in directing care. With modern monitoring systems, a physiologic-based approach is increasingly applicable, allowing focused treatment for intracranial hypertension and ischemia. It is important to balance and integrate the care of the injured brain into the overall care of the polytrauma patient.	Univ Washington, Harborview Med Ctr, Dept Neurosurg, Seattle, WA 98104 USA	Chesnut, RM (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurosurg, 325 9Th Ave,Box 359766, Seattle, WA 98104 USA.	chesnutr@u.washington.edu					AARABI B, 2001, J TRAUMA S, V51, P86; ADELSON PD, 2003, PEDIAT CRIT CARE M S, V4, P71; ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Brodie HA, 1997, ARCH OTOLARYNGOL, V123, P749; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; CHESNUT RM, 1997, J TRAUMA S, V42, P4; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cooper P R, 1976, Surg Neurol, V5, P25; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Dutton RP, 2006, J TRAUMA, V60, pS70, DOI 10.1097/01.ta.0000200856.47545.64; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P643, DOI 10.3109/02688699308995093; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FULTON RL, 1993, SURG GYNECOL OBSTET, V176, P327; GAAB MR, 1990, ACT NEUR S, V51, P326; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Ghajar J, 1995, New Horiz, V3, P395; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HORAN MJ, 1987, HYPERTENSION, V10, P115, DOI 10.1161/01.HYP.10.1.115; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marion DW, 2006, NEUROSURGERY, V58, P655; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1983, J NEUROSURG, V58, P566, DOI 10.3171/jns.1983.58.4.0566; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; Monro Alexander, 1783, OBSERVATIONS STRUCTU; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Napolitano L, 2006, J TRAUMA, V60, pS26, DOI 10.1097/01.ta.0000199979.95789.17; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; Ratilal B, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004884.pub2; Robertson C S, 1995, New Horiz, V3, P410; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Schneider GH, 2002, ACT NEUR S, V81, P77; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Shiozaki T, 2003, J NEUROSURG, V99, P47, DOI 10.3171/jns.2003.99.1.0047; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wakai A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub2; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	77	20	23	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0039-6109	1558-3171		SURG CLIN N AM	Surg. Clin.-North Am.	FEB	2007	87	1					119	+		10.1016/j.suc.2006.09.018			39	Surgery	Surgery	123NI	WOS:000243302200009	17127126				2021-06-18	
J	Carpenter, J; Weinstein, S; Myseros, J; Vezina, G; Bell, MJ				Carpenter, Jessica; Weinstein, Steve; Myseros, John; Vezina, Gilbert; Bell, Michael J.			Inadvertent hyponatremia leading to acute cerebral edema and early evidence of herniation	NEUROCRITICAL CARE			English	Article						cerebral edema; hyponatremia; child; hypertonic saline; hyponatremic encephalopathy	INTENSIVE-CARE-UNIT; ENCEPHALOPATHY; SEIZURE; INJURY	Introduction For years, the maintenance of normal or supranormal serum sodium (Na) concentrations has been believed to be beneficial in brain injuries. Recently published guidelines for cerebral trauma recommend the use of hypertonic saline to achieve hypernatremia for the management of increased intracranial pressure and these standards are generally practiced across most diseases in neurocritical care including stroke, hemorrhage and tumors. Severe hyponatremia has long been known to be detrimental, but objective evidence for the harm of mild hyponatremia as a secondary injury has been scarce. Description of Case In this case report, we describe a child with aneurysmal subarachnoid hemorrhage who had a sudden, inadvertent decrease in serum Na (128 meq/l) that was associated with a deterioration of her neurological examination and evidence of early transtentorial herniation on emergent brain CT scan. These findings were quickly reversed after the serum Na was corrected. Discussion This report emphasizes that close monitoring of serum Na and osmolarity in acute head injured children is important, and provides evidence that alterations of these parameters is a substantial risk for cerebral edema in children with evolving brain injuries and briefly reviews the literature regarding the risks of hyponatremia in children.	Childrens Natl Med Ctr, Neurosci Res Ctr, Childrens Res Inst, Washington, DC 20010 USA; Childrens Natl Med Ctr, Dept Neurol, Childrens Res Inst, Washington, DC 20010 USA; Childrens Natl Med Ctr, Dept Neurosurg, Childrens Res Inst, Washington, DC 20010 USA; Childrens Natl Med Ctr, Dept Neuroradiol, Childrens Res Inst, Washington, DC 20010 USA; Childrens Natl Med Ctr, Dept Crit Care Med, Childrens Res Inst, Washington, DC 20010 USA	Bell, MJ (corresponding author), Childrens Natl Med Ctr, Neurosci Res Ctr, Childrens Res Inst, Washington, DC 20010 USA.	jcarpent@cnmc.org; sweinste@cnmc.org; jmyseros@cnmc.org; gvezina@cnmc.org; mbell@cnmc.org					Arieff AI, 1998, PAEDIATR ANAESTH, V8, P1, DOI 10.1046/j.1460-9592.1998.00730.x; Ashrafian H, 2001, EUR J NEUROL, V8, P103, DOI 10.1046/j.1468-1331.2001.00176.x; Ayus JC, 1999, JAMA-J AM MED ASSOC, V281, P2299, DOI 10.1001/jama.281.24.2299; Bennani SL, 2003, REV MED INTERNE, V24, P224, DOI 10.1016/S0248-8663(02)00811-1; DEVITA MV, 1990, CLIN NEPHROL, V34, P163; Donati-Genet PCM, 2001, J PEDIATR SURG, V36, P1094, DOI 10.1053/jpsu.2001.24770; Fedutes BA, 2003, ANN PHARMACOTHER, V37, P1506, DOI 10.1345/aph.1C464; Fraser CL, 1997, AM J MED, V102, P67, DOI 10.1016/S0002-9343(96)00274-4; Frye RE, 2005, PEDIATR NEUROL, V32, P213, DOI 10.1016/j.pediatrneurol.2004.07.012; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; Klein KM, 2004, SEIZURE-EUR J EPILEP, V13, P196, DOI 10.1016/S1059-1311(03)00077-3; Kumar S, 2006, NEUROL RES, V28, P360, DOI 10.1179/016164106X110346; Massieu L, 2004, NEUROCHEM RES, V29, P73, DOI 10.1023/B:NERE.0000010435.06586.e2; Moon G, 1995, HEALTH PLACE, V1, P1, DOI 10.1016/1353-8292(95)90006-V; Moritz ML, 2003, PEDIATRICS, V111, P227, DOI 10.1542/peds.111.2.227; Restuccia T, 2004, HEPATOLOGY, V39, P1613, DOI 10.1002/hep.20237; Singh Sonal, 2005, MedGenMed, V7, P11; STERNS RH, 1989, KIDNEY INT, V35, P69, DOI 10.1038/ki.1989.9; Upadhyay A, 2006, AM J MED, V119, pS30, DOI 10.1016/j.amjmed.2006.05.005	19	20	25	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2007	6	3					195	199		10.1007/s12028-007-0032-x			5	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	184FO	WOS:000247626700007	17572863				2021-06-18	
J	Frey, KL; Rojas, DC; Anderson, CA; Arciniegas, DB				Frey, Kimberly L.; Rojas, Donald C.; Anderson, C. Alan; Arciniegas, David B.			Comparison of the O-Log and GOAT as measures of posttraumatic amnesia	BRAIN INJURY			English	Article						traumatic brain injury; posttraumatic amnesia; memory; rating scales	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; GALVESTON ORIENTATION; COGNITIVE ORIENTATION; PRACTICAL SCALE; REHABILITATION; RECOVERY; RESOLUTION; SEVERITY; DURATION	Primary objective: To compare PTA severity and duration assessments made by Orientation Log ( O-Log) and the Galveston Orientation and Amnesia Test ( GOAT) and the relationship of data yielded by these assessments to rehabilitation outcomes. Research design: Retrospective study. Methods and procedures: O-Log, GOAT, demographic, length of stay, and Functional Independence Measure ( FIM) data among 83 inpatient subjects with recent TBI requiring inpatient care were reviewed. Main outcomes and results: PTA severity and duration as assessed by the O-Log and the GOAT are statistically similar and correlate similarly with rehabilitation LOS and discharge total FIM score. Simple linear regression models suggest that O-Log scores better predict rehabilitation outcomes than GOAT scores. Conclusions: Although the O-Log and GOAT perform similarly as measures of PTA severity and duration, PTA assessments using the O-Log offers better prediction of rehabilitation outcomes. Further study of the O-Log as an alternate assessment of PTA is warranted.	Spalding Rehabil Hosp, Brain Injury Rehabil Unit, HealthONE, Aurora, CO 80011 USA; Univ Colorado, Sch Med, Dept Psychiat, Neuropsychiat Serv, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Neurol Behav Neurol Sect, Denver, CO USA; Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO USA	Frey, KL (corresponding author), Spalding Rehabil Hosp, Brain Injury Rehabil Unit, HealthONE, 900 Potomac St, Aurora, CO 80011 USA.	Kim.Frey@uchsc.edu	Arciniegas, David/A-3792-2009; Rojas, Don/AAX-6678-2020; Rojas, Don/F-4296-2012	Rojas, Don/0000-0001-6560-9616; 			Ahmed S, 2000, BRAIN INJURY, V14, P765; Alderson AL, 2002, J HEAD TRAUMA REHAB, V17, P210, DOI 10.1097/00001199-200206000-00003; Avesani R, 2005, BRAIN INJURY, V19, P933, DOI 10.1080/02699050400002371; Baird A, 2005, BRAIN INJURY, V19, P811, DOI 10.1080/02699050500149213; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Dowler RN, 2000, BRAIN INJURY, V14, P117, DOI 10.1080/026990500120781; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JENNETT B, 1975, LANCET, V1, P480; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MARROSSZEKY N, 1998, GUIDELINES USING WES; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Tate RL, 2001, J HEAD TRAUMA REHAB, V16, P525, DOI 10.1097/00001199-200112000-00002; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; VONWOWERN F, 1966, ACTA NEUROL SCAND, V42, P373; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	29	20	20	0	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	5					513	520		10.1080/02699050701311026			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	175FI	WOS:000246998000008	17522991				2021-06-18	
J	Katz, N; Golstand, S; Bar-Ilan, RT; Parush, S				Katz, Noomi; Golstand, Sarina; Bar-Ilan, Ruthie Traub; Parush, Shula			The Dynamic Occupational Therapy Cognitive Assessment for Children (DOTCA-Ch): A new instrument for assessing learning potential	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						attention deficit hyperactivity disorder (ADHD); cognition; learning disability; pediatric; traumatic brain injury (TBI)	ECOLOGICAL VALIDITY; ASSESSMENT LOTCA; PERFORMANCE; BATTERY; SKILLS	OBJECTIVE. To describe the development and psychometric properties of the Dynamic Occupational Therapy Cognitive Assessment for Children (DOTCA-Ch), a dynamic criterion-referenced assessment of cognitive abilities and learning potential for children with cognitive and learning difficulties. METHOD. A series of studies analyzed the age standards, criterion cutoff scores, and percentage of mediation cues required for typically developing children 6-12 years of age, as well as reliability and validity. RESULTS. MANOVA analyses determined four age groups that best fit the outcome data: 6-6.11, 7-8.11, 9-10.11, and 11-12 years. Criterion cutoff scores of 25% for at-risk and under 10% for deficient performance were obtained for each age group. Dynamic percentage scores were determined. Significant high interrater reliability and moderate to high internal consistency reliability were found. Construct validity was supported by comparing children with traumatic brain injury and learning disabilities to typically developing children, and ecological validity of children with attention deficit hyperactivity disorder by comparing performance on the DOTCA-Ch to the School Function Assessment. CONCLUSIONS. The DOTCA-Ch is a reliable and valid assessment that provides learning potential and can facilitate intervention for cognitive difficulties that manifest themselves in daily functions among school-age children.	Hebrew Univ Jerusalem, Sch Occupat Therapy, POB 24026,Mt Scopus, IL-91240 Jerusalem, Israel	Katz, N (corresponding author), Hebrew Univ Jerusalem, Sch Occupat Therapy, POB 24026,Mt Scopus, IL-91240 Jerusalem, Israel.	noomi.katz@huji.ac.il					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Annes G, 1996, OCCUPATIONAL THERAPY, V3, P157; AVERBUCH S, 2005, COGNITION OCCUPATION, P113; AVERSA SML, 1999, CLIN LUNG CANCER, V1, P1; CERMAK S, 1984, SENSORY INTEGRATION, V7, P3; CERMAK SA, 1995, AM J OCCUP THER, V49, P500, DOI 10.5014/ajot.49.6.500; CERMAK SA, 2005, COGNITION OCCUPATION, P277; CERMAK SA, 1984, SENSORY INTEGRATION, V7, P1; Conners CK., 1997, CONNERS RATING SCALE; Coster W., 1998, SCH FUNCTION ASSESSM; Creedy Debra, 2004, Contemp Nurse, V18, P46; CROCKER L, 1986, INTRO VCLASSICAL MOD; DELAVEGA M, 2004, THESIS TEL AVIV U TE; Fabio RA, 2005, J GEN PSYCHOL, V132, P41, DOI 10.3200/GENP.132.1.41-66; Feuerstein R., 1980, INSTRUMENTAL ENRICHM; Feuerstein R., 1979, DYNAMIC ASSESSMENT R; Grigorenko EL, 1998, PSYCHOL BULL, V124, P75, DOI 10.1037/0033-2909.124.1.75; Guthke J, 2000, ADV COGN ED, V6, P17; Henderson S. E., 1992, MOVEMENT ASSESSMENT; HUNG SS, 1987, AM J OCCUP THER, V41, P790, DOI 10.5014/ajot.41.12.790; Itzkovich M., 2000, LOEWENSTEIN OCCUPATI; Itzkovich M, 1996, GERIATRIC VERSION LO; KATZ N, 1989, AM J OCCUP THER, V43, P184, DOI 10.5014/ajot.43.3.184; Katz N, 2000, OCCUP THER J RES, V20, P3, DOI 10.1177/153944920002000101; KATZ N, 2003, DYN OCC THER COGN AS; Katz N, 2005, DYNAMIC OCCUPATIONAL; KATZ N, 2002, OCCUPATIONAL THERAPY, V22, P1; KIPKE MD, 1998, FOR NAT AC SCI NAT R; LAW M, 2001, MEASURING OCCUPATION, P287; LEZAK MD, 1995, EUROPSYCHOLOGICAL AS; Lidz CS, 2000, ADV COGN ED, V6, P3; Long C. J., 1996, ECOLOGICAL VALIDITY; MISSIUNA C, 2004, PRCEIVED EFFICACY GO; MOZLIN R, 1995, J BEHAV OPTOMETRY, V6, P115; Parush S., 2000, OCCUPATIONAL THERAPY, V7, P216, DOI [10.1002/oti.124, DOI 10.1002/OTI.124]; Rosenblum S, 2000, PERCEPT MOTOR SKILL, V90, P587, DOI 10.2466/PMS.90.2.587-594; Roth Thomas, 2003, Clin Cornerstone, V5, P5, DOI 10.1016/S1098-3597(03)90031-7; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Solan H A, 1987, J Am Optom Assoc, V58, P88; Solan H A, 1986, J Am Optom Assoc, V57, P28; Toglia J. P., 2005, COGNITION OCCUPATION, P29; Toglia JP, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P5; TOGLIA JP, 1994, DYNAMIC ASSESSMENT C; Vygotsky L. S., 1978, MIND SOC DEV HIGHER; Williams Jane, 2004, J Child Health Care, V8, P34, DOI 10.1177/1367493504041852; YU P, 2004, USE DYNAMIC OCUPATIO; ZIVIANI J., 2004, NZ J OCCUPATIONAL TH, V51, P17	47	20	21	0	9	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	JAN-FEB	2007	61	1					41	52		10.5014/ajot.61.1.41			12	Rehabilitation	Rehabilitation	130EM	WOS:000243782300005	17302104				2021-06-18	
J	Kuruvilla, M; Murdoch, B; Goozee, J				Kuruvilla, Mili; Murdoch, Bruce; Goozee, Justine			Electromagnetic articulography assessment of articulatory function in adults with dysarthria following traumatic brain injury	BRAIN INJURY			English	Article						EMA assessment; severe TBI; mild TBI; dysarthria; articulation	CLOSED-HEAD-INJURY; KINEMATIC ANALYSIS; SPEECH; TASK; SPEAKERS	Primary objective: To explore articulatory kinematic differences between normal and dysarthric speakers post-traumatic brain injury (TBI) during syllable and sentence productions. Research design: A comparison between the control, mild (MTBI) and severe TBI groups for all measured kinematic parameters was carried out using the Kruskal Wallis test. Methods and procedures: Ten participants with a severe TBI and six post-MTBI formed the experimental group. The control group consisted of 14 age and sex matched non- neurologically impaired speakers. Articulatory kinematic profiles for the three groups were obtained using the Electromagnetic Articulograph (EMA) while repeating sentence and syllable embedded /t/ and /k/ productions at a habitual rate and loudness level. Main outcomes and results: Significant differences between the severe TBI and control group were identified only for the release phase of the /t/ sentence productions wherein an increase in mean maximum acceleration was observed for the severe TBI group. Conclusions: While a simple syllable repetition task at a moderate rate was unable to differentiate the three groups, a complex sentence production task precipitated an increase in mean maximum acceleration which may be indicative of increased articulatory effort and impaired speech motor control even at a convenient rate for the severe group.	Univ Queensland, Motor Speech Res Unit, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Div Speech Pathol, Brisbane, Qld 4072, Australia	Kuruvilla, M (corresponding author), Univ Queensland, Motor Speech Res Unit, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.	m.kuruvilla@shrs.uq.edu.au	Murdoch, Bruce E/C-1397-2012	Kuruvilla-Dugdale, Mili/0000-0001-7900-2364			Darley F., 1975, MOTOR SPEECH DISORDE; Goozee JV, 2000, BRAIN INJURY, V14, P153, DOI 10.1080/026990500120817; HARDCASTLE WJ, 1985, BRIT J DISORD COMMUN, V20, P249; Jaeger M, 2000, FOLIA PHONIATR LOGO, V52, P187, DOI 10.1159/000021533; Kent RD, 2000, FOLIA PHONIATR LOGO, V52, P48, DOI 10.1159/000021512; KENT RD, 1975, J SPEECH HEAR DISORD, V40, P467, DOI 10.1044/jshd.4004.467; KLATT DH, 1972, J ACOUST SOC AM, V51, P101, DOI 10.1121/1.1981241; Kuehn D. P., 1976, J PHONETICS, V4, P303; Murdoch B. E., 1987, AUSTR J HUMAN COMMUN, V15, P15; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Shaiman S, 2002, EXP BRAIN RES, V146, P411, DOI 10.1007/s00221-002-1195-5; Tasko SM, 2004, J SPEECH LANG HEAR R, V47, P85, DOI 10.1044/1092-4388(2004/008); THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; WEISMER G, 1991, DYSARTHRIA APRAXIA S; ZIEGLER W, 1993, J SPEECH HEAR RES, V36, P683, DOI 10.1044/jshr.3604.683; Ziegler W, 2002, BRAIN LANG, V80, P556, DOI 10.1006/brln.2001.2614; ZYSKI BJ, 1987, J COMMUN DISORD, V20, P367, DOI 10.1016/0021-9924(87)90025-6	18	20	23	0	11	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	6					601	613		10.1080/02699050701427525			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	192LU	WOS:000248204100007	17577711				2021-06-18	
J	Scherer, M				Scherer, Matthew			Gait rehabilitation with body weight-supported treadmill training for a blast injury survivor with traumatic brain injury	BRAIN INJURY			English	Article						blast injury; traumatic brain injury; gait training; body weight-supported treadmill training	NONAMBULATORY HEMIPARETIC PATIENTS; WALK TEST; AMBULATION; RECOVERY; STROKE; LOCOMOTION; THERAPY; SPEED	Background and purpose: Research supports the use of body weight-supported treadmill training (BWSTT) in patients with hemi-paresis and may show promise as a gait training and neuromuscular re-education intervention in the blast-injured, traumatic brain injury (TBI) population. The purpose of this case study is to document the use BWSTT and goal-directed therapy in the improvement of gait quality, gait speed and maximum distance ambulated in a blast injury survivor with TBI. Case description: A 36-year-old male soldier injured by a rocket propelled grenade in Iraq who began physical therapy and gait training incorporating purposeful postural stability and mobility interventions as well as BWSTT. Outcomes: Missouri Assisted Gait scores, six-minute walk distances, and maximum distance ambulated all increased post gait training with BWSTT as a component to PT intervention. Discussion: Intensive gait training including BWSTT may have some efficacy in managing significant blast trauma patients with TBI however, further research is necessary to establish efficacy and appropriateness in this patient population.	Walter Reed Army Med Ctr, Washington, DC 20039 USA	Scherer, M (corresponding author), Walter Reed Army Med Ctr, 6900 Georgia Ave, Washington, DC 20039 USA.	matthew.scherer@us.army.mil					AMIR H, 1999, J HEAD TRAUMA REHAB, V14, P146; BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Brown TH, 2005, J HEAD TRAUMA REHAB, V20, P402, DOI 10.1097/00001199-200509000-00002; Grillner S, 1979, Prog Brain Res, V50, P227; Harada ND, 1999, ARCH PHYS MED REHAB, V80, P837, DOI 10.1016/S0003-9993(99)90236-8; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; HESSE S, 1994, ARCH PHYS MED REHAB, V75, P1087, DOI 10.1016/0003-9993(94)90083-3; KATZ D, 1997, TRAUMATIC BRAIN INJU, pCH4; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Laufer Y, 2001, J REHABIL RES DEV, V38, P69; Moseley AM, 2004, J HEAD TRAUMA REHAB, V19, P341, DOI 10.1097/00001199-200407000-00008; MOSELEY AM, 2005, COCHRANE DATABASE SY, V1; Mossberg KA, 2003, AM J PHYS MED REHAB, V82, P385, DOI 10.1097/01.PHM.0000052589.96202.BE; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; Platz T, 1999, RESTOR NEUROL NEUROS, V14, P161; Sullivan KJ, 2002, ARCH PHYS MED REHAB, V83, P683, DOI 10.1053/apmr.2002.32488; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; WERNIG A, 1995, EUR J NEUROSCI, V7, P823, DOI 10.1111/j.1460-9568.1995.tb00686.x; WERNIG A, 1991, PLASTICITY MOTORNEUR, pCH49; Wilson DJ, 2006, AM J PHYS MED REHAB, V85, P68, DOI 10.1097/01.phm.0000193507.28759.37; Wilson DJ, 2002, BRAIN INJURY, V16, P259, DOI 10.1080/02699050110103922	22	20	21	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2007	21	1					93	100		10.1080/02699050601149104			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	141FQ	WOS:000244564600011	17364524				2021-06-18	
J	Yang, L; Benardo, LS; Valsamis, H; Ling, DSF				Yang, Lie; Benardo, Larry S.; Valsamis, Helen; Ling, Douglas S. F.			Acute injury to superficial cortex leads to a decrease in synaptic inhibition and increase in excitation in neocortical layer V pyramidal cells	JOURNAL OF NEUROPHYSIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; STATUS EPILEPTICUS MODELS; DEPENDENT PROTEIN-KINASE; NEUROTROPHIN EXPRESSION; POSTTRAUMATIC SEIZURES; RAT NEOCORTEX; AMINO-ACIDS; HEAD-INJURY; IN-VITRO; HIPPOCAMPAL-NEURONS	Injury to the superficial layers of cerebral cortex produces alterations in the synaptic responses of local circuits that promote the development of seizures. To further delineate the specific changes in synaptic strength that are induced by this type of cortical injury, whole cell voltage-clamp recordings were used to examine evoked and spontaneous synaptic events from layer V pyramidal cells in coronal slices prepared from surgically traumatized rat neocortices in which the superficial third of the cortex (layers I, II, and part of III) was removed. Slices from intact neocortices were used as controls. Examinations of fast inhibitory postsynaptic currents (IPSCs) indicated that traumatized slices were disinhibited, exhibiting evoked IPSCs (eIPSCs) with lower peak amplitudes. Measurements of spontaneous IPSCs (sIPSCs) revealed no difference in the mean amplitudes of sIPSCs recorded in traumatized versus control slices. However, the mean sIPSC frequency was lower in traumatized slices, indicative of a decrease in GABA release at these inhibitory synapses. Traumatized slices also displayed an increase in synaptic excitation, exhibiting spontaneous EPSCs (sESPCs) with larger peak amplitudes and higher frequencies. Peak-scaled nonstationary fluctuation analysis of sEPSCs and sIPSCs was used to obtain estimates of the unit conductance and number of functional receptor channels. EPSC and IPSC channel numbers and IPSC unit conductance did not differ between traumatized and intact slices. However, the mean unit conductance of EPSCs was higher (+ 25%) in traumatized slices. These findings suggest that acute injury to the superficial neocortical layers results in a disinhibition of cortical circuits that stems from a decline in GABA release likely due to the loss of superficial inhibitory interneurons and an enhancement of synaptic excitation consequent to an increase in the AMPA receptor unit conductance.	Suny Downstate Med Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Brooklyn, NY 11203 USA	Yang, L (corresponding author), Suny Downstate Med Ctr, Dept Physiol & Pharmacol, 450 Clarkson Ave,Box 29, Brooklyn, NY 11203 USA.	lie.yang@downstate.edu			NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH051677, R29MH051677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038132] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 51677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38132] Funding Source: Medline		Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Benardo LS, 1997, J NEUROPHYSIOL, V77, P3134; Benke TA, 1998, NATURE, V393, P793; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149; CHEN QX, 1990, J PHYSIOL-LONDON, V420, P207, DOI 10.1113/jphysiol.1990.sp017908; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Chu ZG, 2003, J NEUROSCI, V23, P96; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Connors B. W., 1993, EPILEPSY MODELS MECH, P388; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318; Douglas R, 1990, SYNAPTIC ORG BRAIN, P389; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; GALL CM, 1992, TRENDS PHARMACOL SCI, V13, P401, DOI 10.1016/0165-6147(92)90123-N; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; JONES EG, 1993, CEREB CORTEX, V3, P361, DOI 10.1093/cercor/3.5.361-a; Lauterborn JC, 2000, J NEUROSCI, V20, P8, DOI 10.1523/JNEUROSCI.20-01-00008.2000; Li HF, 2005, J NEUROPHYSIOL, V93, P146, DOI 10.1152/jn.00665.2004; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Ling DSF, 2006, HIPPOCAMPUS, V16, P443, DOI 10.1002/hipo.20171; Ling DSF, 2005, CEREB CORTEX, V15, P921, DOI 10.1093/cercor/bhh191; Ling DSF, 2002, NAT NEUROSCI, V5, P295, DOI 10.1038/nn829; LING DSF, 1994, NEUROSCIENCE, V63, P937, DOI 10.1016/0306-4522(94)90561-4; Ling DSF, 1999, J NEUROPHYSIOL, V82, P1793; Ling DSF, 1998, SYNAPSE, V28, P91, DOI 10.1002/(SICI)1098-2396(199801)28:1<91::AID-SYN11>3.0.CO;2-0; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; Lowenstein D H, 1996, Epilepsy Res Suppl, V11, P45; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Moyer JR, 1998, J NEUROSCI METH, V86, P35, DOI 10.1016/S0165-0270(98)00143-5; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; OTIS TS, 1991, BRAIN RES, V545, P142, DOI 10.1016/0006-8993(91)91280-E; POLVISHOCK JT, 2005, J HEAD TRAUMA REHAB, V20, P76; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; RAMAMURTHI B, 1980, SURG NEUROL, V14, P415; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Salin PA, 1996, J NEUROPHYSIOL, V75, P1589; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Thomson AM, 2003, CEREB CORTEX, V13, P5, DOI 10.1093/cercor/13.1.5; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; TRAYNELIS SF, 1993, NEURON, V11, P279, DOI 10.1016/0896-6273(93)90184-S; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WILLMORE LJ, 1990, EPILEPSIA, V31, P67; Yang L, 2002, NEUROSCIENCE, V111, P303, DOI 10.1016/S0306-4522(01)00622-4; Yang L, 1997, J NEUROPHYSIOL, V78, P2804; Yang L, 1998, NEUROSCI LETT, V257, P33, DOI 10.1016/S0304-3940(98)00798-8; Yang L, 2000, EPILEPSIA, V41, P1507; YANG L, 2004, SOC NEUR ABSTR, V970, P13	67	20	22	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	JAN	2007	97	1					178	187		10.1152/jn.01374.2005			10	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	126RO	WOS:000243532900018	16987927				2021-06-18	
J	Eisele, JA; Kegler, SR; Trent, RB; Coronado, VG				Eisele, Julie A.; Kegler, Scott R.; Trent, Roger B.; Coronado, Victor G.			Nonfatal traumatic brain injury-related hospitalization in very young children - 15 states, 1999	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						injury surveillance; pediatric injury; traumatic brain injury		Objective: To document age-related patterns of nonfatal hospitalization associated with traumatic brain injury (TBI) among children younger than 2 years of age, by intent/cause and diagnosis. Methods: Data describing 2536 nonfatal TBI-related hospitalizations in 15 states for the year 1999 were obtained from the Centers for Disease Control and Prevention Central Nervous System Injury surveillance system for children younger than 2 years of age (0-23 months) at the time of injury. Main Outcome Measures: Incidence rates (overall, by intent/cause, and by diagnosis) were calculated by combining TBI surveillance data with population data from the US Census Bureau and the National Center for Health Statistics. Results: Overall rates of nonfatal TBI-related hospitalization peaked at I month of age (178.0 cases per 100,000 person-years) followed by a secondary peak at 8 months of age (127.9 cases per 100,000 person-years). Rates for fall-related (unintentional) cases and assault-related cases were significantly higher for infants (0-11 months) than for 1-year-olds (12-23 months), with rates for both types of cases peaking in the earliest months of life. Rates for cases with diagnoses of skull fracture and/or intracranial injury were also significantly higher for the younger group. Assault-related cases frequently coincided with a diagnosis of intracranial injury regardless of age. Conclusions: Prevention efforts should focus on falls and assaults, which account for the majority of TBI-related hospitalizations in early childhood. Such efforts may also need to emphasize the unusually high risk during the first few months of life.	Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Calif Dept Hlth Serv, Epidemiol & Prevent Injury Control Branch, Sacramento, CA USA; Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA USA	Kegler, SR (corresponding author), Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,Mailstop K-59, Atlanta, GA 30341 USA.	skegler@cdc.gov					Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; *AM MED ASS, 1997, INT CLASS DIS 9 REV; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; BRILLINGER DR, 1986, BIOMETRICS, V42, P693, DOI 10.2307/2530689; *CDCP, REC FRAM E COD GROUP; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; *NAT CTR HLTH STAT, 1999, NAT VIT STAT REP, V49; *NAT CTR HLTH STAT, 1999, NAT VIT STAT REP, V50; *NAT CTR HLTH STAT, 2001, LIV BIRTHS STAT RES; *NAT CTR HLTH STAT, 1999, INF GEN FIL GMWK264B; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; *SAS I INC, 1999, SAS PROC GUID VERS 8; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US CENS BUR, 1999, POP EST US STAT SING; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005	18	20	22	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					537	543		10.1097/00001199-200611000-00008			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400008	17122684				2021-06-18	
J	Jhanjee, R; van Dijk, JG; Sakaguchi, S; Benditt, DG				Jhanjee, Rajat; van Dijk, J. Gert; Sakaguchi, Scott; Benditt, David G.			Syncope in adults: Terminology, classification, and diagnostic strategy	PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY			English	Article						syncope; unconsciousness; transient loss of consciousness	AMERICAN-HEART-ASSOCIATION; MANAGEMENT; GUIDELINES; HISTORY; RECOMMENDATIONS; STATEMENT; CRITERIA; COLLEGE; SOCIETY	Syncope is a relatively common clinical syndrome that is a subset of a broader range of conditions that cause transient loss of consciousness (TLOC). Other TLOC conditions include seizures, concussions, and intoxications. However, despite frequent confusion in the medical literature, syncope is and should be clearly distinguished from those other causes of TLOC by virtue of its pathophysiology; specifically, syncope is the result of self-terminating inadequacy of global cerebral nutrient perfusion, while the other forms of TLOC have different etiologies. Unfortunately, the diagnostic evaluation of syncope remains for the most part poorly managed and inefficient. Careful history-taking, physical examination, and judicious use of tests can not only increase the diagnostic yield of the evaluation, but also increase patient safety and reduced overall healthcare costs.	Univ Minnesota, Sch Med, Dept Med, Cardiovasc Div,Cardiac Arrhythmia Ctr, Minneapolis, MN 55455 USA; Leiden Univ, Med Ctr, Dept Neurol & Clin Neurophysiol, Leiden, Netherlands	Benditt, DG (corresponding author), Mail Code 508,420 Delaware St SE, Minneapolis, MN 55455 USA.	bendi001@umn.edu					Alboni P, 2001, J AM COLL CARDIOL, V37, P1921, DOI 10.1016/S0735-1097(01)01241-4; Barton GM, 2004, NAT IMMUNOL, V5, P472, DOI 10.1038/ni0504-472; Benditt DG, 2005, CARDIAC ARRHYTHMIAS 2005, P655; Benditt DG, 2006, EUR HEART J, V27, P7, DOI 10.1093/eurheartj/ehi626; Benditt DG, 2003, J AM COLL CARDIOL, V41, P791, DOI 10.1016/S0735-1097(02)02928-5; Blanc JJ, 2002, EUR HEART J, V23, P815, DOI 10.1053/euhj.2001.2975; Brignole M, 2004, EUROPACE, V6, P467, DOI 10.1016/j.eupc.2004.08.008; Brignole M, 2006, EUR HEART J, V27, P76, DOI 10.1093/eurheartj/ehi647; Brignole M, 2003, EUROPACE, V5, P425, DOI 10.1016/S1099-5129(03)00088-6; Brignole M, 2003, EUROPACE, V5, P293, DOI 10.1016/S1099-5129(03)00047-3; BRIGNOLE M, 1995, AM J CARDIOL, V76, P273, DOI 10.1016/S0002-9149(99)80080-0; CALKINS H, 1995, AM J MED, V98, P365, DOI 10.1016/S0002-9343(99)80315-5; Chen-Scarabelli C, 2004, BMJ-BRIT MED J, V329, P336, DOI 10.1136/bmj.329.7461.336; Crawford MH, 1999, CIRCULATION, V100, P886, DOI 10.1161/01.CIR.100.8.886; Epstein AE, 1996, CIRCULATION, V94, P1147, DOI 10.1161/01.CIR.94.5.1147; Ermis C, 2003, AM J CARDIOL, V92, P815, DOI 10.1016/S0002-9149(03)00889-0; Fitzpatrick AP, 2003, EVALUATION AND TREATMENT OF SYNCOPE: A HANDBOOK FOR CLINICAL PRACTICE, P63; Flecher E., 2005, Annales de Cardiologie et d'Angeiologie, V54, P141, DOI 10.1016/j.ancard.2005.04.007; Joshi AK, 2005, AM J CARDIOL, V95, P878, DOI 10.1016/j.amjcard.2004.12.015; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; Kenny RA, 2002, AGE AGEING, V31, P272, DOI 10.1093/ageing/31.4.272; Krahn AD, 1999, CIRCULATION, V99, P406, DOI 10.1161/01.CIR.99.3.406; Krahn AD, 2003, J AM COLL CARDIOL, V42, P495, DOI 10.1016/S0735-1097(03)00659-4; Krahn AD, 2001, CIRCULATION, V104, P46, DOI 10.1161/01.CIR.104.1.46; Linzer M, 1997, ANN INTERN MED, V126, P989, DOI 10.7326/0003-4819-126-12-199706150-00012; Lu F, 2003, EVALUATION AND TREATMENT OF SYNCOPE: A HANDBOOK FOR CLINICAL PRACTICE, P80; Moya A, 2001, CIRCULATION, V104, P1261, DOI 10.1161/hc3601.095708; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; ROSS D, 2003, CAN CARD SOC CONS C; Sheldon R, 2006, EUR HEART J, V27, P344, DOI 10.1093/eurheartj/ehi584; Sheldon R, 2002, J AM COLL CARDIOL, V40, P142, DOI 10.1016/S0735-1097(02)01940-X; Shen WK, 2004, CIRCULATION, V110, P3636, DOI 10.1161/01.CIR.0000149236.92822.07; Soteriades ES, 2002, NEW ENGL J MED, V347, P878, DOI 10.1056/NEJMoa012407; SRA JS, 1991, ANN INTERN MED, V114, P1013, DOI 10.7326/0003-4819-114-12-1013; Strickberger SA, 2006, CIRCULATION, V113, P316, DOI 10.1161/CIRCULATIONAHA.105.170274; Sutton R, 2003, EVALUATION AND TREATMENT OF SYNCOPE: A HANDBOOK FOR CLINICAL PRACTICE, P31; Thijs RD, 2004, CLIN AUTON RES, V14, P4, DOI 10.1007/s10286-004-1002-4; van Dijk JG, 2003, EVALUATION AND TREATMENT OF SYNCOPE: A HANDBOOK FOR CLINICAL PRACTICE, P184; van Dijk JG, 2003, EVALUATION AND TREATMENT OF SYNCOPE: A HANDBOOK FOR CLINICAL PRACTICE, P102	39	20	21	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0147-8389	1540-8159		PACE	PACE-Pacing Clin. Electrophysiol.	OCT	2006	29	10					1160	1169		10.1111/j.1540-8159.2006.00508.x			10	Cardiac & Cardiovascular Systems; Engineering, Biomedical	Cardiovascular System & Cardiology; Engineering	104XY	WOS:000241995100015	17038147				2021-06-18	
J	Alessandri, B; Nishioka, T; Heimann, A; Bullock, RM; Kempski, O				Alessandri, B.; Nishioka, T.; Heimann, A.; Bullock, R. M.; Kempski, O.			Caspase-dependent cell death involved in brain damage after acute subdural hematoma in rats	BRAIN RESEARCH			English	Article						subdural hemorrhage; caspase inhibitor; apoptotic cell death; neuroprotection; brain	CEREBRAL-BLOOD-FLOW; FREE-RADICAL PRODUCTION; INTRACEREBRAL HEMORRHAGE; INDUCED APOPTOSIS; TEMPORAL PROFILE; ARTERY OCCLUSION; NEURONAL DEATH; HEAD-INJURY; ISCHEMIA; INFLAMMATION	Traumatic brain injury is associated with acute subdural hematoma (ASDH) that worsens outcome. Although early removal of blood can reduce mortality, patients still die or remain disabled after surgery and additional treatments are needed. The blood mass and extravasated blood induce pathomechanisms such as high intracranial pressure (ICP), ischemia, apoptosis and inflammation which lead to acute as well as delayed cell death. Only little is known about the basis of delayed cell death in this type of injury. Thus, the purpose of the study was to investigate to which extent caspase-dependent intracellular processes are involved in the lesion development after ASDH in rats. A volume of 300 mu L blood was infused into the subdural space under monitoring of ICP and tissue oxygen concentration. To asses delayed cell death mechanisms, DNA fragmentation was measured 1, 2, 4 and 7 days after ASDH by TUNEL staining, and the effect of the pan-caspase inhibitor zVADfmk on lesion volume was assessed 7 days post-ASDH. A peak of TUNEL-positive cells was found in the injured cortex at day 2 after blood infusion (53.4 +/- 11.6 cells/mm(2)). zVADfmk (160ng), applied by intracerebroventricular injection before ASDH, reduced lesion volume significantly by more than 50% (vehicle: 23.79 +/- 7.62mm(3); zVADfmk: 9.06 +/- 4.08). The data show for the first time that apoptotic processes are evident following ASDH and that caspase-dependent mechanisms play a crucial role in the lesion development caused by the blood effect on brain tissue. (c) 2006 Elsevier B.V. All rights reserved.	Univ Mainz, Inst Neurosurg Pathophysiol, D-55131 Mainz, Germany; Nara Med Univ, Dept Neurosurg, Kashihara, Nara 6348521, Japan; Virginia Commonwealth Univ, Coll Med, Dept Neurosurg, Richmond, VA USA	Alessandri, B (corresponding author), Univ Mainz, Inst Neurosurg Pathophysiol, Langenbeckstr 1, D-55131 Mainz, Germany.	beat.alessandri@uni-mainz.de		Heimann, Axel/0000-0003-2510-3228			Alessandri B, 1999, ACT NEUR S, V75, P21; Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Chen J, 1998, J NEUROSCI, V18, P4914; Chiari P, 2000, J HEART LUNG TRANSPL, V19, P675, DOI 10.1016/S1053-2498(00)00127-3; Conti AC, 1998, J NEUROSCI, V18, P5663; Didenko VV, 2002, MOL MED, V8, P347, DOI 10.1007/BF03402015; Eijkenboom M, 1999, NEUROSCIENCE, V94, P373, DOI 10.1016/S0306-4522(99)00332-2; Eijkenboom M, 2000, NEUROPHARMACOLOGY, V39, P817, DOI 10.1016/S0028-3908(00)00002-2; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Gong C, 2001, NEUROSURGERY, V48, P875, DOI 10.1097/00006123-200104000-00037; Hengartner MO, 2001, NATURE, V412, P27, DOI 10.1038/35083663; INGLIS FM, 1990, ACT NEUR S, V51, P277; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KURODA Y, 1992, NEUROSURGERY, V30, P687; Kwon TH, 2003, J NEUROTRAUM, V20, P337, DOI 10.1089/089771503765172291; LINNIK MD, 1995, MOL BRAIN RES, V32, P116, DOI 10.1016/0169-328X(95)00069-5; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Matsushita K, 2000, J CEREBR BLOOD F MET, V20, P396, DOI 10.1097/00004647-200002000-00022; Mauler F, 2004, EUR J NEUROSCI, V20, P1761, DOI 10.1111/j.1460-9568.2004.03615.x; Mayne M, 2001, STROKE, V32, P240, DOI 10.1161/01.STR.32.1.240; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Namura S, 1998, J NEUROSCI, V18, P3659; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Patel TR, 1999, J NEUROTRAUM, V16, P1049, DOI 10.1089/neu.1999.16.1049; Patel TR, 1999, BRAIN RES, V829, P125, DOI 10.1016/S0006-8993(99)01378-5; Peeling J, 2001, EXP NEUROL, V167, P341, DOI 10.1006/exnr.2000.7564; Qureshi AI, 2001, CRIT CARE MED, V29, P152, DOI 10.1097/00003246-200101000-00030; RINK A, 1995, AM J PATHOL, V147, P1575; Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100; Sasaki C, 2000, NEUROL RES, V22, P223, DOI 10.1080/01616412.2000.11741065; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Soehle M, 2001, J NEUROSCI METH, V110, P91, DOI 10.1016/S0165-0270(01)00422-8; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tenneti L, 2000, J NEUROCHEM, V74, P134, DOI 10.1046/j.1471-4159.2000.0740134.x; Tsuchida E, 1999, J NEUROTRAUM, V16, P595, DOI 10.1089/neu.1999.16.595; Xue MZ, 2000, STROKE, V31, P1721, DOI 10.1161/01.STR.31.7.1721; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	48	20	24	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	SEP 21	2006	1111						196	202		10.1016/j.brainres.2006.06.105			7	Neurosciences	Neurosciences & Neurology	089TY	WOS:000240905200024	16890922				2021-06-18	
J	Toczylowska, B; Chalimoniuk, M; Wodowska, M; Mayzner-Zawadzka, E				Toczylowska, Beata; Chalimoniuk, Malgorzata; Wodowska, Magdalena; Mayzner-Zawadzka, Ewa			Changes in concentration of cerebrospinal fluid components in patients with traumatic brain injury	BRAIN RESEARCH			English	Article						cerebrospinal fluid; brain trauma; nitric oxide; amino acid; proton NMR spectroscopy	MAGNETIC-RESONANCE SPECTROSCOPY; AMINO-ACIDS; GLUTAMATE; ISCHEMIA; EXCITOTOXICITY; DEGENERATION; BLOCKERS; GENDER; IMPACT; DAMAGE	Brain injury, like other central nervous system pathologies, causes changes in the composition of the cerebrospinal fluid (CSF). In this study, changes in the concentration of small molecules of the CSF, which are in the minimal micromolar concentration, were observed and monitored using high-resolution proton (NMR) spectroscopy. Twenty-two patients with isolated traumatic brain injuries (TBI) and 15 patients making up the control group were recruited for the study. CSF samples were collected by lumbar puncture from the lumbar subarachnoid space in the patients just before commencement of therapy and on the first, third, seventh and fourteenth days of therapy at the ICU. Forty-four signals of the NMR spectra and NO concentration of the CSF samples were analyzed. The analysis shows that the amino acid and organic acid concentrations change during the therapy and mostly are higher than in the control group. Significant differences in concentration of the analyzed CSF components between the TBI patients and the control group have been noted. The rate of the lactate to pyruvate conversion increased because the L/P ratio showed no significant differences between the TBI group and the control group, while the concentrations of both components were significantly higher in the TBI patients than in the control group. Citrulline, arginine and nitric oxide concentrations were the focus of the analysis. Citrulline concentration changes overlapped NO changes from 0 until 3rd day of therapy, while for the remaining days of observation the NO concentration stabilized at the control level, whereas citrulline concentration significantly decreased. (c) 2006 Elsevier B.V. All rights reserved.	Polish Acad Sci, Inst Biochem & Biophys, PL-02109 Warsaw, Poland; Polish Acad Sci, Inst Biocybernet & Biomed Engn, PL-02109 Warsaw, Poland; Polish Acad Sci, Med Res Ctr, Dept Cellular Signaling, PL-02109 Warsaw, Poland; Med Univ Warsaw, Dept Anaesthesia & Intens Therapy, PL-02005 Warsaw, Poland	Toczylowska, B (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, 5A Pawinskiego St, PL-02109 Warsaw, Poland.	beatat@ibib.waw.pl	; Chalimoniuk, Malgorzata/Y-4440-2018	Toczylowska, Beata/0000-0002-5031-6228; Chalimoniuk, Malgorzata/0000-0003-0361-8626			Aquilani R, 2003, ARCH PHYS MED REHAB, V84, P1258, DOI 10.1016/S0003-9993(03)00148-5; BARKER PB, 2001, FUNDAMENTALS CLIN MR, P168; Baumgartner WA, 1997, J CARDIAC SURG, V12, P300; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Calzada JI, 2002, NEUROCHEM RES, V27, P79, DOI 10.1023/A:1014854606309; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; Kalloniatis M, 1995, J Am Optom Assoc, V66, P750; Li W, 1999, J INTERF CYTOK RES, V19, P121, DOI 10.1089/107999099314261; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Martin RL, 1997, J CLIN NEUROSCI, V4, P290, DOI 10.1016/S0967-5868(97)90096-5; Mascalchi M, 1998, ANN NEUROL, V43, P244, DOI 10.1002/ana.410430215; McAdoo DJ, 2005, BRAIN RES, V1038, P92, DOI 10.1016/j.brainres.2005.01.024; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; ROSENBERG GA, 1980, AM J PHYSIOL, V238, pF42; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; SADASIVUDU B, 1976, J NEUROCHEM, V27, P785, DOI 10.1111/j.1471-4159.1976.tb10409.x; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; SHUAIB A, 1994, BRAIN RES, V666, P99, DOI 10.1016/0006-8993(94)90287-9; Silberstein M, 2002, AM J NEURORADIOL, V23, P389; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; Takahashi T, 1997, Nihon Shinkei Seishin Yakurigaku Zasshi, V17, P7; Tedeschi G, 1997, BRAIN, V120, P1541, DOI 10.1093/brain/120.9.1541; Vannucci RC, 1999, DEV BRAIN RES, V118, P147, DOI 10.1016/S0165-3806(99)00142-X; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; WEVERS RA, 1995, CLIN CHEM, V41, P744; WILLIAMS S, 2001, ISMRM EMSRMB JOINT A, P329; Yang CL, 2001, J PSYCHOLINGUIST RES, V30, P21, DOI 10.1023/A:1005252123299; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266	32	20	21	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 9	2006	1104						183	189		10.1016/j.brainres.2006.05.057			7	Neurosciences	Neurosciences & Neurology	082XR	WOS:000240421000018	16793028				2021-06-18	
J	Geeraerts, T; Ract, C; Tardieu, M; Fourcade, O; Mazoit, JX; Benhamou, D; Duranteau, J; Vigue, B				Geeraerts, Thomas; Ract, Catherine; Tardieu, Marc; Fourcade, Olivier; Mazoit, Jean-Xavier; Benhamou, Dan; Duranteau, Jacques; Vigue, Bernard			Changes in cerebral energy metabolites induced by impact-acceleration brain trauma and hypoxic-hypotensive injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						brain metabolism; hypoxia-hypotension; microdialysis; rat; secondary insult; traumatic brain injury	LASER-DOPPLER FLOWMETRY; MITOCHONDRIAL DYSFUNCTION; HEAD-INJURY; BLOOD-FLOW; MICRODIALYSIS; MODEL; ACID; GLYCOLYSIS; DEPRESSION; SEVERITY	The aim of this study was to describe, in rats, brain energy metabolites changes after different levels of head trauma (T) complicated by hypoxia-hypotension (HH). Male Sprague Dawley rats (n = 7 per groups) were subjected to T by impact-acceleration with 450-g weight drop from 1.50 or 1.80 m (T 1.50 or T 1.80), or to a 15-min period of HH (controlled hemorrhage to mean arterial pressure [MAP] of 40 mm Hg, and mechanical ventilation with N-2 90%/O-2 10%), or to their association (T followed by HH). Invasive MAP, intraparenchymental intracranial pressure (ICP), and cerebral blood flow (CBF using Laser Doppler flowmetry) were recorded during the 5 post-traumatic hours. Cerebral microdialysis was used to measure each hour interstitial brain glucose, lactate, pyruvate, and glutamate. For the entire period, the levels of cerebral glucose, pyruvate, and glutamate were not statistically different between groups. In addition, there were no differences associated with the lactate-glucose ratio. Lactate was significantly higher overtime only in T 1.80 + HH group (p < 0.001 vs. every other groups). The lactate-pyruvate ratio increased with trauma level, and was significantly different vs. sham for the entire study period in T 1.50 + HH, in T 1.80, and in T 1.80 + HH. There was no correlation between CBF variations and the lactate-pyruvate ratio (r(2) = 0.00001). The cerebral perfusion pressure was greater than 70 mm Hg in all groups. The prolonged post-traumatic impairment in brain energy metabolism may be related to traumatic brain injury (TBI) severity. It became worse when T was complicated by HH, but was not related to changes in CBF.	Fac Med Paris Sud, INSERM, Lab Immunol Antivirale Syst & Cerebrale, EMI 0109, F-94276 Le Kremlin Bicetre, France; Fac Med Paris Sud, Lab UPRES 3540, F-94276 Le Kremlin Bicetre, France; Hop Bicetre, Dept Anesthesiol & Intens Care, F-94276 Le Kremlin Bicetre, France; AP HP, Paris, France	Geeraerts, T (corresponding author), Fac Med Paris Sud, INSERM, Lab Immunol Antivirale Syst & Cerebrale, EMI 0109, 63 Rue Gabriel Peri, F-94276 Le Kremlin Bicetre, France.	thgeeraerts@hotmail.com					ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Anderson CM, 2002, J NEUROSCI, V22, P9203; Beaumont A, 2002, ACT NEUR S, V81, P217; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Carre E, 2004, J NEUROSCI METH, V140, P23, DOI 10.1016/j.jneumeth.2004.04.037; CHANCE B, 1963, J BIOL CHEM, V238, P418; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FUKUDA O, 1995, NEUROSURGERY, V36, P358, DOI 10.1227/00006123-199502000-00016; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; Hillered L, 1999, ACT NEUR S, V75, P3; Holtzer S, 2001, CRIT CARE MED, V29, P1609, DOI 10.1097/00003246-200108000-00018; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jones DA, 2000, J NEUROCHEM, V75, P1703, DOI 10.1046/j.1471-4159.2000.0751703.x; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KINOSHITA Y, 1970, JPN J PHARMACOL, V20, P599, DOI 10.1254/jjp.20.599; Kristian T, 2004, CELL CALCIUM, V36, P221, DOI 10.1016/j.ceca.2004.02.016; KUHR WG, 1988, J CEREBR BLOOD F MET, V8, P130, DOI 10.1038/jcbfm.1988.17; MAGISTRETTI PJ, 2003, FUNDAMENTAL NEUROSCI, P339; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487	36	20	20	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2006	23	7					1059	1071		10.1089/neu.2006.23.1059			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	069UG	WOS:000239473200002	16866619				2021-06-18	
J	Lellouche, F; Qader, S; Taille, S; Lyazidi, A; Brochard, L				Lellouche, Francois; Qader, Siham; Taille, Solenne; Lyazidi, Aissam; Brochard, Laurent			Under-humidification and over-humidification during moderate induced hypothermia with usual devices	INTENSIVE CARE MEDICINE			English	Article; Proceedings Paper	17th Annual Congress of the European-Society-of-Intensive-Care-Medicine	OCT 10-13, 2004	Berlin, GERMANY	European Soc Intens Care Med		adverse effects; heated humidifiers; heat and moisture exchangers; humidification devices; hypothermia; mechanical ventilation	TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; MOISTURE EXCHANGERS; THERAPEUTIC HYPOTHERMIA; MECHANICAL VENTILATION; HEATED HUMIDIFIERS; CARDIAC-ARREST; INSPIRED GAS; TEMPERATURE; HUMIDITY	Objective: In mechanically ventilated patients with induced hypothermia, the efficacy of heat and moisture exchangers and heated humidifiers to adequately humidify the airway is poorly known. The aim of the study was to assess the efficacy of different humidification devices during moderate hypothermia. Design: Prospective, cross-over randomized study. Settings: Medical Intensive Care Unit in a University Hospital. Patients and participants: Nine adult patients hospitalized after cardiac arrest in whom moderate hypothermia was induced (33 degrees C for 24 h). Interventions: Patients were ventilated at admission (period designated "normothermia") with a heat and moisture exchanger, and were randomly ventilated during hypothermia with a heat and moisture exchanger, a heated humidifier, and an active heat and moisture exchanger. Measurements and results: Core temperature, inspired and expired gas absolute and relative humidity were measured. Each system demonstrated limitations in its ability to humidify gases in the specific situation of hypothermia. Performances of heat and moisture exchangers were closely correlated to core temperature (r(2) = 0.84). During hypothermia, heat and moisture exchangers led to major under-humidification, with absolute humidity below 25 mgH(2)O/l. The active heat and moisture exchanger slightly improved humidification. Heated humidifiers were mostly adequate but led to over-humidification in some patients, with inspiratory absolute humidity higher than maximal water content at 33 degrees C with a positive balance between inspiratory and expiratory water content. Conclusions: These results suggest that in the case of moderate hypothermia, heat and moisture exchangers should be used cautiously and that heated humidifiers may lead to over-humidification with the currently recommended settings.	Univ Paris 12, Hop Henri Mondor, APHP, Serv Reanimat Med,INSERM,U651, F-94010 Creteil, France	Brochard, L (corresponding author), Univ Paris 12, Hop Henri Mondor, APHP, Serv Reanimat Med,INSERM,U651, 51 Av Marechal de Lattre de Tassigny, F-94010 Creteil, France.	laurent.brochard@hmn.ap-hop-paris.fr	Lellouche, Francois/AAB-9014-2019				*AM ASS RESP CAR, 1992, RESP CARE, V37, P887; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Boots RJ, 1997, CRIT CARE MED, V25, P1707, DOI 10.1097/00003246-199710000-00021; BRANSON RD, 1993, CHEST, V104, P1800, DOI 10.1378/chest.104.6.1800; Campbell R S, 2000, Respir Care, V45, P306; CHALON J, 1979, CAN ANAESTH SOC J, V26, P361, DOI 10.1007/BF03006448; COHEN IL, 1988, CRIT CARE MED, V16, P277, DOI 10.1097/00003246-198803000-00013; DREYFUSS D, 1995, AM J RESP CRIT CARE, V151, P986; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jaber S, 2004, ANESTHESIOLOGY, V100, P782, DOI 10.1097/00000542-200404000-00006; Jiang JY, 2000, J NEUROSURG, V93, P718; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kimura A, 2002, CRIT CARE MED, V30, P1499, DOI 10.1097/00003246-200207000-00017; Lacherade JC, 2005, AM J RESP CRIT CARE, V172, P1276, DOI 10.1164/rccm.200408-1028OC; Lellouche F, 2004, AM J RESP CRIT CARE, V170, P1073, DOI 10.1164/rccm.200309-1245OC; Lellouche F, 2003, INTENS CARE MED, V29, pS169; LELLOUCHE L, 2003, AM J RESP CRIT CARE, V167, pA909; Maggiore SM, 2003, AM J RESP CRIT CARE, V167, P1215, DOI 10.1164/rccm.200203-195OC; MARTIN C, 1990, CHEST, V97, P144, DOI 10.1378/chest.97.1.144; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MIYAO H, 1992, CRIT CARE MED, V20, P674, DOI 10.1097/00003246-199205000-00021; NOGUCHI H, 1973, BRIT J ANAESTH, V45, P844, DOI 10.1093/bja/45.8.844; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; PETERSON BD, 1998, HUMIDIFICATION CURRE, P243; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2004, INTENS CARE MED, V30, P1860, DOI 10.1007/s00134-004-2383-5; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Rathgeber J, 2002, INTENS CARE MED, V28, P731, DOI 10.1007/s00134-002-1275-9; Ricard JD, 1999, CHEST, V115, P1646, DOI 10.1378/chest.115.6.1646; Ricard JD, 2000, AM J RESP CRIT CARE, V161, P104, DOI 10.1164/ajrccm.161.1.9902062; ROUSTAN JP, 1992, INTENS CARE MED, V18, P97, DOI 10.1007/BF01705040; SHELLY MP, 1988, INTENS CARE MED, V14, P1, DOI 10.1007/BF00254114; Sterz Fritz, 2003, Curr Opin Crit Care, V9, P205, DOI 10.1097/00075198-200306000-00006; Taille S, 2001, INTENS CARE MED, V27, pS211; Taniguchi T, 2003, CLIN DIAGN LAB IMMUN, V10, P940, DOI 10.1128/CDLI.10.5.940-943.2003; Thomachot L, 1998, CHEST, V114, P1383, DOI 10.1378/chest.114.5.1383; Thomachot L, 1999, CRIT CARE MED, V27, P923, DOI 10.1097/00003246-199905000-00026; Todd DA, 2001, J PAEDIATR CHILD H, V37, P489, DOI 10.1046/j.1440-1754.2001.00750.x; TODD TRJ, 1989, AM REV RESPIR DIS, V140, P1585, DOI 10.1164/ajrccm/140.6.1585; TSUDA T, 1977, BRIT J ANAESTH, V49, P965, DOI 10.1093/bja/49.10.965; WILKES AR, 1998, HUMIDIFICATION CURRE, P261; Williams R, 1996, CRIT CARE MED, V24, P1920, DOI 10.1097/00003246-199611000-00025; Williams R B, 1998, Respir Care Clin N Am, V4, P215; Wu XR, 2005, J TRAUMA, V59, P291, DOI 10.1097/01.ta.0000179445.76729.2c; 2005, HLTH DEVICES, V34, P46	48	20	23	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUL	2006	32	7					1014	1021		10.1007/s00134-006-0192-8			8	Critical Care Medicine	General & Internal Medicine	056CJ	WOS:000238498400010	16791663				2021-06-18	
J	Mangano, FT; Menendez, JA; Smyth, MD; Leonard, JR; Narayan, P; Park, TS				Mangano, Francesco T.; Menendez, Jose A.; Smyth, Matthew D.; Leonard, Jeffrey R.; Narayan, Prithvi; Park, Tae Sung			Pediatric neurosurgical injuries associated with all-terrain vehicle accidents: a 10-year experience at St. Louis Children's Hospital	JOURNAL OF NEUROSURGERY			English	Article						all-terrain vehicle; head trauma; spinal cord injury; pediatric neurosurgery	CRASHES; TRAUMA; MORTALITY; PATTERNS; HELMET; ATV	Object. All-terrain vehicles (ATVs) have been characterized as inherently unstable and are associated with significant pediatric injuries in the US. The authors performed a study to analyze data obtained in pediatric patients who had sustained neurological injuries in ATV-related accidents, identify potential risk factors, and propose preventive measures. The study is based on a 10-year experience at the St. Louis Children's Hospital. Methods. The authors retrospectively analyzed data obtained in all patients admitted to the St. Louis Children's Hospital between 1993 and 2003, limiting their focus to pediatric cases involving ATV-related accidents. A total of 185 patients were admitted with these criteria. Sixty-two patients (33.5%) suffered neurological injuries; there were 42 male and 20 female patients whose age ranged from 2 to 17 years. The most common injuries included skull fracture (37 cases) and closed head injury (30 cases). There were 39 cases of intracranial hemorrhage and 11 of spinal fracture. A total of 15 types of neurosurgical procedure were performed: six craniotomies for hematoma drainage, five craniotomies for elevation of depressed fractures, two procedures to allow placement of an intracranial pressure monitor, one to allow placement of an external ventricular drain, and one to allow the insertion of a ventriculoperitoneal shunt. Two patients had sustained spinal cord injury, and three procedures were performed for spinal decompression or stabilization. The duration of hospital stay ranged from I to 143 days (mean 6.6 days). Fifty-seven patients (30.8%) were eventually discharged from the hospital, three (1.6%) were transferred to another hospital, two (1.1%) died, and 123 (66.4%) required in-patient rehabilitation. Conclusions. Children suffered significant injuries due to ATV accidents. In passengers there was a statistically significant increased risk of neurological injury. The relative risk of neurological injury in patients not wearing helmets was higher than that in those who wore helmets, but the difference did not reach statistical significance. Further efforts must be made to improve the proper operation and safety of ATVs, both through the education of parents and children and through the creation of legislation requiring stricter laws concerning ATV use.	Washington Univ, St Louis Childrens Hosp, Dept Neurol Surg, St Louis, MO 63110 USA; Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Neurol Surg, Cincinnati, OH USA	Park, TS (corresponding author), Washington Univ, St Louis Childrens Hosp, Dept Neurol Surg, 1 Childrens Pl,Suite 4S20, St Louis, MO 63110 USA.	park@nsurg.wustl.edu	Mangano, Francesco/AAG-6184-2019				[Anonymous], 1987, Pediatrics, V79, P306; Baruchin Abraham M., 1995, Harefuah, V129, P246; Bercher D L, 2001, J Ark Med Soc, V97, P351; Bhutta ST, 2004, PEDIATR RADIOL, V34, P130, DOI 10.1007/s00247-003-1085-4; Brown RL, 2002, J PEDIATR SURG, V37, P375, DOI 10.1053/jpsu.2002.30826; Bull MJ, 2000, PEDIATRICS, V105, P1352, DOI 10.1542/peds.105.6.1352; Carr AM, 2004, NEUROSURGERY, V54, P861, DOI 10.1227/01.NEU.0000114922.46342.38; DEMAS PN, 1992, J ORAL MAXIL SURG, V50, P1280, DOI 10.1016/0278-2391(92)90227-Q; Edmonson BC, 2004, OPHTHAL PLAST RECONS, V20, P99, DOI 10.1097/01.IOP.0000116381.80520.4E; Gibbs L, 1997, J La State Med Soc, V149, P276; HARGARTEN SW, 1991, AM J EMERG MED, V9, P149, DOI 10.1016/0735-6757(91)90178-M; Keenan HT, 2004, PEDIATRICS, V113, pE330, DOI 10.1542/peds.113.4.e330; Lister DG, 1998, J PEDIATR SURG, V33, P1081, DOI 10.1016/S0022-3468(98)90535-8; Lynch JM, 1998, J PEDIATR SURG, V33, P329, DOI 10.1016/S0022-3468(98)90456-0; Mangus RS, 2004, INJURY PREV, V10, P56, DOI 10.1136/ip.2003.002626; MARGOLIS JL, 1988, J TRAUMA, V28, P395, DOI 10.1097/00005373-198803000-00017; Moroney P, 2003, INJURY, V34, P203, DOI 10.1016/S0020-1383(02)00317-0; Murphy N, 2004, J TRAUMA, V56, P1185, DOI 10.1097/01.TA.0000123038.94864.E2; POSTL BD, 1987, CAN MED ASSOC J, V137, P297; Rodgers GB, 1999, ACCIDENT ANAL PREV, V31, P409, DOI 10.1016/S0001-4575(98)00080-3; Rodgers GB, 2001, AM J EPIDEMIOL, V153, P1112, DOI 10.1093/aje/153.11.1112; RODGERS GB, 1993, ACCIDENT ANAL PREV, V25, P335, DOI 10.1016/0001-4575(93)90027-T; Russell A, 1998, PEDIATR EMERG CARE, V14, P31, DOI 10.1097/00006565-199802000-00009; STEVENS WS, 1986, J PEDIATR-US, V109, P25, DOI 10.1016/S0022-3476(86)80566-2; Stueland D, 1991, Wis Med J, V90, P275; STUELAND D, 1991, WIS MED J, V90, P441; TerKonda S, 1990, Mo Med, V87, P89; TRAGER GW, 1986, ANN EMERG MED, V15, P1293, DOI 10.1016/S0196-0644(86)80612-6; Upperman JS, 2003, J PEDIATR SURG, V38, P1284, DOI 10.1016/S0022-3468(03)00383-X	29	20	20	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	2006	105	1		S			2	5		10.3171/ped.2006.105.1.2			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	061EB	WOS:000238852900002	16871862				2021-06-18	
J	Connelly, J; Chell, S; Tennant, A; Rigby, AS; Airey, CM				Connelly, J.; Chell, S.; Tennant, A.; Rigby, A. S.; Airey, C. M.			Modelling 5-year functional outcome in a major traumatic injury survivor cohort	DISABILITY AND REHABILITATION			English	Article						five year outcome; disability; traumatic brain injury; major traumatic injury	BRAIN-INJURY; MULTIPLE INJURIES; FOLLOW-UP; REHABILITATION; PREDICTION; DISABILITIES; IMPAIRMENTS; PREVALENCE	Aim. To estimate associations between possible predictors of functional disability outcome at 5 years in a working adult population cohort of survivors of major traumatic injury and to develop a prognostic model of outcome. Design. Population based retrospective cohort study. Population. Persons who had experienced major traumatic injury (Injury Seventy Score > 15) in the area of the former Yorkshire Regional Health Authority during the period 30 September 1988 to 1 October 1989 and who survived for 5 years (average 5.3 years). Methods. The same interviewer saw each survivor at their home and used the OPCS Adult Disability Schedule to ascertain levels of functional disability. Disability scores for each survivor were then combined in accordance with the OPCS guidance to calculate a level of disability between 0 ( no disability) to 10 ( maximum disability). The OPCS level was then dichotomised with a cut-point at 4/5. Possible predictor and confounding variables from pre-injury, injury and post-injury periods were modelled in a logistic regression to identify those that predicted outcome level. Two reduced models were developed to allow early prognosis of late outcome. Results. The full model correctly classified 91% of observed outcomes. Inpatient length of stay OR 1.031 (95% CI 1.014,1.048) per day predicted poorer 5-year outcome; Glasgow Coma Score OR 0.790(0.629,0.992) per 1 point increase; stay in Intensive Care Unit OR 0.931 (0.877,0.987) per day; attainment of degree-level education OR 0.014 (0.000,0.707); single civil status OR 0.110 (0.013,0.908); being taken initially to a hospital with a neurosurgical facility OR 0.064(0.010,0.420); being in paid work during the 2 weeks before index injury OR 0.093(0.009,0.969) predicted better 5-year disability outcome. Two reduced models were constructed that included a simple set of variables, one of these models excluded any rehabilitation variables but still correctly classified 85% of the observed outcomes. Conclusion. As well as level of traumatic brain injury (TBI) and total inpatient stay, Pre-injury educational attainment and employment, civil status, immediate care in a hospital with a neurosurgical facility and stay in an Intensive Care Unit determined 5-year outcome. It is possible to efficiently predict outcome at an early stage. Previous work on predictors of disablement have suffered from large selection and attrition biases.	Univ Reading, Sch Hlth & Social Care, Inst Hlth Sci, Reading RG6 1HY, Berks, England; Univ Leeds, Nuffield Inst Hlth, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Rehabil Res Unit, Leeds LS2 9JT, W Yorkshire, England; Univ Sheffield, Med Stat Unit, Sheffield S10 2TN, S Yorkshire, England	Connelly, J (corresponding author), Univ Reading, Sch Hlth & Social Care, Inst Hlth Sci, Bulmershe Court, Reading RG6 1HY, Berks, England.	j.b.connelly@reading.ac.uk					Airey CM, 2001, DISABIL REHABIL, V23, P509; AIREY CM, 1995, INJURY, V26, P25, DOI 10.1016/0020-1383(95)90548-C; ANDERSON EM, 2000, ARCH PHYS MED REHAB, V81, P515; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; Ashley MJ, 1997, BRAIN INJURY, V11, P677; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Braithwaite IJ, 1998, INJURY, V29, P55; *COMM TRAUM, 1993, RES OPT CAR INJ PAT; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DAY RJ, 1994, MED J AUSTRALIA, V160, P675, DOI 10.5694/j.1326-5377.1994.tb125903.x; Department of Health, 1999, SAV LIV OUR HLTH NAT; Fleming J, 1999, BRAIN INJURY, V13, P417; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; GRUNDY E, 1998, DISABILITY GREAT BRI; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kleinbaum D, 1982, EPIDEMIOLOGIC RES PR; Lehmann U, 1999, EUR J SURG, V165, P1116, DOI 10.1080/110241599750007603; Martin J, 1988, PREVALENCE DISABILIT; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; *ROY COLL SURG ENG, 1988, REP WORK PART MAN PA; Selvin S., 1996, STAT ANAL EPIDEMIOLO; Townsend P., 1992, INEQUALITIES HLTH BL; VANDERSLUIS CK, 1995, J TRAUMA, V38, P681, DOI 10.1097/00005373-199505000-00001; VanDongen S, 1993, Rehabil Nurs, V18, P76; VARZQUEZ MG, 1996, INFECT CRITICAL CARE, V41, P326; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; 1980, OFFICE POPULATIONS C	31	20	21	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	MAY	2006	28	10					629	636		10.1080/09638280500276513			8	Rehabilitation	Rehabilitation	041QO	WOS:000237471000006	16690576				2021-06-18	
J	Koponen, S; Taiminen, T; Kurki, T; Portin, R; Isoniemi, H; Himanen, L; Hinkka, S; Salokangas, RKR; Tenovuo, O				Koponen, S; Taiminen, T; Kurki, T; Portin, R; Isoniemi, H; Himanen, L; Hinkka, S; Salokangas, RKR; Tenovuo, O			MRI findings and Axis I and II psychiatric disorders after traumatic brain injury: A 30-year retrospective follow-up study	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						brain injuries; mental disorders; magnetic resonance imaging	ALZHEIMERS-DISEASE; HEAD TRAUMA; PERSONALITY-CHANGE; MILD; DEPRESSION; NEUROPSYCHIATRY; POPULATION; SECONDARY; HEALTH; RISK	We studied the association between psychiatric disorders and the presence and location of traumatic lesions on magnetic resonance imaging (MRI) in 58 patients, on average, 30 years after traumatic brain injury. Axis I psychiatric disorders that had begun after the injury were assessed with the Schedules for Clinical Assessment in Neuropsychiatry (version 2.1), and Axis 11 disorders with the Structured Clinical Interview for DSM-III-R Personality Disorders. A 1.5-Tesla MRI scanner was used. One-third of the subjects had traumatic lesions visible on MRI. Only three psychiatric disorders, that is, delusional disorder, dementia, and the disinhibited type of organic personality syndrome, were significantly more common in subjects with contusions. Concerning the location of contusions, organic personality syndrome and its disinhibited subtype were associated with frontal lesions, and major depression was, surprisingly, inversely associated with temporal lesions. These results, which should be interpreted with caution due to the limited size of the study group, suggest that the majority of psychiatric disorders after traumatic brain injury are not closely related to the specific location or even the presence of contusions detectable with post-acute MRI. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Turku Univ Hosp, Dept Psychiat, FI-20521 Turku, Finland; Turku Univ Hosp, Dept Radiol, FI-20521 Turku, Finland; Turku Univ Hosp, Dept Neurol, FI-20521 Turku, Finland; Univ Turku, Dept Biostat, Turku, Finland	Koponen, S (corresponding author), Turku Univ Hosp, Dept Psychiat, PL 52, FI-20521 Turku, Finland.	salla.koponen@utu.fi		Kurki, Timo/0000-0001-5532-3534; Himanen, Leena/0000-0001-7261-8027			Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fujii DEM, 1996, NEUROPSY NEUROPSY BE, V9, P133; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; HILLBOM E, 1960, ACT PSYCHIAT NEUROLO, V142, P35; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; O'Driscoll K, 1998, BRIT MED J, V317, P1673, DOI 10.1136/bmj.317.7174.1673a; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Price TR, 1997, STROKE, V28, P1158, DOI 10.1161/01.STR.28.6.1158; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Spitzer R.L., 1989, STRUCTURED CLIN INTE; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Vataja R, 2001, ARCH GEN PSYCHIAT, V58, P925, DOI 10.1001/archpsyc.58.10.925; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589	30	20	20	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927			PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	APR 30	2006	146	3					263	270		10.1016/j.pscychresns.2005.05.015			8	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	057ON	WOS:000238605200007	16507345				2021-06-18	
J	Degeneffe, CE; Lynch, RT				Degeneffe, CE; Lynch, RT			Correlates of depression in adult siblings of persons with traumatic brain injury	REHABILITATION COUNSELING BULLETIN			English	Article							MENTAL-RETARDATION; SOCIAL SUPPORT; FAMILY-MEMBER; HEAD-INJURY; STRESS; INDIVIDUALS; PERCEPTIONS; PARENTS; ILLNESS; BURDEN	Using Pearlin's stress process model, this study examined correlates of depression in 170 adult siblings of persons with traumatic brain injury (TBI). Approximately 39% of adult sibling participants evinced Center for Epidemiologic Studies-Depression (CES-D; Radloff, 1977) scores indicating clinically significant depressive symptoms. Background characteristics found to be related to higher ratings of depression included being female and history of a pre-TBI depressive episode. In addition, results indicated that perceptions of more restrictions in valued family activities and less accessibility to social support were related to higher ratings of depression. Contrary to study hypotheses, an inverse relationship was found between subjective caregiving burden and depression. Practice and research implications of these findings are discussed.	San Diego State Univ, Dept Adm Rehabil & Postsecondary Educ, San Diego, CA 92108 USA; Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA	Degeneffe, CE (corresponding author), San Diego State Univ, Dept Adm Rehabil & Postsecondary Educ, 3590 Camino Rio N, San Diego, CA 92108 USA.	cdegeneffe@csufresno.edu					ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bergmann J, 2001, Z SOZIOL, V30, P1; *BRAIN INJ ASS INC, 2000, COSTS CAUS TRAUM BRA; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Cutrona C, 1987, ADV PERSONAL RELATIO, V1, P33; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; GATZ M, 1990, PSYCHOL AGING, V5, P284, DOI 10.1037/0882-7974.5.2.284; Gill D. J., 2000, REHABILITATION NURSI, V25, P48, DOI [DOI 10.1002/J.2048-7940.2000.TB01862.X, 10.1002/j.2048-7940.2000.tb01862.x]; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; GRIFFITHS DL, 1994, FAM RELAT, V43, P221, DOI 10.2307/585326; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harris JKJ, 2001, BRAIN INJURY, V15, P223; HAUSER RM, 2004, WISCONSIN LONGITUDIN; HOLROYD J, 1976, AM J MENT DEF, V80, P431; HOLROYD J, 1986, J CLIN PSYCHOL, V42, P552, DOI 10.1002/1097-4679(198607)42:4<552::AID-JCLP2270420403>3.0.CO;2-8; HOLROYD J, 1985, QUESTIONNAIRE RESOUR; HORWITZ AV, 1993, J MARRIAGE FAM, V55, P623, DOI 10.2307/353343; INANAMI M, 1980, JAPANESE J SPECIAL E, V18, P33; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/0090-5550.39.4.215; KOSCIULEK JF, 1993, THESIS U WISCONSIN M; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Leathem J, 1996, BRAIN INJURY, V10, P27; MARASCUILO LA, 1983, MULTIVARIATE STAT SO; *NIH, 1999, REP NIH CONS DEV C R; Orsillo SM, 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199303000-00010, 10.1097/00001199-199303000-00010]; PEARLIN LI, 1989, J HEALTH SOC BEHAV, V30, P241, DOI 10.2307/2136956; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Pruchno RA, 1996, FAM RELAT, V45, P318, DOI 10.2307/585504; RADLOFF LS, 1977, APPL PSYCH MEAS, V3, P385; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SELTZER GB, 1991, FAM RELAT, V40, P310, DOI 10.2307/585017; Seltzer M. M., 1996, AGING FAMILIES ADULT; SELTZER MM, 1989, AM BEHAV SCI, V33, P107, DOI 10.1177/0002764289033001010; Seltzer MM, 1997, FAM RELAT, V46, P395, DOI 10.2307/585099; SPRIGGS VT, 1998, PROMOTING CULTURAL C, P149; STEBBINS P, 1997, AUSTR J REHABILITATI, V3, P30; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; Willer B., 1990, CANADIAN J REHABILIT, V3, P167	44	20	20	0	1	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897 USA	0034-3552			REHABIL COUNS BULL	Rehabil. Couns. Bull.	SPR	2006	49	3					130	142		10.1177/00343552060490030101			13	Rehabilitation	Rehabilitation	027HA	WOS:000236404500001					2021-06-18	
J	Vanderploeg, RD; Collins, RC; Sigford, B; Date, E; Schwab, K; Warden, D				Vanderploeg, RD; Collins, RC; Sigford, B; Date, E; Schwab, K; Warden, D		Defense Veterans Brain Injury Ctr	Practical and theoretical considerations in designing rehabilitation trials - The DVBIC cognitive-didactic versus functional-experiential treatment study experience	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	Galveston Brain Injury Conference (GBIC)	APR, 2005	Galveston, TX	Moody Fdn		outcome assessment; randomized controlled trials; rehabilitation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; REORGANIZATION; PROGRAM	This is a descriptive article outlining issues in the development and implementation of a multisite randomized rehabilitation trial for brain injury treatment. The goal of this article is to present practical and theoretical considerations in designing and conducting multicenter rehabilitation trials. Practical issues discussed include (a) treatment setting, (b) patient accessibility in determining the research question of interest, as well as inclusion and exclusion criteria, (c) research protocol development in the context of rehabilitation standard of care, and (d) protocol treatments in the context of realistic cost-benefits analysis. Rehabilitation theory is discussed as playing an important role designing the specifics of the protocol interventions. The Defense and Veterans Brain Injury Center Veterans Health Administration cognitive-didactic versus functional-experiential study methodology is used for illustrative purposes. This study evaluated 2 alternative approaches to treatment: one focusing on underlying cognitive processes and the second on errorless learning in everyday functional situations. Lessons learned over the course of completing the treatment trial are discussed.	Univ S Florida, James A Haley Vet Affairs Med Ctr, Def & Vet Brain Injury Ctr, Tampa, FL USA; Univ S Florida, Dept Psychiat & Behav Sci, Tampa, FL USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Vet Affairs Med Ctr, Def & Vet Brain Injury Ctr, Minneapolis, MN USA; Def & Vet Brain Injury Ctr, Minneapolis, MN USA; Univ Minnesota, Dept Phys Med & Rehabil, Minneapolis, MN USA; Vet Affairs Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, Palo Alto, CA USA; Stanford Univ, Dept Phys Med & Rehabil, Sch Med, Palo Alto, CA 94304 USA; Uniformed Serv Univ Hlth Sci, Dept Epidemiol & Stat, Def & Vet Brain Injury Ctr, Bethesda, MD 20814 USA; Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; Walter Reed Army Med Ctr, Def & Vet Brain Injury, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Dept Neurol & Psychiat, Bethesda, MD 20814 USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, Tampa, FL 33612 USA.	rodney.vanderploeg@va.gov					BENEDICT RHB, 1989, CLIN PSYCHOL REV, V9, P605; BENYISHAY Y, 1987, NEUROPSYCHOL REHABIL, P165; BERROL S, 1990, ARCH NEUROL-CHICAGO, V47, P219, DOI 10.1001/archneur.1990.00530020127025; BUTLER RW, 1988, J NEUROLOGICAL REHAB, V2, P97; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 1999, J HEAD TRAUMA REHAB, V14, P316, DOI 10.1097/00001199-199906000-00011; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Cramer SC, 2000, NEUROPHARMACOLOGY, V39, P842, DOI 10.1016/S0028-3908(99)00258-0; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; GILES GM, 1993, BRAIN INJURY REHABIL; GORDON WA, 1991, COGNITIVE REHABILITA, P13; Hartley L. L., 1995, COGNITIVE COMMUNICAT; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82; Kaas JH, 1997, NEUROSCIENTIST, V3, P123, DOI 10.1177/107385849700300211; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Mateer CA, 1988, NEUROPSYCHOLOGICAL S, P202; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; PRUTTING CA, 1982, J SPEECH HEAR DISORD, V47, P123, DOI 10.1044/jshd.4702.123; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1057; Ricker J H, 1998, Appl Neuropsychol, V5, P184, DOI 10.1207/s15324826an0504_3; ROSENTHAL R, 1963, BEHAV SCI, V8, P183; Rosenthal R., 1976, EXPT EFFECTS BEHAV R; ROSENTHAL R, 2002, PREV TREAT; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SEITZ RJ, 1994, HUM BRAIN MAPP, V1, P81; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; Sohlberg M. M., 1992, IMPROVING PRAGMATIC; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; SOHLBERG MM, 1994, MANUAL TEACHING PATI; SOHLBERG MM, 1986, ATTENTION PROCESS TR; SOHLBERG MM, 1993, ATTENTION PROCESS TR; SOHLBERG MM, 1989, PROSPECTIVE MEMORY T; SOHLBERG MM, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; Spilker B., 1991, GUIDE CLIN TRIALS; SQUIRE LR, 1987, MEMORY BRAIN; Sterr A, 1998, NATURE, V391, P134, DOI 10.1038/34322; Taub E, 1999, J REHABIL RES DEV, V36, P237; TEASDALE G, 1974, LANCET, V2, P81; Terrace H. S., 1966, OPERANT BEHAV AREAS; TERRACE HS, 1963, J EXP ANAL BEHAV, V6, P1, DOI 10.1901/jeab.1963.6-1; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; VONGIESEN HJ, 1994, EXP BRAIN RES, V99, P94; VONMONAKOW C, 1914, LOKALISATION GROSSBI; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P308, DOI 10.1055/s-2008-1064205	61	20	22	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2006	21	2					179	193		10.1097/00001199-200603000-00010			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	031PK	WOS:000236716300009	16569991				2021-06-18	
J	Elliott, TR; Bush, BA; Chen, YY				Elliott, TR; Bush, BA; Chen, YY			Social problem-solving abilities predict pressure sore occurrence in the first 3 years of spinal cord injury	REHABILITATION PSYCHOLOGY			English	Article						social problem solving; spinal cord injury; pressure sores	TRAUMATIC BRAIN-INJURY; FAMILY CAREGIVERS; STROKE SURVIVORS; ADJUSTMENT; APPRAISAL; RISK; ULCERS; DEPRESSION; BEHAVIORS; THERAPY	Objective: To test the hypothesis that social problem-solving abilities of persons with recent-onset spinal cord injury (SCI) would be predictive of pressure sore occurrence in the 1st 3 years following discharge from initial inpatient rehabilitation. Design: Prospective study of persons with recently incurred SCI and their subsequent pressure sore evaluations over a 3-year period in annual clinic evaluations. Setting: Inpatient SCI rehabilitation center and outpatient clinic. Participants: 188 persons with recent-onset SCI approaching discharge from initial inpatient SCI rehabilitation, with outpatient pressure sore evaluations for those who returned for pressure sore evaluations. Main Outcome Measure: Pressure sore occurrence as determined in annual outpatient evaluations conducted over the 1st 3 years of SCI. Results: 2 separate statistical models indicated that social problem-solving abilities significantly contributed to the prediction of pressure sore occurrence. Conclusions: Social problem-solving abilities are implicated in the development of pressure sores. Persons with ineffective problem-solving abilities may be at risk for pressure sores; these individuals might require strategic monitoring and training from clinical programs.	Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA	Elliott, TR (corresponding author), Univ Alabama Birmingham, Dept Psychol, CH 415,1530 3rd Ave S, Birmingham, AL 35294 USA.	telliott@uab.edu	Elliott, Timothy R./I-5301-2012	Elliott, Timothy R./0000-0002-6608-7714			ARBUCKLE JL, 2003, AMOS VERSION 5 0 COM; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Bollen K.A., 1989, STRUCTURAL EQUATIONS, P514, DOI 10.1002/9781118619179; Bollen K.A., 1993, TESTING STRUCTURAL E; BOLLEN KA, 1989, SOCIOL METHOD RES, V17, P303, DOI 10.1177/0049124189017003004; Browne M.W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002005; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Byrne B.M., 1989, PRIMER LISREL BASIC; Canupp KC, 1997, SPINAL CORD, V35, P314, DOI 10.1038/sj.sc.3100367; Carmines E. G., 1981, SOCIAL MEASUREMENT P, P65; Chen YY, 2005, ARCH PHYS MED REHAB, V86, P1208, DOI 10.1016/j.apmr.2004.12.023; Consortium for Spinal Cord Medicine, 2000, PRESS ULC PREV TREAT; D'Zurilla T. J., 1999, PROBLEM SOLVING THER; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Dreer LE, 2004, J CLIN PSYCHOL MED S, V11, P7, DOI 10.1023/B:JOCS.0000016265.62022.82; DUGAS MJ, 1995, COGNITIVE THER RES, V19, P109, DOI 10.1007/BF02229679; DZurilla T. J., 2002, SOCIAL PROBLEM SOLVI; ELLIOTT T, 2005, ENCY COGNITIVE BEHAV, P324; Elliott T, 2004, SOCIAL PROBLEM SOLVI, P117, DOI DOI 10.1037/10805-007; ELLIOTT TR, 1991, COGNITIVE THER RES, V15, P387, DOI 10.1007/BF01173033; Elliott TR, 2002, REHABIL PSYCHOL, V47, P278, DOI 10.1037//0090-5550.47.3.278; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Elliott TR, 1999, REHABIL PSYCHOL, V44, P315, DOI 10.1037/0090-5550.44.4.315; Elliott TR, 2001, J CLIN PSYCHOL MED S, V8, P283, DOI 10.1023/A:1011920914079; Elliott TR, 1996, J COUNS DEV, V74, P645, DOI 10.1002/j.1556-6676.1996.tb02305.x; ELLIOTT TR, 1995, J COUNS PSYCHOL, V42, P105, DOI 10.1037/0022-0167.42.1.105; ELLIOTT TR, 1994, J COUNS DEV, V72, P531, DOI 10.1002/j.1556-6676.1994.tb00987.x; Elliott TR, 2003, COMPREHENSIVE HDB PS, P415; ENIS JE, 1973, ORTHOPAEDIC REV, V2, P25; FEHRENBACH A, 1989, J CONSULT CLIN PSYCH, V5, P388; Garber SL, 2000, ARCH PHYS MED REHAB, V81, P465, DOI 10.1053/mr.2000.3889; Godshall FJ, 1997, J APPL SOC PSYCHOL, V27, P929, DOI 10.1111/j.1559-1816.1997.tb00279.x; Grant JS, 2004, REHABIL PSYCHOL, V49, P172, DOI 10.1037/0090-5550.49.2.172; Grant JS, 2002, STROKE, V33, P2060, DOI 10.1161/01.STR.0000020711.38824.E3; Heppner PP., 1988, PROBLEM SOLVING INVE; HERRICK S, 1994, J CLIN PSYCHOL MED S, V1, P269, DOI 10.1007/BF01989628; Herrick SM, 2001, J CLIN PSYCHOL, V57, P75, DOI 10.1002/1097-4679(200101)57:1<75::AID-JCLP9>3.0.CO;2-6; JOHNSON M, IN PRESS HLTH PSYCHO; Kerns RD, 2002, ANN BEHAV MED, V24, P100, DOI 10.1207/S15324796ABM2402_06; Krause J., 1996, TOP SPINAL CORD INJ, V2, P58; Krause JS, 2004, ARCH PHYS MED REHAB, V85, P1257, DOI 10.1016/j.apmr.2003.08.108; Krause JS, 2001, ARCH PHYS MED REHAB, V82, P107, DOI 10.1053/apmr.2001.18050; Long JS., 1983, CONFIRMATORY FACTOR; MACNAIR RR, 1992, J RES PERS, V26, P150, DOI 10.1016/0092-6566(92)90051-5; MARSH HW, 1988, PSYCHOL BULL, V103, P391, DOI 10.1037/0033-2909.103.3.391; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; Nezu AM, 2004, BEHAV THER, V35, P1, DOI 10.1016/S0005-7894(04)80002-9; Nezu AM, 2003, J CONSULT CLIN PSYCH, V71, P1036, DOI 10.1037/0022-006X.71.6.1036; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rimmer JH, 2002, AM J HEALTH PROMOT, V16, P220, DOI 10.4278/0890-1171-16.4.220; Shanmugham K, 2004, NEUROREHABILITATION, V19, P259; Shewchuk RM, 2000, BEHAV RES THER, V38, P727, DOI 10.1016/S0005-7967(99)00122-9; Stover S., 1995, SPINAL CORD INJURY C; TURK DC, 1989, HDB CLIN PSYCHOL MED, P249; Yarkony Gary M., 1995, P100; YARKONY GM, 1994, ARCH PHYS MED REHAB, V75, P908, DOI 10.1016/0003-9993(94)90117-1	57	20	21	0	4	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2006	51	1					69	77		10.1037/0090-5550.51.1.69			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	022FH	WOS:000236040000010					2021-06-18	
J	De Tanti, A; Gasperini, G; Rossini, M				De Tanti, A; Gasperini, G; Rossini, M			Paroxysmal episodic hypothalamic instability with hypothermia after traumatic brain injury	BRAIN INJURY			English	Article						autonomic dysfunction syndrome; hypothalamic instability; spontaneous periodic hypothermia; traumatic brain injury	HYPERHIDROSIS; DYSAUTONOMIA; HYPERTHERMIA; HYPERTENSION; AGENESIS	This case report describes a patient in vegetative state after severe traumatic brain injury (TBI) with hypothalamic damage and clinical manifestations of autonomic dysfunction. He also presented late onset paroxysmal hypothermia associated with mild bradycardia and hypotension. Hypothermia due to traumatic lesions of the hypothalamus is an uncommon clinical problem and few cases have been reported; no cases could be found in the literature which evidenced periodic hypothermia associated with clinical features of autonomic dysfunction after TBI. In the article, the main causes and the primary pathophysiology of hypothermia after TBI are discussed. The manifestations in this patient have been interpreted as possible consequences of autonomic dysfunction and considered atypical and rare clinical expression of acute post-traumatic hypothalamic instability.	Osped Valduce, Dept Rehabil Med, Costamasnaga, Lecco, Italy	De Tanti, A (corresponding author), Ctr Cardinal Ferrari, Via 4 Novembre 21, I-43012 Fontanellato, Pr, Italy.	a.detanti@gsante.it		Rossini, Mauro/0000-0002-7670-5758			ARROYO HA, 1990, NEUROLOGY, V40, P556, DOI 10.1212/WNL.40.3_Part_1.556-a; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Bernardo L M, 1999, Int J Trauma Nurs, V5, P101, DOI 10.1016/S1075-4210(99)90057-3; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; DeRoche ME, 2002, OBSTET GYNECOL, V99, P880, DOI 10.1016/S0029-7844(01)01604-0; ELGAMAL N, 1995, ANESTH ANALG, V80, P1245, DOI 10.1097/00000539-199506000-00032; FOX RH, 1973, BRIT MED J, V2, P693, DOI 10.1136/bmj.2.5868.693; Fritsch D E, 1995, AACN Clin Issues, V6, P196, DOI 10.1097/00044067-199505000-00004; GRIFFITH ER, 1990, REHABILITATION ADULT; Hagen C, 1979, REHABILITATION HEAD; JENNETT B, 1975, LANCET, V1, P480; Klein CJ, 2001, NEUROLOGY, V56, P254, DOI 10.1212/WNL.56.2.254; KLOOS RT, 1995, MEDICINE, V74, P268, DOI 10.1097/00005792-199509000-00004; Kubota M, 1991, No To Shinkei, V43, P81; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; LEWITT PA, 1983, NEUROLOGY, V33, P1122, DOI 10.1212/WNL.33.9.1122; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; Magnifico F, 2002, NEUROLOGY, V58, P1300, DOI 10.1212/WNL.58.8.1300; MENARD MR, 1991, ARCH PHYS MED REHAB, V72, P421; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; Moulignier A, 2003, NEUROLOGY, V61, P418, DOI 10.1212/01.WNL.0000073539.21469.b7; Mouton P, 1996, ANN MED INTERNE, V147, P107; Ogawa T, 1997, CLIN AUTONOMIC DISOR, P83; Penfield W, 1929, ARCH NEURO PSYCHIATR, V22, P358, DOI 10.1001/archneurpsyc.1929.02220020174010; PFEIFFER RF, 1990, NEUROLOGY, V40, P383; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RATCLIFFE PJ, 1983, J NEUROL NEUROSUR PS, V46, P72, DOI 10.1136/jnnp.46.1.72; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; Ruiz C, 2003, PEDIATR NEUROL, V28, P304, DOI 10.1016/S0887-8994(02)00631-8; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; SHAPIRO WR, 1969, BRAIN, V92, P423, DOI 10.1093/brain/92.2.423; SHETH RD, 1994, PEDIATR NEUROL, V10, P58, DOI 10.1016/0887-8994(94)90069-8; THOMAS DJ, 1973, BRIT MED J, V2, P696, DOI 10.1136/bmj.2.5868.696; Thompson HJ, 2003, NEUROBIOL DIS, V12, P163, DOI 10.1016/S0969-9961(02)00030-X; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698; Tuettenberg J, 2003, J NEUROSURG, V99, P610, DOI 10.3171/jns.2003.99.3.0610; WHYTE J, 1993, AM J PHYS MED REHAB, V72, P281, DOI 10.1097/00002060-199310000-00006; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	43	20	20	1	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2005	19	14					1277	1283		10.1080/02699050500309270			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZF	WOS:000233270200012	16286344				2021-06-18	
J	Gahm, C; Danilov, A; Holmin, S; Wiklund, PN; Brundin, L; Mathiesen, T				Gahm, C; Danilov, A; Holmin, S; Wiklund, PN; Brundin, L; Mathiesen, T			Reduced neuronal injury after treatment with N-G-nitro-L-arginine methyl ester (L-NAME) or 2-sulfo-phenyl-N-tert-butyl nitrone (S-PBN) following experimental brain contusion	NEUROSURGERY			English	Article						apoptosis; brain injury; L-NAME; neuronal injury; nitric oxide; nitrotyrosine; S-PBN	FOCAL CEREBRAL-ISCHEMIA; TERT-BUTYL-NITRONE; OXIDE SYNTHASE EXPRESSION; PERIVASCULAR TYROSINE NITRATION; FREE-RADICAL SCAVENGERS; CORTICAL IMPACT INJURY; RAT-BRAIN; PEROXYNITRITE FORMATION; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS	OBJECTIVE: Nitric oxide (NO) and oxygen free radicals are implicated in the pathophysiology of traumatic brain-injury (TBI). Peroxynitrite formation from NO and superoxide contributes to secondary neuronal injury but the neuroprotective effects of nitric oxide synthase (NOS)-inhibitors have been contradictory. This study was undertaken to examine whether PTtic administration of the (NOS)-inhibitor- N-G-nitro-L-arginine methyl ester (L-NAME), and a combination of L-NAME and the nitrone radical scavenger 2-sulfo-phenyl-N-tert-butyl nitrone (S-PBN) favorable affects neuronal injury in a model of TBI. METHODS: A weight-drop model of TBI was used. The animals received L-NAME, S-PBN or a combination of the drugs 15 minutes prothrombin time (PT) and sacrificed after 24 hours or six days. NOS activity was measured by the conversion of L-[U-C-14]arginine to L-[U-C-14] citrulline. Peroxynitrite formation, cellular apoptosis, neuronal degeneration and survival were assessed by nitrotyrosine-, TUNEL-, Fluoro-Jade and NeuN-stainings. RESULTS: eNOS and nNOS activity was significantly reduced in animals that received L-NAME alone or the combination with S-PBN. iNOS activity or iNOS immunoreactivity was not affected. All treatments significantly reduced neuronal degeneration and nitrotyrosine immunoreactivity at 24 hours and increased neuronal survival at six days PT. No differences were detected between L-NAME and L-NAME + S-PBN groups. CONCLUSION: NO from NOS contributes to secondary neuronal injury in this TBI-model. PTtic treatment does not inhibit early beneficial NO-related effects. L-NAME and S-PBN limit peroxynitrite formation, promoting neuronal survival. The combination of L-NAME and S-PBN was neuroprotective; surprisingly no additive effects were found on nitrotyrosine formation, apoptosis or neuronal survival.	Karolinska Inst, Dept Clin Neurosci, Sect Clin CNS Res, Neuroimmunol Grp,Ctr Mol Med, SE-17176 Stockholm, Sweden; Karolinska Inst, Dept Surg, Urol Sect, Stockholm, Sweden	Gahm, C (corresponding author), Karolinska Inst, Dept Clin Neurosci, Sect Clin CNS Res, Neuroimmunol Grp,Ctr Mol Med, SE-17176 Stockholm, Sweden.	Caroline.Gahm@karolinska.se		Holmin, Staffan/0000-0002-1628-1615; Brundin, Lou/0000-0003-4408-7817; Mathiesen, Tiit/0000-0001-9463-1919; Wiklund, Peter/0000-0001-6497-4697			Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229, DOI DOI 10.1016/S0076-6879(94)33026-3; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; Catania MV, 2003, NEUROCHEM RES, V28, P607; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Coeroli L, 1998, J NEUROCHEM, V70, P2516; Conti AC, 1998, J NEUROSCI, V18, P5663; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Forster C, 1999, ACTA NEUROPATHOL, V97, P215, DOI 10.1007/s004010050977; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169; Greenberg JH, 1997, NEUROSCI LETT, V229, P1, DOI 10.1016/S0304-3940(97)00395-9; Gursoy-Ozdemir Y, 2000, STROKE, V31, P1974, DOI 10.1161/01.STR.31.8.1974; Gursoy-Ozdemir Y, 2004, STROKE, V35, P1449, DOI 10.1161/01.STR.0000126044.83777.f4; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; HOGG N, 1993, FEBS LETT, V326, P199, DOI 10.1016/0014-5793(93)81790-7; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hooper DC, 2000, FASEB J, V14, P691; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Ischiropoulos H, 1996, J CLIN INVEST, V97, P2260, DOI 10.1172/JCI118667; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOTAKE Y, 1998, BIOCHIM BIOPHYS ACTA, V1, P77; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MALIS CD, 1986, J BIOL CHEM, V261, P14201; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MIYAJIMA T, 1995, BIOCHEM BIOPH RES CO, V215, P114, DOI 10.1006/bbrc.1995.2440; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nagashima T, 2000, ACTA NEUROCHIR SUPPL, V76, P471; Naito Y, 2002, ANTIOXID REDOX SIGN, V4, P195, DOI 10.1089/152308602753625951; Packer MA, 2003, P NATL ACAD SCI USA, V100, P9566, DOI 10.1073/pnas.1633579100; Povlishock J T, 1992, Hum Cell, V5, P345; QUAST MJ, 1995, BRAIN RES, V677, P204, DOI 10.1016/0006-8993(95)00134-C; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; RINK A, 1995, AM J PATHOL, V147, P1575; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; Samuelsson C, 2003, EPILEPSY RES, V56, P165, DOI 10.1016/j.eplepsyres.2003.09.004; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Singh A, 1996, AM J HYPERTENS, V9, P867, DOI 10.1016/S0895-7061(96)00104-5; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yang Y, 2000, EXP NEUROL, V163, P39, DOI 10.1006/exnr.2000.7364; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; YUI Y, 1991, J BIOL CHEM, V266, P12544; ZHANG FY, 1995, J CEREBR BLOOD F MET, V15, P595, DOI 10.1038/jcbfm.1995.73	91	20	24	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2005	57	6					1272	1281		10.1227/01.NEU.0000187317.32529.06			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	991PQ	WOS:000233826300056	16331176				2021-06-18	
J	Walker, AJ; Onus, M; Doyle, M; Clare, J; McCarthy, K				Walker, AJ; Onus, M; Doyle, M; Clare, J; McCarthy, K			Cognitive rehabilitation after severe traumatic brain injury: A pilot programme of goal planning and outdoor adventure course participation	BRAIN INJURY			English	Article						traumatic brain injury; cognitive rehabilitation; community rehabilitation; goal planning; outward bound		Primary objective: To describe and evaluate a pilot community based rehabilitation programme for severe brain injury. Research design: A prospective repeated-measures design with a single convenience sample was conducted. Methods and procedures: Eleven participants with a history of severe brain injury completed the programme, which featured an outdoor adventure course, skill development and goal-based learning. In the first stage, practical activities facilitated the development of social skills, group cohesiveness and community integration. The second stage was a 9-day outdoor adventure course, which included physically challenging activities such as camping, bushwalking, abseiling, caving and high rope work. The third stage encouraged individuals to work on the personal goals they had developed. Main outcomes and results: Over 80% of stated goals were achieved; suggesting that such a programme may be effective in enabling clients to attain specified goals. Conclusions: The programme shows promise as a form of community rehabilitation.	Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia	Walker, AJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	awalker@biru.wsahs.nsw.gov.au					Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Deckersbach T, 2000, J CLIN EXP NEUROPSYC, V22, P640, DOI 10.1076/1380-3395(200010)22:5;1-9;FT640; Deloche G., 2000, INT HDB NEUROPSYCHOL, P81; Dupuy HJ, 1987, MEASURING HLTH GUIDE, P125; HEATON RK, 1990, WISCONSIN CARD SORTI; LEMMON J, 1996, J COGNITIVE REHA JUL, P18; LOVIBOND SH, 1995, MANUAL DEPRESSION AN; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P195; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P103; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Spreen O., 1998, COMPENDIUM NEUROPSYC; Thomas M, 2004, BRAIN INJURY, V18, P1271, DOI 10.1080/02699050410001698776; Wechsler D., 1997, WECHSLER ADULT INTEL; Wilson BA, 2002, J HEAD TRAUMA REHAB, V17, P542, DOI 10.1097/00001199-200212000-00006; Wilson PN, 2003, REV AGRIC ECON, V25, P30, DOI 10.1111/1467-9353.00044; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; Ylvisaker M., 2003, BRAIN IMPAIR, V4, P1, DOI [10.1375/brim.4.1.1.27031, DOI 10.1375/brim.4.1.1.27031]	20	20	20	0	13	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2005	19	14					1237	1241		10.1080/02699050500309411			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZF	WOS:000233270200007	16286339				2021-06-18	
J	Chiarugi, A				Chiarugi, A			Intrinsic mechanisms of poly(ADP-ribose) neurotoxicity: Three hypotheses	NEUROTOXICOLOGY			English	Article; Proceedings Paper	1st international Porto Pirgos Conference on Advances in Neuroscience	SEP 22-25, 2004	Calabria, ITALY			neurodegeneration; PARP; PARG; poly(ADP-ribose); gene expression; brain ischemia	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; POLY-ADP-RIBOSYLATION; NITRIC-OXIDE SYNTHASE; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS-INDUCING FACTOR; ISCHEMIC CELL-DEATH; GENE-EXPRESSION; NEURODEGENERATIVE DISORDERS; TRANSCRIPTIONAL ACTIVATION	Poly(ADP-ribose) (PAR) is a branched and negatively charged polymeric macromolecule formed by poly(ADP-ribose) polymerases. Targeting of PAR onto acceptor proteins affects their functioning and regulates cellular homeostasis. A large body of evidence demonstrates that increased neo-formation of PAR has a crucial role in neurodegeneration. Consistently, strategies aimed at reducing PAR synthesis are of therapeutic relevance to treatment of several experimental neurodegenerative diseases. However, how PAR causes neuronal death is still elusive. This review provides all appraisal of the possible molecular mechanisms underlying PAR neurotoxicity, highlighting the pleiotypic effects of the polymer on neural cells exposed to different stressful conditions. (c) 2005 Elsevier Inc. All rights reserved.	Univ Florence, Dept Pharmacol, I-50139 Florence, Italy	Chiarugi, A (corresponding author), Univ Florence, Dept Pharmacol, I-50139 Florence, Italy.	alberto.chiarugi@unifi.it					Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; ALTHAUS FR, 1995, BIOCHIMIE, V77, P423, DOI 10.1016/0300-9084(96)88155-7; ALTHAUS FR, 1990, ACTA BIOL HUNG, V41, P9; ALTHAUS FR, 1994, MOL CELL BIOCHEM, V138, P53, DOI 10.1007/BF00928443; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Carty SM, 2002, MOL CELL PROTEOMICS, V1, P598, DOI 10.1074/mcp.M200029-MCP200; Chang P, 2004, NATURE, V432, P645, DOI 10.1038/nature03061; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Chiarugi A, 2002, BRIT J PHARMACOL, V137, P761, DOI 10.1038/sj.bjp.0704934; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; Cohen-Armon M, 2004, SCIENCE, V304, P1820, DOI 10.1126/science.1096775; Cosi C, 1998, BRAIN RES, V809, P58, DOI 10.1016/S0006-8993(98)00829-4; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; DU L, 2003, J BIOL CHEM; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Dumitriu IE, 2004, CELL DEATH DIFFER, V11, P314, DOI 10.1038/sj.cdd.4401348; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; Gagne JP, 2003, BIOCHEM J, V371, P331, DOI 10.1042/BJ20021675; GENOVESE T, 2004, J PHARM EXP THER; Goto S, 2002, STROKE, V33, P1101, DOI 10.1161/01.STR.0000014203.65693.1E; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hanai S, 2004, P NATL ACAD SCI USA, V101, P82, DOI 10.1073/pnas.2237114100; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; HERCEG Z, 2001, BIOCHEM J, V477, P97; Homburg S, 2000, J CELL BIOL, V150, P293, DOI 10.1083/jcb.150.2.293; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Hortobagyi T, 2003, NEUROSCIENCE, V121, P983, DOI 10.1016/S0306-4522(03)00482-2; Iwashita A, 2004, J PHARMACOL EXP THER, V310, P425, DOI 10.1124/jpet.104.066944; Iwashita A, 2004, J PHARMACOL EXP THER, V309, P1067, DOI 10.1124/jpet.103.064642; Koedel U, 1999, BRAIN PATHOL, V9, P57; Koh SH, 2004, EUR J NEUROSCI, V20, P1461, DOI 10.1111/j.1460-9568.2004.03632.x; Komjati K, 2004, INT J MOL MED, V13, P373; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Kun E, 2002, J BIOL CHEM, V277, P39066, DOI 10.1074/jbc.C200410200; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; Lipton P, 1999, PHYSIOL REV, V79, P1431; Malanga M, 2004, J BIOL CHEM, V279, P5244, DOI 10.1074/jbc.C300437200; Malanga M, 2000, BIOL CHEM, V381, P1047, DOI 10.1515/BC.2000.129; Mandir AS, 2000, J NEUROSCI, V20, P8005; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Mishra OP, 2003, NEUROSCIENCE, V119, P1023, DOI 10.1016/S0306-4522(03)00166-0; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; Nakajima H, 2004, J BIOL CHEM, V279, P42774, DOI 10.1074/jbc.M407923200; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Nucci C, 2000, BIOCHEM BIOPH RES CO, V278, P360, DOI 10.1006/bbrc.2000.3811; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Park EM, 2004, STROKE, V35, P2896, DOI 10.1161/01.STR.0000147042.53659.6c; Paschen W, 2000, J NEUROCHEM, V75, P1675, DOI 10.1046/j.1471-4159.2000.0751675.x; Plaschke K, 2000, NEUROSCI LETT, V284, P109, DOI 10.1016/S0304-3940(00)00988-5; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Satoh M, 2001, STROKE, V32, P225, DOI 10.1161/01.STR.32.1.225; Scott GS, 2004, J PHARMACOL EXP THER, V310, P1053, DOI 10.1124/jpet.103.063214; Scott GS, 2001, J NEUROIMMUNOL, V117, P78, DOI 10.1016/S0165-5728(01)00329-0; Scovassi AI, 2004, FASEB J, V18, P1487, DOI 10.1096/fj.04-1841rev; Skaper SD, 2003, CNS NEUROL DISORD-DR, V2, P279, DOI 10.2174/1568007033482733; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; SUGN YJ, 2004, BIOESSAYS, V26, P1268; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; TASKER RC, 1998, J CEREB BLOOD FLOW M, V18, P13; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; WANG H, 2003, SOC NEUROSCI, V34, P1232; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yang J, 2004, PHARMACOL BIOCHEM BE, V78, P179, DOI 10.1016/j.pbb.2004.03.007; Yang J, 2002, NEUROSCI LETT, V333, P91, DOI 10.1016/S0304-3940(02)01005-4; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	94	20	21	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0161-813X			NEUROTOXICOLOGY	Neurotoxicology	OCT	2005	26	5			SI		847	855		10.1016/j.neuro.2005.01.012			9	Neurosciences; Pharmacology & Pharmacy; Toxicology	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	979BH	WOS:000232916600014	15923038				2021-06-18	
J	Lippert-Gruener, M; Weinert, U; Greisbach, T; Wedekind, C				Lippert-Gruener, M; Weinert, U; Greisbach, T; Wedekind, C			Foreign accent syndrome following traumatic brain injury	BRAIN INJURY			English	Article						FAS; traumatic temporal haemorrhage; rehabilitation; speech disorder		Foreign accent syndrome (FAS) is a very rare disorder, caused by lesions of the dominant brain hemisphere and defined as a loss of normal phonetic contrast when using the mother language. The pronounciation is perceived by native speakers as compromised by a foreign accent. This study reports about a 35-years old women, with a FAS following a brain injury with a traumatic left temporal haemorrhage, who experienced excellent remission after 2 years.	Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany; Univ Cologne, Dept Neurol, Cologne, Germany; Univ Cologne, Inst Phonet, Cologne, Germany	Wedekind, C (corresponding author), Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany.	drchrwedekind@web.de					BERTHIER ML, 1994, NEUROLOGY, V44, P990, DOI 10.1212/WNL.44.5.990-a; BLUMSTEIN SE, 1987, BRAIN LANG, V31, P215, DOI 10.1016/0093-934X(87)90071-X; Carbary TJ, 2000, BRAIN COGNITION, V43, P78; Gonzalez-Alvarez J, 2003, REV NEUROLOGIA, V36, P227, DOI 10.33588/rn.3603.2002306; Gurd JM, 2001, CORTEX, V37, P715, DOI 10.1016/S0010-9452(08)70622-1; GURD JM, 1988, NEUROPSYCHOLOGIA, V26, P237, DOI 10.1016/0028-3932(88)90077-2; KLEIN D, 1994, NEUROREPORT, V5, P2295, DOI 10.1097/00001756-199411000-00022; Kurowski KM, 1996, BRAIN LANG, V54, P1, DOI 10.1006/brln.1996.0059; MATAS M, 1991, CAN J PSYCHIAT, V36, P363, DOI 10.1177/070674379103600509; Moonis M., 1996, NEUROLOGY, V43, P381; NEILSON JM, 1961, B LOS ANGELES NEUROL, V26, P157; TAKAYAMA Y, 1993, NEUROLOGY, V43, P1361, DOI 10.1212/WNL.43.7.1361	12	20	22	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2005	19	11					955	958		10.1080/02699050500109506			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983YY	WOS:000233269500011	16243750				2021-06-18	
J	Yehuda, R; Bryant, R; Marmar, C; Zohar, J				Yehuda, R; Bryant, R; Marmar, C; Zohar, J			Pathological responses to terrorism	NEUROPSYCHOPHARMACOLOGY			English	Article						terrorism; posttraumatic stress disorder; risk factors; biological studies; prospective studies	POSTTRAUMATIC-STRESS-DISORDER; MOTOR-VEHICLE ACCIDENTS; 2-YEAR PROSPECTIVE EVALUATION; AUDITORY STARTLE RESPONSE; TRAUMATIC BRAIN-INJURY; ROAD TRAFFIC ACCIDENTS; DELAYED-ONSET PTSD; NEW-YORK-CITY; PERITRAUMATIC DISSOCIATION; PREDICTING PTSD	Many important gains have been made in understanding PTSD and other responses to trauma as a result of neuroscience- based observations. Yet there are many gaps in our knowledge that currently impede our ability to predict those who will develop pathologic responses. Such knowledge is essential for developing appropriate strategies for mounting a mental health response in the aftermath of terrorism and for facilitating the recovery of individuals and society. This paper reviews clinical and biological studies that have led to an identification of pathologic responses following psychological trauma, including terrorism, and highlights areas of future-research. It is important to not only determine risk factors for the development of short-and long-term mental health responses to terrorism, but also apply these risk factors to the prediction of such responses on an individual level. It is also critical to consider the full spectrum of responses to terrorism, as well as the interplay between biological and psychological variables that contribute to these responses. Finally, it is essential to remove the barriers to collecting data in the aftermath of trauma by creating a culture of education in which the academic community can communicate to the public what is and is not known so that survivors of trauma and terrorism will understand the value of their participation in research to the generation of useful knowledge, and by maintaining the acquisition of knowledge as a priority for the government and those involved in the immediate delivery of services in the aftermath of large-scale disaster or trauma.	Bronx Vet Affairs Med Ctr, Psychiat OOMH, Bronx, NY 10468 USA	Yehuda, R (corresponding author), Bronx Vet Affairs Med Ctr, Psychiat OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.	Rachel.Yehuda@med.va.gov	Bryant, Richard/AAA-6479-2019; Marmar, Charles R./O-1902-2017	Bryant, Richard/0000-0002-9607-819X; Marmar, Charles R./0000-0001-8427-5607			*AM PSYCH ASS, 1994, DIAGN STAT MAN 4 R; Andrews B, 2000, J ABNORM PSYCHOL, V109, P69, DOI 10.1037/0021-843X.109.1.69; BOHUS B, 1968, INT J NEUROPHARMACOL, V7, P301; Boscarino JA, 1996, J CONSULT CLIN PSYCH, V64, P191, DOI 10.1037/0022-006X.64.1.191; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Breslau N, 1999, AM J PSYCHIAT, V156, P902, DOI 10.1176/ajp.156.6.902; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Brunet A, 2001, AM J PSYCHIAT, V158, P1480, DOI 10.1176/appi.ajp.158.9.1480; Bryant RA, 2003, BIOL PSYCHIAT, V53, P789, DOI 10.1016/S0006-3223(02)01895-4; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 2001, BEHAV RES THER, V39, P961, DOI 10.1016/S0005-7967(00)00086-3; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2002, AUST NZ J PSYCHIAT, V36, P205, DOI 10.1046/j.1440-1614.2002.01009.x; Buckley TC, 1996, J ABNORM PSYCHOL, V105, P617, DOI 10.1037/0021-843X.105.4.617; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; Dancu CV, 1996, J TRAUMA STRESS, V9, P253, DOI 10.1002/jts.2490090208; de Quervain DJF, 2000, NAT NEUROSCI, V3, P313, DOI 10.1038/73873; Delahanty DL, 1997, J CONSULT CLIN PSYCH, V65, P560, DOI 10.1037/0022-006X.65.4.560; Delahanty DL, 2000, BIOL PSYCHIAT, V48, P940, DOI 10.1016/S0006-3223(00)00896-9; Difede J, 2002, PSYCHOSOM MED, V64, P826, DOI 10.1097/01.PSY.0000024237.11538.08; Dunmore E, 2001, BEHAV RES THER, V39, P1063, DOI 10.1016/S0005-7967(00)00088-7; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Galea S, 2002, NEW ENGL J MED, V346, P982, DOI 10.1056/NEJMsa013404; Galea S, 2003, AM J EPIDEMIOL, V158, P514, DOI 10.1093/aje/kwg187; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; GREEN BL, 1990, AM J ORTHOPSYCHIAT, V60, P43, DOI 10.1037/h0079168; Guthrie RM, 2005, AM J PSYCHIAT, V162, P283, DOI 10.1176/appi.ajp.162.2.283; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 2002, PSYCHOL BULL, V128, P886, DOI 10.1037//0033-2909.128.6.886; Holeva V, 2001, BEHAV THER, V32, P65, DOI 10.1016/S0005-7894(01)80044-7; Holsboer F, 2000, NEUROPSYCHOPHARMACOL, V23, P477, DOI 10.1016/S0893-133X(00)00159-7; Keane T., 2001, DISSOCIATIVE STATES, P21; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Klimesch W, 1996, NEUROREPORT, V7, P1235, DOI 10.1097/00001756-199605170-00002; KOOPMAN C, 1995, J TRAUMA STRESS, V8, P29, DOI 10.1007/BF02105405; KOOPMAN C, 1994, AM J PSYCHIAT, V151, P888; Maes M, 2001, J AFFECT DISORDERS, V63, P113, DOI 10.1016/S0165-0327(00)00173-7; MARMAR C, 2003, UNPUB IMPACT WORLD T; MARMAR CR, 1994, AM J PSYCHIAT, V151, P902; Marmar CR, 1999, J NERV MENT DIS, V187, P15, DOI 10.1097/00005053-199901000-00004; Marshall GN, 2002, J ABNORM PSYCHOL, V111, P626, DOI 10.1037//0021-843X.111.4.626; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCFARLANE AC, 1989, BRIT J PSYCHIAT, V154, P221, DOI 10.1192/bjp.154.2.221; McNally RJ, 2003, BIOL PSYCHIAT, V53, P779, DOI 10.1016/S0006-3223(02)01663-3; Murray J, 2002, BRIT J PSYCHIAT, V180, P363, DOI 10.1192/bjp.180.4.363; Neylan TC, 2003, NEUROPSYCHOPHARMACOL, V28, P1666, DOI 10.1038/sj.npp.1300215; Nietzel MT, 1996, CONTEMP PSYCHOL, V41, P642; Nishith P, 2000, J ABNORM PSYCHOL, V109, P20, DOI 10.1037/0021-843X.109.1.20; North Carol S, 2002, CNS Spectr, V7, P580; Orr SP, 2003, ARCH GEN PSYCHIAT, V60, P283, DOI 10.1001/archpsyc.60.3.283; Orr SP, 1997, ANN NY ACAD SCI, V821, P114, DOI 10.1111/j.1749-6632.1997.tb48273.x; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; PACAK K, 1995, FRONT NEUROENDOCRIN, V16, P89, DOI 10.1006/frne.1995.1004; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; Pitman RK, 2000, NEW COGNITIVE NEUROS, P687; RAUSCH LS, 1997, PSYCHOL TRAUMA ANN R, V17, P67; RESNICK HS, 1995, AM J PSYCHIAT, V152, P1675; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Schuster MA, 2001, NEW ENGL J MED, V345, P1507, DOI 10.1056/NEJM200111153452024; SHALEV AY, 1992, J NERV MENT DIS, V180, P505, DOI 10.1097/00005053-199208000-00005; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1997, BRIT J PSYCHIAT, V170, P558, DOI 10.1192/bjp.170.6.558; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Shalev AY, 2000, AM J PSYCHIAT, V157, P255, DOI 10.1176/appi.ajp.157.2.255; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; Silva RR, 2000, AM J PSYCHIAT, V157, P1229, DOI 10.1176/appi.ajp.157.8.1229; Simeon D, 2003, PSYCHIAT RES, V121, P93, DOI 10.1016/S0165-1781(03)00205-1; Smith K, 2000, BEHAV RES THER, V38, P709, DOI 10.1016/S0005-7967(99)00096-0; SOLOMON Z, 1989, PSYCHIATRY, V52, P428, DOI 10.1080/00332747.1989.11024467; Southwick SM, 1997, ARCH GEN PSYCHIAT, V54, P749; SOUTHWICK SM, 1993, ARCH GEN PSYCHIAT, V50, P266; Staab JP, 1996, ANXIETY, V2, P219, DOI 10.1002/(SICI)1522-7154(1996)2:5<219::AID-ANXI3>3.0.CO;2-H; Stein MB, 2002, AM J PSYCHIAT, V159, P1675, DOI 10.1176/appi.ajp.159.10.1675; TRUE WR, 1993, ARCH GEN PSYCHIAT, V50, P257, DOI 10.1001/archpsyc.1993.01820160019002; Vaiva G, 2004, BIOL PSYCHIAT, V55, P250, DOI 10.1016/j.biopsych.2003.08.009; Wong CM, 2002, PSYCHIAT CLIN N AM, V25, P369, DOI 10.1016/S0193-953X(01)00006-5; Yehuda R, 2000, AM J PSYCHIAT, V157, P1252, DOI 10.1176/appi.ajp.157.8.1252; Yehuda R, 1998, BIOL PSYCHIAT, V44, P1305, DOI 10.1016/S0006-3223(98)00276-5; Yehuda R, 1999, CAN J PSYCHIAT, V44, P34, DOI 10.1177/070674379904400104; Yehuda R, 2002, NEW ENGL J MED, V346, P108, DOI 10.1056/NEJMra012941; YEHUDA R, 1995, AM J PSYCHIAT, V152, P1705; Yehuda R, 2001, J PSYCHIAT RES, V35, P261, DOI 10.1016/S0022-3956(01)00032-2; YEHUDA R, 1999, RISK FACTORS POSTRAU; Zangrossi H, 1999, EUR J PHARMACOL, V369, P267, DOI 10.1016/S0014-2999(99)00075-8	89	20	20	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	OCT	2005	30	10					1793	1805		10.1038/sj.npp.1300816			13	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	965VJ	WOS:000231978200003	16012535	Bronze			2021-06-18	
J	Aimaretti, G; Ghigo, E				Aimaretti, Gianluca; Ghigo, Ezio			Traumatic brain injury and hypopituitarism	THESCIENTIFICWORLDJOURNAL			English	Article						traumatic brain injury (TBI); hypopituitarism; pituitary deficits	ANEURYSMAL SUBARACHNOID HEMORRHAGE; HEAD-INJURY; NEUROENDOCRINE DYSFUNCTION; PITUITARY DYSFUNCTION; EPIDEMIOLOGY; PREVALENCE; LESIONS	Results of recent and ongoing studies have made it clear that brain injuries like traumatic brian injury (TBI) pose substantial risk to pituitary function, perhaps even greater risk than previously believed. Patients with TBI should be screened both prospectively and retrospectively for isolated, multiple, and even total pituitary deficits. It is well known that patients with "classical" hypopituitarism (due to primary hypothalamic-pituitary pathologies) do benefit from hormonal replacement therapy. It has been suggested that patients with TBI-induced hypopituitarism may benefit with appropriate hormonal replacement receiving replacement therapy such as antidiuretic hormone (ADH), glucocorticoid, and thyroid hormones when needed. Gonadal and recombinant human growth hormone (rhGH) replacement therapy should also be introduced if there are deficiencies demonstrated and even reconfirmed in a second step. The signs and symptoms of post-TBI hypopituitarism may be masked by what has been assumed to be merely the post-traumatic syndrome. By increasing awareness among physicians of the risks of brain injuries-induced endocrinopathies and the need for appropriate endocrinological testing, it may be possible to improve the quality of life and enhance the rehabilitation prospects for these patients. In most instances, these patients are first seen and treated by trauma surgeons and neurosurgeons, and subsequently by rehabilitation physicians; they must be knowledgeable about the risks of hypopituitarism so that they can determine which patients are candidates for screening for hypopituitarism. In addition, endocrinologists and internists must be educated about TBI-induced hypopituitarism and encouraged to actively share their expertise with other physicians.	Univ Turin, Dept Internal Med, Div Endocrinol & Metab, I-10126 Turin, Italy	Ghigo, E (corresponding author), Univ Turin, Dept Internal Med, Div Endocrinol & Metab, Corso Dogliotti 14, I-10126 Turin, Italy.	gianluca.aimaretti@unito.it; ezio.ghigo@unito.it					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; AIMARETTI G, 2005, UNPUB J CLIN ENDOCRI; ALTMAN R, 1961, ANN INTERN MED, V55, P149, DOI 10.7326/0003-4819-55-1-149; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Brandt L, 2004, ACTA NEUROL SCAND, V109, P91, DOI 10.1046/j.0001-6314.2003.00189.x; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; DANIEL PM, 1959, LANCET, V2, P927; De Marinis L, 1999, CLIN ENDOCRINOL, V50, P741; EDWARDS OM, 1986, MEDICINE, V65, P281; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Hillier SL, 1997, BRAIN INJURY, V11, P649; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; KUSUNAGI H, 2000, J NIPPON MED SCH, V67, P130; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Servadei F, 2002, NEUROEPIDEMIOLOGY, V21, P297, DOI 10.1159/000065523; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328	27	20	20	0	9	THESCIENTIFICWORLD LTD	NEWBURY	29-34, VENTURE WEST, NEW GREENHAM PARK, NEWBURY, BERKSHIRE RG19 6HX, ENGLAND	1537-744X			THESCIENTIFICWORLDJO	TheScientificWorldJOURNAL	SEP	2005	5						777	781		10.1100/tsw.2005.100			5	Environmental Sciences; Multidisciplinary Sciences	Environmental Sciences & Ecology; Science & Technology - Other Topics	110NL	WOS:000242385500009	16170439	DOAJ Gold, Green Published			2021-06-18	
J	Card, JP; Santone, DJ; Gluhovsky, MY; Adelson, PD				Card, JP; Santone, DJ; Gluhovsky, MY; Adelson, PD			Plastic reorganization of hippocampal and neocortical circuitry in experimental traumatic brain injury in the immature rat	JOURNAL OF NEUROTRAUMA			English	Article						development; head trauma; pseudorabies virus; transneuronal tracing	CONTROLLED CORTICAL IMPACT; PSEUDORABIES VIRUS-INFECTION; CENTRAL AUTONOMIC CIRCUITS; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; NEURAL PATHWAYS; HEAD-INJURY; APOPTOSIS; MODELS; DEATH	The reorganization of circuitry in the immature forebrain resulting from controlled cortical impact was examined with viral transneuronal tracing. Animals injured on postnatal day (PND) 17 and sham controls from the same litters received an intracerebral injection of a recombinant strain of pseudorabies virus (PRV) into the entorhinal cortex on PND 45. Fifty hours following injection of virus the animals were perfused and infected neurons were localized immunohistochemically with antisera specific for PRV. Prior studies have demonstrated that the PRV recombinant used in this analysis moves exclusively in the retrograde direction through synaptically linked neurons. CCI induced a necrotic loss of cortex at the site of impact and variable damage to the underlying corpus callosum and rostral (dorsal) hippocampus that was not present in sham controls. Analysis of viral transport in sham controls revealed retrograde transport of virus through hippocampal and neocortical circuitry in a pattern consistent with established patterns of connectivity and topography. Injured animals exhibited preservation of topographically organized connections in both the hippocampus and neocortex. However, the magnitude of labeling in the injured hemisphere was significantly increased relative to control animals and correlated with the magnitude of the injury. The distribution of infected neurons in the contralateral uninjured hemisphere also conformed to known connections. However differences in the involvement of the corpus callosum in the injury resulted in greater variability in the number of infected neurons among cases. These data provide novel insights into trauma induced reorganization of the developing brain and add to the experimental tools that can be used to assess the basis for functional recovery in animal models of developmental traumatic brain injury.	Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA	Card, JP (corresponding author), Univ Pittsburgh, Dept Neurosurg, 446 Crawford Hall, Pittsburgh, PA 15260 USA.	card@bns.pitt.edu	Adelson, David/W-2083-2019	Card, John/0000-0002-6148-7364			Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Adelson PD, 1999, EXP TOXICOL PATHOL, V51, P130; Amaral David G., 1995, P443; Billig I, 2000, J NEUROSCI, V20, P7446; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Cano G, 2004, J COMP NEUROL, V471, P462, DOI 10.1002/cne.20040; Card J.P., 1999, CURRENT PROTOCOLS NE, P151; Card JP, 1995, J NEUROVIROL, V1, P349, DOI 10.3109/13550289509111024; CARD JP, 1990, J NEUROSCI, V10, P1974; Card JP, 1999, J COMP NEUROL, V407, P438, DOI 10.1002/(SICI)1096-9861(19990510)407:3<438::AID-CNE11>3.0.CO;2-2; CARD JP, 1993, J NEUROSCI, V13, P2515; Card JP, 2001, ADV VIRUS RES, V56, P39, DOI 10.1016/S0065-3527(01)56004-2; Clark RSB, 1997, J NEUROSCI, V17, P9172; Conti AC, 1998, J NEUROSCI, V18, P5663; Dixon C. E., 1995, CENTRAL NERVOUS SYST, P255; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Enquist LW, 1999, ADV VIRUS RES, V51, P237; GALL C, 1980, J COMP NEUROL, V193, P1047, DOI 10.1002/cne.901930416; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HOFF SF, 1986, NEUROSCIENCE, V19, P1227, DOI 10.1016/0306-4522(86)90136-3; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Keyvani K, 2002, J NEUROPATH EXP NEUR, V61, P831, DOI 10.1093/jnen/61.10.831; Kim ES, 2002, J NEUROTRAUM, V19, P787, DOI 10.1089/08977150260139156; Kovac AD, 2004, BRAIN PATHOL, V14, P249; KRISTT DA, 1987, J NEUROPATH EXP NEUR, V46, P668, DOI 10.1097/00005072-198711000-00006; Lee JW, 2000, J COMP NEUROL, V418, P484; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARCHAND CF, 1986, BRAIN RES, V383, P262, DOI 10.1016/0006-8993(86)90024-7; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Pickard GE, 2002, J NEUROSCI, V22, P2701, DOI 10.1523/JNEUROSCI.22-07-02701.2002; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Rinaman L, 1999, DEV BRAIN RES, V114, P207, DOI 10.1016/S0165-3806(99)00039-5; Rinaman L, 2000, J NEUROSCI, V20, P2731; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STEVENSON HW, 2000, J PSYCHOL CHINESE SO, V1, P1; Sugaya K, 1997, NEUROSCI LETT, V223, P197, DOI 10.1016/S0304-3940(97)13433-4; VAHLNE A, 1980, INFECT IMMUN, V28, P675; VAHLNE A, 1978, J GEN VIROL, V40, P359, DOI 10.1099/0022-1317-40-2-359; WATSON RE, 1986, PEPTIDES, V7, P155, DOI 10.1016/0196-9781(86)90076-8; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	51	20	20	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2005	22	9					989	1002		10.1089/neu.2005.22.989			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	967HP	WOS:000232082600006	16156714				2021-06-18	
J	Fuller, DA; Mark, A; Keenan, MAE				Fuller, DA; Mark, A; Keenan, MAE			Excision of heterotopic ossification from the knee - A functional outcome study	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; FLEXION CONTRACTURES; BONE-FORMATION; HEAD TRAUMA; RESECTION; PROPHYLAXIS; RADIATION; ADULTS; GAIT	We retrospectively reviewed 17 consecutive patients with neurologic injuries (22 knees) who had excision of heterotopic ossification (22 knees, five bilateral) of the knees. Our primary research goal was to determine the change in range of motion at the knee after resection of heterotopic ossification in patients with neurologic injuries. Our secondary research goal was to determine the mobility gains measured regarding ambulatory and sitting functions for these patients. Diagnoses included traumatic brain injury (15 patients), anoxia (one patient), and spinal cord injury (one patient). The average age of the patients was 33 years (range, 19-51 years). Data were collected by an independent observer and included range of motion of the knee, ambulatory ability according to a five-level scale, and sitting ability according to a three-level scale. The average followup was 32 months. Range of motion improved by 65 degrees postoperatively. Extension improved from a preoperative mean of 16 degrees to a postoperative mean of 2 degrees. Flexion improved from a preoperative mean of 57 degrees to a postoperative mean of 107 degrees. Ambulatory and sitting function improved as a result of treatment. Surgical excision of heterotopic ossification of the knee is an effective procedure to increase joint mobility and function.	Moss Rehab Hosp, Philadelphia, PA USA	Fuller, DA (corresponding author), Univ Med & Dent New Jersey, Cooper Hosp, 3 Cooper Plaza,Suite 411, Camden, NJ 08103 USA.	dafuller1230@hotmail.com	Keenan, Mary Ann/ABB-1551-2020				BONTKE CB, 1988, J HEAD TRAUMA REHAB, V3, P86; Botte MJ, 1997, ORTHOPEDICS, V20, P335; CERNY K, 1994, ORTHOPEDICS, V17, P501; Charnley G, 1996, INJURY, V27, P125, DOI 10.1016/0020-1383(95)00180-8; Chidel MA, 2001, J ARTHROPLASTY, V16, P1, DOI 10.1054/arth.2001.16492; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; FREED JH, 1982, PARAPLEGIA, V20, P208, DOI 10.1038/sc.1982.39; GACON G, 1978, REV CHIR ORTHOP, V64, P375; GACON G, 1975, REV CHIR ORTHOP, V61, P269; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P59; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; Gennarelli T A, 1988, Brain Inj, V2, P175, DOI 10.3109/02699058809150942; HERNANDEZ GR, 2000, REV ESP MED NUCL, V19, P495; HOFFINGER SA, 1993, J PEDIATR ORTHOPED, V13, P722, DOI 10.1097/01241398-199311000-00006; Ippolito E, 1999, J BONE JOINT SURG AM, V81A, P783, DOI 10.2106/00004623-199906000-00005; Johns JS, 1999, J HEAD TRAUMA REHAB, V14, P269, DOI 10.1097/00001199-199906000-00007; Keenan M A, 1988, Orthop Rev, V17, P1185; KEENAN MA, 1984, FOOT ANKLE, V5, P35, DOI 10.1177/107110078400500105; Kolessar DJ, 1996, J HEAD TRAUMA REHAB, V11, P78, DOI 10.1097/00001199-199608000-00010; MALONEY WJ, 1992, CLIN ORTHOP RELAT R, P230; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; PETERS WJ, 1990, J BURN CARE REHABIL, V114, P318; POTTER PJ, 1991, AM J PHYS MED REHAB, V70, P301; Rubenstein J H, 1992, J Fla Med Assoc, V79, P828; Subbarao J V, 1999, J Spinal Cord Med, V22, P273; Subbarao J V, 1987, J Am Paraplegia Soc, V10, P3	28	20	22	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	SEP	2005		438					197	203		10.1097/01.blo.0000170718.86747.da			7	Orthopedics; Surgery	Orthopedics; Surgery	962HN	WOS:000231721800033	16131891				2021-06-18	
J	Schmitter-Edgecombe, M; Bales, JW				Schmitter-Edgecombe, M; Bales, JW			Understanding text after severe closed-head injury: Assessing inferences and memory operations with a think-aloud procedure	BRAIN AND LANGUAGE			English	Article						traumatic brain injury; closed-head injury; think-aloud; protocol analysis; language; discourse; comprehension; inferences; memory; working memory	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; RIGHT-HEMISPHERE; COMPREHENSION; DEFICITS; ABILITIES; COHERENCE; CAPACITY; LESIONS; SKILL	A think-aloud method was used to examine. the content of information available to working memory during narrative comprehension in a CHI population. Twenty severe CHI participants (> 1 year post-injury) and 20 controls talked aloud after they read each sentence of story narratives. Trabasso and Magliano's (1996a) verbal protocol analysis was then used to code for the production of inferential and non-inferential clauses and the memory operations that supported inferential clause, production. We found that CHI and control groups produced a comparable number of clauses, that inferences dominated narrative comprehension, and that both groups produced more, explanatory inferences than predictive or associative inferences. Despite these qualitative similarities, the CHI group demonstrated poorer comprehension, generated proportionately fewer inferences, relied less on retrieval as a memory source for explanatory inferences, and produced more non-inferential clauses and associative inferences. (c) 2005 Elsevier Inc. All rights reserved.	Washington State Univ, Dept Psychol, Pullman, WA 99164 USA	Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.	schmitter-a@wsu.edu					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BEEMAN M, 1993, BRAIN LANG, V44, P80, DOI 10.1006/brln.1993.1006; Benton A., 1976, MULTILINGUAL APHASIA; BIHRLE AM, 1986, BRAIN COGNITION, V5, P399, DOI 10.1016/0278-2626(86)90042-4; BRITTON BK, 1983, DISCOURSE PROCESS, V6, P39, DOI 10.1080/01638538309544553; BROWNELL HH, 1986, BRAIN LANG, V27, P310, DOI 10.1016/0093-934X(86)90022-2; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Cote N, 1999, CONSTRUCTION OF MENTAL REPRESENTATIONS DURING READING, P169; Delis DC, 1987, CALIFORNIA VERBAL LE; Ericsson K.A., 1993, PROTOCOL ANAL VERBAL; Ferstl EC, 2002, NEUROPSYCHOLOGY, V16, P292, DOI 10.1037//0894-4105.16.3.292; Ferstl EC, 2001, COGNITIVE BRAIN RES, V11, P325, DOI 10.1016/S0926-6410(01)00007-6; Fonteyn M. E., 1993, QUAL HEALTH RES, V3, P430, DOI DOI 10.1177/104973239300300403; German D.J., 1991, TEST WORD FINDING DI; GERNSBACHER MA, 1990, J EXP PSYCHOL LEARN, V16, P430, DOI 10.1037/0278-7393.16.3.430; Gernsbacher MA, 1997, AGING NEUROPSYCHOL C, V4, P175, DOI 10.1080/13825589708256646; Golden J. C., 1978, STROOP COLOR WORD TE; Graesser A., 1991, HDB READING RES, P171; GRAESSER AC, 1993, DISCOURSE PROCESS, V16, P145, DOI 10.1080/01638539309544833; GRAESSER AC, 1994, PSYCHOL REV, V101, P371, DOI 10.1037/0033-295X.101.3.371; GRAESSER AC, 1985, STRUCTURES PROCEDURE; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HAUT M W, 1990, Brain Injury, V4, P281, DOI 10.3109/02699059009026178; Haut MW, 1991, NEUROPSYCHOLOGY, V5, P81, DOI 10.1037/0894-4105.5.2.81; Heaton R., 1981, MANUAL WISCONSIN CAR; Laing SP, 2002, J LEARN DISABIL-US, V35, P436; Langston MC, 1999, LANG SPEECH & COMMUN, P181; Lehman-Blake MT, 2001, J SPEECH LANG HEAR R, V44, P639, DOI 10.1044/1092-4388(2001/052); LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; Magliano JP, 2003, COGNITION INSTRUCT, V21, P251, DOI 10.1207/S1532690XCI2103_02; Magliano JP, 1999, J EDUC PSYCHOL, V91, P615, DOI 10.1037/0022-0663.91.4.615; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Nicholas L.E., 1995, AM J SPEECH LANGUAGE, V4, P69, DOI [10.1044/1058-0360.0403.69, DOI 10.1044/1058-0360.0403.69]; Pressley M., 1995, VERBAL PROTOCOLS REA; Smith A., 1991, SYMBOL DIGIT MODALIT; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; TEASDALE G, 1974, LANCET, V2, P81; TRABASSO T, 1993, DISCOURSE PROCESS, V16, P3, DOI 10.1080/01638539309544827; Trabasso T, 1996, DISCOURSE PROCESS, V21, P255, DOI 10.1080/01638539609544959; TRABASSO T, 1985, J MEM LANG, V24, P612, DOI 10.1016/0749-596X(85)90049-X; Trabasso T., 1984, LEARNING COMPREHENSI; TRABASSO T, 1996, 1 R EVERY CHILDS RIG; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WHITNEY P, 1991, DISCOURSE PROCESS, V14, P133, DOI 10.1080/01638539109544779; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Zwaan RA, 1996, DISCOURSE PROCESS, V21, P289, DOI 10.1080/01638539609544960	52	20	21	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	SEP	2005	94	3					331	346		10.1016/j.bandl.2005.01.007			16	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	959NO	WOS:000231524900007	16098381				2021-06-18	
J	Egan, J; Worrall, L; Oxenham, D				Egan, J; Worrall, L; Oxenham, D			An Internet training intervention for people with traumatic brain injury: Barriers and outcomes	BRAIN INJURY			English	Article						TBI; brain injury; aphasia-friendly; digital divide; accessibility; disability; Internet; training; computers	CLOSED HEAD-INJURY	Primary objective: To test whether people with cognitive-linguistic impairments following traumatic brain injury could learn to use the Internet using specialized training materials. Research design: Pre-post test design. Methods and procedures: Seven participants were each matched with a volunteer tutor. Basic Internet skills were taught over six lessons using a tutor's manual and a student manual. Instructions used simple text and graphics based on Microsoft Internet Explorer 5.5. Students underwent Internet skills assessments and interviews pre- and post-training. Tutors completed a post-training questionnaire. Main outcomes and results: Six of seven participants reached moderate-to-high degrees of independence. Literacy impairment was an expected training barrier; however, cognitive impairments affecting concentration, memory and motivation were more significant. Conclusions: Findings suggest that people with cognitive-linguistic impairments can learn Internet skills using specialized training materials. Participants and their carers also reported positive outcomes beyond the acquisition of Internet skills.	Univ Queensland, Commun Disabil Ageing Res Unit, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia	Worrall, L (corresponding author), Univ Queensland, Commun Disabil Ageing Res Unit, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia.	l.worrall@uq.edu.au	Worrall, Linda/D-2579-2010	Worrall, Linda/0000-0002-3283-7038			BODDY G, 1997, HIGHER ED RES DEV, V16, P342; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; Egan J, 2004, APHASIOLOGY, V18, P265, DOI 10.1080/02687030344000562; FIFIELD MG, 1997, TECHNOLOGY DISABILIT, V6, P77; FRANCIK E, 2001, TELECOMMUNICATION PR; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; HARTLEY LL, 1995, NEUROGENIC COMMUNICA, V2, P289; Kertesz A., 1982, W APHASIA BATTERY; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; King NS, 2003, HDB CLIN NEUROPSYCHO, P487; Lezak MD, 1995, NEUROPSYCHOLOGICAL A, P17; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OWENS J, 2001, LIT REV COMPUTER INT; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rowlands A, 2001, FAM SOC-J CONTEMP H, V82, P273, DOI 10.1606/1044-3894.201; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Simpson G., 2002, AUSTR SOCIAL WORK, V55, P24, DOI DOI 10.1080/03124070208411669; SNOW P, 1995, TRAUMATIC BRAIN INJU, P137; SNOW P, 1995, TRAUMATIC BRAIN INJU, P65; Sohlberg MM, 2003, BRAIN INJURY, V17, P609, DOI 10.1080/0269905031000070189; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Togher L., 2000, BRAIN DAM B, P1; Webb D, 1998, SOCIOLOGY, V32, P541, DOI 10.1017/S003803859800008X; WILLIAMS BW, 1989, NEUROPSYCHOLOGIA, V27, P1073, DOI 10.1016/0028-3932(89)90186-3	27	20	20	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2005	19	8					555	568		10.1080/02699050400013659			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	933IS	WOS:000229622700001	16175810				2021-06-18	
J	Body, R; Parker, M				Body, R; Parker, M			Topic repetitiveness after traumatic brain injury: An emergent, jointly managed behaviour	CLINICAL LINGUISTICS & PHONETICS			English	Article						topic repetitiveness; traumatic brain injury; emergence; social cognition	COMMUNICATION BREAKDOWN; EXECUTIVE DYSFUNCTION; CONVERSATION; DISCOURSE; ABILITY; PEOPLE	Topic repetitiveness is a common component of pragmatic impairment and a powerful contributor to social exclusion. Despite this, description, characterization and intervention remain underdeveloped. This article explores the nature of repetitiveness in traumatic brain injury (TBI). A case study of one individual after TBI provides the basis for a conceptualization of topic repetitiveness in terms of two major strands of thinking in pragmatics. Firstly, it is viewed as an emergent response to underlying deficits in non-linguistic abilities. Secondly, it is described in terms of joint management of topic development between the person with TBI and his interlocutor.	Univ Sheffield, Dept Human Commun Sci, Sheffield S10 2TA, S Yorkshire, England; Head Injury Rehabil Ctr, Sheffield, S Yorkshire, England	Body, R (corresponding author), Univ Sheffield, Dept Human Commun Sci, 31 Claremont Crescent, Sheffield S10 2TA, S Yorkshire, England.	r.body@sheffield.ac.uk					ALDERMAN N, 1991, NEUROPSYCHOL REHABIL, V1, P65, DOI DOI 10.1080/09602019108401380; Bar-On R, 2003, BRAIN, V126, P1790, DOI 10.1093/brain/awg177; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; BODY R, 1999, BRAIN DAM B, P81; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Brown G., 1983, DISCOURSE ANAL; BUTTON G, 1985, HUM STUD, V8, P3, DOI 10.1007/BF00143022; Clark H. H., 1996, USING LANGUAGE; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Croteau C, 2004, APHASIOLOGY, V18, P291, DOI 10.1080/02687030344000616; Damasio A., 1994, DESCARTESERROR EMOTI; DOBBINSON S, 2000, THESIS U SHEFFIELD; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; EDMONDS PE, 1988, J COMMUN DISORD, V21, P209, DOI 10.1016/0021-9924(88)90030-5; Ellmo W, 1995, MEASURE COGNITIVE LI; Friedland D, 1998, BRAIN INJURY, V12, P1, DOI 10.1080/026990598122818; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; HOTZ G, 1995, BRAIN INJURY, V9, P151, DOI 10.3109/02699059509008188; Lindsay J, 1999, APHASIOLOGY, V13, P305, DOI 10.1080/026870399402118; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; McDonald S, 2000, APHASIOLOGY, V14, P339, DOI 10.1080/026870300401397; MCDONALD S, 1999, BRAIN DAM B, P19; McDonald S., 2002, AWARENESS SOCIAL INF; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Park NW, 2001, NEUROPSYCHOLOGIA, V39, P7, DOI 10.1016/S0028-3932(00)00101-9; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; Perkins L Whitworth A Lesser R, 1997, CONVERSATION ANAL PR; Perkins M, 2002, INVESTIGATIONS IN CLINICAL PHONETICS AND LINGUISTICS, P1; Perkins M. R., 1995, CASE STUDIES CLIN LI, P293; Perkins MR, 2005, CLIN LINGUIST PHONET, V19, P367, DOI 10.1080/02699200400027155; POWELL JA, 1995, EUR J DISORDER COMM, V30, P65; Radford J, 2000, CLIN LINGUIST PHONET, V14, P387; SCHEUERMANN EA, 1979, ERNAHRUNGSWIRTSCHAFT, P23; Selting M, 2000, LANG SOC, V29, P477, DOI 10.1017/S0047404500004012; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Van Borsel J, 2001, CLIN LINGUIST PHONET, V15, P663; WALLESCH CW, 1990, APHASIOLOGY, V4, P133, DOI 10.1080/02687039008249066; WILLCOX A, 1995, CLIN LINGUIST PHONET, V9, P235, DOI 10.3109/02699209508985335; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Ylvisaker M., 1998, COLLABORATIVE BRAIN	48	20	20	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9206	1464-5076		CLIN LINGUIST PHONET	Clin. Linguist. Phon.	JUL-AUG	2005	19	5					379	392		10.1080/02699200400027189			14	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	935EB	WOS:000229761200003	16019782				2021-06-18	
J	Mathe, JF; Richard, I; Rome, J				Mathe, JF; Richard, I; Rome, J			Serious brain injury and public health, epidemiologic and financial considerations, comprehensive management and care	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article						brain injury; traumatic coma; Glasgow Outcome Scale GOS; community reintegration; care network	HEAD-INJURY; CONSCIOUSNESS	The management of persons with traumatic brain injury affects a large spectrum of interventions from acute phase to the hospital discharge and the return to community. The incidence of brain injuries on mortality and morbidity constitutes a serious problem in front of the Health Administration. The traffic accidents remain the main cause but the falls in elderly are increasing. In the both cases preventive measures can be efficiency. In France, each year, there are about 150,000 new cases, 8000 of them will be dead and 4000 with coma. It is likely that 30,000 persons are living to day with important sequela of a brain injury. The management requires various types of interventions, each of them with specific and specialized techniques. It is necessary to have an overview of the problem and to work together in a comprehensive network. So French Health Ministery has just published an official note to precise some directives and co-ordination of the different interventions. (C) 2005 Elsevier SAS. Tous droits reserves.	CHU Nantes, Hop St Jacques, Serv Med Phys & Readaptat, F-44093 Nantes, France; CRRRF Les Capucins, Serv Med Phys & Readaptat, F-49024 Angers, France	Mathe, JF (corresponding author), CHU Nantes, Hop St Jacques, Serv Med Phys & Readaptat, F-44093 Nantes, France.	jeanfrancois.mathe@chu-nantes.fr					ALAOUI P, 1998, ANN READAPT MED PHYS, V43, P171; CHOI SC, 1996, NEUROTRAUMA, P779; ELOVIC E, 1996, MED REHABILITATION T, P1; FREREBEAU P, 1992, NEUROCHIRURGIE, V38, P35; JENNETT B, 1975, LANCET, V1, P480; KRAUS JF, 1996, NEUROTRAUMA, P13; LINDSAY JT, 1998, J NEUROTRAUM, V15, P573; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Masson F, 2000, ANN FR ANESTH, V19, P261; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; ODELL MW, 1996, MED REHABILITATION T, P103; PENTLAND B, 1988, BRIT J NEUROSURGERY, V2, P601; Ricard-Hibon A, 2000, ANN FR ANESTH, V19, P286; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; Sosin DM, 1996, BRAIN INJURY, V10, P47; STEIN SC, 1996, NEUROTRAUMA, P755; TEASDALE G, 1974, LANCET, V2, P81; Tentillier E, 2000, ANN FR ANESTH, V19, P275; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Vigue B, 2003, NEUROCHIRURGIE, V49, P583; 2004, 280 DHOSSDO01DGSSD5D; 1999, ANN FR ANESTH REANIM, V18, P11; 2002, J NEUROTRAUMA, V19, P111; 2000, J NEUROTRAUMA, V17, P453; 2002, 96 DASDEDSSDH; 2002, 288 DHOSO2DGS2002DGA	27	20	23	0	2	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0750-7658	1769-6623		ANN FR ANESTH	Ann. Fr. Anest. Reanim.	JUN	2005	24	6					688	694		10.1016/j.annfar.2005.03.029			7	Anesthesiology	Anesthesiology	941QZ	WOS:000230230600022	15950118				2021-06-18	
J	Agha, A; Ryan, J; Sherlock, M; Thompson, CJ				Agha, A; Ryan, J; Sherlock, M; Thompson, CJ			Spontaneous recovery from posttraumatic hypopituitarism	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						hypopituitarism; growth hormone; somatotroph recovery; adrenocorticotropin hormone; cortisol; rehabilitation	TRAUMATIC BRAIN-INJURY; GROWTH-HORMONE; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; GLUCAGON; ADULTS; DEFICIENCY; DIAGNOSIS; LESIONS	Hypopituitarism is an increasingly recognized complication of traumatic brain injury that can have significant potential to impair recovery and rehabilitation in affected survivors, Although posttraumatic cranial diabetes insipidus is known to be transient in many cases, recovery of established anterior pituitary hormone deficiency is thought to be a very rare event. We report the case of a 25-yr-old man who incurred severe traumatic brain injury in 1997. Sixteen months later, dynamic pituitary stimulation tests revealed severe growth hormone and adrenocorticotropin hormone deficiency. He was treated with recombinant human growth hormone and hydrocortisone. Five years after traumatic brain injury, repeat neuroendocrine assessment, prompted by an increasing serum insulin-like growth factor-1 level, showed normal growth hormone and adrenocorticotropin hormone responses. This is the first case report, to our knowledge, to show that adult posttraumatic growth hormone deficiency can be reversible. The recognition that anterior pituitary dysfunction can recover after traumatic brain injury has implications for the follow-up of patients with hypopituitarism secondary to head trauma to avoid unnecessary, expensive, and potentially harmful therapy.	Beaumont Hosp, Dept Endocrinol, Dublin 9, Ireland	Agha, A (corresponding author), Beaumont Hosp, Dept Endocrinol, Beaumont Rd, Dublin 9, Ireland.						Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Benvenga S, 1997, J ENDOCRINOL INVEST, V20, P675, DOI 10.1007/BF03348031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; CACCIARI E, 1992, J CLIN ENDOCR METAB, V74, P1284, DOI 10.1210/jc.74.6.1284; Ceballos R, 1966, Ala J Med Sci, V3, P185; COCKRELL JR, 1988, PSYCHOPHARMACOL BULL, V24, P689; Conceicao FL, 2003, J ENDOCRINOL INVEST, V26, P1065, DOI 10.1007/BF03345251; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; DANIEL PM, 1959, LANCET, V2, P927; DOWARD LC, 1995, QUAL LIFE RES, V4, P420; EDWARDS OM, 1986, MEDICINE, V65, P281; EIHOLZER U, 1986, EUR J PEDIATR, V145, P128, DOI 10.1007/BF00441873; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; HOFFMAN DM, 1994, LANCET, V343, P1065; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MONSON JP, 2003, EUR J ENDOCRINOL S2, V148, P9; PIERUCCI G, 1971, Pathologica (Genoa), V63, P71; RAO RH, 1987, METABOLISM, V36, P658, DOI 10.1016/0026-0495(87)90150-8; VANCE ML, 1994, NEW ENGL J MED, V330, P1651, DOI 10.1056/NEJM199406093302306; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	27	20	20	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAY	2005	84	5					381	385		10.1097/01.PHM.0000156898.47097.93			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	921NF	WOS:000228770600009	15829786				2021-06-18	
J	Giugni, E; Sabatini, U; Hagberg, GE; Formisano, R; Castriota-Scanderbeg, A				Giugni, E; Sabatini, U; Hagberg, GE; Formisano, R; Castriota-Scanderbeg, A			Fast detection of diffuse axonal damage in severe traumatic brain injury: Comparison of gradient-recalled echo and turbo Proton Echo Planar Spectroscopic Imaging MRI sequences	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							PERSISTENT VEGETATIVE STATE; MAGNETIC-RESONANCE; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; PRACTICAL SCALE; LESIONS; AMANTADINE; IMAGES; COMA	BACKGROUND AND PURPOSE: Diffuse axonal injury (DAI) is a common type of primary neuronal injury in patients with severe traumatic brain injury (TBI), and is frequently accompanied by tissue tear hemorrhage. T2*-weighted gradient-recalled echo (GRE) sequences are more sensitive than T2-weighted spin-echo images for detection of hemorrhage. The purpose of this study is to compare turbo Proton Echo Planar Spectroscopic Imaging (t-PEPSI), an extremely fast sequence, with GRE sequence in the detection of DAI. METHODS: Twenty-one patients (mean age 26.8 years) with severe TBI occurred at least 3 months earlier, underwent a brain MR Imaging study on a 1.5-T scanner. A qualitative evaluation of the t-PEPSI sequences was performed by identifying the optimal echo time and in-plane resolution. The number and size of DAI lesions, as well as the signal intensity contrast ratio (SI CR), were computed for each set of GRE and t-PEPSI images, and divided according to their anatomic location as lobar and/or deep brain. RESULTS: There was no significant difference between GRE and t-PEPSI sequences in the detection of the total number of DAI lesions (291 vs. 230, respectively). GRE sequence delineated a higher number of DAI in the temporal lobe compared to the t-PEPSI sequence (74 vs. 37, P < .004), while no differences were found for the other regions. The SI CR was significantly lower with the t-PEPSI than the GRE sequence (P < .00001). CONCLUSION. Owing to its very short scan time and high sensitivity to the hemorrhage foci, the t-PEPSI sequence may be used as an alternative to the GRE to assess brain DAI in severe TBI patients, especially if uncooperative and medically unstable.	IRCCS, Fdn S Lucia, I-00179 Rome, Italy	Giugni, E (corresponding author), IRCCS, Fdn S Lucia, Via Ardeatina 306, I-00179 Rome, Italy.		Hagberg, Gisela E/A-2134-2010; Sabatini, Umberto/A-8484-2010; Sabatini, Umberto/K-4659-2016	Hagberg, Gisela E/0000-0003-2176-7086; Sabatini, Umberto/0000-0001-5321-8626; Bastianello, Stefano/0000-0002-8414-9077			ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; DELAPAZ RL, 1994, RADIOGRAPHICS, V14, P1045, DOI 10.1148/radiographics.14.5.7991813; EDELMAN RR, 1994, RADIOLOGY, V192, P600, DOI 10.1148/radiology.192.3.8058920; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; GEAN AD, 1994, IMAGING HEAD TRAUMA, P207; GENTRY LR, 1994, RADIOLOGY, V297, P1; GOLDSTEIN LB, 1991, J NEUROL REHABIL, V5, P129; Graham DI, 1996, NEUROTRAUMA, P43; Hagberg GE, 2002, MAGNET RESON MED, V48, P877, DOI 10.1002/mrm.10283; JENNETT B, 1975, LANCET, V1, P480; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Kinoshita T, 2000, STROKE, V31, P1646, DOI 10.1161/01.STR.31.7.1646; Kuzma BB, 2000, SURG NEUROL, V53, P400; Lee BCP, 1999, AM J NEURORADIOL, V20, P1239; Liang LX, 1999, AM J NEURORADIOL, V20, P1527; Lin DDM, 2001, AM J NEURORADIOL, V22, P1275; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; MCLELLAN DR, 1990, COMA EMERGING PATIEN, P389; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Patel MR, 1999, AM J ROENTGENOL, V173, P479, DOI 10.2214/ajr.173.2.10430158; Patel MR, 1996, STROKE, V27, P2321, DOI 10.1161/01.STR.27.12.2321; Posse S, 1999, MAGN RESON MED, V42, P87, DOI 10.1002/(SICI)1522-2594(199907)42:1<87::AID-MRM13>3.0.CO;2-O; Posse S, 1997, MAGN RESON MED, V37, P858, DOI 10.1002/mrm.1910370609; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reichenbach JR, 1998, MAGN RESON MATER PHY, V6, P62, DOI 10.1016/S1352-8661(98)00011-8; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; TEASDALE G, 1974, LANCET, V2, P81; TOIDE K, 1990, PHARMACEUT RES, V7, P670, DOI 10.1023/A:1015890800131; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Wolansky LJ, 2000, J NEUROIMAGING, V10, P131, DOI 10.1111/jon2000103131; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	43	20	21	0	6	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2005	26	5					1140	1148					9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	928XV	WOS:000229306100028	15891173				2021-06-18	
J	Delaney, JS; Al-Kashmiri, A				Delaney, JS; Al-Kashmiri, A			Neck injuries presenting to emergency departments in the United States from 1990 to 1999 for ice hockey, soccer, and American football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPINE INJURIES; BRAIN-INJURY; HEAD; CONCUSSIONS; EPIDEMIOLOGY; PLAYERS; IMPACT; CANADA	Objective: To examine the number and rate of neck injuries in the community as a whole for ice hockey, soccer, and American football by analysing data from patients presenting to emergency departments in the United States from 1990 to 1999. Methods: Data compiled for the US Consumer Product Safety Commission were used to generate estimates for the total number of neck injuries and the more specific diagnoses of neck fractures, dislocations, contusions, sprains, strains, and lacerations occurring nationally from 1990 to 1999. These data were combined with yearly participation figures to generate rates of injury presenting to emergency departments for each sport. Results: There were an estimated 5038 neck injuries from ice hockey, 19 341 from soccer, and 114 706 from American football. These could be broken down as follows: 4964 contusions, sprains, or strains from ice hockey, 17 927 from soccer, and 104 483 from football; 105 neck fractures or dislocations from ice hockey, 214 from soccer, and 1588 from football; 199 neck lacerations for ice hockey, 0 for soccer, and 621 for football. The rates for total neck injuries and combined neck contusions, sprains, or strains were higher for football than for ice hockey or soccer in all years for which data were available. Conclusion: The rate of neck injury in the United States was higher in football than in ice hockey or soccer in the time period studied.	McGill Univ, Ctr Hlth, Montreal, PQ, Canada; McGill Univ, Royal Coll Emergency Med Residency Training Progr, Montreal, PQ H3A 2T5, Canada	Delaney, JS (corresponding author), McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada.	j.delaney@mcgill.ca	Al-Kashmiri, Ammar/AAG-4008-2020				Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88; Clarke KS, 1998, CLIN SPORT MED, V17, P1, DOI 10.1016/S0278-5919(05)70056-9; Clarke KS, 1998, CLIN SPORT MED, V17, P83, DOI 10.1016/S0278-5919(05)70063-6; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Gillogly S D, 2000, J Med Assoc Ga, V89, P39; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Jorgensen U, 1986, Br J Sports Med, V20, P7; MARZO JM, 1991, NEW YORK STATE J MED, V91, P46; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Molsa J, 1997, AM J SPORT MED, V25, P495, DOI 10.1177/036354659702500412; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; TATOR CH, 1987, CLIN SPORT MED, V6, P101; Tator CH, 2000, CAN MED ASSOC J, V162, P787; Tator CH, 1998, CLIN SPORT MED, V17, P183, DOI 10.1016/S0278-5919(05)70072-7; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; TORG JS, 1991, AM J SPORT MED, V19, P6, DOI 10.1177/036354659101900103; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	33	20	20	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR 1	2005	39	4							e21	10.1136/bjsm.2004.015735			5	Sport Sciences	Sport Sciences	911CV	WOS:000227980000006	15793079	Green Published, Bronze			2021-06-18	
J	Centonze, D; Palmieri, MG; Boffa, L; Pierantozzi, M; Stanzione, P; Brusa, L; Marciani, G; Siracusano, A; Bernardi, G; Caramia, D				Centonze, D; Palmieri, MG; Boffa, L; Pierantozzi, M; Stanzione, P; Brusa, L; Marciani, G; Siracusano, A; Bernardi, G; Caramia, D			Cortical hyperexcitability in post-traumatic stress disorder secondary to minor accidental head trauma: a neurophysiologic study	JOURNAL OF PSYCHIATRY & NEUROSCIENCE			English	Article						cortical excitability; hyperarousal; stress disorders; post-traumatic; transcranial magnetic stimulation	TRANSCRANIAL MAGNETIC STIMULATION; LONG-TERM POTENTIATION; MOTOR CORTEX EXCITABILITY; HIPPOCAMPAL VOLUME; MATTER VOLUME; SEXUAL ABUSE; WHITE-MATTER; BRAIN; INJURY; PTSD	Objective: We applied paired transcranial magnetic stimulation (pTMS) to patients with post-traumatic stress disorder (PTSD) secondary to minor accidental head trauma. Our purpose was to determine the potential abnormality of motor cortex excitability in this pathologic condition. Methods: pTMS stimulation, according to the conditioning-test paradigm employing interstimulus intervals (ISIs) of 1-6 ms, was used to investigate intracortical inhibition in control subjects and patients with PTSD. The study population consisted of 14 patients who had developed PTSD following minor head trauma, 12 healthy volunteers without a clinical history of head trauma and 11 healthy subjects who had reported accidental minor head trauma 1-4 months before the study. This clinical electrophysiologic study was performed at the Department of Neuroscience, University of Rome "Tor Vergata." Results: All patients with PTSD exhibited a significantly lower motor evoked potential (MEP) inhibition than controls at 2 ms, 3 ms and 4 ms ISI. The statistical analysis of the pTMS protocol showed a significant effect (F-2,F-36 = 25.63, p < 0.001) of the factor "group," because patients with PTSD showed a mean conditioned MEP amplitude higher than that observed in both control groups for all 6 ISIs analyzed. The "ISI" factor was also significant (F-5,F-180 = 89.85, Greenhouse-Geisser epsilon = 0.35; p < 0.001), with the mean conditioned MEP amplitude increasing from 22.5% to 127.8% as the ISI increased from 1 ms to 6 ms. Finally, the interaction of group with ISI was also significant (F-10,F-180 = 8.97, p < 0.001), showing that the condition of PTSD secondary to head trauma was able to affect the MEP amplitude at different ISIs. Conclusions: Our results demonstrate that PTSD can give rise to abnormalities in intracortical inhibition. Our results provide further evidence that alterations in cortical inhibitory circuits may underlie specific forms of neuroticism in humans.	Univ Roma Tor Vergata, Dipartimento Neurosci, Neurol Clin, I-00133 Rome, Italy; Fdn Santa Lucia, Rome, Italy; Policlin Tor Vergata, Serv Neurofisiopatol, Rome, Italy; Univ Roma Tor Vergata, Dipartimento Neurosci, Clin Psichiatr, Rome, Italy	Centonze, D (corresponding author), Univ Roma Tor Vergata, Dipartimento Neurosci, Neurol Clin, Via Montpellier 1, I-00133 Rome, Italy.	centonze@uniroma2.it	Centonze, Diego/J-7767-2016	Centonze, Diego/0000-0002-8390-8545; SIRACUSANO, ALBERTO/0000-0001-8406-093X; maria grazia, marciani/0000-0001-6324-916X			Agartz I, 1999, ARCH GEN PSYCHIAT, V56, P356, DOI 10.1001/archpsyc.56.4.356; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Blank T, 2002, J NEUROSCI, V22, P3788; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bonne O, 2001, AM J PSYCHIAT, V158, P1248, DOI 10.1176/appi.ajp.158.8.1248; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Bryant RA, 2003, BIOL PSYCHIAT, V53, P789, DOI 10.1016/S0006-3223(02)01895-4; Caramia MD, 1996, ELECTROEN CLIN NEURO, V98, P14, DOI 10.1016/0013-4694(95)00150-6; Caramia MD, 2000, NEUROLOGY, V54, P58, DOI 10.1212/WNL.54.1.58; Carrion VG, 2001, BIOL PSYCHIAT, V50, P943, DOI 10.1016/S0006-3223(01)01218-5; Charpier S, 1997, P NATL ACAD SCI USA, V94, P7036, DOI 10.1073/pnas.94.13.7036; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; De Bellis MD, 1999, BIOL PSYCHIAT, V45, P1271, DOI 10.1016/S0006-3223(99)00045-1; De Bellis MD, 2002, BIOL PSYCHIAT, V51, P544, DOI 10.1016/S0006-3223(01)01374-9; De Bellis MD, 2001, BIOL PSYCHIAT, V50, P305, DOI 10.1016/S0006-3223(01)01105-2; Evans R. W., 1996, NEUROLOGY TRAUMA, P91; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Greenberg BD, 2000, NEUROLOGY, V54, P142, DOI 10.1212/WNL.54.1.142; Grisaru N, 1998, BIOL PSYCHIAT, V44, P52, DOI 10.1016/S0006-3223(98)00016-X; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; HATHAWAY RS, 1951, MANUAL MINNESOTA MUL; Hoffman RE, 2002, AM J PSYCHIAT, V159, P1093, DOI 10.1176/appi.ajp.159.7.1093; Hull AM, 2002, BRIT J PSYCHIAT, V181, P102; Kim JJ, 2001, J NEUROSCI, V21, P5222, DOI 10.1523/JNEUROSCI.21-14-05222.2001; Kim JJ, 1998, TRENDS NEUROSCI, V21, P505, DOI 10.1016/S0166-2236(98)01322-8; KUJIRAI T, 1993, J PHYSL, V473, P501; Liepert J, 1997, J NEURAL TRANSM, V104, P1207, DOI 10.1007/BF01294721; McCann UD, 1998, ARCH GEN PSYCHIAT, V55, P276, DOI 10.1001/archpsyc.55.3.276; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Pitman RK, 2001, J CLIN PSYCHIAT, V62, P47; Rauch SL, 1996, ARCH GEN PSYCHIAT, V53, P380; Ricker JH, 2000, J HEAD TRAUMA REHAB, V15, P859, DOI 10.1097/00001199-200004000-00007; RIDDING MC, 1995, ANN NEUROL, V37, P181, DOI 10.1002/ana.410370208; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; ROSSINI PM, 1991, BRAIN RES, V567, P111, DOI 10.1016/0006-8993(91)91442-4; Rothwell JC, 1999, EEG CL N SU, P113; Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7; Schuff N, 2001, BIOL PSYCHIAT, V50, P952, DOI 10.1016/S0006-3223(01)01245-8; Shaw ME, 2002, NEUROIMAGE, V15, P661, DOI 10.1006/nimg.2001.1024; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; Shin LM, 1997, ARCH GEN PSYCHIAT, V54, P233; Spielberg CD., 1983, MANUAL STATE TRAIT A; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; vanderKolk BA, 1997, ANN NY ACAD SCI, V821, P99; Villarreal G, 2002, BIOL PSYCHIAT, V52, P119, DOI 10.1016/S0006-3223(02)01359-8; Villarreal G, 2002, CAN J PSYCHIAT, V47, P666; Villarreal G, 2001, Semin Clin Neuropsychiatry, V6, P131, DOI 10.1053/scnp.2001.21840; Wassermann EM, 2001, BIOL PSYCHIAT, V50, P377, DOI 10.1016/S0006-3223(01)01210-0; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306	53	20	20	0	0	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	1180-4882	1488-2434		J PSYCHIATR NEUROSCI	J. Psychiatry Neurosci.	MAR	2005	30	2					127	132					6	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	899DO	WOS:000227125300007	15798788				2021-06-18	
J	Long, JB; Yourick, DL; Slusher, BS; Robinson, MB; Meyerhoff, JL				Long, JB; Yourick, DL; Slusher, BS; Robinson, MB; Meyerhoff, JL			Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						NMDA; (N-methyl-D-asparune); NAAG; (N-acetylasparlylglutamate); neuroprotection; GCP II; (glutamate carboxypeptidase II); NAALADase; (N-acetylated-ot-linked acidic dipeptidase); dynorphin A	ACETYL-ASPARTYL-GLUTAMATE; TRAUMATIC BRAIN-INJURY; N-ACETYLASPARTYLGLUTAMATE; NEUROPROTECTIVE ACTIVITY; BLOOD-FLOW; RECEPTORS; ACID; RESPONSES; BINDING; MOTOR	Glutamate carboxypeptidase (GCP) II (EC 3.4.17.21), which is also known as N-acetylated-alpha-linked acidic dipeptidase (NAALADase), hydrolyses the endogenous acidic dipeptide N-acetylaspartylglutamate (NAAG), yielding N-acetyl-aspartate and glutamate. Inhibition of this enzyme by 2-(phosphonomethyl) pentanedioic acid (2-PMPA) has been shown to protect against ischemic injury to the brain and hypoxic and metabolic injury to neuronal cells in culture, presumably by increasing and decreasing the extracellular concentrations of NAAG and glutamate, respectively. Since both NAAG and GCP II are found in especially high concentrations in the spinal cord, injuries to the spinal cord involving pathophysiological elevations in extracellular glutamate might be particularly responsive to GCP II inhibition. Lumbar subarachnoid injections of dynorphin A in rats cause ischernic spinal cord injury, elevated extracellular glutamate and a persistent hindlimb paralysis that is mediated through excitatory amino acid receptors. We therefore used this injury model to evaluate the protective effects of 2PMPA. When coadministered with dynorphin A, 2-PMPA significantly attenuated the dynorphin A-induced elevations in cerebrospinal fluid glutamate levels and by 24 h postinjection caused significant dose-dependent improvements in motor scores that were associated with marked histopathological improvements. These results indicate that 2-PMPA provides effective protection against excitotoxic spinal cord injury. Published by Elsevier B.V.	Walter Reed Army Inst Res, Dept Polytrauma & Resucitat Res, Div Mil Casualty Res, Silver Spring, MD 20910 USA; Walter Reed Army Inst Res, Div Neurosci, Silver Spring, MD 20910 USA; Guildford Pharmaceut Inc, Baltimore, MD 21224 USA; Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Long, JB (corresponding author), Walter Reed Army Inst Res, Dept Polytrauma & Resucitat Res, Div Mil Casualty Res, Silver Spring, MD 20910 USA.	joseph.long@na.amedd.army.mil	Yourick, Debra/A-2121-2011				BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; BAKSHI R, 1990, NEUROSCI LETT, V110, P113, DOI 10.1016/0304-3940(90)90797-D; Berman Y, 1999, J BIOCHEM, V125, P641, DOI 10.1093/oxfordjournals.jbchem.a022331; Bruno V, 1998, NEUROSCIENCE, V85, P751, DOI 10.1016/S0306-4522(97)00531-9; Bruno V, 1998, J NEUROSCI, V18, P9594; Bruno V, 1997, J NEUROSCI, V17, P1891; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; BURLINA AP, 1994, J NEUROCHEM, V63, P1174; CAUDLE RM, 1988, BRAIN RES, V443, P329, DOI 10.1016/0006-8993(88)91628-9; Chen L, 1998, J PHARMACOL EXP THER, V284, P826; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; Coyle JT, 1997, NEUROBIOL DIS, V4, P231, DOI 10.1006/nbdi.1997.0153; FADEN AI, 1984, BRIT J PHARMACOL, V81, P271, DOI 10.1111/j.1476-5381.1984.tb10074.x; GILLAN MGC, 1985, J NEUROCHEM, V45, P1034, DOI 10.1111/j.1471-4159.1985.tb05520.x; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; ISAAC L, 1990, BRAIN RES, V531, P83, DOI 10.1016/0006-8993(90)90760-9; KOENIG ML, 1994, NEUROREPORT, V5, P1063, DOI 10.1097/00001756-199405000-00012; KOLLER KJ, 1985, J NEUROSCI, V5, P2882; KOLLER KJ, 1984, DEV BRAIN RES, V15, P137, DOI 10.1016/0165-3806(84)90150-0; LONG JB, 1987, BRAIN RES, V436, P374, DOI 10.1016/0006-8993(87)91683-0; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1167; LONG JB, 1988, EUR J PHARMACOL, V149, P287, DOI 10.1016/0014-2999(88)90659-0; LONG JB, 1994, J PHARMACOL EXP THER, V269, P358; LONG JB, 1992, J PHARMACOL EXP THER, V260, P1425; LONG JB, 1994, EUR J PHARMACOL, V261, P295, DOI 10.1016/0014-2999(94)90120-1; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MIYAKE M, 1981, J NEUROCHEM, V36, P804, DOI 10.1111/j.1471-4159.1981.tb01665.x; Neale JH, 2000, J NEUROCHEM, V75, P443, DOI 10.1046/j.1471-4159.2000.0750443.x; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PUTTFARCKEN PS, 1993, J PHARMACOL EXP THER, V266, P796; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; ROBINSON MB, 1993, J NEUROCHEM, V61, P2099, DOI 10.1111/j.1471-4159.1993.tb07447.x; SanchezPrieto J, 1996, TRENDS NEUROSCI, V19, P235, DOI 10.1016/0166-2236(96)10031-X; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SEKIGUCHI M, 1989, BRAIN RES, V482, P87, DOI 10.1016/0006-8993(89)90545-3; Shukla VK, 1997, J PHARMACOL EXP THER, V283, P604; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; STEVENS CW, 1986, J PHARMACOL EXP THER, V238, P833; Tang QB, 1999, J PHARMACOL EXP THER, V291, P760; Thomas AG, 2001, EUR J PHARMACOL, V426, P35, DOI 10.1016/S0014-2999(01)01198-0; Thomas AG, 2001, EUR J PHARMACOL, V430, P33, DOI 10.1016/S0014-2999(01)01239-0; THORNHILL JA, 1989, BRAIN RES, V490, P174, DOI 10.1016/0006-8993(89)90447-2; Tortella FC, 2000, EUR J PHARMACOL, V402, P31, DOI 10.1016/S0014-2999(00)00519-7; VALIVULLAH HM, 1994, J NEUROCHEM, V63, P1714; Wroblewska B, 1997, J NEUROCHEM, V69, P174; Wroblewska B, 1998, GLIA, V24, P172, DOI 10.1002/(SICI)1098-1136(199810)24:2<172::AID-GLIA2>3.0.CO;2-6; WROBLEWSKA B, 1993, J NEUROCHEM, V61, P943, DOI 10.1111/j.1471-4159.1993.tb03606.x	49	20	20	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	JAN 31	2005	508	1-3					115	122		10.1016/j.ejphar.2004.12.008			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	895WF	WOS:000226894000014	15680261				2021-06-18	
J	Hattiangadi, N; Pillion, JP; Slomine, B; Christensen, J; Trovato, MK; Speedie, LJ				Hattiangadi, N; Pillion, JP; Slomine, B; Christensen, J; Trovato, MK; Speedie, LJ			Characteristics of auditory agnosia in a child with severe traumatic brain injury: A case report	BRAIN AND LANGUAGE			English	Article						auditory agnosia; auditory perception; auditory brain stem response; verbal comprehension; language processing; complex sound processing; pure word deafness; temporal processing; traumatic brain injury; pediatric	PURE WORD DEAFNESS; ENVIRONMENTAL SOUNDS; SUBCORTICAL LESIONS; SPEECH-PERCEPTION; DISORDERS; DISSOCIATIONS; RECOGNITION; POTENTIALS	We present a case that is unusual in many respects from other documented incidences of auditory agnosia, including the mechanism of injury, age of the individual, and location of neurological insult. The clinical presentation is one of disturbance in the perception of spoken language, music, pitch, emotional prosody, and temporal auditory processing in the absence of significant deficits in the comprehension of written language, expressive language production, or peripheral auditory function. Furthermore, the patient demonstrates relatively preserved function in other aspects of audition such as sound localization, voice recognition, and perception of animal noises and environmental sounds. This case study demonstrates that auditory agnosia is possible following traumatic brain injury in a child, and illustrates the necessity of assessment with a wide variety of auditory stimuli to fully characterize auditory agnosia in a single individual. (C) 2004 Elsevier Inc. All rights reserved.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Dept Audiol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Dept Phys Med & Rehabil, Baltimore, MD 21218 USA	Hattiangadi, N (corresponding author), Childrens Hosp Philadelphia, Dept Psychol, 3405 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	hattiangadi@email.chop.edu		Thomas, Nina/0000-0002-4452-3626			BOWERS D, 1992, FLORIDA AFFECT BATTE; BUCHMAN AS, 1986, J NEUROL NEUROSUR PS, V49, P489, DOI 10.1136/jnnp.49.5.489; Delis DC, 2001, DELISKAPLAN EXECUTIV; Dunn L. M., 1997, PPVT 3 PEABODY PICTU; Elliott C.D., 1990, DIFFERENTIAL ABILITY; Elliott L., 1980, NW U CHILDRENS PERCE; Finitzo-Hieber T, 1977, SOUND EFFECTS RECOGN; Fitch RH, 1997, ANNU REV NEUROSCI, V20, P331, DOI 10.1146/annurev.neuro.20.1.331; FRANKLIN S, 1989, APHASIOLOGY, V3, P189, DOI 10.1080/02687038908248991; GOODGLASS H, 1978, ASSESSMENT APHASIA R; Griffiths TD, 1999, NEUROCASE, V5, P365, DOI 10.1080/13554799908402733; Griffiths TD, 2002, BRIT MED BULL, V63, P107, DOI 10.1093/bmb/63.1.107; HARMS MP, 1998, NEUROIMAGE, V7, pS365; Haskins H., 1949, PHONETICALLY BALANCE; Johkura K, 1998, J NEUROL SCI, V161, P91, DOI 10.1016/S0022-510X(98)00261-5; KATZ J, 1998, CENTRAL AUDITORY PRO, P215; Keith RW, 2000, RANDOM GAP DETECTION; Korkman M, 1998, NEPSY DEV NEUROPSYCH; LAMBERT J, 1989, CORTEX, V25, P71, DOI 10.1016/S0010-9452(89)80007-3; Liepmann H, 2001, CORTEX, V37, P547, DOI 10.1016/S0010-9452(08)70594-X; MENDEZ MF, 1988, J NEUROL NEUROSUR PS, V51, P1, DOI 10.1136/jnnp.51.1.1; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MOTOMURA N, 1986, BRAIN, V109, P379, DOI 10.1093/brain/109.3.379; Musiek F E, 1994, J Am Acad Audiol, V5, P265; Noffsinger D, 1994, J Am Acad Audiol, V5, P248; Noffsinger D, 1994, J Am Acad Audiol, V5, P231; Pinard M, 2002, NEUROCASE, V8, P40, DOI 10.1093/neucas/8.1.40; RAPIN I, 1977, DEV MED CHILD NEUROL, V2, P197; Saygin AP, 2003, BRAIN, V126, P928, DOI 10.1093/brain/awg082; SCHERG M, 1986, ELECTROEN CLIN NEURO, V65, P344, DOI 10.1016/0168-5597(86)90014-6; Semel E. M., 1995, CLIN EVALUATION LANG; SHANNON RV, 1995, SCIENCE, V270, P303, DOI 10.1126/science.270.5234.303; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Shivashankar N, 2001, CLIN NEUROL NEUROSUR, V103, P201, DOI 10.1016/S0303-8467(01)00136-6; SIDTIS JJ, 1981, NEUROPSYCHOLOGIA, V19, P103, DOI 10.1016/0028-3932(81)90050-6; Sidtis John J., 2003, Seminars in Speech and Language, V24, P93, DOI 10.1055/s-2003-38901; Simons J. S., 1999, NEUROCASE, V5, P379; Taniwaki T, 2000, CLIN NEUROL NEUROSUR, V102, P156, DOI 10.1016/S0303-8467(00)00090-1; TREHUB SE, 1995, J ACOUST SOC AM, V98, P2532, DOI 10.1121/1.414396; Vignolo LA, 2003, ANN NY ACAD SCI, V999, P50, DOI 10.1196/annals.1284.005; Vitte E, 2002, NEUROLOGY, V58, P970, DOI 10.1212/WNL.58.6.970; VONSTOCKERT TR, 1982, BRAIN LANG, V16, P133, DOI 10.1016/0093-934X(82)90077-3; Wechsler D., 1991, WECHSLER INTELLIGENC; WIER CC, 1977, J ACOUST SOC AM, V61, P178, DOI 10.1121/1.381251; Wilson R H, 1996, J Am Acad Audiol, V7, P358; WOODCOCK RW, 1989, JOHNSON WOODCOCK JOH; Zatorre RJ, 2001, CEREB CORTEX, V11, P946, DOI 10.1093/cercor/11.10.946	47	20	21	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JAN	2005	92	1					12	25		10.1016/j.bandl.2004.05.003			14	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	889NU	WOS:000226450500002	15582032				2021-06-18	
J	Hoane, MR				Hoane, MR			Treatment with magnesium improves reference memory but not working memory while reducing GFAP expression following traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						MgCl2; recovery of function; rat; sensorimotor; cognition; neurotrauma; neuroprotection; gliosis	FACILITATE RECOVERY; SENSORIMOTOR CORTEX; FUNCTIONAL RECOVERY; COGNITIVE DEFICITS; NMDA ANTAGONISTS; RATS; THERAPY; LESIONS; EFFICACY; CHLORIDE	Purpose: Previous studies have shown that administration of MgCl2 in animal models of brain injury significantly improves functional recovery: however, few studies have examined cognitive recovery. The present study evaluated the effect of MgCl2 pharmacotherapy on recovery of function following medial frontal cortex contusion injury. Methods: Groups of rats were assigned to either MgCl2 (1.0 mmol/kg) or saline treatment conditions and prepared with contusion injuries or shams. Drug treatment was administered 15 min and 24 hr following injury. Rats were examined on tests of sensorimotor performance (bilateral tactile adhesive removal) and cognitive ability (reference and working memory). Results: Administration of MgCl2 following injury significantly reduced the behavioral impairments observed on the bilateral tactile removal test. The acquisition of reference memory was also significantly improved compared to saline-treated rats; however, treatment did not improve working memory performance. Lesion analysis revealed that administration of MgCl2 did not significantly reduce lesion size compared to saline-treatment. Examination of glial fibrillary acidic protein (GFAP) expression showed that MgCl2 did significantly reduce the number of GFAP(+) cells. Conclusion: These results indicate that MgCl2 administration significantly improved behavioral outcome following injury in a task dependent manner and reduced GFAP expression.	So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Brain & Cognit Sci Program, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Brain & Cognit Sci Program, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657			ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; BARTH TM, 1990, STROKE, V21, P153; Browne KD, 2004, J NEUROSCI RES, V77, P878, DOI 10.1002/jnr.20215; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Esen F, 2003, J NEUROSURG ANESTH, V15, P119, DOI 10.1097/00008506-200304000-00009; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; Hoane Michael R, 2004, Clin Calcium, V14, P65; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2003, BRAIN RES BULL, V60, P105, DOI 10.1016/S0361-9230(03)00022-4; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kramer JH, 2003, EXP BIOL MED, V228, P665; Lee JS, 2004, J NEUROTRAUM, V21, P549, DOI 10.1089/089771504774129883; LEVIN JR, 1994, PSYCHOL BULL, V115, P153, DOI 10.1037/0033-2909.115.1.153; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van den Heuvel Corinna, 2004, Clin Calcium, V14, P9; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; Vink R, 1990, Magnes Res, V3, P163; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757	45	20	20	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2005	23	2					67	77					11	Neurosciences	Neurosciences & Neurology	963UP	WOS:000231831900002	15990413				2021-06-18	
J	Ng, YS; Chua, KSG				Ng, YS; Chua, KSG			States of Severely Altered Consciousness: Clinical characteristics, medical complications and functional outcome after rehabilitation	NEUROREHABILITATION			English	Article						rehabilitation; persistent vegetative state; minimally conscious state; traumatic brain injury; outcomes	PERSISTENT VEGETATIVE STATE; DISABILITY RATING-SCALE; TRAUMATIC BRAIN-INJURY; STROKE REHABILITATION; HEAD-INJURY; RECOVERY; DIAGNOSIS; COMA	Objective: To identify and characterize demographics, injury variables, complications, and functional outcomes in Asian patients presenting in States of Severely Altered Consciousness (SSAC). Design: Descriptive case series review. Setting/Subjects: Acute rehabilitation unit with intensive, comprehensive neurological rehabilitation program. Thirty consecutive patients diagnosed to be in persistent vegetative state (PVS) or minimally conscious (MCS) state over a 4-year period were included. Main Outcome Measures: Disability Rating Scale (DRS), Ranchos Los Amigos Scale (RLAS), Modified Barthel Index (MBI). Results: Seventeen (57%) were male, with a mean age of 31.8 years (median 25y, range 15-74, SD 16.3y). Twenty-one (70%) had traumatic brain injury, and median GCS on acute admission was 5. The mean length of stays (LOS) in acute and rehabilitation facilities was 90.1 days and 106.3 days respectively. Tracheostomized patients had longer acute LOS. (p = 0.03). All patients had improvement in their DRS scores upon rehabilitation discharge. The MBI was insensitive in identifying low-level changes; though paired analyses were significant for improvement. Seventeen (57%) patients were in PVS and the rest in MCS on admission to rehabilitation. Twelve patients progressed to a state of awareness, with eye responses as the most frequent first sign. There was a greater spread of higher RLAS categories on rehabilitation discharge. Urinary tract infection (16 patients, 53%) was the most common medical complication. Nineteen (63%) had central fever and this group was more functionally disabled (P = 0.045). The mean number of medications on discharge was 6. The majority of patients (22 patients, 73%) were discharged home, and patients continued to make functional progress post-discharge. Conclusions: Despite SSAC states, the majority improve, however profound disability persists. Possible predictors of a worse outcome include tracheostomy, severity of initial disability, initial RLAS II level and presence of central fever.	Singapore Gen Hosp, Dept Rehabil Med, Singapore 169608, Singapore; Tan Tock Seng Hosp, Dept Rehabil Med, Singapore, Singapore	Ng, YS (corresponding author), Singapore Gen Hosp, Dept Rehabil Med, Outram Rd, Singapore 169608, Singapore.	grunys@sgh.com.sg		Ng, Yee-Sien/0000-0003-1377-5852			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; CHILDERS MK, 1994, BRAIN INJURY, V8, P335, DOI 10.3109/02699059409150984; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Chua KSG, 1999, INT J REHABIL RES, V22, P189, DOI 10.1097/00004356-199909000-00005; Clinchot DM, 1997, AM J PHYS MED REHAB, V76, P323, DOI 10.1097/00002060-199707000-00012; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GORDON C, 1987, BRIT MED J, V295, P411, DOI 10.1136/bmj.295.6595.411; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Hagen C., 1972, LEVELS COGNITIVE FUN; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Kraus J. F., 1999, REHABILITATION ADULT, P3; Krimchansky BZ, 1999, BRAIN INJURY, V13, P899; LOMBARDI F, 2002, COCHRANE DATABASE, V2; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roth EJ, 2001, STROKE, V32, P523, DOI 10.1161/01.STR.32.2.523; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; SIEGLER EL, 1994, ARCH INTERN MED, V154, P2185, DOI 10.1001/archinte.154.19.2185; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; Wade DT, 1999, BMJ-BRIT MED J, V319, P841, DOI 10.1136/bmj.319.7213.841; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; 2000, SING DEP STAT	27	20	20	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2005	20	2					97	105					9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	966EG	WOS:000232001800006	15920302				2021-06-18	
J	Quinn, TJ; Smith, C; Murray, L; Stewart, J; Nicoll, JAR; Graham, DI				Quinn, TJ; Smith, C; Murray, L; Stewart, J; Nicoll, JAR; Graham, DI			There is no evidence of an association in children and teenagers between the apolipoprotein E epsilon 4 allele and post-traumatic brain swelling	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						apolipoprotein E polymorphism; brain swelling; traumatic brain injury	HEAD-INJURED CHILDREN; CEREBRAL BLOOD-FLOW; E GENOTYPE; E POLYMORPHISM; INTRACEREBRAL HEMORRHAGE; CEREBROVASCULAR-DISEASE; COGNITIVE DECLINE; APOE GENOTYPE; SURVIVAL; EDEMA	Traumatic brain injury (TBI) is an important cause of mortality and disability in children and teenagers. A particular feature of the neuropathology at post-mortem is brain swelling. The cause of the swelling in some cases is not known, while in others it is associated with traumatic axonal injury or hypoxia. Apolipoprotein E (APOE) epsilon4 allele is known to be an important genetic determinant of outcome in children after TBI. We hypothesized a relationship between possession of APOEepsilon4 and diffuse traumatic brain swelling. A total of 165 cases aged between 2 and 19 years were identified from the department's tissue archive. APOE genotype was determined by polymerase chain reaction (PCR) in 106 cases. Bilateral swelling was present in 44 cases (11 with APOEepsilon4), unilateral swelling in 25 cases (7 with APOEepsilon4) and in 36 cases (9 with APOEepsilon4) there was no evidence of brain swelling. There was no significant relationship between possession of APOEepsilon4 and the presence of cerebral swelling (chi(2) = 0.09, df = 2, P = 0.96). The 95% confidence interval for difference in proportions with swelling in those with and without the APOE epsilon4 is -19% to 22%. Thus, a significant relationship was not found between diffuse brain swelling and possession of APOEepsilon4, and in this cohort of patients there was an identifying cause of the brain swelling in all cases.	Univ Glasgow, So Gen Hosp, Acad Unit Neuropathol, Glasgow, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Univ Southampton, Div Clin Neurosci, Southampton, Hants, England	Graham, DI (corresponding author), S Glasgow Univ Hosp NHS Trust, So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	D.Graham@clinmed.gla.ac.uk	Quinn, Terence Joseph/H-7000-2019; Nicoll, James/I-9253-2017	Quinn, Terence Joseph/0000-0003-1401-0181; Nicoll, James/0000-0002-9444-7246			ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Duhaime Ann-Christine, 1996, P1553; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HIXSON JE, 1991, ARTERIOSCLER THROMB, V11, P1237, DOI 10.1161/01.ATV.11.5.1237; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kraus J, 2000, HEAD INJURY, P1; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Luerssen T G, 1991, Neurosurg Clin N Am, V2, P399; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Reichard RR, 2003, J NEUROTRAUM, V20, P347, DOI 10.1089/089771503765172309; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Weiner H. L., 2000, HEAD INJURY, P419; Weir CJ, 2001, NEUROLOGY, V57, P1097, DOI 10.1212/WNL.57.6.1097	43	20	20	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	DEC	2004	30	6					569	575		10.1111/j.1365-2990.2004.00581.x			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	870RJ	WOS:000225075200001	15540997				2021-06-18	
J	Iohom, G; Szarvas, S; Larney, V; O'Brien, J; Buckley, E; Butler, M; Shorten, G				Iohom, G; Szarvas, S; Larney, V; O'Brien, J; Buckley, E; Butler, M; Shorten, G			Perioperative plasma concentrations of stable nitric oxide products are predictive of cognitive dysfunction after laparoscopic cholecystectomy	ANESTHESIA AND ANALGESIA			English	Article							NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; GENERAL-ANESTHESIA; CARDIAC-SURGERY; NEUROBIOCHEMICAL MARKERS; SERUM CONCENTRATION; S-100 PROTEIN; SYNTHASE; ISCHEMIA	In this study our objectives were to determine the incidence of postoperative cognitive dysfunction (POCD) after laparoscopic cholecystectomy under sevoflurane anesthesia in patients aged >40 and <85 yr and to examine the associations between plasma concentrations of i) S-100beta protein and ii) stable nitric oxide (NO) products and POCD in this clinical setting. Neuropsychological tests were performed on 42 ASA physical status I-II patients the day before, and 4 days and 6 wk after surgery. Patient spouses (n = 13) were studied as controls. Cognitive dysfunction was defined as deficit in one or more cognitive domain(s). Serial measurements of serum concentrations of S-1000 protein and plasma concentrations of stable NO products (nitrate/nitrite, NOx) were performed perioperatively. Four days after surgery, new cognitive deficit was present in 16 (40%) patients and in 1 (7%) control subject (P = 0.01). Six weeks postoperatively, new cognitive deficit was present in 21 (53%) patients and 3 (23%) control subjects (P = 0.03). Compared with the "no deficit" group, patients who demonstrated a new cognitive deficit 4 days postoperatively had larger plasma NOx at each perioperative time point (P < 0.05 for each time point). Serum S-100beta protein concentrations were similar in the 2 groups. In conclusion, preoperative (and postoperative) plasma concentrations of stable NO products (but not S-100beta) are associated with early POCD. The former represents a potential biochemical predictor of POCD.	Cork Univ Hosp, Dept Anesthesia & Intens Care Med, Cork, Ireland; Cork Univ Hosp, Dept Clin Biochem, Cork, Ireland	Shorten, G (corresponding author), Cork Univ Hosp, Dept Anesthesia & Intens Care Med, Cork, Ireland.	shorteng@shb.ie					ABERG T, 1982, LANCET, V1, P1139; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Ayata C, 1997, J NEUROSCI, V17, P6908; Bruggemans EF, 1997, J CLIN EXP NEUROPSYC, V19, P543, DOI 10.1080/01688639708403743; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Cockroft KM, 1996, STROKE, V27, P1393, DOI 10.1161/01.STR.27.8.1393; DENIS R, 1984, ANESTH ANALG, V63, P653; ENDOH M, 1994, BRAIN RES, V651, P92, DOI 10.1016/0006-8993(94)90683-1; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; Fujioka S, 2000, SURG TODAY, V30, P871, DOI 10.1007/s005950070036; Granger DL, 1999, METHOD ENZYMOL, V301, P49; HARMON D, IN PRESS EUR J ANAES; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Johnson T, 2002, ANESTHESIOLOGY, V96, P1351, DOI 10.1097/00000542-200206000-00014; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; Linstedt U, 2002, ACTA ANAESTH SCAND, V46, P384, DOI 10.1034/j.1399-6576.2002.460409.x; Linstedt U, 2000, ANAESTHESIST, V49, P887, DOI 10.1007/s001010070042; Martin R, 2002, EPILEPSIA, V43, P1551, DOI 10.1046/j.1528-1157.2002.23602.x; McKeating EG, 1998, ACT NEUR S, V71, P117; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; MURKIN JM, 1995, ANN THORAC SURG, V59, P1289, DOI 10.1016/0003-4975(95)00106-U; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; Troy Anne Marie, 2002, Curr Opin Anaesthesiol, V15, P647, DOI 10.1097/00001503-200212000-00008; Tzabar Y, 1996, BRIT J ANAESTH, V76, P194; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; ZHANG ZG, 1994, BRAIN RES, V654, P85; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	20	25	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2004	99	4					1245	1252		10.1213/01.ANE.0000132971.00206.4A			8	Anesthesiology	Anesthesiology	856IW	WOS:000224039900053	15385384				2021-06-18	
J	Colantonio, A; Ratcliff, G; Chase, S; Vernich, L				Colantonio, A; Ratcliff, G; Chase, S; Vernich, L			Aging with traumatic brain injury: long-term health conditions	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						long-term outcome; traumatic brain injury	DISORDERS	Although traumatic brain injury (TBI) is a leading cause of death and disability in young adults, older adults over the age of 75 are also at high risk for TBI. As even mild injury can lead to disabling consequences, the long-term consequences of TBI need to be better understood, especially as the survival rate has increased dramatically in the last few decades. This research examined the prevalence of long-term health conditions after TBI. Using a retrospective cohort design, we examined consecutive records of adults with moderate to severe TBI discharged from a large rehabilitation hospital in Pennsylvania from 1974 to 1989. Baseline clinical information was abstracted from medical records. We interviewed consenting participants up to 24 years after injury. Our findings show a higher than expected prevalence of self-reported arthritis in the middle-aged population. There was also a high prevalence of problems with sleep and nerves many years post-injury. Some of the health conditions documented in this study could potentially be addressed early in rehabilitation; this study supports the screening of more physical health conditions in persons aging with TBI.	Univ Toronto, Dept Occupat Therapy, Toronto, ON M5G 1V7, Canada; Toronto Rehabil Inst, Toronto, ON M5G 1V7, Canada; HealthS Harmarville Rehabil Hosp, Pittsburgh, PA USA; CCC SLP Working Order, Pittsburgh, PA USA; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada	Colantonio, A (corresponding author), Univ Toronto, Dept Occupat Therapy, 500 Univ Ave,Room 950, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33 AG05856-01A1] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34740-2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33AG005856] Funding Source: NIH RePORTER		Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; *CDCP, 1996, NAT HLTH INT SURV 19; Clarke P, 2002, STROKE, V33, P1016, DOI 10.1161/01.STR.0000013066.24300.F9; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; *COUNC CLIN CLASS, 1980, INT CLASS DIS; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Kim JH, 1997, ASIAN AUSTRAL J ANIM, V10, P178, DOI 10.5713/ajas.1997.178; KINGMA J, 1992, 9201 ASS RES INC; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; RAO V, 2002, CURRENT TREATMENT OP, V9, P77; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	14	20	20	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0342-5282	1473-5660		INT J REHABIL RES	Int. J. Rehabil. Res.	SEP	2004	27	3					209	214		10.1097/00004356-200409000-00006			6	Rehabilitation	Rehabilitation	858BA	WOS:000224163900006	15319691				2021-06-18	
J	Kontos, AP; Collins, M; Russo, SA				Kontos, AP; Collins, M; Russo, SA			An introduction to sports concussion for the sport psychology consultant	JOURNAL OF APPLIED SPORT PSYCHOLOGY			English	Article							APOLIPOPROTEIN-E EPSILON-4; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; FOOTBALL PLAYERS; MILD; PERFORMANCE; ADOLESCENTS; PREVENTION; GUIDELINES; SYMPTOMS	This paper was designed to introduce the sport psychology consultant (SPC) to the relevant practical and theoretical information pertaining to sports concussion. The paper discusses four key areas related to sports concussion: I) recognition, 2) management, 3) psychological issues following a concussion, and 4) prevention and education. Throughout the paper, the authors emphasize the role of the SPC in each of these four areas. An integrated review of the sport concussion literature and current research and guidelines regarding the definition, pathophysiology, symptoms, neuropsychological testing, and risk factors for concussion is presented. The SPC's roles in educating and helping athletes deal with post-concussion issues such as the pressure to return to play and fear of reinjury are examined. The authors highlight the need for baseline neuropsychological testing of athletes; and advocate a multidimensional team approach to sport concussion, involving the SPC as a key member of that team.	Univ New Orleans, Behav Performance Lab, New Orleans, LA 70148 USA; Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Pittsburgh, PA 15260 USA; UPMC, Sports Med Concuss Program, Pittsburgh, PA 15260 USA	Kontos, AP (corresponding author), Univ New Orleans, Behav Performance Lab, 109 Human Performance Ctr, New Orleans, LA 70148 USA.	akontos@uno.edu		Kontos, Anthony/0000-0002-3749-4310			American-Psychiatric-Association, 1997, DIAGN STAT MAN MENT, V4th edn; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; BAILES JE, 2001, NEUROLOGICAL SPORTS, P1; Bandura A., 1997, SELF EFFICACY EXERCI; Barth JT., 1989, MILD HEAD INJURY, P257; BOHENEN N, 1992, NEUROSURGERY, V30, P692; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 2001, NEUROLOGICAL SPORTS, P25; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins Michael W, 2002, Curr Sports Med Rep, V1, P12; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; COLLINS MW, 2001, ANN NEW DEV SPORTS R; COLLINS MW, 2002, ORTH SOC SPORTS MED; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; EVANS L, 1995, J SPORT EXERCISE PSY, V17, P227, DOI 10.1123/jsep.17.3.227; FELER CA, 1992, HDB HEAD TRAUMA ACUT, P19; FIELD M, 2002, ANN NEW DEV SPORTS R; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Giza CC, 2001, J ATHL TRAINING, V36, P228; GONZALEZ J, 1994, ADOLESCENCE, V29, P701; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Gronwall D, 1989, MILD HEAD INJURY, P153; Groveman AM, 1987, NEUROPSYCHOLOGY, V1, P19, DOI 10.1037//0894-4105.1.1.19; Harre N, 2000, DEV REV, V20, P206, DOI 10.1006/drev.1999.0498; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 1998, PHYSICIAN SPORTSMED, V26, P25, DOI 10.3810/psm.1998.02.928; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; KONTOS AP, 2002, ANN NEW DEV SPORTS R; KONTOS AP, IN PRESS J PEDIAT PS; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Larson GA, 1996, SPORT PSYCHOL, V10, P37, DOI 10.1123/tsp.10.1.37; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; LOVELL MR, 2001, NEUROLOGICAL SPORTS, P169; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; MAROON JC, 2001, ANN NEW DEV SPORTS R; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Petitpas A., 1995, Sport psychology interventions., P255; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rotella RJ, 1999, PSYCHOL BASES SPORT, P111; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; Tysvaer A, 1981, Br J Sports Med, V15, P163; Walton G. L., 1881, BOSTON MED SURG J, V109, P337, DOI 10.1056/NEJM188310111091501; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; Williams J. M., 1993, HDB RES SPORT PSYCHO, P815; YARNELL PR, 1970, LANCET, V1, P863	57	20	20	0	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1041-3200			J APPL SPORT PSYCHOL	J. Appl. Sport Psychol.	SEP	2004	16	3					220	235		10.1080/10413200490485568			16	Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences	Social Sciences - Other Topics; Psychology; Sport Sciences	852VN	WOS:000223785000002					2021-06-18	
J	Meyerhoff, JL; Lee, JK; Rittase, BW; Tsang, AY; Yourick, DL				Meyerhoff, JL; Lee, JK; Rittase, BW; Tsang, AY; Yourick, DL			Lipoic acid pretreatment attenuates ferric chloride-induced seizures in the rat	BRAIN RESEARCH			English	Article						seizure; brain injury; hemoglobin; iron; antioxidant; lipoic acid; free radical	INTENSIVE-CARE-UNIT; POSTTRAUMATIC EPILEPSY; CEREBRAL-ISCHEMIA; CONTINUOUS EEG; EPILEPTIFORM DISCHARGES; RECURRENT SEIZURES; IRON INJECTION; BRAIN-INJURY; HEAD-INJURY; ACUTE-PHASE	Traumatic brain injury (TBI) is often complicated by the occurrence of seizures, which adversely affect clinical outcome. The risk of seizures increases to the extent that the injury is associated with sub-arachnoid hemorrhage and hematoma. A likely mechanism of seizure development post-TBI is decompartmentalization of iron from extravasated hemoglobin (Hb). It is well known that iron can catalyze formation of reactive oxygen species (ROS). Based on this proposed mechanism, a descriptive model of TBI-induced seizures, using intracortical injection of iron salts, was developed by Willmore. We have added modifications to enhance the quantifiability of seizure activity and have used the model to examine the therapeutic efficacy of lipoic acids (ROS-scavenging antioxidants). Male SD rats were pretreated with alpha-lipoic acid (ALA) and dihydrolipoic acid (DHLA) or appropriate vehicles. Under anesthesia, unilateral intracortical infusions of ferric choride were performed stereotaxically. EEG was recorded via extradural electrodes. EEG was sampled for 10 s of every 60-s interval over a 24-h period following injection of ferric chloride. We measured the number of seconds of epileptiform discharges or seizure activity in every 10-s EEG sample during the 24 h. The EEGs of rats pretreated with ALA and DHLA exhibited 55% less seizure activity than vehicle-treated ferric chloride-injected animals, suggesting that lipoic acids may be Of use in preventing or attenuating TBI-induced seizures.	Walter Reed Army Inst Res, Div Neurosci, Silver Spring, MD 20910 USA	Meyerhoff, JL (corresponding author), Walter Reed Army Inst Res, Div Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	james.meyerhoff@na.amedd.army.mil					Biewenga GP, 1997, GEN PHARMACOL, V29, P315, DOI 10.1016/S0306-3623(96)00474-0; CELESIA GG, 1976, JAMA-J AM MED ASSOC, V235, P1571, DOI 10.1001/jama.235.15.1571; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; Engstrom ER, 2001, EPILEPSY RES, V43, P135, DOI 10.1016/S0920-1211(00)00191-1; Han D, 1997, AM J PHYSIOL-REG I, V273, pR1771; JENNETT B, 1974, J NEUROSURG, V41, P208, DOI 10.3171/jns.1974.41.2.0208; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Koenig M. L., 1999, Society for Neuroscience Abstracts, V25, P2093; KUCHIWAKI H, 1989, NEUROCHIRURGIA, V32, P116; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MEYERHOFF JL, 2000, SOC NEUR ABSTR, V26, P2304; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; Panigrahi M, 1996, BRAIN RES, V717, P184, DOI 10.1016/0006-8993(96)00009-1; PAYAN H, 1970, EPILEPSIA, V11, P81, DOI 10.1111/j.1528-1157.1970.tb03869.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; ROSEN AD, 1979, EXP NEUROL, V66, P277, DOI 10.1016/0014-4886(79)90080-3; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; Suzer T, 2000, RES EXP MED, V199, P223; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Ueda Y, 1998, EXP NEUROL, V153, P123, DOI 10.1006/exnr.1998.6869; WILLMORE LJ, 1983, BRAIN RES, V277, P393, DOI 10.1016/0006-8993(83)90954-X; WILLMORE LJ, 1981, NEUROLOGY, V31, P63, DOI 10.1212/WNL.31.1.63; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; Wolz P, 1996, NEUROPHARMACOLOGY, V35, P369, DOI 10.1016/0028-3908(95)00172-7; Young GB, 1996, NEUROLOGY, V47, P83; ZIEGLER D, 1995, DIABETOLOGIA, V38, P1425, DOI 10.1007/BF00400603	35	20	22	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 6	2004	1016	2					139	144		10.1016/j.brainres.2004.03.019			6	Neurosciences	Neurosciences & Neurology	841IH	WOS:000222923000001	15246849				2021-06-18	
J	DeKosky, ST; Abrahamson, EE; Taffe, KM; Dixon, CE; Kochanek, PM; Ikonomovic, MD				DeKosky, ST; Abrahamson, EE; Taffe, KM; Dixon, CE; Kochanek, PM; Ikonomovic, MD			Effects of post-injury hypothermia and nerve growth factor infusion on antioxidant enzyme activity in the rat: implications for clinical therapies	JOURNAL OF NEUROCHEMISTRY			English	Article						catalase; glutathione peroxidase; hippocampus; reactive oxygen species; superoxide dismutase; traumatic brain injury	TRAUMATIC BRAIN-INJURY; GLUTATHIONE-PEROXIDASE ACTIVITY; CORTICAL IMPACT INJURY; NGF RESTORES DECREASE; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; CATALASE; INCREASE; DEFICITS; RNA	The pathological sequelae of traumatic brain injury (TBI) include increased oxidative stress due to the production of reactive oxygen species (ROS). Regulation of ROS levels following TBI is determined primarily by antioxidant enzyme activity that in turn can be influenced by nerve growth factor (NGF). Hypothermia is one of the current therapies designed to combat the deleterious effects of TBI. However, it has been shown to suppress post-trauma increases in NGF levels in rat brain. The present study sought to determine whether post-injury hypothermia also impairs the antioxidant response to injury, and if such an effect could be reversed by infusion of exogenous NGF. We employed a lateral controlled cortical impact injury model in rat, followed by moderate hypothermia treatment with supplemental intracerebroventricular infusion of NGF or vehicle. The time course of changes in post-injury/intervention levels of NGF and activity of three major enzymes responsible for ROS scavenging, catalase (CAT), glutathione peroxidase (GPx) and superoxide dismutase (SOD), was determined in the hippocampus. Relative to levels in injured, normothermic animals, hypothermia treatment not only suppressed NGF levels, but also attenuated CAT and GPx activity, and increased SOD activity. Infusion of NGF in injured, hypothermia-treated animals was ineffective in restoring hippocampal antioxidant enzymes activity to levels produced after injury under normothermic conditions, although it was able to increase septal cholinergic (choline acetyltransferase) enzyme activity. These results have implications for clinical treatment of TBI, demonstrating that moderate hypothermia suppresses NGF and the antioxidant response after TBI; the latter cannot be countered by exogenous NGF administration.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA	DeKosky, ST (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, 3471 5th Ave,Suite 811, Pittsburgh, PA 15213 USA.	DeKoskyST@upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07391, NS30318] Funding Source: Medline		AEBI H, 1984, METHOD ENZYMOL, V105, P121; ANDERSON KD, 1995, J COMP NEUROL, V357, P296, DOI 10.1002/cne.903570209; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; CHAN PH, 1992, J NEUROTRAUM, V9, pS417; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Clerch LB, 1996, BIOCHEM BIOPH RES CO, V222, P590, DOI 10.1006/bbrc.1996.0788; Clerch LB, 1996, AM J PHYSIOL-LUNG C, V270, pL790; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; FRIM DM, 1994, EXP NEUROL, V128, P172, DOI 10.1006/exnr.1994.1125; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; GAROFALO L, 1994, EXP NEUROL, V125, P195, DOI 10.1006/exnr.1994.1024; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HALL ED, 1993, RES P ARNMD, V71, P81; JACKSON GR, 1990, J NEUROSCI RES, V25, P360, DOI 10.1002/jnr.490250313; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Ninkovic M B, 2000, Vojnosanit Pregl, V57, P257; NISTICO G, 1991, NEUROSCI LETT, V130, P117, DOI 10.1016/0304-3940(91)90241-K; NISTICO G, 1992, FREE RADICAL BIO MED, V12, P177, DOI 10.1016/0891-5849(92)90024-B; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Povlishock J T, 1992, Hum Cell, V5, P345; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; SAMPATH D, 1994, J NEUROCHEM, V62, P2476; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739	40	20	21	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2004	90	4					998	1004		10.1111/j.1471-4159.2004.02575.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	842WC	WOS:000223034200026	15287906				2021-06-18	
J	Prigatano, GP; Johnson, SC; Gale, SD				Prigatano, GP; Johnson, SC; Gale, SD			Neuroimaging correlates of the Halstead Finger Tapping Test several years post-traumatic brain injury	BRAIN INJURY			English	Article							IMPAIRED AWARENESS; ACTIVATION	Eight healthy volunteers and seven post-acute patients with a history of severe traumatic brain injury (TBI) performed the Halstead Finger Tapping Test while undergoing functional magnetic resonance imaging (fMRI). Patients with TBI were on average 18.5 years post-trauma and at that time had normal or near normal tapping speeds. The fMRI analysis revealed greater bilateral frontal activation in healthy controls while tapping only in the right hand compared to patients with TBI. The maximum area of activation differences involved the supplementary motor area. Voxel-based morphometry (VBM) failed to reveal signs of atrophy to explain these findings. Different patterns of brain activation in patients with TBI compared to healthy controls may be seen even when the level of behavioural performance of patients is generally within normal limits.	St Josephs Hosp, Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA	Prigatano, GP (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 350 W thomas Rd, Phoenix, AZ 85013 USA.	gprigat@chw.edu					Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; DETTMERS C, 1995, J NEUROPHYSIOL, V74, P802; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Halstead WC., 1947, BRAIN INTELLIGENCE Q; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEATON RK, 1978, J NERV MENT DIS, V166, P408, DOI 10.1097/00005053-197806000-00004; Holmes AP, 1998, NEUROIMAGE, V7, pS754, DOI DOI 10.1016/S1053-8119(18)31587-8; Johnson M. T., 2000, Information Display, V16, P12; Johnson SC, 2001, J INT NEUROPSYCH SOC, V7, P55, DOI 10.1017/S135561770171106X; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mead LA, 2002, J INT NEUROPSYCH SOC, V8, P735, DOI 10.1017/S1355617702860015; Mesulam M., 1985, PRINCIPLES BEHAV NEU; Passingham RE, 1997, HUMAN BRAIN FUNCTION, P243; Prigatano GP, 1999, REHABIL PSYCHOL, V44, P145, DOI 10.1037/0090-5550.44.2.145; PRIGATANO GP, 1976, J CONSULT CLIN PSYCH, V44, P527, DOI 10.1037/0022-006X.44.4.527; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1997, ARCH PHYS MED REHAB, V78, P847, DOI 10.1016/S0003-9993(97)90198-2; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; REITAN RM, 1994, CLIN NEUROPSYCHOL, V8, P193, DOI 10.1080/13854049408401557; REITAN RM, 1956, J NERV MENT DIS, V123, P536; Rosen HJ, 2002, NEUROLOGY, V58, P198, DOI 10.1212/WNL.58.2.198; VEGA A, 1967, J CONSULT PSYCHOL, V31, P619, DOI 10.1037/h0025112; Winterer G, 2002, NEUROIMAGE, V17, P851, DOI 10.1006/nimg.2002.1232; WORSLEY KJ, 1995, UNIFIED STAT APPROAC	28	20	20	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2004	18	7					661	669		10.1080/02699050310001646170			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	821HJ	WOS:000221450700003	15204327				2021-06-18	
J	Enblad, P; Nilsson, P; Chambers, I; Citerio, G; Fiddes, H; Howells, T; Kiening, K; Ragauskas, A; Sahuquillo, J; Yau, YH; Contant, C; Piper, I				Enblad, P; Nilsson, P; Chambers, I; Citerio, G; Fiddes, H; Howells, T; Kiening, K; Ragauskas, A; Sahuquillo, J; Yau, YH; Contant, C; Piper, I			R3-Survey of traumatic brain injury management in European Brain IT centres year 2001	INTENSIVE CARE MEDICINE			English	Article						head injury; management; survey	SEVERE HEAD-INJURY; CARE MANAGEMENT; INTENSIVE-CARE; UNITED-KINGDOM; GUIDELINES; CONSORTIUM	Objective. To obtain knowledge about the conditions and management of traumatic brain injury (TBI) in a collaborative network of Brain Information Technology centres. Design. The Brain IT (Brain monitoring with Information Technology) survey comprised two parts: local conditions and policies (part A), and a case study part (part B). The information was gathered by written questionnaires followed by telephone interviews. Participants. Twenty-four Brain IT centres participated (two respondents from 18 sites). Results. The average proportion of agreement between duplicate respondents was 0.79 (range 0.44-1.00). All Brain IT centres monitored ICP. The reported order of treatment for intracranial hypertension was: evacuation of mass-lesions and head elevation (1), increase of sedation and Mannitol scheme (2), hyperventilation (3), ventricular drainage (4), craniectomy and pentothal coma (5), and decompressive lobectomy (6). The respondents were less prone to evacuate expansive contusions in relation to extra cerebral hematomas. The most common suggested interventions (alone or in combination) for treatment of intracranial hypertension without mass lesions was the Mannitol scheme (included in 71% of the suggestions), CSF drainage (included in 56%), hyperventilation (included in 32%), and pentothal coma (included in 22%). Conclusions. The suggested management of TBI was mainly in accordance with published guidelines, although a minor proportion of the answers deviated to some extent. The suggested order and combinations of different treatment interventions varied. Variation of treatment within the range of prescribed standards provides optimal conditions for an interesting future analysis of treatment and monitoring data as collected prospectively in a Brain IT database.	Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, S-75185 Uppsala, Sweden; Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Osped San Gerardo, Dept Anaesthesia, Monza, Italy; S Glasgow Univ Hosp NHS Trust, Dept Neurosurg, Glasgow, Lanark, Scotland; Virchow Hosp, Charite, Dept Neurosurg, Berlin, Germany; Kaunas Univ Technol, Dept Bioengn, Kaunas, Lithuania; Vall Hebron Univ Hosp, Dept Neurosurg, Barcelona, Spain; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; S Glasgow Univ Hosp NHS Trust, Dept Clin Phys, Glasgow, Lanark, Scotland	Enblad, P (corresponding author), Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, S-75185 Uppsala, Sweden.	Per.Enblad@neurokir.uu.se	Citerio, Giuseppe/B-1839-2015; Sahuquillo, Juan/B-3577-2008; Ragauskas, Art/J-7486-2016	Citerio, Giuseppe/0000-0002-5374-3161; Sahuquillo, Juan/0000-0003-0713-5875; Ragauskas, Art/0000-0002-3536-554X			Bullock MR, 1996, J NEUROTRAUM, V13, P643; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Piper I, 2003, ACTA NEUROCHIR, V145, P615, DOI 10.1007/s00701-003-0066-6; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825	8	20	20	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUN	2004	30	6					1058	1065		10.1007/s00134-004-2206-8			8	Critical Care Medicine	General & Internal Medicine	825BF	WOS:000221730300010	15024565				2021-06-18	
J	Lepeintre, JF; D'Arbigny, P; Mathe, JF; Vigue, B; Loubert, G; Delcour, J; Kempf, C; Tadie, M				Lepeintre, JF; D'Arbigny, P; Mathe, JF; Vigue, B; Loubert, G; Delcour, J; Kempf, C; Tadie, M			Neuroprotective effect of gacyclidine - A multicenter double-blind pilot trial in patients with acute traumatic brain injury	NEUROCHIRURGIE			English	Article						clinical trial design; traumatic brain injury; gacyclidine; N-methyl-D-aspartate; NMDA; neuroprotection; favorable outcome; Glasgow outcome scale	SPINAL-CORD-INJURY; SEVERE HEAD-INJURY; AMINO-ACIDS; EXTRACELLULAR LEVELS; ADULT-RATS; GLUTAMATE; SECONDARY; ANTAGONISTS; NIMODIPINE; RECEPTORS	The aim of this study was to assess the safety and efficacy of intravenous (IV) injections of gacyclidine, a novel NMDA receptor antagonist, for neurological and functional recovery following acute traumatic brain injury. This multicenter, prospective, randomized, placebo-controlled, double-blind study compared four parallel groups. Two IV doses were administrated (placebo, 2x0.005mg/kg, 2x0.001mg/kg, 2x0.02mg/kg): the first dose was given within 2 hours following the trauma, and the second dose 4 hours after the first. Fifty-one patients were enrolled and 48 studied between March 1995 and June 1997 in France. Evaluation criteria for safety were physical examination, cardiovascular parameters, blood chemistry, hematology, ECG, and neuropsychological changes monitored after medication. Primary evaluation criteria for efficacy was the Glasgow coma scale complemented by the initial CT-scan and Glasgow outcome scale, motor deficiencies, neuropsychological changes, and functional indenpendence at D90 and D365 or endpoint. Intracranial pressure (ICP) monitoring was not taken into account because all the clinical centers participating in this study did not use this technique in daily practice during the inclusion period. Twelve patients died during the follow-up period, none of these deaths being related to the drug. Serious adverse events (181) were reported by most of the patients with no significant differences between groups. Only 10 of these adverse events were considered to be drug-related. Safety-related laboratory tests did not show any relevant. Concerning efficacy, the predefined prognostic factors (initial CT-scan score, initial Glasgow Coma Scale and occurrence of low systolic blood pressure during the first 24 hours) largely determinated the patient's outcome. When the prognostic factors were taken into account together with the dose level in a logistic regression model, gacyclidine showed a beneficial long-term effect and a best dose-result in the 0.04mg/kg treated group. Data obtained in this clinical trial appeared sufficient to warrant a European multicenter study on gacyclidine using the same evaluation criteria and ICP monitoring.	CHU Bicetre, Serv Neurochirurg, AP HP, F-94275 Le Kremlin Bicetre, France; Beaufour Ipsen Pharma, Res & Dev, F-75781 Paris, France; CHU Nantes, Hop St Jacques, Serv Reeduc Fonctionnelle, F-44035 Nantes 01, France; CHU Bicetre, Serv Anesthesie Reanimat, AP HP, F-94275 Le Kremlin Bicetre, France; Hop Raymond Poincare, Dept Anesthesie, AP HP, F-92380 Garches, France; CHU Amiens, Serv Neurochirurg Neurotraumatol B, F-80054 Amiens 01, France; Integrated Clin Data, F-67530 Ottrott, France	Lepeintre, JF (corresponding author), CHU Bicetre, Serv Neurochirurg, AP HP, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	jf.lepeintre@bct.ap-hop-paris.fr					BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; CHAUDIEU I, 1987, EUR J MED CHEM, V22, P359, DOI 10.1016/0223-5234(87)90274-1; CHOI D, 1989, TRENDS NEUROSCI, V11, P21; CHOI DW, 1987, J NEUROSCI, V7, P369; Drian MJ, 1999, J NEUROSCI RES, V57, P927, DOI 10.1002/(SICI)1097-4547(19990915)57:6<927::AID-JNR18>3.0.CO;2-C; DRIAN MJ, 1991, J NEUROSCI RES, V29, P133, DOI 10.1002/jnr.490290116; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; Gaviria M, 2000, J NEUROTRAUM, V17, P19, DOI 10.1089/neu.2000.17.19; Gaviria M, 2000, BRAIN RES, V874, P200, DOI 10.1016/S0006-8993(00)02581-6; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Hirbec H, 2001, CNS DRUG REV, V7, P172; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KAMENKA JM, 1982, J MED CHEM, V25, P431, DOI 10.1021/jm00346a019; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lallement G, 1997, NEUROTOXICOLOGY, V18, P851; Lallement G, 1999, ARCH TOXICOL, V73, P115, DOI 10.1007/s002040050595; LEVALLOIS C, 1995, CELL BIOL TOXICOL, V11, P155, DOI 10.1007/BF00756517; LEVALLOIS C, 1992, BRAIN RES, V573, P327, DOI 10.1016/0006-8993(92)90782-5; Li S, 1999, SPINAL CORD, V37, P820, DOI 10.1038/sj.sc.3100941; Lu YM, 1996, J NEUROSCI, V16, P5457; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MAIER CM, 1995, J NEUROCHEM, V65, P652; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MICHAUD M, 1994, EUR J MED CHEM, V29, P869, DOI 10.1016/0223-5234(94)90109-0; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Murray GD, 1996, ACTA NEUROCHIR, V138, P1163, DOI 10.1007/BF01809745; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PENCALET P, 1993, J NEUROSURG, V78, P603, DOI 10.3171/jns.1993.78.4.0603; Ribotta MGY, 1998, CURR OPIN NEUROL, V11, P647, DOI 10.1097/00019052-199812000-00007; RONDOUIN G, 1988, NEUROSCI LETT, V91, P199, DOI 10.1016/0304-3940(88)90768-9; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	43	20	21	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0028-3770	1773-0619		NEUROCHIRURGIE	Neurochirurgie	JUN	2004	50	2-3	1				83	95					13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	832KR	WOS:000222266900001	15213636				2021-06-18	
J	Vespa, P; McArthur, DL; Alger, J; O'Phelan, K; Hattori, N; Wu, C; Glenn, T; Bergsneider, M; Martin, NI; Hovda, DA				Vespa, P; McArthur, DL; Alger, J; O'Phelan, K; Hattori, N; Wu, C; Glenn, T; Bergsneider, M; Martin, NI; Hovda, DA			Regional heterogeneity of post-traumatic brain metabolism as studied by microdialysis, magnetic resonance Spectroscopy and positron emission tomography	BRAIN PATHOLOGY			English	Article							CEREBRAL-BLOOD-FLOW; HUMAN HEAD-INJURY; GLUCOSE; LACTATE		Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA 90095 USA	Vespa, P (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Div Neurosurg, 10833 Le Conte Ave,CHS 18-218,Mail Code 713909, Los Angeles, CA 90095 USA.	Pvespa@mednet.ucla.edu	McArthur, David/E-6442-2013; Hattori, Naoya/AAR-6405-2020; Hattori, Naoya/G-2298-2012	McArthur, David/0000-0003-3385-1314; Glenn, Thomas/0000-0003-4273-3408; Martin, Neil/0000-0002-6565-4131			Alessandri B, 1999, ACT NEUR S, V75, P21; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; VANDERKNAAP MS, 1990, RADIOLOGY, V176, P509, DOI 10.1148/radiology.176.2.2164237; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF	19	20	20	0	1	INT SOC NEUROPATHOLOGY	LOS ANGELES	UCLA MEDICAL CENTER, SECTION NEUROPATHOLGY, C H S 18-126, LOS ANGELES, CA 90095-1732 USA	1015-6305			BRAIN PATHOL	Brain Pathol.	APR	2004	14	2					210	214		10.1111/j.1750-3639.2004.tb00055.x			5	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	820SZ	WOS:000221410900012	15193034				2021-06-18	
J	af Geijerstam, JL; Britton, M; Marke, LA				af Geijerstam, JL; Britton, M; Marke, LA			Mild head injury: observation or computed tomography? Economic aspects by literature review and decision analysis	EMERGENCY MEDICINE JOURNAL			English	Article							TRAUMATIC BRAIN INJURY; MANAGEMENT; ADMISSION; RISK	Objectives: To compare the costs of two strategies for acute management of mild head injury: inhospital observation compared with acute computed tomography (CT) and home care. Methods: Studies comparing costs for the two strategies that seem to have similar outcomes for patients were systematically reviewed. A decision tree analysis to compare the costs was also constructed, based on Swedish national costs and the risks found in a recent review on mild head injury complications. Results: No studies were found that directly measured and compared risks, benefits, and costs of the two strategies. In the four studies retrieved, involving 4126 patients, the costs for hospital observation were factual, but a model was used to evaluate costs for the CT strategy. On average, costs were one third lower with CT. Also, the decision tree analysis demonstrated that the CT strategy was one third less expensive than inhospital observation. A sensitivity analysis showed this to be valid for nearly all cases. If these calculations hold true, a change of strategy could result in annual savings of pound280 000/million inhabitants. Conclusion: The CT strategy seems to cost one third less than hospital observation.	Karolinska Hosp, Dept Med, Clin Epidemiol Unit, S-10401 Stockholm, Sweden	af Geijerstam, JL (corresponding author), Karolinska Hosp, Dept Med N4 01, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden.	jean-luc.af.geijerstam@medks.ki.se					af Geijerstam JL, 2000, EUR J SURG, V166, P526; BAKER SR, 1985, RADIOLOGY, V156, P409, DOI 10.1148/radiology.156.2.4011903; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Brell M, 2001, NEUROCIRUGIA, V12, P105; *CTR EP, 1998, HOSP CAR 1996 PAT AD; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; JONES JJ, 1981, LANCET, V2, P850; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; MITCHELL KA, 1994, J PEDIATR SURG, V29, P851, DOI 10.1016/0022-3468(94)90001-9; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; *SO HLTH CAR DISTR, 1997, REG PRIC 1998; Stalhammar D, 1986, Acta Neurochir Suppl (Wien), V36, P63; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; *SWED COUNC TECHN, 2000, 153 SWED COUNC TECH; *SWED FED COUNT CO, 1999, COST ADM PAT 1996; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Von Wild K, 2001, BRAIN INJURY, V15, P273; VYDARENY KH, 1983, INVEST RADIOL, V18, P390, DOI 10.1097/00004424-198307000-00019; WILLIAMS RJL, 1994, J ROY SOC MED, V87, P83	31	20	20	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	JAN 1	2004	21	1					54	58		10.1136/emj.2003.003178			5	Emergency Medicine	Emergency Medicine	765DC	WOS:000188251000016	14734377	Bronze, Green Published			2021-06-18	
J	Branca, B; Lake, AE				Branca, B; Lake, AE			Psychological and neuropsychological integration in multidisciplinary pain management after TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						chronic pain; neuropsychology; pain management; post-concussion syndrome; posttraumatic headache; psychotherapy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; DISABILITY INDEX; NEUROPATHIC PAIN; OPIOID USE; HEADACHE; INVENTORY; QUESTIONNAIRE; PERSONALITY	The intersection of traumatic brain injury and posttraumatic chronic pain poses a significant challenge for the health practitioner. Effective intervention requires psychological and neuropsychological evaluation, multidisciplinary teamwork, and an understanding of a wide range of pain disorders and their relationship to traumatic brain injury. Assessment must include documentation of both current functioning and premorbid history. Pain interacts with cognitive impairment, mood and anxiety disorders, dysinhibition syndromes, and personality disorders, posing significant diagnostic dilemmas and treatment challenges. Coordinated care requires multiple, ongoing interventions from a variety of specialists. Patient involvement, focusing on internal locus of control, mediates successful treatment.	Michigan Head Pain & Neurol Inst, Ann Arbor, MI 48104 USA	Branca, B (corresponding author), Michigan Head Pain & Neurol Inst, 3120 Profess Dr, Ann Arbor, MI 48104 USA.	bbranca@mhni.com					[Anonymous], 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001822; ARONOFF GM, 1992, EVALUATION TREATMENT; Barclay S, 2003, PALLIATIVE MED, V17, P27, DOI 10.1191/0269216303pm665oa; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; Blomqvist K, 2003, J ADV NURS, V41, P575, DOI 10.1046/j.1365-2648.2003.02569.x; BRANCA B, 1992, 34 ANN M AM ASS STUD, V32, P260; BRESLAU N, 1994, NEUROLOGY, V44, P17; Breslau N, 2001, NEUROLOGY, V56, P350, DOI 10.1212/WNL.56.3.350; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; BRYANT RA, 1998, AM J PSYCHIAT, V13, P31; Burgess CP, 2000, ASTROPART PHYS, V14, P1, DOI 10.1016/S0927-6505(00)00102-X; Burns JW, 2003, J CONSULT CLIN PSYCH, V71, P81, DOI 10.1037/0022-006X.71.1.81; Carlson J, 2003, J PAIN SYMPTOM MANAG, V25, P264, DOI 10.1016/S0885-3924(02)00677-2; Chandler CC, 2001, APPL COGNITIVE PSYCH, V15, P3, DOI 10.1002/1099-0720(200101/02)15:1<3::AID-ACP669>3.0.CO;2-1; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Deb S, 1999, AM J PSYCHIAT, V156, P374; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Dewar Anne, 2003, Health Expect, V6, P44, DOI 10.1046/j.1369-6513.2003.00208.x; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Fillingim RB, 2003, SPINE, V28, P143, DOI 10.1097/00007632-200301150-00010; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2; Folzer SM, 2001, AM J ORTHOPSYCHIAT, V71, P245, DOI 10.1037/0002-9432.71.2.245; Frazier SK, 2003, AM J CRIT CARE, V12, P19, DOI 10.4037/ajcc2003.12.1.19; Gatchel RJ, 2002, CLIN J PAIN, V18, P139, DOI 10.1097/00002508-200205000-00001; Gilron I, 2003, CAN J ANAESTH, V50, P42, DOI 10.1007/BF03020185; Goldfinch EP, 2002, RADIAT PROT DOSIM, V102, P3; Greve KW, 2001, BRAIN INJURY, V15, P255; Gustafsson M, 2002, J REHABIL MED, V34, P119, DOI 10.1080/165019702753714147; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Haythornthwaite JA, 1998, PAIN, V77, P33, DOI 10.1016/S0304-3959(98)00078-5; Haythornthwaite JA, 2000, CLIN J PAIN, V16, pS101, DOI 10.1097/00002508-200006001-00017; Hill J, 2003, RHEUMATOLOGY, V42, P280, DOI 10.1093/rheumatology/keg079; International Headache Society, 1988, CEPHALALGIA S7, V8, P9; JENSEN MP, 1992, PAIN, V50, P157, DOI 10.1016/0304-3959(92)90156-6; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; Klein E, 2003, CAN J PSYCHIAT, V48, P28; Klepstad P, 2002, J PAIN SYMPTOM MANAG, V24, P517, DOI 10.1016/S0885-3924(02)00526-2; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kosinski M., 2001, CEPHALALGIA, V21, P334; Kramer BJ, 2002, ARTHRIT RHEUM-ARTHR, V47, P588, DOI 10.1002/art.10795; Lake AE, 1999, J HEAD TRAUMA REHAB, V14, P70, DOI 10.1097/00001199-199902000-00008; Lane Judy C., 2002, Curr Treat Options Neurol, V4, P89, DOI 10.1007/s11940-002-0007-3; Lemstra M, 2002, HEADACHE, V42, P845, DOI 10.1046/j.1526-4610.2002.02202.x; Linehan MM., 1993, COGNITIVE BEHAV TREA; Manias E, 2003, J ADV NURS, V41, P585, DOI 10.1046/j.1365-2648.2003.02570.x; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; Martin PG, 2000, ACCIDENT ANAL PREV, V32, P541, DOI 10.1016/S0001-4575(99)00076-7; Max JE, 1998, BRAIN INJURY, V12, P41; McCracken LM, 2002, SPINE, V27, P2564, DOI 10.1097/00007632-200211150-00033; McIntosh Aileen, 2003, Health Expect, V6, P19, DOI 10.1046/j.1369-6513.2003.00197.x; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; MERIKANGAS KR, 1997, NEUROLOGIC CLIN ADV, P115; Mersky H, 1994, CLASSIFICATION CHRON; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; OKIFUJI A, 1999, HDB PAIN SYNDROMES B; Potter M, 2003, AUST J PHYSIOTHER, V49, P53, DOI 10.1016/S0004-9514(14)60188-4; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Ravens-Sieberer U, 2002, RESTOR NEUROL NEUROS, V20, P151; Saper JR, 2002, HEADACHE, V42, P663, DOI 10.1046/j.1526-4610.2002.02156.x; SAPER JR, 1999, HDB HEADACHE MANAGME; Schofield Patricia, 2003, Prof Nurse, V18, P276; Sherer M, 1999, BRAIN INJURY, V13, P973; SILBERSTEIN SD, 2003, 45 ANN SCI M AM HEAD; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stewart WF, 1999, CEPHALALGIA, V19, P107, DOI 10.1046/j.1468-2982.1999.019002107.x; Stroud MW, 2000, PAIN, V84, P347, DOI 10.1016/S0304-3959(99)00226-2; TAIT RC, 1990, PAIN, V40, P171, DOI 10.1016/0304-3959(90)90068-O; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x; TUSA RJ, 1994, NEUROLOGY, V44, P528, DOI 10.1212/WNL.44.3_Part_1.528; Verri AP, 1998, CEPHALALGIA, V18, P45, DOI 10.1177/0333102498018S2112; Viguier D, 2001, BRAIN INJURY, V15, P263; Vodopiutz J, 2002, J WOMEN HEALTH GEN-B, V11, P719, DOI 10.1089/15409990260363670; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; Walker Barbara B, 2002, Med Health R I, V85, P269; WEISSMAN MM, 1993, J PERS DISORD, V7, P44	87	20	20	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2004	19	1					40	57		10.1097/00001199-200401000-00005			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	768UT	WOS:000188554000005	14732830				2021-06-18	
J	Kumar, R; Gupta, RK; Rao, SB; Chawla, S; Husain, M; Rathore, RKS				Kumar, R; Gupta, RK; Rao, SB; Chawla, S; Husain, M; Rathore, RKS			Magnetization transfer and T2 quantitation in normal appearing cortical gray matter and white matter adjacent to focal abnormality in patients with traumatic brain injury	MAGNETIC RESONANCE IMAGING			English	Article						traumatic brain injury; T2 relaxometry; MT ratio quantitation; gray matter; white matter	DIFFUSE AXONAL INJURY; CLOSED HEAD-INJURY; MULTIPLE-SCLEROSIS; TRANSFER RATIO; HISTOPATHOLOGIC CORRELATION; COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; RELAXATION-TIME; LESIONS; ATROPHY	Traumatic brain injury (TBI) is one of the commonest causes of morbidity and mortality in the developed countries with posttraumatic epilepsy and functional disability being its major sequelae. The purpose of this study was to test the hypothesis whether the normal appearing adjacent gray and white matter regions on T2 and T1 weighted magnetization transfer (MT) weighted images show any abnormality on quantitative imaging in patients with TBI. A total of 51 patients with TBI and 10 normal subjects were included in this study. There were significant differences in T2 and MT ratio values of T2 weighted and T1 weighted MT normal appearing gray matter regions adjacent to focal image abnormality compared to normal gray matter regions in the normal individuals as corresponding contralateral regions of the TBI patient's group (p < 0.05). However the adjoining normal appearing white matter quantitative values did not show any significant change compared to the corresponding contralateral normal white matter values. We conclude that quantitative T2 and MT ratio values provide additional abnormality in patients with TBI that is not discernable on conventional T2 weighted and T1 weighted MT imaging especially in gray matter. This additional information may be of value in overall management of these patients with TBI. (C) 2003 Elsevier Inc. All rights reserved.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, Lucknow, Uttar Pradesh, India; King Georges Med Coll, Dept Neurosurg, Lucknow, Uttar Pradesh, India; Indian Inst Technol, Dept Math, Kanpur, Uttar Pradesh, India	Gupta, RK (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, Lucknow, Uttar Pradesh, India.	rgupta@sgpgi.ac.in					ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; BALABAN R S, 1992, Magnetic Resonance Quarterly, V8, P116; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Blinkenberg M, 1999, NEUROLOGY, V53, P149, DOI 10.1212/WNL.53.1.149; BOORSTEIN JM, 1994, RADIOLOGY, V191, P799, DOI 10.1148/radiology.191.3.8184068; Bozzali M, 2001, NEUROLOGY, V57, P1135, DOI 10.1212/WNL.57.6.1135; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; COMI G, 1995, J NEUROL SCI, V132, P222, DOI 10.1016/0022-510X(95)00168-2; Convit A, 2000, NEUROBIOL AGING, V21, P19, DOI 10.1016/S0197-4580(99)00107-4; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; Duncan JS, 1996, AM J NEURORADIOL, V17, P1805; ELIAS RM, 1998, RADIOLOGY, V209, P551; FILIPPI M, 1995, NEUROLOGY, V45, P478, DOI 10.1212/WNL.45.3.478; Ge YL, 2002, J COMPUT ASSIST TOMO, V26, P62, DOI 10.1097/00004728-200201000-00009; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GOMORI JM, 1993, AM J NEURORADIOL, V14, P871; Gupta RK, 2001, J COMPUT ASSIST TOMO, V25, P698, DOI 10.1097/00004728-200109000-00006; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Kabani NJ, 2002, NEUROIMAGE, V15, P604, DOI 10.1006/nimg.2001.0992; Kasner SE, 1997, NEUROLOGY, V48, P534, DOI 10.1212/WNL.48.2.534; Kathuria MK, 1998, JMRI-J MAGN RESON IM, V8, P473, DOI 10.1002/jmri.1880080231; Kato Y, 1997, AM J NEURORADIOL, V18, P1541; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kumar R, 2002, NEUROIMAGE, V15, P1015, DOI 10.1006/nimg.2001.1036; KURTZKE JF, 1987, CLIN NEUROLOGY, P1; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; LOEVNER LA, 1995, RADIOLOGY, V196, P511, DOI 10.1148/radiology.196.2.7617869; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; Namer IJ, 1999, EPILEPSIA, V40, P1424, DOI 10.1111/j.1528-1157.1999.tb02015.x; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; RAINE CS, 1989, LAB INVEST, V60, P714; Swann A, 1997, INT J GERIATR PSYCH, V12, P1182, DOI 10.1002/(SICI)1099-1166(199712)12:12<1182::AID-GPS714>3.3.CO;2-D; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Vavasour IM, 1998, MAGNET RESON MED, V40, P763, DOI 10.1002/mrm.1910400518; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113	46	20	21	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	OCT	2003	21	8					893	899		10.1016/S0730-725X(03)00189-9			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	740QA	WOS:000186412000009	14599540				2021-06-18	
J	Lehnung, M; Leplow, B; Ekroll, V; Benz, B; Ritz, A; Mehdorn, M; Ferstl, R				Lehnung, M; Leplow, B; Ekroll, V; Benz, B; Ritz, A; Mehdorn, M; Ferstl, R			Recovery of spatial memory and persistence of spatial orientation deficits after traumatic brain injury during childhood	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; MORRIS WATER MAZE; 9-MONTH-OLD INFANTS; PLACE NAVIGATION; SCHOOL-CHILDREN; IMMATURE RAT; RADIAL MAZE; ONTOGENY; IMPAIRMENT; LOCALIZATION	The present study set out to examine the recovery of spatial learning and cognitive mapping skills after severe TBI in childhood. A prospective investigation was carried out with repeated measures. Children with TBI (n = 18) and healthy matched controls ( n = 18) were investigated while the children with TBI stayed in a rehabilitation facility (t(0)) and 4 years later (t(1)). Children were assessed with the Kiel Locomotor Maze, where they had to remember defined locations in an experimental chamber with completely controlled intra- and extra-maze cues until the learning criterion was reached. During probe trials, cognitive mapping strategies were assessed. Results showed (i) that spatial learning is functionally restituted 4 years post-trauma and (ii) that cognitive mapping skills are still impaired 4 years post-trauma. It was concluded that cognitive performance of children who survived a severe TBI may be overestimated, having far reaching consequences for the children.	Univ Kiel, Dept Psychol, D-24098 Kiel, Germany; Univ Kiel, Clin Neurosurg, D-24098 Kiel, Germany; Univ Halle Wittenberg, Dept Psychol, Halle An Der Saale, Germany; Childrens Rehabil Ctr, Bremen, Germany	Lehnung, M (corresponding author), Univ Kiel, Dept Psychol, Olshausenstr 62, D-24098 Kiel, Germany.	marialehnung@aol.com	Mehdorn, Maximilian/D-2495-2010	Ekroll, Vebjorn/0000-0002-9383-7322			AADLAND J, 1985, DEV PSYCHOBIOL, V18, P163, DOI 10.1002/dev.420180208; Achenbach TM, 1983, MANUAL CHILD BEHAV C; ACREDOLO LP, 1979, DEV PSYCHOL, V15, P666, DOI 10.1037/0012-1649.15.6.666; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Bakker K, 1999, Pediatr Rehabil, V3, P149; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BENZ B, 1996, KINDH ENTWICK, V5, P201; BOHOT V, 1984, NEUR ABSTR, V20, P361; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; BREMNER JG, 1978, DEV PSYCHOL, V14, P346, DOI 10.1037/0012-1649.14.4.346; Brown RW, 1997, DEV PSYCHOBIOL, V30, P329, DOI 10.1002/(SICI)1098-2302(199705)30:4<329::AID-DEV6>3.0.CO;2-Q; Bures J, 1997, P NATL ACAD SCI USA, V94, P343, DOI 10.1073/pnas.94.1.343; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 1999, Pediatr Rehabil, V3, P167; CHAPILLON P, 1995, DEV PSYCHOBIOL, V28, P429, DOI 10.1002/dev.420280805; Chapillon P, 1996, DEV PSYCHOBIOL, V29, P529; CORNELL EH, 1989, DEV PSYCHOL, V25, P755, DOI 10.1037/0012-1649.25.5.755; DALE PS, 1995, APPL PSYCHOLINGUIST, V16, P173, DOI 10.1017/S0142716400007074; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FOREMAN N, 1984, DEV PSYCHOBIOL, V17, P129, DOI 10.1002/dev.420170204; FOREMAN N, 1990, J GEN PSYCHOL, V117, P267; Geary DC, 2000, J EXP CHILD PSYCHOL, V77, P337, DOI 10.1006/jecp.2000.2594; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Jacobs WJ, 1997, LEARN MOTIV, V28, P521, DOI 10.1006/lmot.1997.0977; KERMOIAN R, 1988, CHILD DEV, V59, P908, DOI 10.2307/1130258; Lehnung M, 2001, CHILD NEUROPSYCHOL, V7, P59, DOI 10.1076/chin.7.2.59.3129; Lehnung M, 2001, PSYCHOL ERZ UNTERR, V48, P246; Lehnung M, 1998, BRIT J PSYCHOL, V89, P463, DOI 10.1111/j.2044-8295.1998.tb02697.x; LEHNUNG MM, 2000, ENNTWICKLUNG RAUMLIC; LEPLOW B, 1994, UNPUB NEUROPSYCHOLOG; LEPLOW B, 1998, LECT NOTES ARTIF INT, P9; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LordMaes J, 1996, J LEARN DISABIL, V29, P609, DOI 10.1177/002221949602900605; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Morse S, 1999, Pediatr Rehabil, V3, P139; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1978, J COMP PHYSIOL PSYCH, V92, P609, DOI 10.1037/h0077492; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; Overman WH, 1996, BEHAV NEUROSCI, V110, P1205, DOI 10.1037/0735-7044.110.6.1205; Piaget J., 1948, REPRESENTATION ESPAC; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Reid I., 1995, NEUR ABSTR, V21, P1446; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; THOMPSON NM, 1999, NEUROPSYCHOLOGY, V8, P333; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; Verger K, 2000, BRAIN INJURY, V14, P495; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530	61	20	20	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2003	17	10					855	869		10.1080/0269905031000089369			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	719CR	WOS:000185186500004	12963552				2021-06-18	
J	Hayman-Abello, SE; Rourke, BP; Fuerst, DR				Hayman-Abello, SE; Rourke, BP; Fuerst, DR			Psychosocial status after pediatric traumatic brain injury: A subtype analysis using the Child Behavior Checklist	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	28th Annual Meeting of the International-Neuropsychological-Society	FEB 09-12, 2000	DENVER, COLORADO	Int Neuropsychol Soc		TBI; psychosocial; subtypes; CBCL	CLOSED-HEAD-INJURY; NEUROBEHAVIORAL SYMPTOMS; PSYCHIATRIC-DISORDERS; ADOLESCENTS; MILD; PERFORMANCE; PREVALENCE; OUTCOMES	This study identified subtypes of psychosocial functioning in children who had sustained traumatic brain injury (TBI). Child Behavior Checklist (CBCL) profiles for 92 participants, aged 12 to 18 years, who had sustained a mild, moderate. or severe TBI were subjected to Q-Factor analysis. Sixty-four of the participants (75%) were classified into a four-category psychosocial typology labelled Normal (n = 32), Attention (n = 14), Delinquent (n = 10). and Withdrawn-Somatic (n = 8). This typology was found to overlap in part with previous TBI psychosocial typology (Butler et at., 1997), and with three of the clinical profile types derived by Achenbach (1993) for the CBCL. The majority of participants, including those who sustained severe TBI, were assigned to the Normal subtype and the overall level of psychosocial deviance was relatively mild in the other three subtypes. The results of this study support previous typology efforts and confirm the heterogeneous presentation of social and emotional functioning following TBI.	Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; Yale Univ, New Haven, CT 06520 USA; Wayne State Univ, Sch Med, Detroit, MI USA	Hayman-Abello, SE (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.						Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach TM, 1983, MANUAL CHILD BEHAV C; ACHENBACH TM, 1993, EMPIRICALLY BASED TA; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Butler K, 1997, CHILD NEUROPSYCHOL, V3, P98, DOI 10.1080/09297049708401371; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; DROTAR D, 1995, J CLIN CHILD PSYCHOL, V24, P184, DOI 10.1207/s15374424jccp2402_6; EWINGCOBBS L, 1995, SYNDROME NONVERBAL L, P433; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; FLETCHER JM, 1997, ASSESSMENT CHILDHOOD, P453; FUERST DR, 1990, J CONSULT CLIN PSYCH, V58, P657, DOI 10.1037/0022-006X.58.5.657; FUERST DR, 1991, THESIS U WINDSOR ONT; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Green ML, 1998, J PEDIATR PSYCHOL, V23, P289, DOI 10.1093/jpepsy/23.5.289; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; PELCO L, 1992, Brain Injury, V6, P29, DOI 10.3109/02699059209008119; PORTER JE, 1985, NEUROPSYCHOLOGY LEAR, P257; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Rourke B. P., 1991, LEARNING DISABILITIE; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Shaffer D, 1975, Ciba Found Symp, P191; SHAFFER D, 1995, TRAUMATIC HEAD INJUR, P55; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Tsatsanis KD, 1997, J LEARN DISABIL, V30, P490, DOI 10.1177/002221949703000505; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	39	20	20	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2003	9	6					887	898		10.1017/S1355617703960097			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	714YA	WOS:000184941000009	14632248				2021-06-18	
J	Riley, GA; Simmonds, LV				Riley, GA; Simmonds, LV			How robust is performance on the National Adult Reading Test following traumatic brain injury?	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; DEMOGRAPHIC-VARIABLES; PREMORBID INTELLIGENCE; NART PERFORMANCE; REGRESSION; IQ; RELIABILITY; EQUATION; APHASIA	Objective. To investigate whether National Adult Reading Test (NART) performance may be impaired by severe traumatic brain injury (TBI). Method. A sample of 26 people who had been given a NART within 12 months of a severe TBI was given a second NART at least 12 months after the first NART. Results. Mean performance on the second NART was significantly better than performance on the first NART. Of the participants, 11 (42%) showed an improvement of more than 5 IQ points in respect of the verbal IQ estimates based on their NART scores, with three participants showing an improvement of 20 points. In applying the NART to determine the presence of an acquired intellectual impairment, use of the first NART scores alone would have resulted in such impairments being missed in at least 25% of a subsample of 16 participants for whom an actual verbal IQ had been obtained at the time of the first NART. Conclusion. An NART given within 12 months of a severe TBI runs the risk of significantly underestimating pre-morbid IQ. If applied in this context, it is recommended that the NART score is used in conjunction with other methods of estimation, such as those based on demographic data.	Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England	Riley, GA (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.		Riley, Gerard/A-4328-2008; riley, gerard/AAP-1439-2020; Riley, Gerard Anthony/J-1646-2012	Riley, Gerard Anthony/0000-0002-1167-8023			Alcott D, 1999, BRIT J CLIN PSYCHOL, V38, P431, DOI 10.1348/014466599162926; Basso MR, 2000, CLIN NEUROPSYCHOL, V14, P325, DOI 10.1076/1385-4046(200008)14:3;1-P;FT325; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P192, DOI 10.1080/13854049708407050; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P97, DOI 10.1348/014466501163517; CRAWFORD JR, 1989, BRIT J CLIN PSYCHOL, V28, P267, DOI 10.1111/j.2044-8260.1989.tb01376.x; CRAWFORD JR, 1990, BRIT J CLIN PSYCHOL, V29, P435, DOI 10.1111/j.2044-8260.1990.tb00908.x; CRAWFORD JR, 1988, BRIT J CLIN PSYCHOL, V27, P181, DOI 10.1111/j.2044-8260.1988.tb00770.x; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Howell D. C., 1997, STAT METHODS PSYCHOL; Joseph J, 2001, J LEARN DISABIL-US, V34, P566, DOI 10.1177/002221940103400609; KERR C, 1995, BRAIN INJURY, V9, P777, DOI 10.3109/02699059509008234; Kiyosawa M, 1996, GRAEF ARCH CLIN EXP, V234, P110, DOI 10.1007/BF00695250; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LAMBONRALPH MA, 2000, NEUROCASE, V6, P141; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; OCARROLL RE, 1987, BRIT J CLIN PSYCHOL, V26, P229, DOI 10.1111/j.2044-8260.1987.tb01352.x; ODONNELL JP, 1990, J CLIN PSYCHOL, V46, P310, DOI 10.1002/1097-4679(199005)46:3<310::AID-JCLP2270460311>3.0.CO;2-G; RIMNEL RW, 1990, REHABILITATION ADULT, P8; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Syder D., 1993, SHEFFIELD SCREENING; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; Veiel HOF, 2001, PSYCHOL ASSESSMENT, V13, P356, DOI 10.1037/1040-3590.13.3.356; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilson, 1991, NATL ADULT READING T; Wilson B., 1987, BEHAV INATTENTION TE; WILSON BA, 1994, J CLIN EXP NEUROPSYC, V16, P354, DOI 10.1080/01688639408402646; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	20	20	0	4	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND	0144-6657			BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	SEP	2003	42		3				319	328		10.1348/01446650360703410			10	Psychology, Clinical	Psychology	730TY	WOS:000185847300008	14565896				2021-06-18	
J	Herskovits, EH; Gerring, JP				Herskovits, EH; Gerring, JP			Application of a data-mining method based on Bayesian networks to lesion-deficit analysis	NEUROIMAGE			English	Article							CLOSED-HEAD INJURY; HYPERACTIVITY DISORDER; ANATOMIC CHARACTERISTICS; PROBABILISTIC NETWORKS; CORPUS-CALLOSUM; BRAIN; PREVALENCE; CHILDREN; IMAGES	Although lesion-deficit analysis (LDA) has provided extensive information about structure-function associations in the human brain, LDA has suffered from the difficulties inherent to the analysis of spatial data, i.e., there are many more variables than subjects, and data may be difficult to model using standard distributions, such as the normal distribution. We herein describe a Bayesian method for LDA; this method is based on data-mining techniques that employ Bayesian networks to represent structure-function associations. These methods are computationally tractable, and can represent complex, nonlinear structure-function associations. When applied to the evaluation of data obtained from a study of the psychiatric sequelae of traumatic brain injury in children, this method generates a Bayesian network that demonstrates complex, nonlinear associations among lesions in the left caudate, right globus pallidus, right side of the corpus callosum, right caudate, and left thalamus, and subsequent development of attention-deficit hyperactivity disorder, confirming and extending our previous statistical analysis of these data. Furthermore, analysis of simulated data indicates that methods based on Bayesian networks may be more sensitive and specific for detecting associations among categorical variables than methods based on chi-square and Fisher exact statistics. (C) 2003 Elsevier Science (USA). All rights reserved.	Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; Johns Hopkins Bayview Med Ctr, Dept Psychiat, Baltimore, MD 21224 USA	Herskovits, EH (corresponding author), Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.	herskovits@rad.upenn.edu			NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG013743] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG 13743] Funding Source: Medline		Baumgardner TL, 1996, NEUROLOGY, V47, P477, DOI 10.1212/WNL.47.2.477; BERKER EA, 1986, ARCH NEUROL-CHICAGO, V43, P1065, DOI 10.1001/archneur.1986.00520100069017; Boling W, 1999, NEUROCHIRURGIE, V45, P208; Bouckaert R. R., 1994, Uncertainty in Artificial Intelligence. Proceedings of the Tenth Conference (1994), P110; Bryan RN, 1999, AM J NEURORADIOL, V20, P1273; Bryan RN, 1997, RADIOLOGY, V202, P47, DOI 10.1148/radiology.202.1.8988191; Buntine W, 1996, IEEE T KNOWL DATA EN, V8, P195, DOI 10.1109/69.494161; CAPUTI F, 1995, J NEUROSURG, V83, P933, DOI 10.3171/jns.1995.83.5.0933; Cheng J., 1997, P CIKM, P325; COOPER GF, 1992, MACH LEARN, V9, P309, DOI 10.1023/A:1022649401552; Cowie SE, 2000, J INVEST SURG, V13, P297, DOI 10.1080/089419300750059334; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Damasio H., 1989, LESION ANAL NEUROPSY; Davatzikos C, 1997, COMPUT VIS IMAGE UND, V66, P207, DOI 10.1006/cviu.1997.0605; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Friedman N, 1999, UNCERTAINTY IN ARTIFICIAL INTELLIGENCE, PROCEEDINGS, P206; FRISTON KJ, 1995, J CEREBR BLOOD F MET, V15, P361, DOI 10.1038/jcbfm.1995.45; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Giedd JN, 2001, ANN NY ACAD SCI, V931, P33; Harris LJ, 1999, SCHIZOPHRENIA BULL, V25, P11, DOI 10.1093/oxfordjournals.schbul.a033359; Heckerman D, 1997, DATA MIN KNOWL DISC, V1, P79, DOI 10.1023/A:1009730122752; Hejlesen OK, 1995, LECT NOTES ARTIF INT, V934, P151; Henrion M., 1988, UNCERTAINTY ARTIFICI, V5, P149, DOI 10.1016/B978-0-444-70396-5.50019-4; Herskovits E., 1991, COMPUTER BASED PROBA; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Herskovits EH, 2000, METHOD INFORM MED, V39, P291; Howard RA., 1984, READINGS PRINCIPLES; KIIVERI H, 1984, J AUST MATH SOC A, V36, P30, DOI 10.1017/S1446788700027312; LAURITZEN SL, 1992, J AM STAT ASSOC, V50, P157; Lyoo IK, 1996, BIOL PSYCHIAT, V40, P1060; Max JE, 2002, J AM ACAD CHILD PSY, V41, P563, DOI 10.1097/00004583-200205000-00014; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; PEARL J, 1986, ARTIF INTELL, V29, P241, DOI 10.1016/0004-3702(86)90072-X; Pearl J., 1988, PROBABILISTIC REASON; REY D, 2001, MED IMAGE COMPUTING, P1232; Robinson Robert W, 1977, COMBINATORIAL MATH, P28, DOI 10.1007/BFb0069178; SHACHTER RD, 1989, MANAGE SCI, V35, P527, DOI 10.1287/mnsc.35.5.527; Shen DG, 2002, IEEE T MED IMAGING, V21, P1421, DOI 10.1109/TMI.2002.803111; Shen DG, 2001, IEEE T MED IMAGING, V20, P257, DOI 10.1109/42.921475; SHOCK NW, 1984, US PUBLIC HLTH SERVI; Suzuki J, 1999, IEICE T INF SYST, VE82D, P356; Tyler KL, 2000, NEUROLOGY, V55, P1015, DOI 10.1212/WNL.55.7.1015; ZAMETKIN AJ, 1993, ARCH GEN PSYCHIAT, V50, P333	46	20	23	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	AUG	2003	19	4					1664	1673		10.1016/S1053-8119(03)00231-3			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	717GK	WOS:000185079000036	12948721				2021-06-18	
J	Abe, M; Udono, H; Tabuchi, K; Uchino, A; Yoshikai, T; Taki, K				Abe, M; Udono, H; Tabuchi, K; Uchino, A; Yoshikai, T; Taki, K			Analysis of ischemic brain damage in cases of acute subdural hematomas	SURGICAL NEUROLOGY			English	Article						head injury; cerebral blood flow; subdural hematoma; cerebral herniation	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; PRACTICAL SCALE; CONSCIOUSNESS; HERNIATION; METABOLISM; MORTALITY; ARTERIES; REMOVAL	BACKGROUND Ischemic damage of the brain is one of the most important factors for the sequelae of acute subdural hematomas (ASDHs). However, ischemic damage is infrequently addressed in a systematic manner in the clinical setting. METHODS The analysis of ischemic brain damage was performed based on serial computed tomography (CT) scans in 80 patients with traumatic ASDHs. Single photon emission computed tomography (SPECT) for regional blood flow and/or magnetic resonance imaging (MRI) were also performed. RESULTS Follow-up CT scans showed ischemic brain damage in 19 patients and no significant damage in 35 patients. The remaining 26 patients progressively deteriorated to the point of brain death. The ischemic brain damage was seen most frequently in the territory of the anterior cerebral artery (13 cases), followed by the territory of the posterior cerebral artery (12 cases). The ischemic damages in the pallidum, the hypothalamus and the thalamus were demonstrated in 4, 8, and 4 cases, respectively. The ischemic damage in the underlying brain that was probably because of the direct compression of the hematoma was seen in only two cases. CONCLUSION Most of the ischemic brain damage noted in this study was because of arterial compression secondary to the brain shift and brain herniation, rather than the direct effect of the hematoma upon the underlying brain. Ischemic brain damage adversely affects outcome morbidity, and the difficulty in preventing ischemic damage in cases with marked brain shift leads to poor outcome in patients with ASDHs. (C) 2003 Elsevier Inc. All rights reserved.	Saga Med Sch, Dept Neurosurg, Saga 8498501, Japan; Saga Med Sch, Dept Radiol, Saga 8498501, Japan; Saga Med Sch, Dept Emergency Med, Saga 8498501, Japan	Abe, M (corresponding author), Saga Med Sch, Dept Neurosurg, Nabeshima 5-1-1, Saga 8498501, Japan.						BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; FUJISAWA H, 1994, ACT NEUR S, V60, P193; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HAYMAN LA, 1981, AM J ROENTGENOL, V137, P13, DOI 10.2214/ajr.137.1.13; JENNETT B, 1975, LANCET, V1, P480; KURODA Y, 1992, NEUROSURGERY, V30, P687; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LINDENBERG R, 1955, J NEUROPATH EXP NEUR, V14, P223, DOI 10.1097/00005072-195507000-00001; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; Lubillo S, 1999, J NEUROSURG, V91, P581, DOI 10.3171/jns.1999.91.4.0581; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MORETTI JL, 1990, EUR J NUCL MED, V16, P17, DOI 10.1007/BF01566007; Niikawa S, 1988, No To Shinkei, V40, P1151; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; ROSENORN J, 1978, J NEUROSURG, V48, P345, DOI 10.3171/jns.1978.48.3.0345; ROSS DA, 1989, J NEUROSURG, V71, P498, DOI 10.3171/jns.1989.71.4.0498; ROTHFUS WE, 1987, AM J NEURORADIOL, V8, P1073; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SATO M, 1986, NEUROSURGERY, V18, P300, DOI 10.1227/00006123-198603000-00007; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; TEASDALE G, 1974, LANCET, V2, P81; WERNICK S, 1989, J COMPUT ASSIST TOMO, V13, P323, DOI 10.1097/00004728-198903000-00027; WESTBERG G, 1966, ACTA RADIOL DIAGN, V5, P581, DOI 10.1177/02841851660050P163; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Yoshikai T, 1997, Radiat Med, V15, P419; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	33	20	20	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JUN	2003	59	6					464	472		10.1016/S0090-3019(03)00078-8			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	695QN	WOS:000183841900012	12826344				2021-06-18	
J	Singh, P				Singh, P			Missile injuries of the brain: Results of less aggressive surgery	NEUROLOGY INDIA			English	Article						missile injury; cerebral contusion; skull bone fracture; Glasgow-coma scale	PENETRATING CRANIOCEREBRAL INJURIES; INTRACRANIAL INFECTION; LEBANESE CONFLICT; BONE FRAGMENTS; VIETNAM; WOUNDS; HEAD; WAR	Sixty cases of missile injuries (59 males, average age 25 years) were studied over a period of one year. Forty-three patients had suffered splinter injuries, 12 had gunshot wounds and 5 had suffered injuries from improvised explosive devices. The Glasgow coma scale was <5 in 8 patients, 5-8 in 14, 8-12 in 30 and 13-15 in 8 patients. Extensive comminution of skull bones was found in 10 patients. Thirty-five patients had penetration of the skull and the rest had orbito-cranial or facio-cranial wounds. CT scan revealed small hemorrhagic contusion with in-driven bones without mass effect in 15, contusion with mass effect in 36 cases, cortical contusions without in-driven bones (tangential injuries) in 3, distant intracranial contusions in 4, intraventricular hemorrhages in 5, multilobar injuries in 14, and unilobar injury in 40. Fifty-two patients were operated upon at our center, of which 30 were operated within 24 hrs, 10 between 24 to 48 hrs, and 12 between 48 to 72 hrs. Six patients were treated conservatively and 2 underwent only a simple closure of scalp wound. Craniectomy was done in 10 and craniotomy in 42 patients. Two patients developed wound sepsis, one had aspiration pneumonia, one had septicemia and one had deep vein thrombosis while one had post-traumatic hydrocephalus. On follow-up at 6 months, the outcome as per the Glasgow outcome scale was as follows: Good outcome in 42, moderate disability in 7, severe disability in 6 and death of 5 patients. Retained bone fragments were found in 36.3 % on follow-up CT scan but no one had brain abscess.	Army Hosp R&R, Neurosurg Ctr, Delhi 110010, India	Singh, P (corresponding author), Army Hosp R&R, Neurosurg Ctr, Delhi 110010, India.						ARABI B, 1987, NEUROSURGERY, V20, P61; Ascroft PB, 1943, LANCET, V2, P211; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Cairns H, 1944, Br Med J, V1, P33; COOPER WL, 1979, P SOC THERIOGENOLOGY, V1, P1; Cushing H, 1918, BRIT J SURG, V5, P558; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HADDAD FS, 1978, CAN J SURG, V21, P233; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; MALTBY GL, 1946, J NEUROSURG, V3, P239, DOI 10.3171/jns.1946.3.3.0239; MATSON DD, 1958, NEUROSURGERY, V1, P123; MEIRWOSKY AM, 1968, MIL MED, V33, P887; MYERS PW, 1989, J NEUROSURG, V70, pA319; PITLYK PJ, 1970, J NEUROSURG, V33, P19, DOI 10.3171/jns.1970.33.1.0019; RISH BL, 1981, NEUROSURGERY, V9, P535, DOI 10.1227/00006123-198111000-00008; RISH BL, 1980, J NEUROSURG, V53, P772, DOI 10.3171/jns.1980.53.6.0772; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Splavski B, 2000, INJURY, V31, P233, DOI 10.1016/S0020-1383(99)00273-9; TAHA JM, 1991, NEUROSURGERY, V29, P864, DOI 10.1227/00006123-199112000-00010; Tudor M, 1998, MIL MED, V163, P486; Vrankovic D, 1996, J Neurosurg Sci, V40, P107; WANNAMAKER GT, 1958, J NEUROSURG, V15, P512, DOI 10.3171/jns.1958.15.5.0512; WEBSTER JE, 1946, J NEUROSURG, V3, P7, DOI 10.3171/jns.1946.3.1.0007	23	20	21	0	2	NEUROL SOC INDIA	CHANDIGARH	C/O J S CHOPRA, PGIMER, DEPT NEUROLOGY, CHANDIGARH 160 012, INDIA	0028-3886			NEUROL INDIA	Neurol. India	JUN	2003	51	2					215	219					5	Neurosciences	Neurosciences & Neurology	743BT	WOS:000186553100012	14571007				2021-06-18	
J	Kumar, R; Gupta, RK; Husain, M; Vatsal, DK; Chawla, S; Rathore, RKS; Pradhan, S				Kumar, R; Gupta, RK; Husain, M; Vatsal, DK; Chawla, S; Rathore, RKS; Pradhan, S			Magnetization transfer MR imaging in patients with posttraumatic epilepsy	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	10th Annual Meeting of the International-Society-for-Magnetic-Resonance-in-Medicine (ISMRM)	MAY 18-24, 2002	HONOLULU, HAWAII	Int Soc Magnet Resonance Med			DIFFUSE AXONAL INJURY; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; INTRACTABLE EPILEPSY; PERILESIONAL GLIOSIS; SEIZURES; NEUROCYSTICERCOSIS; CALCIFICATION; PROPHYLAXIS	BACKGROUND AND PURPOSE: Intractable epilepsy is a well-recognized complication following head trauma, and many factors have been implicated in its pathogenesis. This study was performed to determine the severity of tissue damage after severe head injury as assessed with magnetization transfer (MT) MR imaging and the relationship of this damage with seizure intractability. METHODS: Forty-four patients, 13 without seizures (disease controls) and 31 with seizures, underwent T1-weighted MT MR imaging 1-10 years after head trauma. Phase-corrected gradient-echo (GRE) imaging was also performed in all patients to look for the presence of hemosiderin. All patients were evaluated for the presence of an MT abnormality beyond an abnormality seen on T2-weighted images, an MT abnormality within a T2 abnormality, and hemosiderin deposition. RESULTS: Patients with an MT abnormality beyond a T2 abnormality had a significantly higher intractability of seizures compared with those with an MT abnormality within a T2 abnormality (P <.05). In addition, the mere presence of hemosiderin deposit was not associated with seizure intractability; however, gliosis around the hemosiderin as seen on T1-weighted MT images was associated with seizure intractability. CONCLUSIONS: T1-weighted MT imaging may be of value in predicting the intractability of the seizure in delayed posttraumatic epilepsy.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiol, Lucknow 226014, Uttar Pradesh, India; Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurol, Lucknow 226014, Uttar Pradesh, India; King Georges Med Coll, Dept Neurosurg, Lucknow, Uttar Pradesh, India; Indian Inst Technol, Dept Math, Kanpur 208016, Uttar Pradesh, India	Gupta, RK (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, MR Sect, Dept Radiodiag, Lucknow 226014, Uttar Pradesh, India.						Annegers J.F., 1996, TREATMENT EPILEPSY P, P165; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P421, DOI 10.1111/j.1365-2990.1991.tb00742.x; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; DUNN LT, 1994, ANN ROY COLL SURG, V76, P147; Gupta RK, 1999, LANCET, V354, P44, DOI 10.1016/S0140-6736(99)00881-8; Gupta RK, 2001, J COMPUT ASSIST TOMO, V25, P698, DOI 10.1097/00004728-200109000-00006; Iudice A, 2000, DRUGS, V59, P1091, DOI 10.2165/00003495-200059050-00005; JENNET WB, 1975, EPILEPSY NONMISSILE; Kabuto H, 1996, EPILEPSY RES, V25, P65, DOI 10.1016/0920-1211(96)00063-0; Kazemi NJ, 1997, EPILEPSIA, V38, P670, DOI 10.1111/j.1528-1157.1997.tb01236.x; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kumar R, 2002, NEUROIMAGE, V15, P1015, DOI 10.1006/nimg.2001.1036; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NIEMI PT, 1992, JMRI-J MAGN RESON IM, V2, P197, DOI 10.1002/jmri.1880020213; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; Pradhan S, 2000, ANN NEUROL, V48, P181, DOI 10.1002/1531-8249(200008)48:2&lt;181::AID-ANA7&gt;3.0.CO;2-C; RATHORE RKS, 2001, P 9 M INT SOC MAGN R, P794; RUBIN JJ, 1980, EXP NEUROL, V67, P472, DOI 10.1016/0014-4886(80)90119-3; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; Yamada N, 1996, RADIOLOGY, V198, P171, DOI 10.1148/radiology.198.1.8539373	31	20	22	0	2	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2003	24	2					218	224					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	738UT	WOS:000186306800011	12591637				2021-06-18	
J	Zemlan, FP; Mulchahey, JJ; Gudelsky, GA				Zemlan, FP; Mulchahey, JJ; Gudelsky, GA			Quantification and localization of kainic acid-induced neurotoxicity employing a new biomarker of cell death: Cleaved microtubule-associated protein-tau (C-tau)	NEUROSCIENCE			English	Article						kainic acid; neurotoxicity; C-tau; ELISA; immunohistochemistry; neurodegeneration	RAT-BRAIN; AMYGDALOID PROJECTIONS; EFFERENT CONNECTIONS; CORTICAL PROJECTIONS; NUCLEUS-ACCUMBENS; NEURONAL DAMAGE; BINDING-SITES; ORGANIZATION; INJURY; AUTORADIOGRAPHY	Previous studies of neuronal degeneration induced by the neurotoxin, kainic acid, employed silver stain techniques that are non-quantitative or ELISA measurement of the non-neuronal protein, glial fibrillary acidic protein. As previous studies employed biomarkers that were either non-quantitative or non-neuronal, the present study employed a new neuronally localized biomaker of neuronal damage, cleaved microtubule-associated protein (MAP)-tau (C-tau). The time course of kainate neurotoxicity was quantitatively determined in several brain regions in the present study employing a C-tau specific ELISA. Differences in ELISA determined regional brain levels of C-tau were compared with the density of somatodendritic C-tau labeling qualitatively determined in immunohistochemical anatomical mapping studies of kainic acid-treated animals. Immunoblot studies revealed that the C-tau antibodies employed in the present study were highly specific for proteolytic cleaved C-tau. Immunolabeling of 45 kD-50 kD C-tau proteins was observed only in brain samples from kainic acid-treated but not vehicle-treated rats. Time course studies revealed that C-tau levels determined by ELISA were maximal 3 days after kainic acid with C-tau levels increasing 26-fold in hippocampus, 16-fold in cortex and four-fold in both striatum and hypothalamus. These statistical differences in maximal C-tau levels observed in the ELISA studies were similar to differences qualitatively observed in C-tau immunohistochemical studies. C-tau immunohistochemistry revealed extensive damage in hippocampal regions CA1 and 3, moderate damage in several cortical regions and mild damage in striatum and hypothalamus. Similar cleavage of rat MAP-tau to C-tau has been reported after neuronal degeneration induced by neurotoxic doses of methamphetamine and neuronal degeneration resulting from bacterial meningitis. In humans, C-tau proteolysis has been demonstrated to be a reliable biomarker of neuronal damage in traumatic brain injury and stroke where cerebrospinal C-tau levels are correlated with patient clinical outcome. These data suggest that C-tau proteolysis may prove a reliable species independent biomarker of neuronal degeneration regardless of source of injury. (C) 2003 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Pharm, Cincinnati, OH 45267 USA	Zemlan, FP (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, 231 Sabin Ave, Cincinnati, OH 45267 USA.				NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA007427, R43DA013300, R44DA013300] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA07427, DA13300] Funding Source: Medline		BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BROADWELL RD, 1975, J COMP NEUROL, V163, P329, DOI 10.1002/cne.901630306; Crawford N, 1999, J PHARMACOL TOXICOL, V42, P121, DOI 10.1016/S1056-8719(00)00040-X; DollemanVanderWeel MJ, 1996, J COMP NEUROL, V364, P637; Friedman LK, 1998, HIPPOCAMPUS, V8, P511, DOI 10.1002/(SICI)1098-1063(1998)8:5<511::AID-HIPO9>3.0.CO;2-W; Geinisman Y, 2000, CEREB CORTEX, V10, P952, DOI 10.1093/cercor/10.10.952; Hampson David R., 1998, Natural Toxins, V6, P153, DOI 10.1002/(SICI)1522-7189(199805/08)6:3/4<153::AID-NT16>3.0.CO;2-1; HEGGLI DE, 1981, BRAIN RES, V230, P253, DOI 10.1016/0006-8993(81)90405-4; Irazuzta JE, 2000, BRAIN RES, V881, P88, DOI 10.1016/S0006-8993(00)02894-8; Irazuzta JE, 2001, BRAIN RES, V913, P95, DOI 10.1016/S0006-8993(01)02764-0; Kaasinen K, 2000, EUR J NEUROSCI, V12, P540, DOI 10.1046/j.1460-9568.2000.00940.x; KOSIK KS, 1987, J NEUROSCI, V7, P3142; KRETTEK JE, 1977, J COMP NEUROL, V171, P157, DOI 10.1002/cne.901710204; KRETTEK JE, 1978, J COMP NEUROL, V178, P225, DOI 10.1002/cne.901780204; MCDONALD AJ, 1991, NEUROSCIENCE, V44, P15, DOI 10.1016/0306-4522(91)90248-M; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; MULCHAHEY JJ, 2002, SOC NEUR ABSTR, V606, P1; NADLER JV, 1979, LIFE SCI, V24, P289, DOI 10.1016/0024-3205(79)90325-4; PATEL S, 1986, NEUROSCI LETT, V70, P301, DOI 10.1016/0304-3940(86)90569-0; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Risold PY, 1996, SCIENCE, V272, P1484, DOI 10.1126/science.272.5267.1484; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Shibata H, 2000, NEUROSCI RES, V38, P303, DOI 10.1016/S0168-0102(00)00174-7; SWANSON LW, 1977, J COMP NEUROL, V172, P49, DOI 10.1002/cne.901720104; Tarazi FI, 1998, SYNAPSE, V30, P227, DOI 10.1002/(SICI)1098-2396(199810)30:2<227::AID-SYN13>3.0.CO;2-Z; Tarazi FI, 1999, J NEUROSCI RES, V55, P401, DOI 10.1002/(SICI)1097-4547(19990215)55:4<401::AID-JNR1>3.0.CO;2-H; Vertes RP, 2002, J COMP NEUROL, V442, P163, DOI 10.1002/cne.10083; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zhang JW, 1998, EUR J NEUROSCI, V10, P3358, DOI 10.1046/j.1460-9568.1998.00347.x	32	20	22	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2003	121	2					399	409		10.1016/S0306-4522(03)00459-7			11	Neurosciences	Neurosciences & Neurology	729YW	WOS:000185803300015	14521998				2021-06-18	
J	Onaya, M				Onaya, M			Neuropathological investigation of cerebral white matter lesions caused by closed head injury	NEUROPATHOLOGY			English	Article						axonal retraction ball; brain swelling; diffuse axonal injury; diffuse brain injury; head injury	DIFFUSE AXONAL INJURY; BETA-APP; MARKER	In order to ascertain whether there is widespread axonal disruption of cerebral white matter in the so-called 'diffuse axonal injury' (DAI), a type of closed head injury, proposed by Adams et al. the author investigated his own cases clinicopathologically. Twenty-six male autopsied cases of head injury, aged between 19 and 84, 15 of which had sustained road traffic accidents, were examined; the others were due to falling from heights and so on. The study group all belonged to non-missile head injuries and included 12 cases of diffuse brain injury, as well as 14 cases of focal brain injury, according to the classification of Gennarelli et al. The survival time ranged from 2 h to 21 years. Formalin-fixed brains were cut coronally so as to make paraffin-embedded hemispheric sections. Then these sections were stained conventionally (HE, Bodian, Kluver-Barrera and Holzer) and immunohistochemically (GFAP) to assess axonal decrease, myelin pallor and gliosis by the use of light microscopy. In the 13 chronic cases that died more than I month after the accidents, the intensities of gliosis, myelin pallor and axonal decrease tended to correlate with each other. In the 13 acute cases who died less than 1 month after their accident, the degree of axonal decrease in white matter seemed to correlate with the severity of myelin pallor. Regardless of types of trauma, however, axonal retraction balls, the so-called hallmark of DAI, were found only with myelin pallor suggesting the presence of brain swelling after the injury. Therefore these findings indicate that it may be difficult to accept the notion of DAI, that is, the presence of axonal retraction balls without brain swelling. In addition, diffuse vascular injury (2 cases) as well as rarefaction of subcortical white matter (6 cases) were presented and their pathogenesis individually discussed based on a literature review.	Shimofusa Natl Hosp, Midori Ku, Chiba 2660007, Japan	Onaya, M (corresponding author), Shimofusa Natl Hosp, Midori Ku, 578 Heta Cho, Chiba 2660007, Japan.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ADAMS JH, 1992, GREENFIELDS NEUROPAT, P122; Akima M, 1993, NEUROPATHOLOGY, V13, P99; Gennarelli T A, 1984, Emerg Med Clin North Am, V2, P749; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, V1, P224; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; KIKUCHI T, 1992, NEUROTRAUMATOLOGY, V15, P125; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lubillo S, 2000, ACT NEUR S, V76, P415; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; ONAYA M, 1996, KEIO IGAKU, V73, P259; PETERS G, 1943, ZBL NEUROCHIR, V8, P172; SEKINO H, 1995, INJURY BRAIN SPINAL, P55; SHIGEMORI M, 1991, NEUROTRAUMATOLOGY, V14, P133; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SYMONDS C, 1962, LANCET, V1, P1; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959	25	20	22	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	DEC	2002	22	4					243	251		10.1046/j.1440-1789.2002.00456.x			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	638KL	WOS:000180570100003	12564763				2021-06-18	
J	Hains, BC; Black, JA; Waxman, SG				Hains, BC; Black, JA; Waxman, SG			Primary motor neurons fail to up-regulate voltage-gated sodium channel Na(v)1.3/brain type III following axotomy resulting from spinal cord injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						spasticity; seizure; trauma; hyperexcitability	NERVE GROWTH-FACTOR; RAT CORTICOSPINAL NEURONS; SENSORY NEURONS; MESSENGER-RNAS; NEUROTROPHIC FACTOR; PYRAMIDAL NEURONS; POSTTRAUMATIC EPILEPTOGENESIS; DOWN-REGULATION; ALPHA-SNS; EXPRESSION	Epilepsy occurs in a small proportion of patients with spinal cord injury (SCI), but whether it is due to concomitant traumatic head injury or to changes in cortical motor neurons secondary to axotomy within the spinal cord is not known. Na(v)1.3/brain type Ill sodium channel expression is up-regulated following peripheral axotomy of dorsal root ganglion (DRG) and facial motor neurons, but, to date, Na(v)1.3 expression has not been examined in upper (cortical) motor neurons following axotomy associated with SCI. In the present study, we examine Na(v)1.3 expression in upper motor neurons within rat primary motor cortex following midthoracic (T9) dorsal column transection, which severs the axons of those cells. Axotomized pyramidal cells were identified by retrograde transport of fluorogold. Immunolabeled cells were confined to layer V of the primary motor cortex and exhibited low levels of Na(v)1.3 staining. After axotomy, no significant changes were detected in Na(v)1.3 density or distribution in injured or uninjured cells, compared with control brains, in contrast to up-regulation of Na(v)1.3 in ipsilateral DRG neurons after sciatic nerve transection. These results do not preclude a role for voltage-gated sodium channels in post-SCI epilepsy but suggest that up-regulated expression of Na(v)1.3 channel is not involved. (C) 2002 Wiley-Liss, Inc.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Paralyzed Vet Amer Eastern Paralyzed Vet Assoc Ct, New Haven, CT 06510 USA; VA Connecticut Healthcare Syst, Rehabil Res & Dev Ctr, West Haven, CT USA	Waxman, SG (corresponding author), Yale Univ, Sch Med, Dept Neurol, 333 Cedar St, New Haven, CT 06510 USA.	stephen.waxman@yale.edu	Waxman, Stephen/Z-2507-2019	Waxman, Stephen/0000-0001-5718-7177	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007224] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 T32 NS07224] Funding Source: Medline		AGUAYO LG, 1992, BRAIN RES, V570, P61, DOI 10.1016/0006-8993(92)90564-P; ARONIADOU VA, 1993, J NEUROPHYSIOL, V70, P1553; Barth JL, 2001, TRENDS CARDIOVAS MED, V11, P26, DOI 10.1016/S1050-1738(01)00080-9; BECKH S, 1989, EMBO J, V8, P3611, DOI 10.1002/j.1460-2075.1989.tb08534.x; Black JA, 1999, J NEUROPHYSIOL, V82, P2776; Black JA, 1997, NEUROREPORT, V8, P2331, DOI 10.1097/00001756-199707070-00046; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; BRYSCH W, 1991, EXP BRAIN RES, V86, P562; Bush PC, 1999, J NEUROPHYSIOL, V82, P1748; Chen YH, 2000, EUR J NEUROSCI, V12, P4281, DOI 10.1046/j.1460-9568.2000.01336.x; Coward K, 2001, NEUROREPORT, V12, P495, DOI 10.1097/00001756-200103050-00014; Cummins TR, 1997, J NEUROSCI, V17, P3503; Cummins TR, 2001, J NEUROSCI, V21, P5952; Deng LLYS, 2000, NEUROSCI RES, V38, P183; DEUCHARS J, 1994, J PHYSIOL-LONDON, V478, P423, DOI 10.1113/jphysiol.1994.sp020262; DEVOR M, 1992, PAIN, V48, P261, DOI 10.1016/0304-3959(92)90067-L; Dib-Hajj SD, 1998, J NEUROPHYSIOL, V79, P2668; DibHajj S, 1996, P NATL ACAD SCI USA, V93, P14950, DOI 10.1073/pnas.93.25.14950; Elliott EJ, 1997, BRAIN RES, V755, P221, DOI 10.1016/S0006-8993(97)00100-5; Escayg A, 2000, NAT GENET, V24, P343; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; Fjell J, 1999, J NEUROPHYSIOL, V81, P803; Fjell J, 1999, J NEUROSCI RES, V57, P39, DOI 10.1002/(SICI)1097-4547(19990701)57:1<39::AID-JNR5>3.3.CO;2-D; FRANCESCHETTI S, 1995, BRAIN RES, V696, P127, DOI 10.1016/0006-8993(95)00807-3; FURUYAMA T, 1993, MOL BRAIN RES, V17, P169, DOI 10.1016/0169-328X(93)90087-6; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Hablitz JJ, 2000, EPILEPSIA, V41, P1082, DOI 10.1111/j.1528-1157.2000.tb00309.x; IWAHASHI Y, 1994, MOL BRAIN RES, V22, P341, DOI 10.1016/0169-328X(94)90064-7; KALMAN D, 1990, NEURON, V4, P355, DOI 10.1016/0896-6273(90)90048-K; Kaneko T, 2000, J COMP NEUROL, V423, P52, DOI 10.1002/1096-9861(20000717)423:1<52::AID-CNE5>3.0.CO;2-F; Kharazia VN, 2001, NEUROSCIENCE, V102, P23, DOI 10.1016/S0306-4522(00)00467-X; Kim CH, 2001, MOL BRAIN RES, V95, P153, DOI 10.1016/S0169-328X(01)00226-1; Kolb B, 1997, NEUROSCIENCE, V76, P1139, DOI 10.1016/S0306-4522(96)00448-4; Kolb B, 1997, BRAIN RES, V751, P289, DOI 10.1016/S0006-8993(96)01410-2; KORSCHING S, 1985, NEUROSCI LETT, V54, P201, DOI 10.1016/S0304-3940(85)80079-3; KORSCHING S, 1985, EMBO J, V4, P1389, DOI 10.1002/j.1460-2075.1985.tb03791.x; Landy HJ, 1998, HUM REPROD UPDATE, V4, P177, DOI 10.1093/humupd/4.2.177; LESSER SS, 1995, J NEUROSCI, V15, P253; Liebl DJ, 2001, EXP NEUROL, V167, P15, DOI 10.1006/exnr.2000.7548; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MATZNER O, 1992, BRAIN RES, V597, P92, DOI 10.1016/0006-8993(92)91509-D; MCBRIDE RL, 1989, J NEUROPATH EXP NEUR, V48, P568, DOI 10.1097/00005072-198909000-00007; Moulard B, 2001, BRAIN RES REV, V36, P275, DOI 10.1016/S0165-0173(01)00104-7; NAGATA Y, 1987, J NEUROCHEM, V49, P296, DOI 10.1111/j.1471-4159.1987.tb03429.x; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; NISHIO T, 1994, NEUROSCIENCE, V60, P67, DOI 10.1016/0306-4522(94)90204-6; Novakovic SD, 2001, TRENDS NEUROSCI, V24, P473, DOI 10.1016/S0166-2236(00)01884-1; OMRI G, 1990, J MEMBRANE BIOL, V115, P13, DOI 10.1007/BF01869102; Oyelese AA, 1997, J NEUROPHYSIOL, V78, P31; Pasikova N V, 2001, Neurosci Behav Physiol, V31, P497, DOI 10.1023/A:1010470730416; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PIORO EP, 1990, NEUROSCIENCE, V34, P57, DOI 10.1016/0306-4522(90)90304-M; Pitts AF, 1995, SOMATOSENS MOT RES, V12, P329, DOI 10.3109/08990229509093666; Prince DA, 1998, EPILEPSY RES, V32, P83, DOI 10.1016/S0920-1211(98)00042-4; Ragsdale DS, 1998, BRAIN RES REV, V26, P16, DOI 10.1016/S0165-0173(97)00054-4; RUDY B, 1987, J NEUROSCI, V7, P1613; Schutte A, 2000, NEUROSCI LETT, V290, P185, DOI 10.1016/S0304-3940(00)01351-3; TOPKA H, 1991, NEUROLOGY, V41, P1276, DOI 10.1212/WNL.41.8.1276; TSENG GF, 1993, J COMP NEUROL, V335, P92, DOI 10.1002/cne.903350107; Tuszynski MH, 1996, NEUROSCIENCE, V71, P761, DOI 10.1016/0306-4522(95)00440-8; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466; Whitaker WRJ, 2000, J COMP NEUROL, V422, P123, DOI 10.1002/(SICI)1096-9861(20000619)422:1<123::AID-CNE8>3.0.CO;2-X; Whitaker WRJ, 2001, NEUROSCIENCE, V106, P275, DOI 10.1016/S0306-4522(01)00212-3; White HS, 1999, EPILEPSIA, V40, P28; ZHOU XF, 1994, J NEUROSCI METH, V54, P95, DOI 10.1016/0165-0270(94)90163-5	67	20	20	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV 15	2002	70	4					546	552		10.1002/jnr.10402			7	Neurosciences	Neurosciences & Neurology	610RX	WOS:000178975500002	12404508				2021-06-18	
J	Wilson, BM; Proctor, A				Wilson, BM; Proctor, A			Written discourse of adolescents with closed head injury	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; CHILDREN; ADULTS	Written discourse of adolescents with closed head injury (CHI) was compared to that of normal controls. It was expected that the writing of adolescents with CHI would be disordered on one or more of the eight measurements used (productivity, efficiency, lexical, incomplete, or elliptic cohesion, global or local coherence, and maze use). Eight adolescents with closed head injury and matched controls provided written descriptions of a pictured activity. Analysis using t-tests indicated that adolescents with CHI used fewer words to express each idea in writing ( p = 0.05), and that the relationship between successive ideas was rated as less than that of controls ( p = 0.002). Implications are that written as well as oral discourse should be assessed after CHI. Writing is a more controlled process than speaking; and, therefore, may be used clinically to structure the development of ideas after CHI.	Eastern Illinois Univ, Charleston, IL 61920 USA; Univ Illinois, Urbana, IL 61801 USA	Wilson, BM (corresponding author), Eastern Illinois Univ, 600 Lincoln Ave, Charleston, IL 61920 USA.						Adamovich B. B., 1992, SCALES COGNITIVE ABI; BRASWELL D, 1992, PROFILE EXECUTIVE CO; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; ENTWISLE DR, 1994, CHILD DEV, V65, P1521, DOI 10.2307/1131278; ERLICH JS, 1988, J COMMUN DISORD, V21, P1; Glosser G., 1990, BRAIN LANG, V40, P67; GOLDMAN R, 1974, RECOGNITION MEMORY G; GOODCLASS H, 1983, BOSTON DIAGNOSTIC AP; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HARTLEY LL, 1995, DEV FUNCTIONAL APPRO, P10; HUGHES D, 1997, GUIDE NARRATIVE LANG, P207; HUNT K, 1993, DEV LANGUAGE, P370; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LOBAN W, 1997, GUIDE NARRATIVE LANG, P207; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; NELSON N, 1993, CHILDHOOD LANGUAGE D, P426; NIPPOLD MA, 1998, LATER LANGUAGE DEV S, P39; PAYNEJOHNSON JC, 1986, J COMMUN DISORD, V19, P237, DOI 10.1016/0021-9924(86)90030-4; RUBIN DL, 1987, TOP LANG DISORD, V7, P1, DOI 10.1097/00011363-198709000-00003; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1997, BRAIN INJURY, V11, P409; SPEAKER R, 1992, READ RES INSTRUCT, V31, P64; SPEIRS JC, 1990, POST GRAD COURS REH; Wilson BM, 2000, BRAIN COGNITION, V43, P425; WILSON BM, 1997, AM SPEECH LANG HEAR	28	20	20	0	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2002	16	11					1011	1024		10.1080/02699050210147248			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	609PQ	WOS:000178914500007	12443550				2021-06-18	
J	Smith, DH; Meaney, DF				Smith, DH; Meaney, DF			Roller coasters, G forces, and brain trauma: On the wrong track?	JOURNAL OF NEUROTRAUMA			English	Article						G force; head rotational acceleration; roller coaster; traumatic brain injury	DIFFUSE AXONAL INJURY; COMA	There has been enormous attention in the general press on the possibility that high G force roller coasters are inducing brain injury in riders. Armed with a handful of anecdotal case reports of brain injuries, the U.S. Congress has recently proposed legislation to regulate the level of G forces of roller coasters. However, high G forces are well tolerated during many activities and, therefore, are a poor measure for the risk of brain injury. Rather, accelerations of the head that can be caused by G forces are the key to producing injury. To determine the extent of head accelerations during roller coaster-rides, we acquired G force data from three popular high G roller coasters. We used the highest recorded G forces in a simple mathematical model of head rotational acceleration, with the head rigidly pivoting from the base of the skull at a radius representing typical men and women. With this model, we calculated peak head rotational accelerations in three directions. Even for a conservative worst-case scenario, we found that the highest estimated peak head accelerations induced by roller coasters were far below conventional levels that are predicted for head injuries. Accordingly, our findings do not support the contention that current roller coaster rides produce high enough forces to mechanically deform and injure the brain.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007	Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, F32NS041699, P01NS008803, P50NS008803, R01NS035712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38104, NS41699, NS08803, NS35712] Funding Source: Medline; ODCDC CDC HHS [CCR312712] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALLEN ME, 1994, SPINE, V19, P1285, DOI 10.1097/00007632-199405310-00017; Braksiek RJ, 2002, ANN EMERG MED, V39, P65, DOI 10.1067/mem.2002.120127; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; LOWENHIELM P, 1974, Z RECHTSMED, V75, P131, DOI 10.1007/BF02114709; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; PINCEMAILLE Y, 1988, DTRS5786C00037 DOT; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; WHINNERY JE, 1990, ARCH NEUROL-CHICAGO, V47, P764, DOI 10.1001/archneur.1990.00530070058012; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	13	20	20	0	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2002	19	10					1117	1120		10.1089/08977150260337921			4	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	605MJ	WOS:000178681400001	12427321				2021-06-18	
J	Belayev, L; Becker, DA; Alonso, OF; Liu, YT; Busto, R; Ley, JJ; Ginsberg, MD				Belayev, L; Becker, DA; Alonso, OF; Liu, YT; Busto, R; Ley, JJ; Ginsberg, MD			Stilbazulenyl nitrone, a novel azulenyl nitrone antioxidant: improved neurological deficit and reduced contusion size after traumatic brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						oxygen radicals; reactive oxygen species; neuroprotection; traumatic brain injury; histopathological study; neurobehavioral outcome; rat	CEREBRAL-ARTERY OCCLUSION; RADICAL-TRAPPING AGENT; PHARMACOLOGICAL STRATEGIES; HISTOPATHOLOGICAL DAMAGE; COLORIMETRIC DETECTION; DELAYED TREATMENT; HEAD-INJURY; BLOOD-FLOW; ISCHEMIA; PBN	Object. Stilbazulenyl nitrone (STAZN) is a second-generation azulenyl nitrone that has markedly enhanced antioxidant properties compared with those of conventional alpha-phenyl nitrones. In this study, the authors assessed the potential efficacy of STAZN in a rodent model of fluid-percussion brain injury, which results in a consistent cortical contusion. Methods. After anesthesia had been induced in normothermic Sprague-Dawley rats (brain temperature 36-36.5degreesC) by halothane-nitrous oxide, the animals were subjected to a right parietooccipital parasagittal fluid-percussion injury (1.5-2 atm). The agent (STAZN, 30 mg/kg; eight animals) or vehicle (dimethyl sulfoxide; eight animals) was administered intraperitoneally at 5 minutes and 4 hours after trauma. The neurological status of each rat was evaluated on Days 1, 2, and 7 postinjury (normal score 0, maximum injury 12). Seven days after trauma, the rat brains were perfusion fixed, coronal sections at various levels were digitized, and areas of contusion were measured. Treatment with STAZN significantly improved neurological scores on Days 2 and 7 postinjury compared with vehicle-treated rats. Administration of STAZN also significantly reduced the total contusion area by 63% (1.8 +/- 0.5 mm(2) in STAZN-treated animals compared with 4.8 +/- 2.1 mm(2) in vehicle-treated animals; p = 0.04) and the deep cortical contusion area by 60% (1.2 +/- 0.2 mm(2) in STAZN-treated animals compared with 2.9 +/- 1.2 mm(2) in vehicle-treated animals; p = 0.03). By contrast, hippocampal cell loss in the CA3 sector was unaffected by STAZN treatment. Conclusions. Therapy with STAZN, a novel potent antioxidant, administered following traumatic brain injury, markedly improves neurological and histological outcomes. Azulenyl nitrones appear to represent a promising class of neuroprotective agents for combating this devastating condition.	Univ Miami, Sch Med, Dept Neurol D45, Cerebral Vasc Dis Res Ctr, Miami, FL 33101 USA; Florida Int Univ, Dept Chem, Miami, FL 33199 USA	Ginsberg, MD (corresponding author), Univ Miami, Sch Med, Dept Neurol D45, Cerebral Vasc Dis Res Ctr, POB 016960, Miami, FL 33101 USA.	mdginsberg@stroke.med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS005820, P50NS005820, P50NS030291, R01NS038221] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 05820, NS 38221, NS 30291] Funding Source: Medline		Althaus JS, 1998, FREE RADICAL BIO MED, V24, P738, DOI 10.1016/S0891-5849(97)00338-9; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Becker DA, 1999, CELL MOL LIFE SCI, V56, P626, DOI 10.1007/s000180050457; Becker DA, 1998, ORG SYN TH, V4, P155; Becker DA, 1996, J AM CHEM SOC, V118, P905, DOI 10.1021/ja952895z; Becker DA, 1998, J CHEM SOC PERK T 2, P1289, DOI 10.1039/a708702k; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, NEUROREPORT, V8, P55, DOI 10.1097/00001756-199612200-00012; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; BUSTO R, 1984, ANN NEUROL, V15, P441, DOI 10.1002/ana.410150507; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; Castagna V, 1999, NEUROSCIENCE, V93, P313, DOI 10.1016/S0306-4522(99)00138-4; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Gido G, 2000, ACTA PHYSIOL SCAND, V168, P277; Ginsberg MD, 2001, J NEUROSURG, V94, P499, DOI 10.3171/jns.2001.94.3.0499; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; HALL ED, 1994, FREE RADICAL DAMAGE, P217; HALL ED, 1998, CEREBROVASC DIS, P710; Hensley K, 1997, INT REV NEUROBIOL, V40, P299; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Klivenyi P, 1998, EXP NEUROL, V152, P163, DOI 10.1006/exnr.1998.6824; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lees KR, 2001, STROKE, V32, P675, DOI 10.1161/01.STR.32.3.675; LEMKE M, 1990, NEUROSCI LETT, V108, P201, DOI 10.1016/0304-3940(90)90731-N; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marshall JWB, 2001, STROKE, V32, P190, DOI 10.1161/01.STR.32.1.190; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Novelli G P, 1986, Free Radic Res Commun, V1, P321, DOI 10.3109/10715768609080971; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924; Peeling J, 2001, NEUROPHARMACOLOGY, V40, P433, DOI 10.1016/S0028-3908(00)00170-2; PHILLIS JW, 1990, NEUROSCI LETT, V116, P315, DOI 10.1016/0304-3940(90)90093-O; Povlishock J T, 1992, Hum Cell, V5, P345; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	56	20	20	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2002	96	6					1077	1083		10.3171/jns.2002.96.6.1077			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	559LD	WOS:000176026900024	12066910				2021-06-18	
J	Aoyama, N; Katayama, Y; Kawamata, T; Maeda, T; Mori, T; Yamamoto, T; Kikuchi, T; Uwahodo, Y				Aoyama, N; Katayama, Y; Kawamata, T; Maeda, T; Mori, T; Yamamoto, T; Kikuchi, T; Uwahodo, Y			Effects of antioxidant, OPC-14117, on secondary cellular damage and behavioral deficits following cortical contusion in the rat	BRAIN RESEARCH			English	Article						cerebral contusion; edema formation; tissue osmolality; cognitive behavior; free radical scavenger; rat	TRAUMATIC BRAIN INJURY; CEREBRAL-ISCHEMIA; LIPID-PEROXIDATION; IMPACT INJURY; FREE-RADICALS; HEAD-INJURY; BLOOD; DEATH; EDEMA; GENERATION	In the present study, we examined the effects of OPC-14117, a superoxide radical scavenger, on the secondary cellular damage and cognitive dysfunction occurring in a rat model of cerebral contusion induced by a controlled cortical impact (CCI). Histological examinations revealed that the contusion necrosis volume reached 13.6 +/- 5.3 mm(3) in non-treated animals and declined to 1.9 +/- 0.6 mm(3) in OPC-14117-treated animals (P < 0.01). The cell number of the CA3 region was 120.0 +/- 12.4 cells/mm in the normal controls, 73.6 +/- 19.9 cells/min in the non-treated animals, and 111.2 +/- 10.2 cells/mm in the OPC-14117-treated animals, indicating that CCI-induced selective neuronal cell death in the CA3 region was attenuated by the OPC-14117 administration (P < 0.01). The tissue osmolality, as determined with a vapor pressure osmometer, was 314.5 +/- 15.4 mmol/kg in the normal brain and increased to 426.0 +/- 20.1 mmol/kg at 12 h following CCI. The increase in tissue osmolality was significantly attenuated by OPC-14117 administration (P < 0.01). The OPC-14117 administration also attenuated the CCI-induced cognitive deficits. The OPC-14117-treated animals showed a tendency to improve on the Morris water maze performance test. The impairment of the habituation of exploratory activity elicited by CCI was significantly attenuated by OPC-14117 administration (P < 0.05). In conclusion, OPC-14117 may have a potential for decreasing secondary cellular damage due to traumatic brain injury since it is as efficacious as any other compound tested in this model. (C) 2002 Elsevier Science B.V. All rights reserved.	Nihon Univ, Sch Med, Dept Neurol Surg, Tokyo, Japan; Otsuka Pharmaceut Co Ltd, Tokushima Inst New Drug Res 3, Tokushima 77101, Japan	Aoyama, N (corresponding author), 30-1 Oyaguchikamimachi,Itabashi Ku, Tokyo 1738610, Japan.	aonao17@dream.com					ALEXANDER MJ, 1994, ACTA NEUROCHIR, P479; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BULLOCK R, 1990, ACT NEUR S, V51, P286; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FISHER M, 1992, J NEUROL SCI, V109, P107, DOI 10.1016/0022-510X(92)90102-Q; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOSSMANN KA, 1976, EXP NEUROL, V51, P124, DOI 10.1016/0014-4886(76)90057-1; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; JESBERGER JA, 1991, INT J NEUROSCI, V57, P1, DOI 10.3109/00207459109150342; Katayama Y, 1998, ACT NEUR S, V71, P289; KATAYAMA Y, 1992, NEURORADIOLOGY, V34, P381, DOI 10.1007/BF00596494; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1995, NEUROCHEMICAL MONITO, P72; Katayama Yoichi, 1995, Journal of Neurotrauma, V12, P358; KINUTA Y, 1989, J NEUROSURG, V71, P421, DOI 10.3171/jns.1989.71.3.0421; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maeda T, 1997, ACT NEUR S, V70, P102; MAEDA T, 1995, ADV NEUROTRAUMA RES, V6, P10; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; NELSON CW, 1992, AM J PHYSIOL, V263, pH1356; NISANTHA MB, 1978, STROKE, V9, P249; OSHIRO Y, 1991, J MED CHEM, V34, P2014, DOI 10.1021/jm00111a014; PLATEL A, 1982, PSYCHOPHARMACOLOGY, V78, P346, DOI 10.1007/BF00433739; RINK A, 1995, AM J PATHOL, V147, P1575; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Stein DG, 1991, J NEUROTRAUM, V8, P281, DOI 10.1089/neu.1991.8.281; TOTTORI K, 1995, JPN J PHARM S1, V67, P144; TRUELOVE D, 1994, FREE RADICAL BIO MED, V17, P445, DOI 10.1016/0891-5849(94)90171-6	45	20	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 3	2002	934	2					117	124	PII S0006-8993(02)02366-1	10.1016/S0006-8993(02)02366-1			8	Neurosciences	Neurosciences & Neurology	557FL	WOS:000175897600004	11955474				2021-06-18	
J	Cahill, LM; Murdoch, BE; Theodoros, DG				Cahill, LM; Murdoch, BE; Theodoros, DG			Perceptual analysis of speech following traumatic brain injury in childhood	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; POSTERIOR-FOSSA SURGERY; DYSARTHRIC SPEAKERS; CEREBELLAR MUTISM; TRANSIENT MUTISM; CHILDREN; DISORDERS; PATTERNS; RECOVERY; TUMORS	Primary objective: To investigate perceptually the speech dimensions, oromotor function, and speech intelligibility of a group of individuals with traumatic brain injury (TBI) acquired in childhood. Research design: The speech of 24 children with TBI was analysed perceptually and compared with that of a group of non-neurologically impaired children matched for age and sex. Main outcome and results: The 16 dysarthric TBI subjects were significantly less intelligible than the control subjects, and demonstrated significant impairment in 12 of the 33 speech dimensions rated. In addition, the eight non-dysarthric TBI subjects were significantly impaired in many areas of oromotor function on the Frenchay Dysarthria Assessment, indicating some degree of pre-clinical speech impairment. Conclusion The results of the perceptual analysis are discussed in terms of the possible underlying pathophysiological bases of the deviant speech features identified, and the need for a comprehensive instrumental assessment, to more accurately determine the level of breakdown in the speech production mechanism in children following TBI.	Univ Queensland, Dept Speech Pathol & Audiol, Motor Speech Res Unit, Brisbane, Qld 4072, Australia	Cahill, LM (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Motor Speech Res Unit, Brisbane, Qld 4072, Australia.	l.cahill@mailbox.uq.edu.au	Murdoch, Bruce E/C-1397-2012; Theodoros, Deborah/F-1362-2010; Cahill, Louise/C-7919-2012	Cahill, Louise/0000-0003-3662-896X			ALJARALLAH A, 1994, J SURG ONCOL, V55, P126, DOI 10.1002/jso.2930550214; ALMATEEN M, 1988, NEUROLOGY, V38, P1155, DOI 10.1212/WNL.38.7.1155; ARAM DM, 1983, ARCH NEUROL-CHICAGO, V40, P614, DOI 10.1001/archneur.1983.04050090050007; ASAMOTO M, 1994, CHILD NERV SYST, V10, P275, DOI 10.1007/BF00301168; BAK E, 1983, DEV MED CHILD NEUROL, V25, P81; BELLAIRE K, 1986, J COMMUN DISORD, V19, P271, DOI 10.1016/0021-9924(86)90033-X; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Cahill LM, 2000, J MED SPEECH-LANG PA, V8, P347; Chenery H.J., 1990, AUST J HUMAN COMMUN, V18, p19 ; Chenery HJ, 1988, AUSTR J HUMAN COMMUN, V16, P17, DOI [10.3109/asl2.1988.16.issue-2.02., DOI 10.3109/ASL2.1988.16.ISSUE-2.02]; CHENERY HJ, 1992, AUSTR J HUMAN COMMUN, V16, P17; CORNWELL PL, 2001, ASIA PACIFIC J SPEEC, V6, P21; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; DANIELWHITNEY B, 1989, RECENT ADVANCES IN CLINICAL DYSARTHRIA, P129; Darley F., 1975, MOTOR SPEECH DISORDE; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; DARLEY FL, 1984, SEMINARS SPEECH LANG, V5, P267; DIETZE D, 1990, PEDIATR NEUROL, V4, P228; ENDERBY P, 1990, BRIT J DISORD COMMUN, V25, P341; ENDERBY PM, 1983, FRENCHAY DYSARTHRIA; FERRANTE L, 1990, J NEUROSURG, V72, P959, DOI 10.3171/jns.1990.72.6.0959; FISHER H, 1971, FISHERLOGEMANN TEST; Goozee JV, 1999, J MED SPEECH-LANG PA, V7, P209; Hartelius L, 1993, SCANDINAVIAN J LOGOP, V18, P131, DOI DOI 10.3109/14015439309101359; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; HERB E, 1992, NEUROPEDIATRICS, V23, P144, DOI 10.1055/s-2008-1071330; HOODIN RB, 1989, FOLIA PHONIATR, V41, P249, DOI 10.1159/000265976; Jaeger M, 2000, FOLIA PHONIATR LOGO, V52, P187, DOI 10.1159/000021533; KEARNS KP, 1988, J SPEECH HEAR RES, V31, P131, DOI 10.1044/jshr.3101.131; KENT R, 1975, J SPEECH HEAR DISORD, V40, P115, DOI 10.1044/jshd.4001.115; KENT RD, 1979, J SPEECH HEAR RES, V22, P627, DOI 10.1044/jshr.2203.627; KENT RD, 1989, J SPEECH HEAR DISORD, V54, P482, DOI 10.1044/jshd.5404.482; KENT RD, 1982, BRAIN LANG, V15, P259, DOI 10.1016/0093-934X(82)90060-8; LANGMORE SE, 1994, J SPEECH HEAR RES, V37, P28, DOI 10.1044/jshr.3701.28; Ludlow C. L., 1984, DYSARTHRIAS PHYSL AC, P163; Marquardt TP, 1990, TRAUMATIC BRAIN INJU, P181; MCHENRY MA, 1994, J SPEECH HEAR RES, V37, P1271, DOI 10.1044/jshr.3706.1271; McHenry MA, 1998, ARCH PHYS MED REHAB, V79, P545, DOI 10.1016/S0003-9993(98)90071-5; Murdoch B E, 1989, Brain Inj, V3, P41, DOI 10.3109/02699058909008072; Murdoch B E, 1999, Pediatr Rehabil, V3, P5; Murdoch B E, 1998, Motor Control, V2, P148; Murdoch B. E., 1987, AUSTR J HUMAN COMMUN, V15, P15; MURDOCH BE, 1991, J SPEECH HEAR RES, V34, P768, DOI 10.1044/jshr.3404.768; MURDOCH BE, 1994, EUR J DISORDER COMM, V29, P379; MURDOCH BE, 1993, BRAIN INJURY, V7, P295, DOI 10.3109/02699059309034956; Murdoch BE, 1997, INT CONGR SER, V1146, P621; MURDOCH BE, 1993, J MED SPEECH-LANG PA, V1, P107; MURDOCH BE, 1998, DYSARTHRIA PHYSL APP, P373; NAGATANI K, 1991, SURG NEUROL, V36, P307, DOI 10.1016/0090-3019(91)90094-P; NETSELL R, 1979, ARCH PHYS MED REHAB, V60, P502; ODELL K, 1991, J SPEECH HEAR RES, V34, P67, DOI 10.1044/jshr.3401.67; ORLIKOFF R F, 1992, Seminars in Speech and Language, V13, P25, DOI 10.1055/s-2008-1064184; POLLACK IF, 1995, NEUROSURGERY, V37, P885, DOI 10.1227/00006123-199511000-00006; PRANZATELLI MR, 1994, PEDIATR NEUROL, V10, P131, DOI 10.1016/0887-8994(94)90045-0; RAMIG LO, 1992, INTELLIGIBILITY SPEE, P355; Samuel C, 1998, J NEUROL NEUROSUR PS, V64, P482, DOI 10.1136/jnnp.64.4.482; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; Stierwalt JAG, 1996, DISORDERS MOTOR SPEE, P241; THEODOROS D, 1993, BRAIN INJURY, V7, P59, DOI 10.3109/02699059309008157; Theodoros D G, 1998, Pediatr Rehabil, V2, P107; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; THEODOROS DG, 1995, BRAIN INJURY, V9, P237, DOI 10.3109/02699059509008196; THEODOROS DG, 1994, BRAIN INJURY, V8, P667, DOI 10.3109/02699059409151021; THEODOROS DG, 1995, BRAIN INJURY, V9, P671, DOI 10.3109/02699059509008225; THOMPSON B, 1995, WILDLIFE SOC B, V23, P1; THOMPSON EC, 1995, J COMMUN DISORD, V28, P261, DOI 10.1016/0021-9924(94)00013-P; van Mourik M, 1997, PEDIATR NEUROL, V17, P299; van Mourik M, 1998, PEDIATR NEUROL, V18, P411, DOI 10.1016/S0887-8994(97)00232-4; VANDONGEN HR, 1994, NEUROLOGY, V44, P2040, DOI 10.1212/WNL.44.11.2040; VOGEL M, 1983, FOLIA PHONIATR, V35, P294, DOI 10.1159/000265705; VOLCAN I, 1986, ARCH NEUROL-CHICAGO, V43, P313, DOI 10.1001/archneur.1986.00520040003002; Weismer G., 1984, SEMINARS SPEECH LANG, V5, P293; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P239, DOI 10.1055/s-2008-1064200; Yorkston K. M., 1984, DYSARTHRIAS PHYSL AC, P131; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; YORKSTON KM, 1989, ARCH PHYS MED REHAB, V70, P313; Yorkston KM., 1999, MANAGEMENT MOTOR SPE; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173	81	20	21	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2002	16	5					415	446		10.1080/02699050110119871			32	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	553TX	WOS:000175692500005	12097225				2021-06-18	
J	Huh, JW; Laurer, HL; Raghupathi, R; Helfaer, MA; Saatman, KE				Huh, JW; Laurer, HL; Raghupathi, R; Helfaer, MA; Saatman, KE			Rapid loss and partial recovery of neurofilament immunostaining following focal brain injury in mice	EXPERIMENTAL NEUROLOGY			English	Article						neurofilament; controlled cortical impact; traumatic brain injury; cytoskeleton; phosphorylation; immunohistochemistry	SPINAL-CORD INJURY; MONOCLONAL-ANTIBODIES DISTINGUISH; GANGLION-CELL NEURONS; MEDIATED PROTEOLYSIS; AXONAL-TRANSPORT; CORTICAL IMPACT; NERVOUS-SYSTEM; PROTEINS; PHOSPHORYLATION; RAT	Neurofilaments (NF), the intermediate filaments of the neuronal cytoskeleton, provide mechanical stability to the cell. High-molecular-weight NF (NFH) comprises a heavily phosphorylated carboxyl terminal ("sidearm") domain which helps determine interfilament spacing distances. Experimental evidence suggests that dephosphorylation greatly increases the rate and extent of proteolysis of NFH. Because NF proteolysis has been implicated as one pathogenic mechanism underlying cell death following traumatic brain injury (TBI), we analyzed the patterns of acute NFH damage in relation to phosphorylation state following focal, concussive, controlled cortical impact (CCI) brain injury in mice. Brains from C57BL/6 male mice (n = 4 injured and n = 1 sham per time point) were evaluated 5 min, 15 min, 90 min, 4 h, and 24 h following CCI injury (1 min depth, 5 m/s). Immunohistochemistry was performed using antibodies that recognize epitopes on either dephosphorylated (d-NFH) or phosphorylated (p-NFH) sidearms or on the core (c-NFH) domain. As early as 5-15 min postinjury, immunoreactivity for d-, p-, and c-NFH decreased in the ipsilateral cortex, and hippocampal CA3, CA1, and dentate areas. This marked decrease of NFH labeling occurred in the absence of notable cell loss. Furthermore, partial recovery of NFH labeling was observed as early as 90 min postinjury in the cortex and by 24 h postinjury in hippocampal CA3 and dentate. The results of this study suggest that both phosphorylated and dephosphorylated NFH are vulnerable almost immediately following focal brain injury in mice, but that injured neurons may have an adaptive capability to partially restore this important cytoskeletal protein. (C) 2002 Elsevier Science (USA).	Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Huh, JW (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER		BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; DASH PK, 1995, J NEUROSCI, V15, P2030; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Galvin JE, 2000, EXP NEUROL, V165, P77, DOI 10.1006/exnr.2000.7461; GOLDSTEIN ME, 1987, J NEUROSCI, V7, P1586; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; LEE V, 1982, P NATL ACAD SCI-BIOL, V79, P6089, DOI 10.1073/pnas.79.19.6089; LEE VMY, 1986, J NEUROSCI, V6, P2179; LEE VMY, 1986, J NEUROSCI, V6, P850; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1984, J NEUROCHEM, V42, P25, DOI 10.1111/j.1471-4159.1984.tb09692.x; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; MANSOUR H, 1989, J COMP NEUROL, V283, P481, DOI 10.1002/cne.902830404; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; *NAT RES COUNC, 1996, GUID CAR US LAB; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; NIXON RA, 1987, J NEUROSCI, V7, P1145; OBLINGER MM, 1987, J NEUROSCI, V7, P453; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Pant HC, 1995, BIOCHEM CELL BIOL, V73, P575, DOI 10.1139/o95-063; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; Raabe TD, 1996, J NEUROSCI, V16, P1605; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; SAATMAN KE, 1999, J NEUROTRAUM, V16, P1002; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SCHMIDT ML, 1987, LAB INVEST, V56, P282; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; StraubeWest K, 1996, J CELL SCI, V109, P2319; TROJANOWSKI JQ, 1985, J HISTOCHEM CYTOCHEM, V33, P557, DOI 10.1177/33.6.3889140; TROJANOWSKI JQ, 1986, J NEUROSCI, V6, P650; YANG KY, 1994, J NEUROTRAUM, V11, P523, DOI 10.1089/neu.1994.11.523	47	20	22	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2002	175	1					198	208		10.1006/exnr.2002.7880			11	Neurosciences	Neurosciences & Neurology	550YN	WOS:000175532800018	12009772				2021-06-18	
J	Hawn, KL; Visser, MF; Sexton, PJ				Hawn, KL; Visser, MF; Sexton, PJ			Enforcement of mouthguard use and athlete compliance in National Collegiate Athletic Association Men's Collegiate Ice Hockey Competition	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; mild brain injury; injury prevention; protective equipment	INJURIES	Objective: To determine enforcement patterns and athlete compliance with the National Collegiate Athletic Association (NCAA) rule requiring the wearing of mouthguards in men's collegiate ice hockey games during a single competitive season. Design and Setting: We developed a questionnaire and sent it to certified athletic trainers (ATCs) directly responsible for men's varsity collegiate ice hockey at 127 NCAA-affiliated institutions. Then chi(2) analyses were conducted to determine whether significant differences existed in the pattern of responses by division of play (Division I, II, or III or independent). Subjects: A total of 104 ATCs responded. We obtained data from 94 questionnaires with complete answers to primary questions addressing program enforcement of the rule and mouthguard use. Measurements: Our questionnaire asked about types of mouthguards used, attitudes of the sports medicine and coaching staffs regarding the role of mouthguards in prevention of injury, enforcement of mouthguard use, and actual numbers of athletes wearing mouthguards in competition. Respondents also provided an estimate of the number of penalties assessed against their team for mouthguard violations during the previous season. Results: Most ATCs (93%) reported that they believed mouthguards play a role in injury prevention. Respondents indicated someone on the coaching or sports medicine staff enforced the rule at 74% of the institutions, with a trend toward greater enforcement at the Division II and III levels. Overall, ATCs reported 63% of athletes consistently wore mouthguards in competition, with significantly higher compliance at the Division II and III levels. A total of 19 penalties were reportedly assessed for violation of the mouthguard rule the previous season. Conclusions: Our data suggest that the use of mouthguards in competition is not consistently enforced by ATCs, coaches, or game officials and that mouthguards are not routinely worn by athletes. These results raise legitimate concerns for all physicians, athletic trainers, coaches, and governing bodies involved with men's collegiate ice hockey.	Minnesota State Univ, Mankato, MN 56001 USA; Univ Pittsburgh, Ctr Sports Med, Pittsburgh, PA USA	Visser, MF (corresponding author), Minnesota State Univ, 213 Morris Hall, Mankato, MN 56001 USA.						CASTALDI CR, 1993, SAFETY ICE HOCKEY, P164; Castaldi CR, 1988, SPORTS MED DIGEST, V10, P1; Chapman P, 1985, AUST J SCI MED SPORT, V17, P23; CHAPMAN PJ, 1989, AM J SPORT MED, V17, P690, DOI 10.1177/036354658901700518; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; DEYOUNG AK, 1994, J AM DENT ASSOC, V125, P1112, DOI 10.14219/jada.archive.1994.0121; DICK R, 1993, SAFETY ICE HOCKEY, P21; FARBER M, 1996, SPORTS ILLUSTRATED, V85, P100; Francis K T, 1991, Br J Sports Med, V25, P227; KERR IL, 1986, SPORTS MED, V3, P415, DOI 10.2165/00007256-198603060-00003; *NAT COLL ATHL ASS, 2001, 2001 MENS WOM IC HOC; *NAT COLL ATHL ASS, 1996, INJ SURV SYST 1997 9; NATT P, 1983, J ROY SOC HEALTH, V103, P180, DOI 10.1177/146642408310300506; Putukian M, 1996, PHYSICIAN SPORTSMED, V24, P25, DOI 10.3810/psm.1996.11.1283; Shaull K L, 1985, Trends Tech Contemp Dent Lab, V2, P12; Siegal S., 1988, NONPARAMETRIC STAT B, V2nd; 2001, US TODAY COM SPORTS	17	20	20	0	5	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	APR-JUN	2002	37	2					204	208					5	Sport Sciences	Sport Sciences	558UA	WOS:000175983900015					2021-06-18	
J	Sellars, C; Hughes, T; Langhorne, P				Sellars, C; Hughes, T; Langhorne, P			Speech and language therapy for dysarthria due to nonprogressive brain damage: a systematic Cochrane review	CLINICAL REHABILITATION			English	Article							INTELLIGIBILITY; STROKE	Background: Dysarthria is a common sequel of nonprogressive brain damage (typically stroke and traumatic brain damage). Impairment-based therapy and a wide variety of compensatory management strategies are undertaken by speech and language therapists with this patient population. Objective: To determine the efficacy of speech and language therapy interventions for adults with dysarthria following nonprogressive brain damage. Design: Systematic review. Search strategy: This review has drawn on the search strategies developed for the following Cochrane Groups as a whole: Stroke, Injuries, and Infectious Diseases. Relevant trials were identified in the Specialised Registers of Controlled Trials. We also searched the trials register of the Cochrane Rehabilitation and Related Therapies Field. The Cochrane Controlled Trials Register, MEDLINE, EMBASE, CINAHL, PsycLIT, and Linguistics and Language Behavior Abstracts were electronically searched. Hand-searching of the International Journal of Language and Communication Disorders and of reference lists from relevant articles and conference proceedings was also undertaken. Colleagues were approached to identify other possible published and unpublished studies. Selection criteria: Unconfounded randomized controlled trials. Data collection and analysis: One reviewer assessed trial quality. Two co-reviewers were available to examine any potential trials for possible inclusion in the review. Main results: No trials of the required standard were identified. Reviewers' conclusions: There is no evidence of the quality required by this review to support or refute the effectiveness of speech and language therapy interventions for dysarthria following nonprogressive brain damage. There is an urgent need for good quality research in this area.	Glasgow Royal Infirm, Acad Sect Geriatr Med, STEP Project, Glasgow G4 0SF, Lanark, Scotland; Glasgow Royal Infirm, Dept Speech & Language Therapy, Glasgow G4 0SF, Lanark, Scotland; Rookwood Hosp, Welsch Spinal Injuries & Neurol Rehabil Unit, Cardiff, S Glam, Wales	Sellars, C (corresponding author), Glasgow Royal Infirm, Acad Sect Geriatr Med, STEP Project, 3rd Floor,Ctr Block,Castle St, Glasgow G4 0SF, Lanark, Scotland.						ARBOIX A, 1990, STROKE, V21, P842, DOI 10.1161/01.STR.21.6.842; Baum HM, 1999, MED CARE RES REV, V56, P139; Berry W., 1983, CLIN DYSARTHRIA, P203; COHEN NS, 1993, J MUSIC THER, V30, P81, DOI 10.1093/jmt/30.2.81; CROW E, 1989, RECENT ADVANCES IN CLINICAL DYSARTHRIA, P99; ENDERBY P, 1990, BRIT J DISORD COMMUN, V25, P341; Fukusako Y., 1989, ANN B RILP, V23, P119; GREENER J, 2000, COCHRANE LIB; INCE LP, 1973, ARCH PHYS MED REHAB, V54, P233; Keenan J, 1993, AUGMENTATIVE ALTERNA, V9, P184, DOI DOI 10.1080/07434619312331276591; Kent R, 1998, J MED SPEECH-LANG PA, V6, P165; Kent RD, 1999, J MED SPEECH-LANG PA, V7, P83; MCNAMARA RD, 1983, CLIN DYSARTHRIA, P191; MELO TP, 1992, NEUROLOGY, V42, P789, DOI 10.1212/WNL.42.4.789; NETSELL R, 1984, SEMINARS LANGUAGE, P279; Pilon MA, 1998, BRAIN INJURY, V12, P793, DOI 10.1080/026990598122188; Robey RR, 1999, APHASIOLOGY, V13, P445, DOI 10.1080/026870399402028; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; TUDOR C, 1974, BRIT J DISORD COMMUN, V9, P117; WARLOW CP, 1996, STROKE PRACTICAL GUI; YORKSTON KM, 1981, J SPEECH HEAR DISORD, V46, P398, DOI 10.1044/jshd.4604.398; YORKSTON KM, 1990, J SPEECH HEAR DISORD, V55, P550, DOI 10.1044/jshd.5503.550; Yorkston KM, 1996, J SPEECH HEAR RES, V39, pS46, DOI 10.1044/jshr.3905.s46; YORKSTON KM, 1987, CLIN MANAGEMENT DYSA; Yorkston KM, 1989, J HEAD TRAUMA REHAB, V4, P1	25	20	21	0	11	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	FEB	2002	16	1					61	68		10.1191/0269215502cr468oa			8	Rehabilitation	Rehabilitation	517FH	WOS:000173600100008	11837527				2021-06-18	
J	Azcoitia, I; Doncarlos, LL; Garcia-Segura, LM				Azcoitia, Inigo; Doncarlos, Lydia L.; Garcia-Segura, Luis M.			Estrogen and brain vulnerability	NEUROTOXICITY RESEARCH			English	Article						Apoptosis; Neuroprotection; Estrogen; Estrogen receptor; Neurotrophins; Insulin-like growth factor I; Alzheimer's disease; Stroke; Schizophrenia		Accumulated clinical and basic evidence suggests that gonadal steroids affect the onset and progression of several neurodegenerative diseases and schizophrenia, and the recovery from traumatic neurological injury such as stroke. Thus, our view on gonadal hormones in neural function must be broadened to include not only their function in neuroendocrine regulation and reproductive behaviors, but also to include a direct participation in response to degenerative disease or injury. Recent findings indicate that the brain up-regulates both estrogen synthesis and estrogen receptor expression at sites of injury. Genetic or pharmacological inactivation of aromatase, the enzyme involved in estrogen synthesis, indicates that the induction of this enzyme in the brain after injury has a neuroprotective role. Some of the mechanisms underlying the neuroprotective effects of estrogen may be independent of the classically defined nuclear estrogen receptors (ERs). Other neuroprotective effects of estrogen do depend on the classical nuclear ERs, through which estrogen alters expression of estrogen responsive genes that play a role in apoptosis, axonal regeneration, or general trophic support. Yet another possibility is that non-classical ERs in the membrane or cytoplasm alter phosphorylation cascades, such as those involved in the signaling of insulin-like growth factor-I (IGF-I). Indeed, ERs and IGF-I receptor interact in the activation of PI3K and MAPK signaling cascades and in the promotion of neuroprotection. The decrease in estrogen and IGF-I levels with aging may thus result in an increased risk for neural pathological alterations after different forms of brain injury.	[Azcoitia, Inigo] Univ Complutense, Fac Biol, Dept Biol Celular, E-28040 Madrid, Spain; [Doncarlos, Lydia L.] Loyola Univ Chicago, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA; [Garcia-Segura, Luis M.] Inst Cajal, CSIC, Ave Dr Arce 37, E-28002 Madrid, Spain	Garcia-Segura, LM (corresponding author), Inst Cajal, CSIC, Ave Dr Arce 37, E-28002 Madrid, Spain.	lmgs@cajal.csic.es	Garcia-Segura, Luis M/U-3711-2017; Azcoitia, Inigo/A-6208-2011	Garcia-Segura, Luis M/0000-0002-2450-2916; Azcoitia, Inigo/0000-0002-5791-9144	Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission [01/1214]; Comunidad de MadridComunidad de Madrid [08.5/0047.1/2000]; DEGESIC [PM98-0110]; Commission of the European Communities, specific RTD programme "Quality of Life and Management of Living Resources" [QLK6-CT-2000-00179]; USPHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MH 48794]	Supported by grants from the Instituto de Salud Carlos III (01/1214), Comunidad de Madrid (08.5/0047.1/2000), DEGESIC (PM98-0110), Commission of the European Communities, specific RTD programme "Quality of Life and Management of Living Resources" (QLK6-CT-2000-00179) and USPHS MH 48794.	Akama K.T, 2000, SOC NEUR ABSTR, V26, P409; Alkayed NJ, 2001, J NEUROSCI, V21, P7543; ARIMATSU Y, 1986, DEV BRAIN RES, V26, P151, DOI 10.1016/0165-3806(86)90017-9; Asthana S, 2001, NEUROLOGY, V57, P605, DOI 10.1212/WNL.57.4.605; Azcoitia I, 1998, NEUROREPORT, V9, P3075, DOI 10.1097/00001756-199809140-00029; Azcoitia I, 1999, J NEUROSCI RES, V58, P815, DOI 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R; Azcoitia I, 1999, GLIA, V26, P260; Azcoitia I, 2001, Prog Brain Res, V132, P469; Azcoitia I, 1999, J NEUROCYTOL, V28, P699, DOI 10.1023/A:1007025219044; Azcoitia I, 2001, J NEUROBIOL, V47, P318, DOI 10.1002/neu.1038; Baulieu EE, 1998, PSYCHONEUROENDOCRINO, V23, P963, DOI 10.1016/S0306-4530(98)00071-7; Behl C, 1999, TRENDS PHARMACOL SCI, V20, P441, DOI 10.1016/S0165-6147(99)01392-9; Behl C, 2000, J NEUROCYTOL, V29, P351, DOI 10.1023/A:1007109222673; Blurton-Jones M, 2001, J COMP NEUROL, V433, P115, DOI 10.1002/cne.1129; Bogdanov MB, 1999, NEUROSCI LETT, V262, P33, DOI 10.1016/S0304-3940(99)00047-6; Brinton RD, 1997, NEUROCHEM RES, V22, P1339, DOI 10.1023/A:1022015005508; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; Cardona-Gomez G.P., 2000, SOC NEUR ABSTR, V26, P1095; Cardona-Gomez GP, 2000, NEUROSCIENCE, V99, P751, DOI 10.1016/S0306-4522(00)00228-1; Cardona-Gomez GP, 2001, BRAIN RES REV, V37, P320, DOI 10.1016/S0165-0173(01)00137-0; Chan SL, 1999, J NEUROCHEM, V73, P502, DOI 10.1046/j.1471-4159.1999.0730502.x; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen J, 1998, NEUROSCIENCE, V87, P817, DOI 10.1016/S0306-4522(98)00198-5; Chowen JA, 2000, J PEDIATR ENDOCR MET, V13, P1045; CHOWEN JA, 1992, NEUROENDOCRINOLOGY, V56, P895, DOI 10.1159/000126321; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Costa MM, 1999, BIOL PSYCHIAT, V46, P182, DOI 10.1016/S0006-3223(98)00355-2; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; Culmsee C, 2001, J CEREBR BLOOD F MET, V21, P334, DOI 10.1097/00004647-200104000-00002; Dluzen DE, 2000, J NEUROCYTOL, V29, P387, DOI 10.1023/A:1007117424491; Dodel RC, 1999, J NEUROCHEM, V73, P1453, DOI 10.1046/j.1471-4159.1999.0731453.x; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; Duan WZ, 1999, ANN NEUROL, V46, P587, DOI 10.1002/1531-8249(199910)46:4<587::AID-ANA6>3.0.CO;2-M; Duan WZ, 1999, J NEUROCHEM, V72, P2312, DOI 10.1046/j.1471-4159.1999.0722312.x; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Duenas M, 1996, NEUROSCIENCE, V74, P531, DOI 10.1016/0306-4522(96)00142-X; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; Finley SK, 1999, J NEUROBIOL, V40, P446; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; Garcia-Segura LM, 2000, J NEUROCYTOL, V29, P425, DOI 10.1023/A:1007125626308; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; GarciaSegura LM, 1996, FRONT NEUROENDOCRIN, V17, P180, DOI 10.1006/frne.1996.0005; Garnier M, 1997, J NEUROSCI, V17, P4591; Gibbs RB, 2000, NEUROSCIENCE, V101, P931, DOI 10.1016/S0306-4522(00)00433-4; Gollapudi L, 1999, J NEUROSCI RES, V56, P471, DOI 10.1002/(SICI)1097-4547(19990601)56:5<471::AID-JNR3>3.3.CO;2-T; Gollapudi L, 1999, J NEUROSCI RES, V56, P99, DOI 10.1002/(SICI)1097-4547(19990401)56:1<99::AID-JNR13>3.0.CO;2-G; GOMEZMANCILLA B, 1992, NEUROSCI LETT, V135, P129, DOI 10.1016/0304-3940(92)90152-W; Grandbois M, 2000, NEUROREPORT, V11, P343, DOI 10.1097/00001756-200002070-00024; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Gudino-Cabrera G, 1999, J NEUROBIOL, V40, P458, DOI 10.1002/(SICI)1097-4695(19990915)40:4<458::AID-NEU4>3.0.CO;2-9; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; Hoff AL, 2001, AM J PSYCHIAT, V158, P1134, DOI 10.1176/appi.ajp.158.7.1134; Hogervorst E, 2000, NEUROSCIENCE, V101, P485, DOI 10.1016/S0306-4522(00)00410-3; Holm K, 1999, TRENDS NEUROSCI, V22, P269, DOI 10.1016/S0166-2236(98)01352-6; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Hosli E, 2001, INT J DEV NEUROSCI, V19, P11, DOI 10.1016/S0736-5748(00)00082-4; Ishunina TA, 2001, NEUROBIOL AGING, V22, P417, DOI 10.1016/S0197-4580(00)00255-4; Jakab RL, 2001, J COMP NEUROL, V430, P396, DOI 10.1002/1096-9861(20010212)430:3<396::AID-CNE1039>3.0.CO;2-0; Jones KJ, 1999, J NEUROBIOL, V40, P560, DOI 10.1002/(SICI)1097-4695(19990915)40:4<560::AID-NEU11>3.0.CO;2-I; Jordan CL, 1999, J NEUROBIOL, V40, P434, DOI 10.1002/(SICI)1097-4695(19990915)40:4<434::AID-NEU2>3.0.CO;2-T; Kulkarni J, 2001, SCHIZOPHR RES, V48, P137, DOI 10.1016/S0920-9964(00)00088-8; LANGUB MC, 1992, ENDOCRINOLOGY, V130, P364, DOI 10.1210/en.130.1.364; Lindamer LA, 2001, BIOL PSYCHIAT, V49, P47, DOI 10.1016/S0006-3223(00)00995-1; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; Meda C, 2000, J NEUROENDOCRINOL, V12, P1051, DOI 10.1046/j.1365-2826.2000.00541.x; Melcangi RC, 1999, J NEUROBIOL, V40, P471, DOI 10.1002/(SICI)1097-4695(19990915)40:4<471::AID-NEU5>3.3.CO;2-G; Mong JA, 1999, J NEUROBIOL, V40, P602, DOI 10.1002/(SICI)1097-4695(19990915)40:4<602::AID-NEU14>3.0.CO;2-O; Mor G, 1999, J NEUROBIOL, V40, P484, DOI 10.1002/(SICI)1097-4695(19990915)40:4<484::AID-NEU6>3.0.CO;2-C; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Nichols NR, 1999, J NEUROBIOL, V40, P585, DOI 10.1002/(SICI)1097-4695(19990915)40:4<585::AID-NEU13>3.3.CO;2-T; Ojeda SR, 1999, J NEUROBIOL, V40, P528, DOI 10.1002/(SICI)1097-4695(19990915)40:4<528::AID-NEU9>3.0.CO;2-V; Paganini-Hill A, 2001, MATURITAS, V38, P243, DOI 10.1016/S0378-5122(01)00167-0; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; PaganiniHill A, 1996, ARCH INTERN MED, V156, P2213, DOI 10.1001/archinte.156.19.2213; Patrone C, 1999, P NATL ACAD SCI USA, V96, P10905, DOI 10.1073/pnas.96.19.10905; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Peterson RS, 2001, J NEUROENDOCRINOL, V13, P317, DOI 10.1046/j.1365-2826.2001.00647.x; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Rabbani O, 1997, EXP NEUROL, V146, P179, DOI 10.1006/exnr.1997.6516; Regan RF, 1997, BRAIN RES, V764, P133, DOI 10.1016/S0006-8993(97)00437-X; Reibel S, 2000, NEUROSCI LETT, V281, P79, DOI 10.1016/S0304-3940(00)00784-9; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; SANDYK R, 1987, PEDIATR NEUROL, V3, P122, DOI 10.1016/0887-8994(87)90042-7; Saunders-Pullman R, 1999, NEUROLOGY, V52, P1417, DOI 10.1212/WNL.52.7.1417; Sawada H, 1998, J NEUROSCI RES, V54, P707, DOI 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T; Sawada M, 2000, J CEREBR BLOOD F MET, V20, P112, DOI 10.1097/00004647-200001000-00015; Schonknecht P, 2001, NEUROSCI LETT, V307, P122, DOI 10.1016/S0304-3940(01)01896-1; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Singer CA, 1999, J NEUROSCI, V19, P2455; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; Singh M, 1999, J NEUROSCI, V19, P1179; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; Slooter AJC, 1999, J NEUROL NEUROSUR PS, V67, P779, DOI 10.1136/jnnp.67.6.779; Soares CD, 2001, ARCH GEN PSYCHIAT, V58, P529; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; Stone DJ, 1998, ENDOCRINOLOGY, V139, P3202, DOI 10.1210/en.139.7.3202; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; Tsang KL, 2000, NEUROLOGY, V54, P2292, DOI 10.1212/WNL.54.12.2292; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Vegeto E, 2001, J NEUROSCI, V21, P1809, DOI 10.1523/JNEUROSCI.21-06-01809.2001; Vegeto E, 1999, FASEB J, V13, P793; Wang Q, 1999, STROKE, V30, P630, DOI 10.1161/01.STR.30.3.630; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Wilson M.E, 2000, SOC NEUR ABSTR, V26, P923; Wilson ME, 2000, BRAIN RES, V873, P235, DOI 10.1016/S0006-8993(00)02479-3; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; Wise PM, 2001, ENDOCRINOLOGY, V142, P969, DOI 10.1210/en.142.3.969; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; Wise PM, 2000, J PEDIATR ENDOCR MET, V13, P1425; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; Zaulyanov LL, 1999, CELL MOL NEUROBIOL, V19, P705, DOI 10.1023/A:1006948921855; Zhang L, 2001, NEUROREPORT, V12, P1919, DOI 10.1097/00001756-200107030-00030; Zhang Y, 2001, J NEUROSCI, V21, part. no.; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	133	20	21	0	0	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1029-8428	1476-3524		NEUROTOX RES	Neurotox. Res.	JAN	2002	4	3					235	245		10.1080/10298420290033232			11	Neurosciences	Neurosciences & Neurology	VJ3BG	WOS:000574981300007	12829404				2021-06-18	
J	McDonald, JW; Stefovska, VG; Liu, XZ; Shin, H; Liu, S; Choi, DW				McDonald, JW; Stefovska, VG; Liu, XZ; Shin, H; Liu, S; Choi, DW			Neurotrophin potentiation of iron-induced spinal cord injury	NEUROSCIENCE			English	Article						nerve growth factor; brain-derived neurotrophic factor; neurotrophin-3; neurotrophin-4/5; excitotoxicity; free radicals	NERVE GROWTH-FACTOR; ASPARTATE RECEPTOR SUBUNIT-1; STRIATAL CHOLINERGIC NEURONS; PARTIAL FUNCTIONAL RECOVERY; TRAUMATIC BRAIN INJURY; RETINAL GANGLION-CELLS; NITRIC-OXIDE SYNTHASE; REDUCES INFARCT SIZE; CORTICAL-NEURONS; ADULT-RAT	Previous studies have shown that pretreatment with neurotrophins can potentiate the vulnerability of cultured neurons to excitotoxic and free radical-induced necrosis, in contrast to their well known neuroprotective effects against apoptosis. Here we tested the hypothesis that this unexpected injury-potentiating effect of neurotrophins would also take place in the adult rat spinal cord. Fe3+-citrate was injected stereotaxically into spinal cord gray matter in adult rats in amounts sufficient to produce minimal tissue injury 24 It later. Twenty-four-hour pretreatment with brain-derived neurotrophic factor, neurotrophin-3, or neurotrophin-4/5, but not nerve growth factor, markedly enhanced tissue injury in the gray matter as evidenced by an increase in the damaged area, as well as the loss of neurons and oligodendrocytes. Consistent with maintained free radical mediation, the neurotrophin-potentiated iron-induced spinal cord damage was blocked by co-application of the antioxidant N-tert-butyl-(2-sulfophenyl)-nitrone. These data support the hypothesis that the overall neuroprotective properties of neurotrophins in models of acute injury to the spinal cord may be limited by an underlying potentiation of free radical-mediated necrosis. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Choi, DW (corresponding author), Merck Sharp & Dohme Ltd, Res Labs, West Point, PA 19486 USA.	wildersp@neuro.wustl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036265, P01NS032636, K08NS001931] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS32636, NS01931, NS36265] Funding Source: Medline		ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; Andsberg G, 1998, EUR J NEUROSCI, V10, P2026, DOI 10.1046/j.1460-9568.1998.00214.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; Bai G, 1997, J BIOL CHEM, V272, P5936, DOI 10.1074/jbc.272.9.5936; Chan KM, 1996, NEUROCHEM RES, V21, P763, DOI 10.1007/BF02532298; CHENG B, 1994, BRAIN RES, V650, P331, DOI 10.1016/0006-8993(94)91801-5; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; DAVIES SW, 1992, NEUROSCI LETT, V140, P161, DOI 10.1016/0304-3940(92)90092-L; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dreyfus CF, 1999, J NEUROSCI RES, V56, P1, DOI 10.1002/(SICI)1097-4547(19990401)56:1<1::AID-JNR1>3.0.CO;2-3; FERNANDEZSANCHEZ MT, 1993, FEBS LETT, V335, P124, DOI 10.1016/0014-5793(93)80453-2; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; Giehl KM, 2001, J NEUROSCI, V21, P3492, DOI 10.1523/JNEUROSCI.21-10-03492.2001; Glazner GW, 2000, EXP NEUROL, V161, P442, DOI 10.1006/exnr.1999.7242; Grill R, 1997, J NEUROSCI, V17, P5560; Gwag BJ, 1995, NEUROREPORT, V7, P93, DOI 10.1097/00001756-199512000-00022; HEFTI F, 1986, J NEUROSCI, V6, P2155; Heppenstall PA, 2001, P NATL ACAD SCI USA, V98, P8107, DOI 10.1073/pnas.141015098; Houle JD, 1999, NEUROSCIENCE, V94, P929, DOI 10.1016/S0306-4522(99)00359-0; Houweling DA, 1998, NEUROSCI LETT, V251, P193, DOI 10.1016/S0304-3940(98)00536-9; Houweling DA, 1998, EXP NEUROL, V153, P49, DOI 10.1006/exnr.1998.6867; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Isenmann S, 1998, EUR J NEUROSCI, V10, P2751, DOI 10.1046/j.1460-9568.1998.00325.x; Jakeman LB, 1998, EXP NEUROL, V154, P170, DOI 10.1006/exnr.1998.6924; Jarvis CR, 1997, J NEUROPHYSIOL, V78, P2363; Johnson EM, 1996, BRAIN PATHOL, V6, P397, DOI 10.1111/j.1750-3639.1996.tb00872.x; Johnston M V, 2000, Semin Neonatol, V5, P75, DOI 10.1053/siny.1999.0116; Kirschner PB, 1996, BRAIN RES, V713, P178, DOI 10.1016/0006-8993(95)01513-2; Klocker N, 1998, J NEUROSCI, V18, P1038; Kobayashi H, 1997, BRAIN RES BULL, V43, P17, DOI 10.1016/S0361-9230(96)00343-7; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Lever IJ, 2001, J NEUROSCI, V21, P4469, DOI 10.1523/JNEUROSCI.21-12-04469.2001; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Lin SY, 1998, MOL BRAIN RES, V55, P20, DOI 10.1016/S0169-328X(97)00349-5; Lobner D, 1996, NEUROSCIENCE, V72, P335, DOI 10.1016/0306-4522(95)00561-7; MCDONALD JW, 1989, EXP NEUROL, V106, P289, DOI 10.1016/0014-4886(89)90162-3; McTigue DM, 1998, J NEUROSCI, V18, P5354; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; Park EC, 1998, NEUROREPORT, V9, P687, DOI 10.1097/00001756-199803090-00023; Pitts AF, 2000, J COMP NEUROL, V418, P241, DOI 10.1002/(SICI)1096-9861(20000313)418:3<241::AID-CNE1>3.0.CO;2-M; Prehn JHM, 1996, EUR J PHARMACOL, V306, P81, DOI 10.1016/0014-2999(96)00225-7; Samdani AF, 1997, J NEUROSCI, V17, P4633; Scarisbrick IA, 1999, J NEUROSCI, V19, P7757; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Schutte A, 2000, NEUROSCI LETT, V290, P185, DOI 10.1016/S0304-3940(00)01351-3; SENGSTOCK GJ, 1992, BRAIN RES BULL, V28, P645, DOI 10.1016/0361-9230(92)90118-H; SHIGENO T, 1991, J NEUROSCI, V11, P2914; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Small DL, 1998, NEUROSCI LETT, V252, P211, DOI 10.1016/S0304-3940(98)00587-4; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; Takei N, 1998, J BIOL CHEM, V273, P27620, DOI 10.1074/jbc.273.42.27620; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; Won SJ, 2000, NEUROBIOL DIS, V7, P251, DOI 10.1006/nbdi.2000.0284; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; Yan Q, 1997, J COMP NEUROL, V378, P135	57	20	20	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2002	115	3					931	939	PII S0306-4522(02)00342-1	10.1016/S0306-4522(02)00342-1			9	Neurosciences	Neurosciences & Neurology	620FV	WOS:000179524100027	12435430				2021-06-18	
J	Moor, E; Kohen, R; Reiter, RJ; Shohami, E				Moor, E; Kohen, R; Reiter, RJ; Shohami, E			Closed head injury increases extracellular levels of antioxidants in rat hippocampus in vivo: an adaptive mechanism?	NEUROSCIENCE LETTERS			English	Article						head trauma; closed head injury; microdialysis; antioxidants; oxidative stress; uric acid; ascorbic acid	URIC-ACID; IN-VIVO; ISCHEMIA-REPERFUSION; ASCORBIC-ACID; BRAIN INJURY; RELEASE; GLUTAMATE; STRIATUM	Reactive oxygen species (ROS) are a major cause of secondary brain injury following head trauma. Low molecular weight antioxidants (LMWA) protect the tissue against oxidative damage caused by ROS. In the present study, we measured the extracellular levels of the LMWA ascorbic acid and uric acid in the rat brain before, during and after experimental closed head injury (CHI). A dialysis probe was inserted into the right ventral hippocampus through a chronically implanted guide. CHI was applied to the left hemisphere using a weight-drop device. CHI induced a rapid but transient increase in ascorbic acid levels. Uric acid levels increased to 250% of baseline shortly after CHI and remained elevated at 2 h after CHI. Previous results show that the overall reducing power of brain tissue decreases following CHI. Together with previous results, the current findings suggest that ascorbic acid and uric acid are mobilized from brain cells to the extracellular space. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA	Moor, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.						AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; BECKER BF, 1993, FREE RADICAL BIO MED, V14, P615, DOI 10.1016/0891-5849(93)90143-I; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Benzie IFF, 1996, REDOX REP, V2, P231, DOI 10.1080/13510002.1996.11747055; Berry EM, 1999, MED HYPOTHESES, V53, P397, DOI 10.1054/mehy.1998.0786; Elangovan V, 2000, J NEUROTRAUM, V17, P1013, DOI 10.1089/neu.2000.17.1013; Enrico P, 1997, PHARMACOL RES, V35, P577, DOI 10.1006/phrs.1997.0193; GHASEMZEDAH B, 1991, BRAIN RES, V547, P162; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; HILLERED L, 1988, NEUROSCI LETT, V95, P1; Islekel S, 1999, RES EXP MED, V199, P167, DOI 10.1007/s004330050121; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Lomnitski L, 2000, EXP TOXICOL PATHOL, V52, P177; MAJEWSKA MD, 1990, BRAIN RES, V537, P328, DOI 10.1016/0006-8993(90)90379-P; Miele M, 2000, BRIT J PHARMACOL, V129, P582, DOI 10.1038/sj.bjp.0703066; MIELE M, 1994, NEUROSCIENCE, V62, P87, DOI 10.1016/0306-4522(94)90316-6; MOTCHNIK PA, 1994, METHOD ENZYMOL, V234, P115; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; RYAN M, 1997, ANN CLIN BIOCHEM, V35, P553; SEVANIAN A, 1991, AM J CLIN NUTR, V54, pS1129, DOI 10.1093/ajcn/54.6.1129s; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Tayag EC, 1996, BRAIN RES, V733, P287, DOI 10.1016/0006-8993(96)00669-5; Yu ZF, 1998, J NEUROSCI RES, V53, P613, DOI 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1; Yusa T, 2000, NEUROSCI LETT, V293, P123, DOI 10.1016/S0304-3940(00)01501-9; Yusa T, 2001, BRAIN RES, V897, P104, DOI 10.1016/S0006-8993(01)02099-6	25	20	20	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	DEC 28	2001	316	3					169	172		10.1016/S0304-3940(01)02394-1			4	Neurosciences	Neurosciences & Neurology	511MT	WOS:000173268200011	11744229				2021-06-18	
J	Simpson, G; Tate, R; Ferry, K; Hodgkinson, A; Blaszczynski, A				Simpson, G; Tate, R; Ferry, K; Hodgkinson, A; Blaszczynski, A			Social, neuroradiologic, medical, and neuropsychologic correlates of sexually aberrant behavior after traumatic brain injury: A controlled study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						frontal lobe; paraphilias; sex offenses; traumatic brain injury	HEAD-INJURY; ADJUSTMENT; SEQUELAE	Objective: To identify social, neuroradiological, medical, and neuropsychological correlates of sexually aberrant behavior (SAB) after traumatic brain injury (TBI). Design: A controlled study using a retrospective file review. Setting: A brain injury unit providing inpatient and outpatient rehabilitation services. Participants: A sample of males (n = 25) exhibiting SABs and a control group (n = 25) matched for gender, severity of injury, age at injury, and time after injury. Main Outcome Measures: A protocol that recorded data on demographic, injury, radiological, medical, and neuropsychological variables. Results: The SAB group had a significantly higher incidence of postinjury psychosocial disturbance in areas of nonsexual crime and failure to return to work than the matched TBI group. There were no significant differences between the two groups in the incidence of premorbid psychosocial disturbance or postinjury radiological, medical, or neuropsychological variables. Conclusions: The study results caution against simplistic explanations of SAB as the product of damage to the frontal-lobe systems or premorbid psychosocial disturbance. Furthermore, the results suggest that a wide-ranging assessment of people with TBI who exhibit SABs is required, because results of neuropsychological examination alone cannot be considered conclusive. Future research into the etiology of SABs could examine additional factors such as lack of insight, lack of empathy, and premorbid history of family dysfunction.	Liverpool Hosp, Brain Injury Rehabil Unit, Liverpool, NSW 1871, Australia; Univ Sydney, Rehabil Studies Unit, Ryde, NSW, Australia; Univ Sydney, Westmead, NSW 2145, Australia; Dept Med Psychol, Westmead, NSW 2145, Australia	Simpson, G (corresponding author), Liverpool Hosp, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool, NSW 1871, Australia.		Blaszczynski, Alexander/G-2713-2013; Simpson, Grahame K/W-1074-2019	Blaszczynski, Alexander/0000-0003-1476-0791; Simpson, Grahame K/0000-0001-8156-9060			AGETON SS, 1983, SEXUAL ASSAULT ADOLE; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; Crowe SF, 1999, BRAIN INJURY, V13, P347; EMORY LE, 1995, J HEAD TRAUMA REHAB, V10, P47; FAHY TJ, 1967, LANCET, V2, P475; Goldberg R L, 1982, Int J Psychiatry Med, V12, P275; GRABER B, 1982, J FORENSIC SCI, V27, P125; HALL HV, 1993, DISORDERS EXECUTIVE, P37; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Heilman K.M.V.E., 1993, CLIN NEUROPSYCHOLOGY; HENN FA, 1976, AM J PSYCHIAT, V133, P694; Horn LJ, 1990, J HEAD TRAUMA REHAB, V5, P1; Hucker S, 1988, ANN SEX RES, V1, P33; JAMIESON KG, 1966, 13 NAT HLTH MED RES; Knight R. A., 1985, RAPE SEXUAL ASSAULT; KOZOL HL, 1946, ARCH NEURO PSYCHIATR, V56, P245, DOI 10.1001/archneurpsyc.1946.02300200002001; KOZOL HL, 1945, ARCH NEURO PSYCHIATR, V53, P358, DOI 10.1001/archneurpsyc.1945.02300050032004; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LANGEVIN R, 1990, HDB SEXUAL ASSAULT I, P103; Langevin R, 1985, EROTIC PREFERENCE GE, P39; LEHNE G, 1986, SEX DISABIL, V7, P145; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Marshall W.L., 1990, HDB SEXUAL ASSAULT; Meyer W J 3rd, 1992, Bull Am Acad Psychiatry Law, V20, P249; MILLER BL, 1986, J NEUROL NEUROSUR PS, V49, P867, DOI 10.1136/jnnp.49.8.867; MONEY J, 1990, AM J PSYCHOTHER, V44, P26; REGESTEIN QR, 1978, J NERV MENT DIS, V166, P794, DOI 10.1097/00005053-197811000-00007; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROSENTHAL M, 1990, REHABILITATION ADULT; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; SCOTT ML, 1984, J FORENSIC SCI, V29, P1114; Simpson G, 1999, J HEAD TRAUMA REHAB, V14, P567, DOI 10.1097/00001199-199912000-00005; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; WEINSTEIN EA, 1961, PSYCHIATR, V24, P69; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163	45	20	20	0	5	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2001	16	6					556	572		10.1097/00001199-200112000-00004			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	501AL	WOS:000172660800004	11732971				2021-06-18	
J	James, LE; MacKay, DG				James, LE; MacKay, DG			HM, word knowledge, and aging: Support for a new theory of long-term retrograde amnesia	PSYCHOLOGICAL SCIENCE			English	Article							CLOSED-HEAD-INJURY; HIPPOCAMPAL SYSTEM; OLDER ADULTS; MEMORY; CONSOLIDATION; RECOGNITION; DISEASE; BINDING; TONGUE; YOUNG	This study develops a new theory of long-term retrograde amnesia that encompasses episodic and semantic memory, including word knowledge. Under the theory, retrograde amnesia in both normal individuals and hippocampal amnesics reflects transmission deficits caused by aging, nonrecent use of connections, and infrequent use of connections over the life span. However, transmission deficits cause severe and irreversible retrograde amnesia only in amnesics who (unlike normal persons) cannot readily form new connections to replace nonfunctioning ones. The results of this study are consistent with this theory: For low-frequency but not high-frequency words, a famous "hippocampal amnesic" (H.M.) at age 71 performed worse than memory-normal control participants in a lexical decision experiment and a meaning-definition task (e.g., What does squander mean?). Also as predicted, H.M.'s lexical decision performance declined dramatically between ages 57 and 71 for low-frequency words, but was age invariant for high-frequency words.	Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA	MacKay, DG (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.	mackay@psych.ucla.edu			NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG009755] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG 09755] Funding Source: Medline		ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; BURKE DM, 1991, J MEM LANG, V30, P542, DOI 10.1016/0749-596X(91)90026-G; CARPENTER GA, 1993, TRENDS NEUROSCI, V16, P131, DOI 10.1016/0166-2236(93)90118-6; Corkin S, 1997, J NEUROSCI, V17, P3964; CORKIN S, 1984, SEMIN NEUROL, V4, P249, DOI 10.1055/s-2008-1041556; GABRIELI JDE, 1988, BRAIN COGNITION, V7, P157, DOI 10.1016/0278-2626(88)90027-9; GRAFMAN J, 1996, BASIC APPL MEMORY TH, P259; Helmuth LI, 1997, LEARN MEMORY, V3, P456, DOI 10.1101/lm.3.6.456; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; Ivry R B, 1989, J Cogn Neurosci, V1, P136, DOI 10.1162/jocn.1989.1.2.136; James LE, 2000, J EXP PSYCHOL LEARN, V26, P1378, DOI 10.1037//0278-7393.26.6.1378; KAPUR N, 1993, CORTEX, V29, P217, DOI 10.1016/S0010-9452(13)80177-3; Kopelman MD, 1999, NEUROPSYCHOLOGIA, V37, P939, DOI 10.1016/S0028-3932(98)00143-2; LACKNER JR, 1974, NEUROPSYCHOLOGIA, V12, P199, DOI 10.1016/0028-3932(74)90005-0; LAVER GD, 1993, PSYCHOL AGING, V8, P34, DOI 10.1037/0882-7974.8.1.34; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; MacKay D. G., 1990, RELATIONSHIPS PERCEP, P269; MacKay D. G., 1987, ORG PERCEPTION ACTIO; MacKay DG, 1998, J MEM LANG, V38, P28, DOI 10.1006/jmla.1997.2544; MacKay DG, 1998, J COGNITIVE NEUROSCI, V10, P377, DOI 10.1162/089892998562807; MacKay DG, 2001, LANG COGNITIVE PROC, V16, P419, DOI 10.1080/01690960042000102; MACKAY DG, 1990, AGING COGNITION KNOW, P281, DOI DOI 10.1016/S0166-4115(08)60159-4; MACKAY DG, 1999, UNPUB HMS READING DE; MARSLENWILSON W, 1970, UNPUB RAW DATA; MARSLENWILSON WD, 1975, NEUROPSYCHOLOGIA, V13, P353, DOI 10.1016/0028-3932(75)90013-5; MCCLELLAND JL, 1985, ANN NY ACAD SCI, V444, P1, DOI 10.1111/j.1749-6632.1985.tb37576.x; METCALFE J, 1992, J COGNITIVE NEUROSCI, V4, P289, DOI 10.1162/jocn.1992.4.3.289; Milner B, 1975, Adv Neurol, V8, P299; Morris RGM, 1999, CURR BIOL, V9, pR890; Murre JMJ, 1996, HIPPOCAMPUS, V6, P675, DOI 10.1002/(SICI)1098-1063(1996)6:6<675::AID-HIPO10>3.0.CO;2-Y; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; Ribot T., 1882, DIS MEMORY; WICKELGREN WA, 1979, PSYCHOL REV, V86, P44, DOI 10.1037/0033-295X.86.1.44; 1949, WEBSTERS NEW COLLEGI	34	20	20	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0956-7976	1467-9280		PSYCHOL SCI	Psychol. Sci.	NOV	2001	12	6					485	492		10.1111/1467-9280.00390			8	Psychology, Multidisciplinary	Psychology	491MQ	WOS:000172112700009	11760136				2021-06-18	
J	Ract, C; Vigue, B; Bodjarian, N; Mazoit, JX; Samii, K; Tadie, M				Ract, C; Vigue, B; Bodjarian, N; Mazoit, JX; Samii, K; Tadie, M			Comparison of dopamine and norepinephrine after traumatic brain injury and hypoxic-hypotensive insult	JOURNAL OF NEUROTRAUMA			English	Article						catecholamines; cerebral perfusion pressure; dopamine; head trauma; hypoxic-hypotensive injury; intracranial pressure; norepinephrine	CEREBRAL BLOOD-FLOW; DIFFUSE AXONAL INJURY; HEAD-INJURY; PERFUSION-PRESSURE; HEMORRHAGIC-SHOCK; IMPACT INJURY; RATS; PHENYLEPHRINE; METABOLISM; ARTERIES	After severe brain trauma, blood-brain barrier disruption and alteration of cerebral arteriolar vasoreactive properties may modify the cerebral response to catecholamines. Therefore, the goal of the present study was to compare the effects of dopamine and norepinephrine in a model of brain injury that consisted of a weight-drop model of injury complicated by a 15-min hypoxic-hypotensive insult (HH). Sprague-Dawley rats (n = 7 in each group) received, after brain injury, an infusion of either norepinephrine (TNE group) or dopamine (TDA group) in order to increase cerebral perfusion pressure (CPP) above 70 mm Hg. In addition, a control group (C group, no trauma) and a trauma group (T group, brain injury, no catecholamine infusion) were studied. Mean arterial pressure (MAP), intracranial pressure (ICP, intraparenchymal fiberoptic device), and local cerebral blood flow (LCBF, extradural laser-Doppler fiber) were measured throughout the protocol. In T group, brain injury and RH induced a decrease in CPP (by an increase of ICP and a decrease of MAP), and a decrease of LCBF. Both norepinephrine and dopamine failed to increase CPP, and ICP was significantly higher in TNE and TDA groups than in T group. Interestingly, norepinephrine was not able to alleviate the decrease in MAP. Neither norepinephrine or dopamine could induce an increase of MAP. LCBF decreased similarly in T, TNE and TDA groups. In conclusion, norepinephrine and dopamine are not able to restore values of CPP above 70 mm Hg in a model of severe brain trauma. Furthermore, their systemic vasopressor properties are altered.	Hop Bicetre, Dept Anesthesie Reanimat, Lab Neurochirurg, F-94275 Le Kremlin Bicetre, France; Hop Broussais, F-75674 Paris, France; Univ Paris Sud, Fac Med, Lab Anesthesiol, F-94275 Le Kremlin Bicetre, France	Vigue, B (corresponding author), Hop Bicetre, Dept Anesthesie Reanimat, Lab Neurochirurg, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BANDRES J, 1992, J NEUROSURG ANESTH, V4, P250, DOI 10.1097/00008506-199210000-00004; BARZO P, 1993, NEUROSURGERY, V32, P611; BAUKNIGHT GC, 1992, STROKE, V23, P1522, DOI 10.1161/01.STR.23.10.1522; BRYAN RM, 1990, AM J PHYSIOL, V259, pH269; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; DARBY JM, 1994, J NEUROSURG, V80, P857, DOI 10.3171/jns.1994.80.5.0857; EDVINSSON L, 1979, ACTA PHYSIOL SCAND, V107, P289, DOI 10.1111/j.1748-1716.1979.tb06478.x; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; Fulton R L, 1993, J Invest Surg, V6, P117, DOI 10.3109/08941939309141603; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HARPER SL, 1984, AM J PHYSIOL, V246, pH17; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P489; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MERTES PM, 1994, TRANSPLANTATION, V58, P414, DOI 10.1097/00007890-199408270-00004; MONTASSER A, 1994, J NEUROSURG, V80, P301; OLESEN J, 1972, NEUROLOGY, V22, P978, DOI 10.1212/WNL.22.9.978; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PILATI CF, 1992, AM J PHYSIOL, V263, pH784; POPP AJ, 1982, J SURG RES, V32, P416, DOI 10.1016/0022-4804(82)90121-4; ROGERS AT, 1988, ANESTHESIOLOGY, V69, P547, DOI 10.1097/00000542-198810000-00015; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SAMORAJSKI T, 1962, J HISTOCHEM CYTOCHEM, V10, P392, DOI 10.1177/10.4.392; SERCOMBE R, 1990, J CEREBR BLOOD F MET, V10, P808, DOI 10.1038/jcbfm.1990.137; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; SOKRAB TEO, 1989, ACTA PHYSIOL SCAND, V137, P101, DOI 10.1111/j.1748-1716.1989.tb08725.x; TODA N, 1983, EXPERIENTIA, V39, P1131, DOI 10.1007/BF01943144; TUOR UI, 1986, AM J PHYSIOL, V251, pH824; URSINO M, 1991, CRIT REV BIOMED ENG, V18, P255; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1975, STROKE, V6, P654, DOI 10.1161/01.STR.6.6.654; WEILMALHERBE H, 1959, SCIENCE, V129, P1226, DOI 10.1126/science.129.3357.1226; WEILMALHERBE H, 1961, J NEUROCHEM, V8, P55, DOI 10.1111/j.1471-4159.1961.tb13526.x; WHITE M, 1995, CIRCULATION, V92, P2183, DOI 10.1161/01.CIR.92.8.2183; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408	43	20	22	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2001	18	11					1247	1254		10.1089/089771501317095287			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	491KC	WOS:000172106700006	11721743				2021-06-18	
J	Sato, S; Iida, H; Hirayama, H; Endo, M; Ohwada, T; Fujii, K				Sato, S; Iida, H; Hirayama, H; Endo, M; Ohwada, T; Fujii, K			Traumatic basilar artery occlusion caused by a fracture of the clivus - Case report	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						clivus fracture; basilar artery occlusion		A 56-year-old man presented with a rare traumatic basilar artery occlusion caused by a fracture of the clivus. He fell from the height of 2 meters and immediately fell into a coma. Head computed tomography (CT) revealed an open depressed fracture, an acute epidural hematoma 1 cm thick in the left middle frontal fossa, and a longitudinal fracture of the clivus. Emergency removal of the hematoma was performed with cranioplasty. Head CT 8 hours 50 minutes after injury showed infarctions in the brain stem, cerebellum, and occipital lobes. Cerebral angiography revealed occlusion of the basilar artery in the middle part of the clivus. The patient died after 3 days. Autopsy revealed that the basilar artery was trapped in the clivus fracture site. Vertebrobasilar artery occlusion due to trapping in a clivus fracture has a very poor prognosis. Diagnosis is difficult and generally only confirmed at autopsy. Cerebral angiography is recommended in a patient in a deep coma without massive brain contusion at the early stage of head injury to identify the possibility of vertebrobasilar artery occlusion in a clivus fracture.	Int Goodwill Hosp, Dept Neurosurg, Izumi Ku, Kanagawa 2450006, Japan; Kitasato Univ, Sch Med, Dept Neurosurg, Kanagawa, Japan; Kitasato Univ, Sch Med, Dept Crit Care & Emergency Med, Kanagawa, Japan	Sato, S (corresponding author), Int Goodwill Hosp, Dept Neurosurg, Izumi Ku, 1-28-1 Nishigaoka, Kanagawa 2450006, Japan.						ANTHONY DC, 1987, J NEUROSURG, V66, P929, DOI 10.3171/jns.1987.66.6.0929; CORRADINO G, 1990, NEUROSURGERY, V27, P592, DOI 10.1227/00006123-199010000-00015; GUHA A, 1989, CAN J NEUROL SCI, V16, P81, DOI 10.1017/S0317167100028560; JOSLYN JN, 1988, RADIOLOGY, V166, P817, DOI 10.1148/radiology.166.3.3340778; KAPILA A, 1985, J COMPUT ASSIST TOMO, V9, P1142, DOI 10.1097/00004728-198511000-00033; LINDENBERG R, 1966, J NEUROSURG, V24, P908, DOI 10.3171/jns.1966.24.5.0908; LOOP JW, 1964, RADIOLOGY, V83, P36, DOI 10.1148/83.1.36; SATO H, 1990, Neurological Surgery, V18, P1147; SHAW CM, 1972, J NEUROL NEUROSUR PS, V35, P247, DOI 10.1136/jnnp.35.2.247; SIGHTS WP, 1968, J NEUROSURG, V28, P588, DOI 10.3171/jns.1968.28.6.0588	10	20	21	0	0	JAPAN NEUROSURGICAL SOC	TOKYO	C/O AKAMON-MAE IWATA BLDG, 5-27-8 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105			NEUROL MED-CHIR	Neurol. Med.-Chir.	NOV	2001	41	11					541	544		10.2176/nmc.41.541			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	492GR	WOS:000172160500010	11758706	Bronze			2021-06-18	
J	Levin, HS; Song, J; Ewing-Cobbs, L; Roberson, G				Levin, HS; Song, J; Ewing-Cobbs, L; Roberson, G			Porteus maze performance following traumatic brain injury in children	NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; SPATIAL WORKING-MEMORY; FRONTAL-LOBE LESIONS; PREFRONTAL CORTEX; COGNITIVE-DEVELOPMENT; DEVELOPMENTAL-CHANGES; ORBITOFRONTAL CORTEX; SUSTAINED ATTENTION; ADOLESCENTS	To investigate planning in traumatically brain injured children, the authors gave the Porteus Maze Test (PMT; S. D. Porteus, 1959) to 276 pediatric patients who had sustained a traumatic brain injury (TBI) at least 3 years previously. Sensitivity of the PMT to TBI severity, age at test, and volume of focal brain lesions detected by magnetic resonance imaging was also studied. The Peabody Picture Vocabulary Test-Revised (L. M. Dunn & L. M. Dunn, 1981) was also administered as a control measure. Results indicated that the PMT was highly sensitive to TBI severity and to volume of circumscribed prefrontal lesions. In contrast to the PMT data, receptive vocabulary was related to injury severity but not to discrete prefrontal lesions, Implications for mechanisms of cognitive deficit after TBI in children are discussed.	Baylor Coll Med, Cognit Neurosci Lab, Dept Psychiat, Houston, TX 77030 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX 78284 USA	Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Psychiat, 6560 Fannin St,Box 67,Suite 1144, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		Anderson P, 1996, CLIN NEUROPSYCHOL, V10, P54, DOI 10.1080/13854049608406663; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BENCH CJ, 1993, NEUROPSYCHOLOGIA, V31, P907, DOI 10.1016/0028-3932(93)90147-R; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BJORKLUND DF, 1990, DEV REV, V10, P48, DOI 10.1016/0273-2297(90)90004-N; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; CANAVAN AGM, 1983, NEUROPSYCHOLOGIA, V21, P375, DOI 10.1016/0028-3932(83)90024-6; CASE R, 1992, BRAIN COGNITION, V20, P51, DOI 10.1016/0278-2626(92)90061-P; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; DEMPSTER FN, 1992, DEV REV, V12, P45, DOI 10.1016/0273-2297(92)90003-K; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DENNIS M, 1990, DISCOURSE ABILITY BR, P199; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DIAMOND A, 1990, P394; DREWE E A, 1975, Cortex, V11, P8; Dunn L., 1981, PEABODY PICTURE VOCA; Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308; Eslinger P. J., 1996, ATTENTION MEMORY EXE, P367; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; FUSTER JM, 1989, PREFRONTAL CORTEX AN; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GERSTADT CL, 1994, COGNITION, V53, P129, DOI 10.1016/0010-0277(94)90068-X; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; GOLDMAN PS, 1970, EXP NEUROL, V27, P291, DOI 10.1016/0014-4886(70)90222-0; GoldmanRakic PS, 1996, PHILOS T ROY SOC B, V351, P1445, DOI 10.1098/rstb.1996.0129; HILLMAN GR, 1991, J COMPUT ASSIST TOMO, V15, P640, DOI 10.1097/00004728-199107000-00021; IVERSEN SD, 1970, EXP BRAIN RES, V11, P376; Krikorian R, 1998, CLIN NEUROPSYCHOL, V12, P305, DOI 10.1076/clin.12.3.305.1984; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Lorsbach TC, 1997, J EXP CHILD PSYCHOL, V64, P317, DOI 10.1006/jecp.1996.2350; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Machin D, 1997, SAMPLE SIZE TABLES C, V2nd; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; Owen AM, 1996, EUR J NEUROSCI, V8, P353, DOI 10.1111/j.1460-9568.1996.tb01219.x; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; Pennington B.F., 1996, ATTENTION MEMORY EXE, P327; PENNINGTON BF, 1994, MAC FDN MEN, P243; Porteus S. D., 1959, MAZE TEST CLIN PSYCH; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Porteus SD, 1944, GENET PSYCHOL MONOGR, V29, P3; RAIZNER RD, IN PRESS DEV NEUROPS; Roberts RJ, 1996, DEV NEUROPSYCHOL, V12, P105, DOI 10.1080/87565649609540642; Rolls ET, 1996, PHILOS T ROY SOC B, V351, P1433, DOI 10.1098/rstb.1996.0128; Rolls ET, 1999, BRAIN EMOTION; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Smith EE, 1997, COGNITIVE PSYCHOL, V33, P5, DOI 10.1006/cogp.1997.0658; TEASDALE G, 1974, LANCET, V2, P81; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Zacks R. T., 1994, INHIBITORY PROCESSES	74	20	24	0	8	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2001	15	4					557	567		10.1037//0894-4105.15.4.557			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	494KQ	WOS:000172281800015	11761045				2021-06-18	
J	Logan, SM; Bell, GW; Leonard, JC				Logan, SM; Bell, GW; Leonard, JC			Acute subdural hematoma in a high school football player after 2 unreported episodes of head trauma: A case report	JOURNAL OF ATHLETIC TRAINING			English	Article						second-impact syndrome; head injury; concussion; seizure	CONCUSSION; GUIDELINES; SPORTS; MANAGEMENT; DIAGNOSIS; INJURIES	Objective: To discuss the association between 2 unreported episodes of head trauma and an acute subdural hematoma in a high school football player; to address the role of the sport health care team in secondary schools when caring for an athlete with head trauma; and to recognize the importance of educating athletes and coaches about this condition. Background. A previously healthy athlete experienced 2 unreported episodes of head trauma during a single game. The athlete was conscious and oriented to person, time, and place, but he vomited and complained of severe headache, nausea, and vertigo. During transfer, the athlete appeared to have a seizure. Differential Diagnosis: Subdural hematoma, epidural hematoma, intracerebral hemorrhage, second-impact syndrome, cervical spine injury, or epilepsy. Treatment: Computed tomography scan indicated fluid over the left frontal temporal fossa. Conservative treatment was begun, and the fluid resolved without incident. Uniqueness: A single episode of blunt trauma has been thought to cause an acute subdural hematoma. However, multiple concussions can also result in this condition. Conclusion: Single or multiple episodes of head trauma can lead to an acute subdural hematoma. This case study reflects the importance of proper education in the recognition and care of head trauma and return-to-play guidelines for athletes and coaches. A sport health care team in all secondary schools can provide the immediate and appropriate intervention for such injuries.	Univ Illinois, Champaign, IL 61820 USA; Carle Sports Med, Urbana, IL USA	Logan, SM (corresponding author), 4434 Smokerise Dr, Stow, OH 44224 USA.	Smlogan21@aol.com					ALBRIGHT L, 1983, HLTH CARE YOUNG ATHL, P263; *AM SPORT ED PROGR, 1998, RAIS STAND 1998 NAT; BRUNO LA, 1987, CLIN SPORT MED, V6, P17; Cantu RC, 1999, PHYSICIAN SPORTSMED, V27, P35, DOI 10.3810/psm.1999.08.945; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kersey RD, 1998, J ATHL TRAINING, V33, P264; Lyznicki JM, 1999, J ATHL TRAINING, V34, P272; MCLATCHIE G, 1994, BRIT MED J, V308, P1624; Mueller F O, 1991, Exerc Sport Sci Rev, V19, P261; Narayan RK, 1996, NEUROTRAUMA; *NCCA NEWS, 2000, NEWS FEAT; NELSON W, 1984, J ATHL TRAINING, V19, P95; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ransone J, 1999, J ATHL TRAINING, V34, P267; Report of the Sports Medicine Committee, 1990, GUID MAN CONC SPORTS; SHELL D, 1993, PHYSICIAN SPORTSMED, V21, P74, DOI 10.1080/00913847.1993.11710364; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; TORG JS, 1981, ATHLETIC INJURIES HE; Warren WL, 1998, CLIN SPORT MED, V17, P13, DOI 10.1016/S0278-5919(05)70057-0	27	20	21	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2001	36	4					433	436					4	Sport Sciences	Sport Sciences	554QK	WOS:000175747800017	12937485				2021-06-18	
J	Fleming, PRI; Crompton, JL; Simpson, DA				Fleming, PRI; Crompton, JL; Simpson, DA			Neuro-ophthalmological sequelae of horse-related accidents	CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						equestrian; helmets; horse riding; injury; neuro-ophthalmological injuries	RIDING INJURIES	Purpose: The aim of this study was to highlight the neuro-ophthalmological dangers associated with horse riding, and working around horses, and the importance of wearing adequate headgear to protect the rider from neuro- ophthalmic injuries. It raises the questions of whether the current laws regarding helmet use are satisfactory, and whether helmets currently used are of an adequate standard. Methods: The records over a 20-year period of one neuro-ophthalmologist in Adelaide were reviewed producing 22 patients with neuro-ophthalmological sequelae of head injuries as a result of horse-related accidents. Results: There were 22 patients (16 female, six male), one of whom was involved in three separate accidents. Of these, seven were professional riders and 15 amateur. In 20 of the 24 accidents, patients were either thrown or fell from the horse. Helmets were worn in 15 of the accidents. All the patients had closed head injuries of varying severity. The most common neuro-ophthalmological complication found was a fourth-nerve palsy in 11 patients. Five patients had a significant loss of vision and two of these were severe enough to warrant a blind pension. Conclusions: Horse riding and working around horses constitute an occupation or recreation with inherent dangers. Previous studies have shown that wearing of protective headgear reduces the risk and severity of head injuries, and helmet use should be vigorously promoted. The current laws and practices regarding helmet use are not uniform and seem to be inadequate. The current standard for equestrian safety helmets (AS/NZS 3838:1998) embodies improvements on earlier helmet standards and certainly increases the rider's chances of surviving a severe impact. Nevertheless, serious brain injuries have occurred in wearers of approved helmets, and further research is desirable to ensure the optimum degree of protection compatible with rider acceptance.	Univ Adelaide, Royal Adelaide Hosp, Adelaide, SA, Australia; Univ Adelaide, Rd Accid Res Unit, Adelaide, SA, Australia	Crompton, JL (corresponding author), 22 Walter St, Adelaide, SA 5006, Australia.						BARBER HM, 1973, BRIT MED J, V3, P532, DOI 10.1136/bmj.3.5879.532; BARONE GW, 1989, J TRAUMA, V29, P245, DOI 10.1097/00005373-198902000-00019; BIXBYHAMMETT DM, 1987, AM FAM PHYSICIAN, V36, P209; BROOKS WH, 1988, PHYSICIAN SPORTSMED, V16, P84, DOI 10.1080/00913847.1988.11709646; BUCKLEY SM, 1993, AUST J PUBLIC HEALTH, V17, P269; Chapman M A, 1991, Br J Sports Med, V25, P121; Chitnavis JP, 1996, INJURY, V27, P103, DOI 10.1016/0020-1383(95)00176-X; CHRISTEY GL, 1994, J FAM PRACTICE, V39, P148; CONDIE C, 1993, PUBLIC HEALTH REP, V108, P121; DABREU F, 1976, LANCET, V1, P1241; GIERUP J, 1976, ACTA CHIR SCAND, V142, P57; GROSSMAN JAI, 1978, JAMA-J AM MED ASSOC, V240, P1881, DOI 10.1001/jama.240.17.1881; HAMILTON MG, 1993, J TRAUMA, V34, P227, DOI 10.1097/00005373-199302000-00008; ILGREN EB, 1984, CLIN NEUROPATHOL, V3, P253; INGEMARSON H, 1989, J TRAUMA, V29, P25, DOI 10.1097/00005373-198901000-00005; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; Lloyd R G, 1987, Br J Sports Med, V21, P22; MAHALEY MS, 1976, P 18 C MED ASP SPORT; MCLATCHIE GB, 1979, BRIT J SPORT MED, V13, P632; MILLS NJ, 1990, P INT RES C BIOM IMP, P155; MUWANGA LC, 1985, ARCH EMERG MED, V2, P85; NELSON DE, 1994, PHYSICIAN SPORTSMED, V10, P53; NELSON DE, 1994, PHYSICIAN SPORTSMED, V10, P59; NICHOLL JP, 1990, BRIT MED J, V301, P496, DOI 10.1136/bmj.301.6750.496-b; Paix BR, 1999, BRIT J SPORT MED, V33, P46, DOI 10.1136/bjsm.33.1.46; POUNDER DJ, 1984, MED J AUSTRALIA, V141, P632, DOI 10.5694/j.1326-5377.1984.tb113173.x; RANDALLBOND G, 1995, PEDIATRICS, V95, P487; *STAND AUSTR, 1998, 3838 ASNZS; Whitlock M R, 1987, Br J Sports Med, V21, P25	29	20	20	0	2	BLACKWELL SCIENCE ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	1442-6404			CLIN EXP OPHTHALMOL	Clin. Exp. Ophthalmol.	AUG	2001	29	4					208	212		10.1046/j.1442-9071.2001.00430.x			5	Ophthalmology	Ophthalmology	482ZE	WOS:000171606500002	11545416				2021-06-18	
J	Freeman, J; Godfrey, HPD; Harris, JKJ; Partridge, FM				Freeman, J; Godfrey, HPD; Harris, JKJ; Partridge, FM			Utility of a demographic equation in detecting impaired NART performance after TBI	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							ADULT READING TEST; PREMORBID INTELLIGENCE; HEAD-INJURY; VALIDITY; DEMENTIA; HOLD	Objectives. This study applies a demographic regression equation devised by Crawford, Allan, Cochrane, and Parker (1990) to determine its utility in New Zealand, and to determine the proportion of persons with traumatic brain injury (TBI) with impaired performance on the National Adult Reading Test (NART). Method. The NART was administered to 80 community participants, 65 people with traumatic brain injury (TBI), and 27 orthopaedic controls. The Crawford et al. (1990) equation was applied to all three samples. Results. The Crawford er al. (1990) equation was applicable in the New Zealand community sample. It was found that 30% of the TDI sample had impaired performance on the NART. Using corrected NART scores, a significantly larger proportion of the TBI sample was detected as intellectually impaired than in the control sample. Conclusion. Nearly one-third of the TBI sample evidenced impaired performance on the NART. Consequently, clinicians that use the NART in assessing people with TBI should use the demographic equation to check the accuracy of NART performances, and correct the NART scores if this is indicated.	Univ Otago, Dept Psychol, Dunedin, New Zealand	Godfrey, HPD (corresponding author), Univ Otago, Dept Psychol, POB 56, Dunedin, New Zealand.						CRAWFORD JR, 1992, BRIT J PSYCHIAT, V161, P69, DOI 10.1192/bjp.161.1.69; CRAWFORD JR, 1990, BRIT J CLIN PSYCHOL, V29, P435, DOI 10.1111/j.2044-8260.1990.tb00908.x; CRAWFORD JR, 1987, BRIT J CLIN PSYCHOL, V26, P313, DOI 10.1111/j.2044-8260.1987.tb01366.x; Freeman J, 2000, BRIT J CLIN PSYCHOL, V39, P95, DOI 10.1348/014466500163130; FROMM D, 1991, CORTEX, V27, P367, DOI 10.1016/S0010-9452(13)80032-9; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; Nelson L. S., 1982, High Temperatures - High Pressures, V14, P259; OCARROLL RE, 1987, BRIT J CLIN PSYCHOL, V26, P315, DOI 10.1111/j.2044-8260.1987.tb01367.x; Raven J., 1960, GUIDE STANDARD PROGR; Stebbins Glenn T, 1990, Clin Neuropsychol, V4, P18, DOI 10.1080/13854049008401493; VANDENBROEK MD, 1994, BRIT J CLIN PSYCHOL, V33, P509	13	20	20	0	4	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND	0144-6657			BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	JUN	2001	40		2				221	224		10.1348/014466501163562			4	Psychology, Clinical	Psychology	444ZV	WOS:000169433200012	11446244				2021-06-18	
J	Zink, BJ; Schultz, CH; Stern, SA; Mertz, M; Wang, X; Johnston, P; Keep, RF				Zink, BJ; Schultz, CH; Stern, SA; Mertz, M; Wang, X; Johnston, P; Keep, RF			Effects of ethanol and naltrexone in a model of traumatic brain injury with hemorrhagic shock	ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						ethanol; naltrexone; brain injury; hemorrhagic shock	SEVERE HEAD-INJURY; ALCOHOL-INTOXICATION; OPIATE ANTAGONISTS; ENDOGENOUS OPIOIDS; IMPROVES SURVIVAL; BLOOD-FLOW; NALOXONE; RATS; RESPONSES; ENDORPHINS	Background: Ethanol predisposes to traumatic injury and causes respiratory depression and cardiovascular compromise in models of traumatic brain injury (TBI) and hemorrhagic shock (IIS). Endogenous opioids may play a role in ethanol intoxication and TBI. We studied the effects of ethanol and the opiate antagonist agent naltrexone (NTX) in a TBI/HS model. Methods: Fifty-six pigs (20 kg) were anesthetized with isoflurane, intubated, instrumented, and subjected to fluid percussion TBI with concurrent 30 ml/kg hemorrhage over 30 min. Seven groups were studied: Control, EtOH, NTX, INJ, INJ/EtOH, INJ/NTX, and INJ/EtOH/NTX. Ethanol (2 g/kg IV) was given preinjury, followed by infusion of 0.4 g/kg/hr. NTX 0.3 mg/kg intravenous was given 5 min postinjury. Parameters monitored for 120 min postinjury included minute ventilation (V,), blood pressure (MAP), cerebral perfusion pressure (CPP), cerebral venous lactate (Lac), arterial and cerebral venous blood gases, and brain tissue PtiO2. Results: Ethanol levels at injury were 220 mg/dL. Ethanol-treated animals had depression of hypercapnic ventilatory response, which was reversed by administration of naltrexone. MAP and CPP were significantly lower in injured animals, but were not significantly improved by NTX. Cerebral venous pH was lower and lactate was higher in ethanol-treated animals. Conclusion: In this TBI/HS model, NTX reverses ethanol-induced depression of hypercapnic ventilatory response but does not improve MAP, CPP, or metabolic acidosis. This suggests that the respiratory effects of ethanol in TBI, but not the hemodynamic effects, may be mediated by opiate receptor activation.	Univ Michigan, Dept Emergency Med, Emergency Med Res Lab, Ann Arbor, MI 48109 USA; Univ Michigan, Crosby Neurosurg Lab, Ann Arbor, MI 48109 USA	Zink, BJ (corresponding author), Univ Michigan, Dept Emergency Med, Emergency Med Res Lab, Ann Arbor, MI 48109 USA.			Keep, Richard/0000-0001-6441-5334	NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [5 K08 AA00184-03] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [K08AA000184] Funding Source: NIH RePORTER		ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ARMSTEAD WM, 1994, BRAIN RES, V660, P19, DOI 10.1016/0006-8993(94)90834-6; Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; BAROR D, 1982, NEW ENGL J MED, V306, P1363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; CURTIS MT, 1980, AM J PHYSIOL, V239, pH416; Dereeper E, 1998, RESUSCITATION, V36, P15, DOI 10.1016/S0300-9572(97)00080-4; DeWitt DS, 1997, J NEUROTRAUM, V14, P931, DOI 10.1089/neu.1997.14.931; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FELL JC, 1990, 34 ANN P ASS ADV AUT, P69; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GURLL NJ, 1981, SURGERY, V89, P364; GURLL NJ, 1982, J PHARMACOL EXP THER, V220, P625; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JEFFCOATE WJ, 1979, LANCET, V1, P1157; JEFFERYS DB, 1980, LANCET, V1, P308; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Komjati K, 1997, SHOCK, V7, P288, DOI 10.1097/00024382-199704000-00008; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Lightfoot JT, 2000, CRIT CARE MED, V28, P684, DOI 10.1097/00003246-200003000-00014; LYETH BG, 1995, NEUROPEPTIDES, V29, P11, DOI 10.1016/0143-4179(95)90051-9; Masse J, 2000, J NEUROTRAUM, V17, P421, DOI 10.1089/neu.2000.17.421; MAYFIELD KP, 1992, BRAIN RES, V582, P226, DOI 10.1016/0006-8993(92)90137-X; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1986, J SURG RES, V40, P265, DOI 10.1016/0022-4804(86)90160-5; MCINTOSH TK, 1985, CIRC SHOCK, V17, P313; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; MICHIELS TM, 1983, J APPL PHYSIOL, V55, P929; MOSS IR, 1981, J APPL PHYSIOL, V50, P1001; NEWSOME HH, 1988, J TRAUMA, V28, P1, DOI 10.1097/00005373-198801000-00001; PETROZZINO JJ, 1993, AM REV RESPIR DIS, V147, P607, DOI 10.1164/ajrccm/147.3.607; REYNOLDS DG, 1989, RESUSCITATION, V18, P243, DOI 10.1016/0300-9572(89)90026-9; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SAHN SA, 1975, CLIN SCI MOL MED, V49, P33, DOI 10.1042/cs0490033; SALERNO TA, 1981, SURG GYNECOL OBSTET, V152, P773; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; TOTH PD, 1986, CIRC SHOCK, V20, P35; VINK R, 1991, AM J PHYSIOL, V261, pR1527; VINK R, 1990, J NEUROSCI, V10, P3524; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; Wichmann MW, 2000, CRIT CARE MED, V28, P184, DOI 10.1097/00003246-200001000-00030; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Zhang LX, 1999, J NEUROTRAUM, V16, P243, DOI 10.1089/neu.1999.16.243; Zink B J, 1994, Acad Emerg Med, V1, P171; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1996, ALCOHOL CLIN EXP RES, V20, P1518, DOI 10.1111/j.1530-0277.1996.tb01693.x; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	56	20	20	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0145-6008			ALCOHOL CLIN EXP RES	Alcoholism (NY)	JUN	2001	25	6					916	923					8	Substance Abuse	Substance Abuse	442YN	WOS:000169312700018	11410729				2021-06-18	
J	Suominen, E; Tukiainen, E				Suominen, E; Tukiainen, E			Close-range shotgun and rifle injuries to the face	CLINICS IN PLASTIC SURGERY			English	Article							FREE-FLAP RECONSTRUCTION; GUNSHOT WOUNDS; HIGH-ENERGY; MANDIBULAR RECONSTRUCTION; HEAD; MANAGEMENT; DEFECTS; NECK; BONE; LIP	This article addresses the reconstructive approach to close-range shotgun and rifle injuries to the face. Emergency management, acute surgical management, secondary management, and case reports are reviewed.	Univ Helsinki, Cent Hosp, Toolo Hosp, Dept Plast Surg, SF-00260 Helsinki, Finland	Suominen, E (corresponding author), Univ Helsinki, Cent Hosp, Toolo Hosp, Dept Plast Surg, Topeliuksenkatu 5, SF-00260 Helsinki, Finland.						AVIV JE, 1991, ARCH OTOLARYNGOL, V117, P1242; Clark N, 1996, PLAST RECONSTR SURG, V98, P583, DOI 10.1097/00006534-199609001-00001; COLEMAN JJ, 1991, PLAST RECONSTR SURG, V87, P682, DOI 10.1097/00006534-199104000-00013; COSTA H, 1993, BRIT J PLAST SURG, V46, P223, DOI 10.1016/0007-1226(93)90172-8; Demetriades D, 1998, J TRAUMA, V45, P39, DOI 10.1097/00005373-199807000-00007; DEMUTH WE, 1971, J TRAUM, V11, P219, DOI 10.1097/00005373-197103000-00003; DENNY AD, 1992, ANN PLAS SURG, V29, P564, DOI 10.1097/00000637-199212000-00014; GRUSS JS, 1991, PLAST RECONSTR SURG, V87, P436, DOI 10.1097/00006534-199103000-00008; GRUSS JS, 1989, BRIT J PLAST SURG, V42, P385, DOI 10.1016/0007-1226(89)90003-9; HENRIKSSON TG, 1990, SCAND J PLAST RECONS, V24, P81, DOI 10.3109/02844319009004525; HIDALGO DA, 1994, CLIN PLAST SURG, V21, P27; Kuzon WM, 1998, MICROSURG, V18, P372, DOI 10.1002/(SICI)1098-2752(1998)18:6<372::AID-MICR6>3.3.CO;2-6; Lorenzetti F, 1999, MICROSURG, V19, P196, DOI 10.1002/(SICI)1098-2752(1999)19:4<196::AID-MICR6>3.0.CO;2-5; MANSON PN, 1985, PLAST RECONSTR SURG, V76, P1; MLADICK RA, 1970, PLAST RECONSTR SURG, V45, P186, DOI 10.1097/00006534-197002000-00017; OLDING M, 1993, ANN PLAS SURG, V31, P82; ORDOG GJ, 1988, J TRAUMA, V28, P624, DOI 10.1097/00005373-198805000-00011; ORIGITANO TC, 1992, NEUROSURGERY, V30, P570; Pribaz JJ, 1999, PLAST RECONSTR SURG, V104, P357, DOI 10.1097/00006534-199908000-00005; SADOVE RC, 1993, PLAST RECONSTR SURG, V92, P141, DOI 10.1097/00006534-199307000-00022; SHEPARD GH, 1980, J TRAUMA, V20, P1065, DOI 10.1097/00005373-198012000-00011; Shvyrkov MB, 1999, BRIT J ORAL MAX SURG, V37, P261, DOI 10.1054/bjom.1999.0120; SUOMINEN EA, 1995, T 11 C INT CONF PLAS, P13; THORNE CH, 1992, CLIN PLAST SURG, V19, P233; Vasconez HC, 1996, ANN PLAS SURG, V36, P18, DOI 10.1097/00000637-199601000-00005; VITKUS K, 1990, J RECONSTR MICROSURG, V6, P279, DOI 10.1055/s-2007-1006831; Vrankovic D, 1998, INJURY, V29, P369, DOI 10.1016/S0020-1383(98)00054-0; WALKER ML, 1990, SURG GYNECOL OBSTET, V170, P97; WEINZWEIG N, 1994, PLAST RECONSTR SURG, V94, P685, DOI 10.1097/00006534-199410000-00017	29	20	22	1	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0094-1298			CLIN PLAST SURG	Clin. Plast. Surg.	APR	2001	28	2					323	+					16	Surgery	Surgery	437LX	WOS:000168994100009	11400826				2021-06-18	
J	Friedmann, I; Yoles, E; Schwartz, M				Friedmann, I; Yoles, E; Schwartz, M			Thrombin attenuation is neuroprotective in the injured rat optic nerve	JOURNAL OF NEUROCHEMISTRY			English	Article						CNS; injury; NAPAP; prothrombin; tissue repair; wound healing	PROTHROMBIN MESSENGER-RNA; NEURITE OUTGROWTH; NEURONAL CELLS; BRAIN EDEMA; SYSTEM; RECEPTOR; ASTROCYTES; ACTIVATION; DEGENERATION; REPAIR	The functional loss that often follows injury of the mammalian CNS has been attributed not only to the immediate neural loss, but also to secondary neuronal degeneration caused by toxic biochemical mediators in the environment of the injured nerve. We report here that a high thrombin content, produced as a result of injury-induced activation of prothrombin, appears to be an important mediator of secondary damage. Measurement of post-traumatic neuronal survival in vivo revealed that post-traumatic local application of the thrombin inhibitor N-alpha-(2-naphthylsulphonylglycyl)-4-(D,L)-amidinophenylalanine piperidide acetate in the rat optic nerve subjected to mild partial crush injury left twice as many retinal ganglion cells with functioning axons as in controls. Thus, by readjusting thrombin activity, thereby possibly obtaining a moderate post-traumatic increase and thus gaining the benefit of thrombin without its toxic effects, it may be possible to create an environment that is more favourable towards post-traumatic survival.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.						BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BENEZRA M, 1993, SEMIN THROMB HEMOST, V19, P405, DOI 10.1055/s-2007-993292; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; Debeir T, 1996, BRAIN RES, V708, P159, DOI 10.1016/0006-8993(95)01237-0; DESCHEPPER CF, 1991, MOL BRAIN RES, V11, P355, DOI 10.1016/0169-328X(91)90045-Y; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; Donovan FM, 1997, J NEUROSCI, V17, P5316; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Friedmann I, 1999, FASEB J, V13, P533; GRABHAM PW, 1991, EUR J NEUROSCI, V3, P663, DOI 10.1111/j.1460-9568.1991.tb00852.x; GRIFFIN JH, 1995, NATURE, V378, P337, DOI 10.1038/378337a0; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; Hauptmann J, 1999, THROMB RES, V93, P203, DOI 10.1016/S0049-3848(98)00192-3; Kubo Y, 2000, J NEUROTRAUM, V17, P163, DOI 10.1089/neu.2000.17.163; LazarovSpiegler O, 1996, FASEB J, V10, P1296; LEE KR, 1995, J NEUROSURG, V83, P1045, DOI 10.3171/jns.1995.83.6.1045; Masada T, 2000, BRAIN RES, V867, P173, DOI 10.1016/S0006-8993(00)02302-7; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MONARD D, 1983, PROG BRAIN RES, V58, P359, DOI 10.1016/S0079-6123(08)60037-0; Motohashi O, 1997, J NEUROTRAUM, V14, P747, DOI 10.1089/neu.1997.14.747; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Ramon y Cajal S, 1959, DEGENERATION REGENER; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; STIERNBERG J, 1993, THROMB HAEMOSTASIS, V70, P158; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; Xi GH, 1999, STROKE, V30, P1247, DOI 10.1161/01.STR.30.6.1247; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; Yamazaki Y, 1999, J BIOCHEM-TOKYO, V126, P655, DOI 10.1093/oxfordjournals.jbchem.a022499; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811	35	20	21	0	1	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	FEB	2001	76	3					641	649		10.1046/j.1471-4159.2001.00001.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	397UG	WOS:000166715300001	11158234	Bronze			2021-06-18	
J	Markgraf, CG; Clifton, GL; Aguirre, M; Chaney, SF; Knox-du Bois, C; Kennon, K; Verma, N				Markgraf, CG; Clifton, GL; Aguirre, M; Chaney, SF; Knox-du Bois, C; Kennon, K; Verma, N			Injury severity and sensitivity to treatment after controlled cortical impact in rats	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; motor deficit; cognitive deficit; hypothermia; recovery	TRAUMATIC BRAIN INJURY; CEREBRAL-ARTERY OCCLUSION; FLUID-PERCUSSION MODEL; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; HEAD-INJURY; DEFICITS; ISCHEMIA; DAMAGE; TEMPERATURE	We sought to determine sensitivity of the cortical impact injury model of traumatic brain injury (TBI) to severity of injury and to treatment. We examined the pattern of motor and cognitive deficits and recovery following TBI over a range of injury severities, and examined the efficacy of surface-induced moderate hypothermia at three disparate injury levels. In experiment I, Sprague-Dawley rats were injured at one of eight injury severity levels from 0 mm (sham) to 2.5 mm depth of penetration. On postinjury day 1, balance beam, rotorod performance, and posture reflexes were evaluated. Motor outcome was increasingly impaired with increasing injury levels, with the pattern of deficits showing a step-like function. Cognitive deficits, assessed using water maze on day 7, were more severe for the 2.5-mm group than for the 1.6-mm injury group, while the 1.0-mm group did not differ from the sham controls. In experiments II-IV, hypothermia, 30 degreesC for 3-h duration or normothermia was applied to three injury levels: 1.0 mm, the least cortical deformation; 2.5 mm, the most deformation; and 1.6 mm, representing a level in-between. Neurologic outcome was assessed relative to shams on postinjury days 1, 3, and 5. The 1.0-mm group exhibited small deficits that recovered completely by day 3; the 1.6-mm group recovered to the level of shams by day 5, and the 2.5-mm group did not show significant recovery during the testing period. Hypothermia effectively attenuated behavioral deficits for the 1.6-mm group, but had no effect on the other two groups. These three observations-that increasing injury severity is associated with increasing motor and cognitive deficits, that injury severity is related to recovery time, and that hypothermia treatment is selectively effective-have each been reported in the human TBI population; thus, moderate cortical impact injury in rats may be a model with clinical predictability for evaluating neuroprotective therapies.	Univ Texas, Dept Neurosurg, Vivian L Smith Fdn Neurol Res, Sch Med, Houston, TX 77030 USA	Markgraf, CG (corresponding author), Univ Texas, Dept Neurosurg, Vivian L Smith Fdn Neurol Res, Sch Med, 6431 Fannin St,Ste 7-136, Houston, TX 77030 USA.						BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BULLOCK R, 1996, NEUROTRAUMA, P375; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; CLIFTON GL, 1989, STROKE, V20, P1545, DOI 10.1161/01.STR.20.11.1545; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CLIFTON GL, 1983, CLIN NEUROSCIENCES, P1269; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MUIZELAAR JP, 1989, TXB HEAD INJURY, P221; ONESTI ST, 1991, NEUROSURGERY, V29, P369, DOI 10.1227/00006123-199109000-00005; PERSSON L, 1989, STROKE, V20, P641, DOI 10.1161/01.STR.20.5.641; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; WARNER DS, 1993, ANESTHESIOLOGY, V79, P985, DOI 10.1097/00000542-199311000-00017; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98	34	20	20	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2001	18	2					175	186		10.1089/08977150150502604			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	402PW	WOS:000166998200005	11229710				2021-06-18	
J	Rousseau, V; Sabel, BA				Rousseau, V; Sabel, BA			Restoration of vision IV: role of compensatory soma swelling of surviving retinal ganglion cells in recovery of vision after optic nerve crush	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						vision; plasticity; retinal ganglion cells; recovery of function; recovery of vision; ICON; contrast discrimination; neurotrauma; rat	AXONAL INJURY; CONTRAST-SENSITIVITY; SUBSEQUENT RECOVERY; TECTAL ABLATION; RESIDUAL VISION; VISUAL-CORTEX; BRAIN-DAMAGE; PLASTICITY; MODEL; RATS	Purpose: Diffuse axonal injury following partial optic nerve crush (ONC) leads to severe visual deficits from which rats can partially recover within 2-3 weeks, To evaluate the role of surviving retinal ganglion cells (RGCs) in recovery, we have observed their morphology repeatedly in vivo with ICON-microscopy and correlated cell size changes with recovery of vision which we observed in parallel in the same animals. Methods,, After rats had learned a visual contrast discrimination task using an automated, computer-based test, RGCs were labeled retrogradely with fluorescent beads. Animals then received either no lesion, a complete axotomy or bilateral mild, moderate or severe ONC, Before surgery and for 40 days post-operatively, RGC number and soma size was repeatedly quantified every five days with the in vivo confocal neuroimaging method (Sabel et al., Nature med, 3, 1997, p. 244). In parallel, visual function was quantified with the contrast-discrimination task, Results: After ONC about 70 % of the RGCs died after having undergone a fast and massive soma swelling. The extent of cell death was independend of crush severity, RGCs surviving the injury did not change their body size over time in the severe group and these animals also did not recover their vision, In contrast, after a mild or moderate crush, about half of the surviving RGCs experienced a slow and moderate, "compensatory" cell soma swelling and the rats showed partial recovery of vision. Both the number of RGC showing such compensatory soma swelling and the extent of the swelling correlated highly (r = 0.96) with recovery of contrast discrimination performance at post-operative days 23 and 38, Conclusions: Depending on the time course and extent, soma swelling after neurotrauma may be associated either with cell death or recovery of function, Because of the very high correlation between extent of recovery and amount of soma swelling, moderate soma swelling contributes in a prominent way to recovery of vision. We believe that these cells provide an important structural substrate for neuronal tissue repair and therefore term these cells "compensatory neurons".	Otto Von Guericke Univ, Inst Med Psychol, D-39120 Magdeburg, Germany	Sabel, BA (corresponding author), Otto Von Guericke Univ, Inst Med Psychol, Leipzigerstr 44, D-39120 Magdeburg, Germany.	Bernhard.Sabel@Medizin.Uni-Magdeburg.de	Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543			Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Berardi N, 1999, RESTOR NEUROL NEUROS, V15, P125; Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; CASTANEDA E, 1990, J NEUROSCI, V10, P1847; Chino YM, 1999, RESTOR NEUROL NEUROS, V15, P165; Chino YM, 1995, CAN J PHYSIOL PHARM, V73, P1323, DOI 10.1139/y95-187; CHOW KL, 1972, EXP NEUROL, V34, P409, DOI 10.1016/0014-4886(72)90038-6; COWEY A, 1982, EXP BRAIN RES, V48, P149; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; Eysel UT, 1999, RESTOR NEUROL NEUROS, V15, P153; EYSEL UT, 1985, EXP NEUROL, V88, P757, DOI 10.1016/0014-4886(85)90086-X; FENDRICH R, 1992, SCIENCE, V258, P1489, DOI 10.1126/science.1439839; FINGER S, 1982, BRAIN DAMAGE RECOVER; FLOHR AP, 1988, POST LESION NEURAL P; Frost DO, 1999, RESTOR NEUROL NEUROS, V15, P107; Galuske RAW, 1999, RESTOR NEUROL NEUROS, V15, P115; Gennarelli T.A., 1986, MECHANISMS SECONDARY, P15; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Grafstein B, 1978, NEURONAL PLASTICITY, P155; HARVEY LO, 1997, BEHAV RES METH INSTR, V18, P623; HEYWOD CA, 1988, EXP BRAIN RES, V70, P513; Innocenti GM, 1999, RESTOR NEUROL NEUROS, V15, P219; Inoue T, 2000, RESTOR NEUROL NEUROS, V17, P23; Kasten E, 1998, NAT MED, V4, P1083, DOI 10.1038/2079; Kasten E, 1999, RESTOR NEUROL NEUROS, V15, P273; Keller J, 2000, J NEUROSCI METH, V97, P103, DOI 10.1016/S0165-0270(00)00173-4; Kerkhoff G, 1999, RESTOR NEUROL NEUROS, V15, P255; Kreutz MR, 1998, J NEUROSCI, V18, P8278; Lashley KS, 1939, J COMP NEUROL, V70, P45, DOI 10.1002/cne.900700104; LAU KC, 1991, RESTOR NEUROL NEUROS, V3, P235, DOI 10.3233/RNN-1991-3502; LINDEN R, 1983, EXP BRAIN RES, V51, P368; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Moore S, 1996, NEUROSCI LETT, V207, P117, DOI 10.1016/0304-3940(96)12500-3; MOORE T, 1995, P NATL ACAD SCI USA, V92, P8215, DOI 10.1073/pnas.92.18.8215; Payne BR, 1999, RESTOR NEUROL NEUROS, V15, P81; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Quan MZ, 1999, INVEST OPHTH VIS SCI, V40, P2360; Rousseau V, 1999, NEUROREPORT, V10, P3387, DOI 10.1097/00001756-199911080-00024; Sabel BA, 1999, RESTOR NEUROL NEUROS, V15, P177; Sabel BA, 1997, NEUROSCIENTIST, V3, P366, DOI 10.1177/107385849700300609; Sabel BA, 1997, NAT MED, V3, P244, DOI 10.1038/nm0297-244; Sabel BA, 1997, ADV NEUROL, V73, P251; SABEL BA, 1995, EXP BRAIN RES, V106, P93; Sabel BA, 1997, BRAIN PLASTICITY; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; Schmitt U, 1996, J NEUROTRAUM, V13, P791, DOI 10.1089/neu.1996.13.791; Schmitt U, 1996, EXP NEUROL, V139, P17, DOI 10.1006/exnr.1996.0076; STEIN DG, 1983, BEHAV NEURAL BIOL, V37, P185, DOI 10.1016/S0163-1047(83)91216-5; STEWARD O, 1982, INT REV NEUROBIOL, V23, P197, DOI 10.1016/S0074-7742(08)60626-1; TABATA T, 1992, NEUROREPORT, V3, P709, DOI 10.1097/00001756-199208000-00015; THANOS S, 1995, J NEUROSCI, V15, P1057, DOI 10.1523/jneurosci.15-02-01057.1995; Werth R, 1999, RESTOR NEUROL NEUROS, V15, P229; Wessinger CM, 1999, RESTOR NEUROL NEUROS, V15, P243; Worgotter F, 1999, RESTOR NEUROL NEUROS, V15, P137	55	20	20	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2001	18	4					177	189					13	Neurosciences	Neurosciences & Neurology	525CK	WOS:000174049500005	11847441				2021-06-18	
J	Walker, R; Staton, M; Leukefeld, CG				Walker, R; Staton, M; Leukefeld, CG			History of head injury among substance users: Preliminary findings	SUBSTANCE USE & MISUSE			English	Article						service utilization; incarcerated males; drug abuse	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SHORT-TERM-MEMORY; ABUSE; IMPAIRMENT; ALCOHOLICS; DEFICITS	Traumatic brain injury is associated with a variety of problems in cognitive functioning that may be related to substance use and that may influence recovery. This pilot study of 591 inmates in medium and minimum-security prisons examined self-reports of head injury, mental health problems, and health service utilization in three groups: no head injury, one head injury, and two or more head injuries. The group with multiple head injuries reported significantly more emergency room visits, more hospital admission, and number of hospital stays when compared with those with no head injury. This preliminary analysis reflects a need for additional research on brain injury among substance misusers.	Ctr Drug & Alcohol Res, Lexington, KY 40506 USA	Walker, R (corresponding author), Ctr Drug & Alcohol Res, 333 Bowman Hall, Lexington, KY 40506 USA.	jrwalkO@pop.uky.edu			NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA011309] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 11309-01] Funding Source: Medline		AMEN DG, 1992, J PSYCHOACTIVE DRUGS, V29, P307; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; BOYLE MJ, 1991, J ROY SOC MED, V84, P608; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Bremner JD, 1995, PSYCHIAT RES, V59, P97; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Brown BS, 1997, TREATING DRUG ABUSER, P99; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; FOGEL BS, 1994, J NEUROPSYCH CLIN N, V6, P343; Halgren Eric, 1995, P1137; HARDEN PW, 1997, ADDICTIVE BEHAV READ, P488; Hart T, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P133; HESTAD K, 1995, SCAND J PSYCHOL, V36, P246, DOI 10.1111/j.1467-9450.1995.tb00984.x; Kaplan H.I, 1998, SYNOPSIS PSYCHIAT BE, V8th; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kraus Jess F., 1994, P3; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Malec JF, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P15; MCALLISTER TW, 1994, EVALUATION TREATMENT, P347; MEEK PS, 1989, J PSYCHOACTIVE DRUGS, V21, P153, DOI 10.1080/02791072.1989.10472155; MILLER L, 1992, INT J LAW PSYCHIAT, V15, P303, DOI 10.1016/0160-2527(92)90005-L; Moes Elisabeth, 1994, P217; Morse Philip A., 1994, P107; Nixon SJ, 1999, PSYCHOL SCI, V10, P181, DOI 10.1111/1467-9280.00130; PIHL RO, 1995, ALCOHOL HEALTH RES W, V19, P142; Raine A., 1993, PSYCHOPATHOLOGY CRIM; RAPHAELY RC, 1980, PEDIATR CLIN N AM, V27, P715; SAPOLSKY RM, 1990, PROG BRAIN RES, V86, P13; SHALLICE T, 1998, PREFRONTAL CORTEX EX, P22; SILVER JM, 1997, AM PSYCHIAT PRESS TX, P521; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOLOMON RA, 1992, NEUROSURG QUART, V2, P1; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; SPARADEO FR, 1992, NEUROREHABILITATION, V2, P65; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; VOLAVKA J, 1995, NEUROBIOLOGY VIOLENC; WEINBERGER NM, BRAIN ORG MEMORY CEL, P285	40	20	20	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1082-6084	1532-2491		SUBST USE MISUSE	Subst. Use Misuse		2001	36	6-7					757	770		10.1081/JA-100104089			14	Substance Abuse; Psychiatry; Psychology	Substance Abuse; Psychiatry; Psychology	455PH	WOS:000170034900006	11697609				2021-06-18	
J	Harry, GJ; d'Hellencourt, CL; Bruccoleri, A; Schmechel, D				Harry, GJ; d'Hellencourt, CL; Bruccoleri, A; Schmechel, D			Age-dependent cytokine responses: Trimethyltin hippocampal injury in wild-type, APOE knockout, and APOE4 mice	BRAIN BEHAVIOR AND IMMUNITY			English	Article						apolipoprotein E; GFAP; EB22; TNF alpha; MIP-1 alpha; TGF-beta 1	E-DEFICIENT MICE; NECROSIS-FACTOR-ALPHA; APOLIPOPROTEIN-E POLYMORPHISM; MOLECULE-1 GENE-EXPRESSION; ALZHEIMERS-DISEASE CERAD; DIFFERENT PLAQUE TYPES; CLOSED-HEAD INJURY; INTERFERON-GAMMA; MESSENGER-RNA; NERVOUS-SYSTEM	In this study, the hippocampal neurotoxicant trimethyltin (TMT) was used to examine possible differential susceptibility associated with the apolipoprotein E genotype. Mice-wild type (C57BL6J), APOE knockout, and APOE4 transgenic-received either saline or TMT (2 mg/kg, ip) at either 21 days or 8 months of age. At both ages, similar mRNA levels were seen in the hippocampus across genotypes for ICAM-1, A20, and MAC-I. GFAP mRNA was higher in the APOE knockouts and APOE4 as compared to wild-type mice. Within 24 h, TMT produced cell death of hippocampal dentate granule neurons and mild astrogliosis in all animals. In 21-day-old mice, TMT exposure significantly increased mRNA levels for ICAM-1 and MIP-1 alpha in all genotypes. EB-22, GFAP, TNF alpha, and TGF-beta1 levels were significantly elevated in both wild-type and APOE knockout mice following TMT. At 8 months of age, genotype specific differences were observed. mRNA levels for GFAP, TNF beta, TNF alpha, and MIP-1 alpha were increased in both APOE knockout and APOE4 mice compared to wild-type mice. TMT exposure significantly increased mRNA levels for GFAP and MIP-1 alpha in all animals. TNF alpha mRNA levels were increased in wild-type and APOE4 mice while EB22 mRNA levels were increased in both the APOE knockout and APOE4 mice but not wild-type mice. These data suggest an age-dependent effect on both microglia early inflammatory responses to injury associated with the APOE genotype. (C) 2000 Academic Press.	NIEHS, Neurotoxicol Grp, Toxicol Lab, Res Triangle Pk, NC 27709 USA; Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Dept Med Neurol, Durham, NC 27710 USA	Harry, GJ (corresponding author), NIEHS, Neurotoxicol Grp, Toxicol Lab, POB 12233, Res Triangle Pk, NC 27709 USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [5P50 AG-05128] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [Y01-ES-40290] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [Z01ES021154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005128] Funding Source: NIH RePORTER		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ABRAHAM CR, 1992, RES IMMUNOL, V143, P631, DOI 10.1016/0923-2494(92)80047-O; Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Baskin F, 1997, J NEUROL SCI, V148, P15, DOI 10.1016/S0022-510X(96)05335-X; BENNETT C, 1995, AM J MED GENET, V60, P1, DOI 10.1002/ajmg.1320600102; Boschert U, 1999, NEUROBIOL DIS, V6, P508, DOI 10.1006/nbdi.1999.0251; Bruccoleri A, 1999, J NEUROSCI RES, V57, P916, DOI 10.1002/(SICI)1097-4547(19990915)57:6<916::AID-JNR17>3.3.CO;2-A; Bruccoleri A, 1998, J NEUROCHEM, V71, P1577; BUTCHER EC, 1990, AM J PATHOL, V136, P3; Cacabelos R, 1996, ACTA NEUROL SCAND, V93, P72; CACABELOS R, 1996, METH FIND EXP CLI SA, V18, P161; CAMPBELL IL, 1994, J IMMUNOL, V152, P716; CHANG LW, 1982, NEUROBEH TOXICOL TER, V4, P149; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cruts M, 1998, ANN MED, V30, P560, DOI 10.3109/07853899809002605; de Bont N, 1999, J LIPID RES, V40, P680; DELACOURTE A, 1990, NEUROLOGY, V40, P33, DOI 10.1212/WNL.40.1.33; DELREE P, 1993, BRAIN RES BULL, V30, P231, DOI 10.1016/0361-9230(93)90249-B; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Egensperger R, 1998, BRAIN PATHOL, V8, P439; EIKELENBOOM P, 1994, TRENDS PHARMACOL SCI, V15, P447, DOI 10.1016/0165-6147(94)90057-4; FINSEN BR, 1993, GLIA, V7, P41, DOI 10.1002/glia.440070109; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; Higgins GA, 1997, PHARMACOL BIOCHEM BE, V56, P675, DOI 10.1016/S0091-3057(96)00420-0; HOBBS MV, 1993, J IMMUNOL, V150, P3602; Hogan B., 1994, MANIPULATING MOUSE E, V2nd edn; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Hull M, 1996, EUR ARCH PSY CLIN N, V246, P124, DOI 10.1007/BF02189112; Hyman BT, 1997, NEUROBIOL AGING, V18, pS27, DOI 10.1016/S0197-4580(97)00066-3; INGLIS JD, 1991, GENE, V106, P213, DOI 10.1016/0378-1119(91)90201-L; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; Kerr M E, 1998, AACN Clin Issues, V9, P524, DOI 10.1097/00044067-199811000-00007; KIEFER R, 1995, INT J DEV NEUROSCI, V13, P331; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; LEFEBVRE PP, 1992, NEUROREPORT, V3, P295, DOI 10.1097/00001756-199204000-00001; Licastro F, 1998, J NEUROIMMUNOL, V88, P105, DOI 10.1016/S0165-5728(98)00096-4; Licastro F, 1999, AM J PATHOL, V155, P869, DOI 10.1016/S0002-9440(10)65186-3; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCGEER PL, 1994, TOHOKU J EXP MED, V174, P269, DOI 10.1620/tjem.174.269; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; MURPHY GM, 1995, J NEUROSCI RES, V40, P755, DOI 10.1002/jnr.490400607; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; Overmyer M, 1999, DEMENT GERIATR COGN, V10, P252, DOI 10.1159/000017128; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; REUHL KR, 1983, NEUROTOXICOLOGY, V4, P19; ROGISTER B, 1993, J NEUROSCI RES, V34, P32, DOI 10.1002/jnr.490340105; Roselaar SE, 1998, J LIPID RES, V39, P1740; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; Saitoh T, 1997, GERONTOLOGY, V43, P109; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHMECHEL DE, 1999, ADV NEUROCHEM, V9, P215; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Sheng JG, 1996, NEUROPATH APPL NEURO, V22, P334, DOI 10.1111/j.1365-2990.1996.tb01112.x; SHRIKANT P, 1994, J NEUROIMMUNOL, V51, P209, DOI 10.1016/0165-5728(94)90083-3; SHRIKANT P, 1995, J IMMUNOL, V155, P1489; STENGARD JH, 1995, CIRCULATION, V91, P265, DOI 10.1161/01.CIR.91.2.265; Streit WJ, 1996, NEUROTOXICOLOGY, V17, P671; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TARDIFF B, 1994, CIRCULATION, V90, P201; Trieu VN, 2000, BIOCHEM BIOPH RES CO, V268, P835, DOI 10.1006/bbrc.2000.2205; UCHIHARA T, 1995, NEUROSCI LETT, V195, P5, DOI 10.1016/0304-3940(95)11763-M; Unger JW, 1998, MICROSC RES TECHNIQ, V43, P24, DOI 10.1002/(SICI)1097-0029(19981001)43:1<24::AID-JEMT4>3.0.CO;2-P; Xu PT, 1998, NEUROSCI LETT, V246, P65, DOI 10.1016/S0304-3940(98)00247-X; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023	80	20	20	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	DEC	2000	14	4					288	304		10.1006/brbi.2000.0606			17	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	388HE	WOS:000166174100005	11120597				2021-06-18	
J	Leoni, MJ; Chen, XH; Mueller, AL; Cheney, J; McIntosh, TK; Smith, DH				Leoni, MJ; Chen, XH; Mueller, AL; Cheney, J; McIntosh, TK; Smith, DH			NPS 1506 attenuates cognitive dysfunction and hippocampal neuron death following brain trauma in the rat	EXPERIMENTAL NEUROLOGY			English	Article						brain trauma; fluid percussion; hippocampus; memory; NMDA; NPS 1506	CONTROLLED CORTICAL IMPACT; REGIONAL CEREBRAL EDEMA; D-ASPARTATE RECEPTORS; CLOSED-HEAD INJURY; SELECTIVE VULNERABILITY; NMDA ANTAGONIST; DAMAGE; HYPOTHERMIA; ISCHEMIA; MK-801	Although several noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists have been shown to be substantially efficacious in experimental models of brain trauma, side effects associated with this class of compounds have impeded clinical application. Therefore, new noncompetitive NMDA receptor antagonists have been developed, including NPS 1506, that appear to be nontoxic but retain efficacy. In the present study, we evaluated the efficacy of NPS 1506 in a model of parasagittal fluid percussion brain trauma in the anesthetized rat. Administration of 1 mg/kg NPS 1506 at both 10 min and 4 h posttrauma induced no changes in brain temperature, mean arterial pressure, pulse, or arterial blood gasses. At 1 week postinjury, animals treated with the same dosing regimen of NPS 1506 demonstrated a dramatic attenuation of memory dysfunction evaluated by a water maze task (P < 0.02) and had greatly reduced neuron death in the CA3 subfield of the hippocampus (P < 0.01). However, NPS 1506 treatment did not significantly affect the extent of cortical tissue loss following injury. Since memory dysfunction and hippocampal damage are common and potentially related consequences of brain trauma in humans, our results suggest that NPS 1506 treatment may have clinical utility. (C) 2000 Academic Press.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; NPS Pharmaceut Inc, Salt Lake City, UT USA	Leoni, MJ (corresponding author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS038104, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS38104] Funding Source: Medline		Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Brady EM, 1998, NEUROLOGY, V50, pA346; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BUCHAN A, 1990, J NEUROSCI, V10, P311; CHOI DW, 1987, J NEUROSCI, V7, P369; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FADEN AI, 1989, SCIENCE, V244, P789; Graham D.I., 1993, HEAD INJURY, P91; Gurevich B, 1998, J NEUROSURG, V88, P1066, DOI 10.3171/jns.1998.88.6.1066; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kimelberg H.K., 1982, HEAD INJURY BASIC CL, P31; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LEVIN HS, 1985, STATUS REPORT CENTRA, P281; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1986, NEUROSCI LETT, V68, P29, DOI 10.1016/0304-3940(86)90224-7; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P316; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Smith D H, 1995, New Horiz, V3, P562; Smith DH, 1997, NEUROSCI LETT, V231, P135, DOI 10.1016/S0304-3940(97)00551-X; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITH SA, 1993, P AQUACULTURE ASS CA, V10, P62; Soares HD, 1995, J NEUROSCI, V15, P8223; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	57	20	20	0	2	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	2000	166	2					442	449		10.1006/exnr.2000.7513			8	Neurosciences	Neurosciences & Neurology	380PB	WOS:000165709300024	11085909				2021-06-18	
J	McCluskey, AE				McCluskey, AE			Paid attendant carers hold important and unexpected roles which contribute to the lives of people with brain injury	BRAIN INJURY			English	Article							CAREGIVER; SERVICES	Objective: Paid attendant carers spend many hours assisting people with a brain injury. Despite this considerable responsibility, most carers receive little support or training and their roles are often ill-defined. This exploratory study set out to define the key roles of paid carers. Method: Ten semi-structured interviews were conducted. Perspectives were sought from 10 participants: five people with a traumatic brain injury and five paid carers. A computer software package, NUD*IST was used during analysis to help identify and categorize commonly recurring themes. Results: Five major roles were identified: Attendant, Protector, Friend, Coach and Negotiator. Friendship was the most important aspect of the care relationship for three of the people with a brain injury, most of whom had lost their pre-injury friends and associates. Carers were required to negotiate frequently with clients and their families, and with other service providers. Sound communication skills were required. Conclusion: In addition to further research, industry guidelines are required which take account of the wider suite of roles fulfilled by paid carers, address training and support needs, and occupational health and safety issues.	Univ Western Sydney Macarthur, Fac Hlth, Div Occupat Therapy, Campbelltown, NSW 2560, Australia	McCluskey, AE (corresponding author), Univ Western Sydney Macarthur, Fac Hlth, Div Occupat Therapy, POB 555, Campbelltown, NSW 2560, Australia.						*ALL OEH I, 1990, MAK FRIENDS DEV REL; AMADO AN, 1990, FRIENDS MANUAL CONNE; ANDREWS SS, 1995, VARIETY COMMUNITY EX, P101; ATKINS BJ, 1982, J REHABIL, V48, P20; Beatty PW, 1998, ARCH PHYS MED REHAB, V79, P674, DOI 10.1016/S0003-9993(98)90043-0; Bell RobertR., 1981, WORLDS FRIENDSHIP; Carr J, 1998, NEUROLOGICAL REHABIL, P23; Cichon E. J., 1993, COMMUNICATION Q, V41, P477, DOI [10.1080/01463379309369907, DOI 10.1080/01463379309369907]; FISHER CB, 1989, FAM RELAT, V38, P83, DOI 10.2307/583615; *FOC LEARN SYST, 1998, TRAIN NEEDS ATT CAR; Frosch S, 1997, BRAIN INJURY, V11, P891; Gilson S F, 1997, J Case Manag, V6, P13; Hardy ME, 1988, ROLE THEORY PERSPECT, P159; HUTCHINS RK, 1978, AM REHABILITATION, V4, P18; Law MJS, 1998, CLIENT CTR OCCUPATIO; Lutfiyya Z., 1993, FRIENDSHIPS COMMUNIT, P97; Magill RA, 1993, MOTOR LEARNING CONCE; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; Miller E L, 1987, Rehabil Nurs, V12, P185; MORSE JM, 1991, J ADV NURS, V16, P455, DOI 10.1111/j.1365-2648.1991.tb03436.x; NOSEK MA, 1991, REHABIL COUNS BULL, V35, P105; Nosek MA, 1990, J APPLIED REHABILITA, V21, P3, DOI [10.1891/0047-2220.21.4.3, DOI 10.1891/0047-2220.21.4.3]; Opie N D, 1989, Arch Psychiatr Nurs, V3, P205; Parsons T., 1951, SOCIAL SYSTEM; Perske R., 1988, CIRCLES FRIENDS PEOP; PRINCE JM, 1995, ARCH PHYS MED REHAB, V76, P919, DOI 10.1016/S0003-9993(95)80067-0; Rees RJ, 1996, AUST J SOC ISSUES, V31, P392, DOI 10.1002/j.1839-4655.1996.tb01286.x; RICHARDS T, 1991, QUALITATIVE SOCIOLOG, V14, P289; SHOULTZ B, 1995, VARIETY COMMUNITY EX, P9; SMITH NK, 1981, REHABIL LIT, V42, P258; Stake R.E., 1995, ART CASE STUDY RES; STAMP GH, 1994, COMMUN MONOGR, V61, P89, DOI 10.1080/03637759409376327; STELMACH M, 1981, REHABIL LIT, V42, P130; Strauss A., 1998, BASICS QUALITATIVE R; WELLS J, 1993, FRIENDSHIPS COMMUNIT, P197; WILLER B, 1994, BRAIN INJURY, V8, P647, DOI 10.3109/02699059409151017; Zencius AH, 1999, BRAIN INJURY, V13, P723	38	20	20	0	0	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2000	14	11					943	957		10.1080/02699050050191896			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	373UC	WOS:000165306800001	11104135				2021-06-18	
J	Dawson, DR; Levine, B; Schwartz, M; Stuss, DT				Dawson, DR; Levine, B; Schwartz, M; Stuss, DT			Quality of life following traumatic brain injury: A prospective study	BRAIN AND COGNITION			English	Article							STATE	The purpose of this study was to describe QOL following TBI and to determine whether early signs of injury severity predict QOL at 4 years postinjury. Early measures included Glasgow Coma Scale, loss of consciousness (LOC), and a measure of PTA (days to recall of three words (REC)). Quality of life measures included the Reintegration to Normal Living Index, Flanagan's QOL Scale, and a single QOL item. Subjects (n = 49) seen at follow-up (mean 4.4 years postinjury) had a significantly longer LOC than those lost to follow-up (n = 43). Results showed that 70 to 80% of subjects reported a good QOL. Multivariate regression showed REC to be the only significant predictor of QOL. These findings suggest that factors other than injury severity and PTA contributing to QOL. (C) 2000 Academic Press.	Univ Toronto, Toronto, ON, Canada	Dawson, DR (corresponding author), Univ Toronto, 100 Coll St, Toronto, ON, Canada.		Levine, Brian/O-2725-2019; Dawson, Deirdre R/I-8882-2014	Levine, Brian/0000-0003-4343-811X; Dawson, Deirdre R/0000-0001-7517-6121			FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583	5	20	20	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	OCT	2000	44	1					35	39					5	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	358FJ	WOS:000089547300009					2021-06-18	
J	Yamaguchi, S; Nakahara, K; Miyagi, T; Tokutomi, T; Shigemori, M				Yamaguchi, S; Nakahara, K; Miyagi, T; Tokutomi, T; Shigemori, M			Neurochemical monitoring in the management of severe head-injured patients with hypothermia	NEUROLOGICAL RESEARCH			English	Article						severe head injury; glutamate; aspartate; NO2; microdialysis; hypothermia	TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; INTRACEREBRAL MICRODIALYSIS; NEURONAL DEATH; RAT-BRAIN; GLUTAMATE	The neuroprotective action and effect of hypothermia on the neurochemical system is not well understood. The present study was performed using six patients with GCS scores of 5 or less to clarify the relationship between monitored brain temperature, intracranial pressure (ICP) cerebral perfusion pressure (CPP) and oxygen saturation of the jugular venous blood (SjO(2)). Changes in concentration of excitatory amino acids, glutamate (GLU) and aspartate (ASP) and NO2 were studied using intracerebral microdialysis as well as in jugular venous blood and cerebrospinal fluid (CSF). Changes in brain temperature, CPP and SjO(2) resulting from hypothermia and brain death associated with markedly higher concentrations of and fluctuations in the concentrations of GLU, ASP and NO2 were observed in the dialysate than in the jugular venous blood or CSF. Hypothermic treatment significantly reduces excitatory amino acid and NO2 concentrations, a finding which was associated with an improvement in CPP and SjO(2). Measurement of GLU and ASP using intracerebral microdialysis is a clinically useful method for clarifying abnormal neurochemical events associated with severe head injury and for evaluating the effects of hypothermia.	Kurume Univ, Sch Med, Dept Neurosurg, Kurume, Fukuoka 830, Japan	Yamaguchi, S (corresponding author), Kurume Univ, Sch Med, Dept Neurosurg, 67 Asahi Machi, Kurume, Fukuoka 830, Japan.						ALBINA JE, 1993, J IMMUNOL, V150, P5080; ARCHER S, 1993, FASEB J, V7, P349; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BUCHAN A, 1990, J NEUROSCI, V10, P311; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CHRISTOPH M, 1996, J NEUROSURG, V85, P533; CLERK RSB, 1996, CRIT CARE MED, V24, P1243; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HAGBERG H, 1987, NEUROSCI LETT, V78, P311, DOI 10.1016/0304-3940(87)90379-X; HILLERED L, 1990, J CEREBR BLOOD F MET, V10, P149; ICHIMORI K, 1994, REV SCI INSTRUM, V65, P2714, DOI 10.1063/1.1144674; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; KEHR J, 1988, J NEUROCHEM, V51, P1308, DOI 10.1111/j.1471-4159.1988.tb03101.x; KORF J, 1985, J NEUROCHEM, V45, P1341, DOI 10.1111/j.1471-4159.1985.tb07198.x; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; NAKAHARA K, 1994, J KURUME MED ASS, V57, P1131; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; Saveland H, 1996, NEUROSURGERY, V38, P12, DOI 10.1097/00006123-199601000-00004; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wieloch T, 1985, Neurol Res, V7, P24	41	20	20	0	0	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	OCT	2000	22	7					657	664					8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	373LH	WOS:000165290600002	11091969				2021-06-18	
J	Passineau, MJ; Zhao, W; Busto, R; Dietrich, WD; Alonso, O; Loor, JY; Bramlett, HM; Ginsberg, MD				Passineau, MJ; Zhao, W; Busto, R; Dietrich, WD; Alonso, O; Loor, JY; Bramlett, HM; Ginsberg, MD			Chronic metabolic sequelae of traumatic brain injury: prolonged suppression of somatosensory activation	AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY			English	Article						deoxyglucose; autoradiography; trauma; barrel circuit; vibrissae	CEREBRAL GLUCOSE-UTILIZATION; BLOOD-FLOW; POSTTRAUMATIC HYPOTHERMIA; INTRALUMINAL SUTURE; DISPARITY ANALYSIS; ARTERY OCCLUSION; DYNAMIC CHANGES; RAT; APOPTOSIS; AUTORADIOGRAPHY	Injuries to the brain acutely disrupt normal metabolic function and may deactivate functional circuits. It is unknown whether these metabolic abnormalities improve over time. We used 2-deoxyglucose (2-DG) autoradiographic image-averaging to assess local cerebral glucose utilization (1CMR(Glc)) of the rat brain 2 mo after moderate (1.7-2.1 atm) fluid-percussion traumatic brain injury (FPI). Four animal groups (n = 5 each) were studied: sham-injured rats with and without stimulation of the vibrissae-barrel field ipsilateral to injury; and animals with prior FPI, with or without this stimulation. In sham-injured rats, resting 1CMR(Glc) was normal, and vibrissae stimulation produced right-sided metabolic activation of the ventrolateral thalamic and somatosensory-cortical projection areas. In rats with prior injury, 1CMR(Glc) contralateral to injury was normal, but 1CMR(Glc) of the ipsilateral forebrain was depressed by similar to 38-45% compared with shams. Whisker stimulation in rats with prior trauma failed to induce metabolic activation of either cortex or thalamus. Image-mapping of histological material obtained in the same injury model was undertaken to assess the possible influence of injury-induced regional brain atrophy on computed 1CMR(Glc); an effect was found only in the lateral cortex at the trauma epicenter. Our results show that, 2 mo after trauma, resting cerebral metabolic perturbations persist, and the whisker-barrel somatosensory circuit shows no signs of functional recovery.	Univ Miami, Sch Med, Cerebral Vasc Dis Res Ctr, Dept Neurol D4 5, Miami, FL 33101 USA; Univ Miami, Sch Med, Cerebral Vasc Dis Res Ctr, Dept Neurol Surg, Miami, FL 33101 USA; Univ Miami, Sch Med, Program Neurosci, Miami, FL 33101 USA; Univ Miami, Sch Med, Neurotrauma Res Ctr, Miami, FL 33101 USA	Ginsberg, MD (corresponding author), Univ Miami, Sch Med, Cerebral Vasc Dis Res Ctr, Dept Neurol D4 5, POB 016960, Miami, FL 33101 USA.	mdginsberg@stroke.med.miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-05820, NS-30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, P50NS005820, P01NS005820] Funding Source: NIH RePORTER		Belayev L, 1997, J CEREBR BLOOD F MET, V17, P1266, DOI 10.1097/00004647-199712000-00002; BELFORD GR, 1979, J COMP NEUROL, V183, P305, DOI 10.1002/cne.901830207; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Conti AC, 1998, J NEUROSCI, V18, P5663; COX SB, 1993, J CEREBR BLOOD F MET, V13, P899, DOI 10.1038/jcbfm.1993.113; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1986, J CEREBR BLOOD F MET, V6, P405, DOI 10.1038/jcbfm.1986.73; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; GINSBERG MD, 1989, J CEREBR BLOOD F MET, V9, P329, DOI 10.1038/jcbfm.1989.51; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GINSBERG MD, 1987, NEUROLOGY, V37, P11, DOI 10.1212/WNL.37.1.11; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Sasaki M, 1993, Nihon Ika Daigaku Zasshi, V60, P215; SAVAKI HE, 1980, J NEUROCHEM, V35, P495, DOI 10.1111/j.1471-4159.1980.tb06293.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Thatte U, 1997, DRUGS, V54, P511, DOI 10.2165/00003495-199754040-00002; VANDERLOOS H, 1976, NEUROSCI LETT, V2, P1, DOI 10.1016/0304-3940(76)90036-7; WELKER C, 1974, J COMP NEUROL, V158, P437, DOI 10.1002/cne.901580405; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang XJ, 1996, P NATL ACAD SCI USA, V93, P475, DOI 10.1073/pnas.93.1.475; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZHAO WZ, 1995, J CEREBR BLOOD F MET, V15, P552, DOI 10.1038/jcbfm.1995.69; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510; Zhao WZ, 1997, J CEREBR BLOOD F MET, V17, P1281, DOI 10.1097/00004647-199712000-00003; ZHAO WZ, 1993, IEEE T MED IMAGING, V12, P782, DOI 10.1109/42.251130; Zilles K., 1985, CORTEX RAT	34	20	20	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6135	1522-1539		AM J PHYSIOL-HEART C	Am. J. Physiol.-Heart Circul. Physiol.	SEP	2000	279	3					H924	H931					8	Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease	Cardiovascular System & Cardiology; Physiology	355HC	WOS:000089379400007	10993751				2021-06-18	
J	Sinal, SH; Petree, AR; Herman-Giddens, M; Rogers, MK; Enand, C; DuRant, RH				Sinal, SH; Petree, AR; Herman-Giddens, M; Rogers, MK; Enand, C; DuRant, RH			Is race or ethnicity a predictive factor in shaken baby syndrome?	CHILD ABUSE & NEGLECT			English	Article							ABUSIVE HEAD TRAUMA; CHILD-ABUSE; INJURY; MECHANISMS	Objective: Previous studies have concluded that shaken baby syndrome occurs more often among Whites than among Blacks. The purpose of this study was to determine whether race is a predictive factor in Shaken Baby Syndrome when population and referral patterns are considered, Methods: A retrospective medical record review of closed head injuries due to child abuse during the time period January 1992 to July 1997 was conducted at three pediatric tertiary care medical centers in North Carolina. Patients included children, ages 0-4 years, identified from medical record reviews and child abuse databases, Only North Carolina residents were included. The specific rates of shaken baby syndrome in Whites versus non-Whites in the referral area were computed. Results: The difference in the rate of shaken baby syndrome from the referral area was not statistically significant among Whites versus non-Whites (26.7/100,000 versus 38.6/100,000, p = .089) Most of the perpetrators were male (68%), and most victims (76%), lived with their mothers and biologic father or mother's boyfriend. Conclusion: Race was not a significant factor in predicting shaken baby syndrome in the referral area studied, and therefore is not a useful factor in targeting groups for intervention. (C) 2000 Elsevier Science Ltd.	Wake Forest Univ, Bowman Gray Sch Med, Brenner Childrens Hosp, Brenner Ctr Child & Adolescent Hlth,Dept Pediat, Winston Salem, NC 27157 USA; Off N Carolina Med Examiner, Chapel Hill, NC USA; Carolinas Med Ctr, Dept Pediat, Charlotte, NC 28203 USA	Sinal, SH (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.				NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK 7400] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T35DK007400] Funding Source: NIH RePORTER		BRENNER SL, 1989, J NATL MED ASSOC, V81, P183; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Guterman NB, 1999, CHILD ABUSE NEGLECT, V23, P863, DOI 10.1016/S0145-2134(99)00062-9; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HAHN YS, 1983, CHILD BRAIN, V10, P229; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kramer M.S., 1988, CLIN EPIDEMIOLOGY BI; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; STARLING SP, 1995, PEDIATRICS, V95, P259; TSAI FY, 1980, CT-J COMPUT TOMOGR, V4, P277; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	11	20	21	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	SEP	2000	24	9					1241	1246		10.1016/S0145-2134(00)00177-0			6	Family Studies; Psychology, Social; Social Work	Family Studies; Psychology; Social Work	352NQ	WOS:000089225100011	11057709				2021-06-18	
J	Keller, M; Hiltbrunner, B; Dill, C; Kesselring, J				Keller, M; Hiltbrunner, B; Dill, C; Kesselring, J			Reversible neuropsychological deficits after mild traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						brain injury; attention; neuropsychology	HEAD-INJURY; WHIPLASH INJURY; FOLLOW-UP; ATTENTION	Objectives-To determine the influence of motivation on performance in a divided attention test of patients after mild traumatic brain injury (MBI). Methods-Comparison of the performance of 12 patients with MBI with 10 patients with severe brain injury (SBI) and 11 healthy controls in a computer supported divided attention task before (T1) and after (T2) verbal motivation. Results-At T1, the MBI group performed the same as the SBI group but significantly worse than the controls in all variables. At T2, the MBI group performed worse than the controls at T2 but the results were equal to the results of the controls at T1 and significantly better than the SBI group at T1 or T2. At T2 the MBI group performed at the level of published norms for the rest. Conclusion-Before verbal motivation the MBI group's results in the divided attention task were comparable with those from patients with severe brain injury. They failed to exploit their performance potential when it depended on self motivation but were able to perform at the level of the control group when external motivation was applied.	Rehabil Ctr Valens, Dept Neurol, CH-7317 Valens, Switzerland; Suva, CH-6002 Luzern, Switzerland	Keller, M (corresponding author), Rehabil Ctr Valens, Dept Neurol, CH-7317 Valens, Switzerland.	b.rutz@klinik-valens.ch					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDERSON SW, 1996, HEAD INJURY POSTCONC, V23, P457; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; BERG M, 1992, BENUTZERHANDBUCH ZUM; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRENNER H, 1981, Z KLIN PSYCHOL-FORSC, V10, P167; Cassens G, 1990, J Neuropsychiatry Clin Neurosci, V2, P202; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; DEBRUNNER HU, 1996, SUMEST MED STAT SUVA; FISCHER R, 1998, SUMEST MED STAT SUVA; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Goldstein G, 1998, HUMAN BRAIN FUNCT, P63; Goldstein K, 1942, EFFECTS BRAIN INJURI; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KEIDEL M, 1992, NERVENARZT, V63, P731; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, V7, P170; McClelland, 1969, MOTIVATING EC ACHIEV; Mesulam M-M, 1985, PRINCIPLES BEHAV NEU, P125; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; MossMorris R, 1996, J NEUROL NEUROSUR PS, V60, P474, DOI 10.1136/jnnp.60.5.474; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; PEARCE JMS, 1994, NEUROLOGY, V44, P1993, DOI 10.1212/WNL.44.11.1993; *QUEB TASK FORC WH, 1995, SPINE S8, V20, pS12; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; Seligman M. E., 1975, HELPLESSNESS DEPRESS; STURM W, 1982, NERVENARZT, V53, P395; STUSS DT, 1995, NEUROLOGY, V45, P1251, DOI 10.1212/WNL.45.7.1251; World Health Organization, 1992, ICD 10 CLASS MENT BE	31	20	20	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2000	68	6					761	764		10.1136/jnnp.68.6.761			4	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	316NY	WOS:000087174900014	10811701	Green Published, Bronze			2021-06-18	
J	Kita, T; Tanaka, T; Tanaka, N; Kinoshita, Y				Kita, T; Tanaka, T; Tanaka, N; Kinoshita, Y			The role of tumor necrosis factor-alpha in diffuse axonal injury following fluid-percussive brain injury in rats	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						traumatic head injury; diffuse axonal injury; tumor necrosis factor-alpha; beta-amyloid precursor protein; fluid percussion device; glial cell	AMYLOID PRECURSOR PROTEIN; IL-1 RECEPTOR ANTAGONIST; CLOSED-HEAD INJURY; EXPRESSION; PHOSPHORYLATION; PERMEABILITY; MODULATION; DIAGNOSIS; CALIBER; DAMAGE	The immunolocalization of tumor necrosis factor-alpha (TNF alpha) after diffuse axonal injury (DAI) is demonstrated using a midline fluid percussion rat model (moderate brain injury of 1000 mm Hg was generated) and the effects of TNF alpha on the axolemmal permeability using horseradish peroxidase as a tracer. In addition, the accumulation of beta-amyloid precursor protein (beta-APP) was investigated, which has recently been shown to be a reliable marker fur the diagnosis of DAI in cases with fatal head injury. TNF alpha levels in brain tissues from the impact site and the col tex including the corpus callosum, gradually increased during the first 1 h, rose to a maximal elevation at 3 h, gradually decreased at 6 h and decreased further at 24 h. Horseradish peroxidase (HRP) tracer experiments revealed that primary axonal damage appeared as early as 15 min after impact but rapidly recovered and that 1 h after impact, secondary axonal damage occurred in the corpus callosum and the brain stem. By immunoelectron microscopy it was seen that beta-APP accumulated in the axon from 1 h after impact demonstrating that there was functional axonal damage. TNF alpha reactions were detected in the lysosomes of microglia 30 min after impact and 1 h after impact these reactions were mainly detected in the glial cells (such as microglia, astrocytes and oligodendrocytes) in the corpus callosum and the blain stem. It is generally accepted that TNF alpha directly induces primary demyelination and oligodendrocyte apoptosis. Therefore, TNF alpha conveyed from the microglial cells is one cofactor contributing to the formation of the delayed axonal damage observed Lit these sites. The present study suggests that TNF alpha conveyed from the glial cells may contribute to the pathogenic mechanism of DAI formation following fluid percussive brain injury.	Univ Occupat & Environm Hlth, Sch Med, Dept Forens Med, Yahata Nishi Ku, Kitakyushu, Fukuoka 807, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Neurosurg, Yahata Nishi Ku, Kitakyushu, Fukuoka 807, Japan	Kita, T (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Forens Med, Yahata Nishi Ku, Kitakyushu, Fukuoka 807, Japan.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763			Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Creange A, 1997, EUR CYTOKINE NETW, V8, P145; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; FEDER N, 1971, J CELL BIOL, V51, P339, DOI 10.1083/jcb.51.1.339; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; HIRANO A, 1969, J ULTRA MOL STRUCT R, V28, P141, DOI 10.1016/S0022-5320(69)90012-4; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Ladiwala U, 1998, J NEUROSCI, V18, P1297; Madigan MC, 1996, NEUROL RES, V18, P233; Matsukawa A, 1997, CYTOKINE, V9, P307, DOI 10.1006/cyto.1996.0170; MATSUKAWA A, 1994, IMMUNOL INVEST, V23, P129, DOI 10.3109/08820139409087794; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MERRICK B A, 1992, Applied and Theoretical Electrophoresis, V2, P177; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; OZAWA Y, 1991, Neurologia Medico-Chirurgica, V31, P685, DOI 10.2176/nmc.31.685; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Previtali SC, 1997, AM J PATHOL, V151, P1425; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613	31	20	27	0	3	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0937-9827			INT J LEGAL MED	Int. J. Legal Med.	JUN	2000	113	4					221	228		10.1007/s004149900095			8	Medicine, Legal	Legal Medicine	334WK	WOS:000088208500006	10929238				2021-06-18	
J	Golding, EM; Robertson, CS; Bryan, RM				Golding, EM; Robertson, CS; Bryan, RM			L-arginine partially restores the diminished CO2 reactivity after mild controlled cortical impact injury in the adult rat	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						carbon dioxide reactivity; free radicals; L-arginine; nitric oxide; rat; traumatic brain injury	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; NITRIC-OXIDE SYNTHASE; SENSITIVE POTASSIUM CHANNELS; CEREBROVASCULAR REACTIVITY; HYPERTENSIVE RATS; CARBON-DIOXIDE; K+ CHANNELS; HYPERCAPNIA; SUPEROXIDE	Using an open cranial window technique, The authors investigated the mechanisms associated with the suppressed CO2 reactivity after mild controlled cortical impact (CCI) injury in rats. The dilation of arterioles (n = 7) to hypercapnia before injury was 38 +/- 12%, which was significantly reduced both at 1 hour (23 +/- 15% dilation) and at 2 hours after injury (11 +/- 19% dilation). In the presence of L-arginine (10 mmol/L topical suffusion, 300 mg/kg intravenous infusion), the dilation of pial arterioles (n = 6) to hypercapnia was partially restored to 30 +/- 6% at 2 hours after injury. In the presence of the nitric ox ide (NO) donor, S-nitroso-N-acetylpenicillamine (SNAP) (10(-8) mol/L topical suffusion), the dilation of pial arterioles (n = 5) to hypercapnia remained diminished (5 +/- 7%) at 2 hours after injury. The dilation of pial arterioles (n = 4) to hypercapnia also remained suppressed (5 +/- 6%) with topical suffusion of the free radical scavengers, polyethylene glycol-superoxide dismutase (60 units/mL) and polyethylene glycol-catalase (40 units/mL). The authors have shown that L-arginine at least partially restores the diminished response to hypercapnia after mild CCI injury. Furthermore, these data suggest that the beneficial effects of L-arginine are mediated by a combination of providing substrate for NO synthase and scavenging free radicals.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA	Golding, EM (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Suite 944, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [PHS P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		AOKI E, 1991, BRAIN RES, V547, P190, DOI 10.1016/0006-8993(91)90961-T; BAUMBACH GL, 1989, J PHYSIOL-LONDON, V416, P123, DOI 10.1113/jphysiol.1989.sp017753; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; Cherian L, 1999, CRIT CARE MED, V27, pA52, DOI 10.1097/00003246-199901001-00091; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FABRICIUS M, 1994, AM J PHYSIOL, V266, pH1457; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARACI FM, 1994, STROKE, V25, P1679, DOI 10.1161/01.STR.25.8.1679; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; HARPER SL, 1984, HYPERTENSION, V6, P408, DOI 10.1161/01.HYP.6.3.408; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Holm P, 1998, EUR J PHARMACOL, V346, P97, DOI 10.1016/S0014-2999(98)00009-0; IADECOLA C, 1992, P NATL ACAD SCI USA, V89, P3913, DOI 10.1073/pnas.89.9.3913; JACOB TD, 1993, J TRAUMA, V35, P590, DOI 10.1097/00005373-199310000-00015; KJALLQUIST A, 1969, ACTA PHYSIOL SCAND, V76, P485; KLATT P, 1993, J BIOL CHEM, V268, P14781; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; Kontos HA, 1996, AM J PHYSIOL-HEART C, V271, pH1498; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pelligrino DA, 1995, BRAIN RES, V704, P61, DOI 10.1016/0006-8993(95)01105-6; POU S, 1992, J BIOL CHEM, V267, P24173; Rehman A, 1997, BRIT J PHARMACOL, V122, P1702, DOI 10.1038/sj.bjp.0701556; REID JM, 1995, AM J PHYSIOL-HEART C, V269, pH916; Reis DJ, 1999, ANN NY ACAD SCI, V881, P65, DOI 10.1111/j.1749-6632.1999.tb09343.x; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; Sobey CG, 1997, STROKE, V28, P392, DOI 10.1161/01.STR.28.2.392; Sobey CG, 1997, STROKE, V28, P2290, DOI 10.1161/01.STR.28.11.2290; WADA K, 1997, J NEUROTRAUM, V14, P760; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; Wang QO, 1998, BRAIN RES, V793, P187, DOI 10.1016/S0006-8993(98)00173-5; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	39	20	20	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2000	20	5					820	828		10.1097/00004647-200005000-00008			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	312WM	WOS:000086967000008	10826532	Bronze			2021-06-18	
S	Han, SH; Chung, SY		Kalaria, RN; Ince, P		Han, SH; Chung, SY			Marked hippocampal neuronal damage without motor deficits after mild concussive-like brain injury in apolipoprotein E-deficient mice	VASCULAR FACTORS IN ALZHEIMER'S DISEASE	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Conference on Vascular Factors in Alzheimers Disease	MAY 25-28, 1999	NEWCASTLE TYNE, ENGLAND	Bayer AG, Eisai Ltd, GJ Livanos Trust, Alzheimers Report, Hoechst Marrion Roussel, Janssen Pharmaceut, Novartis Pharma AG, Parke Davis, Pfizer Inc, SmithKline Beecham Pharmaceut, Zeneca, Med Res Council, Inst Brain & Blood Vessels, Akita, Inst Hlth Elderly, Univ Newcastle Upon Tyne			CLOSED-HEAD INJURY; FAMILIAL ALZHEIMERS-DISEASE; E EPSILON-4; RAT HIPPOCAMPUS; TYPE-4 ALLELE; AMYLOID-BETA; RISK	Of various biological factors, only allele epsilon 4 of apolipoprotein E (apoE, protein; APOE4, gene) has been thus far suggested as a major determinant of genetic risk for sporadic and late-onset familial Alzheimer's disease (AD), Environmental influences such as lack of education, traumatic brain injury, oxidative stress, environmental toxins, hormonal imbalances, and alterations in immune or inflammatory responses may also contribute to the pathogenesis of AD. Thus genetic susceptibility and environmental risk factors may have synergistic effects on the development of AD. The purpose of present report was to assess whether the gene (APOE) and the environmental risk factor (traumatic brain injury) could interact in hippocampal neuronal degeneration, We investigated the histopathological changes of hipoccampal regions after mild concussive-like brain injury without motor deficits in apoE-deficient mice using the recently described novel weight-drop device, Control mice revealed minimal neurodegenerative changes limited to CA2 and CA3, while apoE-deficient mice showed widespread neuronal degeneration throughout hippocampal subfields and part of dentate gyrus, We also observed widespread glial fibrillary acidic protein (GFAP) immunoreactivity throughout the hippocampus, which was more intense in apoE-deficient mice, The results of this study indicate that even very mild traumatic brain injury could result in widespread hippocampal damage in apoE-deficient mice, This again supports the hypothesis that apoE might play a neurotrophic or neuroprotective function in the central nervous system.	Chungbuk Natl Univ Hosp, Dept Neurol, Chungbuk 361711, South Korea; Catholic Univ, Dept Pediat, Our Lady Mercy Hosp, Med Ctr,Bupyong Ku, Inchon 403016, South Korea	Han, SH (corresponding author), Chungbuk Natl Univ Hosp, Dept Neurol, 62 Gaeshin Dong, Chungbuk 361711, South Korea.						ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Bodjarian N, 1997, NEUROREPORT, V8, P3951, DOI 10.1097/00001756-199712220-00020; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; HOLZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Small GW, 1998, J CLIN PSYCHIAT, V59, P7; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; TEASDALE MCG, 1977, LANCET, V350, P1069; VANDUIJN CM, 1991, LANCET, V20, P337; Veinbergs I, 1999, NEUROSCI LETT, V265, P218, DOI 10.1016/S0304-3940(99)00243-8	26	20	20	0	5	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-251-7	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2000	903						357	365		10.1111/j.1749-6632.2000.tb06387.x			9	Multidisciplinary Sciences; Clinical Neurology; Peripheral Vascular Disease	Science & Technology - Other Topics; Neurosciences & Neurology; Cardiovascular System & Cardiology	BQ26Z	WOS:000087756800046	10818526				2021-06-18	
J	Goldstein, FC; Levin, HS; Goldman, WP; Kalechstein, AD; Clark, AN; Kenehan-Altonen, T				Goldstein, FC; Levin, HS; Goldman, WP; Kalechstein, AD; Clark, AN; Kenehan-Altonen, T			Cognitive and behavioral sequelae of closed head injury in older adults according to their significant others	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN INJURY; FOLLOW-UP; INITIAL FINDINGS; RELATIVES VIEW; CONSEQUENCES; RECOVERY	This study examined the neurobehavioral effects Of closed head injury (CHI) in older adults according to their significant of others. Informants of 17 mild and moderate CHI patients greater than or equal to 50 years old when injured completed the Geriatric Evaluation of Relative's Rating Instrument, a questionnaire inquiring about the patient's cognition, affect, interpersonal relations, and daily activities. The significant others provided retrospective ratings of preinjury functioning and completed the same instrument an average of 4 and 13 months post-injury. The significant others of 10 community-residing, normal control subjects completed the questionnaire at comparable intervals between each rating. Compared with their preinjury functioning, and unlike the control subjects, patients showed declines in cognition and moon. The possible impact of these changes, including their effect on subjective burden in caregivers, is discussed.	Wesley Woods Hlth Ctr, Dept Neurol, Atlanta, GA 30329 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA	Goldstein, FC (corresponding author), Wesley Woods Hlth Ctr, Dept Neurol, 1841 Clifton Rd NE, Atlanta, GA 30329 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Brooks N, 1984, CLOSED HEAD INJURY P, P123; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; GOLDSTEIN FC, 1997, J NEUROPSYCHIATRY CL, V9, P173; GOLDSTEIN FC, 1998, J INT NEUROPSYCH SOC, V4, P9; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; HOLBROOK TL, 1994, J TRAUMA, V36, P74, DOI 10.1097/00005373-199401000-00011; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1975, LANCET, V1, P480; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1987, HEAD INJURY, P1; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; MAZZUCCHI A, 1992, J NEUROL, V239, P256; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SCHWARTZ GE, 1983, PSYCHOL REP, V53, P479, DOI 10.2466/pr0.1983.53.2.479; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1991, J NEUROSURG, V75, P537; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	36	20	20	0	2	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1999	11	1					38	44		10.1176/jnp.11.1.38			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	162PC	WOS:000078354800006	9990554				2021-06-18	
J	Munte, TF; Troger, MC; Nusser, I; Wieringa, BM; Matzke, M; Johannes, S; Dengler, R				Munte, TF; Troger, MC; Nusser, I; Wieringa, BM; Matzke, M; Johannes, S; Dengler, R			Abnormalities of visual search behaviour in ALS patients detected with event-related brain potentials	AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS			English	Article						ALS; visual search; event-related potential; P3; attention	AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR NEURON DISEASE; MULTIMODALITY EVOKED-POTENTIALS; POSITRON EMISSION TOMOGRAPHY; FRONTAL-LOBE FUNCTION; CLOSED-HEAD-INJURY; SELECTIVE ATTENTION; PRESENILE-DEMENTIA; ELECTROPHYSIOLOGICAL EVIDENCE; PARALLEL	A number of recent reports have emphasized neuropyschological symptoms in ALS, including frontal functions, memory and attention. We investigated visual search behaviour of ALS in two types of tasks: a simple, relatively effortless parallel search task and a more complex attention-demanding serial search task. Behavioural parameters and cognitive event-related potentials (ERP) from 19 scalp channels were obtained from 13 ALS patients and 13 matched controls during task performance. ALS patients showed the same target detection rates as controls in the parallel task but were significantly impaired in the serial task. Performance was slower in the patients than in the controls. This slowing could be attributed to cognitive rather than motor impairments, by inspection of the latency of the P3 component, which was delayed by 120 ms in the patients. In addition, the ERPs in the serial task showed a grossly reduced P3 amplitude, indicating disturbed stimulus evaluation in the patients under these conditions. Changes of an early attention-sensitive ERP component suggest an attention deficit underlying the disturbances in search behaviour.	Hannover Med Sch, Dept Neurol, D-30693 Hannover, Germany; Otto von Guericke Univ, Dept Neuropsychol, Magdeburg, Germany	Munte, TF (corresponding author), Hannover Med Sch, Dept Neurol, D-30693 Hannover, Germany.		Munte, Thomas/C-2077-2014				ABRAHAMS S, 1995, J NEUROL SCI, V129, P44, DOI 10.1016/0022-510X(95)00060-F; Abrahams S, 1997, J NEUROL NEUROSUR PS, V62, P464, DOI 10.1136/jnnp.62.5.464; BERGEN JR, 1983, NATURE, V303, P696, DOI 10.1038/303696a0; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; CAVALLERI F, 1994, ACTA NEUROL SCAND, V89, P391; DALAKAS MC, 1987, ANN NEUROL, V22, P580, DOI 10.1002/ana.410220504; DAVID AS, 1986, PSYCHOSOMATICS, V27, P441, DOI 10.1016/S0033-3182(86)72673-X; Delay J, 1959, REV NEUROL, V100, P191; DEYMEER F, 1989, NEUROLOGY, V39, P58, DOI 10.1212/WNL.39.1.58; Frank B, 1997, CLIN NEUROL NEUROSUR, V99, P79, DOI 10.1016/S0303-8467(96)00598-7; GALLASSI R, 1985, ACTA NEUROL SCAND, V71, P480; GALLASSI R, 1989, EUR NEUROL, V29, P115, DOI 10.1159/000116391; GHEZZI A, 1989, ACTA NEUROL SCAND, V79, P353, DOI 10.1111/j.1600-0404.1989.tb03799.x; GIL R, 1995, ARCH NEUROL-CHICAGO, V52, P890, DOI 10.1001/archneur.1995.00540330068017; HATAZAWA J, 1988, J COMPUT ASSIST TOMO, V12, P630, DOI 10.1097/00004728-198807000-00019; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; HILLYARD SA, 1983, ANNU REV PSYCHOL, V34, P33, DOI 10.1146/annurev.ps.34.020183.000341; HILLYARD SA, 1984, PERCEPT PSYCHOPHYS, V36, P185, DOI 10.3758/BF03202679; HOROUPIAN DS, 1984, ANN NEUROL, V16, P305, DOI 10.1002/ana.410160306; HUDSON AJ, 1981, BRAIN, V104, P217, DOI 10.1093/brain/104.2.217; JENNINGS JR, 1976, PSYCHOPHYSIOLOGY, V13, P277; JOHANNES S, 1995, COGNITIVE BRAIN RES, V2, P189, DOI 10.1016/0926-6410(95)90008-X; Johannes S, 1997, EUR J NEUROL, V4, P152, DOI 10.1111/j.1468-1331.1997.tb00321.x; JOHNSON R, 1986, PSYCHOPHYSIOLOGY, V23, P367, DOI 10.1111/j.1469-8986.1986.tb00649.x; KEW JJM, 1993, BRAIN, V116, P1001; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; LUCK SJ, 1990, PERCEPT PSYCHOPHYS, V48, P603, DOI 10.3758/BF03211606; LUCK SJ, 1994, PSYCHOPHYSIOLOGY, V31, P291, DOI 10.1111/j.1469-8986.1994.tb02218.x; LUDOLPH AC, 1992, ACTA NEUROL SCAND, V85, P81, DOI 10.1111/j.1600-0404.1992.tb04003.x; MATHESON JK, 1986, ARCH NEUROL-CHICAGO, V43, P338, DOI 10.1001/archneur.1986.00520040026013; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; MITSUYAMA Y, 1984, J NEUROL NEUROSUR PS, V47, P953, DOI 10.1136/jnnp.47.9.953; MITSUYAMA Y, 1979, ARCH NEUROL-CHICAGO, V36, P592, DOI 10.1001/archneur.1979.00500450086021; MORITA K, 1987, ARCH GERONTOL GERIAT, V6, P263, DOI 10.1016/0167-4943(87)90026-4; Munte TF, 1998, J NEUROL, V245, P206, DOI 10.1007/s004150050206; Munte TF, 1998, ACTA NEUROL SCAND, V98, P110; MUNTE TF, 1994, ARCH NEUROL-CHICAGO, V51, P482, DOI 10.1001/archneur.1994.00540170058017; Munte TF, 1997, ARCH NEUROL-CHICAGO, V54, P1089, DOI 10.1001/archneur.1997.00550210027009; PALMA V, 1983, ELECTROMYOGR CLIN NE, V33, P167; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; RADTKE RA, 1986, NEUROLOGY, V36, P796, DOI 10.1212/WNL.36.6.796; Regan D., 1988, HDB ELECTROENCEPHALO, V3, P159; TREISMAN A, 1985, J EXP PSYCHOL GEN, V114, P285, DOI 10.1037/0096-3445.114.3.285; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; VIEREGGE P, 1994, COGNITIVE BRAIN RES, V2, P117, DOI 10.1016/0926-6410(94)90008-6; WIKSTROM J, 1982, ARCH NEUROL-CHICAGO, V39, P681, DOI 10.1001/archneur.1982.00510230007002; Ziegler LH, 1930, ARCH NEURO PSYCHIATR, V24, P930, DOI 10.1001/archneurpsyc.1930.02220170050006	49	20	20	0	1	MARTIN DUNITZ LTD	LONDON	LIVERY HOUSE, 7-9 PRATT ST, LONDON NW1 0AE, ENGLAND	1466-0822			AMYOTROPH LATERAL SC	Amyotroph. Lateral. Scler. Mot. Neuron Disord.	DEC	1999	1	1					21	27					7	Clinical Neurology	Neurosciences & Neurology	366TJ	WOS:000090020400005	12365064				2021-06-18	
J	Hemphill, JC; Gress, DR; Halbach, VV				Hemphill, JC; Gress, DR; Halbach, VV			Endovascular therapy of traumatic injuries of the intracranial cerebral arteries	CRITICAL CARE CLINICS			English	Article							INTERNAL CAROTID-ARTERY; ELECTROLYTICALLY DETACHABLE COILS; TRANSVENOUS EMBOLIZATION; CAVERNOUS FISTULAS; VASCULAR-LESIONS; SIGMOID SINUSES; ANEURYSMS; OCCLUSION; DIAGNOSIS; PSEUDOANEURYSM	Dissections, pseudoaneurysms, and fistulas may result from traumatic injuries to the intracranial arteries in the setting of closed head injury, penetrating skull trauma, or angiography. Endovascular therapy with particle or coil embolization, balloon occlusion, or stent deployment are potential treatments for this heterogeneous group of lesions. These arterial injuries usually manifest in a delayed fashion with intracranial hemorrhage, cerebral ischemia, or epistaxis. Principles of neurologic critical care that minimize secondary brain injury are essential adjuncts in patient management. This article emphasizes a coordinated approach to the endovascular treatment and neurologic critical care of these patients.	San Francisco Gen Hosp, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	Hemphill, JC (corresponding author), San Francisco Gen Hosp, Dept Neurol, Room 4M62,1001 Potrero Ave, San Francisco, CA 94110 USA.		Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525			ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; Bavinzski G, 1997, NEURORADIOLOGY, V39, P81, DOI 10.1007/s002340050371; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BERGER MS, 1984, J NEUROSURG, V61, P882, DOI 10.3171/jns.1984.61.5.0882; BRUGIERES P, 1989, J NEURORADIOLOGY, V16, P1; BULLOCK R, 1995, GUIDELINES MANAGEMEN; Chen DS, 1998, LARYNGOSCOPE, V108, P326, DOI 10.1097/00005537-199803000-00004; Cooper A, 1836, GUYS HOSP REP, V1, P53; DALISE M, 1997, CEREBROVASC DIS, P1169; DOLENC V, 1983, J NEUROSURG, V58, P824, DOI 10.3171/jns.1983.58.6.0824; DRATZ HM, 1947, J NEUROPATH EXP NEUR, V6, P286, DOI 10.1097/00005072-194707000-00009; ENDO S, 1980, CHILD BRAIN, V6, P131; FELDGES A, 1989, INTENS CARE MED, V15, P400; FELDMAN RA, 1980, NEUROSURGERY, V6, P670, DOI 10.1227/00006123-198006000-00013; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FEUERMAN TF, 1984, ARCH OTOLARYNGOL, V110, P412; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; GELBERT F, 1991, NEURORADIOLOGY, V33, P111, DOI 10.1007/BF00588245; GILLER CA, 1994, J NEUROSURG, V81, P15, DOI 10.3171/jns.1994.81.1.0015; Goto K, 1986, Acta Radiol Suppl, V369, P576; GRAVES VB, 1995, NEUROSURGERY, V37, P640, DOI 10.1227/00006123-199510000-00006; GREATZ KW, 1991, INT J ORAL MAXILLOF, V20, P280; HALBACH VV, 1987, AM J ROENTGENOL, V149, P587, DOI 10.2214/ajr.149.3.587; HALBACH VV, 1988, AM J NEURORADIOL, V9, P741; HALBACH VV, 1989, AM J NEURORADIOL, V10, P377; HALBACH VV, 1987, RADIOLOGY, V163, P437, DOI 10.1148/radiology.163.2.3562823; HALBACH VV, 1989, AM J NEURORADIOL, V10, P385; HALBACH VV, 1987, RADIOLOGY, V163, P443, DOI 10.1148/radiology.163.2.3562824; HALBACH VV, 1991, AM J NEURORADIOL, V12, P429; HAN MH, 1994, LARYNGOSCOPE, V104, P370; HIESHIMA GB, 1978, SURG NEUROL, V9, P293; Higashida R T, 1986, Acta Radiol Suppl, V369, P580; HIGASHIDA RT, 1989, AM J ROENTGENOL, V153, P577, DOI 10.2214/ajr.153.3.577; HIGASHIDA RT, 1990, J NEUROSURG, V72, P857, DOI 10.3171/jns.1990.72.6.0857; HOLMES B, 1993, J TRAUMA, V35, P855, DOI 10.1097/00005373-199312000-00009; HUND E, 1995, NEUROL CLIN, V13, P511, DOI 10.1016/S0733-8619(18)30032-X; JACKSON F, 1976, HDB CLIN NEUROLOGY, P381; JOHNSON AC, 1977, SURG NEUROL, V7, P49; JOSEPH S, 1983, ACTA NEUROL SCAND, V88, P320; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; KING MA, 1989, PEDIATRICS, V84, P128; Lempert TE, 1998, AM J NEURORADIOL, V19, P907; Lylyk P, 1986, Acta Radiol Suppl, V369, P584; Malek AM, 1998, NEUROIMAG CLIN N AM, V8, P445; MATHIS JM, 1995, AM J NEURORADIOL, V16, P749; McDougall CG, 1996, J NEUROSURG, V84, P393, DOI 10.3171/jns.1996.84.3.0393; MENDEL R, 1995, NEUROVASCULAR SURG, P1301; MOAR JJ, 1987, FORENSIC SCI INT, V34, P227, DOI 10.1016/0379-0738(87)90036-3; PATEL AN, 1971, J NEUROSURG, V35, P571, DOI 10.3171/jns.1971.35.5.0571; Polin RS, 1996, J NEUROSURG, V84, P755, DOI 10.3171/jns.1996.84.5.0755; PROLO DJ, 1971, J NEUROSURG, V35, P237, DOI 10.3171/jns.1971.35.2.0237; Quintana F, 1996, AM J NEURORADIOL, V17, P283; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; SERBINENKO FA, 1974, J NEUROSURG, V41, P125, DOI 10.3171/jns.1974.41.2.0125; SHAW CM, 1968, J NEUROSURG, V28, P475, DOI 10.3171/jns.1968.28.5.0475; STEHBENS WE, 1989, J NEUROSURG, V70, P823, DOI 10.3171/jns.1989.70.6.0823; Teitelbaum GP, 1998, NEUROSURGERY, V42, P1394, DOI 10.1097/00006123-199806000-00134; THOMPSON JR, 1973, AM J ROENTGENOL, V118, P163, DOI 10.2214/ajr.118.1.163; TSAI F, 1984, NEURORADIOLOGY HEAD, P243; VENTUREYRA ECG, 1994, CHILD NERV SYST, V10, P361, DOI 10.1007/BF00335125; YONAS H, 1980, NEUROSURGERY, V7, P499, DOI 10.1227/00006123-198011000-00016; YONAS H, 1977, SURG NEUROL, V8, P407; YOUNG WL, 1994, ANESTHESIOLOGY, V80, P427	63	20	22	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0749-0704			CRIT CARE CLIN	Crit. Care Clin.	OCT	1999	15	4					811	+		10.1016/S0749-0704(05)70089-0			21	Critical Care Medicine	General & Internal Medicine	256CU	WOS:000083709000010	10569123				2021-06-18	
J	Mechoulam, R				Mechoulam, R			Recent advances in cannabinoid research	FORSCHENDE KOMPLEMENTARMEDIZIN			English	Article						tetrahydrocannabinol (THC) arachidonylethanolamide (anandamide); 2-arachidonylglycerol (2-AG); HU-211; emesis; appetite enhancement; multiple sclerosis; spinal injury; closed head injury	RECEPTOR; BRAIN; BINDS	Although the active component of cannabis Delta(9)-THC was isolated by our group 35 years ago, until recently its mode of action remained obscure. In the last decade it was established that Delta(9)-THC acts through specific receptors - CB1 and CB2 and mimics the physiological activity of endogenous cannabinoids of two types, the best known representatives being arachidonoytethanolamide (anandamide) and 2-arachidonoylglycerol (2-AG). THC is officially used against vomiting caused by cancer chemotherapy and for enhancing appetite, particularly in AIDS patients. Illegally, usually by smoking marijuana, it is used for ameliorating the symptoms of multiple sclerosis, against pain, and in a variety of other diseases. A synthetic cannabinoid, HU-211, is in advanced clinical tests against brain damage caused by closed head injury. It may prove to be valuable against stroke and other neurological diseases.	Hebrew Univ Jerusalem, Fac Med, IL-91120 Jerusalem, Israel	Mechoulam, R (corresponding author), Hebrew Univ Jerusalem, Fac Med, IL-91120 Jerusalem, Israel.						ABRAHAMOV A, 1995, LIFE SCI, V56, P2097, DOI 10.1016/0024-3205(95)00194-B; Consroe P, 1997, EUR NEUROL, V38, P44, DOI 10.1159/000112901; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 1998, PROGR MED CHEM, V35, P199, DOI 10.1016/S0079-6468(08)70037-7; Mechoulam R, 1998, EUR J PHARMACOL, V362, pR1, DOI 10.1016/S0014-2999(98)00777-8; MECHOULAM R, 1994, CNS DRUGS, V2, P255, DOI 10.2165/00023210-199402040-00001; Mechoulam R, 1987, Prog Med Chem, V24, P159, DOI 10.1016/S0079-6468(08)70422-3; MECHOULAM R, 1973, CHEM PHARM METABOLIS; MECHOULAM R, 1992, MARIJUANA CANNABINOI, P1; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; PLASSE TF, 1991, PHARMACOL BIOCHEM BE, V40, P695, DOI 10.1016/0091-3057(91)90385-F; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Varga K, 1998, FASEB J, V12, P1035	17	20	20	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7096			FORSCH KOMPLEMENTMED	Forsch. Komplement.med.	OCT	1999	6			3			16	20		10.1159/000057151			5	Integrative & Complementary Medicine	Integrative & Complementary Medicine	262EW	WOS:000084053500004	10575284				2021-06-18	
J	Klein, BY; Shohami, E; Reikhinshtein, Y; Ben-Bassat, H; Liebergall, M				Klein, BY; Shohami, E; Reikhinshtein, Y; Ben-Bassat, H; Liebergall, M			Serum-mediated osteogenic effects of head injury on cultured rat marrow stromal cells	CALCIFIED TISSUE INTERNATIONAL			English	Article						osteoprogenitors; closed head injury; marrow-stroma; alkaline phosphatase; mineralization; cell proliferation	BONE-FORMATION; MINERALIZATION; COMMITMENT; FRACTURE; INVITRO; TISSUE	Central nervous system (CNS) injuries in humans are frequently associated with heterotopic ossification (HO) and with enhanced fracture healing. In search for an experimental HO model we tested sera, from an established rat model of closed head injury (CHI), for their osteogenic effects on rat marrow stromal cells. Most normal pat sera increased cell proliferation not discriminating between osteoprogenitors and other stromal cells. Rats followed longitudinally by sequential blood sampling were bled 24 hours before and 24 hours, 48 hours, and 7 days after CHI. Sera obtained 24 and 48 hours after CHI progressively decreased cell proliferation and specific alkaline phosphatase (ALP) activity compared with pre-CHI sera of the same rats. Sera obtained from these rats, 7 days post-CHI, partially recovered proliferation induction, more than recovering induction of specific ALP activity. A positive correlation between day 11 ALP activity and day 21 mineralization was found under stimulation by pre-CHI sera. However, no correlation was found on stimulation with sera obtained 48 hours after CHI. Correlation between ALP and mineralization partially recovered in cultures exposed to sera obtained 7 days after CHI. In cross-sectional experiments where rats were subjected to single blood sampling, sera of 24 hours and 7 days post-CHI induced proliferation, whereas sera of 48 hours and 14 days post-CHI did not. The results indicate that 48 hours post-CHI, the mitogenicity of sera decreased in both cross-sectional and longitudinal blood sampling. In addition, 48 hours post-CHI, the specific ALP activity increases in cultured marrow stromal cells. Thus, changes in bone-seeking factors, causing serum-mediated osteogenic activity in rats, are expected close on 48 hour post-CNS injury.	Hadassah Med Ctr, Expt Surg Lab, IL-91120 Jerusalem, Israel; Hadassah Med Ctr, Dept Orthoped, IL-91120 Jerusalem, Israel; Hadassah Med Ctr, Dept Anesthesiol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Klein, BY (corresponding author), Hadassah Med Ctr, Expt Surg Lab, Ein Kerem POB 12000, IL-91120 Jerusalem, Israel.						Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; DEJERINE A, 1991, CLIN ORTHOP RELAT R, P3; Garland D E, 1992, J Bone Joint Surg Am, V74, P152; GARLAND DE, 1980, CLIN ORTHOP RELAT R, P198; JABER S, 1995, BONE, V16, P81; KLEIN BY, 1995, J CELL BIOCHEM, V57, P530, DOI 10.1002/jcb.240570318; KLEIN BY, 1993, J CELL BIOCHEM, V53, P114, DOI 10.1002/jcb.240530204; KLEIN BY, 1993, J CELL BIOCHEM, V51, P190, DOI 10.1002/jcb.240510211; KLEIN BY, 1994, J CELL BIOCHEM, V54, P354, DOI 10.1002/jcb.240540311; Klein BY, 1997, J CELL BIOCHEM, V65, P420; Klein BY, 1996, J CELL BIOCHEM, V63, P115; KLEIN BY, 1994, CELL MATER, V4, P73; MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317; MOHAN S, 1991, CLIN ORTHOP RELAT R, P30; ORZEL JA, 1985, J NUCL MED, V26, P125; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; POKWINSE SM, 1992, J CELL BIOCHEM, V49, P310; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; RODAN SB, 1987, CANCER RES, V47, P4961; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; STEIN GS, 1990, FASEB J, V4, P3111	26	20	22	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0171-967X			CALCIFIED TISSUE INT	Calcif. Tissue Int.	SEP	1999	65	3					217	222		10.1007/s002239900686			6	Endocrinology & Metabolism	Endocrinology & Metabolism	224GJ	WOS:000081889400008	10441654				2021-06-18	
J	Ippolito, E; Formisano, R; Caterini, R; Farsetti, P; Penta, F				Ippolito, E; Formisano, R; Caterini, R; Farsetti, P; Penta, F			Resection of elbow ossification and continuous passive motion in postcomatose patients	JOURNAL OF HAND SURGERY-AMERICAN VOLUME			English	Article						heterotopic ossification; surgical treatment; coma; elbow; continuous passive motion	HETEROTOPIC OSSIFICATION	Heterotopic periarticular ossifications were surgically excised in 16 elbows of 14 traumatic brain injury patients an average of 18.9 months (range, 4-67 months) after the end of coma. In 11 elbows the ulnohumeral joint was ankylosed in a position that ranged from 0 degrees to 100 degrees of flexion (group 1); in 5 elbows the arc of flexion ranged from 10 degrees to 25 degrees (group 2). Full pronation and supination were present in 15 of the elbows; in 1 the radiocapitellar joint was fixed at 30 degrees of pronation by a partial ossification of the interosseous membrane. The are of flexion attained after surgery averaged 115 degrees (range, 90 degrees to 145 degrees) in the group 1 elbows and 128 degrees (range, 115 degrees to 140 degrees) in the group 2 elbows. In an attempt to prevent postoperative loss of motion and recurrence of ossification, continuous passive motion was applied to the affected elbow for 6 weeks before starting a fully active rehabilitation program. All the patients were examined at regular intervals after the surgery. The follow-up period ranged from 12 to 60 months (average, 30.7 months). During the follow-up period, all the elbows showed improvement in range of motion and the are of flexion averaged 95 degrees (range, 30 degrees to 135 degrees) in the group 1 elbows and 116 degrees (range, 80 degrees to 145 degrees) in the group 2 elbows. Patients with poor neuromuscular control lost part of their postoperative range of motion and partial recurrence was observed in 3 elbows. We believe that our improved results, compared with those obtained by previous investigators, may have been due to the prolonged application of continuous passive motion after surgery. Copyright (C) 1999 by the American Society for Surgery of the Hand.	Univ Roma Tor Vergata, Dept Orthoped Surg, Rome, Italy	Ippolito, E (corresponding author), Via Cattaro 28, I-00198 Rome, Italy.						GACON G, 1978, REV CHIR ORTHOP, V64, P375; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GATES HS, 1992, J BONE JOINT SURG AM, V74A, P1229, DOI 10.2106/00004623-199274080-00013; McAuliffe JA, 1997, J BONE JOINT SURG AM, V79A, P749, DOI 10.2106/00004623-199705000-00015; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; ROBERTS JB, 1979, J BONE JOINT SURG AM, V61, P760, DOI 10.2106/00004623-197961050-00018; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120; VASEN AP, 1995, J HAND SURG A, V20, P289	10	20	20	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0363-5023			J HAND SURG-AM	J. Hand Surg.-Am. Vol.	MAY	1999	24A	3					546	553					8	Orthopedics; Surgery	Orthopedics; Surgery	197AU	WOS:000080343100016	10357534				2021-06-18	
J	Sasaki, S; Iwata, M				Sasaki, S; Iwata, M			Immunoreactivity of beta-amyloid precursor protein in amyotrophic lateral sclerosis	ACTA NEUROPATHOLOGICA			English	Article						amyotrophic lateral sclerosis; beta-amyloid precursor protein; immunohistochemistry; fast axonal transport; anterior horn neuron	TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; AXONAL DAMAGE; CORTICAL-NEURONS; GOLGI-APPARATUS; SECRETED FORMS; MOTOR-NEURONS; SPINAL-CORD; RAT; CYTOSKELETON	We investigated the localization and extent of beta-amyloid precursor protein (beta-APP(695)) immunoreactivity as a sensitive marker for impairment of fast axonal transport in the spinal cords of 21 patients with amyotrophic lateral sclerosis (ALS), paying special attention to anterior horn neurons. Specimens from 18 patients without neurological disease served as controls. Increased beta-APP immunoreactivity was frequently recognized in the anterior hems of the ALS patients with short clinical courses or with mild depletion of anterior horn cells, while no beta-APP immunoreactivity was demonstrated in those with severe depletion of anterior horn neurons or with long-standing clinical courses. Increased beta-APP immunoreactivity in the anterior horn neurons was mainly confined to the perikarya and no immunoreactivity was recognized in the dendrites or proximal axons directly emanating from the somata, except some spheroids (proximal axonal swellings) which showed increased immunoreactivity of beta-APP. Increased beta-APP immunoreactivity was spotted or focally aggregated in the perikarya of normal-looking large anterior horn neurons, while it was frequently diffuse in that of degenerative neurons such as central chromatolytic cells and or those with simple atrophy. On the other hand, the controls showed no immunostaining with beta-APP in the spinal cord. These findings suggest that increased immunoreactivity of beta-APP in neuronal perikarya of the anterior horn cells and in some proximal axonal swellings is an early change of ALS, and may be a response of the increased synthesis of beta-APP resulting from neuronal damage, or the impairment of fast axonal transport.	Tokyo Womens Med Coll, Neurol Inst, Dept Neurol, Shinjuku Ku, Tokyo 162, Japan	Sasaki, S (corresponding author), Tokyo Womens Med Coll, Neurol Inst, Dept Neurol, Shinjuku Ku, 8-1 Kawadacho, Tokyo 162, Japan.						ALLINQUANT B, 1994, J NEUROSCI, V14, P6842; AMARATUNGA A, 1995, J NEUROCHEM, V64, P2374; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Giometto B, 1997, ANN NEUROL, V42, P34, DOI 10.1002/ana.410420108; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GONATAS NK, 1992, AM J PATHOL, V140, P731; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472; MURAKAMI S, 1995, NEUROPATHOLOGY, V15, P289; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Pierce JES, 1996, J NEUROSCI, V16, P1083; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; REFOLO LM, 1991, J NEUROSCI, V11, P3888; ROBERTS GW, 1992, LANCET, V338, P131; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; SASAKI S, 1992, ACTA NEUROPATHOL, V83, P598, DOI 10.1007/BF00299408; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; SUENAGA T, 1994, ACTA NEUROPATHOL, V87, P450; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95	34	20	20	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	MAY	1999	97	5					463	468		10.1007/s004010051015			6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	189TU	WOS:000079922900005	10334483				2021-06-18	
J	Seif-Naraghi, AH; Herman, RM				Seif-Naraghi, AH; Herman, RM			A novel method for locomotion training	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						body weight support; central pattern generator; cerebral palsy; cerebrovascular accident; gait training; partial weight bearing; sensory stimulation; spinal cord injury; traumatic brain injury; treadmill training	SPINAL-CORD INJURY; BODY-WEIGHT SUPPORT; RECOVERY; REFLEXES; CATS; GAIT; CYPROHEPTADINE; MICTURITION; MODULATION; GENERATOR	This article describes a novel therapeutic system for locomotion training and learning for patients with a wide range of neurological and musculoskeletal disorders. The technique embraces che notion that loco motion therapy should be goal oriented and task specific. The task specificity Includes a partial weightbearing device that permits the posture/equilibrium, movement, and weight-bearing components of gait function to operate concurrently, even in patients with serious deficits. In addition, it allows interaction with therapists and others to facilitate locomotion control, particularly during the early stages of gait therapy. Neurobiological bases for this technique and early clinical results are discussed, and two case studies of patients with traumatic brain injury (TBI) are presented. Although well-designed efficacy studies are needed, clearly this therapeutic approach to locomotor disorders among TBI patients meets the various criteria for recovery of gait function established in this article.	Mobil Res LLC, Tempe, AZ 85281 USA; Arizona State Univ, Chem Biol & Mat Engn Dept, Tempe, AZ USA; Arizona State Univ, Dept Pharmacol, Tempe, AZ USA	Seif-Naraghi, AH (corresponding author), Mobil Res LLC, 2209 W 1st St,105, Tempe, AZ 85281 USA.						BAJD T, 1994, GAIT POSTURE, V2, P5, DOI 10.1016/0966-6362(94)90011-6; BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; BARBEAU H, 1994, CURR OPIN NEUROL, V7, P517, DOI 10.1097/00019052-199412000-00008; BUSSEL B, 1989, BRAIN RES B, V58, P1168; CALANCIE B, 1994, BRAIN, V117, P1143, DOI 10.1093/brain/117.5.1143; Chau C, 1998, J NEUROPHYSIOL, V79, P2941; DIETZ V, 1995, ANN NEUROL, V37, P574, DOI 10.1002/ana.410370506; Dobkin BH, 1996, NEUROLOGIST, V2, P239; Dobkin BH, 1995, J NEUROL REHABIL, V9, P183; FINCH L, 1986, Physiotherapy Canada, V38, P36; FUNG J, 1990, J NEUROL SCI, V100, P85, DOI 10.1016/0022-510X(90)90017-H; Grillner S, 1998, BRAIN RES REV, V26, P184, DOI 10.1016/S0165-0173(98)00002-2; HERMAN R, 1985, SPINE, V10, P1, DOI 10.1097/00007632-198501000-00001; HERMAN R, 1973, CONTROL POSTURE LOCO; HERMAN RM, 1991, ARCH PHYS MED REHAB, V72, P539; HERMAN RM, 1988, ANESTHESIOLOGY, V69, P313, DOI 10.1097/00000542-198809000-00005; HERMAN RM, 1970, SPINAL CORD DYSFUNCT; HERMAN RM, 1988, SOC NEUR ABSTR, V14, P1302; HERMAN RM, 1991, RESTORATIVE NEUROLOG, P5; HERMAN RM, 1986, NEUROBIOLOGY VERTEBR; HESSE S, 1994, ARCH PHYS MED REHAB, V75, P1087, DOI 10.1016/0003-9993(94)90083-3; IWAHARA T, 1991, BRAIN RES B, V28, P99; Kojima N, 1998, EXP BRAIN RES, V120, P139, DOI 10.1007/s002210050387; LOVELY RG, 1990, BRAIN RES, V514, P206, DOI 10.1016/0006-8993(90)91417-F; LOVELY RG, 1986, EXP NEUROL, V92, P421, DOI 10.1016/0014-4886(86)90094-4; MANN R, 1979, J BONE JOINT SURG, V2, P232; MASSION J, 1988, NEWS PHYSIOL SCI, V3, P88; Menier, 1997, PEDIAT PHYS THER, V9, P158, DOI DOI 10.1097/00001577-199700940-00002; NASHNER LM, 1976, EXP BRAIN RES, V26, P59; Nicol DJ, 1998, MED ENG PHYS, V20, P182, DOI 10.1016/S1350-4533(98)00012-5; PEARSON KG, 1992, J NEUROSCI METH, V42, P75, DOI 10.1016/0165-0270(92)90137-3; PRINCE F, 1994, GAIT POSTURE, V2, P19, DOI 10.1016/0966-6362(94)90013-2; Rossignol S, 1993, J Am Paraplegia Soc, V16, P190; THOR KB, 1983, J UROLOGY, V129, P202, DOI 10.1016/S0022-5347(17)51984-9; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; WAINBERG M, 1990, J NEUROL NEUROSUR PS, V53, P754, DOI 10.1136/jnnp.53.9.754; WERNIG A, 1991, RESTORATIVE NEUROLOG, P5; YANG YF, 1998, J PHYSL, V507, P927	38	20	20	1	8	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1999	14	2					146	162		10.1097/00001199-199904000-00005			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	187DN	WOS:000079771800005	10191373				2021-06-18	
J	Di, X; Gordon, J; Bullock, R				Di, X; Gordon, J; Bullock, R			Fluid percussion brain injury exacerbates glutamate-induced focal damage in the rat	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; glutamate; fluid percussion; excitotoxicity	EXCITATORY AMINO-ACIDS; EXTRACELLULAR GLUTAMATE; BLOOD-FLOW; CELL-DEATH; RELEASE; REDUCTION; ISCHEMIA	The role of glutamate-mediated neuronal damage in neurotrauma remains controversial. The cerebral levels measured in patients by microdialysis are sufficient to kill neurons in culture, but not in the intact brain of the normal rat. A synergistic effect between excitatory amino acid-mediated damage and other posttrauma mechanisms must therefore be proposed, if glutamate is indeed a significant cause of posttraumatic brain damage. The presence of such a synergistic mechanism was therefore investigated by combining in vivo glutamate perfusion and fluid percussion injury (FPI). Twenty-four adult male Sprague Dawley rats were randomly assigned to three groups: (1) vehicle (n = 9): mock cerebrospinal fluid (CSF) perfusion plus FPI; (2) glutamate + FPI (n = 9): 0.1 M glutamate intracortical perfusion plus FPI; and (3) glutamate without FPI (n = 6), After preparation for central FPI, at a moderate level of injury (2 +/- 0.5 atm), glutamate or mock CSF perfusion was performed via a CMA/12 microdialysis probe (3 mm), Animals were then perfusion fixed, under deep anesthesia, after 3-h survival, for volumetric histopathology, The glutamate perfusion + FPI group (2.42 +/- 1.63 mm(3)) produced a significantly bigger lesion than mock CSF perfusion + FPI (0.063 +/- 0.41 mm(3)) and glutamate perfusion alone (1.00 +/- 0.47 mm(3)). Traumatic brain injury thus seems to enhance glutamate-mediated brain damage, and this may be due to qualitative changes induced in ion channels and receptors, such as the N-methyl-D-aspartate channel, after shear injury.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Box 980631,MCV Stn, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; BULLOCK R, 1993, GLUTAMATE TRANSMITTE, P113; CHOI DW, 1994, PROG BRAIN RES, V100, P47; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CHOI DW, 1991, EXCITATORY AMINO ACI, P216; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FUJISAWA H, 1993, J CEREB BLOOD FLO S1, V13, pS784; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; Huang R, 1997, NEUROSCI BIOBEHAV R, V21, P129, DOI 10.1016/S0149-7634(96)00002-4; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Landolt H, 1998, J CLIN NEUROSCI, V5, P193, DOI 10.1016/S0967-5868(98)90037-6; LANDOLT H, 1993, J CEREB BLOOD FLO S1, V13, pS644; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	17	20	20	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1999	16	3					195	201		10.1089/neu.1999.16.195			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	178QQ	WOS:000079277800001	10195467				2021-06-18	
J	Geisler, MW; Schlotfeldt, CR; Middleton, CB; Dulay, MF; Murphy, C				Geisler, MW; Schlotfeldt, CR; Middleton, CB; Dulay, MF; Murphy, C			Traumatic brain injury assessed with olfactory event-related brain potentials	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						head trauma; olfactory; trigeminal; olfactory event-related potential (OERP)	CLOSED-HEAD-INJURY; CHEMOSENSORY EVOKED-POTENTIALS; CONTINGENT NEGATIVE-VARIATION; INDIVIDUAL-DIFFERENCES; CHEMICAL-STIMULATION; ODOR IDENTIFICATION; ALZHEIMERS-DISEASE; NASAL-MUCOSA; P300; AGE	Olfactory event-related potentials (OERPs) were evaluated to develop an objective, quantitative assessment of sensory and cognitive olfactory loss following traumatic brain injury (TBI). Subjects included 25 TBI patients and 25 age/gender-matched healthy controls. Following standard clinical evaluation of smell function, TBI patients were divided into three groups: 12 anosmics (loss of smell), 6 hyposmics (reduced smell), and 7 normosmics (normal smell). Cognitive ability was assessed using the Trail Making Test (A and B). OERPs were recorded monopolarly from midline electrode sites using an amyl acetate stimulus with a 60-second interstimulus interval; subjects estimated the magnitude of each odor stimulus. Anosmic TBI patients were also tested with OERPs using ammonia to ensure trigeminal nerve function. Amyl acetate OERPs demonstrated that the sensory N1 and P2 amplitudes and the cognitive P3 amplitudes were absent in the anosmic TBI patients and greatly reduced in the hyposmic and normosmic TBI patients compared to healthy controls. The trigeminal OERPs from the anosmic TBI patients were within normal limits, indicating that the primary olfactory deficits were objectively measured with OERPs. The relationship between the OERPs and neuropsychologic test performance supports the cognitive loss associated with TBI. The present study lends support to the utility of OERPs as an objective tool for measuring sensory and cognitive loss after traumatic brain injury.	San Diego State Univ, Dept Psychol, San Diego, CA 92120 USA; Univ Calif San Diego, Ctr Med, San Diego, CA 92103 USA	Murphy, C (corresponding author), San Diego State Univ, Dept Psychol, 6363 Alvarado Ct,Suite 101, San Diego, CA 92120 USA.				NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC00032, DC02064] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [T32DC000032, R01DC002064] Funding Source: NIH RePORTER		Army Individual Test Battery, 1944, MAN DIR SCOR; AUFFERMANN H, 1993, ANN OTO RHINOL LARYN, V102, P6, DOI 10.1177/000348949310200102; BICKERSTAFF ER, 1973, NEUROLOGICAL EXAMINA, P33; CAIN WS, 1988, LARYNGOSCOPE, V98, P83; COMETTOMUNIZ JE, 1991, PHARMACOL BIOCHEM BE, V39, P983, DOI 10.1016/0091-3057(91)90063-8; Costanzo RM, 1986, CLIN MEASUREMENTS TA, P565; Costanzo RM, 1991, SMELL TASTE HLTH DIS, P711; COSTANZO RM, 1987, NY ACAD SCI, V510, P242; Costanzo RM, 1992, J HEAD TRAUMA REHAB, V7, P15, DOI DOI 10.1097/00001199-199203000-00005; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; Cui LY, 1997, ELECTROEN CLIN NEURO, V102, P303, DOI 10.1016/S0013-4694(96)96109-X; DAVIDSON TM, 1995, POSTGRAD MED, V98, P107; Davidson TM, 1997, ARCH OTOLARYNGOL, V123, P591; DAVIDSON TM, 1987, WESTERN J MED, V146, P434; Donchin E, 1986, PSYCHOPHYSIOLOGY SYS, P244; DONCHIN E, 1988, BEHAV BRAIN SCI, V59, P238; Doty R. L., 1992, J HEAD TRAUMA, V7, P47; DOTY RL, 1975, PHYSIOL BEHAV, V14, P855, DOI 10.1016/0031-9384(75)90081-5; DOTY RL, 1989, ANN NY ACAD SCI, V561, P76, DOI 10.1111/j.1749-6632.1989.tb20971.x; DOTY RL, 1984, SCIENCE, V226, P1441, DOI 10.1126/science.6505700; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; DOTY RL, PHYSL BEHAV, V20, P175; ESON ME, 1978, J NEUROL NEUROSUR PS, V41, P1036, DOI 10.1136/jnnp.41.11.1036; Etcoff LM, 1996, NEUROPSYCHOL REV, V6, P171, DOI 10.1007/BF01874896; EVANS WJ, 1995, ELECTROEN CLIN NEURO, V95, P293; EVANS WJ, 1993, CHEM SENSES, V18, P751, DOI 10.1093/chemse/18.6.751; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; GEISLER MW, 1990, BIOL PSYCHOL, V31, P117, DOI 10.1016/0301-0511(90)90012-L; Geisler MW, 1996, J NEUROL REHABIL, V10, P17; GEISLER MW, 1992, PSYCHOPHYSIOLOGY, V29, P76, DOI 10.1111/j.1469-8986.1992.tb02017.x; GEISLER MW, 1992, PSYCHOPHYSIOLOGY, V29, P86, DOI 10.1111/j.1469-8986.1992.tb02019.x; GEISLER MW, IN PRESS J CLIN EXP; GORKE W, 1991, BRAIN DYSFUNCT, V4, P147; Haines ME, 1995, NEUROPSYCHOL REV, V5, P125, DOI 10.1007/BF02208438; Halstead WC, 1947, BRAIN INTELLIGENCE; JAFEK BW, 1989, ARCH NEUROL-CHICAGO, V46, P300, DOI 10.1001/archneur.1989.00520390066018; KOBAL G, 1985, PAIN, V22, P151, DOI 10.1016/0304-3959(85)90175-7; KOBAL G, 1992, CHEM SENSES, V17, P233, DOI 10.1093/chemse/17.3.233; KOBAL G, 1988, ELECTROEN CLIN NEURO, V71, P241, DOI 10.1016/0168-5597(88)90023-8; Kobal G, 1981, ELEKTROPHYSIOLOGISCH; KOBAL G, 1989, CHEM SENSES, V2, P123; Kobal G, 1991, SMELL TASTE HLTH DIS, P255; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LORIG TS, 1995, PSYCHOPHYSIOLOGY, V32, P393, DOI 10.1111/j.1469-8986.1995.tb01222.x; Lorig TS, 1996, INT J PSYCHOPHYSIOL, V23, P199, DOI 10.1016/S0167-8760(96)00061-X; Morgan CD, 1997, EVOKED POTENTIAL, V104, P351, DOI 10.1016/S0168-5597(97)00020-8; MORGAN CD, 1995, J CLIN EXP NEUROPSYC, V17, P793, DOI 10.1080/01688639508405168; MORGAN CD, IN PRESS PSYCHOPHYSI; MUNTE TF, 1994, ARCH NEUROL-CHICAGO, V51, P482, DOI 10.1001/archneur.1994.00540170058017; MURPHY C, 1994, CHEM SENSES, V19, P47, DOI 10.1093/chemse/19.1.47; MURPHY C, 1990, NEUROBIOL AGING, V11, P465, DOI 10.1016/0197-4580(90)90014-Q; MURPHY C, 1986, PHYSIOL BEHAV, V37, P177, DOI 10.1016/0031-9384(86)90402-6; MURPHY C, 1992, J HEAD TRAUMA REHAB, V7, P76; MURPHY C, 1994, OLFACTION TASTE, V11, P609; NATIV A, 1994, ARCH PHYS MED REHAB, V75, P1322; ODONNELL BF, 1992, INT J PSYCHOPHYSIOL, V12, P187, DOI 10.1016/0167-8760(92)90010-9; ODONNELL BF, 1987, BIOL PSYCHOL, V24, P23, DOI 10.1016/0301-0511(87)90097-4; ODONNELL BF, 1990, NEUROPSY NEUROPSY BE, V3, P164; Parker RS, 1996, NEUROPSYCHOL REV, V6, P135, DOI 10.1007/BF01874895; Pause BM, 1996, PSYCHOPHYSIOLOGY, V33, P376, DOI 10.1111/j.1469-8986.1996.tb01062.x; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Polich J, 1998, J CLIN NEUROPHYSIOL, V15, P14, DOI 10.1097/00004691-199801000-00004; POLICH J, 1994, ELECTROEN CLIN NEURO, V92, P253, DOI 10.1016/0168-5597(94)90068-X; POLICH J, 1985, J GERONTOL, V40, P721, DOI 10.1093/geronj/40.6.721; PONTIUS AA, 1980, J NERV MENT DIS, V168, P111, DOI 10.1097/00005053-198002000-00008; Rauh C, 1967, HNO, V15, P271; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; REITEN RM, 1974, CLIN NEUROPSYCHOLOGY; ROSENFELD JP, 1995, INT J PSYCHOPHYSIOL, V19, P1, DOI 10.1016/0167-8760(94)00057-L; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUTHERFORD WH, 1977, LANCET, V1, P1; SOUSTIEL JF, 1995, BRAIN INJURY, V9, P805, DOI 10.3109/02699059509008236; Sumner D, 1975, HDB CLIN NEUROLOGY, P1; Trueblood W, 1997, ARCH CLIN NEUROPSYCH, V12, P13, DOI 10.1016/S0887-6177(96)00027-3	77	20	22	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0736-0258	1537-1603		J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	JAN	1999	16	1					77	86		10.1097/00004691-199901000-00008			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	176TW	WOS:000079168700008	10082095				2021-06-18	
J	Uchiyama, H; Nishizawa, S; Satoh, A; Yokoyama, T; Uemura, K				Uchiyama, H; Nishizawa, S; Satoh, A; Yokoyama, T; Uemura, K			Post-traumatic pituitary apoplexy - Two case reports	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						head injury; pituitary apoplexy; pituitary tumor; transsphenoidal surgery		A 60-year-old Female and a 66-year-old male presented with post-traumatic pituitary apoplexy associated with clinically asymptomatic pituitary macroadenoma manifesting as severe visual disturbance that had not developed immediately after the head injury. Skull radiography showed a unilateral linear occipital fracture. Magnetic resonance imaging revealed pituitary tumor with dumbbell-shaped suprasellar extension and fresh intratumoral hemorrhage. Transsphenoidal surgery was performed in the first patient, and the visual disturbance subsided. Decompressive craniectomy was performed in the second patient to treat brain contusion and part of the tumor was removed to decompress the optic nerves. The mechanism of post-traumatic pituitary apoplexy may occur as follows. The intrasellar part of the tumor ir; fixed by the bony structure forming the sella, and the suprasellar part is free to move, so a rotational force acting on the occipital region on one side will create a shearing strain between the intra- and suprasellar part of the tumor, resulting in pituitary apoplexy. Recovery of visual function, no matter how severely impaired, can be expected if an emergency operation is performed to decompress the optic: nerves. Transsphenoidal surgery is the most advantageous procedure, as even partial removal of the tumor may be adequate to decompress the optic nerves in the acute stage. Staged transsphenoidal surgery is indicated to achieve total removal later.	Hamamatsu Univ Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Red Cross Hosp, Dept Neurosurg, Hamamatsu, Shizuoka, Japan	Nishizawa, S (corresponding author), Hamamatsu Univ Sch Med, Dept Neurosurg, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.						BROUGHAM M, 1950, J NEUROSURG, V7, P421, DOI 10.3171/jns.1950.7.5.0421; CARDOSO ER, 1984, NEUROSURGERY, V14, P363, DOI 10.1227/00006123-198403000-00021; JOLLEY GL, 1958, J MED ASS GA, V47, P75; Nishizawa S, 1998, NEUROL MED-CHIR, V38, P213, DOI 10.2176/nmc.38.213; OKUDA O, 1994, SURG NEUROL, V42, P19, DOI 10.1016/0090-3019(94)90244-5; Perpetuo F O, 1976, Arq Neuropsiquiatr, V34, P298; REICHENTHAL E, 1980, ACTA NEUROCHIR, V54, P251, DOI 10.1007/BF01407092; SACHDEV Y, 1976, BRIT MED J, V1, P942, DOI 10.1136/bmj.1.6015.942; VanWagenen WP, 1932, ANN SURG, V95, P625; WAKAI S, 1981, J NEUROSURG, V55, P187, DOI 10.3171/jns.1981.55.2.0187; WEISBERG LA, 1977, AM J MED, V63, P109, DOI 10.1016/0002-9343(77)90122-X; WRIGHT RL, 1965, ARCH NEUROL-CHICAGO, V12, P326, DOI 10.1001/archneur.1965.00460270102013	12	20	20	0	4	JAPAN NEUROSURGICAL SOC	TOKYO	7-3-1 HONGO BUNKYO-KU, TOKYO, 113-8655, JAPAN	0470-8105			NEUROL MED-CHIR	Neurol. Med.-Chir.	JAN	1999	39	1					36	39		10.2176/nmc.39.36			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	168XM	WOS:000078718500015	10093459	Bronze			2021-06-18	
J	Piek, J				Piek, J		Working Grp Neurosurgical Intensive Care Europe	Guidelines for the pre-hospital care of patients with severe head injuries	INTENSIVE CARE MEDICINE			English	Article							CEREBRAL PERFUSION-PRESSURE; HYPERTONIC SALINE; HEMORRHAGIC-SHOCK; INTRACRANIAL HYPERTENSION; BRAIN INJURY; MILD HYPOTHERMIA; CLINICAL-TRIAL; TRAUMATIC COMA; BLOOD-FLOW; RESUSCITATION		European Soc Intens Care Med, B-1070 Brussels, Belgium	Piek, J (corresponding author), European Soc Intens Care Med, Av J Wybran 40, B-1070 Brussels, Belgium.	esicm@pophost.eunet.be					BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BERGER S, 1994, ACT NEUR S, V60, P494; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHESNUT RM, 1993, HEAD INJURY, P225; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COTTRELL JE, 1977, ANESTHESIOLOGY, V47, P28, DOI 10.1097/00000542-197707000-00006; DeWitt DS, 1996, CRIT CARE MED, V24, P109, DOI 10.1097/00003246-199601000-00019; DUHAIME AC, NEUROTRAUMA, P365; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; GAAB MR, 1989, NEUROCHIRURGIA, V32, P93; GAAB MR, 1995, ZBL NEUROCHIR, V55, P135; GENTLEMAN D, 1986, BRIT MED J, V292, P449, DOI 10.1136/bmj.292.6518.449; GENTLEMAN D, 1992, INT SURG, V77, P297; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HARTL R, 1995, SHOCK, V3, P274; HILLS MW, 1993, J TRAUMA, V34, P549, DOI 10.1097/00005373-199304000-00011; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; JENNETT B, 1978, INJURY, V10, P31; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; MACIVER IN, 1958, LANCET, V1, P390; MANINGAS PA, 1989, AM J SURG, V157, P528, DOI 10.1016/0002-9610(89)90654-5; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MCQUEEN JD, 1964, J NEUROSURG, V21, P118, DOI 10.3171/jns.1964.21.2.0118; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1975, J NEUROSURG, V42, P274, DOI 10.3171/jns.1975.42.3.0274; MILLER JD, 1978, JAMA-J AM MED ASSOC, V4, P439; MOSKOPP D, 1990, UNFALLCHIRURG, V93, P120; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; NEWFIELD P, 1980, CRIT CARE MED, V8, P254, DOI 10.1097/00003246-198004000-00123; PAGNI CA, 1991, ACTA NEUROCHIR, V111, P1, DOI 10.1007/BF01402506; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PIEK J, 1993, ADV NEUROS, V21, P192; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; ROCHAESILVA M, 1986, CIRC SHOCK, V19, P165; ROSE J, 1977, BRIT MED J, V21, P615; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; Sheikh AA, 1996, CRIT CARE MED, V24, P1226, DOI 10.1097/00003246-199607000-00027; SHENKIN HA, 1962, J NEUROSURG, V19, P897, DOI 10.3171/jns.1962.19.10.0897; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SINGBARTL G, 1985, ANASTH INTENSIV NOTF, V20, P251, DOI 10.1055/s-2007-1003119; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; VALESCO IT, 1980, AM J PHYSIOL, V239, pH664; VAN WAGONER F H, 1961, J Trauma, V1, P401; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WAHJOEPRAMONO EJ, 1993, ADV NEUROS, V21, P184; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	67	20	20	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	NOV	1998	24	11					1221	1225		10.1007/s001340050748			5	Critical Care Medicine	General & Internal Medicine	144XU	WOS:000077341700017	9876987				2021-06-18	
J	Golding, EM; Steenberg, ML; Cherian, L; Marrelli, SP; Robertson, CS; Bryan, RM				Golding, EM; Steenberg, ML; Cherian, L; Marrelli, SP; Robertson, CS; Bryan, RM			Endothelial-mediated dilations following severe controlled cortical impact injury in the rat middle cerebral artery	JOURNAL OF NEUROTRAUMA			English	Article						endothelium; middle cerebral artery; nitric oxide; purinoceptors; traumatic brain injury; vascular smooth muscle	TRAUMATIC BRAIN INJURY; NITRIC-OXIDE; DEPENDENT RELAXATION; STIMULATED ACTIVITY; ACUTE HYPERTENSION; BASILAR ARTERY; L-ARGININE; BASAL; AORTA; CATS	The mechanisms associated with dysfunction of the cerebral vasculature following head trauma have not yet been fully elucidated. In an attempt to shed more light on the matter, we investigated the endothelial-mediated dilations in the rat middle cerebral artery (MCA) following severe traumatic brain injury (TBI). Rats were subjected to severe controlled cortical impact injury (CCI; 5 m/s, 130 ms duration, 3 mm deformation) over the right parietal cortex. At 24 h postinjury, ipsilateral segments of MCA and corresponding contralateral segments were isolated, mounted in a vessel chamber, and pressurized. The responses to 2 methylthio-ATP (2MeSATP), a selective agonist for the P2Y(1) purinoceptors, NW-nitro-L-arginine (L-NAME), an NO synthase inhibitor, and S-nitroso-N-acetylpenicillamine (SNAP), an exogenous NO donor,were determined. 2MeSATP elicited concentration dependent dilations in all MCAs studied. Ipsilateral MCAs harvested following TBI or sham-TBI, showed similar maximum dilations to 2MeSATP [70 +/- 4% (n = 17) and 72 +/- 6% (n = 13), respectively]. However, TBI reduced the concentration of 2MeSATP necessary to elicit one-half of the maximum dilation (EC50) from 15 to 9 nM (p < 0.05). Inhibition of NO synthase with 10(-5) M L-NAME abolished the dilation to 2MeSATP in both TBI and sham-TBI MCAs. The constriction to L-NAME was significantly reduced in TBI MCAs compared to sham vessels. Dilations to SNAP, an NO donor, were not altered by TBI indicating that the mechanisms of dilation involving NO in the vascular smooth muscle were not affected. Unlike other pathological conditions which often diminish endothelial-mediated responses, severe TBI enhanced the sensitivity to 2MeSATP without altering the maximum response.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA; Baylor Coll Med, Cardiovasc Sci Program, Houston, TX 77030 USA	Golding, EM (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Ste 944, Houston, TX 77030 USA.				NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL07816] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		ARMSTEAD WM, 1996, AM J PHYSIOL, V270, pH2172; Betz AL, 1996, ADV NEUROL, V71, P301; BRUHWYLER J, 1993, NEUROSCI BIOBEHAV R, V17, P373, DOI 10.1016/S0149-7634(05)80114-9; Bryan RM, 1996, ANESTHESIOLOGY, V85, P82, DOI 10.1097/00000542-199607000-00012; BRYAN RM, 1995, AM J PHYSIOL-HEART C, V269, pH1171; Bukoski RD, 1997, AM J PHYSIOL-HEART C, V272, pH1406; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; FARACI FM, 1992, PHARMACOL THERAPEUT, V56, P1, DOI 10.1016/0163-7258(92)90035-X; FREW JD, 1993, BRIT J PHARMACOL, V110, P1003, DOI 10.1111/j.1476-5381.1993.tb13913.x; HATAKE K, 1992, STROKE, V23, P1111, DOI 10.1161/01.STR.23.8.1111; JOHANSSON B, 1989, J HYPERTENS, V7, pS5; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; Marrelli Sean P., 1997, Society for Neuroscience Abstracts, V23, P1379; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; Mayhan WG, 1996, J CEREBR BLOOD F MET, V16, P500, DOI 10.1097/00004647-199605000-00017; MAYHAN WG, 1995, BRAIN RES, V686, P99, DOI 10.1016/0006-8993(95)00460-8; MIAN KB, 1995, BRIT J PHARMACOL, V115, P993, DOI 10.1111/j.1476-5381.1995.tb15909.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; PAULSON OB, 1970, NEUROLOGY, V20, P63, DOI 10.1212/WNL.20.1.63; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; RUBANYI GM, 1991, J CELL BIOCHEM, V46, P27, DOI 10.1002/jcb.240460106; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781; You JP, 1997, AM J PHYSIOL-HEART C, V273, pH1472	28	20	20	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1998	15	8					635	644		10.1089/neu.1998.15.635			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	111KP	WOS:000075436500007	9726262				2021-06-18	
J	Childers, MK; Holland, D; Ryan, MG; Rupright, J				Childers, MK; Holland, D; Ryan, MG; Rupright, J			Obsessional disorders during recovery from severe head injury: report of four cases	BRAIN INJURY			English	Article							GLUCOSE METABOLIC RATES; COMPULSIVE DISORDER	Four cases of transient obsessional disorders following severe head injury are described within the context of recovery from acute traumatic brain injury (TBI). obsessional features following TBI have important treatment implications in brain injury rehabilitation settings, since emergence of this disorder in the acutely brain injured patient poses a significant obstacle to interdisciplinary rehabilitation. Although the numbers of patients described here and in previous reports are too small to draw conclusions about the incidence of obsessional disorders following TBI, these cases illustrate the importance of correctly identifying and treating obsessional symptoms in the brain injured patient.	Univ Missouri, Dept Phys Med & Rehabil, Howard A Rusk Rehabil Ctr, Columbia, MO 65212 USA; Missouri Rehabil Ctr, Mt Vernon, MO USA	Childers, MK (corresponding author), Univ Missouri, Dept Phys Med & Rehabil, Howard A Rusk Rehabil Ctr, DC046-00 1 Hosp Dr, Columbia, MO 65212 USA.			Childers, Martin/0000-0003-4754-0883			BACTER LR, 1987, ARCH GEN PSYCHIAT, V44, P800; BAXTER LR, 1988, AM J PSYCHIAT, V145, P1560; BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P681; BAXTER LR, 1987, ARCH GEN PSYCHIAT, V44, P211; BEHAR D, 1984, AM J PSYCHIAT, V141, P363; Bond M. R., 1990, REHABILITATION ADULT, P179; DRUMMOND LM, 1988, BRIT J PSYCHIAT, V153, P839, DOI 10.1192/bjp.153.6.839; Goldstein K, 1942, EFFECTS BRAIN INJURI; GOLDSTEIN K, 1930, ORGANISM; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; MCKEON J, 1984, BRIT J PSYCHIAT, V144, P190, DOI 10.1192/bjp.144.2.190; WALKER VJ, 1973, BRIT J PSYCHIAT, V123, P675, DOI 10.1192/bjp.123.6.675; YARYURATOBIA JA, 1997, OBSESSIVE COMPULSIVE; 1994, DIAGNOSTIC STAT MANU, P417	15	20	20	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1998	12	7					613	616					4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZX249	WOS:000074495200007	9653524				2021-06-18	
J	Minassian, AT; Melon, E; Leguerinel, C; Lodi, CA; Bonnet, F; Beydon, L				Minassian, AT; Melon, E; Leguerinel, C; Lodi, CA; Bonnet, F; Beydon, L			Changes in cerebral blood flow during PaCO2 variations in patients with severe closed head injury: comparison between the Fick and transcranial Doppler methods	JOURNAL OF NEUROSURGERY			English	Article						Doppler ultrasonography; head injury; cerebral hemodynamics; cerebral vasoreactivity	CARBON-DIOXIDE; SUBARACHNOID HEMORRHAGE; HYPEREMIA; VELOCITY; ARTERY; AUTOREGULATION; HYPERTENSION; ULTRASOUND; VASOSPASM; PRESSURE	Object. The aim of this study was to reassess whether middle cerebral artery blood flow velocity (MCAv) variations measured by transcranial Doppler ultrasonography during acute PaCO2 manipulation adequately reflect cerebral blood flow (CBF) changes in patients with severe closed head injury. Methods. The study was performed by comparing MCAv variations to changes in CBF as assessed by measurements of the difference in the arteriovenous content in oxygen (AVDO(2)). The authors initiated 35 CO2 challenges in 12 patients with severe closed head injury during the acute stage. By simultaneous recording of systemic and cerebral hemody namic parameters, 105 AVDO(2) measurements were obtained. Patients were stratified into two groups, "high" and "low," with respect to whether their resting values of MCAv were greater than 100 cm/second during moderate hyperventilation. Four patients displayed an elevated MCAv, which was related to vasospasm in three cases and to hyper emia in one case. The PaCO2 and intracranial pressure levels were not different between the two groups. The slope of the regression line between 1 divided by the change in (Delta)AVDO(2) and Delta MCAv was not different from identity in the low group (1/Delta AVDO(2) = 1.08 x Delta MCAv -0.07, r = 0.93, p < 0.001) and significantly differed (p < 0.05) from the slope of the high group (1/Delta AVDO(2) = 1.46 X Delta MCAv -0.4, r = 0.83, p < 0.001). Conclusions. In patients with severe closed head injury, MCAv variations adequately reflect CBF changes as assessed by AVDO, measurements in the absence of a baseline increase in MCAv. These observations indicate that both moderate variations in PaCO2 and variations in cerebral perfusion pressure do not act noticeably on the diameter of the MCA. The divergence from the expected relationship in the high group seems to be due to the heterogeneity of CO2-induced changes in cerebrovascular resistance between differing arterial territories.	Hop Henri Mondor, Surg Intens Care Unit, F-94010 Creteil, France; Hop Henri Mondor, Dept Anesthesia, F-94010 Creteil, France; Hop Henri Mondor, Dept Neurosurg, F-94010 Creteil, France; Univ Bologna, Dept Elect Comp Sci & Syst, Bologna, Italy	Minassian, AT (corresponding author), Hop Larrey, Dept Anesthesie Reanimat Chirurg, 4 Rue Larrey, F-49033 Angers 01, France.	lBeydon.angers@invivo.edu					AUER L, 1978, EUR NEUROL, V17, P351, DOI 10.1159/000114974; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRASS LM, 1988, STROKE, V19, P1466, DOI 10.1161/01.STR.19.12.1466; CHAN KH, 1992, NEUROSURGERY, V30, P697; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GIBBS EL, 1945, AM J PSYCHIAT, V102, P184, DOI 10.1176/ajp.102.2.184; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; GREENBERG JH, 1978, CIRC RES, V43, P324, DOI 10.1161/01.RES.43.2.324; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; LAM JMK, 1994, INTRACRANIAL PRESSUR, V9, P38; Lindegaard K F, 1988, Acta Neurochir Suppl (Wien), V42, P81; MARKWALDER TM, 1984, J CEREBR BLOOD F MET, V4, P368, DOI 10.1038/jcbfm.1984.54; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; SADOSHIMA S, 1980, BRAIN RES, V189, P115, DOI 10.1016/0006-8993(80)90011-6; Sahuquillo J, 1994, INTRACRANIAL PRESSUR, P48; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; Steiger HJ, 1996, STROKE, V27, P2048, DOI 10.1161/01.STR.27.11.2048; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; TAKEUCHI H, 1991, NEUROSURGERY, V28, P41, DOI 10.1227/00006123-199101000-00007; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762	24	20	20	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	1998	88	6					996	1001		10.3171/jns.1998.88.6.0996			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ZP267	WOS:000073735200009	9609293				2021-06-18	
J	Sturmi, JE; Smith, C; Lombardo, JA				Sturmi, JE; Smith, C; Lombardo, JA			Mild brain trauma in sports - Diagnosis and treatment guidelines	SPORTS MEDICINE			English	Article							CLOSED HEAD-INJURY; CEREBRAL CONCUSSION; PREVENTION; FOOTBALL; MANAGEMENT; SYMPTOMS; SEQUELAE; PLAYERS; DAMAGE; BOXERS	Much has been written about the evaluation and management of mild brain trauma in sports. No less than 10 different 'guidelines' have been proposed and published to aid the clinician in the diagnosis of this condition. Too often, these guidelines have creating confusion instead of promoting an understanding of the spectrum of brain injury. As the understanding of the basic science of mild brain injury evolves, so must the approach to the concussed athlete. This article presents an up-to-date and clinically useful approach to the management of the athlete with a mild brain injury. The definition of 'concussion' is discussed and clarified and pertinent epidemiological data which highlight the importance of management skills as applied to athletes in a wide variety of sports are also reviewed. There is really no such thing as a 'mild concussion' if one considers the rare but catastrophic outcome of the second impact syndrome. For this reason, we review and expand upon the mechanisms of injury and pathophysiology. The accurate diagnosis of mild brain injury requires considerable experience, a high index of suspicion, a careful history and a series of examinations of the athlete, and a working knowledge of the athlete's personality and the likelihood of minimising their symptoms. The value of orientation questions pertinent to the athlete is now well established. Any focal neurological deficit or the deterioration of an athlete's condition warrants immediate hospitalisation, brain imaging and neurosurgical consultation. More commonly, athletes present with a brief alteration of consciousness, headache and amnesia and require careful examination and observation before returning to competition. The astute clinician will always err on the side of conservative management. The complete resolution of all symptoms before a return to play is imperative. Computerised tomography is very sensitive in the imaging of mild brain injuries. Neuropsychological testing is also very sensitive in the evaluation of brain injuries in athletes, and may become more clinically useful in the future.	Ohio State Univ, Athlet Dept, Columbus, OH 43210 USA	Sturmi, JE (corresponding author), Ohio State Univ Sports Med, 97b E Main St, New Albany, OH 43054 USA.						ALVES WM, 1991, ATHLETIC INJURIES HE; Archer P, 1996, JAMA-J AM MED ASSOC, V275, P1072; Barth JT., 1989, MILD HEAD INJURY, P257; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bruce D A, 1982, Clin Sports Med, V1, P495; BRUNO LA, 1987, CLIN SPORT MED, V6, P17; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1995, CLIN SPORT MED, V14, P517; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; *CMS SPORTS MED CO, 1990, GUID MAN CONC SPORTS; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; ECHEMENDIA RJ, 1997, AM MED SOC SPORTS ME; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; GIBBS N, 1993, AM J SPORT MED, V21, P696, DOI 10.1177/036354659302100510; GIERUP J, 1976, ACTA CHIR SCAND, V142, P57; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; HOVDA D, 1997, AM MED SOC SPORTS ME, P127; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; Jorgensen U, 1986, Br J Sports Med, V20, P7; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KASTE M, 1982, LANCET, V2, P1186; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LOVELL MR, 1997, AM MED SOC SPORTS ME, P147; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Maroon J C, 1980, Clin Neurosurg, V27, P414; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MCKEAG DB, 1996, CONCUSSION SYLLABUS; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SALAZAR AM, 1996, SCI AM, V11, P1; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Shawdon A, 1994, Aust J Sci Med Sport, V26, P59; TEASDALE G, 1974, LANCET, V2, P81; TORG JS, 1994, ORTHOPEDIC SPORTS ME, P422; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863	53	20	20	0	6	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0112-1642			SPORTS MED	Sports Med.	JUN	1998	25	6					351	358		10.2165/00007256-199825060-00001			8	Sport Sciences	Sport Sciences	101HC	WOS:000074862700001	9680657				2021-06-18	
J	Varney, NR; Bushnell, D				Varney, NR; Bushnell, D			NeuroSPECT findings in patients with posttraumatic anosmia: A quantitative analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED-HEAD-INJURY; TRAUMATIC BRAIN INJURY; SPECT	Objective: To investigate quantitative neuroSPECT findings, particularly from orbital frontal cortex, in patients rendered totally anosmic from head injury. Setting: Veterans Administration (VA) Medical Center. Subjects: Eighteen patients with head injury resulting in severe anosmia and five normal controls. Al 18 patients had sustained their head injuries at least 5 years prior to involvement in the study. Measures: Quantitative neuroSPECT (count density) from sagittal regions of interest (ROIs) ranging circumferentially from orbital frontal cortex to occipital pole. Results: Quantitative evaluation of neuroSPECT findings for anosmic patients as a group showed substantial orbital frontal hypoperfusion compared with controls, with 67% of individual anosmic patients showing orbital frontal hypoperfusion at a level two or more standard deviations below that of the worst control subject. By contrast, there were no between-group differences for five other ROIs (inferior frontal pole, superior frontal pole, posterior superior frontal lobe, the parasagittal region, and occipital pole), and individual abnormalities were infrequent in these areas. In addition, orbital frontal count was significantly correlated with ratings of outcome, the only ROI to have such a relationship Conclusions: Findings strongly suggest that posttraumatic anosmia and the neuropsychological deficits typically associated with posttraumatic anosmia are closely and specifically associated with hypoperfusion in orbital frontal cortex. The results also underscore the importance of posttraumatic anosmia as a clinical sign of orbital frontal damage, which is particularly important in patients with mild head injury who have normal computed tomography and magnetic resonance imaging scans.	Vet Adm Med Ctr, Psychol Serv 116B, Iowa City, IA 52246 USA; Univ Iowa, Coll Med, Dept Nucl Med, Iowa City, IA 52242 USA	Varney, NR (corresponding author), Vet Adm Med Ctr, Psychol Serv 116B, Iowa City, IA 52246 USA.			Bushnell, David/0000-0002-2768-396X			American Medical Association, 1993, GUID EV PERM IMP; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRAY BG, 1992, J NUCL MED, V33, P52; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; Newberg AB, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199612000-00009; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; RICHARDSON ED, 1994, CLIN NEUROPSYCHOL, V8, P416, DOI 10.1080/13854049408402044; SUMNER D, 1976, HDB CLIN NEUROLOGY, V27; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239; Varney NR, 1996, ARCH CLIN NEUROPSYCH, V11, P345, DOI 10.1016/0887-6177(95)00015-1; VARNEY NR, 1989, IOWA COLLATERAL HEAD; ZUSHO H, 1982, ARCH OTOLARYNGOL, V108, P90	17	20	20	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1998	13	3					63	72					10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZT046	WOS:000074042200006	9582179				2021-06-18	
J	Zhao, X; Newcomb, JK; Posmantur, RM; Wang, KKW; Pike, BR; Hayes, RL				Zhao, X; Newcomb, JK; Posmantur, RM; Wang, KKW; Pike, BR; Hayes, RL			pH dependency of mu-calpain and m-calpain activity assayed by casein zymography following traumatic brain injury in the rat	NEUROSCIENCE LETTERS			English	Article						calpain; traumatic brain injury; casein zymography; proteolysis	ACTIVATED NEUTRAL PROTEINASE; ENERGY PHOSPHATE-METABOLISM; MAGNETIC-RESONANCE; CALCIUM; FORMS	Studies employing casein zymographic assays analyzed the effects of varying pH (from pH 6.8 to pH 8.0) on changes in mu-calpain and m-calpain activity in naive, sham-injured and injured rat cortex 3 h following unilateral cortical impact injury. mu-Calpain activity following cortical impact injury was enhanced between pH values of 7.2 and 7.8, with pH 7.5 being optimal. m-Calpain activity was readily detected only between pH values of 7.2 and 7.4, with pH 7.3 producing the most prominent proteolytic activity. These observations suggest that strict control of pH is an important consideration in assessments of brain pH activation by casein zymography. Moreover, activation of different calpain isoforms, especially after traumatic brain injury, may be differentially influenced by smaller changes ir physiological pH than previously recognized. (C) 1998 Published by Elsevier Science Ireland Ltd.	Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, Houston, TX 77030 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Lab Neurobiochem, Dept Neurosci Therapeut, Ann Arbor, MI 48105 USA	Zhao, X (corresponding author), Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, 6431 Fannin,Suite 7-154, Houston, TX 77030 USA.			Wang, Kevin/0000-0002-9343-6473			BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; DEROSBO NK, 1986, J NEUROCHEM, V47, P1007; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KMAPFL A, 1997, J NEUROTRAUM, V14, P121; MALIK MN, 1987, BIOCHIM BIOPHYS ACTA, V916, P135, DOI 10.1016/0167-4838(87)90220-2; MARMAROU A, 1992, J NEUROTRAUM, V9, P551; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NILSSON E, 1986, J NEUROCHEM, V47, P1086; NILSSON E, 1991, MOL CHEM NEUROPATHOL, V14, P99, DOI 10.1007/BF03159930; NILSSON P, 1993, J CEREB BLOOD FLOW M, V13, P185; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; RASER KJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P211, DOI 10.1006/abbi.1995.1284; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAATMAN KE, 1996, J NEUROPATH EXP NEUR, V55, P852; SHAPIRA Y, 1989, Neurological Research, V11, P169; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1997, J CEREBR BLOOD F MET, V17, P50, DOI 10.1097/00004647-199701000-00007; VITTO A, 1986, J NEUROCHEM, V47, P1039; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YUEN PW, 1996, EXPERT OPIN INV DRUG, V5, P1291; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	36	20	20	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAY 8	1998	247	1					53	57		10.1016/S0304-3940(98)00219-5			5	Neurosciences	Neurosciences & Neurology	ZP138	WOS:000073720200014	9637408				2021-06-18	
J	Marion, DW				Marion, DW			Head and spinal cord injury	NEUROLOGIC CLINICS			English	Article							CEREBRAL BLOOD-FLOW; CIVILIAN GUNSHOT WOUNDS; TRAUMATIC BRAIN INJURY; INTRACRANIAL HYPERTENSION; COMPUTERIZED-TOMOGRAPHY; POSTTRAUMATIC SEIZURES; SURGICAL INTERVENTION; SUBDURAL-HEMATOMA; COMATOSE PATIENTS; EARLY DIAGNOSIS	Traumatic brain and spinal cord injuries remain the leading cause of death and disability for individuals under 50 years of age. This article describes common causes of primary and secondary central nervous system injuries. Particular emphasis is placed on the initial evaluation of trauma patients, detection of head and spinal cord injuries, and critical care of these patients. Definitive management of central nervous system injuries and prognosis and long-term management issues are also discussed.	Univ Pittsburgh, Dept Neurol Surg, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Injury Res & Control, Pittsburgh, PA 15213 USA	Marion, DW (corresponding author), Univ Pittsburgh, Dept Neurol Surg, Brain Trauma Res Ctr, 200 Lothrop St,Suite B400, Pittsburgh, PA 15213 USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702			ARABI B, 1990, NEUROSURGERY, V27, P692; BACHULIS BL, 1987, AM J SURG, V153, P473, DOI 10.1016/0002-9610(87)90796-3; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BEERS GJ, 1988, J COMPUT ASSIST TOMO, V12, P755, DOI 10.1097/00004728-198809010-00007; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BINGHAM WF, 1986, SURG NEUROL, V25, P340, DOI 10.1016/0090-3019(86)90207-7; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; BURNEY RE, 1993, ARCH SURG-CHICAGO, V128, P596; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; CLARK RSB, 1997, J NEUROSURG; COOPER A, 1987, J PEDIATR SURG, V22, P24, DOI 10.1016/S0022-3468(87)80008-8; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEKOSKY ST, 1994, J NEUROTRAUMA, V11, P106; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P424; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; GRONWALL D, 1975, LANCET, V2, P995; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HELLING TS, 1992, J TRAUMA, V32, P398, DOI 10.1097/00005373-199203000-00019; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P199, DOI 10.1007/BF01808959; HOFFMAN JR, 1992, ANN EMERG MED, V21, P1454, DOI 10.1016/S0196-0644(05)80059-9; HOWELL DA, 1959, BRAIN, V82, P525, DOI 10.1093/brain/82.4.525; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; JANSSEN L, 1989, SPINE, V14, P23, DOI 10.1097/00007632-198901000-00005; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; KAUFMAN HH, 1991, NEUROSURGERY CLIN N, P387; KIWERSKI JE, 1993, PARAPLEGIA, V31, P192, DOI 10.1038/sc.1993.36; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; KREIPKE DL, 1989, J TRAUMA, V29, P1438, DOI 10.1097/00005373-198910000-00024; LEWIS LM, 1991, ANN EMERG MED, V20, P117, DOI 10.1016/S0196-0644(05)81205-3; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1994, SPORTS INJURIES MECH, P813; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1987, J NEUROSURG, V66, P400, DOI 10.3171/jns.1987.66.3.0400; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1983, J NEUROSURG, V58, P566, DOI 10.3171/jns.1983.58.4.0566; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; *MED RES COUNC, 1986, AIDS EX PER NERV SYS, P1; MILLER J, 1994, JAMA-J AM MED ASSOC, V240, P439; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1982, CLIN NEUR, V29, P162; MORAN SG, 1994, AM SURGEON, V60, P533; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PENNEY MD, 1979, INTENS CARE MED, V5, P23, DOI 10.1007/BF01738998; POLLANEN MS, 1992, CAN J NEUROL SCI, V19, P196, DOI 10.1017/S0317167100042256; PRZYBYLSKI GJ, 1996, TRAUMA, P307; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Resnick DK, 1997, NEUROSURGERY, V40, P1177, DOI 10.1097/00006123-199706000-00012; RIMOLDI RL, 1992, SPINE, V17, P1443, DOI 10.1097/00007632-199212000-00001; ROBERGE R J, 1992, Journal of Emergency Medicine, V10, P539, DOI 10.1016/0736-4679(92)90133-E; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STONE JL, 1995, NEUROSURGERY, V37, P1104, DOI 10.1227/00006123-199512000-00010; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TEAL JS, 1973, J NEUROSURG, V38, P568, DOI 10.3171/jns.1973.38.5.0568; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1	78	20	21	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0733-8619			NEUROL CLIN	Neurol. Clin.	MAY	1998	16	2					485	+		10.1016/S0733-8619(05)70073-6			20	Clinical Neurology; Neurosciences	Neurosciences & Neurology	ZN686	WOS:000073671500012	9537971				2021-06-18	
J	Tariq, M; Morais, C; Kishore, PN; Biary, N; Al Deeb, S; Al Moutaery, K				Tariq, M; Morais, C; Kishore, PN; Biary, N; Al Deeb, S; Al Moutaery, K			Neurological recovery in diabetic rats following spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						diabetes; electrophysiology; glutathione; oxidative stress; spinal cord injury; vitamin E	SOMATOSENSORY EVOKED-POTENTIALS; BLOOD-FLOW; LIPID-PEROXIDATION; EXTRACELLULAR CALCIUM; ALPHA-TOCOPHEROL; VITAMIN-E; METHYLPREDNISOLONE TREATMENT; CEREBRAL-ISCHEMIA; BIOCHEMICAL BASIS; SCIATIC-NERVE	This study was designed to assess the effect of spinal cord injury on neurobehavioral, electrophysiological, structural, and biochemical changes in normal and diabetic rats, Experimental diabetes was induced in Sprague-Dawley male rats (weighing 250-280 g) with streptozotocin (50 mg/kg IP). Eight weeks after the treatment with streptozotocin the animals were anaesthetized with chloral hydrate and laminectomy was performed at T 7-8 level leaving the dura intact. A compression plate (2.2 x 5.0 mm) loaded with a weight of 35 g was placed on the exposed spinal cord for 5 min, Postoperative neurological function was assessed using inclined plane test, modified Tarlov score, and vocal and sensory score daily for 10 days, Electrophysiological changes were assessed using somatosensory and corticomotor evoked-potentials, The animals were sacrificed at different time intervals and injured site of the spinal cord was analyzed for changes in vitamin E and glutathione levels (as markers of oxidative stress), Pathological changes in spinal cord were also studied using light microscopy, The data on neurobehavioral study clearly indicated that the compression of spinal cord produced highly significant neurological deficit and poor recovery in diabetic rats as compared to nondiabetic rats, Our histopathological and electrophysiological results also confirmed that diabetic animals are more susceptible to compressive spinal cord injury as compared to nondiabetic animals, A higher depletion of antioxidant defense markers (vitamin E and glutathione) was observed in diabetic rats as compared to nondiabetic rats, These results point toward the role of free radicals in poor recovery in diabetic rats following neurotrauma, Further studies are warranted to assess the neuroprotective potential of antioxidants to retard the secondary pathophysiological events following neurotrauma and to enhance the recovery.	Armed Forces Hosp, Dept Neurosurg, Riyadh 11159, Saudi Arabia; Armed Forces Hosp, Res Ctr, Riyadh 11159, Saudi Arabia	Tariq, M (corresponding author), Armed Forces Hosp, Dept Neurosurg, W-912,POB 7897, Riyadh 11159, Saudi Arabia.		Morais, Christudas/G-3736-2016; Morais, Christudas/G-4412-2010	Morais, Christudas/0000-0002-0862-418X; 			Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ANDERSON DK, 1980, J NEUROSURG, V53, P375, DOI 10.3171/jns.1980.53.3.0375; ANDERSON DK, 1982, J NEUROSURG, V56, P106, DOI 10.3171/jns.1982.56.1.0106; ANDERSON DK, 1985, ANN EMERG MED, V14, P816, DOI 10.1016/S0196-0644(85)80064-0; ASBURY AK, 1988, NEW ENGL J MED, V319, P577, DOI 10.1056/NEJM198809013190909; BALENTINE JD, 1978, LAB INVEST, V39, P236; BALENTINE JD, 1985, NEUROLOGICAL SURG TR, P285; BASKIN DS, 1987, NEUROSURGERY, V20, P871, DOI 10.1227/00006123-198706000-00009; BLACK P, 1986, NEUROSURGERY, V19, P752, DOI 10.1227/00006123-198611000-00006; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BRAUGHLER JM, 1983, J NEUROSURG, V59, P256, DOI 10.3171/jns.1983.59.2.0256; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CALCUTT NA, 1991, J NEUROL SCI, V103, P116, DOI 10.1016/0022-510X(91)90294-H; CARSTEN RE, 1989, DIABETES, V38, P730, DOI 10.2337/diabetes.38.6.730; CLENDENON NR, 1978, J NEUROSURG, V49, P563, DOI 10.3171/jns.1978.49.4.0563; CRACCO J, 1984, ANN NEUROL, V15, P55, DOI 10.1002/ana.410150110; DELACRUZ JP, 1992, THROMB RES, V66, P277, DOI 10.1016/0049-3848(92)90278-I; DELAMARTER RB, 1995, J BONE JOINT SURG AM, V77A, P1042, DOI 10.2106/00004623-199507000-00010; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DEMEPOULOS HB, 1980, ACTA PHYSL SCAND S, V492, P91; DEXTER DT, 1992, ANN NEUROL, V32, P591, DOI 10.1002/ana.410320420; DOLMAN CL, 1963, NEUROLOGY, V13, P135, DOI 10.1212/WNL.13.2.135; DYCK PJ, 1989, NEUROLOGY, V39, P111, DOI 10.1212/WNL.39.1.111; EKSTROM PAR, 1990, EXP NEUROL, V109, P200, DOI 10.1016/0014-4886(90)90074-3; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GREENBAUM D, 1964, BRAIN, V87, P201, DOI 10.1093/brain/87.2.201; GREENE DA, 1988, DIABETES, V37, P688, DOI 10.2337/diabetes.37.6.688; GREGERSEN G, 1968, J NEUROL NEUROSUR PS, V31, P175, DOI 10.1136/jnnp.31.2.175; Griggs DE, 1937, ARCH NEURO PSYCHIATR, V38, P564, DOI 10.1001/archneurpsyc.1937.02260210130009; GUPTA PR, 1981, NEUROLOGY, V31, P841, DOI 10.1212/WNL.31.7.841; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; HALL ED, 1987, P UPJOHN S OX FREE R, P92; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; Hass W K, 1983, Neurol Clin, V1, P345; HOLTZ A, 1989, SURG NEUROL, V31, P350, DOI 10.1016/0090-3019(89)90066-9; HOLTZ A, 1990, NEUROSURGERY, V26, P952, DOI 10.1227/00006123-199006000-00005; HSU CY, 1985, J NEUROL SCI, V70, P275, DOI 10.1016/0022-510X(85)90169-8; HSU CY, 1986, J NEUROL SCI, V74, P289, DOI 10.1016/0022-510X(86)90114-0; HSU CY, 1988, J NEUROL SCI, V83, P55, DOI 10.1016/0022-510X(88)90019-6; IKATA T, 1989, SPINE, V14, P1096, DOI 10.1097/00007632-198910000-00012; ILDAN F, 1995, NEUROSURG REV, V18, P35, DOI 10.1007/BF00416476; JACOBS TP, 1987, STROKE, V18, P741, DOI 10.1161/01.STR.18.4.741; JONSSON HT, 1976, PROSTAGLANDINS, V11, P51, DOI 10.1016/0090-6980(76)90172-6; KAPPELLE AC, 1993, BRIT J PHARMACOL, V108, P780, DOI 10.1111/j.1476-5381.1993.tb12878.x; KARPEN CW, 1981, PROSTAGLANDINS, V22, P651, DOI 10.1016/0090-6980(81)90074-5; KIRSCH JR, 1979, STROKE, V10, P288, DOI 10.1161/01.STR.10.3.288; Kunisaki M, 1996, DIABETES, V45, pS117, DOI 10.2337/diab.45.3.S117; KURIHARA M, 1985, J NEUROSURG, V62, P743, DOI 10.3171/jns.1985.62.5.0743; LOW PA, 1991, DIABETES, V40, P873, DOI 10.2337/diabetes.40.7.873; LOWERY JM, 1990, DIABETES, V39, P1498, DOI 10.2337/diabetes.39.12.1498; MANGINO MJ, 1991, AM J PHYSIOL, V261, pF841; MCCAY PB, 1989, ANN NY ACAD SCI, V570, P32; MILVY P, 1973, ANN NY ACAD SCI, V222, P1102, DOI 10.1111/j.1749-6632.1973.tb15327.x; MOORADIAN AD, 1988, ENDOCR REV, V9, P346, DOI 10.1210/edrv-9-3-346; MYERS RE, 1976, J NEUROPATH EXP NEUR, V35, P301, DOI 10.1097/00005072-197605000-00011; NIELSEN ER, 1968, DIABETOLOGIA, V4, P34; NUKADA H, 1993, J NEUROL SCI, V119, P162, DOI 10.1016/0022-510X(93)90129-M; NUKADA H, 1986, DIABETES, V35, P1058, DOI 10.2337/diabetes.35.9.1058; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P467, DOI 10.1111/j.1600-0404.1988.tb03689.x; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P460, DOI 10.1111/j.1600-0404.1988.tb03688.x; OLSSON Y, 1968, PASTORAL REV GRAZIER'S REC, V3, P62; REDDY CC, 1982, LIFE SCI, V31, P571, DOI 10.1016/0024-3205(82)90486-6; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; RELKIN R, 1976, NEW YORK STATE J MED, V76, P281; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RIVLIN AS, 1978, SURG NEUROL, V10, P39; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SIEMKOWICZ E, 1978, ACTA NEUROL SCAND, V58, P1; SILBERBAUER K, 1979, NEW ENGL J MED, V300, P366; SLAGER UT, 1978, ARCH PATHOL LAB MED, V102, P467; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; SUBBIAH MTR, 1980, BIOCHEM MED METAB B, V23, P231, DOI 10.1016/0006-2944(80)90076-9; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P271, DOI 10.1001/archneurpsyc.1954.02320390001001; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; VINK R, 1989, ANN NEUROL, V25, P26, DOI 10.1002/ana.410250105; WALLACE MC, 1986, NEUROSURGERY, V18, P433; WOLTMAN HW, 1929, NEW ENGL J MED, V295, P1416; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; Zochodne DW, 1996, DIABETES, V45, P627, DOI 10.2337/diabetes.45.5.627	85	20	22	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1998	15	4					239	251		10.1089/neu.1998.15.239			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZF401	WOS:000072893800002	9555970				2021-06-18	
J	Moulton, RJ; Brown, JIM; Konasiewicz, SJ				Moulton, RJ; Brown, JIM; Konasiewicz, SJ			Monitoring severe head injury: a comparison of EEG and somatosensory evoked potentials	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							COMPRESSED SPECTRAL ARRAY; INTRACRANIAL-PRESSURE; PREDICTION; COMA	We report on our experience with long-term monitoring of the EEG power spectrum and somatosensory evoked potentials (SSEPs) in 103 patients with severe closed head injury (Glasgow Coma Scale - GCS less than or equal to 8). Patients were monitored for an average of 5 days post injury and monitoring was terminated when they died, regained consciousness or their intracranial physiologic parameters (primarily intracranial pressure - ICP) were stable for 2-3 days, Patients were treated according to a standard protocol that included mechanical ventilation, sedation, and neuromuscular blockade, At 7 of 9 twelve hour time intervals post injury, SSEPs were significantly (p < .05) different between outcome groups using the Glasgow Outcome Score collapsed to 3 categories. The percent slow (delta) activity in the EEG was not significantly different between outcome groups at any time point, post injury. The total power in the EEG power spectrum differed only at the last time epoch post injury (108 hr.). Based on the superior prognostic capabilities of the SSEP, we routinely base critical management decisions on SSEP values. We have not been able to rely on EEG parameters for these same decisions due to the lack of clear distinction between good and poor prognosis groups based on common EEG parameters.	St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1A6, Canada; Univ Toronto, Toronto, ON, Canada	Moulton, RJ (corresponding author), St Michaels Hosp, Div Neurosurg, 38 Shuter St, Toronto, ON M5B 1A6, Canada.						BICKFORD RG, 1977, DIDACTIC REV METHODS, P215; BRICOLO A, 1978, ELECTROEN CLIN NEURO, V45, P211, DOI 10.1016/0013-4694(78)90005-6; GARCIALARREA L, 1992, J NEUROL NEUROSUR PS, V55, P792, DOI 10.1136/jnnp.55.9.792; HUTCHINSON DO, 1991, ELECTROEN CLIN NEURO, V78, P228, DOI 10.1016/0013-4694(91)90037-5; KARNAZE DS, 1982, NEUROLOGY, V32, P289, DOI 10.1212/WNL.32.3.289; KETY SS, 1945, AM J PHYSIOL, V143, P53; KONASIEWICZ SJ, 1994, CAN J NEUROL SCI, V21, P219, DOI 10.1017/S0317167100041196; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; MOULTON R, 1991, J TRAUMA, V31, P676, DOI 10.1097/00005373-199105000-00012; MOULTON RJ, 1994, CAN J NEUROL SCI, V21, pS17, DOI 10.1017/S0084255900007567; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; STOCKARD JJ, 1975, HDB CLIN NEUROLOGY, V23, P317; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x	15	20	22	0	0	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY, AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	FEB	1998	25	1					S7	S11		10.1017/S031716710003465X			5	Clinical Neurology	Neurosciences & Neurology	YW720	WOS:000071965900018	9532290	Bronze			2021-06-18	
J	Smirnova, IV; Salazar, A; Arnold, PM; Glatt, S; Handler, M; Festoff, BW				Smirnova, IV; Salazar, A; Arnold, PM; Glatt, S; Handler, M; Festoff, BW			Thrombin and its precursor in human cerebrospinal fluid	THROMBOSIS AND HAEMOSTASIS			English	Article							PROTEASE-NEXIN-I; NERVOUS-SYSTEM INJURY; NEURITE OUTGROWTH; RECEPTOR ACTIVATION; ALZHEIMERS-DISEASE; ALTERNATIVE PATHWAY; COAGULATION CASCADE; ANTITHROMBIN-III; SERINE PROTEASES; PROTHROMBIN	The blood coagulation cascade proteolytic enzyme, thrombin, affects many cell types, including neurons and astrocytes, in which it prevents process outgrowth and induces significant morphological degeneration and even cell death. Since thrombin may contribute significantly to pathological conditions in the central nervous system (CNS), where it is synthesized locally, we measured the levels of thrombin and its precursor, prothrombin, in the cerebrospinal fluid (CSF) of 67 individuals from 6 groups: non-neurologic controls (NNC); spinal degenerative disease (SDD); peripheral nerve disease (PND); cerebrovascular, neuroimmune and seizure disorders and tumor (CNSD); traumatic brain injury (TBI) and neurodegenerative disorders (NDD). We employed a sensitive chromogenic assay utilizing the thrombin specific tripeptide substrate, S-2238, to evaluate CSF levels of thrombin and prothrombin. The latter estimated after its conversion to active enzyme by the snake venom prothrombinase, ecarin. No measurable active thrombin was detected in these CSF samples. However, activatable prothrombin was measured in all groups. The mean activatable prothrombin concentrations (in nM) were 7.26 +/- 3.39 (NNC); 8.85 +/- 3.09 (SDD); 6.78 +/- 2.58 (PND); 6.33 +/- 3.87 (CNSD); 5.10 +/- 1.86 (TBI), and 7.80 +/- 3.27 (NDD). Duncan's multiple comparison test showed significant reduction (p <0.05) in prothrombin levels of the TBI group. Our data suggests that the prothrombin zymogen gains access to the CSF, likely across either an intact or compromised blood-brain barrier (BBB), in increased amounts with age. Reduced levels in TBI patients may have diagnostic and/or prognostic value.	VET ADM MED CTR, NEUROBIOL RES LAB 151R, KANSAS CITY, MO 64128 USA; UNIV KANSAS, MED CTR, DEPT NEUROL, KANSAS CITY, KS 66103 USA; UNIV KANSAS, MED CTR, DEPT SURG NEUROSURG, KANSAS CITY, KS 66103 USA; UNIV KANSAS, MED CTR, DEPT PATHOL & ONCOL NEUROPATHOL, KANSAS CITY, KS 66103 USA; WALTER REED ARMY MED CTR, DEPT CLIN INVEST, WASHINGTON, DC 20307 USA							ABRAHAM CR, 1992, RES IMMUNOL, V143, P631, DOI 10.1016/0923-2494(92)80047-O; Akenami FOT, 1996, J CLIN PATHOL, V49, P577, DOI 10.1136/jcp.49.7.577; AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; BAKER JB, 1986, RECEPTORS, P153; BEECHER KL, 1994, J NEUROSCI RES, V37, P108, DOI 10.1002/jnr.490370115; Benzakour O, 1995, J CELL BIOCHEM, V59, P514, DOI 10.1002/jcb.240590411; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; COLOVER J, 1991, J CLIN PATHOL, V44, P69, DOI 10.1136/jcp.44.1.69; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; DESCHEPPER CF, 1991, MOL BRAIN RES, V11, P355, DOI 10.1016/0169-328X(91)90045-Y; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; DUBE RK, 1980, INDIAN J MED RES, V72, P454; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FENTON JW, 1991, HAEMOSTASIS, V21, P27; FESTOFF BW, 1992, NEUROLOGY, V42, P1361, DOI 10.1212/WNL.42.7.1361; Festoff BW, 1996, SEMIN THROMB HEMOST, V22, P267, DOI 10.1055/s-2007-999018; FORSYTH KD, 1994, CLIN EXP IMMUNOL, V95, P277; GARTON MJ, 1991, J NEUROL SCI, V104, P74, DOI 10.1016/0022-510X(91)90218-V; GIJBELS K, 1993, J NEUROSCI RES, V36, P432, DOI 10.1002/jnr.490360409; GRABHAM P, 1995, J NEUROCHEM, V64, P583; GRABHAM PW, 1991, EUR J NEUROSCI, V3, P663, DOI 10.1111/j.1460-9568.1991.tb00852.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HARRINGTON MG, 1985, CLIN CHEM, V31, P722; HO GJ, 1994, BIOMED PHARMACOTHER, V48, P296, DOI 10.1016/0753-3322(94)90175-9; LEE KR, 1995, J NEUROSURG, V83, P1045, DOI 10.3171/jns.1995.83.6.1045; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; LINDAHL U, 1989, ARCH BIOCHEM BIOPHYS, V273, P180, DOI 10.1016/0003-9861(89)90177-X; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; MATSUBARA E, 1990, ANN NEUROL, V28, P561, DOI 10.1002/ana.410280414; Monard D, 1993, Perspect Dev Neurobiol, V1, P165; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; NISHINO A, 1994, ACTA NEUROCHIR, P86; POUYSSEGUR J, 1993, NOUV REV FR HEMATOL, V35, P263; RAYFORD A, 1992, J NEUROCHEM, V58, P88, DOI 10.1111/j.1471-4159.1992.tb09281.x; ROZNIECKI JJ, 1995, ANN NEUROL, V37, P63, DOI 10.1002/ana.410370112; Schisano G, 1994, J Neurosurg Sci, V38, P77; SCHWAGERL AL, 1995, J NEUROCHEM, V64, P443; SCHWARTZ BS, 1982, J EXP MED, V155, P1464, DOI 10.1084/jem.155.5.1464; SEKIYA F, 1994, J BIOL CHEM, V269, P32441; SMIRNOVA IV, 1994, SEMIN THROMB HEMOST, V20, P426, DOI 10.1055/s-2007-1001931; Smirnova IV, 1996, J NEUROCHEM, V67, P2188; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; SUZUKI M, 1994, THROMB HAEMOSTASIS, V71, P155; SUZUKI M, 1992, STROKE, V23, P1181, DOI 10.1161/01.STR.23.8.1181; TURNELL AS, 1995, BIOCHEM J, V308, P965, DOI 10.1042/bj3080965; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; VAUGHAN PJ, 1994, BRAIN RES, V668, P160, DOI 10.1016/0006-8993(94)90521-5; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAGNER SL, 1989, P NATL ACAD SCI USA, V86, P8284, DOI 10.1073/pnas.86.21.8284	53	20	20	0	5	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0340-6245	2567-689X		THROMB HAEMOSTASIS	Thromb. Haemost.	DEC	1997	78	6					1473	1479					7	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	YK789	WOS:A1997YK78900011	9423797				2021-06-18	
J	Fugate, LP; Spacek, LA; Kresty, LA; Levy, CE; Johnson, JC; Mysiw, WJ				Fugate, LP; Spacek, LA; Kresty, LA; Levy, CE; Johnson, JC; Mysiw, WJ			Definition of agitation following traumatic brain injury .1. A survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY; SCALE; ORIENTATION; PATIENT	Objective: To determine national patterns of defining agitation after traumatic brain injury (TBI) by physiatrists with expressed interest in treating TBI survivors. Design: A random sample of 70% of the members of the. Brain Injury Special Interest Group (SIG) of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) were surveyed by telephone. Results: The 129 members who responded yielded an 82% response rate. Respondents rated 18 characteristics from established rating scales on a 5-point scale according to each characteristic's relation to its clinical definition of agitation. Physical aggression, explosive anger, increased psychomotor activity, impulsivity, verbal aggression, disorganized thinking, perceptual disturbances, and reduced ability to maintain or appropriately shift attention were rated by at least 50% of the sample as very important or essential to agitation. Delirium, as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM), has been proposed as a standard definition of agitation. The degree to which all characteristics from the 3rd revised edition of the DSM (DSM-IIIR), considered together, were perceived to relate to agitation predicted 24% of the degree to which the term ''delirium'' was perceived to relate to agitation (Canonical correlation r = .48, p = .0002). Physicians' ratings of individual delirium characteristics from the DSM-IIIR were examined to determine if a sufficient number were similarly ranked to fulfill the diagnostic criteria for delirium. A significant number of physicians rated diagnostic criteria for delirium in one direction, yet did not rank the term ''delirium'' accordingly (McNemar's p = .04). Conclusions: There is considerable variation among physiatrists in their rating of characteristics that define agitation. Many define agitation during the acute recovery phase as posttraumatic amnesia plus an excess of behavior such as aggression, disinhibition, and/or emotional lability. Less support was given to defining agitation by the DSM-IIIR or DSM-IV diagnostic criteria for delirium. Delirium appears related to, but is not sufficient for, a diagnosis of agitation. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	OHIO STATE UNIV,DEPT PREVENT MED,COLUMBUS,OH 43210; UNIV MISSOURI,MED INFORMAT GRP,COLUMBIA,MO	Fugate, LP (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,1018 DODD HALL,480 W 9TH AVE,COLUMBUS,OH 43210, USA.		Levy, Carlos/AAN-7226-2020; Mysiw, Walter/E-3724-2011	Johnson, Jane/0000-0002-8825-5926	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD007892] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD07892-01] Funding Source: Medline		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P917; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1996, RECOVERY TRAUMATIC B, P129; Dillman D.A., 1978, MAIL TELEPHONE SURVE; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MALKMUS D, 1980, REHABILITATION HEAD; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SANDEL ME, 1995, NEUROREHABILITATION, V5, P299, DOI 10.3233/NRE-1995-5404; SANEDA D L, 1992, Brain Injury, V6, P167, DOI 10.3109/02699059209029655; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	18	20	20	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1997	78	9					917	923		10.1016/S0003-9993(97)90050-2			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	XV776	WOS:A1997XV77600001	9305261				2021-06-18	
J	Goodman, TA; Merkel, PA; Perlmutter, G; Doyle, MK; Krane, SM; Polisson, RP				Goodman, TA; Merkel, PA; Perlmutter, G; Doyle, MK; Krane, SM; Polisson, RP			Heterotopic ossification in the setting of neuromuscular blockade	ARTHRITIS AND RHEUMATISM			English	Article							BONE-FORMATION; MYOSITIS-OSSIFICANS; DISODIUM ETIDRONATE; PREVENTION; GROWTH; DIFFERENTIATION; INJURY	Objective, Heterotopic ossification (HO) is a disorder characterized by the formation of new bone in tissue that does not ossify under normal conditions, We report a series of 6 cases in which HO occurred in the setting of adult respiratory distress syndrome (ARDS). We wished to show that HO can occur after neuromuscular blockade and that these cases might provide additional evidence that HO is influenced by neural mechanisms, Methods, Cases of HO were selected from the consultation services at the Massachusetts General Hospital and the Brigham and Women's Hospital, Affected patients all had ARDS and had been treated vith a neuromuscular blocking agent. Patients with a history of stroke, burn, head trauma, spinal cord injury, or joint replacement were excluded from this study, Results. Heterotopic bone appeared around large joints in a pattern identical to that seen in patients with paralysis, traumatic brain injury, severe burns, or trauma, New bone formation was self-limited over a period of 1-2 years, Alkaline phosphatase and technetium bone scan were sensitive ways of detecting early disease and monitoring disease activity, Medical therapies had limited benefit, Surgical excision of mature new bone appeared to be the only definitive therapy. Conclusion. Neuromuscular blockade in the setting of ARDS appears to be an important risk factor for the development of HO, The similarity of these cases of HO occurring in patients with brain or spinal cord injury raises the possibility that neural mechanisms may be important in the pathogenesis of this disease. Whether the type of neuromuscular blocking agent and the duration of use are important determinants of disease severity remains to be determined.	BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Goodman, TA (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,ARTHRIT UNIT,BULFINCH 165,55 FRUIT ST,BOSTON,MA 02114, USA.						Brailsford J.F., 1948, RADIOLOGY BONES JOIN; BURING K, 1975, CLIN ORTHOP RELAT R, V110, P293; BUSCHBACHER R, 1992, AM J PHYS MED REHAB, V71, P86, DOI 10.1097/00002060-199204000-00005; BUSCHBACHER R, 1991, AM J PHYS MED REHAB, V70, P309; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CLEMENTS NC, 1993, CHEST, V104, P1526, DOI 10.1378/chest.104.5.1526; COPE R, 1990, SOUTH MED J, V83, P1058, DOI 10.1097/00007611-199009000-00020; DEFLITCH CJ, 1993, RADIOLOGY, V188, P265, DOI 10.1148/radiology.188.1.8511309; EKELUND A, 1991, CLIN ORTHOP RELAT R, V263, P102; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FINERMAN GAM, 1981, METAB BONE DIS RELAT, V3, P337, DOI 10.1016/0221-8747(81)90050-3; FURMAN R, 1970, J BONE JOINT SURG AM, VA 52, P1131, DOI 10.2106/00004623-197052060-00005; GARLAND DE, 1989, CLIN ORTHOP RELAT R, V242, P169; GARLAND DE, 1983, CLIN ORTHOP RELAT R, V176, P197; GARLAND DE, 1991, CLIN ORTHOPAEDICS, V263, P13; GOLDBERG MA, 1977, ARCH INTERN MED, V137, P619, DOI 10.1001/archinte.137.5.619; JENSEN LL, 1988, AM J PHYS MED, V66, P351; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kjaersgaard-Andersen P., 1988, CLIN ORTHOP RELAT R, V234, P102; KJAERSGAARDANDE.P, 1991, CLIN ORTHOP RELAT R, V263, P78; LINDHOLM TS, 1987, SCAND J RHEUMATOL, V16, P33; MALONEY WJ, 1992, CLIN ORTHOPAEDICS, V280, P230; MICHELSSON JE, 1980, J BONE JOINT SURG AM, V62, P811, DOI 10.2106/00004623-198062050-00017; ORZEL JA, 1985, J NUCL MED, V26, P125; RIPAMONTI U, 1992, CRIT REV ORAL BIOL M, V3, P1; ROSEN V, 1994, J BONE MINER RES, V9, P1759; SAWYER JR, 1991, CALCIFIED TISSUE INT, V49, P208, DOI 10.1007/BF02556120; SEEGENSCHMIEDT MH, 1993, RADIOLOGY, V188, P257, DOI 10.1148/radiology.188.1.8511308; SPIELMAN G, 1983, ARCH PHYS MED REHAB, V64, P539; STOVER SL, 1976, J BONE JOINT SURG AM, V58, P683, DOI 10.2106/00004623-197658050-00019; STOVER SL, 1991, CLIN ORTHOPAEDICS, V263, P71; SUZUKI Y, 1974, RADIOLOGY, V111, P663, DOI 10.1148/111.3.663; TANAKA T, 1977, RADIOLOGY, V123, P217, DOI 10.1148/123.1.217; URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220	35	20	20	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0004-3591			ARTHRITIS RHEUM	Arthritis Rheum.	SEP	1997	40	9					1619	1627		10.1002/art.1780400911			9	Rheumatology	Rheumatology	XY539	WOS:A1997XY53900010	9324016				2021-06-18	
J	OFlaherty, CA; Douglas, JM				OFlaherty, CA; Douglas, JM			Living with cognitive-communicative difficulties following traumatic brain injury: using a model of interpersonal communication to characterize the subjective experience	APHASIOLOGY			English	Article							CLOSED HEAD-INJURY; FAMILY; RELATIVES; ADULTS; LIFE	This study was undertaken to better understand the subjective experience of long-term cognitive-communicative impairments following severe cerebral insult. An additional aim was to explore the utility of a model of interpersonal communication in elucidating how such difficulties affect communicative interactions. Participants in the study were five dyads in which one member had sustained a severe traumatic brain injury (TBI). Data collection and analysis utilized both qualitative and quantitative methodology. It was found that individuals with long-term TBT continue to experience significant communication difficulties, which in combination with problems of memory, fatigue and irritability commonly generate unsatisfactory interpersonal communication experiences. The model of interpersonal communication provided a useful framework for considering why these interactions are ineffective or unsatisfactory. It is felt that the methodology outlined in this paper may offer a useful means of investigating the relationship between neurogenic communication impairments/disabilities and interpersonal communication difficulties experienced by individuals from a variety of clinical populations.	LA TROBE UNIV,MELBOURNE,VIC,AUSTRALIA			Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			Adamovich BL, 1991, COGNITIVE REHABILITA, P75; Argyle M, 1986, SOCIAL INTERACTION; Bateson Gregory, 1951, COMMUNICATION SOCIAL; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BOWMAN ML, 1990, J MARRIAGE FAM, V52, P463, DOI 10.2307/353040; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Chwalisz K, 1996, Appl Neuropsychol, V3, P28, DOI 10.1207/s15324826an0301_5; COOK M, 1981, BASES HUMAN SEXUAL A; Damico JS, 1985, COMMUNICATION SKILLS, P165; DANZIGER K, 1976, INTERPERSONAL COMMUN; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; DIRMEN S, 1993, BRAIN INJURY, V7, P113; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; DOUGLAS JM, 1997, UNPUB DEV EVALUATION; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HARTLEY LL, 1995, COGNITIVE COMMUNICAT, P21; HARTLEY P, 1993, INTERPERSONAL COMMUN; Jackson, 1967, PRAGMATICS HUMAN COM; KELLEY HH, 1973, AM PSYCHOL, V28, P107, DOI 10.1037/h0034225; KENNY DA, 1994, INTERPERSONAL PERCEP, P16; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; LEDORZE G, 1995, APHASIOLOGY, V9, P239; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Marquardt TP, 1990, TRAUMATIC BRAIN INJU, P181; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; Menaghan E., 1983, MARRIAGE FAM REV, V6, P113; NICOTERA AM, 1993, INTERPERSONAL COMMUN; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Panting A., 1972, REHABILITATION, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PONSFORD JL, 1995, TRAUMATIC BRAIN INJU, P15; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P18; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SDOROW L, 1990, PSYCHOLOGY, P590; Swann W. B, 1990, HDB MOTIVATION COGNI, V2, P408; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P117; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P239, DOI 10.1055/s-2008-1064200	48	20	20	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0268-7038			APHASIOLOGY	Aphasiology	SEP	1997	11	9					889	911		10.1080/02687039708250463			23	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	XW027	WOS:A1997XW02700005					2021-06-18	
J	Diringer, MN; Edwards, DF				Diringer, MN; Edwards, DF			Does modification of the innsbruck and the Glasgow Coma Scales improve their ability to predict functional outcome?	ARCHIVES OF NEUROLOGY			English	Article							REACTION-LEVEL-SCALE; HEAD-INJURY; CONSCIOUSNESS; SURVIVAL	Background: The accurate prediction of functional outcome requires the development of multivariate models. To enhance their contribution to such models, the predictive power of each component must be optimized. Objectives: To improve the predictive power of coma scales as the first step in building more sophisticated multivariate models to predict specific levels of functional outcome. Design: Prospective descriptive study. Setting: Neurology and neurosurgery intensive care unit (NNICU) in a tertiary care academic center. Patients: Eighty-four patients with acute traumatic brain injury, intracerebral hemorrhage, subarachnoid hemorrhage, or ischemic stroke. Interventions: None. Main Outcome Measures: The Glasgow Coma Scale (GCS) and Innsbruck Coma Scale (ICS) were administered within 24 hours of admission to the NNICU and then at 48-hour intervals until discharge of the patient from the NNICU. The assessments were performed by 3 occupational therapy graduate students working under the supervision of the medical director of the NNICU. The functional outcome at 3 months after discharge from the hospital was assessed by telephone by the same nurse using the following categories: (1) dead, (2) receiving nursing home or custodial care, (3) home with help, or (4) independent. Cronbach's alpha estimates of reliability for each scale were computed using all scores obtained during the study. The analyses indicated that the verbal response item of the GCS and the oral automatisms item of the ICS were less reliable in this patient population. The scales were modified by deleting those items, and predictive validity for the original and modified scales was computed using a discriminant function of the admission scores. Results: Before modification, both scales were best at predicting independence (GCS and ICS, 71% correct) and mortality (GCS, 60% correct, ICS, 56% correct). The modifications produced a modest improvement in the ability of both scales to better predict levels of outcome (modified GCS: home with help, 33% correct, independent, 71% correct; modified ICS: home with help, 0% correct, independent, 74% correct). Conclusions: By deleting items with low reliability from the ICS and the GCS we achieved improved reliability and predictive validity. The improvement in predictive power, however, was inadequate to accurately predict functional outcome. Combining clinical scales with other demographic, physiological, functional, and radiographic data will be needed to achieve useful predictions of functional outcome.	WASHINGTON UNIV,SCH MED,PROGRAM OCCUPAT THERAPY,ST LOUIS,MO 63110	Diringer, MN (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,660 S EUCLID AVE,BOX 8111,ST LOUIS,MO 63110, USA.		Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537			BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; DISNEY L, 1988, NEUROSURGERY, V23, P1; EDWARDS DF, 1995, STROKE, V26, P1852, DOI 10.1161/01.STR.26.10.1852; Ellis A, 1992, Intensive Crit Care Nurs, V8, P94, DOI 10.1016/0964-3397(92)90037-K; JAGGER J, 1983, LANCET, V2, P97; JOHNSTONE AJ, 1993, BRAIN INJURY, V7, P501, DOI 10.3109/02699059309008177; KLECKA WR, 1980, DISCRIMINANT ANAL, P67; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; NUNNALLY JC, 1979, PSYCHOMETRIC THEORY, P229; Price D J, 1986, Acta Neurochir Suppl (Wien), V36, P106; Robinson S, 1992, Axone, V14, P21; SARLE WS, 1991, SAS STAT USERS GUIDE, P360; SEGATORE M, 1992, HEART LUNG, V21, P548; SOUSTIEL JF, 1993, ELECTROEN CLIN NEURO, V87, P277, DOI 10.1016/0013-4694(93)90180-4; *SPSS, 1990, SPSS ADV STAT US GUI, P245; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; TUHRIM S, 1988, ANN NEUROL, V24, P258, DOI 10.1002/ana.410240213	24	20	21	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	MAY	1997	54	5					606	611		10.1001/archneur.1997.00550170078017			6	Clinical Neurology	Neurosciences & Neurology	WY809	WOS:A1997WY80900014	9152117				2021-06-18	
J	Johannes, S; Weber, A; MullerVahl, KR; Kolbe, H; Dengler, R; Munte, TF				Johannes, S; Weber, A; MullerVahl, KR; Kolbe, H; Dengler, R; Munte, TF			Event-related brain potentials show changed attentional mechanisms in Gilles de la Tourette Syndrome	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						Gilles de la Tourette Syndrome; attention; even-related brain potentials; basal ganglia; frontal lobes	CLOSED HEAD-INJURY; DEFICIT HYPERACTIVITY DISORDER; AUDITORY ODDBALL TASK; ELECTROPHYSIOLOGICAL EVIDENCE; VISUAL-SEARCH; BASAL GANGLIA; DYSFUNCTION; PERFORMANCE; INFORMATION; CHILDREN	In many patients the Gilles de la Tourette Syndrome (TS) is associated with the childhood Attention Deficit Hyperactivity Disorder. To gain a general view of attentional processes in TS we recorded event-related brain potentials (ERPs) in 12 TS patients and in a matched control group. Four visual attention experiments with different levels of complexity were done (oddball task, pop-out experiment, figure extraction and figure conjunction task). The reaction times did not differ significantly between groups. The Tourette patients' event-related brain potentials showed an increased amplitude of the N2 component to targets in the simple oddball and pop-out experiments. While both groups had similar P3b latencies to targets in the figure extraction experiment, Tourette patients responded less accurately in the most complex figure conjunction task and had increased P3b latencies. This is interpreted as evidence for a stronger attentional effort of the Tourette patients to obtain behavioural results similar to control subjects in easy attentional tasks. Consequently, Tourette patients show a reduced performance in complex attentional tasks.				Munte, Thomas/C-2077-2014	Muller-Vahl, Kirsten/0000-0002-7181-7419			American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Bornstein R A, 1991, J Neuropsychiatry Clin Neurosci, V3, P157; BORNSTEIN RA, 1991, AM J PSYCHIAT, V148, P468; BRAUN AR, 1993, NEUROPSYCHOPHARMACOL, V9, P277, DOI 10.1038/npp.1993.64; BROOKSHIRE BL, 1994, J CLIN EXP NEUROPSYC, V16, P289, DOI 10.1080/01688639408402639; BURD L, 1992, J LEARN DISABIL, V25, P598, DOI 10.1177/002221949202500909; CATH DC, 1992, ADV NEUROL, V58, P33; Cohen D. J., 1988, TOURETTES SYNDROME T; COMINGS DE, 1990, J CLIN PSYCHIAT, V51, P275; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; FITZGERALD PG, 1983, BIOL PSYCHOL, V17, P241, DOI 10.1016/0301-0511(83)90003-0; GEDYE A, 1991, J CLIN PSYCHOL, V47, P233, DOI 10.1002/1097-4679(199103)47:2<233::AID-JCLP2270470209>3.0.CO;2-N; GEORGE MS, 1992, PSYCHIAT RES-NEUROIM, V45, P143, DOI 10.1016/0925-4927(92)90022-V; GEORGIOU N, 1995, J NEUROL NEUROSUR PS, V58, P184, DOI 10.1136/jnnp.58.2.184; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; HILLYARD SA, 1993, CURR OPIN NEUROBIOL, V3, P217, DOI 10.1016/0959-4388(93)90213-I; HILLYARD SA, 1983, ANNU REV PSYCHOL, V34, P33, DOI 10.1146/annurev.ps.34.020183.000341; HILLYARD SA, 1990, MACHINERY OF THE MIND, P186; JENNINGS JR, 1976, PSYCHOPHYSIOLOGY, V13, P277; JOHANNES S, 1995, COGNITIVE BRAIN RES, V2, P189, DOI 10.1016/0926-6410(95)90008-X; JOHANNES S, 1996, UNPUB GILLES TOURETT; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KNELL ER, 1993, J CLIN PSYCHIAT, V54, P331; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LANSER JBK, 1993, BRIT J PSYCHIAT, V163, P116, DOI 10.1192/bjp.163.1.116; LUCK S J, 1988, Society for Neuroscience Abstracts, V14, P1013; LUCK SJ, 1990, PERCEPT PSYCHOPHYS, V48, P603, DOI 10.3758/BF03211606; MANGUN GR, 1993, ATTENTION PERFORMANC, V14; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; NAATANEN R, 1986, CEREBRAL PSYCHOPHYSI, P169; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PETERSON B, 1993, NEUROLOGY, V43, P941, DOI 10.1212/WNL.43.5.941; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; ROBERTSON MM, 1989, BRIT J PSYCHIAT, V154, P147, DOI 10.1192/bjp.154.2.147; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; SEGALOWITZ SJ, 1993, PSYCHOPHYSIOLOGY, V30, P451, DOI 10.1111/j.1469-8986.1993.tb02068.x; Shapiro A. K., 1988, GILLES TOURETTE SYND; SIEG KG, 1993, CLIN NUCL MED, V18, P255, DOI 10.1097/00003072-199303000-00022; SINGER HS, 1993, NEUROLOGY, V43, P950, DOI 10.1212/WNL.43.5.950; SINGER HS, 1991, MEDICINE, V70, P15, DOI 10.1097/00005792-199101000-00002; STOETTER B, 1992, ADV NEUROL, V58, P213; *TOUR SYNDR CLASS, 1993, ARCH NEUROL-CHICAGO, V50, P1013; VANWOERKOM TCAM, 1994, ACTA NEUROL SCAND, V90, P116; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; WEATE SJ, 1993, CLIN ELECTROENCEPHAL, V24, P188, DOI 10.1177/155005949302400410; WICKENS C, 1983, SCIENCE, V221, P1080, DOI 10.1126/science.6879207	47	20	20	0	3	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	1351-5101			EUR J NEUROL	Eur. J. Neurol.	MAR	1997	4	2					152	161		10.1111/j.1468-1331.1997.tb00321.x			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	XC957	WOS:A1997XC95700012	24283908				2021-06-18	
J	Wilson, DJ; Childers, MK; Cooke, DL; Smith, BK				Wilson, DJ; Childers, MK; Cooke, DL; Smith, BK			Kinematic changes following botulinum toxin injection after traumatic brain injury	BRAIN INJURY			English	Article							SPASTICITY; GAIT; HEMIPLEGIA; VARIABLES; PERFORMANCE; MANAGEMENT; STROKE; FOOT	The objectives of this study were to: (1) demonstrate the use of computerized, three-dimensional gait analysis as a functional assessment instrument following clinical intervention; and (2) objectively quantify the effects of focal muscle denervation via botulinum toxin type A (BTXA) injection in a hemiparetic patient with lower extremity spasticity following traumatic brain injury (TBI). A desired outcome of this intervention was to realize kinematics more closely resembling those reported for normal patients. The design was a single-subject case study. Ten trials of walking gait were analysed pre-injection (PI), 1 week post-injection (1PO) and 4 weeks post-injection(4PO). The PI and 1PO sessions were found to be appreciably different from the 1PO on the joint angles of the ankle and knee at each phase of the gait cycle. These differences resulted in a reduced asymmetry of ambulation. Stride time, stance time, percentage stance time, percentage swing rime and walking speed improved, showing progress towards a more efficient gait pattern. Decreased stride time and increased walking speed supported improved functional ability. The inter-trial variability of the gait parameters showed the analysis to be a consistently reproducible protocol. Conclusions based on the results included encouraging findings for the efficacy of botulinum toxin A as a therapy for the reduction of spasticity.	UNIV MISSOURI,DEPT PHYS MED & REHABIL,COLUMBIA,MO 65212; UNIV MISSOURI,DEPT HLTH & EXERCISE SCI,COLUMBIA,MO 65212				Childers, Martin/0000-0003-4754-0883	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD 07460-03] Funding Source: Medline		Abdel-Aziz Y., 1971, P S CLOS RANG PHOT, P1, DOI DOI 10.1080/10671188.1967.10616517; BEER FP, 1977, VECTOR MECH ENG STAT, P1; BOHANNON RW, 1987, ARCH PHYS MED REHAB, V68, P777; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BORGSTEIN J, 1993, AM J PHYS MED REHAB, V72, P364; BRANDSTATER ME, 1983, ARCH PHYS MED REHAB, V64, P583; DAS TK, 1989, BRIT J CLIN PRACT, V43, P401; DAS TK, 1989, POSTGRAD MED J, V65, P208, DOI 10.1136/pgmj.65.762.208; DENGLER R, 1992, J NEUROL, V239, P375; DETTMANN MA, 1987, AM J PHYS MED REHAB, V66, P77; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; GRAZKO MA, 1995, NEUROLOGY, V45, P712, DOI 10.1212/WNL.45.4.712; HESSE S, 1994, J NEUROL NEUROSUR PS, V57, P1312; KAO I, 1976, SCIENCE, V193, P1256, DOI 10.1126/science.785600; KERRIGAN DC, 1994, AM J PHYS MED REHAB, V73, P421, DOI 10.1097/00002060-199411000-00007; KNUTZEN KM, 1987, MED SCI SPORT EXER, V19, P303; KOMAN LA, 1993, J PEDIATR ORTHOPED, V13, P489, DOI 10.1097/01241398-199307000-00013; LEHMANN JF, 1987, ARCH PHYS MED REHAB, V68, P763; MEMIN B, 1992, REV NEUROL, V148, P212; OLNEY SJ, 1994, PHYS THER, V74, P872, DOI 10.1093/ptj/74.9.872; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; VONSCHROEDER HP, 1995, J REHABIL RES DEV, V32, P25; WALL JC, 1986, ARCH PHYS MED REHAB, V67, P550	23	20	21	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAR	1997	11	3					157	167		10.1080/026990597123610			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WL158	WOS:A1997WL15800001	9057998				2021-06-18	
J	Nguyen, C; Katner, HP				Nguyen, C; Katner, HP			Myeloperoxidase deficiency manifesting as pustular candidal dermatitis	CLINICAL INFECTIOUS DISEASES			English	Article							DISSEMINATED CANDIDIASIS; CEFTRIAXONE; MENINGITIS	Myeloperoxidase deficiency is the most common neutrophilic lysosomal enzyme deficiency. Case studies indicate that individuals with myeloperoxidase deficiency are not susceptible to serious infection in the absence of coexisting conditions such as diabetes mellitus. We present a case of myeloperoxidase deficiency manifesting as disseminated pustular candidal dermatilis in a nondiabetic male, Ceftriaxone therapy was administered to the patient for 8 days after he received a closed head injury and before the development of fever and pustular dermatitis. Candida albicans was isolated from the skin lesion. His neutrophils demonstrated a qualitative lack of myeloperoxidase. Patients who develop rapidly disseminated fungal dermatitis while they are receiving antimicrobial therapy that is relatively limited in coverage should be evaluated for myeloperoxidase deficiency.	MERCER UNIV,SCH MED,DEPT INTERNAL MED,INFECT DIS SECT,MACON,GA 31207				Katner, Harold/0000-0002-2529-9817			ADU A, 1995, DRUGS, V50, P423, DOI 10.2165/00003495-199550030-00002; BODEY GP, 1974, JAMA-J AM MED ASSOC, V229, P1466, DOI 10.1001/jama.229.11.1466; CARLSON J, 1987, SCAND J INFECT DIS, V19, P687, DOI 10.3109/00365548709117205; GROSSMAN ME, 1980, J AM ACAD DERMATOL, V2, P111, DOI 10.1016/S0190-9622(80)80388-4; LEHRER RI, 1969, J CLIN INVEST, V48, P1478, DOI 10.1172/JCI106114; LUDVIKSSON BR, 1993, PEDIATR INFECT DIS J, V12, P162, DOI 10.1097/00006454-199302000-00015; MOSKOVITZ BL, 1984, AM J MED, V77, P84; NAUSEEF WM, 1988, HEMATOL ONCOL CLIN N, V2, P135; OKUDA T, 1991, J ORAL MAXIL SURG, V49, P183, DOI 10.1016/0278-2391(91)90108-X; PARRY MF, 1981, ANN INTERN MED, V95, P293, DOI 10.7326/0003-4819-95-3-293; TSAKONAS DP, 1994, CLIN LAB HAEMATOL, V16, P337	11	20	20	0	1	UNIV CHICAGO PRESS	CHICAGO	5720 S WOODLAWN AVE, CHICAGO, IL 60637	1058-4838			CLIN INFECT DIS	Clin. Infect. Dis.	FEB	1997	24	2					258	260		10.1093/clinids/24.2.258			3	Immunology; Infectious Diseases; Microbiology	Immunology; Infectious Diseases; Microbiology	WH302	WOS:A1997WH30200030	9114158	Bronze			2021-06-18	
J	Dave, JR; Bauman, RA; Long, JB				Dave, JR; Bauman, RA; Long, JB			Hypoxia potentiates traumatic brain injury-induced expression of c-fos in rats	NEUROREPORT			English	Article						c-fos mRNA; fluid percussion; hypoxia; immediate-early genes; ischemia; oncogene activation; rat brain; traumatic brain injury	CORTICAL IMPACT INJURY; MESSENGER-RNA; ACCUMULATION; INDUCTION; CALCIUM; NMDA	HALOTHANE-anesthetized male rats were subjected to either moderately severe parasagittal fluid percussion-induced traumatic brain injury (TBI) or sham injury, and for 30 min immediately after injury hypoxia was induced in half the rats from each group by substituting a 13% O-2, source to deliver halothane for continued anesthesia. At 60 min post-TBI, Northern blot analysis showed a significant increase in c-fos mRNA levels, by 60-100% above sham control levels in the frontal cortex, cerebellum and hippocampus. Although hypoxia in sham-injured rats did not by itself alter c-fos mRNA levels, it did significantly potentiate the TBI-induced changes in c-fos mRNA in all three brain regions. These findings show that hypoxia is an important factor influencing genomic responses to TBI.		Dave, JR (corresponding author), WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DIV NEUROSCI,BLDG 40,WASHINGTON,DC 20307, USA.						BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Dave J. R., 1993, Society for Neuroscience Abstracts, V19, P1771; DAVE JR, 1992, PHARM COMMUN, V1, P319; DRAGUNOW M, 1990, NEUROSCI LETT, V109, P128, DOI 10.1016/0304-3940(90)90550-S; EUMANNHAEFELIN T, 1994, J CEREBR BLOOD FLOW, V14, P206; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KINOUCHI H, 1994, J CEREBR BLOOD F MET, V14, P808, DOI 10.1038/jcbfm.1994.101; LUTZ HA, 1982, HEAD INJURY BASIC CL, P221; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORGAN PF, 1991, NEUROREPORT, V2, P251, DOI 10.1097/00001756-199105000-00009; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Raghupathi Ramesh, 1994, Society for Neuroscience Abstracts, V20, P542; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	25	20	23	0	0	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	JAN 20	1997	8	2					395	398		10.1097/00001756-199701200-00002			4	Neurosciences	Neurosciences & Neurology	WX340	WOS:A1997WX34000003	9080414				2021-06-18	
J	DunnMeynell, AA; Yarlagadda, Y; Levin, BE				DunnMeynell, AA; Yarlagadda, Y; Levin, BE			alpha(1)-adrenoceptor blockade increases behavioral deficits in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						contusion; desmethylimipramine; head trauma; norepinephrine; pharmacology; prazosin; somatosensory cortex	SENSORIMOTOR CORTEX INJURY; RAT-BRAIN; NORADRENERGIC DENERVATION; FUNCTIONAL RECOVERY; INCOMPLETE ISCHEMIA; NEURONAL DAMAGE; MOTOR RECOVERY; LOCUS-CERULEUS; NOREPINEPHRINE; NEUROTRANSMITTER	Experimental enhancement of noradrenergic activity following traumatic brain injury (TBI) accelerates behavioral recovery if performed at a time when brain norepinephrine (NE) turnover is decreased. But, since NE turnover is markedly increased immediately after TBI, the present study was undertaken to evaluate the effect of modulating these early changes in NE metabolism on recovery of function. Rats were pretrained on a modified beam walking task. Thirty minutes prior to unilateral somatosensory cortex contusion they were treated with a NE reuptake blocker [desmethylimipramine (DMI); 10 mg/kg, ip, n = 6] or an alpha(1)-adrenoreceptor antagonist [prazosin (PRZ); 3 mg/kg, ip, n = 6]. PRZ pretreatment markedly worsened beam walking performance throughout the 3 weeks following injury, whilst DMI pretreatment did not affect performance compared to injured controls (n = 4). Despite the marked behavioral deficits, PRZ-treated animals showed no apparent worsening of histological damage (n = 11 per group) and lesion size was the same in all groups. In separate experiments (n = 4 per group), PRZ lowered basal blood pressure and prevented the rise in pressure immediately following TBI. However, blood pressures in the three groups came to the same level within 20 sec following TBI. This suggests that the action of PRZ was not simply due to hypotension-induced ischemia. It is possible that blockade of al-adrenoreceptors in the immediate posttrauma period leads to enhancement of excitatory neurotransmission, which exacerbates behavioral deficits.	UNIV MED & DENT NEW JERSEY,DEPT NEUROSCI,NEWARK,NJ 07103	DunnMeynell, AA (corresponding author), DEPT VET AFFAIRS MED CTR,NEUROL SERV 127C,BLDG 7,385 TREMONS AVE,E ORANGE,NJ 07018, USA.						ARAKI T, 1989, ACTA NEUROL SCAND, V80, P451, DOI 10.1111/j.1600-0404.1989.tb03908.x; BOYESON MG, 1993, AM J PHYS MED REHAB, V72, P286, DOI 10.1097/00002060-199310000-00007; BOYESON MG, 1992, PHARMACOL BIOCHEM BE, V43, P771, DOI 10.1016/0091-3057(92)90407-7; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; CAVERO I, 1980, LIFE SCI, V27, P1525, DOI 10.1016/0024-3205(80)90561-5; CLINESCHMIDT BV, 1979, ARCH INT PHARMACOD T, V242, P59; Cooper JR, 1991, BIOCH BASIS NEUROPHA; CROWDER JM, 1987, EUR J PHARMACOL, V143, P343, DOI 10.1016/0014-2999(87)90458-4; DAVIS JN, 1989, CEREBROVASC DIS, P109; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; DUNNMEYNELL AA, 1994, BRAIN RES, V600, P88; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; GOLDSTEIN LB, 1993, RESTOR NEUROL NEUROS, V5, P371, DOI 10.3233/RNN-1993-55608; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; GUSTAFSON I, 1991, EXP BRAIN RES, V86, P555; HALONEN T, 1995, BRAIN RES, V693, P217, DOI 10.1016/0006-8993(95)00744-B; HARIK SI, 1984, ANN NEUROL, V15, P568, DOI 10.1002/ana.410150609; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOFFMAN WE, 1991, ANESTHESIOLOGY, V75, P328, DOI 10.1097/00000542-199108000-00022; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; ITO U, 1975, ACTA NEUROPATHOL, V32, P209, DOI 10.1007/BF00696570; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KAMISAKI Y, 1992, EUR J PHARMACOL, V217, P57, DOI 10.1016/0014-2999(92)90511-2; KO KH, 1984, EXPERIENTIA, V40, P70, DOI 10.1007/BF01959107; Kobayashi H, 1990, Adv Neurol, V52, P127; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; Krobert K. A., 1992, Society for Neuroscience Abstracts, V18, P172; LAWTHO D, 1993, EUR J NEUROSCI, V5, P1494, DOI 10.1111/j.1460-9568.1993.tb00217.x; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYNCH MA, 1988, NEUROPHARMACOLOGY, V25, P493; MANIAS B, 1983, EUR J PHARMACOL, V95, P305, DOI 10.1016/0014-2999(83)90652-0; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MENKES DB, 1981, N-S ARCH PHARMACOL, V317, P273, DOI 10.1007/BF00503830; MOURADIAN RD, 1991, BRAIN RES, V546, P83, DOI 10.1016/0006-8993(91)91162-T; NEVANDER G, 1986, EXP BRAIN RES, V63, P439; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; Pappius HM, 1995, NEUROCHEM RES, V20, P1311, DOI 10.1007/BF00992506; PAPPIUS HM, 1988, METAB BRAIN DIS, V3, P303, DOI 10.1007/BF00999542; PI F, 1992, N-S ARCH PHARMACOL, V345, P653, DOI 10.1007/BF00164579; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Prasad RM, 1995, RESTOR NEUROL NEUROS, V9, P65, DOI 10.3233/RNN-1995-9201; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RADISAVLJEVIC Z, 1994, INT J DEV NEUROSCI, V12, P353, DOI 10.1016/0736-5748(94)90085-X; READER TA, 1983, BRAIN RES BULL, V11, P687, DOI 10.1016/0361-9230(83)90012-6; REID JL, 1986, CARDIOLOGY, V73, P164, DOI 10.1159/000174002; RUFFOLO RR, 1994, PHARMACOL THERAPEUT, V61, P1, DOI 10.1016/0163-7258(94)90058-2; SARMENTO A, 1991, N-S ARCH PHARMACOL, V343, P633; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; SUTIN J, 1985, NEUROSCIENCE, V14, P973, DOI 10.1016/0306-4522(85)90269-6; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, pS181; SUTTON RL, 1994, NEUROLOGICAL REHABIL, P469; WERNER C, 1990, ANESTHESIOLOGY, V73, P923, DOI 10.1097/00000542-199011000-00021; WOOD AJ, 1975, CLIN EXP PHARMACOL P, V2, P297, DOI 10.1111/j.1440-1681.1975.tb01836.x; WU HQ, 1987, EUR J PHARMACOL, V138, P309, DOI 10.1016/0014-2999(87)90468-7	63	20	20	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1997	14	1					43	52		10.1089/neu.1997.14.43			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WK032	WOS:A1997WK03200005	9048310				2021-06-18	
J	Hartl, R; Ghajar, J; Hochleuthner, H; Mauritz, W				Hartl, R; Ghajar, J; Hochleuthner, H; Mauritz, W			Treatment of refractory intracranial hypertension in severe traumatic brain injury with repetitive hypertonic/hyperoncotic infusions	ZENTRALBLATT FUR CHIRURGIE			English	Article						head injury; hypertonic saline; small-volume resuscitation; colloids; intracranial pressure	7.5-PERCENT SODIUM-CHLORIDE; CEREBRAL BLOOD-FLOW; HYPERTONIC HYPERONCOTIC SOLUTIONS; SMALL-VOLUME RESUSCITATION; HEMORRHAGIC-SHOCK; SALINE DEXTRAN; HEAD-INJURY; FLUID RESUSCITATION; MULTICENTER TRIAL; WATER-CONTENT	Rapid resuscitation of clinical and experimental traumatic brain injury (TBI) with hypertonic saline (HS) has been shown to improve neurological function and decrease intracranial pressure (ICP). The purpose of the present study was to test the efficacy of administration of HS (7,5 %) combined with 6 % hydroxyethyl starch (molecular weight 200,000/0.60-0.66; HHES) for the treatment of intracranial hypertension refractory to standard therapy in patients with severe TBI. With approval of the Institutional Ethics Committee six consecutive patients with severe TBI (GCS < 8) between 22 and 47 years of age (mean 32) who met the inclusion criteria (therapy resistant ICP > 25 mmHg, cerebral perfusion pressure (CPP) < 60 mmHg, plasma-Na+ < 150 mOsm and > 4 hours since the last HS/HHES treatment) were proepectively enrolled in the study. Patients received between one and ten bolus infusions of maximal 250ml HS/HHES at a rate of 20 ml/min. A total of 32 infusions were given. ICP and CPP before treatment were 45 +/- 15 and 52 +/- 18 mmHg, respectively. Administration of HS/HHES significantly lowered ICP to 25 +/- 14 mmHg and improved CPP to 72 +/- 16 mmHg at 30 min without affecting arterial blood pressure or blood gases. Plasma sodium normalized within 30 min. HS/HES might become an interesting addition to conventional treatment maneuvers currently used for ICP therapy. It reduces otherwise therapy-resistant intracranial hypertension without negatively affecting blood pressure, blood gases and cerebral perfusion.	TRAUMA HOSP,VIENNA,AUSTRIA							BATTISTELLA F, 1992, CIRC SHOCK, V37, P16; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BULLOCK R, 1995, GUIDELINES MANAGEMEN; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HARTL R, 1995, SHOCK, V3, P274; Hartl R., 1995, Journal of Neurotrauma, V12, P416; HARTL R, 1993, INTRACRANIAL PRESSUR, V8, P612; KRAMER GC, 1986, SURGERY, V100, P239; KREIMEIER U, 1990, J SURG RES, V49, P493, DOI 10.1016/0022-4804(90)90174-Z; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; Meier-Hellmann A, 1990, EUR SURG RES, V22, P303; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MURR R, 1992, CURR OPIN ANAESTH, V5, P285; PROUGH D S, 1991, Anesthesia and Analgesia, V73, P738; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; PROUGH DS, CRIT CARE MED, V13, P407; SCHACKFORD SR, 1988, SURGERY, V104, P553; SCHURER L, 1992, EUR SURG RES, V24, P1, DOI 10.1159/000129183; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Vassar MJ, 1991, ARCH SURG-CHICAGO, V126, P43; VELASCO IT, 1989, CRIT CARE MED, V17, P261, DOI 10.1097/00003246-198903000-00012; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	34	20	22	0	0	JOHANN AMBROSIUS BARTH VERLAG	HEIDELBERG	IM WEIHER 10, D-69121 HEIDELBERG, GERMANY	0044-409X			ZBL CHIR	Zent.bl. Chir.		1997	122	3					181	185					5	Surgery	Surgery	WU705	WOS:A1997WU70500010	9128912				2021-06-18	
J	Vitale, AE; Jankowski, LW; Sullivan, SJ				Vitale, AE; Jankowski, LW; Sullivan, SJ			Reliability of a walk/run test to estimate aerobic capacity in a brain-injured population	BRAIN INJURY			English	Article							WALKING TEST; RESPIRATORY-DISEASE; TREADMILL WALKING; DISABILITY	The purpose of this study was to establish the test-retest reliability of a modified 20 m shuttle walk/run test of aerobic capacity for adults with traumatic brain injuries (TBI). A convenience sample of 18 TBI patients (16 males, two females) between 19 and 58 years of age, was tested using an externally paced, progressive, maximal shuttle walk/run, on two separate occasions, within a 1-week period. The test involved walking or running a 20 m shuttle course while maintaining the pace determined by signals from a prerecorded audiotape. The initial slow walking pace (2.4 km/h) was increased gradually, each minute, until the patient could not continue. Statistical analyses revealed excellent reliability for the number of levels completed (ICC = 0.976), total walk/run test time (S)(ICC = 0.983) and maximal heart rate attained during the final level (bpm) (ICC = 0.964). Although small but significant increases were noted for the number of levels completed during the second test, the modified 20 m shuttle walk/run seems to be a reliable field test which may be useful for assessing the aerobic capacity of brain-injured adults.	CONCORDIA UNIV,DEPT EXERCISE SCI,MONTREAL,PQ H4B 1R6,CANADA; UNIV MONTREAL,FAC MED,MONTREAL,PQ H3C 3J7,CANADA; INST READAPTAT MONTREAL,CTR RECH,MONTREAL,PQ,CANADA							American College of Sports Medicine, 1991, GUID EX TEST PRESCR; AUERBACH SH, 1989, PHYSICAL MED REHABIL, V3, P1; BEAUMONT A, 1985, THORAX, V40, P459, DOI 10.1136/thx.40.6.459; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; COOPER KH, 1968, J AMER MED ASSOC, V203, P201, DOI 10.1001/jama.203.3.201; EVANS RM, 1979, ACTA NEUROCHIRURGI S, V28, P52; FROST EAM, 1989, NEUROTRAUMA TREATMEN, V1, P29; Greenleaf J E, 1982, Exerc Sport Sci Rev, V10, P84; Guyton AC, 1991, TXB MED PHYSL; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; KOTTKE FJ, 1966, J AMER MED ASSOC, V196, P825, DOI 10.1001/jama.196.10.825; Leger L, 1980, Can J Appl Sport Sci, V5, P77; LEGER L, 1988, PHYSICIAN SPORTSMED, V16, P143, DOI 10.1080/00913847.1988.11709511; Leger L, 1984, Can J Appl Sport Sci, V9, P64; Leger LA, 1988, J SPORT SCI, V6, P93, DOI 10.1080/02640418808729800; Leger L A, 1983, Can J Appl Sport Sci, V8, P47; LEGER LA, 1982, EUR J APPL PHYSIOL O, V49, P1, DOI 10.1007/BF00428958; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; LIPKIN DP, 1986, BRIT MED J, V292, P653, DOI 10.1136/bmj.292.6521.653; LOWENSOHN RI, 1977, LANCET, V1, P626; MCGAVIN CR, 1978, BRIT MED J, V2, P241, DOI 10.1136/bmj.2.6132.241; MONTGOMERY DL, 1992, CAN J SPORT SCI, V17, P309; ROSSI C, IN PRESS ARCH PHYSIC; SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; SWERTS PMJ, 1990, PHYS THER, V70, P439, DOI 10.1093/ptj/70.7.439; Vitale AE, 1996, BRAIN INJURY, V10, P367, DOI 10.1080/026990596124377; VITALE AE, 1995, PERCEPT MOTOR SKILL, V80, P57, DOI 10.2466/pms.1995.80.1.57; Whyte J, 1993, REHABILITATION MED P, P825; Wolman RL, 1994, CLIN REHABIL, V8, P253	31	20	20	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1997	11	1					67	76		10.1080/026990597123827			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WB723	WOS:A1997WB72300007	9012553				2021-06-18	
J	Chappell, JE; McBride, WJ; Shackford, SR				Chappell, JE; McBride, WJ; Shackford, SR			Diaspirin cross-linked hemoglobin resuscitation improves cerebral perfusion after head injury and shock	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						diaspirin cross-linked hemoglobin; head injury; shock; cerebral perfusion pressure	FLUID-PERCUSSION MODEL; BRAIN-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; OXYGEN DELIVERY; HEMODYNAMICS; EPIDEMIOLOGY; HYPOTENSION; DISABILITY; HEMORRHAGE	Background: Shock associated with traumatic brain injury (TBI) doubles the mortality of TBI alone by inducing a secondary ischemic injury, Rapid correction of cerebral perfusion pressure (CPP) is thought to be essential to improving outcome, Diaspirin cross-linked hemoglobin (DCLHb) has been shown to improve cerebral blood flow, increase mean arterial pressure (MAP), and reduce lesion size in models of occlusive cerebral ischemia but has not been evaluated in a model of TBI combined with hemorrhagic shock. Methods: We studied the effects of DCLHb resuscitation in a porcine model of cryogenic TBI and hemorrhagic shock (MAP = 50 mmHg). After combined insults, animals were randomized to receive a bolus of 4 mL/kg of either lactated Ringer's solution (n = 5) or DCLHb (n = 6), Lactated Ringer's solution was then infused in both groups to maintain MAP at baseline, Shed blood was returned 1 hour after the initiation of resuscitation (R1), Animals were studied for 24 hours. Results: DCLHb infusion resulted in a significantly greater MAP at R1 and R24 (95 +/- 4 vs, 82 +/- 2 and 99 +/- 3 vs, 85 +/-3 mm Hg, respectively) and a significantly greater CPP at R1 and R24 (83 +/- 10 vs, 68 +/- 5 and 89 +/- 6 vs, 71 +/- 11 mm Hg, respectively), Intracranial pressure was lower in the DCLHb group, but this difference was not significant, There was no significant difference between the groups in cerebral oxygen delivery, DCLHb animals required less fluid to maintain MAP (12,094 +/- 552 vs, 15,542 +/- 1094 mL, p < 0.05). Conclusion: These data suggest that DCLHb is beneficial in the early resuscitation of head injury and shock and that further investigation is warranted.	UNIV VERMONT, DEPT SURG, BURLINGTON, VT 05401 USA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030324] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20-NS30324-03] Funding Source: Medline		ALI J, 1993, HEAD TRAUMA, P159; AUKLAND K, 1964, CIRC RES, V14, P164, DOI 10.1161/01.RES.14.2.164; BROWN MM, 1985, BRAIN, V108, P81, DOI 10.1093/brain/108.1.81; BUCCI E, 1992, J BIOMAT ARTIF CELLS, V20, P76; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLASEN RA, 1953, SURG GYNECOL OBSTET, V96, P605; COLE DJ, 1993, ANESTHESIOLOGY, V78, P335, DOI 10.1097/00000542-199302000-00018; COLE DJ, 1990, ACTA NEUROPATHOL, V80, P152, DOI 10.1007/BF00308918; GUYTON AC, 1996, TXB MED PHYSL, V9, P516; KAIEDA R, 1989, NEUROSURGERY, V24, P671, DOI 10.1227/00006123-198905000-00003; KIEPERT PE, 1992, J BIOMAT ARTIF CELLS, V20, P516; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NELSON D, 1992, BIOMAT ARTIF CELL IM, V20, P423, DOI 10.3109/10731199209119662; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PRZYBELSKI RJ, 1990, J LAB CLIN MED, V115, P579; PRZYBELSKI RJ, 1991, J LAB CLIN MED, V117, P143; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SCHMOKER JD, 1993, J TRAUMA, V35, P627; SCHULTZ SC, 1993, J TRAUMA, V35, P619, DOI 10.1097/00005373-199310000-00019; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHACKFORD SR, 1992, J INTENSIVE CARE MED, V7, P170; SHARMA AC, 1994, J LAB CLIN MED, V123, P299; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; TODA N, 1990, AM J PHYSIOL, V258, pH57; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023; Zornow M H, 1995, New Horiz, V3, P488; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005	36	20	21	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	1996	41	5					781	788		10.1097/00005373-199611000-00003			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	VR635	WOS:A1996VR63500003	8913204				2021-06-18	
J	Bigler, ED				Bigler, ED			Brain imaging and behavioral outcome in traumatic brain injury	JOURNAL OF LEARNING DISABILITIES			English	Article							INDUCED DEGENERATIVE CHANGES; HEAD-INJURY; MEMORY; CT; MORPHOLOGY; INDEX; MODEL; MRI	Brain imaging studies have become an essential diagnostic assessment procedure in evaluating the effects of traumatic brain injury (TBI). Such imaging studies provide a wealth of information about structural and functional deficits following TBI. But how pathologic changes identified by brain imaging methods relate to neurobehavioral outcome is not as well known. Thus, the focus of this article is on brain imaging findings and outcome following TBI. The article starts with an overview of current research dealing with the cellular pathology associated with TBI. Understanding the cellular elements of pathology permits extrapolation to what is observed with brain imaging. Next, this article reviews the relationship of brain imaging findings to underlying pathology and how that pathology relates to neurobehavioral outcome. The brain imaging techniques of magnetic resonance imaging, computerized tomography, and single photon emission computed tomography are reviewed. Various image analysis procedures, and how such findings relate to neuropsychological testing, are discussed. The importance of brain imaging in evaluating neurobehavioral deficits following brain injury is stressed.		Bigler, ED (corresponding author), BRIGHAM YOUNG UNIV, DEPT PSYCHOL, 1086 KIMBALL TOWER, PROVO, UT 84602 USA.						ADAM C, 1994, ARCH NEUROL-CHICAGO, V51, P130, DOI 10.1001/archneur.1994.00540140036012; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; Bigler E. D., 1989, NEUROPSYCHOLOGICAL F; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; BIGLER ED, 1994, PERSP INDIV, P1; BIGLER ED, 1987, J LEARN DISABIL, V20, P454, DOI 10.1177/002221948702000803; BIGLER ED, 1994, FUNCTIONAL NEUROIMAG, P121; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; COURCHESNE E, 1994, NEUROLOGY, V44, P203, DOI 10.1212/WNL.44.2.203; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FISHMAN PS, 1993, J NEUROTRAUM, V10, P457, DOI 10.1089/neu.1993.10.457; Fishman RA., 1992, CEREBROSPINAL FLUID; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; HAYES RL, 1989, HEAD INJURY, P427; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; ICHISE M, 1994, J NUCL MED, V35, P217; JOHNSON SC, 1994, BRAIN RES BULL, V35, P373, DOI 10.1016/0361-9230(94)90116-3; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOSSLYN SM, 1993, CEREB CORTEX, V3, P567, DOI 10.1093/cercor/3.6.567; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; NEUWELT EA, 1989, IMPLICATIONS MOOD BR, V1; NEUWELT EA, 1989, IMPLICATIONS BLOOD B, V2; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1993, ANN M INT ASS STUD T; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; SCHMIDT RH, 1993, J NEUROTRAUMA, V10, P425; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99	41	20	20	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0022-2194			J LEARN DISABIL-US	J. Learn. Disabil.	SEP	1996	29	5					515	530		10.1177/002221949602900507			16	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	VJ057	WOS:A1996VJ05700007	8870522				2021-06-18	
J	Freitas, J; Puig, J; Rocha, AP; Lago, P; Teixeira, J; Carvalho, MJ; Costa, O; deFreitas, AF				Freitas, J; Puig, J; Rocha, AP; Lago, P; Teixeira, J; Carvalho, MJ; Costa, O; deFreitas, AF			Heart rate variability in brain death	CLINICAL AUTONOMIC RESEARCH			English	Article						brain death; heart rate variability; autonomic central reflexes	POWER SPECTRUM ANALYSIS; INJURY	The sensitivity and specificity of heart rare variability (HRV) in the corroboration of brain death diagnosis in patients with acute traumatic intracranial lesions was evaluated in 20 patients with clinical criteria of brain death, nine patients in deep coma (Glasgow scale < 7) and 18 normal controls, all age marched. The electrocardiogram was sampled at 650 Hz and several parameters of HRV were calculated, in both rime and frequency domains. The HRV parameters were significantly lower in the brain death group compared with the deep coma group. Linear discriminant analysis between brain death and deep coma patients was performed on a data set made of nine randomly selected patients with clinical criteria of brain death and nine patients in deep coma. Cross-validation was performed on the remaining 11 patients with clinical criteria of brain death. All patients in the data set were correctly classified (sensitivity and specificity of 100%). All patients in the cross-validation set were correctly classified (sensitivity of 100%). Further studies are necessary to evaluate the specificity of the method in the independent set: of deep coma patients and in the follow-up of comatose and vegetative patients to identify irreversibility of HRV. Nevertheless, these results suggest that HRV analysis constitutes a fully sensitive and specific method for assessing brain death in potential organ donors with acute traumatic lesions of the brain. This fast, quantitative and bedside method seems very promising for the early confirmation of brain death, which is an important factor for the success of transplantation procedures and could have a high predictive value of brain death in comatose patients with brain injuries without fully diagnostic criteria.	UNIV PORTO, HOSP SAO JOAO, FDN AUTON CORINO ANDRADE & CIRURG VASC, CTR ESTUDOS, P-4200 OPORTO, PORTUGAL; UNIV PORTO, GRP MATEMAT APLICADA, P-4200 OPORTO, PORTUGAL			Costa, Ovidio/L-7319-2014; Rocha, Ana Paula/D-2813-2012; Freitas, Joao/AAT-6698-2020	Costa, Ovidio/0000-0001-7279-3706; Rocha, Ana Paula/0000-0003-3218-7001; Freitas, Joao/0000-0001-7478-3042	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [14370497] Funding Source: KAKEN		AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; BERNARDI L, 1993, BLOOD PRESSURE HEART, P143; CARVALHO MJ, 1991, J HYPERTENS, V9, pS62; CLIFTON GL, 1983, J NEUROSURG, V59, P637; COSTA O, 1994, J ELECTROCARDIOL, V27, P251, DOI 10.1016/S0022-0736(94)80009-X; FRANK JI, 1992, ARCH NEUROL-CHICAGO, V49, P1200, DOI 10.1001/archneur.1992.00530350122028; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P228, DOI 10.1097/00003246-199302000-00014; KITA Y, 1993, J AUTONOM NERV SYST, V44, P101, DOI 10.1016/0165-1838(93)90022-M; KLEIGER R E, 1992, Cardiology Clinics, V10, P487; LACQUANITI LG, 1993, INT J CLIN MONIT COM, V10, P181, DOI 10.1007/BF01246453; ORI Z, 1992, Cardiology Clinics, V10, P499; RUBENSTEIN E, SCI AM MED, P1; SANDS KEF, 1989, CIRCULATION, V79, P76, DOI 10.1161/01.CIR.79.1.76; SCWARTZ G, 1987, FUNCTIONAL NEUROLOGY, V2, P149; TEASDALE G, 1974, LANCET, V2, P81; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875	16	20	20	0	2	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-9851			CLIN AUTON RES	Clin. Auton. Res.	JUN	1996	6	3					141	146		10.1007/BF02281900			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	UZ057	WOS:A1996UZ05700002	8832122				2021-06-18	
J	Ham, LP; Packard, RC				Ham, LP; Packard, RC			A retrospective, follow-up study of biofeedback-assisted relaxation therapy in patients with posttraumatic headache	BIOFEEDBACK AND SELF-REGULATION			English	Article						post-traumatic headache; EMG biofeedback; thermal biofeedback; mild head injury; relaxation training	TENSION HEADACHE; BRAIN INJURY; PSYCHOTHERAPY; EFFICACY	Although biofeedback in the treatment of migraine and tension-type headache has been widely researched, there is little research examining biofeedback therapy in posttraumatic headache (PTH). In this retrospective study, 40 subjects with PTH who had received biofeedback-assisted relaxation at our headache clinic were questioned at least 3 months following the completion of therapy. Subjects were queried about improvements in headache increases in ability to relax and cope with pain, and overall benefits, lasting effectiveness, and continued use of biofeedback in daily life. Results indicate 53% reported at least moderate improvement in headaches; 80% reported at least moderate improvement in ability to relax and cope with pain; 93% found biofeedback helpful to some degree; 85% felt headache relief achieved through biofeedback had continued at least somewhat; and 95% stared they were continuing to use biofeedback skills in daily life. A correlation analysis revealed a negative relationship between response to biofeedback and increased chronicity of the disorder. In other words, the more chronic the disorder, the poorer the response to treatment. A stepwise regression analysis found that chronicity of the disorder and number of treatment sessions significantly affected response to treatment. Data suggest that biofeedback-assisted relaxation should at least be considered when planning treatment strategies for posttraumatic headache.		Ham, LP (corresponding author), HEADACHE MANAGEMENT & NEUROL,5500 N DAVIS HIGHWAY,SUITE 1,PENSACOLA,FL 32503, USA.						ADLER CS, 1976, HEADACHE, V16, P189, DOI 10.1111/j.1526-4610.1976.hed1604189.x; ADLER CS, 1987, PSYCHIAT ASPECTS HEA, P349; ADLER CS, 1985, UPDATING HEADACHE, P246; ANDRASIK F, 1984, J CONSULT CLIN PSYCH, V52, P609, DOI 10.1037/0022-006X.52.4.609; ANDRASIK F, 1987, BIOFEEDBACK STUDIES, P281; BELL NW, 1983, HEADACHE, V23, P162, DOI 10.1111/j.1526-4610.1983.hed2304162.x; Blanchard E. B., 1987, BIOFEEDBACK STUDIES, P1; BLANCHARD EB, 1982, J CONSULT CLIN PSYCH, V50, P562, DOI 10.1037/0022-006X.50.4.562; BLANCHARD EB, 1985, HEADACHE, V25, P214, DOI 10.1111/j.1526-4610.1985.hed2504214.x; BLANCHARD EB, 1981, BEHAV THER, V12, P711, DOI 10.1016/S0005-7894(81)80142-6; BLANCHARD EB, 1982, BEHAV RES THER, V20, P469, DOI 10.1016/0005-7967(82)90068-7; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; BUDZYNSKI T, 1970, J BEHAV THER EXP PSY, V1, P205, DOI 10.1016/0005-7916(70)90004-2; CAHN T, 1980, BIOFEEDBACK SELF-REG, V5, P265, DOI 10.1007/BF00998602; DIAMOND S, 1979, HEADACHE, V19, P90, DOI 10.1111/j.1526-4610.1979.hed1902090.x; DIAMOND S, 1984, HEADACHE, V24, P5, DOI 10.1111/j.1526-4610.1984.hed2401005.x; DIAMOND S, 1979, HEADACHE, V19, P180, DOI 10.1111/j.1526-4610.1979.hed1903180.x; DUCKRO PN, 1985, HEADACHE, V25, P328; ELKIND AH, 1992, PRACTICING PHYSICIAN, P146; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; EVANS RW, 1992, NEUROL CLIN, V10, P975; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; McGrady AV, 1983, J HOLISTIC MED, V5, P130; MEDINA JL, 1992, HEADACHE, V32, P180, DOI 10.1111/j.1526-4610.1992.hed3204180.x; MORGAN AS, 1989, J NATL MED ASSOC, V81, P1133; OLSON RP, 1988, BIOFEEDBACK SELF-REG, V13, P331; PACKARD RC, 1993, HEADACHE, V33, P133, DOI 10.1111/j.1526-4610.1993.hed3303133.x; PACKARD RC, 1992, HEADACHE, V32, P496, DOI 10.1111/j.1526-4610.1992.hed3210496.x; PACKARD RC, 1994, SEMIN NEUROL, V14, P40, DOI 10.1055/s-2008-1041057; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; PACKARD RC, 1993, WOLFFS HEADACHE OTHE, P462; SCHWARTZ MS, 1995, BIOFEEDBACK PRACTITI, P313; SPEED WG, 1986, PRACTICING PHYSICIAN, P113; 1988, CEPHALALGIA S7, V8, P1	35	20	20	0	1	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0363-3586			BIOFEEDBACK SELF-REG	Biofeedback Self-Regul.	JUN	1996	21	2					93	104		10.1007/BF02284689			12	Psychology, Clinical	Psychology	UT735	WOS:A1996UT73500001	8805960				2021-06-18	
J	Richard, I; Giraud, M; PerrouinVerbe, B; Hiance, D; delaGreve, IM; Mathe, JF				Richard, I; Giraud, M; PerrouinVerbe, B; Hiance, D; delaGreve, IM; Mathe, JF			Laryngotracheal stenosis after intubation or tracheostomy in patients with neurological disease	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; INTENSIVE-CARE UNIT; ENDOTRACHEAL INTUBATION; AIRWAY COMPLICATIONS; ASSISTED VENTILATION; PROLONGED INTUBATION; PATHOGENESIS; TRACHEOTOMY	Objective: This retrospective study evaluated the incidence of ah-way complications in neurological patients following translaryngeal intubation, tracheostomy, or both. Design: The medical records of 315 consecutive patients (200 with traumatic brain injuries, 31 traumatic tetraplegics, and 84 with other neurological disorders) were reviewed. The type of artificial airway, duration of intubation, and use of nocturnal ventilation were recorded. Eighty-six percent of the patients underwent some combination of tracheal tomograms, flow-volume loop analysis, and fiberoptic tracheolaryngoscopy. Stenosis was classified as severe if it required surgery, if it required maintaining the tracheostomy, or was lethal. It was classified as benign if it was successfully treated by medical or local means. Results: Fifty-five percent of the patients were intubated translaryngeally only (mean = 17 days). Three percent underwent tracheostomy only, and 42% underwent tracheostomy after intubation for a mean of 13 days. The overall incidence of airway stenosis was 20%, 1/4 of which was severe, Fifteen percent of these patients died as a result of tracheal complications. The incidence of stenosis was higher following tracheostomy than following intubation only (29% vs 13%,p <.01). The incidence of severe stenosis in intubated-only patients was low (1%) compared with that following tracheostomy (10%, p <.01). No significant relationship was found between the length of intubation or the timing of tracheostomy. Conclusion: Fewer complications are associated with transtracheal intubation than with tracheostomy. The data suggest that longer periods of intubation be used when attempting ventilator weaning before resorting to tracheostomy if weaning fails. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	CHRU NANTES,HOP ST JACQUES,CLIN OTORHINOLAYNGOL & CHIRURG CERVICOFACIAL,F-44035 NANTES,FRANCE	Richard, I (corresponding author), CHRU NANTES,HOP ST JACQUES,SERV REEDUC FONCT,85 RUE ST JACQUES,F-44035 NANTES,FRANCE.						ANDREWS MJ, 1971, ANN SURG, V173, P249, DOI 10.1097/00000658-197102000-00012; AROLA MK, 1981, ACTA CHIR SCAND, V147, P183; Bach J R, 1991, J Am Paraplegia Soc, V14, P158; BACH JR, 1993, CHEST, V104, P1553, DOI 10.1378/chest.104.5.1553; BISHOP MJ, 1984, ANESTH ANALG, V63, P335; CITTAPIETROLUNGO TJ, 1993, ARCH PHYS MED REHAB, V74, P905; COLICE GL, 1989, CHEST, V96, P877, DOI 10.1378/chest.96.4.877; COMBES P, 1991, REAN SOINS INTENS ME, V7, P254; DANE TEB, 1975, CHEST, V67, P398, DOI 10.1378/chest.67.4.398; DAYAL VS, 1986, LARYNGOSCOPE, V96, P58; DUNHAM CM, 1984, J TRAUMA, V24, P120, DOI 10.1097/00005373-198402000-00005; ENRIQUE VR, 1981, CRIT CARE MED, V9, P637; GAYNOR EB, 1985, LARYNGOSCOPE, V95, P1461; HEFFNER JE, 1986, CHEST, V90, P269, DOI 10.1378/chest.90.2.269; HEFFNER JE, 1986, CHEST, V90, P430, DOI 10.1378/chest.90.3.430; KASTANOS N, 1983, CRIT CARE MED, V11, P362, DOI 10.1097/00003246-198305000-00009; KIRCHNER JC, 1988, LARYNGOSCOPE, V98, P1165; KLINGBEIL GEG, 1988, ARCH PHYS MED REHAB, V69, P493; LEWIS FR, 1970, AM J SURG, V135, P452; LEWIS RJ, 1992, CLIN CHEST MED, V13, P137; MARSH HM, 1989, CHEST, V96, P190, DOI 10.1378/chest.96.1.190; MCCAFFREY TV, 1992, LARYNGOSCOPE, V102, P1335, DOI 10.1288/00005537-199212000-00004; MILLER JD, 1984, SURG NEUROL, V22, P186, DOI 10.1016/0090-3019(84)90050-8; NOWAK P, 1987, AM J OTOLARYNG, V8, P91, DOI 10.1016/S0196-0709(87)80030-3; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; RASHKIN MC, 1986, CHEST, V89, P165, DOI 10.1378/chest.89.2.165; Richard I., 1993, Annales de Readaptation et de Medecine Physique, V36, P401; SQUIRE R, 1990, LARYNGOSCOPE, V100, P765; STAUFFER JL, 1981, AM J MED, V70, P65, DOI 10.1016/0002-9343(81)90413-7; STREITZ JM, 1991, SURG CLIN N AM, V71, P1211; VOGELHUT MM, 1979, CHEST, V76, P110, DOI 10.1378/chest.76.1.110; WAIN JC, 1990, ANN THORAC SURG, V49, P881, DOI 10.1016/0003-4975(90)90860-9; WHITED RE, 1984, LARYNGOSCOPE, V94, P364; WOO P, 1989, LARYNGOSCOPE, V99, P725	34	20	22	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	1996	77	5					493	496		10.1016/S0003-9993(96)90039-8			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	UM466	WOS:A1996UM46600013	8629927				2021-06-18	
J	Kopke, R; Staecker, H; Lefebvre, P; Malgrange, B; Moonen, G; Ruben, RJ; VandeWater, TR				Kopke, R; Staecker, H; Lefebvre, P; Malgrange, B; Moonen, G; Ruben, RJ; VandeWater, TR			Effect of neurotrophic factors on the inner ear: Clinical implications	ACTA OTO-LARYNGOLOGICA			English	Article						auditory neurons; brain derived neurotrophic factor (BDNF); neuritogenesis; neuronal survival; neurotrophin-3 (NT-3); sensorineural deafness	ADULT AUDITORY NEURONS; TRANSLABYRINTHINE APPROACH; HEARING PRESERVATION; EXPRESSION; GANGLION; SURVIVAL; CULTURE	Loss of auditory neurons is commonly associated with sensorineural deafness, and may result from either direct neuronal injury or be a consequence of sensory hair cell loss (i.e. loss of a source of trophic factors). Developmental studies and in vitro studies of adult auditory neurons have begun to identify growth factors important for the development, maintenance, and rescue/repair of auditory neurons. Specific neurotrophic factors have been shown to enhance the auditory neurons' ability to withstand traumatic loss of target tissue connections and toxic injury. Promising initial in vivo studies confirm that specific neurotrophins are able to support neuronal survival and promote neuronal repair in an intact animal following injury to the cochlea. Further study into unique methods and routes of growth factor delivery will provide insights into the possibility of neurotrophic growth factors to act as drugs for the treatment of injured or stressed auditory neurons.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT OTOLARYNGOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461; UNIV LIEGE,DEPT HUMAN PHYSIOL & PATHOPHYSIOL,LIEGE,BELGIUM			Malgrange, Brigitte/A-4887-2019	Malgrange, Brigitte/0000-0002-8957-2528; Staecker, Hinrich/0000-0002-0348-3015	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC00008] Funding Source: Medline		ARD MD, 1985, NEUROSCIENCE, V16, P151, DOI 10.1016/0306-4522(85)90053-3; BROWN JN, 1993, HEARING RES, V70, P167, DOI 10.1016/0378-5955(93)90155-T; ERNFORS P, 1995, NEURON, V14, P1153, DOI 10.1016/0896-6273(95)90263-5; FISHMAN JB, 1987, J NEUROSCI RES, V18, P299, DOI 10.1002/jnr.490180206; HIRSCH BE, 1993, AM J OTOL, V14, P533; JUHN SK, 1981, ANN OTO RHINOL LARYN, V90, P135, DOI 10.1177/000348948109000208; LEFEBVRE PP, 1992, NEUROREPORT, V3, P295, DOI 10.1097/00001756-199204000-00001; LEFEBVRE PP, 1994, NEUROREPORT, V5, P865, DOI 10.1097/00001756-199404000-00003; LEFEBVRE PP, 1992, HEARING RES, V58, P185, DOI 10.1016/0378-5955(92)90127-9; LEFEBVRE PP, 1991, BRAIN RES, V567, P306, DOI 10.1016/0006-8993(91)90809-A; LEFEBVRE PP, 1991, NEUROREPORT, V2, P305, DOI 10.1097/00001756-199106000-00001; LUO L, 1993, HEARING RES, V69, P182; MARSH MA, 1991, 26 ANN SCI M AM NEUR; MCELVEEN JT, 1993, OTOLARYNG HEAD NECK, V108, P671, DOI 10.1177/019459989310800608; MONSELL EM, 1993, OTOLARYNG CLIN N AM, V26, P737; NADOL JB, 1989, ANN OTO RHINOL LARYN, V98, P411, DOI 10.1177/000348948909800602; SPEONDLIN H, 1988, OTOLOGIC MED SURG, P117; STAECKER H, 1995, NEUROREPORT, V6, P1533, DOI 10.1097/00001756-199507310-00017; STAECKER H, 1996, IN PRESS AM J OTOL; STAECKER H, 1995, MIDW M ASS RES OT FE; VANDEWATER TR, 1995, CLIN ASPECTS HEARING; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; YLIKOSKI J, 1993, HEARING RES, V65, P69, DOI 10.1016/0378-5955(93)90202-C; ZHANG JL, 1995, J NEUROSCI, V15, P5079; ZHOU XN, 1987, ACTA OTO-LARYNGOL, V104, P90, DOI 10.3109/00016488709109052	25	20	21	0	1	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0001-6489			ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	MAR	1996	116	2					248	252		10.3109/00016489609137834			5	Otorhinolaryngology	Otorhinolaryngology	UF493	WOS:A1996UF49300024	8725525				2021-06-18	
J	Cornelius, CP; Altenmuller, E; Ehrenfeld, M				Cornelius, CP; Altenmuller, E; Ehrenfeld, M			The use of flash visual evoked potentials in the early diagnosis of suspected optic nerve lesions due to craniofacial trauma	JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY			English	Article							INJURY; FRACTURES	Craniofacial trauma encroaching on the orbital apex and optic canal can result in direct or indirect optic nerve lesions, leading to visual impairment or blindness, Early diagnosis of a visual loss and immediate therapy are generally considered crucial for a successful restoration of vision in indirect trauma. However, in comatose or sedated patients the assessment of optic nerve function by testing pupillary reactivity may be severely compromised or impossible because of tensely swollen eyelids, conjunctival oedema, concussion of the ciliary muscle or pharmacological effects, In the event that clinical ophthalmic examination, computer tomography or nuclear magnetic resonance scanning fail to clarify the state of the optic nerve, visual evoked potentials (VEPs) to flash stimulation appear to provide reliable information on function within the visual pathway, On this basis, treatment with corticosteroids and/or surgical decompression can be rapidly initiated, Our results in a preliminary patient series confirm the value of acutely monitored VEPs as an objective test of optic nerve function in cases of suspected optic nerve injury immediately after admission to the emergency care unit, The imaging techniques usually applied may be complemented by VEPs to show the functional significance of structural abnormalities found in the vicinity of the optic nerve.	UNIV TUBINGEN,DEPT NEUROL,D-72076 TUBINGEN,GERMANY	Cornelius, CP (corresponding author), UNIV TUBINGEN,KLIN KIEFER GESICHTSCHIRURG,DEPT MAXILLOFACIAL SURG,OSIANDERSTR 2-8,D-72076 TUBINGEN,GERMANY.						ALTENMULLER E, 1991, EEG-EMG-Z ELEK ELEKT, V22, P224; Altenmuller E, 1989, EVOZIERTE POTENTIALE, P279; BEHRENSBAUMANN W, 1979, KLIN MONATSBL AUGENH, V175, P584; BEUTHNER D, 1974, LARYNG RHINOL OTOL V, V53, P830; BRIHAYE J, 1981, CRANIAL NERVES, P116; CELESIA GG, 1977, NEUROLOGY, V27, P637, DOI 10.1212/WNL.27.7.637; CLIFFORDJONES RE, 1980, J NEUROL SCI, V46, P239, DOI 10.1016/0022-510X(80)90082-9; Dumbach J, 1991, Fortschr Kiefer Gesichtschir, V36, P162; FEINSOD M, 1973, EUR NEUROL, V9, P56, DOI 10.1159/000114201; FEINSOD M, 1976, HEAD INJURIES, P95; Frenkel R E, 1987, Adv Ophthalmic Plast Reconstr Surg, V6, P71; FUKADO Y, 1981, CRANIAL NERVES, P125; HAMMER B, 1995, ORBITAL FRACTURES DI; HASSLER W, 1985, ACTA NEUROCHIR, V74, P87, DOI 10.1007/BF01418794; HOLT GR, 1983, OTOLARYNG HEAD NECK, V91, P276, DOI 10.1177/019459988309100313; KALLELA I, 1994, J CRANIO MAXILL SURG, V22, P220, DOI 10.1016/S1010-5182(05)80561-X; KLINE LB, 1984, NEUROSURGERY, V14, P756, DOI 10.1227/00006123-198406000-00021; LIPKIN AF, 1987, ARCH OTOLARYNGOL, V113, P81; MAHAPATRA AK, 1989, SURG NEUROL, V31, P339, DOI 10.1016/0090-3019(89)90064-5; NEUBAUER H, 1987, FORTSCHR KIEFER GESI, V32, P223; OBERTACKE U, 1986, UNFALLCHIRURG, V89, P132; ORD RA, 1981, BRIT J ORAL SURG, V19, P202, DOI 10.1016/0007-117X(81)90005-6; OSGUTHORPE JD, 1988, OTOLARYNG CLIN N AM, V21, P155; Perneczky A, 1993, ENDOSCOPIC ANATOMY N; PICTON TW, 1987, TXB CLIN NEUROPHYSIO, P23; RICE DH, 1993, ENDOSCOPIC PARANSAL; SAMII M, 1989, SURGERY SKULL BASE I; SCHRODER M, 1989, LARYNGO RHINO OTOL, V68, P534, DOI 10.1055/s-2007-998394; SHAKED A, 1982, ACTA NEUROCHIR, V62, P91, DOI 10.1007/BF01402214; SPOOR TC, 1990, AM J OPHTHALMOL, V110, P665, DOI 10.1016/S0002-9394(14)77065-5; STOLL W, 1988, J CRANIO MAXILL SURG, V16, P308, DOI 10.1016/S1010-5182(88)80068-4; WALSH FB, 1979, OCULAR TRAUMA; WIEGAND ME, 1989, ENDOSKOPISCHE CHIRUR; Wilhelm H., 1991, PUPILLENREAKTIONEN P; Zrenner E, 1989, PROG RETIN RES, V9, P427	35	20	20	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH, MIDLOTHIAN, SCOTLAND EH1 3AF	0301-0503			J CRANIO MAXILL SURG	J. Cranio-MaxilloFac. Surg.	FEB	1996	24	1					1	11		10.1016/S1010-5182(96)80070-9			11	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	UE792	WOS:A1996UE79200001	8707935				2021-06-18	
J	Jordan, FM; Ashton, R				Jordan, FM; Ashton, R			Language performance of severely closed head injured children	BRAIN INJURY			English	Article							ADOLESCENTS; CHILDHOOD	The language functioning of a group of children who had sustained a severe closed head injury (CHI) was evaluated. The subjects were administered a battery of language assessments including measures of syntax, semantics and pragmatics. Performance of the experimental group was compared with that of a control group matched for age and sex. Results indicated that all areas of language competence assessed (syntax, semantics, pragmatics) appeared to be compromised by the childhood CHI. The findings of this study are considered in light of the implications for the existence of different language components (syntax, semantics, pragmatics) as opposed to a unified concept of language. Also considered is the evidence of a specific linguistic impairment in the childhood CHI population as opposed to a more generalized cognitive decline expressed as an overall decrease in performance across all domains of language skill.		Jordan, FM (corresponding author), UNIV QUEENSLAND,DEPT PSYCHOL,BRISBANE,QLD 4072,AUSTRALIA.						ARAM DM, 1991, ACQUIRED APHASIA, P425; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Bishop D.V.M., 1989, TEST RECEPTION GRAMM; BRUCE DA, 1983, PAEDIATRIC HEAD TRAU, P27; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DENNIS M, 1981, BRAIN LANG, V12, P33, DOI 10.1016/0093-934X(81)90004-3; DENNIS M, 1987, J CLIN EXP NEUROPSYC, V9, P723, DOI 10.1080/01688638708405213; Dennis M., 1988, CLIN NEUROPSYCHOLOGY, P85; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; FISHER J, 1992, HUNDRED PICTURES NAM; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Murdoch B. E., 1990, ACQUIRED SPEECH LANG; PAQUIER P, 1993, APHASIOLOGY, V7, P421, DOI 10.1080/02687039308248618; TEASDALE G, 1974, LANCET, V2, P81; Wiig E.H., 1985, TEST LANGUAGE COMPET; Wiig E. H., 1991, TEST WORD KNOWLEDGE; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	22	20	20	0	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1996	10	2					91	97		10.1080/026990596124575			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UB726	WOS:A1996UB72600002	8696319				2021-06-18	
J	ODell, MW; Jasin, P; Lyons, N; Stivers, M; Meszaros, F				ODell, MW; Jasin, P; Lyons, N; Stivers, M; Meszaros, F			Standardized assessment instruments for minimally-responsive, brain-injured patients	NEUROREHABILITATION			English	Article						traumatic brain injury; vegetative state; functional assessment; rehabilitation; health status; minimally responsive	HEAD-INJURY; RECOVERY; SCALE; COMA	Among the most significant advances in the care and rehabilitation of severely brain injured, minimally-responsive patients (MRP) has been the development of standardized assessment scales. Currently available instruments include the Coma/Near Coma Scale (CNC), Coma Recovery Scale (CRS), Sensory Stimulation Assessment Measure (SSAM), and the Western Neuro Sensory Stimulation Profile (WNSSP). Each scale is reviewed in terms of content, psychometric properties, and clinical attributes. Data is then presented comparing converted, percentile admission scores for the CRS, WNSSP, and CNC in a group of ten MRP at Rancho Levels II-IV, with a mean age of 31 years and mean time from injury of 37.5 days. Admission CNC and CRS scores tended to group in the middle range, while WNSSP scores tended to group in the lower quartile. This suggests the potential concern for 'floor effect' with the WNSSP. At admission, none of the three scales was able to effectively distinguish between dichotomized outcome variables: disposition (home vs. nursing home), advancement to active rehabilitation, or discharge Functional Independence Measure score (> 80 vs. < 80). The data indicate the CRS demonstrates moderately strong relationships with both the CNC and WNSSP. Full delineation of how these scales relate to one another awaits both cross-sectional and longitudinal analyses in larger samples and should include the SSAM.	DRAKE CTR INC,DEPT PSYCHOL,BRAIN INJURY REHABIL PROGRAM,CINCINNATI,OH; DRAKE CTR INC,DEPT SPEECH PSYCHOL,BRAIN INJURY REHABIL PROGRAM,CINCINNATI,OH; DRAKE CTR INC,DEPT THERAPEUT RECREAT,BRAIN INJURY REHABIL PROGRAM,CINCINNATI,OH	ODell, MW (corresponding author), UNIV CINCINNATI,COLL MED,DEPT PHYS MED & REHABIL,5161 MED SCI BLDG,MAIL LOCAT 530,CINCINNATI,OH 45267, USA.						Ansell B. J., 1993, J HEAD TRAUMA REHAB, V8, P88, DOI DOI 10.1097/00001199-199309000-00011; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; BINDMAN AB, 1990, MED CARE, V28, P1142, DOI 10.1097/00005650-199012000-00003; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; ELSTON RC, 1987, ESSENTIALS BIOSTATIS, P196; GIACINO J T, 1991, Archives of Physical Medicine and Rehabilitation, V72, P798; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Giacino JT, 1993, ARCH PHYS MED REHAB, V74, P662; GIACINO JT, 1994, ARCH PHYS MED REHAB, V75, P723; GRANGER CV, 1988, DEV UNIFORM NATL DAT; Hagen C, 1979, REHABILITATION HEAD, P87; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL M E, 1992, Brain Injury, V6, P435, DOI 10.3109/02699059209008139; ODELL MW, MED REHABILITATION T; ODELL MW, 1992, 54 ANN M AM AC PHYS; ODELL MW, IN PRESS J HEAD TRAU; Rader M A, 1989, Brain Inj, V3, P141, DOI 10.3109/02699058909004545; RADER MA, 1994, BRAIN INJURY, V8, P309, DOI 10.3109/02699059409150982; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; TALBOT LR, 1994, BRAIN INJURY, V8, P689, DOI 10.3109/02699059409151023; TEASDALE G, 1974, LANCET, V2, P81; 1995, ARCH PHYS MED REHAB, V76, P205	23	20	20	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1053-8135			NEUROREHABILITATION	Neurorehabilitation	FEB	1996	6	1					45	55		10.1016/1053-8135(95)00147-6			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TZ377	WOS:A1996TZ37700006	24525685				2021-06-18	
J	Papaefthymiou, G; Oberbauer, R; Pendl, G				Papaefthymiou, G; Oberbauer, R; Pendl, G			Craniocerebral birth trauma caused by vacuum extraction: A case of growing skull fracture as a perinatal complication	CHILDS NERVOUS SYSTEM			English	Article						perinatal head trauma; growing skull fracture; head injury in infancy and childhood; vacuum extraction	CHILDREN	A case of growing skull fracture following birth trauma and caused by vacuum extraction is reported in order to emphasize the incidence of this peculiar head injury at the beginning of extrauterine life and to point out its relation to possible neuropsychological disturbances that may appear later in childhood. Delivery by vacuum extraction increases the incidence of perinatal injuries and consequently the incidence of neurological deficits in children. Neurosurgical repair is advocated as the appropriate treatment, with the aim not only of cosmetically correcting the lesion's typical subgaleal protuberance with cranioplasty, but also of performing a water-tight closure of the dura, enabling the cerebral cortex to ''fill in'' the intracerebral lesion. The surgical technique and gross pathology of the lesion are described together with radiological findings before and after surgery. Reports by other authors are reviewed in an attempt to identify the conditioning factors and pathological features of this traumatic injury to skull and brain in neonates and infants. The literature on cranial fractures associated with intracerebral lesions at this age shows a significant difference in recovery and outcome from that after similar lesions in older children.		Papaefthymiou, G (corresponding author), KARL FRANZENS UNIV GRAZ, UNIV KLIN NEUROCHIRURG, AUENBRUGGERPLATZ 29, A-8036 GRAZ, AUSTRIA.						ARSENI C, 1981, CHILD BRAIN, V8, P161; AVRAHAMI E, 1993, NEURORADIOLOGY, V35, P107, DOI 10.1007/BF00593964; BARKOVICH AJ, 1990, CONT NEUROIMAGING, V1, P64; Benaron D A, 1993, J Perinatol, V13, P228; Chiofalo N., 1986, HEAD INJURIES NEWBOR, P217; Choux M., 1986, HEAD INJURIES NEWBOR, P163; EBEN A, 1969, J NEUROSURG, V30, P446; HOPPEHIRSCH E, 1993, CRIT REV NEUROSURG, V3, P260; Hovind KH, 1986, HEAD INJURIES NEWBOR, P87; KINGSLEY D, 1978, J NEUROL NEUROSUR PS, V41, P312, DOI 10.1136/jnnp.41.4.312; LENDE RA, 1961, J NEUROSURG, V18, P479, DOI 10.3171/jns.1961.18.4.0479; RAIMONDI AJ, 1986, HEAD INJURIES NEWBOR, P141; RAMAMURTHI B, 1970, J NEUROSURG, V32, P427, DOI 10.3171/jns.1970.32.4.0427; Rifkinson-Mann Stephanie, 1993, Contemporary Neurosurgery, V15, P1; SCARFF TB, 1985, NEUROSURGERY, P1627; SCARFO GB, 1989, CHILD NERV SYST, V5, P163, DOI 10.1007/BF00272120; TANDON PN, 1987, ACTA NEUROCHIR, V88, P1, DOI 10.1007/BF01400508; TAVERAS JM, 1953, J NEUROSURG, V10, P233, DOI 10.3171/jns.1953.10.3.0233; Velardi F., 1986, HEAD INJURIES NEWBOR, P125	19	20	20	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	FEB	1996	12	2					117	120		10.1007/BF00819511			4	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	TW380	WOS:A1996TW38000017	8674080				2021-06-18	
J	VecchieriniBlineau, MF; Nogues, B; Louvet, S; Desfontaines, O				VecchieriniBlineau, MF; Nogues, B; Louvet, S; Desfontaines, O			Positive temporal sharp waves in electroencephalograms of the premature newborn	NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY			English	Article						prematurity; EEG; waves	INTRAVENTRICULAR HEMORRHAGE; EEG RECORDINGS; NEONATAL EEG; FULL-TERM; INFANTS; PRETERM	Positive temporal sharp waves (PTS) were studied in electroencephalograms (EEG) of 92 premature infants born either at 31 and 32 weeks of gestational age, recorded during the first week of life. The infants were assigned either to a reference group (asymptomatic) or to one of three pathologic groups (neonatal asphyxia, hypoglycemia or hypocalcemia, or periventricular leukomalacia with rolandic positive sharp waves), Regardless of the group, no significant differences in PTS criteria (morphology, frequency, amplitude, duration and lateralization) were Found between 31- and 32-week infants. The PTS observed in 558 of the asymptomatic infants were characterized by low frequency (0.13 +/- 0.12/min), a mean amplitude of 109.8 +/- 25.8 mu V and a mean duration of 148.7 +/- 35.4 ms. For PTS recorded in 72 to 758 of pathologic infants, mean duration and amplitude were significantly greater in all groups than in asymptomatic infants, whereas frequency was significantly greater only in the group presenting with asphyxia. Discriminant analysis based un the three PTS criteria frequency, amplitude and duration) allowed correct classification for only 30 to 54% of infants in the four groups. The frequency of PTS decreased rapidly during the second week of life in asymptomatic infants, but persisted in a larger number of infants in the pathologic groups. This study shows that PTS have no negative significant with they are few in number, short in duration, moderate in amplitude and rapidly regressive, thus probably reflecting the vulnerability of the temporal lobe during the traumatic period of birth. However, they require attention when they are abundant and/or slow, ample or tend to persist. They may thus constitute a nonspecific response to injury to an immature brain.		VecchieriniBlineau, MF (corresponding author), LAB PHYSIOL APPL EXPLORAT FONCT,1 RUE GASTON VEIL,F-44035 NANTES,FRANCE.						BLUME WT, 1982, ELECTROEN CLIN NEURO, V53, P277, DOI 10.1016/0013-4694(82)90085-2; CHUNG HJ, 1991, ELECTROEN CLIN NEURO, V79, P256; CLANCY RR, 1984, NEUROLOGY, V34, P583, DOI 10.1212/WNL.34.5.583; CLANCY RR, 1984, ELECTROEN CLIN NEURO, V57, P395, DOI 10.1016/0013-4694(84)90068-3; Cukier F, 1972, Rev Electroencephalogr Neurophysiol Clin, V2, P318, DOI 10.1016/S0370-4475(72)80037-6; CURZIDASCALOVA L, 1993, PEDIATR RES, V34, P624, DOI 10.1203/00006450-199311000-00013; HUGHES JR, 1991, CLIN ELECTROENCEPHAL, V22, P30, DOI 10.1177/155005949102200108; HUGUES JR, 1987, ELECTROENCEPHALOGR C, V67, P7; JAMMES JL, 1983, DEV HUMAN BRAIN GROW, P87; KELLAWAY P, 1982, PRACTICE PEDIAT NEUR, P96; LACEY DJ, 1986, NEUROLOGY, V36, P1084, DOI 10.1212/WNL.36.8.1084; LOMBROSO CT, 1985, J CLIN NEUROPHYSIOL, V2, P105, DOI 10.1097/00004691-198504000-00002; MARRET S, 1992, ARCH DIS CHILD, V67, P948, DOI 10.1136/adc.67.7.948; MARRET S, 1986, NEUROPEDIATRICS, V17, P199, DOI 10.1055/s-2008-1052529; MARRET S, 1989, ARCH FR PEDIATR, V46, P249; NOVOTNY EJ, 1987, NEUROLOGY, V37, P1481, DOI 10.1212/WNL.37.9.1481; NOWACK W J, 1987, Journal of Clinical Neurophysiology, V4, P315; NOWACK WJ, 1989, CLIN ELECTROENCEPHAL, V20, P196, DOI 10.1177/155005948902000314; Nowack WJ, 1990, AM J EEG TECHNOL, V30, P211; POPE JE, 1992, ATLAS NEONATAL ELECT; SCHER MS, 1994, ELECTROEN CLIN NEURO, V90, P173, DOI 10.1016/0013-4694(94)90088-4; SCHER MS, 1994, ELECTROEN CLIN NEURO, V90, P179, DOI 10.1016/0013-4694(94)90089-2; VECCHIERINI-BLINEAU M F, 1990, Neurophysiologie Clinique, V20, p11S; VECCHIERINIBLIN.MF, 1993, ELECTROENCEPHALOGR C, V86; VecchieriniBlineau MF, 1996, NEUROPHYSIOL CLIN, V26, P102, DOI 10.1016/0987-7053(96)83150-9; Werner SS, 1977, ATLAS NEONATAL ELECT	26	20	21	0	1	EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	141 RUE JAVEL, 75747 PARIS, FRANCE	0987-7053			NEUROPHYSIOL CLIN	Neurophysiol. Clin.-Clin. Neurophysiol.		1996	26	6					350	362		10.1016/S0987-7053(97)89149-6			13	Clinical Neurology; Neurosciences; Physiology	Neurosciences & Neurology; Physiology	WA726	WOS:A1996WA72600003	9018697				2021-06-18	
J	Yamaki, T; Yoshino, E; Fujimoto, M; Ohmori, Y; Imahori, Y; Ueda, S				Yamaki, T; Yoshino, E; Fujimoto, M; Ohmori, Y; Imahori, Y; Ueda, S			Chronological positron emission tomographic study of severe diffuse brain injury in the chronic stage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							COMPUTERIZED-TOMOGRAPHY; TRAUMATIC COMA; HEAD-INJURY; DISORDERS; PET; MRI	Cerebral blood flow and metabolism were investigated in five patients with severe diffuse brain injury in the chronic stage, using positron emission tomography (PET). Regional cerebral blood flow, regional oxygen extraction fraction, regional cerebral blood volume, regional cerebral metabolic rate for oxygen, and regional cerebral metabolic rate for glucose were measured bilaterally in the frontal, temporal, occipital, and parietal gray matter, as well as the white matter of the centrum semiovale. In 4 of 5 patients, a follow-up PET study was also performed. In three cases, below-normal regional cerebral blood flow and regional cerebral metabolic rate for oxygen values accompanied by above-normal regional oxygen extraction fraction values, as well as low metabolism, were demonstrated in the initial PET studies. In two of three cases, clinical improvements were observed, and follow-up PET data also improved. These findings suggest that chronological PET studies may he able to assess quantitatively clinical improvements in patients with diffuse brain injury.	SAISEIKAI SHIGA HOSP, DEPT NEUROSURG, SAISEIKAI, JAPAN	Yamaki, T (corresponding author), KYOTO PREFECTURAL UNIV MED, DEPT NEUROSURG, KAMIGYO KU, KAWARAMACHI HIROKOJI, KYOTO 602, JAPAN.						ALAVI A, 1986, J NUCL MED, V27, P919; ALAVI A, 1987, J CEREB BLOOD FLO S1, V7, pS646; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ANSELL BJ, 1991, J SPEECH HEAR RES, V34, P1017, DOI 10.1044/jshr.3405.1017; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; HUTCHINS GD, 1984, J CEREBR BLOOD F MET, V4, P35, DOI 10.1038/jcbfm.1984.5; JAMIESON D, 1988, RADIOL CLIN N AM, V26, P1075; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, MANAGEMENT HEAD INJU, P153; JOLLES PR, 1989, J NUCL MED, V30, P1589; JONES T, 1976, BRIT J RADIOL, V49, P339, DOI 10.1259/0007-1285-49-580-339; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; NAKAGAWA Y, 1991, NEUROTRAUMATOLOGY, V14, P127; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; TEASDALE G, 1974, LANCET, V2, P81; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37	23	20	20	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1996	40	1					50	56		10.1097/00005373-199601000-00010			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	TU074	WOS:A1996TU07400011	8576999				2021-06-18	
J	SOUSTIEL, JF; HAFNER, H; CHISTYAKOV, AV; BARZILAI, A; FEINSOD, M				SOUSTIEL, JF; HAFNER, H; CHISTYAKOV, AV; BARZILAI, A; FEINSOD, M			TRIGEMINAL AND AUDITORY-EVOKED RESPONSES IN MINOR HEAD-INJURIES AND POST-CONCUSSION SYNDROME	BRAIN INJURY			English	Article							BRAIN-STEM RESPONSES; POTENTIALS; CONDUCTION; TRAUMA	Forty patients who sustained minor head trauma were investigated by brainstem trigeminal and auditory evoked potentials (BTEP, BAEP) and middle-latency auditory evoked potentials (MLAEP). The patients were evaluated within the first 48 h following their admission and at 3 months after the injury. Outcome was scored at the follow-up examination according to six complaints: failure to resume previous professional activity, headache, memory disorders, dizziness and vertigo, behavioural and emotional disturbances, and other symptoms of a neurological nature. Post-concussion syndrome (PCS) was defined by the presence of four or more of the listed features. All three evoked potential modalities showed significantly increased latencies at the initial assessment, disclosing disseminated axonal damage. Unlike the BTEPs and the BAEPs, the MLAEPs proved to correlate to outcome at 3 months, especially in its psychocognitive aspects. These findings suggest that organic diencephalic-paraventricular primary damage may account for the occurrence of PCS.	TECHNION ISRAEL INST TECHNOL,FAC MED,RAMBAM MAIMONIDES MED CTR,DEPT SURG A,IL-31096 HAIFA,ISRAEL	SOUSTIEL, JF (corresponding author), TECHNION ISRAEL INST TECHNOL,FAC MED,RAMBAM MAIMONIDES MED CTR,DEPT NEUROSURG,IL-31096 HAIFA,ISRAEL.						ADAMS JH, 1982, RECENT ADV NEUROPATH, P165; ALVES WM, 1990, NEUROLOGICAL SURGERY, V4, P2230; ANDERSON DW, 1980, J NEUROSURG, V53, pS1; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BROWN WJ, 1972, AM J PATHOL, V67, P41; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Cook J B, 1972, Scand J Rehabil Med, V4, P27; DEIBER MP, 1988, ELECTROEN CLIN NEURO, V71, P187, DOI 10.1016/0168-5597(88)90004-4; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GRONWALL D, LANCET, V2, P605; HASHIMOTO I, 1982, ELECTROEN CLIN NEURO, V53, P652, DOI 10.1016/0013-4694(82)90141-9; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JENNETT B, 1982, MANAGEMENT HEAD INJU, P253; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; MILLER H, 1961, BRIT MED J, V3, P919; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; PICTON TW, 1974, ELECTROEN CLIN NEURO, V36, P179, DOI 10.1016/0013-4694(74)90155-2; PODOSHIN L, 1990, J LARYNGOL OTOL, V104, P191, DOI 10.1017/S0022215100112241; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; RUTHERFORD WH, 1977, LANCET, V1, P1; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SCHOENHUBER R, 1987, ARCH NEUROL-CHICAGO, V44, P1181, DOI 10.1001/archneur.1987.00520230061015; SCHOENHUBER R, 1988, J NEUROSURG, V68, P724; SOUSTIEL JF, 1993, ELECTROEN CLIN NEURO, V87, P277, DOI 10.1016/0013-4694(93)90180-4; YOUNG B, 1985, NEUROSURGERY, V2, P1688	31	20	21	1	4	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	NOV-DEC	1995	9	8					805	813		10.3109/02699059509008236			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TH499	WOS:A1995TH49900005	8605513				2021-06-18	
J	BOGNER, J; CORRIGAN, JD				BOGNER, J; CORRIGAN, JD			EPIDEMIOLOGY OF AGITATION FOLLOWING BRAIN INJURY	NEUROREHABILITATION			English	Article						BRAIN INJURY; AGITATION; INCIDENCE; AGGRESSION; LABILITY; DISINHIBITION	CLOSED HEAD-INJURY; SCALE	Agitation, while considered an important factor influencing outcome following traumatic brain injury (TBI), has been a poorly defined construct. As a result, the literature on agitation has been confusing and incomplete in regard to incidence rates, causes and correlates, intervention methods, and long-term outcomes. In this article, we review previous research on incidence rates, concluding that differences in definition have greatly limited current knowledge. We then review how agitation has been operationalized in previous clinical and research efforts, and we recommend a definition that we believe will allow future studies to proceed in a more systematic manner.	OHIO STATE UNIV,DEPT PHYS MED & REHABIL,COLUMBUS,OH 43210			Corrigan, John D./E-2921-2011				BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; COHENMANSFIELD J, 1989, J GERONTOL, V44, pM77, DOI 10.1093/geronj/44.3.M77; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; FICHERA SM, 1993, J CLIN EXP NEUROPSYC, V15, P105; FUGATE LP, 1994, THESIS OHIO STATE U; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; MALKMUS D, 1980, PROFESSIONAL STAFF A; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; ZIELINSKI R, 1994, 10IND ANN APA CONV L	13	20	20	0	4	ELSEVIER SCI PUBL IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1053-8135			NEUROREHABILITATION	Neurorehabilitation	OCT	1995	5	4					293	297		10.1016/1053-8135(95)00128-X			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TJ211	WOS:A1995TJ21100002	24525573				2021-06-18	
J	EMORY, LE; COLE, CM; MEYER, WJ				EMORY, LE; COLE, CM; MEYER, WJ			USE OF DEPO-PROVERA TO CONTROL SEXUAL AGGRESSION IN PERSONS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							MEDROXYPROGESTERONE ACETATE; THERAPY; PARAPHILIAS; MEN; ANTIANDROGEN; OFFENDERS	Objective: To determine the effectiveness of medroxyprogesterone acetate (Depo-Provera) treatment in conjunction with psychological counseling on the hypersexual behavior seen in individuals with traumatic brain injury. Design: A retrospective review of the use of Depo-Provera in adult male patients who sustained a traumatic brain injury from blunt trauma and subsequently exhibited hypersexual behavior. Ah individuals were treated with a combination of weekly Depo-Provera injections and psychological counseling; the latter was educational/behavioral in nature and took into account such problems as deficits in awareness and empathy, poor memory, concreteness, and rigidity. Follow-up examinations were done every 3 months for at least 2 years and every 6 months thereafter. Setting: Individuals were seen in outpatient treatment and reside in community environments. Patients: Eight males (average age = 17.5 years at the time of head trauma) who developed problematic hypersexual behavior approximately 3 years later. These individuals were consecutive referrals to a psychiatric practice with expertise in the treatment of hypersexual behavior. Intervention: Weekly intramuscular Depo-Provera injections were used in conjunction with counseling. Main Outcome Measures: Incidence of hypersexual behavior; change in testosterone level. Results: In all cases, cessation of the unacceptable sexual behavior was noted while the men received treatment (mean duration = 42 months). Three individuals remain on Depo-Provera, and two have successfully discontinued treatment for 2 and 10 years, respectively, with no further problems. The remaining three reoffended when medication was discontinued, a decision made unilaterally by their families. Conclusions: The use of Depo-Provera in conjunction with counseling may offer an opportunity to control aberrant sexual behaviors after brain injury. However, only a minority of individuals stay in good control after discontinuing Depo-Provera.	UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550	EMORY, LE (corresponding author), ROSENBERG CLIN,GALVESTON,TX, USA.						BENYISHAY Y, 1989, NEUROPSYCHOLOGY TREA; BERLIN FS, 1981, JOHNS HOPKINS MED J, V149, P119; BLACKERBY W, 1989, PHYSICAL MED REHABIL; BLUMER D, 1975, J NERV MENT DIS, V160, P127, DOI 10.1097/00005053-197502000-00007; BRADFORD JMW, 1988, ANN NY ACAD SCI, V58, P193; DAVIS DL, 1990, J HEAD TRAUMA REHAB, V5, P31, DOI DOI 10.1097/00001199-199005020-00006; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; GEE KW, 1988, MOL NEUROBIOL, V2, P291, DOI 10.1007/BF02935636; GOTTESMAN HG, 1993, J CLIN PSYCHIAT, V54, P182; Griffith ER, 1993, SEXUALITY PERSON TRA; Gronwall Dorothy, 1990, HEAD INJURY FACTS GU; HARVEY JA, 1987, PSYCHOPHARMACOLOGY 3; KAFKA MP, 1992, J CLIN PSYCHIAT, V53, P351; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; KRUESI MJP, 1992, ARCH SEX BEHAV, V21, P587, DOI 10.1007/BF01542257; LEFEBVRE KA, 1990, J HEAD TRAUMA REHABI, V5, P25; LEHNE G, 1986, SEX DISABIL, V7, P145; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MEYER J, 1971, J NEUROVISCERAL RE S, V10, P519; Meyer W J 3rd, 1992, Bull Am Acad Psychiatry Law, V20, P249; MEYER WJ, 1992, RES COMMUN CHEM PATH, V75, P69; MEYER WJ, 1985, FERTIL STERIL, V43, P102; MILLER BL, 1986, J NEUROL NEUROSUR PS, V49, P867, DOI 10.1136/jnnp.49.8.867; Miller L., 1993, PSYCHOTHERAPY BRAIN; MONEY J, 1987, J SEX MARITAL THER, V13, P219; MONEY J, 1981, INT J MENT HEALTH, V10, P122, DOI 10.1080/00207411.1981.11448890; MONEY J, 1975, PSYCHONEUROENDOCRINO, V1, P165, DOI 10.1016/0306-4530(75)90008-6; Pithers W, 1990, HDB SEXUAL ASSAULT I; UZZELL BP, 1988, NEUROPSYCHOLOGICAL R; WALKER PA, 1984, GUIDELINES USE PSYCH; ZASLER ND, 1990, J HEAD TRAUMA REHAB, V5, P14, DOI DOI 10.1097/00001199-199005020-00004	32	20	20	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1995	10	3					47	58					12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RC717	WOS:A1995RC71700005					2021-06-18	
J	NAGERIS, B; HANSEN, MC; LAVELLE, WG; VANPELT, FA				NAGERIS, B; HANSEN, MC; LAVELLE, WG; VANPELT, FA			TEMPORAL BONE-FRACTURES	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						TEMPORAL BONE FRACTURE; CSF OTORRHEA; FACIAL NERVE PARALYSIS		The diagnosis and monitoring of patients presenting to an emergency department with blunt temporal bone fracture and complications requiring acute management were reviewed for a four-month period, Of 104 trauma patients with closed head injury, 15 patients were diagnosed with temporal bone fracture, 12 of whom survived their injuries. Four patients developed cerebrospinal fluid (CSF) otorrhea and two patients developed facial nerve paralysis; all patients had resolution of complications with conservative management. Significant shortcomings in the initial evaluation and monitoring of patients with temporal bone fracture were identified. Specific and thorough facial nerve examinations were not initially conducted on temporal bone fracture patients and subsequent inpatient monitoring for facial nerve paralysis and CSF otorrhea was incomplete. The outcome of temporal bone fracture is discussed. This article reminds the emergency physician of the importance of initial diagnosis and documentation of temporal bone fractures. ((C) 1995 by W.B. Saunders Company)		NAGERIS, B (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,55 LAKE AVE N,WORCESTER,MA 01655, USA.							0	20	21	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAR	1995	13	2					211	214		10.1016/0735-6757(95)90096-9			4	Emergency Medicine	Emergency Medicine	QQ147	WOS:A1995QQ14700021	7893311				2021-06-18	
J	COOKE, DL; KAUSLER, DH				COOKE, DL; KAUSLER, DH			CONTENT MEMORY AND TEMPORAL MEMORY FOR ACTIONS IN SURVIVORS OF TRAUMATIC BRAIN INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							ADULT AGE-DIFFERENCES; ACTION EVENTS; FRONTAL-LOBE; HEAD-INJURY; FREQUENCY; LESIONS; WORDS	Memory for performed actions, a rehearsal-independent form of memory, was compared to verbal memory in 30 survivors of traumatic brain injury (TBI) and 30 demographically matched controls. Subjects were tested on recognition and recall memory for the content of recently performed actions in the laboratory, as well as the ability to reconstruct the temporal order in which the actions were performed. Each subject performed actions under incidental and intentional memory instructions. Half of the subjects performed 12 actions, the other half 24 actions, with an equal number of usual and unusual actions in each list. Verbal memory was assessed with paired-associate and temporal order tests, Although recall was more proficient overall for the control compared to the brain-injured subjects on both content and temporal memory for actions, memory for actions was better than verbal memory in both groups. Both groups performed better overall on the short compared to the long list of actions and recalled unusual actions better than usual actions. The rehearsal-independent nature of action memory was supported, with no advantage for the intentional instruction. It is proposed that a retrieval deficit may be in part responsible for deficits in memory for actions following TBI. However, preserved ability to benefit from the abundant contextual cues available through motor actions may account for the better recall of actions compared to words.		COOKE, DL (corresponding author), UNIV MISSOURI,RUSK REHABIL CTR 501,DEPT PHYS MED & REHABIL,COLUMBIA,MO 65211, USA.				NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG008214] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG08214] Funding Source: Medline		BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; COHEN RL, 1983, MEM COGNITION, V11, P575, DOI 10.3758/BF03198282; COHEN RL, 1987, PSYCHOL AGING, V2, P280, DOI 10.1037/0882-7974.2.3.280; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DIAMOND A, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P339; DICK MB, 1989, BRAIN COGNITION, V9, P71, DOI 10.1016/0278-2626(89)90045-6; EAKMAN AM, 1992, THESIS W MICHIGAN U; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; Haut MW, 1991, NEUROPSYCHOLOGY, V5, P81, DOI 10.1037/0894-4105.5.2.81; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; KAUSLER DH, 1990, EXP AGING RES, V16, P147, DOI 10.1080/07340669008251542; KAUSLER DH, 1990, PSYCHOL AGING, V5, P530, DOI 10.1037/0882-7974.5.4.530; KAUSLER DH, 1988, COGNITIVE DEV ADULTH, P93, DOI DOI 10.1007/978-1-4612-3852-2_4; KNOPF M, 1989, DEV PSYCHOL, V25, P780, DOI 10.1037/0012-1649.25.5.780; LARSSON C, 1987, SCAND J REHABIL MED, V19, P99; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; LICHTY W, 1986, THESIS U MISSOURI CO; Milner B, 1964, FRONTAL GRANULAR COR, P313; ODONNELL JP, 1988, J GEN PSYCHOL, V115, P355, DOI 10.1080/00221309.1988.9710572; OLTON DS, 1989, NEUROPSYCHOLOGIA, V27, P121, DOI 10.1016/0028-3932(89)90094-8; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; SALTHOUSE TA, 1988, PSYCHOL AGING, V3, P29, DOI 10.1037/0882-7974.3.1.29; SANDERS RE, 1990, PSYCHOL AGING, V5, P172, DOI 10.1037/0882-7974.5.2.172; SCHACTER DL, 1987, PSYCHOBIOLOGY, V15, P21; SHIMAMURA AP, 1990, NEUROPSYCHOLOGIA, V28, P803, DOI 10.1016/0028-3932(90)90004-8; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; TULVING E, 1989, AM SCI, V77, P361; TWEEDY JR, 1988, J CLIN EXP NEUROPSYC, V10, P664, DOI 10.1080/01688638808402803; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WIEGERSMA S, 1990, NEUROPSYCHOLOGIA, V28, P95, DOI 10.1016/0028-3932(90)90089-7; WILKINS AJ, 1986, ACTA NEUROL SCAND, V74, P109, DOI 10.1111/j.1600-0404.1986.tb04869.x	32	20	22	1	2	SWETS ZEITLINGER BV	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	1995	17	1					90	99		10.1080/13803399508406585			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	QJ150	WOS:A1995QJ15000011	7608307				2021-06-18	
J	BEHRMAN, SW; KUDSK, KA; BROWN, RO; VEHE, KL; WOJTYSIAK, SL				BEHRMAN, SW; KUDSK, KA; BROWN, RO; VEHE, KL; WOJTYSIAK, SL			THE EFFECT OF GROWTH-HORMONE ON NUTRITIONAL MARKERS IN ENTERALLY FED IMMOBILIZED TRAUMA PATIENTS	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article							POSITIVE NITROGEN-BALANCE; SEVERE HEAD-INJURY; PARENTERAL-NUTRITION; GASTROINTESTINAL SURGERY; CATABOLIC RESPONSE; PROTEIN; METABOLISM; SUPPORT; CELLS	Background: Earlier clinical studies have demonstrated improved nitrogen balance in nonstressed patients receiving hypocaloric feedings and growth hormone (GH). This study investigates the effect of GH on nitrogen balance, on serum protein concentrations, and on other indices of nutrition when combined with enteral feeding in immobilized patients after closed-head injury or spinal cord injury. Methods: Sixteen patients who tolerated enteral feedings and remained nonseptic were randomized to receive either placebo or 0.2 mg/kg recombinant human GH for 7 to 13 days. Nitrogen balances were collected daily, and serum proteins were measured at study entrance and exit. Results: GH treatment resulted in higher GH and insulin-like growth factor-1 concentrations but did not improve nitrogen balance. GH treatment also resulted in increased transferrin and serum albumin levels and total lymphocyte count during the study period. Conclusions: Adjuvant recombinant human GH has no effect on nitrogen balance in highly stressed, totally immobilized patients after head or spinal cord injury, but it significantly enhances constitutive serum protein concentrations and other indices of nutritional repletion.	UNIV TENNESSEE,CTR HLTH SCI,DEPT SURG,MEMPHIS,TN 38163; UNIV TENNESSEE,CTR HLTH SCI,DEPT CLIN PHARM,MEMPHIS,TN 38163							BROWN RO, 1990, J AM COLL NUTR, V9, P523; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; Cuthbertson DP, 1929, BIOCHEM J, V23, P1328, DOI 10.1042/bj0231328; CUTHBERTSON DP, 1969, MAMMALIAN PROTEIN ME, P373; DAHN MS, 1984, JPEN-PARENTER ENTER, V8, P690, DOI 10.1177/0148607184008006690; FELDMAN Z, 1993, J TRAUMA, V34, P806, DOI 10.1097/00005373-199306000-00010; GATZEN C, 1992, SURGERY, V112, P181; INGENBLEEK Y, 1985, INT J VITAM NUTR RES, V55, P91; JIANG ZM, 1989, ANN SURG, V210, P513, DOI 10.1097/00000658-198910000-00012; KOLPEK JH, 1993, JPEN, V15, P277; KUDSK KA, 1994, ARCH SURG-CHICAGO, V129, P66; MADDAIAH VT, 1973, J BIOL CHEM, V248, P4263; MANSON JM, 1986, SURGERY, V100, P188; MANSON JM, 1988, ANN SURG, V208, P136, DOI 10.1097/00000658-198808000-00002; MARIMEE TJ, 1973, METABOLISM, V22, P1235; NIEDERMAN MS, 1984, ANN INTERN MED, V100, P795, DOI 10.7326/0003-4819-100-6-795; OKAMURA K, 1989, JPEN-PARENTER ENTER, V13, P450, DOI 10.1177/0148607189013005450; PHILLIPS LS, 1980, NEW ENGL J MED, V302, P371, DOI 10.1056/NEJM198002143020704; PHILLIPS LS, 1980, NEW ENGL J MED, V438, P446; PONTING GA, 1988, LANCET, V1, P438; RAPAPORT R, 1987, LIFE SCI, V41, P2319, DOI 10.1016/0024-3205(87)90545-5; SOROFF HS, 1967, ANN SURG, V166, P739, DOI 10.1097/00000658-196711000-00002; SOROFF HS, 1967, J TRAUM, V7, P130; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; THORSSON AV, 1977, BIOCHEM BIOPH RES CO, V74, P1566, DOI 10.1016/0006-291X(77)90621-0; VARATHORBECK R, 1993, WORLD J SURG, V17, P530, DOI 10.1007/BF01655116; VARATHORBECK R, 1992, HEPATO-GASTROENTEROL, V39, P270; VOERMAN HJ, 1992, ANN SURG, V216, P648, DOI 10.1097/00000658-199212000-00006; WARD HC, 1987, ANN SURG, V206, P56, DOI 10.1097/00000658-198707000-00009; WILMORE DW, 1974, SURG GYNECOL OBSTET, V138, P875; ZIEGLER TR, 1988, ANN SURG, V208, P6, DOI 10.1097/00000658-198807000-00002; ZIEGLER TR, 1990, JPEN-PARENTER ENTER, V14, P574, DOI 10.1177/0148607190014006574	33	20	20	0	0	AMER SOC PARENTERAL & ENTERAL NUTRITION	SILVER SPRING	8630 FENTON STREET SUITE 412, SILVER SPRING, MD 20910	0148-6071			JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	JAN-FEB	1995	19	1					41	46		10.1177/014860719501900141			6	Nutrition & Dietetics	Nutrition & Dietetics	QA886	WOS:A1995QA88600008	7658599				2021-06-18	
J	PATIR, R; SOOD, S; BHATIA, R				PATIR, R; SOOD, S; BHATIA, R			POSTTRAUMATIC BRAIN-ABSCESS - EXPERIENCE OF 36 PATIENTS	BRITISH JOURNAL OF NEUROSURGERY			English	Article						ABSCESS; CLOSED HEAD INJURY; COMPOUND HEAD INJURY	MANAGEMENT; FRACTURE; WOUNDS	Thirty-six patients with post-traumatic brain abscess were managed over 18 years. They constituted 9.3% of all brain abscesses encountered during the same period. The head injury was associated with an external compound fracture in 20, internal compounding in three and was closed in 13 patients. The mean interval between the time of injury to presentation with an abscess was 113 days. This did not differ significantly in patients with closed and compound head injury, and amongst patients who had wound sepsis and with clean wounds after the injury. The occurrence of focal neurological deficit was more frequent in patients with a dosed injury (p<0.05). Twenty patients underwent primary excision of the abscess with recurrence of the abscess in one patient. Of the 14 patients in whom the abscess was initially aspirated, eight patients required a subsequent excision. Excision was required in 18 patients (94.7%) with external compound injury, five (50%) of those with closed injury and in all patients with internally compound injuries. Two patients had 'coned' and died before they could be operated upon. The operative mortality in the absence of signs of herniation preoperatively was 12.5% in patients with compound injury and none among patients with dosed head injury.	ALL INDIA INST MED SCI,CTR NEUROSCI,DEPT NEUROSURG,NEW DELHI 110029,INDIA							Bhatia R, 1983, Indian J Pediatr, V50, P591, DOI 10.1007/BF02957724; Bhatia R, 1973, Int Surg, V58, P565; BLACK P, 1975, J NEUROSURG, P705; CAIRNS H, 1947, BR J SURG WAR SURG S, V1, P198; CAREY ME, 1971, J NEUROSURG, V34, P145, DOI 10.3171/jns.1971.34.2part1.0145; DETRIBOLET N, 1979, SURG NEUROL, V11, P187; Dinakar I, 1971, J Postgrad Med, V17, P137; Evans W, 1931, LANCET, V1, P1231; EVERETT ED, 1980, NEUROSURGERY, V6, P691; GILLINGHAM FJ, 1947, BR J SURG WAR SURG S, V1, P80; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; JENNETT B, 1972, J NEUROSURG, V36, P333, DOI 10.3171/jns.1972.36.3.0333; LEGG NJ, 1973, BRAIN, V96, P259, DOI 10.1093/brain/96.2.259; MAMPALAM TJ, 1988, NEUROSURGERY, V23, P451, DOI 10.1227/00006123-198810000-00008; MEIROWSKY AM, 1965, NEUROLOGICAL SURGYER; MOSKOPP D, 1985, NEUROCHIRURGIA, V28, P147; RATH SA, 1989, CHILD NERV SYST, V5, P121, DOI 10.1007/BF00571124; SANDERMANN J, 1986, CHILD NERV SYST, V2, P49, DOI 10.1007/BF00274036; WEBSTER JE, 1950, SURG GYNECOL OBSTET, V90, P209; YANG SY, 1981, J NEUROSURG, V55, P794, DOI 10.3171/jns.1981.55.5.0794	20	20	20	0	0	CARFAX PUBL CO	ABINGDON	PO BOX 25, ABINGDON, OXON, ENGLAND OX14 3UE	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.		1995	9	1					29	35					7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	QQ175	WOS:A1995QQ17500005	28168911				2021-06-18	
J	BRAZZELLI, M; COCCHINI, G; DELLASALA, S; SPINNLER, H				BRAZZELLI, M; COCCHINI, G; DELLASALA, S; SPINNLER, H			ALZHEIMER PATIENTS SHOW A SENSITIVITY DECREMENT OVER TIME ON A TONIC ALERTNESS TASK	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; SUSTAINED-ATTENTION; DIVIDED ATTENTION; WORKING MEMORY; DISEASE; DEMENTIA; DIAGNOSIS; DEFICITS	Tonic alertness was investigated in Alzheimer patients and normal elderly subjects. Sensitivity acid criterion shifts were investigated across 45 min of continuous testing using a high event rate test with very low target probability. Alzheimer patients showed a significant sensitivity decrement over time that was unrelated to dementia severity. These results suggest that tonic alertness is impaired by Alzheimer's disease even in its early stages.	UNIV MILAN,OSPED SAN PAOLO BARONA,NEUROL CLIN 3,I-20142 MILAN,ITALY; MED CTR VERUNO,FDN CLIN LAVORO,DEPT NEUROL,NEUROPSYCHOL UNIT,NOVARA,ITALY; UNIV ABERDEEN,DEPT PSYCHOL,ABERDEEN,SCOTLAND; UNIV MILAN,DEPT NEUROL 3,MILAN,ITALY							ALEXANDER DA, 1973, PSYCHOL REP, V32, P229, DOI 10.2466/pr0.1973.32.1.229; BADDELEY A, 1986, Q J EXP PSYCHOL-A, V38, P603, DOI 10.1080/14640748608401616; BADDELEY AD, 1991, BRAIN, V114, P2521, DOI 10.1093/brain/114.6.2521; BRAZZELLI M, UNPUB NEUROPSYCHOLOG; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; CAPITANI E, 1988, J GERONTOL, V43, P157; COSSA FM, 1989, NEUROPSYCHOLOGIA, V27, P887, DOI 10.1016/0028-3932(89)90012-2; Davies D.R., 1982, PSYCHOL VIGILANCE; DAVIES DR, 1984, VARIETIES ATTENTION, P418; DEESE J, 1955, PSYCHOL REV, V62, P359, DOI 10.1037/h0042393; DELLASALA S, 1986, ITAL J NEUROL SCI, V7, P27, DOI 10.1007/BF02230415; DELLASALA S, 1992, PSYCHOL MED, V22, P885, DOI 10.1017/S0033291700038460; GRADY CL, 1989, ARCH NEUROL-CHICAGO, V46, P317, DOI 10.1001/archneur.1989.00520390083021; Guilford JP, 1954, PSYCHOMETRIC METHODS; Jones, 1968, MEASUREMENT PREDICTI; JORM AF, 1986, PSYCHOL MED, V16, P77, DOI 10.1017/S0033291700002567; LANZETTA TM, 1987, HUM FACTORS, V29, P625; MACKWORTH JF, 1970, VIGILANCE ATTENTION; MACKWORTH NH, 1950, MRC268 SPEC REP; MACKWORTH NH, 1957, ADVANCEMENT SCIENCE, V53, P389; MAYEUX R, 1987, NEUROLOGY, V37, P1130, DOI 10.1212/WNL.37.7.1130; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Nebes R. D., 1992, HDB AGING COGNITION, P373; NEBES RD, 1989, CORTEX, V25, P305, DOI 10.1016/S0010-9452(89)80045-0; NEBES RD, 1993, CORTEX, V29, P77, DOI 10.1016/S0010-9452(13)80213-4; NESTOR PG, 1991, NEUROPSYCHOLOGIA, V29, P379, DOI 10.1016/0028-3932(91)90026-5; NEUCHTERLEIN KH, 1983, SCIENCE, V220, P327; PARASURAMAN R, 1979, SCIENCE, V205, P924, DOI 10.1126/science.472714; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PARASURAMAN R, 1989, PSYCHOL AGING, V4, P339, DOI 10.1037/0882-7974.4.3.339; PARASURAMAN R, 1984, VARIETIES ATTENTION, P243; Parasuraman R., 1985, ATTENTION PERFORM, P493; Parasuraman R., 1993, NEUROPSYCHOLOGY, V7, P242, DOI DOI 10.1037/0894-4105.7.3.242; Parasuraman R., 1977, VIGILANCE THEORY OPE, P559; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Posner MI, 1975, HDB PSYCHOBIOLOGY, P441, DOI DOI 10.1016/B978-0-12-278656-3.50019-3; Posner MI., 1978, CHRONOMETRIC EXPLORA; SALMASO D, 1982, PERCEPT MOTOR SKILL, V55, P127; SPINNLER H, 1988, J NEUROL, V235, P258, DOI 10.1007/BF00314172; SPINNLER H, 1991, HDB NEUROPSYCHOLOGY, V5, P79; VANZOMEREN AH, 1981, REACTION TIME ATTENT, P69	41	20	20	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1994	16	6					851	860		10.1080/01688639408402698			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	PV080	WOS:A1994PV08000004	7890820				2021-06-18	
J	YAMAKI, T; MURAKAMI, N; IWAMOTO, Y; YOSHINO, E; NAKAGAWA, Y; UEDA, S; HORIKAWA, J; TSUJII, T				YAMAKI, T; MURAKAMI, N; IWAMOTO, Y; YOSHINO, E; NAKAGAWA, Y; UEDA, S; HORIKAWA, J; TSUJII, T			A MODIFIED FLUID PERCUSSION DEVICE	JOURNAL OF NEUROTRAUMA			English	Article							DIFFUSE AXONAL INJURY; BRAIN INJURY; HEAD-INJURY; MODEL; RAT; CAT; CONCUSSION	This report examines a modified fluid percussion device with specific improvements made to address deficiencies found in previously reported devices. These improvements include the use of a cylindrical saline reservoir made of stainless steel, placement of the reservoir in a 15-degree head-up position for the easy release of air bubbles, placement of the fluid flushing outlet and the pressure transducer close to the piston on the same plane, with both perpendicular to the direction of the piston, an adjustable reservoir volume to vary the waveform of the pressure pulse, and a metallic central injury screw secured to the animal's skull over the exposed dura. Using this device, midline fluid percussion (MFP) and lateral fluid percussion (LFP) injuries were performed in 70 rats. Histopathologic findings included diffuse axonal injury in the MFP model and cortical contusion in the LFP model. Survival rate was 41.4% in MFP animals and 100% in LFM animals when the device settings were 178 mm(3) of the cylindrical reservoir and 50 degrees-60 degrees in height of the pendulum. Our results suggest that this modified fluid percussion device may offer significant improvements over previously reported fluid percussion models for use in experimental head injury.	SHIMADZU CO LTD,DIV TESTING & WEIGHING EQUIPMENT,KYOTO,JAPAN	YAMAKI, T (corresponding author), KYOTO PREFECTURAL UNIV MED,DEPT NEUROSURG,KAMIGYO KU,KYOTO 602,JAPAN.						Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOVONS SR, 1972, EXP NEUROL, V34, P121, DOI 10.1016/0014-4886(72)90193-8; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; MASUZAWA H, 1976, Neurologia Medico-Chirurgica, V16, P77, DOI 10.2176/nmc.16pt1.77; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; SHAW NA, 1985, PHYSIOL BEHAV, V35, P637, DOI 10.1016/0031-9384(85)90154-4; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Stalhammar D, 1987, Brain Inj, V1, P73, DOI 10.3109/02699058709034448; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311	21	20	22	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1994	11	5					613	622		10.1089/neu.1994.11.613			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PR237	WOS:A1994PR23700013	7861452				2021-06-18	
J	DIAMOND, BJ; VALENTINE, T; MAYES, AR; SANDEL, ME				DIAMOND, BJ; VALENTINE, T; MAYES, AR; SANDEL, ME			EVIDENCE OF COVERT RECOGNITION IN A PROSOPAGNOSIC PATIENT	CORTEX			English	Article							UNDERSTANDING FACE RECOGNITION; FACIAL RECOGNITION; OVERT RECOGNITION; AGNOSIA; DISSOCIATION; FAMILIAR	This is a case-study of a patient (ET) who suffers from prosopagnosia, in the context of impairment to cognitive functions, following traumatic brain injury. Despite severe perceptual difficulties in tests involving non-face stimuli and matching unfamiliar faces, ET showed evidence of ''covert'' recognition of familiar faces in a number of tasks. Although densely prosopagnosic, she performed at normal levels in word and object recognition tasks, and is unimpaired in her ability to recognise names of celebrities. She performed at the same level as controls in her ability to make a forced-choice of the correct name for a famous face, even though it evoked no feeling of familiarity for her. She performed at chance in a forced-choice face familiarity decision task, but showed evidence of covert recognition in a ''true'' versus ''untrue'' face-name learning task. ET showed overt recognition of some famous faces using a procedure based on Sergent and Poncet's (1990) semantic activation task. The pattern of impariment of ET's face processing abilities is interpreted in terms of an interactive activation model of face processing.	UNIV DURHAM,DEPT PSYCHOL,DURHAM DH1 3LE,ENGLAND; UNIV LIVERPOOL,DEPT PSYCHOL,LIVERPOOL L69 3BX,ENGLAND; UNIV PENN,DEPT REHABIL MED,DIV NEUROREHABIL,PHILADELPHIA,PA	DIAMOND, BJ (corresponding author), KESSLER INST REHABIL,DEPT RES,PLEASANT VALLEY WAY,W ORANGE,NJ 07052, USA.		Valentine, Tim/A-5761-2012	Valentine, Tim/0000-0001-6049-6229			Bauer R. M., 1986, ASPECTS FACE PROCESS, P253, DOI 10.1007/978-94-009-4420-6_27.; BAUER RM, 1984, NEUROPSYCHOLOGIA, V22, P457, DOI 10.1016/0028-3932(84)90040-X; BENTON A, 1990, CORTEX, V26, P491, DOI 10.1016/S0010-9452(13)80299-7; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BENTON AL, 1980, AM PSYCHOL, V35, P176, DOI 10.1037/0003-066X.35.2.176; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; BRUYER R, 1983, BRAIN COGNITION, V2, P257, DOI 10.1016/0278-2626(83)90014-3; BRUYER R, 1991, BRAIN COGNITION, V15, P223, DOI 10.1016/0278-2626(91)90027-6; BURTON AM, 1991, COGNITION, V39, P129, DOI 10.1016/0010-0277(91)90041-2; BURTON AM, 1990, BRIT J PSYCHOL, V81, P361, DOI 10.1111/j.2044-8295.1990.tb02367.x; BURTON AM, 1993, IN PRESS BRIT J PSYC; CAMPBELL R, 1986, BRAIN, V109, P509, DOI 10.1093/brain/109.3.509; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; DAMASIO AR, 1985, TRENDS NEUROSCI, V8, P132, DOI 10.1016/0166-2236(85)90051-7; De Haan E.H., 1991, EUR J COGN PSYCHOL, V3, P51, DOI [DOI 10.1080/09541449108406219, 10.1080/09541449108406219]; DEHAAN EHF, 1987, COGN NEUROPSYCHOL, V4, P385, DOI 10.1080/02643298708252045; DEHAAN EHF, 1991, BRAIN, V114, P2575, DOI 10.1093/brain/114.6.2575; DEHAAN EHF, 1987, CORTEX, V23, P309, DOI 10.1016/S0010-9452(87)80041-2; DERENZI E, 1986, NEUROPSYCHOLOGIA, V24, P385; DERENZI E, 1991, CORTEX, V27, P213, DOI 10.1016/S0010-9452(13)80125-6; Ekman P., 1975, UNMASKING FACE; FLUDE BM, 1993, IN PRESS BRAIN COGNI; KURUCZ J, 1979, J AM GERIATR SOC, V27, P225, DOI 10.1111/j.1532-5415.1979.tb06037.x; LANDIS T, 1988, BRAIN, V111, P1287, DOI 10.1093/brain/111.6.1287; MALONE DR, 1982, J NEUROL NEUROSUR PS, V45, P820, DOI 10.1136/jnnp.45.9.820; MEADOWS JC, 1974, J NEUROL NEUROSUR PS, V37, P489, DOI 10.1136/jnnp.37.5.489; NEWCOMBE F, 1989, NEUROPSYCHOLOGIA, V27, P179, DOI 10.1016/0028-3932(89)90170-X; SERGENT J, 1989, BRAIN, V112, P975, DOI 10.1093/brain/112.4.975; SERGENT J, 1990, BRAIN, V113, P989, DOI 10.1093/brain/113.4.989; SHUTTLEWORTH EC, 1982, BRAIN COGNITION, V1, P302, DOI DOI 10.1016/0278-2626(82)90031-8; Valentine T., 1991, EUROPEAN J COGNITIVE, V3, P147, DOI DOI 10.1080/09541449108406224; WALLACE MA, 1992, J COGNITIVE NEUROSCI, V4, P150, DOI 10.1162/jocn.1992.4.2.150; YOUNG A, 1989, HDB RES FACE PROCESS; YOUNG AW, 1988, COGNITIVE NEUROPSYCH, V5, P317, DOI 10.1080/02643298808252938; YOUNG AW, 1991, NEUROPSYCHOLOGY CONS	35	20	21	0	6	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	SEP	1994	30	3					377	393		10.1016/S0010-9452(13)80336-X			17	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	PH095	WOS:A1994PH09500002	7805381				2021-06-18	
J	HEYER, NJ; FRANKLIN, GM				HEYER, NJ; FRANKLIN, GM			WORK-RELATED TRAUMATIC BRAIN INJURY IN WASHINGTON-STATE, 1988 THROUGH 1990	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							HEAD-INJURY	Objectives. Brain trauma is a major cause of disability in the United States, especially among young adults. Work-related brain trauma cases represent a subpopulation that may be amenable to intervention efforts, but largely because of unavailability of data, this group has not previously been studied. Methods. Washington State workers' compensation data were used to identify brain trauma cases and to describe incidence rates with respect to age, gender, and industrial classification. Cause of injury was evaluated for industrial classifications with numerous cases. Results. Washington State workers experienced 301 brain traumas over a 3-year period (9.4/100000 full-time-equivalent workers per year). One third of all traumatic brain injury claims were concentrated among seven industrial classifications, Cause of injury was highly correlated with specific industrial classifications. Conclusions. This study demonstrates the usefulness of diagnosis-related group codes to identify cases of traumatic brain injury. These injuries are concentrated among a few industries, with a dominant specific cause for each industry. This suggests that intervention methods may be efficiently introduced to reduce traumatic brain injuries in the workplace.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT ENVIRONM HLTH,SEATTLE,WA 98103; UNIV WASHINGTON,SCH MED NEUROL,SEATTLE,WA 98195; WASHINGTON STATE DEPT LABOR & IND,OLYMPIA,WA							ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P91; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; FRANKLIN GM, 1991, AM J PUBLIC HEALTH, V81, P741, DOI 10.2105/AJPH.81.6.741; HEYER NJ, 1992, AM J PUBLIC HEALTH, V82, P557, DOI 10.2105/AJPH.82.4.557; JAMESON KG, 1974, AUST NZ J SURG, V44, P241; JENNETT B, 1977, Lancet, V2, P696; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KERR TA, 1971, BRIT J PREV SOC MED, V25, P179; KLONOFF H, 1969, CAN MED ASSOC J, V100, P235; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; KRAUS JF, 1991, NEUROEPIDEMIOLOGY TR, P333; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; TANAKA S, 1988, J OCCUP ENVIRON MED, V30, P488, DOI 10.1097/00043764-198806000-00010	16	20	20	0	1	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	JUL	1994	84	7					1106	1109		10.2105/AJPH.84.7.1106			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	PB870	WOS:A1994PB87000011	8017533	Bronze, Green Published			2021-06-18	
J	MOULTON, RJ; SHEDDEN, PM; TUCKER, WS; MULLER, PJ				MOULTON, RJ; SHEDDEN, PM; TUCKER, WS; MULLER, PJ			SOMATOSENSORY-EVOKED POTENTIAL MONITORING FOLLOWING SEVERE CLOSED-HEAD INJURY	CLINICAL AND INVESTIGATIVE MEDICINE			English	Article						HEAD INJURY; EVOKED POTENTIALS; CEREBRAL METABOLISM	INTRACRANIAL HYPERTENSION; BRAIN-FUNCTION; DYSFUNCTION; CONDUCTION; METABOLISM; TRAUMA; COMA	This paper describes the results of somatosensory evoked potential (SSEP) monitoring in 65 patients with severe head injury. Intracranial pressure (ICP) monitoring data were available for 63 patients, and arterial-jugular oxygen content (AVDO(2)) data for 52 patients. Eighty-nine percent of patients with no SSEP activity beyond 50 msec post-stimulus in either hemisphere died or were vegetative survivors (3 month Glasgow Outcome Score). All 17 patients with a good or moderate outcome had long latency cortical activity (i.e. greater than or equal to 70 msec post-stimulus) in both hemispheres. Among patients with absent activity in 1 hemisphere, 53% died and 47% were severely disabled (chi(2) = 40, P = 0.0000). In the latter group, age was a significant factor among patients who died or were severely disabled (p < 0.02). Forty-four of 65 patients had either clear-cut deterioration or improvement in SSEPs over the course of monitoring. There were no significant differences in peak ICP between patients with improving or deteriorating SSEPs. In contrast, those with deteriorating SSEPs had a significant drop in AVDO(2), compared with patients with improving SSEPs (p < 0.01). Long-term continuous monitoring of SSEPs shows that following severe injury, neurologic function may. undergo significant change in approximately two-thirds of patients. Furthermore, ICP does not appear to play a prominent role in neurologic deterioration. AVDO(2) measurements indicate that deterioration is more likely associated with perturbation of cerebral oxidative metabolism. SSEP monitoring following severe head injury has proven prognostic value, and is recommended for patients who must be pharmacologically paralyzed for ICP or ventilator management.		MOULTON, RJ (corresponding author), ST MICHAELS HOSP, DIV NEUROSURG, 38 SHUTER ST, TORONTO M5B 1A6, ON, CANADA.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; DELATORRE JC, 1978, EXP NEUROL, V60, P304, DOI 10.1016/0014-4886(78)90085-7; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JENNETT B, 1975, LANCET, V1, P480; KONASIEWICZ SJ, IN PRESS CAN J NEURO; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MOULTON R, 1991, J TRAUMA, V31, P676, DOI 10.1097/00005373-199105000-00012; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P154, DOI 10.1177/155005948101200402; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P167, DOI 10.1177/155005948101200403; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SHEDDEN P M, 1990, Pediatric Neurosurgery, V16, P203, DOI 10.1159/000120527; STRICH SJ, 1961, LANCET, V2, P443; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; YAMADA T, 1988, EVOKED POTENTIAL, P705	23	20	21	0	2	CANADIAN SOC CLINICAL INVESTIGATION	OTTAWA	CSCI HEAD OFFICE, 774 ECHO DRIVE, OTTAWA, ON K1S 5N8, CANADA	0147-958X	1488-2353		CLIN INVEST MED	Clin. Invest. Med.	JUN	1994	17	3					187	195					9	Medicine, Research & Experimental	Research & Experimental Medicine	NR184	WOS:A1994NR18400001	7923995				2021-06-18	
J	FRICKER, R; GACHTER, A				FRICKER, R; GACHTER, A			LATERAL FLEXION EXTENSION RADIOGRAPHS - STILL RECOMMENDED FOLLOWING CERVICAL SPINAL-INJURY	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article							CORD CONCUSSION	We present the case of a patient who sustained a cervical spinal injury and subsequent transient quadriplegia with full recovery from the spinal cord concussion. Initial plain X-ray films and magnetic resonance imaging did not show any pathological findings, but lateral radiographs in flexion and extension performed 10 days later revealed a fracture of the C4 spinous process without ligamentous instability, confirming significant injury to the cervical spine.		FRICKER, R (corresponding author), UNIV BASEL,KANTONSSPITAL,DEPT SURG,DIV ORTHOPED & TRAUMA SURG,CH-4031 BASEL,SWITZERLAND.						DELBIGIO MR, 1989, SPINE, V14, P37, DOI 10.1097/00007632-198901000-00007; HIRSH LF, 1991, J NEUROSURG, V75, P131, DOI 10.3171/jns.1991.75.1.0131; TORG JS, 1986, J BONE JOINT SURG AM, V68A, P1354, DOI 10.2106/00004623-198668090-00008; ZWIMPFER TJ, 1990, J NEUROSURG, V72, P894, DOI 10.3171/jns.1990.72.6.0894	4	20	20	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0936-8051			ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	FEB	1994	113	2					115	116		10.1007/BF00572919			2	Orthopedics; Surgery	Orthopedics; Surgery	MY878	WOS:A1994MY87800015	8186047				2021-06-18	
J	SCHALEN, W; NORDSTROM, G; NORDSTROM, CH				SCHALEN, W; NORDSTROM, G; NORDSTROM, CH			ECONOMIC-ASPECTS OF CAPACITY FOR WORK AFTER SEVERE TRAUMATIC BRAIN-LESIONS	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; REHABILITATION	During 1981-84310 patients with severe traumatic brain lesions were treated at the Department of Neurosurgery in Lund, Sweden. A total of 161 patients were treated after the introduction of a more aggressive management protocol in 1983. In this first part of a long-term follow-up study we concentrate on the economic aspects. Two questions were addressed: first, what was the vocational outcome after severe head injuries? and second, what were the long-term effects of the new protocol? Out of 147 patients classified as good recovery/moderate disability (GR/MD) 6-months after injury, 106 patients agreed to participate in the study. Five to 8 years after injury 70 patients were classified as capable of working: 57 of these patients were actually at work, nine were studying and four were unemployed. Twenty-two patients had received disability pension and 14 patients had retired because of old age. In the age groups up to 60 years, 70% of patients had returned to work or school. The number of patients who returned to work was significantly higher after introduction of the more aggressive management protocol: 38 of 57 patients who had returned to work were in the group treated between 1983 and 1984. Mean income for patients who had returned to work was close to the average for the corresponding age groups in Sweden. Mean sick leave 5-8 years after severe head injuries was only slightly higher than average in Sweden. Our data show that a majority of the patients classified as GR/MD 6 months after severe traumatic brain lesions have the capacity to return to work. The improvements in the primary management of patients with severe head injuries introduced in 1983 increased the number of patients who work and thus increased the number of patients who favourably contributed to the economy of the community.	UNIV LUND HOSP,DEPT NEUROSURG,S-22185 LUND,SWEDEN; UNIV LUND HOSP,DEPT PSYCHIAT,S-22185 LUND,SWEDEN							BENGTSSON K, 1990, OPINIONS SWEDISH NAT, V5; Bond M R, 1975, Ciba Found Symp, P141; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; JENNETT B, 1975, LANCET, V1, P480; LEWIN W, 1968, BMJ-BRIT MED J, V1, P465, DOI 10.1136/bmj.1.5590.465; LUNDBERG N, 1960, ACTA PSYCHIATRICA  S, V149, P1; MELLARGARD P, 1990, J SWEDISH MED ASS, V87, P1348; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; Nordstrom C H, 1989, Brain Inj, V3, P267, DOI 10.3109/02699058909029640; Nordstrom C H, 1989, Brain Inj, V3, P247, DOI 10.3109/02699058909029639; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; SCHALEN W, BRAIN INJURY, V8, P49; Sundbarg G, 1989, Brain Inj, V3, P283, DOI 10.3109/02699058909029641; SUNDBARG G, 1987, J NEUROSURG, V67, P841, DOI 10.3171/jns.1987.67.6.0841; SUNDBARG G, 1989, BRIT J NEUROSURG, V2, P485; UZZELL BP, 1987, SURG NEUROL, V27, P419, DOI 10.1016/0090-3019(87)90247-3; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; 1990, BE20 SM9002 STAT SWE, P15	21	20	21	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1994	8	1					37	47		10.3109/02699059409150957			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	MQ291	WOS:A1994MQ29100005	8124316				2021-06-18	
J	SHOHAMI, E; NOVIKOV, M; HOROWITZ, M				SHOHAMI, E; NOVIKOV, M; HOROWITZ, M			LONG-TERM EXPOSURE TO HEAT REDUCES EDEMA FORMATION AFTER CLOSED-HEAD INJURY IN THE RAT	ACTA NEUROCHIRURGICA			English	Article						BBB; HEAD TRAUMA; HEAT ACCLIMATION; BRAIN EDEMA	BRAIN	Cerebral edema is one of the major consequences of head trauma (HT); its evolution may cause secondary ischemia and neuronal damage. In a closed head injury model in rats, we have shown BBB disruption and edema formation during the post traumatic period. We have previously shown that chronic exposure to moderate heat improves clinical outcome of rats subjected to HT. Long term exposure to heat results in the achievement of a stable acclimated state, characterized by a lower metabolic rate and improved heat tolerance. In the present study, we investigated the effect of chronic exposure to heat on edema formation after HT. Rats were held at 24-degrees-C (CON) or 34-degrees-C (ACC) for one month. Injury was then induced under ether anesthesia by a weight drop device. Four or 48 hours later, they were sacrificed for evaluation of BBB integrity (Evans blue, EB, extravasation) or edema formation (specific gravity, SG, or percent water). We found that EB uptake by the contused hemisphere was 6 fold lower in the ACC rats as compared to CON (p < 0.001). Furthermore, edema measured at 48 h by both SG and percent water methods was significantly lower in the acclimated rats (p < 0.01). We suggest that heat acclimation offers protection to rats subjected to head injury, possibly by reduction of plasma proteins extravasation.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT PHYSIOL, IL-91010 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, SCH DENT MED, IL-91010 JERUSALEM, ISRAEL	SHOHAMI, E (corresponding author), HADASSAH SCH PHARM, DEPT PHARMACOL, POB 1172, IL-91010 JERUSALEM, ISRAEL.						HADAS H, 1989, INT CONGR SER, V871, P395; HOROWITZ M, 1976, PFLUG ARCH EUR J PHY, V366, P173, DOI 10.1007/BF00585874; LEVI E, 1993, IN PRESS J APPL PHYS; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1993, IN PRESS J ANASTH AN; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; YOUSEF MK, 1975, AM J PHYSIOL, V229, P427	9	20	21	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1994				60			443	445					3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NX226	WOS:A1994NX22600121	7976614				2021-06-18	
J	VONBERENBERG, P; UNTERBERG, A; SCHNEIDER, GH; LANKSCH, WR				VONBERENBERG, P; UNTERBERG, A; SCHNEIDER, GH; LANKSCH, WR			TREATMENT OF TRAUMATIC BRAIN EDEMA BY MULTIPLE DOSES OF MANNITOL	ACTA NEUROCHIRURGICA			English	Article						CEREBRAL EDEMA; MANNITOL; COLD INJURY; RATS		Mannitol is frequently used to reduce elevated intracranial pressure often associated with brain edema. In cases of a damaged blood-brain barrier, however, mannitol might aggravate vasogenic cerebral edema, as has recently been stressed. The aim of this study was to investigate whether multiple doses of mannitol administered during development of vasogenic brain edema following a cryogenic cortical injury affect hemispheric swelling and edema. Sprague-Dawley rats were anesthetized with ketamine and xylazine. A cortical freezing lesion was applied to the right parietal region. A first series of eight rats received four doses of 20% mannitol (0.4 g/kg within 10 minutes) thirty minutes, 3, 6 and 9 hours after trauma. Twelve hours after cryogenic injury, the brains were removed for determination of hemispheric swelling and cerebral water content. Eight control rats were infused with saline only. In a second series nine rats received eight doses of 20% mannitol 30 minutes, 3, 6, 9, 12, 15, 18 and 21 hours after trauma. In this series, the brains were removed 24 hours after freezing. Again respective control animals were infused with saline only. Hemispheric swelling was 7.2 +/- 0.5% after four doses of mannitol compared to 7.6 +/- 0,5% in control animals (n.s.). Following eight doses of mannitol hemispheric swelling was 8.9 +/- 0.4% compared to 10.1 +/- 0.4% in control rats (p < 0.05). Accordingly, the water content of traumatized hemispheres was lower following repeated mannitol treatment (80.5 versus 80.8%). Water content in control hemispheres was not affected by mannitol. Taken together, these results indicate that multiple doses of mannitol do not aggravate total hemispheric swelling, nor global water content following induction of vasogenic edema. In contrast, repeated administration of mannitol reduces traumatic swelling, thus favouring repeated mannitol application even when the blood-brain barrier is defective.		VONBERENBERG, P (corresponding author), FREE UNIV BERLIN, RUDOLF VIRCHOW MED CTR, DEPT NEUROSURG, AUGUSTENBURGER PL 1, W-1000 BERLIN 33, GERMANY.						HARTWELL RC, 1993, NEUROSURGERY, V32, P444, DOI 10.1227/00006123-199303000-00017; KAUFMANNAM, 1992, J NEUROSURG, V77, P584; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; LONG DM, 1972, STEROIDS BRAIN EDEMA, P87; MACGOVERN GJ, 1984, CIRCULATION S1, V70, P191; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; NATH F, 1986, J NEUROSURG, V65, P41, DOI 10.3171/jns.1986.65.1.0041; PAPPIUS HM, 1965, ARCH NEUROL-CHICAGO, V13, P295; RICKELS E, ZENTRALBL NEUROCHIR, V54, P3; UNTERBERG A, 1990, ACT NEUR S, V51, P104	10	20	20	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1994				60			531	533					3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NX226	WOS:A1994NX22600146	7976640				2021-06-18	
J	MILLER, L				MILLER, L			FAMILY-THERAPY OF BRAIN INJURY - SYNDROMES, STRATEGIES, AND SOLUTIONS	AMERICAN JOURNAL OF FAMILY THERAPY			English	Article							SEVERE HEAD-INJURY; MOOD DISORDERS; DEPRESSION; MANAGEMENT; RELATIVES; DIAGNOSIS; DAMAGE	Brain injury presents the family therapist with some unique problems and challenges. This paper describes the effects that the brain-injured patient may be expected to have on the family system and the kinds of reactions typically seen in the family members. It then describes strategies of family therapy in brain injury, including education, supportive counseling, and more intensive family therapy modalities. Finally, the paper closes with some thoughts on the goals and outcomes of family therapy with this group and recommendations for improving the family therapy process.								BENSON DF, 1977, APHASIA ASSESSMENT T; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; FAHY TJ, 1967, LANCET, V2, P475; GALASKO CSB, 1974, INJURY, V6, P107, DOI 10.1016/0020-1383(74)90004-7; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; JAMIESON KG, 1971, HEAD INJURIES, P12; LEFTOFF S, 1983, J CLIN NEUROPSYCHOL, V5, P51, DOI 10.1080/01688638308401150; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; LONDON P S, 1967, Annals of the Royal College of Surgeons of England, V41, P460; McDaniel S., 1992, MED FAMILY THERAPY B; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; McLaughlin A. M., 1985, COGNITIVE REHABILITA, V3, P14; MILLER L, 1992, INT J LAW PSYCHIAT, V15, P303, DOI 10.1016/0160-2527(92)90005-L; Miller L., 1990, COGN REHABIL, V8, P14; MILLER L, 1989, COGNITIVE REHABILITA, V7, P26; MILLER L, 1990, PSYCHOTHERAPY PRIVAT, V8, P12; Miller L., 1993, PSYCHOTHERAPY BRAIN; MILLER L, 1991, J COGNITIVE REHABILI, V9, P24; MILLER L, 1990, COGNITIVE REHABILITA, V8, P12; MILLER L, 1990, INNER NATURES BRAIN; MILLER L, 1992, J COGNITIVE REHABILI, V10, P14; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Panting A., 1972, REHABILITATION, V38, P33; PARKER R, 1990, TRAUMATIC BRAIN INJU; PASNAU RO, 1981, FAMILY THERAPY MAJOR, P301; POTTER JM, 1967, POSTGRAD MED J, V43, P574, DOI 10.1136/pgmj.43.503.574; ROBINSON RG, 1985, PSYCHOSOMATICS, V26, P769, DOI 10.1016/S0033-3182(85)72790-9; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1986, HOSP PRACT, V21, P83; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; ROSS ED, 1981, ARCH NEUROL-CHICAGO, V38, P561, DOI 10.1001/archneur.1981.00510090055006; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; ROSS ED, 1987, J NERV MENT DIS, V175, P165, DOI 10.1097/00005053-198703000-00007; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	45	20	20	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0192-6187	1521-0383		AM J FAM THER	Am. J. Fam. Ther.	SUM	1993	21	2					111	121		10.1080/01926189308250910			11	Psychology, Clinical; Family Studies	Psychology; Family Studies	LK370	WOS:A1993LK37000002					2021-06-18	
J	KAUFMAN, HH				KAUFMAN, HH			HISTORICAL VIGNETTE - TREATMENT OF HEAD-INJURIES IN THE AMERICAN CIVIL-WAR	JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; GUNSHOT WOUND; NEUROSURGICAL HISTORY; INFECTION		At the time of the American Civil War (1861-1865), a great deal was known about closed head injury and gunshot wounds to the head. Compression was differentiated from concussion, but localization of lesion's was not precise. Ether and especially chloroform were used to provide anesthesia. Failure to understand how to prevent infection discouraged physicians from aggressive surgery. Manuals written to educate inexperienced doctors at the onset of the war provide an overview of the advice given by senior surgeons. The Union experiences in the treatment of head injury in the Civil War were discussed in the three surgical volumes of The Medical and Surgical History of the War of the Rebellion. Wounds were divided into incised and puncture wounds, blunt injuries, and gunshot wounds, which were analyzed separately. Because the patients were not stratified by severity of injury and because there was no neuroimaging, it is difficult to understand the clinical problems and the effectiveness of surgery. Almost immediately after the war, increased knowledge about cerebral localization and the development of antisepsis (and then asepsis) permitted the development of modern neurosurgery.		KAUFMAN, HH (corresponding author), W VIRGINIA UNIV,MED CTR,SCH MED,DEPT NEUROSURG,MORGANTOWN,WV 26506, USA.						Adams George Washington, 1952, DOCTORS BLUE MED HIS; CHISOLM JJ, 1861, MANUAL MILITARY SURG, P237; Coco Gregory A., 1988, VAST SEA MISERY HIST; Cunningham H. H., 1958, DOCTORS GRAY CONFEDE; DAMMANN G, 1988, PICTORIAL ENCY CIVIL, V2; DAMMANN G, 1983, PICTORIAL ENCY CIVIL, V1; DONAHUE MP, 1985, NURSING FINEST ART; FORMENTO F, 1963, NOTES OBSERVATIONS A, P37; GILLETT MC, 1987, ARMY MED DEPT 1818 1; GROSS SD, 1859, SYSTEM SURGERY PATHO, V2, P254; GROSS SD, 1861, MANUAL MILITARY SURG, P98; Guthrie GJ, 1842, INJURIES HEAD AFFECT; HALL COURTNEY R., 1952, BULL HIST MED, V26, P231; HAMILTON FH, 1864, AM MED TIMES    0213, P73; HAMILTON FH, 1864, AM MED TIMES    0227, P97; HAMILTON FH, 1864, AM MED TIMES    0206, P61; HAMILTON FH, 1864, AM MED TIMES    0220, P85; HAMILTON FH, 1861, PRACTICAL TREATISE M, P152; HAMILTON FH, 1865, TREATISE MILITARY SU, P228; HOGG IV, 1985, ILLUSTRATED ENCY AMM; KEEN WW, 1922, BOSTON MED SURG J, V187, P592; MAHER MD, 1989, BLIND WOUNDS CATHOLI; MCAULAY JD, 1987, CIVIL WAR BREECH LOA; MCLEOD GHB, 1858, NOTES SURGERY WAR CR; Middleton W S, 1966, Bull Hist Med, V40, P14; Mitchell Silas Weir, 1905, T COLL PHYS PHILA, V27, P87; Paget S., 1920, V HORSLEY STUDY HIS; SMITH S, 1862, HDB SURGICAL OPERATI, P237; THOMPSON CJS, 1942, HIST EVOLUTION SURGI; TRIPLER CS, 1861, HDB MILITARY SURGEON, P90; WARREN E, 1863, EPITOME PRACTICAL SU, P1369; ZELLEM RT, 1985, NEUROSURGERY, V17, P850, DOI 10.1227/00006123-198511000-00024; 1870, MED SURGICAL HIST WA, V1; 1877, MED SURGICAL HIST WA, V2; 1883, MED SURGICAL HIST WA, V3; 1863, MANUAL MILITARY SURG, P49	36	20	20	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1993	78	5					838	845		10.3171/jns.1993.78.5.0838			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KY468	WOS:A1993KY46800024	8468618				2021-06-18	
J	GOLDSTEIN, FC; MCKENDALL, RR; HAUT, MW				GOLDSTEIN, FC; MCKENDALL, RR; HAUT, MW			GIST RECALL IN MULTIPLE-SCLEROSIS	ARCHIVES OF NEUROLOGY			English	Article							CLOSED-HEAD INJURY; MEMORY DISTURBANCE; IMPAIRMENT; DEFICITS; AMNESIA; DISABILITY; DISEASE; PROSE; UNITS	This study examined gist recall (memory for important story ideas) in patients with multiple sclerosis. Twelve patients with clinically probable or definite multiple sclerosis and 10 neurologically intact control subjects were read prose passages from the Wechsler Memory Scale-Revised Logical Memory subtest. The idea units from these passages contained low, medium, and high information content to the stories. In comparison with the control subjects, the patients recalled fewer total elements over immediate and delayed conditions. However, similar to controls, they recalled more ideas that were of high rather than low or medium importance. These results suggest that semantic sensitivity to important ideas of narratives is a relatively preserved feature in multiple sclerosis.	UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT MICROBIOL,GALVESTON,TX 77550; W VIRGINIA UNIV,MED CTR,SCH MED,DEPT PSYCHIAT,MORGANTOWN,WV 26506; W VIRGINIA UNIV,MED CTR,SCH MED,DEPT NEUROL,MORGANTOWN,WV 26506; W VIRGINIA UNIV,MED CTR,SCH MED,DEPT BEHAV MED,MORGANTOWN,WV 26506; EMORY UNIV,SCH MED,DEPT NEUROL,NEUROBEHAV PROGRAM,ATLANTA,GA 30322	GOLDSTEIN, FC (corresponding author), WESLEY WOODS HLTH CTR,DEPT NEUROL,1841 CLIFTON RD NE,ATLANTA,GA 30329, USA.			Haut, Marc/0000-0003-0235-362X			Bartlett F.C., 1932, REMEMBERING; BEATTY WW, 1988, ARCH NEUROL-CHICAGO, V45, P611, DOI 10.1001/archneur.1988.00520300029013; BROWN AL, 1977, CHILD DEV, V48, P1, DOI 10.2307/1128873; CAINE ED, 1986, ARCH NEUROL-CHICAGO, V43, P249, DOI 10.1001/archneur.1986.00520030039009; CARROLL M, 1984, NEUROPSYCHOLOGIA, V22, P297, DOI 10.1016/0028-3932(84)90076-9; FREEDMAN M, 1986, BRAIN COGNITION, V5, P108, DOI 10.1016/0278-2626(86)90063-1; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; GRAFMAN J, 1991, ARCH NEUROL-CHICAGO, V48, P1072, DOI 10.1001/archneur.1991.00530220094025; Grafman J, 1990, NEUROBEHAVIORAL ASPE, P102; HAUT M W, 1990, Brain Injury, V4, P281, DOI 10.3109/02699059009026178; Haut MW, 1991, NEUROPSYCHOLOGY, V5, P81, DOI 10.1037/0894-4105.5.2.81; JOHNSON RE, 1970, J VERB LEARN VERB BE, V9, P12, DOI 10.1016/S0022-5371(70)80003-2; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LITVAN I, 1988, ARCH NEUROL-CHICAGO, V45, P281, DOI 10.1001/archneur.1988.00520270059021; LITVAN I, 1988, ARCH NEUROL-CHICAGO, V45, P607, DOI 10.1001/archneur.1988.00520300025012; MOSCOVITCH M, 1982, HUMAN MEMORY AMNESIA, P337; PETERSEN RC, 1991, MEMORY DISORDERS, P457; PREVEY ML, 1988, CORTEX, V24, P301, DOI 10.1016/S0010-9452(88)80038-8; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P699, DOI 10.1080/01688638908400926; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1984, ARCH NEUROL-CHICAGO, V41, P625, DOI 10.1001/archneur.1984.04210080033010; RUBIN DC, 1981, INT J NEUROSCI, V13, P81, DOI 10.3109/00207458109043304; SQUIRE LR, 1982, J EXP PSYCHOL LEARN, V8, P560, DOI 10.1037/0278-7393.8.6.560; VANDENBURG W, 1987, ARCH NEUROL-CHICAGO, V44, P494, DOI 10.1001/archneur.1987.00520170024017; Wechsler D., 1987, WECHSLER MEMORY SCAL; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; ZELINSKI EM, 1985, NEW DIRECTIONS AGING, P519	29	20	20	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	OCT	1992	49	10					1060	1064		10.1001/archneur.1992.00530340080021			5	Clinical Neurology	Neurosciences & Neurology	JR326	WOS:A1992JR32600013	1417514				2021-06-18	
J	HELLER, L; KEREN, O; ALONI, R; DAVIDOFF, G				HELLER, L; KEREN, O; ALONI, R; DAVIDOFF, G			AN OPEN TRIAL OF VACUUM PENILE TUMESCENCE - CONSTRICTION THERAPY FOR NEUROLOGICAL IMPOTENCE	PARAPLEGIA			English	Article						MALE NEUROLOGICAL IMPOTENCE; VACUUM PENILE CONSTRICTION TUMESCENCE		Sexual dysfunction is a frequent result of traumatic and non traumatic neurological disorders, including spinal cord injury, stroke, traumatic brain injury and autonomic neuropathy (for example, as may be seen in patients with diabetes mellitus). Although many methods have been suggested for the treatment of some of these problems in male patients, most are invasive and have a substantial morbidity. This is the report of a pilot trial of vacuum tumescence constriction therapy for 30 patients with chronic neurological impotence. Seventeen of these patients, following sexual counselling and training, decided to purchase such a device. At follow up, a mean of 21 months, over 50% of those who had purchased the device were still actively using it. The frequency of coitus increased from 0.3/wk to 1.5/wk (t = -5.7; p < 0.00001). No significant morbidity was reported by patients. Vacuum tumescence constriction therapy shows promise as a noninvasive method for the treatment of neurological impotence.	LOEWENSTEIN HOSP & REHABIL CTR,CTR REHABIL,278 AHUZA,POB 3,RAANANA,ISRAEL								0	20	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0031-1758			PARAPLEGIA	Paraplegia	AUG	1992	30	8					550	553		10.1038/sc.1992.113			4	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	JU300	WOS:A1992JU30000003	1522995	Bronze			2021-06-18	
J	MARKIANOS, M; SERETIS, A; KOTSOU, S; BALTAS, I; SACHAROGIANNIS, H				MARKIANOS, M; SERETIS, A; KOTSOU, S; BALTAS, I; SACHAROGIANNIS, H			CSF NEUROTRANSMITTER METABOLITES AND SHORT-TERM OUTCOME OF PATIENTS IN COMA AFTER HEAD-INJURY	ACTA NEUROLOGICA SCANDINAVICA			English	Article						HEAD INJURY; COMA; CSF; METHOXYHYDROXYPHENYLGLYCOL; HOMOVANILLIC ACID; 5-HYDROXYINDOLEACETIC ACID; OUTCOME	CEREBROSPINAL-FLUID; BRAIN; RECOVERY; RELEASE	The main metabolites of the neurotransmitters noradrenalin, dopamin, and serotonin, methoxyhydroxyphenylglycol (MHPG), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5HIAA) respectively, were estimated by HPLC with electrochemical detection in CSF samples from 24 patients in coma after head injury, 1 to 12 (mean 3.0) days from accident, and from 24 age- and sex-matched subjects undergoing myelography for possible herniated disk. Analysis of variance with-age as covariate, revealed significantly elevated levels of all three metabolites in the patients group. The concentrations of 5HIAA were negatively correlated to the score in the Glasgow Coma Scale. Fourteen patients who recovered with no or minor neurological deficits, had significantly lower CSF 5HIAA levels compared to the ten patients who had a bad outcome (death), while there were no differences regarding HVA or MHPG concentrations. The possibility of a connection of the high neurotransmitter turnover during coma to the development of post-traumatic depression is discussed.	ASCLEPEION HOSP,DEPT NEUROSURG,VOULA ATHENS,GREECE	MARKIANOS, M (corresponding author), UNIV ATHENS,EGINIT HOSP,MED SCH,PSYCHIAT CLIN,VAS SOPHIAS 74,GR-11528 ATHENS,GREECE.			Markianos, Manolis/0000-0002-4751-1014			ALTAR CA, 1987, J NEUROCHEM, V48, P390, DOI 10.1111/j.1471-4159.1987.tb04106.x; BUSTO R, 1985, ANN NEUROL, V18, P329, DOI 10.1002/ana.410180310; INAGAWA T, 1980, J NEUROSURG, V52, P635, DOI 10.3171/jns.1980.52.5.0635; JEQUIER E, 1974, SURG NEUROL, V2, P247; MOHABAYED M, 1990, J AFFECT DISORDERS, V19, P237; ODINK J, 1989, ACTA NEUROL SCAND, V80, P6, DOI 10.1111/j.1600-0404.1989.tb03834.x; PAPPIUS HM, 1987, J NEUROCHEM, V49, P321, DOI 10.1111/j.1471-4159.1987.tb03433.x; PAPPIUS HM, 1988, J CEREBR BLOOD F MET, V8, P324, DOI 10.1038/jcbfm.1988.67; WESTER P, 1990, J NEUROCHEM, V54, P1148, DOI 10.1111/j.1471-4159.1990.tb01942.x; WESTER P, 1987, ACTA NEUROL SCAND, V76, P473, DOI 10.1111/j.1600-0404.1987.tb03605.x; YATES CM, 1979, J NEUROL NEUROSUR PS, V42, P887, DOI 10.1136/jnnp.42.10.887; ZHANG WQ, 1988, BRAIN RES, V461, P335, DOI 10.1016/0006-8993(88)90264-8; 1990, BRIT J PHARMACOL, V99, P741	13	20	21	1	1	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	AUG	1992	86	2					190	193		10.1111/j.1600-0404.1992.tb05064.x			4	Clinical Neurology	Neurosciences & Neurology	JL205	WOS:A1992JL20500015	1384260				2021-06-18	
J	SCHWINGER, RHG; BOHM, M; LAROSEE, K; SCHMIDT, U; SCHULZ, C; ERDMANN, E				SCHWINGER, RHG; BOHM, M; LAROSEE, K; SCHMIDT, U; SCHULZ, C; ERDMANN, E			NA+-CHANNEL ACTIVATORS INCREASE CARDIAC GLYCOSIDE SENSITIVITY IN FAILING HUMAN MYOCARDIUM	JOURNAL OF CARDIOVASCULAR PHARMACOLOGY			English	Article						CARDIAC GLYCOSIDES; NA+-CHANNEL ACTIVATOR; BDF-9148; HEART FAILURE; POSITIVE INOTROPIC AGENTS; HUMAN MYOCARDIUM	HUMAN VENTRICULAR MYOCARDIUM; SODIUM-CALCIUM EXCHANGE; DPI 201-106; HEART-FAILURE; STROPHANTHIDIN INOTROPY; DILATED CARDIOMYOPATHY; INTRACELLULAR SODIUM; DOWN-REGULATION; PUMP ACTIVITY; MUSCLE	Na+-channel activators increase intracellular Na+ and thereby enhance the transport rate of sarcolemmal Na+, K+-ATPase. We investigated the interaction of the new Na+-channel activator BDF 9148 (BDF) with the cardiac glycoside ouabain (OUA) in human myocardium. The influence of OUA (0.01-0.1-mu-M) and of OUA after prestimulation with BDF (0.1-mu-M, 1-mu-M; BDF + OUA) on isometric force of contraction (FOC, force of contraction; +T/-T, peak rate of tension increase/decay) of electrically driven (1 Hz, 37-degrees-C) papillary muscle strips from terminally failing [New York Heart Association classification IV (NYHA IV) heart transplants, n = 19] human myocardium was studied. We also examined the effects of BDF and OUA on nonfailing human myocardium (brain death resulting from traumatic injury, n = 5). 0.01-mu-M OUA enhanced FOC only after prestimulation with BDF (NYHA IV + 2.9 +/- 0.4 mN; p < 0.01). The time until maximal (T(max): BDF + OUA 117 min, OUA 166 min), half-maximal (T1/2max: BDF + OUA 47 min, OUA 85 min) inotropic effects and time until toxic signs (contracture, extrasystoles) occurred were significantly shorter with BDF + OUA as compared with OUA alone. BDF influenced T(max), T1/2max, and time until toxic side effects occurred (T(tox)) of the OUA-mediated inotropism in a concentration-dependent manner. Both OUA and BDF enhanced +T and -T. The effectiveness of OUA and BDF in increasing FOC was similar to that of Ca2+ (1.8-15 mM) but significantly (p < 0.01) higher as compared with the beta-adrenoceptor-agonist isoprenaline in NYHA IV. In myocardial membranes, [H-3]ouabain binding (B(max), K(d)) was not affected by BDF. These results suggest that BDF enhances the potency of OUA to increase FOC in human myocardium but also enhances toxicity of OUA. The influence of BDF on the effects of OUA is probably indirect and may be related to cellular Na+ load. Because BDF 9148 can decrease the inotropic and toxic concentration for cardiac glycosides, great caution appears to be necessary when these compounds are used simultaneously to treat human heart failure.		SCHWINGER, RHG (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,MED KLIN 1,MARCHIONINISTR 15,W-8000 MUNICH 70,GERMANY.						AKERA T, 1981, BIOCHIM BIOPHYS ACTA, V640, P779, DOI 10.1016/0005-2736(81)90108-5; Akera T, 1978, PHARMACOL REV, V29, P187; ALSEN C, 1982, J CARDIOVASC PHARM, V4, P63, DOI 10.1097/00005344-198201000-00011; ARMAH B I, 1990, Naunyn-Schmiedeberg's Archives of Pharmacology, V341, pR50; BARCENASRUIZ L, 1987, SCIENCE, V238, P1720, DOI 10.1126/science.3686010; BOHM M, 1988, J CARDIOVASC PHARM, V12, P726; BOHM M, 1989, AM J CARDIOL, V64, P812, DOI 10.1016/0002-9149(89)90773-X; BORCHARD M, 1986, EUR J PHARMACOL, V131, P269, DOI 10.1016/0014-2999(86)90581-9; BRASCH H, 1991, BRIT J PHARMACOL, V103, P1939, DOI 10.1111/j.1476-5381.1991.tb12356.x; BRIGGS GM, 1987, CIRCULATION S4, V76, P613; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BUGGISCH D, 1985, EUR J PHARMACOL, V118, P303, DOI 10.1016/0014-2999(85)90141-4; ERDMANN E, 1983, EUR HEART J, V4, P61, DOI 10.1093/eurheartj/4.suppl_A.61; ERDMANN E, 1973, BIOCHIM BIOPHYS ACTA, V307, P386, DOI 10.1016/0005-2736(73)90104-1; FELDMAN AM, 1988, J CLIN INVEST, V82, P189, DOI 10.1172/JCI113569; FELDMAN MD, 1987, CIRCULATION, V75, P331, DOI 10.1161/01.CIR.75.2.331; GRUPP I, 1985, J PHYSIOL-LONDON, V360, P149, DOI 10.1113/jphysiol.1985.sp015609; GWATHMEY JK, 1990, CIRCULATION, V82, P1266, DOI 10.1161/01.CIR.82.4.1266; GWATHMEY JK, 1988, J CLIN INVEST, V82, P1592, DOI 10.1172/JCI113771; HAJJAR RJ, 1988, J CLIN INVEST, V82, P1578, DOI 10.1172/JCI113769; HERZIG S, 1988, J PHYSIOL-LONDON, V396, P105, DOI 10.1113/jphysiol.1988.sp016953; HERZIG S, 1991, J CARDIOVASC PHARM, V18, P182, DOI 10.1097/00005344-199108000-00002; HONERJAEGER P, 1990, Naunyn-Schmiedeberg's Archives of Pharmacology, V341, pR51; HONERJAGER P, 1975, N-S ARCH PHARMACOL, V289, P1, DOI 10.1007/BF00498026; KENNEDY RH, 1983, EUR J PHARMACOL, V89, P199, DOI 10.1016/0014-2999(83)90495-8; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEE CO, 1985, J MOL CELL CARDIOL, V17, P1043, DOI 10.1016/S0022-2828(85)80120-6; LI T, 1986, CAN J PHYSIOL PHARM, V64, P1385, DOI 10.1139/y86-235; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEUMANN J, 1988, LANCET, V2, P936; PACKER M, 1988, CIRCULATION, V77, P721, DOI 10.1161/01.CIR.77.4.721; PFEIFER T, 1990, Naunyn-Schmiedeberg's Archives of Pharmacology, V341, pR51; PORT JD, 1988, FASEB J, V2, pA602; RAVENS U, 1989, J CARDIOVASC PHAR S3, V14, pS3; SCHMITZ W, 1989, J CARDIOVASC PHARM, V14, pS11, DOI 10.1097/00005344-198914003-00003; SCHOLTYSIK G, 1985, N-S ARCH PHARMACOL, V329, P316, DOI 10.1007/BF00501887; SCHOLTYSIK G, 1989, J CARDIOVASC PHARM, V14, pS24, DOI 10.1097/00005344-198914003-00006; SCHOLTYSIK G, 1989, J CARDIOVASC PHARM, V13, P342, DOI 10.1097/00005344-198902000-00026; SCHOLTYSIK G, 1986, TRIANGLE, V25, P105; SCHWINGER RHG, 1991, J MOL CELL CARDIOL, V23, P461, DOI 10.1016/0022-2828(91)90170-Q; SCHWINGER RHG, 1990, J CARDIOVASC PHARM, V15, P692, DOI 10.1097/00005344-199005000-00002; SCHWINGER RHG, 1990, AM HEART J, V119, P889; SHEU SS, 1982, J GEN PHYSIOL, V80, P325, DOI 10.1085/jgp.80.3.325; SMITH TW, 1984, PROG CARDIOVASC DIS, V26, P413, DOI 10.1016/0033-0620(84)90012-4; SMITH TW, 1989, THERAPIE, V44, P431; THORMANN J, 1986, J CARDIOVASC PHARM, V8, P749; YAJIMA M, 1984, JPN J PHARMACOL, V36, pP277	48	20	20	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0160-2446			J CARDIOVASC PHARM	J. Cardiovasc. Pharmacol.	APR	1992	19	4					554	561		10.1097/00005344-199204000-00012			8	Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy	Cardiovascular System & Cardiology; Pharmacology & Pharmacy	HK716	WOS:A1992HK71600012	1380598				2021-06-18	
J	RIBAS, GC; JANE, JA				RIBAS, GC; JANE, JA			TRAUMATIC CONTUSIONS AND INTRACEREBRAL HEMATOMAS	JOURNAL OF NEUROTRAUMA			English	Article							SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; INTRA-CEREBRAL HEMATOMAS; COMA DATA-BANK; COMPUTERIZED-TOMOGRAPHY; CT SCAN; INTRACRANIAL-PRESSURE; CRANICAL PRESSURE; CORPUS-CALLOSUM; BRAIN-DAMAGE	The authors review acute and delayed traumatic intracerebral hemorrhages. Based on recent experimental and clinical data, these injuries' clinical presentation, pathologic characteristics, and treatment are discussed. A description of traumatic hemorrhage based on biomechanics is emphasized.	UNIV VIRGINIA, HLTH SCI CTR, DEPT NEUROL SURG, BOX 212, CHARLOTTESVILLE, VA 22908 USA; HOSP ALBERT EINSTEIN, SAO PAULO, BRAZIL							Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; Adams J H, 1981, Acta Neuropathol Suppl, V7, P26; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1986, ARCH PATHOL LAB MED, V110, P485; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ADAMS JH, 1975, HDB CLINICAL NEUROLO, V23, P35; AMACHER AL, 1987, NEUROSURGERY, V20, P954; ANDREWS BT, 1988, J NEUROSURG, V69, P518, DOI 10.3171/jns.1988.69.4.0518; ANTTINEN EE, 1957, ACTA PSYCH NEUROL, V32, P103; AUSTARHEIM KR1STEN, 1956, ACTA PATHOL ET MICROBIOL SCAND, V38, P177; BARATHAM G, 1972, J NEUROL NEUROSUR PS, V35, P698, DOI 10.1136/jnnp.35.5.698; BECKER DP, 1982, NEUROLOGICAL SURGERY, V4, P1938; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; BROADDUS WC, 1989, INTRACRANIAL PRESSUR, V7, P41; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; BRUNETTI J, 1979, NEURORADIOLOGY, V18, P43, DOI 10.1007/BF00346211; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; CLASEN RA, 1987, HEAD INJURY, P285; COLQUHOUN IR, 1989, CLIN RADIOL, V40, P619, DOI 10.1016/S0009-9260(89)80324-1; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; Courville CB, 1942, ARCH SURG-CHICAGO, V45, P19, DOI 10.1001/archsurg.1942.01220010022002; Courville CB, 1940, ARCH SURG-CHICAGO, V41, P1; CROWE NW, 1989, NEUROLOGY, V39, P863, DOI 10.1212/WNL.39.6.863; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAWSON SL, 1980, HUM PATHOL, V11, P155, DOI 10.1016/S0046-8177(80)80136-5; De Vet AC, 1976, HDB CLIN NEUROLOGY, V24, P351; DeJong RN, 1942, ARCH NEURO PSYCHIATR, V48, P257, DOI 10.1001/archneurpsyc.1942.02290080103004; DEMIERRE B, 1987, NEUROCHIRURGIE, V33, P12; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; DOHRMANN PJ, 1983, AUST NZ J SURG, V53, P169, DOI 10.1111/j.1445-2197.1983.tb02421.x; DUBLIN AB, 1977, RADIOLOGY, V122, P365, DOI 10.1148/122.2.365; ELSNER H, 1990, J NEUROSURG, V72, P813, DOI 10.3171/jns.1990.72.5.0813; EVANS JP, 1946, J NEUROSURG, V3, P101, DOI 10.3171/jns.1946.3.2.0101; FRENCH BN, 1977, SURG NEUROL, V7, P171; FUKAMACHI A, 1985, ACTA NEUROCHIR, V74, P35, DOI 10.1007/BF01413274; FUKAMACHI A, 1985, J TRAUMA, V25, P145, DOI 10.1097/00005373-198502000-00010; GALBRAITH S, 1987, BRIT MED J, V294, P325, DOI 10.1136/bmj.294.6568.325; GALBRAITH S, 1981, J NEUROSURG, V55, P75, DOI 10.3171/jns.1981.55.1.0075; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1979, 23RD P STAPP CAR CRA, P561; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; Graham D. I., 1987, HEAD INJURY, P72; GRAHAM DI, 1971, LANCET, V1, P265; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; GURDJIAN ES, 1975, IMAPCT HEAD INJURY; HEISKANEN O, 1972, ACTA NEUROCHIR, V27, P29, DOI 10.1007/BF01402170; HIRSH LF, 1979, NEUROSURGERY, V5, P653, DOI 10.1227/00006123-197912000-00001; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; JAMIESON KG, 1972, J NEUROSURG, V37, P528, DOI 10.3171/jns.1972.37.5.0528; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KOMATSU S, 1979, NEUROSURGERY, V5, P32, DOI 10.1227/00006123-197907010-00005; KUROKAWA Y, 1989, Neurological Surgery, V17, P335; LANGFITT TW, 1982, CLIN NEUR, V29, P353; LARA VV, 1974, THESIS LIMA; LARSON S J, 1965, J Trauma, V5, P482, DOI 10.1097/00005373-196507000-00006; LEVINTHAL R, 1977, SURG NEUROL, V7, P269; LINDENBERG R, 1960, ARCH PATHOL, V69, P440; LINDENBERG R, 1955, AM J PATHOL, V31, P297; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LONG DM, 1982, CLIN NEUR, V29, P174; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LR, 1985, ANN M AM ASS NEUROLO; MCLAURIN RL, 1965, J NEUROSURG, V23, P296, DOI 10.3171/jns.1965.23.3.0296; MCLAURIN RL, 1956, ANN SURG, V143, P294, DOI 10.1097/00000658-195603000-00002; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; MILLER JD, 1982, CLIN NEUR, V29, P103; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MIZUTANI T, 1990, SURG NEUROL, V33, P178, DOI 10.1016/0090-3019(90)90181-N; MODESTI LM, 1982, NEUROSURGERY, V10, P689, DOI 10.1227/00006123-198206010-00002; MORIN MA, 1970, J NEUROSURG, V33, P542, DOI 10.3171/jns.1970.33.5.0542; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; NICHONJI T, 1984, ACTA NEUROCHIR, V71, P69; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; REILLY PL, 1975, LANCET, V2, P375; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; RIETH KG, 1980, RADIOLOGY, V135, P343, DOI 10.1148/radiology.135.2.6768102; ROBERSON FC, 1979, SURG NEUROL, V12, P161; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; ROESSMAN U, 1968, ACTA NEUROPATHOL, V10, P151, DOI 10.1007/BF00691309; ROSS DA, 1989, J NEUROSURG, V71, P498, DOI 10.3171/jns.1989.71.4.0498; Rowbotham GF, 1964, ACUTE INJURIES HEAD; SACKETT JF, 1975, RADIOLOGY, V116, P95, DOI 10.1148/116.1.95; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; Schonauer M, 1979, J Neurosurg Sci, V23, P279; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHIGEMORI M, 1986, ACTA NEUROCHIR, V81, P36, DOI 10.1007/BF01456262; SMITH D R, 1969, Journal of Neurosurgery, V30, P664, DOI 10.3171/jns.1969.30.6.0664; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; TANEDA M, 1979, ACTA NEUROCHIR, V51, P73, DOI 10.1007/BF01401796; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; Tornheim P A, 1976, Surg Neurol, V5, P171; TORNHEIM PA, 1985, CENTRAL NERVOUS SYST, P431; TORNHEIM PA, 1985, TRAUMA NERVOUS SYSTE, P141; TORRES H, 1972, NEUROCHIRURGIA, V15, P62; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; TSAI FY, 1978, NEURORADIOLOGY, V16, P314, DOI 10.1007/BF00395286; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; VOIGT GE, 1977, ACTA NEUROPATHOL, V39, P201, DOI 10.1007/BF00691698; WEAVER DD, 1982, J NEUROSURG, V56, P660, DOI 10.3171/jns.1982.56.5.0660; WINN HR, 1977, SURG NEUROL, V8, P41; Yashon D, 1978, Neurosurgery, V2, P103; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P320, DOI 10.1007/BF00395288; ZUCCARELLO M, 1980, ACTA NEUROCHIR, V54, P265, DOI 10.1007/BF01407094	135	20	20	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S265	S278					14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600025	1588615				2021-06-18	
J	WROBLEWSKI, BA; JOSEPH, AB				WROBLEWSKI, BA; JOSEPH, AB			THE USE OF INTRAMUSCULAR MIDAZOLAM FOR ACUTE SEIZURE CESSATION OR BEHAVIORAL EMERGENCIES IN PATIENTS WITH TRAUMATIC BRAIN INJURY	CLINICAL NEUROPHARMACOLOGY			English	Article						MIDAZOLAM; SEIZURES; BEHAVIOR; AGGRESSION; BRAIN INJURY		Brain-injured patients involved in rehabilitation programs are susceptible to the occurrence of acute seizures or severe behavioral episodes. Effective pharmacological management in this setting should ideally include rapid onset without severe adverse effects. Previous treatments have generally included intramuscular diazepam or lorazepam, as well as intramuscular antipsychotic drugs. These options have proved problematic due to poor absorption, slow onset of activity, or potential for unacceptable side effects. We report 10 cases involving the use of intramuscular midazolam, a rapid-acting, short half-life benzodiazepine, in treating acute seizures or behavioral problems. We conclude that this drug demonstrates great promise for the rapid, effective treatment of these conditions without significant adverse effects and deserves further study in these areas.	GREENERY REHABIL CTR, 99 CHESTNUT HILL AVE, BRIGHTON, MA 02135 USA; TUFTS UNIV, SCH MED, DEPT REHABIL MED, BOSTON, MA 02111 USA; MASSACHUSETTS COLL PHARM & ALLIED HLTH SCI, DEPT PHARM, BOSTON, MA 02115 USA; HARVARD UNIV, MCLEAN HOSP, SCH MED, DEPT PSYCHIAT, BELMONT, MA 02178 USA; CTR NEUROBEHAV REHABIL MIDDLESEX HOSP, WALTHAM, MA USA; HARVARD UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02115 USA							BOND WS, 1989, AM J PSYCHIAT, V146, P925; DUNDEE JW, 1984, DRUGS, V28, P519, DOI 10.2165/00003495-198428060-00002; EGLI M, 1981, 12TH WORLD C NEUR KY, P144; GALVIN GM, 1987, ARCH EMERG MED, V4, P169; JAWAD S, 1986, J NEUROL NEUROSUR PS, V49, P1050, DOI 10.1136/jnnp.49.9.1050; MAYHUE FE, 1988, ANN EMERG MED, V17, P643, DOI 10.1016/S0196-0644(88)80408-6; MENDOZA R, 1987, J CLIN PSYCHIAT, V48, P291; VONALBERT HH, 1986, MIDAZOLAM ANESTHESIO, P255; 1986, VERSED PRODUCT INFOR	9	20	20	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-5664	1537-162X		CLIN NEUROPHARMACOL	Clin. Neuropharmacol.	FEB	1992	15	1					44	49		10.1097/00002826-199202000-00006			6	Clinical Neurology; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	GZ748	WOS:A1992GZ74800006	1576597				2021-06-18	
J	SCHURER, L; DAUTERMANN, C; HARTL, R; MURR, R; BERGER, S; ROHRICH, F; MESSMER, K; BAETHMANN, A				SCHURER, L; DAUTERMANN, C; HARTL, R; MURR, R; BERGER, S; ROHRICH, F; MESSMER, K; BAETHMANN, A			TREATMENT OF HEMORRHAGIC HYPOTENSION WITH HYPERTONIC HYPERONCOTIC SOLUTIONS - EFFECTS ON REGIONAL CEREBRAL BLOOD-FLOW AND BRAIN SURFACE OXYGEN-TENSION	EUROPEAN SURGICAL RESEARCH			English	Article						HYPERTONIC HYPERONCOTIC; NACL DEXTRAN; SMALL-VOLUME RESUSCITATION; CEREBRAL BLOOD FLOW; CEREBRAL O2 SUPPLY; HEMORRHAGIC HYPOVOLEMIA	SMALL-VOLUME RESUSCITATION; INTRACRANIAL-PRESSURE; TRAUMATIC SHOCK; SALINE DEXTRAN; HEAD-INJURY; TISSUE; MICROCIRCULATION; TRANSPORT; PROTEINS; BARRIER	Hypertonic/hyperoncotic solutions (e.g. HHS: 7.2% NaCl/10% dextran-60) are highly effective to normalize cardiovascular function in hemorrhagic shock due to rapid mobilization of fluid from the extravascular compartment. Since experiences are limited with regard to potential side effects of this treatment on the central nervous system, the present studies were carried out under particular consideration of the cerebral blood flow and O2 supply. HHS was administered in albino rabbits subjected to alpha-chloralose anesthesia and artificial ventilation with and without hemorrhagic hypovolemia. Hemorrhagic hypovolemia of 30 min duration was induced by withdrawal of approximately one third of the circulating blood volume resulting in a decrease in arterial blood pressure to 40 mm Hg. HHS was studied in addition in normovolemic animals. Cardiac output was rapidly normalized by infusion of HHS in animals with hypovolemia, while it increased intermittently in normovolemic animals. In animals with hemorrhagic shock arterial blood pressure recovered by treatment to approximately 70% of normal, whereas blood pressure remained unchanged after infusion of HHS in normovolemic controls. Cerebral blood flow, which was assessed by H2 clearance at the brain surface, had a range of 43.0-50.3 ml/100 g/min under control conditions. It remained virtually unchanged during hemorrhagic hypovolemia and also after infusion of HHS in normovolemic animals. Treatment of shock by HHS was followed 90 or 120 min later by a moderate increase in regional cerebral blood flow to 61 ml/100 g/min. Local tissue P(O2) at the brain surface was obtained by an O2 multiwire electrode in the vicinity of the H2 clearance measurements using a weightless suspension system to avoid compression of the brain surface. Infusion of HHS in normovolemic animals did not affect the O2 supply of the brain. Hemorrhagic hypovolemia which led to a left shift of the cerebral P(O2) histogram was followed by gradual normalization after fluid resuscitation. The current findings taken together do not indicate adverse side effects of this efficient method of fluid resuscitation with regard to the cerebral blood and O2 supple. The results make worthwhile further investigations on HHS in the presence of a focal brain lesion causing brain edema to find out whether the HHS are useful also for the treatment of intracranial hypertension.	LUDWIG MAXIMILIANS UNIV, KLINIKUM GROSSHADERN, DEPT NEUROSURG, W-8000 MUNICH 70, GERMANY; LUDWIG MAXIMILLIAN UNIV, KLINIKUM GROSSHADERN, INST ANESTHESIOL, W-8000 MUNICH 70, GERMANY	SCHURER, L (corresponding author), LUDWIG MAXIMILIANS UNIV, KLINIKUM GROSSHADERN, INST SURG RES, MARCHIONINISTR 15, W-8000 MUNICH 70, GERMANY.						ALBRIGHT AL, 1984, J NEUROSURG, V60, P481, DOI 10.3171/jns.1984.60.3.0481; ARVIDSSON S, 1981, ACTA ANAESTH SCAND, V25, P153, DOI 10.1111/j.1399-6576.1981.tb01626.x; AUKLAND DK, 1964, CIRC RES, V17, P85; BITTERMAN H, 1987, CIRC SHOCK, V21, P271; CHAN R, 1983, INT J MICROCIRC, V2, P297; GAAB M, 1978, ACTA NEUROCHIR, V40, P203, DOI 10.1007/BF01774747; Groger U, 1990, Adv Neurol, V52, P215; GUNNAR W, 1988, SURGERY, V103, P398; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; IVANOV KP, 1979, MICROVASC RES, V18, P434, DOI 10.1016/0026-2862(79)90049-9; Jennett B, 1981, MANAGEMENT HEAD INJU; KESSLER M, 1976, ANESTHESIOLOGY, V45, P184, DOI 10.1097/00000542-197608000-00007; KOZNIEWSKA E, 1987, J CEREBR BLOOD F MET, V7, P464, DOI 10.1038/jcbfm.1987.89; KRAMER GC, 1986, SURGERY, V100, P239; KREIMEIER U, 1990, CIRC SHOCK, V32, P83; KREIMEIER U, 1988, EUR SURG RES, V20, P277, DOI 10.1159/000128773; KREIMEIER U, 1987, SURGICAL RES RECENT, P39; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; KUROIWA T, 1985, ACTA NEUROPATHOL, V66, P3, DOI 10.1007/BF00698288; LUBBERS DW, 1972, HIRNKREISLAUF, P214; MAEKAWA T, 1979, ANESTHESIOLOGY, V51, P313, DOI 10.1097/00000542-197910000-00007; MANINGAS PA, 1987, CRIT CARE MED, V15, P1121, DOI 10.1097/00003246-198712000-00009; Mattar J A, 1973, Crit Care Med, V1, P293; MATTAR JA, 1989, CRIT CARE MED, V17, P297, DOI 10.1097/00003246-198903000-00020; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629; MAZZONI MC, 1987, MICROCIRCULATION UPD, V1, P289; MCKEE AC, 1988, NEUROLOGY, V38, P1211, DOI 10.1212/WNL.38.8.1211; PRAZMA J, 1978, J APPL PHYSIOL, V44, P977; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; RUBIN MJ, 1985, AM J PHYSIOL, V249, pH540; SHACKFORD SR, 1990, CRIT CARE MED, V5, P59; SILVA PA, 1986, J LEARN DISABIL, V19, P165, DOI 10.1177/002221948601900307; SMITH GJ, 1985, J SURG RES, V39, P517, DOI 10.1016/0022-4804(85)90120-9; SMITH RH, 1977, MICROVASC RES, V13, P233, DOI 10.1016/0026-2862(77)90088-7; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; WADE CE, 1989, CIRC SHOCK, V29, P193; WIERNSPERGER N, 1981, EUR NEUROL, V20, P200, DOI 10.1159/000115234; WIERNSPERGER N, 1978, DRUG RES, V28, P768; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9	40	20	21	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0014-312X	1421-9921		EUR SURG RES	Eur. Surg. Res.	JAN-FEB	1992	24	1					1	12		10.1159/000129183			12	Surgery	Surgery	HT026	WOS:A1992HT02600001	1375157				2021-06-18	
J	GOLDSTEIN, FC; LEVIN, HS				GOLDSTEIN, FC; LEVIN, HS			QUESTION-ASKING STRATEGIES AFTER SEVERE CLOSED HEAD-INJURY	BRAIN AND COGNITION			English	Article							SCALE		EMORY UNIV,SCH MED,DEPT NEUROL,ATLANTA,GA 30322; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550	GOLDSTEIN, FC (corresponding author), WESLEY WOODS GERIATR HOSP,EMORY NEUROBEHAV PROGRAM,1821 CLIFTON RD NE,ATLANTA,GA 30329, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline		BENYISHAY Y, 1983, REHABILITATION HEAD; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; DENNEY DR, 1973, DEV PSYCHOL, V9, P275, DOI 10.1037/h0035092; DENNEY NW, 1979, HUM DEV, V22, P23, DOI 10.1159/000272426; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; GOLDSTEIN FC, 1987, NEUROPSYCHOLOGICAL R; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Luria A. R, 1973, WORKING BRAIN; LURIA AR, 1964, FRONTAL GRANULAR COR; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Mosher F. A., 1966, STUDIES COGNITIVE GR; ODDY M, 1984, CLOSED HEAD INJURY P; OLVER RR, 1966, STUDIES COGNITIVE GR; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEASDALE G, 1974, LANCET, V2, P81	18	20	20	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0278-2626			BRAIN COGNITION	Brain Cogn.	SEP	1991	17	1					23	30		10.1016/0278-2626(91)90063-E			8	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	GV410	WOS:A1991GV41000002	1781978				2021-06-18	
J	LANG, DA; HADLEY, DM; TEASDALE, GM; MACPHERSON, P; TEASDALE, E				LANG, DA; HADLEY, DM; TEASDALE, GM; MACPHERSON, P; TEASDALE, E			GADOLINIUM DTPA ENHANCED MAGNETIC-RESONANCE-IMAGING IN ACUTE HEAD-INJURY	ACTA NEUROCHIRURGICA			English	Article						HEAD INJURY; MAGNETIC RESONANCE IMAGING; GADOLINIUM DTPA; BLOOD BRAIN BARRIER	GD-DTPA; COMPUTED-TOMOGRAPHY; CEREBRAL INFARCTION; BRAIN INFARCTS; HEMORRHAGE	We studied the effect of contrast enhancement on magnetic resonance imaging (Gadolinium DTPA Magnetic REsonance) in 10 patients with a recent head injury. The use of contrast did not increase the number of traumatic lesions identified and we did not detect evidence of altered blood brain barrier permeability in any of the 7 patients, who had a total of 27 lesions, imaged between one and 4 days after injury. Enhancement was found in each of 3 patients imaged 6 or more days after injury. These findings suggest that traumatic cortical and intraparenchymal lesions are not associated with increased cerebrovascular permeability within the first 96 hours of a head injury.	UNIV GLASGOW,SO GEN HOSP,INST NEUROL SCI,DEPT NEUROSURG,GLASGOW G51 4TF,SCOTLAND							ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, pCH7; BARSCH RC, 1983, RADIOLOGY, V147, P781; BECKER H, 1988, DIAGNOSTIC IMAGING S, V1, P18; BULLOCK R, 1989, INTRACRANIAL PRESSUR, P637; CAILLE JM, 1983, AM J NEURORADIOL, V4, P1041; ENZMANN DR, 1981, AM J NEURORADIOL, V2, P517; GARCIA JH, 1974, J NEUROPATH EXP NEUR, V33, P408, DOI 10.1097/00005072-197407000-00007; HADLEY DM, 1988, CLIN RADIOL, V39, P131; HOSSMANN KA, 1980, STROKE, V11, P583, DOI 10.1161/01.STR.11.6.583; IMAKITA S, 1987, NEURORADIOLOGY, V29, P422, DOI 10.1007/BF00341737; JENKINS A, 1986, LANCET, V2, P445; KILGORE DP, 1986, RADIOLOGY, V160, P757, DOI 10.1148/radiology.160.3.3488563; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Klatzo I, 1967, BRAIN EDEMA, P554; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; MACPHERSON P, 1989, NEURORADIOLOGY, V31, P293, DOI 10.1007/BF00344169; MAUSER HW, 1984, NEURORADIOLOGY, V26, P31, DOI 10.1007/BF00328200; MCNAMARA MT, 1987, MAGNETIC RESONANCE I, P97; NATH FP, 1987, J NEUROSURG, V66, P555, DOI 10.3171/jns.1987.66.4.0555; NATH FP, 1985, INTRACRANIAL PRESSUR, V6, P581; OLSSON Y, 1971, ACTA NEUROPATHOL, V18, P89, DOI 10.1007/BF00687597; PETITO CK, 1979, J NEUROPATH EXP NEUR, V38, P222, DOI 10.1097/00005072-197905000-00003; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; VIRAPONGSE C, 1986, RADIOLOGY, V161, P785, DOI 10.1148/radiology.161.3.3786734; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011	27	20	21	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1991	109	1-2					5	11		10.1007/BF01405689			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FJ152	WOS:A1991FJ15200002	2068967				2021-06-18	
J	WEHMAN, P; WEST, M; FRY, R; SHERRON, P; GROAH, C; KREUTZER, J; SALE, P				WEHMAN, P; WEST, M; FRY, R; SHERRON, P; GROAH, C; KREUTZER, J; SALE, P			EFFECT OF SUPPORTED EMPLOYMENT ON THE VOCATIONAL OUTCOMES OF PERSONS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF APPLIED BEHAVIOR ANALYSIS			English	Article										WEHMAN, P (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,BOX 2011,RICHMOND,VA 23284, USA.						BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; ELLARD D, IN PRESS VOCATIONAL; FRASER RT, 1988, REHABILITATION ED, V2, P179; HEGEL T, 1988, BRAIN INJURY, V2, P333; HERSEN M, 1976, SINGLE CASE EXPT DES; HILL M, 1988, VOCATIONAL REHABILIT, P31; JELLINEK HM, 1982, ARCH PHYS MED REHAB, V63, P160; KAY T, 1986, ANNOTATED BIBLIOGRAP; KREUTZER J, IN PRESS COMMUNITY I; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; KREUTZER JS, 1989, REHABIL PSYCHOL, V34, P117; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; MCMORDIE W, 1988, BRAIN INJURY, V2, P359; MOON S, 1986, SUPPORTED WORK MODEL; PECK E, 1984, ANN M INT NEUROPSYCH; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Rosen CD, 1986, HEAD TRAUMA ED REINT; RUSCH F, 1986, COMPETITIVE EMPLOYME; STAPLETON M, IN PRESS VOCATIONAL; STAPLETON MC, 1986, COGNITIVE REHABIL, V4, P34; STONNINGTON HH, 1987, AM REHABILITATION, V10, P66; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN P, 1988, VOCATIONAL REHABILIT; Wehman P., 1988, J HEAD TRAUMA REHAB, V3, P82, DOI DOI 10.1097/00001199-198812000-00012; WEHMAN P, IN PRESS BRAIN INJUR; WEHMAN P, IN PRESS VOCATIONAL; WEHMAN P, 1989, J HEAD TRAUMA REHAB, V4, P66; Wehman P, 1985, J ASSOC PERS SEVERE, V10, P3; YLVISAKER M, 1985, HEAD INJURY REHABILI	32	20	20	0	1	JOURNAL APPL BEHAV ANAL	LAWRENCE	DEPT HUMAN DEVELOPMENT, UNIV KANSAS, LAWRENCE, KS 66045	0021-8855			J APPL BEHAV ANAL	J. Appl. Behav. Anal.	WIN	1989	22	4					395	405		10.1901/jaba.1989.22-395			11	Psychology, Clinical	Psychology	CV433	WOS:A1989CV43300006	2515185	Green Published			2021-06-18	
J	Wilson, JTL; Wiedmann, KD; Hadley, DM; Brooks, DN				Wilson, J. T. L.; Wiedmann, K. D.; Hadley, D. M.; Brooks, D. N.			The Relationship between Visual Memory Function and Lesions Detected by Magnetic Resonance Imaging after Closed Head Injury	NEUROPSYCHOLOGY			English	Article						Head injury; magnetic resonance imaging; visual and verbal memory		Forty-five patients with closed head injuries were followed up 6 months postinjury with magnetic resonance imaging (MRl) and neuropsychological assessment. Patients were tested on visual and verbal measures of short-term memory and learning: Pattern Span, Pattern Learning, Path Span, Path Learning, Digit Span, and Digit Learning. Visual memory for patterns and paths was tested using a recall procedure. Compared with a matched control group (n = 22), patients were significantly impaired on pattern span but not on path span or digit span. Patients were also significantly impaired on measures of path learning and digit learning. Performance on the visual memory tasks, but not measures of verbal memory, was related to a rating of ventricular enlargement derived from MRI. There was some evidence for differential relationships between pattern span and pattern learning and lesions in hemispheric sites. However, despite the sensitivity of MRl to focal lesions, it appears that diffuse damage remains of importance in predicting neuropsychological impairment in head injury.	[Wilson, J. T. L.; Wiedmann, K. D.] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; [Hadley, D. M.] So Gen Hosp, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland; [Brooks, D. N.] Univ Glasgow, Dept Psychol Med, Glasgow, Lanark, Scotland	Wilson, JTL (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.		Wilson, Lindsay/A-3659-2009; Wilson, Lindsay/O-8883-2019	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328	Medical Research Council of Great BritainUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	This study was supported by the Medical Research Council of Great Britain.	ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; Baddeley A. D., 1986, WORKING MEMORY; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BROOKS N, 1984, CLOSED HEAD INJURY P, P44; DERENZI E, 1977, CORTEX, V13, P424, DOI 10.1016/S0010-9452(77)80022-1; DRACHMAN DA, 1966, ARCH NEUROL-CHICAGO, V15, P52, DOI 10.1001/archneur.1966.00470130056005; FRICK RW, 1985, MEM COGNITION, V13, P346, DOI 10.3758/BF03202502; HADLEY DM, 1988, CLIN RADIOL, V39, P131; JENNETT WB, 1969, SPECIAL PUBLICATION, V4; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; PHILLIPS WA, 1983, PHILOS T ROY SOC B, V302, P295, DOI 10.1098/rstb.1983.0056; Rey A, 1941, ARCH PSYCHOL, V28; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; WARRINGTON EK, 1967, NEUROPSYCHOLOGIA, V5, P253, DOI 10.1016/0028-3932(67)90040-1; Wechsler D., 1955, MANUAL WECHSLER ADUL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WILSON JTL, 1987, BRIT J DEV PSYCHOL, V5, P249, DOI 10.1111/j.2044-835X.1987.tb01060.x	28	20	20	0	1	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology		1989	3	4					255	265		10.1037//0894-4105.3.4.255			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	V44JW	WOS:000209746300005					2021-06-18	
J	ADOUR, KK; BOYAJIAN, JA; KAHN, ZM; SCHNEIDER, GS				ADOUR, KK; BOYAJIAN, JA; KAHN, ZM; SCHNEIDER, GS			SURGICAL AND NONSURGICAL MANAGEMENT OF FACIAL PARALYSIS FOLLOWING CLOSED HEAD-INJURY	LARYNGOSCOPE			English	Article									KAISER PERMANENTE MED CTR,OAKLAND,CA 94611							ADOUR KK, 1974, NEUROLOGY, V24, P1112, DOI 10.1212/WNL.24.12.1112; ADOUR KK, 1972, NEW ENGL J MED, V287, P1268, DOI 10.1056/NEJM197212212872503; ALFORD BR, 1971, LARYNGOSCOPE, V81, P620, DOI 10.1288/00005537-197105000-00002; Binns P M, 1967, Trans Am Acad Ophthalmol Otolaryngol, V71, P665; BOONE P C, 1959, Acta Neurochir (Wien), V7, P221, DOI 10.1007/BF01405890; BOYLE WF, 1967, LARYNGOSCOPE, V77, P1168, DOI 10.1288/00005537-196707000-00009; BUNNELL S, 1952, AMA ARCH OTOLARYNGOL, V55, P417; DEVRIESE PP, 1972, ARCHIV OTOLARYNGOL, V95, P350; FISCH U, 1974, LARYNGOSCOPE, V84, P2141, DOI 10.1288/00005537-197412000-00005; GREER JA, 1974, ANN OTO RHINOL LARYN, V83, P582, DOI 10.1177/000348947408300503; GROVES J, 1973, P ROY SOC MED, V66, P545, DOI 10.1177/003591577306600625; POTTER J M, 1964, J Laryngol Otol, V78, P654, DOI 10.1017/S0022215100062563	12	20	21	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0023-852X			LARYNGOSCOPE	Laryngoscope		1977	87	3					380	390		10.1288/00005537-197703000-00011			11	Medicine, Research & Experimental; Otorhinolaryngology	Research & Experimental Medicine; Otorhinolaryngology	CY646	WOS:A1977CY64600011	839932	Bronze			2021-06-18	
J	GOVONS, SR; GOVONS, RB; HEUSNER, WW; VANHUSS, WD				GOVONS, SR; GOVONS, RB; HEUSNER, WW; VANHUSS, WD			BRAIN CONCUSSION IN RAT	EXPERIMENTAL NEUROLOGY			English	Article																Denny-Brown D, 1941, BRAIN, V64, P7; FOLTZ EL, 1956, J NEUROSURG, V13, P145, DOI 10.3171/jns.1956.13.2.0145; FRIEDE RL, 1961, ARCH NEUROL-CHICAGO, V4, P449, DOI 10.1001/archneur.1961.00450100097012; GOVONS SR, 1968, CONFIN NEUROL, V30, P77; GOVONS SR, 1971, AEROSPACE MED, V42, P421; GOVONS SR, 1947, J NEUROPATH EXP NEUR, V6, P95, DOI 10.1097/00005072-194702000-00008; GRANIT R, 1955, RECEPTORS SENSORY PE; Magnus R, 1926, LANCET, V2, P531; Magnus R, 1926, LANCET, V2, P585; MAGOUN HW, 1958, WAKING BRAIN; Roberts TDM, 1967, NEUROPHYSIOLOGY POST; Sherrington C, 1906, INTEGRATIVE ACTION N; SYMONDS CP, 1943, INJURIES SKULL BRAIN, P65; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WALKER AE, 1966, HEAD INJURY C P, P13; WARD AA, 1958, J NEUROSURG, V15, P129, DOI 10.3171/jns.1958.15.2.0129; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WITKOWSKI L, 1877, VIRCHOWS ARCH, V69, P498; 1968, 1024 PUBL HEALTH SCI, P10	19	20	20	0	0	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.		1972	34	1					121	&		10.1016/0014-4886(72)90193-8			0	Neurosciences	Neurosciences & Neurology	L5514	WOS:A1972L551400012	5009503				2021-06-18	
J	BROWN, GW; BROWN, ML				BROWN, GW; BROWN, ML			CARDIOVASCULAR RESPONSES TO EXPERIMENTAL CEREBRAL CONCUSSION IN THE RHESUS MONKEY - DISCUSSION OF SIMILARITY OF RESPONSES TO ELECTROCONVULSIVE SHOCK AND CEREBRAL CONCUSSION IN DOGS, MONKEYS, AND MAN	AMA ARCHIVES OF NEUROLOGY AND PSYCHIATRY			English	Article																BATSON OV, 1944, FED PROC, V3, P139; BROWN GW, 1952, AM J PHYSIOL, V170, P294; BROWN ML, 1952, AM J PSYCHIAT, V109, P27, DOI 10.1176/ajp.109.1.27; BROWN ML, 1953, AMA ARCH NEUROL PSY, V69, P609, DOI 10.1001/archneurpsyc.1953.02320290061007; BROWN ML, 1953, AMA ARCH NEUROL PSY, V69, P601, DOI 10.1001/archneurpsyc.1953.02320290053006; Davis E. W., 1944, AMER JOUR PSYCHIATRY, V100, P825; Heymans C, 1937, ARCH NEURO PSYCHIATR, V38, P304, DOI 10.1001/archneurpsyc.1937.02260200076006; KOENIG H, 1945, STAIN TECHNOL, V20, P13, DOI 10.3109/10520294509107124; RICHARDSON AW, 1949, J LAB CLIN MED, V34, P1706; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; Walker AE, 1945, A RES NERV MENT DIS, V24, P437	11	20	20	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0096-6886			AMA ARCH NEUROL PSY			1954	71	6					707	713		10.1001/archneurpsyc.1954.02320420035004			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	UF344	WOS:A1954UF34400004	13157700				2021-06-18	
J	Davies, H; Falconer, MA				Davies, H; Falconer, MA			Ventricular changes after closed head injury	JOURNAL OF NEUROLOGY AND PSYCHIATRY			English	Article																Abramowitsch D, 1930, Z GESAMTE NEUROL PSY, V127, P454, DOI 10.1007/BF02864217; Bagley C, 1928, ARCH SURG-CHICAGO, V17, P18, DOI 10.1001/archsurg.1928.01140070021002; Bennett AE, 1933, ARCH SURG-CHICAGO, V26, P397, DOI 10.1001/archsurg.1933.01170030054004; Bielschowsky P, 1928, Z GESAMTE NEUROL PSY, V117, P55, DOI 10.1007/BF02876518; Cairns H, 1941, BRIT MED J, V1941, P465, DOI 10.1136/bmj.2.4213.465; Davidoff LM, 1937, NORMAL ENCEPHALOGRAM; Evans WA, 1942, ARCH NEURO PSYCHIATR, V47, P931, DOI 10.1001/archneurpsyc.1942.02290060069004; Fischer M, 1928, ARCH PSYCHIAT NERVEN, V82, P403, DOI 10.1007/BF01828873; FLUGEL FE, 1932, ERG INN MED KINDERHK, V44, P327; FRIEDMAN ED, 1932, ARCH NEUROL PSYCHIAT, V27, P791; HASSIN GB, 1940, INJURIES SKULL BRAIN; Hauptmann A, 1932, ARCH PSYCHIAT NERVEN, V96, P84, DOI 10.1007/BF02064325; LIPPENS A, 1934, PR MED, V42, P455; LYSHOLM E, 1935, ACTA RADIOL STOCKH S, V24; MONEY RA, 1932, AUST N Z J SURG, V2, P47; Schwab O, 1926, Z GESAMTE NEUROL PSY, V102, P294, DOI 10.1007/BF02962279; SCHWAB O, 1926, DTSCH Z NERVENHEILK, V89, P44; SWIFT GW, 1931, SURG GYNECOL OBSTET, V52, P576; TRAVERS JT, 1937, RADIOLOGY, V28, P704; Winkelman NW, 1934, ARCH NEURO PSYCHIATR, V31, P956, DOI 10.1001/archneurpsyc.1934.02250050074002	20	20	20	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0368-329X			J NEUROL PSYCHIATRY	J. Neurol. Psychiatry	JAN-APR	1943	6	1/2					52	68		10.1136/jnnp.6.1-2.52			17	Clinical Neurology	Neurosciences & Neurology	V21BH	WOS:000201422900007	21611417	Bronze, Green Published			2021-06-18	
J	Plog, BA; Lou, NH; Pierre, CA; Cove, A; Kenney, HM; Hitomi, E; Kang, HY; Iliff, JJ; Zeppenfeld, DM; Nedergaard, M; Vates, GE				Plog, Benjamin A.; Lou, Nanhong; Pierre, Clifford A.; Cove, Alex; Kenney, H. Mark; Hitomi, Emi; Kang, Hongyi; Iliff, Jeffrey J.; Zeppenfeld, Douglas M.; Nedergaard, Maiken; Vates, G. Edward			When the air hits your brain: decreased arterial pulsatility after craniectomy leading to impaired glymphatic flow	JOURNAL OF NEUROSURGERY			English	Article						craniectomy; cranioplasty; syndrome of the trephined; glymphatic; CSF; arterial pulsatility	CEREBRAL HEMODYNAMIC-CHANGES; DECOMPRESSIVE CRANIECTOMY; INTERSTITIAL FLUID; MOUSE MODEL; HEAD-INJURY; BLOOD-FLOW; CRANIOPLASTY; HYDROCEPHALUS; PHYSIOLOGY; PATHWAY	OBJECTIVE Cranial neurosurgical procedures can cause changes in brain function. There are many potential explanations, but the effect of simply opening the skull has not been addressed, except for research into syndrome of the trephined. The glymphatic circulation, by which CSF and interstitial fluid circulate through periarterial spaces, brain parenchyma, and perivenous spaces, depends on arterial pulsations to provide the driving force for bulk flow; opening the cranial cavity could dampen this force. The authors hypothesized that a craniectomy, without any other pathological insult, is sufficient to alter brain function due to reduced arterial pulsatility and decreased glymphatic flow. Furthermore, they postulated that glymphatic impairment would produce activation of astrocytes and microglia; with the reestablishment of a closed cranial compartment, the glymphatic impairment, astrocytic/microglial activation, and neurobehavioral decline caused by opening the cranial compartment might be reversed. METHODS Using two-photon in vivo microscopy, the pulsatility index of cortical vessels was quantified through a thinned murine skull and then again after craniectomy. Glymphatic influx was determined with ex vivo fluorescence microscopy of mice 0, 14, 28, and 56 days following craniectomy or cranioplasty; brain sections were immunohistochemically labeled for GFAP and CD68. Motor and cognitive performance was quantified with rotarod and novel object recognition tests at baseline and 14, 21, and 28 days following craniectomy or cranioplasty. RESULTS Penetrating arterial pulsatility decreased significantly and bilaterally following unilateral craniectomy, producing immediate and chronic impairment of glymphatic CSF influx in the ipsilateral and contralateral brain parenchyma. Craniectomy-related glymphatic dysfunction was associated with an astrocytic and microglial inflammatory response, as well as with the development of motor and cognitive deficits. Recovery of glymphatic flow preceded reduced gliosis and return of normal neurological function, and cranioplasty accelerated this recovery. CONCLUSIONS Craniectomy causes glymphatic dysfunction, gliosis, and changes in neurological function in this murine model of syndrome of the trephined.	[Plog, Benjamin A.; Lou, Nanhong; Pierre, Clifford A.; Cove, Alex; Kenney, H. Mark; Hitomi, Emi; Kang, Hongyi; Nedergaard, Maiken; Vates, G. Edward] Univ Rochester, Med Ctr, Dept Neurosurg, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Plog, Benjamin A.] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA; [Iliff, Jeffrey J.; Zeppenfeld, Douglas M.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA; [Iliff, Jeffrey J.; Zeppenfeld, Douglas M.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA	Nedergaard, M (corresponding author), Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA.	nedergaard@urmc.rochester.edu		Kenney, H. Mark/0000-0002-0598-3232	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS078394, RF1AG057575, AG048769]; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation	This work was supported by the National Institutes of Health grant nos. NS078394, RF1AG057575, and AG048769 (M.N.) and by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (M.N.).	Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; Cai RY, 2019, NAT NEUROSCI, V22, P317, DOI 10.1038/s41593-018-0301-3; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; CSERR HF, 1981, AM J PHYSIOL, V240, pF319; CSERR HF, 1971, PHYSIOL REV, V51, P273; Daboussi A, 2009, J NEUROSURG ANESTH, V21, P339, DOI 10.1097/ANA.0b013e3181b1dbba; Damkier HH, 2013, PHYSIOL REV, V93, P1847, DOI 10.1152/physrev.00004.2013; De Bonis P, 2013, CLIN NEUROL NEUROSUR, V115, P1308, DOI 10.1016/j.clineuro.2012.12.011; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; Eide PK, 2015, ACTA RADIOL OPEN, V4, DOI 10.1177/2058460115609635; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Herisson F, 2018, NAT NEUROSCI, V21, P1209, DOI 10.1038/s41593-018-0213-2; HOLNESS CL, 1993, BLOOD, V81, P1607; Honeybul S, 2012, J NEUROTRAUM, V29, P1872, DOI 10.1089/neu.2012.2356; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Hong JY, 2011, SPINE J, V11, P1121, DOI 10.1016/j.spinee.2011.11.001; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Joseph V, 2009, J NEUROSURG, V111, P650, DOI 10.3171/2009.3.JNS0984; Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106; Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271; Kurland DB, 2015, NEUROCRIT CARE, V23, P292, DOI 10.1007/s12028-015-0144-7; Lazaridis C, 2012, J CLIN NEUROSCI, V19, P1052, DOI 10.1016/j.jocn.2011.08.039; Lee HD, 2015, J NEUROSCI, V35, P11034, DOI 10.1523/JNEUROSCI.1625-15.2015; Louveau A, 2017, J CLIN INVEST, V127, P3210, DOI 10.1172/JCI90603; Lundgaard I, 2017, J CEREBR BLOOD F MET, V37, P2112, DOI 10.1177/0271678X16661202; Peng WG, 2016, NEUROBIOL DIS, V93, P215, DOI 10.1016/j.nbd.2016.05.015; Plog BA, 2018, ANNU REV PATHOL-MECH, V13, P379, DOI 10.1146/annurev-pathol-051217-111018; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Ratner V, 2015, PROC SPIE, V9413, DOI 10.1117/12.2076289; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Shih AY, 2012, JOVE-J VIS EXP, V61, P1; Soustiel JF, 2010, NEUROSURGERY, V67, P65, DOI 10.1227/01.NEU.0000370604.30037.F5; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; SZENTISTVANYI I, 1984, AM J PHYSIOL, V246, pF835; Thrane VR, 2013, SCI REP-UK, V3, DOI 10.1038/srep02582; Timofeev I, 2006, INJURY, V37, P1125, DOI 10.1016/j.injury.2006.07.031; Vertosick FT, 1996, AIR HITS YOUR BRAIN; Wang MH, 2012, J NEUROSCI, V32, P17948, DOI 10.1523/JNEUROSCI.1860-12.2012; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	47	19	19	4	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2020	133	1					210	223		10.3171/2019.2.JNS182675			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	OK0VT	WOS:000584371500037	31100725	Green Accepted			2021-06-18	
J	DeBaun, MR; Jordan, LC; King, AA; Schatz, J; Vichinsky, E; Fox, CK; McKinstry, RC; Telfer, P; Kraut, MA; Daraz, L; Kirkham, FJ; Murad, MH				DeBaun, M. R.; Jordan, L. C.; King, A. A.; Schatz, J.; Vichinsky, E.; Fox, C. K.; McKinstry, R. C.; Telfer, P.; Kraut, M. A.; Daraz, L.; Kirkham, F. J.; Murad, M. H.			American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults	BLOOD ADVANCES			English	Article							SILENT CEREBRAL INFARCTS; DOPPLER FLOW VELOCITIES; HEALTH-CARE PROFESSIONALS; ACUTE ISCHEMIC-STROKE; BLOOD-TRANSFUSION THERAPY; FUNCTION PERFORMANCE-TEST; DECISION ETD FRAMEWORKS; TRAUMATIC BRAIN-INJURY; TRANSCRANIAL DOPPLER; EXECUTIVE FUNCTION	Background: Central nervous system (CNS) complications are among the most common, devastating sequelae of sickle cell disease (SCD) occurring throughout the lifespan. Objective: These evidence-based guidelines of the American Society of Hematology are intended to support the SCD community in decisions about prevention, diagnosis, and treatment of the most common neurological morbidities in SCD. Methods: The Mayo Evidence-Based Practice Research Program supported the guideline development process, including updating or performing systematic evidence reviews. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations. Results: The panel placed a higher value on maintaining cognitive function than on being alive with significantly less than baseline cognitive function. The panel developed 19 recommendations with evidence-based strategies to prevent, diagnose, and treat CNS complications of SCD in low-middle- and high-income settings. Conclusions: Three of 19 recommendations immediately impact clinical care. These recommendations include: use of transcranial Doppler ultrasound screening and hydroxyurea for primary stroke prevention in children with hemoglobin SS (HbSS) and hemoglobin S beta(0) (HbS beta(0)) thalassemia living in low-middle-income settings; surveillance for developmental delay, cognitive impairments, and neurodevelopmental disorders in children; and use of magnetic resonance imaging of the brain without sedation to detect silent cerebral infarcts at least once in early-school-age children and once in adults with HbSS or HbS beta(0) thalassemia. Individuals with SCD, their family members, and clinicians should become aware of and implement these recommendations to reduce the burden of CNS complications in children and adults with SCD.	[DeBaun, M. R.] Vanderbilt Univ, Med Ctr, Vanderbilt Meharry Ctr Excellence Sickle Cell Dis, Dept Pediat, Nashville, TN 37203 USA; [Jordan, L. C.] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Neurol, Nashville, TN 37203 USA; [King, A. A.] Washington Univ, Sch Med, Program Occupat Therapy, Dept Med,Dept Pediat,Div Hematol, St Louis, MO 63110 USA; [Schatz, J.] Univ South Carolina, Dept Psychol, Columbia, SC 29208 USA; [Vichinsky, E.] Childrens Hosp, Oakland Res Inst, 747 52nd St, Oakland, CA 94609 USA; [Fox, C. K.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Fox, C. K.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [McKinstry, R. C.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [McKinstry, R. C.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Telfer, P.] Queen Mary Univ London, Blizard Inst, Ctr Genom & Child Hlth, London, England; [Kraut, M. A.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Daraz, L.; Murad, M. H.] Mayo Clin, Evidence Based Practice Ctr, Rochester, MN USA; [Kirkham, F. J.] UCL Great Ormond St Inst Child Hlth, Dev Neurosci Sect, London, England; [Kirkham, F. J.] Univ Southampton, Clin & Expt Sci, Southampton, Hants, England; [Kirkham, F. J.] Univ Hosp Southampton, Dept Child Hlth, Southampton, Hants, England	DeBaun, MR (corresponding author), Vanderbilt Univ, Med Sch, Vanderbilt Meharry Ctr Excellence Sickle Cell Dis, 2525 West End Ave,Suite 750, Nashville, TN 37203 USA.	m.debaun@vumc.org	Murad, M. Hassan/AAW-4367-2020; Kirkham, Fenella/C-2442-2009	DeBaun, Michael/0000-0002-0574-1604; Murad, Mohammad Hassan/0000-0001-5502-5975; Jordan, Lori/0000-0001-7240-0415; King, Allison/0000-0002-1951-6176; Kirkham, Fenella/0000-0002-2443-7958			Abdullahi SU, 2019, PEDIATR NEUROL, V95, P73, DOI 10.1016/j.pediatrneurol.2019.01.008; Abraham MG, 2013, CURRENT PROCEDURAL T; Adamkiewicz TV, 2009, BLOOD, V114, P4632, DOI 10.1182/blood-2009-02-203323; Adams RJ, 2005, NEW ENGL J MED, V353, P2769; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Adams RJ, 2017, STROKE, V48, P686, DOI 10.1161/STROKEAHA.116.015412; Adegoke SA, 2018, J STROKE CEREBROVASC, V27, P425, DOI 10.1016/j.jstrokecerebrovasdis.2017.09.020; Ahn SN, 2017, NEUROREHABILITATION, V40, P285, DOI 10.3233/NRE-161416; AHO K, 1980, B WORLD HEALTH ORGAN, V58, P113; Akl EA, 2014, J CLIN EPIDEMIOL, V67, P1222, DOI 10.1016/j.jclinepi.2014.05.006; Alamri A, 2019, BRIT J NEUROSURG, V33, P161, DOI 10.1080/02688697.2017.1339227; Alexy T, 2006, TRANSFUSION, V46, P912, DOI 10.1111/j.1537-2995.2006.00823.x; Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2089; Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2016; American Psychological Association Practice Organization, DIST SCREEN ASS MENT; [Anonymous], 2015, FED REGISTER, V79, P67576; Atkins D, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-38; Aygun B, 2015, BRIT J HAEMATOL, V169, P262, DOI 10.1111/bjh.13280; Aygun B, 2012, AM J HEMATOL, V87, P428, DOI 10.1002/ajh.23105; Bardakdjian-Michau J, 2009, J CLIN PATHOL, V62, P31, DOI 10.1136/jcp.2008.058867; Barger B, 2018, DISABIL HEALTH J, V11, P420, DOI 10.1016/j.dhjo.2018.01.002; Baum CM, 2017, NEUROPSYCHOL REHABIL, V27, P603, DOI 10.1080/09602011.2016.1176934; Baum CM, 2008, AM J OCCUP THER, V62, P446, DOI 10.5014/ajot.62.4.446; Bernaudin F, 2020, HAEMATOLOGICA, V105, P91, DOI 10.3324/haematol.2018.213207; Bernaudin F, 2019, JAMA-J AM MED ASSOC, V321, P266, DOI 10.1001/jama.2018.20059; Bernaudin F, 2015, BLOOD, V125, P1653, DOI 10.1182/blood-2014-09-599852; Bond M, 2015, BRIT J HEALTH PSYCH, V20, P792, DOI 10.1111/bjhp.12142; Boustani M, 2003, SCREENING DEMENTIA; Brambilla DJ, 2007, PEDIATR BLOOD CANCER, V49, P318, DOI 10.1002/pbc.21142; Brito JP, 2013, J CLIN ENDOCR METAB, V98, P3246, DOI 10.1210/jc.2013-1814; Brush LN, 2013, NEUROLOGY, V80, P1225, DOI 10.1212/WNL.0b013e3182896ffb; Bush AM, 2016, AM J HEMATOL, V91, P912, DOI 10.1002/ajh.24441; Choudhury NA, 2018, NEUROLOGY, V90, pE239, DOI 10.1212/WNL.0000000000004832; Cicerone KD, 2019, ARCH PHYS MED REHAB, V100, P1515, DOI 10.1016/j.apmr.2019.02.011; COHEN AR, 1991, J PEDIATR-US, V118, P405, DOI 10.1016/S0022-3476(05)82155-9; Coupland AP, 2017, J ROY SOC MED, V110, P9, DOI 10.1177/0141076816680121; Day ME, 2019, BRIT J HAEMATOL, V185, P153, DOI 10.1111/bjh.15400; de la Fuente J, 2019, BIOL BLOOD MARROW TR, V25, P1197, DOI 10.1016/j.bbmt.2018.11.027; DeBaun MR, 2014, NEW ENGL J MED, V371, P699, DOI 10.1056/NEJMoa1401731; Debaun Michael R, 2016, Trans Am Clin Climatol Assoc, V127, P17; DeBaun MR, 2016, BLOOD, V127, P829, DOI 10.1182/blood-2015-09-618579; DeBaun MR, 2012, BLOOD, V119, P4587, DOI 10.1182/blood-2011-02-272682; Diamini N, 2017, NEUROLOGY, V89, P2406, DOI 10.1212/WNL.0000000000004728; Dichgans M, 2017, CIRC RES, V120, P573, DOI 10.1161/CIRCRESAHA.116.308426; Dobson SR, 2002, BLOOD, V99, P3144, DOI 10.1182/blood.V99.9.3144; Dormandy E, 2018, J PUBLIC HEALTH-UK, V40, pE291, DOI 10.1093/pubmed/fdx172; Drazen CH, 2016, PEDIATR BLOOD CANCER, V63, P504, DOI 10.1002/pbc.25838; Enninful-Eghan H, 2010, J PEDIATR-US, V157, P479, DOI 10.1016/j.jpeds.2010.03.007; Faye BF, 2017, ADV HEMATOL, V2017; Ferriero DM, 2019, STROKE, V50, pE51, DOI 10.1161/STR.0000000000000183; Files B, 2002, J PEDIAT HEMATOL ONC, V24, P284, DOI 10.1097/00043426-200205000-00013; Fitzhugh CD, 2017, BLOOD ADV, V1, P652, DOI 10.1182/bloodadvances.2016002972; Ford AL, 2018, BLOOD, V132, P1714, DOI 10.1182/blood-2018-04-841247; Fryer RH, 2003, PEDIATR NEUROL, V29, P124, DOI 10.1016/S0887-8994(03)00047-X; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Galadanci NA, 2017, AM J HEMATOL, V92, P780, DOI 10.1002/ajh.24770; GLAUSER TA, 1995, J CHILD NEUROL, V10, P88, DOI 10.1177/088307389501000203; Guilliams KP, 2018, BLOOD, V131, P1012, DOI 10.1182/blood-2017-06-789842; Gulbis B, 2005, BLOOD, V105, P2685, DOI 10.1182/blood-2004-07-2704; Guyatt G, 2010, ANN INTERN MED, V152, P738, DOI 10.7326/0003-4819-152-11-201006010-00254; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2016, J CLIN EPIDEMIOL, V80, P3, DOI 10.1016/j.jclinepi.2016.07.006; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; Hall EM, 2016, PEDIATR BLOOD CANCER, V63, P1431, DOI 10.1002/pbc.26022; Hankins JS, 2015, AM J HEMATOL, V90, P1099, DOI 10.1002/ajh.24198; Hankinson TC, 2008, J NEUROSURG-PEDIATR, V1, P211, DOI 10.3171/PED/2008/1/3/211; Haskins EC, 2012, COGNITIVE REHABILITA; Hassell KL, 2010, AM J PREV MED, V38, pS512, DOI 10.1016/j.amepre.2009.12.022; Hayes TL, 2009, J AGING HEALTH, V21, P567, DOI 10.1177/0898264309332836; Hogan AM, 2005, DEV MED CHILD NEUROL, V47, P824, DOI 10.1017/S001216220500174X; Hulbert ML, 2006, J PEDIATR-US, V149, P710, DOI 10.1016/j.jpeds.2006.06.037; Hulbert ML, 2011, BLOOD, V117, P772, DOI 10.1182/blood-2010-01-261123; HURLETJENSEN AM, 1994, STROKE, V25, P1688, DOI 10.1161/01.STR.25.8.1688; Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, 2011, CLIN PRACTICE GUIDEL; Jabbarli R, 2019, CURR NEUROVASC RES, V16, P63, DOI 10.2174/1567202616666190131160847; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; Jordan LC, 2018, NEUROLOGY, V91, pE781, DOI 10.1212/WNL.0000000000006047; Jordan LC, 2019, AM J HEMATOL, V94, pE155, DOI 10.1002/ajh.25455; Jordan LC, 2018, AM J HEMATOL, V93, P760, DOI 10.1002/ajh.25085; Juttukonda MR, 2019, J MAGN RESON IMAGING, V49, P466, DOI 10.1002/jmri.26213; Kassim AA, 2016, BLOOD, V127, P2038, DOI 10.1182/blood-2016-01-694562; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kim HC, 2014, HEMATOL-AM SOC HEMAT, P450, DOI 10.1182/asheducation-2014.1.450; King AA, 2007, NEUROLOGY, V68, P2008, DOI 10.1212/01.wnl.0000264421.24415.16; King AA, 2019, BIOL BLOOD MARROW TR, V25, pE174, DOI 10.1016/j.bbmt.2019.01.008; King AA, 2014, AM J HEMATOL, V89, pE188, DOI 10.1002/ajh.23805; King AA, 2014, AM J HEMATOL, V89, P162, DOI 10.1002/ajh.23604; Krantz SB, 2015, THORAC SURG CLIN, V25, P155, DOI 10.1016/j.thorsurg.2014.11.003; Kratovil T, 2006, PEDIATR BLOOD CANCER, V47, P894, DOI 10.1002/pbc.20819; Kwiatkowski JL, 2011, PEDIATR BLOOD CANCER, V56, P777, DOI 10.1002/pbc.22951; Lagunju I A, 2013, Niger Postgrad Med J, V20, P181; Lagunju IA, 2013, PEDIATR BLOOD CANCER, V60, P1940, DOI 10.1002/pbc.24698; Lagunju I, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27252; Lagunju I, 2015, PEDIATR BLOOD CANCER, V62, P1587, DOI 10.1002/pbc.25529; Lefevre N, 2008, BLOOD, V111, P963, DOI 10.1182/blood-2007-08-102244; Lo B, 2009, CONFLICT INTEREST ME; Lopes FCM, 2015, HAEMATOLOGICA, V100, P730, DOI 10.3324/haematol.2014.119727; Makin SDJ, 2015, STROKE, V46, P3142, DOI 10.1161/STROKEAHA.115.010665; Martin Leslie R, 2005, Ther Clin Risk Manag, V1, P189; Lopes FCM, 2014, MICROVASC RES, V94, P106, DOI 10.1016/j.mvr.2014.05.009; McCavit TL, 2013, PEDIATR BLOOD CANCER, V60, P823, DOI 10.1002/pbc.24392; McEwen SE, 2010, NEUROPSYCHOL REHABIL, V20, P541, DOI 10.1080/09602011003638194; Mentz RJ, 2018, AM HEART J, V200, P51, DOI 10.1016/j.ahj.2018.03.007; Murad MH, 2019, BLOOD ADV, V3, P3945, DOI 10.1182/bloodadvances.2019000931; Murad MH, 2017, MAYO CLIN PROC, V92, P423, DOI 10.1016/j.mayocp.2017.01.001; Ng J, 2012, CHILD NERV SYST, V28, P1041, DOI 10.1007/s00381-012-1743-7; Ohene-Frempong K, 1998, BLOOD, V91, P288; Panepinto JA, 2012, PEDIATR BLOOD CANCER, V59, P685, DOI 10.1002/pbc.24028; PEGELOW CH, 1995, J PEDIATR-US, V126, P896, DOI 10.1016/S0022-3476(95)70204-0; Pegelow CH, 2001, ARCH NEUROL-CHICAGO, V58, P2017, DOI 10.1001/archneur.58.12.2017; Pegelow CH, 1997, AM J MED, V102, P171; Petersen RC, 2018, NEUROLOGY, V90, P126, DOI 10.1212/WNL.0000000000004826; Piel FB, 2013, LANCET, V381, P142, DOI 10.1016/S0140-6736(12)61229-X; Polatajko HJ, 2012, AM J OCCUP THER, V66, P104, DOI 10.5014/ajot.2012.001784; Polatajko Helene J., 2001, Physical and Occupational Therapy in Pediatrics, V20, P107, DOI 10.1300/J006v20n02_07; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Prohovnik I, 2009, J CEREBR BLOOD F MET, V29, P803, DOI 10.1038/jcbfm.2009.6; Prussien KV, 2019, J PEDIATR PSYCHOL, V44, P948, DOI 10.1093/jpepsy/jsz031; Qaseem A, 2012, ANN INTERN MED, V156, P525, DOI 10.7326/0003-4819-156-7-201204030-00009; Reeves SL, 2016, JAMA PEDIATR, V170, P550, DOI 10.1001/jamapediatrics.2015.4859; Rigano P, 2018, BLOOD CELL MOL DIS, V69, P82, DOI 10.1016/j.bcmd.2017.08.017; Rivkin MJ, 2016, PEDIATR NEUROL, V56, P8, DOI 10.1016/j.pediatrneurol.2016.01.016; Roebuck-Spencer TM, 2017, ARCH CLIN NEUROPSYCH, V32, P491, DOI 10.1093/arclin/acx021; Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca; Sand N, 2005, PEDIATRICS, V116, P174, DOI 10.1542/peds.2004-1809; Saver JL, 2006, STROKE, V37, P263, DOI 10.1161/01.STR.0000196957.55928.ab; Schatz J, 2006, MENT RETARD DEV D R, V12, P200, DOI 10.1002/mrdd.20115; SCHMALZER EA, 1987, TRANSFUSION, V27, P228, DOI 10.1046/j.1537-2995.1987.27387235626.x; Schunemann HJ, 2014, CAN MED ASSOC J, V186, pE123, DOI 10.1503/cmaj.131237; Schunemann HJ, 2009, AM J RESP CRIT CARE, V180, P564, DOI 10.1164/rccm.200901-0126ST; Schunemann HJ, 2003, CAN MED ASSOC J, V169, P677; Schunemann HJ, 2017, J CLIN EPIDEMIOL, V81, P101, DOI 10.1016/j.jclinepi.2016.09.009; Schunemann HJ, 2016, J CLIN EPIDEMIOL, V76, P89, DOI 10.1016/j.jclinepi.2016.01.032; Schunemann HJ, 2015, ANN INTERN MED, V163, P548, DOI 10.7326/M14-1885; Scothorn DJ, 2002, J PEDIATR-US, V140, P348, DOI 10.1067/mpd.2002.122498; Seet RCS, 2012, CEREBROVASC DIS, V34, P106, DOI 10.1159/000339675; Silva GS, 2009, STROKE, V40, P2408, DOI 10.1161/STROKEAHA.108.537415; Smith ER, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.01.FOCUS08307; Stilley CS, 2010, HEALTH PSYCHOL, V29, P50, DOI 10.1037/a0016940; Swerdlow Paul S, 2006, Hematology Am Soc Hematol Educ Program, P48; Tarazi RA, 2007, CHILD NEUROPSYCHOL, V13, P155, DOI 10.1080/09297040600611312; Tate R, 2014, J HEAD TRAUMA REHAB, V29, P338, DOI 10.1097/HTR.0000000000000068; Therrell BL, 2015, SEMIN PERINATOL, V39, P238, DOI 10.1053/j.semperi.2015.03.008; Thornburg CD, 2009, PEDIATR BLOOD CANCER, V52, P609, DOI 10.1002/pbc.21738; Tshilolo L, 2019, NEW ENGL J MED, V380, P121, DOI [10.1056/NEJMoa1813598, 10.1056/nejmoa1813598]; VENKETASUBRAMANIAN N, 1994, STROKE, V25, P2153, DOI 10.1161/01.STR.25.11.2153; Vermeer SE, 2003, STROKE, V34, P1126, DOI 10.1161/01.STR.0000068408.82115.D2; Vichinsky EP, 2010, JAMA-J AM MED ASSOC, V303, P1823, DOI 10.1001/jama.2010.562; Vichinsky EP, 2001, TRANSFUSION, V41, P1086, DOI 10.1046/j.1537-2995.2001.41091086.x; Vieira C, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26342; Ware RE, 2016, LANCET, V387, P661, DOI 10.1016/S0140-6736(15)01041-7; Ware RE, 2012, BLOOD, V119, P3925, DOI 10.1182/blood-2011-11-392340; Winstead M, 2017, PEDIATR HEMAT ONCOL, V34, P100, DOI 10.1080/08880018.2017.1313917; Winstein CJ, 2016, STROKE, V47, pE98, DOI 10.1161/STR.0000000000000098; Wolf TJ, 2016, AM J OCCUP THER, V70, DOI 10.5014/ajot.2016.017293; Wood JC, 2016, BRIT J HAEMATOL, V172, P122, DOI 10.1111/bjh.13791; World Health Assembly, 2006, SICKL CELL AN REP SE; Yang WY, 2017, J NEUROSURG-PEDIATR, V20, P232, DOI 10.3171/2017.1.PEDS16576; Yawn BP, 2014, JAMA-J AM MED ASSOC, V312, P1033, DOI 10.1001/jama.2014.10517; Zimmerman SA, 2007, BLOOD, V110, P1043, DOI 10.1182/blood-2006-11-057893; ZINKHAM WH, 1994, J PEDIATR-US, V124, P215, DOI 10.1016/S0022-3476(94)70306-X	163	19	19	1	4	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	2473-9529	2473-9537		BLOOD ADV	Blood Adv.	APR 28	2020	4	8					1554	1588		10.1182/bloodadvances.2019001142			35	Hematology	Hematology	LJ4VF	WOS:000530164200001	32298430	Bronze, Green Published			2021-06-18	
J	McLean, SA; Ressler, K; Koenen, KC; Neylan, T; Germine, L; Jovanovic, T; Clifford, GD; Zeng, DL; An, XM; Linnstaedt, S; Beaudoin, F; House, S; Bollen, KA; Musey, P; Hendry, P; Jones, CW; Lewandowski, C; Swor, R; Datner, E; Mohiuddin, K; Stevens, JS; Storrow, A; Kurz, MC; McGrath, ME; Fermann, GJ; Hudak, LA; Gentile, N; Chang, AM; Peak, DA; Pascual, JL; Seamon, MJ; Sergot, P; Peacock, WF; Diercks, D; Sanchez, LD; Rathlev, N; Domeier, R; Haran, JP; Pearson, C; Murty, VP; Insel, TR; Dagum, P; Onnela, JP; Bruce, SE; Gaynes, BN; Joormann, J; Miller, MW; Pietrzak, RH; Buysse, DJ; Pizzagalli, DA; Rauch, SL; Harte, SE; Young, LJ; Barch, DM; Lebois, LAM; van Rooij, SJH; Luna, B; Smoller, JW; Dougherty, RF; Pace, TWW; Binder, E; Sheridan, JF; Elliott, JM; Basu, A; Fromer, M; Parlikar, T; Zaslavsky, AM; Kessler, R				McLean, Samuel A.; Ressler, Kerry; Koenen, Karestan Chase; Neylan, Thomas; Germine, Laura; Jovanovic, Tanja; Clifford, Gari D.; Zeng, Donglin; An, Xinming; Linnstaedt, Sarah; Beaudoin, Francesca; House, Stacey; Bollen, Kenneth A.; Musey, Paul; Hendry, Phyllis; Jones, Christopher W.; Lewandowski, Christopher; Swor, Robert; Datner, Elizabeth; Mohiuddin, Kamran; Stevens, Jennifer S.; Storrow, Alan; Kurz, Michael Christopher; McGrath, Meghan E.; Fermann, Gregory J.; Hudak, Lauren A.; Gentile, Nina; Chang, Anna Marie; Peak, David A.; Pascual, Jose L.; Seamon, Mark J.; Sergot, Paulina; Peacock, W. Frank; Diercks, Deborah; Sanchez, Leon D.; Rathlev, Niels; Domeier, Robert; Haran, John Patrick; Pearson, Claire; Murty, Vishnu P.; Insel, Thomas R.; Dagum, Paul; Onnela, Jukka-Pekka; Bruce, Steven E.; Gaynes, Bradley N.; Joormann, Jutta; Miller, Mark W.; Pietrzak, Robert H.; Buysse, Daniel J.; Pizzagalli, Diego A.; Rauch, Scott L.; Harte, Steven E.; Young, Larry J.; Barch, Deanna M.; Lebois, Lauren A. M.; van Rooij, Sanne J. H.; Luna, Beatriz; Smoller, Jordan W.; Dougherty, Robert F.; Pace, Thaddeus W. W.; Binder, Elisabeth; Sheridan, John F.; Elliott, James M.; Basu, Archana; Fromer, Menachem; Parlikar, Tushar; Zaslavsky, Alan M.; Kessler, Ronald			The AURORA Study: a longitudinal, multimodal library of brain biology and function after traumatic stress exposure	MOLECULAR PSYCHIATRY			English	Article							MAXIMUM-LIKELIHOOD-ESTIMATION; STRUCTURAL EQUATION MODELS; MOTOR-VEHICLE COLLISION; POSTTRAUMATIC-STRESS; WIDESPREAD PAIN; DISORDER; US; INJURY; PREDICTORS; SYMPTOMS	Adverse posttraumatic neuropsychiatric sequelae (APNS) are common among civilian trauma survivors and military veterans. These APNS, as traditionally classified, include posttraumatic stress, postconcussion syndrome, depression, and regional or widespread pain. Traditional classifications have come to hamper scientific progress because they artificially fragment APNS into siloed, syndromic diagnoses unmoored to discrete components of brain functioning and studied in isolation. These limitations in classification and ontology slow the discovery of pathophysiologic mechanisms, biobehavioral markers, risk prediction tools, and preventive/treatment interventions. Progress in overcoming these limitations has been challenging because such progress would require studies that both evaluate a broad spectrum of posttraumatic sequelae (to overcome fragmentation) and also perform in-depth biobehavioral evaluation (to index sequelae to domains of brain function). This article summarizes the methods of the Advancing Understanding of RecOvery afteR traumA (AURORA) Study. AURORA conducts a large-scale (n = 5000 target sample) in-depth assessment of APNS development using a state-of-the-art battery of self-report, neurocognitive, physiologic, digital phenotyping, psychophysical, neuroimaging, and genomic assessments, beginning in the early aftermath of trauma and continuing for 1 year. The goals of AURORA are to achieve improved phenotypes, prediction tools, and understanding of molecular mechanisms to inform the future development and testing of preventive and treatment interventions.	[McLean, Samuel A.; An, Xinming; Linnstaedt, Sarah] UNC Sch Med, Inst Trauma Recovery, Dept Anesthesiol, Chapel Hill, NC 27599 USA; [Ressler, Kerry; Germine, Laura; Pizzagalli, Diego A.; Rauch, Scott L.; Lebois, Lauren A. M.] McLean Hosp, Dept Psychiat, Boston, MA USA; [Koenen, Karestan Chase; Basu, Archana] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Neylan, Thomas] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Jovanovic, Tanja] Wayne State Univ, Dept Psychiat & Behav Neurosci, Sch Med, Detroit, MI 48207 USA; [Clifford, Gari D.] Emory Univ, Sch Med, Dept Biomed Informat, Atlanta, GA USA; [Zeng, Donglin] UNC Gillings Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA; [Beaudoin, Francesca] Brown Univ, Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA; [House, Stacey] Washington Univ, Sch Med, Dept Emergency Med, St Louis, MO USA; [Bollen, Kenneth A.] Univ N Carolina, Dept Stat & Operat Res, Chapel Hill, NC 27515 USA; [Musey, Paul] Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN 46202 USA; [Hendry, Phyllis] Univ Florida, Coll Med, Dept Emergency Med, Jacksonville, FL USA; [Jones, Christopher W.] Cooper Univ Hlth Care, Dept Emergency Med, Camden, NJ USA; [Lewandowski, Christopher] Henry Ford Hosp, Dept Emergency Med, Detroit, MI 48202 USA; [Swor, Robert] William Beaumont Sch Med, Dept Emergency Med, Royal Oak, MI USA; [Datner, Elizabeth] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Mohiuddin, Kamran] Einstein Hlth Med Ctr, Dept Emergency Med, Philadelphia, PA USA; [Stevens, Jennifer S.; Young, Larry J.; van Rooij, Sanne J. H.; Binder, Elisabeth] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA; [Storrow, Alan] Vanderbilt Univ, Med Ctr, Dept Emergency Med, Nashville, TN USA; [Kurz, Michael Christopher] Univ Alabama Birmingham, Sch Med, Dept Emergency Med, Birmingham, AL USA; [McGrath, Meghan E.] Boston Univ, Med Ctr, Dept Emergency Med, Boston, MA USA; [Fermann, Gregory J.] Univ Cincinnati, Med Ctr, Dept Emergency Med, Cincinnati, OH 45267 USA; [Hudak, Lauren A.] Emory Univ Hosp, Dept Emergency Med, 1364 Clifton Rd NE, Atlanta, GA 30322 USA; [Gentile, Nina] Temple Univ, Lewis Katz Sch Med, Dept Emergency Med, Philadelphia, PA 19122 USA; [Chang, Anna Marie] Thomas Jefferson Univ Hosp, Dept Emergency Med, Philadelphia, PA 19107 USA; [Peak, David A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Pascual, Jose L.; Seamon, Mark J.] Univ Penn, Dept Surg, Perelman Sch Med, Philadelphia, PA 19104 USA; [Sergot, Paulina] Univ Texas Houston, McGovern Med Sch, Dept Emergency Med, Houston, TX USA; [Peacock, W. Frank] Baylor Coll Med, Dept Emergency Med, Houston, TX 77030 USA; [Diercks, Deborah] UT Southwestern Med Ctr, Dept Emergency Med, Dallas, TX USA; [Sanchez, Leon D.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Rathlev, Niels] Baystate Med Ctr, Dept Emergency Med, Springfield, MA USA; [Domeier, Robert] St Joseph Mercy Ann Arbor Hosp, Dept Emergency Med, Ypsilanti, MI USA; [Haran, John Patrick] Univ Massachusetts, Sch Med, Dept Emergency Med, Worcester, MA USA; [Pearson, Claire] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI USA; [Murty, Vishnu P.] Temple Univ, Dept Psychol, Coll Liberal Arts, Philadelphia, PA 19122 USA; [Insel, Thomas R.; Dagum, Paul; Dougherty, Robert F.] Mindstrong Hlth, Mountain View, CA USA; [Onnela, Jukka-Pekka] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Bruce, Steven E.] Univ Missouri, Dept Psychol Sci, St Louis, MO 63121 USA; [Gaynes, Bradley N.] UNC Sch Med, Dept Psychiat, Chapel Hill, NC USA; [Joormann, Jutta] Yale Univ, Dept Psychol, New Haven, CT USA; [Miller, Mark W.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Pietrzak, Robert H.] Yale Sch Med, Dept Psychiat, West Haven, CT USA; [Buysse, Daniel J.; Luna, Beatriz] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Harte, Steven E.] Univ Michigan, Dept Anesthesiol, Sch Med, Ann Arbor, MI 48109 USA; [Barch, Deanna M.] Washington Univ, Sch Med, Dept Psychol & Brain Sci, St Louis, MO USA; [Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Pace, Thaddeus W. W.] Univ Arizona, Coll Med, Dept Psychiat, Tucson, AZ USA; [Sheridan, John F.] Ohio State Univ, Coll Dent, Sch Med, Columbus, OH 43210 USA; [Elliott, James M.] Northwestern Univ, Feinberg Sch Med, Phys Therapy & Human Movement Sci, Chicago, IL 60611 USA; [Fromer, Menachem; Parlikar, Tushar] Verily Life Sci, San Francisco, CA USA; [Zaslavsky, Alan M.; Kessler, Ronald] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA	McLean, SA (corresponding author), UNC Sch Med, Inst Trauma Recovery, Dept Anesthesiol, Chapel Hill, NC 27599 USA.	Samuel_McLean@med.unc.edu	Buysse, Daniel/AAJ-1608-2021; Lebois, Lauren/AAB-3224-2021; Seamon, Mark/AAM-4713-2021; Stevens, Jennifer/T-4290-2018	Buysse, Daniel/0000-0002-3288-1864; Lebois, Lauren/0000-0001-5816-9181; Stevens, Jennifer/0000-0003-4674-0314; Linnstaedt, Sarah/0000-0001-5295-7072; McLean, Samuel/0000-0001-9482-3582; Sergot, Paulina/0000-0003-0796-8009	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U01MH110925]; US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); One Mind Foundation; Mayday Fund	Funding for the study was provided by NIMH U01MH110925, the US Army Medical Research and Material Command, The One Mind Foundation, and The Mayday Fund. Verily Life Sciences and Mindstrong Health provided some of the hardware and software used to perform study assessments.	Alarcon LH, 2012, J TRAUMA ACUTE CARE, V72, P629, DOI 10.1097/TA.0b013e31824416aa; American College of Emergency Physicians (ACEP), 2017, ER VIS INCR HIGH REC; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bollen KA, 1995, SOCIOL METHODOL, V25, P223, DOI 10.2307/271068; BOLLEN KA, 1987, SOCIOL METHOD RES, V15, P375, DOI 10.1177/0049124187015004002; Boscarino JA, 2006, ANN EPIDEMIOL, V16, P248, DOI 10.1016/j.annepidem.2005.03.009; CHERNOW B, 1987, ARCH INTERN MED, V147, P1273, DOI 10.1001/archinte.147.7.1273; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Elklit A, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.24221; Freeman D, 2013, PSYCHOL MED, V43, P2673, DOI 10.1017/S003329171300038X; Giannoudis PV, 2007, SPINE, V32, P776, DOI 10.1097/01.brs.0000259223.77957.76; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Hastie T., 2001, ELEMENTS STAT LEARNI, DOI [DOI 10.1007/B94608, 10.1007/978-0-387-84858-7, DOI 10.1007/978-0-387-84858-7]; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hu JM, 2016, PAIN, V157, P438, DOI 10.1097/j.pain.0000000000000388; JAKSCHIK BA, 1974, J CLIN INVEST, V54, P842, DOI 10.1172/JCI107824; Jenewein J, 2009, J PSYCHOSOM RES, V66, P119, DOI 10.1016/j.jpsychores.2008.07.011; Kessler RC, 2016, MOL PSYCHIATR, V21, P1366, DOI 10.1038/mp.2015.198; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Kessler RC, 2015, JAMA PSYCHIAT, V72, P49, DOI 10.1001/jamapsychiatry.2014.1754; Kessler RC, 2014, WORLD PSYCHIATRY, V13, P265, DOI 10.1002/wps.20150; Klein A, 2000, PSYCHOMETRIKA, V65, P457, DOI 10.1007/BF02296338; Klein AG, 2007, MULTIVAR BEHAV RES, V42, P647, DOI 10.1080/00273170701710205; Koenen KC, RO1 IDENTIFYING RISK, P2014; LEFER AM, 1969, AM J PHYSIOL, V216, P314; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lew HL, 2009, J REHABIL RES DEV, V46, P697702; MacKinnon D.P., 2008, INTRO STAT MEDIATION; McLean SA, 2014, PAIN, V155, P309, DOI 10.1016/j.pain.2013.10.016; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Hospital Ambulatory Medical Care Survey, 2011, 2011 EM DEP SUMM TAB; Roberts AL, 2011, PSYCHOL MED, V41, P71, DOI 10.1017/S0033291710000401; Shih RA, 2010, J TRAUMA, V69, P1560, DOI 10.1097/TA.0b013e3181e59c05; SPATHSCHWALBE E, 1991, BIOL PSYCHIAT, V29, P575, DOI 10.1016/0006-3223(91)90093-2; Sterling M, 2011, PAIN, V152, P1272, DOI 10.1016/j.pain.2011.01.056; UDELSMAN R, 1987, J SURG RES, V43, P539, DOI 10.1016/0022-4804(87)90128-4; Ulirsch JC, 2014, EUR J PAIN, V18, P559, DOI 10.1002/j.1532-2149.2013.00395.x; Ulirsch JC, 2014, PAIN, V155, P2116, DOI 10.1016/j.pain.2014.07.025; Vanderhaeghen M, 2007, AIP CONF PROC, V904, P25; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Wynne-Jones G, 2006, J RHEUMATOL, V33, P968; Zatzick DF, 2003, PSYCHOSOMATICS, V44, P479, DOI 10.1176/appi.psy.44.6.479; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	45	19	19	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	FEB	2020	25	2					283	296		10.1038/s41380-019-0581-3			14	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	KH7UM	WOS:000510855100005	31745239	Green Accepted			2021-06-18	
J	Sulhan, S; Lyon, KA; Shapiro, LA; Huang, JH				Sulhan, Suraj; Lyon, Kristopher A.; Shapiro, Lee A.; Huang, Jason H.			Neuroinflammation and blood-brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article; Proceedings Paper	17th International Conference on Brain Edema and Cellular Injury	DEC 08-10, 2017	Guangzhou, PEOPLES R CHINA			Blood-brain barrier; brain edema; neuroinflammation; traumatic brain injury	CONTROLLED CORTICAL IMPACT; MATRIX METALLOPROTEINASES; NLRP3 INFLAMMASOME; AXONAL INJURY; DOUBLE-BLIND; FUNCTIONAL RECOVERY; TRANEXAMIC ACID; CEREBRAL EDEMA; NITRIC-OXIDE; RAT MODEL	Traumatic Brain Injury (TBI) is the most frequent cause of death and disability in young adults and children in the developed world, occurring in over 1.7 million persons and resulting in 50,000 deaths in the United States alone. The Centers for Disease Control and Prevention estimate that between 3.2 and 5.3 million persons in the United States live with a TBI-related disability, including several neurocognitive disorders and functional limitations. Following the primary mechanical injury in TBI, literature suggests the presence of a delayed secondary injury involving a variety of neuroinflammatory changes. In the hours to days following a TBI, several signaling molecules and metabolic derangements result in disruption of the blood-brain barrier, leading to an extravasation of immune cells and cerebral edema. The primary, sudden injury in TBI occurs as a direct result of impact and therefore cannot be treated, but the timeline and pathophysiology of the delayed, secondary injury allows for a window of possible therapeutic options. The goal of this review is to discuss the pathophysiology of the primary and delayed injury in TBI as well as present several preclinical studies that identify molecular targets in the potential treatment of TBI. Additionally, certain recent clinical trials are briefly discussed to demonstrate the current state of TBI investigation.	[Sulhan, Suraj; Lyon, Kristopher A.; Huang, Jason H.] Baylor Scott & White Neurosci Inst, Dept Neurosurg, Temple, TX 76504 USA; [Sulhan, Suraj; Lyon, Kristopher A.; Shapiro, Lee A.; Huang, Jason H.] Texas A&M Univ, Coll Med, Temple, TX 76508 USA	Huang, JH (corresponding author), Baylor Scott & White Neurosci Inst, Dept Neurosurg, Temple, TX 76504 USA.	jason.huang@bswhealth.org	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168; Sulhan, Suraj/0000-0002-6462-4635	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS067435] Funding Source: Medline		Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abdul-Muneer PM, 2016, MOL NEUROBIOL, V53, P6106, DOI 10.1007/s12035-015-9520-8; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Alluri H, 2016, J BIOL CHEM, V291, P26958, DOI 10.1074/jbc.M116.735365; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Ashafaq M, 2012, NEUROCHEM RES, V37, P1747, DOI 10.1007/s11064-012-0786-1; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Bai XF, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009532; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Barrett EC, 2014, ADV NUTR, V5, P268, DOI 10.3945/an.113.005280; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Bralic M, 2012, COLLEGIUM ANTROPOL, V36, P1319; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Centers for Disease Control and Prevention, 2015, REP C TRAUM BRAIN IN; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fakharian E, 2018, WORLD NEUROSURG, V109, pE748, DOI 10.1016/j.wneu.2017.10.075; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Fischer S, 2005, EUR J CELL BIOL, V84, P687, DOI 10.1016/j.ejcb.2005.03.002; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hammond FM, 2015, J NEUROTRAUM, V32, P1230, DOI 10.1089/neu.2014.3803; Haorah J, 2007, J NEUROCHEM, V101, P566, DOI 10.1111/j.1471-4159.2006.04393.x; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; Hsieh HL, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-88; Hunt BJ, 2015, ANAESTHESIA, V70, DOI 10.1111/anae.12910; Jiang ZX, 2017, EXP PHYSIOL, V102, P1269, DOI 10.1113/EP086520; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kanazawa M, 2015, BRAIN, V138, P1932, DOI 10.1093/brain/awv079; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim A, 2018, J MOV DISORD, V11, P65, DOI 10.14802/jmd.18005; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Li ZM, 2016, CLIN NEUROL NEUROSUR, V150, P80, DOI 10.1016/j.clineuro.2016.09.001; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu YL, 2017, ACTA PHARMACOL SIN, V38, P1445, DOI 10.1038/aps.2017.103; Ma QY, 2014, ANN NEUROL, V75, P209, DOI 10.1002/ana.24070; Mandel SA, 2008, CNS NEUROSCI THER, V14, P352, DOI 10.1111/j.1755-5949.2008.00060.x; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Menzel L, 2017, GLIA, V65, P278, DOI 10.1002/glia.23091; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Muneer PMA, 2012, ARTERIOSCL THROM VAS, V32, P1167, DOI 10.1161/ATVBAHA.112.247668; Murakami M, 2008, J CLIN INVEST, V118, P3355, DOI 10.1172/JCI35298; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakase Hiroyuki, 2006, Neurosurgery, V58, pE1219, DOI 10.1227/01.NEU.0000215996.62828.76; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nikolian VC, 2018, CRIT CARE MED, V46, pE59, DOI 10.1097/CCM.0000000000002800; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Park ES, 2014, CARDIOVASC TOXICOL, V14, P1, DOI 10.1007/s12012-013-9232-0; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Perry DC, 2013, JAMA NEUROL, V70, P774, DOI 10.1001/2013.jamaneurol.393; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Prakash R, 2015, CURR OPIN NEUROL, V28, P556, DOI 10.1097/WCO.0000000000000248; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; Samadani U., 2016, WILL CLIN TRIAL TRAU; Sangobowale MA, 2018, J NEUROTRAUM, V35, P907, DOI 10.1089/neu.2017.5348; Schreibelt G, 2007, FASEB J, V21, P3666, DOI 10.1096/fj.07-8329com; Sorby-Adams AJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081788; Spritzer SD, 2015, NEUROLOGIST, V19, P61, DOI 10.1097/NRL.0000000000000001; Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tian QY, 2014, METHODS MOL BIOL, V1155, P163, DOI 10.1007/978-1-4939-0669-7_14; Tuli HS, 2013, LIFE SCI, V93, P863, DOI 10.1016/j.lfs.2013.09.030; Villapol S, 2015, BRAIN, V138, DOI 10.1093/brain/awv172; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang ZX, 2016, MOL NEUROBIOL, V53, P1905, DOI 10.1007/s12035-015-9143-0; Wei X, 2016, J HUAZHONG U SCI-MED, V36, P576, DOI 10.1007/s11596-016-1628-1; Winkler EA, 2016, NEUROSURG CLIN N AM, V27, P473, DOI 10.1016/j.nec.2016.05.008; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yuan J, 2016, BRAIN RES BULL, V127, P171, DOI 10.1016/j.brainresbull.2016.09.010; Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20; Zehtabchi S, 2014, AM J EMERG MED, V32, P1503, DOI 10.1016/j.ajem.2014.09.023; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang HY, 2013, MOL NEUROBIOL, V48, P452, DOI 10.1007/s12035-013-8432-8; Zhao HL, 2016, SCI REP-UK, V6, DOI 10.1038/srep23286; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	99	19	21	11	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN	2020	98	1					19	28		10.1002/jnr.24331			10	Neurosciences	Neurosciences & Neurology	JM0CE	WOS:000495891200003	30259550	Green Accepted			2021-06-18	
J	Stemper, BD; Shah, AS; Harezlak, J; Rowson, S; Duma, S; Mihalik, JP; Riggen, LD; Brooks, A; Cameron, KL; Giza, CC; Houston, MN; Jackson, J; Posner, MA; McGinty, G; DiFiori, J; Broglio, SP; McAllister, TW; McCrea, M; Hoy, AM; Hazzard, JB; Kelly, LA; Ortega, JD; Port, N; Putukian, M; Langford, TD; Tierney, R; Goldman, JT; Benjamin, HJ; Buckley, T; Kaminski, TW; Clugston, JR; Schmidt, JD; Feigenbaum, LA; Eckner, JT; Guskiewicz, K; Miles, JD; Anderson, S; Master, CL; Collins, M; Kontos, AP; Bazarian, JJ; Chrisman, SPO; O'Donnell, P; Cameron, K; Susmarski, A; Dum, S; Rowson, S; Bullers, CT; Miles, CM; Dykhuizen, BH; Lintner, L				Stemper, Brian D.; Shah, Alok S.; Harezlak, Jaroslaw; Rowson, Steven; Duma, Stefan; Mihalik, Jason P.; Riggen, Larry D.; Brooks, Alison; Cameron, Kenneth L.; Giza, Christopher C.; Houston, Megan N.; Jackson, Jonathan; Posner, Matthew A.; McGinty, Gerald; DiFiori, John; Broglio, Steven P.; McAllister, Thomas W.; McCrea, Michael; Hoy, April Marie (Reed); Hazzard, Joseph B., Jr.; Kelly, Louise A.; Ortega, Justus D.; Port, Nicholas; Putukian, Margot; Langford, T. Dianne; Tierney, Ryan; Goldman, Joshua T.; Benjamin, Holly J.; Buckley, Thomas; Kaminski, Thomas W.; Clugston, James R.; Schmidt, Julianne D.; Feigenbaum, Luis A.; Eckner, James T.; Guskiewicz, Kevin; Miles, Jessica Dysart; Anderson, Scott; Master, Christina L.; Collins, Micky; Kontos, Anthony P.; Bazarian, Jeffrey J.; Chrisman, Sara P. O.; O'Donnell, Patrick; Cameron, Kenneth; Susmarski, Adam; Dum, Stefan; Rowson, Steve; Bullers, Christopher Todd; Miles, Christopher M.; Dykhuizen, Brian H.; Lintner, Laura		CARE Consortium Investigators	Repetitive Head Impact Exposure in College Football Following an NCAA Rule Change to Eliminate Two-A-Day Preseason Practices: A Study from the NCAA-DoD CARE Consortium	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Sport-related concussion; Injury biomechanics; Traumatic brain injury; Acceleration	DIVISION-I; CONCUSSION DIAGNOSIS; PLAYERS; SEASON; FREQUENCY; LOCATION; SYSTEM; COHORT	Repetitive head impact exposure sustained by athletes of contact sports has been hypothesized to be a mechanism for concussion and a possible explanation for the high degree of variability in sport-related concussion biomechanics. In an attempt to limit repetitive head impact exposure during the football preseason, the NCAA eliminated two-a-day practices in 2017, while maintaining the total number of team practice sessions. The objective of this study was to quantify head impact exposure during the preseason and regular season in Division I college football athletes to determine whether the 2017 NCAA ruling decreased head impact exposure. 342 unique athletes from five NCAA Division I Football Bowl Subdivision (FBS) programs were consented and enrolled. Head impacts were recorded using the Head Impact Telemetry (HIT) System during the entire fall preseasons and regular seasons in 2016 and 2017. Despite the elimination of two-a-day practices, the number of preseason contact days increased in 2017, with an increase in average hourly impact exposure (i.e., contact intensity), resulting in a significant increase in total head impact burden (+ 26%) for the 2017 preseason. This finding would indicate that the 2017 NCAA ruling was not effective at reducing the head impact burden during the football preseason. Additionally, athletes sustained a significantly higher number of recorded head impacts per week (+ 40%) during the preseason than the regular season, implicating the preseason as a time of elevated repetitive head impact burden. With increased recognition of a possible association between repetitive head impact exposure and concussion, increased preseason exposure may predispose certain athletes to a higher risk of concussion during the preseason and regular season. Accordingly, efforts at reducing concussion incidence in contact sports should include a reduction in overall head impact exposure.	[Stemper, Brian D.] Marquette Univ, Joint Dept Biomed Engn, Milwaukee, WI 53233 USA; [Stemper, Brian D.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Stemper, Brian D.; Shah, Alok S.; McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Stemper, Brian D.; Shah, Alok S.; McCrea, Michael] Clement J Zablocki Vet Affairs Med Ctr, Neurosci Res, Milwaukee, WI USA; [Harezlak, Jaroslaw; Riggen, Larry D.] Indiana Univ, Dept Epidemiol & Biostat, Univ Sch Publ Hlth, Bloomington, IN USA; [Rowson, Steven; Duma, Stefan] Virginia Tech, Dept Biomed Engn & Mech, Blacksburg, VA USA; [Mihalik, Jason P.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27515 USA; [Brooks, Alison] Univ Wisconsin, Dept Orthoped, Sch Med & Publ Hlth, Madison, WI USA; [Cameron, Kenneth L.; Houston, Megan N.; Posner, Matthew A.] US Mil Acad, Keller Army Hosp, West Point, NY 10996 USA; [Jackson, Jonathan; McGinty, Gerald] US Air Force Acad, Dept Sports Med, Colorado Springs, CO 80840 USA; [Broglio, Steven P.] Univ Michigan, Michigan Concuss Ctr, Ann Arbor, MI 48109 USA; [McAllister, Thomas W.] Indiana Sch Med, Dept Psychiat, Indianapolis, IN USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, UCLA Steve Tisch BrainSPORT Program, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, UCLA Steve Tisch BrainSPORT Program, Los Angeles, CA 90095 USA; [DiFiori, John] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA; [Hoy, April Marie (Reed)] Azusa Pacific Univ, Azusa, CA 91702 USA; [Hazzard, Joseph B., Jr.] Bloomsburg Univ, Bloomsburg, PA USA; [Kelly, Louise A.] Calif Lutheran Univ, Thousand Oaks, CA USA; [Ortega, Justus D.] Humboldt State Univ, Arcata, CA 95521 USA; [Port, Nicholas] Indiana Univ, Bloomington, IN 47405 USA; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Langford, T. Dianne; Tierney, Ryan] Temple Univ, Philadelphia, PA 19122 USA; [Giza, Christopher C.; Goldman, Joshua T.] Univ Calif Los Angeles, Los Angeles, CA USA; [Benjamin, Holly J.] Univ Chicago, Chicago, IL 60637 USA; [Buckley, Thomas; Kaminski, Thomas W.] Univ Delaware, Newark, DE 19716 USA; [Clugston, James R.] Univ Florida, Gainesville, FL 32611 USA; [Schmidt, Julianne D.] Univ Georgia, Athens, GA 30602 USA; [Feigenbaum, Luis A.] Univ Miami, Coral Gables, FL 33124 USA; [Eckner, James T.] Univ Michigan, Ann Arbor, MI 48109 USA; [Mihalik, Jason P.; Guskiewicz, Kevin] Univ N Carolina, Chapel Hill, NC 27515 USA; [Miles, Jessica Dysart] Univ North Georgia, Dahlonega, GA USA; [Anderson, Scott] Univ Oklahoma, Norman, OK 73019 USA; [Master, Christina L.] Univ Penn, Philadelphia, PA 19104 USA; [Collins, Micky; Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; [Bazarian, Jeffrey J.] Univ Rochester, Rochester, NY 14627 USA; [Chrisman, Sara P. O.] Univ Washington, Seattle, WA 98195 USA; [Brooks, Alison] Univ Wisconsin, Madison, WI 53706 USA; [Jackson, Jonathan; McGinty, Gerald] US Air Force Acad, Colorado Springs, CO 80840 USA; [O'Donnell, Patrick] US Coast Guard Acad, New London, CT USA; [Houston, Megan N.; Cameron, Kenneth] US Mil Acad, West Point, NY 10996 USA; [Susmarski, Adam] US Naval Acad, Annapolis, MD 21402 USA; [Dum, Stefan; Rowson, Steve] Virginia Tech, Blacksburg, VA USA; [Bullers, Christopher Todd; Miles, Christopher M.] Wake Forest Univ, Winston Salem, NC 27101 USA; [Dykhuizen, Brian H.] Wilmington Coll, Wilmington, OH USA; [Lintner, Laura] Winston Salem Univ, Winston Salem, NC USA	Stemper, BD (corresponding author), Marquette Univ, Joint Dept Biomed Engn, Milwaukee, WI 53233 USA.; Stemper, BD (corresponding author), Med Coll Wisconsin, Milwaukee, WI 53226 USA.	bstemper@mcw.edu	Rowson, Steven/B-1270-2012; Stemper, Brian/AAX-7611-2020; Buckley, Thomas A/B-7525-2016; Harezlak, Jaroslaw/P-8557-2014	Rowson, Steven/0000-0002-3227-0596; Buckley, Thomas A/0000-0002-0515-0150; Master, Christina/0000-0002-6717-4270; Chrisman, Sara/0000-0001-5373-7223; Cameron, Kenneth/0000-0002-6276-4482; Susmarski, Adam/0000-0003-3698-4163; Harezlak, Jaroslaw/0000-0002-3070-7686; Ortega, Justus/0000-0002-9931-5605	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - Department of Defense (DoD); U.S. Army Medical Research Acquisition Activity, Chandler Street, Ford Detrick MD; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]; UCLA	This investigation was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded, by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DoD). The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Ford Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award NO W81XWH-14-2-0151. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense (DHP funds). The authors have no other financial conflicts of interest to disclose. UCLA would like to acknowledge the Tisch BrainSPORT program which provided funds to purchase the HIT System for their team. The study team would also like to acknowledge the HIT System operators that participated in this study: Julia Ford (UNC), Gus Hendricks (UCLA), Quinn Lukens (UW), Brett Griesemer (VT), Alex Black (VT), Lewis Young (VT), Dom Calhoun (USAFA), and Sean Roach (USMA). Results of this study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation. The conclusions herein are those of the authors. They do not represent official policy of the Department of the Air Force, Department of the Army, or the Department of Defense. CARE Consortium Investigators are listed alphabetically by institution: April Marie (Reed) Hoy, MS, ATC (Azusa Pacific University); Joseph B. Hazzard Jr., EdD, ATC (Bloomsburg University); Louise A. Kelly, PhD (California Lutheran University); Justus D. Ortega, PhD (Humboldt State University); Nicholas Port, PhD (Indiana University); Margot Putukian MD (Princeton University); T. Dianne Langford, PhD, and Ryan Tierney, PhD, ATC (Temple University); Christopher C. Giza, MD and Joshua T. Goldman, MD, MBA (University of California, Los Angeles); Holly J. Benjamin MD (University of Chicago); Thomas Buckley, EdD, ATC, and Thomas W. Kaminski, PhD, ATC (University of Delaware); James R. Clugston, MD, MS (University of Florida); Julianne D. Schmidt, PhD, ATC (University of Georgia); Luis A. Feigenbaum, DPT, ATC (University of Miami); James T. Eckner, MD, MS (University of Michigan); Kevin Guskiewicz, PhD, ATC, and Jason P. Mihalik, PhD, CAT(C), ATC (University of North Carolina at Chapel Hill); Jessica Dysart Miles, PhD, ATC (University of North Georgia); Scott Anderson, ATC (University of Oklahoma); Christina L. Master, MD (University of Pennsylvania); Micky Collins, PhD, and Anthony P. Kontos, PhD (University of Pittsburgh Medical Center); Jeffrey J. Bazarian, MD, MPH (University of Rochester); Sara P.O. Chrisman, MD, MPH (University of Washington); Alison Brooks, MD, MPH (University of WisconsinMadison); Jonathan Jackson, MD, and Gerald McGinty, DPT (United States Air Force Academy); Patrick O'Donnell, MHA (United States Coast Guard Academy); Kenneth Cameron, PhD, MPH, ATC; Megan N. Houston, PhD, ATC (United States Military Academy); Adam Susmarski, MD (United States Naval Academy); Stefan Duma, PhD and Steve Rowson, PhD (Virginia Tech); Christopher Todd Bullers, MD, and Christopher M. Miles, MD (Wake Forest University); Brian H. Dykhuizen, MS, ATC (Wilmington College); Laura Lintner DO (Winston-Salem University).	Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Belson K., 2016, NY TIMES; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Broglio SP, 2017, J NEUROTRAUM, V34, P2675, DOI 10.1089/neu.2016.4767; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Davenport Elizabeth M, 2016, Concussion, V1, pCNC19, DOI 10.2217/cnc-2016-0003; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Kelley ME, 2019, J NEUROSURG-PEDIATR, V23, P381, DOI 10.3171/2018.9.PEDS18314; Kerr ZY, 2015, J NEUROTRAUM, V32, P1083, DOI 10.1089/neu.2014.3666; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; Krill MK, 2017, PHYSICIAN SPORTSMED, V45, P26, DOI 10.1080/00913847.2017.1279520; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; Rowson S, 2018, J NEUROTRAUM, V35, P681, DOI 10.1089/neu.2017.5169; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Slobounov SM, 2017, NEUROIMAGE-CLIN, V14, P708, DOI 10.1016/j.nicl.2017.03.006; Stemper BD, 2019, ANN BIOMED ENG, V47, P2057, DOI 10.1007/s10439-018-02136-6; Talavage TM, 2016, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00273; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; The National Collegiate Athletic Association (NCAA) and I. Manual, 2017, 2017 18 NCAA DIV MAN; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z	38	19	19	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2019	47	10			SI		2073	2085		10.1007/s10439-019-02335-9			13	Engineering, Biomedical	Engineering	JQ0HT	WOS:000498636800004	31388849	Green Published, Other Gold			2021-06-18	
J	Gratz, J; Guting, H; Thorn, S; Brazinova, A; Gorlinger, K; Schafer, N; Schochl, H; Stanworth, S; Maegele, M				Gratz, J.; Gueting, H.; Thorn, S.; Brazinova, A.; Goerlinger, K.; Schaefer, N.; Schoechl, H.; Stanworth, S.; Maegele, M.			Protocolised thromboelastometric-guided haemostatic management in patients with traumatic brain injury: a pilot study	ANAESTHESIA			English	Article						anaemia; coagulation; point-of-care testing; thromboelastometry; traumatic brain injury; management	COAGULOPATHY; TRANSFUSION; RESUSCITATION; SURGERY; CARE	Coagulopathy in patients with traumatic brain injury is associated with an increase in morbidity and mortality. Although timely and aggressive treatment of coagulopathy is of paramount importance, excessive transfusion of blood products has been linked with poor long-term outcomes in patients with traumatic brain injury. A point-of-care thromboelastometric-guided algorithm could assist in creating a more individually tailored approach to each patient. The aim of this study was to evaluate the feasibility of implementing a thromboelastometric-guided algorithm in centres that were formerly naive to thromboelastometry. Hence, we developed such an algorithm and provided training to four centres across Europe to direct the haemostatic management of patients with severe traumatic brain injury. The primary outcome was adherence to the algorithm and timing of the availability of relevant results. Thirty-two patients were included in the study. Complete adherence to the algorithm was observed in 20 out of 32 cases. The availability of thromboelastometric results after hospital admission was reported significantly earlier than conventional coagulation tests (median (IQR [range]) 33 (20-40 [14-250]) min vs. 71 (51-101 [32-290]) min; p = 0.037). Although only 5 out of 32 patients had abnormalities of conventional coagulation tests, 21 out of 32 patients had a coagulopathic baseline thromboelastometric trace. Implementing a thromboelastometric-guided algorithm for the haemostatic therapy of traumatic brain injury is feasible in centres formerly naive to this technology and may lead to more rapid and precise coagulation management. Further large-scale studies are warranted to confirm the results of this pilot trial and evaluate clinical outcomes.	[Gratz, J.] Med Univ Vienna, Dept Anaesthesia Crit Care & Pain Med, Vienna, Austria; [Gueting, H.; Schaefer, N.; Maegele, M.] Univ Witten Herdecke, Inst Res Operat Med, Cologne, Germany; [Thorn, S.] Monash Univ Melbourne, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Brazinova, A.] Comenius Univ, Fac Med, Inst Epidemiol, Bratislava, Slovakia; [Goerlinger, K.] Univ Hosp Essen, Dept Anaesthesia & Intens Care Med, Essen, Germany; [Goerlinger, K.] TEM Innovat GmbH, Munich, Germany; [Schoechl, H.] Paracelsus Med Univ Salzburg, Acad Teaching Hosp, AUVA Trauma Ctr Salzburg, Dept Anaesthesia & Intens Care Med, Salzburg, Austria; [Schoechl, H.] AUVA Trauma Res Ctr Vienna, Ludwig Boltzmann Inst Expt & Clin Traumatol, Vienna, Austria; [Stanworth, S.] Univ Oxford, Oxford Univ Hosp NHS Fdn Trust, Radcliffe Dept Med, Dept Haematol, Oxford, England; [Maegele, M.] Cologne Merheim Med Ctr, Dept Traumatol & Orthoped Surg, Cologne, Germany	Maegele, M (corresponding author), Univ Witten Herdecke, Inst Res Operat Med, Cologne, Germany.; Maegele, M (corresponding author), Cologne Merheim Med Ctr, Dept Traumatol & Orthoped Surg, Cologne, Germany.	marc.maegele@t-online.de	Gratz, Johannes/AAH-3566-2020; Brazinova, Alexandra/C-4265-2016	Brazinova, Alexandra/0000-0003-0625-256X; Gratz, Johannes/0000-0001-8717-0544	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [602150]; CSL Behring; Astra ZenecaAstraZeneca; BayerBayer AG; Biotest; IL Werfen/TEM International; LFB Biomedicaments	The authors thank all participating centres and staff for their commitment. The study was registered at the German Registry of Clinical Trials before the beginning of patient enrolment. This trial was conducted as an embedded sub-study within CENTER-TBI. As such it was supported by the European Commission 7th Framework Program (FP7/2007-2013) under grant agreement number 602150 (CENTER-TBI). The funder had no role in the design of the study; collection, analyses and interpretation of data; nor in writing the manuscript. JG has received support for congress travels and speaker fees from CSL Behring and Mitsubishi Tanabe Pharma. KG is Medical Director of Tem Innovations GmbH since 2012 and has received speaker fees and travel expenses reimbursement from CSL Behring and Octapharma. HS has received honoraria for participation in advisory board meetings for Bayer Healthcare, Bohringer Ingelheim, Werfen/TEM international and study grants from CSL Behring. Moreover, he has received speaker fees from CSL Behring, Cardinal Health, Roche, Haemonetics and Shire. MM has received support for congress travels, services to speaker bureaus and advisory boards and for research projects from Astra Zeneca, Bayer, Biotest, CSL Behring, IL Werfen/TEM International and LFB Biomedicaments. All other authors declare that they have no relevant competing interests.	Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Baksaas-Aasen K, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2224-9; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Dunbar NM, 2009, TRANSFUSION, V49, P2652, DOI 10.1111/j.1537-2995.2009.02335.x; Epstein DS, 2016, J CLIN NEUROSCI, V29, P64, DOI 10.1016/j.jocn.2015.11.024; Girdauskas E, 2010, J THORAC CARDIOV SUR, V140, P1117, DOI 10.1016/j.jtcvs.2010.04.043; Gorlinger K, 2013, BRIT J ANAESTH, V110, P222, DOI 10.1093/bja/aes374; Goerlinger K, 2006, HAMOSTASEOLOGIE S1, V26, P64; Gorlinger K, 2011, ANESTHESIOLOGY, V115, P1179, DOI 10.1097/ALN.0b013e31823497dd; Gonzalez E, 2017, CRIT CARE CLIN, V33, P119, DOI 10.1016/j.ccc.2016.09.002; Greuters S, 2011, CRITICAL CARE, V15, P1; Haas T, 2015, BRIT J ANAESTH, V114, P217, DOI 10.1093/bja/aeu303; Hagemo JS, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0823-y; Inaba K, 2015, J TRAUMA ACUTE CARE, V78, P1220, DOI 10.1097/TA.0000000000000536; Khan S, 2014, J TRAUMA ACUTE CARE, V76, P561, DOI 10.1097/TA.0000000000000146; Leeper CM, 2018, J TRAUMA ACUTE CARE, V85, P12, DOI 10.1097/TA.0000000000001836; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Moore HB, 2014, J TRAUMA ACUTE CARE, V77, P811, DOI 10.1097/TA.0000000000000341; Rossaint R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1265-x; Schafer N, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0147-6; Schenk B, 2019, ANAESTHESIA, V74, P348, DOI 10.1111/anae.14542; Schochl H, 2012, HAMOSTASEOLOGIE, V32, P22, DOI 10.5482/ha-1178; Schochl H, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-15; Schochl H, 2011, J NEUROTRAUM, V28, P2033, DOI 10.1089/neu.2010.1744; Stein P, 2017, ANAESTHESIA, V72, P1317, DOI 10.1111/anae.13920; Warner MA, 2010, J NEUROSURG, V113, P539, DOI 10.3171/2009.12.JNS091337; Wikkelso A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007871.pub3; Yuan Q, 2016, J NEUROTRAUM, V33, P1279, DOI 10.1089/neu.2015.4205; Zhang D., 2015, BIOMED RES INT, V2015, P1; Zhang JN, 2012, J NEUROTRAUM, V29, P2597, DOI 10.1089/neu.2012.2348	32	19	19	2	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	JUL	2019	74	7					883	890		10.1111/anae.14670			8	Anesthesiology	Anesthesiology	IC4LO	WOS:000470937400010	31032890	Bronze			2021-06-18	
J	Iverson, GL; Luoto, TM; Karhunen, PJ; Castellani, RJ				Iverson, Grant L.; Luoto, Teemu M.; Karhunen, Pekka J.; Castellani, Rudolph J.			Mild Chronic Traumatic Encephalopathy Neuropathology in People With No Known Participation in Contact Sports or History of Repetitive Neurotrauma	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Brain injury; Chronic traumatic encephalopathy; Concussion; Sports	BRAIN-INJURY; ALZHEIMERS-DISEASE; TAU PATHOLOGY; SINGLE; TAUOPATHY; OUTCOMES; TDP-43	It has been asserted that chronic traumatic encephalopathy (CTE) pathology is only present in former athletes and others who have been exposed to repetitive concussions, subconcussive blows, or both. We hypothesized that CTE pathology would be present in men who had no known history of repetitive neurotrauma. Comprehensive medical record reviews and health surveys completed by a family member were available for the 8 men in this case series, none of whom had known exposure to repetitive neurotrauma but 2 of whom had a history of traumatic brain injury (TBI). Postmortem tissue was immunostained for hyperphosphorylated tau (p-tau) to assess for CTE pathology, Braak stage, and aging-related p-tau. The neuropathologist was blind to age, personal history, and clinical history. Six of the 8 cases (75%) showed p-tau in neurons, astrocytes, and cell processes around small blood vessels in an irregular pattern at the depths of the cortical sulci. The changes were focal and limited in terms of overall extent, and some of the cases had a clearer pattern of pathology and some could be considered equivocal. Two of the 8 cases had a history of TBI and one of them showed CTE pathology. Five of the 6 cases with no known history of neurotrauma appeared to meet consensus criteria for CTE. This study adds to the emerging literature indicating that CTE pathology is present in people not known to have experienced multiple concussions or subconcussive blows to the head.	[Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Spaulding Res Inst, Boston, MA USA; [Iverson, Grant L.] MassGeneral Hosp Children Sports Concuss Program, Boston, MA USA; [Iverson, Grant L.] Home Base, Boston, MA USA; [Luoto, Teemu M.] Tampere Univ Hosp, Dept Neurosurg, Tampere, Finland; [Luoto, Teemu M.] Univ Tampere, Tampere, Finland; [Karhunen, Pekka J.] Univ Tampere, Fac Med & Life Sci, Dept Forens Med, Tampere, Finland; [Karhunen, Pekka J.] Fimlab Labs, Tampere, Finland; [Karhunen, Pekka J.] Finnish Cardiovasc Res Ctr Tampere, Tampere, Finland; [Castellani, Rudolph J.] Rockefeller Neurosci Inst, Dept Pathol Anat & Lab Med, Morgantown, WV USA; [Castellani, Rudolph J.] Rockefeller Neurosci Inst, Dept Neurosci, Morgantown, WV USA; [Castellani, Rudolph J.] West Virginia Univ, Sch Med, Morgantown, WV 26506 USA	Iverson, GL (corresponding author), Ctr Hlth & Rehabil Res, Dept Phys Med & Rehabil, 79-96 Thirteenth St, Charlestown, MA 02129 USA.	giverson@mgh.harvard.edu	Luoto, Teemu/W-6468-2018	Luoto, Teemu/0000-0002-7329-3284	Harvard Integrated Program to Protect and Improve the Health of NFLPA Members; Mooney-Reed Charitable Foundation; Heniz Family Foundation; ImPACT Applications, Inc.; Western Michigan University Homer Stryker MD School of Medicine; ImPACT Applications Systems; Psychological Assessment Resources; CNS Vital Signs	Dr Grant Iverson has been reimbursed by the government, professional scientific bodies, and commercial organizations for discussing or presenting research relating to MTBI and sport-related concussion at meetings, scientific conferences, and symposiums. He has a clinical practice in forensic neuropsychology involving individuals who have sustained mild TBIs (including athletes). He has received honorariums for serving on research panels that provide scientific peer review of programs. He is a coinvestigator, collaborator, or consultant on grants relating to mild TBI funded by the federal government and other organizations. He has received research support from test publishing companies in the past, including ImPACT Applications Systems, Psychological Assessment Resources, and CNS Vital Signs. He has received support from the Harvard Integrated Program to Protect and Improve the Health of NFLPA Members. He serves as a scientific advisor for BioDirection, Inc. He acknowledges unrestricted philanthropic support from the Mooney-Reed Charitable Foundation, Heniz Family Foundation, and ImPACT Applications, Inc. Dr. Castellani has been reimbursed for travel for speaking at educational programs and has received fees for medicolegal consulting. He has received intramural research funding at Western Michigan University School of Medicine, unrelated to this study. He is subcontracted to the NIH Neurobiobank at the University of Maryland and the Lieber Institute for Brain Development. The neuropathological examinations for this study were funded by Western Michigan University Homer Stryker MD School of Medicine.	Armstrong RA, 2017, NEUROPATH APPL NEURO, V43, P154, DOI 10.1111/nan.12323; Asken BM, 2018, J ORTHOP SPORT PHYS, V48, P672, DOI 10.2519/jospt.2018.0612; Asken BM, 2017, JAMA NEUROL, V74, P1255, DOI 10.1001/jamaneurol.2017.2396; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Crary JF, 2014, ACTA NEUROPATHOL, V128, P755, DOI 10.1007/s00401-014-1349-0; Fournier CN, 2015, NEUROLOGY, V84, P1788, DOI 10.1212/WNL.0000000000001522; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; HIXSON JE, 1990, J LIPID RES, V31, P545; Holleran L, 2017, ACTA NEUROPATHOL, V133, P367, DOI 10.1007/s00401-017-1686-x; Hsu ET, 2018, ACTA NEUROPATHOL, V136, P955, DOI 10.1007/s00401-018-1902-3; Iverson GL, 2018, J ALZHEIMERS DIS, V61, P17, DOI 10.3233/JAD-170654; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Koga S, 2016, J NEUROPATH EXP NEUR, V75, P963, DOI 10.1093/jnen/nlw073; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Ling H, 2017, NEUROPATH APPL NEURO, V43, P467, DOI 10.1111/nan.12425; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Noy S, 2016, J NEUROPATH EXP NEUR, V75, P1145, DOI 10.1093/jnen/nlw092; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Puvenna V, 2016, BRAIN RES, V1630, P225, DOI 10.1016/j.brainres.2015.11.007; Randolph C, 2018, ARCH CLIN NEUROPSYCH, V33, P644, DOI 10.1093/arclin/acy063; Riley DO, 2015, BRAIN INJURY, V29, P154, DOI 10.3109/02699052.2014.965215; Schwab N, 2018, J ALZHEIMERS DIS, V64, P1067, DOI 10.3233/JAD-180373; Shively SB, 2017, ACTA NEUROPATHOL, V133, P353, DOI 10.1007/s00401-016-1649-7; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Solomon G, 2018, DEV NEUROPSYCHOL, V43, P279, DOI 10.1080/87565641.2018.1447575; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Zanier ER, 2018, BRAIN, V141, P2685, DOI 10.1093/brain/awy193; Zuckerman SL, 2018, J ALZHEIMERS DIS, V66, P37, DOI 10.3233/JAD-180218	58	19	19	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUL	2019	78	7					615	625		10.1093/jnen/nlz045			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	JI3QO	WOS:000493382600004	31169877	Green Published, Bronze			2021-06-18	
J	Ezekiel, L; Collett, J; Mayo, NE; Pang, L; Field, L; Dawes, H				Ezekiel, Leisle; Collett, Johnny; Mayo, Nancy E.; Pang, Lori; Field, Leanne; Dawes, Helen			Factors Associated With Participation in Life Situations for Adults With Stroke: A Systematic Review	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the Royal-College-of-Occupational-Therapists	JUN 20, 2017	Birmingham, ENGLAND	Royal Coll Occupat Therapists		Rehabilitation; Social participation; Stroke	QUALITY-OF-LIFE; SICKNESS IMPACT PROFILE; TRAUMATIC BRAIN-INJURY; SOCIAL-PARTICIPATION; OUTCOME MEASURES; INTERNATIONAL CLASSIFICATION; COMMUNITY REINTEGRATION; PSYCHOMETRIC PROPERTIES; ISCHEMIC-STROKE; YOUNG-ADULTS	Objectives: To identify biopsychosocial factors associated with participation outcomes for adults with stroke and to investigate factors associated with participation at different time points poststroke. Data Sources: Medline, CINAHL, AMED, PyschINFO, and Web of Science were systematically searched using keywords stroke, participation, and outcomes and their synonyms on May 15, 2017. Study Selection: Observational studies reporting on biopsychosocial factors and participation outcomes for community-dwelling adults with stroke were selected. Studies were eligible for inclusion if participation outcomes were measured using indices that mapped to the participation domain of the International Classification of Functioning, Disability and Health (ICF). Intervention studies were excluded. A second reviewer checked all studies against eligibility criteria at each stage. Data Extraction: Data were extracted on any statistically determined association between biopsychosocial factors and participation outcomes. Data Synthesis: The proportion of studies reporting significant associations with variables was classified according to the ICF. The exact binomial test was used to determine the probability that the proportion of studies reporting significant associations was due to chance alone. Qualitative descriptive summaries of each study allowed consideration of interactions between variables and changes in participation over time points. Conclusions: Although depressive symptoms, cognitive functioning, and mobility were found to have the strongest associations with participation, we found that other frequently occurring factors (such as fatigue and environmental factors) were less extensively considered. The diversity of outcome measures encountered within the review highlight the need for a consensus on a core set of outcome measures to evaluate long-term participation in life situations poststroke. (C) 2018 by the American Congress of Rehabilitation Medicine	[Ezekiel, Leisle; Collett, Johnny; Field, Leanne; Dawes, Helen] Oxford Brookes Univ, Oxford Inst Nursing Midwifery & Allied Hlth Res O, Fac Hlth & Life Sci, Gipsy Lane, Oxford OX3 0BP, England; [Mayo, Nancy E.] McGill Univ, Canadian Acad Hlth Sci, Dept Med, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Pang, Lori] Cent London Community Healthcare NHS Trust, London, England	Ezekiel, L (corresponding author), Oxford Brookes Univ, Oxford Inst Nursing Midwifery & Allied Hlth Res O, Fac Hlth & Life Sci, Gipsy Lane, Oxford OX3 0BP, England.	lezekiel@brookes.ac.uk	Ezekiel, Leisle/I-3632-2019	Dawes, Helen/0000-0002-2933-5213; Ezekiel, Leisle/0000-0002-5904-3019; , Johnny/0000-0003-4138-2589	Oxford Brookes University; Elizabeth Casson Trust; National Institute for Health Research, Oxford Biomedical Research CentreNational Institute for Health Research (NIHR); Heath Education England Thames Valley; Health Education England Thames Valley INTALECA program	Leisle Ezekiel was supported by Oxford Brookes University. Helen Dawes was supported by the Elizabeth Casson Trust and National Institute for Health Research, Oxford Biomedical Research Centre. Johnny Collett was supported by Heath Education England Thames Valley and Oxford Brookes University. Leanne Field was supported by Health Education England Thames Valley INTALECA program.	Atler K, 2015, DISABIL REHABIL, V37, P121, DOI 10.3109/09638288.2014.910560; Bartlett DJ, 2006, DISABIL REHABIL, V28, P1169, DOI 10.1080/09638280600551567; Baum C.M., 2001, ACTIVITY CARD SORT; Bejot Y, 2014, J NEUROL NEUROSUR PS, V85, P509, DOI 10.1136/jnnp-2013-306203; Bentsen L, 2014, J STROKE CEREBROVASC, V23, P1944, DOI 10.1016/j.jstrokecerebrovasdis.2014.02.002; Berges IM, 2012, DISABIL REHABIL, V34, P2119, DOI 10.3109/09638288.2012.673684; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Blomer AMV, 2015, ARCH PHYS MED REHAB, V96, P456, DOI 10.1016/j.apmr.2014.09.003; Butler Andrew, 2006, J Neurol Phys Ther, V30, P148; Cardol M, 2001, ARCH PHYS MED REHAB, V82, P210, DOI 10.1053/apmr.2001.18218; Carod-Artal FJ, 2009, J NEUROL SCI, V284, P63, DOI 10.1016/j.jns.2009.04.008; Carter BS, 2000, NEUROSURGERY, V46, P1326, DOI 10.1097/00006123-200006000-00008; Chahal N, 2011, NEUROEPIDEMIOLOGY, V37, P31, DOI 10.1159/000328647; Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263; Clarke PJ, 1999, DISABIL REHABIL, V21, P116, DOI 10.1080/096382899297855; Coole C, 2013, J OCCUP REHABIL, V23, P406, DOI 10.1007/s10926-012-9401-1; Cooper CL, 2015, BRIT J CLIN PSYCHOL, V54, P181, DOI 10.1111/bjc.12068; Cooper H, 2009, HDB RES SYNTHESIS ME; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Craig P, 2013, INT J NURS STUD, V50, P587, DOI 10.1016/j.ijnurstu.2012.09.010; Crichton SL, 2016, J NEUROL NEUROSUR PS, V87, P1091, DOI 10.1136/jnnp-2016-313361; Dehlendorff C, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001967; Desrosiers J, 2005, J REHABIL MED, V37, P353, DOI 10.1080/16501970510037096; Desrosiers J, 2002, DISABIL REHABIL, V24, P774, DOI 10.1080/09638280210125814; Desrosiers J, 2008, NEUROREHAB NEURAL RE, V22, P288, DOI 10.1177/1545968307307116; Desrosiers J, 2006, TOP STROKE REHABIL, V13, P86, DOI 10.1310/tsr1304-86; Dijkers MP, 2010, ARCH PHYS MED REHAB, V91, pS5, DOI 10.1016/j.apmr.2009.10.036; Duncan F, 2012, J PSYCHOSOM RES, V73, P18, DOI 10.1016/j.jpsychores.2012.04.001; Duncan PW, 1999, STROKE, V30, P2131, DOI 10.1161/01.STR.30.10.2131; Egan M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1872-5; Egan M, 2014, ARCH PHYS MED REHAB, V95, P262, DOI 10.1016/j.apmr.2013.08.013; Eyssen IC, 2011, ARCH PHYS MED REHAB, V92, P983, DOI 10.1016/j.apmr.2011.01.006; Ezekiel L, 2015, PROTOCOL FACTORS ASS; Fallahpour M, 2011, J REHABIL MED, V43, P388, DOI 10.2340/16501977-0789; Gall SL, 2009, CEREBROVASC DIS, V27, P123, DOI 10.1159/000177919; Gottlieb A, 2001, AGING-CLIN EXP RES, V13, P11, DOI 10.1007/BF03351488; Graven C, 2011, DISABIL REHABIL, V33, P1501, DOI 10.3109/09638288.2010.542874; Greenland S., 2008, MODERN EPIDEMIOLOGY, P652; Gum A, 2006, PSYCHOL HEALTH, V21, P319, DOI 10.1080/14768320500422907; HARWOOD RH, 1994, J NEUROL NEUROSUR PS, V57, P825, DOI 10.1136/jnnp.57.7.825; Harwood RH, 1997, DISABIL REHABIL, V19, P205, DOI 10.3109/09638289709166528; Heinemann AW, 2015, ARCH PHYS MED REHAB, V96, P589, DOI 10.1016/j.apmr.2013.11.024; Jansen HE, 2012, J REHABIL MED, V44, P47, DOI 10.2340/16501977-0908; Kessler D, 2012, BRIT J OCCUP THER, V75, P403, DOI 10.4276/030802212X13470263980757; Lakshminarayan K, 2014, STROKE, V45, P2575, DOI 10.1161/STROKEAHA.114.005512; Levasseur M, 2010, SOC SCI MED, V71, P2141, DOI 10.1016/j.socscimed.2010.09.041; Mallinson T, 2010, ARCH PHYS MED REHAB, V91, pS29, DOI 10.1016/j.apmr.2010.04.027; Mayo NE, 2002, ARCH PHYS MED REHAB, V83, P1035, DOI 10.1053/apmr.2002.33984; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Mercer VS, 2009, PHYS THER, V89, P1061, DOI 10.2522/ptj.20080368; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Naess H, 2006, STROKE, V37, P1232, DOI 10.1161/01.STR.0000217652.42273.02; National Heart Lung and Blood Institute, QUAL ASS TOOL OBS CO; NHLBI, BACKGR DEV US STUD Q; Noonan VK, 2009, DISABIL REHABIL, V31, P1883, DOI 10.1080/09638280902846947; Noreau L, 2004, DISABIL REHABIL, V26, P346, DOI 10.1080/09638280410001658649; Northcott S, 2016, CLIN REHABIL, V30, P811, DOI 10.1177/0269215515602136; Obembe AO, 2016, NEUROREHAB NEURAL RE, V30, P384, DOI 10.1177/1545968315597072; Ostir GV, 2006, ARCH PHYS MED REHAB, V87, P1043, DOI 10.1016/j.apmr.2006.04.024; Patel MD, 2006, AGE AGEING, V35, P273, DOI 10.1093/ageing/afj074; Perenboom RJM, 2003, DISABIL REHABIL, V25, P577, DOI 10.1080/0963828031000137081; Poole C, 2006, INT J EPIDEMIOL, V35, P370, DOI 10.1093/ije/dyi248; Popay J., 2006, GUIDANCE CONDUCT NAR; Post MWM, 2008, J REHABIL MED, V40, P620, DOI 10.2340/16501977-0223; Post MWM, 2012, DISABIL REHABIL, V34, P478, DOI 10.3109/09638288.2011.608148; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rosenthal, 2008, ESSENTIALS BEHAV RES; Salinas J, 2016, STROKE, V47, P180, DOI 10.1161/STROKEAHA.115.010898; Salter K, 2005, DISABIL REHABIL, V27, P507, DOI 10.1080/0963828040008552; Salter K., 2013, OUTCOME MEASURES STR; Salter K, 2008, J REHABIL MED, V40, P595, DOI 10.2340/16501977-0238; Schepers VP, 2005, ARCH PHYS MED REHAB, V86, P1472, DOI 10.1016/j.apmr.2004.11.039; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; Singam A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144344; Sivan M, 2011, J REHABIL MED, V43, P181, DOI 10.2340/16501977-0674; Skolarus LE, 2014, STROKE, V45, P224, DOI 10.1161/STROKEAHA.113.002874; Stummer C, 2015, DISABIL REHABIL, V37, P942, DOI 10.3109/09638288.2014.948137; Sturm JW, 2002, STROKE, V33, P2888, DOI 10.1161/01.STR.0000040407.44712.C7; Sturm JW, 2002, STROKE, V33, P762, DOI 10.1161/hs0302.103815; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tse T, 2017, TOP STROKE REHABIL, V24, P405, DOI 10.1080/10749357.2017.1318339; Tse T, 2013, ARCH PHYS MED REHAB, V94, P177, DOI 10.1016/j.apmr.2012.09.002; Veras M, 2017, J TELEMED TELECARE, V23, P567, DOI 10.1177/1357633X16656235; Verhoeven CLM, 2011, J STROKE CEREBROVASC, V20, P450, DOI 10.1016/j.jstrokecerebrovasdis.2010.02.018; Walsh ME, 2015, DISABIL REHABIL, V37, P1599, DOI 10.3109/09638288.2014.974834; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whiteneck G., 2006, WORKSH DIS AM NEW LO, P50; Whiteneck GG, 2010, ARCH PHYS MED REHAB, V91, pS54, DOI 10.1016/j.apmr.2009.08.154; Wolf TJ, 2012, BRAIN IMPAIR, V13, P16, DOI 10.1017/BrImp.2012.1; Wood JP, 2010, CLIN REHABIL, V24, P1045, DOI 10.1177/0269215510375901; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; Woodman P, 2014, DISABIL REHABIL, V36, P2031, DOI 10.3109/09638288.2014.887796; World Health Organization, 2013, US ICF PRACT MAN US; World Health Organization, 2001, INT CLASS FUNCT DIS; World Health Organization ( WHO ), 2002, COMM LANG FUNCT DIS; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; 2012, TOP STROKE REHABIL, V19, P457, DOI DOI 10.1310/TSR1906-457; 2010, NEUROLOGY, V75, P1597; 2015, ARCH PHYS MED REHAB, V96, P1684, DOI DOI 10.1016/J.APMR.2015.05.005; 2008, STROKE, V39, P148, DOI DOI 10.1161/STROKEAHA.107.491399	100	19	19	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2019	100	5					945	955		10.1016/j.apmr.2018.06.017			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HW3UV	WOS:000466619100019	29981316				2021-06-18	
J	Donvito, G; Piscitelli, F; Muldoon, P; Jackson, A; Vitale, RM; D'Aniello, E; Giordano, C; Ignatowska-Jankowska, BM; Mustafa, MA; Guida, F; Petrie, GN; Parker, L; Smoum, R; Sim-Selley, L; Maione, S; Lichtman, AH; Damaj, MI; Di Marzo, V; Mechoulam, R				Donvito, Giulia; Piscitelli, Fabiana; Muldoon, Pretal; Jackson, Asti; Vitale, Rosa Maria; D'Aniello, Enrico; Giordano, Catia; Ignatowska-Jankowska, Bogna M.; Mustafa, Mohammed A.; Guida, Francesca; Petrie, Gavin N.; Parker, Linda; Smoum, Reem; Sim-Selley, Laura; Maione, Sabatino; Lichtman, Aron H.; Damaj, M. Imad; Di Marzo, Vincenzo; Mechoulam, Raphael			N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice	NEUROPHARMACOLOGY			English	Article						N-oleoyl glycine; Nicotine withdrawal; Cannabinoid receptor-1 (CB1); Conditioned place preference (CPP); Insular cortex; Peroxisome proliferator-activated receptor alpha (PPAR-alpha)	INSULAR CORTEX; ACETYLCHOLINE-RECEPTOR; CANNABINOID RECEPTORS; MOLECULAR-DYNAMICS; DOPAMINE; ACID; ADDICTION; SMOKING; SEEKING; SYSTEM	Cigarette smokers with brain damage involving the insular cortex display cessation of tobacco smoking, suggesting that this region may contribute to nicotine addiction. In the present study, we speculated that molecules in the insular cortex that are sensitive to experimental traumatic brain injury (TBI) in mice might provide leads to ameliorate nicotine addiction. Using targeted lipidomics, we found that TBI elicited substantial increases of a largely uncharacterized lipid, N-acyl-glycine, N-oleoyl-glycine (OlGly), in the insular cortex of mice. We then evaluated whether intraperitoneal administration of OlGly would alter withdrawal responses in nicotine-dependent mice as well as the rewarding effects of nicotine, as assessed in the conditioned place preference paradigm (CPP). Systemic administration of OlGly reduced mecamylamine-precipitated withdrawal responses in nicotine-dependent mice and prevented nicotine CPP. However, OlGly did not affect morphine CPP, demonstrating a degree of selectivity. Our respective in vitro and in vivo observations that OlGly activated peroxisome proliferator-activated receptor alpha (PPAR-alpha) and the PPAR-alpha antagonist GW6471 prevented the OlGly-induced reduction of nicotine CPP in mice suggests that this lipid acts as a functional PPAR-alpha agonist to attenuate nicotine reward. These findings raise the possibility that the long chain fatty acid amide OlGly may possess efficacy in treating nicotine addiction. (C) 2018 Published by Elsevier Ltd.	[Donvito, Giulia; Muldoon, Pretal; Jackson, Asti; Ignatowska-Jankowska, Bogna M.; Mustafa, Mohammed A.; Sim-Selley, Laura; Lichtman, Aron H.; Damaj, M. Imad] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA USA; [Piscitelli, Fabiana; Vitale, Rosa Maria; D'Aniello, Enrico; Di Marzo, Vincenzo] CNR, Inst Biomol Chem, Endocannabinoid Res Grp, Via Campi Flegrei 34, I-80078 Naples, Italy; [Giordano, Catia; Guida, Francesca; Maione, Sabatino] Univ Naples 2, Pharmacol Sect, Dept Expt Med, Endocannabinoid Res Grp, Naples, Italy; [Petrie, Gavin N.; Parker, Linda] Univ Guelph, Dept Psychol, Guelph, ON, Canada; [Petrie, Gavin N.; Parker, Linda] Univ Guelph, Collaborat Neurosci Grad Program, Guelph, ON, Canada; [Smoum, Reem; Mechoulam, Raphael] Hebrew Univ Jerusalem, Fac Med, Inst Drug Res, Jerusalem, Israel; [D'Aniello, Enrico] Stn Zool Anton Dohrn, Dept Biol & Evolut Marine Organisms, Naples, Italy; [Lichtman, Aron H.] Virginia Commonwealth Univ, Dept Med Chem, Med Coll Virginia Campus, Richmond, VA USA	Di Marzo, V (corresponding author), CNR, Inst Biomol Chem, Endocannabinoid Res Grp, Via Campi Flegrei 34, I-80078 Naples, Italy.; Lichtman, AH; Damaj, MI (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, POB 980613,Kontos Med Sci Bldg, Richmond, VA 23298 USA.	alichtma@vcu.edu; m.damaj@vcuhealth.org; vdimarzo@icb.cnr.it	Vitale, Rosa Maria/AAY-1522-2020; Piscitelli, Fabiana/A-7100-2014; Ignatowska-Jankowska, Bogna/T-2021-2019; Di Marzo, Vincenzo/AAD-7742-2019; Ignatowska-Jankowska, Bogna/A-8767-2018	Vitale, Rosa Maria/0000-0001-9243-1307; Di Marzo, Vincenzo/0000-0002-1490-3070; Ignatowska-Jankowska, Bogna/0000-0002-8427-1128; Maione, Sabatino/0000-0003-3850-6704	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01DA009789, R01DA039942, P30DA033934, R01 DA032246, P50DA039841, T32DA007027]; VCU School of Pharmacy; NSERCNatural Sciences and Engineering Research Council of Canada (NSERC) [92056]; CIHRCanadian Institutes of Health Research (CIHR) [137122]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA032246, R01DA039942, T32DA007027, P30DA033934, P50DA039841] Funding Source: NIH RePORTER	This work was supported by NIH grants P01DA009789, R01DA039942, P30DA033934 (AHL); R01 DA032246 and P50DA039841 (MID), T32DA007027 (AJ), and startup funds from the VCU School of Pharmacy. NSERC (92056) and CIHR (137122) grants to LAP.	Abdolahi A, 2010, EUR J NEUROSCI, V31, P733, DOI 10.1111/j.1460-9568.2010.07114.x; Alajaji M, 2016, NEUROPHARMACOLOGY, V105, P308, DOI 10.1016/j.neuropharm.2016.01.032; Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008; Bisogno T, 2009, EUR J LIPID SCI TECH, V111, P53, DOI 10.1002/ejlt.200800233; Boger DL, 1998, P NATL ACAD SCI USA, V95, P4810, DOI 10.1073/pnas.95.9.4810; Bradshaw HB, 2009, VITAM HORM, V81, P191, DOI 10.1016/S0083-6729(09)81008-X; Burstein SH, 2011, J CELL BIOCHEM, V112, P3227, DOI 10.1002/jcb.23245; Castane A, 2005, PHARMACOL BIOCHEM BE, V81, P381, DOI 10.1016/j.pbb.2005.01.025; Castane A, 2002, NEUROPHARMACOLOGY, V43, P857, DOI 10.1016/S0028-3908(02)00118-1; Chaturvedi S, 2006, PROSTAG OTH LIPID M, V81, P136, DOI 10.1016/j.prostaglandins.2006.09.001; Chatzakos V, 2012, LIPIDS, V47, P355, DOI 10.1007/s11745-011-3639-9; Cohen A, 2015, ADDICT BIOL, V20, P56, DOI 10.1111/adb.12077; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; De Biasi M, 2011, ANNU REV NEUROSCI, V34, P105, DOI 10.1146/annurev-neuro-061010-113734; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Fedorova I, 2001, J PHARMACOL EXP THER, V299, P332; Forget B, 2010, BIOL PSYCHIAT, V68, P265, DOI 10.1016/j.biopsych.2010.01.029; Forget B, 2009, PSYCHOPHARMACOLOGY, V205, P613, DOI 10.1007/s00213-009-1569-5; Gamaleddin I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029900; Gamaleddin IH, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00041; Gotz AW, 2012, J CHEM THEORY COMPUT, V8, P1542, DOI 10.1021/ct200909j; Hassinen T, 2001, J COMPUT CHEM, V22, P1229, DOI 10.1002/jcc.1080; Heishman SJ, 2010, PSYCHOPHARMACOLOGY, V210, P453, DOI 10.1007/s00213-010-1848-1; Huitron-Resendiz S, 2004, SLEEP, V27, P857, DOI 10.1093/sleep/27.5.857; Ignatowska-Jankowska BM, 2015, NEUROPSYCHOPHARMACOL, V40, P2948, DOI 10.1038/npp.2015.148; Ignatowska-Jankowska BM, 2013, PSYCHOPHARMACOLOGY, V229, P591, DOI 10.1007/s00213-013-3117-6; Jackson A, 2017, NEUROPHARMACOLOGY, V118, P38, DOI 10.1016/j.neuropharm.2017.03.005; Jackson KJ, 2008, J PHARMACOL EXP THER, V325, P302, DOI 10.1124/jpet.107.132977; Jackson KJ, 2009, NEUROPHARMACOLOGY, V56, P970, DOI 10.1016/j.neuropharm.2009.01.023; Justinova Z, 2015, NEUROPSYCHOPHARMACOL, V40, P2185, DOI 10.1038/npp.2015.62; Kollman, 2014, AMBER 14; Kota D, 2007, J PHARMACOL EXP THER, V322, P399, DOI 10.1124/jpet.107.121616; Kutlu MG, 2013, BEHAV BRAIN RES, V256, P273, DOI 10.1016/j.bbr.2013.08.005; Le Foll B, 2004, NEUROREPORT, V15, P2139, DOI 10.1097/00001756-200409150-00028; LITTLE PJ, 1988, J PHARMACOL EXP THER, V247, P1046; MARTIN BR, 1991, PHARMACOL BIOCHEM BE, V40, P471, DOI 10.1016/0091-3057(91)90349-7; Mascia P, 2011, BIOL PSYCHIAT, V69, P633, DOI 10.1016/j.biopsych.2010.07.009; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Melis M, 2014, PHARMACOL RES, V86, P42, DOI 10.1016/j.phrs.2014.03.009; Melis M, 2013, J NEUROSCI, V33, P6203, DOI 10.1523/JNEUROSCI.4647-12.2013; Merritt LL, 2008, J PHARMACOL EXP THER, V326, P483, DOI 10.1124/jpet.108.138321; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926; Naqvi NH, 2014, ANN NY ACAD SCI, V1316, P53, DOI 10.1111/nyas.12415; Naqvi NH, 2010, BRAIN STRUCT FUNCT, V214, P435, DOI 10.1007/s00429-010-0268-7; Navarrete F, 2013, NEUROPSYCHOPHARMACOL, V38, P2515, DOI 10.1038/npp.2013.157; Ortar G, 2007, J MED CHEM, V50, P6554, DOI 10.1021/jm070678q; Panlilio LV, 2012, NEUROPSYCHOPHARMACOL, V37, P1838, DOI 10.1038/npp.2012.31; Perkins KA, 2016, NICOTINE TOB RES, V18, P74, DOI 10.1093/ntr/ntv085; Piscitelli F, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-51; Pushparaj A, 2015, BEHAV BRAIN RES, V290, P77, DOI 10.1016/j.bbr.2015.04.039; Pushparaj A, 2013, NEUROPSYCHOPHARMACOL, V38, P690, DOI 10.1038/npp.2012.235; Robinson JD, 2018, ADDICT BIOL, V23, P291, DOI 10.1111/adb.12508; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Scheggi S, 2016, NEUROPHARMACOLOGY, V110, P251, DOI 10.1016/j.neuropharm.2016.07.024; Simonnet A, 2013, ADDICT BIOL, V18, P930, DOI 10.1111/j.1369-1600.2012.00476.x; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Valjent E, 2002, BRIT J PHARMACOL, V135, P564, DOI 10.1038/sj.bjp.0704479; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wang SB, 2015, BIOCHEM BIOPH RES CO, V466, P438, DOI 10.1016/j.bbrc.2015.09.046; Watkins S S, 2000, Nicotine Tob Res, V2, P19; Wiley JL, 2003, EUR J PHARMACOL, V471, P185, DOI 10.1016/S0014-2999(03)01856-9	64	19	19	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2019	148						320	331		10.1016/j.neuropharm.2018.03.020			12	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	HR4OE	WOS:000463125000031	29567093	Green Accepted			2021-06-18	
J	Cardoso, MGD; Faleiro, RM; de Paula, JJ; Kummer, A; Caramelli, P; Teixeira, AL; de Souza, LC; Miranda, AS; Silva, AP; Campos, ABB; Costa, CC; Antonio, CP; Loures, DLEM; Ponte, EF; Guarconi, FV; Barbosa, GRM; Miranda, INS; Queiroz, JC; Salomao, LG; Oliveira, MD; Nassif, MCL; Valadao, MB; Moura, MVB; Rodrigues, OF; Leal, PIL; Diamantino, TC; Araujo, LS; Furlan, TD; da Silva, EWM; Roque, IG; da Silva, AN				de Freitas Cardoso, Maira Gloria; Faleiro, Rodrigo Moreira; de Paula, Jonas Jardim; Kummer, Arthur; Caramelli, Paulo; Teixeira, Antonio Lucio; de Souza, Leonardo Cruz; Miranda, Aline Silva; Silva, Ananda Peixoto; Bacilar Campos, Antonio Bernardes; Costa, Camila Carvalhais; Antonio, Christian Pereira; Lanna e Melo Loures, Daniela; Ponte, Eduarda Felix; Guarconi, Felipe Vieira; Mansur Barbosa, Guilherme Ribeiro; Santos Miranda, Ilanna Naoli; Queiroz, Jordana Campos; Salomao, Leonardo Gomes; Oliveira, Monteiro de Souza; Landim Nassif, Maria Cecilia; Valadao, Mariana Braga; Brandao Moura, Millena Vieira; Rodrigues, Otavio Fonseca; Lodde Leal, Pedro Ilenrique; Diamantino, Tatiana Costa; Araujo, Leticia Siqueira; Furlan, Thiago de Oliveira; Machado da Silva, Ewelin Wasner; Roque, Isadora Goncalves; da Silva, Alessandra Noronha		Minas Gerais Traumatic Brain Injur	Cognitive Impairment Following Acute Mild Traumatic Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; cognitive impairment; loss of consciousness; Brazilian patients; episodic memory	MINI-MENTAL-STATE; NEUROPSYCHOLOGICAL OUTCOMES; CONSCIOUSNESS; ASSOCIATION; CONCUSSION; SYMPTOMS; HISTORY; RESERVE; STRESS	Patients with mild traumatic brain injury (mTBI) may present cognitive deficits within the first 24 h after trauma, herein called "acute phase," which in turn may lead to long-term functional impairment and decrease in quality of life. Few studies investigated cognition in mTBI patients during the acute phase. The objectives of this study were to investigate the cognitive profile of patients with mTBI during the acute phase, compared to controls and normative data, and whether loss of consciousness (LOC), previous TBI and level of education influence cognition at this stage. Fifty-three patients with mTBI (aged 19-64 years) and 28 healthy controls participated in the study. All patients were evaluated at bedside within 24 h post-injury. Demographic and clinical data were registered. Cognitive function was assessed with the Mini-mental state examination (MMSE), the Frontal Assessment Battery (FAB), Digit Span (working memory), and the Visual Memory Test/Brief Cognitive Battery (for episodic memory). The clinical sample was composed mainly by men (58.5%). The mean age was 39 years-old and 64.3% of the patients had more than 8 years of education. The most common causes of mTBI were fall from own height (28.3%), aggression (24.5%), and fall from variable heights (24.5%). Compared to controls, mTBI patients exhibited significantly worse performance on MMSE, FAB, naming, incidental memory, immediate memory, learning, and delayed recall. Compared to normative data, 26.4% of patients had reduced global cognition as measured by the MMSE. Episodic memory impairment (13.2%) was more frequent than executive dysfunction (9.4%). No significant differences were found in cognitive performance when comparing patients with or without LOC or those with or without history of previous TBI. Patients with lower educational level had higher rates of cognitive impairment (VMT naming-28.6 vs. 4.2%; VMT immediate memory-32 vs. 4.2%; VMT learning-39.3 vs. 4.2%, all p < 0.05). In sum, we found significant cognitive impairment in the acute phase of mTBI, which was not associated with LOC or history of TBI, but appeared more frequently in patients with lower educational level.	[de Freitas Cardoso, Maira Gloria] Univ Fed Minas Gerais, Lab Interdisciplinar Invest Med, Neurosci Program, Belo Horizonte, MG, Brazil; [Faleiro, Rodrigo Moreira] Fundacao Hosp Estado Minas Gerais, Fac Ciencias Med Minas Gerais, Belo Horizonte, MG, Brazil; [de Paula, Jonas Jardim] Fac Ciencias Med Minas Gerais, Belo Horizonte, MG, Brazil; [Kummer, Arthur] Eli Lilly & Co Brasil, Lab Interdisciplinar Invest Med, Sao Paulo, Brazil; [Caramelli, Paulo] Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Belo Horizonte, MG, Brazil; [Teixeira, Antonio Lucio] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Psychiat & Behav Sci, Santa Casa BH Ensino & Pesquisa Neuropsychiat Pro, Houston, TX 77030 USA; [de Souza, Leonardo Cruz] Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Lab Interdisciplinar Invest Med, Belo Horizonte, MG, Brazil; [Miranda, Aline Silva] Univ Fed Minas Gerais, Fac Med, Lab Interdisciplinar Invest Med, Belo Horizonte, MG, Brazil; [Miranda, Aline Silva] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, Lab Neurobiol, Belo Horizonte, MG, Brazil	Miranda, AS (corresponding author), Univ Fed Minas Gerais, Fac Med, Lab Interdisciplinar Invest Med, Belo Horizonte, MG, Brazil.; Miranda, AS (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, Lab Neurobiol, Belo Horizonte, MG, Brazil.	mirandas.aline@gmail.com	CARAMELLI, PAULO/H-9735-2012; de Paula, Jonas J/I-8066-2012; Kummer, Arthur/AAU-3317-2020; de Souza, Leonardo C/C-1833-2016	CARAMELLI, PAULO/0000-0002-4786-6990; de Souza, Leonardo C/0000-0001-5027-9722	Brain & Behavior Research FoundationNARSAD [25414]; FAPEMIGFundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	This work was supported by the 2016 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (grant number 25414), and FAPEMIG to ASM. LCS is supported by CNPq and MGFC is supported by CAPES.	Barker-Collo S, 2015, BRAIN INJURY, V29, P1604, DOI 10.3109/02699052.2015.1075143; Beato Rogério Gomes, 2007, Dement. neuropsychol., V1, P59, DOI 10.1590/S1980-57642008DN10100010; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014; Castro Stephanie, 2009, Dement. neuropsychol., V3, P327, DOI 10.1590/S1980-57642009DN30400011; Cho YE, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00168; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; Dall'Acqua P, 2017, J NEUROTRAUM, V34, P3270, DOI 10.1089/neu.2017.5124; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Figueiredo Vera L. M. de, 2007, Psic.: Teor. e Pesq., V23, P313, DOI 10.1590/S0102-37722007000300010; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fonseca Rochele Paz, 2012, Psychol. Neurosci., V5, P183, DOI 10.3922/j.psns.2012.2.08; Gardner AJ, 2016, HAND CLINIC, V138, P207, DOI 10.1016/B978-0-12-802973-2.00012-4; Gauthier S, 2018, J COMMUN DISORD, V73, P77, DOI 10.1016/j.jcomdis.2018.04.003; De la Blanca MAIP, 2018, BRAIN INJURY, V32, P99, DOI 10.1080/02699052.2017.1382716; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Larrabee GJ, 2013, BEHAV SCI LAW, V31, P686, DOI 10.1002/bsl.2087; Leary JB, 2018, J HEAD TRAUMA REHAB, V33, pE28, DOI 10.1097/HTR.0000000000000329; MagalhAes A LG, 2017, REV BRAS NEUROL, V53, P15; Massey JS, 2015, NEUROPSYCHOLOGY, V29, P530, DOI 10.1037/neu0000192; Mathias JL, 2015, NEUROSCI BIOBEHAV R, V55, P573, DOI 10.1016/j.neubiorev.2015.06.001; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Mortensen L, 2006, LANG COGNITIVE PROC, V21, P238, DOI 10.1080/01690960444000278; Nelson LD, 2018, J NEUROTRAUM, V35, P249, DOI 10.1089/neu.2017.4988; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; NITRINI R, 1994, ARQ NEURO-PSIQUIAT, V52, P457, DOI 10.1590/S0004-282X1994000400001; Norris JN, 2014, BRAIN INJURY, V28, P1052, DOI 10.3109/02699052.2014.891761; Oldenburg C, 2016, BRAIN INJURY, V30, P146, DOI 10.3109/02699052.2015.1089598; Paolieri D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191656; Pereira N., 2016, ACTA COLOMB PSICOL, V19, DOI [https://doi.org/10.14718/ACP.2016.19.2.6, DOI 10.14718/ACP.2016.19.2.6]; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rojas N, 2019, APPL NEUROPSYCH-ADUL, V26, P319, DOI 10.1080/23279095.2017.1422506; de Almeida CER, 2016, WORLD NEUROSURG, V87, P540, DOI 10.1016/j.wneu.2015.10.020; Sivak S, 2014, BRAIN INJURY, V28, P341, DOI 10.3109/02699052.2013.865270; Sofko CA, 2016, BRAIN INJURY, V30, P1561, DOI 10.1080/02699052.2016.1199897; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Stein MB, 2016, J NEUROTRAUM, V33, P2125, DOI 10.1089/neu.2015.4320; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; TEASDALE G, 1974, LANCET, V2, P81; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; Van Patten R, 2016, J CLIN EXP NEUROPSYC, V38, P12, DOI 10.1080/13803395.2015.1091064; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; Yue JK, 2017, J CLIN NEUROSCI, V45, P293, DOI 10.1016/j.jocn.2017.07.022	50	19	19	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	MAR 8	2019	10								198	10.3389/fneur.2019.00198			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	HO3FN	WOS:000460805200001	30906278	DOAJ Gold, Green Published			2021-06-18	
J	Shandra, O; Winemiller, AR; Heithoff, BP; Munoz-Ballester, C; George, KK; Benko, MJ; Zuidhoek, IA; Besser, MN; Curley, DE; Edwards, GF; Mey, A; Harrington, AN; Kitchen, JP; Robel, S				Shandra, Oleksii; Winemiller, Alexander R.; Heithoff, Benjamin P.; Munoz-Ballester, Carmen; George, Kijana K.; Benko, Michael J.; Zuidhoek, Ivan A.; Besser, Michelle N.; Curley, Dallece E.; Edwards, G. Franklin, III; Mey, Anroux; Harrington, Alexys N.; Kitchen, Jeremy P.; Robel, Stefanie			Repetitive Diffuse Mild Traumatic Brain Injury Causes an Atypical Astrocyte Response and Spontaneous Recurrent Seizures	JOURNAL OF NEUROSCIENCE			English	Article						astrogliosis; concussion; diffuse TBI; gap junctions; neuroinflammation; posttraumatic epilepsy	POSTTRAUMATIC EPILEPSY; REACTIVE ASTROCYTES; SCAR FORMATION; ANIMAL-MODELS; HEAD-INJURY; IN-VITRO; POPULATION; GLIA; DEFICITS; RISK	Focal traumatic brain injury (TBI) induces astrogliosis, a process essential to protecting uninjured brain areas from secondary damage. However, astrogliosis can cause loss of astrocyte homeostatic functions and possibly contributes to comorbidities such as posttraumatic epilepsy (PTE). Scar-forming astrocytes seal focal injuries off from healthy brain tissue. It is these glial scars that are associated with epilepsy originating in the cerebral cortex and hippocampus. However, the vast majority of human TBIs also present with diffuse brain injury caused by acceleration-deceleration forces leading to tissue shearing. The resulting diffuse tissue damage may be intrinsically different from focal lesions that would trigger glial scar formation. Here, we used mice of both sexes in a model of repetitive mild/concussive closed-head TBI, which only induced diffuse injury, to test the hypothesis that astrocytes respond uniquely to diffuse TBI and that diffuse TBI is sufficient to cause PTE. Astrocytes did not form scars and classic astrogliosis characterized by upregulation of glial fibrillary acidic protein was limited. Surprisingly, an unrelated population of atypical reactive astrocytes was characterized by the lack of glial fibrillary acidic protein expression, rapid and sustained downregulation of homeostatic proteins and impaired astrocyte coupling. After a latency period, a subset of mice developed spontaneous recurrent seizures reminiscent of PTE in human TBI patients. Seizing m ice had larger areas of atypical astrocytes compared with nonseizing mice, suggesting that these atypical astrocytes might contribute to epileptogenesis after diffuse TBI.	[Shandra, Oleksii; Winemiller, Alexander R.; Heithoff, Benjamin P.; Munoz-Ballester, Carmen; George, Kijana K.; Benko, Michael J.; Zuidhoek, Ivan A.; Besser, Michelle N.; Curley, Dallece E.; Edwards, G. Franklin, III; Mey, Anroux; Harrington, Alexys N.; Kitchen, Jeremy P.; Robel, Stefanie] Virginia Tech Caril, Fralin Biomed Res Inst, Roanoke, VA 24016 USA; [Heithoff, Benjamin P.; Robel, Stefanie] Virginia Tech, Dept Biol Sci, Blacksburg, VA 24060 USA; [Curley, Dallece E.; Edwards, G. Franklin, III; Mey, Anroux; Robel, Stefanie] Virginia Tech, Sch Neurosci, Blacksburg, VA 24060 USA; [George, Kijana K.; Zuidhoek, Ivan A.; Edwards, G. Franklin, III; Kitchen, Jeremy P.] Virginia Tech, Grad Program Translat Biol Med & Hlth, Roanoke, VA 24016 USA; [Benko, Michael J.] VTCSOM Caril Clin, Dept Neurosurg, Blacksburg, VA 24014 USA	Robel, S (corresponding author), Virginia Tech Caril, Fralin Biomed Res Inst, Roanoke, VA 24016 USA.; Robel, S (corresponding author), Virginia Tech, Dept Biol Sci, Blacksburg, VA 24060 USA.; Robel, S (corresponding author), Virginia Tech, Sch Neurosci, Blacksburg, VA 24060 USA.	srobel@vt.edu	Shandra, Oleksii/AAD-2622-2020; Robel, Stefanie/AAA-7166-2019	Shandra, Oleksii/0000-0003-4447-3312; Munoz-Ballester, Carmen/0000-0002-2298-7753	National Institute of Neurological Disorders and Stroke at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS105807, R21NS107941]; Institute for Critical Technology and Applied Science (ICTAS) at Virginia Tech; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS105807, R21NS107941] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke at the National Institutes of Health (Grants R01NS105807 and R21NS107941) and the Institute for Critical Technology and Applied Science (ICTAS) at Virginia Tech. Wethank Kelly McKay and John-Paul O'Shea for assistance with brain tissue processing and Western blot analysis and Katherine E. Horwath for assistance with area quantification.	Abou-Abbass H, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005342; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Anderson MA, 2014, NEUROSCI LETT, V565, P23, DOI 10.1016/j.neulet.2013.12.030; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bedner P, 2015, BRAIN, V138, P1208, DOI 10.1093/brain/awv067; Bouchat J, 2018, GLIA, V66, P606, DOI 10.1002/glia.23268; Buckingham SC, 2011, NAT MED, V17, P1269, DOI 10.1038/nm.2453; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Christensen J, 2012, EPILEPSIA, V53, P43, DOI 10.1111/j.1528-1167.2012.03612.x; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Condamine S, 2018, JOVE-J VIS EXP, DOI 10.3791/58116; DERMIETZEL R, 1991, J NEUROSCI, V11, P1421; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Foresti ML, 2011, BRAIN RES REV, V66, P115, DOI 10.1016/j.brainresrev.2010.09.002; Freeman MR, 2010, SCIENCE, V330, P774, DOI 10.1126/science.1190928; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gee JM, 2014, NEURON, V83, P1058, DOI 10.1016/j.neuron.2014.07.024; Glushakov AV, 2016, METHODS MOL BIOL, V1462, P481, DOI 10.1007/978-1-4939-3816-2_27; Gotz M, 2015, GLIA, V63, P1452, DOI 10.1002/glia.22850; Griemsmann S, 2015, CEREB CORTEX, V25, P3420, DOI 10.1093/cercor/bhu157; Grosche A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069143; Gusel'nikova VV, 2015, ACTA NATURAE, V7, P42, DOI 10.32607/20758251-2015-7-2-42-47; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Jany PL, 2013, ASN NEURO, V5, P81, DOI 10.1042/AN20130003; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Komar AA, 2011, CELL CYCLE, V10, P229, DOI 10.4161/cc.10.2.14472; KONIETZKO U, 1994, HIPPOCAMPUS, V4, P297, DOI 10.1002/hipo.450040313; Kumar R, 2003, AM J NEURORADIOL, V24, P218; Levine J, 2016, GLIA, V64, P668, DOI 10.1002/glia.22953; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lioy DT, 2011, NATURE, V475, P497, DOI 10.1038/nature10214; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Mader EC, 2012, CLIN MED INSIGHT-CAS, V5, P99, DOI 10.4137/CCRep.S9861; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou Christina R., 2009, P393, DOI 10.1007/978-1-60327-185-1_34; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Neshige S, 2015, J NEUROL SCI, V359, P318, DOI 10.1016/j.jns.2015.09.358; Nichols JN, 2016, BEHAV BRAIN RES, V298, P111, DOI 10.1016/j.bbr.2015.10.052; NIQUET J, 1994, J NEUROCYTOL, V23, P641, DOI 10.1007/BF01191558; Olsen ML, 2008, J NEUROCHEM, V107, P589, DOI 10.1111/j.1471-4159.2008.05615.x; Ortinski PI, 2010, NAT NEUROSCI, V13, P584, DOI 10.1038/nn.2535; Ostergard T, 2016, J NEUROSCI METH, V272, P50, DOI 10.1016/j.jneumeth.2016.03.023; Pannasch U, 2013, TRENDS NEUROSCI, V36, P405, DOI 10.1016/j.tins.2013.04.004; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; POLLEN D A, 1970, Science (Washington D C), V167, P1252, DOI 10.1126/science.167.3922.1252; Reyes RC, 2012, ASN NEURO, V4, P33, DOI 10.1042/AN20110059; Robel S, 2017, NEUROSCIENTIST, V23, P152, DOI 10.1177/1073858416645498; Robel S, 2016, NAT NEUROSCI, V19, P28, DOI 10.1038/nn.4184; Robel S, 2015, J NEUROSCI, V35, P3330, DOI 10.1523/JNEUROSCI.1574-14.2015; Robel S, 2011, J NEUROSCI, V31, P12471, DOI 10.1523/JNEUROSCI.2696-11.2011; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Robert SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8103; Samoilova M, 2008, EXP NEUROL, V210, P762, DOI 10.1016/j.expneurol.2008.01.005; Seifert G, 2010, BRAIN RES REV, V63, P212, DOI 10.1016/j.brainresrev.2009.10.004; Shandra O, 2019, METHODS MOL BIOL, V1938, P233, DOI 10.1007/978-1-4939-9068-9_16; Shandra O, 2017, ADV PROTEIN CHEM STR, V108, P59, DOI 10.1016/bs.apcsb.2017.01.005; Simon C, 2011, GLIA, V59, P869, DOI 10.1002/glia.21156; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020420; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Steinhauser C, 2012, GLIA, V60, P1192, DOI 10.1002/glia.22313; Tong XP, 2014, NAT NEUROSCI, V17, P694, DOI 10.1038/nn.3691; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; Wallraff A, 2006, J NEUROSCI, V26, P5438, DOI 10.1523/JNEUROSCI.0037-06.2006; Wennberg R, 2018, CAN J NEUROL SCI, V45, P275, DOI 10.1017/cjn.2017.300; Wetherington J, 2008, NEURON, V58, P168, DOI 10.1016/j.neuron.2008.04.002; Ye ZC, 1998, PROG BRAIN RES, V118, P241; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang Y, 2010, CURR OPIN NEUROBIOL, V20, P588, DOI 10.1016/j.conb.2010.06.005; Zhang ZH, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.03.35; Zhao MR, 2007, EPILEPSIA, V48, P2059, DOI 10.1111/j.1528-1167.2007.01229.x; Zhao YQ, 2012, SEIZURE-EUR J EPILEP, V21, P322, DOI 10.1016/j.seizure.2012.02.007	81	19	19	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	MAR 6	2019	39	10					1944	1963		10.1523/JNEUROSCI.1067-18.2018			20	Neurosciences	Neurosciences & Neurology	HN7WJ	WOS:000460403400015	30665946	Bronze, Green Published			2021-06-18	
J	Caccese, JB; DeWolf, RM; Kaminski, TW; Broglio, SP; McAllister, TW; McCrea, M; Buckley, TA; Hoy, AM; Hazzard, JB; Kelly, LA; Ortega, JD; Port, N; Putukian, M; Langford, TD; Benjamin, HJ; Clugston, JR; Schmidt, JD; Feigenbaum, LA; Eckner, JT; Mihalik, JP; Miles, JD; Anderson, S; Master, CL; Collins, M; Kontos, AP; Chrisman, SPO; Brooks, A; Jackson, J; McGinty, G; Cameron, K; Susmarski, A; Duma, S; Rowson, S; Miles, CM; Dykhuizen, BH; Lintner, L				Caccese, Jaclyn B.; DeWolf, Ryan M.; Kaminski, Thomas W.; Broglio, Steven P.; McAllister, Thomas W.; McCrea, Michael; Buckley, Thomas A.; Hoy, April Marie (Reed); Hazzard, Joseph B., Jr.; Kelly, Louise A.; Ortega, Justus D.; Port, Nicholas; Putukian, Margot; Langford, T. Dianne; Benjamin, Holly J.; Clugston, James R.; Schmidt, Julianne D.; Feigenbaum, Luis A.; Eckner, James T.; Mihalik, Jason P.; Miles, Jessica Dysart; Anderson, Scott; Master, Christina L.; Collins, Micky; Kontos, Anthony P.; Chrisman, Sara P. O.; Brooks, Alison; Jackson, Jonathan; McGinty, Gerald; Cameron, Kenneth; Susmarski, Adam; Duma, Stefan; Rowson, Steve; Miles, Christopher M.; Dykhuizen, Brian H.; Lintner, Laura		CARE Consortium Investigators	Estimated Age of First Exposure to American Football and Neurocognitive Performance Amongst NCAA Male Student-Athletes: A Cohort Study	SPORTS MEDICINE			English	Article							TEST-RETEST RELIABILITY; HEAD IMPACT EXPOSURE; HIGH-SCHOOL FOOTBALL; POST-CONCUSSION ASSESSMENT; LIFE COGNITIVE IMPAIRMENT; CONSTRUCT-VALIDITY; ONLINE VERSION; HUMAN-BRAIN; COLLEGIATE; SENSITIVITY	Background Repetitive head impacts in young athletes are potentially detrimental to later life (e.g., age 50+ years) neurological function; however, it is unknown what the short-term effects (e.g., age 20 years) are in collegiate student-athletes. Objective The purpose of this study was to determine the effect of the estimated age of first exposure to American tackle football participation on neurocognitive performance and symptom severity scores in collegiate student-athletes. Methods We used a cohort study in which neurocognitive performance was assessed using the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) test in 4376 male athletes (age 19.3 +/- 1.5 years, mass 96.3 +/- 20.3 kg, height 185.0 +/- 7.4 cm). Athletes were grouped by sport participation [American football (n = 3462) or non-contact (n = 914)] and estimated age of first exposure [< 12 years (n= 3022) or >= 12 years (n = 1354)]. The outcome measures were the four primary cognitive scores and the symptom severity score from ImPACT. We assessed primary outcomes across groups, controlling for age, learning accommodations, and concussion history. Results Neurocognitive performance was not associated with the estimated age of first exposure-by-group interaction. Conclusion Our findings indicate that participation in American tackle football before age 12 years does not result in neurocognitive deficits in college. Therefore, we suggest the following: the consequences of early exposure to repetitive head impacts do not manifest by college, the ImPACT test was not sensitive enough to identify the effects of an earlier estimated age of first exposure, or there is no association between an earlier estimated age of first exposure and neurocognitive functioning. Future longitudinal studies are warranted.	[Caccese, Jaclyn B.; Kaminski, Thomas W.; Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, 349 Tower STAR,100 Discovery Blvd, Newark, DE 19713 USA; [DeWolf, Ryan M.] Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02114 USA; [Kaminski, Thomas W.; Buckley, Thomas A.] Univ Delaware, Biomech & Movement Sci Interdisciplinary Program, Newark, DE USA; [Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Injury Ctr, Ann Arbor, MI 48109 USA; [Buckley, Thomas A.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg & Neurol, Milwaukee, WI 53226 USA; [Hoy, April Marie (Reed)] Azusa Pacific Univ, Azusa, CA USA; [Hazzard, Joseph B., Jr.] Bloomsburg Univ, Bloomsburg, PA USA; [Kelly, Louise A.] Calif Lutheran Univ, Thousand Oaks, CA USA; [Ortega, Justus D.] Humboldt State Univ, Arcata, CA USA; [Port, Nicholas] Indiana Univ, Bloomington, IN 47405 USA; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Langford, T. Dianne] Temple Univ, Philadelphia, PA 19122 USA; [Benjamin, Holly J.] Univ Chicago, Chicago, IL 60637 USA; [Clugston, James R.] Univ Florida, Gainesville, FL 32611 USA; [Schmidt, Julianne D.] Univ Georgia, Athens, GA 30602 USA; [Feigenbaum, Luis A.] Univ Miami, Coral Gables, FL 33124 USA; [Clugston, James R.] Univ Michigan, Ann Arbor, MI 48109 USA; [Mihalik, Jason P.] Univ N Carolina, Chapel Hill, NC 27515 USA; [Miles, Jessica Dysart] Univ North Georgia, Dahlonega, GA USA; [Anderson, Scott] Univ Oklahoma, Norman, OK 73019 USA; [Master, Christina L.] Univ Penn, Philadelphia, PA 19104 USA; [Collins, Micky; Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; [Chrisman, Sara P. O.] Univ Washington, Seattle, WA 98195 USA; [Brooks, Alison] Univ Wisconsin, Madison, WI 53706 USA; [Jackson, Jonathan; McGinty, Gerald] US Air Force Acad, Colorado Springs, CO 80840 USA; [Susmarski, Adam] US Naval Acad, Annapolis, MD 21402 USA; [Duma, Stefan; Rowson, Steve] Virginia Tech, Blacksburg, VA USA; [Miles, Christopher M.] Wake Forest Univ, Winston Salem, NC 27109 USA; [Dykhuizen, Brian H.] Wilmington Coll, Wilmington, OH USA; [Lintner, Laura] Winston Salem Univ, Winston Salem, NC USA	Caccese, JB (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, 349 Tower STAR,100 Discovery Blvd, Newark, DE 19713 USA.	tbuckley@udel.edu	Buckley, Thomas A/B-7525-2016; Rowson, Steven/B-1270-2012; Caccese, Jaclyn B./AAH-4571-2020	Buckley, Thomas A/0000-0002-0515-0150; Rowson, Steven/0000-0002-3227-0596; Caccese, Jaclyn B./0000-0003-2329-3603; Clugston, James/0000-0002-2103-1039; Master, Christina/0000-0002-6717-4270; Susmarski, Adam/0000-0003-3698-4163; Cameron, Kenneth/0000-0002-6276-4482; Chrisman, Sara/0000-0001-5373-7223; Ortega, Justus/0000-0002-9931-5605	Grand Alliance CARE Consortium - National Collegiate Athletic Association; Department of Defence; United States Army Medical Research Acquisition Activity, Ford Detrick, MD, USA; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	This publication was made possible, in part, with support from the Grand Alliance CARE Consortium, funded by the National Collegiate Athletic Association and the Department of Defence. The United States Army Medical Research Acquisition Activity, Ford Detrick, MD, USA is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award No. W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense (Defense Health Program funds).	Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; Alosco ML, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.197; Alosco ML, 2018, ANN NEUROL, V83, P886, DOI 10.1002/ana.25245; Alsalaheen B, 2016, SPORTS MED, V46, P1487, DOI 10.1007/s40279-016-0532-y; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Belanger HG, 2016, J HEAD TRAUMA REHAB, V31, P159, DOI 10.1097/HTR.0000000000000138; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2018, J NEUROTRAUM, V35, P2776, DOI 10.1089/neu.2018.5643; Broglio SP, 2018, SPORTS MED, V48, P1255, DOI 10.1007/s40279-017-0813-0; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Buckley TA, 2015, J ATHL TRAINING, V50, P879, DOI 10.4085/1062-6050-50.7.04; Caccese JB, 2016, INTERNATIONAL RESEARCH IN SCIENCE AND SOCCER II, P133; Caccese JB, 2016, RES SPORTS MED, V24, P407, DOI 10.1080/15438627.2016.1230549; Caccese JB, 2016, SPORTS MED, V46, P1591, DOI 10.1007/s40279-016-0544-7; Catenaccio E, 2016, RES SPORTS MED, V24, P416, DOI 10.1080/15438627.2016.1234472; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Epstein HT, 1999, BRAIN DEV-JPN, V21, P535, DOI 10.1016/S0387-7604(99)00066-2; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Erlanger DM, 2015, BRAIN INJURY, V29, P171, DOI 10.3109/02699052.2014.965211; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Houck Z, 2018, J INT NEUROPSYCH SOC, V24, P1, DOI 10.1017/S1355617717000716; Iverson G.L., 2003, IMMEDIATE POSTCONCUS; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Janssen PHH, 2017, MAYO CLIN PROC, V92, P66, DOI 10.1016/j.mayocp.2016.09.004; Katz BP, 2018, SPORTS MED, V48, P1971, DOI 10.1007/s40279-018-0875-7; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; Kuhn AW, 2017, SPORTS HEALTH, V9, P30, DOI 10.1177/1941738116674006; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lehman EJ, 2016, AM J SPORT MED, V44, P2486, DOI 10.1177/0363546516645093; Lovell M, 2007, IMPACT 2007 6 0 CLIN; Maerlender A, 2013, CLIN NEUROPSYCHOL, V27, P290, DOI 10.1080/13854046.2012.744098; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Maroon JC, 2015, NEUROLOGY, V85, P1007, DOI 10.1212/WNL.0000000000001942; Martini DN, 2018, INT J PSYCHOPHYSIOL, V132, P25, DOI 10.1016/j.ijpsycho.2017.09.019; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schultz V, 2018, J NEUROTRAUM, V35, P278, DOI 10.1089/neu.2017.5145; Shaw P, 2006, NATURE, V440, P676, DOI 10.1038/nature04513; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Solomon GS, 2016, AM J SPORT MED, V44, P1106, DOI 10.1177/0363546515626164; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stone A. A., 1999, SCI SELF REPORT IMPL; Taylor KM, 2018, AM J SPORT MED, V46, P3262, DOI 10.1177/0363546518798801; Trudeau F, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-10; Uematsu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046970; Zeigler DW, 2005, PREV MED, V40, P23, DOI 10.1016/j.ypmed.2004.04.044	69	19	19	0	5	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	MAR	2019	49	3					477	487		10.1007/s40279-019-01069-x			11	Sport Sciences	Sport Sciences	HQ6FA	WOS:000462506700010	30747378				2021-06-18	
J	Li, YJ; Wang, L; Zhang, B; Gao, F; Yang, CM				Li, Ya-jun; Wang, Lin; Zhang, Bei; Gao, Fei; Yang, Chun-Mei			Glycyrrhizin, an HMGB1 inhibitor, exhibits neuroprotective effects in rats after lithium-pilocarpine-induced status epilepticus	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article						high mobility group box 1; blood brain barrier; status epilepticus; glycyrrhizin; inflammation	MOBILITY GROUP BOX-1; BLOOD-BRAIN-BARRIER; ACUTE LIVER-INJURY; INTRACEREBRAL HEMORRHAGE; CHROMATIN PROTEIN; RECEPTOR 4; IN-VITRO; ACID; EPILEPSY; ANTIBODY	Objectives It has been proven that extracellular HMGB1 is involved in progression of neurologic disorders, such as stroke, traumatic brain injury, meningitis and epilepsy. Glycyrrhizin (GL) is a direct inhibitor of HMGB1, and blocks HMGB1 release into the extracellular. We aim in this study to investigate the neuroprotective effects of GL in a rat model after lithium-pilocarpine-induced status epilepticus (SE). Methods Adult male SD rats were divided into three groups: Sham group, SE-group and (SE + GL)-treated group. The HMGB1 expression in serum and hippocampus, the damage extent of blood brain barrier (BBB) and hippocampal neuronal damage were evaluated by enzyme-linked immunosorbent assay, immunohistochemistry, western blot and nissl's staining. Key findings Glycyrrhizin markedly reduced HMGB1 expression in serum and hippocampus, prevented HMGB1 translocation from nucleus to cytoplasm in hippocampal CA1, CA3 and hilus areas of SE rats. Meanwhile, GL significantly ameliorated neuronal damage in the CA1, CA3 and hilus areas of hippocampus, and protected BBB disruption after SE. The administration of GL significantly decreased the mortality from 25 to 8.9% in rats. Conclusions Glycyrrhizin may exert neuroprotective effects via inhibiting HMGB1 and protect BBB permeability in lithium-pilocarpine-induced rats with SE.	[Li, Ya-jun; Wang, Lin; Zhang, Bei; Gao, Fei; Yang, Chun-Mei] Xian Med Univ, Affiliated Hosp 1, Dept Neurol, 48 West Fenghao Rd, Xian 710077, Shaanxi, Peoples R China	Li, YJ (corresponding author), Xian Med Univ, Affiliated Hosp 1, Dept Neurol, 48 West Fenghao Rd, Xian 710077, Shaanxi, Peoples R China.	liyajun9@hotmail.com		Li, Ya-jun/0000-0002-0716-5823	Shaanxi province science and technology research and development program [2014SF2-17]	This work was supported by grants from Shaanxi province science and technology research and development program (No. 2014SF2-17). We thank Qiang Luo, Bin Sun for their technical assistance and Dr. Austin Cape for careful reading and feedback.	Ashfaq UA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-112; Asl MN, 2008, PHYTOTHER RES, V22, P709, DOI 10.1002/ptr.2362; Choi J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-135; Costa-Ferro ZSM, 2010, SEIZURE-EUR J EPILEP, V19, P84, DOI 10.1016/j.seizure.2009.12.003; Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019; Faraco G, 2007, J NEUROCHEM, V103, P590, DOI 10.1111/j.1471-4159.2007.04788.x; Fink MP, 2014, CRIT CARE, V18, DOI 10.1186/cc13810; Gong G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089450; Haleagrahara N, 2011, INT J MOL SCI, V12, P7100, DOI 10.3390/ijms12107100; Hayakawa K, 2012, P NATL ACAD SCI USA, V109, P7505, DOI 10.1073/pnas.1121146109; Isbrucker RA, 2006, REGUL TOXICOL PHARM, V46, P167, DOI 10.1016/j.yrtph.2006.06.002; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kim HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104743; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Kwan P, 2011, NEW ENGL J MED, V365, P919, DOI 10.1056/NEJMra1004418; Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x; Lee CH, 2007, BIOL PHARM BULL, V30, P1898, DOI 10.1248/bpb.30.1898; Lei C, 2013, NEUROSCIENCE, V228, P190, DOI 10.1016/j.neuroscience.2012.10.023; Li Z, 2013, NEUROREPORT, V24, P785, DOI 10.1097/WNR.0b013e328363fed3; Liu AH, 2014, EPILEPSY BEHAV, V39, P105, DOI 10.1016/j.yebeh.2014.08.005; Long Q, 2012, NEUROSCIENCE, V212, P214, DOI 10.1016/j.neuroscience.2012.04.002; Luo L, 2014, CELL MOL NEUROBIOL, V34, P987, DOI 10.1007/s10571-014-0075-4; Luo Lidan, 2013, Exp Neurobiol, V22, P107, DOI 10.5607/en.2013.22.2.107; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marchi N, 2007, EPILEPSIA, V48, P1934, DOI 10.1111/j.1528-1167.2007.01185.x; Marchi N, 2007, EPILEPSIA, V48, P732, DOI 10.1111/j.1528-1167.2007.00988.x; Marchi N, 2009, NEUROBIOL DIS, V33, P171, DOI 10.1016/j.nbd.2008.10.002; Marianecci C, 2012, J CONTROL RELEASE, V164, P17, DOI 10.1016/j.jconrel.2012.09.018; Maroso M, 2011, J INTERN MED, V270, P319, DOI 10.1111/j.1365-2796.2011.02431.x; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Ming LJ, 2013, NAT PROD COMMUN, V8, P415; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; MORRISETT RA, 1987, EXP NEUROL, V97, P193, DOI 10.1016/0014-4886(87)90293-7; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Narvaez-Rivera RM, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-15; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Ohnishi M, 2011, NEUROPHARMACOLOGY, V61, P975, DOI 10.1016/j.neuropharm.2011.06.026; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Perucca E, 2007, LANCET NEUROL, V6, P793, DOI 10.1016/S1474-4422(07)70215-6; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Reddy DS, 2013, INT J MOL SCI, V14, P18284, DOI 10.3390/ijms140918284; Saeedi M, 2003, J Dermatolog Treat, V14, P153, DOI 10.1080/09546630310014369; Sansing LH, 2011, ANN NEUROL, V70, P646, DOI 10.1002/ana.22528; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Sun Q, 2013, MED HYPOTHESES, V81, P681, DOI 10.1016/j.mehy.2013.07.026; Tang XH, 2013, CHINESE MED J-PEKING, V126, P1900, DOI 10.3760/cma.j.issn.0366-6999.20122710; Tang ZH, 2015, PLANTA MED, V81, P1670, DOI 10.1055/s-0035-1558227; Tsai JJ, 2013, INT J MOL SCI, V14, P12563, DOI 10.3390/ijms140612563; Uzawa A, 2013, CLIN EXP IMMUNOL, V172, P37, DOI 10.1111/cei.12036; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Walker L, 2012, EPILEPSY CURR, V12, P8, DOI 10.5698/1535-7511-12.1.8; Wang W, 2013, CRIT CARE, V17, DOI 10.1186/cc12558; Zhang JC, 2014, BRAIN RES, V1582, P176, DOI 10.1016/j.brainres.2014.07.002; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334	56	19	19	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3573	2042-7158		J PHARM PHARMACOL	J. Pharm. Pharmacol.	MAR	2019	71	3					390	399		10.1111/jphp.13040			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HK2NQ	WOS:000457750000010	30417405				2021-06-18	
J	Zhou, Z; Li, XG; Kleiven, S				Zhou, Zhou; Li, Xiaogai; Kleiven, Svein			Fluid-structure interaction simulation of the brain-skull interface for acute subdural haematoma prediction	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Traumatic brain injury; Brain-skull interface; Fluid-structure interaction; Arbitrary Lagrangian-Eulerian; Finite element analysis	FINITE-ELEMENT-ANALYSIS; PERIODIC MOTION; HEAD IMPACT; DURA-MATER; INJURY; MODEL; MECHANICS; TISSUE; VALIDATION; CAVITATION	Traumatic brain injury is a leading cause of disability and mortality. Finite element-based head models are promising tools for enhanced head injury prediction, mitigation and prevention. The reliability of such models depends heavily on adequate representation of the brain-skull interaction. Nevertheless, the brain-skull interface has been largely simplified in previous three-dimensional head models without accounting for the fluid behaviour of the cerebrospinal fluid (CSF) and its mechanical interaction with the brain and skull. In this study, the brain-skull interface in a previously developed head model is modified as a fluid-structure interaction (FSI) approach, in which the CSF is treated on a moving mesh using an arbitrary Lagrangian-Eulerian multi-material formulation and the brain on a deformable mesh using a Lagrangian formulation. The modified model is validated against brain-skull relative displacement and intracranial pressure responses and subsequently imposed to an experimentally determined loading known to cause acute subdural haematoma (ASDH). Compared to the original model, the modified model achieves an improved validation performance in terms of brain-skull relative motion and is able to predict the occurrence of ASDH more accurately, indicating the superiority of the FSI approach for brain-skull interface modelling. The introduction of the FSI approach to represent the fluid behaviour of the CSF and its interaction with the brain and skull is crucial for more accurate head injury predictions.	[Zhou, Zhou; Li, Xiaogai; Kleiven, Svein] Royal Inst Technol KTH, Neuron Engn, Stockholm, Sweden	Zhou, Z (corresponding author), Royal Inst Technol KTH, Neuron Engn, Stockholm, Sweden.	zhouz@kth.se		zhou, zhou/0000-0002-3910-0418; Li, Xiaogai/0000-0001-8522-4705	European Union's Horizon 2020 research and innovation programme under the Marie-Curie Grant [642662]	This research has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie-Curie Grant Agreement No. 642662. The help of Markos Kapeliotis from KU Leuven in providing the experimental data is gratefully acknowledged. The authors declare that they have no conflict of interest.	Aimedieu P, 2004, J NEUROSURG, V100, P111, DOI 10.3171/jns.2004.100.1.0111; Al-Bsharat A. S., 1999, STAPP CAR CRASH J, V43, P321; Aquelet N, 2006, COMPUT METHOD APPL M, V195, P110, DOI 10.1016/j.cma.2005.01.010; Batterbee DC, 2011, P I MECH ENG H, V225, P1036, DOI 10.1177/0954411911420002; BENSON DJ, 1989, COMPUT METHOD APPL M, V72, P305, DOI 10.1016/0045-7825(89)90003-0; Bloomfield IG, 1998, PEDIATR NEUROSURG, V28, P246, DOI 10.1159/000028659; Bradshaw DRS, 2001, P 17 INT TECHN C ENH; BYLSKI DI, 1986, J BIOMECH, V19, P19, DOI 10.1016/0021-9290(86)90105-3; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Cheng J, 2010, J BIOMECH, V43, P2887, DOI 10.1016/j.jbiomech.2010.07.023; Claessans M., 1997, P 41 STAPP CAR CRASH, P315, DOI DOI 10.4271/973338; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Cui ZY, 2017, COMPUT METHOD BIOMEC, V20, P530, DOI 10.1080/10255842.2016.1255942; Darvish K. K., 2002, P 2002 INT IRCOBI C, P339; Depreitere B, 2006, J NEUROSURG, V104, P950, DOI 10.3171/jns.2006.104.6.950; Dobratz B.M., 1981, LLNL EXPLOSIVES HDB; Fahlstedt M, 2015, THESIS; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FELIPPA CA, 1984, COMPUT METHOD APPL M, V44, P297, DOI 10.1016/0045-7825(84)90134-8; Fontenier B, 2014, COMPUT METHOD BIOMEC, V17, P46, DOI 10.1080/10255842.2014.931104; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Gehre C., 2009, 21 INT TECHN C ENH S; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Giordano Chiara, 2016, Stapp Car Crash J, V60, P363; Goriely A, 2015, BIOMECH MODEL MECHAN, V14, P931, DOI 10.1007/s10237-015-0662-4; Gu LX, 2012, COMPOS PART B-ENG, V43, P3160, DOI 10.1016/j.compositesb.2012.04.014; Hallquist JO, 2007, LS DYNA KEYW US MAN; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Herbert E, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.041603; Ho J, 2017, J BIOMECH, V60, P243, DOI 10.1016/j.jbiomech.2017.06.023; Ho J, 2009, INT J CRASHWORTHINES, V14, P555, DOI 10.1080/13588260902895708; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Iwamoto Masami, 2015, Stapp Car Crash J, V59, P53; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Jin X, 2014, ANN BIOMED ENG, V42, P812, DOI 10.1007/s10439-013-0948-6; Jin X, 2011, J BIOMECH, V44, P467, DOI 10.1016/j.jbiomech.2010.09.035; Jin X, 2007, STAPP CAR CRASH JO, V51, P115; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Klug C, 2013, EXPT SPHERE IN SPHER, P483; Larson BC, 2002, NATURE, V415, P887, DOI 10.1038/415887a; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; Li XG, 2017, BIOMECH MODEL MECHAN, V16, P823, DOI 10.1007/s10237-016-0855-5; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Luraghi G, 2017, J BIOMECH, V58, P45, DOI 10.1016/j.jbiomech.2017.04.004; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Mao HJ, 2011, INT J NUMER METH BIO, V27, P357, DOI 10.1002/cnm.1403; Miller LE, 2016, BIOMECH MODEL MECHAN, V15, P1201, DOI 10.1007/s10237-015-0754-1; Nahum AM, 1977, P 21 STAPP CAR CRASH, P337; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Salzar RS, 2017, J NEUROTRAUM, V34, P1589, DOI 10.1089/neu.2016.4600; Scott GG, 2016, BIOMECH MODEL MECHAN, V15, P1101, DOI 10.1007/s10237-015-0747-0; Scott GG, 2015, IEEE T MED IMAGING, V34, P1452, DOI 10.1109/TMI.2015.2396527; Souli M, 2000, COMPUT METHOD APPL M, V190, P659, DOI 10.1016/S0045-7825(99)00432-6; Stitzel Joel D, 2002, Stapp Car Crash J, V46, P81; Van Leer B, 1997, J COMPUT PHYS, V135, P229, DOI 10.1006/jcph.1997.5704; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; Zhang A, 2006, INT J CRASHWORTHINES, V11, P291, DOI 10.1533/ijcr.2005.0105; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; Zhao W, 2015, BIOMECH MODEL MECHAN, V14, P753, DOI 10.1007/s10237-014-0634-0; Zhou C, 1995, P 39 STAPP CAR CRASH, V39, P121, DOI DOI 10.4271/952714; Zhou Z, 2016, COMPUT METH PROG BIO, V131, P13, DOI 10.1016/j.cmpb.2016.04.013	70	19	20	0	5	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	FEB	2019	18	1					155	173		10.1007/s10237-018-1074-z			19	Biophysics; Engineering, Biomedical	Biophysics; Engineering	HK4ZU	WOS:000457974500012	30151812	Other Gold, Green Published			2021-06-18	
J	Rao, F; Zhang, DY; Fang, TJZ; Lu, CF; Wang, B; Ding, X; Wei, S; Zhang, YR; Pi, W; Xu, HL; Wang, YH; Jiang, BG; Zhang, PX				Rao, Feng; Zhang, Dianying; Fang, Tengjiaozi; Lu, Changfeng; Wang, Bo; Ding, Xiao; Wei, Shuai; Zhang, Yiran; Pi, Wei; Xu, Hailin; Wang, Yanhua; Jiang, Baoguo; Zhang, Peixun			Exosomes from Human Gingiva-Derived Mesenchymal Stem Cells Combined with Biodegradable Chitin Conduits Promote Rat Sciatic Nerve Regeneration	STEM CELLS INTERNATIONAL			English	Article							TRAUMATIC BRAIN-INJURY; EXTRACELLULAR VESICLES; AXONAL REGENERATION; NEURITE OUTGROWTH; SCHWANN-CELLS; GAP; DEGENERATION; RECOVERY; SCAFFOLD	At present, repair methods for peripheral nerve injury often fail to get satisfactory result. Although various strategies have been adopted to investigate the microenvironment after peripheral nerve injury, the underlying molecular mechanisms of neurite outgrowth remain unclear. In this study, we evaluate the effects of exosomes from gingival mesenchymal stem cells (GMSCs) combined with biodegradable chitin conduits on peripheral nerve regeneration. GMSCs were isolated from human gingival tissue and characterized by surface antigen analysis and in vitro multipotent differentiation. The cell supernatant was collected to isolate the exosomes. The exosomes were characterized by transmission electron microscopy, Western blot, and size distribution analysis. The effects of exosomes on peripheral nerve regeneration in vitro were evaluated by coculture with Schwann cells and DRGs. The chitin conduit was prepared and combined with the exosomes to repair rat sciatic nerve defect. Histology, electrophysiology, and gait analysis were used to test the effects of exosomes on sciatic nerve function recovery in vivo. We have successfully cultured GMSCs and isolated exosomes. The exosomes from GMSCs could significantly promote Schwann cell proliferation and DRG axon growth. The in vivo studies showed that chitin conduit combined with exosomes from GMSCs could significantly increase the number and diameter of nerve fibers and promote myelin formation. In addition, muscle function, nerve conduction function, and motor function were also obviously recovered. In summary, this study suggests that GMSC-derived exosomes combined with biodegradable chitin conduits are a useful and novel therapeutic intervention in peripheral nerve repair.	[Rao, Feng; Zhang, Dianying; Lu, Changfeng; Wang, Bo; Zhang, Yiran; Pi, Wei; Xu, Hailin; Wang, Yanhua; Jiang, Baoguo; Zhang, Peixun] Peking Univ, Dept Orthoped & Trauma, Peoples Hosp, Beijing, Peoples R China; [Fang, Tengjiaozi] Peking Univ, Sch & Hosp Stomatol, Dept Pediat Dent, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing 100081, Peoples R China; [Fang, Tengjiaozi] Beijing Key Lab Digital Stomatol, Beijing 100081, Peoples R China; [Lu, Changfeng; Ding, Xiao; Wei, Shuai] Chinese Peoples Liberat Army Gen Hosp, Beijing Key Lab Regenerat Med Orthoped, Inst Orthoped, Beijing, Peoples R China	Jiang, BG; Zhang, PX (corresponding author), Peking Univ, Dept Orthoped & Trauma, Peoples Hosp, Beijing, Peoples R China.	jiangbaoguo@vip.sina.com; zhangpeixun@bjmu.edu.cn	wei, shuai/AAN-7430-2021	wei, shuai/0000-0002-2435-815X	Major R&D Program of National Ministry of Science and Technology [2018YFB1105504]; National Key R&D Program of China [2016YFC1101604]; National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [31771322, 31571235, 81671215]; Beijing Municipal Science and Technology Commission Science and Technology Nova Cross Project [2018019]; R&D Foundation of PKUPH [2018-01, 2017-01]; Ministry of Education Innovation Program of China [IRT_16R01]; National S&T Major Project of China [SQ2018ZX100301]	The authors would like to thank Kuan Chen from Beijing Hui Fukang Medical Device Co. Ltd. for his technical help about the preparation of chitin conduits and Xin Chang from School of Basic Medical Sciences, Peking University, for the help with transmission electron microscopy. This work was supported by the Major R&D Program of National Ministry of Science and Technology (2018YFB1105504), National Key R&D Program of China (2016YFC1101604), National Natural Science Foundation (31771322, 31571235, and 81671215), Beijing Municipal Science and Technology Commission Science and Technology Nova Cross Project (2018019), R&D Foundation of PKUPH (2018-01, 2017-01), Ministry of Education Innovation Program of China (IRT_16R01), and National S&T Major Project of China (SQ2018ZX100301).	Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007; Lopez-Verrilli MA, 2013, GLIA, V61, P1795, DOI 10.1002/glia.22558; Ansari S, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700670; Asplund M, 2009, NEUROEPIDEMIOLOGY, V32, P217, DOI 10.1159/000197900; Beigi MH, 2014, J BIOMED MATER RES A, V102, P4554, DOI 10.1002/jbm.a.35119; Bell JHA, 2012, TISSUE ENG PART B-RE, V18, P116, DOI [10.1089/ten.teb.2011.0498, 10.1089/ten.TEB.2011.0498]; Bernardo ME, 2013, CELL STEM CELL, V13, P392, DOI 10.1016/j.stem.2013.09.006; Bucan V, 2019, MOL NEUROBIOL, V56, P1812, DOI 10.1007/s12035-018-1172-z; Burrello J, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00083; Cao Y, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/9328347; Chen PW, 2015, ACTA NEUROPATHOL, V130, P605, DOI 10.1007/s00401-015-1482-4; Ching RC, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1017-8; Court FA, 2011, GLIA, V59, P1529, DOI 10.1002/glia.21196; Daly W, 2012, J R SOC INTERFACE, V9, P202, DOI 10.1098/rsif.2011.0438; Defrancesco-Lisowitz A, 2015, NEUROSCIENCE, V302, P174, DOI 10.1016/j.neuroscience.2014.09.027; Del Fattore A, 2015, CELL TRANSPLANT, V24, P2615, DOI 10.3727/096368915X687543; Diomede F, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00419; Diomede F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020329; Du J, 2018, BIOMATERIALS, V181, P347, DOI 10.1016/j.biomaterials.2018.07.015; Gu XS, 2014, BIOMATERIALS, V35, P6143, DOI 10.1016/j.biomaterials.2014.04.064; Gu Y, 2014, BIOMATERIALS, V35, P2253, DOI 10.1016/j.biomaterials.2013.11.087; Hao ZC, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12359; Hu XY, 2009, TISSUE ENG PT A, V15, P3297, DOI [10.1089/ten.tea.2009.0017, 10.1089/ten.TEA.2009.0017]; Huang S, 2018, FASEB J, V32, P512, DOI 10.1096/fj.201700673R; Jiang BG, 2010, ARTIF CELL BLOOD SUB, V38, P1, DOI 10.3109/10731190903495652; Jiang BG, 2006, ARTIF CELL BLOOD SUB, V34, P55, DOI 10.1080/10731190500430149; Kou XX, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aai8524; Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev-physiol-021014-071641; Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003; Li R, 2018, BIOMATERIALS, V168, P24, DOI 10.1016/j.biomaterials.2018.03.044; Li Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0648-5; Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542; Marquardt LM, 2013, CURR OPIN BIOTECH, V24, P887, DOI 10.1016/j.copbio.2013.05.006; Noble J, 1998, J TRAUMA, V45, P116, DOI 10.1097/00005373-199807000-00025; Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575; Phinney DG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9472; Rani S, 2016, ADV MATER, V28, P5542, DOI 10.1002/adma.201504009; Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44; Sanen K, 2017, J TISSUE ENG REGEN M, V11, P3362, DOI 10.1002/term.2249; Shi Q, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00904; Taylor CA, 2008, AM J PHYS MED REHAB, V87, P381, DOI 10.1097/PHM.0b013e31815e6370; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Todorova D, 2017, CIRC RES, V120, P1658, DOI 10.1161/CIRCRESAHA.117.309681; Togel F, 2007, AM J PHYSIOL-RENAL, V292, pF1626, DOI 10.1152/ajprenal.00339.2006; Wang YF, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0632-0; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Zhang B, 2015, STEM CELL TRANSL MED, V4, P513, DOI 10.5966/sctm.2014-0267; Zhang B, 2014, STEM CELLS DEV, V23, P1233, DOI 10.1089/scd.2013.0479; Zhang PX, 2015, LANCET, V386, P40; Zhang QZ, 2018, MOL NEUROBIOL, V55, P6965, DOI 10.1007/s12035-018-0913-3; Zhang QZ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24888-w; Zhang QZ, 2017, STEM CELL TRANSL MED, V6, P458, DOI 10.5966/sctm.2016-0177; Zhang QZ, 2009, J IMMUNOL, V183, P7787, DOI 10.4049/jimmunol.0902318	54	19	20	2	6	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1687-966X	1687-9678		STEM CELLS INT	Stem Cells Int.		2019	2019								2546367	10.1155/2019/2546367			12	Cell & Tissue Engineering	Cell Biology	IG0IS	WOS:000473475000001	31191669	DOAJ Gold, Green Published			2021-06-18	
J	Ji, W; Alvarez, Z; Edelbrock, AN; Sato, K; Stupp, SI				Ji, Wei; Alvarez, Zaida; Edelbrock, Alexandra N.; Sato, Kohei; Stupp, Samuel, I			Bioactive Nanofibers Induce Neural Transdifferentiation of Human Bone Marrow Mesenchymal Stem Cells	ACS APPLIED MATERIALS & INTERFACES			English	Article						peptide amphiphile; human mesenchymal stem cell; IKVAV; transdifferentiation; neurons	STROMAL CELLS; EXTRACELLULAR-MATRIX; NERVOUS-SYSTEM; NEURONAL DIFFERENTIATION; NEURITE OUTGROWTH; CLINICAL-TRIALS; BRAIN; BIOMATERIALS; NEUROGENESIS; MIGRATION	The combination of biomaterials with stem cells is a promising therapeutic strategy to repair traumatic injuries in the central nervous system, and human bone marrow mesenchymal stem cells (BMSCs) offer a clinically translatable option among other possible sources of stem cells. We report here on the use of a supramolecular bioactive material based on a peptide amphiphile (PA), displaying a laminin-mimetic IKVAV sequence to drive neural transdifferentiation of human BMSCs. The IKVAV-PA self-assembles into supramolecular nanofibers that induce neuroectodermal lineage commitment after 1 week, as evidenced by the upregulation of the neural progenitor gene nestin (NES) and glial fibrillary acidic protein (GFAP). After 2 weeks, the bioactive IKVAV-PA nanofibers induce significantly higher expression of neuronal markers beta-III tubulin (TUJ-1), microtubule-associated protein-2 (MAP-2), and neuronal nuclei (NEUN), as well as the extracellular matrix laminin (LMN). Furthermore, the human BMSCs exposed to the biomaterial reveal a polarized cytoskeletal architecture and a decrease in cellular size, resembling neuron-like cells. We conclude that the investigated supramolecular biomaterial opens the opportunity to transdifferentiate adult human BMSCs into neuronal lineage.	[Ji, Wei; Alvarez, Zaida; Edelbrock, Alexandra N.; Sato, Kohei; Stupp, Samuel, I] Northwestern Univ, Simpson Querrey Inst, Chicago, IL 60611 USA; [Stupp, Samuel, I] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [Ji, Wei] Katholieke Univ Leuven, Dept Dev & Regenerat, Skeletal Biol & Engn Res Ctr, B-3000 Leuven, Belgium; [Edelbrock, Alexandra N.; Stupp, Samuel, I] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA; [Sato, Kohei; Stupp, Samuel, I] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; [Stupp, Samuel, I] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA; [Sato, Kohei] Tokyo Inst Technol, Dept Life Sci & Technol, Yokohama, Kanagawa 2268501, Japan	Stupp, SI (corresponding author), Northwestern Univ, Simpson Querrey Inst, Chicago, IL 60611 USA.; Stupp, SI (corresponding author), Northwestern Univ, Dept Med, Chicago, IL 60611 USA.; Stupp, SI (corresponding author), Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.; Stupp, SI (corresponding author), Northwestern Univ, Dept Chem, Evanston, IL 60208 USA.; Stupp, SI (corresponding author), Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA.	s-stupp@northwestern.edu	Stupp, Samuel/B-6737-2009; alvarez, zaida/AAA-3132-2020; Sato, Kohei/V-8820-2018; Ji, Wei/G-8947-2011; Edelbrock, Alexandra N/R-2060-2018	Sato, Kohei/0000-0002-8948-8537; Ji, Wei/0000-0002-1473-5222; Edelbrock, Alexandra N/0000-0003-3172-977X; Alvarez, Zaida/0000-0001-5104-1388	Center for Regenerative Nanomedicine at the Simpson Querrey Institute at Northwestern University; Research Foundation-Flanders (FWO)FWO [12G2718N]; University of Leuven (KU Leuven)KU Leuven [JUMO-15-0514]; Beatriu de Pinos Fellowship from Agencia de Gestio d'Ajust Universitaris i de Recerca, (AGAUR), Spain [2014 BP -A 00007]; Paralyzed Veterans of America (PVA) Research Foundation [PVA17_RF_0008]; U.S. Army Research Office; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Northwestern University; Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource [NSF ECCS-1542205, NSF NNCI-1542205]; Materials Research Science and Engineering Center (MRSEC) program at the Materials Research Center [NSF DMR-1720139]; International Institute for Nanotechnology (IIN); Keck FoundationW.M. Keck Foundation; State of Illinois, through the IIN	This work was primarily supported by the Center for Regenerative Nanomedicine at the Simpson Querrey Institute at Northwestern University. W.J. received postdoctoral support from Research Foundation-Flanders (FWO) Postdoctoral Mandates 12G2718N, and by a Junior Mobility Travel grant from University of Leuven (KU Leuven) (JUMO-15-0514). Z.A. received postdoctoral support from a Beatriu de Pinos Fellowship from Agencia de Gestio d'Ajust Universitaris i de Recerca, (AGAUR), Spain 2014 BP -A 00007, and by grant #PVA17_RF_0008 from the Paralyzed Veterans of America (PVA) Research Foundation. This work was also supported by the following core facilities of Northwestern University: the Peptide Synthesis Core and the Analytical Bionanotechnology Equipment Core both at the Simpson Querrey Institute. The U.S. Army Research Office, the U.S. Army Medical Research and Materiel Command, and Northwestern University provided funding to develop these facilities and ongoing support is being received from the Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource (NSF NNCI-1542205). This work made use of the microscopic facility of the Center for Advanced Microscopy (NCI CCSG P30 CA060553), as well as the EPIC facility of Northwestern University's NUANCE Center, which has received support from the Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource (NSF ECCS-1542205); the Materials Research Science and Engineering Center (MRSEC) program (NSF DMR-1720139) at the Materials Research Center; the International Institute for Nanotechnology (IIN); the Keck Foundation; and the State of Illinois, through the IIN. The authors also thank Max Mu Wang's technical assistance and Mark Seniw for the preparation of illustrations for the manuscript.	Ahmed AI, 2012, J NEUROTRAUM, V29, P828, DOI 10.1089/neu.2011.1923; Alvarez Z, 2014, BIOMATERIALS, V35, P4769, DOI 10.1016/j.biomaterials.2014.02.051; Amer MH, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0789-1; Banik BL, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00041; Barros CS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005108; Berns EJ, 2016, ACTA BIOMATER, V37, P50, DOI 10.1016/j.actbio.2016.04.010; Berns EJ, 2014, BIOMATERIALS, V35, P185, DOI 10.1016/j.biomaterials.2013.09.077; Bianco P, 2014, ANNU REV CELL DEV BI, V30, P677, DOI 10.1146/annurev-cellbio-100913-013132; Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Burdick JA, 2016, CELL STEM CELL, V18, P13, DOI 10.1016/j.stem.2015.12.004; Cheng P, 2013, DEVELOPMENT, V140, P2587, DOI 10.1242/dev.089052; Crunkhorn S, 2017, NAT REV DRUG DISCOV, V16, P600, DOI [10.1038/nrd.2017.156, 10.1038/nrd.2017.181]; Curtis E, 2018, CELL STEM CELL, V22, P941, DOI 10.1016/j.stem.2018.05.014; Faissner A, 2015, GLIA, V63, P1330, DOI 10.1002/glia.22839; Farrukh A, 2017, STEM CELL REP, V9, P1432, DOI 10.1016/j.stemcr.2017.09.002; Vallone VBF, 2013, DIFFERENTIATION, V85, P1, DOI 10.1016/j.diff.2012.08.004; Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820; Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004; Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002; Goldberger JE, 2011, ANGEW CHEM INT EDIT, V50, P6292, DOI 10.1002/anie.201100202; Goldman SA, 2018, NAT MED, V24, P388, DOI 10.1038/nm.4531; Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234; Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369; Guler MO, 2005, NANO LETT, V5, P249, DOI 10.1021/nl048238z; Halfon S, 2011, STEM CELLS DEV, V20, P53, DOI 10.1089/scd.2010.0040; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187; Hussey GS, 2018, NAT REV MATER, V3, P159, DOI 10.1038/s41578-018-0023-x; Jiang HZ, 2007, SOFT MATTER, V3, P454, DOI 10.1039/b614426h; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Khaing ZZ, 2014, MATER TODAY, V17, P332, DOI 10.1016/j.mattod.2014.05.011; Kim BJ, 2002, NEUROREPORT, V13, P1185, DOI 10.1097/00001756-200207020-00023; Kim J, 2013, SCI REP-UK, V3, DOI 10.1038/srep03552; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116; Krabbe C, 2005, APMIS, V113, P831, DOI 10.1111/j.1600-0463.2005.apm_3061.x; Kubinova S, 2017, NEURAL REGEN RES, V12, P1430, DOI 10.4103/1673-5374.215249; Lacour SP, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.63; Hong LTA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00583-8; Lee J, 2016, ACTA BIOMATER, V42, P46, DOI 10.1016/j.actbio.2016.06.037; Li A, 2014, BIOMATERIALS, V35, P8780, DOI 10.1016/j.biomaterials.2014.06.049; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Maltman DJ, 2011, NEUROCHEM INT, V59, P347, DOI 10.1016/j.neuint.2011.06.008; Mendicino M, 2014, CELL STEM CELL, V14, P141, DOI 10.1016/j.stem.2014.01.013; Montzka K, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-16; Mothe AJ, 2012, J CLIN INVEST, V122, P3824, DOI 10.1172/JCI64124; Mruthyunjaya S, 2015, J BIOMED MATER RES A, V103, P746, DOI 10.1002/jbm.a.35221; Mruthyunjaya S, 2011, FEBS LETT, V585, P1915, DOI 10.1016/j.febslet.2011.04.072; Mruthyunjaya S, 2010, BIOCHEM BIOPH RES CO, V391, P43, DOI 10.1016/j.bbrc.2009.10.158; Nagoshi N, 2008, CELL STEM CELL, V2, P392, DOI 10.1016/j.stem.2008.03.005; NSCIS C., 2014, SPIN CORD INJ FACTS; Okolicsanyi RK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137255; Okolicsanyi RK, 2014, DEV BIOL, V388, P1, DOI 10.1016/j.ydbio.2014.01.024; Pan LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104335; Pierret C, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-5; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Qian LC, 2004, BIOMATERIALS, V25, P1331, DOI 10.1016/j.biomaterials.2003.08.013; Ramos TL, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-015-0124-8; Rice CM, 2013, LANCET, V382, P1204, DOI 10.1016/S0140-6736(13)61810-3; Samsonraj RM, 2017, STEM CELL TRANSL MED, V6, P2173, DOI 10.1002/sctm.17-0129; Samsonraj RM, 2015, STEM CELLS, V33, P1878, DOI 10.1002/stem.1982; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sato K, 2018, CHEM SOC REV, V47, P7539, DOI 10.1039/c7cs00735c; Scuteri A, 2011, CURR STEM CELL RES T, V6, P82, DOI 10.2174/157488811795495486; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Sofroniew MV, 2018, NATURE, V557, P343, DOI 10.1038/s41586-018-0068-4; Sun YB, 2012, ANNU REV BIOPHYS, V41, P519, DOI 10.1146/annurev-biophys-042910-155306; Sur S, 2012, BIOMATERIALS, V33, P545, DOI 10.1016/j.biomaterials.2011.09.093; Theocharidis U, 2014, PROG BRAIN RES, V214, P3, DOI 10.1016/B978-0-444-63486-3.00001-3; Treiser MD, 2010, P NATL ACAD SCI USA, V107, P610, DOI 10.1073/pnas.0909597107; Tropel P, 2006, STEM CELLS, V24, P2868, DOI 10.1634/stemcells.2005-0636; Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007; Tysseling VM, 2010, J NEUROSCI RES, V88, P3161, DOI 10.1002/jnr.22472; Tysseling-Mattiace VM, 2008, J NEUROSCI, V28, P3814, DOI 10.1523/JNEUROSCI.0143-08.2008; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Vecino E., 2016, COMPOSITION FUNCTION; White R. E., 2008, J COMP NEUROL, V26, P1370; Willis C. M., 2016, COMPOSITION FUNCTION; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yamada M, 2002, FEBS LETT, V530, P48, DOI 10.1016/S0014-5793(02)03393-8; Yim EKF, 2007, EXP CELL RES, V313, P1820, DOI 10.1016/j.yexcr.2007.02.031; Yourek G, 2007, ASAIO J, V53, P219, DOI 10.1097/MAT.0b013e31802deb2d	84	19	19	4	41	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1944-8244	1944-8252		ACS APPL MATER INTER	ACS Appl. Mater. Interfaces	DEC 5	2018	10	48					41046	41055		10.1021/acsami.8b13653			10	Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science & Technology - Other Topics; Materials Science	HD6XR	WOS:000452694100012	30475573				2021-06-18	
J	Shin, S; Burnett, RT; Kwong, JC; Hystad, P; van Donkelaar, A; Brook, JR; Copes, R; Tu, K; Goldberg, MS; Villeneuve, PJ; Martin, RV; Murray, BJ; Wilton, AS; Kopp, A; Chen, H				Shin, Saeha; Burnett, Richard T.; Kwong, Jeffrey C.; Hystad, Perry; van Donkelaar, Aaron; Brook, Jeffrey R.; Copes, Ray; Tu, Karen; Goldberg, Mark S.; Villeneuve, Paul J.; Martin, Randall V.; Murray, Brian J.; Wilton, Andrew S.; Kopp, Alexander; Chen, Hong			Effects of ambient air pollution on incident Parkinson's disease in Ontario, 2001 to 2013: a population-based cohort study	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						Parkinson's disease; neurodegenerative diseases; air pollution; incidence	FINE PARTICULATE MATTER; LONG-TERM EXPOSURE; TRAUMATIC BRAIN-INJURY; RISK; BURDEN; TRANSMISSION; ASSOCIATION; MORTALITY; MODELS; HEALTH	Background: Despite recent studies linking air pollution to neurodegenerative illness, evidence relating air pollution and Parkinson's disease (PD) remains scarce. We conducted a population-based cohort study in Ontario, Canada, to determine the association between air pollution and incident PD. Methods: Using health administrative databases, we identified all adults aged 55-85 years, free of PD, and who lived in Ontario on 1 April 2001 (similar to 2.2 million). Individuals were followed up until 31 March 2013. We derived long-term average exposures to fine particulate matter (particles <= 2.5 mu m in diameter, or PM2.5), nitrogen dioxide (NO2) and ozone from satellite-based estimates, land-use regression models and optimal interpolation methods, respectively. Using 2-year lags in exposures, we linked these estimates to individuals' annual postal codes from 1994 (7 years before cohort inception). We applied spatial random-effects Cox proportional hazards models, adjusting for individual- and area-level characteristics. We also performed sensitivity analyses, such as considering longer lags in exposures and stratifying by selected characteristics. Results: During the study period, we identified 38 745 newly diagnosed cases of PD. Each interquartile increment (3.8 mu g/m(3)) of PM2.5 was associated with a 4% increase in incident PD (95% confidence interval, 1.01-1.08) after adjusting for various covariates. We also found positive associations for NO2 and ozone [hazard ratios (HRs) ranged from 1.03 to 1.04]. The associations for all exposures were unaltered with various sensitivity analyses except for considering longer lags, which somewhat attenuated the estimates, particularly for NO2 and ozone. Conclusions: Exposure to air pollution, especially PM2.5, was found to be related to incident PD.	[Shin, Saeha; Copes, Ray; Chen, Hong] Publ Hlth Ontario, Dept Environm & Occupat Hlth, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada; [Shin, Saeha; Kwong, Jeffrey C.; Brook, Jeffrey R.; Copes, Ray; Chen, Hong] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Burnett, Richard T.] Hlth Canada, Populat Studies Div, Ottawa, ON, Canada; [Kwong, Jeffrey C.; Wilton, Andrew S.; Kopp, Alexander; Chen, Hong] Inst Clin Evaluat Sci, Primary Care & Populat Hlth Res Program, Toronto, ON, Canada; [Kwong, Jeffrey C.; Tu, Karen] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Kwong, Jeffrey C.; Tu, Karen] Univ Hlth Network, Toronto Western Hosp, Family Hlth Team, Toronto, ON, Canada; [Kwong, Jeffrey C.] Publ Hlth Ontario, Dept Appl Immunizat Res, Toronto, ON, Canada; [Hystad, Perry] Oregon State Univ, Coll Publ Hlth & Human Studies, Corvallis, OR 97331 USA; [van Donkelaar, Aaron] Dalhousie Univ, Dept Phys & Atmospher Sci, Halifax, NS, Canada; [Brook, Jeffrey R.] Environm Canada, Air Qual Res Div, Toronto, ON, Canada; [Goldberg, Mark S.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Goldberg, Mark S.] McGill Univ, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ, Canada; [Villeneuve, Paul J.] Carleton Univ, Dept Hlth Sci, Ottawa, ON, Canada; [Martin, Randall V.] Harvard Smithsonian Ctr Astrophys, Smithsonian Astrophys Observ, 60 Garden St, Cambridge, MA 02138 USA; [Murray, Brian J.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Murray, Brian J.] Sunnybrook Hlth Sci Ctr, Div Neurol, Toronto, ON, Canada	Chen, H (corresponding author), Publ Hlth Ontario, Dept Environm & Occupat Hlth, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada.	hong.chen@oahpp.ca	van Donkelaar, Aaron/AAF-8355-2021; Martin, Randall/C-1205-2014	Martin, Randall/0000-0003-2632-8402; Villeneuve, Paul/0000-0001-7786-7997	Health Canada [MOA-4500314182]; Public Health Ontario (PHO); Institute for Clinical Evaluative Sciences (ICES) - Ontario Ministry of Health and Long-Term Care (MOHLTC)Ministry of Health and Long-Term Care, Ontario; New Investigator Award from the Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Clinician Scientist Award from the Department of Family and Community Medicine, University of Toronto; Department of Family and Community Medicine, University of TorontoUniversity of Toronto	This study was funded by Health Canada (MOA-4500314182). This study was also supported by Public Health Ontario (PHO) and the Institute for Clinical Evaluative Sciences (ICES), which are funded by annual grants from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed in the material are those of the author(s), and not necessarily those of PHO, ICES, MOHLTC or CIHI. J.K. is supported by a New Investigator Award from the Canadian Institutes of Health Research and a Clinician Scientist Award from the Department of Family and Community Medicine, University of Toronto. K.T. is supported by a research scholar award from the Department of Family and Community Medicine, University of Toronto. H.C. is the guarantor who had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.	Becker C, 2010, PARKINSONISM RELAT D, V16, P31, DOI 10.1016/j.parkreldis.2009.06.005; Beelen R, 2014, LANCET, V383, P785, DOI 10.1016/S0140-6736(13)62158-3; Block ML, 2009, TRENDS NEUROSCI, V32, P506, DOI 10.1016/j.tins.2009.05.009; Butt DA, 2014, NEUROEPIDEMIOLOGY, V43, P28, DOI 10.1159/000365590; Calderon-Garciduenas L, 2008, TOXICOL PATHOL, V36, P289, DOI 10.1177/0192623307313011; Calderon-Garciduenas L, 2010, EXP TOXICOL PATHOL, V62, P91, DOI 10.1016/j.etp.2009.02.117; Chen H, 2017, INT J EPIDEMIOL, V46, P405, DOI 10.1093/ije/dyw030; Chen H, 2016, ENVIRON HEALTH PERSP, V124, P1421, DOI 10.1289/EHP185; Chen H, 2013, ENVIRON HEALTH PERSP, V121, P804, DOI 10.1289/ehp.1205958; Chen H, 2013, EPIDEMIOLOGY, V24, P35, DOI 10.1097/EDE.0b013e318276c005; Crouse DL, 2012, ENVIRON HEALTH PERSP, V120, P708, DOI 10.1289/ehp.1104049; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; Driver JA, 2008, DIABETES CARE, V31, P2003, DOI 10.2337/dc08-0688; Finkelstein MM, 2007, ENVIRON RES, V104, P420, DOI 10.1016/j.envres.2007.03.002; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Genc S, 2012, J TOXICOL-US, V2012, DOI 10.1155/2012/782462; Huse DM, 2005, MOVEMENT DISORD, V20, P1449, DOI 10.1002/mds.20609; Hystad P, 2011, ENVIRON HEALTH PERSP, V119, P1123, DOI 10.1289/ehp.1002976; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045; Jellinger KA, 2012, MOVEMENT DISORD, V27, P8, DOI 10.1002/mds.23795; Kirrane EF, 2015, J OCCUP ENVIRON MED, V57, P509, DOI 10.1097/JOM.0000000000000451; Kowal SL, 2013, MOVEMENT DISORD, V28, P311, DOI 10.1002/mds.25292; Kralj B, 2000, ONT MED REV, V67, P33; Lee PC, 2016, ENVIRON INT, V96, P75, DOI 10.1016/j.envint.2016.08.017; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; Leibson CL, 2006, MOVEMENT DISORD, V21, P446, DOI 10.1002/mds.20685; Levesque S, 2011, ENVIRON HEALTH PERSP, V119, P1149, DOI 10.1289/ehp.1002986; Li X, 2015, ARCH GERONTOL GERIAT, V61, P510, DOI 10.1016/j.archger.2015.08.004; Liu R, 2016, ENVIRON HEALTH PERSP, V124, P1759, DOI 10.1289/EHP135; Luk KC, 2012, SCIENCE, V338, P949, DOI 10.1126/science.1227157; Ma RJ, 2003, BIOMETRIKA, V90, P157, DOI 10.1093/biomet/90.1.157; Mougenot AL, 2012, NEUROBIOL AGING, V33, P2225, DOI 10.1016/j.neurobiolaging.2011.06.022; Naira PM, 2006, J CHEM NEUROANAT, V31, P114, DOI 10.1016/j.jchemneu.2005.09.006; Palacios N, 2017, REV ENVIRON HEALTH, V32, P303, DOI 10.1515/reveh-2017-0009; Palacios N, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP259; Palacios N, 2014, ENVIRON HEALTH-GLOB, V13, DOI 10.1186/1476-069X-13-80; Palacios N, 2014, ENVIRON HEALTH PERSP, V122, P933, DOI 10.1289/ehp.1307218; Pohar SL, 2009, ARCH GERONTOL GERIAT, V49, P317, DOI 10.1016/j.archger.2008.11.006; Pudykiewicz JA, 1997, TELLUS B, V49, P231, DOI 10.1034/j.1600-0889.49.issue3.1.x; Qiu CX, 2011, HYPERTENSION, V57, P1094, DOI 10.1161/HYPERTENSIONAHA.111.171249; Ritz B, 2016, ENVIRON HEALTH PERSP, V124, P351, DOI 10.1289/ehp.1409313; Robichaud A, 2014, ATMOS CHEM PHYS, V14, P1769, DOI 10.5194/acp-14-1769-2014; Santiago-Lopez D, 2010, TOXICOL LETT, V197, P193, DOI 10.1016/j.toxlet.2010.05.020; Shin HH, 2014, ENVIRON RES, V134, P482, DOI 10.1016/j.envres.2014.05.016; Siderowf A, 2012, MOVEMENT DISORD, V27, P608, DOI 10.1002/mds.24954; van Donkelaar A, 2015, ENVIRON SCI TECHNOL, V49, P10482, DOI 10.1021/acs.est.5b02076; van Donkelaar A, 2015, ENVIRON HEALTH PERSP, V123, P135, DOI 10.1289/ehp.1408646; Veronesi B, 2005, INHAL TOXICOL, V17, P235, DOI 10.1080/08958370590912888; WHO, 2014, NEUR DIS PUBL HLTH C; Willis AW, 2010, AM J EPIDEMIOL, V172, P1357, DOI 10.1093/aje/kwq303; Wirdefeldt K, 2011, EUR J EPIDEMIOL, V26, pS1, DOI 10.1007/s10654-011-9581-6; Yang F, 2015, BRAIN, V138, P269, DOI 10.1093/brain/awu323	55	19	19	2	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	DEC	2018	47	6					2038	2048		10.1093/ije/dyy172			11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	HI7VN	WOS:000456664500035	30124852				2021-06-18	
J	Hale, AT; Stonko, DP; Brown, A; Lim, J; Voce, DJ; Gannon, SR; Le, TM; Shannon, CN				Hale, Andrew T.; Stonko, David P.; Brown, Amber; Lim, Jaims; Voce, David J.; Gannon, Stephen R.; Le, Truc M.; Shannon, Chevis N.			Machine-learning analysis outperforms conventional statistical models and CT classification systems in predicting 6-month outcomes in pediatric patients sustaining traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						neurotrauma; traumatic brain injury; artificial neural network	ARTIFICIAL NEURAL-NETWORKS; INTENSIVE-CARE-UNIT; GLASGOW COMA SCALE; CLINICAL MEDICINE; DECISION-SUPPORT; FULL OUTLINE; UNRESPONSIVENESS; TOMOGRAPHY; DIAGNOSIS; SCORE	OBJECTIVE Modern surgical planning and prognostication requires the most accurate outcomes data to practice evidence-based medicine. For clinicians treating children following traumatic brain injury (TBI) these data are severely lacking. The first aim of this study was to assess published CT classification systems in the authors' pediatric cohort. A pediatric-specific machine-learning algorithm called an artificial neural network (ANN) was then created that robustly outperformed traditional CT classification systems in predicting TBI outcomes in children. METHODS The clinical records of children under the age of 18 who suffered a TBI and underwent head CT within 24 hours after TBI (n = 565) were retrospectively reviewed. RESULTS "Favorable" outcome (alive with Glasgow Outcome Scale [GOS] score >= 4 at 6 months postinjury, n = 533) and "unfavorable" outcome (death at 6 months or GOS score <= 3 at 6 months postinjury, n = 32) were used as the primary outcomes. The area under the receiver operating characteristic (ROC) curve (AUC) was used to delineate the strength of each CT grading system in predicting survival (Helsinki, 0.814; Rotterdam, 0.838; and Marshall, 0.781). The AUC for CT score in predicting GOS score <= 3, a measure of overall functionality, was similarly predictive (Helsinki, 0.717; Rotterdam, 0.748; and Marshall, 0.663). An ANN was then constructed that was able to predict 6-month outcomes with profound accuracy (AUC = 0.9462 +/- 0.0422). CONCLUSIONS This study showed that machine-learning can be leveraged to more accurately predict TBI outcomes in children.	[Hale, Andrew T.; Brown, Amber; Lim, Jaims; Gannon, Stephen R.; Shannon, Chevis N.] Monroe Carell Jr Childrens Hosp Vanderbilt, Surg Outcomes Ctr Kids, Nashville, TN USA; [Le, Truc M.] Monroe Carell Jr Childrens Hosp Vanderbilt, Div Pediat Crit Care Med, Nashville, TN USA; [Hale, Andrew T.] Vanderbilt Univ, Sch Med, Med Scientist Training Program, Nashville, TN 37212 USA; [Stonko, David P.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Voce, David J.; Shannon, Chevis N.] Vanderbilt Univ, Dept Neurosurg, Med Ctr, Nashville, TN USA	Hale, AT (corresponding author), Vanderbilt Childrens Hosp, Nashville, TN 37232 USA.	andrew.hale@vanderbilt.edu		Hale, Andrew/0000-0003-3182-2966			BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; Buscema PM, 2014, SUBST USE MISUSE, V49, P1555, DOI 10.3109/10826084.2014.933009; Cross SS, 2003, LANCET, V362, P1250, DOI 10.1016/S0140-6736(03)14612-0; FORSSTROM JJ, 1995, ANN MED, V27, P509, DOI 10.3109/07853899509002462; Gholipour C, 2015, J CLIN DIAGN RES, V9, pOC19, DOI 10.7860/JCDR/2015/9467.5828; Jamal A, 2017, WORLD J EMERG MED, V8, P55, DOI 10.5847/wjem.j.1920-8642.2017.01.010; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Momenyan S, 2017, NEUROCRIT CARE, V27, P229, DOI 10.1007/s12028-016-0324-0; Penny W, 1996, MED DECIS MAKING, V16, P386, DOI 10.1177/0272989X9601600409; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Rughani AI, 2010, J NEUROSURG, V113, P585, DOI 10.3171/2009.11.JNS09857; Shi HY, 2013, J NEUROSURG, V118, P746, DOI 10.3171/2013.1.JNS121130; Walczak S, 2005, IEEE T INF TECHNOL B, V9, P468, DOI 10.1109/TITB.2005.847510; Wise ES, 2017, HEART SURG FORUM, V20, pE7, DOI 10.1532/hsf.1566; Yoldas O, 2012, AM J EMERG MED, V30, P1245, DOI 10.1016/j.ajem.2011.06.019; Zou Jinming, 2008, V458, P15	19	19	19	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2018	45	5							E2	10.3171/2018.8.FOCUS17773			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GY9PY	WOS:000448981700002	30453455	Bronze			2021-06-18	
J	Howell, DR; Zemek, R; Brilliant, AN; Mannix, RC; Master, CL; Meehan, WP				Howell, David R.; Zemek, Roger; Brilliant, Anna N.; Mannix, Rebekah C.; Master, Christina L.; Meehan, William P., III			Identifying Persistent Postconcussion Symptom Risk in a Pediatric Sports Medicine Clinic	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						mild traumatic brain injury; pediatric; recovery; postconcussion syndrome; assessment	ERROR SCORING SYSTEM; CONCUSSION MANAGEMENT; RECOVERY; ADOLESCENTS; DURATION; BALANCE; CHILDREN; ADULTS; ASSOCIATION; POPULATION	Background: Although most children report symptom resolution within a month of a concussion, some patients experience persistent postconcussion symptoms (PPCS) that continues for more than 1 month. Identifying patients at risk for PPCS soon after an injury can provide useful clinical information. Purpose: To determine if the Predicting Persistent Post-concussive Problems in Pediatrics (5P) clinical risk score, an emergency department (ED)-derived and validated tool, is associated with developing PPCS when obtained in a primary care sports concussion setting. Study Design: Cohort study; Level of evidence, 3. Methods: We conducted a study of patients seen at a pediatric sports medicine concussion clinic between May 1, 2013, and October 1, 2017, who were <19 years of age and evaluated within 10 days of a concussion. The main outcome was PPCS, defined as symptoms lasting >28 days. Nine variables were used to calculate the 5P clinical risk score, and we assessed the association between the 5P clinical risk score and PPCS occurrence. The secondary outcome was total symptom duration. Results: We examined data from 230 children (mean age, 14.8 +/- 2.5 years; 50% female; mean time from injury to clinical assessment, 5.6 +/- 2.7 days). In univariable analyses, a greater proportion of those who developed PPCS reported feeling slowed down (72% vs 44%, respectively; P < .001), headache (94% vs 72%, respectively; P < .001), sensitivity to noise (71% vs 43%, respectively; P < .001), and fatigue (82% vs 51%, respectively; P < .001) and committed >= 4 errors in tandem stance (33% vs 7%, respectively; P < .001) than those who did not. Higher 5P clinical risk scores were associated with increased odds of developing PPCS (adjusted odds ratio [OR], 1.62 [95% CI, 1.30-2.02]) and longer symptom resolution times (beta = 8.40 [95% CI, 3.25-13.50]). Among the individual participants who received a high 5P clinical risk score (9-12), the majority (82%) went on to experience PPCS. The area under the curve for the 5P clinical risk score was 0.75 (95% CI, 0.66-0.84). After adjusting for the effect of covariates, fatigue (adjusted OR, 2.93) and >= 4 errors in tandem stance (adjusted OR, 7.40) were independently associated with PPCS. Conclusion: Our findings extend the potential use for an ED-derived clinical risk score for predicting the PPCS risk into the sports concussion clinic setting. While not all 9 predictor variables of the 5P clinical risk score were independently associated with the PPCS risk in univariable or multivariable analyses, the combination of factors used to calculate the 5P clinical risk score was significantly associated with the odds of developing PPCS. Thus, obtaining clinically pragmatic risk scores soon after a concussion may be useful for early treatments or interventions to mitigate the PPCS risk.	[Howell, David R.; Zemek, Roger; Brilliant, Anna N.; Mannix, Rebekah C.; Master, Christina L.; Meehan, William P., III] Boston Childrens Hosp, Sports Concuss Clin, Boston, MA USA; [Howell, David R.] Childrens Hosp Colorado, Ctr Sports Med, 13123 East 16th Ave,B060, Aurora, CO 80045 USA; [Howell, David R.] Univ Colorado, Sch Med, Dept Orthoped, Aurora, CO USA; [Howell, David R.; Brilliant, Anna N.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Zemek, Roger] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON, Canada; [Brilliant, Anna N.; Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Mannix, Rebekah C.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Mannix, Rebekah C.; Meehan, William P., III] Boston Childrens Hosp, Dept Pediat, Boston, MA USA; [Master, Christina L.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Philadelphia, PA 19104 USA; [Master, Christina L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	Howell, DR (corresponding author), Childrens Hosp Colorado, Ctr Sports Med, 13123 East 16th Ave,B060, Aurora, CO 80045 USA.	David.Howell@ucdenver.edu	Mannix, Rebekah/AAD-8702-2020	Master, Christina/0000-0002-6717-4270	National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament; Boston Children's Hospital; Cincinnati Children's Hospital Medical Center; ElMindA	D.R.H. and A.N.B. were supported, in part, through a research contract between Boston Children's Hospital, Cincinnati Children's Hospital Medical Center, and ElMindA. W.P.M. receives royalties from ABC-CLIO for the sale of his books (Kids, Sports, and Concussion: A Guide for Coaches and Parents and Concussions), Springer for the sale of a book (Head and Neck Injuries in Young Athletes), and Wolters Kluwer for working as an author for UpToDate. His research is funded, in part, by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.	Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Heyer GL, 2016, J PEDIATR-US, V174, P33, DOI 10.1016/j.jpeds.2016.03.014; Houston MN, 2016, BRAIN INJURY, V30, P891, DOI 10.3109/02699052.2016.1146960; Howell DR, 2017, J NEUROTRAUM, V34, P3288, DOI 10.1089/neu.2017.5191; Howell DR, 2017, CLIN J SPORT MED, V27, P444, DOI 10.1097/JSM.0000000000000374; Howell DR, 2016, ACTA PAEDIATR, V105, pE426, DOI 10.1111/apa.13486; Howell DR, 2016, AM J SPORT MED, V44, P1040, DOI 10.1177/0363546515625045; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Iverson GL, 2013, BRAIN INJURY, V27, P596, DOI 10.3109/02699052.2013.772237; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McDevitt J, 2015, BRAIN INJURY, V29, P1674, DOI 10.3109/02699052.2015.1075252; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Oldham JR, 2018, MED SCI SPORT EXER, V50, P1162, DOI 10.1249/MSS.0000000000001540; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Stache S, 2016, CLIN J SPORT MED, V26, P381, DOI 10.1097/JSM.0000000000000270; Worster A, 2004, ACAD EMERG MED, V11, P187, DOI 10.1197/j.aem.2003.03.002; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	32	19	19	1	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2018	46	13					3254	3261		10.1177/0363546518796830			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	HA5WM	WOS:000450350300021	30265817				2021-06-18	
J	Jha, RM; Koleck, TA; Puccio, AM; Okonkwo, DO; Park, SY; Zusman, BE; Clark, RSB; Shutter, LA; Wallisch, JS; Empey, PE; Kochanek, PM; Conley, YP				Jha, Ruchira Menka; Koleck, Theresa A.; Puccio, Ava M.; Okonkwo, David O.; Park, Seo-Young; Zusman, Benjamin E.; Clark, Robert S. B.; Shutter, Lori A.; Wallisch, Jessica S.; Empey, Philip E.; Kochanek, Patrick M.; Conley, Yvette P.			Regionally clustered ABCC8 polymorphisms in a prospective cohort predict cerebral oedema and outcome in severe traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SULFONYLUREA RECEPTOR 1; SINGLE NUCLEOTIDE POLYMORPHISMS; EFFICACY; SYSTEM; VISUALIZATION; ASSOCIATION; GLYBURIDE; VARIANTS; GENOTYPE	Objective ABCC8 encodes sulfonylurea receptor 1, a key regulatory protein of cerebral oedema in many neurological disorders including traumatic brain injury (TBI). Sulfonylurea-receptor-1 inhibition has been promising in ameliorating cerebral oedema in clinical trials. We evaluated whether ABCC8 tag single-nucleotide polymorphisms predicted oedema and outcome in TBI. Methods DNA was extracted from 485 prospectively enrolled patients with severe TBI. 410 were analysed after quality control. ABCC8 tag single-nucleotide polymorphisms (SNPs) were identified (Hapmap, r(2)>0.8, minor-allele frequency >0.20) and sequenced (iPlex-Gold, MassArray). Outcomes included radiographic oedema, intracranial pressure (ICP) and 3-month Glasgow Outcome Scale (GOS) score. Proxy SNPs, spatial modelling, amino acid topology and functional predictions were determined using established software programs. Results Wild-type rs7105832 and rs2237982 alleles and genotypes were associated with lower average ICP (beta=-2.91, p=0.001; beta=-2.28, p=0.003) and decreased radiographic oedema (OR 0.42, p=0.012; OR 0.52, p=0.017). Wild-type rs2237982 also increased favourable 3-month GOS (OR 2.45, p=0.006); this was partially mediated by oedema (p=0.03). Different polymorphisms predicted 3-month outcome: variant rs11024286 increased (OR 1.84, p=0.006) and wild-type rs4148622 decreased (OR 0.40, p=0.01) the odds of favourable outcome. Significant tag and concordant proxy SNPs regionally span introns/exons 2-15 of the 39-exon gene. Conclusions This study identifies four ABCC8 tag SNPs associated with cerebral oedema and/or outcome in TBI, tagging a region including 33 polymorphisms. In polymorphisms predictive of oedema, variant alleles/genotypes confer increased risk. Different variant polymorphisms were associated with favourable outcome, potentially suggesting distinct mechanisms. Significant polymorphisms spatially clustered flanking exons encoding the sulfonylurea receptor site and transmembrane domain 0/loop 0 (juxtaposing the channel pore/binding site). This, if validated, may help build a foundation for developing future strategies that may guide individualised care, treatment response, prognosis and patient selection for clinical trials.	[Jha, Ruchira Menka; Clark, Robert S. B.; Shutter, Lori A.; Wallisch, Jessica S.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Sch Med, Pittsburgh, PA 15260 USA; [Jha, Ruchira Menka; Shutter, Lori A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Jha, Ruchira Menka; Puccio, Ava M.; Okonkwo, David O.; Zusman, Benjamin E.; Shutter, Lori A.] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Jha, Ruchira Menka; Clark, Robert S. B.; Wallisch, Jessica S.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Jha, Ruchira Menka; Empey, Philip E.; Kochanek, Patrick M.; Conley, Yvette P.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA; [Koleck, Theresa A.] Columbia Univ, Sch Nursing, New York, NY USA; [Park, Seo-Young] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Park, Seo-Young] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA; [Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesia, Pittsburgh, PA USA; [Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Human Genet, Sch Med, Pittsburgh, PA USA	Jha, RM (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Neurol, Neurosurg, Pittsburgh, PA 15260 USA.	jharm3@upmc.edu	Shutter, Lori A/G-2957-2013; Empey, Philip/L-9604-2019	Empey, Philip/0000-0001-7474-2339; Jha, Ruchira/0000-0002-3047-7649; Conley, Yvette/0000-0002-1784-6067; Wallisch, Jessica/0000-0002-7908-9479; Shutter, Lori/0000-0002-1390-0628	U.S. Department of Health and Human Services; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T-32HL007820, NCATS KL2-TR000146, NCATS KL2-TR001856, NINDS K23NS101036, NINR F31NR014590, T32NR007969, NINR R00 NR013176, NICHD T32-HD040686, 1R01NS087978-01, NINR R01NR013342]; UPP Foundation Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001856, KL2TR000146] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS101036, R01NS087978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013342, R00NR013176, F31NR014590, T32NR007969] Funding Source: NIH RePORTER	This study was funded by U.S. Department of Health and Human Services. RMJ discloses funding by the following NIH grants: T-32HL007820, NCATS KL2-TR000146, NCATS KL2-TR001856 and NINDS K23NS101036. TAK discloses NIH funding NINR F31NR014590 and T32NR007969. AMP discloses funding by the NIH grant NINR R00 NR013176. JSW discloses funding by the NIH grant NICHD T32-HD040686. PEE reports no disclosures. PMK discloses funding by the NIH grant 1R01NS087978-01. YPC discloses funding by the NIH grant NINR R01NR013342. RMJ have received a UPP Foundation Award.	Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Feng Y, 2008, DIABETES CARE, V31, P1939, DOI 10.2337/dc07-2248; Flanagan SE, 2009, HUM MUTAT, V30, P170, DOI 10.1002/humu.20838; Jablonski KA, 2010, DIABETES, V59, P2672, DOI 10.2337/db10-0543; Jha RM, 2017, NEUROCRIT CARE, V26, P213, DOI 10.1007/s12028-016-0309-z; Jha Ruchira M, 2017, Crit Care Med, V45, pe255, DOI 10.1097/CCM.0000000000002079; Kimberly WT, 2014, NEUROCRIT CARE, V20, P193, DOI 10.1007/s12028-013-9917-z; Knuppel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068941; Lee PH, 2009, BIOINFORMATICS, V25, P1048, DOI 10.1093/bioinformatics/btp103; Li NN, 2017, CELL, V168, P101, DOI 10.1016/j.cell.2016.12.028; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; Mall T, 2016, BIOINFORMATICS, V32, P2499, DOI 10.1093/bioinformatics/btw068; Marmarou A, 2007, NEUROSURG FOCUS, V22, pE1, DOI DOI 10.3171/F0C.2007.22.5.2; Martinez-Valverde T, 2015, J NEUROTRAUM, V32, P1478, DOI 10.1089/neu.2014.3706; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; Narum SR, 2006, CONSERV GENET, V7, P783, DOI 10.1007/s10592-005-9056-y; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; Omasits U, 2014, BIOINFORMATICS, V30, P884, DOI 10.1093/bioinformatics/btt607; Osier ND, 2017, J NEUROTRAUM, V34, P86, DOI 10.1089/neu.2015.4343; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Schwamm LH, 2014, NEW ENGL J MED, V371, P2522, DOI 10.1056/NEJMe1412951; Shah S, 2016, SEMIN NEUROL, V36, P502, DOI 10.1055/s-0036-1592109; Sheth KN, 2016, LANCET NEUROL, V15, P1160, DOI 10.1016/S1474-4422(16)30196-X; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Weaver SM, 2014, BRAIN IMAGING BEHAV, V8, P420, DOI 10.1007/s11682-012-9197-9; Winkler EA, 2017, J CLIN NEUROSCI, V35, P109, DOI 10.1016/j.jocn.2016.09.017; Winkler EA, 2016, NEUROGENETICS, V17, P31, DOI 10.1007/s10048-015-0467-8; Woo SK, J BIOL CHEM; Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157; Yue JK, 2017, NEUROGENETICS, V18, P29, DOI 10.1007/s10048-016-0500-6; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098	39	19	19	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2018	89	11					1152	1162		10.1136/jnnp-2017-317741			11	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	HA6VV	WOS:000450420200006	29674479	Green Accepted			2021-06-18	
J	Zheng, B; Zhang, SC; Ying, YL; Guo, XY; Li, HC; Xu, LX; Ruan, XC				Zheng, Bin; Zhang, Shuncai; Ying, Yanlu; Guo, Xinying; Li, Hengchang; Xu, Lixin; Ruan, Xiangcai			Administration of Dexmedetomidine inhibited NLRP3 inflammasome and microglial cell activities in hippocampus of traumatic brain injury rats	BIOSCIENCE REPORTS			English	Article							INNATE IMMUNE-RESPONSE; ACTIVATION; EXPRESSION; ISCHEMIA; STRESS	The abnormally high nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activity is a typical characteristic of traumatic brain injury (TBI). Dexmedetomidine (Dex) is a highly selective alpha-2 adrenergic receptor agonist that inhibits the activation of NLRP3. Thus, it was hypothesized that Dex could attenuate TBI by inhibiting NLRP3 inflammasome activity in hippocampus. Rats were subjected to controlled cortical impact method to induce TBI, and treated with Dex. The effect of Dex treatment on the cognitive function, NLRP3 activity, and microglial activation in rat brain tissues was assessed. The administration of Dex improved performance of TBI rats in Morris water maze (MWM) test, which was associated with the increased neurone viability and suppressed microglia activity. Moreover, the administration of Dex inhibited the neuroinflammation in brain tissue as well as the expressions of NLRP3 and caspase-1. Additionally, Dex and NLRP3 inhibitor, BAY-11-7082 had a synergistic effect in inhibiting NLRP3/caspase-1 axis activity and improving TBI. The findings outlined in the current study indicated that the improvement effect of Dex on TBI was related to its effect on NLRP3 activity.	[Zheng, Bin] Jinan Univ, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China; [Zheng, Bin; Zhang, Shuncai; Ying, Yanlu; Guo, Xinying; Li, Hengchang; Xu, Lixin; Ruan, Xiangcai] South China Univ Technol, Guangzhou Peoples Hosp 1, Dept Anesthesiol, Sch Med, Guangzhou, Guangdong, Peoples R China; [Zhang, Shuncai] Jieyang Peoples Hosp, Dept Anesthesiol, Jieyang, Peoples R China	Ruan, XC (corresponding author), South China Univ Technol, Guangzhou Peoples Hosp 1, Dept Anesthesiol, Sch Med, Guangzhou, Guangdong, Peoples R China.	xc_ruan@hotmail.com	Ruan, Xiangcai/L-9904-2016	Ruan, Xiangcai/0000-0001-6112-7994	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271196]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2016A030313440]; Guangzhou Planned Project of Scinece and Technology [201607010119, 201607010132]	This work was supported by the National Natural Science Foundation of China [grant number 81271196]; the Natural Science Foundation of Guangdong Province [grant number 2016A030313440]; and the Guangzhou Planned Project of Scinece and Technology [grant numbers 201607010119, 201607010132].	Chi XH, 2016, J CARDIOTHOR VASC AN, V30, P44, DOI 10.1053/j.jvca.2015.06.026; Cho JS, 2016, KIDNEY INT, V89, P693, DOI 10.1038/ki.2015.306; [褚芹 Chu Qin], 2005, [中国行为医学科学, Chinese Journal of Behavioral Medical Science], V14, P964; Dowling JK, 2012, CRIT REV BIOCHEM MOL, V47, P424, DOI 10.3109/10409238.2012.694844; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Faul M., 2004, EMERGENCY SERVICE HO, V16, pA268; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Franchi L, 2014, J IMMUNOL, V193, P4214, DOI 10.4049/jimmunol.1400582; Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231; Gao SQ, 2015, INT J CLIN EXP PATHO, V8, P3144; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Keating GM, 2015, DRUGS, V75, P1119, DOI 10.1007/s40265-015-0419-5; Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu CZ, 2006, EXP NEUROL, V201, P452, DOI 10.1016/j.expneurol.2006.04.025; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu YJ, 2017, BMC ANESTHESIOL, V17, DOI 10.1186/s12871-017-0413-4; Lv MH, 2018, INT IMMUNOPHARMACOL, V54, P46, DOI 10.1016/j.intimp.2017.10.030; Man SM, 2015, IMMUNOL REV, V265, P6, DOI 10.1111/imr.12296; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Sahin T, 2013, J SURG RES, V183, P385, DOI 10.1016/j.jss.2012.11.034; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sato K, 2010, ACTA ANAESTH SCAND, V54, P377, DOI 10.1111/j.1399-6576.2009.02139.x; Schoeler M, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-20; Sha WW, 2014, P NATL ACAD SCI USA, V111, P16059, DOI 10.1073/pnas.1412487111; Shen M, 2017, BIOMED PHARMACOTHER, V95, P885, DOI 10.1016/j.biopha.2017.08.125; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wu J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23003-3; Zendedel A, 2018, MOL NEUROBIOL, V55, P1364, DOI 10.1007/s12035-017-0400-2; Zhang MH, 2018, MOL MED REP, V17, P8079, DOI 10.3892/mmr.2018.8898; Zhang QY, 2017, CELL PHYSIOL BIOCHEM, V42, P1907, DOI 10.1159/000479609; Zhou KR, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9238290	42	19	19	0	5	PORTLAND PRESS LTD	LONDON	5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND	0144-8463	1573-4935		BIOSCIENCE REP	Biosci. Rep.	OCT 31	2018	38		5						BSR20180892	10.1042/BSR20180892			11	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	GY8QO	WOS:000448897800077	30232232	DOAJ Gold, Green Published			2021-06-18	
J	Valera, EM; Cao, AH; Pasternak, O; Shenton, ME; Kubicki, M; Makris, N; Adra, N				Valera, Eve M.; Cao, Aihua; Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek; Makris, Nikos; Adra, Noor			White Matter Correlates of Mild Traumatic Brain Injuries in Women Subjected to Intimate-Partner Violence: A Preliminary Study	JOURNAL OF NEUROTRAUMA			English	Article						corona radiata; diffusion tensor imaging; domestic violence; intimate-partner violence; mild traumatic brain injury	FREE-WATER ELIMINATION; TOPOGRAPHIC PARCELLATION; SALIENCE NETWORK; IN-VIVO; DIFFUSION; CONCUSSION; MULTISITE; PREVALENCE; INTEGRITY; FASCICLE	A large proportion (range of 44-75%) of women who experience intimate-partner violence (IPV) have been shown to sustain repetitive mild traumatic brain injuries (mTBIs) from their abusers. Further, despite requests for research on TBI-related health outcomes, there are currently only a handful of studies addressing this issue and only one prior imaging study that has investigated the neural correlates of IPV-related TBIs. In response, we examined specific regions of white matter microstructure in 20 women with histories of IPV. Subjects were imaged on a 3-Tesla Siemens Magnetom TrioTim scanner using diffusion magnetic resonance imaging. We investigated the association between a score reflecting number and recency of IPV-related mTBIs and fractional anisotropy (FA) in the posterior and superior corona radiata as well as the posterior thalamic radiation, brain regions shown previously to be involved in mTBI. We also investigated the association between several cognitive measures, namely learning, memory, and cognitive flexibility, and FA in the white matter regions of interest. We report a negative correlation between the brain injury score and FA in regions of the posterior and superior corona radiata. We failed to find an association between our cognitive measures and FA in these regions, but the interpretation of these results remains inconclusive due to possible power issues. Overall, these data build upon the small but growing literature demonstrating potential consequences of mTBIs for women experiencing IPV, and further underscore the urgent need for larger and more comprehensive studies in this area.	[Valera, Eve M.; Cao, Aihua; Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek; Makris, Nikos; Adra, Noor] Harvard Med Sch, Dept Psychiat, Boston, MA USA; [Valera, Eve M.; Cao, Aihua; Kubicki, Marek; Makris, Nikos; Adra, Noor] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA; [Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek; Makris, Nikos] Harvard Med Sch, Dept Radiol, Boston, MA USA; [Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA; [Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek] Brigham & Womens Hosp, Dept Psychiat, 75 Francis St, Boston, MA 02115 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA; [Makris, Nikos] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA; [Adra, Noor] Wellesley Coll, Wellesley, MA 02181 USA	Valera, EM (corresponding author), Massachusetts Gen Hosp, Psychiat, Room 2660,149 Thirteenth St, Charlestown, MA 02129 USA.	eve_valera@hms.harvard.edu	Shenton, Martha/V-8780-2019	Adra, Noor/0000-0001-7214-6293	Harvard Medical School Center of Excellence grant from the HMS Fund for Women's Health; NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR14075, P41 EB015896]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1S10RR023043, 1S10RR023401]; VA Merit AwardUS Department of Veterans Affairs [I01 RX00928]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81401131]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2015M572049]; China State Scholarship Fund;  [NIH R21AT008865];  [NIH R01 AG042512];  [NIH R01 MH102377];  [NIH R01 MH112748];  [NIH K24 MH110807];  [NIH P41 EB015902];  [NIH R01MH111917];  [R01MH112748]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AT008865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015896, P41EB015902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH102377, R01MH112748, K24MH110807, R01MH111917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG042512] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000928] Funding Source: NIH RePORTER	We thank all of the women who participated in this study. We thank Brittany LeBlanc for data management assistance, Drs. Michael Alexander, Margaret O'Connor, and Gregory Sorensen for helpful advice in developing this project. This work was supported by a Harvard Medical School Center of Excellence grant from the HMS Fund for Women's Health (EMV), and grants provided to the Athinoula A. Martinos Center for Biomedical Imaging, NCRR P41RR14075 and P41 EB015896. This work also involved the use of instrumentation supported by the National Institutes of Health (NIH) Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program; specifically, grant numbers 1S10RR023043 and 1S10RR023401. The study was also supported by the following grants: NIH R21AT008865, NIH R01 AG042512, NIH R01 MH102377, NIH R01 MH112748, NIH K24 MH110807 to MK; NIH P41 EB015902 to OP; NIH R01MH111917 and R01MH112748 to NM; VA Merit Award I01 RX00928 to MS; and National Natural Science Foundation of China, grant 81401131, China Postdoctoral Science Foundation, grant 2015M572049, and China State Scholarship Fund to AC.	Albi A, 2017, HUM BRAIN MAPP, V38, P12, DOI 10.1002/hbm.23350; [Anonymous], 2011, NATL INTIMATE PARTNE; Army Individual Test Battery, 1944, MAN DIR SCOR; Averill C.L., 2017, CHRONIC STRESS, P1; Baumgartner C., 2012, UNIFIED TRACTOGRAPHY; Bernstein DP, 1997, J AM ACAD CHILD PSY, V36, P340, DOI 10.1097/00004583-199703000-00012; BERNSTEIN DP, 1994, AM J PSYCHIAT, V151, P1132, DOI 10.1176/ajp.151.8.1132; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Campbell JC, 2003, AM J PUBLIC HEALTH, V93, P1089, DOI 10.2105/AJPH.93.7.1089; Catalano S.M., 2013, INTIMATE PARTNER VIO; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Committee on Mild Traumatic Brain Injury and American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P48; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Defense & Veterans Brain Injury Center, 2017, DOD WORLDW NUMB TBI; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; Devries KM, 2013, SCIENCE, V340, P1527, DOI 10.1126/science.1240937; Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001; Finkbeiner NWB, 2016, CAN J PSYCHIAT, V61, P270, DOI 10.1177/0706743716644953; Gajawelli N, 2013, WORLD NEUROSURG, V80, P824, DOI 10.1016/j.wneu.2013.10.020; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Jahanshad N, 2013, NEUROIMAGE, V81, P455, DOI 10.1016/j.neuroimage.2013.04.061; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Kircanski K, 2018, JAMA PSYCHIAT, V75, P631, DOI 10.1001/jamapsychiatry.2018.0468; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; Lipsky S, 2007, PSYCHIAT SERV, V58, P822, DOI 10.1176/appi.ps.58.6.822; Makris N, 1999, NEUROIMAGE, V9, P18, DOI 10.1006/nimg.1998.0384; Makris N, 2005, CEREB CORTEX, V15, P854, DOI 10.1093/cercor/bhh186; Makris N, 2007, NEUROIMAGE, V37, P1100, DOI 10.1016/j.neuroimage.2007.05.042; MARSHALL LL, 1992, J FAM VIOLENCE, V7, P103, DOI 10.1007/BF00978700; McAllister T, 2017, J ATHL TRAINING, V52, P309, DOI 10.4085/1062-6050-52.1.14; Metzler-Baddeley C, 2012, NEUROIMAGE, V59, P1394, DOI 10.1016/j.neuroimage.2011.08.043; Meyer JW, 1999, NEUROIMAGE, V9, P1, DOI 10.1006/nimg.1998.0383; Mori S., 2005, MRI ATLAS HUMAN WHIT; Murray CE, 2016, TRAUMA VIOLENCE ABUS, V17, P298, DOI 10.1177/1524838015584364; Murrough JW, 2016, HUM BRAIN MAPP, V37, P3214, DOI 10.1002/hbm.23235; National Center for Injury Prevention and Control, 2003, COSTS INTIMATE PARTN; National Football League, 2018, NFL REL INJ DAT 2017; Pasternak O, 2012, LECT NOTES COMPUT SC, V7511, P305, DOI 10.1007/978-3-642-33418-4_38; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Plichta SB, 2001, WOMEN HEALTH ISS, V11, P244, DOI 10.1016/S1049-3867(01)00085-8; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; St Ivany A, 2016, FAM COMMUNITY HEALTH, V39, P129, DOI 10.1097/FCH.0000000000000094; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; The United States Censu Burea, 2011, AGE SEX COMPOSITION; Valera E., 2016, TRAUMA BRAIN IMAGING, V11, P1664, DOI DOI 10.1007/s11682-016-9643-1; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wilkinson G, 1993, WRAT3 WIDE RANGE ACH; Wilson M, 1994, Juristat, V14, P1; Wrocklage KM, 2017, EUR NEUROPSYCHOPHARM, V27, P515, DOI 10.1016/j.euroneuro.2017.02.010; Zieman G, 2017, J NEUROTRAUM, V34, P876, DOI 10.1089/neu.2016.4579	55	19	19	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2019	36	5					661	668		10.1089/neu.2018.5734		OCT 2018	8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HR2BG	WOS:000446466800001	29873292	Green Published			2021-06-18	
J	Abe, N; Choudhury, ME; Watanabe, M; Kawasaki, S; Nishihara, T; Yano, H; Matsumoto, S; Kunieda, T; Kumon, Y; Yorozuya, T; Tanaka, J				Abe, Naoki; Choudhury, Mohammed E.; Watanabe, Minori; Kawasaki, Shun; Nishihara, Tasuku; Yano, Hajime; Matsumoto, Shirabe; Kunieda, Takehiro; Kumon, Yoshiaki; Yorozuya, Toshihiro; Tanaka, Junya			Comparison of the detrimental features of microglia and infiltrated macrophages in traumatic brain injury: A study using a hypnotic bromovalerylurea	GLIA			English	Article						CCL2; FACS; glycolysis; mitochondria; oxidative stress; ROS	NITRIC-OXIDE SYNTHASE; NG2 PROTEOGLYCAN; OXIDATIVE STRESS; NEURONAL DEATH; CELL-DEATH; STROKE; DAMAGE; NEUROPROTECTION; EXPRESSION; CONTRIBUTE	Microglia and blood-borne macrophages in injured or diseased brains are difficult to distinguish because they share many common characteristics. However, the identification of microglia-specific markers and the use of flow cytometry have recently made it easy to discriminate these types of cells. In this study, we analyzed the features of blood-borne macrophages, and activated and resting microglia in a rat traumatic brain injury (TBI) model. Oxidative injury was indicated in macrophages and neurons in TBI lesions by the presence of 8-hydroxy-2'-deoxyguanosine (8-OHdG). Generation of mitochondrial reactive oxygen species (ROS) was markedly observed in granulocytes and macrophages, but not in activated or resting microglia. Dihydroethidium staining supported microglia not being the major source of ROS in TBI lesions. Furthermore, macrophages expressed NADPH oxidase 2, interleukin-1 beta (IL-1 beta), and CD68 at higher levels than microglia. In contrast, microglia expressed transforming growth factor beta 1 (TGF beta 1), interleukin-6 (IL-6), and tumor necrosis factor alpha at higher levels than macrophages. A hypnotic, bromovalerylurea (BU), which has anti-inflammatory effects, reduced both glycolysis and mitochondrial oxygen consumption. BU administration inhibited chemokine CCL2 expression, accumulation of monocytes/macrophages, 8-OHdG generation, mitochondrial ROS generation, and proinflammatory cytokine expression, and markedly ameliorated the outcome of the TBI model. Yet, BU did not inhibit microglial activation or expression of TGF beta 1 and insulin-like growth factor 1 (IGF-1). These results indicate that macrophages are the major aggravating cell type in TBI lesions, in particular during the acute phase. Activated microglia may even play favorable roles. Reduction of cellular energy metabolism in macrophages and suppression of CCL2 expression in injured tissue may lead to amelioration of TBI.	[Abe, Naoki; Choudhury, Mohammed E.; Watanabe, Minori; Kawasaki, Shun; Yano, Hajime; Tanaka, Junya] Ehime Univ, Grad Sch Med, Dept Mol & Cellular Physiol, Toon, Ehime 7910295, Japan; [Abe, Naoki; Nishihara, Tasuku; Yorozuya, Toshihiro] Ehime Univ, Grad Sch Med, Dept Anesthesia & Perioperat Med, Toon, Ehime, Japan; [Kawasaki, Shun] Fujita Hlth Univ, Dept Surg & Palliat Med, Sch Med, Toyoake, Aichi, Japan; [Matsumoto, Shirabe; Kunieda, Takehiro; Kumon, Yoshiaki] Ehime Univ, Grad Sch Med, Dept Neurosurg, Toon, Ehime, Japan	Tanaka, J (corresponding author), Ehime Univ, Grad Sch Med, Dept Mol & Cellular Physiol, Toon, Ehime 7910295, Japan.	jtanaka@m.ehime-u.ac.jp	Tanaka, Junya/Y-1033-2019	Tanaka, Junya/0000-0003-1056-5948	Ministry of Education; Ehime University	Ministry of Education; Ehime University; Ehime University	Ansari MA, 2014, FREE RADICAL BIO MED, V77, P21, DOI 10.1016/j.freeradbiomed.2014.08.025; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Banh RS, 2016, NAT CELL BIOL, V18, P803, DOI 10.1038/ncb3376; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Berman JW, 1996, J IMMUNOL, V156, P3017; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Chouchani ET, 2014, NATURE, V515, P431, DOI 10.1038/nature13909; Chu HX, 2015, STROKE, V46, P1929, DOI 10.1161/STROKEAHA.115.009426; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Gao L, 2008, VET CLIN N AM-SMALL, V38, P137, DOI 10.1016/j.cvsm.2007.10.004; Garaude J, 2016, NAT IMMUNOL, V17, P1037, DOI 10.1038/ni.3509; Gyoneva S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0443-0; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hattori T, 2017, GLIA, V65, P974, DOI 10.1002/glia.23139; Heid ME, 2013, J IMMUNOL, V191, P5230, DOI 10.4049/jimmunol.1301490; Higaki H, 2016, NEUROCHEM INT, V99, P158, DOI 10.1016/j.neuint.2016.06.013; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Islam A, 2018, BBA-MOL BASIS DIS, V1864, P721, DOI 10.1016/j.bbadis.2017.12.022; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kawasaki S, 2017, J PHARMACOL SCI, V134, P116, DOI 10.1016/j.jphs.2017.05.007; Kikuchi S, 2015, BIOCHEM BIOPH RES CO, V459, P319, DOI 10.1016/j.bbrc.2015.02.111; Konishi H, 2017, GLIA, V65, P1927, DOI 10.1002/glia.23204; Lashgari R, 2006, BEHAV BRAIN RES, V171, P324, DOI 10.1016/j.bbr.2006.04.013; Latz E, 2010, BLOOD, V116, P1393, DOI 10.1182/blood-2010-06-287342; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu S, 2013, J MOL NEUROSCI, V51, P1021, DOI 10.1007/s12031-013-0091-8; Matsumoto H, 2007, J NEUROSCI RES, V85, P994, DOI 10.1002/jnr.21198; Matsumoto H, 2008, J CEREBR BLOOD F MET, V28, P149, DOI 10.1038/sj.jcbfm.9600519; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Miro-Mur F, 2016, BRAIN BEHAV IMMUN, V53, P18, DOI 10.1016/j.bbi.2015.08.010; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Neher JJ, 2013, P NATL ACAD SCI USA, V110, pE4098, DOI 10.1073/pnas.1308679110; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Nishihara T, 2011, EXP NEUROL, V229, P507, DOI 10.1016/j.expneurol.2011.04.006; Nishioka R, 2016, EXP NEUROL, V277, P150, DOI 10.1016/j.expneurol.2015.12.016; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Rastogi L, 2006, EXP NEUROL, V200, P290, DOI 10.1016/j.expneurol.2006.02.013; Ritzel RM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0329-1; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Satoh J, 2016, NEUROPATHOLOGY, V36, P39, DOI 10.1111/neup.12235; Semple BD, 2015, NEUROBIOL DIS, V74, P263, DOI 10.1016/j.nbd.2014.12.003; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Serrano-Nascimento C, 2014, ENDOCRINOLOGY, V155, P1145, DOI 10.1210/en.2013-1665; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smirkin A, 2010, J CEREBR BLOOD F MET, V30, P603, DOI 10.1038/jcbfm.2009.233; Song L, 2011, J LIPID RES, V52, P1542, DOI 10.1194/jlr.M015412; Song SJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071418; Stankovic ND, 2016, ACTA NEUROPATHOL, V131, P347, DOI 10.1007/s00401-015-1524-y; Sugimoto K, 2014, GLIA, V62, P185, DOI 10.1002/glia.22598; Tanaka J, 1998, GLIA, V24, P198, DOI 10.1002/(SICI)1098-1136(199810)24:2<198::AID-GLIA5>3.3.CO;2-S; Taylor RA, 2017, J CLIN INVEST, V127, P280, DOI 10.1172/JCI88647; Tei N, 2013, J NEUROSCI RES, V91, P681, DOI 10.1002/jnr.23202; Toku K, 1998, J NEUROSCI RES, V53, P415, DOI 10.1002/(SICI)1097-4547(19980815)53:4<415::AID-JNR3>3.0.CO;2-9; Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684; Vilalta A, 2018, FEBS J, V285, P3566, DOI 10.1111/febs.14323; Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016; Weaver KD, 2000, J TRAUMA, V48, P1081, DOI 10.1097/00005373-200006000-00014; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yokoyama A, 2006, GLIA, V53, P754, DOI 10.1002/glia.20332; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	70	19	20	3	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	OCT	2018	66	10					2158	2173		10.1002/glia.23469			16	Neurosciences	Neurosciences & Neurology	HA5LA	WOS:000450312100008	30194744				2021-06-18	
J	Garrigan, B; Adlam, ALR; Langdon, PE				Garrigan, Beverley; Adlam, Anna L. R.; Langdon, Peter E.			Moral decision-making and moral development: Toward an integrative framework	DEVELOPMENTAL REVIEW			English	Article						Moral decision-making; Moral development; Moral reasoning; Perspective taking; Social information processing	TRAUMATIC BRAIN-INJURY; INFORMATION-PROCESSING PROBLEMS; WORKING-MEMORY; CHILDRENS CONCEPTIONS; FACIAL EXPRESSIONS; AGGRESSIVE-BEHAVIOR; ATTENTION NETWORKS; AFFECTIVE EMPATHY; SOCIAL COGNITION; RISK-TAKING	How moral decision-making occurs, matures over time and relates to behaviour is complex. To develop a full picture of moral decision-making, moral development and moral behaviour it is necessary to understand: (a) how real-time moral decisions are made (including relevant social and contextual factors), (b) what processes are required to develop to enable mature moral decisions, (c) how these processes develop over time, and (d) how moral decisions relate to behaviour. In this paper, psychological and social neuroscience theories of moral decision-making and development are briefly reviewed, as is the development of relevant component processes. Various component processes and factors are seen as required for moral decision-making and development, yet there is no comprehensive framework incorporating these components into one explanation of how real-time moral decisions are made and mature. In this paper, we integrated these components into a new framework based on social information processing (SIP) theory. Situational factors, and how both cognitive and affective processes guide moral decisions was incorporated into the Social Information Processing-Moral Decision-Making (SIP-MDM) framework, drawing upon theories and findings from developmental psychology and social neuroscience. How this framework goes beyond previous SIP models was outlined, followed by a discussion of how it can explain both real-time moral decisions and moral development. We concluded with how the SIP-MDM framework could be used to guide future research and theory development in this area.	[Garrigan, Beverley] Univ East Anglia, Norwich Med Sch, Dept Clin Psychol, Norwich, Norfolk, England; [Adlam, Anna L. R.] Univ Exeter, Coll Life & Environm Sci, Sch Psychol, Exeter, Devon, England; [Langdon, Peter E.] Hertfordshire Partnership Univ NHS Fdn Trust Norf, Broadland Clin, Exeter, Devon, England	Langdon, PE (corresponding author), Univ Kent, Tizard Ctr, Canterbury CT2 7LR, Kent, England.	P.E.Langdon@kent.ac.uk	Langdon, Peter/B-3212-2008	Langdon, Peter/0000-0002-7745-1825	University of East Anglia; National Institute for Health Research Postdoctoral FellowshipNational Institute for Health Research (NIHR); National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); National Institute for Health ResearchNational Institute for Health Research (NIHR) [PDF-2011-04-040, PB-PG-0214-33040] Funding Source: researchfish	Beverley Garrigan is supported by a PhD studentship stipend from the University of East Anglia.; Peter E Langdon is funded by a National Institute for Health Research Postdoctoral Fellowship. This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health.	Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Amso D, 2015, NAT REV NEUROSCI, V16, P606, DOI 10.1038/nrn4025; Anderson CA, 2002, ANNU REV PSYCHOL, V53, P27, DOI 10.1146/annurev.psych.53.100901.135231; Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; Anderson V., 2012, DEV SOCIAL NEUROSCIE, P3; Arsenio WF, 2004, CHILD DEV, V75, P987, DOI 10.1111/j.1467-8624.2004.00720.x; Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; Baird A.A., 2008, MORAL PSYCHOL NEUROS, V3, P323; Beauchamp MH, 2013, BRAIN INJURY, V27, P896, DOI 10.3109/02699052.2013.775486; Bechara A, 2005, GAME ECON BEHAV, V52, P336, DOI 10.1016/j.geb.2004.06.010; Bujoreanu IS, 2008, DEV NEUROPSYCHOL, V33, P584, DOI 10.1080/87565640802254364; Burks VS, 1999, SOC DEV, V8, P220; Calvete E, 2012, J ABNORM CHILD PSYCH, V40, P105, DOI 10.1007/s10802-011-9546-y; CAMPOS JJ, 1989, DEV PSYCHOL, V25, P394, DOI 10.1037/0012-1649.25.3.394; Carlo G, 2010, PERS INDIV DIFFER, V48, P872, DOI 10.1016/j.paid.2010.02.010; Carlo G, 2011, INT J BEHAV DEV, V35, P116, DOI 10.1177/0165025410375921; Carrigan B, 2016, BRAIN COGNITION, V108, P88, DOI 10.1016/j.bandc.2016.07.007; Chiasson V, 2017, CLIN NEUROPSYCHOL, V31, P515, DOI 10.1080/13854046.2016.1268650; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Cigala A, 2015, EARLY CHILD DEV CARE, V185, P1199, DOI 10.1080/03004430.2014.987272; COLBY A, 1983, MONOGR SOC RES CHILD, V48, P1, DOI 10.2307/1165935; CRICK NR, 1994, PSYCHOL BULL, V115, P74, DOI 10.1037/0033-2909.115.1.74; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Crone EA, 2009, DEVELOPMENTAL SCI, V12, P55, DOI 10.1111/j.1467-7687.2008.00743.x; Cushman F, 2013, COGNITION, V127, P6, DOI 10.1016/j.cognition.2012.11.008; Damasio R., 1994, DESCARTES ERROR EMOT; Darki F, 2015, CEREB CORTEX, V25, P1587, DOI 10.1093/cercor/bht352; de Sousa A, 2011, CORTEX, V47, P526, DOI 10.1016/j.cortex.2010.02.004; de Sousa A, 2010, NEUROPSYCHOLOGIA, V48, P3585, DOI 10.1016/j.neuropsychologia.2010.08.008; de Wilde A, 2016, J ABNORM CHILD PSYCH, V44, P19, DOI 10.1007/s10802-015-0053-4; Decety J, 2014, TRENDS COGN SCI, V18, P337, DOI 10.1016/j.tics.2014.04.008; DENTON K, 1990, J PERS SOC PSYCHOL, V59, P242, DOI 10.1037/0022-3514.59.2.242; Dodge KA, 2002, PSYCHOL ASSESSMENT, V14, P60, DOI 10.1037//1040-3590.14.1.60; Dooley JJ, 2010, BRAIN IMPAIR, V11, P152, DOI 10.1375/brim.11.2.152; Dosch M, 2010, NEUROIMAGE, V50, P837, DOI 10.1016/j.neuroimage.2009.12.013; Dumontheil I, 2014, DEV COGN NEUROS-NETH, V10, P57, DOI 10.1016/j.dcn.2014.07.009; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; Duska R., 1977, MORAL DEV GUIDE PIAG; Eisenberg N, 2000, CHILD DEV, V71, P1367, DOI 10.1111/1467-8624.00233; EISENBERG N, 1995, CHILD DEV, V66, P1179, DOI 10.2307/1131806; Engle RW, 1999, J EXP PSYCHOL GEN, V128, P309, DOI 10.1037/0096-3445.128.3.309; Etkin A, 2011, TRENDS COGN SCI, V15, P85, DOI 10.1016/j.tics.2010.11.004; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Farrant K, 2015, DEV COGN NEUROS-NETH, V12, P165, DOI 10.1016/j.dcn.2015.02.001; Fiedler S, 2015, CURR OPIN PSYCHOL, V6, P139, DOI 10.1016/j.copsyc.2015.08.008; Fransson N., 2010, OPEN PSYCHOL J, V3, P67, DOI [10.2174/1874350101003010067, DOI 10.2174/1874350101003010067]; Fumagalli M, 2012, BRAIN, V135, P2006, DOI 10.1093/brain/awr334; Garaigordobil M., 2009, INT J PSYCHOL PSYCHO, V9, P217, DOI DOI 10.1037/T28278-000; Gardner M, 2005, DEV PSYCHOL, V41, P625, DOI 10.1037/0012-1649.41.4.625; Gathercole SE, 2004, DEV PSYCHOL, V40, P177, DOI 10.1037/0012-1649.40.2.177; Gibbs J. C., 1992, MORAL MATURITY MEASU; Gilligan C., 1982, DIFFERENT VOICE PSYC, P326; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI 10.1023/B:JOBA.0000007455.08539.94; Greene J. D., 2009, COGNITIVE NEUROSCIEN, P987; Greene JD, 2004, NEURON, V44, P389, DOI 10.1016/j.neuron.2004.09.027; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Greene JD, 2008, COGNITION, V107, P1144, DOI 10.1016/j.cognition.2007.11.004; Gruhn D, 2008, EMOTION, V8, P753, DOI 10.1037/a0014123; Haidt J, 2001, PSYCHOL REV, V108, P814, DOI 10.1037//0033-295X.108.4.814; Haidt J, 2001, J APPL SOC PSYCHOL, V31, P191, DOI 10.1111/j.1559-1816.2001.tb02489.x; Haidt J., 2008, MORAL PSYCHOL, P181; Hamlin JK, 2010, DEVELOPMENTAL SCI, V13, P923, DOI 10.1111/j.1467-7687.2010.00951.x; Hare TA, 2011, J NEUROSCI, V31, P11077, DOI 10.1523/JNEUROSCI.6383-10.2011; Harenski CL, 2012, DEV COGN NEUROS-NETH, V2, P162, DOI 10.1016/j.dcn.2011.09.002; Hinson JM, 2003, J EXP PSYCHOL LEARN, V29, P298, DOI 10.1037/0278-7393.29.2.298; Hinson JM, 2002, COGN AFFECT BEHAV NE, V2, P341, DOI 10.3758/CABN.2.4.341; Hoffman M.L., 2000, EMPATHY MORAL DEV IM; Humphries M. L., 2000, J BLACK PSYCHOL, V26, P51, DOI [10.1177/0095798400026001003, DOI 10.1177/0095798400026001003]; Kagan J., 2008, NEUROSCIENCE MORALIT, V2, P297; Kahneman D., 2011, THINKING FAST SLOW; Killen M, 1999, CHILD DEV, V70, P486, DOI 10.1111/1467-8624.00035; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Kohlberg L., 1981, PHILOS MORAL DEV MOR; Kohlberg L., 1976, MORAL DEV BEHAV THEO, P31; Kohlberg L., 1984, PSYCHOL MORAL DEV NA, V2; Kohlberg L., 1984, ESSAYS MORAL DEV, V2; Krebs D. L., 2014, HDB MORAL BEHAV DEV, P139; Krebs DL, 2005, PSYCHOL REV, V112, P629, DOI 10.1037/0033-295X.112.3.629; Lansford JE, 2006, J ABNORM CHILD PSYCH, V34, P715, DOI 10.1007/s10802-006-9057-4; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; Lourenco O, 2014, NEW IDEAS PSYCHOL, V32, P1, DOI 10.1016/j.newideapsych.2013.08.001; Lovett BJ, 2007, CLIN PSYCHOL REV, V27, P1, DOI 10.1016/j.cpr.2006.03.003; Nobes G, 2016, COGNITION, V157, P190, DOI 10.1016/j.cognition.2016.08.019; Nobes G, 2009, J EXP CHILD PSYCHOL, V104, P382, DOI 10.1016/j.jecp.2009.08.001; Nucci L. P., 2001, ED MORAL DOMAIN; Oostermeijer S, 2016, PERS INDIV DIFFER, V90, P54, DOI 10.1016/j.paid.2015.10.035; Palmer EJ, 2000, CLIN PSYCHOL PSYCHOT, V7, P303, DOI 10.1002/1099-0879(200010)7:4<303::AID-CPP263>3.0.CO;2-K; Palmer Emma J., 2003, OFFENDING BEHAV MORA; Penton-Voak IS, 2013, PSYCHOL SCI, V24, P688, DOI 10.1177/0956797612459657; Peterson C, 2016, DEV PSYCHOL, V52, P46, DOI 10.1037/a0039833; Piaget Jean, 1932, MORAL JUDGMENT CHILD; Powell NL, 2012, J EXP CHILD PSYCHOL, V113, P186, DOI 10.1016/j.jecp.2012.03.006; Pozuelos JP, 2014, DEV PSYCHOL, V50, P2405, DOI 10.1037/a0037469; Rest J. R., 1999, POST CONVENTIONAL MO; Rest JR, 1984, MORALITY MORAL BEHAV, P24; Robinson L, 2012, INT J LAW PSYCHIAT, V35, P57, DOI 10.1016/j.ijlp.2011.11.009; Ross-Sheehy S, 2015, INFANCY, V20, P467, DOI 10.1111/infa.12087; Roth-Hanania R, 2011, INFANT BEHAV DEV, V34, P447, DOI 10.1016/j.infbeh.2011.04.007; Rueda MR, 2005, P NATL ACAD SCI USA, V102, P14931, DOI 10.1073/pnas.0506897102; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Salas CE, 2016, SOC COGN AFFECT NEUR, V11, P1528, DOI 10.1093/scan/nsw075; Scherf KS, 2006, J COGNITIVE NEUROSCI, V18, P1045, DOI 10.1162/jocn.2006.18.7.1045; Sebastian CL, 2012, SOC COGN AFFECT NEUR, V7, P53, DOI 10.1093/scan/nsr023; SELMAN RL, 1976, MORAL DEV BEHAV THEO, P299; SERRANO JM, 1992, DEV PSYCHOBIOL, V25, P411, DOI 10.1002/dev.420250603; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2011, NEUROSCIENTIST, V17, P18, DOI 10.1177/1073858410379268; Morris AS, 2007, SOC DEV, V16, P361, DOI 10.1111/j.1467-9507.2007.00389.x; Smetana JG, 2006, HANDBOOK OF MORAL DEVELOPMENT, P119; SMETANA JG, 1985, DEV PSYCHOL, V21, P18, DOI 10.1037/0012-1649.21.1.18; SNAREY JR, 1985, PSYCHOL BULL, V97, P202, DOI 10.1037/0033-2909.97.2.202; Sodian B, 2007, DEVELOPMENTAL SCI, V10, P199, DOI 10.1111/j.1467-7687.2007.00580.x; Solomon M, 2011, J AUTISM DEV DISORD, V41, P32, DOI 10.1007/s10803-010-1017-8; Somsen RJM, 2007, DEVELOPMENTAL SCI, V10, P664, DOI 10.1111/j.1467-7687.2007.00613.x; SONG MJ, 1987, DEV PSYCHOL, V23, P577, DOI 10.1037/0012-1649.23.4.577; Sprengelmeyer R, 1998, P ROY SOC B-BIOL SCI, V265, P1927, DOI 10.1098/rspb.1998.0522; Steinberg L, 2007, CURR DIR PSYCHOL SCI, V16, P55, DOI 10.1111/j.1467-8721.2007.00475.x; Susac A., 2014, FRONTIERS HUMAN NEUR, V8; Svetlova M, 2010, CHILD DEV, V81, P1814, DOI 10.1111/j.1467-8624.2010.01512.x; Taber-Thomas B. C., 2012, DEV SOCIAL NEUROSCIE, P65; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Thomas LA, 2007, DEVELOPMENTAL SCI, V10, P547, DOI 10.1111/j.1467-7687.2007.00614.x; Thompson R A, 1994, Monogr Soc Res Child Dev, V59, P25, DOI 10.2307/1166137; TISAK MS, 1988, DEV PSYCHOL, V24, P352, DOI 10.1037/0012-1649.24.3.352; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turiel E., 1983, DEV SOCIAL KNOWLEDGE; Van Bavel JJ, 2015, CURR OPIN PSYCHOL, V6, P167, DOI 10.1016/j.copsyc.2015.08.009; Van der Graaff J, 2014, DEV PSYCHOL, V50, P881, DOI 10.1037/a0034325; van Nieuwenhuijzen M, 2011, RES DEV DISABIL, V32, P358, DOI 10.1016/j.ridd.2010.10.012; Vera-Estay E, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00227; Vetter NC, 2013, DEV NEUROPSYCHOL, V38, P114, DOI 10.1080/87565641.2012.733786; Walker LJ, 2002, J MORAL EDUC, V31, P353, DOI 10.1080/0305724022000008160; Wikstrom P.O.H., 2012, BREAKING RULES SOCIA; Yeates KO, 2012, DEV SOCIAL NEUROSCIE, P207; Ziv Y, 2011, J EXP CHILD PSYCHOL, V109, P412, DOI 10.1016/j.jecp.2011.02.009	135	19	21	3	32	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0273-2297	1090-2406		DEV REV	Dev. Rev.	SEP	2018	49						80	100		10.1016/j.dr.2018.06.001			21	Psychology, Developmental	Psychology	GS8AY	WOS:000443929900006		Green Published, Green Accepted, Other Gold			2021-06-18	
J	Ponsford, J; Alway, Y; Gould, KR				Ponsford, Jennie; Alway, Yvette; Gould, Kate Rachel			Epidemiology and Natural History of Psychiatric Disorders After TBI	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; DSM-IV DISORDERS; COMORBIDITY SURVEY REPLICATION; AXIS-I; MENTAL-HEALTH; PSYCHOTIC DISORDER; MAJOR DEPRESSION; HEAD-INJURY; RISK-FACTOR	This article outlines the epidemiology of psychiatric disorders in individuals with traumatic brain injury (TBI), with a focus on DSM axis I disorders diagnosed on the basis of structured clinical interview. The epidemiology of psychiatric disorders in the general population is described as a basis for understanding the disorders that occur before and after TBI. For each disorder category, including mood disorders, anxiety disorders, acute stress disorder, posttraumatic stress disorder (PTSD), substance use disorders, psychotic disorders, eating disorders, somatoform disorders, and adjustment disorders, the evidence from retrospective, cross-sectional and prospective studies is reviewed, showing the frequency, time course, and predictors of the disorders. Studies show elevated rates of depressive and anxiety disorders after TBI, most commonly major depressive disorder and PTSD, usually emerging in the first year postinjury but with delayed onset in severe injury cases. Although individuals with a preinjury history are more likely to develop these disorders, the nature of the disorders may change after injury, and novel psychiatric disorders are also common. Even though the frequency of anxiety disorders diminishes over the years postinjury, depressive disorders are more persistent during postinjury years. Substance use-while high before injury-declines after injury. The frequency of psychotic, eating, somatoform, and adjustment disorders do not exceed population rates.	[Ponsford, Jennie; Alway, Yvette; Gould, Kate Rachel] Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia; [Ponsford, Jennie; Alway, Yvette; Gould, Kate Rachel] Monash Univ, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia; [Ponsford, Jennie; Alway, Yvette; Gould, Kate Rachel] Epworth Healthcare, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia.; Ponsford, J (corresponding author), Monash Univ, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia.; Ponsford, J (corresponding author), Epworth Healthcare, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia.	jennie.ponsford@monash.edu	Gould, Kate/AAA-5511-2020	Gould, Kate/0000-0002-3564-7408			Alway Y, 2016, PSYCHOL MED, V46, P1331, DOI 10.1017/S0033291715002986; Alway Y, 2016, J NEUROTRAUM, V33, P825, DOI 10.1089/neu.2015.3992; Alway Y, 2016, DEPRESS ANXIETY, V33, P19, DOI 10.1002/da.22396; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Australian Bureau of Statistics, 2009, NAT SURV MENT HLTH W; Batty RA, 2013, BRAIN IMPAIR, V14, P21, DOI 10.1017/BrImp.2013.10; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Broomhall LGJ, 2009, J NERV MENT DIS, V197, P178, DOI 10.1097/NMD.0b013e318199fe7f; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 2013, JAMA PSYCHIAT, V70, P839, DOI 10.1001/jamapsychiatry.2013.1137; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Deb S, 1999, AM J PSYCHIAT, V156, P374; Diaz AP, 2014, REV BRAS PSIQUIATR, V36, P213, DOI 10.1590/1516-4446-2013-1303; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Fujii D, 2012, J NEUROPSYCH CLIN N, V24, P278, DOI 10.1176/appi.neuropsych.11070176; Gibson R, 2015, BRAIN INJURY, V29, P306, DOI 10.3109/02699052.2014.896471; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Harter M, 2007, PSYCHOTHER PSYCHOSOM, V76, P354, DOI 10.1159/000107563; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jablensky A, 2000, AUST NZ J PSYCHIAT, V34, P221, DOI 10.1046/j.1440-1614.2000.00728.x; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koponen S, 2011, BRAIN INJURY, V25, P1029, DOI 10.3109/02699052.2011.607783; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Mallya S, 2015, J NEUROTRAUM, V32, P411, DOI 10.1089/neu.2014.3504; Molloy C, 2011, SCHIZOPHRENIA BULL, V37, P1104, DOI 10.1093/schbul/sbr091; Orlovska S, 2014, AM J PSYCHIAT, V171, P463, DOI 10.1176/appi.ajp.2013.13020190; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; Silver JM, 1997, NEUROCASE, V3, P151, DOI 10.1093/neucas/3.2.151; Slade T, 2009, AUST NZ J PSYCHIAT, V43, P594, DOI 10.1080/00048670902970882; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wade TD, 2006, AUST NZ J PSYCHIAT, V40, P121, DOI 10.1111/j.1440-1614.2006.01758.x; Wells JE, 2006, AUST NZ J PSYCHIAT, V40, P845, DOI 10.1111/j.1440-1614.2006.01903.x; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa	55	19	20	0	5	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2018	30	4					262	270		10.1176/appi.neuropsych.18040093			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	GX8GY	WOS:000448023000002	29939106	Bronze			2021-06-18	
J	Zhang, L; Wang, HD; Zhou, YL; Zhu, YH; Fei, MX				Zhang, Li; Wang, Handong; Zhou, Yali; Zhu, Yihao; Fei, Maoxin			Fisetin alleviates oxidative stress after traumatic brain injury via the Nrf2-ARE pathway	NEUROCHEMISTRY INTERNATIONAL			English	Article						Fisetin; Neuroprotection; Traumatic brain injury; Nrf2-ARE pathway	ANTIOXIDANT RESPONSE ELEMENT; ACID PHENETHYL ESTER; PROVIDES NEUROPROTECTION; SUBARACHNOID HEMORRHAGE; ACTIVATION; MICE; PROTECTS; MODULATION; EXPRESSION; MODELS	Fisetin, a natural flavonoid, has neuroprotection properties in many brain injury models. However, its role in traumatic brain injury (TBI) has not been fully explained. In the present study, we aimed to explore the neuroprotective effects of fisetin in a mouse model of TBI. We found that fisetin improved neurological function, reduced cerebral edema, attenuated brain lesion and ameliorated blood-brain barrier (BBB) disruption after TBI. Moreover, the up-regulation of malondialdehyde (MDA) and the activity of glutathione peroxidase (GPx) were reversed by fisetin treatment. Furthermore, administration of fisetin suppressed neuron cell death and apoptosis, increased the expression of B-cell lymphoma 2 (Bcl-2), while decreased the expression of Bcl-2-associated X protein (Bax) and caspase-3 after TBI. In addition, fisetin activated the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway following TBI. However, fisetin only failed to suppress oxidative stress in Nrf2(-/-) mice. In conclusion, our data provided the first evidence that fisetin played a critical role in neuroprotection after TBI partly through the activation of the Nrf2-ARE pathway.	[Zhang, Li; Wang, Handong; Zhou, Yali; Zhu, Yihao; Fei, Maoxin] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81672503, 81702484]	This work was supported by Grants from the National Natural Science Foundation of China (No. 81672503 and 81702484).	Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Arai Y, 2000, J NUTR, V130, P2243; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Chandran R., 2017, J CEREB BLOOD FLOW M, DOI DOI 10.1177/0271678X1773870129083257; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Friedrich V, 2012, NEUROSCI LETT, V512, P6, DOI 10.1016/j.neulet.2012.01.036; Gelderblom M, 2012, J CEREBR BLOOD F MET, V32, P835, DOI 10.1038/jcbfm.2011.189; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Higa S, 2003, J ALLERGY CLIN IMMUN, V111, P1299, DOI 10.1067/mai.2003.1456; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Jin W, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/502564; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Kalayci M, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-75; Kerman M, 2012, J MOL HISTOL, V43, P49, DOI 10.1007/s10735-011-9376-9; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Liu-Smith F, 2016, MOL NUTR FOOD RES, V60, P1264, DOI 10.1002/mnfr.201500822; Lu XY, 2014, J SURG RES, V188, P206, DOI 10.1016/j.jss.2013.11.1106; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Nabavi SF, 2016, CURR TOP MED CHEM, V16, P1910, DOI 10.2174/1568026616666160204121725; Nagai K, 2009, BRIT J PHARMACOL, V158, P907, DOI 10.1111/j.1476-5381.2009.00365.x; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Sandireddy R, 2016, CELL MOL NEUROBIOL, V36, P883, DOI 10.1007/s10571-015-0272-9; Sauzeau V, 2003, J BIOL CHEM, V278, P9472, DOI 10.1074/jbc.M212776200; Sun Q, 2016, ALCOHOL CLIN EXP RES, V40, P2076, DOI 10.1111/acer.13172; Tsai CY, 2013, INT J CARDIOL, V168, P1286, DOI 10.1016/j.ijcard.2012.12.004; Villeneuve NF, 2010, ANTIOXID REDOX SIGN, V13, P1699, DOI 10.1089/ars.2010.3211; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu PY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040782; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep46763; Zhang L, 2016, CELL MOL NEUROBIOL, V36, P131, DOI 10.1007/s10571-015-0227-1; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858; Zhou CH, 2015, BRAIN RES, V1629, P250, DOI 10.1016/j.brainres.2015.10.016; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	44	19	20	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	SEP	2018	118						304	313		10.1016/j.neuint.2018.05.011			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	GO0ZC	WOS:000439674200033	29792955				2021-06-18	
J	Foks, KA; van den Brand, CL; Lingsma, HF; van der Naalt, J; Jacobs, B; de Jong, E; den Boogert, HF; Sir, O; Patka, P; Polinder, S; Gaakeer, MI; Schutte, CE; Jie, KE; Visee, HF; Hunink, MGM; Reijners, E; Braaksma, M; Schoonman, GG; Steyerberg, EW; Jellema, K; Dippel, DWJ				Foks, Kelly A.; van den Brand, Crispijn L.; Lingsma, Hester F.; van der Naalt, Joukje; Jacobs, Bram; de Jong, Eline; den Boogert, Hugo F.; Sir, Ozcan; Patka, Peter; Polinder, Suzanne; Gaakeer, Menno I.; Schutte, Charlotte E.; Jie, Kim E.; Visee, Huib F.; Hunink, Myriam G. M.; Reijners, Eef; Braaksma, Meriam; Schoonman, Guus G.; Steyerberg, Ewout W.; Jellema, Korne; Dippel, Diederik W. J.			External validation of computed tomography decision rules for minor head injury: prospective, multicentre cohort study in the Netherlands	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; NEW-ORLEANS CRITERIA; INTRACRANIAL INJURY; METAANALYSIS; EPIDEMIOLOGY; MANAGEMENT; MORTALITY; ADULTS	OBJECTIVE To externally validate four commonly used rules in computed tomography (CT) for minor head injury. DESIGN Prospective, multicentre cohort study. SETTING Three university and six non-university hospitals in the Netherlands. PARTICIPANTS Consecutive adult patients aged 16 years and over who presented with minor head injury at the emergency department with a Glasgow coma scale score of 13-15 between March 2015 and December 2016. MAIN OUTCOME MEASURES The primary outcome was any intracranial traumatic finding on CT; the secondary outcome was a potential neurosurgical lesion on CT, which was defined as an intracranial traumatic finding on CT that could lead to a neurosurgical intervention or death. The sensitivity, specificity, and clinical usefulness (defined as net proportional benefit, a weighted sum of true positive classifications) of the four CT decision rules. The rules included the CT in head injury patients (CHIP) rule, New Orleans criteria (NOC), Canadian CT head rule CCHR), and National Institute for Health and Care Excellence (NICE) guideline for head injury. RESULTS For the primary analysis, only six centres that included patients with and without CT were selected. Of 4557 eligible patients who presented with minor head injury, 3742 (82%) received a CT scan; 384 (8%) had a intracranial traumatic finding on CT, and 74 (2%) had a potential neurosurgical lesion. The sensitivity for any intracranial traumatic finding on CT ranged from 73% (NICE) to 99% (NOC); specificity ranged from 4% (NOC) to 61% (NICE). Sensitivity for a potential neurosurgical lesion ranged between 85% (NICE) and 100% (NOC); specificity from 4% (NOC) to 59% (NICE). Clinical usefulness depended on thresholds for performing CT scanning: the NOC rule was preferable at a low threshold, the NICE rule was preferable at a higher threshold, whereas the CHIP rule was preferable for an intermediate threshold. CONCLUSIONS Application of the CHIP, NOC, CCHR, or NICE decision rules can lead to a wide variation in CT scanning among patients with minor head injury, resulting in many unnecessary CT scans and some missed intracranial traumatic findings. Until an existing decision rule has been updated, any of the four rules can be used for patients presenting minor head injuries at the emergency department. Use of the CHIP rule is recommended because it leads to a substantial reduction in CT scans while missing few potential neurosurgical lesions.	[Foks, Kelly A.; Lingsma, Hester F.; Polinder, Suzanne; Steyerberg, Ewout W.] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Foks, Kelly A.; Dippel, Diederik W. J.] Erasmus MC Univ Med Ctr Rotterdam, Dept Neurol, Rotterdam, Netherlands; [van den Brand, Crispijn L.; de Jong, Eline] Haaglanden Med Ctr, Dept Emergency Med, The Hague, Netherlands; [van den Brand, Crispijn L.; Patka, Peter] Erasmus MC Univ Med Ctr Rotterdam, Dept Emergency Med, Rotterdam, Netherlands; [van der Naalt, Joukje; Jacobs, Bram] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [den Boogert, Hugo F.] Radboud Univ Nijmegen, Dept Neurosurg, Med Ctr, Nijmegen, Netherlands; [Sir, Ozcan] Radboud Univ Nijmegen, Dept Emergency Med, Med Ctr, Nijmegen, Netherlands; [Gaakeer, Menno I.; Schutte, Charlotte E.] Admiraal De Ruyter Hosp, Dept Emergency Med, Goes, Netherlands; [Jie, Kim E.] Jeroen Bosch Hosp, Dept Emergency Med, sHertogenbosch, Netherlands; [Visee, Huib F.] Jeroen Bosch Hosp, Dept Neurol, sHertogenbosch, Netherlands; [Hunink, Myriam G. M.] Erasmus MC Univ Med Ctr Rotterdam, Dept Radiol, Rotterdam, Netherlands; [Hunink, Myriam G. M.] Erasmus MC Univ Med Ctr Rotterdam, Dept Epidemiol, Rotterdam, Netherlands; [Hunink, Myriam G. M.] Harvard TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA USA; [Reijners, Eef] Elisabeth Tweesteden Hosp, Dept Emergency Med, Tilburg, Netherlands; [Braaksma, Meriam; Schoonman, Guus G.] Elisabeth Tweesteden Hosp, Dept Neurol, Tilburg, Netherlands; [Steyerberg, Ewout W.] Leiden Univ, Dept Biomed Data Sci, Med Ctr, Leiden, Netherlands; [Jellema, Korne] Haaglanden Med Ctr, Dept Neurol, The Hague, Netherlands	Foks, KA (corresponding author), Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.; Foks, KA (corresponding author), Erasmus MC Univ Med Ctr Rotterdam, Dept Neurol, Rotterdam, Netherlands.	k.foks@erasmusmc.nl	Dippel, Diederik/AAJ-2192-2020; Boogert, Hugo F den/B-2782-2016	Dippel, Diederik/0000-0002-9234-3515; 	St Jacobus Foundation	This study did not receive any specific funding. CLvdB received a personal grant from the St Jacobus Foundation, which is a non-profit organisation that supports research; the funder played no role in the design, analysis, or presentation of the study.	af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b605; Batchelor JS, 2012, BRIT J NEUROSURG, V26, P525, DOI 10.3109/02688697.2011.650736; Bouida W, 2013, ANN EMERG MED, V61, P521, DOI 10.1016/j.annemergmed.2012.07.016; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Dunning J, 2004, J NEUROTRAUM, V21, P877, DOI 10.1089/0897715041526122; Easter JS, 2015, JAMA-J AM MED ASSOC, V314, P2672, DOI 10.1001/jama.2015.16316; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Harnan SE, 2011, J TRAUMA, V71, P245, DOI 10.1097/TA.0b013e31820d090f; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hunink MGM, 2014, DECISION MAKING HLTH, DOI [10.1017/CBO9781139506779, DOI 10.1017/CB09781139506779]; Leard Statistics, 2018, COCHR Q TEST US SPSS; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Marincowitz C, 2018, J NEUROTRAUM, V35, P703, DOI 10.1089/neu.2017.5259; Moons KGM, 2012, HEART, V98, P691, DOI 10.1136/heartjnl-2011-301247; National Clinical Guideline C. National Clinical Guidance Centre, 2014, CG 176 HEAD INJ TRIA; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Smits M, 2007, J NEUROL NEUROSUR PS, V78, P1359, DOI 10.1136/jnnp.2007.117143; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Steyerberg E., 2009, CLIN PREDICTION MODE, DOI 10.1007/978-0-387-77244-8; Steyerberg EW, 2016, J CLIN EPIDEMIOL, V69, P245, DOI 10.1016/j.jclinepi.2015.04.005; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sullivan TR, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0414-5; Van den Brand CL, 2018, EUR J EMERG MED, V25, P355, DOI 10.1097/MEJ.0000000000000457; van Essen TA, 2017, J NEUROTRAUM, V34, P881, DOI 10.1089/neu.2016.4495; Vickers AJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i6	31	19	20	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 24	2018	362								k3527	10.1136/bmj.k3527			11	Medicine, General & Internal	General & Internal Medicine	GR8SY	WOS:000443000000002	30143521	Green Published, Other Gold			2021-06-18	
J	Erdodi, LA; Hurtubise, JL; Charron, C; Dunn, A; Enache, A; McDermott, A; Hirst, RB				Erdodi, Laszlo A.; Hurtubise, Jessica L.; Charron, Carly; Dunn, Alexa; Enache, Anca; McDermott, Abigail; Hirst, Rayna B.			The D-KEFS Trails as Performance Validity Tests	PSYCHOLOGICAL ASSESSMENT			English	Article						performance validity; embedded validity indicators; Erdodi Index; trail making test; D-KEFS	TRAUMATIC BRAIN-INJURY; FORCED-CHOICE RECOGNITION; ADULT INTELLIGENCE SCALE; COMPLEX IDEATIONAL MATERIAL; FALSE-POSITIVE RATES; VERBAL-LEARNING TEST; RESPONSE BIAS; CLASSIFICATION ACCURACY; NEUROPSYCHOLOGICAL ASSESSMENT; MULTIPLE PERFORMANCE	This study was designed to examine the potential of the Delis-Kaplan Executive System (D-KEFS) version of the Trail Making Test (TMT) as a performance validity test (PVT). Data were collected from a mixed clinical sample of 157 consecutively referred outpatients (49% male, M-Age = 47.1, M-Education = 13.6) undergoing neuropsychological assessment at an academic medical center in the northeastern United States. Sensitivity and specificity of the D-KEFS Trails to psychometrically defined invalid responding was calculated across various cutoffs and criterion PVTs. The D-KEFS Trails produced classification accuracy comparable to the original version of the TMT, hovering around the "Larrabee limit" (.50 sensitivity at.90 specificity). Different cutoffs (age-corrected scaled score = 5 on Trails 1-3, <= 4 on Trails 4 and <= 8 on Trails 5) were needed to achieve the same classification accuracy across the five trials. Combining multiple cutoffs improved the signal detection performance. The study provides preliminary evidence of the utility of D-KEFS Trails as a PVT. Embedded PVTs are valuable, because they make a multivariate approach to validity assessment feasible. Combining validity indicators is superior to relying on single cutoffs. Public Significance Statement Unusually low performance on visuomotor processing speed test is more likely to reflect noncredible performance than genuine impairment. Public Significance Statement Unusually low performance on visuomotor processing speed test is more likely to reflect noncredible performance than genuine impairment.	[Erdodi, Laszlo A.; Hurtubise, Jessica L.; Charron, Carly; Dunn, Alexa; Enache, Anca; McDermott, Abigail] Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Hirst, Rayna B.] Palo Alto Univ, Neuropsychol Program, Palo Alto, CA USA	Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.co		Charron, Carly/0000-0001-5647-6903			An KY, 2017, CLIN NEUROPSYCHOL, V31, P193, DOI 10.1080/13854046.2016.1217046; An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Ashendorf L, 2017, CLIN NEUROPSYCHOL, V31, P857, DOI 10.1080/13854046.2017.1285961; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Barhon LI, 2015, APPL NEUROPSYCH-ADUL, V22, P114, DOI 10.1080/23279095.2013.863775; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Bilder RM, 2014, CLIN NEUROPSYCHOL, V28, P1212, DOI 10.1080/13854046.2014.969774; Boone K., 2013, CLINICAL PRACTICE OF; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis D, 1994, CALIFORNIA VERBAL LE; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Erdodi L. A., 2017, ARCH CLIN NEUROPSYCH, DOI [10. 1093/arclin/acx110, DOI 10.1093/ARCLIN/ACX110]; Erdodi L, 2017, APPL NEUROPSYCH-ADUL, V24, P264, DOI 10.1080/23279095.2016.1154856; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P327, DOI 10.1080/23279095.2017.1298600; Erdodi LA, 2017, BRAIN INJURY, V31, P1362, DOI 10.1080/02699052.2017.1332386; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P19, DOI 10.1080/23279095.2016.1232262; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Halasz I, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00136; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Johnson DE, 2001, ARCH CLIN NEUROPSYCH, V16, P587; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Larrabee G. J., 2012, FORENSIC NEUROPSYCHO, P117; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, CLIN NEUROPSYCHOL, V28, P1230, DOI 10.1080/13854046.2014.988754; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Lichtenstein JD, 2018, CHILD NEUROPSYCHOL, V24, P247, DOI 10.1080/09297049.2016.1259402; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Neipert L, 2014, BRAIN INJURY, V28, P1667, DOI 10.3109/02699052.2014.947623; Odland AP, 2015, PSYCHOL INJ LAW, V8, P46, DOI 10.1007/s12207-015-9216-4; Pearson, 2009, ADV CLIN SOL WAIS 4; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1964, EXAMEN CLIN PSYCHOL; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Roth R.M., 2017, PSYCHOL NEUROSCI, V10, DOI [https//doi.org/10.1037/pne0000103, DOI 10.1037/PNE0000103]; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Schwartz ES, 2016, J INT NEUROPSYCH SOC, V22, P851, DOI 10.1017/S1355617716000746; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Silk-Eglit GM, 2015, APPL NEUROPSYCH-ADUL, V22, P335, DOI 10.1080/23279095.2014.938809; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Whiteside DM, 2015, J CLIN EXP NEUROPSYC, V37, P220, DOI 10.1080/13803395.2014.1002758	72	19	19	0	2	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	AUG	2018	30	8					1082	1095		10.1037/pas0000561			14	Psychology, Clinical	Psychology	GP1HU	WOS:000440566800009	29952596				2021-06-18	
J	Haber, M; James, J; Kim, J; Sangobowale, M; Irizarry, R; Ho, J; Nikulina, E; Grin'kina, NM; Ramadani, A; Hartman, I; Bergold, PJ				Haber, Margalit; James, Jessica; Kim, Justine; Sangobowale, Michael; Irizarry, Rachel; Ho, Johnson; Nikulina, Elena; Grin'kina, Natalia M.; Ramadani, Albana; Hartman, Isabella; Bergold, Peter J.			Minocycline plus N-acteylcysteine induces remyelination, synergistically protects oligodendrocytes and modifies neuroinflammation in a rat model of mild traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Brain trauma; immunohistochemistry; inflammation; microglia; white matter; oligodendrocytes	WHITE-MATTER INJURY; TUMOR-NECROSIS-FACTOR; MICROGLIA/MACROPHAGE POLARIZATION; MULTIPLE-SCLEROSIS; WORKING-MEMORY; NITRIC-OXIDE; CELL-DEATH; ACETYLCYSTEINE; INFLAMMATION; ACTIVATION	Mild traumatic brain injury afflicts over 2 million people annually and little can be done for the underlying injury. The Food and Drug Administration-approved drugs Minocycline plus N-acetylcysteine (MINO plus NAC) synergistically improved cognition and memory in a rat mild controlled cortical impact (mCCI) model of traumatic brain injury.(3) The underlying cellular and molecular mechanisms of the drug combination are unknown. This study addressed the effect of the drug combination on white matter damage and neuroinflammation after mCCI. Brain tissue from mCCI rats given either sham-injury, saline, MINO alone, NAC alone, or MINO plus NAC was investigated via histology and qPCR at four time points (2, 4, 7, and 14 days post-injury) for markers of white matter damage and neuroinflammation. MINO plus NAC synergistically protected resident oligodendrocytes and decreased the number of oligodendrocyte precursor cells. Activation of microglia/macrophages (MP/MG) was synergistically increased in white matter two days post-injury after MINO plus NAC treatment. Patterns of M1 and M2 MP/MG were also altered after treatment. The modulation of neuroinflammation is a potential mechanism to promote remyelination and improve cognition and memory. These data also provide new and important insights into how drug treatments can induce repair after traumatic brain injury.	[Haber, Margalit; James, Jessica; Kim, Justine; Sangobowale, Michael; Irizarry, Rachel; Ho, Johnson; Nikulina, Elena; Grin'kina, Natalia M.; Ramadani, Albana; Hartman, Isabella; Bergold, Peter J.] Suny Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA	Bergold, PJ (corresponding author), Suny Downstate Med Ctr, Dept Physiol & Pharmacol, Box 29,450 Clarkson Ave, Brooklyn, NY 11203 USA.	pbergold@downstate.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1070512]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the NIH grant RO1070512 to P.J.B.	Abdel Baki S.G., 2010, PLOS ONE, V5; Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; ALLT G, 1988, ACTA NEUROPATHOL, V75, P456, DOI 10.1007/BF00687132; Armstrong RC, 2016, NEUROPHARMACOLOGY, V110, P654, DOI 10.1016/j.neuropharm.2015.04.029; Baron W, 2002, EMBO J, V21, P1957, DOI 10.1093/emboj/21.8.1957; Barros MHM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080908; Birch AM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-25; Blakemore WF, 2008, CURR TOP MICROBIOL, V318, P193; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Bramow S, 2010, BRAIN, V133, P2983, DOI 10.1093/brain/awq250; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; Burke NN, 2014, BRAIN BEHAV IMMUN, V42, P147, DOI 10.1016/j.bbi.2014.06.015; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; Carty ML, 2008, INT J DEV NEUROSCI, V26, P477, DOI 10.1016/j.ijdevneu.2008.02.005; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Cikla U, 2016, J NEUROIMMUNOL, V291, P18, DOI 10.1016/j.jneuroim.2015.12.004; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Cui JX, 2016, J NEUROPHYSIOL, V116, P2892, DOI 10.1152/jn.00603.2016; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Bundel D, 2011, J NEUROSCI, V31, P5792, DOI 10.1523/JNEUROSCI.5465-10.2011; Dean O, 2011, J PSYCHIATR NEUROSCI, V36, P78, DOI 10.1503/jpn.100057; Drescher KM, 2000, BRAIN PATHOL, V10, P1; Duncan ID, 2009, P NATL ACAD SCI USA, V106, P6832, DOI 10.1073/pnas.0812500106; ELLISON JA, 1994, J NEUROSCI RES, V37, P116, DOI 10.1002/jnr.490370116; Fan LW, 2005, J NEUROSCI RES, V82, P71, DOI 10.1002/jnr.20623; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Garrido-Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139; Grin'kina NM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053775; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hellewell SC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/356494; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Jackson SJ, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-76; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Karalija A, 2014, NEUROSCIENCE, V269, P143, DOI 10.1016/j.neuroscience.2014.03.042; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar S, 2013, CLIN NEUROL NEUROSUR, V115, P1326, DOI 10.1016/j.clineuro.2012.12.038; Lampron A, 2015, J EXP MED, V212, P481, DOI 10.1084/jem.20141656; Lechpammer M, 2008, NEUROPATH APPL NEURO, V34, P379, DOI 10.1111/j.1365-2990.2007.00925.x; Lee SM, 2004, J NEUROCHEM, V91, P568, DOI 10.1111/j.1471-4159.2004.02780.x; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li JR, 2008, J NEUROSCI, V28, P5321, DOI 10.1523/JNEUROSCI.3995-07.2008; Licinio J, 1999, MOL MED TODAY, V5, P225, DOI 10.1016/S1357-4310(99)01453-7; Liu MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043924; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; Nayak A, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/563784; Patel J, 2012, INT J MOL SCI, V13, P10647, DOI 10.3390/ijms130810647; Peferoen LAN, 2015, J NEUROPATH EXP NEUR, V74, P48, DOI 10.1097/NEN.0000000000000149; Pi RB, 2004, J NEUROCHEM, V91, P1219, DOI 10.1111/j.1471-4159.2004.02796.x; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Prins M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083835; Rawji KS, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/948976; Riediger T, 2010, PHARMACOL BIOCHEM BE, V97, P112, DOI 10.1016/j.pbb.2010.04.015; Rojo AI, 2014, ANTIOXID REDOX SIGN, V21, P1766, DOI 10.1089/ars.2013.5745; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Shahripour RB, 2014, BRAIN BEHAV, V4, P108, DOI 10.1002/brb3.208; Simpson JE, 2007, NEUROPATH APPL NEURO, V33, P670, DOI 10.1111/j.1365-2990.2007.00890.x; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; VICK RS, 1992, J NEUROTRAUM, V9, pS93; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Yeo YA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-173; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055	78	19	20	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2018	38	8					1312	1326		10.1177/0271678X17718106			15	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	GP2OQ	WOS:000440674900005	28685618	Green Published, Bronze			2021-06-18	
J	Rodriguez-Grande, B; Obenaus, A; Ichkova, A; Aussudre, J; Bessy, T; Barse, E; Hiba, B; Catheline, G; Barriere, G; Badaut, J				Rodriguez-Grande, Beatriz; Obenaus, Andre; Ichkova, Aleksandra; Aussudre, Justine; Bessy, Thomas; Barse, Elodie; Hiba, Bassem; Catheline, Gwenaelle; Barriere, Gregory; Badaut, Jerome			Gliovascular changes precede white matter damage and long-term disorders in juvenile mild closed head injury	GLIA			English	Article						AQP4; astrocyte; mild traumatic brain injury; MRI; pediatric; white matter	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; MYELIN BASIC-PROTEIN; CORPUS-CALLOSUM; CORTICAL CONTUSION; RNA INTERFERENCE; AQUAPORIN 4; MICE; CHILDREN; IMPACT	Traumatic brain injury (TBI) is a leading cause of hospital visits in pediatric patients and often leads to long-term disorders even in cases of mild severity. White matter (WM) alterations are commonly observed in patients months or years after the injury assessed by magnetic resonance imaging (MRI), but little is known about WM pathophysiology early after mild pediatric TBI. To evaluate the status of the gliovascular unit in this context, mild TBI was induced in postnatal-day 17 mice using a closed head injury model with two grades of severity (G1, G2). G2 resulted in significant WM edema (increased T2-signal) and BBB damage (IgG-extravasation immunostaining) whereas decreased T2 and the increased levels of astrocytic water-channel AQP4 were observed in G1 mice 1 day post-injury. Both severities induced astrogliosis (GFAP immunolabeling). No changes in myelin and neurofilament were detected at this acute time point. One month after injury G2 mice exhibited diffusion tensor imaging MRI alterations (decreased fractional anisotropy) accompanied by decreased neurofilament staining in the WM. Both severities induced behavioral impairments at this time point. In conclusion, long-term deficits and WM changes similar to those found after clinical TBI are preceded by distinct early gliovascular phenotype alterations after juvenile mild TBI, revealing AQP4 as a potential candidate for severity-based treatments.	[Rodriguez-Grande, Beatriz; Obenaus, Andre; Ichkova, Aleksandra; Aussudre, Justine; Bessy, Thomas; Barse, Elodie; Hiba, Bassem; Catheline, Gwenaelle; Barriere, Gregory; Badaut, Jerome] Univ Bordeaux, CNRS UMR5287, Inst Neurosci Cognit & Integrat Aquitaine, Bordeaux, France; [Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA USA; [Obenaus, Andre; Badaut, Jerome] Loma Linda Univ, Sch Med, Dept Basic Sci, Loma Linda, CA USA; [Obenaus, Andre] UC Riverside, Div Biomed Sci, Ctr Glial Neuronal Interact, Riverside, CA USA; [Obenaus, Andre] Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA; [Barse, Elodie; Catheline, Gwenaelle] EPHE, PSL, Bordeaux, France	Badaut, J (corresponding author), Bordeaux Univ, UMR CNRS 5287, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	jerome.badaut@u-bordeaux.fr	; Rodriguez-Grande, Beatriz/I-5397-2015	, Andre/0000-0003-0081-6950; Barriere, Gregory/0000-0002-0704-508X; catheline, gwenaelle/0000-0003-1949-8913; Rodriguez-Grande, Beatriz/0000-0002-4638-7576; Bessy, Thomas/0000-0001-9911-4400	Eranet Neuron CNS-aflame; Idex Funding Bordeaux [ANR-10-IDEX-03-02]; BIS-Idex; TRAIL-Laboratory of Excellence TRAIL [ANR-10-LABX-57]	Eranet Neuron CNS-aflame; Idex Funding Bordeaux (ANR-10-IDEX-03-02 to AO & JB); BIS-Idex; TRAIL-Laboratory of Excellence TRAIL (ANR-10-LABX-57 to JB)	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575; Arenth PM, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318289ede5; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Babikian T, 2015, J NEUROTRAUM, V32, P1849, DOI 10.1089/neu.2015.3971; Badaut J, 2014, BBA-GEN SUBJECTS, V1840, P1554, DOI 10.1016/j.bbagen.2013.10.032; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Baldwin SA, 1996, GLIA, V16, P266; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; BERACOCHEA D, 1987, BEHAV BRAIN RES, V25, P63, DOI 10.1016/0166-4328(87)90045-3; Blanchard DC, 2001, NEUROSCI BIOBEHAV R, V25, P205, DOI 10.1016/S0149-7634(01)00009-4; BODHIREDDY SR, 1994, J NEUROPATH EXP NEUR, V53, P144, DOI 10.1097/00005072-199403000-00005; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Cho M, 2009, NAT NEUROSCI, V12, P1085, DOI 10.1038/nn0909-1085; Choy M, 2014, J NEUROSCI, V34, P8672, DOI 10.1523/JNEUROSCI.4806-13.2014; DEAN PJA, 2013, FRONT HUM NEUROSCI, V0007; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Deoni SCL, 2011, J NEUROSCI, V31, P784, DOI 10.1523/JNEUROSCI.2106-10.2011; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Dubois J, 2014, NEUROSCIENCE, V276, P48, DOI 10.1016/j.neuroscience.2013.12.044; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Filosa JA, 2016, NEUROSCIENCE, V323, P96, DOI 10.1016/j.neuroscience.2015.03.064; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Girard N, 2007, J NEURORADIOLOGY, V34, P290, DOI 10.1016/j.neurad.2007.07.007; Hall CS, 1932, U CALIFORNIA PUBLICA, V6, P1; Hanell A, 2015, ACTA NEUROPATHOL, V129, P317, DOI 10.1007/s00401-014-1376-x; Harris NG, 2016, NEUROIMAGE, V133, P129, DOI 10.1016/j.neuroimage.2016.03.012; Hernandez A, 2016, J NEUROCHEM, V136, P18, DOI 10.1111/jnc.13402; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Howarth C, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00103; Iannotti CA, 2011, EXP NEUROL, V230, P3, DOI 10.1016/j.expneurol.2010.03.010; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Laitinen T, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.7015.00128, 10.3389/fnins.2015.00128]; Liang FY, 2015, NEUROSCI LETT, V598, P29, DOI 10.1016/j.neulet.2015.05.006; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lumba-Brown A, 2016, REPORT PEDIAT MILD T; Mallya S, 2015, J NEUROTRAUM, V32, P411, DOI 10.1089/neu.2014.3504; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; Mcauliffe M.J., 2001, P 14 IEEE S COMP BAS; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Petraglia Anthony L, 2014, Neurosurgery, V75 Suppl 4, pS34, DOI 10.1227/NEU.0000000000000472; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Roberts RM, 2014, DEV NEUROPSYCHOL, V39, P600, DOI 10.1080/87565641.2014.973958; Rodriguez-Grande B, 2017, BRAIN EDEMA: FROM MOLECULAR MECHANISMS TO CLINICAL PRACTICE, P163, DOI 10.1016/B978-0-12-803196-4.00009-6; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rowe RK, 2016, METHODS MOL BIOL, V1462, P211, DOI 10.1007/978-1-4939-3816-2_13; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Spitz G, 2017, J NEUROTRAUM, V34, P807, DOI 10.1089/neu.2016.4527; Stokum JA, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0239-6; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Yao XM, 2015, J NEUROTRAUM, V32, P1458, DOI 10.1089/neu.2014.3675	73	19	19	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	AUG	2018	66	8					1663	1677		10.1002/glia.23336			15	Neurosciences	Neurosciences & Neurology	GN1BV	WOS:000438719700009	29665077				2021-06-18	
J	Wang, F; Han, Y; Wang, BY; Peng, Q; Huang, XQ; Miller, K; Wittek, A				Wang, Fang; Han, Yong; Wang, Bingyu; Peng, Qian; Huang, Xiaoqun; Miller, Karol; Wittek, Adam			Prediction of brain deformations and risk of traumatic brain injury due to closed-head impact: quantitative analysis of the effects of boundary conditions and brain tissue constitutive model	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Brain-skull interface; Brain injury; Brain tissue constitutive model; Computational biomechanics of the brain	MECHANICAL-PROPERTIES; BIOMECHANICS MODELS; ELEMENT; REGISTRATION; VALIDATION; GENERATION; SIMON	In this study, we investigate the effects of modelling choices for the brain-skull interface (layers of tissues between the brain and skull that determine boundary conditions for the brain) and the constitutive model of brain parenchyma on the brain responses under violent impact as predicted using computational biomechanics model. We used the head/brain model from Total HUman Model for Safety (THUMS)-extensively validated finite element model of the human body that has been applied in numerous injury biomechanics studies. The computations were conducted using a well-established nonlinear explicit dynamics finite element code LS-DYNA. We employed four approaches for modelling the brain-skull interface and four constitutive models for the brain tissue in the numerical simulations of the experiments on post-mortem human subjects exposed to violent impacts reported in the literature. The brain-skull interface models included direct representation of the brain meninges and cerebrospinal fluid, outer brain surface rigidly attached to the skull, frictionless sliding contact between the brain and skull, and a layer of spring-type cohesive elements between the brain and skull. We considered Ogden hyperviscoelastic, Mooney-Rivlin hyperviscoelastic, neo-Hookean hyperviscoelastic and linear viscoelastic constitutive models of the brain tissue. Our study indicates that the predicted deformations within the brain and related brain injury criteria are strongly affected by both the approach of modelling the brain-skull interface and the constitutive model of the brain parenchyma tissues. The results suggest that accurate prediction of deformations within the brain and risk of brain injury due to violent impact using computational biomechanics models may require representation of the meninges and subarachnoidal space with cerebrospinal fluid in the model and application of hyperviscoelastic (preferably Ogden-type) constitutive model for the brain tissue.	[Wang, Fang; Han, Yong; Wang, Bingyu; Peng, Qian; Huang, Xiaoqun] Xiamen Univ Technol, Sch Mech & Automot Engn, Xiamen 361024, Peoples R China; [Wang, Fang; Han, Yong; Wang, Bingyu; Peng, Qian; Huang, Xiaoqun] Fujian Collaborat Innovat Ctr R&D Coach & Special, Xiamen 361024, Peoples R China; [Miller, Karol; Wittek, Adam] Univ Western Australia, Intelligent Syst Med Lab, Perth, WA 6009, Australia; [Miller, Karol] Cardiff Univ, Inst Mech & Adv Mat, Cardiff Sch Engn, Cardiff, S Glam, Wales	Wang, F (corresponding author), Xiamen Univ Technol, Sch Mech & Automot Engn, Xiamen 361024, Peoples R China.; Wang, F (corresponding author), Fujian Collaborat Innovat Ctr R&D Coach & Special, Xiamen 361024, Peoples R China.	wangfang@xmut.edu.cn	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; WANG, FANG/0000-0002-7409-0841; Wittek, Adam/0000-0001-9780-8361; Miller, Karol/0000-0002-6577-2082	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [51605407, 51505403]; Fujian Provincial Department of Science and Technology [2017J01652]; State Administration of Foreign Experts Affairs P. R. China [GDT20173600566]	The authors would like to gratefully acknowledge the support of National Natural Science Foundation of China (Grant Nos. 51605407, 51505403), Fujian Provincial Department of Science and Technology (Grant No. 2017J01652) and State Administration of Foreign Experts Affairs P. R. China (Grant No. GDT20173600566). All simulations using Total HUman Model for Safety (THUMS) Version 4.0 human body model in this research were conducted at Xiamen University of Technology.	Agrawal S., 2015, COMPUTATIONAL BIOMEC, P83, DOI DOI 10.1007/978-3-319-15503-6_8; Al-Bsharat A. S., 1999, STAPP CAR CRASH J, V43, P321; Antona-Makoshi J, 2013, THESIS; Antona-Makoshi J, 2015, THESIS; Bandak F, 2001, P INT TECHN C ENH SA, P7; Bathe K.J, 2006, FINITE ELEMENT PROCE, V2nd; Bayly PV, 2012, ANNU REV BIOMED ENG, V14, P369, DOI [10.1146/annurev-bioeng-071811-150032, 10.1146/annurev.bioeng-071811-150032]; Bilston LE, 2011, BIOL MED PHYS BIOMED, P69, DOI 10.1007/978-1-4419-9997-9_4; Claessans M., 1997, P 41 STAPP CAR CRASH, P315, DOI DOI 10.4271/973338; Fahlstedt M., 2016, P 2016 IRCOBI C INT, P459; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Garlapati RR, 2014, J NEUROSURG, V120, P1477, DOI 10.3171/2013.12.JNS131165; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Hardy W, 2007, THESIS; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Hu JW, 2007, J NEUROSURG, V106, P164, DOI 10.3171/jns.2007.106.1.164; Iwamoto M, 2015, TRAFFIC INJ PREV, V16, pS36, DOI 10.1080/15389588.2015.1015000; Jin X., 2009, THESIS; Jin X, 2014, ANN BIOMED ENG, V42, P812, DOI 10.1007/s10439-013-0948-6; Jin X, 2011, J BIOMECH, V44, P467, DOI 10.1016/j.jbiomech.2010.09.035; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; LSTC, 2007, LS DYNA KEYW US MAN; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; Mazumder MMG, 2013, ACTA BIOENG BIOMECH, V15, P3, DOI 10.5277/abb130201; McElhaney JH, 1973, DYNAMIC CHARACTERIST; Mihai LA, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0486; Miller K, 2011, BIOL MED PHYS BIOMED, P1, DOI 10.1007/978-1-4419-9997-9; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Miller K, 2010, INT J NUMER METH BIO, V26, P117, DOI 10.1002/cnm.1260; Miller RT, 1998, 983154 SAE, DOI DOI 10.4271/983154; NHTSA, 2010, FED MOT VEH SAF STAN; Ogden R., 1997, NONLINEAR ELASTIC DE; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; de Almeida CER, 2016, WORLD NEUROSURG, V87, P540, DOI 10.1016/j.wneu.2015.10.020; Shigeta K, 2009, INT TECHN C ENH SAF, P09; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Wang FJ, 2017, COMM COM INF SC, V739, P159, DOI 10.1007/978-3-319-63184-4_9; Watanabe R, 2011, P 22 ESV C, P11; Wittek A, 2008, COMPUT METHOD BIOMEC, V11, P135, DOI [10.1080/10255840701688095, 10.1080/10255840802296665]; Wittek A, 2003, JSME INT J C-MECH SY, V46, P1388, DOI 10.1299/jsmec.46.1388; Wittek A, 2007, J BIOMECH, V40, P919, DOI 10.1016/j.jbiomech.2006.02.021; Wittek A, 2016, ANN BIOMED ENG, V44, P3, DOI 10.1007/s10439-015-1469-2; Wittek A, 2010, PROG BIOPHYS MOL BIO, V103, P292, DOI 10.1016/j.pbiomolbio.2010.09.001; Yang JK, 2011, COMPUTATIONAL BIOMECHANICS FOR MEDICINE: SOFT TISSUES AND THE MUSCULOSKELETAL SYSTEM, P5, DOI 10.1007/978-1-4419-9619-0_2; Yang JK, 2008, CHIN J MECH ENG-EN, V21, P81, DOI 10.3901/CJME.2008.04.081; Yang KH, 2011, BIOL MED PHYS BIOMED, P91, DOI 10.1007/978-1-4419-9997-9_5; Zhang L, 2001, Stapp Car Crash J, V45, P369	58	19	21	3	24	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	AUG	2018	17	4					1165	1185		10.1007/s10237-018-1021-z			21	Biophysics; Engineering, Biomedical	Biophysics; Engineering	GN3RH	WOS:000438924400018	29754317				2021-06-18	
J	McKee, K; Glass, S; Adams, C; Stephen, CD; King, F; Parlrnan, K; Perez, DL; Kontos, N				McKee, Kathleen; Glass, Sean; Adams, Caitlin; Stephen, Christopher D.; King, Franklin; Parlrnan, Kristin; Perez, David L.; Kontos, Nicholas			The Inpatient Assessment and Management of Motor Functional Neurological Disorders: An Interdisciplinary Perspective	PSYCHOSOMATICS			English	Article						Conversion disorder; Psychogenic nonepileptic seizures; Functional movement disorders; Somatization; Neuropsychiatry	PSYCHOGENIC NONEPILEPTIC SEIZURES; TRAUMATIC BRAIN-INJURY; CONVERSION DISORDER; DIAGNOSTIC-VALUE; CLINICAL SIGNS; SYMPTOMS; EPILEPSY; PSYCHIATRISTS; WEAKNESS; CHILDREN	Background: Motor functional neurologic disorders (FND) previously termed "hysteria" and later "con- version disorder" are exceedingly common and frequently encountered in the acute hospital setting. Despite their high prevalence, patients with motor FND can be challenging to diagnose accurately and manage effectively. To date, there is limited guidance on the inpatient approach to the neuropsychiatric evaluation of patients with functional (psychogenic) neurologic symptoms. Objective: The authors outline an inpatient multidisciplinary approach, involving neurology, psychiatry, and physical therapy, for the assessment and acute inpatient management of motor FND. Methods: A vignette of a patient with motor FND is presented followed by a discussion of general assessment principles. Thereafter, a detailed description of the neurologic and psychiatric assessments is outlined Delivery of a "rule-in" diagnosis is emphasized and specific guidance for what can be accomplished postdiagnosis in the hospital is suggested. Discussion: We encourage an interdisciplinary approach beginning at the early stages of the diagnostic assessment once an individual is suspected of having motor FND. Conclusions: Practical suggestions for the inpatient assessment of motor FND are presented. It is also important to individualize the diagnostic assessment. Future research should be conducted to test best practices for motor FND management in the acute inpatient hospital setting.	[McKee, Kathleen; Stephen, Christopher D.] Massachusetts Gen Hosp, Dept Neurol, Movement Disorders Unit, Boston, MA 02114 USA; [Glass, Sean; Perez, David L.] Massachusetts Gen Hosp, Dept Psychiat, Neuropsychiat Unit, Boston, MA 02114 USA; [Glass, Sean; Adams, Caitlin; Perez, David L.] Massachusetts Gen Hosp, Dept Neurol, Cognit Behav Neurol Unit, Funct Neurol Res Grp, Boston, MA 02114 USA; [Glass, Sean; Adams, Caitlin; King, Franklin; Kontos, Nicholas] Massachusetts Gen Hosp, Dept Psychiat, Consultat Liaison Psychiat Serv, Boston, MA 02114 USA; [Adams, Caitlin] Massachusetts Gen Hosp, Dept Psychiat, Inpatient Psychiat Serv, Boston, MA 02114 USA; [Parlrnan, Kristin] Massachusetts Gen Hosp, Dept Phys Therapy, Boston, MA 02114 USA	Perez, DL; Kontos, N (corresponding author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.	dlperez@nmr.mgh.harvard.edu; nkontos@mgh.harvard.edu	Stephen, Christopher/AAF-4956-2021; Perez, David/AAB-6453-2020	Perez, David/0000-0003-2721-583X	Sidney R. Baer Jr. Foundation; Massachusetts General Hospital Physician-Scientist Award	D.L.P. was funded by the Sidney R. Baer Jr. Foundation and the Massachusetts General Hospital Physician-Scientist Award.	American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, V5th; Asadi-Pooya AA, 2015, EPILEPSY BEHAV, V46, P60, DOI 10.1016/j.yebeh.2015.03.015; Avbersek A, 2010, J NEUROL NEUROSUR PS, V81, P719, DOI 10.1136/jnnp.2009.197996; Barbey A, 2017, CURR OPIN NEUROL, V30, P427, DOI 10.1097/WCO.0000000000000464; Baslet G, 2015, CLIN EEG NEUROSCI, V46, P54, DOI 10.1177/1550059414557025; Baslet G, 2011, SEIZURE-EUR J EPILEP, V20, P1, DOI 10.1016/j.seizure.2010.10.032; Beghi M, 2017, SEIZURE-EUR J EPILEP, V52, P182, DOI 10.1016/j.seizure.2017.10.014; Behrouz R, 2014, J STROKE CEREBROVASC, V23, pE243, DOI 10.1016/j.jstrokecerebrovasdis.2013.11.010; Benbadis SR, 2005, EPILEPSY BEHAV, V6, P264, DOI 10.1016/j.yebeh.2004.12.007; Brigo F, 2013, SEIZURE-EUR J EPILEP, V22, P85, DOI 10.1016/j.seizure.2012.10.011; Brown RJ, 2016, CLIN PSYCHOL REV, V47, P55, DOI 10.1016/j.cpr.2016.06.003; Brown RJ, 2013, EPILEPSY BEHAV, V29, P178, DOI 10.1016/j.yebeh.2013.07.019; Carson Alan, 2016, Pract Neurol, V16, P56, DOI 10.1136/practneurol-2015-001242; COYLE PK, 1986, AM J PSYCHIAT, V143, P648; Czarnecki K, 2012, PARKINSONISM RELAT D, V18, P247, DOI 10.1016/j.parkreldis.2011.10.011; Daum C, 2014, J NEUROL NEUROSUR PS, V85, P180, DOI 10.1136/jnnp-2012-304607; Dixit R, 2013, EPILEPSY BEHAV, V28, P137, DOI 10.1016/j.yebeh.2013.05.004; Edwards MJ, 2014, MOVEMENT DISORD, V29, P849, DOI 10.1002/mds.25562; Friedman JH, 2010, ARCH NEUROL-CHICAGO, V67, P753, DOI 10.1001/archneurol.2010.91; Gardiner P., 2017, CNS SPECTRUMS, V23, P1; Gedzelman ER, 2014, NEUROPSYCH DIS TREAT, V10, P1979, DOI 10.2147/NDT.S49531; Gelauff J, 2014, J NEUROL NEUROSUR PS, V85, P220, DOI 10.1136/jnnp-2013-305321; Goldstein LH, 2006, J NEUROL NEUROSUR PS, V77, P616, DOI 10.1136/jnnp.2005.066878; Hall-Patch L, 2010, EPILEPSIA, V51, P70, DOI 10.1111/j.1528-1167.2009.02099.x; Hendrickson R, 2014, EPILEPSY BEHAV, V37, P210, DOI 10.1016/j.yebeh.2014.06.026; Jimenez XF, 2016, PSYCHOSOMATICS, V57, P440, DOI 10.1016/j.psym.2016.02.014; Jimenez XF, 2016, EPILEPSY BEHAV, V56, P149, DOI 10.1016/j.yebeh.2015.12.035; Jimenez XF, 2015, EPILEPSY BEHAV, V45, P164, DOI 10.1016/j.yebeh.2015.02.001; Kanaan R, 2009, BRAIN, V132, P2889, DOI 10.1093/brain/awp060; Kanaan RA, 2016, NEUROPSYCH DIS TREAT, V12, P1181, DOI 10.2147/NDT.S96330; Kanner AM, 2003, EPILEPSY BEHAV, V4, P597, DOI 10.1016/j.yebeh.2003.09.013; Kanner AM, 2011, NEUROL CLIN, V29, P163, DOI 10.1016/j.ncl.2010.11.002; Kenney C, 2007, J NEUROL SCI, V263, P94, DOI 10.1016/j.jns.2007.06.008; Kozlowska K, 2018, CLIN CHILD PSYCHOL P, V23, P140, DOI 10.1177/1359104517732118; Kozlowska K, 2018, CLIN CHILD PSYCHOL P, V23, P160, DOI 10.1177/1359104517730116; LaFrance WC, 2013, EPILEPSIA, V54, P2005, DOI 10.1111/epi.12356; LaFrance WC, 2013, EPILEPSIA, V54, P718, DOI 10.1111/epi.12053; LaFrance WC, 2013, EPILEPSIA, V54, P53, DOI 10.1111/epi.12106; LaFrance WC, 2002, EPILEPSY BEHAV, V3, pS19, DOI 10.1016/S1525-5069(02)00505-4; Lang AE, 2011, MOVEMENT DISORD, V26, P1175, DOI 10.1002/mds.23571; Lawley A, 2015, EPILEPSY BEHAV, V53, P26, DOI 10.1016/j.yebeh.2015.09.032; Matin N, 2017, J NEUROPSYCHIATRY CL; Maurer CW, 2016, PARKINSONISM RELAT D, V30, P18, DOI 10.1016/j.parkreldis.2016.06.009; McKenzie PS, 2011, J NEUROL NEUROSUR PS, V82, P967, DOI 10.1136/jnnp.2010.231886; McWhirter L, 2011, J PSYCHOSOM RES, V71, P384, DOI 10.1016/j.jpsychores.2011.09.003; Nielsen G, 2017, J NEUROL NEUROSUR PS, V88, P484, DOI 10.1136/jnnp-2016-314408; Nielsen G, 2015, J NEUROL NEUROSUR PS, V86, P1113, DOI 10.1136/jnnp-2014-309255; Parees I, 2014, J NEUROL SCI, V338, P174, DOI 10.1016/j.jns.2013.12.046; Perez DL, 2016, COGN BEHAV NEUROL, V29, P197, DOI 10.1097/WNN.0000000000000106; Perez DL, 2016, CNS SPECTRUMS, V21, P239, DOI 10.1017/S109285291600002X; Rao SR, 2017, EPILEPSY BEHAV, V77, P50, DOI 10.1016/j.yebeh.2017.09.005; Rawlings GH, 2017, SEIZURE-EUR J EPILEP, V48, P22, DOI 10.1016/j.seizure.2017.03.015; Reuber M, 2007, PSYCHOSOMATICS, V48, P230, DOI 10.1176/appi.psy.48.3.230; Reuber M, 2009, NEUROL CLIN, V27, P909, DOI 10.1016/j.ncl.2009.06.004; Robbins NM, 2016, EPILEPSY BEHAV, V55, P174, DOI 10.1016/j.yebeh.2015.12.022; Roper Louise S, 2013, Pract Neurol, V13, P396, DOI 10.1136/practneurol-2013-000549; Salinsky M, 2015, J HEAD TRAUMA REHAB, V30, pE65, DOI 10.1097/HTR.0000000000000057; Schrag A, 2004, BRAIN, V127, P2360, DOI 10.1093/brain/awh262; Stone J, 2016, HAND CLINIC, V139, P213, DOI 10.1016/B978-0-12-801772-2.00018-7; Stone J, 2016, HAND CLINIC, V139, P543, DOI 10.1016/B978-0-12-801772-2.00044-8; Stone J, 2010, CLIN NEUROL NEUROSUR, V112, P747, DOI 10.1016/j.clineuro.2010.05.011; Stone Jon, 2016, Pract Neurol, V16, P7, DOI 10.1136/practneurol-2015-001241; Stone Jon, 2015, Continuum (Minneap Minn), V21, P818, DOI 10.1212/01.CON.0000466669.02477.45; Stone J, 2012, NEUROLOGY, V79, P282, DOI 10.1212/WNL.0b013e31825fdf63; Stone J, 2011, J PSYCHOSOM RES, V71, P369, DOI 10.1016/j.jpsychores.2011.07.005; Stone J, 2010, BRAIN, V133, P1537, DOI 10.1093/brain/awq068; Stone J, 2009, BRAIN, V132, P2878, DOI 10.1093/brain/awp220; Stone Jon, 2009, Pract Neurol, V9, P179, DOI 10.1136/jnnp.2009.177204; Thenganatt MA, 2014, TREMOR OTHER HYPERK, V4, DOI 10.7916/D8FJ2F0Q; Torous J, 2015, ASIAN J PSYCHIATR, V17, P116, DOI 10.1016/j.ajp.2015.05.007; Westbrook LE, 1998, EPILEPSIA, V39, P978, DOI 10.1111/j.1528-1157.1998.tb01447.x; Williams DT, 2016, HAND CLINIC, V139, P631, DOI 10.1016/B978-0-12-801772-2.00051-5	72	19	19	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0033-3182			PSYCHOSOMATICS	Psychosomatics	JUL-AUG	2018	59	4					358	368		10.1016/j.psym.2017.12.006			11	Psychiatry; Psychology	Psychiatry; Psychology	GK8MT	WOS:000436479700006	29628294				2021-06-18	
J	Piccirillo, S; Castaldo, P; Macri, ML; Amoroso, S; Magi, S				Piccirillo, Silvia; Castaldo, Pasqualina; Macri, Maria Loredana; Amoroso, Salvatore; Magi, Simona			Glutamate as a potential "survival factor" in an in vitro model of neuronal hypoxia/reoxygenation injury: leading role of the Na+/Ca2+ exchanger	CELL DEATH & DISEASE			English	Article							AMINO-ACID TRANSPORTERS; SODIUM-CALCIUM EXCHANGE; NEUROBLASTOMA SH-SY5Y CELLS; OXYGEN-GLUCOSE DEPRIVATION; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; NA+-CA2+ EXCHANGER; ADULT-RAT; EAAC1; DEATH	In brain ischemia, reduction in oxygen and substrates affects mitochondrial respiratory chain and aerobic metabolism, culminating in ATP production impairment, ionic imbalance, and cell death. The restoration of blood flow and reoxygenation are frequently associated with exacerbation of tissue injury, giving rise to ischemia/reperfusion (I/R) injury. In this setting, the imbalance of brain bioenergetics induces important metabolic adaptations, including utilization of alternative energy sources, such as glutamate. Although glutamate has long been considered as a neurotoxin, it can also be used as intermediary metabolite for ATP synthesis, and both the Na/+Ca2+ exchanger (NCX) and the Na+-dependent excitatory amino-acid transporters (EAATs) are essential in this pathway. Here we analyzed the role of NCX in the potential of glutamate to improve metabolism and survival of neuronal cells subjected to hypoxia/reoxygenation (H/R). In SH-SY5Y neuroblastoma cells differentiated into a neuron-like state, H/R produced a significant cell damage, a decrease in ATP cellular content, and intracellular Ca2+ alterations. Exposure to glutamate at the onset of the reoxygenation phase attenuated H/R-induced cell damage and evoked a significant raise in intracellular ATP levels. Furthermore, we found that in H/R cells NCX reverse-mode activity was reduced, and that glutamate limited such reduction. All the effects induced by glutamate supplementation were lost when cells were transfected with small interfering RNA against NCX1 and EAAT3, suggesting the need of a specific functional interplay between these proteins for glutamate-induced protection. Collectively, our results revealed the potential beneficial effect of glutamate in an in vitro model of H/R injury and focused on the essential role exerted by NCX1. Although preliminary, these findings could be a starting point to further investigate in in vivo systems such protective effect in ischemic settings, shedding a new light on the classical view of glutamate as detrimental factor.	[Piccirillo, Silvia; Castaldo, Pasqualina; Macri, Maria Loredana; Amoroso, Salvatore; Magi, Simona] Univ Politecn Marche, Sch Med, Dept Biomed Sci & Publ Hlth, Via Tronto 10-A, I-60126 Ancona, Italy	Magi, S (corresponding author), Univ Politecn Marche, Sch Med, Dept Biomed Sci & Publ Hlth, Via Tronto 10-A, I-60126 Ancona, Italy.	s.magi@univpm.it	MAGI, Simona/O-4651-2019	MAGI, Simona/0000-0002-8115-8226	"Ricerca Scientifica di Ateneo" (RSA) Grants from University "Politecnica delle Marche"	We are grateful to Gerardo Galeazzi, Franco Pettinari, and Carlo Alfredo Violet for their excellent technical assistance. This work was supported by "Ricerca Scientifica di Ateneo" (RSA) Grants (2015-2017) from University "Politecnica delle Marche".	Albrecht J, 2010, NEURON GLIA BIOL, V6, P263, DOI 10.1017/S1740925X11000093; Amoroso S, 1997, BRIT J PHARMACOL, V121, P303, DOI 10.1038/sj.bjp.0701092; Aoyama K, 2006, NAT NEUROSCI, V9, P119, DOI 10.1038/nn1609; Berman AE, 2011, ANN NEUROL, V69, P509, DOI 10.1002/ana.22162; BIEDLER JL, 1978, CANCER RES, V38, P3751; Bjorn-Yoshimoto WE, 2016, NEUROCHEM INT, V98, P4, DOI 10.1016/j.neuint.2016.05.007; Blaustein MP, 1999, PHYSIOL REV, V79, P763; Bonde C, 2005, NEUROSCIENCE, V136, P779, DOI 10.1016/j.neuroscience.2005.07.020; Canzoniero LMT, 2006, J NEUROSCI RES, V84, P692, DOI 10.1002/jnr.20971; Castaldo P, 2007, NEUROPHARMACOLOGY, V53, P369, DOI 10.1016/j.neuropharm.2007.05.019; Castaldo P, 2017, EUR J PHARMACOL, V794, P246, DOI 10.1016/j.ejphar.2016.11.045; Chen YM, 2003, J NEUROCHEM, V84, P1332, DOI 10.1046/j.1471-4159.2003.01630.x; Choi BY, 2014, INT J MOL SCI, V15, P19444, DOI 10.3390/ijms151119444; Cross JL, 2012, NEUROSCI RES, V73, P191, DOI 10.1016/j.neures.2012.04.007; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Denton RM, 2009, BBA-BIOENERGETICS, V1787, P1309, DOI 10.1016/j.bbabio.2009.01.005; Dirnagl U, 2008, NEUROPHARMACOLOGY, V55, P334, DOI 10.1016/j.neuropharm.2008.02.017; Divito CB, 2014, NEUROCHEM INT, V73, P172, DOI 10.1016/j.neuint.2013.12.008; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Filograna R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136769; Gobbi P, 2007, PHARMACOL RES, V56, P556, DOI 10.1016/j.phrs.2007.10.005; Gottlieb M, 2000, J CEREBR BLOOD F MET, V20, P678, DOI 10.1097/00004647-200004000-00005; Hilgemann DW, 2018, J GEN PHYSIOL, V150, P211, DOI 10.1085/jgp.201711875; Husson A, 2003, EUR J BIOCHEM, V270, P1887, DOI 10.1046/j.1432-1033.2003.03559.x; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Iwamoto T, 2004, MOL PHARMACOL, V66, P45, DOI 10.1124/mol.66.1.45; KATSURA K, 1994, BIOCHEM SOC T, V22, P991, DOI 10.1042/bst0220991; Kim AY, 2017, NEUROSCIENCE, V340, P487, DOI 10.1016/j.neuroscience.2016.11.007; Lariccia V, 2011, J GEN PHYSIOL, V137, P111, DOI 10.1085/jgp.201010468; Li LL, 2011, J CEREBR BLOOD F MET, V31, P1283, DOI 10.1038/jcbfm.2010.222; Magi S, 2005, J PHARMACOL EXP THER, V315, P291, DOI 10.1124/jpet.105.088948; Magi S, 2015, EUR J PHARMACOL, V746, P31, DOI 10.1016/j.ejphar.2014.10.054; Magi S, 2013, MOL PHARMACOL, V84, P603, DOI 10.1124/mol.113.087775; Magi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034015; Maiolino M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13478-x; Matsuda T, 2001, J PHARMACOL EXP THER, V298, P249; McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444; Miglio G, 2004, EUR J PHARMACOL, V489, P157, DOI 10.1016/j.ejphar.2004.03.006; Minelli A, 2007, CELL CALCIUM, V41, P221, DOI 10.1016/j.ceca.2006.06.004; NAARALA J, 1993, FEBS LETT, V330, P222, DOI 10.1016/0014-5793(93)80278-3; Nelson RM, 2003, BRAIN RES, V964, P1, DOI 10.1016/S0006-8993(02)03691-0; Olianas MC, 2017, EUR J PHARMACOL, V794, P135, DOI 10.1016/j.ejphar.2016.11.030; Pascual JM, 1998, STROKE, V29, P1048, DOI 10.1161/01.STR.29.5.1048; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Pignataro G, 2004, STROKE, V35, P2566, DOI 10.1161/01.STR.0000143730.29964.93; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250; Reeves JP, 2003, J GEN PHYSIOL, V122, P621, DOI 10.1085/jgp.200308915; Rink C, 2017, FASEB J, V31, P1709, DOI 10.1096/fj.201601033R; Rink C, 2011, ANTIOXID REDOX SIGN, V14, P1777, DOI 10.1089/ars.2011.3930; Ronsisvalle N, 2014, CURR ALZHEIMER RES, V11, P714, DOI 10.2174/1567205011666140618104430; Scorziello A, 2004, J NEUROSCI RES, V76, P812, DOI 10.1002/jnr.20096; Seal RP, 1999, ANNU REV PHARMACOL, V39, P431, DOI 10.1146/annurev.pharmtox.39.1.431; Shenoda B, 2015, TRANSL STROKE RES, V6, P181, DOI 10.1007/s12975-015-0395-9; Shimamoto K, 1998, MOL PHARMACOL, V53, P195; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Sisalli MJ, 2014, CELL DEATH DIFFER, V21, P1142, DOI 10.1038/cdd.2014.32; Sonnewald U, 2002, NEUROCHEM RES, V27, P43, DOI 10.1023/A:1014846404492; Staiano RL, 2009, EUR J IMMUNOL, V39, P1405, DOI 10.1002/eji.200838792; Sun DD, 1998, AM J PHYSIOL-CELL PH, V275, pC772; Sun ZW, 2010, NEUROSCI BULL, V26, P8, DOI 10.1007/s12264-010-0813-7; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699	63	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	JUN 28	2018	9								731	10.1038/s41419-018-0784-6			14	Cell Biology	Cell Biology	GK9OQ	WOS:000436581500003	29955038	DOAJ Gold, Green Published			2021-06-18	
J	Dai, WJ; Liu, AZ; Kaminga, AC; Deng, J; Lai, ZW; Yang, JZ; Wen, SW				Dai, Wenjie; Liu, Aizhong; Kaminga, Atipatsa C.; Deng, Jing; Lai, Zhiwei; Yang, Jianzhou; Wen, Shi Wu			Prevalence of acute stress disorder among road traffic accident survivors: a meta-analysis	BMC PSYCHIATRY			English	Article						Acute stress disorder; Road traffic accident; Prevalence; meta-analysis	MOTOR-VEHICLE ACCIDENTS; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS; RANDOMIZED-TRIALS; RISK-FACTORS; CHILDREN; SYMPTOMS; ASSOCIATION; ADOLESCENTS; DEPRESSION	Background: Road traffic accident (RTA), an unexpected traumatic event, may not only lead to death and serious physical injuries, but also could put survivors at an increased risk for a wide range of psychiatric disorders, particularly acute stress disorder (ASD). Early assessment of trauma-related psychological responses is important because acute trauma responses in the early post-traumatic period are among the robust predictors of long-term mental health problems. However, estimates of the prevalence of ASD among RTA survivors varied considerably across studies. Therefore, this meta-analysis aimed to identify the pooled prevalence of ASD among RTA survivors. Methods: A systematic literature search in the databases of PubMed, PsycINFO, PsycARTICLES, Embase and Web of Science was performed from their inception dates to December 2017. Subject headings were used to identify relevant articles, and the search strategy was adjusted across databases. Heterogeneity across studies was evaluated by Cochran's chi(2) test and quantified by the I-2 statistic. Subgroup analyses were performed to identify the pooled prevalence in relation to the country of study, instrument used to identify ASD, age, gender and traumatic brain injury. When significant heterogeneity was observed, the influence of some potential moderators was explored using meta-regression analyses. Results: Thirteen eligible studies conducted in 8 countries were included. A total of 2989 RTA survivors were assessed, of which 287 were identified with ASD. The overall heterogeneity was high across studies (I-2=96.8%, P < 0.001), and the pooled prevalence of ASD among RTA survivors was 15.81% (95% confidence interval: 8.27-25.14%). Subgroup analyses indicated that the prevalence of ASD among RTA survivors differed significantly with regard to the country of study, instrument used to identify ASD, age and gender (P < 0.05). Meta-regression analyses showed that mean age of participants and quality assessment score were significant moderators for heterogeneity (P < 0.05). Conclusions: Nearly one-sixth of RTA survivors suffer from ASD, indicating the need for regular assessment of early trauma responses among RTA survivors, as well as the importance of implementing early psychological interventions.	[Dai, Wenjie; Liu, Aizhong; Kaminga, Atipatsa C.; Deng, Jing; Wen, Shi Wu] Cent S Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China; [Dai, Wenjie; Wen, Shi Wu] Univ Ottawa, Dept Obstet & Gynecol, OMNI Res Grp, Fac Med, Ottawa, ON, Canada; [Dai, Wenjie; Wen, Shi Wu] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Dai, Wenjie; Wen, Shi Wu] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Fac Med, Ottawa, ON, Canada; [Kaminga, Atipatsa C.] Mzuzu Univ, Dept Math, Mzuzu, Malawi; [Lai, Zhiwei] Hunan Prov Ctr Dis Control & Prevent, Immunizat Programme Dept, Changsha, Hunan, Peoples R China; [Yang, Jianzhou] Changzhi Med Coll, Dept Prevent Med, Changzhi, Shanxi, Peoples R China	Liu, AZ; Wen, SW (corresponding author), Cent S Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China.; Wen, SW (corresponding author), Univ Ottawa, Dept Obstet & Gynecol, OMNI Res Grp, Fac Med, Ottawa, ON, Canada.; Wen, SW (corresponding author), Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.; Wen, SW (corresponding author), Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Fac Med, Ottawa, ON, Canada.	lazroy@live.cn; swwen@ohri.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [FDN-148438]; Specialized Research Fund for the Doctoral Program of Higher EducationSpecialized Research Fund for the Doctoral Program of Higher Education (SRFDP) [20130162110054]; Natural Science Foundation of Hunan Province, ChinaNatural Science Foundation of Hunan Province [2016JJ2153]; Fundamental Research Funds for the postgraduates of Central South University [2015zzts282]; Applied Basic Research Project of Shanxi Province [2016011092]	This study was supported in part, by the Canadian Institutes of Health Research (FDN-148438), the Specialized Research Fund for the Doctoral Program of Higher Education (20130162110054), the Natural Science Foundation of Hunan Province, China (2016JJ2153), the Fundamental Research Funds for the postgraduates of Central South University (2015zzts282), and the Applied Basic Research Project of Shanxi Province (2016011092).	Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643; Alisic E, 2011, CLIN PSYCHOL REV, V31, P736, DOI 10.1016/j.cpr.2011.03.001; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bassuk EL, 2015, J AM ACAD CHILD PSY, V54, P86, DOI 10.1016/j.jaac.2014.11.008; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Bryant B, 2004, PSYCHOL MED, V34, P335, DOI 10.1017/S0033291703001053; Bryant RA, 2000, PSYCHOL ASSESSMENT, V12, P61, DOI 10.1037/1040-3590.12.1.61; Bryant RA, 2003, AUST NZ J PSYCHIAT, V37, P226, DOI 10.1046/j.1440-1614.2003.01130.x; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant RA, 2011, DEPRESS ANXIETY, V28, P802, DOI 10.1002/da.20737; Dai WJ, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0891-9; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Einsle F, 2012, J PSYCHOSOM RES, V72, P434, DOI 10.1016/j.jpsychores.2012.02.008; Elklit Ask, 2003, Violence Vict, V18, P461, DOI 10.1891/vivi.2003.18.4.461; Fernandez CA, 2017, INT J EPIDEMIOL, V46, P440, DOI 10.1093/ije/dyw094; Fuglsang AK, 2004, NORD J PSYCHIAT, V58, P223, DOI 10.1080/08039480410006278; Griffiths J, 2007, INTENS CARE MED, V33, P1506, DOI 10.1007/s00134-007-0730-z; Haag AC, 2015, EUR J PSYCHOTRAUMATO, V6, DOI 10.3402/ejpt.v6.29074; Hamanaka S, 2006, GEN HOSP PSYCHIAT, V28, P234, DOI 10.1016/j.genhosppsych.2006.02.007; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; Kessler RC, 2017, EUR J PSYCHOTRAUMATO, V8, DOI 10.1080/20008198.2017.1353383; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; KOOPMAN C, 1995, J TRAUMA STRESS, V8, P29, DOI 10.1007/BF02105405; Ladeira Roberto Marini, 2017, Rev. bras. epidemiol., V20, P157, DOI 10.1590/1980-5497201700050013; Li XM, 2017, J AFFECT DISORDERS, V218, P322, DOI 10.1016/j.jad.2017.03.048; Loney P L, 1998, Chronic Dis Can, V19, P170; McKibben JBA, 2008, J BURN CARE RES, V29, P22, DOI 10.1097/BCR.0b013e31815f59c4; Meiser-Stedman R, 2007, J TRAUMA STRESS, V20, P359, DOI 10.1002/jts.20211; Melroy-Greif WE, 2017, TWIN RES HUM GENET, V20, P197, DOI 10.1017/thg.2017.12; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Muldoon OT, 2003, J CHILD PSYCHOL PSYC, V44, P193, DOI 10.1111/1469-7610.00113; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; Pailler ME, 2007, GEN HOSP PSYCHIAT, V29, P357, DOI 10.1016/j.genhosppsych.2007.04.003; Roberge MA, 2008, PSYCHOSOM MED, V70, P1028, DOI 10.1097/PSY.0b013e318189a920; Salmon K, 2007, BRIT J CLIN PSYCHOL, V46, P203, DOI 10.1348/014466506X160704; Siqveland J, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00164; Spottswood M, 2017, HARVARD REV PSYCHIAT, V25, P159, DOI 10.1097/HRP.0000000000000136; Staab JP, 1996, ANXIETY, V2, P219, DOI 10.1002/(SICI)1522-7154(1996)2:5<219::AID-ANXI3>3.0.CO;2-H; Swartzman S, 2017, DEPRESS ANXIETY, V34, P327, DOI 10.1002/da.22542; Tousignant B, 2018, NEUROPSYCHOL REHABIL, V28, P429, DOI 10.1080/09602011.2016.1158114; van den Heuvel L, 2016, ANXIETY STRESS COPIN, V29, P616, DOI 10.1080/10615806.2016.1163545; Vasterling JJ, 2018, J INT NEUROPSYCH SOC, V24, P311, DOI 10.1017/S1355617717001059; Williamson V, 2018, AM J GERIAT PSYCHIAT, V26, P534, DOI 10.1016/j.jagp.2017.11.001; Wilson JL, 2017, VET REC, V180, P195, DOI 10.1136/vr.103859; Winston FK, 2005, ARCH PEDIAT ADOL MED, V159, P1074, DOI 10.1001/archpedi.159.11.1074; Winston FK, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e90; Yahav R, 2007, SOC PSYCH PSYCH EPID, V42, P830, DOI 10.1007/s00127-007-0237-5; Yang CS, 2017, TRAFFIC INJ PREV, V18, P724, DOI 10.1080/15389588.2017.1309650; Yasan A, 2009, PSYCHOPATHOLOGY, V42, P236, DOI 10.1159/000218521; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zhang LJ, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1234-1; Zhou PL, 2016, PSYCH J, V5, P206, DOI 10.1002/pchj.136	56	19	19	0	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-244X			BMC PSYCHIATRY	BMC Psychiatry	JUN 13	2018	18								188	10.1186/s12888-018-1769-9			11	Psychiatry	Psychiatry	GJ5GT	WOS:000435410200003	29895273	DOAJ Gold, Green Published			2021-06-18	
J	Chou, A; Krukowski, K; Morganti, JM; Riparip, LK; Rosi, S				Chou, Austin; Krukowski, Karen; Morganti, Josh M.; Riparip, Lara-Kirstie; Rosi, Susanna			Persistent Infiltration and Impaired Response of Peripherally-Derived Monocytes after Traumatic Brain Injury in the Aged Brain	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						traumatic brain injury; monocyte; inflammation; ageing; cognition	CONTROLLED CORTICAL IMPACT; ALTERNATIVE ACTIVATION; COGNITIVE FUNCTION; MICROGLIA DERIVE; MICE; MACROPHAGES; CCR2; PLASTICITY; BIOMARKERS; DYNAMICS	Traumatic brain injury (TBI) is a leading cause for neurological disabilities world-wide. TBI occurs most frequently among the elderly population, and elderly TBI survivors suffer from reduced recovery and poorer quality of life. The effect of age on the pathophysiology of TBI is still poorly understood. We previously established that peripherally-derived monocytes (CCR2(+)) infiltrate the injured brain and contribute to chronic TBI-induced cognitive deficits in young animals. Furthermore, age was shown to amplify monocyte infiltration acutely after injury. In the current study, we investigated the impact of age on the subchronic response of peripherally-derived monocytes (CD45(hi); CCR2(+)) and their role in the development of chronic cognitive deficits. In the aged brain, there was a significant increase in the number of peripherally-derived monocytes after injury compared to young, injured animals. The infiltration rate of peripherally-derived monocytes remained elevated subchronically and corresponded with enhanced expression of CCR2 chemotactic ligands. Interestingly, the myeloid cell populations observed in injured aged brains had impaired anti-inflammatory responses compared to those in young animals. Additionally, in the aged animals, there was an expansion of the blood CCR2(+) monocyte population after injury that was not present in the young animals. Importantly, knocking out CCR2 to inhibit infiltration of peripherally-derived monocytes prevented chronic TBI-induced spatial memory deficits in the aged mice. Altogether, these results demonstrate the critical effects of age on the peripherally-derived monocyte response during the progression of TBI pathophysiology.	[Chou, Austin; Krukowski, Karen; Morganti, Josh M.; Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Chou, Austin; Krukowski, Karen; Morganti, Josh M.; Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, San Francisco, CA 94143 USA; [Rosi, Susanna] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Rosi, Susanna] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94158 USA; [Rosi, Susanna] Univ Calif San Francisco, Kavli Inst Fundamental Neurosci, San Francisco, CA 94158 USA	Rosi, S (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94158 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Kavli Inst Fundamental Neurosci, San Francisco, CA 94158 USA.	austin.chou@ucsf.edu; karen.krukowski@ucsf.edu; josh.morganti@uky.edu; lriparip@gmail.com; susanna.rosi@ucsf.edu	Morganti, Josh/AAL-9727-2020	Morganti, Josh/0000-0002-4183-0049; Chou, Austin/0000-0003-4328-5811	NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042016]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087458]; NIH/NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG056770]; NRSA post-doctoral fellowship NIA [F32AG054126]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG056770] Funding Source: NIH RePORTER	This work was supported by research grants: NIA R21AG042016 (SR), NIH/NINDS R21NS087458 (SR), NIH/NIA R01AG056770 (SR), NRSA post-doctoral fellowship NIA F32AG054126 (KK).	Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Alamed J, 2006, NAT PROTOC, V1, P1671, DOI 10.1038/nprot.2006.275; Alliot F, 1999, DEV BRAIN RES, V117, P145, DOI 10.1016/S0165-3806(99)00113-3; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Davies LC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2877; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gliem M, 2016, BBA-MOL BASIS DIS, V1862, P329, DOI 10.1016/j.bbadis.2015.11.004; Gong DP, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-31; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gyoneva S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0443-0; Hazeldine J, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00235; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Itoh T, 2013, BRAIN STRUCT FUNCT, V218, P209, DOI 10.1007/s00429-012-0394-5; Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee DC, 2013, NEUROBIOL AGING, V34, P1610, DOI 10.1016/j.neurobiolaging.2012.12.014; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu S, 2013, J MOL NEUROSCI, V51, P1021, DOI 10.1007/s12031-013-0091-8; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Prinz M, 2010, J NEUROIMMUNOL, V224, P80, DOI 10.1016/j.jneuroim.2010.05.015; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569; Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001	50	19	19	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	JUN	2018	19	6							1616	10.3390/ijms19061616			15	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	GK8UZ	WOS:000436506600071	29848996	DOAJ Gold, Green Published			2021-06-18	
J	Lilja-Cyron, A; Kelsen, J; Andresen, M; Fugleholm, K; Juhler, M				Lilja-Cyron, Alexander; Kelsen, Jesper; Andresen, Morten; Fugleholm, Kare; Juhler, Marianne			Feasibility of Telemetric Intracranial Pressure Monitoring in the Neuro Intensive Care Unit	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; ICP; TBI; telemetric; telemetry	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; DECOMPRESSIVE CRANIECTOMY; INTRACEREBRAL HEMORRHAGE; MANAGEMENT; TRIAL; COMPLICATIONS; MULTICENTER; REACTIVITY; HYDROCEPHALUS	Intracranial pressure (ICP) monitoring is crucial in the management of acute neurosurgical conditions such as traumatic brain injury (TBI). However, pathological ICP may persist beyond the admission to the neuro intensive care unit (NICU). We investigated the feasibility of telemetric ICP monitoring in the NICU, as this technology provides the possibility of long-term ICP assessment beyond NICU discharge. In this prospective investigation, we implanted telemetric ICP sensors (Raumedic Neurovent-P-tel) instead of conventional, cabled ICP sensors in patients undergoing decompressive craniectomy. We recorded ICP curves, duration of ICP monitoring, signal quality, and complications. Seventeen patients were included (median age 55 years) and diagnoses were: severe TBI (8), malignant middle cerebral artery infarction (8), and spontaneous intracerebral hemorrhage (1). In total, 3015 h of ICP monitoring were performed, and the median duration of ICP monitoring was 188 h (interquartile range [IQR] 54-259). The ICP signal was lost 613 times (displacement of the reader unit on the skin) for a median of 1.5 min, corresponding to 0.8% of the total monitoring period. When the signal was lost, it could always be restored by realignment of the reader unit on the skin above the telemetric sensor. Sixteen of 17 patients survived the NICU admission, and ICP gradually decreased from 10.7mm Hg (IQR 7.5-13.6) during the first postoperative day to 6.3mm Hg (IQR 4.0-8.3) after 1 week in the NICU. All 17 implanted telemetric sensors functioned throughout the NICU admission, and no wound infections were observed. Therefore, telemetric ICP monitoring in an acute neurosurgical setting is feasible. Signal quality and stability are sufficient for clinical decision making based on mean ICP. The low sampling frequency (5 Hz) does not permit analysis of intracranial pulse wave morphology, but resolution is sufficient for calculation of derived indices such as the pressure reactivity index (PRx).	[Lilja-Cyron, Alexander; Andresen, Morten; Fugleholm, Kare; Juhler, Marianne] Rigshosp, Dept Neurosurg, Blegdamsvej 9, DK-2100 Copenhagen, Denmark; [Kelsen, Jesper] Rigshosp, Dept Orthoped Surg, Spine Sect, Copenhagen, Denmark	Lilja-Cyron, A (corresponding author), Rigshosp, Dept Neurosurg, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	alexander.lilja-cyron@regionh.dk	Kelsen, Jesper/AAH-7372-2020	Fugleholm, Kare/0000-0002-1520-7122; Andresen, Morten/0000-0002-3802-6033; Lilja-Cyron, Alexander/0000-0003-2915-249X	The Council of the Danish Victims Fund	This project was supported by The Council of the Danish Victims Fund through a research grant to M.J., to improve treatment of patients with severe TBI.	Andresen M, 2014, J NEUROSURG, V121, P797, DOI 10.3171/2014.2.JNS132209; Andresen M, 2013, J NEUROSURG, V119, P1119, DOI 10.3171/2013.7.JNS13506; Antes S, 2016, WORLD NEUROSURG, V91, P133, DOI 10.1016/j.wneu.2016.03.096; Antes S, 2014, ACTA NEUROCHIR, V156, P1009, DOI 10.1007/s00701-013-1991-7; Antes S, 2014, CHILD NERV SYST, V30, P331, DOI 10.1007/s00381-013-2269-3; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Arroyo-Palacios J, 2016, NEUROCRIT CARE, V25, P424, DOI 10.1007/s12028-016-0268-4; ATKINSON JR, 1967, J NEUROSURG, V27, P428, DOI 10.3171/jns.1967.27.5.0428; Beez T, 2016, J CRANIOFAC SURG, V27, P1032, DOI 10.1097/SCS.0000000000002556; Bor-Seng-Shu E, 2012, J NEUROSURG, V117, P589, DOI 10.3171/2012.6.JNS101400; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2015, J NEUROTRAUM, V32, P1722, DOI 10.1089/neu.2015.3976; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Citerio G, 2008, NEUROSURGERY, V63, P1152, DOI 10.1227/01.NEU.0000335148.87042.D7; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Eide PK, 2007, NEUROL RES, V29, P578, DOI 10.1179/016164107X172167; Eide PK, 2011, NEUROSURGERY, V69, P1105, DOI 10.1227/NEU.0b013e318227e0e1; Fenoy AJ, 2014, J NEUROSURG, V120, P132, DOI 10.3171/2013.10.JNS131225; Freimann FB, 2014, CHILD NERV SYST, V30, P689, DOI 10.1007/s00381-013-2324-0; Freimann FB, 2013, PEDIATR NEUROSURG, V49, P29, DOI 10.1159/000355561; Fung C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149169; Gelabert-Gonzalez M, 2006, ACTA NEUROCHIR, V148, P435, DOI 10.1007/s00701-005-0683-3; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Holm S, 2009, MED ENG PHYS, V31, P601, DOI 10.1016/j.medengphy.2008.12.001; Hu X, 2010, IEEE T BIO-MED ENG, V57, P1070, DOI 10.1109/TBME.2009.2037607; Hu X, 2008, ACTA NEUROCHIR SUPPL, V102, P131, DOI 10.1007/978-3-211-85578-2_27; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Jamjoom AAB, 2018, J NEUROL NEUROSUR PS, V89, P120, DOI 10.1136/jnnp-2017-316415; Kammersgaard LP, 2013, NEUROREHABILITATION, V33, P473, DOI 10.3233/NRE-130980; Kiefer Michael, 2012, Acta Neurochir Suppl, V114, P111, DOI 10.1007/978-3-7091-0956-4_20; Koskinen LOD, 2013, ACTA NEUROCHIR, V155, P2141, DOI 10.1007/s00701-013-1856-0; Kurland DB, 2015, NEUROCRIT CARE, V23, P292, DOI 10.1007/s12028-015-0144-7; Lazaridis C, 2016, NEUROSURG CLIN N AM, V27, P509, DOI 10.1016/j.nec.2016.05.010; Lilja A, 2014, CLIN NEUROL NEUROSUR, V120, P36, DOI 10.1016/j.clineuro.2014.02.010; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Magneli S, 2016, CHILD NERV SYST, V32, P1311, DOI 10.1007/s00381-016-3023-4; Mansson PK, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013389; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Picetti E, 2017, ACTA NEUROCHIR, V159, P615, DOI 10.1007/s00701-017-3118-z; Quinn TM, 2011, ACTA NEUROL SCAND, V123, P239, DOI 10.1111/j.1600-0404.2010.01397.x; Santos E, 2011, ACTA NEUROCHIR, V153, P2189, DOI 10.1007/s00701-011-1148-5; Schmitt M, 2012, ACTA NEUROCHIR SUPPL, V113, P109, DOI 10.1007/978-3-7091-0923-6_22; Smielewski P, 2005, ACT NEUR S, V95, P43; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 2014, ACTA NEUROCHIR, V156, P1615, DOI 10.1007/s00701-014-2127-4; Tavakoli S, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.8.FOCUS17450; Timofeev I, 2012, Adv Tech Stand Neurosurg, V38, P115, DOI 10.1007/978-3-7091-0676-1_6; Weintraub AH, 2017, ARCH PHYS MED REHAB, V98, P312, DOI 10.1016/j.apmr.2016.08.478; Welschehold S, 2012, NEUROSURGERY, V70, DOI 10.1227/NEU.0b013e31822dda12; Wijdicks EFM, 2014, STROKE, V45, P1222, DOI 10.1161/01.str.0000441965.15164.d6; Zacchetti L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1137-9	55	19	19	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	14					1578	1586		10.1089/neu.2017.5589		MAY 2018	9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GK9FP	WOS:000431464200001	29648985				2021-06-18	
J	Gauthier, S; LeBlanc, J; Seresova, A; Laberge-Poirier, A; Correa, JA; Alturki, AY; Marcoux, J; Maleki, M; Feyz, M; de Guise, E				Gauthier, Sandra; LeBlanc, Joanne; Seresova, Alena; Laberge-Poirier, Andreanne; Correa, Jose A.; Alturki, Abdulrahman Y.; Marcoux, Judith; Maleki, Mohammed; Feyz, Mitra; de Guise, Elaine			Acute prediction of outcome and cognitive-communication impairments following traumatic brain injury: The influence of age, education and site of lesion	JOURNAL OF COMMUNICATION DISORDERS			English	Article						Traumatic brain injury; Communication; Language; Acute care; Outcome	BOSTON NAMING TEST; VERBAL FLUENCY; POSTTRAUMATIC AMNESIA; NORMATIVE DATA; HEAD-INJURY; DISCOURSE; ADULTS; COMPREHENSION; PERFORMANCE; ABILITIES	Background. Communication impairment following a traumatic brain injury (TBI) has been well documented, yet information regarding communication skills in the acute period following the injury is limited in the literature. Also, little is known about the influence of TBI severity (mild, moderate or severe) on cognitive-communication impairments and how these impairments are related to short-term functional outcome. The goal of this study was to assess the performance of adults with mild, moderate and severe TBI on different language tests and to determine how this performance is related to functional capacity. We also aimed to explore which variables among age, sex, education, TBI severity and site of cerebral damage would predict initial language impairments. Methods: Several language tests were administered to a sample of 145 adult patients with TBI of a range of severities admitted to an acute care service and to 113 healthy participants from the community. Results: TBI patients of a range of severities performed poorly on all language tests in comparison to the healthy controls. In addition, patients with mild TBI performed better than the moderate and severe groups, except on the reading test and on the semantic naming test. In addition, their performance on verbal fluency, conversational discourse and procedural discourse tasks predicted acute functional outcome. Finally, age, education and TBI severity and site of lesion predicted some language performance. A left temporal lesion was associated with poorer performance in conversational discourse and auditory comprehension tasks, a left frontal lesion with a decrease in the verbal fluency results and a right parietal lesion with decreased auditory comprehension and reasoning skills. Conclusion Health care professionals working in the acute care setting should be aware of the possible presence of cognitive-communication impairments in patients with TBI, even for those with mild TBI. These deficits can lead to functional communication problems and assistance may be required for tasks frequently encountered in acute care requiring intact comprehension and expression.	[Gauthier, Sandra; de Guise, Elaine] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Gauthier, Sandra; de Guise, Elaine] Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada; [LeBlanc, Joanne; Seresova, Alena; Laberge-Poirier, Andreanne; Feyz, Mitra] McGill Univ, Hlth Ctr, Traumat Brain Injury Program, Montreal, PQ, Canada; [Correa, Jose A.] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada; [Alturki, Abdulrahman Y.; Marcoux, Judith; Maleki, Mohammed] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Alturki, Abdulrahman Y.; de Guise, Elaine] Natl Neurosci Inst, Dept Neurosurg, Riyadh, Saudi Arabia; [de Guise, Elaine] McGill Univ, Hlth Ctr, Res Inst, Montreal, PQ, Canada	de Guise, E (corresponding author), Univ Montreal, Campus Laval,1700 Rue Jacques Tetreault,Bur 6230, Laval, PQ H7N 0B6, Canada.	elaine.de.guise@umontreal.ca			Research Institute of the McGill University Health Center	We thank the Research Institute of the McGill University Health Center for their support as well as Marie-Michelle Boudreau Duhaime, Lucie C. Frenette, Camelie Archontakis, Laurence Malo-Veronneau, Dorothee Guilbault and Benedicte Santoire for their help in the recruitment and assessment of the control participants.	Adamovich B. B., 1992, SCALES COGNITIVE ABI; Arciniegas DB, 2014, PSYCHIAT CLIN N AM, V37, P31, DOI 10.1016/j.psc.2013.12.001; Avramovic P, 2017, BRAIN INJURY, V31, P502, DOI 10.1080/02699052.2017.1280854; Baker H. J., 1965, DETROIT TEST LEARNIN; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Benton A., 1976, MULTILINGUAL APHASIA; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Bracy C. A., 2005, BRAIN IMPAIR, V6, P1, DOI [10.1375/brim.6.1.1.65476., DOI 10.1375/BRIM.6.1.1.65476, DOI 10.1375/brim.6.1.1.65476]; Byom L, 2017, INT J LANG COMM DIS, V52, P501, DOI 10.1111/1460-6984.12289; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Chabok SY, 2012, NEUROPSYCHOLOGIA, V50, P1444, DOI 10.1016/j.neuropsychologia.2012.02.029; Chapman JC, 1923, J EDUC RES, V8, P389; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Connor LT, 2004, J GERONTOL B-PSYCHOL, V59, pP203, DOI 10.1093/geronb/59.5.P203; De Guise E, 2005, BRAIN INJURY, V19, P1087, DOI 10.1080/02699050500149882; de Guise E, 2006, J HEAD TRAUMA REHAB, V21, P527, DOI 10.1097/00001199-200611000-00007; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Elbourn E, 2017, INT J SPEECH-LANG PA, V19, P1, DOI 10.1080/17549507.2016.1193896; Ellis C, 2009, NEUROREHABILITATION, V24, P255, DOI 10.3233/NRE-2009-0476; Evans K, 2011, BRAIN INJURY, V25, P767, DOI 10.3109/02699052.2011.576307; Federmeier KD, 2005, PSYCHOPHYSIOLOGY, V42, P133, DOI 10.1111/j.1469-8986.2005.00274.x; Federmeier KD, 2003, PSYCHOL AGING, V18, P858, DOI 10.1037/0882-7974.18.4.858; Feyereisen P, 1997, J SPEECH LANG HEAR R, V40, P1328, DOI 10.1044/jslhr.4006.1328; Finnanger TG, 2013, BRAIN INJURY, V27, P1606, DOI 10.3109/02699052.2013.831127; Goodglass H., 1983, ASSESSMENT APHASIA R; Guinaud F., 2014, J READAPTATION MED P, V34, P155, DOI [10.1016/j.jrm.2014.07.001, DOI 10.1016/J.JRM.2014.07.001]; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Holliday R, 2005, BRAIN LANG, V95, P74, DOI 10.1016/j.bandl.2005.07.041; Honan CA, 2015, BRAIN LANG, V150, P69, DOI 10.1016/j.bandl.2015.08.007; Hooson JM, 2013, NEUROPSYCHOL REHABIL, V23, P19, DOI 10.1080/09602011.2012.713314; Isaki E, 2000, BRAIN INJURY, V14, P441; Joanette Y., 2004, PROTOCOLE MONTREAL E; Kaplan E., 2001, Boston naming test; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Keuleers E, 2015, Q J EXP PSYCHOL, V68, P1665, DOI 10.1080/17470218.2015.1022560; Le K., 2011, ASHA LEADER, V16, P1821, DOI [10.1044/leader.FTR4.16022011.18, DOI 10.1044/LEADER.FTR4.16022011.18]; LeBlanc J, 2006, BRAIN INJURY, V20, P1391, DOI 10.1080/02699050601081927; LeBlanc J, 2014, BRAIN INJURY, V28, P951, DOI 10.3109/02699052.2014.888760; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Marini A, 2014, NEUROPSYCHOLOGIA, V64, P282, DOI 10.1016/j.neuropsychologia.2014.09.042; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; Mathias JL, 2007, BRIT J CLIN PSYCHOL, V46, P457, DOI 10.1348/014466507X190197; Mathuranath PS, 2003, J CLIN EXP NEUROPSYC, V25, P1057, DOI 10.1076/jcen.25.8.1057.16736; Mortensen L, 2006, LANG COGNITIVE PROC, V21, P238, DOI 10.1080/01690960444000278; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; NEILS J, 1995, J SPEECH HEAR RES, V38, P1143, DOI 10.1044/jshr.3805.1143; Peach RK, 2013, AM J SPEECH-LANG PAT, V22, pS285, DOI 10.1044/1058-0360(2013/12-0081); Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; Rassovsky Y, 2015, J CLIN EXP NEUROPSYC, V37, P354, DOI 10.1080/13803395.2015.1015498; Ratcliff G, 1998, BRAIN LANG, V61, P115, DOI 10.1006/brln.1997.1858; Rietdijk R, 2013, BRAIN INJURY, V27, P812, DOI 10.3109/02699052.2013.775491; Rigon A, 2016, J INT NEUROPSYCH SOC, V22, P705, DOI 10.1017/S1355617716000539; Rodriguez-Aranda C, 2006, DEV NEUROPSYCHOL, V30, P697, DOI 10.1207/s15326942dn3002_3; ROSS TP, 1995, CLIN NEUROPSYCHOL, V9, P321, DOI 10.1080/13854049508400496; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Silagi ML, 2014, CODAS, V26, P407, DOI 10.1590/2317-1782/20142013058; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Sohlberg MM, 2014, AM J SPEECH-LANG PAT, V23, P160, DOI 10.1044/2013_AJSLP-12-0005; Spitz G, 2013, BRAIN COGNITION, V83, P34, DOI 10.1016/j.bandc.2013.06.007; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Steel J, 2015, NEUROREHABILITATION, V37, P221, DOI 10.3233/NRE-151255; Steel J, 2013, BRAIN INJURY, V27, P819, DOI 10.3109/02699052.2013.775492; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P30, DOI 10.1097/HTR.0b013e3182048f7c; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P239, DOI 10.1055/s-2008-1064200; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951; Zec RF, 2005, J INT NEUROPSYCH SOC, V11, P716, DOI 10.1017/S1355617705050897	82	19	19	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	MAY-JUN	2018	73						77	90		10.1016/j.jcomdis.2018.04.003			14	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	GI4WI	WOS:000434371500007	29709658				2021-06-18	
J	Korley, FK; Nikolian, VC; Williams, AM; Dennahy, IS; Weykamp, M; Alam, HB				Korley, Frederick K.; Nikolian, Vahagn C.; Williams, Aaron M.; Dennahy, Isabel S.; Weykamp, Michael; Alam, Hasan B.			Valproic Acid Treatment Decreases Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels in Swine Subjected to Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						animal studies; biomarkers; glial fibrillary acidic protein; head trauma; neurofilament light chain; traumatic brain injury; valproic acid	HEMORRHAGIC-SHOCK; INTRACRANIAL LESIONS; CEREBROSPINAL-FLUID; BIOMARKERS; MILD; GFAP; RESUSCITATION; INTERVENTION; MARKER; SIZE	The primary aim of this study was to examine the effects of valproic acid (VPA) treatment on serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NF-L) levels. To achieve this aim, we obtained serum samples from: 1) 10 Yorkshire swine subjected to controlled cortical impact traumatic brain injury (CCI TBI) + polytrauma and randomized to receive either normal saline (NS) + VPA (n=5) or NS alone (n=5) and 2) five additional swine subjected to CCI TBI without polytrauma and treated with VPA. GFAP and NF-L levels were measured in samples obtained from baseline until 10 days post-injury using a digital immunoassay from Quanterix Corporation. We found that elevated GFAP and NF-L levels were first detected at 2 h post-injury; and peaked at 24 h and 72 h respectively. GFAP levels returned to baseline levels by Day 10, while NF-L remained elevated at Day 10. In TBI + polytrauma swine, the magnitude and duration of biomarker elevation, quantified by the area under the biomarker-concentration-versus-time curve during the first 10 days (AUC(0-10days)), was higher in the NS group, compared with the VPA group. For GFAP, the AUC(0-10days) was 45,535 (IQR: 35,741-105,711) and 22,837 (IQR: 8,082-46,627) for the NS and NS+VPA groups, respectively. For NF-L, the AUC(0-10days) was 43,073 (IQR: 18,739-120,794) and 4,475 (2,868-11,157) for the NS and NS+VPA groups, respectively. Twenty-four hour GFAP and NF-L levels had the strongest correlation with lesion size and time to normalization of behavior. Accordingly, we conclude that treatment with VPA results in significantly lower serum GFAP and NF-L levels. The time-point at which GFAP and NF-L levels have the strongest correlation with outcome is 24 h post-injury.	[Korley, Frederick K.] Univ Michigan, Sch Med, Dept Emergency Med, 24 Frank Lloyd Wright Dr,Suite H-3100, Ann Arbor, MI 48106 USA; [Nikolian, Vahagn C.; Williams, Aaron M.; Dennahy, Isabel S.; Alam, Hasan B.] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI USA; [Weykamp, Michael] Duke Univ Hosp, Durham, NC USA	Korley, FK (corresponding author), Univ Michigan, Sch Med, Dept Emergency Med, 24 Frank Lloyd Wright Dr,Suite H-3100, Ann Arbor, MI 48106 USA.	korley@med.umich.edu			US Army Medical Research Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-09-1-0520]; Joyce and Don Massey Family Foundation through the Michigan Center for Integrative Research in Critical Care (MCIRCC) at the University of Michigan	This research was supported by Award Number: W81XWH-09-1-0520 from the US Army Medical Research Materiel Command and by the Joyce and Don Massey Family Foundation, through the Michigan Center for Integrative Research in Critical Care (MCIRCC) at the University of Michigan.	Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Bagnato S, 2017, J NEUROTRAUM, V34, P2475, DOI 10.1089/neu.2016.4837; Chia S, 2008, JACC-CARDIOVASC INTE, V1, P415, DOI 10.1016/j.jcin.2008.04.010; Georgoff PE, 2018, CLIN PHARMACOKINET, V57, P209, DOI 10.1007/s40262-017-0553-1; Georgoff PE, 2016, J TRAUMA ACUTE CARE, V81, P1020, DOI 10.1097/TA.0000000000001249; Halaweish I, 2015, J TRAUMA ACUTE CARE, V79, P911, DOI 10.1097/TA.0000000000000789; Halaweish I, 2015, SHOCK, V44, P6, DOI 10.1097/SHK.0000000000000319; Higgins GA, 2017, PHARM RES-DORDR, V34, P1658, DOI 10.1007/s11095-017-2130-6; Hol EM, 2015, CURR OPIN CELL BIOL, V32, P121, DOI 10.1016/j.ceb.2015.02.004; Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; Nikolian V.C., 2017, J TRAUMA ACUTE CARE; Nikolian VC, 2017, J TRAUMA ACUTE CARE, V83, P1066, DOI 10.1097/TA.0000000000001612; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Oliver JM, 2016, MED SCI SPORT EXER, V48, P974, DOI 10.1249/MSS.0000000000000875; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Paziana K, 2015, FUTUR NEUROL, V10, P281, DOI 10.2217/FNL.15.13; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Posti J.P., 2017, J NEUROTRAUMA; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; You B, 2010, UROLOGY, V76, P423, DOI 10.1016/j.urology.2010.02.049; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	29	19	20	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2018	35	10					1185	1191		10.1089/neu.2017.5581			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GF8DL	WOS:000432198500010	29415612				2021-06-18	
J	Gao, Y; Zhang, MY; Wang, T; Fan, YY; Yu, LS; Ye, GH; Wang, ZF; Gao, C; Wang, HC; Luo, CL; Tao, LY				Gao, Yuan; Zhang, Ming-yang; Wang, Tao; Fan, Yan-yan; Yu, Lin-sheng; Ye, Guang-hua; Wang, Zu-feng; Gao, Cheng; Wang, Hao-chen; Luo, Cheng-liang; Tao, Lu-yang			IL-33/ST2L Signaling Provides Neuroprotection Through Inhibiting Autophagy, Endoplasmic Reticulum Stress, and Apoptosis in a Mouse Model of Traumatic Brain Injury	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						autophagy; endoplasmic reticulum (ER) stress; IL-33-ST2L signaling; neurobehavioral deficits; traumatic brain injury	INDUCED CELL-DEATH; IMMUNE-RESPONSE; UP-REGULATION; RECEPTOR ST2; ER STRESS; INTERLEUKIN-33; MITOCHONDRIAL; MICE; MICROGLIA/MACROPHAGES; CONTRIBUTES	Interleukin-33 (IL-33) is a member of the interleukin-1 (IL-1) cytokine family and an extracellular ligand for the orphan IL-1 receptor ST2. Accumulated evidence shows that the IL-33/ST2 axis plays a crucial role in the pathogenesis of central nervous system (CNS) diseases and injury, including traumatic brain injury (TBI). However, the roles and molecular mechanisms of the IL-33/ST2 axis after TBI remain poorly understood. In this study, we investigated the role of IL-33/ST2 signaling in mouse TBI-induced brain edema and neurobehavioral deficits, and further exploited underlying mechanisms, using salubrinal (SAL), the endoplasmic reticulum (ER) stress inhibitor and anti-ST2L. The increase in IL-33 level and the decrease in ST2L level at injured cortex were first observed at 24 h post-TBI. By immunofluorescent double-labeled staining, IL-33 co-localized in GFAP-positive astrocytes, and Olig-2-positive oligodendrocytes, and predominantly presented in their nucleus. Additionally, TBI-induced brain water content, motor function outcome, and spatial learning and memory deficits were alleviated by IL-33 treatment. Moreover, IL-33 and SAL alone, or their combination prevented TBI-induced the increase of IL-1 beta and TNF-alpha levels, suppressed the up-regulation of ER stress, apoptosis and autophagy after TBI. However, anti-ST2L treatment could significantly invert the above effects of IL-33. Together, these data demonstrate that IL-33/ST2 signaling mitigates TBI-induced brain edema, motor function outcome, spatial learning and memory deficits, at least in part, by a mechanism involving suppressing autophagy, ER stress, apoptosis and neuroinflammation.	[Gao, Yuan; Zhang, Ming-yang; Wang, Tao; Wang, Zu-feng; Gao, Cheng; Wang, Hao-chen; Luo, Cheng-liang; Tao, Lu-yang] Soochow Univ, Med Sch, Dept Forens Sci, Suzhou, Peoples R China; [Gao, Yuan; Fan, Yan-yan; Yu, Lin-sheng; Ye, Guang-hua] Wenzhou Med Univ, Dept Forens Sci, Wenzhou, Peoples R China	Luo, CL; Tao, LY (corresponding author), Soochow Univ, Med Sch, Dept Forens Sci, Suzhou, Peoples R China.	clluo@suda.edu.cn; taoluyang@suda.edu.cn	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81530062, 81373251, 81400999, 81601643, 81601306, 81301039]; National High Technology Research and Development Program of China (863 Program)National High Technology Research and Development Program of China [2015AA020503]; Shanghai Key Lab of Forensic Medicine [KF1805, KF1801, KF1701]; Wenzhou Medical University Research Development Fund [89218004]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This study was supported by Grant Nos. 81530062, 81373251, 81400999, 81601643, 81601306 and 81301039 from the National Natural Science Foundation of China, National High Technology Research and Development Program of China (863 Program, No. 2015AA020503), Shanghai Key Lab of Forensic Medicine (No. KF1805, KF1801 and KF1701), Wenzhou Medical University Research Development Fund (No. 89218004) and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412; Allan D, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0344-1; Balduini W, 2009, AUTOPHAGY, V5, P221, DOI 10.4161/auto.5.2.7363; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Blixt J, 2018, J NEUROTRAUM, V35, P671, DOI 10.1089/neu.2017.5015; Chandran R, 2018, J CEREBR BLOOD F MET, V38, P1818, DOI 10.1177/0271678X17738701; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Decuypere Jean-Paul, 2012, Cells, V1, P284, DOI 10.3390/cells1030284; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, AUTOPHAGY, V3, P561, DOI 10.4161/auto.4713; Erlich S, 2006, AUTOPHAGY, V2, P49, DOI 10.4161/auto.2156; Gadani SP, 2015, NEURON, V85, P703, DOI 10.1016/j.neuron.2015.01.013; Gao Y, 2017, MOL NEUROBIOL, V54, P3879, DOI 10.1007/s12035-016-9947-6; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gu YQ, 2016, EXP THER MED, V12, P3767, DOI 10.3892/etm.2016.3821; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Huang LT, 2015, CELL MOL NEUROBIOL, V35, P493, DOI 10.1007/s10571-014-0143-9; Jafarzadeh Abdollah, 2016, Oman Med J, V31, P40, DOI 10.5001/omj.2016.08; Jin YC, 2015, WORLD NEUROSURG, V84, P420, DOI 10.1016/j.wneu.2015.03.039; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lee JY, 2012, BRAIN, V135, P2375, DOI 10.1093/brain/aws171; Lee WS, 2015, CURR MOL MED, V15, P735, DOI 10.2174/1566524015666150921105453; Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913; Logsdon AF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00421; Longhi-Balbinot DT, 2016, CHEM-BIOL INTERACT, V256, P1, DOI 10.1016/j.cbi.2016.06.009; Lucke-Wold BP, 2015, SEIZURE-EUR J EPILEP, V33, P13, DOI 10.1016/j.seizure.2015.10.002; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2013, J NEUROTRAUM, V30, P597, DOI 10.1089/neu.2012.2425; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Manetti M, 2010, ANN RHEUM DIS, V69, P598, DOI 10.1136/ard.2009.119321; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Messer JS, 2017, CELL MOL LIFE SCI, V74, P1281, DOI 10.1007/s00018-016-2403-y; Miller AM, 2008, J EXP MED, V205, P339, DOI 10.1084/jem.20071868; Molofsky AB, 2015, IMMUNITY, V42, P1005, DOI 10.1016/j.immuni.2015.06.006; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nakka VP, 2016, MOL NEUROBIOL, V53, P532, DOI 10.1007/s12035-014-9029-6; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Pozuelo-Rubio M, 2011, AUTOPHAGY, V7, P240, DOI 10.4161/auto.7.2.14286; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Santopietro John, 2015, N C Med J, V76, P96; Schiavone S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09202-4; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Wang J, 2017, FREE RADICAL BIO MED, V113, P119, DOI 10.1016/j.freeradbiomed.2017.09.017; Wicher G, 2017, J NEUROTRAUM, V34, P3173, DOI 10.1089/neu.2016.4900; Xiong Z, 2014, J ALZHEIMERS DIS, V40, P297, DOI 10.3233/JAD-132081; Yasuoka S, 2011, BRAIN RES, V1385, P8, DOI 10.1016/j.brainres.2011.02.045; Zhang J, 2008, AUTOPHAGY, V4, P354, DOI 10.4161/auto.5552; Zhang MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087241	57	19	19	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5102		FRONT CELL NEUROSCI	Front. Cell. Neurosci.	APR 25	2018	12								95	10.3389/fncel.2018.00095			17	Neurosciences	Neurosciences & Neurology	GD9IH	WOS:000430825900001	29922130	DOAJ Gold, Green Published			2021-06-18	
J	Tanqueiro, SR; Ramalho, RM; Rodrigues, TM; Lopes, LV; Sebastiao, AM; Diogenes, MJ				Tanqueiro, Sara R.; Ramalho, Rita M.; Rodrigues, Tiago M.; Lopes, Luisa V.; Sebastiao, Ana M.; Diogenes, Maria J.			Inhibition of NMDA Receptors Prevents the Loss of BDNF Function Induced by Amyloid beta	FRONTIERS IN PHARMACOLOGY			English	Article						Alzheimer's disease; brain-derived neurotrophic factor; TrkB receptor; extrasynaptic N-methyl-d-aspartate receptors; memantine; long-term potentiation; spine density; synaptic plasticity	LONG-TERM POTENTIATION; TRUNCATED TRKB RECEPTORS; TRAUMATIC BRAIN-INJURY; D-ASPARTATE RECEPTORS; ALZHEIMERS-DISEASE; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; MOUSE MODEL; HIPPOCAMPAL-NEURONS; CULTURED HIPPOCAMPAL	Brain-derived neurotrophic factor (BDNF) plays important functions in cell survival and differentiation, neuronal outgrowth and plasticity. In Alzheimer's disease (AD), BDNF signaling is known to be impaired, partially because amyloid beta (A beta) induces truncation of BDNF main receptor, TrkB-full length (TrkB-FL). We have previously shown that such truncation is mediated by calpains, results in the formation of an intracellular domain (ICD) fragment and causes BDNF loss of function. Since calpains are Ca2+-dependent proteases, we hypothesized that excessive intracellular Ca2+ build-up could be due to dysfunctional N-methyl-d-aspartate receptors (NMDARs) activation. To experimentally address this hypothesis, we investigated whether TrkB-FL truncation by calpains and consequent BDNF loss of function could be prevented by NMDAR blockade. We herein demonstrate that a NMDAR antagonist, memantine, prevented excessive calpain activation and TrkB-FL truncation induced by A beta(25-35). When calpains were inhibited by calpastatin, BDNF was able to increase the dendritic spine density of neurons exposed to A beta(25135). Moreover, NMDAR inhibition by memantine also prevented A beta-driven deleterious impact of BDNF loss of function on structural (spine density) and functional outcomes (synaptic potentiation). Collectively, these findings support NMDAR/Ca2+/calpains mechanistic involvement in A beta-triggered BDNF signaling disruption.	[Tanqueiro, Sara R.; Ramalho, Rita M.; Rodrigues, Tiago M.; Sebastiao, Ana M.; Diogenes, Maria J.] Univ Lisbon, Fac Med, Inst Farmacol & Neurociencias, Lisbon, Portugal; [Tanqueiro, Sara R.; Ramalho, Rita M.; Rodrigues, Tiago M.; Lopes, Luisa V.; Sebastiao, Ana M.; Diogenes, Maria J.] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal; [Rodrigues, Tiago M.] Ctr Hosp & Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal	Diogenes, MJ (corresponding author), Univ Lisbon, Fac Med, Inst Farmacol & Neurociencias, Lisbon, Portugal.; Diogenes, MJ (corresponding author), Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal.	diogenes@medicina.ulisboa.pt		Sebastiao, Ana M/0000-0001-9030-6115; Lopes, Luisa/0000-0001-8367-3005; Rodrigues, Tiago M./0000-0002-0973-9763; Tanqueiro, Sara/0000-0002-9151-7149	Fundacao para a Ciencia e a TecnologiaPortuguese Foundation for Science and TechnologyEuropean Commission [SFRH/BPD/94474/2013, PD/BD/128091/2016, LISBOA-01-0145-FEDER-007391]; Santa Casa da Misericordia [MB-37-2017]; SynaNet from the European Union's Horizon research and innovation program [692340]; FEDER, through POR Lisboa - Programa Operacional Regional de Lisboa, PORTUGAL [LISBOA-01-0145-FEDER-007391]; Fundacao para a Ciencia e a TecnologiaPortuguese Foundation for Science and TechnologyEuropean Commission	RR was supported by Fundacao para a Ciencia e a Tecnologia (SFRH/BPD/94474/2013). ST was supported by Fundacao para a Ciencia e a Tecnologia (PD/BD/128091/2016). LL is an Investigator FCT. This work was supported by Santa Casa da Misericordia (MB-37-2017) and SynaNet which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 692340. LISBOA-01-0145-FEDER-007391, project cofunded by FEDER, through POR Lisboa 2020 - Programa Operacional Regional de Lisboa, PORTUGAL 2020, and Fundacao para a Ciencia e a Tecnologia.	Albensi BC, 2007, EXP NEUROL, V204, P1, DOI 10.1016/j.expneurol.2006.12.009; Alberdi E, 2010, CELL CALCIUM, V47, P264, DOI 10.1016/j.ceca.2009.12.010; Allen SJ, 1999, BIOCHEM BIOPH RES CO, V264, P648, DOI 10.1006/bbrc.1999.1561; Alonso M, 2004, LEARN MEMORY, V11, P172, DOI 10.1101/lm.67804; Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; Arancio O, 2007, CURR OPIN NEUROBIOL, V17, P325, DOI 10.1016/j.conb.2007.03.013; Arevalo JC, 2006, CELL MOL LIFE SCI, V63, P1523, DOI 10.1007/s00018-006-6010-1; Bi H, 2002, J NEUROL SCI, V200, P11, DOI 10.1016/S0022-510X(02)00087-4; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Caba E, 2002, J NEUROSCI RES, V67, P787, DOI 10.1002/jnr.10163; Caselli RJ, 2013, J ALZHEIMERS DIS, V33, pS405, DOI 10.3233/JAD-2012-129026; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen QS, 2000, J NEUROSCI RES, V60, P65, DOI 10.1002/(SICI)1097-4547(20000401)60:1<65::AID-JNR7>3.0.CO;2-Q; Citri A, 2008, NEUROPSYCHOPHARMACOL, V33, P18, DOI 10.1038/sj.npp.1301559; Connor B, 1997, MOL BRAIN RES, V49, P71, DOI 10.1016/S0169-328X(97)00125-3; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; DELCERRO S, 1994, NEUROSCI LETT, V167, P149, DOI 10.1016/0304-3940(94)91049-9; Devi L, 2012, NEUROPSYCHOPHARMACOL, V37, P434, DOI 10.1038/npp.2011.191; Diogenes MJ, 2011, NEUROPSYCHOPHARMACOL, V36, P1823, DOI 10.1038/npp.2011.64; Dorsey SG, 2006, NEURON, V51, P21, DOI 10.1016/j.neuron.2006.06.009; Eide FF, 1996, J NEUROSCI, V16, P3123; Ferreira IL, 2012, CELL CALCIUM, V51, P95, DOI 10.1016/j.ceca.2011.11.008; Ferrer I, 1999, J NEUROPATH EXP NEUR, V58, P729, DOI 10.1097/00005072-199907000-00007; Ferrer I, 2001, ACTA NEUROPATHOL, V101, P229; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Folch J, 2018, J ALZHEIMERS DIS, V62, P1223, DOI 10.3233/JAD-170672; Fontinha BM, 2008, NEUROPHARMACOLOGY, V54, P924, DOI 10.1016/j.neuropharm.2008.01.011; Gilson V, 2015, J ALZHEIMERS DIS, V47, P453, DOI 10.3233/JAD-142529; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gomes JR, 2012, J NEUROSCI, V32, P4610, DOI 10.1523/JNEUROSCI.0374-12.2012; Granic I, 2010, NEUROPHARMACOLOGY, V59, P334, DOI 10.1016/j.neuropharm.2010.07.013; Hanson JE, 2015, NEUROBIOL DIS, V74, P254, DOI 10.1016/j.nbd.2014.11.017; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Holsinger RMD, 2000, MOL BRAIN RES, V76, P347, DOI 10.1016/S0169-328X(00)00023-1; Hunt DL, 2012, CURR OPIN NEUROBIOL, V22, P496, DOI 10.1016/j.conb.2012.01.007; Hynd MR, 2004, J NEUROCHEM, V90, P913, DOI 10.1111/j.1471-4159.2004.02548.x; Ittner LM, 2011, NAT REV NEUROSCI, V12, P67, DOI 10.1038/nrn2967; Jeronimo-Santos A, 2015, CEREB CORTEX, V25, P3107, DOI 10.1093/cercor/bhu105; Ji YY, 2010, NAT NEUROSCI, V13, P302, DOI 10.1038/nn.2505; Ji YY, 2005, NAT NEUROSCI, V8, P164, DOI 10.1038/nn1381; Kaminsky YG, 2010, EXP NEUROL, V221, P26, DOI 10.1016/j.expneurol.2009.09.005; Kellner Yves, 2014, Front Synaptic Neurosci, V6, P5, DOI 10.3389/fnsyn.2014.00005; Kelly BL, 2007, NEUROSCIENCE, V147, P60, DOI 10.1016/j.neuroscience.2007.03.047; Kelly BL, 2006, J BIOL CHEM, V281, P28079, DOI 10.1074/jbc.M605081200; Kemppainen S, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.11.006; Knobloch M, 2008, MOL NEUROBIOL, V37, P73, DOI 10.1007/s12035-008-8018-z; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1998, NEUROPHARMACOLOGY, V37, P553, DOI 10.1016/S0028-3908(98)00035-5; Koskinen M, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00074; Kumar V, 2005, J NEUROSCI, V25, P11288, DOI 10.1523/JNEUROSCI.2284-05.2005; Leveille F, 2008, FASEB J, V22, P4258, DOI 10.1096/fj.08-107268; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Li SM, 2011, J NEUROSCI, V31, P6627, DOI 10.1523/JNEUROSCI.0203-11.2011; Lipton SA, 2007, CURR DRUG TARGETS, V8, P621, DOI 10.2174/138945007780618472; Lu B, 2013, NAT REV NEUROSCI, V14, P401, DOI 10.1038/nrn3505; Luscher C, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005710; Martinez-Senac MD, 1999, EUR J BIOCHEM, V265, P744, DOI 10.1046/j.1432-1327.1999.00775.x; McShane R, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003154.pub5; Medeiros R, 2012, AM J PATHOL, V181, P616, DOI 10.1016/j.ajpath.2012.04.020; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; Minichiello L, 2002, NEURON, V36, P121, DOI 10.1016/S0896-6273(02)00942-X; Mishizen-Eberz AJ, 2004, NEUROBIOL DIS, V15, P80, DOI 10.1016/j.nbd.2003.09.016; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Nguyen KQ, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00037; Nixon RA, 2003, AGEING RES REV, V2, P407, DOI 10.1016/S1568-1637(03)00029-1; Ono Y, 2012, BBA-PROTEINS PROTEOM, V1824, P224, DOI 10.1016/j.bbapap.2011.08.005; Pang PT, 2004, AGEING RES REV, V3, P407, DOI 10.1016/j.arr.2004.07.002; Paoletti P, 2013, NAT REV NEUROSCI, V14, P383, DOI 10.1038/nrn3504; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Parameshwaran K, 2008, EXP NEUROL, V210, P7, DOI 10.1016/j.expneurol.2007.10.008; PARSONS CG, 1993, NEUROPHARMACOLOGY, V32, P1337, DOI 10.1016/0028-3908(93)90029-3; Parsons CG, 2007, NEUROPHARMACOLOGY, V53, P699, DOI 10.1016/j.neuropharm.2007.07.013; Parsons MP, 2014, NEURON, V82, P279, DOI 10.1016/j.neuron.2014.03.030; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; Pinho J, 2017, NEUROPHARMACOLOGY, V114, P12, DOI 10.1016/j.neuropharm.2016.11.017; Plotkin JL, 2014, NEURON, V83, P178, DOI 10.1016/j.neuron.2014.05.032; Porritt MJ, 2005, EXP NEUROL, V192, P226, DOI 10.1016/j.expneurol.2004.11.030; Ronicke R, 2011, NEUROBIOL AGING, V32, P2219, DOI 10.1016/j.neurobiolaging.2010.01.011; Rogawski MA, 2003, CNS DRUG REV, V9, P275, DOI 10.1111/j.1527-3458.2003.tb00254.x; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rueda CB, 2016, BBA-BIOENERGETICS, V1857, P1158, DOI 10.1016/j.bbabio.2016.04.003; Schindowski K, 2008, GENES BRAIN BEHAV, V7, P43, DOI 10.1111/j.1601-183X.2007.00378.x; Schober ME, 2012, METAB BRAIN DIS, V27, P167, DOI 10.1007/s11011-012-9309-7; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; Shrestha BR, 2006, MOL CELL NEUROSCI, V33, P274, DOI 10.1016/j.mcn.2006.07.011; Smith DL, 2009, P NATL ACAD SCI USA, V106, P16877, DOI 10.1073/pnas.0908706106; Smith JP, 2009, BRAIN RES, V1269, P176, DOI 10.1016/j.brainres.2009.03.007; Song JH, 2015, MOL NEUROBIOL, V52, P1477, DOI 10.1007/s12035-014-8958-4; Spires TL, 2005, J NEUROSCI, V25, P7278, DOI 10.1523/JNEUROSCI.1879-05.2005; Spires-Jones TL, 2007, AM J PATHOL, V171, P1304, DOI 10.2353/ajpath.2007.070055; Talantova M, 2013, P NATL ACAD SCI USA, V110, pE2518, DOI 10.1073/pnas.1306832110; Tartaglia N, 2001, J BIOL CHEM, V276, P37585, DOI 10.1074/jbc.M101683200; Tejeda GS, 2016, J PATHOL, V238, P627, DOI 10.1002/path.4684; Texido L, 2011, CELL CALCIUM, V49, P184, DOI 10.1016/j.ceca.2011.02.001; Toni N, 1999, NATURE, V402, P421; Trinchese F, 2008, J CLIN INVEST, V118, P2796, DOI 10.1172/JCI34254; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vidaurre OG, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.143; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Wang YB, 2013, J NEUROSCI, V33, P18880, DOI 10.1523/JNEUROSCI.3293-13.2013; Wei W, 2010, NAT NEUROSCI, V13, P190, DOI 10.1038/nn.2476; Xia P, 2010, J NEUROSCI, V30, P11246, DOI 10.1523/JNEUROSCI.2488-10.2010; Xu J, 2009, J NEUROSCI, V29, P9330, DOI 10.1523/JNEUROSCI.2212-09.2009; Yan XX, 2012, CURR GERIATR REP, V1, P85, DOI 10.1007/s13670-012-0009-2; Zhou Q, 2013, NEUROPHARMACOLOGY, V74, P69, DOI 10.1016/j.neuropharm.2013.03.030	108	19	20	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	APR 11	2018	9								237	10.3389/fphar.2018.00237			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GC2XH	WOS:000429647200001	29695962	DOAJ Gold, Green Published			2021-06-18	
J	Becker, RE; Kapogiannis, D; Greig, NH				Becker, Robert E.; Kapogiannis, Dimitrios; Greig, Nigel H.			Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?	ALZHEIMERS & DEMENTIA			English	Article						Concussion; Alzheimer's disease; Neuropathology; Anecrotic cell death; Preprogrammed cell death; Timing of therapeutic interventions; Drug targets	AMYLOID PRECURSOR PROTEIN; CLINICAL-TRIALS; RISK-FACTOR; COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; PATHOLOGICAL LINK; PIFITHRIN-ALPHA; BLOOD EXOSOMES; DOUBLE-BLIND; EARLIER AGE	Introduction: Neurodegenerative disorders have been a graveyard for hundreds of well-intentioned efforts at drug discovery and development. Concussion and other traumatic brain injuries (TBIs) and Alzheimer's disease (AD) share many overlapping pathologies and possible clinical links. Methods: We searched the literature since 1995 using MEDLINE and Google Scholar for the terms concussion, AD, and shared neuropathologies. We also studied a TBI animal model as a supplement to transgenic (Tg) mouse AD models for evaluating AD drug efficacy by preventing neuronal losses. To evaluate TBI/AD pathologies and neuronal self-induced cell death (apoptosis), we are studying brain extracellular vesicles in plasma and (-)-phenserine pharmacology to probe, in animal models of AD and humans, apoptosis and pathways common to concussion and AD. Results: Neuronal cell death and a diverse and significant pathological cascade follow TBIs. Many of the developing pathologies are present in early AD. The use of an animal model of concussion as a supplement to Tg mice provides an indication of an AD drug candidate's potential for preventing apoptosis and resulting progression toward dementia in AD. This weight drop supplementation to Tg mouse models, the experimental drug (-)-phenserine, and plasma-derived extracellular vesicles enriched for neuronal origin to follow biomarkers of neurodegenerative processes, each and in combination, show promise as tools useful for probing the progression of disease in AD, TBI/AD pathologies, apoptosis, and drug effects on rates of apoptosis both preclinically and in humans. (-)-Phenserine both countered many subacute post-TBI pathologies that could initiate clinical AD and, in the concussion and other animal models, showed evidence consistent with direct inhibition of neuronal preprogrammed cell death in the presence of TBI/AD pathologies. Discussion: These findings may provide support for expanding preclinical Tg mouse studies in AD with a TBI weight drop model, insights into the progression of pathological targets, their relations to apoptosis, and timing of interventions against these targets and apoptosis. Such studies may demonstrate the potential for drugs to effectively and safely inhibit preprogrammed cell death as a new drug development strategy for use in the fight to defeat AD. Published by Elsevier Inc. on behalf of the Alzheimer's Association.	[Becker, Robert E.] Aristea Translat Med Corp, Park City, UT 84098 USA; [Kapogiannis, Dimitrios] NIA, Lab Neurosci, Intramural Res Program, Baltimore, MD 21224 USA; [Becker, Robert E.; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program, Baltimore, MD 21224 USA	Becker, RE (corresponding author), Aristea Translat Med Corp, Park City, UT 84098 USA.; Becker, RE (corresponding author), NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program, Baltimore, MD 21224 USA.	rebecker@aristeatm.com; greign@nih.gov	Kapogiannis, Dimitrios/AAW-4934-2020	Kapogiannis, Dimitrios/0000-0003-2181-3118	Intramural Research Program of the National Institute on Aging, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000311, ZIAAG000975] Funding Source: NIH RePORTER	The authors appreciate the comments and observations of the Editors, Alzheimer's & Dementia. These assisted greatly in the preparation of this article. The authors thank Lauren Brick, Visual Media Services, Intramural Research Program, National Institute on Aging, NIH, in relation to Figure 1. R.E.B. is the president of Aristea Translational Medicine Corporation and an inventor on a patent pending on a method to treat concussion and prevent Alzheimer's disease assigned to Aristea Translational Medicine Corporation. N.H.G. and D.K. have no conflicts of interest to declare and are supported by the Intramural Research Program of the National Institute on Aging, NIH.	Acosta SA, 2017, J CELL PHYSIOL, V232, P665, DOI 10.1002/jcp.25629; Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Becker R, 2000, CLIN DRUG INVEST, V19, P33, DOI 10.2165/00044011-200019010-00005; Becker RE, 2010, CURR ALZHEIMER RES, V7, P642; Becker RE, 1998, ALZ DIS ASSOC DIS, V12, P54, DOI 10.1097/00002093-199803000-00009; Becker RE, 1996, ALZ DIS ASSOC DIS, V10, P124, DOI 10.1097/00002093-199601030-00003; Becker RE, 2001, CLIN DRUG INVEST, V21, P727, DOI 10.2165/00044011-200121100-00007; Becker RE., 2016, J PATIENT SAF; Becker RE, 2008, J ALZHEIMERS DIS, V15, P303; Becker RE, 2015, LANCET PSYCHIAT, V2, P756, DOI 10.1016/S2215-0366(15)00214-X; Becker RE, 2014, CURR ALZHEIMER RES, V11, P215, DOI 10.2174/156720501103140329210642; Becker RE, 2014, NAT REV DRUG DISCOV, V13, P157, DOI 10.1038/nrd3842-c2; Becker RE, 2013, ALZHEIMERS DEMENT, V9, P50, DOI 10.1016/j.jalz.2012.01.007; Becker RE, 2012, CURR ALZHEIMER RES, V9, P1174; Becker RE, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000446; Chang CF, 2017, BRAIN RES, V1677, P118, DOI 10.1016/j.brainres.2017.09.015; Chang JR, 2012, NEURODEGENER DIS, V9, P68, DOI 10.1159/000329999; Checler F, 2014, PHARMACOL THERAPEUT, V142, P99, DOI 10.1016/j.pharmthera.2013.11.009; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Cummings JL, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0173-2; Dams-O'Connor K, 2016, NEURODEGENER DIS MAN, V6, P417, DOI 10.2217/nmt-2016-0017; Esquerda-Canals G, 2017, J ALZHEIMERS DIS, V57, P1171, DOI 10.3233/JAD-170045; Eve DJ, 2016, NEUROPSYCH DIS TREAT, V12, P2689, DOI 10.2147/NDT.S110126; Fargo KN, 2016, ALZHEIMERS DEMENT, V12, P1113, DOI 10.1016/j.jalz.2016.10.001; Feynman R.P., 1974, ENG SCI, V37, P10; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Franzblau M, 2013, MED HYPOTHESES, V81, P842, DOI 10.1016/j.mehy.2013.09.012; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goedert M, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0495-z; Goetzl EJ, 2016, FASEB J, V30, P4141, DOI 10.1096/fj.201600816R; Goetzl EJ, 2016, FASEB J, V30, P3853, DOI 10.1096/fj.201600756R; Goetzl EJ, 2015, ANN CLIN TRANSL NEUR, V2, P769, DOI 10.1002/acn3.211; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greig Nigel H., 2005, Current Alzheimer Research, V2, P483, DOI 10.2174/156720505774330564; Greig Nigel H., 2005, Current Alzheimer Research, V2, P281, DOI 10.2174/1567205054367829; Gupta R, 2016, REV NEUROSCIENCE, V27, P93, DOI 10.1515/revneuro-2015-0017; Hardy J, 2017, FEBS J, V284, P1040, DOI 10.1111/febs.14004; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hoffer BJ, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0377-1; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Itoh T, 2009, MOL CELL BIOCHEM, V324, P191, DOI 10.1007/s11010-008-0013-1; Jan A, 2010, NAT PROTOC, V5, P1186, DOI 10.1038/nprot.2010.72; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kamat P.K., 2014, THER TARGETS NEUROL, V1; Kapogiannis D, 2015, FASEB J, V29, P589, DOI 10.1096/fj.14-262048; Khachaturian ZS, 2012, ADV BIOL PSYCH-KARG, V28, P179; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kwak YD, 2014, BIOCHEM BIOPH RES CO, V447, P394, DOI 10.1016/j.bbrc.2014.03.139; Lahiri DK, 2007, J PHARMACOL EXP THER, V320, P386, DOI 10.1124/jpet.106.112102; Lilja AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054887; Lipska K., 2016, NY TIMES; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LoBue C, 2017, CLIN NEUROPSYCHOL, V31, P85, DOI 10.1080/13854046.2016.1257069; Lobue C, 2016, J ALZHEIMERS DIS, V51, P727, DOI 10.3233/JAD-150895; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Mikkilineni S, 2012, PARKINSONS DIS, V2012, P5; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Moyron RB, 2017, PROTEOM CLIN APPL, V11, DOI 10.1002/prca.201700095; Mustapic M, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00278; Nakamura K, 2012, CELL, V149, P232, DOI 10.1016/j.cell.2012.02.016; Nigro A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00017; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sambamurti K., 2007, ALZHEIMERS DIS NEW A, P571; Schneider LS, 2014, J INTERN MED, V275, P251, DOI 10.1111/joim.12191; Shahaduzzaman M, 2013, MED HYPOTHESES, V81, P675, DOI 10.1016/j.mehy.2013.07.025; Shimohama S, 2000, APOPTOSIS, V5, P9, DOI 10.1023/A:1009625323388; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Supramaniam V, 2013, PEDIATR RES, V73, P301, DOI 10.1038/pr.2012.186; Sutphen CL, 2015, JAMA NEUROL, V72, P1029, DOI 10.1001/jamaneurol.2015.1285; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Takeda S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9490; Taylor DD, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0503; Tweedie D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156493; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vella MA, 2017, SURG CLIN N AM, V97, P1015, DOI 10.1016/j.suc.2017.06.003; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Winblad B, 2010, J ALZHEIMERS DIS, V22, P1201, DOI 10.3233/JAD-2010-101311; Yang LY, 2015, EXP NEUROL, V269, P56, DOI 10.1016/j.expneurol.2015.03.015; Yang LY, 2016, NEUROBIOL DIS, V96, P216, DOI 10.1016/j.nbd.2016.08.012; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhu XW, 2013, J ALZHEIMERS DIS, V33, pS253, DOI 10.3233/JAD-2012-129005	95	19	19	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	APR	2018	14	4					431	443		10.1016/j.jalz.2017.11.007			13	Clinical Neurology	Neurosciences & Neurology	GC6LN	WOS:000429903200001	29245000	Green Accepted			2021-06-18	
J	Dijkland, SA; Voormolen, DC; Venema, E; Roozenbeek, B; Polinder, S; Haagsma, JA; Nieboer, D; Chalos, V; Yoo, AJ; Schreuders, J; van der Lugt, A; Majoie, CBLM; Roos, YBWEM; van Zwam, WH; van Oostenbrugge, RJ; Steyerberg, EW; Dippel, DWJ; Lingsma, HF				Dijkland, Simone A.; Voormolen, Daphne C.; Venema, Esmee; Roozenbeek, Bob; Polinder, Suzanne; Haagsma, Juanita A.; Nieboer, Daan; Chalos, Vicky; Yoo, Albert J.; Schreuders, Jennifer; van der Lugt, Aad; Majoie, Charles B. L. M.; Roos, Yvo B. W. E. M.; van Zwam, Wim H.; van Oostenbrugge, Robert J.; Steyerberg, Ewout W.; Dippel, Diederik W. J.; Lingsma, Hester F.		MR CLEAN Investigators	Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials A Simulation Study	STROKE			English	Article						brain ischemia; odds ratio; quality of life; self-report; stroke	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; ACUTE ISCHEMIC-STROKE; INTRAARTERIAL TREATMENT; HEALTH STATES; DUTCH	Background and Purpose-The utility-weighted modified Rankin Scale (UW-mRS) has been proposed as a new patient-centered primary outcome in stroke trials. We aimed to describe utility weights for the mRS health states and to evaluate the statistical efficiency of the UW-mRS to detect treatment effects in stroke intervention trials. Methods-We used data of the 500 patients enrolled in the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). Utility values were elicited from the EuroQol Group 5-Dimension Self-Report Questionnaire assessed at 90 days after inclusion, simultaneously with the mRS. Utility weights were determined by averaging the utilities of all patients within each mRS category. We performed simulations to evaluate statistical efficiency. The simulated treatment effect was an odds ratio of 1.65 in favor of the treatment arm, similar for all mRS cutoffs. This treatment effect was analyzed using 3 approaches: linear regression with the UW-mRS as outcome, binary logistic regression with a dichotomized mRS (0-1/2-6, 0-2/3-6, and 0-4/5-6), and proportional odds logistic regression with the ordinal mRS. The statistical power of the 3 approaches was expressed as the proportion of 10 000 simulations that resulted in a statistically significant treatment effect (P <= 0.05). Results-The mean utility values (SD) for mRS categories 0 to 6 were: 0.95 (0.08), 0.93 (0.13), 0.83 (0.21), 0.62 (0.27), 0.42 (0.28), 0.11 (0.28), and 0 (0), respectively, but varied substantially between individual patients within each category. The UW-mRS approach was more efficient than the dichotomous approach (power 85% versus 71%) but less efficient than the ordinal approach (power 85% versus 87%). Conclusions-The UW-mRS as primary outcome does not capture individual variation in utility values and may reduce the statistical power of a randomized trial.	[Dijkland, Simone A.; Voormolen, Daphne C.; Venema, Esmee; Polinder, Suzanne; Haagsma, Juanita A.; Nieboer, Daan; Chalos, Vicky; Steyerberg, Ewout W.; Lingsma, Hester F.] Erasmus MC Univ, Med Ctr, Dept Publ Hlth, Room Na2424,POB 2040, NL-3000 CA Rotterdam, Netherlands; [Venema, Esmee; Roozenbeek, Bob; Chalos, Vicky; Schreuders, Jennifer; Dippel, Diederik W. J.] Erasmus MC Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands; [Roozenbeek, Bob; Chalos, Vicky; van der Lugt, Aad] Erasmus MC Univ, Med Ctr, Dept Radiol, Rotterdam, Netherlands; [Yoo, Albert J.] Texas Stroke Inst, Div Neurointervent, Dallas, TX USA; [Schreuders, Jennifer] Elisabeth TweeSteden Hosp, Dept Neurol, Tilburg, Netherlands; [Majoie, Charles B. L. M.] Acad Med Ctr, Dept Radiol, Amsterdam, Netherlands; [Roos, Yvo B. W. E. M.] Acad Med Ctr, Dept Neurol, Amsterdam, Netherlands; [van Zwam, Wim H.] Maastricht Univ, Med Ctr, Dept Radiol, Maastricht, Netherlands; [van Oostenbrugge, Robert J.] Maastricht Univ, Med Ctr, Dept Neurol, Cardiovasc Res Inst, Maastricht, Netherlands; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands	Dijkland, SA (corresponding author), Erasmus MC Univ, Med Ctr, Dept Publ Hlth, Room Na2424,POB 2040, NL-3000 CA Rotterdam, Netherlands.	s.dijkland@erasmusmc.nl	Roos, Yvo BWEM/B-9843-2013; Dippel, Diederik/AAJ-2192-2020	Dippel, Diederik/0000-0002-9234-3515; Venema, Esmee/0000-0003-1631-6635	Dutch Heart FoundationNetherlands Heart Foundation [ISRCTNI0888758]; AngioCare BV; Medtronic/Covidien/EV3; MEDAC Gmbh/LAMEPRO; Penumbra, Inc; Top Medical/Concentric	The MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) (International Standard Randomised Controlled Trial Number registry: ISRCTNI0888758) was partly funded by the Dutch Heart Foundation and by unrestricted grants from AngioCare BV, Medtronic/Covidien/EV3, MEDAC Gmbh/LAMEPRO, Penumbra, Inc, and Top Medical/Concentric. The funding sources had no role in the study design and conduct; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Ali M, 2013, STROKE, V44, P3161, DOI 10.1161/STROKEAHA.113.001126; Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Broderick JP, 2017, STROKE, V48, P2007, DOI 10.1161/STROKEAHA.117.017866; Carod-Artal FJ, 2009, CEREBROVASC DIS, V27, P204, DOI 10.1159/000200461; Chaisinanunkul N, 2015, STROKE, V46, P2238, DOI 10.1161/STROKEAHA.114.008547; Cnossen MC, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0641-9; Gershon RC, 2012, QUAL LIFE RES, V21, P475, DOI 10.1007/s11136-011-9958-8; Harrison JK, 2013, CLIN INTERV AGING, V8, P201, DOI 10.2147/CIA.S32405; HUGHES RAC, 1978, LANCET, V2, P750, DOI 10.1016/s0140-6736(78)92644-2; Kapoor A, 2017, STROKE, V48, P1688, DOI 10.1161/STROKEAHA.117.016728; Lamers LM, 2006, HEALTH ECON, V15, P1121, DOI 10.1002/hec.1124; Lees KR, 2016, STROKE, V47, P2154, DOI 10.1161/STROKEAHA.116.012966; Lees KR, 2012, STROKE, V43, P1163, DOI 10.1161/STROKEAHA.111.641423; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442; PATRICK DL, 1994, MED DECIS MAKING, V14, P9, DOI 10.1177/0272989X9401400102; Post PN, 2001, STROKE, V32, P1425, DOI 10.1161/01.STR.32.6.1425; Prieto Luis, 2003, Health Qual Life Outcomes, V1, P80, DOI 10.1186/1477-7525-1-80; Quinn TJ, 2009, STROKE, V40, P762, DOI [10.1161/STROKEAHA.108.522516, 10.1161/STROKEAHA.109.557256]; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Saver JL, 2011, STROKE, V42, P2356, DOI 10.1161/STROKEAHA.111.619122; Schreuders J, 2017, INT J STROKE, V12, P708, DOI 10.1177/1747493017706244; Senn S, 2009, STAT MED, V28, P3189, DOI 10.1002/sim.3603; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	27	19	19	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	2018	49	4					965	+		10.1161/STROKEAHA.117.020194			11	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	GB6BW	WOS:000429153900037	29535271	Green Published, Other Gold			2021-06-18	
J	Griffith, J; Cluff, K; Eckerman, B; Aldrich, J; Becker, R; Moore-Jansen, P; Patterson, J				Griffith, Jacob; Cluff, Kim; Eckerman, Brandon; Aldrich, Jessica; Becker, Ryan; Moore-Jansen, Peer; Patterson, Jeremy			Non-Invasive Electromagnetic Skin Patch Sensor to Measure Intracranial Fluid-Volume Shifts	SENSORS			English	Article						dielectrics; health monitoring systems; intracranial pressure sensors; microwave sensors; point-of-care technologies; volume measurement; wearable sensors	MAGNETIC INDUCTION; SPECTROSCOPY; PRESSURE; BRAIN; CONCUSSION; MODEL; ICP	Elevated intracranial fluid volume can drive intracranial pressure increases, which can potentially result in numerous neurological complications or death. This study's focus was to develop a passive skin patch sensor for the head that would non-invasively measure cranial fluid volume shifts. The sensor consists of a single baseline component configured into a rectangular planar spiral with a self-resonant frequency response when impinged upon by external radio frequency sweeps. Fluid volume changes (10 mL increments) were detected through cranial bone using the sensor on a dry human skull model. Preliminary human tests utilized two sensors to determine feasibility of detecting fluid volume shifts in the complex environment of the human body. The correlation between fluid volume changes and shifts in the first resonance frequency using the dry human skull was classified as a second order polynomial with R-2 = 0.97. During preliminary and secondary human tests, a approximate to 24 MHz and an average of approximate to 45.07 MHz shifts in the principal resonant frequency were measured respectively, corresponding to the induced cephalad bio-fluid shifts. This electromagnetic resonant sensor may provide a non-invasive method to monitor shifts in fluid volume and assist with medical scenarios including stroke, cerebral hemorrhage, concussion, or monitoring intracranial pressure.	[Griffith, Jacob; Cluff, Kim; Eckerman, Brandon; Aldrich, Jessica; Becker, Ryan] Wichita State Univ, Biomed Engn, Wichita, KS 67260 USA; [Moore-Jansen, Peer] Wichita State Univ, Dept Anthropol, Wichita, KS 67260 USA; [Patterson, Jeremy] Wichita State Univ, Human Performance Studies, Wichita, KS 67260 USA; [Patterson, Jeremy] Wichita State Univ, Inst Interdisciplinary Creat, Wichita, KS 67260 USA	Cluff, K (corresponding author), Wichita State Univ, Biomed Engn, Wichita, KS 67260 USA.	jlgriffith2@shockers.wichita.edu; kim.cluff@wichita.edu; bdeckerman@shockers.wichita.edu; jxaldrich@shockers.wichita.edu; linkxor@gmail.com; pmojan@wichita.edu; jeremy.patterson@wichita.edu		Aldrich, Jessica/0000-0001-9291-7876; Cluff, Kim/0000-0001-5703-0137	National Aeronautics and Space Administration (NASA)National Aeronautics & Space Administration (NASA) [NNX16AQ99A]; Kansas NASA EPSCoR Program (KNEP) grant; John A. See innovation	This work was supported in part by a grant from the National Aeronautics and Space Administration (NASA) (Grant number: NNX16AQ99A), a Kansas NASA EPSCoR Program (KNEP) grant, and the John A. See innovation in research award. This material is also the result of work supported in part with the resources and the use of facilities at Wichita State University. The authors would also like to acknowledge George Szatkowski and Kenneth Dudley from NASA, Langley Research Center, for providing expertise in electromagnetics and open circuit resonators.	Abraham M., 2015, J NEUROANAESTHESIOL, V2, P193, DOI DOI 10.4103/2348-0548.165039; Alruwaili FH, 2017, J AM COLL CARDIOL, V69, P1068; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Bey T, 2009, WEST J EMERG MED, V10, P6; Bolouri H, 2012, ACTA NEUROL SCAND, V125, P241, DOI 10.1111/j.1600-0404.2011.01614.x; Cluff K, 2018, IEEE T BIO-MED ENG, V65, P847, DOI 10.1109/TBME.2017.2723001; Engelborghs K, 1997, ACT NEUR S, V70, P123; Flores O, 2008, IEEE ENG MED BIO, P678, DOI 10.1109/IEMBS.2008.4649243; Gonzalez CA, 2006, P 27 ANN INT C IEEE, P3518, DOI DOI 10.1109/IEMBS.2005.1617238; Gonzalez CA, 2007, P ANN INT IEEE EMBS, P2346, DOI 10.1109/IEMBS.2007.4352797; Gonzalez CA, 2007, IEEE T BIO-MED ENG, V54, P953, DOI 10.1109/TBME.2006.889183; Gonzalez CA, 2010, COMPUT SIST, V14, P187; Griffith J., 2017, P AM SOC GRAV SPAC R; Griffith JL, 2016, INT CONF WEARAB IMPL, P211, DOI 10.1109/BSN.2016.7516261; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Herczynski A, 2013, AM J PHYS, V81, P202, DOI 10.1119/1.4773441; Kim S, 2012, IEEE T BIO-MED ENG, V59, P619, DOI 10.1109/TBME.2010.2093897; Kumari S., 2015, INT J MICROWAVE OPTI, V10, P190; Mobashsher AT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152351; Mobashsher AT, 2016, SCI REP-UK, V6, DOI 10.1038/srep20459; Mohammed BJ, 2014, MICROW OPT TECHN LET, V56, P979, DOI 10.1002/mop.28229; Nelson Emily S., 2014, Life-Basel, V4, P621, DOI 10.3390/life4040621; Onorio I., 2016, MEAS SCI TECHNOL, V27; Raboel PH, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/950393; Rogers J, 2016, ARTERIOSCL THROM VAS, V36; Rojas R, 2008, PHYSIOL MEAS, V29, pS255, DOI 10.1088/0967-3334/29/6/S22; Rosenberg JB, 2011, NEUROCRIT CARE, V15, P599, DOI 10.1007/s12028-011-9545-4; Scharfetter H, 2003, IEEE T BIO-MED ENG, V50, P870, DOI 10.1109/TBME.2003.813533; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Szatkowski G. N., 2014, NASATP2014218554; Wang LJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep42063; Watkins W, 2017, J APPL PHYSIOL, V123, P260, DOI 10.1152/japplphysiol.00091.2017; Watson S, 2008, MEAS SCI TECHNOL, V19, DOI 10.1088/0957-0233/19/4/045501; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Woodard S.E., 2011, P IEEE AER C MAR, P1, DOI DOI 10.1109/AER0.2011.5747495; Woodard SE, 2010, IEEE T INSTRUM MEAS, V59, P3206, DOI 10.1109/TIM.2010.2047546; Zhang LF, 2014, AVIAT SPACE ENVIR MD, V85, P78, DOI 10.3357/ASEM.3789.2014; Zhang ZY, 2014, BIO-MED MATER ENG, V24, P3579, DOI 10.3233/BME-141184	38	19	19	0	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1424-8220		SENSORS-BASEL	Sensors	APR	2018	18	4							1022	10.3390/s18041022			17	Chemistry, Analytical; Engineering, Electrical & Electronic; Instruments & Instrumentation	Chemistry; Engineering; Instruments & Instrumentation	GJ7NS	WOS:000435574800094	29596338	DOAJ Gold, Green Published			2021-06-18	
J	Hocke, LM; Duszynski, CC; Debert, CT; Dleikan, D; Dunn, JF				Hocke, Lia M.; Duszynski, Chris C.; Debert, Chantel T.; Dleikan, Diane; Dunn, Jeff F.			Reduced Functional Connectivity in Adults with Persistent Post-Concussion Symptoms: A Functional Near-Infrared Spectroscopy Study	JOURNAL OF NEUROTRAUMA			English	Article						concussion; DLPFC; fNIRS; functional connectivity; mTBI; working memory task	TRAUMATIC BRAIN-INJURY; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; MILD; ACTIVATION; NETWORK; STATE; MRI; ABNORMALITIES; DYSFUNCTION	Concussion, or mild traumatic brain injury (mTBI), accounts for approximate to 80% of all TBIs across North America. The majority of mTBI patients recover within days to weeks; however, 14-36% of the time, acute mTBI symptoms persist for months or even years and develop into persistent post-concussion symptoms (PPCS). There is a need to find biomarkers in patients with PPCS, to improve prognostic ability and to provide insight into the pathophysiology underlying chronic symptoms. Recent research has pointed toward impaired network integrity and cortical communication as a biomarker. In this study we investigated functional near-infrared spectroscopy (fNIRS) as a technique to assess cortical communication deficits in adults with PPCS. Specifically, we aimed to identify cortical communication patterns in prefrontal and motor areas during rest and task, in adult patients with persistent symptoms. We found that (1) the PPCS group showed reduced connectivity compared with healthy controls, (2) increased symptom severity correlated with reduced coherence, and (3) connectivity differences were best distinguishable during task and in particular during the working memory task (n-back task) in the right and left dorsolateral prefrontal cortex (DLPFC). These data show that reduced brain communication may be associated with the pathophysiology of mTBI and that fNIRS, with a relatively simple acquisition paradigm, may provide a useful biomarker of this injury.	[Hocke, Lia M.; Duszynski, Chris C.; Debert, Chantel T.; Dleikan, Diane; Dunn, Jeff F.] Hotchkiss Brain Inst, Calgary, AB, Canada; [Hocke, Lia M.; Duszynski, Chris C.; Dleikan, Diane; Dunn, Jeff F.] Expt Imaging Lab, Dept Radiol, Calgary, AB, Canada; [Hocke, Lia M.; Duszynski, Chris C.; Debert, Chantel T.; Dleikan, Diane; Dunn, Jeff F.] Foothills Med Ctr, Dept Clin Neurosci, Calgary, AB, Canada; [Hocke, Lia M.; Duszynski, Chris C.; Debert, Chantel T.; Dleikan, Diane; Dunn, Jeff F.] Cumming Sch Med Calgary, Calgary, AB, Canada	Dunn, JF (corresponding author), Expt Imaging Lab, 3280 Hosp Dr NW, Calgary, AB T2N 4Z6, Canada.	dunnj@ucalgary.ca	Hocke, Lia/AAE-3454-2020	Hocke, Lia/0000-0003-3157-8801; Debert, Chantel/0000-0002-2704-0438	Collaborative Health Research Program (CHRP) through the Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [CIHR - CPG-140174]; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR [NSERC - CHRP/478476-2015]; NSERC CREATE (Collaborative Research and Training Experience) I3T (International and Industrial Imaging Training) Program	We thank the patients who volunteered. This work was funded by the Collaborative Health Research Program (CHRP) through the Canadian Institutes of Health Research (CIHR - CPG-140174) and Natural Sciences and Engineering Research Council of Canada (NSERC - CHRP/478476-2015) as well as the NSERC CREATE (Collaborative Research and Training Experience) I3T (International and Industrial Imaging Training) Program.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beam W, 2009, BRAIN STIMUL, V2, P50, DOI 10.1016/j.brs.2008.09.006; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Boas DA, 2014, NEUROIMAGE, V85, P1, DOI 10.1016/j.neuroimage.2013.11.033; Buxton RB, 1998, MAGNET RESON MED, V39, P855, DOI 10.1002/mrm.1910390602; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; CHANCE B, 1993, P NATL ACAD SCI USA, V90, P3770, DOI 10.1073/pnas.90.8.3770; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Dean PJA, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.292; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Fekete T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024322; Ferrari M, 2012, NEUROIMAGE, V63, P921, DOI 10.1016/j.neuroimage.2012.03.049; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Helmich I, 2016, MED SCI SPORT EXER, V48, P2362, DOI 10.1249/MSS.0000000000001028; Helmich I, 2015, J NEUROPSYCH CLIN N, V27, P287, DOI 10.1176/appi.neuropsych.14100276; Hockey A, 2004, INTELLIGENCE, V32, P591, DOI 10.1016/j.intell.2004.07.009; Hoshi Y, 1998, NEUROSCI LETT, V245, P147, DOI 10.1016/S0304-3940(98)00197-9; HOSHI Y, 1993, NEUROSCI LETT, V150, P5, DOI 10.1016/0304-3940(93)90094-2; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huppert TJ, 2009, APPL OPTICS, V48, pD280, DOI 10.1364/AO.48.00D280; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jimenez JJ, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.7.076008; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KATO T, 1993, J CEREBR BLOOD F MET, V13, P516, DOI 10.1038/jcbfm.1993.66; Kontos AP, 2014, BRAIN IMAGING BEHAV, V8, P621, DOI 10.1007/s11682-014-9289-9; Lannsjo M, 2013, EUR J NEUROL, V20, P124, DOI 10.1111/j.1468-1331.2012.03813.x; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Sasai S, 2011, NEUROIMAGE, V56, P252, DOI 10.1016/j.neuroimage.2010.12.075; Sato H, 2004, NEUROIMAGE, V21, P1554, DOI 10.1016/j.neuroimage.2003.12.017; Scholkmann F, 2010, PHYSIOL MEAS, V31, P649, DOI 10.1088/0967-3334/31/5/004; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Sun FT, 2004, NEUROIMAGE, V21, P647, DOI 10.1016/j.neuroimage.2003.09.056; Urban KJ, 2015, J NEUROTRAUM, V32, P833, DOI 10.1089/neu.2014.3577; Varshney VP, 2012, J EUR OPT SOC-RAPID, V7, DOI 10.2971/jeos.2012.12047; VILLRINGER A, 1993, NEUROSCI LETT, V154, P101, DOI 10.1016/0304-3940(93)90181-J; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	64	19	19	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2018	35	11					1224	1232		10.1089/neu.2017.5365		MAR 2018	9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GG7EW	WOS:000428446000001	29373947	Green Published, Bronze			2021-06-18	
J	Perez-Garcia, G; Sosa, MAG; De Gasperi, R; Lashof-Sullivan, M; Maudlin-Jeronimo, E; Stone, JR; Haghighi, F; Ahlers, ST; Elder, GA				Perez-Garcia, Georgina; Sosa, Miguel A. Gama; De Gasperi, Rita; Lashof-Sullivan, Margaret; Maudlin-Jeronimo, Eric; Stone, James R.; Haghighi, Fatemeh; Ahlers, Stephen T.; Elder, Gregory A.			Chronic post-traumatic stress disorder-related traits in a rat model of low-level blast exposure	BEHAVIOURAL BRAIN RESEARCH			English	Article						Animal models; Blast; Postconcussion syndrome; Post-traumatic stress disorder; Rat; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; PERSISTENT POSTCONCUSSIVE SYMPTOMS; MILITARY SERVICE MEMBERS; OXIDATIVE STRESS; STARTLE RESPONSE; RODENT MODEL; MOUSE MODEL; MILD TBI; OVERPRESSURE; VETERANS	The postconcussion syndrome following mild traumatic brain injuries (mTBI) has been regarded as a mostly benign syndrome that typically resolves in the immediate months following injury. However, in some individuals, symptoms become chronic and persistent. This has been a striking feature of the mostly blast-related mTBIs that have been seen in veterans returning from the recent conflicts in Iraq and Afghanistan. In these veterans a chronic syndrome with features of both the postconcussion syndrome and post-traumatic stress disorder has been prominent. Animal modeling of blast-related TBI has developed rapidly over the last decade leading to advances in the understanding of blast pathophysiology. However, most studies have focused on acute to subacute effects of blast on the nervous system and have typically studied higher intensity blast exposures with energies more comparable to that involved in human moderate to severe TBI. Fewer animal studies have addressed the chronic effects of lower level blast exposures that are more comparable to those involved in human mTBI or subclinical blast. Here we describe a rat model of repetitive low-level blast exposure that induces a variety of anxiety and PTSD-related behavioral traits including exaggerated fear responses that were present when animals were tested between 28 and 35 weeks after the last blast exposure. These animals provide a model to study the chronic and persistent behavioral effects of blast including the relationship of PTSD to mTBI in dual diagnosis veterans. Published by Elsevier B.V.	[Perez-Garcia, Georgina; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave Levy Pl, New York, NY 10029 USA; [Perez-Garcia, Georgina; Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh] James J Peters Dept Vet Affairs, Med Ctr, Res & Dev Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Perez-Garcia, Georgina; Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, 1 Gustave Levy Pl, New York, NY 10029 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, 1 Gustave Levy Pl, New York, NY 10029 USA; [Lashof-Sullivan, Margaret; Maudlin-Jeronimo, Eric; Ahlers, Stephen T.] US Naval Med Res Ctr, Dept Neurotrauma, Operat & Undersea Med Directorate, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Stone, James R.] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA 22908 USA; [Stone, James R.] Univ Virginia, Dept Neurosurg, Charlottesville, VA 22908 USA; [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, 1 Gustave Levy Pl, New York, NY 10029 USA; [Haghighi, Fatemeh] James J Peters Dept Vet Affairs, Med Ctr, Neurol Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA	Elder, GA (corresponding author), James J Peters VA Med Ctr, Neurol Serv 3E16, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.	gregory.elder@va.gov			NMRCNational Medical Research Council, Singapore [0000B999.0000.000.A1503]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service AwardUS Department of Veterans Affairs [1I01RX000996-01]; Veterans AffairsUS Department of Veterans Affairs [I21RX002069, I01RX000996, I01RX001705] Funding Source: NIH RePORTER	This work was supported by NMRC work unit number 0000B999.0000.000.A1503 and by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Award 1I01RX000996-01. The funding source played no direct role in the study design, execution, the writing of the report or the decision to submit the article for publication.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Ainge JA, 2012, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00008; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Awwad HO, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00132; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; BUTLER RW, 1990, AM J PSYCHIAT, V147, P1308; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; Dere E, 2007, NEUROSCI BIOBEHAV R, V31, P673, DOI 10.1016/j.neubiorev.2007.01.005; Divani AA, 2015, J NEUROTRAUM, V32, P1109, DOI 10.1089/neu.2014.3686; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Genovese RF, 2013, NEUROSCIENCE, V254, P120, DOI 10.1016/j.neuroscience.2013.09.021; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guley NH, 2016, J NEUROTRAUM, V33, P403, DOI 10.1089/neu.2015.3886; Haghighi F, 2015, J NEUROTRAUM, V32, P1200, DOI 10.1089/neu.2014.3640; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang E, 2013, BRAIN RES, V1529, P125, DOI 10.1016/j.brainres.2013.06.042; Jablonski SA, 2013, BEHAV BRAIN RES, V256, P140, DOI 10.1016/j.bbr.2013.07.055; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Miyazaki H, 2015, ACTA NEUROCHIR, V157, P2111, DOI 10.1007/s00701-015-2613-3; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Ning YL, 2015, CHIN J TRAUMATOL, V18, P204, DOI 10.1016/j.cjtee.2015.10.003; Paylor R, 1997, PSYCHOPHARMACOLOGY, V132, P169, DOI 10.1007/s002130050333; Perez-Garcia G, 2016, SCI REP-UK, V6, DOI 10.1038/srep21275; Perez-Polo JR, 2015, J NEUROSCI RES, V93, P549, DOI 10.1002/jnr.23513; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Sajja VSSS, 2015, SHOCK, V44, P71, DOI 10.1097/SHK.0000000000000311; Sajja VSSS, 2014, MOL CELL NEUROSCI, V59, P119, DOI 10.1016/j.mcn.2014.02.004; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Stemper BD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00031; Sweis BM, 2016, BEHAV BRAIN RES, V296, P149, DOI 10.1016/j.bbr.2015.09.015; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Tweedie D, 2016, ALZHEIMERS DEMENT, V12, P34, DOI 10.1016/j.jalz.2015.07.489; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Vieweg WVR, 2006, AM J MED, V119, P383, DOI 10.1016/j.amjmed.2005.09.027; Wang H., 2016, J NEUROPATHOL EXP NE; Xie K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064907; Yolken RH, 2014, P NATL ACAD SCI USA, V111, P16106, DOI 10.1073/pnas.1418895111; Zuckerman A., 2016, J NEUROTRAUMA	69	19	19	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 15	2018	340				SI		117	125		10.1016/j.bbr.2016.09.061			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FU9JY	WOS:000424173400014	27693852				2021-06-18	
J	Brooks, BL; Silverberg, N; Maxwel, B; Mannix, R; Zafonte, R; Berkner, PD; Iverson, GL				Brooks, Brian L.; Silverberg, Noah; Maxwel, Bruce; Mannix, Rebekah; Zafonte, Ross; Berkner, Paul D.; Iverson, Grant L.			Investigating Effects of Sex Differences and Prior Concussions on Symptom Reporting and Cognition Among Adolescent Soccer Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						child; adolescent; traumatic brain injury; sports; postconcussion syndrome; cumulative	COLLEGIATE FOOTBALL PLAYERS; MULTIPLE PAST CONCUSSIONS; SPORTS-RELATED CONCUSSION; ICE HOCKEY PLAYERS; HIGH-SCHOOL SOCCER; NEUROCOGNITIVE PERFORMANCE; ELECTROPHYSIOLOGICAL ABNORMALITIES; NEUROPSYCHOLOGICAL PERFORMANCE; FEMALE; HISTORY	Background: There has been increasing concern regarding the possible effect of multiple concussions on the developing brain, especially for adolescent females. Hypothesis/Purpose: The objectives were to determine if there are differences in cognitive functioning, symptom reporting, and/or sex effects from prior concussions. In a very large sample of youth soccer players, it was hypothesized that (1) there would be no differences in cognitive test performance between those with and without prior concussions, (2) baseline preseason symptoms would be better predicted by noninjury factors than concussion history, and (3) males and females with prior concussions would not have differences in cognition or symptoms. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Participants included 9314 youth soccer players (mean = 14.8 years, SD = 1.2) who completed preseason baseline cognitive testing, symptom reporting, and a health/injury history questionnaire from the ImPACT battery (Immediate Post-concussion Assessment and Cognitive Testing). On the basis of injury history, athletes were grouped by number of prior concussions: 0 (boys, n = 4012; girls, n = 3963), 1 (boys, n = 527; girls, n = 457), 2 (boys, n = 130; girls, n = 97), or >= 3 (boys, n = 73; girls, n = 55). The primary measures were the 4 primary cognitive scores and the total symptom ratings from ImPACT. Primary outcomes were assessed across injury groups, controlling for age, sex, learning disability, attention-deficit/hyperactivity disorder (ADHD), treatment for headaches/migraines, substance abuse, and mental health problems. Results: Cognitive test performance was not associated with concussion history but was associated with sex, age, learning disability, ADHD, and prior mental health problems. Greater symptom reporting was more strongly associated with psychiatric problems, older age, learning disability, substance abuse, headaches, being female, and ADHD than with a history of multiple concussions. Boys and girls did not differ on cognitive scores or symptom reporting based on a history of concussion. Conclusion: In this very large sample of youth soccer players with prior concussion, there was no evidence of negative effects on cognition, very weak evidence of negative effects on symptom reporting, and no evidence of sex 3 concussion differences in cognition or symptom reporting.	[Brooks, Brian L.; Silverberg, Noah; Maxwel, Bruce; Mannix, Rebekah; Zafonte, Ross; Berkner, Paul D.; Iverson, Grant L.] Colby Coll, Waterville, ME 04901 USA; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.] Univ Calgary, Dept Pediat, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Alberta Childrens Hosp Res Inst, Calgary, AB, Canada; [Silverberg, Noah] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Silverberg, Noah] Vancouver Coastal Hlth Res Inst, Rehabil Res Program, Vancouver, BC, Canada; [Silverberg, Noah] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Maxwel, Bruce] Colby Coll, Dept Comp Sci, Waterville, ME 04901 USA; [Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, Brain Injury Ctr, Boston, MA USA; [Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Massachusetts Gen Hosp,Brigham & Womens Hosp, Boston, MA USA; [Zafonte, Ross] Home Base, Boston, MA USA; [Berkner, Paul D.] Colby Coll, Hlth Serv, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Dept Biol, Waterville, ME 04901 USA; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Home Base,MassGen Hosp Children Sport Concuss Pro, Boston, MA USA	Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@ahs.ca	Mannix, Rebekah/AAD-8702-2020	Iverson, Grant/0000-0001-7348-9570	Canadian Institutes of Health Research Embedded Clinician Researcher Salary Award; Vancouver Coastal Health Research Institute; Harvard Integrated Program to Protect and Improve the Health of NFLPA members	Goldfarb Center for Public Policy and Civic Engagement / Colby College and the Bill and Joan Alfond Foundation. B.L.B. acknowledges salary support from the Canadian Institutes of Health Research Embedded Clinician Researcher Salary Award; is a principal investigator, coinvestigator, or collaborator on several grants relating to the study of mild traumatic brain injury (TBI) and concussion among youth; and receives royalties for the sales of the Pediatric Forensic Neuropsychology textbook (Oxford University Press) and pediatric neuropsychological tests: Child and Adolescent Memory Profile, Memory Validity Profile, and Multidimensional Everyday Memory Ratings for Youth (all PAR Inc). He has received in-kind support (free test credits) from a computerized cognitive test publisher (CNS Vital Signs). N.S. receives salary support from the Vancouver Coastal Health Research Institute; and has received clinical consulting fees from professional sport organizations, workers' compensation boards, and insurance agencies. R. Z. serves on the Scientific Advisory Board of Myomo, Oxeia Pharma, and ElMInda. G.L.I. has been reimbursed by the government, professional scientific bodies, and commercial organizations for discussing or presenting research relating to mild TBI and sport-related concussion at meetings, scientific conferences, and symposiums; has a clinical practice in forensic neuropsychology involving individuals who have sustained mild TBIs (including athletes); has received honorariums for serving on research panels that provide scientific peer review of programs; is a coinvestigator, collaborator, or consultant on grants relating to mild TBI funded by several organizations; has received research support from test-publishing companies in the past, including ImPACT Applications Systems; has received support from the Harvard Integrated Program to Protect and Improve the Health of NFLPA members; and acknowledges unrestricted philanthropic support from the Mooney-Reed Charitable Foundation and ImPACT Applications, Inc.	Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Black AM, 2017, CLIN J SPORT MED, V27, P52, DOI 10.1097/JSM.0000000000000308; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Brooks BL, 2016, AM J SPORT MED, V44, P3243, DOI 10.1177/0363546516655095; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2016, J ATHL TRAINING, V51, P189, DOI 10.4085/1062-6050-51.3.05; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Federation Internationale de Football Association, 2007, FED RES DIV COUNTR P, P11; Fedor A, 2013, OBESITY FACTS, V6, P185, DOI 10.1159/000351138; Forbes CR, 2016, APPL NEUROPSYCH-CHIL, V5, P14, DOI 10.1080/21622965.2014.933108; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; IBM Corp, 2010, IBM SPSS STAT WIND V; ImPACT Applications Inc., 2011, TECHN MAN ONL IMPACT; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Iverson GL, 2014, APPL NEUROPSYCH-ADUL, V21, P36, DOI 10.1080/09084282.2012.721149; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/316575; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Kriz PK, 2016, J PEDIATR-US, V171, P234, DOI 10.1016/j.jpeds.2015.12.006; Kriz PK, 2016, J PEDIAT, V171, pe1; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJ, 1998, J CLIN EXP NEUROPSYC, V23, P770; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Mckay CD, 2014, J ORTHOP SPORT PHYS, V44, P329, DOI 10.2519/jospt.2014.5053; Miller M, 2016, J PEDIAT NEUROPSYCHO, V2, P99; Moore DR, 2016, INT J PSYCHOPHYSIOL, V99, P85, DOI 10.1016/j.ijpsycho.2015.11.010; Moore RD, 2017, INT J PSYCHOPHYSIOL, V112, P22, DOI 10.1016/j.ijpsycho.2016.11.011; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Ono KE, 2016, AM J SPORT MED, V44, P748, DOI 10.1177/0363546515617746; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Sandel NK, 2017, AM J SPORT MED, V45, P937, DOI 10.1177/0363546516677246; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Tsushima WT, 2016, APPL NEUROPSYCH-CHIL, V5, P9, DOI 10.1080/21622965.2014.902762; Tsushima WT, 2013, APPL NEUROPSYCH-CHIL, V2, P13, DOI 10.1080/09084282.2011.643967; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	62	19	19	2	21	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2018	46	4					961	968		10.1177/0363546517749588			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	GC0IU	WOS:000429461800029	29323926				2021-06-18	
J	Cheng, WH; Stukas, S; Martens, KM; Namjoshi, DR; Button, EB; Wilkinson, A; Bashir, A; Robert, J; Cripton, PA; Wellington, CL				Cheng, Wai Hang; Stukas, Sophie; Martens, Kris M.; Namjoshi, Dhananjay R.; Button, Emily B.; Wilkinson, Anna; Bashir, Asma; Robert, Jerome; Cripton, Peter A.; Wellington, Cheryl L.			Age at injury and genotype modify acute inflammatory and neurofilament-light responses to mild CHIMERA traumatic brain injury in wild-type and APP/PS1 mice	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury (TBI); Closed Head Injury; Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA); Ageing; Inflammation; Neurofilament-light; Alzheimer's disease	WHITE-MATTER ABNORMALITIES; AMYLOID-BETA ACCUMULATION; ALZHEIMERS-DISEASE; A-BETA; HEAD-INJURY; INTERSTITIAL FLUID; PRECURSOR-PROTEIN; INDUCED INCREASES; TERM SURVIVORS; MOUSE MODEL	Peak incidence of traumatic brain injury (TBI) occurs in both young and old individuals, and older age at injury is associated with worse outcome and poorer recovery. Moderate-severe TBI is a reported risk factor for dementia, including Alzheimer's disease (AD), but whether mild TBI (mTBI) alters AD pathogenesis is not clear. To delineate how age at injury and predisposition to amyloid formation affect the acute response to mTBI, we used the Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) model of TBI to induce two mild injuries in wild-type (WT) and APP/PS1 mice at either 6 or 13 months of age and assessed behavioural, histological and biochemical changes up to 14 days post-injury. Age at injury did not alter acute behavioural responses to mTBI, including measures of neurological status, motor performance, spatial memory, fear, or anxiety, in either strain. Young APP/PS1 mice showed a subtle and transient increase in diffuse A beta deposits after injury, whereas old APP/PS1 mice showed decreased amyloid deposits, without significant alterations in total soluble or insoluble A beta levels at either age. Age at injury and genotype showed complex responses with respect to microglial and cytokine outcomes, where post-injury neuroinfiammation is increased in old WT mice but attenuated in old APP/PS1 mice. Intriguingly, silver staining confirmed axonal damage in both strains and ages, yet only young WT and APP/PS1 mice showed neurofilament-positive axonal swellings after mTBI, as this response was almost entirely attenuated in old mice. Plasma neurofilament-light levels were significantly elevated after injury only in young APP/PS1 mice. This study suggests that mild TBI has minimal effects on A beta metabolism, but that age and genotype can each modify acute outcomes related to white matter injury.	[Cheng, Wai Hang; Stukas, Sophie; Martens, Kris M.; Namjoshi, Dhananjay R.; Button, Emily B.; Wilkinson, Anna; Bashir, Asma; Robert, Jerome; Wellington, Cheryl L.] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Dept Pathol & Lab Med, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada; [Cripton, Peter A.] Univ British Columbia, Dept Mech Engn, Int Collaborat Repair Discoveries, Vancouver, BC, Canada	Wellington, CL (corresponding author), Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Dept Pathol & Lab Med, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	wcheryl@mail.ubc.ca	Cripton, Peter/AAC-8268-2020; , Jerome/C-6226-2018	Cripton, Peter/0000-0002-5067-0833; , Jerome/0000-0002-2847-9362; Bashir, Asma/0000-0002-3616-9436; Cheng, Wai Hang/0000-0002-3408-9184	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [CIHR MOP 123461]; Weston Brain Institute [TR140070]; Alzheimer Society Research Program Doctoral Award; Comissao Technica de Atribuicao de Bolsas para Estudos Pos Graduados Macao; Canadian Traumatic Brain Injury Research Consortium; CIHR Graduate FellowshipCanadian Institutes of Health Research (CIHR); University of British Columbia Doctoral Fellowship; CIHR Doctoral ScholarshipCanadian Institutes of Health Research (CIHR); BrightFocus Alzheimer's disease award; Weston Brain Institute Rapid Response grant	Operating funding for this project was obtained from the Canadian Institutes of Health Research (CIHR MOP 123461) to C.L.W., and a Transformational Grant from the Weston Brain Institute (TR140070) to C.L.W. and P.A.C. W.H.C. is supported by Alzheimer Society Research Program Doctoral Award and Comissao Technica de Atribuicao de Bolsas para Estudos Pos Graduados Macao. S.S. is supported by an award from the Canadian Traumatic Brain Injury Research Consortium. A.B. is supported by a CIHR Graduate Fellowship and a University of British Columbia Doctoral Fellowship. E.B. is supported by a CIHR Doctoral Scholarship and a University of British Columbia Doctoral Fellowship. JR is supported by a BrightFocus Alzheimer's disease award and a Weston Brain Institute Rapid Response grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Abrahamson EE, 2013, J CEREBR BLOOD F MET, V33, P826, DOI 10.1038/jcbfm.2013.24; Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Bagnato S., 2017, NEUROREPORT; Bates K, 2014, NEUROBIOL AGING, V35, P1345, DOI 10.1016/j.neurobiolaging.2013.11.020; Bird SM, 2016, NEUROSCI BIOBEHAV R, V64, P215, DOI 10.1016/j.neubiorev.2016.01.004; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Castellani RJ, 2010, DM-DIS MON, V56, P484, DOI 10.1016/j.disamonth.2010.06.001; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gardner RC, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002246; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Graham DI, 1996, ACT NEUR S, V66, P96; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gupta RK, 2016, MOL NEUROBIOL, V53, P3377, DOI 10.1007/s12035-015-9287-y; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Ljungqvist J., 2016, J NEUROTRAUMA; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Marklund N, 2014, J NEUROTRAUM, V31, P42, DOI 10.1089/neu.2013.2964; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; May S., 2011, J NEUROL NEUROSCI, V2; McIntyre A, 2013, BRAIN INJURY, V27, P31, DOI 10.3109/02699052.2012.700086; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Namjoshi D.R., 2017, EXP NEUROL; Namjoshi DR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146540; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Robert J, 2016, BBA-MOL BASIS DIS, V1862, P1027, DOI 10.1016/j.bbadis.2015.10.005; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Sherer M, 2015, REHABIL PSYCHOL, V60, P138, DOI 10.1037/rep0000030; Shibahashi K, 2016, J NEUROTRAUM, V33, P1826, DOI 10.1089/neu.2015.4237; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; TEASDALE G, 1974, LANCET, V2, P81; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00300; Tierney KJ, 2016, J NEUROSURG, V124, P538, DOI 10.3171/2015.4.JNS142440; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	81	19	19	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2018	301		A				26	38		10.1016/j.expneurol.2017.12.007			13	Neurosciences	Neurosciences & Neurology	FX8EW	WOS:000426325100003	29269117				2021-06-18	
J	Kortagere, S; Mortensen, OV; Xia, JS; Lester, W; Fang, YH; Srikanth, Y; Salvino, JM; Fontana, ACK				Kortagere, Sandhya; Mortensen, Ole V.; Xia, Jingsheng; Lester, William; Fang, Yuhong; Srikanth, Yellamelli; Salvino, Joseph M.; Fontana, Andreia C. K.			Identification of Novel Allosteric Modulators of Glutamate Transporter EAAT2	ACS CHEMICAL NEUROSCIENCE			English	Article						EAAT2; EAAT2 activators; glutamate transporter; glutamate uptake; hybrid structure based method; positive allosteric modulation; transport enhancement	TRAUMATIC BRAIN-INJURY; AMINO-ACID TRANSPORTERS; SPINAL-CORD; RAT MODEL; DRUG DISCOVERY; UP-REGULATION; EXPRESSION; CEFTRIAXONE; GLT-1; EXCITOTOXICITY	[Graphics] Dysfunction of excitatory amino acid transporters (EAATs) has been implicated in the pathogenesis of various neurological disorders, such as stroke, brain trauma, epilepsy, and neurodegenerative diseases, among others. EAAT2 is the main subtype responsible for glutamate clearance in the brain, having a key role in regulating transmission and preventing excitotoxicity. Therefore, compounds that increase the expression or activity of EAAT2 have therapeutic potential for neuroprotection. Previous studies identified molecular determinants for EAAT2 transport stimulation in a structural domain that lies at the interface of the rigid trimerization domain and the central substrate binding transport domain. In this work, a hybrid structure based approach was applied, based on this molecular domain, to create a high-resolution pharmacophore. Subsequently, virtual screening of a library of small molecules was performed, identifying 10 hit molecules that interact at the proposed domain. Among these, three compounds were determined to be activators, four were inhibitors, and three had no effect on EAAT2-mediated transport in vitro. Further characterization of the two best ranking EAAT2 activators for efficacy, potency, and selectivity for glutamate over monoamine transporters subtypes and NMDA receptors and for efficacy in cultured astrocytes is demonstrated. Mutagenesis studies suggest that the EAAT2 activators interact with residues forming the interface between the trimerization and transport domains. These compounds enhance the glutamate translocation rate, with no effect on substrate interaction, suggesting an allosteric mechanism. The identification of these novel positive allosteric modulators of EAAT2 offers an innovative approach for the development of therapies based on glutamate transport enhancement.	[Kortagere, Sandhya] Drexel Univ, Coll Med, Ctr Mol Parasitol, Dept Microbiol & Immunol, Philadelphia, PA 19129 USA; [Kortagere, Sandhya] Drexel Univ, Coll Med, Centers Virol & Translat Neurosci, Inst Mol Med, Philadelphia, PA 19129 USA; [Mortensen, Ole V.; Xia, Jingsheng; Srikanth, Yellamelli; Salvino, Joseph M.; Fontana, Andreia C. K.] Drexel Univ, Coll Med, Dept Physiol & Pharmacol, Philadelphia, PA 19102 USA; [Lester, William; Fang, Yuhong] NIH, NCATS, Div Preclin Innovat DPI, Analyt Chem, Rockville, MD 20850 USA	Fontana, ACK (corresponding author), Drexel Univ, Coll Med, Dept Physiol & Pharmacol, Philadelphia, PA 19102 USA.	acm83@drexel.edu	Mortensen, Andreia/AAR-2177-2020	Mortensen, Andreia/0000-0002-4791-8746; Mortensen, Ole Valente/0000-0002-3487-8239; Yellamelli, Valli Venkata Srikanth/0000-0002-5414-0119	Drexel University College of Medicine; Drexel Coulter grant; Faculty development funds from the Department of Microbiology and Immunology	This work was supported by startup funds to O.V.M. and A.C.K.F. (Drexel University College of Medicine) and Drexel Coulter grant and Faculty development funds from the Department of Microbiology and Immunology to S.K.	Akyuz N, 2015, NATURE, V518, P68, DOI 10.1038/nature14158; Akyuz N, 2013, NATURE, V502, P114, DOI 10.1038/nature12265; Amara SG, 2002, NEUROCHEM INT, V41, P313, DOI 10.1016/S0197-0186(02)00018-9; AMATO A, 1994, J PHYSIOL-LONDON, V479, P371, DOI 10.1113/jphysiol.1994.sp020302; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Beart PM, 2007, BRIT J PHARMACOL, V150, P5, DOI 10.1038/sj.bjp.0706949; Bienayme H, 1998, TETRAHEDRON LETT, V39, P2735, DOI 10.1016/S0040-4039(98)00283-4; Boudker O, 2007, NATURE, V445, P387, DOI 10.1038/nature05455; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bunch L, 2009, EXPERT OPIN THER TAR, V13, P719, DOI 10.1517/14728220902926127; Canals M, 2012, J BIOL CHEM, V287, P650, DOI 10.1074/jbc.M111.314278; Canul-Tec JC, 2017, NATURE, V544, P446, DOI 10.1038/nature22064; Chao XD, 2010, NEUROCHEM RES, V35, P1224, DOI 10.1007/s11064-010-0178-3; Chekmarev DS, 2008, CHEM RES TOXICOL, V21, P1304, DOI 10.1021/tx800063r; Chi-Castaneda D, 2017, ADV NEUROBIOL, V16, P199, DOI 10.1007/978-3-319-55769-4_10; Chu K, 2007, STROKE, V38, P177, DOI 10.1161/01.STR.0000252091.36912.65; COUTINHONETTO J, 1981, EPILEPSIA, V22, P289, DOI 10.1111/j.1528-1157.1981.tb04112.x; Crisman TJ, 2009, P NATL ACAD SCI USA, V106, P20752, DOI 10.1073/pnas.0908570106; Cristina A, 2007, MOL PHARMACOL, V72, P1228, DOI 10.1124/mol.107.037127; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dunlop J, 2003, J NEUROSCI, V23, P1688; Dunlop J, 2006, CURR OPIN PHARMACOL, V6, P103, DOI 10.1016/j.coph.2005.09.004; Estrada-Sanchez AM, 2012, BASAL GANGLIA, V2, P57, DOI 10.1016/j.baga.2012.04.029; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fontana ACK, 2003, BRIT J PHARMACOL, V139, P1297, DOI 10.1038/sj.bjp.0705352; Fontana ACK, 2015, J NEUROCHEM, V134, P982, DOI 10.1111/jnc.13200; Ganel R, 2006, NEUROBIOL DIS, V21, P556, DOI 10.1016/j.nbd.2005.08.014; Gegelashvili G, 1997, J NEUROCHEM, V69, P2612; Georgieva ER, 2013, NAT STRUCT MOL BIOL, V20, P215, DOI 10.1038/nsmb.2494; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Guo H, 2003, HUM MOL GENET, V12, P2519, DOI 10.1093/hmg/ddg267; Hammad AM, 2017, BEHAV BRAIN RES, V332, P288, DOI 10.1016/j.bbr.2017.06.017; HARDY J, 1987, NEUROSCI LETT, V73, P77, DOI 10.1016/0304-3940(87)90034-6; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Hota SK, 2008, NEUROBIOL LEARN MEM, V89, P522, DOI 10.1016/j.nlm.2008.01.003; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Jabs R, 2008, EPILEPSIA, V49, P3, DOI 10.1111/j.1528-1167.2008.01488.x; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Kim K, 2011, J CELL PHYSIOL, V226, P2484, DOI 10.1002/jcp.22609; Kim R, 2018, NEUROPHARMACOLOGY, V128, P1, DOI 10.1016/j.neuropharm.2017.09.019; Kong QM, 2014, J CLIN INVEST, V124, P1255, DOI 10.1172/JCI66163; Kortagere S, 2008, PHARM RES-DORDR, V25, P1836, DOI 10.1007/s11095-008-9584-5; Kortagere S, 2006, J COMPUT AID MOL DES, V20, P789, DOI 10.1007/s10822-006-9077-8; Kortagere S, 2009, PHARM RES-DORDR, V26, P1001, DOI 10.1007/s11095-008-9809-7; Lauriat TL, 2007, MOL PSYCHIATR, V12, P1065, DOI 10.1038/sj.mp.4002065; Lee SG, 2008, J BIOL CHEM, V283, P13116, DOI 10.1074/jbc.M707697200; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Li Y, 2011, NEUROPHARMACOLOGY, V60, P1168, DOI 10.1016/j.neuropharm.2010.10.016; Lin CLG, 2012, FUTURE MED CHEM, V4, P1689, DOI [10.4155/fmc.12.122, 10.4155/FMC.12.122]; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Lipski J, 2007, NEUROSCIENCE, V146, P617, DOI 10.1016/j.neuroscience.2007.02.003; LOUZADAJUNIOR P, 1992, J NEUROCHEM, V59, P358, DOI 10.1111/j.1471-4159.1992.tb08912.x; Maas AIR, 2000, CNS DRUGS, V13, P139, DOI 10.2165/00023210-200013020-00007; Maeda S, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-65; Maragakis NJ, 2004, ANN NEUROL, V55, P469, DOI 10.1002/ana.20003; Massieu L, 1998, Neurobiology (Bp), V6, P99; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; MCENTEE WJ, 1993, PSYCHOPHARMACOLOGY, V111, P391, DOI 10.1007/BF02253527; Mehta A, 2013, EUR J PHARMACOL, V698, P6, DOI 10.1016/j.ejphar.2012.10.032; Mortensen OV, 2015, J NEUROCHEM, V133, P199, DOI 10.1111/jnc.13047; Munir M, 2000, NEUROCHEM INT, V37, P147, DOI 10.1016/S0197-0186(00)00018-8; Nederkoorn PJ, 2011, INT J STROKE, V6, P159, DOI 10.1111/j.1747-4949.2010.00555.x; Nicolai J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.10; NILSSON E, 1990, NEUROBIOL AGING, V11, P425, DOI 10.1016/0197-4580(90)90009-O; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; [潘向东 PAN Xingdong], 2011, [浙江大学学报. 医学版, Journal of Zhejiang University. Medical Sciences], V40, P522; Peng S, 2011, MOL BIOL REP, V38, P453, DOI 10.1007/s11033-010-0128-9; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Potter MC, 2013, J NEUROIMMUNE PHARM, V8, P594, DOI 10.1007/s11481-013-9442-z; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Rasmussen B, 2011, DRUG ALCOHOL DEPEN, V118, P484, DOI 10.1016/j.drugalcdep.2011.03.022; Reyes N, 2009, NATURE, V462, P880, DOI 10.1038/nature08616; Rives ML, 2017, BIOCHEM PHARMACOL, V135, P1, DOI 10.1016/j.bcp.2017.02.010; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Sabri F, 2003, BRAIN PATHOL, V13, P84, DOI 10.1111/j.1750-3639.2003.tb00009.x; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Schlag BD, 1998, MOL PHARMACOL, V53, P355; Scofield MD, 2014, NEUROSCIENTIST, V20, P610, DOI 10.1177/1073858413520347; Seal RP, 1999, ANNU REV PHARMACOL, V39, P431, DOI 10.1146/annurev.pharmtox.39.1.431; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Shimizu S, 2011, JOVE-J VIS EXP, DOI 10.3791/3257; SISK DR, 1985, GRAEF ARCH CLIN EXP, V223, P250, DOI 10.1007/BF02153655; Suchak SK, 2003, J NEUROCHEM, V84, P522, DOI 10.1046/j.1471-4159.2003.01553.x; Swanson RA, 1997, J NEUROSCI, V17, P932; Takahashi K, 2015, CELL MOL LIFE SCI, V72, P3489, DOI 10.1007/s00018-015-1937-8; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Thone-Reineke C, 2008, J HYPERTENS, V26, P2426, DOI 10.1097/HJH.0b013e328313e403; Timple JMV, 2013, J NAT PROD, V76, P1889, DOI 10.1021/np400452n; Vandenberg RJ, 2013, PHYSIOL REV, V93, P1621, DOI 10.1152/physrev.00007.2013; Verma R, 2010, EUR J PHARMACOL, V638, P65, DOI 10.1016/j.ejphar.2010.04.021; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wang Y, 2010, APOPTOSIS, V15, P1382, DOI 10.1007/s10495-010-0481-0; Webb B, 2014, METHODS MOL BIOL, V1137, P1, DOI 10.1007/978-1-4939-0366-5_1; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; WEILER IJ, 1995, BEHAV BRAIN RES, V66, P1, DOI 10.1016/0166-4328(94)00116-W; Xia JS, 2014, J PHYSIOL-LONDON, V592, P3443, DOI 10.1113/jphysiol.2014.275065; Xing XC, 2011, BIOORG MED CHEM LETT, V21, P5774, DOI 10.1016/j.bmcl.2011.08.009; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yatomi Y, 2013, NEUROSCIENCE, V244, P113, DOI 10.1016/j.neuroscience.2013.04.018; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zelenaia O, 2000, MOL PHARMACOL, V57, P667; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	110	19	18	0	10	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	MAR	2018	9	3					522	534		10.1021/acschemneuro.7b00308			25	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	GA5EX	WOS:000428356500017	29140675				2021-06-18	
J	Nikolian, VC; Dennahy, IS; Higgins, GA; Williams, AM; Weykamp, M; Georgoff, PE; Eidy, H; Ghandour, MH; Chang, P; Alam, HB				Nikolian, Vahagn C.; Dennahy, Isabel S.; Higgins, Gerald A.; Williams, Aaron M.; Weykamp, Michael; Georgoff, Patrick E.; Eidy, Hassan; Ghandour, Mohamed H.; Chang, Panpan; Alam, Hasan B.			Transcriptomic changes following valproic acid treatment promote neurogenesis and minimize secondary brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Valproic acid; histone deacetylase inhibitor; RNA sequencing; hemorrhage; traumatic brain injury	HEMORRHAGIC-SHOCK; PHARMACOLOGICAL RESUSCITATION; MODEL; RECOVERY; NEURONS; PATHWAY	BACKGROUND Early treatment with valproic acid (VPA) has demonstrated benefit in preclinical models of traumatic brain injury, including smaller brain lesion size, decreased edema, reduced neurologic disability, and faster recovery. Mechanisms underlying these favorable outcomes are not fully understood. We hypothesized that VPA treatment would upregulate genes involved in cell survival and proliferation and downregulate those associated with cell death and the inflammatory response. METHODS Ten female swine were subjected to a protocol of traumatic brain injury and hemorrhagic shock. They were assigned to two groups (n = 5): normal saline (NS; 3x volume of shed blood), or NS + VPA (150 mg/kg). Following 6 hours of observation, brain tissue was harvested to evaluate lesion size and edema. Brain tissue was processed for RNA sequencing. Gene set enrichment and pathway analysis was performed to determine the differential gene expression patterns following injury. RESULTS Animals treated with VPA were noted to have a 46% reduction in brain lesion size and a 57% reduction in ipsilateral brain edema. Valproic acid significantly upregulated genes involved in morphology of the nervous system, neuronal development and neuron quantity. The VPA treatment downregulated pathways related to apoptosis, glial cell proliferation, and neuroepithelial cell differentiation. Ingenuity Pathway Analysis identified VPA as the top upstream regulator of activated transcription, supporting it as a direct cause of these transcriptional changes. Master transcriptional regulator NEUROD1 was also significantly upregulated, suggesting that VPA may induce additional transcription factors. CONCLUSION Administration of VPA attenuated brain lesion size, reduced brain edema, and induced significant changes in the transcriptome of injured brain within 6 hours. Patterns of differential expression were consistent with the proposed neurogenic and prosurvival effects of VPA treatment.	[Nikolian, Vahagn C.; Dennahy, Isabel S.; Williams, Aaron M.; Weykamp, Michael; Georgoff, Patrick E.; Eidy, Hassan; Ghandour, Mohamed H.; Chang, Panpan; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Higgins, Gerald A.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA	Alam, HB (corresponding author), Univ Michigan Hosp, Dept Surg, 2920 Taubman Ctr 5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Higgins, Gerry/0000-0002-0434-1465	US Army Medical Research Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-09-1-0520]; Frederick A. Coller Society Research Fellowship Grant; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM084127] Funding Source: NIH RePORTER	US Army Medical Research Materiel Command W81XWH-09-1-0520 (Alam, HB); Frederick A. Coller Society Research Fellowship Grant (Nikolian, VC).	Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; ANDERS S, 2010, GENOME BIOL, V11, DOI [10.1186/gb-2010-11-10-r106, DOI 10.1186/GB-2010-11-10-R106]; Bambakidis T, 2016, J NEUROTRAUM, V33, P1514, DOI 10.1089/neu.2015.4163; Boone DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046204; Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108; Chen S, 2014, NEUROCHEM RES, V39, P1621, DOI 10.1007/s11064-014-1241-2; Chen YF, 2016, BIOINFORMATICS, V32, P1832, DOI 10.1093/bioinformatics/btw074; de Vries HM, 2014, J TRAUMA ACUTE CARE, V77, P183, DOI 10.1097/TA.0000000000000252; Dekker SE, 2014, J TRAUMA ACUTE CARE, V77, P906, DOI 10.1097/TA.0000000000000345; Delahaye-Duriez A, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1097-7; Dobesova Zdena, 2011, 2011 International Conference on Electrical and Control Engineering, P4866, DOI 10.1109/ICECENG.2011.6057428; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Georgoff PE, 2017, CLIN PHARMACOKINET; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Halaweish I, 2015, J TRAUMA ACUTE CARE, V79, P911, DOI 10.1097/TA.0000000000000789; Higgins GA, 2017, PHARM RES-DORDR, V34, P1658, DOI 10.1007/s11095-017-2130-6; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Jin G, 2010, TRANSL STROKE RES, V1, P65, DOI 10.1007/s12975-009-0009-5; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lin T, 2006, SURGERY, V139, P365, DOI 10.1016/j.surg.2005.08.022; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marinova Z, 2009, J NEUROCHEM, V111, P976, DOI 10.1111/j.1471-4159.2009.06385.x; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Nikolian VC, 2017, J TRAUMA ACUTE CARE, V83, P1066, DOI 10.1097/TA.0000000000001612; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang C, 2014, BRAIN RES, V1555, P1, DOI 10.1016/j.brainres.2014.01.051; Zhang EE, 2009, CELL, V139, P199, DOI 10.1016/j.cell.2009.08.031; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579	35	19	19	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2018	84	3					459	465		10.1097/TA.0000000000001765			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	FY1DU	WOS:000426552800008	29251707	Green Accepted			2021-06-18	
J	Tierney, GJ; Denvir, K; Farrell, G; Simms, CK				Tierney, Gregory J.; Denvir, Karl; Farrell, Garreth; Simms, Ciaran K.			The Effect of Tackler Technique on Head Injury Assessment Risk in Elite Rugby Union	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; HEAD IMPACT; TACKLING; INJURY PREVENTION	INTERNATIONAL-CONFERENCE; VIDEO ANALYSIS; WORLD-CUP; CONCUSSION; SPORT; PERFORMANCE; MECHANISMS; STATEMENT; AGREEMENT; PLAYERS	Purpose This study aimed to use match video evidence of tackles in elite-level rugby union to identify tackler proficiency characteristics, for both lower body and upper body tackles, that result in head injury assessments (HIA) for the tackler. Methods A review of international rugby union matches (2013-2017) and Pro 12/European Rugby Champions Cup matches (2014-2017) from a professional rugby union club was conducted. HIA (n = 74) and non-HIA tackles (n = 233) were categorized as either front-on or side-on upper body or lower body tackles and were scored for tackling proficiency characteristics. A chi-square test (P < 0.05) and phi and Cramer's V were calculated to compare HIA and non-HIA tackling proficiency characteristics. Results In both front- and side-on upper body and lower body tackles, head up and forward/face up and head placement on correct side of ball carrier were identified as having a lower propensity to result in an HIA for the tackler. For both front-on and side-on upper body tackles, identify/track ball carrier onto shoulder and shortening steps were identified. In addition, straight back, centre of gravity forward of support base and identify/track ball carrier onto shoulder were identified for front-on and side-on lower body tackles, respectively. Conclusions This study identified tackle characteristics that had a lower propensity to result in an HIA for the tackler in both front-on and side-on upper body and lower body tackles.	[Tierney, Gregory J.; Simms, Ciaran K.] Trinity Coll Dublin, Trinity Ctr Bioengn, Dublin 2, Ireland; [Denvir, Karl; Farrell, Garreth] Leinster Rugby, Dublin, Ireland	Tierney, GJ (corresponding author), Trinity Coll Dublin, Trinity Ctr Bioengn, Dublin 2, Ireland.	gtierne@tcd.ie	Simms, Ciaran/K-3100-2019	Simms, Ciaran/0000-0001-5564-1620; Tierney, Gregory/0000-0002-4666-4473	Irish Research CouncilIrish Research Council for Science, Engineering and Technology	Funding for this study was provided by the Irish Research Council. The authors report no conflicts of interest.	Altman D. G., 1990, PRACTICAL STAT MED R, P229; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Burger N, 2016, BRIT J SPORT MED, V50, P932, DOI 10.1136/bjsports-2015-095295; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd ed, P77, DOI DOI 10.1001/JAMAPSYCHIATRY.2013.504; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; Deutsch MU, 2007, J SPORT SCI, V25, P461, DOI 10.1080/02640410600631298; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Fuller GW, 2015, BRIT J SPORT MED, V49, P529, DOI 10.1136/bjsports-2014-093498; Gabbett T, 2009, INT J SPORTS SCI COA, V4, P521, DOI 10.1260/174795409790291402; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P625, DOI 10.1519/JSC.0b013e3181635a6a; Gabbett TJ., 2007, INT J SPORTS SCI COA, V2, P467, DOI DOI 10.1260/174795407783359731; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Hendricks S., 2016, BMJ OPEN SPORT EXERC, V2, DOI [10.1136/bmjsem-2015-000053, DOI 10.1136/BMJSEM-2015-000053]; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hendricks S, 2014, EUR J SPORT SCI, V14, P753, DOI 10.1080/17461391.2014.905982; Hendricks S, 2014, J SPORT SCI MED, V13, P715; Hendricks S, 2010, INT J SPORTS SCI COA, V5, P117, DOI 10.1260/1747-9541.5.1.117; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Kemp S, 2016, BRIT J SPORT MED, V50, P644, DOI 10.1136/bjsports-2015-095780; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Montgomery C, 2018, BRIT J SPORT MED, V52, P994, DOI 10.1136/bjsports-2016-096425; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Rugby Football Union, ENGL PROF RUGB INJ S; Tierney GJ, 2015, IRCOBI C P SEP 9 11, P9; Tierney GJ, 2016, ISBS C P ARCH JUL 18, P18; Tierney GJ, 2018, J SCI MED SPORT, V21, P221, DOI 10.1016/j.jsams.2017.06.023; Tierney GJ, 2018, INT J SPORTS SCI COA, V13, P415, DOI 10.1177/1747954117751345; Tierney Gregory J, 2018, Sports Biomech, V17, P33, DOI 10.1080/14763141.2016.1271905; Tierney GJ, 2016, BRAIN INJURY, V30, P1350, DOI 10.1080/02699052.2016.1193630; Viljoen W, 2009, SA RUGBY BOKSMART SA; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9	40	19	19	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	MAR	2018	50	3					603	608		10.1249/MSS.0000000000001461			6	Sport Sciences	Sport Sciences	FW5PC	WOS:000425368300025	29049096	Green Published			2021-06-18	
J	Pati, S; Peng, ZL; Wataha, K; Miyazawa, B; Potter, DR; Kozar, RA				Pati, Shibani; Peng, Zhanglong; Wataha, Katherine; Miyazawa, Byron; Potter, Daniel R.; Kozar, Rosemary A.			Lyophilized plasma attenuates vascular permeability, inflammation and lung injury in hemorrhagic shock	PLOS ONE			English	Article							FRESH-FROZEN PLASMA; TRAUMATIC BRAIN-INJURY; ENDOTHELIAL GLYCOCALYX DEGRADATION; DAMAGE CONTROL RESUSCITATION; SPRAY-DRIED PLASMA; LEUKOCYTE ADHESION; SYNDECAN 1; MODEL; SURVIVAL; COAGULOPATHY	In severe trauma and hemorrhage the early and empiric use of fresh frozen plasma (FFP) is associated with decreased morbidity and mortality. However, utilization of FFP comes with the significant burden of shipping and storage of frozen blood products. Dried or lyophilized plasma (LP) can be stored at room temperature, transported easily, reconstituted rapidly with ready availability in remote and austere environments. We have previously demonstrated that FFP mitigates the endothelial injury that ensues after hemorrhagic shock (HS). In the current study, we sought to determine whether LP has similar properties to FFP in its ability to modulate endothelial dysfunction in vitro and in vivo. Single donor LP was compared to single donor FFP using the following measures of endothelial cell (EC) function in vitro: permeability and transendothelial monolayer resistance; adherens junction preservation; and leukocyte-EC adhesion. In vivo, using a model of murine HS, LP and FFP were compared in measures of HS-induced pulmonary vascular inflammation and edema. Both in vitro and in vivo in all measures of EC function, LP demonstrated similar effects to FFP. Both FFP and LP similarly reduced EC permeability, increased transendothelial resistance, decreased leukocyte-EC binding and persevered adherens junctions. In vivo, LP and FFP both comparably reduced pulmonary injury, inflammation and vascular leak. Both FFP and LP have similar potent protective effects on the vascular endothelium in vitro and in lung function in vivo following hemorrhagic shock. These data support the further development of LP as an effective plasma product for human use after trauma and hemorrhagic shock.	[Pati, Shibani; Wataha, Katherine; Miyazawa, Byron; Potter, Daniel R.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Peng, Zhanglong] Univ Texas Hlth Sci Ctr Houston, Dept Anesthesia, Houston, TX 77030 USA; [Kozar, Rosemary A.] Univ Maryland, Sch Med, Shock Trauma Ctr, Baltimore, MD 21201 USA	Pati, S (corresponding author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.	shibani.pati@ucsf.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1GM107482]; Department of DefenseUnited States Department of Defense [W81XWH-11-2-006]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM107482] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health RO1GM107482 (to RAK) and the Department of Defense W81XWH-11-2-006 (to SP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the National Institutes of Health RO1GM107482 and the Department of Defense W81XWH-11-2-006. There are no conflicts of interest reported.	[Anonymous], 2017, SHOCK, P1; [Anonymous], 2009, SAFETY AUTOLOGOUS LY; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Chappell D, 2010, SHOCK, V34, P133, DOI 10.1097/SHK.0b013e3181cdc363; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; Cotton BA, 2011, ANN SURG, V254, P598, DOI 10.1097/SLA.0b013e318230089e; GIAEVER I, 1986, IEEE T BIO-MED ENG, V33, P242, DOI 10.1109/TBME.1986.325896; Hart ML, 2005, J IMMUNOL, V174, P6373, DOI 10.4049/jimmunol.174.10.6373; Haywood-Watson RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023530; Holcomb JB, 2013, JAMA SURG; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2013, HEMATOL-AM SOC HEMAT, P656, DOI 10.1182/asheducation-2013.1.656; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Imam AM, 2013, J TRAUMA ACUTE CARE, V75, P976, DOI 10.1097/TA.0b013e31829e2186; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jenkins DH, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000140; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Johansson PI, 2011, BIOMED CENTRAL, V15, pR272; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kozar RA, 2015, J TRAUMA ACUTE CARE, V78, pS83, DOI 10.1097/TA.0000000000000631; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Lee TH, 2013, TRANSFUSION, V53, p72S, DOI 10.1111/trf.12039; Letourneau PA, 2011, J TISSUE SCI ENG S3; Lipowsky HH, 2012, ANN BIOMED ENG, V40, P840, DOI 10.1007/s10439-011-0427-x; Matijevic N, 2011, J TRAUMA, V70, P71, DOI 10.1097/TA.0b013e318207abec; Ostrowski SR, 2012, J TRAUMA ACUTE CARE, V73, P60, DOI 10.1097/TA.0b013e31825b5c10; Pati S, 2016, J TRAUMA ACUTE CARE, V80, P576, DOI 10.1097/TA.0000000000000961; Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4; Peng ZL, 2016, J TRAUMA ACUTE CARE, V81, pS171, DOI 10.1097/TA.0000000000001221; Peng ZL, 2013, SHOCK, V40, P195, DOI 10.1097/SHK.0b013e31829f91fc; Peng ZL, 2012, SHOCK, V38, P57, DOI 10.1097/SHK.0b013e31825a188a; Potter DR, 2015, J TRAUMA ACUTE CARE, V78, pS7, DOI 10.1097/TA.0000000000000630; Pusateri AE, 2016, TRANSFUSION, V56, pS128, DOI 10.1111/trf.13580; Query C, 2010, REPORTING SYSTEM WIS; Rahbar E, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0481-5; Sillesen M, 2013, SURGERY, V154, P197, DOI 10.1016/j.surg.2013.04.002; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Spoerke N, 2009, ARCH SURG-CHICAGO, V144, P829, DOI 10.1001/archsurg.2009.154; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Van PY, 2011, J TRAUMA, V71, P20, DOI 10.1097/TA.0b013e3182214f44; Wataha K, 2013, TRANSFUSION, V53, p80S, DOI 10.1111/trf.12040	41	19	19	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2018	13	2							e0192363	10.1371/journal.pone.0192363			13	Multidisciplinary Sciences	Science & Technology - Other Topics	FU7VI	WOS:000424060400039	29394283	DOAJ Gold, Green Published			2021-06-18	
J	Georgoff, PE; Nikolian, VC; Bonham, T; Pai, MP; Tafatia, C; Halaweish, I; To, K; Watcharotone, K; Parameswaran, A; Luo, RJ; Sun, DX; Alam, HB				Georgoff, Patrick E.; Nikolian, Vahagn C.; Bonham, Tess; Pai, Manjunath P.; Tafatia, Celia; Halaweish, Ihab; To, Kathleen; Watcharotone, Kuanwong; Parameswaran, Aishwarya; Luo, Ruijuan; Sun, Duxin; Alam, Hasan B.			Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial	CLINICAL PHARMACOKINETICS			English	Article							TRAUMATIC BRAIN-INJURY; HISTONE DEACETYLASE INHIBITION; PHARMACOLOGICAL RESUSCITATION; HEMORRHAGIC-SHOCK; CLINICAL-TRIAL; MODEL; ACETYLATION; CANCER	Background Valproic acid, a histone deacetylase inhibitor, has beneficial effects in the setting of cancer, neurologic diseases, and traumatic injuries. In animal models of traumatic injury, a single dose of valproic acid has been shown to reduce mortality. The purpose of this trial was to determine the maximum tolerated single dose of intravenous valproic acid in healthy humans. Methods A double-blinded, placebo-controlled, dose-escalation trial design was used to identify dose-limiting toxicities in healthy subjects who received a single dose of intravenous valproic acid. Patients were monitored for adverse events and data were collected for pharmacokinetic, pharmacodynamic, and safety profiling of valproic acid. Results Fifty-nine healthy subjects (mean 30 +/- 12 years) were enrolled. Forty-four subjects received valproic acid in doses from 15 to 150 mg/kg. The most common adverse events were hypoacusis (n = 19), chills (n = 18), and headache (n = 16). The maximum tolerated dose was 140 mg/kg. Dose-limiting toxicities included headache and nausea lasting longer than 12 h. No drug-related abnormalities were seen in other safety measures including laboratory tests, hemodynamic parameters, cardiac rhythm monitoring, and cognitive testing. A two-compartment model was predictive of valproic acid concentration-time profiles, with a strong correlation (R-2 = 0.56) observed between the number of reported adverse events and the dose level. Conclusions The maximum tolerated dose of intravenous valproic acid in healthy subjects is 140 mg/kg. This is significantly higher than the previously established maximum tolerated dose of 60-75 mg/kg. Next, the safety and tolerability of high-dose valproic acid will be tested in trauma patients in hemorrhagic shock.	[Georgoff, Patrick E.; Nikolian, Vahagn C.; Bonham, Tess; Tafatia, Celia; Halaweish, Ihab; To, Kathleen; Alam, Hasan B.] Univ Michigan, Sch Med, Dept Gen Surg, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA; [Pai, Manjunath P.] Univ Michigan, Coll Pharm, Dept Clin Pharm, 428 Church St, Ann Arbor, MI 48109 USA; [Watcharotone, Kuanwong; Parameswaran, Aishwarya] Univ Michigan, Sch Med, Michigan Inst Clin & Hlth Res, Ann Arbor, MI USA; [Luo, Ruijuan; Sun, Duxin] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA	Alam, HB (corresponding author), Univ Michigan, Sch Med, Dept Gen Surg, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu			Department of Defense Office of Naval ResearchOffice of Naval ResearchUnited States Department of Defense [N000141310071]; National Institutes of Health Center for Advancing Translational Sciences [UL1TR000433]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000433, UL1TR002240] Funding Source: NIH RePORTER	This work was funded by the Department of Defense Office of Naval Research (N000141310071) and the National Institutes of Health Center for Advancing Translational Sciences (UL1TR000433). The Michigan Institute for Clinical Health Research provided guidance, data design, and clinical research space. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, or the US Department of Defense.	Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851; BOYUM A, 1977, LYMPHOLOGY, V10, P71; Brown E., 2006, PHARMACOVIGILANCE; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Dekker SE, 2014, J TRAUMA ACUTE CARE, V77, P906, DOI 10.1097/TA.0000000000000345; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fukudome EY, 2010, J SURG RES, V163, P118, DOI 10.1016/j.jss.2010.04.013; Georgoff PE, 2016, J TRAUMA ACUTE CARE, V81, P1020, DOI 10.1097/TA.0000000000001249; Gottlicher M, 2004, Ann Hematol, V83 Suppl 1, pS91; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GUGLER R, 1980, CLIN PHARMACOKINET, V5, P67, DOI 10.2165/00003088-198005010-00002; Halaweish I, 2015, J TRAUMA ACUTE CARE, V79, P911, DOI 10.1097/TA.0000000000000789; Halaweish I, 2015, SHOCK, V44, P6, DOI 10.1097/SHK.0000000000000319; Higgins GA, 2017, NETWORK RECONSTRUCTI, DOI [10.1007/s11095-017-2130-6, DOI 10.1007/S11095-017-2130-6]; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Jepsen CH, 2014, J TRAUMA ACUTE CARE, V77, P292, DOI 10.1097/TA.0000000000000333; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Li YQ, 2010, SURGERY, V148, P246, DOI 10.1016/j.surg.2010.05.003; Munster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165; Nikolian V, 2016, PHARM RESUSCITATION; Perucca E, 2002, CNS DRUGS, V16, P695, DOI 10.2165/00023210-200216100-00004; Pons PT, 2015, J EMERG MED, V49, P878, DOI 10.1016/j.jemermed.2015.09.013; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Spiller HA, 2000, J TOXICOL-CLIN TOXIC, V38, P755, DOI 10.1081/CLT-100102388; Toussirot E, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0002-6; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Zhao T, 2013, SURGERY, V154, P206, DOI 10.1016/j.surg.2013.04.003	30	19	19	0	4	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0312-5963	1179-1926		CLIN PHARMACOKINET	Clin. Pharmacokinet.	FEB	2018	57	2					209	219		10.1007/s40262-017-0553-1			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FT7QS	WOS:000423348300005	28497259	Green Accepted			2021-06-18	
J	Konigs, M; Pouwels, PJW; van Heurn, LWE; Bakx, R; Vermeulen, RJ; Goslings, JC; Poll-The, BT; van der Wees, M; Catsman-Berrevoets, CE; Oosterlaan, J				Konigs, Marsh; Pouwels, Petra J. W.; van Heurn, L. W. Ernest; Bakx, Roel; Vermeulen, R. Jeroen; Goslings, J. Carel; Poll-The, Bwee Tien; van der Wees, Marleen; Catsman-Berrevoets, Coriene E.; Oosterlaan, Jaap			Relevance of neuroimaging for neurocognitive and behavioral outcome after pediatric traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Diffusion tensor imaging; Tract-based spatial statistics; Pediatrics; Traumatic brain injury; Neurocognitive functioning; Behavior problems	IMAGING DTI FINDINGS; CORPUS-CALLOSUM; SPATIAL STATISTICS; WORKING-MEMORY; HEAD-INJURY; CHILDREN; TBI; MICROSTRUCTURE; DEFICITS; MODERATE	This study aims to (1) investigate the neuropathology of mild to severe pediatric TBI and (2) elucidate the predictive value of conventional and innovative neuroimaging for functional outcome. Children aged 8-14 years with trauma control (TC) injury (n = 27) were compared to children with mild TBI and risk factors for complicated TBI (mild(RF+), n = 20) or moderate/severe TBI (n = 17) at 2.8 years post-injury. Neuroimaging measures included: acute computed tomography (CT), volumetric analysis on post-acute conventional T1-weighted magnetic resonance imaging (MRI) and post-acute diffusion tensor imaging (DTI, analyzed using tract-based spatial statistics and voxel-wise regression). Functional outcome was measured using Common Data Elements for neurocognitive and behavioral functioning. The results show that intracranial pathology on acute CT-scans was more prevalent after moderate/severe TBI (65%) than after mild(RF+) TBI (35%; p = .035), while both groups had decreased white matter volume on conventional MRI (ps ae<currency> .029, ds ae<yen> -0.74). The moderate/severe TBI group further showed decreased fractional anisotropy (FA) in a widespread cluster affecting all white matter tracts, in which regional associations with neurocognitive functioning were observed (FSIQ, Digit Span and RAVLT Encoding) that consistently involved the corpus callosum. FA had superior predictive value for functional outcome (i.e. intelligence, attention and working memory, encoding in verbal memory and internalizing problems) relative to acute CT-scanning (i.e. internalizing problems) and conventional MRI (no predictive value). We conclude that children with mild(RF+) TBI and moderate/severe TBI are at risk of persistent white matter abnormality. Furthermore, DTI has superior predictive value for neurocognitive out-come relative to conventional neuroimaging.	[Konigs, Marsh; Oosterlaan, Jaap] FGB VU Univ Amsterdam, Clin Neuropsychol Sect, Van der Boechorststr 1, NL-1081 BT Amsterdam, Netherlands; [Konigs, Marsh; Oosterlaan, Jaap] Emma Childrens Hosp, Acad Med Ctr, Amsterdam, Netherlands; [Pouwels, Petra J. W.] Vrije Univ Amsterdam, Dept Phys & Med Technol, Med Ctr, Amsterdam, Netherlands; [Pouwels, Petra J. W.] Neurosci Campus Amsterdam, Amsterdam, Netherlands; [van Heurn, L. W. Ernest; Bakx, Roel] Emma Childrens Hosp, Acad Med Ctr, Pediat Surg Ctr Amsterdam, Amsterdam, Netherlands; [van Heurn, L. W. Ernest; Bakx, Roel] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Vermeulen, R. Jeroen] Vrije Univ Amsterdam, Dept Pediat Neurol, Med Ctr, Amsterdam, Netherlands; [Vermeulen, R. Jeroen] Maastricht Univ, Dept Pediat Neurol, Med Ctr, Maastricht, Netherlands; [Goslings, J. Carel] Acad Med Ctr, Trauma Unit, Amsterdam, Netherlands; [Poll-The, Bwee Tien] Emma Childrens Hosp, Dept Pediat Neurol, Acad Med Ctr, Amsterdam, Netherlands; [van der Wees, Marleen] Libra Rehabil Med & Audiol, Eindhoven, Netherlands; [Catsman-Berrevoets, Coriene E.] Sophia Childrens Univ Hosp, Erasmus Univ Hosp, Dept Pediat Neurol, Rotterdam, Netherlands; [Oosterlaan, Jaap] Vrije Univ Amsterdam, Dept Pediat, Med Ctr, Amsterdam, Netherlands	Konigs, M (corresponding author), FGB VU Univ Amsterdam, Clin Neuropsychol Sect, Van der Boechorststr 1, NL-1081 BT Amsterdam, Netherlands.; Konigs, M (corresponding author), Emma Childrens Hosp, Acad Med Ctr, Amsterdam, Netherlands.	m.konigs@vu.nl		Konigs, Marsh/0000-0003-0200-0445	Netherlands' Organization for Scientific Research (NWO)Netherlands Organization for Scientific Research (NWO) [022.003.010]; Faculty of Behavioral and Movement Sciences of the Vrije Universiteit Amsterdam	This work was supported by the Netherlands' Organization for Scientific Research (NWO, http://www.nwo.nl) grant number 022.003.010 and the Faculty of Behavioral and Movement Sciences of the Vrije Universiteit Amsterdam.	Adamson C, 2013, BRAIN INJURY, V27, P454, DOI 10.3109/02699052.2012.750756; American College of Surgeons, 2004, ADV TRAUM LIF SUPP P; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bach M, 2014, NEUROIMAGE, V100, P358, DOI 10.1016/j.neuroimage.2014.06.021; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2016, HUM BRAIN MAPP, V37, P3929, DOI 10.1002/hbm.23286; Gerlach R, 2009, PEDIATR EMERG CARE, V25, P164, DOI 10.1097/PEC.0b013e31819a8966; Haberg AK, 2015, J NEUROSCI RES, V93, P1109, DOI 10.1002/jnr.23534; Hayes A., 2013, INTRO MEDIATION MODE, P3, DOI DOI 10.1111/JEDM.12050; IBM corp, 2011, IBM SPSS STAT WINDOW; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson CP, 2011, J INT NEUROPSYCH SOC, V17, P663, DOI 10.1017/S1355617711000464; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Konigs M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144395; Konigs M, 2015, PEDIATRICS, V136, P534, DOI 10.1542/peds.2015-0437; Kort W, 2005, WISC IIINL WECHSLER; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Max J, 1998, CHILD ADOLESC PSYCHI, V37, P932; Max JE, 2012, J AM ACAD CHILD PSY, V51, P1208, DOI 10.1016/j.jaac.2012.08.026; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morey RA, 2010, HUM BRAIN MAPP, V31, P1751, DOI 10.1002/hbm.20973; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Poldrack RA, 2007, SOC COGN AFFECT NEUR, V2, P67, DOI 10.1093/scan/nsm006; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; Roberts RM, 2014, DEV NEUROPSYCHOL, V39, P600, DOI 10.1080/87565641.2014.973958; Roberts RM, 2016, DEV NEUROPSYCHOL, V41, P176, DOI 10.1080/87565641.2016.1186167; Sattler J. M., 2001, ASSESSMENT CHILDREN, V774; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Statistics Netherlands, 2006, ED CAT STAND; Tabachnick B.G., 2012, USING MULTIVARIATE S; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Treble A, 2013, J NEUROTRAUM, V30, P1609, DOI 10.1089/neu.2013.2934; Van Beek L, 2015, BRAIN INJURY, V29, P1701, DOI 10.3109/02699052.2015.1075172; van den Burg W, 1999, ARCH CLIN NEUROPSYCH, V14, P545, DOI 10.1016/S0887-6177(98)00042-0; Verhulst F., 2013, HANDELING ASEBA VRAG; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wechsler D., 1991, WISC 3 WECHSLER INTE; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	58	19	19	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	FEB	2018	12	1					29	43		10.1007/s11682-017-9673-3			15	Neuroimaging	Neurosciences & Neurology	FW4TM	WOS:000425307500004	28092022	Other Gold, Green Published			2021-06-18	
J	Kuzminski, SJ; Clark, MD; Fraser, MA; Haswell, CC; Morey, RA; Liu, C; Choudhury, KR; Guskiewicz, KM; Petrella, JR				Kuzminski, S. J.; Clark, M. D.; Fraser, M. A.; Haswell, C. C.; Morey, R. A.; Liu, C.; Choudhury, K. R.; Guskiewicz, K. M.; Petrella, J. R.			White Matter Changes Related to Subconcussive Impact Frequency during a Single Season of High School Football	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; CNS VITAL SIGNS; MIXED MODELS; CONCUSSION; DIFFUSION; INJURY; RELIABILITY; INTEGRITY; INFERENCE; EXPOSURE	BACKGROUND AND PURPOSE: The effect of exposing the developing brain of a high school football player to subconcussive impacts during a single season is unknown. The purpose of this pilot study was to use diffusion tensor imaging to assess white matter changes during a single high school football season, and to correlate these changes with impacts measured by helmet accelerometer data and neurocognitive test scores collected during the same period. MATERIALS AND METHODS: Seventeen male athletes (mean age, 16 +/- 0.73 years) underwent MR imaging before and after the season. Changes in fractional anisotropy across the white matter skeleton were assessed with Tract-Based Spatial Statistics and ROI analysis. RESULTS: The mean number of impacts over a 10-g threshold sustained was 414 +/- 291. Voxelwise analysis failed to show significant changes in fractional anisotropy across the season or a correlation with impact frequency, after correcting for multiple comparisons. ROI analysis showed significant (P <.05, corrected) decreases in fractional anisotropy in the fornix-stria terminalis and cingulum hippocampus, which were related to impact frequency. The effects were strongest in the fornix-stria terminalis, where decreases in fractional anisotropy correlated with worsening visual memory. CONCLUSIONS: Our findings suggest that subclinical neurotrauma related to participation in American football may result in white matter injury and that alterations in white matter tracts within the limbic system may be detectable after only 1 season of play at the high school level.	[Kuzminski, S. J.; Liu, C.; Choudhury, K. R.; Petrella, J. R.] Duke Univ, Dept Radiol, Durham, NC 27710 USA; [Haswell, C. C.; Morey, R. A.; Liu, C.; Petrella, J. R.] Duke Univ, Brain Imaging & Anal Ctr, Durham, NC USA; [Morey, R. A.] Duke Univ, Dept Translat Neurosci, Durham, NC USA; [Clark, M. D.; Fraser, M. A.; Guskiewicz, K. M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Kuzminski, S. J.] Univ Oklahoma, Hlth Sci Ctr, Dept Radiol Sci, Oklahoma City, OK 73126 USA	Kuzminski, SJ (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Radiol Sci, POB 2690,Garrison Tower,Suite 4G4250, Oklahoma City, OK 73126 USA.	sam@kuzminskis.com	Morey, Rajendra A/P-3079-2018	Morey, Rajendra A/0000-0002-6517-6969; Kuzminski, Sam/0000-0002-4963-4376; Liu, Chunlei/0000-0001-8816-4832; Clark, Michael/0000-0002-5019-0290; Roy Choudhury, Kingshuk/0000-0002-0306-2915; Fraser, Missy/0000-0002-5753-8798	Department Seed Funding, Department of Radiology, Duke University, Durham, North Carolina; National Institutes of Health under the Ruth L. Kirschstein National Research Service Award from the National Institute of Neurological Disorders and Stroke [F30NS090816]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30NS090816] Funding Source: NIH RePORTER	This work was supported by Department Seed Funding, Department of Radiology, Duke University, Durham, North Carolina, and the National Institutes of Health under the Ruth L. Kirschstein National Research Service Award F30NS090816 from the National Institute of Neurological Disorders and Stroke.	Acheson A, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.615; Alhilali LM, 2017, AM J NEURORADIOL, V38, P691, DOI 10.3174/ajnr.A5073; Badgeley MA, 2013, J PHYS ACT HEALTH, V10, P160, DOI 10.1123/jpah.10.2.160; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bates D., 2021, NLME LINEAR NONLINEA, DOI DOI 10.5194/TC-10-2291-2016; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Davis M, 2010, NEUROPSYCHOPHARMACOL, V35, P105, DOI 10.1038/npp.2009.109; Dean CB, 2007, LIFETIME DATA ANAL, V13, P497, DOI 10.1007/s10985-007-9065-x; Detry MA, 2016, JAMA-J AM MED ASSOC, V315, P407, DOI 10.1001/jama.2015.19394; Edlow BL, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-015-0525-8; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Lebow MA, 2016, MOL PSYCHIATR, V21, P450, DOI 10.1038/mp.2016.1; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Littleton AC, 2015, SPORTS HEALTH, V7, P443, DOI 10.1177/1941738115586997; MARKOWSKA AL, 1989, EXP BRAIN RES, V74, P187; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Stanford MS, 2009, PERS INDIV DIFFER, V47, P385, DOI 10.1016/j.paid.2009.04.008; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060	29	19	19	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2018	39	2					245	251		10.3174/ajnr.A5489			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	FX2XE	WOS:000425928300007	29269405	Green Published, Green Accepted, Other Gold			2021-06-18	
J	Ley, EJ; Leonard, SD; Barmparas, G; Dhillon, NK; Inaba, K; Salim, A; O'Bosky, KR; Tatum, D; Azmi, H; Ball, CG; Engels, PT; Dunn, JA; Carrick, MM; Meizoso, JP; Lombardo, S; Cotton, BA; Schroeppel, TJ; Rizoli, S; Chang, DSJ; de Leon, LA; Rezende-Neto, J; Jacome, T; Xiao, J; Mallory, G; Rao, K; Widdel, L; Godin, S; Coates, A; Benedict, LA; Nirula, R; Kaul, S; Li, T				Ley, Eric J.; Leonard, Samuel D.; Barmparas, Galinos; Dhillon, Navpreet K.; Inaba, Kenji; Salim, Ali; O'Bosky, Karen R.; Tatum, Danielle; Azmi, Hooman; Ball, Chad G.; Engels, Paul T.; Dunn, Julie A.; Carrick, Matthew M.; Meizoso, Jonathan P.; Lombardo, Sarah; Cotton, Bryan A.; Schroeppel, Thomas J.; Rizoli, Sandro; Chang, David S. J.; de Leon, Luis Alejandro; Rezende-Neto, Joao; Jacome, Tomas; Xiao, Jimmy; Mallory, Gina; Rao, Krishnamurti; Widdel, Lars; Godin, Samuel; Coates, Angela; Benedict, Leo Andrew; Nirula, Raminder; Kaul, Sanjeev; Li, Tong			Beta blockers in critically ill patients with traumatic brain injury: Results from a multicenter, prospective, observational American Association for the Surgery of Trauma study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Beta blockade; beta blockers; catecholamines; propranolol; traumatic brain injury	PROGENITOR-CELL MOBILIZATION; EARLY PROPRANOLOL; CEREBRAL PERFUSION; HEAD-INJURY; BLOCKADE; METABOLISM; RECEPTORS; SURVIVAL; HISTORY; DEATH	BACKGROUND Beta blockers, a class of medications that inhibit endogenous catecholamines interaction with beta adrenergic receptors, are often administered to patients hospitalized after traumatic brain injury (TBI). We tested the hypothesis that beta blocker use after TBI is associated with lower mortality, and secondarily compared propranolol to other beta blockers. METHODS The American Association for the Surgery of Trauma Clinical Trial Group conducted a multi-institutional, prospective, observational trial in which adult TBI patients who required intensive care unit admission were compared based on beta blocker administration. RESULTS From January 2015 to January 2017, 2,252 patients were analyzed from 15 trauma centers in the United States and Canada with 49.7% receiving beta blockers. Most patients (56.3%) received the first beta blocker dose by hospital day 1. Those patients who received beta blockers were older (56.7 years vs. 48.6 years, p < 0.001) and had higher head Abbreviated Injury Scale scores (3.6 vs. 3.4, p < 0.001). Similarities were noted when comparing sex, admission hypotension, mean Injury Severity Score, and mean Glasgow Coma Scale. Unadjusted mortality was lower for patients receiving beta blockers (13.8% vs. 17.7%, p = 0.013). Multivariable regression determined that beta blockers were associated with lower mortality (adjusted odds ratio, 0.35; p < 0.001), and propranolol was superior to other beta blockers (adjusted odds ratio, 0.51, p = 0.010). A Cox-regression model using a time-dependent variable demonstrated a survival benefit for patients receiving beta blockers (adjusted hazard ratio, 0.42, p < 0.001) and propranolol was superior to other beta blockers (adjusted hazard ratio, 0.50, p = 0.003). CONCLUSION Administration of beta blockers after TBI was associated with improved survival, before and after adjusting for the more severe injuries observed in the treatment cohort. This study provides a robust evaluation of the effects of beta blockers on TBI outcomes that supports the initiation of a multi-institutional randomized control trial. LEVEL OF EVIDENCE Therapeutic/care management, level III.	[Ley, Eric J.; Barmparas, Galinos; Dhillon, Navpreet K.; Li, Tong] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Leonard, Samuel D.; Cotton, Bryan A.] Univ Texas Houston, Dept Surg, Div Acute Care Surg, Houston, TX USA; [Inaba, Kenji; de Leon, Luis Alejandro] Los Angeles Cty & USC Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA USA; [Salim, Ali; Benedict, Leo Andrew] Brigham & Womens Hosp, Dept Surg, Div Trauma Burns & Surg Crit Care, 75 Francis St, Boston, MA 02115 USA; [O'Bosky, Karen R.; Chang, David S. J.] Loma Linda Univ, Loma Linda, CA 92350 USA; [O'Bosky, Karen R.; Chang, David S. J.] Med Ctr, Dept Surg, Div Acute Care Surg, Loma Linda, CA USA; [Tatum, Danielle; Jacome, Tomas] Our Lady Lake Reg Med Ctr, Trauma Specialist Program, Baton Rouge, LA USA; [Azmi, Hooman; Kaul, Sanjeev] Hackensack Univ, Med Ctr, Dept Neurosurg, Hackensack, NJ USA; [Ball, Chad G.; Xiao, Jimmy] Univ Calgary, Foothills Med Ctr, Dept Surg, Calgary, AB, Canada; [Engels, Paul T.; Coates, Angela] McMaster Univ, Hamilton Gen Hosp, Dept Surg, Hamilton, ON, Canada; [Dunn, Julie A.; Widdel, Lars] Med Ctr Rockies, Dept Trauma & Acute Care Surg, Loveland, CO USA; [Carrick, Matthew M.; Mallory, Gina] Med City Plano, Trauma Serv Dept, Plano, TX USA; [Meizoso, Jonathan P.; Rao, Krishnamurti] Univ Miami, Jackson Mem Med Ctr, DeWitt Daughtry Family Dept Surg, Ryder Trauma Ctr, Miami, FL USA; [Lombardo, Sarah; Nirula, Raminder] Univ Utah, Div Gen Surg, Salt Lake City, UT USA; [Schroeppel, Thomas J.; Godin, Samuel] Mem Hosp, Dept Surg, Colorado Springs, CO USA; [Rizoli, Sandro; Rezende-Neto, Joao] St Michaels Hosp, Dept Trauma & Acute Care Surg, Toronto, ON, Canada	Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, 8700 Beverly Blvd,Suite 8215NT, Los Angeles, CA 90048 USA.	Eric.Ley@cshs.org	INABA, KENJI/AAC-8532-2020; Barmparas, Galinos/L-6530-2019; Meizoso, Jonathan/AAF-5777-2019	Meizoso, Jonathan/0000-0002-6616-6682; De Leon Castro, Luis Alejandro/0000-0001-7623-8603			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Ahl R, 2017, EUR J TRAUMA EMERG S, V43, P783, DOI 10.1007/s00068-017-0779-5; Alali AS, 2017, ANN SURG, V266, P952, DOI 10.1097/SLA.0000000000002286; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; [Anonymous], 2014, PROQUEST; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Baranski GM, 2012, J TRAUMA ACUTE CARE, V73, P343, DOI 10.1097/TA.0b013e31825a785a; Beiermeister KA, 2010, J TRAUMA, V69, P338, DOI 10.1097/TA.0b013e3181e5d35e; Bible LE, 2014, J TRAUMA ACUTE CARE, V77, P54, DOI 10.1097/TA.0000000000000264; Bukur M, 2012, J TRAUMA ACUTE CARE, V72, P1013, DOI 10.1097/TA.0b013e318241bc5b; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; Da Luz LT, 2015, CATECHOLAMINES INDEP, V1604258; Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7; Eisenhofer G, 2004, PHARMACOL REV, V56, P331, DOI 10.1124/pr.56.3.1; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Goldstein DS, 2017, CELL MOL NEUROBIOL; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Han RQ, 2009, ANESTH ANALG, V108, P280, DOI 10.1213/ane.0b013e318187ba6b; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Hendrick LE, 2016, AM SURGEON, V82, P575; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Ko A, 2016, J TRAUMA ACUTE CARE, V80, P637, DOI 10.1097/TA.0000000000000959; Kobilka B, 2013, ANGEW CHEM INT EDIT, V52, P6380, DOI 10.1002/anie.201302116; Lefkowitz RJ, 2013, ANGEW CHEM INT EDIT, V52, P6366, DOI 10.1002/anie.201301924; Ley EJ, 2012, J TRAUMA ACUTE CARE, V73, P33, DOI 10.1097/TA.0b013e31825a769b; Ley EJ, 2010, J SURG RES, V163, P142, DOI 10.1016/j.jss.2010.04.046; Ley EJ, 2010, J TRAUMA, V68, P353, DOI 10.1097/TA.0b013e3181c8269a; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Mohr AM, 2011, J TRAUMA, V70, P1043, DOI 10.1097/TA.0b013e3182169326; Mohseni S, 2014, J TRAUMA ACUTE CARE, V76, P804, DOI 10.1097/TA.0000000000000139; Murry JS, 2016, J SURG RES, V200, P221, DOI 10.1016/j.jss.2015.06.045; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; Pasupuleti LV, 2014, J TRAUMA ACUTE CARE, V76, P970, DOI 10.1097/TA.0000000000000181; Rizoli SB, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1620-6; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Schroeppel TJ, 2014, J TRAUMA ACUTE CARE, V76, P504, DOI 10.1097/TA.0000000000000104; Shetty T, 2016, SPORTS HEALTH, V8, P26, DOI 10.1177/1941738115588745; Stapleton MP, 1997, TEX HEART I J, V24, P336; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; Wang J, 2010, J NEUROIMMUNOL, V223, P77, DOI 10.1016/j.jneuroim.2010.04.006; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Zangbar B, 2016, J SURG RES, V200, P586, DOI 10.1016/j.jss.2015.08.020	50	19	20	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2018	84	2					234	244		10.1097/TA.0000000000001747			11	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	FU7QR	WOS:000424048300002	29251711				2021-06-18	
J	Shapira, R; Solomon, B; Efrati, S; Frenkel, D; Ashery, U				Shapira, Ronit; Solomon, Beka; Efrati, Shai; Frenkel, Dan; Ashery, Uri			Hyperbaric oxygen therapy ameliorates pathophysiology of 3xTg-AD mouse model by attenuating neuroinflammation	NEUROBIOLOGY OF AGING			English	Article						Hyperbaric oxygen therapy (HBOT); Alzheimer's disease; Neuroinflammation; Hypoxia; beta-Amyloid	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; GINKGO-BILOBA EXTRACT; ALZHEIMERS-DISEASE; MICROGLIAL ACTIVATION; BLOOD-FLOW; A-BETA; RETROSPECTIVE ANALYSIS; PLAQUE DEPOSITION; OXIDATIVE STRESS	There is a real need for new interventions for Alzheimer's disease (AD). Hyperbaric oxygen therapy (HBOT), the medical administration of 100% oxygen at conditions greater than 1 atmosphere absolute, has been used successfully to treat several neurological conditions, but its effects on AD pathology have never been thoroughly examined. Therefore, we exposed old triple-transgenic (3xTg) and non-transgenic mice to HBOT followed by behavioral, histological, and biochemical analyses. HBOT attenuated neuroinflammatory processes by reducing astrogliosis, microgliosis, and the secretion of proinflammatory cytokines (IL-1 beta and TNF alpha) and increasing expression of scavenger receptor A, arginase1, and antiinflammatory cytokines (IL-4 and IL-10). Moreover, HBOT reduced hypoxia, amyloid burden, and tau phosphorylation in 3xTg mice and ameliorated their behavioral deficits. Therefore, we suggest that HBOT has multifaceted effects that reduce AD pathologies, even in old mice. Given that HBOT is used in the clinic to treat various indications, including neurological conditions, these results suggest HBOT as a novel therapeutic intervention for AD. (C) 2017 Elsevier Inc. All rights reserved.	[Shapira, Ronit; Frenkel, Dan; Ashery, Uri] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiol, Tel Aviv, Israel; [Solomon, Beka] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, Tel Aviv, Israel; [Solomon, Beka; Frenkel, Dan; Ashery, Uri] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel; [Efrati, Shai] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Efrati, Shai] Sagol Ctr Hyperbar Med & Res, Assaf Harofeh Med Ctr, Tel Aviv, Israel	Ashery, U (corresponding author), Tel Aviv Univ, Sagol Sch Neurosci, Dept Neurobiol, George S Wise Fac Life Sci, Tel Aviv, Israel.	uriashery@gmail.com		Ashery, Uri/0000-0001-6338-7888	Israeli Ministry of Science, Technology and Space [3-12069]	The authors would like to thank Dr. Irit Gottfried for assistance throughout this project and for comments on the manuscript and to Professor Frank M. LaFerla for kindly providing us with the 3xTg mice. This work was supported in part by the Israeli Ministry of Science, Technology and Space to UA (grant number 3-12069). Behavioral experiments were carried out at the Myers Neuro-Behavioral Core Facility of Tel Aviv University.	Alsop DC, 2010, J ALZHEIMERS DIS, V20, P871, DOI 10.3233/JAD-2010-091699; Altieri M, 2004, NEUROLOGY, V62, P2193, DOI 10.1212/01.WNL.0000130501.79012.1A; Binnewijzend MAA, 2013, RADIOLOGY, V267, P221, DOI 10.1148/radiol.12120928; Boussi-Gross R, 2015, NEUROPSYCHOLOGY, V29, P610, DOI 10.1037/neu0000149; Calvert JW, 2007, NEUROL RES, V29, P132, DOI 10.1179/016164107X174156; Camporesi EM, 2014, UNDERSEA HYPERBAR M, V41, P247; Chao LL, 2010, ALZ DIS ASSOC DIS, V24, P19, DOI 10.1097/WAD.0b013e3181b4f736; Chen JJ, 2011, NEUROIMAGE, V55, P468, DOI 10.1016/j.neuroimage.2010.12.032; Chen X, 2014, NEUROSCIENCE, V266, P235, DOI 10.1016/j.neuroscience.2013.11.036; Cherry JD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0411-8; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Dagher NN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0366-9; Daniels MJD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12504; Duan SS, 2015, INT J NEUROSCI, V125, P625, DOI 10.3109/00207454.2014.956101; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; ElKhoury J, 1996, NATURE, V382, P716; Ferrer I, 2002, ACTA NEUROPATHOL, V104, P583, DOI 10.1007/s00401-002-002-0587-8; Figueroa XA, 2015, UNDERSEA HYPERBAR M, V42, P333; Frenkel D, 2008, ANN NEUROL, V63, P591, DOI 10.1002/ana.21340; Frenkel D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3030; Galun M, 2007, IEEE I CONF COMP VIS, P722; Geng FY, 2016, NEUROIMMUNOMODULAT, V23, P122, DOI 10.1159/000445689; Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074; Grathwohl SA, 2009, NAT NEUROSCI, V12, P1361, DOI 10.1038/nn.2432; Gunther A, 2005, EUR J NEUROSCI, V21, P3189, DOI 10.1111/j.1460-9568.2005.04151.x; Hadanny A, 2016, UNDERSEA HYPERBAR M, V43, P21; Hadanny A, 2015, RESTOR NEUROL NEUROS, V33, P471, DOI 10.3233/RNN-150517; Harch PG, 2015, MED GAS RES, V5, DOI 10.1186/s13618-015-0030-6; HEINONEN O, 1995, NEUROSCIENCE, V64, P375, DOI 10.1016/0306-4522(94)00422-2; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Honig LS, 2005, NEUROLOGY, V64, P494, DOI 10.1212/01.WNL.0000150886.50187.30; Hoozemans JJM, 2006, INT J DEV NEUROSCI, V24, P157, DOI 10.1016/j.ijdevneu.2005.11.001; Huang L, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-21; Iram T, 2016, NEUROBIOL DIS, V96, P84, DOI 10.1016/j.nbd.2016.08.001; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; Janelsins MC, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-23; Jellinger KA, 1996, NEUROLOGY, V46, P1186, DOI 10.1212/WNL.46.4.1186-b; Kaur C, 2013, J NEUROIMMUNE PHARM, V8, P66, DOI 10.1007/s11481-012-9347-2; Kitazawa M, 2011, J IMMUNOL, V187, P6539, DOI 10.4049/jimmunol.1100620; Koronyo Y, 2015, BRAIN, V138, P2399, DOI 10.1093/brain/awv150; Lai AY, 2006, GLIA, V53, P809, DOI 10.1002/glia.20335; Lavrnja I, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/498405; Leroy K, 2007, NEUROPATH APPL NEURO, V33, P43, DOI 10.1111/j.1365-2990.2006.00795.x; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Lin AJ, 2014, NEUROPHOTONICS, V1, DOI 10.1117/1.NPh.1.1.011005; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Liu S, 2013, NEURAL REGEN RES, V8, P3334, DOI 10.3969/j.issn.1673-5374.2013.35.008; McAlpine FE, 2009, NEUROBIOL DIS, V34, P163, DOI 10.1016/j.nbd.2009.01.006; McGeer PL, 2015, EXPERT OPIN THER TAR, V19, P497, DOI 10.1517/14728222.2014.988707; Medeiros R, 2013, AM J PATHOL, V182, P1780, DOI 10.1016/j.ajpath.2013.01.051; Meirovithz E, 2007, BRAIN RES REV, V54, P294, DOI 10.1016/j.brainresrev.2007.04.004; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Nazem A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0291-y; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oh K. J., 2010, INT J ALZHEIMERS DIS, V2010, DOI [DOI 10.4061/2010/780102, 10.4061/2010/780102]; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Pickering M, 2007, PROG BRAIN RES, V163, P339, DOI 10.1016/S0079-6123(07)63020-9; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Rama Rao Kakulavarapu V, 2015, Clin Exp Neuroimmunol, V6, P245; Rishal I, 2013, DEV NEUROBIOL, V73, P247, DOI 10.1002/dneu.22061; Rockswold SB, 2013, J NEUROSURG, V118, P1317, DOI 10.3171/2013.2.JNS121468; Roher AE, 2012, VASC HEALTH RISK MAN, V8, P599, DOI 10.2147/VHRM.S34874; Sahni T, 2012, BRIT J NEUROSURG, V26, P202, DOI 10.3109/02688697.2011.626879; Schneider JA, 2003, NEUROLOGY, V60, P1082, DOI 10.1212/01.WNL.0000055863.87435.B2; Sheng JG, 2000, EXP NEUROL, V163, P388, DOI 10.1006/exnr.2000.7393; Shi JQ, 2011, BRAIN RES, V1368, P239, DOI 10.1016/j.brainres.2010.10.053; Simsek K., 2015, OXID ANTIOXID MED SC, V4, P17; Simsek K, 2012, SCI WORLD J, P1, DOI 10.1100/2012/849183; Spangenberg EE, 2016, BRAIN, V139, P1265, DOI 10.1093/brain/aww016; Sterniczuk R, 2010, BRAIN RES, V1348, P149, DOI 10.1016/j.brainres.2010.06.011; Tal S., 2015, RESTOR NEUROL NEUROS, V4, P4; Teo JD, 2015, PEDIATR RES, V77, P757, DOI 10.1038/pr.2015.47; TERRY RD, 1964, AM J PATHOL, V44, P269; Theriault P, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0125-2; Thom SR, 2011, PLAST RECONSTR SURG, V127, p131S, DOI 10.1097/PRS.0b013e3181fbe2bf; Thom SR, 2009, J APPL PHYSIOL, V106, P988, DOI 10.1152/japplphysiol.91004.2008; Thomas T, 2015, BRAIN, V138, P1059, DOI 10.1093/brain/awv025; Tian XQ, 2013, BEHAV BRAIN RES, V242, P1, DOI 10.1016/j.bbr.2012.12.026; Tian XQ, 2012, INT J NEUROSCI, V122, P563, DOI 10.3109/00207454.2012.690797; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tobinick Edward, 2006, MedGenMed, V8, P25; Tosun D, 2010, NEUROIMAGE, V52, P186, DOI 10.1016/j.neuroimage.2010.04.033; Tweedie D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-106; van Hulst RA, 2003, CLIN PHYSIOL FUNCT I, V23, P143; Villegas-Llerena C, 2016, CURR OPIN NEUROBIOL, V36, P74, DOI 10.1016/j.conb.2015.10.004; Wang H, 2016, J ALZHEIMERS DIS, V54, P275, DOI 10.3233/JAD-160263; Wang QW, 2005, EUR J NEUROSCI, V22, P2827, DOI 10.1111/j.1460-9568.2005.04457.x; WISNIEWSKI HM, 1989, CAN J NEUROL SCI, V16, P535, DOI 10.1017/S0317167100029887; Yamamoto M, 2007, AM J PATHOL, V170, P680, DOI 10.2353/ajpath.2007.060378; Yang LM, 2015, BRAIN RES, V1627, P21, DOI 10.1016/j.brainres.2015.08.011; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Yu YM, 2004, NEUROREPORT, V15, P2369, DOI 10.1097/00001756-200410250-00014; Zhang X, 2010, EXP NEUROL, V223, P299, DOI 10.1016/j.expneurol.2009.07.033	97	19	20	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	FEB	2018	62						105	119		10.1016/j.neurobiolaging.2017.10.007			15	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	FQ6MM	WOS:000418478600010	29141186				2021-06-18	
J	Chen, WQ; Yang, JH; Li, BB; Peng, GY; Li, TF; Li, LJ; Wang, SS				Chen, Weiqiang; Yang, Jinhua; Li, Bingbing; Peng, Guoyi; Li, Tianfei; Li, Lianjie; Wang, Shousen			Neutrophil to Lymphocyte Ratio as a Novel Predictor of Outcome in Patients With Severe Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Glasgow Coma Scale; Glasgow Outcome Scale; neutrophil to lymphocyte ratio; prognosis; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; CENTRAL-NERVOUS-SYSTEM; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; SURVEILLANCE; MORTALITY; COUNT	Objective: The neutrophil to lymphocyte ratio (NLR) has been reported to be a predictor of outcome in critical illness. Objective of this study was to investigate the changes of the NLR in patients with severe traumatic brain injury (TBI) and analyze the relationship between the NLR and TBI outcome. Setting: China. Participants: A total of 855 patients with severe TBI from January 2007 to April 2012. Design: Retrospective. Main Measurement: Data on the NLR and other indicators were collected. After follow-up until death or 1 year, the relationship between the NLR and TBI outcome was analyzed retrospectively. Results: The final analysis included 688 patients. There were 508 (73.8%) who had an unfavorable outcome by 1 year after head trauma. The value of the NLR on admission was significantly higher in the unfavorable outcome group than in the favorable outcome group (P < .001). Multivariate logistic analysis showed that higher NLR was associated with an unfavorable outcome (odds ratio, 1.100; P < .001). Receiver operating characteristic curve analysis showed that the NLR had a sensitivity of 60.2% and a specificity of 71.1% for predicting unfavorable outcome at 1 year on the basis of the best threshold. Conclusion: The NLR might be useful as a novel predictor for 1-year outcome and mortality in severe TBI.	[Chen, Weiqiang; Li, Bingbing; Li, Tianfei; Li, Lianjie; Wang, Shousen] Xiamen Univ, Coll Med, Dept Neurosurg, Fuzhou Gen Hosp, Fuzhou 350025, Fujian, Peoples R China; [Yang, Jinhua; Peng, Guoyi] Shantou Univ, Coll Med, Dept Neurosurg, Affiliated Hosp 1, Shantou, Guangdong, Peoples R China	Wang, SS (corresponding author), Xiamen Univ, Coll Med, Dept Neurosurg, Fuzhou Gen Hosp, Fuzhou 350025, Fujian, Peoples R China.	wshsen@xmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31170852, 31300761, 81001322, 81001340, 81172795, 81374040, 81471622]; Guangdong Natural Science FoundationNational Natural Science Foundation of Guangdong Province [S2012040007470]; Medical Scientific Research Foundation of Guangdong Province, China [A2015211]; Foundation for Distinguished Young Teachers in Higher Education of Guangdong [Yq2013077, Yq2013079]; Department of Education, Guangdong Government under the Top-tier University Development Scheme for Research and Control of Infectious Diseases [2015026]; Science and Technology Plan of Shantou [2014-62-2]	This study was supported by grants from the National Natural Science Foundation of China (31170852, 31300761, 81001322, 81001340, 81172795, 81374040, and 81471622), Guangdong Natural Science Foundation (S2012040007470), the Medical Scientific Research Foundation of Guangdong Province, China (A2015211), the Foundation for Distinguished Young Teachers in Higher Education of Guangdong (Yq2013077 and Yq2013079), the Department of Education, Guangdong Government under the Top-tier University Development Scheme for Research and Control of Infectious Diseases (2015026), and the Science and Technology Plan of Shantou (2014-62-2).	Akil E, 2014, J STROKE CEREBROVASC, V23, P2328, DOI 10.1016/j.jstrokecerebrovasdis.2014.04.028; Alexiou GA, 2013, J NEURO-ONCOL, V115, P521, DOI 10.1007/s11060-013-1240-1; Benarroch EE, 2013, NEUROLOGY, V81, P1079, DOI 10.1212/WNL.0b013e3182a4a577; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Celikbilek A, 2014, J CLIN LAB ANAL, V28, P27, DOI 10.1002/jcla.21639; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Lang EW, 2016, ACTA NEUROCHIR SUPPL, V122, P221, DOI 10.1007/978-3-319-22533-3_44; Lattanzi S, 2016, STROKE, V47, P1654, DOI 10.1161/STROKEAHA.116.013627; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morotti A, 2016, STROKE, V47, P1473, DOI 10.1161/STROKEAHA.116.013176; Osler T, 2016, INJURY, V47, P1879, DOI 10.1016/j.injury.2016.04.016; Ozdemir HH, 2017, INT J NEUROSCI, V127, P417, DOI 10.1080/00207454.2016.1187606; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sinha S, 2016, J CLIN NEUROSCI, V30, P31, DOI 10.1016/j.jocn.2015.10.051; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Wang KY, 2012, CLIN CHIM ACTA, V413, P1737, DOI 10.1016/j.cca.2012.07.002; Weller RO, 1996, BRAIN PATHOL, V6, P275, DOI 10.1111/j.1750-3639.1996.tb00855.x; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zadora P, 2015, NEUROL NEUROCHIR POL, V49, P41, DOI 10.1016/j.pjnns.2014.12.006	25	19	19	4	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2018	33	1					E53	E59		10.1097/HTR.0000000000000320			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GB0QS	WOS:000428752300007	28520670				2021-06-18	
J	Chibbaro, S; Cebula, H; Todeschi, J; Fricia, M; Vigouroux, D; Abid, H; Kourbanhoussen, H; Pop, R; Nannavecchia, B; Gubian, A; Prisco, L; Ligarotti, GKI; Proust, F; Ganau, M				Chibbaro, Salvatore; Cebula, Helene; Todeschi, Julien; Fricia, Marco; Vigouroux, Doris; Abid, Houssem; Kourbanhoussen, Houssen; Pop, Raoul; Nannavecchia, Beniamino; Gubian, Arthur; Prisco, Lara; Ligarotti, Gianfranco K. I.; Proust, Francois; Ganau, Mario			Evolution of Prophylaxis Protocols for Venous Thromboembolism in Neurosurgery: Results from a Prospective Comparative Study on Low-Molecular-Weight Heparin, Elastic Stockings, and Intermittent Pneumatic Compression Devices	WORLD NEUROSURGERY			English	Article						Deep venous thrombosis (DVT); Intermittent pneumatic compression (IPC) devices; Low-molecular-weight heparin (LMWH); Neurosurgery; Pulmonary embolism (PE)	TRAUMATIC BRAIN-INJURY; THROMBOSIS; HEMORRHAGE; COHORT; RISK	BACKGROUND: The incidence of venous thromboembolism (VT) in neurosurgical practice is astonishingly high, representing a major cause of morbidity and mortality. Prophylaxis strategies include elastic stockings, low-molecular-weight heparin (LMWH), and intermittent pneumatic compression (IPC) devices. OBJECTIVE: To assess the safety and efficacy of 2 different VT prophylaxis protocols implemented in a European neurosurgical center. METHODS: All patients admitted for neurosurgical intervention between 2012 and 2016 were stratified as low, moderate, and high risk of VT and received a combination of elastic stockings and LMWH. The protocol was modified in 2014 with the inclusion of perioperative IPC devices for all patients and only in the high-risk group also postoperatively. RESULTS: At time of post-hoc analysis, data obtained from patients included in this study before 2014 (Protocol A, 3169 patients) were compared with those obtained after the introduction of IPC (Protocol B, 3818 patients). Among patients assigned to protocol A, 73 (2.3%) developed deep-vein thrombosis (DVT) and 28 (0.9%) developed pulmonary embolism (PE), 9 of which were fatal (0.3%). Among patients assigned to protocol B, 32 developed DVT (0.8%) and 7 (0.18%) developed PE, with 2 eventually resulting in the death of the patient. A post-hoc analysis confirmed that the use of preoperative LMWH was not associated with a statistically significant greater risk of postoperative bleeding. CONCLUSIONS: This study, despite its limitations of the nonrandomized design, seems to suggest that perioperative IPC devices are a non-negligible support in the prophylaxis of clinically symptomatic DVT and PE.	[Chibbaro, Salvatore; Cebula, Helene; Todeschi, Julien; Fricia, Marco; Vigouroux, Doris; Abid, Houssem; Kourbanhoussen, Houssen; Pop, Raoul; Nannavecchia, Beniamino; Gubian, Arthur; Prisco, Lara; Ligarotti, Gianfranco K. I.; Proust, Francois; Ganau, Mario] Hop Hautepierre, Dept Neurosurg, Strasbourg, France	Todeschi, J (corresponding author), Hop Hautepierre, Dept Neurosurg, Strasbourg, France.	julien.tod@gmail.com	Chibbaro, Salvatore/AAI-6368-2020; Pop, Raoul/S-9431-2019; Prisco, Lara/I-9267-2019; Ganau, Mario/AAY-7233-2020; Prisco, Lara/X-9310-2018	Pop, Raoul/0000-0003-4417-1496; Prisco, Lara/0000-0001-6727-7870; Ganau, Mario/0000-0002-8676-1147; Gubian, Arthur/0000-0002-3236-8163			Algattas H, 2017, NEUROSURGERY; Alshehri N, 2016, J NEURO-ONCOL, V130, P561, DOI 10.1007/s11060-016-2259-x; Borde TD, 2017, NEUROL INDIA, V65, P787, DOI 10.4103/neuroindia.NI_1237_15; Byrne JP, 2016, J AM COLL SURGEONS, V223, P621, DOI 10.1016/j.jamcollsurg.2016.06.382; Dengler BA, 2016, NEUROCRIT CARE, V25, P215, DOI 10.1007/s12028-016-0280-8; Dickinson LD, 1998, NEUROSURGERY, V43, P1074, DOI 10.1097/00006123-199811000-00039; Gallus AS, 1994, PREVENTION VENOUS TH; Ganau M, 2017, J CLIN NEUROSCI; Ganau M, 2012, CASE REP SURG, V2012, DOI 10.1155/2012/614321; Haines ST, 2003, AM J HEALTH-SYST PH, V60, pS3, DOI 10.1093/ajhp/60.suppl_7.S3; Iorio A, 2000, ARCH INTERN MED, V160, P2327, DOI 10.1001/archinte.160.15.2327; Maimone Giuseppe, 2013, Surg Neurol Int, V4, P67, DOI 10.4103/2152-7806.112605; Prisco L, 2012, J NEUROSURG SCI, V56, P131; Raabe A, 2001, ACTA NEUROCHIR, V143, P1, DOI 10.1007/s007010170131; Roderick P, 2005, HEALTH TECHNOL ASSES, V9, P1; RUFF RL, 1983, ANN NEUROL, V13, P334, DOI 10.1002/ana.410130320; Scherer AG, 2017, J NEUROSURG-PEDIATR, V20, P71, DOI 10.3171/2017.3.PEDS16588; Syrmos N, 2013, CASE REP SURG, V2013, DOI 10.1155/2013/209750; VALLADARES JB, 1980, NEUROSURGERY, V6, P138, DOI 10.1227/00006123-198002000-00004	19	19	22	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2018	109						E510	E516		10.1016/j.wneu.2017.10.012			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FR4DD	WOS:000419015000063	29033376				2021-06-18	
J	Langan, J; Subryan, H; Nwogu, I; Cavuoto, L				Langan, Jeanne; Subryan, Heamchand; Nwogu, Ifeoma; Cavuoto, Lora			Reported use of technology in stroke rehabilitation by physical and occupational therapists	DISABILITY AND REHABILITATION-ASSISTIVE TECHNOLOGY			English	Article						Stroke; rehabilitation; technology; physical therapy; occupational therapy; home exercise program	RANDOMIZED-CONTROLLED-TRIAL; NINTENDO WII SPORTS(TM); TRAUMATIC BRAIN-INJURY; VIRTUAL-REALITY; INPATIENT REHABILITATION; OLDER-ADULTS; ARM FUNCTION; EXERCISE PROGRAMS; FEEDBACK; RECOVERY	Purpose: With the patient care experience being a healthcare priority, it is concerning that patients with stroke reported boredom and a desire for greater fostering of autonomy, when evaluating their rehabilitation experience. Technology has the potential to reduce these shortcomings by engaging patients through entertainment and objective feedback. Providing objective feedback has resulted in improved outcomes and may assist the patient in learning how to self-manage rehabilitation. Our goal was to examine the extent to which physical and occupational therapists use technology in clinical stroke rehabilitation home exercise programs. Materials and methods: Surveys were sent via mail, email and online postings to over 500 therapists, 107 responded. Results: Conventional equipment such as stopwatches are more frequently used compared to newer technology like Wii and Kinect games. Still, less than 25% of therapists' report using a stopwatch five or more times per week. Notably, feedback to patients is based upon objective data less than 50% of the time by most therapists. At the end of clinical rehabilitation, patients typically receive a written home exercise program and non-technological equipment, like theraband and/or theraputty to continue rehabilitation efforts independently. Conclusions: The use of technology is not pervasive in the continuum of stroke rehabilitation. IMPLICATIONS FOR REHABILITATION The patient care experience is a priority in healthcare, so when patients report feeling bored and desiring greater fostering of autonomy in stroke rehabilitation, it is troubling. Research examining the use of technology has shown positive results for improving motor performance and engaging patients through entertainment and use of objective feedback. Physical and occupational therapists do not widely use technology in stroke rehabilitation. Therapists should consider using technology in stroke rehabilitation to better meet the needs of the patient.	[Langan, Jeanne] SUNY Buffalo, Dept Rehabil Sci, 522 Kimball Tower,3435 Main St, Buffalo, NY 14260 USA; [Subryan, Heamchand] SUNY Buffalo, Sch Architecture, Buffalo, NY USA; [Nwogu, Ifeoma] SUNY Buffalo, Comp Sci & Engn, Buffalo, NY USA; [Cavuoto, Lora] SUNY Buffalo, Dept Ind & Syst Engn, Buffalo, NY USA; [Nwogu, Ifeoma] Rochester Inst Technol, Comp Sci, Rochester, NY 14623 USA	Langan, J (corresponding author), SUNY Buffalo, Dept Rehabil Sci, 522 Kimball Tower,3435 Main St, Buffalo, NY 14260 USA.	jlangan@buffalo.edu		Langan, Jeanne/0000-0003-1417-2180	University at Buffalo Center for Excellence in Home Health and Well-Being through Adaptive Smart Environments	Partial funding for this project was received from the University at Buffalo Center for Excellence in Home Health and Well-Being through Adaptive Smart Environments.	Adie K, 2014, INT J STROKE, V9, P9, DOI 10.1111/ijs.12374_13; Anderson Kelly R, 2015, Arch Phys Med Rehabil, V96, P973, DOI 10.1016/j.apmr.2014.09.008; Merchan-Baeza JA, 2015, JMIR RES PROTOC, V4, DOI 10.2196/resprot.4034; Barker RN, 2005, DISABIL REHABIL, V27, P1213, DOI 10.1080/09638280500075717; Birkenmeier RL, 2010, NEUROREHAB NEURAL RE, V24, P620, DOI 10.1177/1545968310361957; Bower KJ, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0057-x; Chen MH, 2015, CLIN REHABIL, V29, P674, DOI 10.1177/0269215514554115; Chiviacowsky S, 2007, RES Q EXERCISE SPORT, V78, P40, DOI 10.1080/02701367.2007.10599402; Colomer C, 2013, NEUROLOGIA, V28, P261, DOI 10.1016/j.nrl.2012.04.017; Conroy BE, 2009, TOP STROKE REHABIL, V16, P34, DOI 10.1310/tsr1601-34; Dobkin BH, 2010, NEUROREHAB NEURAL RE, V24, P235, DOI 10.1177/1545968309357558; Eskes GA, 2015, INT J STROKE, V10, P1130, DOI 10.1111/ijs.12557; Foley N, 2012, DISABIL REHABIL, V34, P2132, DOI 10.3109/09638288.2012.676145; Fulk GD, 2014, PHYS THER, V94, P222, DOI 10.2522/ptj.20120525; Gassaway J, 2005, ARCH PHYS MED REHAB, V86, pS16, DOI 10.1016/j.apmr.2005.08.114; Geraedts H, 2013, PATIENT EDUC COUNS, V91, P14, DOI 10.1016/j.pec.2012.10.018; Harris JE, 2009, STROKE, V40, P2123, DOI 10.1161/STROKEAHA.108.544585; Jette DU, 2009, PHYS THER, V89, P125, DOI 10.2522/ptj.20080234; Jurkiewicz MT, 2011, TOP STROKE REHABIL, V18, P277, DOI 10.1310/tsr1803-277; Klein M, 2014, J BIOMED INFORM, V51, P137, DOI 10.1016/j.jbi.2014.05.005; Langan J, 2013, J REHABIL MED, V45, P217, DOI 10.2340/16501977-1115; Lange BS, 2010, PHYS MED REH CLIN N, V21, P339, DOI 10.1016/j.pmr.2009.12.007; Lenze EJ, 2012, J AM MED DIR ASSOC, V13, P708, DOI 10.1016/j.jamda.2012.06.014; Levin MF, 2015, PHYS THER, V95, P415, DOI 10.2522/ptj.20130579; Lisi AJ, 2010, J REHABIL RES DEV, V47, P1, DOI 10.1682/JRRD.2009.07.0095; Liu KPY, 2014, ARCH PHYS MED REHAB, V95, P1262, DOI 10.1016/j.apmr.2014.03.018; Luker J, 2015, ARCH PHYS MED REHAB, V96, P1698, DOI 10.1016/j.apmr.2015.03.017; Mobini A, 2015, BIOMED ENG ONLINE, V14, DOI 10.1186/s12938-015-0070-0; Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180; Novak I, 2011, CLIN REHABIL, V25, P1066, DOI 10.1177/0269215511410727; Peel NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160906; Proffitt R, 2015, PHYS THER, V95, P441, DOI 10.2522/ptj.20130571; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Russell KL, 2010, REHABIL PSYCHOL, V55, P74, DOI 10.1037/a0018416; Ryan R., 2008, EUROPEAN HLTH PSYCHO, V20, P2, DOI DOI 10.1080/17509840701827437; Schaefer SY, 2013, NEUROREHAB NEURAL RE, V27, P602, DOI 10.1177/1545968313481279; Sigrist R, 2013, PSYCHON B REV, V20, P21, DOI 10.3758/s13423-012-0333-8; Snyder A, 2011, J AM MED DIR ASSOC, V12, P590, DOI 10.1016/j.jamda.2010.06.007; Stanton R, 2015, PHYSIOTHER RES INT, V20, P166, DOI 10.1002/pri.1612; Stone K, 2014, REHABIL NURS, V39, P76, DOI 10.1002/rnj.123; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; Talvitie U, 2000, Physiother Res Int, V5, P173, DOI 10.1002/pri.197; Thogersen-Ntoumani C, 2006, J SPORT SCI, V24, P393, DOI 10.1080/02640410500131670; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; van de Port IGL, 2006, STROKE, V37, P167, DOI 10.1161/01.STR.0000195180.69904.f2; Van Vliet PM, 2006, DISABIL REHABIL, V28, P831, DOI 10.1080/09638280500534937; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Wingham J, 2015, CLIN REHABIL, V29, P295, DOI 10.1177/0269215514542638; Wolf SL, 2010, STROKE, V41, P2309, DOI 10.1161/STROKEAHA.110.588723; Wuest S, 2014, GAMES HEALTH J, V3, P106, DOI 10.1089/g4h.2013.0093; Wutzke CJ, 2015, PHYS THER, V95, P1244, DOI 10.2522/ptj.20140482; Wutzke CJ, 2013, TOP STROKE REHABIL, V20, P233, DOI 10.1310/tsr2003-233	52	19	19	2	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1748-3107	1748-3115		DISABIL REHABIL-ASSI	Disabil. Rehabil.-Assist. Technol.		2018	13	7					641	647		10.1080/17483107.2017.1362043			7	Rehabilitation	Rehabilitation	GR6FJ	WOS:000442740900005	28812386				2021-06-18	
J	Leary, JB; Kim, GY; Bradley, CL; Hussain, UZ; Sacco, M; Bernad, M; Collins, J; Dsurney, J; Chan, L				Leary, Jacob B.; Kim, Grace Y.; Bradley, Catherine L.; Hussain, Uzma Z.; Sacco, Maryanne; Bernad, Martha; Collins, John; Dsurney, John; Chan, Leighton			The Association of Cognitive Reserve in Chronic-Phase Functional and Neuropsychological Outcomes Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive reserve; intelligence; neuropsychological tests; premorbid function; TBI severity; traumatic brain injury	MILD ALZHEIMERS-DISEASE; HEAD-INJURY; OLDER-ADULTS; IMPAIRMENT; EDUCATION; STYLE; RISK; RECOVERY; DEMENTIA; MODERATE	Objective: Examine the association of cognitive reserve (CR) factors (estimated premorbid intelligence quotient [IQ], years of education, and occupational attainment) and traumatic brain injury (TBI) severity with functional and neuropsychological outcomes 1 to 5 years following TBI. Participants: Patients with mild (N = 58), moderate (N = 25), or severe (N = 17) TBI. Main Measures: Cognitive reserve factors (estimated premorbid IQ, years of education, and occupational attainment); neuropsychological test battery; Glasgow Outcome Scale-Extended; Short Form-36 Health Survey. Analyses: Spearman-Brown correlations, linear regression models, and analyses of covariance were used to analyze the relation between CR factors and outcome measures. Results: Analyses revealed significant relations between estimated premorbid IQ and neuropsychological outcomes (P < .004): California Verbal Learning Test, Wechsler Adult Intelligence Scale-Fourth Edition working memory, Booklet Category Test, Trail Making Test B, and Grooved Pegboard Test. There was also a significant correlation between estimated premorbid IQ and Wechsler Adult Intelligence Scale-Fourth Edition processing speed. Years of education had significant relations with California Verbal Learning Test and Wechsler Adult Intelligence Scale-Fourth Edition working memory and processing speed scores. There were significant differences between TBI severity groups and performance on the TrailMaking Test A, Grooved Pegboard Test, and Finger Tapping Test. Conclusions: Cognitive reserve factors may be associated with outcomes following TBI. Additional alternatives to TBI severity are needed to help guide rehabilitative planning postinjury.	[Leary, Jacob B.; Kim, Grace Y.; Bradley, Catherine L.; Hussain, Uzma Z.; Sacco, Maryanne; Bernad, Martha; Chan, Leighton] NIH, Dept Rehabil Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA; [Collins, John] George Mason Univ, Dept Rehabil Sci, Coll Hlth & Human Serv, Fairfax, VA 22030 USA; [Dsurney, John; Chan, Leighton] NIH, Ctr Neurosci & Regenerat Med, Bldg 10, Bethesda, MD 20892 USA	Dsurney, J (corresponding author), NIH, Dept Rehabil Med, 10 Ctr Dr,Room 1-1469 MSC1604, Bethesda, MD 20892 USA.	john.dsurney@nih.gov		Collins, John/0000-0002-3863-0329	Department of Defense (Center for Neuroscience and Regenerative Medicine)United States Department of Defense; National Institutes of Health Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; CLINICAL CENTER [ZIACL060065, ZIACL060079] Funding Source: NIH RePORTER	This work was supported by the Department of Defense (Center for Neuroscience and Regenerative Medicine) and the National Institutes of Health Intramural Research Program.	Beck AT., 1996, BECK DEPRESSION INVE, V2; Bennett DA, 2003, NEUROLOGY, V60, P1909, DOI 10.1212/01.WNL.0000069923.64550.9F; Bigler Erin D, 2015, Handb Clin Neurol, V128, P691, DOI 10.1016/B978-0-444-63521-1.00043-1; Bosch B, 2010, CORTEX, V46, P451, DOI 10.1016/j.cortex.2009.05.006; Duda B, 2014, J CLIN EXP NEUROPSYC, V36, P368, DOI 10.1080/13803395.2014.892916; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Hindle JV, 2016, INT J GERIATR PSYCH, V31, P13, DOI 10.1002/gps.4284; Hudak AM, 2012, J HEAD TRAUMA REHAB, V27, P87, DOI 10.1097/HTR.0b013e3182114efd; Kemppainen NM, 2008, ANN NEUROL, V63, P112, DOI 10.1002/ana.21212; Lopez KC, 2016, J NEUROTRAUM, V33, P1; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Rassovsky Y, 2015, J CLIN EXP NEUROPSYC, V37, P354, DOI 10.1080/13803395.2015.1015498; Salmond CH, 2006, J NEUROTRAUM, V23, P1049, DOI 10.1089/neu.2006.23.1049; Sandry J, 2015, J NEUROL, V12, P2562; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Sela-Kaufman M, 2013, J CLIN EXP NEUROPSYC, V35, P584, DOI 10.1080/13803395.2013.799123; Spitz G, 2013, J HEAD TRAUMA REHAB, V28, P116, DOI 10.1097/HTR.0b013e3182452f4f; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Sumowski JF, 2016, EUR J NEUROL, V23, P39, DOI 10.1111/ene.12662; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Valenzuela MJ, 2006, PSYCHOL MED, V36, P441, DOI 10.1017/S0033291705006264; Verghese J, 2009, J GERIATR PSYCH NEUR, V22, P110, DOI 10.1177/0891988709332938; Wechsler D, 1944, MEASUREMENT ADULT IN, P3	27	19	19	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2018	33	1					E28	E35		10.1097/HTR.0000000000000329			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GB0QS	WOS:000428752300004	28731870	Green Accepted			2021-06-18	
J	Pearce, AJ; Rist, B; Fraser, CL; Cohen, A; Maller, JJ				Pearce, Alan J.; Rist, Billymo; Fraser, Clare L.; Cohen, Adrian; Maller, Jerome J.			Neurophysiological and cognitive impairment following repeated sports concussion injuries in retired professional rugby league players	BRAIN INJURY			English	Article						Sport; concussion; mild traumatic brain injury; transcranial magnetic stimulation; motor cortex inhibition; motor execution slowness; rugby league	TRANSCRANIAL MAGNETIC STIMULATION; MOTOR EVOKED-POTENTIALS; INTERVAL INTRACORTICAL INHIBITION; SILENT PERIOD; FOOTBALL PLAYERS; LONG-TERM; ELECTROPHYSIOLOGICAL CHANGES; PSYCHIATRIC-DISORDERS; CORTEX EXCITABILITY; 1ST EXPOSURE	Background: Concussion is regarded as a common injury in rugby league, however no studies have explored the long-term neurophysiological and cognitive effects of repeated concussion injuries in this sport.Methods: Former professional rugby athletes (n=25) were compared to 25 age-matched participants with no history of a concussion. All participants completed standardised motor dexterity, reaction time, and cognitive tasks for working memory, associative learning and rule acquisition and reversal. Single-pulse transcranial magnetic stimulation (TMS) acquired motor evoked potentials and cortical silent period (cSP), as well as paired-pulse TMS for short latency intracortical inhibition and long intracortical inhibition (LICI).Results: Compared to controls, dexterity and visuomotor reaction time was slower in the rugby group compared to controls (p=0.02, p<0.01, respectively). The rugby group also demonstrated poorer cognitive performance than controls (p range 0.02 to < 0.01). TMS revealed significantly reduced cSP at suprathreshold stimulation intensities (p range 0.02 to <0.01), and increased LICI (p=0.03) in the rugby group.Discussion: These findings of motor and cognitive changes, along with neurophysiological alterations, particularly with intracortical inhibition, nearly two decades post-concussion provides evidence for long-term sequelae for athletes with a history of repeated head trauma in contact sports.	[Pearce, Alan J.; Rist, Billymo] La Trobe Univ, Dept Rehabil Nutr & Sport, Melbourne, Vic, Australia; [Rist, Billymo] Mental Edge Consulting, Melbourne, Vic, Australia; [Fraser, Clare L.] Univ Sydney, Save Sight Inst, Dept Ophthalmol, Sydney, NSW, Australia; [Cohen, Adrian] Univ Sydney, Cent Clin Sch, Discipline Clin Ophthalmol & Eye Hlth, Sydney, NSW, Australia; [Maller, Jerome J.] The Alfred, Monash Alfred Psychiat Res Ctr, Melbourne, Vic, Australia; [Maller, Jerome J.] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia; [Maller, Jerome J.] Gen Elect Healthcare, Melbourne, Vic, Australia	Pearce, AJ (corresponding author), La Trobe Univ, Dept Rehabil Exercise & Sport, Melbourne, Vic, Australia.	alan.pearce@latrobe.edu.au	Pearce, Alan J/W-1195-2018	Pearce, Alan J/0000-0002-9264-9880; Fraser, Clare/0000-0002-0379-7743	Smart Head Play Charity; Impact Technologies; Australian Football League and Samsung Corporation; NHMRCNational Health and Medical Research Council of Australia	This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. AJP is funded, in part, by a grant from Smart Head Play Charity, and Impact Technologies; and has been previously supported by funding from the Australian Football League and Samsung Corporation. AJP has also received equipment support for research from MagVenture and AD Instruments. AC is a director of Necksafe Ltd Charity. JJM has previously been funded by a NHMRC fellowship. Other authors declare no sources of research funding.	AFL Medical Officers Association, 2011, MAN CONC AUSTR FOOTB; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Benwell NM, 2007, EXP BRAIN RES, V179, P255, DOI 10.1007/s00221-006-0790-2; Berger MAM, 2009, APPL ERGON, V40, P145, DOI 10.1016/j.apergo.2008.01.014; Blok J., 1999, EUROPEAN RECOMMENDAT; BRYDEN MP, 1977, NEUROPSYCHOLOGIA, V15, P617, DOI 10.1016/0028-3932(77)90067-7; Bunse T, 2014, BRAIN STIMUL, V7, P158, DOI 10.1016/j.brs.2013.08.009; CANTELLO R, 1992, NEUROLOGY, V42, P1951; Chen R, 1999, EXP BRAIN RES, V128, P539, DOI 10.1007/s002210050878; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; CORLETT EN, 1971, OCCUP PSYCHOL, V45, P57; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Di Virgilio TG, 2016, EBIOMEDICINE, V13, P66, DOI 10.1016/j.ebiom.2016.10.029; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Gardner AJ, 2017, INT J SPORTS MED, V38, P241, DOI 10.1055/s-0042-120843; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; GHEZZI A, 1991, ACTA NEUROL SCAND, V84, P503, DOI 10.1111/j.1600-0404.1991.tb05003.x; GLOSS DS, 1981, PERCEPT MOTOR SKILL, V53, P659, DOI 10.2466/pms.1981.53.2.659; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; Hammond G, 2007, BRAIN RES, V1158, P63, DOI 10.1016/j.brainres.2007.05.014; Haraldsson HM, 2004, SCHIZOPHR RES, V71, P1, DOI 10.1016/j.schres.2003.10.006; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; Hoskins W, 2006, J SCI MED SPORT, V9, P46, DOI 10.1016/j.jsams.2006.03.013; Hume PA, 2017, SPORTS MED, V47, P1209, DOI 10.1007/s40279-016-0608-8; Jordan BD, 2000, NEUROLOGY, V54, pA410; Keller CJ, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0528; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kidgell DJ, 2010, HUM MOVEMENT SCI, V29, P631, DOI 10.1016/j.humov.2010.01.004; Kim DH, 2007, SPINE, V32, P3041, DOI 10.1097/BRS.0b013e31815d0072; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Koerte IK, 2016, BRAIN IMAGING BEHAV, V10, P792, DOI 10.1007/s11682-015-9442-0; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lieberman JA, 2006, ANESTH ANALG, V103, P316, DOI 10.1213/01.ane.0000226142.15746.b2; Livingston SC, 2010, J CLIN MONIT COMPUT, V24, P427, DOI 10.1007/s10877-010-9267-8; Major BP, 2015, CLIN EXP PHARMACOL P, V42, P394, DOI 10.1111/1440-1681.12363; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McGinley M, 2010, EXP GERONTOL, V45, P671, DOI 10.1016/j.exger.2010.04.005; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McMillan TM, 2017, J NEUROL NEUROSUR PS, V88, P505, DOI 10.1136/jnnp-2016-314279; Mills KR, 1999, MAGNETIC STIMULATION; Modugno N, 2001, CLIN NEUROPHYSIOL, V112, P1470, DOI 10.1016/S1388-2457(01)00599-5; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; Nardone Raffaele, 2013, Handb Clin Neurol, V116, P599, DOI 10.1016/B978-0-444-53497-2.00048-6; Nollet H, 2004, EQUINE VET J, V36, P51, DOI 10.2746/0425164044864660; Oliviero A, 2006, NEUROSCI RES, V55, P74, DOI 10.1016/j.neures.2006.02.002; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Pearce AJ, 2000, EXP BRAIN RES, V130, P238, DOI 10.1007/s002219900236; Pearce AJ, 2016, EBIOMEDICINE, V13, P3, DOI 10.1016/j.ebiom.2016.10.043; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Pearce AJ, 2013, BRAIN STIMUL, V6, P306, DOI 10.1016/j.brs.2012.05.010; Pearce AJ, 2010, J SCI MED SPORT, V13, P167, DOI 10.1016/j.jsams.2008.12.632; Pearce AJ, 2009, J SCI MED SPORT, V12, P280, DOI 10.1016/j.jsams.2007.12.005; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Radhu N, 2013, CLIN NEUROPHYSIOL, V124, P1309, DOI 10.1016/j.clinph.2013.01.014; Rijckaert J, 2016, VET J, V216, P178, DOI 10.1016/j.tvjl.2016.08.006; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Roberts SP, 2017, AM J SPORT MED, V45, P480, DOI 10.1177/0363546516668296; Rossini P M, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P171; Sale MV, 2005, J APPL PHYSIOL, V99, P1483, DOI 10.1152/japplphysiol.00371.2005; Sandberg MA, 2011, ENCY CLIN NEUROPSYCH, P480; Sandbrink F., 2008, OXFORD HDB TRANSCRAN, P237, DOI DOI 10.1093/OXFORDHB/9780198568926.001.0001; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Ward A A Jr, 1964, Clin Neurosurg, V12, P95; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1; WILSON SA, 1993, NEUROSCI LETT, V154, P52, DOI 10.1016/0304-3940(93)90169-L; WILSON SA, 1993, J NEUROL SCI, V114, P216, DOI 10.1016/0022-510X(93)90301-E; Yancosek KE, 2009, J HAND THER, V22, P258, DOI 10.1016/j.jht.2008.11.004; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306; Ziemann U., 2008, OXFORD HDB TRANSCRAN, P91; Ziemann Ulf, 2013, Handb Clin Neurol, V116, P387, DOI 10.1016/B978-0-444-53497-2.00032-2	81	19	19	2	18	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	4					498	505		10.1080/02699052.2018.1430376			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FV9WZ	WOS:000424942400014	29388850				2021-06-18	
J	Starkey, NJ; Jones, K; Case, R; Theadom, A; Barker-Collo, S; Feigin, V				Starkey, Nicola J.; Jones, Kelly; Case, Rosalind; Theadom, Alice; Barker-Collo, Suzanne; Feigin, Valery			Post-concussive symptoms after a mild traumatic brain injury during childhood and adolescence	BRAIN INJURY			English	Article						Adolescence; behaviour; child; concussion; longitudinal; mild TBI; symptoms	HEAD-INJURY; POSTCONCUSSION SYNDROME; CHILDREN; POPULATION; OUTCOMES; QUESTIONNAIRE; RELIABILITY; PREDICTORS; ADULTS; SCALE	Objective: Mild traumatic brain injury (mTBI) is common injury during childhood and adolescence but the long-term outcomes are poorly understood. This study examined post-concussive symptoms and behavioural outcomes in children and adolescents up to 24months post-mTBI.Method: Parents of children aged 8-15years with mTBI completed the BASC-2 and Rivermead Post-Concussion Symptoms Questionnaire at baseline, 1-, 6-, 12- and 24months post-injury. An age-matched traumatic brain injury-free cohort was recruited and assessed at 12- and 24months.Results: PCSs decreased significantly over the first 12months post-injury. At 12- and 24months post-injury, the mTBI group reported more PCSs and behavioural symptoms compared to controls. Parents of children with mTBI were more likely to report 4 problematic PCS symptoms (28% at both time points) compared to controls (7.7% and 1.7% at 12 and 24months, respectively). The mTBI group was 4.63 times more likely to have four or more ongoing PCS symptoms at 12months post-injury compared to controls. Headache was the most common acute post-injury symptom (55%), while the most commonly reported persistent symptoms were irritability, frustration, forgetfulness and fatigue.Conclusions: PCSs are common 2years post-mTBI in childhood or adolescence. Given this, additional intervention and support is needed for families post-injury.	[Starkey, Nicola J.] Univ Waikato, Sch Psychol, Private Bag 3105, Hamilton 3204, New Zealand; [Jones, Kelly; Theadom, Alice; Feigin, Valery] AUT Univ, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Case, Rosalind] Cairn Miller Inst, Sch Psychol Counselling & Psychotherapy, Melbourne, Vic, Australia; [Barker-Collo, Suzanne] Univ Auckland, Sch Psychol, Auckland, New Zealand	Starkey, NJ (corresponding author), Univ Waikato, Sch Psychol, Private Bag 3105, Hamilton 3204, New Zealand.	nstarkey@waikato.ac.nz	Starkey, Nicola/AAJ-3795-2020; Feigin, Valery/AAF-2313-2019; Jones, Kelly/I-5199-2019	Starkey, Nicola/0000-0002-4370-8186; Feigin, Valery L./0000-0002-6372-1740; Case, Rosalind/0000-0003-3182-9930	Heath Research Council of New Zealand [09/063A, 11/192]; Lottery Health Grants Board of New Zealand	The study was funded by the Heath Research Council of New Zealand: [Grant Number 09/063A, 11/192] and the Lottery Health Grants Board of New Zealand.	Albicini M, 2015, J CLIN EXP NEUROPSYC, V37, P776, DOI 10.1080/13803395.2015.1053843; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barlow KM, 2015, PEDIATR NEUROL, V53, P491, DOI 10.1016/j.pediatrneurol.2015.04.011; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Beauchamp MH, 2017, J NEUROTRAUM, V34, P2545, DOI 10.1089/neu.2016.4868; Bergman DA, 1999, PEDIATRICS, V104, P1407; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Catroppa C, 2015, J NEUROTRAUM, V32, P109, DOI 10.1089/neu.2013.3276; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Field A., 2013, DISCOVERING STAT USI, V4; Garcia D, 2015, J PEDIATR PSYCHOL, V40, P391, DOI 10.1093/jpepsy/jsu093; Grubenhoff JA, 2011, BRAIN INJURY, V25, P943, DOI 10.3109/02699052.2011.597043; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lloyd J, 2015, BRAIN INJURY, V29, P539, DOI 10.3109/02699052.2014.1002003; Mathias JL, 2013, BRAIN INJURY, V27, P887, DOI 10.3109/02699052.2013.793398; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; McKinlay A, 2018, J CLIN EXP NEUROPSYC, V40, P285, DOI 10.1080/13803395.2017.1342771; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moran LM, 2011, J HEAD TRAUMA REHAB, V26, P348, DOI 10.1097/HTR.0b013e3181f8d32e; Novak Z, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.2900; Olsson K, 2014, BRAIN IMPAIR, V15, P177, DOI 10.1017/BrImp.2014.22; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Peterson RL, 2013, J HEAD TRAUMA REHAB, V28, pE1, DOI 10.1097/HTR.0b013e318263f5ba; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Reynolds C.R., 2004, BEHAV ASSESSMENT SYS; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Stevens Penelope K, 2010, J Trauma Nurs, V17, P178, DOI 10.1097/JTN.0b013e3181ff2789; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TEASDALE G, 1974, LANCET, V2, P81; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	44	19	19	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	5					617	626		10.1080/02699052.2018.1439533			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FY7WL	WOS:000427074200013	29446658				2021-06-18	
J	Yuan, WH; Foss, KDB; Thomas, S; DiCesare, CA; Dudley, JA; Kitchen, K; Gadd, B; Leach, JL; Smith, D; Altaye, M; Gubanich, P; Galloway, RT; McCrory, P; Bailes, JE; Mannix, R; Meehan, WP; Myer, GD				Yuan, Weihong; Foss, Kim D. Barber; Thomas, Staci; DiCesare, Christopher A.; Dudley, Jonathan A.; Kitchen, Katie; Gadd, Brooke; Leach, James L.; Smith, David; Altaye, Mekibib; Gubanich, Paul; Galloway, Ryan T.; McCrory, Paul; Bailes, Julian E.; Mannix, Rebekah; Meehan, William P., III; Myer, Gregory D.			White matter alterations over the course of two consecutive high-school football seasons and the effect of a jugular compression collar: A preliminary longitudinal diffusion tensor imaging study	HUMAN BRAIN MAPPING			English	Article						white matter alteration; subconcussive head impact; neck collar	TRAUMATIC BRAIN-INJURY; HEAD IMPACT EXPOSURE; SPORTS-RELATED CONCUSSION; CORPUS-CALLOSUM; YOUTH FOOTBALL; AXONAL INJURY; ADOLESCENCE; MICROSTRUCTURE; MODEL; CHILDHOOD	The cumulative effects of repetitive subclinical head impacts during sports may result in chronic white matter (WM) changes and possibly, neurodegenerative sequelae. In this pilot study, we investigated the longitudinal WM changes over the course of two consecutive high-school football seasons and explored the long-term effects of a jugular vein compression collar on these WM alterations. Diffusion tensor imaging data were prospectively collected both pre- and postseason in the two consecutive seasons. Participants were assigned into either collar or noncollar groups. Tract-based spatial statistics (TBSS) approach and region of interest-based approach were used to quantify changes in WM diffusion properties. Despite comparable exposure to repetitive head impacts, significant reductions in mean, axial, and/or radial diffusivity were identified in Season 1 in multiple WM regions in the noncollar group but not in the collar group. After an 8- to 9-month long off-season, these changes observed in the noncollar group partially and significantly reversed but also remained significantly different from the baseline. In Season 2, trend level WM alterations in the noncollar group were found but located in spatially different regions than Season 1. Last, the WM integrity in the collar group remained unchanged throughout the four time points. In conclusion, we quantitatively assessed the WM structural changes and partial reversal over the course of two consecutive high-school football seasons. In addition, the mitigated WM alterations in athletes in the collar group might indicate potential effect of the collar in ameliorating the changes against repetitive head impacts. Hum Brain Mapp 39:491-508, 2018. (c) 2017 Wiley Periodicals, Inc.	[Yuan, Weihong; Dudley, Jonathan A.] Cincinnati Childrens Hosp Med Ctr, Pediat Neuroimaging Res Consortium, Cincinnati, OH 45229 USA; [Yuan, Weihong; Dudley, Jonathan A.; Leach, James L.] Cincinnati Childrens Hosp Med Ctr, Div Radiol, Cincinnati, OH 45229 USA; [Yuan, Weihong; Leach, James L.] Univ Cincinnati, Coll Med, Dept Radiol, Cincinnati, OH USA; [Foss, Kim D. Barber; Thomas, Staci; DiCesare, Christopher A.; Kitchen, Katie; Gadd, Brooke; Smith, David; Gubanich, Paul; Galloway, Ryan T.; Myer, Gregory D.] Cincinnati Childrens Hosp Med Ctr, SPORT Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Altaye, Mekibib] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Bailes, Julian E.] NorthShore Univ Hlth Syst, Dept Neurosurg, Evanston, IL USA; [Mannix, Rebekah; Meehan, William P., III; Myer, Gregory D.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Myer, Gregory D.] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA; [Myer, Gregory D.] Univ Cincinnati, Dept Orthopaed Surg, Cincinnati, OH USA; [Myer, Gregory D.] Univ Penn, Dept Orthopaed, Philadelphia, PA 19104 USA	Myer, GD (corresponding author), Cincinnati Childrens Hosp, 3333 Burnet Ave,MLC 10001, Cincinnati, OH 45229 USA.	greg.myer@cchmc.org	DiCesare, Christopher/AAA-3327-2021; McCrory, Paul/Q-8688-2019; DiCesare, Christopher/ABH-9573-2020; Mannix, Rebekah/AAD-8702-2020; Myer, Gregory/H-6572-2016	DiCesare, Christopher/0000-0002-6576-4904; Myer, Gregory/0000-0002-9983-8422; McCrory, Paul/0000-0003-4850-0568; Dudley, Jonathan/0000-0002-5189-9568	Heidt Family Foundation; Robert S. Heidt, Sr. - Wellington Foundation; Q30 Sports Sciences, LLC.	Contract grant sponsors: The Heidt Family Foundation, Robert S. Heidt, Sr. - Wellington Foundation and Q30 Sports Sciences, LLC.	Allison MA, 2015, ANN BIOMED ENG, V43, P1896, DOI 10.1007/s10439-014-1197-z; Alosco ML, 2016, ALZHEIMERS DEMENT, V7, P33; Asato MR, 2010, CEREB CORTEX, V20, P2122, DOI 10.1093/cercor/bhp282; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Budde MD, 2008, NMR BIOMED, V21, P589, DOI 10.1002/nbm.1229; Campbell KR, 2016, ANN BIOMED ENG, V44, P1246, DOI 10.1007/s10439-015-1391-7; Cortes N, 2017, AM J SPORT MED, V45, P2379, DOI 10.1177/0363546517706703; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Di X, 2012, BRAIN CONNECT, V2, P225, DOI 10.1089/brain.2011.0050; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Freund W, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-170; GILLAND O, 1969, AMER J ROENTGENOL RA, V106, P369, DOI 10.2214/ajr.106.2.369; Hanggi J, 2010, HUM BRAIN MAPP, V31, P1196, DOI 10.1002/hbm.20928; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hwang S, 2017, J NEUROTRAUM, V34, P8, DOI 10.1089/neu.2015.4238; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Lao Y, 2015, P SPIE INT SOC OPT E, V9287; Leach JL, 2013, AM SOC NEUR 51 ANN M; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Merchant-Borna K, 2016, ANN BIOMED ENG, V44, P3679, DOI 10.1007/s10439-016-1680-9; Moiseyev N.N., 1968, DYNAMIC STABILITY BO; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Myer GD, 2016, BRIT J SPORT MED, V50, P1276, DOI 10.1136/bjsports-2016-096134; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Rodrigues AC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00038; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Schneider DK, 2016, BRIT J SPORT MED, DOI [10.1136/bjsports-2015-095645<original-structure ref=info:doi/10.1136/bjsports-2015-095645></original-structure>, DOI 10.1136/BJSP0RTS-2015-095645]; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Steinberg L, 2005, TRENDS COGN SCI, V9, P69, DOI 10.1016/j.tics.2004.12.005; Szeszko PR, 2003, NEUROREPORT, V14, P2469, DOI 10.1097/00001756-200312190-00035; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Yuan W, 2017, J NEUROTRAUMA; Yuan W, 2008, J NEUROSURG-PEDIATR, V1, P263, DOI 10.3171/PED/2008/1/4/263; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	58	19	20	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JAN	2018	39	1					491	508		10.1002/hbm.23859			18	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	FP0IF	WOS:000417282000033	29080230	Green Published, Bronze			2021-06-18	
J	Habiyaremye, G; Morales, DM; Morgan, CD; McAllister, JP; CreveCoeur, TS; Han, RH; Gabir, M; Baksh, B; Mercer, D; Limbrick, DD				Habiyaremye, Gakwaya; Morales, Diego M.; Morgan, Clinton D.; McAllister, James P.; CreveCoeur, Travis S.; Han, Rowland H.; Gabir, Mohamed; Baksh, Brandon; Mercer, Deanna; Limbrick, David D., Jr.			Chemokine and cytokine levels in the lumbar cerebrospinal fluid of preterm infants with post-hemorrhagic hydrocephalus	FLUIDS AND BARRIERS OF THE CNS			English	Article						Cytokines; Chemokines; Post-hemorrhagic; Hydrocephalus; CSF; Cerebrospinal fluid; Preterm; Prematurity	NECROSIS-FACTOR-ALPHA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; PREMATURE-INFANTS; IN-VITRO; TRANSFORMING GROWTH-FACTOR-BETA-1; LYMPHOID CHEMOKINES; EXPRESSION; BLOOD	Background: Neuroinflammation has been implicated in the pathophysiology of post-hemorrhagic hydrocephalus (PHH) of prematurity, but no comprehensive analysis of signaling molecules has been performed using human cerebrospinal fluid (CSF). Methods: Lumbar CSF levels of key cytokines (IL-1 alpha, IL-1 beta, IL-4, IL-6, IL-8, IL-10, IL-12, TNF-alpha, TGF-beta 1, IFN-gamma) and chemokines (XCL-1, CCL-2, CCL-3, CCL-19, CXCL-10, CXCL-11, CXCL-12) were measured using conventional and multiplexed Enzyme-linked Immunosorbent Assays and compared between preterm infants with PHH and those with no known neurological injury. The relationships between individual biomarker levels and specific CSF cell counts were examined. Results: Total protein (TP) CSF levels were elevated in the PHH subjects compared to controls. CSF levels of IL-1 alpha, IL-4, IL-6, IL-12, TNF-alpha, CCL-3, CCL-19, and CXCL-10 were significantly increased in PHH whereas XCL-1 was significantly decreased in PHH. When normalizing by TP, IL-1 alpha, IL-1 beta, IL-10, IL-12, CCL-3, and CCL-19 levels were significantly elevated compared to controls, while XCL-1 levels remained significantly decreased. Among those with significantly different levels in both absolute and normalized levels, only absolute CCL-19 levels showed a significant correlation with CSF nucleated cells, neutrophils, and lymphocytes. IL-1 beta and CXCL-10 also were correlated with total cell count, nucleated cells, red blood cells, and neutrophils. Conclusions: Neuroinflammation is likely to be an important process in the pathophysiology of PHH. To our knowledge, this is the first study to investigate CSF levels of chemokines in PHH as well as the only one to show XCL-1 selectively decreased in a diseased state. Additionally, CCL-19 was the only analyte studied that showed significant differences between groups and had significant correlation with cell count analysis. The selectivity of CCL-19 and XCL-1 should be further investigated. Future studies will further delineate the role of these cytokines and chemokines in PHH.	[Habiyaremye, Gakwaya; Morales, Diego M.; McAllister, James P.; CreveCoeur, Travis S.; Han, Rowland H.; Gabir, Mohamed; Baksh, Brandon; Mercer, Deanna] Washington Univ St Louis, Sch Med, Dept Neurol Surg, 1 Childrens Way,4S20, St Louis, MO 63110 USA; [Morgan, Clinton D.] Barrow Neurol Inst, 350 West Thomas Rd, Phoenix, AZ 85013 USA; [Limbrick, David D., Jr.] Washington Univ St Louis, Sch Med, Dept Neurol Surg & Pediat, 1 Childrens Way,4S20, St Louis, MO 63110 USA	Morales, DM (corresponding author), Washington Univ St Louis, Sch Med, Dept Neurol Surg, 1 Childrens Way,4S20, St Louis, MO 63110 USA.	d.morales@wustl.edu	Han, Rowland/J-5210-2019; McAllister, James P./N-9657-2019	Han, Rowland/0000-0002-8615-8532; Morgan, Clinton/0000-0002-7511-0488	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS075151]; ICTS [UL1 TR000448]; CTSAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 RR024992, TL1 TR000449]; Children's Surgical Sciences Institute, St. Louis Children's Hospital; Hydrocephalus Association Innovator Award; Washington University Hope Center for Neurological Disorders; Rudi Schulte Research Institute; STARS-kids; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002345, TL1TR000449, UL1TR000448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T34GM083914] Funding Source: NIH RePORTER	This project was supported by NIH/NINDS K23 NS075151, ICTS UL1 TR000448, CTSA UL1 RR024992, TL1 TR000449, and a grant from the Children's Surgical Sciences Institute, St. Louis Children's Hospital (D.L.). JPM received support from a Hydrocephalus Association Innovator Award, a Seed Grant from the Washington University Hope Center for Neurological Disorders, the Rudi Schulte Research Institute, and STARS-kids.	Alt C, 2002, EUR J IMMUNOL, V32, P2133, DOI 10.1002/1521-4141(200208)32:8<2133::AID-IMMU2133>3.0.CO;2-W; Ambrosini E, 2005, J NEUROPATH EXP NEUR, V64, P706, DOI 10.1097/01.jnen.0000173893.01929.fc; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Baumeister FAM, 2000, INFECTION, V28, P234, DOI 10.1007/s150100070043; Botfield H, 2013, BRAIN, V136, P2842, DOI 10.1093/brain/awt203; BREDER CD, 1993, J COMP NEUROL, V337, P543, DOI 10.1002/cne.903370403; CHAZAL J, 1985, ANAT CLIN, V7, P61, DOI 10.1007/BF01654631; Cherian S, 2004, BRAIN PATHOL, V14, P305; Chow LC, 2005, BIOL NEONATE, V88, P1, DOI 10.1159/000083945; Chui R, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-1; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Di Paolo NC, 2016, NAT IMMUNOL, V17, P906, DOI 10.1038/ni.3503; Dorner BG, 2009, IMMUNITY, V31, P823, DOI 10.1016/j.immuni.2009.08.027; Eder C, 2009, IMMUNOBIOLOGY, V214, P543, DOI 10.1016/j.imbio.2008.11.007; Gahring LC, 1996, NEUROIMMUNOMODULAT, V3, P289, DOI 10.1159/000097283; GOMEZ DG, 1981, ACTA ANAT, V111, P247; HAYASHI M, 1995, J NEUROIMMUNOL, V60, P143, DOI 10.1016/0165-5728(95)00064-9; Heep A, 2004, PEDIATR RES, V56, P768, DOI 10.1203/01.PDR.0000141524.32142.53; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Karman J, 2006, J IMMUNOL, V177, P7750, DOI 10.4049/jimmunol.177.11.7750; Kivisakk P, 2004, ANN NEUROL, V55, P627, DOI 10.1002/ana.20049; Klein RS, 2004, J CELL BIOCHEM, V92, P213, DOI 10.1002/jcb.20052; Krumbholz M, 2007, J NEUROIMMUNOL, V190, P72, DOI 10.1016/j.jneuroim.2007.07.024; Lalor SJ, 2010, J NEUROIMMUNOL, V224, P56, DOI 10.1016/j.jneuroim.2010.05.017; Lei Y, 2012, MICROBES INFECT, V14, P262, DOI 10.1016/j.micinf.2011.10.003; Lekic T, 2012, EXP NEUROL, V236, P69, DOI 10.1016/j.expneurol.2012.04.003; Merhar S, 2012, NEONATOLOGY, V101, P1, DOI 10.1159/000323498; Montgomery SL, 2012, J NEUROIMMUNE PHARM, V7, P42, DOI 10.1007/s11481-011-9287-2; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morales DM, 2017, NEUROSURGERY, V80, P82, DOI 10.1227/NEU.0000000000001415; Morales DM, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.011973; Murphy BP, 2002, ARCH DIS CHILD-FETAL, V87, pF37, DOI 10.1136/fn.87.1.F37; O'Hayon BB, 1998, PEDIATR NEUROSURG, V29, P245, DOI 10.1159/000028730; Okamura T, 2012, J NEUROSCI RES, V90, P2127, DOI 10.1002/jnr.23105; Robinson S, 2012, J NEUROSURG-PEDIATR, V9, P242, DOI 10.3171/2011.12.PEDS11136; Rochfort KD, 2016, J NEUROCHEM, V136, P564, DOI 10.1111/jnc.13408; Rochfort KD, 2015, BIOCHEM SOC T, V43, P702, DOI 10.1042/BST20140319; Rothaug M, 2016, BBA-MOL CELL RES, V1863, P1218, DOI 10.1016/j.bbamcr.2016.03.018; Sakka L, 2011, EUR ANN OTORHINOLARY, V128, P309, DOI 10.1016/j.anorl.2011.03.002; Savman K, 2002, ACTA PAEDIATR, V91, P1357; Schmitz T, 2007, PEDIATR RES, V61, P722, DOI 10.1203/pdr.0b013e31805341f1; Schutt RC, 2012, STROKE, V43, P3382, DOI 10.1161/STROKEAHA.112.660878; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Strahle J, 2012, TRANSL STROKE RES, V3, pS25, DOI 10.1007/s12975-012-0182-9; Szpecht D, 2016, CHILD NERV SYST, V32, P2097, DOI 10.1007/s00381-016-3217-9; Takizawa T, 2001, NEUROL RES, V23, P724, DOI 10.1179/016164101101199243; Trifilo MJ, 2004, VIROLOGY, V327, P8, DOI 10.1016/j.virol.2004.06.027; Trifilo MJ, 2003, J NEUROVIROL, V9, P315, DOI 10.1080/13550280390201029; Tsitouras V, 2011, CHILD NERV SYST, V27, P1595, DOI 10.1007/s00381-011-1521-y; Turner MD, 2014, BBA-MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014; Viscardi RM, 2004, PEDIATR RES, V55, P1009, DOI 10.1203/01.pdr.0000127015.60185.8a; Wellons JC, 2013, J NEUROSURG-PEDIATR, V11, P12, DOI 10.3171/2012.10.PEDS12329; Welser-Alves JV, 2013, NEUROCHEM INT, V63, P47, DOI 10.1016/j.neuint.2013.04.007; Whitelaw A, 1999, PEDIATR RES, V46, P576, DOI 10.1203/00006450-199911000-00014; Williams JL, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00154; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; Xia MQ, 1998, AM J PATHOL, V153, P31, DOI 10.1016/S0002-9440(10)65542-3; Yung YC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002095; Zundler S, 2015, CYTOKINE GROWTH F R, V26, P559, DOI 10.1016/j.cytogfr.2015.07.003	68	19	19	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-8118			FLUIDS BARRIERS CNS	Fluids Barriers CNS	DEC 12	2017	14								35	10.1186/s12987-017-0083-0			10	Neurosciences	Neurosciences & Neurology	FQ2IV	WOS:000418181000001	29228970	DOAJ Gold, Green Published			2021-06-18	
J	Campolettano, ET; Gellner, RA; Rowson, S				Campolettano, Eamon T.; Gellner, Ryan A.; Rowson, Steven			High-magnitude head impact exposure in youth football	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; biomechanics; linear; rotational; acceleration; pediatric; trauma	TRAUMATIC BRAIN-INJURIES; HIGH-SCHOOL FOOTBALL; UNITED-STATES; PLAYERS; EPIDEMIOLOGY; SPORTS; ACCELERATION; CONCUSSIONS; KINEMATICS; LOCATION	OBJECTIVE Even in the absence of a clinically diagnosed concussion, research suggests that neurocognitive changes may develop in football players as a result of frequent head impacts that occur during football games and practices. The objectives of this study were to determine the specific situations in which high-magnitude impacts (accelerations exceeding 40g) occur in youth football games and practices and to assess how representative practice activities are of games with regard to high-magnitude head impact exposure. METHODS A total of 45 players (mean age 10.7 +/- 1.1 years) on 2 youth teams (Juniors [mean age 9.9 +/- 0.6 years; mean body mass 38.9 +/- 9.9 kg] and Seniors [mean age 11.9 +/- 0.6 years; mean body mass 51.4 +/- 11.8 kg]) wore helmets instrumented with accelerometer arrays to record head impact accelerations for all practices and games. Video recordings from practices and games were used to verify all high-magnitude head impacts, identify specific impact characteristics, and determine the amount of time spent in each activity. RESULTS A total of 7590 impacts were recorded, of which 571 resulted in high-magnitude head impact accelerations exceeding 40g (8%). Impacts were characterized based on the position played by the team member who received the impact, the part of the field where the impact occurred, whether the impact occurred during a game or practice play, and the cause of the impact. High-magnitude impacts occurred most frequently in the open field in both games (59.4%) and practices (67.5%). "Back" position players experienced a greater proportion of high-magnitude head impacts than players at other positions. The 2 teams in this study structured their practice sessions similarly with respect to time spent in each drill, but impact rates differed for each drill between the teams. CONCLUSIONS High-magnitude head impact exposure in games and practice drills was quantified and used as the basis for comparison of exposure in the 2 settings. In this cohort, game impact rates exceeded those for practice. Back players, who were often positioned in the open field, were shown to experience elevated levels of head impact exposure relative to players at other positions. The analysis also suggests that practice intensity, which may be influenced by coaching style, may also affect high-magnitude head impact exposure. Future studies should investigate this aspect as a factor affecting head impact exposure.	[Campolettano, Eamon T.; Gellner, Ryan A.; Rowson, Steven] Virginia Tech, Dept Biomed Engn & Mech, Blacksburg, VA 24061 USA	Rowson, S (corresponding author), Virginia Tech, Biomed Engn & Mech, 343 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	rowson@vt.edu	Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	National Institute of Neurological Disorders and Stroke of the NIH [R01NS094410]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094410] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the NIH under Award Number R01NS094410. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. We gratefully acknowledge the Blacksburg youth football teams for their participation in this study.	Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; BRESLOW N.E., 1987, STAT METHODS CANC RE, VII; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Campolettano ET, 2016, J NEUROSURG-PEDIATR, V18, P536, DOI 10.3171/2016.5.PEDS1696; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027872; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Dick R, 2007, J ATHL TRAINING, V42, P221; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Gottschalk AW, 2011, SPORTS MED ARTHROSC, V19, P2, DOI 10.1097/JSA.0b013e31820b95fc; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055	33	19	19	1	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	DEC	2017	20	6					604	612		10.3171/2017.5.PEDS17185			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	FO5JU	WOS:000416892900015	29037104	Bronze, Green Accepted			2021-06-18	
J	Ownsworth, T; Fleming, J; Tate, R; Beadle, E; Griffin, J; Kendall, M; Schmidt, J; Lane-Brown, A; Chevignard, M; Shum, DHK				Ownsworth, Tamara; Fleming, Jennifer; Tate, Robyn; Beadle, Elizabeth; Griffin, Janelle; Kendall, Melissa; Schmidt, Julia; Lane-Brown, Amanda; Chevignard, Mathilde; Shum, David H. K.			Do People With Severe Traumatic Brain Injury Benefit From Making Errors? A Randomized Controlled Trial of Error-Based and Errorless Learning	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						rehabilitation; executive function; neuropsychology; brain injuries	IMPAIRED SELF-AWARENESS; ASSESSING SUPPORT NEEDS; INCOG RECOMMENDATIONS; METACOGNITIVE SKILLS; EXECUTIVE FUNCTION; MANAGEMENT; SCALE; REHABILITATION; INTERVENTION; INDIVIDUALS	Background. Errorless learning (ELL) and error-based learning (EBL) are commonly used approaches to rehabilitation for people with traumatic brain injury (TBI). However, it is unknown whether making errors is beneficial in the learning process to promote skills generalization after severe TBI. Objective. To compare the efficacy of ELL and EBL for improving skills generalization, self-awareness, behavioral competency, and psychosocial functioning after severe TBI. Method. A total of 54 adults (79% male; mean age = 38.0 years, SD = 13.4) with severe TBI were randomly allocated to ELL or EBL and received 8 x 1.5-hour therapy sessions that involved meal preparation and other goal-directed activities. The primary outcome was total errors on the Cooking Task (near-transfer). Secondary outcome measures included the Zoo Map Test (far-transfer), Awareness Questionnaire, Patient Competency Rating Scale, Sydney Psychosocial Reintegration Scale, and Care and Needs Scale. Results. Controlling for baseline performance and years of education, participants in the EBL group made significantly fewer errors at postintervention (mean = 36.25; 95% CI = 32.5-40.0) than ELL participants (mean = 42.57; 95% CI = 38.8-46.3). EBL participants also demonstrated greater self-awareness and behavioral competency at postintervention than ELL participants (P < .05). There were no significant differences on other secondary outcomes (P > .05), or at the 6-month follow-up assessment. Conclusion. EBL was found to be more effective than ELL for enhancing skills generalization on a task related to training and improving self-awareness and behavioral competency.	[Ownsworth, Tamara; Beadle, Elizabeth; Shum, David H. K.] Griffith Univ, Mt Gravatt, Qld, Australia; [Fleming, Jennifer] Univ Queensland, St Lucia, Qld, Australia; [Tate, Robyn] Univ Sydney, Sydney, NSW, Australia; [Griffin, Janelle] Princess Alexandra Hosp, Woolloongabba, Australia; [Kendall, Melissa] Acquired Brain Injury Outreach Serv, Brisbane, Qld, Australia; [Kendall, Melissa] Griffith Univ, Div Rehabil, Metro South Hlth, Brisbane, Qld, Australia; [Schmidt, Julia] Univ British Columbia, Vancouver, BC, Canada; [Schmidt, Julia] La Trobe Univ, Melbourne, Vic, Australia; [Lane-Brown, Amanda] Liverpool Hosp, Sydney, NSW, Australia; [Chevignard, Mathilde] Hop St Maurice, St Maurice, France; [Chevignard, Mathilde] Sorbonne Univ, Paris, France; [Chevignard, Mathilde] GRC UPMC 18 Handicap Cognitif & Readaptat HanCRe, Paris, France; [Shum, David H. K.] Chinese Acad Sci, Beijing, Peoples R China	Ownsworth, T (corresponding author), Griffith Univ, Sch Appl Psychol, Mt Gravatt, Qld 4122, Australia.	t.ownsworth@griffith.edu.au	; Shum, David H. K./A-3914-2008	Schmidt, Julia/0000-0003-2004-4871; Shum, David H. K./0000-0002-4810-9262; Ownsworth, Tamara/0000-0003-1835-7094	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [APP1043677]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This trial was funded by a National Health and Medical Research Council Project Grant (APP1043677). This funding body was otherwise not involved in the study.	Bertens D, 2015, J INT NEUROPSYCH SOC, V21, P639, DOI 10.1017/S1355617715000764; Borrelli B, 2005, J CONSULT CLIN PSYCH, V73, P852, DOI 10.1037/0022-006X.73.5.852; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Chiaravalloti ND, 2016, NEUROREHAB NEURAL RE, V30, P539, DOI 10.1177/1545968315604395; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Clare L, 2008, NEUROPSYCHOL REV, V18, P1, DOI 10.1007/s11065-008-9051-4; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Dunlosky J, 2013, PSYCHOL SCI PUBL INT, V14, P4, DOI 10.1177/1529100612453266; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fernandez J, 2017, METACOGN LEARN, V12, P131, DOI 10.1007/s11409-016-9163-9; Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Lee GY, 2013, CLIN INTERV AGING, V8, P623, DOI 10.2147/CIA.S45726; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2008, J REHABIL MED, V40, P81, DOI 10.2340/16501977-0124; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Ownsworth T, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-369; Ownsworth T, 2010, NEUROPSYCHOL REHABIL, V20, P59, DOI 10.1080/09602010902949223; Poncet F, 2015, NEUROPSYCHOL REHABIL, V25, P298, DOI 10.1080/09602011.2014.971819; Ponsford J, 2016, PSYCHOL MED, V46, P1079, DOI 10.1017/S0033291715002640; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Roediger HL, 2011, TRENDS COGN SCI, V15, P20, DOI 10.1016/j.tics.2010.09.003; Schmidt J, 2013, NEUROREHAB NEURAL RE, V27, P316, DOI 10.1177/1545968312469838; Schmidt J, 2011, J REHABIL MED, V43, P673, DOI 10.2340/16501977-0846; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Soo C, 2010, ARCH PHYS MED REHAB, V91, P905, DOI 10.1016/j.apmr.2009.11.033; Tate RL, 2004, BRAIN INJURY, V18, P445, DOI 10.1080/02699050310001641183; Tate R, 2014, J HEAD TRAUMA REHAB, V29, P338, DOI 10.1097/HTR.0000000000000068; Tate RL, 2011, J REHABIL MED, V43, P609, DOI 10.2340/16501977-0829; The Center for Outcome Measurement in Brain Injury, INTR AW QUEST AQ; Toglia J. P., 2011, COGNITION OCCUPATION, P161; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Velikonja D, 2014, J HEAD TRAUMA REHAB, V29, P369, DOI 10.1097/HTR.0000000000000069; Wilson BA, 1996, BEHAV ASSESSMENT DYS	38	19	19	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	DEC	2017	31	12					1072	1082		10.1177/1545968317740635			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FQ5BW	WOS:000418374500008	29139337	Bronze, Green Published			2021-06-18	
J	Zhang, J; Pu, HJ; Zhang, HY; Wei, ZS; Jiang, XY; Xu, MY; Zhang, LL; Zhang, WT; Liu, JL; Meng, HX; Stetler, RA; Sun, DD; Chen, J; Gao, YQ; Chen, L				Zhang, Jun; Pu, Hongjian; Zhang, Haiyue; Wei, Zhishuo; Jiang, Xiaoyan; Xu, Mingyue; Zhang, Lili; Zhang, Wenting; Liu, Jialin; Meng, Hengxing; Stetler, R. Anne; Sun, Dandan; Chen, Jun; Gao, Yanqin; Chen, Ling			Inhibition of Na+-K+-2Cl(-) cotransporter attenuates blood-brain-barrier disruption in a mouse model of traumatic brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Bumetanide; NKCC1; MMP9	FOCAL CEREBRAL-ISCHEMIA; WHITE-MATTER INJURY; CL-COTRANSPORTER; NEURONAL DAMAGE; EDEMA FORMATION; BREAKDOWN; RATS; MICE; OVEREXPRESSION; PERMEABILITY	Traumatic brain injury (TBI) can lead to long-term motor and cognitive dysfunction, which can be at least partly attributed to blood-brain barrier (BBB) disruption. The mechanisms underlying post-TBI BBB disruption, however, are poorly understood thus far. Na+-K+-2Cl(-) cotransporter isoform 1 (NKCC1) is a universally expressed ion transporter that maintains intracellular ion homeostasis by increasing intra-cellular K+ and Cl-. Having been characterized in stroke models, NKCC1 is activated in various cell types in the ischemic brain, and is thought to mediate BBB disruption, brain edema, and neuronal cell death. In this study, we tested the hypothesis that inhibition of NKCC1 may improve neurological outcomes via protecting against BBB disruption in a TBI mouse model. Adult male C57BL/6 j mice or NKCC1 deficient mice were subjected to controlled cortical impact (CCI). As an alternative to the genetic-based NKCC1 depletion, bumetanide, a selective NKCC1 inhibitor, was administrated (25 mg/kg, i.p.) 15 min after CCI and then every 6 h up to 48 h. Short-term sensorimotor function recovery was determined by rotarod, cylinder test, grid walking and foot fault test. BBB integrity was examined at 48 h post-CCI by measuring Evans blue extravasation, brain water content, and expression levels of tight junction proteins. Our results revealed that administration of bumetanide or genetic depletion of NKCC1 improved short-term neurological recovery against TBI. Bumetanide treatment markedly decreased brain water content and BBB leakage, correlated with reduction of MMP-9 expression and preventing the degradation of tight junction proteins. These findings suggest an important role of NKCC1 activation in mediating BBB disruption after TBI. Thus, NKCC1 inhibition may offer the potential for improving neurological outcomes in clinical TBI. (C) 2017 Published by Elsevier Ltd.	[Zhang, Jun; Liu, Jialin; Meng, Hengxing; Chen, Ling] Gen Hosp PLA, Dept Neurosurg, 28 Fuxing Rd, Beijing 100853, Peoples R China; [Pu, Hongjian; Jiang, Xiaoyan; Xu, Mingyue; Zhang, Wenting; Chen, Jun; Gao, Yanqin] Fudan Univ, State Key Lab Med Neurobiol, Shanghai, Peoples R China; [Pu, Hongjian; Jiang, Xiaoyan; Xu, Mingyue; Zhang, Wenting; Chen, Jun; Gao, Yanqin] Fudan Univ, Inst Brain Sci, Shanghai, Peoples R China; [Pu, Hongjian; Zhang, Haiyue; Wei, Zhishuo; Jiang, Xiaoyan; Xu, Mingyue; Zhang, Lili; Stetler, R. Anne; Sun, Dandan; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Sch Med, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA USA	Chen, L (corresponding author), Gen Hosp PLA, Dept Neurosurg, 28 Fuxing Rd, Beijing 100853, Peoples R China.; Gao, YQ (corresponding author), Fudan Univ, State Key Lab Med Neurobiol, 131 Dongan Rd, Shanghai 200032, Peoples R China.	yqgao@shmu.edu.cn; chen_ling301@163.com	Gao, Yanqin/I-6790-2016; Pu, Hongjian/AAW-3322-2020	Gao, Yanqin/0000-0002-4915-9819; 	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30970939, 81272804, 81571285, 81371306, 81271365]; Shanghai Committee of Science and Technology Support Program [14431907002]	*J.Z. and *H.P. contributed equally to this research. This project was supported by the National Natural Science Foundation of China grants (#30970939 and #81272804 to L.C., #81571285 and #81371306 to Y.G. and #81271365 to J.Z.) and the Shanghai Committee of Science and Technology Support Program (#14431907002 to Y.G.).	Alluri H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154427; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; Cong DM, 2015, CURR MED CHEM, V22, P1171, DOI 10.2174/0929867322666150114151946; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Kahle KT, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/9/E22; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Krueger M, 2015, J CEREBR BLOOD F MET, V35, P292, DOI 10.1038/jcbfm.2014.199; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; Lykke K, 2015, BRIT J PHARMACOL, V172, P4469, DOI 10.1111/bph.13231; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; O'Donnell ME, 2004, J CEREBR BLOOD F MET, V24, P1046, DOI 10.1097/01.WCB.0000130867.32663.90; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shi H, 2015, CNS NEUROSCI THER, V21, P374, DOI 10.1111/cns.12366; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang LX, 2013, ANN NEUROL, V73, P189, DOI 10.1002/ana.23762; Yan YP, 2003, BRAIN RES, V961, P22, DOI 10.1016/S0006-8993(02)03832-5; Yu Qiong, 2011, Front Biosci (Elite Ed), V3, P978; Zhang F, 2006, J NEUROSCI RES, V83, P1241, DOI 10.1002/jnr.20816	31	19	20	1	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2017	111				SI		23	31		10.1016/j.neuint.2017.05.020			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FR3OS	WOS:000418976600004	28577991				2021-06-18	
J	Sun, L; Li, M; Ma, X; Feng, HY; Song, JL; Lv, C; He, YJ				Sun, Lin; Li, Man; Ma, Xun; Feng, Haoyu; Song, Junlai; Lv, Cong; He, Yajun			Inhibition of HMGB1 reduces rat spinal cord astrocytic swelling and AQP4 expression after oxygen-glucose deprivation and reoxygenation via TLR4 and NF-kappa B signaling in an IL-6-dependent manner	JOURNAL OF NEUROINFLAMMATION			English	Article						High mobility group box-1; Aquaporin-4; Toll-like receptor 4; Nuclear factor-kappa B; Interleukin-6; Astrocyte swelling; Spinal cord injury	GROUP BOX 1; TRAUMATIC BRAIN-INJURY; AQUAPORIN-4 EXPRESSION; HEPATIC-ENCEPHALOPATHY; NERVOUS-SYSTEM; RECEPTOR 4; EDEMA; PATHWAY; PROMOTES; ACTIVATION	Background: Spinal cord astrocyte swelling is an important component to spinal cord edema and is associated with poor functional recovery as well as therapeutic resistance after spinal cord injury (SCI). High mobility group box-1 (HMGB1) is a mediator of inflammatory responses in the central nervous system and plays a critical role after SCI. Given this, we sought to identify both the role and underlying mechanisms of HMGB1 in cellular swelling and aquaporin 4 (AQP4) expression in cultured rat spinal cord astrocytes after oxygen-glucose deprivation/reoxygenation (OGD/R). Methods: The post-natal day 1-2 Sprague-Dawley rat spinal cord astrocytes were cultured in vitro, and the OGD/R model was induced. We first investigated the effects of OGD/R on spinal cord astrocytic swelling and HMGB1 and AQP4 expression, as well as HMGB1 release. We then studied the effects of HMGB1 inhibition on cellular swelling, HMGB1 and AQP4 expression, and HMGB1 release. The roles of both toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-kappa B) signaling pathway and interleukin-6 (IL-6) in reducing cellular swelling resulting from HMGB1 inhibition in spinal cord astrocytes after OGD/R were studied. Intergroup data were compared using one-way analysis of variance (ANOVA) followed by Dunnett's test. Results: The OGD/R increased spinal cord astrocytic swelling and HMGB1 and AQP4 expression, as well as HMGB1 release. Inhibition of HMGB1 using either HMGB1 shRNA or ethyl pyruvate resulted in reduced cellular volume, mitochondrial and endoplasmic reticulum swelling, and lysosome number and decreased upregulation of both HMGB1 and AQP4 in spinal cord astrocytes, as well as HMGB1 release. The HMGB1 effects on spinal cord astrocytic swelling and AQP4 upregulation after OGD/R were mediated-at least in part-via activation of TLR4, myeloid differentiation primary response gene 88 (MyD88), and NF-kappa B. These activation effects can be repressed by TLR4 inhibition using CLI-095 or C34, or by NF-kappa B inhibition using BAY 11-7082. Furthermore, either OGD/R or HMGB1 inhibition resulted in changes in IL-6 release. IL-6 was also shown to mediate AQP4 expression in spinal cord astrocytes. Conclusions: HMGB1 upregulates AQP4 expression and promotes cell swelling in cultured spinal cord astrocytes after OGD/R, which is mediated through HMGB1/TLR4/MyD88/NF-kappa B signaling and in an IL-6-dependent manner.	[Sun, Lin; Ma, Xun; Feng, Haoyu; Song, Junlai; Lv, Cong; He, Yajun] Shanxi Med Univ, Shanxi Da Yi Hosp, Shanxi Acad Med Sci, Dept Orthoped, Taiyuan 030032, Shanxi, Peoples R China; [Li, Man] Shanxi Med Univ, Hosp 2, Dept Neurol, Taiyuan 030001, Shanxi, Peoples R China	Sun, L (corresponding author), Shanxi Med Univ, Shanxi Da Yi Hosp, Shanxi Acad Med Sci, Dept Orthoped, Taiyuan 030032, Shanxi, Peoples R China.	sunlin_9999@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81401028]; Youth Science and Technology Research Foundation of Shanxi [2015021201]; Doctoral Foundation of Shanxi Medical University [03201422]	This study was supported by a grant from the National Natural Science Foundation of China (no.: 81401028), the Youth Science and Technology Research Foundation of Shanxi (no.: 2015021201), and the Doctoral Foundation of Shanxi Medical University (no.: 03201422).	Chen KB, 2011, SPINE, V36, P2122, DOI 10.1097/BRS.0b013e318203941c; Dibaj P, 2007, J NEUROCHEM, V103, P2620, DOI 10.1111/j.1471-4159.2007.04979.x; Didangelos A, 2016, SCI REP-UK, V6, DOI 10.1038/srep21607; Fan ZK, 2010, BRAIN RES, V1342, P1, DOI 10.1016/j.brainres.2010.04.038; Fang P, 2012, MOL NEUROBIOL, V45, P499, DOI 10.1007/s12035-012-8264-y; Ge R, 2013, BRAIN RES, V1527, P40, DOI 10.1016/j.brainres.2013.06.009; Gong G, 2012, ACTA PHARMACOL SIN, V33, P11, DOI 10.1038/aps.2011.151; Hayakawa K, 2013, J NEUROCHEM, V125, P273, DOI 10.1111/jnc.12120; Hemley SJ, 2013, J NEUROTRAUM, V30, P1457, DOI 10.1089/neu.2012.2614; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hu AM, 2015, SPINAL CORD, V53, P98, DOI 10.1038/sc.2014.209; Jayakumar AR, 2012, NEUROSCIENCE, V218, P305, DOI 10.1016/j.neuroscience.2012.05.006; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Jayakumar AR, 2014, J NEUROCHEM, V128, P890, DOI 10.1111/jnc.12516; Jian ZH, 2016, BRAIN RES, V1643, P123, DOI 10.1016/j.brainres.2016.05.002; Kerstetter AE, 2012, METHODS MOL BIOL, V814, P93, DOI 10.1007/978-1-61779-452-0_7; Lachmann V, 2013, ARCH BIOCHEM BIOPHYS, V536, P143, DOI 10.1016/j.abb.2013.05.004; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lee SA, 2014, YONSEI MED J, V55, P1165, DOI 10.3349/ymj.2014.55.5.1165; Leonard AV, 2015, J NEUROTRAUM, V32, P397, DOI 10.1089/neu.2014.3543; Li G, 2016, INT J MOL MED, V37, P99, DOI 10.3892/ijmm.2015.2410; Li M, 2014, NEUROCHEM RES, V39, P1440, DOI 10.1007/s11064-014-1333-z; Li M, 2014, INT J MOL MED, V34, P705, DOI 10.3892/ijmm.2014.1820; Li X, 2016, INFLAMMATION, V39, P96, DOI 10.1007/s10753-015-0227-9; Liu SJ, 2017, MOL NEUROBIOL, V54, P6426, DOI 10.1007/s12035-016-0185-8; Liu XW, 2015, BIOMED PAP, V159, P220, DOI 10.5507/bp.2015.012; Ma YQ, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/639563; Malek R, 2007, PHARMACOL REP, V59, P25; Nagelhus EA, 2013, PHYSIOL REV, V93, P1543, DOI 10.1152/physrev.00011.2013; Ni HB, 2015, J SPINAL CORD MED, V38, P199, DOI 10.1179/2045772313Y.0000000179; Ohnishi M, 2014, NEUROCHEM INT, V75, P32, DOI 10.1016/j.neuint.2014.05.007; Oklinski MK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122050; Oklinski MK, 2014, J HISTOCHEM CYTOCHEM, V62, P598, DOI 10.1369/0022155414537495; Papatheodorou A, 2017, J NEUROTRAUM, V34, P746, DOI 10.1089/neu.2016.4596; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Perez-Carrion MD, 2013, PHARM RES-DORDR, V30, P2584, DOI 10.1007/s11095-013-1049-9; Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Rao KVR, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-66; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Shi YQ, 2012, J NEUROSCI, V32, P10833, DOI 10.1523/JNEUROSCI.5628-11.2012; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; Sturdivant NM, 2016, SCI REP-UK, V6, DOI 10.1038/srep33330; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Tang ZH, 2013, NEUROPHARMACOLOGY, V67, P8, DOI 10.1016/j.neuropharm.2012.10.017; Thrane AS, 2014, TRENDS NEUROSCI, V37, P620, DOI 10.1016/j.tins.2014.08.010; Wang LN, 2010, NEUROSCI LETT, V471, P152, DOI 10.1016/j.neulet.2010.01.030; Wang YC, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-134; Xiao M, 2014, CNS NEUROSCI THER, V20, P385, DOI 10.1111/cns.12267; Xie ZF, 2016, CELL MOL NEUROBIOL, V36, P93, DOI 10.1007/s10571-015-0223-5; Yang J, 2013, SPINE, V38, pE1641, DOI 10.1097/BRS.0000000000000005; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334; Zheng CG, 2016, AM J TRANSL RES, V8, P5016; Zu JN, 2014, ACTA HISTOCHEM, V116, P1331, DOI 10.1016/j.acthis.2014.08.004; Zurolo E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-280	56	19	26	1	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	NOV 25	2017	14								231	10.1186/s12974-017-1008-1			18	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	FN8DA	WOS:000416248400004	29178911	DOAJ Gold, Green Published			2021-06-18	
J	Liu, XY; Maurits, NM; Aries, MJH; Czosnyka, M; Ercole, A; Donnelly, J; Cardim, D; Kim, DJ; Dias, C; Cabeleira, M; Smielewski, P				Liu, Xiuyun; Maurits, Natasha M.; Aries, Marcel J. H.; Czosnyka, Marek; Ercole, Ari; Donnelly, Joseph; Cardim, Danilo; Kim, Dong-Joo; Dias, Celeste; Cabeleira, Manuel; Smielewski, Peter			Monitoring of Optimal Cerebral Perfusion Pressure in Traumatic Brain Injured Patients Using a Multi-Window Weighting Algorithm	JOURNAL OF NEUROTRAUMA			English	Article						cerebral autoregulation; CPPopt; multi-window algorithm; pressure reactivity index; TBI	SEVERE HEAD-INJURY; REACTIVITY; AUTOREGULATION; MANAGEMENT; CHILDREN	Methods to identify an autoregulation guided "optimal'' cerebral perfusion pressure (CPPopt) for traumatic brain injury patients (TBI) have been reported through several studies. An important drawback of existing methodology is that CPPopt can be calculated only in similar to 50-60% of the monitoring time. In this study, we hypothesized that the CPPopt yield and the continuity can be improved significantly through application of a multi-window and weighting calculation algorithm, without adversely affecting preservation of its prognostic value. Data of 526 severe TBI patients admitted between 2003 and 2015 were studied. The multi-window CPPopt calculation was based on automated curve fitting in pressure reactivity index (PRx)-CPP plots using data from 36 increasing length time windows (2-8 h). The resulting matrix of CPPopts was then averaged in a weighted manner. The yield, continuity, and stability of CPPopt were studied. The difference between patients' actual CPP and CPPopt (DCPP) was calculated and the association with outcome was analyzed. Overall, the multi-window method demonstrated more continuous and stable presentation of CPPopt in this cohort. The new method resulted in a mean (+/- SE) CPPopt yield of 94%+/- 2.1%, as opposed to the previous single-window-based CPPopt yield of 51%+/- 0.94%. The stability of CPPopt across the whole monitoring period was significantly improved by using the new algorithm (p < 0.001). The relationship between DCPP according to the multi-window algorithm and outcome was similar to that for CPPopt calculated on the basis of a single window. In conclusion, this study validates the use of a new multi-window and weighting algorithm for significant improvement of CPPopt yield in TBI patients. This methodological improvement is essential for its clinical application in future CPPopt trials.	[Liu, Xiuyun; Aries, Marcel J. H.; Czosnyka, Marek; Ercole, Ari; Donnelly, Joseph; Cardim, Danilo; Cabeleira, Manuel; Smielewski, Peter] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Brain Phys Lab,Dept Clin Neurosci, Hills Rd, Cambridge CB2 0QQ, England; [Maurits, Natasha M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Aries, Marcel J. H.] Maastricht Univ, Med Ctr, Dept Intens Care MJHA, Maastricht, Netherlands; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Kim, Dong-Joo] Korea Univ, Dept Brain & Cognit Engn, Seoul, South Korea; [Dias, Celeste] San Joao Univ Hosp, Dept Intens Care, Oporto, Portugal	Liu, XY (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Brain Phys Lab,Dept Clin Neurosci, Hills Rd, Cambridge CB2 0QQ, England.	xl334@cam.ac.uk	Dias, Celeste/L-9901-2014; Dias, Celeste/AAD-8711-2019; Donnelly, Joseph/E-9235-2018; Ercole, Ari/B-6288-2009; Cardim, Danilo Augusto/B-8447-2012; Dias, Celeste/AAV-3820-2020; Donnelly, Joseph/N-6803-2019; Liu, Xiuyun/V-4427-2017	Dias, Celeste/0000-0003-0340-9808; Donnelly, Joseph/0000-0002-6502-8069; Ercole, Ari/0000-0001-8350-8093; Cardim, Danilo Augusto/0000-0002-9261-1321; Dias, Celeste/0000-0003-0340-9808; Donnelly, Joseph/0000-0002-6502-8069; Liu, Xiuyun/0000-0001-9540-4865; Maurits, Natasha/0000-0001-6231-7044	Bill Gates Scholarship (University of Cambridge); Woolf Fisher Trust, New Zealand (Woolf Fisher Scholarship); Cambridge Commonwealth, European AMP; International Trust Scholarship, University of Cambridge; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986] Funding Source: researchfish	ICM+ Software is licensed by Cambridge Enterprise Ltd., Cambridge, United Kingdom, http://www.neurosurg.cam.ac.uk/icmplus/. Peter Smielewski and Marek Czosnyka have a financial interest in a fraction of the licensing fee. Xiuyun Liu is recipient of a Bill Gates Scholarship (University of Cambridge). Joseph Donnelly is funded by the Woolf Fisher Trust, New Zealand (Woolf Fisher Scholarship). Danilo Cardim is supported by a Cambridge Commonwealth, European & International Trust Scholarship, University of Cambridge. The remaining authors have nothing to disclose.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Dias C, 2015, NEUROCRIT CARE, V23, P92, DOI 10.1007/s12028-014-0103-8; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; JENNETT B, 1975, LANCET, V1, P480; Lang E W, 1995, New Horiz, V3, P400; Lang EW, 2015, J NEUROSURG, V122, P588, DOI 10.3171/2014.10.JNS14602; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Lewis PM, 2015, PEDIATR CRIT CARE ME, V16, P739, DOI 10.1097/PCC.0000000000000471; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Obuchowski NA, 2003, RADIOLOGY, V229, P3, DOI 10.1148/radiol.2291010898; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Sanchez-Porras R, 2012, ACTA NEUROCHIR, V154, P1575, DOI 10.1007/s00701-012-1423-0; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Weersink CSA, 2015, CRIT CARE MED, V43, P1952, DOI 10.1097/CCM.0000000000001165; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	24	19	19	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2017	34	22					3081	3088		10.1089/neu.2017.5003			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FL9GC	WOS:000414560000003	28486883				2021-06-18	
J	Nelson, LD; Ranson, J; Ferguson, AR; Giacino, J; Okonkwo, DO; Valadka, AB; Manley, GT; McCrea, MA				Nelson, Lindsay D.; Ranson, Jana; Ferguson, Adam R.; Giacino, Joseph; Okonkwo, David O.; Valadka, Alex B.; Manley, Geoffrey T.; McCrea, Michael A.		TRACK-TBI Investigators	Validating Multi-Dimensional Outcome Assessment Using the Traumatic Brain Injury Common Data Elements: An Analysis of the TRACK-TBI Pilot Study Sample	JOURNAL OF NEUROTRAUMA			English	Article						common data elements; Glasgow Outcome Scale; neuropsychological; outcome assessment; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; SEVERE HEAD-INJURY; POST-CONCUSSION SYMPTOMS; FUNCTIONAL STATUS EXAMINATION; VERBAL-LEARNING TEST; PTSD CHECKLIST; CLINICAL-TRIALS; PRIMARY-CARE; PSYCHOMETRIC PROPERTIES; STRUCTURED INTERVIEWS	The Glasgow Outcome Scale-Extended (GOSE) is often the primary outcome measure in clinical trials for traumatic brain injury (TBI). Although the GOSE's capture of global functional outcome has several strengths, concerns have been raised about its limited ability to identify mild disability and failure to capture the full scope of problems patients exhibit after TBI. This analysis examined the convergence of disability ratings across a multi-dimensional set of outcome domains in the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Pilot Study. The study collected measures recommended by the TBI Common Data Elements (CDE) Workgroup. Patients presenting to three emergency departments with a TBI of any severity enrolled in TRACK-TBI prospectively after injury; outcome measures were collected at 3 and 6 months post-injury. Analyses examined frequency of impairment and overlap between impairment status across the CDE outcome domains of Global Level of Functioning (GOSE), Neuropsychological (cognitive) Impairment, Psychological Status, TBI Symptoms, and Quality of Life. GOSE score correlated in the expected direction with other outcomes (mean [M] Spearman's rho = 0.21 and 0.49 with neurocognitive and self-report outcomes, respectively). The subsample in the Upper Good Recovery (GOSE 8) category appeared quite healthy across most other outcomes, although 19.0% had impaired executive functioning (Trail Making Test Part B). A significant minority of participants in the Lower Good Recovery subgroup (GOSE 7) met criteria for impairment across numerous other outcome measures. The findings highlight the multi-dimensional nature of TBI recovery and the limitations of applying only a single outcome measure.	[Nelson, Lindsay D.; Ranson, Jana; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA; [Ferguson, Adam R.] Univ Calif San Francisco, Dept Neurol Surg, Weill Inst Neurosci Brain & Spinal Injury Ctr BAS, San Francisco, CA USA; [Ferguson, Adam R.] San Francisco VA Med Ctr, San Francisco, CA USA; [Giacino, Joseph] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, Zuckerberg San Francisco Gen Hosp, San Francisco, CA USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Trauma Ctr, San Francisco, CA 94143 USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA	Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.; Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurol, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.	linelson@mcw.edu	Giacino, Joseph/AAF-1952-2021; Yue, John K/P-1348-2015; Ranson, Jana/H-9899-2019	Giacino, Joseph/0000-0002-7916-9698; Yue, John K/0000-0001-9694-7722; Ferguson, Adam/0000-0001-7102-1608; Ranson, PhD, Jana/0000-0003-0967-192X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC2 NS0694909, RC2 NS069409-02S1, R03 NS100691-01]; Department of DefenseUnited States Department of Defense [USAMRAAW81XWH-13-1-0441]	This work was supported by the National Institutes of Health (grant nos. RC2 NS0694909 [to G.T.M.], RC2 NS069409-02S1 [to G.T.M.], and R03 NS100691-01 [to L.D.N.]) and the Department of Defense (USAMRAAW81XWH-13-1-0441; to G.T.M.); Registry: ClinicalTrials.gov Identifier NCT01565551. We thank Anna Klotz for her assistance in processing the neurocognitive outcome data. Editorial support was provided by Amy J. Markowitz, JD.	Agresti A., 2013, CATEGORICAL DATA ANA, V3rd ed., DOI DOI 10.1002/0471249688; Agresti A, 2010, ANAL ORDINAL CATEGOR, V2nd; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; BRANT R, 1990, BIOMETRICS, V46, P1171, DOI 10.2307/2532457; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Centers for Disease and Control, 2016, TRAUM BRAIN INJ CONC; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Clegg F., 1998, SIMPLE STAT COURSE B; Clogg C., 1994, STAT MODELS ORDINAL; Cohen J., 2003, APPL MULTIPLE CORREL; Cohen L., 2011, RES METHODS ED, V7th ed.; Cook JM, 2005, J TRAUMA STRESS, V18, P371, DOI 10.1002/jts.20038; Derogatis L. R., 2001, BSI 18 BRIEF SYMPTOM; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dobie DJ, 2002, GEN HOSP PSYCHIAT, V24, P367, DOI 10.1016/S0163-8343(02)00207-4; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Donders J, 2006, PSYCHOL ASSESSMENT, V18, P458, DOI 10.1037/1040-3590.18.4.458; Drane DL, 2002, NEUROPSY NEUROPSY BE, V15, P39; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Frisch M.B., 1992, PSYCHOL ASSESSMENT, V4, P92, DOI [DOI 10.1037/1040-3590.4.1.92, 10.1037/1040-3590.4.1.92]; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hellawell DJ, 1997, INT J REHABIL RES, V20, P345, DOI 10.1097/00004356-199712000-00001; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; IBM Corp, 2016, IBM SPSS STAT WIND C; ISOAHO R, 1995, SCAND J PRIM HEALTH, V13, P122, DOI 10.3109/02813439508996748; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JUDGE TA, 1993, ORGAN BEHAV HUM DEC, V56, P388, DOI 10.1006/obhd.1993.1061; Keane T., 1994, PTSD CHECKLIST CIVIL; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kohler R., 2011, COGNITIVE REHABILITA; Lang AJ, 2005, BEHAV RES THER, V43, P585, DOI 10.1016/j.brat.2004.04.005; Lang AJ, 2003, J TRAUMA STRESS, V16, P257, DOI 10.1023/A:1023796007788; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LONDON P S, 1967, Annals of the Royal College of Surgeons of England, V41, P460; Long JS, 1997, REGRESSION MODELS CA, V7; Lu J, 2008, J NEUROTRAUM, V25, P641, DOI 10.1089/neu.2007.0510; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Manley G. T., 2017, J NEUROTRAUMA ADV ON, DOI [10.1089/neur.2016.4729, DOI 10.1089/NEUR.2016.4729]; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Manne SL, 1998, J PEDIATR PSYCHOL, V23, P357, DOI 10.1093/jpepsy/23.6.357; Marmarou A., 2001, AM BRAIN INJURY CONS; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; McMillan TM, 2013, J NEUROTRAUM, V30, P970, DOI 10.1089/neu.2012.2703; McMillan T, 2016, NAT REV NEUROL, V12, P477, DOI 10.1038/nrneurol.2016.89; Mellick D., 2000, CRAIG HANDICAP ASSES; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Center for PTSD, 2012, US PTSD CHECKL PCL; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; O'Connell AA, 2011, J MOD APPL STAT METH, V10, P139; O'Connell Ann A., 2006, LOGISTIC REGRESSION; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Scheibel RS, 1998, J NEUROTRAUM, V15, P685, DOI 10.1089/neu.1998.15.685; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherman JJ, 2005, J OROFAC PAIN, V19, P309; Silberstein Morry, 2002, Neurosurg Focus, V13, pecp2, DOI 10.3171/foc.2002.13.1.6; Smead V. S., 1991, ANN CONV AM ASS APPL; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; Terhakopian A, 2008, J TRAUMA STRESS, V21, P290, DOI 10.1002/jts.20341; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; van der Naalt J, 2000, BRAIN INJURY, V14, P781; Walker EA, 2002, GEN HOSP PSYCHIAT, V24, P375, DOI 10.1016/S0163-8343(02)00203-7; Weathers F. W., 2013, PTSD CHECKLIST DSM 5; Wechsler D., 2008, WAIS IV MANUAL; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Widows MR, 2000, PSYCHOSOM MED, V62, P873, DOI 10.1097/00006842-200011000-00018; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 2007, NEUROSURGERY, V61, P123, DOI 10.1227/01.neu.0000279732.21145.9e; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P413, DOI 10.1016/j.acn.2006.06.002; Yeager DE, 2007, GEN HOSP PSYCHIAT, V29, P294, DOI 10.1016/j.genhosppsych.2007.03.004; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	112	19	19	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2017	34	22					3158	3172		10.1089/neu.2017.5139			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FL9GC	WOS:000414560000012	28595478	Green Published			2021-06-18	
J	Thelin, EP; Hall, CE; Gupta, K; Carpenter, KLH; Chandran, S; Hutchinson, PJ; Patani, R; Helmy, A				Thelin, Eric Peter; Hall, Claire E.; Gupta, Kunal; Carpenter, Keri L. H.; Chandran, Siddharthan; Hutchinson, Peter J.; Patani, Rickie; Helmy, Adel			Elucidating Pro-inflammatory Cytokine Responses after Traumatic Brain Injury in a Human Stem Cell Model	JOURNAL OF NEUROTRAUMA			English	Article						cytokine exposure; human embryonic stem cell-derived neurons; interleukin-1 beta; interleukin-6; in vitro; tumor necrosis factor	NECROSIS-FACTOR-ALPHA; INTERLEUKIN-1 RECEPTOR ANTAGONIST; CENTRAL-NERVOUS-SYSTEM; ANTIINFLAMMATORY CYTOKINES; MESSENGER-RNA; NITRIC-OXIDE; HEAD-INJURY; TNF-ALPHA; IN-VITRO; EXPRESSION	Cytokine mediated inflammation likely plays an important role in secondary pathology after traumatic brain injury (TBI). The aim of this study was to elucidate secondary cytokine responses in an in vitro enriched (>80%) human stem cell-derived neuronal model. We exposed neuronal cultures to pre-determined and clinically relevant pathophysiological levels of tumor necrosis factor-alpha (TNF), interleukin-6 (IL-6) and interleukin-1 beta (IL-1 beta), shown to be present in the inflammatory aftermath of TBI. Data from this reductionist human model were then compared with our in vivo data. Human embryonic stem cell (hESC)-derived neurons were exposed to recombinant TNF (1-10,000pg/mL), IL-1 beta (1-10,000pg/mL), and IL-6 (0.1-1000ng/mL). After 1, 24, and 72h, culture supernatant was sampled and analyzed using a human cytokine/chemokine 42-plex Milliplex kit on the Luminex platform. The culture secretome revealed both a dose- and/or time-dependent release of cytokines. The IL-6 and TNF exposure each resulted in significantly increased levels of >10 cytokines over time, while IL-1 beta increased the level of C-X-C motif chemokine 10 (CXCL10/IP10) alone. Importantly, these patterns are consistent with our in vivo (human) TBI data, thus validating our human stem cell-derived neuronal platform as a clinically useful reductionist model. Our data cumulatively suggest that IL-6 and TNF have direct actions, while the action of IL-1 beta on human neurons likely occurs indirectly through inflammatory cells. The hESC-derived neurons provide a valuable platform to model cytokine mediated inflammation and can provide important insights into the mechanisms of neuroinflammation after TBI.	[Thelin, Eric Peter; Carpenter, Keri L. H.; Hutchinson, Peter J.; Helmy, Adel] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Thelin, Eric Peter] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Hall, Claire E.; Patani, Rickie] UCL, Inst Neurol, Dept Mol Neurosci, Queen Sq, London WC1N 3BG, England; [Gupta, Kunal] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA; [Carpenter, Keri L. H.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge, England; [Chandran, Siddharthan] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Patani, Rickie] Francis Crick Inst, London, England	Helmy, A (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.; Patani, R (corresponding author), UCL, Inst Neurol, Dept Mol Neurosci, Queen Sq, London WC1N 3BG, England.	rickie.patani@ucl.ac.uk; adelhelmy@cantab.net	Patani, R/J-3107-2018; Thelin, Eric Peter/K-2144-2012; Helmy, Adel/AAS-3084-2020	Patani, R/0000-0002-3825-7675; Thelin, Eric Peter/0000-0002-2338-4364; Helmy, Adel/0000-0002-0531-0556; Gupta, Kunal/0000-0002-9847-0099; Carpenter, Keri/0000-0001-8236-7727	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986 ID79068]; National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Swedish Society of Medicine [SLS-587221]; National Institute for Health Research Professorship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Medical Research Council/Royal College of Surgeons of England Clinical Research Training FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Royal College of Surgeons of England Pump Priming Grant; Wellcome TrustWellcome TrustEuropean Commission [101149/Z/13/A]; National Institute for Health Research University College London Hospitals Biomedical Research Centre; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0600986, MR/R005036/1, G0802251] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2006-14-004, NIHR-RP-R3-12-013] Funding Source: researchfish; Wellcome TrustWellcome TrustEuropean Commission [101149/Z/13/Z] Funding Source: researchfish	The author(s) gratefully acknowledge receipt of the following financial support. Medical Research Council (Grant No. G0600986 ID79068) and National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme). Authors' support: EPT - Swedish Society of Medicine (Grant no. SLS-587221); KLHC - National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme); PJH - National Institute for Health Research Professorship, Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship and the National Institute for Health Research Biomedical Research Centre, Cambridge; AH - Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship, Royal College of Surgeons of England Pump Priming Grant and the National Institute for Health Research Biomedical Research Centre, Cambridge; RP - Wellcome Trust Intermediate Clinical Fellow (101149/Z/13/A). We acknowledge support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The funding bodies did not participate in the design of the study; collection, analysis, and interpretation of data; and writing of the article.	Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; ALOISI F, 1992, J IMMUNOL, V149, P2358; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; Carlson NG, 1999, J IMMUNOL, V163, P3963; Cavaillon JM, 2001, CELL MOL BIOL, V47, P695; Cebrian C, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00114; Cebrian C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4633; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chatzipanteli K, 2012, THER HYPOTHERMIA TEM, V2, P167, DOI 10.1089/ther.2012.0016; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen WQ, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0847-0; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Deshpande M, 2005, NEUROTOX RES, V7, P183, DOI 10.1007/BF03036448; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; FREIDIN M, 1992, P NATL ACAD SCI USA, V89, P10440, DOI 10.1073/pnas.89.21.10440; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gahring LC, 1996, NEUROIMMUNOMODULAT, V3, P289, DOI 10.1159/000097283; Gougeon PY, 2013, J NEUROSCI, V33, P3339, DOI 10.1523/JNEUROSCI.3564-12.2013; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hall CE, 2017, CELL REP, V19, P1739, DOI 10.1016/j.celrep.2017.05.024; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Helmy A, 2016, J CEREBR BLOOD F MET, V36, P1434, DOI 10.1177/0271678X15620204; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Joannides AJ, 2007, STEM CELLS, V25, P731, DOI 10.1634/stemcells.2006-0562; Johansson S, 2008, STEM CELLS, V26, P2444, DOI 10.1634/stemcells.2008-0116; LEE SC, 1993, J IMMUNOL, V150, P2659; Li J, 2001, J BIOL CHEM, V276, P18579, DOI 10.1074/jbc.M100846200; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Medana IM, 2000, EUR J IMMUNOL, V30, P3623, DOI 10.1002/1521-4141(200012)30:12<3623::AID-IMMU3623>3.0.CO;2-F; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MURPHY PG, 1995, J NEUROSCI, V15, P5130; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; Parnet P, 2002, J NEUROIMMUNOL, V125, P5, DOI 10.1016/S0165-5728(02)00022-X; PARNET P, 1994, MOL BRAIN RES, V27, P63, DOI 10.1016/0169-328X(94)90185-6; Patani R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007327; Perigolo-Vicente R, 2013, BIOCHEM BIOPH RES CO, V430, P512, DOI 10.1016/j.bbrc.2012.12.004; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Prabowo AS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-12; Probert L, 2015, NEUROSCIENCE, V302, P2, DOI 10.1016/j.neuroscience.2015.06.038; Pruszak J, 2007, STEM CELLS, V25, P2257, DOI 10.1634/stemcells.2006-0744; Ringheim GE, 1995, J NEUROIMMUNOL, V63, P113, DOI 10.1016/0165-5728(95)00134-4; Roberts DJ, 2013, J NEUROTRAUM, V30, P1727, DOI 10.1089/neu.2012.2842; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; Schwartz M, 2010, NAT REV NEUROL, V6, P405, DOI 10.1038/nrneurol.2010.71; SEBIRE G, 1993, J IMMUNOL, V150, P1517; Simon DW, 2017, NAT REV NEUROL, V13, P572, DOI 10.1038/nrneurol.2017.116; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; THELIN EP, 2017, FRONT NEUROL, V0008; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; Tsakiri N, 2008, MOL CELL NEUROSCI, V38, P259, DOI 10.1016/j.mcn.2008.02.015; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	72	19	21	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2018	35	2					341	352		10.1089/neu.2017.5155		NOV 2017	12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FT1TA	WOS:000414574900001	28978285	Bronze, Green Published			2021-06-18	
J	Marini, A; Zettin, M; Bencich, E; Bosco, FM; Galetto, V				Marini, Andrea; Zettin, Marina; Bencich, Erica; Bosco, Francesca Marina; Galetto, Valentina			Severity effects on discourse production after TBI	JOURNAL OF NEUROLINGUISTICS			English	Article						Traumatic brain injury; TBI severity; Narrative analysis; Language	TRAUMATIC BRAIN-INJURY; NARRATIVE LANGUAGE; HEAD-INJURY; MULTILEVEL APPROACH; EXECUTIVE FUNCTIONS; STORY NARRATIVES; CONNECTED SPEECH; MILD; ADULTS; DEFICITS	Persons with traumatic brain injury (TBI) often experience macrolinguistic (i.e., pragmatic and discourse) difficulties. However, it is still not clear whether these difficulties are related to their cognitive impairments and little research has investigated communication abilities across the severity spectrum of TBI. This study compared the cognitive profile and narrative performance of persons with mild-to-moderate TBI, individuals with severe TBI and healthy control participants by adopting a multilevel procedure for discourse analysis. The results showed both severity-dependent and severity-independent effects on the participants' cognitive and narrative skills. A series of correlational analyses and two Principal Component Analyses confirmed the articulated nature of their narrative impairments and the complex interplay between cognitive and discourse difficulties in both groups of patients. The results from this study suggest that trauma severity influences the gravity of some of the symptoms observed in persons with TBI. At the same time, however, they highlight the cognitive nature of their narrative difficulties. (C) 2017 Elsevier Ltd. All rights reserved.	[Marini, Andrea] Univ Udine, Dipartimento Lingue & Letterature Comunicaz Forma, Via Margreth 3, I-33100 Udine, Italy; [Marini, Andrea] Claudiana Landesfachhsch Gesundheitsberufe, Lorenz Bohler Str 13, I-39100 Bolzano, Italy; [Bencich, Erica] Univ Trieste, Dipartimento Sci Vita, Trieste, Italy; [Zettin, Marina; Galetto, Valentina] Ctr Puzzle, Turin, Italy; [Zettin, Marina; Bosco, Francesca Marina; Galetto, Valentina] Univ Torino, Dipartimento Psicol, Turin, Italy	Marini, A (corresponding author), Univ Udine, Dipartimento Lingue & Letterature Comunicaz Forma, Via Margreth 3, I-33100 Udine, Italy.	andrea.marini@uniud.it	bosco, francesca marina/B-6746-2013; Marini, Andrea/A-1206-2012	bosco, francesca marina/0000-0001-6101-8587; Marini, Andrea/0000-0002-6058-3864			Andreetta S, 2015, APHASIOLOGY, V29, P705, DOI 10.1080/02687038.2014.979394; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Barker MS, 2017, BRAIN LANG, V168, P23, DOI 10.1016/j.bandl.2017.01.004; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Body R, 2004, BRAIN INJURY, V18, P707, DOI 10.1080/02699050310001596914; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Bosco FM, 2017, BRAIN LANG, V168, P73, DOI 10.1016/j.bandl.2017.01.007; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Carlesimo GA, 1997, CORTEX, V33, P155, DOI 10.1016/S0010-9452(97)80011-1; Carlomagno S, 2011, BRAIN INJURY, V25, P1010, DOI 10.3109/02699052.2011.605097; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho C, 2013, AM J SPEECH-LANG PAT, V22, pS438, DOI 10.1044/1058-0360(2013/12-0076); Coelho C, 2012, NEUROPSYCHOLOGIA, V50, P3564, DOI 10.1016/j.neuropsychologia.2012.09.005; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Ellis C, 2009, NEUROREHABILITATION, V24, P255, DOI 10.3233/NRE-2009-0476; Erez ABH, 2009, AM J OCCUP THER, V63, P634; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Galetto V, 2013, J NEUROLINGUIST, V26, P649, DOI 10.1016/j.jneuroling.2013.05.004; Gernsbacher Morton Ann, 1999, Discourse Stud, V1, P355, DOI 10.1177/1461445699001003004; GERNSBACHER Morton Ann, 1990, LANGUAGE COMPREHENSI; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Green S. B., 2008, USING SASS WINDOW MA; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Heaton R., 1993, WISCONSIN CARD SORTI; HUBER W, 1982, BRAIN LANG, V16, P1, DOI 10.1016/0093-934X(82)90069-4; Indefrey P., 2000, NEW COGNITIVE NEUROS, P845; Jorgensen M, 2009, BRAIN INJURY, V23, P727, DOI 10.1080/02699050903133954; Kave G, 2011, J CLIN EXP NEUROPSYC, V33, P358, DOI 10.1080/13803395.2010.518703; Kertesz A., 1982, W APHASIA BATTERY; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Larson MJ, 2012, J INT NEUROPSYCH SOC, V18, P323, DOI 10.1017/S1355617711001779; Le K, 2012, AM J SPEECH-LANG PAT, V21, pS115, DOI 10.1044/1058-0360(2012/11-0114); Le K, 2011, APHASIOLOGY, V25, P748, DOI 10.1080/02687038.2010.539696; Levelt W. J. M., 1989, SPEAKING INTENTION A; Levelt WJM, 1999, BEHAV BRAIN SCI, V22, P1; Luzzatti C., 1991, AACHENER APHASIE TES; Marini A, 2005, BRAIN LANG, V93, P46, DOI 10.1016/j.bandl.2004.08.002; Marini A, 2011, APHASIOLOGY, V25, P1372, DOI 10.1080/02687038.2011.584690; Marini A, 2014, NEUROPSYCHOLOGIA, V64, P282, DOI 10.1016/j.neuropsychologia.2014.09.042; Marini A, 2012, J COGNITIVE NEUROSCI, V24, P2211, DOI 10.1162/jocn_a_00283; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mozeiko J, 2011, APHASIOLOGY, V25, P826, DOI 10.1080/02687038.2010.543983; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Peach RK, 2013, AM J SPEECH-LANG PAT, V22, pS285, DOI 10.1044/1058-0360(2013/12-0081); Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Raven JC, 1938, PROGRESSIVE MATRICES; Reitan R. M, 1992, TRAIL MAKING TEST; Rey A., 1958, LEXAMEN CLINIQUE PSY; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Sherratt S, 2007, APHASIOLOGY, V21, P375, DOI 10.1080/02687030600911435; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Soldatovic-Stajic B, 2014, EUR REV MED PHARMACO, V18, P1632; Stierwalt Julie A. G., 2002, Seminars in Speech and Language, V23, P129, DOI 10.1055/s-2002-24989; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Tu LV, 2011, BRAIN INJURY, V25, P560, DOI 10.3109/02699052.2011.571655; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wright HH, 2012, APHASIOLOGY, V26, P656, DOI 10.1080/02687038.2012.676855; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951; Zimmermann N, 2015, BRAIN INJURY, V29, P1071, DOI 10.3109/02699052.2015.1015613	72	19	19	1	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0911-6044			J NEUROLINGUIST	J. Neurolinguist.	NOV	2017	44						91	106		10.1016/j.jneuroling.2017.03.005			16	Linguistics; Neurosciences; Psychology, Experimental	Linguistics; Neurosciences & Neurology; Psychology	FH8BZ	WOS:000411418100006					2021-06-18	
J	Vedantam, A; Robertson, CS; Gopinath, SP				Vedantam, Aditya; Robertson, Claudia S.; Gopinath, Shankar P.			Morbidity and mortality associated with hypernatremia in patients with severe traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						severe traumatic brain injury; hypernatremia; neurocritical care; mannitol; mortality	ANEURYSMAL SUBARACHNOID HEMORRHAGE; INTENSIVE-CARE-UNIT; RENAL BLOOD-FLOW; CRITICALLY-ILL; ACQUIRED HYPERNATREMIA; HYPERTONIC SALINE; RISK; THERAPY	OBJECTIVE Hypernatremia is independently associated with increased mortality in critically ill patients. Few studies have evaluated the impact of hypernatremia on early mortality in patients with severe traumatic brain injury (TBI) treated in a neurocritical care unit. METHODS A retrospective review of patients with severe TBI (admission Glasgow Coma Scale score <= 8) treated in a single neurocritical care unit between 1986 and 2012 was performed. Patients with at least 3 serum sodium values were selected for the study. Patients with diabetes insipidus and those with hypernatremia on admission were excluded. The highest serum sodium level during the hospital stay was recorded, and hypernatremia was classified as none (<= 150 mEq/L), mild (151-155 mEq/L), moderate (156-160 mEq/L), and severe (> 160 mEq/L). Multivariate Cox regression analysis was performed to determine independent predictors of early mortality. RESULTS A total of 588 patients with severe TBI were studied. The median number of serum sodium measurements for patients in this study was 17 (range 3-190). No hypernatremia was seen in 371 patients (63.1%), mild hypernatremia in 77 patients (13.1%), moderate hypernatremia in 50 patients (8.5%), and severe hypernatremia in 90 patients (15.3%). Hypernatremia was detected within the 1st week of admission in 79.3% of patients (n = 172), with the majority of patients (46%) being diagnosed within 72 hours after admission. Acute kidney injury, defined as a rise in creatinine of = 0.3 mg/dl, was observed in 162 patients (27.6%) and was significantly associated with the degree of hypernatremia (p < 0.001). At discharge, 148 patients (25.2%) had died. Hypernatremia was a significant independent predictor of mortality (hazard ratios for mild: 3.4, moderate: 4.4, and severe: 8.4; p < 0.001). Survival analysis showed significantly lower survival rates for patients with greater degrees of hypernatremia (log-rank test, p < 0.001). CONCLUSIONS Hypernatremia after admission in patients with severe TBI was independently associated with greater risk of early mortality. In addition to severe hypernatremia, mild and moderate hypernatremia were significantly associated with increased early mortality in patients with severe TBI.	[Vedantam, Aditya; Robertson, Claudia S.; Gopinath, Shankar P.] Baylor Coll Med, Dept Neurosurg, 7200 Cambridge,Ste 9A,MS BCM650, Houston, TX 77030 USA	Gopinath, SP (corresponding author), Baylor Coll Med, Dept Neurosurg, 7200 Cambridge,Ste 9A,MS BCM650, Houston, TX 77030 USA.	shankarg@bcm.edu					Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006; Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; Ayus JC, 1996, J PHYSIOL-LONDON, V492, P243, DOI 10.1113/jphysiol.1996.sp021305; Beseoglu K, 2014, CLIN NEUROL NEUROSUR, V123, P164, DOI 10.1016/j.clineuro.2014.05.022; Darmon M, 2010, NEPHROL DIAL TRANSPL, V25, P2510, DOI 10.1093/ndt/gfq067; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; GERBER JG, 1979, AM J PHYSIOL, V237, pF441; Hadjizacharia P, 2008, J AM COLL SURGEONS, V207, P477, DOI 10.1016/j.jamcollsurg.2008.04.017; KAHN A, 1979, INTENS CARE MED, V5, P27, DOI 10.1007/BF01738999; Kolmodin L, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-35; Li M, 2013, INJURY, V44, P1213, DOI 10.1016/j.injury.2012.05.021; Lindner G, 2007, AM J KIDNEY DIS, V50, P952, DOI 10.1053/j.ajkd.2007.08.016; Lindner G, 2013, J CRIT CARE, V28, P214, DOI 10.1016/j.jcrc.2012.11.017; Lindner G, 2010, INTENS CARE MED, V36, P1718, DOI 10.1007/s00134-010-1968-4; Maggiore U, 2009, CRIT CARE, V13, DOI 10.1186/cc7953; Molitoris BA, 2007, NAT CLIN PRACT NEPHR, V3, P439, DOI 10.1038/ncpneph0551; O'Donoghue SD, 2009, ANAESTHESIA, V64, P514, DOI 10.1111/j.1365-2044.2008.05857.x; Qureshi AI, 2002, NEUROSURGERY, V50, P749, DOI 10.1097/00006123-200204000-00012; Shehata M, 2010, CRIT CARE S1, V14, pP355; Tisdall M, 2006, J NEUROSURG ANESTH, V18, P57, DOI 10.1097/01.ana.0000191280.05170.0f; WILCOX CS, 1983, J CLIN INVEST, V71, P726, DOI 10.1172/JCI110820	21	19	19	1	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2017	43	5							E2	10.3171/2017.7.FOCUS17418			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FL5JE	WOS:000414270800004	29088954	Bronze			2021-06-18	
J	Yuan, WH; Wade, SL; Quatman-Yates, C; Hugentobler, JA; Gubanich, PJ; Kurowski, BG				Yuan, Weihong; Wade, Shari L.; Quatman-Yates, Catherine; Hugentobler, Jason A.; Gubanich, Paul J.; Kurowski, Brad G.			Structural Connectivity Related to Persistent Symptoms After Mild TBI in Adolescents and Response to Aerobic Training: Preliminary Investigation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aerobic training; DTI tractography; graph theory; mild traumatic brain injury; persistent symptom; structural connectivity	TRAUMATIC BRAIN-INJURY; HEALTH-CARE UTILIZATION; BEHAVIOR PROBLEMS; UNITED-STATES; INPATIENT REHABILITATION; EDUCATIONAL-SERVICES; EARLY-CHILDHOOD; YOUNG-CHILDREN; SHORT-TERM; PREDICTORS	Objective: To quantify structural connectivity abnormalities in adolescents with mild traumatic brain injury (mTBI) and to investigate connectivity changes following aerobic training using graph theory and diffusion tensor imaging tractography. Setting: Outpatient research setting. Participants: Twenty-two children (age: 15.83 +/- 1.77 years, 10 females) with 4 to 16 weeks of persistent symptoms aftermTBI and a matched healthy comparison group. Design: Randomized clinical trial of aerobic training and stretching comparison combined with case-control comparison. Main Measures: (1) Five global network measures: global efficiency (Eglob), mean local efficiency, modularity, normalized clustering coefficient (gamma), normalized characteristic path length (lambda), and small-worldness (sigma). (2) The self-reported Post-Concussion Symptom Inventory score. Results: At initial enrollment, adolescents with mTBI had significantly lower Eglob and higher gamma, lambda, and sigma (all P <.05) than healthy peers. After the intervention, significantly increased Eglob and decreased lambda (both P <.05) were found in the aerobic training group. Improvement in Post-Concussion Symptom Inventory scores was significantly correlated with the Eglob increase and lambda decrease in the aerobic training and lambda decrease in the stretching comparison group (all P <.05). Conclusion: This pilot study showed initial evidence that structural connectivity analysis was sensitive to brain network abnormalities and may serve as an imaging biomarker in children with persistent symptoms after mTBI.	[Yuan, Weihong] Cincinnati Childrens Hosp Med Ctr, Pediat Neuroimaging Res Ctr, Cincinnati, OH 45229 USA; [Wade, Shari L.; Kurowski, Brad G.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA; [Quatman-Yates, Catherine; Hugentobler, Jason A.; Gubanich, Paul J.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Yuan, Weihong; Wade, Shari L.; Kurowski, Brad G.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Kurowski, BG (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	Brad.Kurowski@cchmc.org	Quatman-Yates, Catherine/AAK-4507-2021; Quatman-Yates, Catherine/U-9580-2019		Cincinnati Children's Research Foundation Trustees Grant program; Ohio Department of Public Safety; National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD07468]; National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8 UL1 TR000077]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T35HD007468] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077, KL2TR001426] Funding Source: NIH RePORTER	Funding for this study was supported in part by the Cincinnati Children's Research Foundation Trustees Grant program, Ohio Department of Public Safety, National Institute for Child Health and Human Development K23HD07468, and grant 8 UL1 TR000077 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or other supporting agencies.	Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Babikian T, 2015, J NEUROTRAUM, V32, P1849, DOI 10.1089/neu.2015.3971; Ballard DW, 2013, ACAD EMERG MED, V20, P352, DOI 10.1111/acem.12109; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; BEGALI V, 1992, HEAD INJURY CHILDREN; Bennett TD, 2013, ARCH PHYS MED REHAB, V94, P1268, DOI 10.1016/j.apmr.2013.02.021; Brooks BL, 2016, CHILD NEUROPSYCHOL, V22, P1001, DOI 10.1080/09297049.2015.1075491; Bulgren J.A., 2006, TEACHING ADOLESCENTS, P79; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Catroppa C, 2010, STUD NEUROPSYCHOL NE, P439; Catroppa C, 2011, BRAIN INJURY, V25, P858, DOI 10.3109/02699052.2011.589794; Centers for Disease Control National Center for Injury Prevention and Control Division of Unintentional Injury, 2001, RAT TBI REL HOSP AG; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Connery AK, 2016, CLIN NEUROPSYCHOL, V30, P579, DOI 10.1080/13854046.2016.1177596; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Crowe LM, 2005, HDB CLIN NEUROLOGY, V128, P661; Dettmer J, 2014, J HEAD TRAUMA REHAB, V29, P224, DOI 10.1097/HTR.0b013e3182a1cd68; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Ennis SK, 2013, BRAIN INJURY, V27, P179, DOI 10.3109/02699052.2012.729291; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Gfroerer SD, 2008, BRAIN INJURY, V22, P649, DOI 10.1080/02699050802227162; Gioia GA, 2010, J HEAD TRAUMA REHAB, V25, P433, DOI 10.1097/HTR.0b013e3181fbc272; Glang A, 2004, NEUROREHABILITATION, V19, P219; Glang A, 2008, NEUROREHABILTIATION, V23, P13; Glang A, 2015, EXCEPTIONALITY, V23, P211, DOI 10.1080/09362835.2014.986612; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Greene NH, 2014, ARCH PHYS MED REHAB, V95, P1148, DOI 10.1016/j.apmr.2014.02.020; Haarbauer-Krupa J, 2012, THE ASHA LEADER 0703; Haarbauer-Krupa J, 2009, BRAIN INJURY PROFESS, V6; Jimenez N, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3500; Keenan HT, 2013, J HEAD TRAUMA REHAB, V28, P426, DOI 10.1097/HTR.0b013e31825935b8; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2016, J PEDIATR-US, V169, P244, DOI 10.1016/j.jpeds.2015.10.014; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; Moore M, 2016, AM J PHYS MED REHAB, V95, P204, DOI 10.1097/PHM.0000000000000362; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; Pineda JA, 2013, LANCET NEUROL, V12, P45, DOI 10.1016/S1474-4422(12)70269-7; Rivara FP, 2012, ARCH PHYS MED REHAB, V93, P381, DOI 10.1016/j.apmr.2011.08.015; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Savage RC, 1995, PERSPECT NETW, pV; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schootman M, 2000, BRAIN INJURY, V14, P373; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 2015, J HEAD TRAUMA REHAB, V4, P1; Taylor HG., 2006, EXCEPTIONALITY, V14, P141, DOI [10.1207/s15327035ex1403_3, DOI 10.1207/S15327035EX1403_3, DOI 10.1207/S15327035EX1403_]; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Todis B, 2011, J HEAD TRAUMA REHAB, V26, P138, DOI 10.1097/HTR.0b013e3181e5a87a; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P221; Ylvisaker Mark, 2007, Phys Med Rehabil Clin N Am, V18, P133, DOI 10.1016/j.pmr.2006.11.007	82	19	19	2	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2017	32	6					378	384		10.1097/HTR.0000000000000318			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FQ8BO	WOS:000418588100093	28520668	Green Accepted			2021-06-18	
J	Izzy, S; Mazwi, NL; Martinez, S; Spencer, CA; Klein, JP; Parikh, G; Glenn, MB; Greenberg, SM; Greer, DM; Wu, O; Edlow, BL				Izzy, Saef; Mazwi, Nicole L.; Martinez, Sergi; Spencer, Camille A.; Klein, Joshua P.; Parikh, Gunjan; Glenn, Mel B.; Greenberg, Steven M.; Greer, David M.; Wu, Ona; Edlow, Brian L.			Revisiting Grade 3 Diffuse Axonal Injury: Not All Brainstem Microbleeds are Prognostically Equal	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Traumatic axonal injury; Diffuse axonal injury; Gradient-recalled echo MRI; Traumatic microbleed; Brainstem	DISABILITY RATING-SCALE; TRAUMATIC HEAD-INJURY; VASCULAR INJURY; WHITE-MATTER; LESIONS; COMA; MRI; CLASSIFICATION; IMMEDIATE; IMPACT	Recovery of functional independence is possible in patients with brainstem traumatic axonal injury (TAI), also referred to as "grade 3 diffuse axonal injury," but acute prognostic biomarkers are lacking. We hypothesized that the extent of dorsal brainstem TAI measured by burden of traumatic microbleeds (TMBs) correlates with 1-year functional outcome more strongly than does ventral brainstem, corpus callosal, or global brain TMB burden. Further, we hypothesized that TMBs within brainstem nuclei of the ascending arousal network (AAN) correlate with 1-year outcome. Using a prospective outcome database of patients treated for moderate-to-severe traumatic brain injury at an inpatient rehabilitation hospital, we retrospectively identified 39 patients who underwent acute gradient-recalled echo (GRE) magnetic resonance imaging (MRI). TMBs were counted on the acute GRE scans globally and in the dorsal brainstem, ventral brainstem, and corpus callosum. TMBs were also mapped onto an atlas of AAN nuclei. The primary outcome was the disability rating scale (DRS) score at 1 year post-injury. Associations between regional TMBs, AAN TMB volume, and 1-year DRS score were assessed by calculating Spearman rank correlation coefficients. Mean +/- SD number of TMBs was: dorsal brainstem = 0.7 +/- 1.4, ventral brainstem = 0.2 +/- 0.6, corpus callosum = 1.8 +/- 2.8, and global = 14.4 +/- 12.5. The mean +/- SD TMB volume within AAN nuclei was 6.1 +/- 18.7 mm(3). Increased dorsal brainstem TMBs and larger AAN TMB volume correlated with worse 1-year outcomes (R = 0.37, p = 0.02, and R = 0.36, p = 0.02, respectively). Global, callosal, and ventral brainstem TMBs did not correlate with outcomes. These findings suggest that dorsal brainstem TAI, especially involving AAN nuclei, may have greater prognostic utility than the total number of lesions in the brain or brainstem.	[Izzy, Saef; Martinez, Sergi; Spencer, Camille A.; Greenberg, Steven M.; Edlow, Brian L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA; [Izzy, Saef; Klein, Joshua P.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA; [Klein, Joshua P.] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA USA; [Mazwi, Nicole L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Mazwi, Nicole L.; Glenn, Mel B.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA; [Parikh, Gunjan] Univ Maryland, Sch Med, Dept Neurol, Program Trauma, Baltimore, MD 21201 USA; [Wu, Ona; Edlow, Brian L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Greer, David M.] Yale New Haven Med Ctr, Yale Sch Med, Dept Neurol, 20 York St, New Haven, CT 06504 USA; [Wu, Ona] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA	Izzy, S (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA.; Izzy, S (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.	Sizzy@bwh.harvard.edu	Demchuk, Andrew M/E-1103-2012; Parikh, Gunjan/AAS-1375-2020	Demchuk, Andrew M/0000-0002-4930-7789; Parikh, Gunjan/0000-0002-8447-1349; Wu, Ona/0000-0002-5509-9461; Greer, David/0000-0002-2026-8333	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R25NS065743, K23NS094538]; American Academy of Neurology/American Brain Foundation; James S. McDonnell Foundation; National Institute on Disability, Independent Living, and Rehabilitation Research, Administration for Community Living, US Department Health and Human Services [H133A120085]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS094538, R25NS065743] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health (R25NS065743, K23NS094538), the American Academy of Neurology/American Brain Foundation, the James S. McDonnell Foundation, and the National Institute on Disability, Independent Living, and Rehabilitation Research, Administration for Community Living, US Department Health and Human Services to Spaulding Rehabilitation Hospital (H133A120085). However, the contents of this manuscript do not necessarily represent the policy of the Department of Health and Human Services and endorsement by the Federal Government should not be assumed.	ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aguas J, 2005, NEUROCIRUGIA, V16, P14; CROMPTON MR, 1966, LANCET, V2, P938; Edlow BL, 2016, NEUROCRIT CARE, V24, P342, DOI 10.1007/s12028-015-0216-8; Edlow BL, 2016, BRAIN CONNECT, V6, P187, DOI 10.1089/brain.2015.0378; Edlow BL, 2012, J NEUROPATH EXP NEUR, V71, P531, DOI 10.1097/NEN.0b013e3182588293; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Izzy S, 2013, NEUROCRIT CARE, V19, P347, DOI 10.1007/s12028-013-9925-z; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Martinez-Ramirez S, 2015, ALZHEIMERS DEMENT, V11, P1480, DOI 10.1016/j.jalz.2015.04.009; Muehlschlegel S, 2013, NEUROCRIT CARE, V18, P318, DOI 10.1007/s12028-013-9817-2; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Parikh G, 2013, NEUROLOGY, V80, pE205; Parvizi J, 2001, COGNITION, V79, P135, DOI 10.1016/S0010-0277(00)00127-X; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ricciardi MC, 2017, J NEUROTRAUM, V34, P23, DOI 10.1089/neu.2015.4338; Rosenblum WI, 2015, J NEUROPATH EXP NEUR, V74, P198, DOI 10.1097/NEN.0000000000000170; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4	47	19	20	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2017	27	2					199	207		10.1007/s12028-017-0399-2			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	FJ4VC	WOS:000412739900007	28477152	Green Accepted			2021-06-18	
J	Mountney, A; Boutte, AM; Cartagena, CM; Flerlage, WF; Johnson, WD; Rho, C; Lu, XC; Yarnell, A; Marcsisin, S; Sousa, J; Vuong, C; Zottig, V; Leung, LY; Deng-Bryant, Y; Gilsdorf, J; Tortella, FC; Shear, DA				Mountney, Andrea; Boutte, Angela M.; Cartagena, Casandra M.; Flerlage, William F.; Johnson, Wyane D.; Rho, Chanyang; Lu, Xi-Chu; Yarnell, Angela; Marcsisin, Sean; Sousa, Jason; Chau Vuong; Zottig, Victor; Leung, Lai-Yee; Deng-Bryant, Ying; Gilsdorf, Janice; Tortella, Frank C.; Shear, Deborah A.			Functional and Molecular Correlates after Single and Repeated Rat Closed-Head Concussion: Indices of Vulnerability after Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						ataxia; CatWalk; chronic traumatic encephalopathy; concussion; GFAP; mild TBI; Neurobehavioral Severity Scale-Revised; quantitative electroencephalography; rodent gait; tau	TRANSIENT FOCAL ISCHEMIA; COLLEGIATE FOOTBALL PLAYERS; US MILITARY PERSONNEL; CEREBROSPINAL-FLUID; MOUSE MODEL; MATRIX METALLOPROTEINASES; INTRACRANIAL LESIONS; MICRORNA EXPRESSION; GAIT ABNORMALITIES; BALANCE ASSESSMENT	Closed-head concussive injury is one of the most common causes of traumatic brain injury (TBI). Isolated concussions frequently produce acute neurological impairments, and individuals typically recover spontaneously within a short time frame. In contrast, brain injuries resulting from multiple concussions can result in cumulative damage and elevated risk of developing chronic brain pathologies. Increased attention has focused on identification of diagnostic markers that can prognostically serve as indices of brain health after injury, revealing the temporal profile of vulnerability to a second insult. Such markers may demarcate adequate recovery periods before concussed patients can return to required activities. We developed a noninvasive closed-head impact model that captures the hallmark symptoms of concussion in the absence of gross tissue damage. Animals were subjected to single or repeated concussive impact and examined using a battery of neurological, vestibular, sensorimotor, and molecular metrics. A single concussion induced transient, but marked, acute neurological impairment, gait alterations, neuronal death, and increased glial fibrillary acidic protein (GFAP) expression in brain tissue. As expected, repeated concussions exacerbated sensorimotor dysfunction, prolonged gait abnormalities, induced neuroinflammation, and upregulated GFAP and tau. These animals also exhibited chronic functional neurological impairments with sustained astrogliosis and white matter thinning. Acute changes in molecular signatures correlated with behavioral impairments, whereas increased times to regaining consciousness and balance impairments were associated with higher GFAP and neuroinflammation. Overall, behavioral consequences of either single or repeated concussive impact injuries appeared to resolve more quickly than the underlying molecular, metabolic, and neuropathological abnormalities. This observation, which is supported by similar studies in other mTBI models, underscores the critical need to develop more objective prognostic measures for guiding return-to-play decisions.	[Mountney, Andrea; Boutte, Angela M.; Cartagena, Casandra M.; Flerlage, William F.; Johnson, Wyane D.; Rho, Chanyang; Lu, Xi-Chu; Leung, Lai-Yee; Deng-Bryant, Ying; Gilsdorf, Janice; Tortella, Frank C.; Shear, Deborah A.] Walter Reed Army Inst Res, Brain Trauma Neuroprotect & Neurorestorat Branch, Ctr Mil Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Yarnell, Angela] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Behav Biol Branch, Silver Spring, MD USA; [Marcsisin, Sean; Sousa, Jason; Chau Vuong; Zottig, Victor] Walter Reed Army Inst Res, Mil Malaria Res, Div Expt Therapeut, Silver Spring, MD USA	Mountney, A (corresponding author), Walter Reed Army Inst Res, Brain Trauma Neuroprotect & Neurorestorat Branch, Ctr Mil Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	andrea.mountney.mil@mail.mil	Sousa, Jason/A-9177-2011		United States Army grants [W81XWH-12-2-0134, H_024_2014_WRAIR]	This research was supported by United States Army grants W81XWH-12-2-0134 and H_024_2014_WRAIR. The authors are grateful to Weihong Yang, Ying Cao, Matthew Wise, and the Walter Reed Army Institute of Research Pathology Department for their technical assistance. This material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting true views of Department of the Army or Department of Defense.	Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; Allison L., 1999, NEUROL REP, V23, P14; Almeida-Suhett CP, 2014, J NEUROTRAUM, V31, P683, DOI 10.1089/neu.2013.3029; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Belanger HG, 2016, J HEAD TRAUMA REHAB, V31, P159, DOI 10.1097/HTR.0000000000000138; Benedetti MG, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-64; Bey T, 2009, WEST J EMERG MED, V10, P6; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chen ZY, 2012, J NEUROTRAUM, V29, P268, DOI 10.1089/neu.2011.2057; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cunningham TL, 2014, J NEUROTRAUM, V31, P505, DOI 10.1089/neu.2013.2965; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Deng-Bryant Y, 2016, METHODS MOL BIOL, V1462, P539, DOI 10.1007/978-1-4939-3816-2_29; Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Dunkley BT, 2015, NEUROIMAGE-CLIN, V7, P611, DOI 10.1016/j.nicl.2015.02.020; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Fischer H., 2014, GUIDE US MILITARY CA, P1; Freilich RW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079416; Gao HB, 2017, BRAIN RES, V1657, P1, DOI 10.1016/j.brainres.2016.11.028; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Goddeyne C, 2015, J NEUROPHYSIOL, V113, P3268, DOI 10.1152/jn.00970.2014; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; Iverson D, 2010, J OCCUP ENVIRON MED, V52, P1206, DOI 10.1097/JOM.0b013e3181fd276a; Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736; Jia LH, 2015, CELL BIOCHEM FUNCT, V33, P314, DOI 10.1002/cbf.3116; Johnson D, 2015, J NEUROTRAUM, V32, pA36; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Katayama T, 2009, J PHARMACOL SCI, V109, P88, DOI 10.1254/jphs.08298FP; Khalin I, 2016, NEURAL REGEN RES, V11, P630, DOI 10.4103/1673-5374.180749; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Lee MA, 1999, BRAIN, V122, P191, DOI 10.1093/brain/122.2.191; Leung LY, 2014, ANN BIOMED ENG, V42, P1618, DOI 10.1007/s10439-014-1014-8; Lorenzl S, 2003, J NEUROL SCI, V207, P71, DOI 10.1016/S0022-510X(02)00398-2; Lu XCM, 2011, J NEUROTRAUM, V28, P71, DOI 10.1089/neu.2010.1471; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; MacGregor AJ, 2011, J REHABIL RES DEV, V48, P1269, DOI 10.1682/JRRD.2011.01.0013; Madathil SK, 2011, BIOESSAYS, V33, P21, DOI 10.1002/bies.201000069; Maier B, 2006, SHOCK, V26, P122, DOI 10.1097/01.shk.0000223127.41641.f4; Mancini M, 2010, EUR J PHYS REHAB MED, V46, P239; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McAteer KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160220; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miyauchi T, 2014, J NEUROTRAUM, V31, P773, DOI 10.1089/neu.2013.3181; Modarres M, 2016, NEUROBIOL SLEEP CIRC, V1; Mountney A, 2013, J NEUROTRAUM, V30, P1973, DOI 10.1089/neu.2013.3001; Mountney A, 2013, J NEUROSCI METH, V212, P1, DOI 10.1016/j.jneumeth.2012.08.025; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Phillips DJ, 2006, J NEUROTRAUM, V23, P1283, DOI 10.1089/neu.2006.23.1283; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rapp PE, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00011; Rivera S, 2002, EUR J NEUROSCI, V15, P19, DOI 10.1046/j.0953-816x.2001.01838.x; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; SWASH M, 1988, J NEUROL NEUROSUR PS, V51, P785, DOI 10.1136/jnnp.51.6.785; Tan L, 2014, J ALZHEIMERS DIS, V40, P1017, DOI 10.3233/JAD-132144; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; TERASHIMA T, 1995, NEUROSCI RES, V22, P139, DOI 10.1016/0168-0102(95)00895-9; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; Tsai MC, 2008, SURG NEUROL, V70, P19, DOI 10.1016/j.surneu.2007.09.033; Underwood E, 2013, SCIENCE, V339, P1367, DOI 10.1126/science.339.6126.1367; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vyazovskiy VV, 2011, NATURE, V472, P443, DOI 10.1038/nature10009; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Watts RP, 2013, J TRANSPLANT, V2013, DOI 10.1155/2013/521369; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Weinstein E, 2013, J NEUROSURG-PEDIATR, V11, P331, DOI 10.3171/2012.11.PEDS12343; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Williams G, 2009, ARCH PHYS MED REHAB, V90, P587, DOI 10.1016/j.apmr.2008.10.013; Winter D., 1995, GAIT POSTURE, V3, P193, DOI 10.1016/0966-6362(96)82849-9; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu LY, 2015, EXP NEUROL, V273, P168, DOI 10.1016/j.expneurol.2015.08.014; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yamagami S, 1999, J LEUKOCYTE BIOL, V65, P744; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yarnell Angela M, 2016, Curr Protoc Neurosci, V75, DOI 10.1002/cpns.10; Yu FS, 2017, J NEUROTRAUM, V34, P1364, DOI 10.1089/neu.2016.4569; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zheng KB, 2013, NEUROL INDIA, V61, P606, DOI 10.4103/0028-3886.125258; Zuckerman SL, 2015, WORLD NEUROSURG, V83, P1098, DOI 10.1016/j.wneu.2014.12.030	133	19	19	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2017	34	19					2768	2789		10.1089/neu.2016.4679			22	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FI1DZ	WOS:000411672700012	28326890				2021-06-18	
J	Tao, WS; Dvoriantchikova, G; Tse, BC; Pappas, S; Chou, TH; Tapia, M; Porciatti, V; Ivanov, D; Tse, DT; Pelaez, D				Tao, Wensi; Dvoriantchikova, Galina; Tse, Brian C.; Pappas, Steven; Chou, Tsung-Han; Tapia, Manuel; Porciatti, Vittorio; Ivanov, Dmitry; Tse, David T.; Pelaez, Daniel			A Novel Mouse Model of Traumatic Optic Neuropathy Using External Ultrasound Energy to Achieve Focal, Indirect Optic Nerve Injury	SCIENTIFIC REPORTS			English	Article							RETINAL INJURY; CONTRIBUTES; CASCADE; MICE	Traumatic optic neuropathy (TON) is a devastating cause of permanent visual loss following blunt injury to the head. Animal models for TON exist, but most fail to recapitulate the clinical scenario of closed head indirect trauma to the nerve and subsequent neurodegeneration. Thus, we developed a clinically-relevant animal model for TON using a novel ultrasonic pulse injury modality (sonication-induced TON; SI-TON). To trigger TON, a microtip probe sonifier was placed on the supraorbital ridge directly above the entrance of the optic nerve into the bony canal. An ultrasonic pulse was then delivered to the optic nerve. After injury, the number of RGCs in the retina as well as visual function measured by PERG steadily decreased over a two-week period. In the optic nerve, pro-inflammatory markers were upregulated within 6 hours following injury. Immunohistochemistry showed activation of microglia and infiltration of CD45-positive leukocytes in the optic nerve and initiation of a gliotic response. The SI-TON model is capable of delivering a non-contact concussive injury to the optic nerve and induce TON in mice. Thus, our data indicate that the SI-TON model reliably recapitulates the pathophysiology and progressive neurodegeneration seen in the human manifestation.	[Tao, Wensi; Dvoriantchikova, Galina; Tse, Brian C.; Pappas, Steven; Chou, Tsung-Han; Tapia, Manuel; Porciatti, Vittorio; Ivanov, Dmitry; Tse, David T.; Pelaez, Daniel] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dr Nasser Al Rashid Orbital Vis Res Ctr,Dept Opht, Miami, FL 33136 USA; [Ivanov, Dmitry] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Porciatti, Vittorio; Pelaez, Daniel] Univ Miami, Coll Engn, Dept Biomed Engn, Coral Gables, FL 33146 USA	Pelaez, D (corresponding author), Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dr Nasser Al Rashid Orbital Vis Res Ctr,Dept Opht, Miami, FL 33136 USA.; Pelaez, D (corresponding author), Univ Miami, Coll Engn, Dept Biomed Engn, Coral Gables, FL 33146 USA.	dpelaez@miami.edu	Tse, Brian/AAH-4158-2019	Pelaez, Daniel/0000-0002-4483-5160; Ivanov, Dmitry/0000-0002-5573-4402; Porciatti, Vittorio/0000-0002-1592-3532	Dr. Nasser Al-Rashid Orbital Research Fund; NIH NEI R01 Grant [EY019077]; NIH NEI Grant [R01 EY027311]; NIH NIA Grant [R56 AG053369]; NIH Center Core GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30EY014801]; Research to Prevent Blindness Unrestricted Grant, Inc, New York, New York; Dr. Nasser Ibrahim Al-Rashid Orbital Vision Research Fund; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY027311, R01EY019077, P30EY014801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R56AG053369] Funding Source: NIH RePORTER	This work was performed in the Dr. Nasser Al-Rashid Orbital Vision Research Center at the Bascom Palmer Eye Institute, and generously supported by the Dr. Nasser Al-Rashid Orbital Research Fund. We appreciate the valuable comments from several lab members, including Ravi Doddapaneni, and Zenith Acosta Torres. The authors thank Dr. Hong Yu for her expert assistance. We are grateful to Gabriel Gaidosh from the University of Miami Analytical Imaging Core Facility for his assistance with confocal microscopy. This work was supported in part by the NIH NEI R01 Grant EY019077 (V.P.), NIH NEI Grant R01 EY027311 (D.I.), NIH NIA Grant R56 AG053369 (D.I.), NIH Center Core Grant P30EY014801; Research to Prevent Blindness Unrestricted Grant, Inc, New York, New York; and the Dr. Nasser Ibrahim Al-Rashid Orbital Vision Research Fund. The sponsor or funding organizations had no role in the design or conduct of this research.	Camp AS, 2011, INVEST OPHTH VIS SCI, V52, P5226, DOI 10.1167/iovs.10-6307; Carta A, 2003, J NEUROL NEUROSUR PS, V74, P246, DOI 10.1136/jnnp.74.2.246; Chaon BC, 2015, CURR OPIN OPHTHALMOL, V26, P445, DOI 10.1097/ICU.0000000000000198; Chierzi S, 1999, J NEUROSCI, V19, P8367; Chou TH, 2014, INVEST OPHTH VIS SCI, V55, P2469, DOI 10.1167/iovs.14-13943; Dvoriantchikova G, 2014, EUR J NEUROSCI, V40, P2502, DOI 10.1111/ejn.12603; Dvoriantchikova G, 2014, EXP EYE RES, V123, P1, DOI 10.1016/j.exer.2014.04.009; Dvoriantchikova G, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-81; Dvoriantchikova G, 2011, INVEST OPHTH VIS SCI, V52, P7187, DOI 10.1167/iovs.11-7793; Dvoriantchikova G, 2010, MOL VIS, V16, P1907; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldberg RA, 1996, OPHTHALMIC PLAST REC, V12, P163, DOI 10.1097/00002341-199609000-00002; Guy WM, 2014, JAMA OPHTHALMOL, V132, P567, DOI 10.1001/jamaophthalmol.2014.82; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Kumaran AM, 2015, CRANIOMAX TRAUM REC, V8, P31, DOI 10.1055/s-0034-1393734; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; Levkovitch-Verbin H, 2004, EYE, V18, P1066, DOI 10.1038/sj.eye.6701576; Liu Y, 2014, INVEST OPHTH VIS SCI, V55, P3766, DOI 10.1167/iovs.14-13895; Medeiros FA, 2003, AM J OPHTHALMOL, V135, P406, DOI 10.1016/S0002-9394(02)02049-4; Ruggeri M, 2007, INVEST OPHTH VIS SCI, V48, P1808, DOI 10.1167/iovs.06-0815; Schindelin J, 2015, MOL REPROD DEV, V82, P518, DOI 10.1002/mrd.22489; Singman EL, 2016, MILITARY MED RES, V3, DOI 10.1186/s40779-016-0069-2; Solomon AS, 1996, J NEUROSCI METH, V70, P21, DOI 10.1016/S0165-0270(96)00098-2; Steinsapir K D, 1999, Curr Opin Ophthalmol, V10, P340, DOI 10.1097/00055735-199910000-00011; Steinsapir KD, 2011, AM J OPHTHALMOL, V151, P928, DOI 10.1016/j.ajo.2011.02.007; Xue F, 2016, BIOMED REP, V4, P188, DOI 10.3892/br.2016.567; Yu-Wai-Man P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005024.pub3; Yu-Wai-Man P, 2013, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858	28	19	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 18	2017	7								11779	10.1038/s41598-017-12225-6			14	Multidisciplinary Sciences	Science & Technology - Other Topics	FH1RC	WOS:000410916100037	28924145	DOAJ Gold, Green Published			2021-06-18	
J	Impellizzeri, D; Cordaro, M; Bruschetta, G; Siracusa, R; Crupi, R; Esposito, E; Cuzzocrea, S				Impellizzeri, Daniela; Cordaro, Marika; Bruschetta, Giuseppe; Siracusa, Rosalba; Crupi, Rosalia; Esposito, Emanuela; Cuzzocrea, Salvatore			N-Palmitoylethanolamine-Oxazoline as a New Therapeutic Strategy to Control Neuroinflammation: Neuroprotective Effects in Experimental Models of Spinal Cord and Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						ALIAmide; central nervous system; cytokines; inflammation; neurotrophic factors	ACID AMIDE HYDROLASE; FACTOR-KAPPA-B; PPAR-ALPHA; RAT MODEL; INHIBITOR; ASTROCYTES; INFLAMMATION; ACTIVATION; MICROGLIA; ROLES	Modulation of N-acylethanolamine-hydrolyzing acid amidase (NAAA) represents a potential alternative strategy in the treatment of neuroinflammation. Recent studies showed that pharmacological modulation of NAAA could be achieved with the oxazoline of palmitoylethanolamide (PEA; PEA-OXA). The aim of this study was to evaluate the neuroprotective effects of PEA-OXA in the secondary neuroinflammatory events induced by spinal and brain trauma in mice. Animals were subjected to spinal cord and brain injury models and PEA-OXA (10 mg/kg) was administered both intraperitoneally and orally 1 h and 6 h after trauma. PEA-OXA treatment markedly reduced the histological alterations induced by spinal cord injury (SCI) and traumatic brain injury (TBI) and ameliorated the motor function and behavioral deficits, as well. In addition, the expression of neurotrophic factors, such as glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor, and neurotrophin-3 were increased by PEA-OXA treatment. Moreover, PEA-OXA also significantly decreased glial fibrillary acidic protein hyperexpression, the nuclear translocation of nuclear factor (NF)-kappa B, phosphorylation of Ser536 on the NF-kappa B subunit p65, and degradation of I kappa B-alpha, as well as diminished the expression of proinflammatory mediators such as cyclooxygenase-2 (COX-2), inducible nitric oxide synthase, tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 beta. The modulation of intracellular NAAA by PEA-OXA treatment could thus represent a novel therapy to control neuroinflammatory conditions associated with SCI and TBI.	[Impellizzeri, Daniela; Cordaro, Marika; Bruschetta, Giuseppe; Siracusa, Rosalba; Crupi, Rosalia; Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy; [Cuzzocrea, Salvatore] Univ Manchester, Sch Med, Manchester Biomed Res Ctr, Manchester Royal Infirm, Manchester, Lancs, England	Cuzzocrea, S (corresponding author), Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy.	salvator@unime.it	Crupi, Rosalia/U-4364-2019; Cordaro, Marika/K-7329-2016	Cordaro, Marika/0000-0002-3980-0043; Crupi, Rosalia/0000-0002-7629-3132; Impellizzeri, Daniela/0000-0001-9492-3161; Siracusa, Rosalba/0000-0001-7868-2505; Cuzzocrea, Salvatore/0000-0001-6131-3690	 [PON01-02512]	This study was supported by grant PON01-02512.	Ahmad A, 2012, BRAIN BEHAV IMMUN, V26, P1310, DOI 10.1016/j.bbi.2012.07.021; Ahmad A, 2012, BRAIN RES, V1477, P45, DOI 10.1016/j.brainres.2012.08.006; Ahmed AU, 2014, J BIOL CHEM, V289, P27776, DOI 10.1074/jbc.M114.574541; Alhouayek M, 2014, DRUG DISCOV TODAY, V19, P1632, DOI 10.1016/j.drudis.2014.06.007; [Anonymous], 2013, Patent application WO, Patent No. [2013121449 A1, 2013121449]; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Benito C, 2012, BRIT J PHARMACOL, V166, P1474, DOI 10.1111/j.1476-5381.2012.01889.x; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Brahmachari S, 2006, J NEUROSCI, V26, P4930, DOI 10.1523/JNEUROSCI.5480-05.2006; Buckley CD, 2013, NAT REV IMMUNOL, V13, P59, DOI 10.1038/nri3362; Campolo M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0196-1; Carson MJ, 2006, CLIN NEUROSCI RES, V6, P237, DOI 10.1016/j.cnr.2006.09.004; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Esposito E, 2016, EUR J PHARMACOL, V782, P107, DOI 10.1016/j.ejphar.2016.03.033; Esposito E, 2014, PHARMACOL RES, V86, P26, DOI 10.1016/j.phrs.2014.05.009; Esposito E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041880; Fidaleo M, 2014, CURR MED CHEM, V21, P2803, DOI 10.2174/0929867321666140303143455; Genovese T, 2008, J PHARMACOL EXP THER, V326, P12, DOI 10.1124/jpet.108.136903; Hoyer FF, 2014, J MOL CELL CARDIOL, V66, P126, DOI 10.1016/j.yjmcc.2013.11.013; Impellizzeri D, 2016, PHARMACOL RES, V108, P23, DOI 10.1016/j.phrs.2016.04.007; Impellizzeri D, 2015, EUR J PHARMACOL, V761, P28, DOI 10.1016/j.ejphar.2015.04.025; Impellizzeri D, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0136-0; Li YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043023; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Madathil SK, 2011, BIOESSAYS, V33, P21, DOI 10.1002/bies.201000069; Massa PT, 2006, J NEUROCHEM, V97, P607, DOI 10.1111/j.1471-4159.2006.03810.x; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Nencini P, 2003, CEREBROVASC DIS, V15, P215, DOI 10.1159/000068831; Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-91; Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-20; Peferoen LAN, 2015, J NEUROPATH EXP NEUR, V74, P48, DOI 10.1097/NEN.0000000000000149; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Piomelli D, 2014, NAT NEUROSCI, V17, P164, DOI 10.1038/nn.3612; Raso GM, 2014, PHARMACOL RES, V86, P32, DOI 10.1016/j.phrs.2014.05.006; Ribeiro A, 2015, ACS CHEM BIOL, V10, P1838, DOI 10.1021/acschembio.5b00114; Rivera P, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00098; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Sasso O, 2013, PAIN, V154, P350, DOI 10.1016/j.pain.2012.10.018; Saturnino C, 2010, BIOORG MED CHEM LETT, V20, P1210, DOI 10.1016/j.bmcl.2009.11.134; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Siegmund SV, 2013, BIOCHEM BIOPH RES CO, V437, P48, DOI 10.1016/j.bbrc.2013.06.033; Skaper SD, 2015, MOL NEUROBIOL, V52, P1034, DOI 10.1007/s12035-015-9253-8; Skaper SD, 2012, PHILOS T R SOC B, V367, P3312, DOI 10.1098/rstb.2011.0391; Solorzano C, 2009, P NATL ACAD SCI USA, V106, P20966, DOI 10.1073/pnas.0907417106; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Ueda N, 2010, PROG LIPID RES, V49, P299, DOI 10.1016/j.plipres.2010.02.003; Yamano Y, 2012, BIOORGAN MED CHEM, V20, P3658, DOI 10.1016/j.bmc.2012.03.065; Yang LH, 2015, SCI REP-UK, V5, DOI 10.1038/srep13565; Yune TY, 2004, J NEUROTRAUM, V21, P1778, DOI 10.1089/0897715042664858; Zohar O., ACTA NEUROBIOL EXP W, V71, P36	51	19	19	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 15	2017	34	18					2609	2623		10.1089/neu.2016.4808			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FG5SC	WOS:000410395200003	28095731				2021-06-18	
J	Baratz-Goldstein, R; Toussia-Cohen, S; Elpaz, A; Rubovitch, V; Pick, CG				Baratz-Goldstein, Renana; Toussia-Cohen, Shlomi; Elpaz, Aviya; Rubovitch, Vardit; Pick, Chaim G.			Immediate and delayed hyperbaric oxygen therapy as a neuroprotective treatment for traumatic brain injury in mice	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article							ACUTE ISCHEMIC-STROKE; CEREBRAL-BLOOD-FLOW; COGNITIVE DEFICITS; DENTATE GYRUS; ANIMAL-MODEL; RAT MODEL; IN-VIVO; MECHANISMS; DAMAGE; NEUROINFLAMMATION	Background: Traumatic brain injury is the most common cause of death or chronic disability among people under-35-years-old. There is no effective pharmacological treatment currently existing for TBI. Hyperbaric oxygen therapy (HBOT) is defined as the inhalation of pure oxygen in a hyperbaric chamber that is pressurized higher than 1 atm. HBOT offers physiological and mechanical effects by inducing a state of increased pressure and hyperoxia. HBOT has been proposed as an effective treatment for moderate traumatic brain injury (mTBI), yet the exact therapeutic window and mechanism that underlies this effect is not completely understood. Methods: HBOT was administrated for 4 consecutive days, post a mouse closed head weight drop moderate TBI (mTBI) in 2 different time lines: immediate treatment-initiated 3 h post-injury and delayed treatment - initiated 7 days post-injury. Behavioral cognitive tests and biochemical changes were assessed. Results: The results were similar for both the immediate and the delayed treatments. mTBI mice exhibited impairment in learning abilities, whereas mTBI mice treated with HBO displayed significant improvement compared with the mTBI group, performing similar to the sham groups. mTBI mice had a decline in myelin basic protein, an increase in neuronal loss (NeuN staining), and an increase in the number of reactive astrocytes (GFAP). The HBO treated mice in both groups did not exhibit these changes and remained similar to the sham group. Conclusions: The delayed HBOT has a potential to serve as a neuroprotective treatment for mTBI with a long therapeutic window. Further research is needed for fully understanding the cellular changes. (C) 2017 Elsevier Inc. All rights reserved.	[Baratz-Goldstein, Renana; Toussia-Cohen, Shlomi; Elpaz, Aviya; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Elpaz, Aviya; Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Dr Miriam & Sheldon G Adelson Chair, Ctr Biol Addict Dis, IL-69978 Tel Aviv, Israel	Baratz-Goldstein, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	renanaba@post.tau.ac.il			Ari and Regine Aprijaskis Fund, at Tel Aviv University	This research was supported in part by the Ari and Regine Aprijaskis Fund, at Tel Aviv University. This work was performed in partial fulfillment of the M.D. of Shlomi Toussia-Cohen thesis requirements of the Sackler Faculty of Medicine, Tel Aviv University.	Abraini JH, 2013, UNDERSEA HYPERBAR M, V40, P211; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Amaral DG, 2007, PROG BRAIN RES, V163, P3, DOI 10.1016/S0079-6123(07)63001-5; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Armstrong RC, 2016, NEUROPHARMACOLOGY, V110, P654, DOI 10.1016/j.neuropharm.2015.04.029; Assistant Secretary of Defense for Health Affairs, 2007, TRAUM BRAIN INJ DEF; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Boussi-Gross R., 2013, PLOS ONE, V15, P8; Camporesi EM, 2014, UNDERSEA HYPERBAR M, V41, P253; Campos-Pires R, 2015, CRIT CARE MED, V43, P149, DOI 10.1097/CCM.0000000000000624; Chazalviel L, 2016, BRAIN, V139, DOI 10.1093/brain/aww178; Chen X, 2014, NEUROSCIENCE, V266, P235, DOI 10.1016/j.neuroscience.2013.11.036; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cifu DX, 2014, J HEAD TRAUMA REHAB, V29, P11, DOI 10.1097/HTR.0b013e3182a6aaf0; Sanchez EC, 2013, CRIT CARE NURS Q, V36, P290, DOI 10.1097/CNQ.0b013e318294e9e3; David HN, 2012, J APPL PHYSIOL, V112, P2068, DOI 10.1152/japplphysiol.00092.2012; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Demchenko IT, 2005, J CEREBR BLOOD F MET, V25, P1288, DOI 10.1038/sj.jcbfm.9600110; Ding Z, 2013, INTERV NEUROL, V2, P201, DOI 10.1159/000362677; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074; Hampson NB, HYPERBARIC OXYGEN TH; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Hu Q, 2016, MED GAS RES, V6, P102, DOI 10.4103/2045-9912.184720; Hu Q, 2015, MED GAS RES, V5, DOI 10.1186/s13618-015-0033-3; Huang L, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-21; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kraitsy K., 2016, MED SCI MONITOR, V22, P2608; Lavrnja L, 2015, MEDIAL INFLAMM, V2015; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Liu S, 2013, NEURAL REGEN RES, V8, P3334, DOI 10.3969/j.issn.1673-5374.2013.35.008; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; McDonagh MS, 2003, AHRQ PUBLICATION, V03-E050; Meng XE, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15016933; Meng XE, 2016, MED SCI MONITOR, V22, P284, DOI 10.12659/MSM.894148; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NIGHOGHOSSIAN N, 1995, STROKE, V26, P1369, DOI 10.1161/01.STR.26.8.1369; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Poff AM, 2017, COMPR PHYSIOL, V7, P213, DOI 10.1002/cphy.c150032; Saab BJ, 2009, NEURON, V63, P643, DOI 10.1016/j.neuron.2009.08.014; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang Y, 2014, MED GAS RES, V4, DOI 10.1186/2045-9912-4-18; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549; Wright J., 2009, UNDERSEA HYPERB MED, V36; Yang LM, 2015, BRAIN RES, V1627, P21, DOI 10.1016/j.brainres.2015.08.011; Yang Y, 2014, NEUROSCI LETT, V563, P38, DOI 10.1016/j.neulet.2014.01.002; Zhai X, 2016, FREE RADICAL RES, V50, P454, DOI 10.3109/10715762.2015.1136411; Zhang YM, 2014, NEUROCHEM RES, V39, P950, DOI 10.1007/s11064-014-1292-4; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	63	19	19	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	SEP	2017	83						74	82		10.1016/j.mcn.2017.06.004			9	Neurosciences	Neurosciences & Neurology	FG4SO	WOS:000410256000009	28690173				2021-06-18	
J	Denninghoff, KR; Nuno, T; Pauls, Q; Yeatts, SD; Silbergleit, R; Palesch, YY; Merck, LH; Manley, GT; Wright, DW				Denninghoff, Kurt R.; Nuno, Tomas; Pauls, Qi; Yeatts, Sharon D.; Silbergleit, Robert; Palesch, Yuko Y.; Merck, Lisa H.; Manley, Geoff T.; Wright, David W.			Prehospital Intubation is Associated with Favorable Outcomes and Lower Mortality in ProTECT III	PREHOSPITAL EMERGENCY CARE			English	Article						prehospital intubation; traumatic brain injury; TBI; air ambulance; ground transport; outcomes	TRAUMATIC BRAIN-INJURY; ENDOTRACHEAL INTUBATION; HYPERVENTILATION; VENTILATION	Objective: Traumatic brain injury (TBI) causes more than 2.5 million emergency department visits, hospitalizations, or deaths annually. Prehospital endotracheal intubation has been associated with poor outcomes in patients with TBI in several retrospective observational studies. We evaluated the relationship between prehospital intubation, functional outcomes, and mortality using high quality data on clinical practice collected prospectively during a randomized multicenter clinical trial. Methods: ProTECT III was a multicenter randomized, double-blind, placebo-controlled trial of early administration of progesterone in 882 patients with acute moderate to severe nonpenetrating TBI. Patients were excluded if they had an index GCS of 3 and nonreactive pupils, those with withdrawal of life support on arrival, and if they had documented prolonged hypotension and/or hypoxia. Prehospital intubation was performed as per local clinical protocol in each participating EMS system. Models for favorable outcome and mortality included prehospital intubation, method of transport, index GCS, age, race, and ethnicity as independent variables. Significance was set at = 0.05. Favorable outcome was defined by a stratified dichotomy of the GOS-E scores in which the definition of favorable outcome depended on the severity of the initial injury. Results: Favorable outcome was more frequent in the 349 subjects with prehospital intubation (57.3%) than in the other 533 patients (46.0%, p = 0.003). Mortality was also lower in the prehospital intubation group (13.8% v. 19.5%, p = 0.03). Logistic regression analysis of prehospital intubation and mortality, adjusted for index GCS, showed that odds of dying for those with prehospital intubation were 47% lower than for those that were not intubated (OR = 0.53, 95% CI = 0.36-0.78). 279 patients with prehospital intubation were transported by air. Modeling transport method and mortality, adjusted for index GCS, showed increased odds of dying in those transported by ground compared to those transported by air (OR = 2.10, 95% CI = 1.40-3.15). Decreased odds of dying trended among those with prehospital intubation adjusted for transport method, index GCS score at randomization, age, and race/ethnicity (OR = 0.70, 95% CI = 0.37-1.31). Conclusions: In this study that excluded moribund patients, prehospital intubation was performed primarily in patients transported by air. Prehospital intubation and air medical transport together were associated with favorable outcomes and lower mortality. Prehospital intubation was not associated with increased morbidity or mortality regardless of transport method or severity of injury.	[Denninghoff, Kurt R.] Univ Arizona, Emergency Med, Tucson, AZ 85721 USA; [Nuno, Tomas] Univ Arizona, Coll Med, Emergency Med, Tucson, AZ USA; [Pauls, Qi; Yeatts, Sharon D.; Palesch, Yuko Y.] Med Univ South Carolina, Charleston, SC USA; [Silbergleit, Robert] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Merck, Lisa H.] Brown Univ, Alpert Med Sch, Diagnost Imaging & Emergency Med, Providence, RI 02912 USA; [Manley, Geoff T.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Wright, David W.] Emory Univ, Atlanta, GA 30322 USA	Denninghoff, KR (corresponding author), Univ Arizona, Emergency Med, Tucson, AZ 85721 USA.	kdenninghoff@aemrc.arizona.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS062778, U10 NS058962, U01 NS059041, U10 NS059032, U01 NS056975] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS062778, U10NS059032] Funding Source: NIH RePORTER		Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Centers for Disease Control and Prevention, 2015, REP C TRAUM BRAIN IN; Davis DP, 2008, RESUSCITATION, V76, P333, DOI 10.1016/j.resuscitation.2007.08.004; Davis DP, 2010, J TRAUMA, V69, P294, DOI 10.1097/TA.0b013e3181dc6c7f; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Denninghoff KR, 2008, WEST J EMERG MED, V9, P184; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Gaither JB, 2012, ANN EMERG MED, V60, P732, DOI 10.1016/j.annemergmed.2012.06.017; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Noth U, 2008, NMR BIOMED, V21, P464, DOI 10.1002/nbm.1210; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304	18	19	19	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	SEP-OCT	2017	21	5					539	544		10.1080/10903127.2017.1315201			6	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	FH1YU	WOS:000410936500001	28489506	Green Accepted			2021-06-18	
J	Farnsworth, JL; Dargo, L; Ragan, BG; Kang, M				Farnsworth, James L., II; Dargo, Lucas; Ragan, Brian G.; Kang, Minsoo			Reliability of Computerized Neurocognitive Tests for Concussion Assessment: A Meta-Analysis	JOURNAL OF ATHLETIC TRAINING			English	Article						test-retest design; cognitive function; head injuries; traumatic brain injuries	TEST-RETEST RELIABILITY; BASE-LINE; NEUROPSYCHOLOGICAL ASSESSMENT; ASSESSMENT TOOLS; IMPACT; SPORT; MANAGEMENT; STATEMENT; VALIDITY; BATTERY	Objective: Although widely used, computerized neurocognitive tests (CNTs) have been criticized because of low reliability and poor sensitivity. A systematic review was published summarizing the reliability of Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) scores; however, this was limited to a single CNT. Expansion of the previous review to include additional CNTs and a meta-analysis is needed. Therefore, our purpose was to analyze reliability data for CNTs using meta-analysis and examine moderating factors that may influence reliability. Data Sources: A systematic literature search (key terms: reliability, computerized neurocognitive test, concussion) of electronic databases (MEDLINE, PubMed, Google Scholar, and SPORTDiscus) was conducted to identify relevant studies. Study Selection: Studies were included if they met all of the following criteria: used a test-retest design, involved at least 1 CNT, provided sufficient statistical data to allow for effect-size calculation, and were published in English. Data Extraction: Two independent reviewers investigated each article to assess inclusion criteria. Eighteen studies involving 2674 participants were retained. Intraclass correlation coefficients were extracted to calculate effect sizes and determine overall reliability. The Fisher Z transformation adjusted for sampling error associated with averaging correlations. Moderator analyses were conducted to evaluate the effects of the length of the test-retest interval, intraclass correlation coefficient model selection, participant demographics, and study design on reliability. Heterogeneity was evaluated using the Cochran Q statistic. Data Synthesis: The proportion of acceptable outcomes was greatest for the Axon Sports CogState Test (75%) and lowest for the ImPACT (25%). Moderator analyses indicated that the type of intraclass correlation coefficient model used significantly influenced effect-size estimates, accounting for 17% of the variation in reliability. Conclusions: The Axon Sports CogState Test, which has a higher proportion of acceptable outcomes and shorter test duration relative to other CNTs, may be a reliable option; however, future studies are needed to compare the diagnostic accuracy of these instruments.	[Farnsworth, James L., II] Buena Vista Univ, Sch Educ & Exercise Sci, 610 West 4th St, Storm Lake, IA 50588 USA; [Dargo, Lucas] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Kang, Minsoo] Middle Tennessee State Univ, Murfreesboro, TN 37130 USA	Farnsworth, JL (corresponding author), Buena Vista Univ, Sch Educ & Exercise Sci, 610 West 4th St, Storm Lake, IA 50588 USA.	farnsworth@bvu.edu					Ackerman PL, 2009, J EXP PSYCHOL-APPL, V15, P163, DOI 10.1037/a0015719; Ahn S, 2015, INTRO INTERMEDIATE A, P233; Alsalaheen B, 2016, J HEAD TRAUMA REHAB, V31, P242, DOI 10.1097/HTR.0000000000000175; [Anonymous], 2016, R LANGUAGE ENV STAT; Baumgartner TA, 2015, RELIABILITY OBJECTIV, P90; Becker B. J., 2000, HDB APPL MULTIVARIAT, P499, DOI DOI 10.1016/B978-012691360-6/50018-5; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Brunner HI, 2013, ARTHRIT CARE RES, V65, P372, DOI 10.1002/acr.21835; Carrasco JL, 2003, BIOMETRICS, V59, P849, DOI 10.1111/j.0006-341X.2003.00099.x; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Cousino E, 2006, J ATHL TRAINING, V41, pS; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Hedges L.V., 1985, STAT METHODS META AN; Irwin CC, 2014, AM ALL HLTH PHYS ED; Kim Y, 2013, PUBLIC HEALTH NUTR, V16, P440, DOI 10.1017/S1368980012002996; Littleton AC, 2015, SPORTS HEALTH, V7, P443, DOI 10.1177/1941738115586997; Louey AG, 2014, ARCH CLIN NEUROPSYCH, V29, P432, DOI 10.1093/arclin/acu020; MacDonald J, 2015, CLIN J SPORT MED, V25, P367, DOI 10.1097/JSM.0000000000000139; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Prince SA, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-56; Ragan B., 2009, ATHLETIC TRAINING SP, V1, P180; Register-Mihalik JK, 2012, J ATHL TRAINING, V47, P297, DOI 10.4085/1062-6050-47.3.13; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; SILVER NC, 1987, J APPL PSYCHOL, V72, P146, DOI 10.1037/0021-9010.72.1.146; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; Viechtbauer W, 2005, J EDUC BEHAV STAT, V30, P261, DOI 10.3102/10769986030003261; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03	44	19	19	0	7	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP	2017	52	9					826	833		10.4085/1062-6050-52.6.03			8	Sport Sciences	Sport Sciences	FN2LO	WOS:000415824000004	28771032	Bronze, Green Published			2021-06-18	
J	Grauwmeijer, E; Heijenbrok-Kal, MH; Haitsma, IK; Ribbers, GM				Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Haitsma, Ian K.; Ribbers, Gerard M.			Employment Outcome Ten Years after Moderate to Severe Traumatic Brain Injury: A Prospective Cohort Study	JOURNAL OF NEUROTRAUMA			English	Article						outcome measures; prospective studies; rehabilitation; traumatic brain injuries	FOLLOW-UP; RETURN; WORK; IMPACT; EPIDEMIOLOGY; POPULATION; PREDICTORS; EUROPE; TBI	The objective of this prospective cohort study was to evaluate the probability of employment and predictors of employment in patients with moderate-to-severe traumatic brain injury (TBI) over 10-year follow-up. One hundred nine patients (18-67 years) were included with follow-up measurements 3, 6, 12, 18, 24, and 36 months and 10 years post-TBI. Potential predictors of employment probability included patient characteristics, injury severity factors, functional outcome measured at discharge from the hospital with the Glasgow Outcome Scale (GOS), Barthel Index (BI), Functional Independence Measure (FIM), and the Functional Assessment Measure (FAM). Forty-eight patients (42%) completed the 10-year followup. Three months post-TBI, 12% were employed, which gradually, but significantly, increased to 57% after 2-years followup (p < 0.001), followed by a significant decrease to 43% (p = 0.041) after 10 years. Ten years post-TBI, we found that employed persons had less-severe TBI, shorter length of hospital stay (LOS), and higher scores on the GOS, BI, FIM, and FAM at hospital discharge than unemployed persons. No significant differences in age, sex, educational level, living with partner/family or not, pre-injury employment, professional category, psychiatric symptoms, or discharge destination were found. Longitudinal multivariable analysis showed that time, pre-injury employment, FAM, and LOS were independent predictors of employment probability. We concluded that employment probability 10 years after moderate or severe TBI is related to injury severity and pre-injury employment. Future studies on vocational rehabilitation should focus on modifiable factors and take into consideration the effects of national legislation and national labor market forces.	[Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.] Rijndam Rehabil, Rotterdam, Netherlands; [Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.] Erasmus Univ, Med Ctr, Dept Rehabil Med, Rotterdam, Netherlands; [Haitsma, Ian K.] Erasmus Univ, Med Ctr, Dept Neurosurg, Rotterdam, Netherlands	Grauwmeijer, E (corresponding author), Rijndam Rehabil Ctr, Rotterdam Neurorehabil Res RoNeRes, POB 23181, NL-3001 KD Rotterdam, Netherlands.	egrauwmeijer@rijndam.nl	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019; VARRECCHIA, TIWANA/AAJ-8712-2021	Ribbers, Gerard M/0000-0002-6114-349X; Heijenbrok-Kal, Majanka H./0000-0002-2982-4404	Netherlands Organization for Health Research and DevelopmentNetherlands Organization for Health Research and Development [1435.0020]	This study was financially supported by the Netherlands Organization for Health Research and Development (project no.: 1435.0020). We certify that no party having a direct interest in the results of the research supporting this article has or will confer a benefit on us or on any organization with which we are associated.	Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bogner JA, 2017, J HEAD TRAUMA REHAB, V32, pE1, DOI 10.1097/HTR.0000000000000291; Central Bureau for Statistics, STAT UN 2003 2013; Collin C, 1988, Int Disabil Stud, V10, P61; Cuthbert JP, 2015, ARCH PHYS MED REHAB, V96, P2128, DOI 10.1016/j.apmr.2015.07.020; Dahm J, 2015, BRAIN INJURY, V29, P1539, DOI 10.3109/02699052.2015.1075141; Dahm J, 2015, J REHABIL MED, V47, P932, DOI 10.2340/16501977-2016; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Donker-Cools BHPM, 2016, BRAIN INJURY, V30, P113, DOI 10.3109/02699052.2015.1090014; Forslund MV, 2014, BRAIN INJURY, V28, P980, DOI 10.3109/02699052.2014.888770; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Mahoney F. I., 1965, STATE MED J, V14, P61; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Skandsen T, 2008, CLIN REHABIL, V22, P653, DOI 10.1177/0269215508089067; Stergiou-Kita M, 2016, ARCH PHYS MED REHAB, V97, pS40, DOI 10.1016/j.apmr.2015.04.008; Van Baalen B, 2007, BRAIN INJURY, V21, P925, DOI 10.1080/02699050701553197; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377	31	19	20	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2017	34	17					2575	2581		10.1089/neu.2016.4846			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FE6HI	WOS:000408310200011	28447873				2021-06-18	
J	Wang, CX; Hu, ZY; Zou, Y; Xiang, MJ; Jiang, YT; Botchway, BOA; Huo, X; Du, XX; Fang, MR				Wang, Changxing; Hu, Zhiying; Zou, Yang; Xiang, Mingjun; Jiang, Yuting; Botchway, Benson O. A.; Huo, Xue; Du, Xiaoxue; Fang, Marong			The post-therapeutic effect of rapamycin in mild traumatic brain-injured rats ensuing in the upregulation of autophagy and mitophagy	CELL BIOLOGY INTERNATIONAL			English	Article						apoptosis; brain system; mitochondria; neurodegeneration	OXIDATIVE STRESS; RODENT MODEL; PARKIN; MITOCHONDRIA; PINK1; PROMOTES; COMPLEX	Mild traumatic brain injury (mTBI), common in juveniles, has been reported to be caused by sports-related concussion. Many young children may suffer from post-concussion syndrome. mTBI, in early stages of life, could play a part in neuron apoptosis and degeneration, cognitive and motor coordination impairment, as well as dementia. Our study was aimed at further investigating the post-therapeutic efficacy of rapamycin in the recuperation of mTBI while at the same time investigating the metamorphosis in both autophagy and mitophagy in mTBI. We created a weight-drop rat mTBI model with the administration of rapamycin at 4h after every mTBI. Behavioral tests of beam walking and open field task indicated the expected improvement of cognitive and motor coordination functions. Both Western blot and immunofluorescence examinations revealed increased Beclin-1 and PINK1 in the treated rats as well as reduction of caspase-3 and cytochrome C (Cyt C). More so, the TUNEL staining evidenced curtailment of apoptotic cells following treatment with rapamycin. The upregulation of Beclin-1 and PINK1 and the downregulation of caspase-3 and Cyt C extrapolate that rapamycin plays neuroprotective as well as anti-apoptotic role via interposition of both autophagy and mitophagy.	[Wang, Changxing; Zou, Yang] Zhejiang Chinese Med Univ, Affiliated Hosp 2, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China; [Hu, Zhiying] Hangzhou Red Cross Hosp, Dept Obstet & Gynecol, Hangzhou, Zhejiang, Peoples R China; [Xiang, Mingjun; Jiang, Yuting; Botchway, Benson O. A.; Huo, Xue; Du, Xiaoxue; Fang, Marong] Zhejiang Univ, Sch Med, Inst Neurosci, Hangzhou 310058, Zhejiang, Peoples R China	Fang, MR (corresponding author), Zhejiang Univ, Sch Med, Inst Neurosci, Hangzhou 310058, Zhejiang, Peoples R China.	fangmaro@zju.edu.cn		, Marong/0000-0002-6636-4347; Hu, Zhiying/0000-0003-2084-1010; Botchway, Benson/0000-0001-9732-7904	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371493, 81671138]; Traditional Chinese Medicine Science and Technology planning project of Zhejiang province [2017ZA062]	The authors wish to thank Sanhua Fang, from the Core Facilities of Zhejiang University Institute of Neuroscience, for his technical assistance in this project. The work was supported by the National Natural Science Foundation of China (No. 81371493 and No. 81671138), and Traditional Chinese Medicine Science and Technology planning project of Zhejiang province (No. 2017ZA062).	Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Caron AM, 2015, NAT SCI SLEEP, V7, P63, DOI 10.2147/NSS.S82888; Cavallucci V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.511; Corti O, 2011, PHYSIOL REV, V91, P1161, DOI 10.1152/physrev.00022.2010; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Itoh K, 2013, TRENDS CELL BIOL, V23, P64, DOI 10.1016/j.tcb.2012.10.006; Jemmerson R, 2005, ANTIOXID REDOX SIGN, V7, P1158, DOI 10.1089/ars.2005.7.1158; Joselin AP, 2012, HUM MOL GENET, V21, P4888, DOI 10.1093/hmg/dds325; Kawajiri S, 2010, FEBS LETT, V584, P1073, DOI 10.1016/j.febslet.2010.02.016; Khandelwal PJ, 2011, HUM MOL GENET, V20, P2091, DOI 10.1093/hmg/ddr091; Koch JC, 2016, EXP EYE RES, V144, P81, DOI 10.1016/j.exer.2015.08.016; Koehl GE, 2004, TRANSPLANTATION, V77, P1319, DOI 10.1097/00007890-200405150-00002; Lazarou M, 2012, DEV CELL, V22, P320, DOI 10.1016/j.devcel.2011.12.014; Liang CC, 2010, J BIOL CHEM, V285, P3499, DOI 10.1074/jbc.M109.072389; Lucin KM, 2013, NEURON, V79, P873, DOI 10.1016/j.neuron.2013.06.046; Martinez-Vicente M, 2010, NAT NEUROSCI, V20, P172; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Mychasiuk R, 2014, JOVE-J VIS EXP, DOI 10.3791/51820; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Perez-Polo JR, 2016, J NEUROSCI RES, V94, P27, DOI 10.1002/jnr.23617; Pignataro G, 2011, CURR OPIN PHARMACOL, V11, P378, DOI 10.1016/j.coph.2011.05.003; Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036; Rodriguez-Navarro JA, 2010, NEUROBIOL DIS, V39, P423, DOI 10.1016/j.nbd.2010.05.014; Salminen A, 2013, PROG NEUROBIOL, V106, P33, DOI 10.1016/j.pneurobio.2013.06.002; Sepe S, 2014, NEUROBIOL AGING, V35, P96, DOI 10.1016/j.neurobiolaging.2013.07.001; Sigmond T, 2008, METHOD ENZYMOL, V451, P467, DOI 10.1016/S0076-6879(08)03228-X; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Vega GE, 2013, OXID MED CELL LONGEV, V2013, P93; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; Wang P, 2012, AUTOPHAGY, V8, P77, DOI 10.4161/auto.8.1.18274; Xiong H, 2009, J CLIN INVEST, V119, P650, DOI 10.1172/JCI37617; Yang HJ, 2013, NATURE, V497, P217, DOI 10.1038/nature12122; Yang Y, 2015, MEDIAT INFLAMM, V2015	38	19	20	3	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-6995	1095-8355		CELL BIOL INT	Cell Biol. Int.	SEP	2017	41	9					1039	1047		10.1002/cbin.10820			9	Cell Biology	Cell Biology	FD6QX	WOS:000407654100011	28685977				2021-06-18	
J	Schiavone, S; Neri, M; Trabace, L; Turillazzi, E				Schiavone, Stefania; Neri, Margherita; Trabace, Luigia; Turillazzi, Emanuela			The NADPH oxidase NOX2 mediates loss of parvalbumin interneurons in traumatic brain injury: human autoptic immunohistochemical evidence	SCIENTIFIC REPORTS			English	Article							OXIDATIVE STRESS; CEREBROSPINAL-FLUID; PATHOPHYSIOLOGY; BIOMARKER; INVOLVEMENT; DYSFUNCTION; INHIBITION	Pharmacological interventions for traumatic brain injury (TBI) are limited. Together with parvalbumin (PV) loss, increased production of reactive oxygen species (ROS) by the NADPH oxidase NOX enzymes represents a key step in TBI. Here, we investigated the contribution of NOX2-derived oxidative stress to the loss of PV immunoreactivity associated to TBI, performing immunohistochemistry for NOX2, 8-hydroxy-2'-deoxyguanosine (8OHdG) and PV on post mortem brain samples of subjects died following TBI, subjects died from spontaneous intracerebral hemorrhage (SICH) and controls (CTRL). We detected an increased NOX2 expression and 8OHdG immunoreactivity in subjects died from TBI with respect to CTRL and SICH. NOX2 increase was mainly observed in GABAergic PV-positive interneurons, with a minor presence in microglia. No significant differences in other NADPH oxidase isoforms (NOX1 and NOX4) were detected among experimental groups. NOX2-derived oxidative stress elevation appeared a specific TBI-induced phenomenon, as no alterations in the nitrosative pathway were detected. Our results suggest that NOX2-derived oxidative stress might play a crucial role in the TBI-induced loss of PV-positive interneurons.	[Schiavone, Stefania; Neri, Margherita; Trabace, Luigia; Turillazzi, Emanuela] Univ Foggia, Dept Clin & Expt Med, Via Napoli 20, I-71122 Foggia, Italy	Trabace, L (corresponding author), Univ Foggia, Dept Clin & Expt Med, Via Napoli 20, I-71122 Foggia, Italy.	luigia.trabace@unifg.it		trabace, luigia/0000-0003-3073-8404; NERI, Margherita/0000-0002-6459-1669	Intervento cofinanziato dal Fondo di Sviluppo e Coesione - APQ Ricerca Regione Puglia "Programma regionale a sostegno della specializzazione intelligente e della sostenibilita sociale ed ambientale - FutureIn Research", Italy; Pubblicazione realizzata con un contributo sui fondi del 5 x 1000 dell'IRPEF a favore dell'Universita di Foggia, in memoria di Gianluca Montel	This study was supported by Intervento cofinanziato dal Fondo di Sviluppo e Coesione 2007-2013 - APQ Ricerca Regione Puglia "Programma regionale a sostegno della specializzazione intelligente e della sostenibilita sociale ed ambientale - FutureIn Research", Italy to S.S. The open access cost for this paper was supported by "Pubblicazione realizzata con un contributo sui fondi del 5 x 1000 dell'IRPEF a favore dell'Universita di Foggia, in memoria di Gianluca Montel" to LT.	Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Behrens MM, 2007, SCIENCE, V318, P1645, DOI 10.1126/science.1148045; Butterfield D. A., 2016, PROTEOM CLIN APPL, DOI [10.1002/prca.201600003, DOI 10.1002/PRCA.201600003(2016).]; Cahill-Smith S, 2014, BRIT J CLIN PHARMACO, V78, P441, DOI 10.1111/bcp.12357; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Constantinescu R, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00187; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Harmon JL, 2017, J NEUROTRAUM, V34, P487, DOI 10.1089/neu.2015.4395; Herrera-Melero MC, 2015, BRAIN INJURY, V29, P1439, DOI 10.3109/02699052.2015.1071428; Hohl A, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.06.007; Huusko N, 2014, NEUROSCIENCE, V267, P30, DOI 10.1016/j.neuroscience.2014.02.026; Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lorente L, 2015, J NEUROTRAUM, V32, P1, DOI 10.1089/neu.2014.3456; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Marrali G, 2014, J NEUROL, V261, P2178, DOI 10.1007/s00415-014-7470-0; McGinn MJ, 2016, NEUROSURG CLIN N AM, V27, P397, DOI 10.1016/j.nec.2016.06.002; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Motori E, 2013, CELL METAB, V18, P844, DOI 10.1016/j.cmet.2013.11.005; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schiavone S, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.76; Schiavone S, 2016, J CLIN PSYCHOPHARM, V36, P513, DOI 10.1097/JCP.0000000000000560; Schiavone S, 2016, PHARMACOL RES, V107, P195, DOI 10.1016/j.phrs.2016.03.019; Schiavone S, 2009, BIOL PSYCHIAT, V66, P384, DOI 10.1016/j.biopsych.2009.04.033; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]; Sorce S, 2010, J NEUROSCI, V30, P11317, DOI 10.1523/JNEUROSCI.1491-10.2010; Tagliaferri F, 2009, J TRAUMA, V66, P727, DOI 10.1097/TA.0b013e31815edefd; Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wang X, 2013, ANTIOXID REDOX SIGN, V18, P1444, DOI 10.1089/ars.2012.4907; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zengi O, 2012, CLIN CHEM LAB MED, V50, P529, DOI 10.1515/CCLM.2011.792; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	39	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 18	2017	7								8752	10.1038/s41598-017-09202-4			10	Multidisciplinary Sciences	Science & Technology - Other Topics	FE1LP	WOS:000407980000006	28821783	DOAJ Gold, Green Published			2021-06-18	
J	Guiza, F; Meyfroidt, G; Piper, I; Citerio, G; Chambers, I; Enblad, P; Nillson, P; Feyen, B; Jorens, P; Maas, A; Schuhmann, MU; Donald, R; Moss, L; Van den Berghe, G; Depreitere, B				Guiza, Fabian; Meyfroidt, Geert; Piper, Ian; Citerio, Giuseppe; Chambers, Iain; Enblad, Per; Nillson, Pelle; Feyen, Bart; Jorens, Philippe; Maas, Andrew; Schuhmann, Martin U.; Donald, Rob; Moss, Laura; Van den Berghe, Greet; Depreitere, Bart			Cerebral Perfusion Pressure Insults and Associations with Outcome in Adult Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adults; cerebral perfusion pressure; cerebrovascular autoregulation; traumatic brain injury	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; BLOOD-FLOW; REACTIVITY; AUTOREGULATION; HYPERTENSION; HYPOTENSION; MANAGEMENT; HUMANS; TIME	The definition of cerebral perfusion pressure (CPP) secondary insults in severe traumatic brain injury remains unclear. The purpose of the present study is to visualize the association of intensity and duration of episodes below or above CPP thresholds and outcome. The analysis was based on prospectively collected minute-by-minute intracranial pressure (ICP) and blood pressure data and outcome from 259 adult patients. The relationship of episodes of CPP below or above a certain threshold for certain duration with the 6-month Glasgow Outcome Score was visualized separately for episodes of active or deficient autoregulation (AR). In adults <= 65 years, an almost exponential transition curve separates the episodes of CPP associated with better outcomes from the episodes of low CPP associated with worse outcomes, indicating that lower CPP could only be tolerated for a brief time. Analysis of episodes of high CPP again showed a time-intensity dependent association with outcome. When combining the two plots, a safe CPP zone between 60 and 70mm Hg could be delineated-however, only for AR active insults. The AR status predominantly affected the transition curve for insults of low CPP. Episodes with ICP >25mm Hg were associated with poor outcome regardless of CPP. In the present study, the CPP pressure-time burden associated with poor outcome was visualized. A safe zone between 60 and 70mm Hg could be identified for adults <= 65 years, provided AR was active and ICP was <= 25mm Hg. Deficient AR reduces the tolerability for low CPP.	[Guiza, Fabian; Meyfroidt, Geert; Van den Berghe, Greet] Univ Hosp Leuven, Dept Intens Care Med, Leuven, Belgium; [Piper, Ian] Southern Gen Hosp, Dept Clin Phys, Glasgow, Lanark, Scotland; [Citerio, Giuseppe] San Gerardo Hosp, Dept Perioperat Med & Intens Care Med, Monza, Italy; [Chambers, Iain] James Cook Univ Hosp, Med Phys, Middlesbrough, England; [Enblad, Per; Nillson, Pelle] Dept Neurosci, Neurosurg, Uppsala, Sweden; [Feyen, Bart; Maas, Andrew] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Jorens, Philippe] Antwerp Univ Hosp, Dept Intens Care Med, Edegem, Belgium; [Schuhmann, Martin U.] Univ Klinikum Tubingen, Neurochirurg Klin, Tubingen, Germany; [Donald, Rob] Univ Glasgow, Sch Math & Stat, Glasgow, Lanark, Scotland; [Moss, Laura] NHS Greater Glasgow & Clyde, Dept Clin Phys & Bioengn, Glasgow, Lanark, Scotland; [Depreitere, Bart] Univ Hosp Leuven, Dept Neurosurg, Herestr 49, B-3000 Leuven, Belgium	Depreitere, B (corresponding author), Univ Hosp Leuven, Dept Neurosurg, Herestr 49, B-3000 Leuven, Belgium.	bart.depreitere@uzleuven.be	Citerio, Giuseppe/B-1839-2015; Depreitere, Bart/AAA-9846-2020; Maas, Andrew IR/C-5584-2013; Van den Berghe, Greet/J-6788-2018	Citerio, Giuseppe/0000-0002-5374-3161; Depreitere, Bart/0000-0002-7458-0648; Maas, Andrew IR/0000-0003-1612-1264; Van den Berghe, Greet/0000-0002-5320-1362; Moss, Laura/0000-0003-4968-0900; Guiza, Fabian/0000-0001-7026-0957	Fonds voor Wetenschappelijk Onderzoek VlaanderenFWO [G.0904.11, 1846113N]; Methusalem program - Flemish Governement [METH/08/07]; Flemish Governement Agency for Innovation by Science and Technology (IWT);  [FP5-QRLI-2000-00454];  [QLGT-2002-00160];  [FP7-IST-2007-217049]	This study is funded through Fonds voor Wetenschappelijk Onderzoek Vlaanderen (Research Project G.0904.11). Geert Meyfroidt receives funding from Fonds voor Wetenschappelijk Onderzoek Vlaanderen as senior clinical investigator (1846113N), Greet Van den Berghe receives structural research funding via the Methusalem program funded by the Flemish Governement (METH/08/07). Brain-IT was funded by the European Framework Program (FP5-QRLI-2000-00454), QLGT-2002-00160 and FP7-IST-2007-217049). The NEMO project in the Universty Hospital Antwerp was funded by the Flemish Governement Agency for Innovation by Science and Technology (IWT). The authors wish to acknowledge the non-author steering group members of Brain-IT: Barbara Gregson, Tim Howells, Karl Kiening, Arminas Ragauskas, Juan Sahuquillo, and Jan Oliver Neumann.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Drummond JC, 1997, ANESTHESIOLOGY, V86, P1431, DOI 10.1097/00000542-199706000-00034; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; JENNETT B, 1975, LANCET, V1, P480; LASSEN NA, 1959, PHYSIOL REV, V39, P183; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Numan T, 2014, MED ENG PHYS, V36, P1487, DOI 10.1016/j.medengphy.2014.08.001; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Piper I, 2003, ACTA NEUROCHIR, V145, P615, DOI 10.1007/s00701-003-0066-6; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Tan CO, 2012, J APPL PHYSIOL, V113, P1194, DOI 10.1152/japplphysiol.00783.2012; Tzeng YC, 2010, HYPERTENSION, V56, P268, DOI 10.1161/HYPERTENSIONAHA.110.152066; Willie CK, 2014, J PHYSIOL-LONDON, V592, P841, DOI 10.1113/jphysiol.2013.268953; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	29	19	21	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2017	34	16					2425	2431		10.1089/neu.2016.4807			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FC6RI	WOS:000406968400005	28385097	Green Published, Bronze			2021-06-18	
J	AlAzri, A; Mok, K; Chankowsky, J; Mullah, M; Marcoux, J				AlAzri, Ahmed; Mok, Kelvin; Chankowsky, Jeffrey; Mullah, Mohammad; Marcoux, Judith			Placement accuracy of external ventricular drain when comparing freehand insertion to neuronavigation guidance in severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; External ventricular drain; Neuronavigation	CATHETER PLACEMENT; COMPLICATIONS; GUIDE; HYDROCEPHALUS; NAVIGATION; SAFETY; CT	Background External ventricular drain (EVD) placement is a frequently performed neurosurgical procedure. Inaccuracies in drain positioning and the need for multiple passes using the classic freehand insertion technique is well reported in the literature, especially in the traumatic brain injury (TBI) population. The purpose of this study was to evaluate if electromagnetic neuronavigation guidance for EVD insertion improves placement accuracy and minimizes the number of passes in severe TBI patients. Methods Navigation was applied prospectively for all new severe TBI patients who required ventricular catheter placement over a period of 1 year, and compared with a retrospective cohort of severe TBI patients who had EVD inserted freehand in the preceding year. The placement accuracy was evaluated using the Kakarla grading system; the number of passes was also compared. Results Fifty-four cases were recruited: 35 (64.8%) had their EVD placed using the freehand technique and 19 (35.2%) using navigation guidance. In the navigation group, the placement accuracy was: 94.7% (18/19) grade 1, 5.3% (1/19) grade 2, and none at grade 3. In comparison, freehand placement was associated with misplacement (grades 2 and 3) in 42.9% of the cases (p value = 0.009). The number of passes was significantly lower in the navigation group (mean of 1.16 +/- 0.38), compared with the freehand group (mean of 1.63 +/- 0.88) (p value = 0.018). Conclusions Using the navigation to guide EVD placement was associated with a significantly better accuracy and a lower number of passes in severe TBI patients.	[AlAzri, Ahmed; Marcoux, Judith] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [AlAzri, Ahmed; Marcoux, Judith] McGill Univ, Hlth Ctr, Dept Neurosurg, 1650 Cedar Ave,Room L7-516, Montreal, PQ H3G 1A4, Canada; [Mok, Kelvin] McGill Univ, Montreal Neurol Inst, Dept Biomed Engn, Montreal, PQ, Canada; [Chankowsky, Jeffrey] McGill Univ, Dept Diagnost Radiol, Montreal, PQ, Canada; [Chankowsky, Jeffrey] McGill Univ, Hlth Ctr, Dept Radiol, Montreal, PQ, Canada; [Mullah, Mohammad] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada	Marcoux, J (corresponding author), McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada.; Marcoux, J (corresponding author), McGill Univ, Hlth Ctr, Dept Neurosurg, 1650 Cedar Ave,Room L7-516, Montreal, PQ H3G 1A4, Canada.	judith.marcoux@mcgill.ca			StealthStation AxiEM system	Medtronic of Canada Ltd. provided in-kind funding in the form of the StealthStation AxiEM system plus its disposable kits, each containing a registration probe, patient reference device and a sterile navigation stylet. None of the authors received any financial support or any other form of support to conduct this study. The sponsor had no role in the design or conduct of this research.	Abdoh MG, 2012, ACTA NEUROCHIR, V154, P153, DOI 10.1007/s00701-011-1136-9; Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; BOGDAHN U, 1992, NEUROSURGERY, V31, P898, DOI 10.1227/00006123-199211000-00011; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Chai FY, 2013, TURK NEUROSURG, V23, P561, DOI 10.5137/1019-5149.JTN.5724-12.1; Cooke D L, 2011, AJNR Am J Neuroradiol, V32, pE69, DOI 10.3174/ajnr.A2066; Crowley RW, 2014, WORLD NEUROSURG, V81, P397, DOI 10.1016/j.wneu.2013.01.039; Evans WA, 1942, AM J DIS CHILD, V64, P820, DOI 10.1001/archpedi.1942.02010110052006; Fiorella D, 2014, J NEUROINTERV SURG, V6, P457, DOI 10.1136/neurintsurg-2013-010856; Flannery AM, 2014, J NEUROSURG-PEDIATR, V14, P24, DOI 10.3171/2014.7.PEDS14323; Foreman PM, 2015, CLIN NEUROL NEUROSUR, V128, P94, DOI 10.1016/j.clineuro.2014.09.026; Franz AM, 2014, IEEE T MED IMAGING, V33, P1702, DOI 10.1109/TMI.2014.2321777; Gautschi OP, 2014, ACTA NEUROCHIR, V156, P777, DOI 10.1007/s00701-014-2026-8; GHAJAR JBG, 1985, J NEUROSURG, V63, P985, DOI 10.3171/jns.1985.63.6.0985; Grandhi R, 2015, J NEUROIMAGING, V25, P140, DOI 10.1111/jon.12080; Hayhurst C, 2009, J NEUROSURG, V111, P1179, DOI 10.3171/2008.12.JNS08628; Hsieh CT, 2011, ACTA NEUROL BELG, V111, P22; Huyette DR, 2008, J NEUROSURG, V108, P88, DOI 10.3171/JNS/2008/108/01/0088; Kakarla UK, 2008, NEUROSURGERY, V63, P162, DOI 10.1227/01.NEU.0000312390.83127.7F; Kandasamy J, 2011, WORLD NEUROSURG, V75, P155, DOI 10.1016/j.wneu.2010.10.025; Koivukangas T, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-90; Kosty J, 2013, NEUROSURGERY, V72, P208; Krotz M, 2004, EUR RADIOL, V14, P227, DOI 10.1007/s00330-003-2134-y; Lee Ji Hoon, 2010, Journal of Cerebrovascular and Endovascular Neurosurgery, V12, P82; Lollis SS, 2009, BRIT J NEUROSURG, V23, P516, DOI 10.1080/02688690902948192; Mahan M, 2013, J CLIN NEUROSCI, V20, P1718, DOI 10.1016/j.jocn.2013.03.005; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Muirhead WR, 2012, BRIT J NEUROSURG, V26, P710, DOI 10.3109/02688697.2012.671973; Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd; O'Leary ST, 2000, J NEUROSURG, V92, P801, DOI 10.3171/jns.2000.92.5.0801; Park YG, 2011, J KOREAN NEUROSURG S, V50, P317, DOI 10.3340/jkns.2011.50.4.317; Phillips SB, 2014, WORLD NEUROSURG, V82, P739, DOI 10.1016/j.wneu.2013.08.030; Phillips SB, 2012, NEUROCRIT CARE, V17, P255, DOI 10.1007/s12028-011-9571-2; Rehman T, 2013, WORLD NEUROSURG, V80, P173, DOI 10.1016/j.wneu.2012.12.012; Rosenbaum BP, 2013, CLIN NEUROL NEUROSUR, V115, P1514, DOI 10.1016/j.clineuro.2012.12.008; Rosenow JM, 2007, STEREOT FUNCT NEUROS, V85, P75, DOI 10.1159/000097922; Ruchholtz S, 1998, J TRAUMA, V45, P505, DOI 10.1097/00005373-199809000-00013; Saladino A, 2009, NEUROCRIT CARE, V10, P248, DOI 10.1007/s12028-008-9154-z; Schuette AJ, 2012, WORLD NEUROSURG, V77, DOI 10.1016/j.wneu.2011.09.015; Srinivasan VM, 2014, J NEUROSURG, V120, P228, DOI 10.3171/2013.6.JNS121577; Stangl AP, 1998, SURG NEUROL, V50, P77, DOI 10.1016/S0090-3019(97)00301-7; Stieglitz LH, 2010, NEUROSURGERY, V67, P131, DOI 10.1227/01.NEU.0000382964.72262.9A; Stroszczynski C, 2006, MINIMALLY INVASIVE T; Thomale UW, 2013, CHILD NERV SYST, V29, P131, DOI 10.1007/s00381-012-1943-1; Toma AK, 2009, NEUROSURGERY, V65, P1197, DOI 10.1227/01.NEU.0000356973.39913.0B; Wilson TJ, 2013, J NEUROSURG, V119, P66, DOI 10.3171/2012.11.JNS111384; Yamada SM, 2012, CLIN NEUROL NEUROSUR, V114, P622, DOI 10.1016/j.clineuro.2011.12.025	47	19	21	0	5	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	AUG	2017	159	8					1399	1411		10.1007/s00701-017-3201-5			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FA6CM	WOS:000405530900005	28555269				2021-06-18	
J	Chou, R; Totten, AM; Carney, N; Dandy, S; Fu, RW; Grusing, S; Pappas, M; Wasson, N; Newgard, CD				Chou, Roger; Totten, Annette M.; Carney, Nancy; Dandy, Spencer; Fu, Rongwei; Grusing, Sara; Pappas, Miranda; Wasson, Ngoc; Newgard, Craig D.			Predictive Utility of the Total Glasgow Coma Scale Versus the Motor Component of the Glasgow Coma Scale for Identification of Patients With Serious Traumatic Injuries	ANNALS OF EMERGENCY MEDICINE			English	Article							BRAIN-INJURY; SCORE; CHILDREN; OUTCOMES; RISK; CONSCIOUSNESS; METAANALYSIS; VALIDATION; CARE; TOOL	Study objective: The motor component of the Glasgow Coma Scale (mGCS) has been proposed as an easier-to-use alternative to the total GCS (tGCS) for field assessment of trauma patients by emergency medical services. We perform a systematic review and meta-analysis to compare the predictive utility of the tGCS versus the mGCS or Simplified Motor Scale in field triage of trauma for identifying patients with adverse outcomes (inhospital mortality or severe brain injury) or who underwent procedures (neurosurgical intervention or emergency intubation) indicating need for high-level trauma care. Methods: Ovid MEDLINE, Cumulative Index to Nursing and Allied Health Literature, PsycINFO, Health and Psychosocial Instruments, and the Cochrane databases were searched through June 2016 for English-language cohort studies. We included studies that compared the area under the receiver operating characteristic curve (AUROC) of the tGCS versus the mGCS or Simplified Motor Scale assessed in the field or shortly after arrival in the emergency department for predicting the outcomes described above. Meta-analyses were performed with a random-effects model, and subgroup and sensitivity analyses were conducted. Results: We included 18 head-to-head studies of predictive utility (n=1,703,388). For inhospital mortality, the tGCS was associated with slightly greater discrimination than the mGCS (pooled mean difference in [AUROC] 0.015; 95% confidence interval [CI] 0.009 to 0.022; I-2=85%; 12 studies) or the Simplified Motor Scale (pooled mean difference in AUROC 0.030; 95% CI 0.024 to 0.036; I-2=0%; 5 studies). The tGCS was also associated with greater discrimination than the mGCS or Simplified Motor Scale for nonmortality outcomes (differences in AUROC from 0.03 to 0.05). Findings were robust in subgroup and sensitivity analyses. Conclusion: The tGCS is associated with slightly greater discrimination than the mGCS or Simplified Motor Scale for identifying severe trauma. The small differences in discrimination are likely to be clinically unimportant and could be offset by factors such as convenience and ease of use.	[Chou, Roger; Totten, Annette M.; Carney, Nancy; Dandy, Spencer; Fu, Rongwei; Grusing, Sara; Pappas, Miranda; Wasson, Ngoc] Oregon Hlth & Sci Univ, Pacific Northwest Evidence Based Practice Ctr, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Chou, Roger] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; [Fu, Rongwei] Oregon Hlth & Sci Univ, Sch Publ Hlth, Portland, OR 97201 USA; [Newgard, Craig D.] Oregon Hlth & Sci Univ, Dept Emergency Med, Ctr Policy & Res Emergency Med, Portland, OR 97201 USA	Chou, R (corresponding author), Oregon Hlth & Sci Univ, Pacific Northwest Evidence Based Practice Ctr, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.; Chou, R (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.	chour@ohsu.edu	Totten, Annette/P-7909-2019	Totten, Annette/0000-0002-9100-8678; Chou, Roger/0000-0001-9889-8610	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services [290-2015-00009-I]	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. This project was funded under contract 290-2015-00009-I from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services.	Acker SN, 2014, J TRAUMA ACUTE CARE, V77, P304, DOI 10.1097/TA.0000000000000300; Agency for Healthcare Research and Quality, 2014, AHRQ PUBLICATION; Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BAZZOLI GJ, 1995, JAMA-J AM MED ASSOC, V273, P395; Beskind DL, 2014, PREHOSP EMERG CARE, V18, P68, DOI 10.3109/10903127.2013.844870; Beskind DL, 2011, ACAD EMERG MED, V18, P988, DOI 10.1111/j.1553-2712.2011.01148.x; Bewick V, 2004, CRIT CARE, V8, P508, DOI 10.1186/cc3000; Brown JB, 2014, J TRAUMA ACUTE CARE, V77, P95, DOI 10.1097/TA.0000000000000280; Caterino JM, 2012, EMERG MED J, V29, P492, DOI 10.1136/emj.2010.110437; Chang SM, 2012, METHODS GUIDE MED TE; Chou R, 2016, AHRQ PUBLICATION, P290; Cicero MX, 2013, PEDIATR EMERG CARE, V29, P43, DOI 10.1097/PEC.0b013e31827b52bf; Cornell JE, 2014, ANN INTERN MED, V160, P267, DOI 10.7326/M13-2886; Corrigan JD, 2014, J NEUROTRAUM, V31, P1000, DOI 10.1089/neu.2013.3145; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Eken C, 2009, EUR J EMERG MED, V16, P29, DOI 10.1097/MEJ.0b013e32830346ab; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2006, ACAD EMERG MED, V13, P968, DOI 10.1197/j.aem.2006.05.019; Graham E, 2016, CRD42016035944; Haukoos JS, 2007, ANN EMERG MED, V50, P18, DOI 10.1016/j.annemergmed.2006.10.004; Hayden JA, 2013, ANN INTERN MED, V158, P280, DOI 10.7326/0003-4819-158-4-201302190-00009; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Kupas DF, 2016, ANN EMERG MED, V68, P744, DOI 10.1016/j.annemergmed.2016.06.017; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Nance ML, 2013, NATL TRAUMA DATA BAN; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Rotondo MFC, 2014, RESOURCES OPTIMAL CA; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Singh B, 2013, BRAIN INJURY, V27, P293, DOI 10.3109/02699052.2012.743182; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Thompson DO, 2011, ANN EMERG MED, V58, P417, DOI 10.1016/j.annemergmed.2011.05.033; Van de Voorde P, 2008, RESUSCITATION, V76, P175, DOI 10.1016/j.resuscitation.2007.07.007; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; ZWEIG MH, 1993, CLIN CHEM, V39, P561	38	19	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	AUG	2017	70	2					143	157		10.1016/j.annemergmed.2016.11.032			15	Emergency Medicine	Emergency Medicine	FD1OI	WOS:000407306200005	28089112				2021-06-18	
J	Wang, WZ; Zhang, H; Lee, DH; Yu, JT; Cheng, T; Hong, M; Jiang, SS; Fan, H; Huang, X; Zhou, JY; Wang, J				Wang, Wenzhu; Zhang, Hong; Lee, Doon-Hoon; Yu, Jintao; Cheng, Tian; Hong, Michael; Jiang, Shanshan; Fan, Heng; Huang, Xi; Zhou, Jinyuan; Wang, Jian			Using functional and molecular MRI techniques to detect neuroinflammation and neuroprotection after traumatic brain injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						APT imaging; Flavonoid; Molecular imaging; MRI; Neuroinflammation; Neuroprotection; Traumatic brain injury	CEREBRAL-BLOOD-FLOW; INTRACEREBRAL HEMORRHAGE; ISCHEMIC PENUMBRA; WHITE-MATTER; RAT-BRAIN; PINOCEMBRIN; PROTECTS; STROKE; MODEL; DIFFERENTIATION	This study was designed to investigate whether functional and molecular MRI techniques are sensitive biomarkers for assessment of neuroinflammation and drug efficacy after traumatic brain injury (TBI) in rats. We subjected rats to a controlled cortical impact model and used behavioral tests, histology, and immunofluorescence to assess whether flavonoid pinocembrin provides cerebral protection and improves functional recovery. Most importantly, we used multiple noninvasive structural, functional, and molecular MRI techniques to examine whether the pinocembrin-related neuroprotection and attenuation of neuroinflammation can be detected in vivo. Significant increases in cerebral blood flow (CBF) and amide proton transfer-weighted (APTw) MRI signals were observed in the perilesional areas in untreated TBI rats at 3 days and could be attributed to increased glial response. In addition, increased apparent diffusion coefficient and decreased magnetization transfer ratio signals in untreated TBI rats over time were likely due to edema. Post-treatment with pinocembrin decreased microglial/macrophage activation at 3 days, consistent with the recovery of CBF and APTw MRI signals in regions of secondary injury. These findings suggest that pinocembrin provides cerebral protection for TBI and that multiple MRI signals, CBF and APTw in particular, are sensitive biomarkers for identification and assessment of neuroinflammation and drug efficacy in the TBI model. (C) 2017 Elsevier Inc. All rights reserved.	[Wang, Wenzhu; Wang, Jian] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Sch Med, Baltimore, MD 21205 USA; [Wang, Wenzhu] Huazhong Univ Sci & Technol, Union Hosp, Dept Integrated Chinese & Western Med, Tongji Med Coll, Wuhan 430022, Hunan, Peoples R China; [Jiang, Shanshan] Johns Hopkins Univ, Div MR Res, Dept Radiol, Sch Med, Baltimore, MD 21287 USA; [Zhang, Hong] Beijing Childrens Hosp, Capital Med Univ, Dept Radiol, Beijing 100045, Peoples R China; [Hong, Michael] Huazhong Univ Sci & Technol, Union Hosp, Dept Otorhinolaryngol, Tongji Med Coll, Wuhan 430022, Hunan, Peoples R China; [Huang, Xi] Affiliated Hosp Nanjing Univ Chinese Med, Gerontol Dept, Nanjing 210029, Jiangsu, Peoples R China; [Huang, Xi] Nanjing Univ Chinese Med, Inst TCM Related Comorbid Depress, 138 Xianling Rd, Nanjing 210046, Jiangsu, Peoples R China	Wang, J (corresponding author), Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Sch Med, Baltimore, MD 21205 USA.	huangx59@163.com; jzhou@mri.jhu.edu; jwang79@jhmi.edu	Lee, Dong-Hoon/G-4959-2016; Wang, Jian/I-4874-2019; hong, zhang/AAM-3862-2020; Jiang, Shanshan/O-8265-2019	Lee, Dong-Hoon/0000-0002-5013-4440; Wang, Jian/0000-0003-2291-640X; Jiang, Shanshan/0000-0003-2853-9991	American Heart AssociationAmerican Heart Association [13GRNT15730001]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317, R01NS078026, R01EB009731, R01CA166171, R01NS083435]; "Stimulating and Advancing ACCM Research (StAAR)" grant from the Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University; China Scholarship Council Joint PhD Training award (CSC) [201406370078]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS083435, R01NS078026] Funding Source: NIH RePORTER	We thank Claire Levine for assistance with this manuscript. This work was supported by grants from the American Heart Association (13GRNT15730001), the National Institutes of Health (R01AT007317, R01NS078026, R01EB009731, R01CA166171, R01NS083435), and a "Stimulating and Advancing ACCM Research (StAAR)" grant from the Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University. Wenzhu Wang is the recipient of the China Scholarship Council Joint PhD Training award (CSC NO. 201406370078).	Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; Cao GY, 2015, J ETHNOPHARMACOL, V168, P31, DOI 10.1016/j.jep.2015.03.041; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; de Oliveira M. R., 2016, MOL NEUROBIOL; Frey L, 2014, NEUROL RES, V36, P26, DOI 10.1179/1743132813Y.0000000269; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; Guang HM, 2006, EUR J PHARMACOL, V542, P77, DOI 10.1016/j.ejphar.2006.04.054; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Han XN, 2016, J CEREBR BLOOD F MET, V36, P1059, DOI 10.1177/0271678X15606462; Jaiswal MK, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00148; Jiang SS, 2016, EUR RADIOL, V26, P64, DOI 10.1007/s00330-015-3805-1; Jin T, 2012, NEUROIMAGE, V59, P1218, DOI 10.1016/j.neuroimage.2011.08.014; Kapoor S, 2013, J AGR FOOD CHEM, V61, P1416, DOI 10.1021/jf304482d; Lan X, 2017, BRAIN BEHAV IMMUN, V61, P326, DOI 10.1016/j.bbi.2016.12.012; Lan X, 2016, MOL NEUROBIOL, V53, P1794, DOI 10.1007/s12035-015-9125-2; Li W, 2016, BRAIN RES, V1646, P53, DOI 10.1016/j.brainres.2016.05.036; Liu R, 2008, BRAIN RES, V1216, P104, DOI 10.1016/j.brainres.2008.03.049; Liu R, 2014, NEUROBIOL AGING, V35, P1275, DOI 10.1016/j.neurobiolaging.2013.12.031; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Long JA, 2015, J CEREBR BLOOD F MET, V35, P1852, DOI 10.1038/jcbfm.2015.143; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maegele M, 2015, ACTA RADIOL OPEN, V4, DOI 10.1177/2047981614555142; Mao W, 2013, P NATL ACAD SCI USA, V110, P8842, DOI 10.1073/pnas.1303884110; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Meng FR, 2014, EXP THER MED, V8, P1285, DOI 10.3892/etm.2014.1923; NAKASU Y, 1995, AM J NEURORADIOL, V16, P1185; Niv F, 2012, STROKE, V43, P2468, DOI 10.1161/STROKEAHA.112.660977; Rasul A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/379850; Saad MA, 2015, PHARMACOL REP, V67, P115, DOI 10.1016/j.pharep.2014.08.014; Sayre CL, 2015, J PHARM PHARM SCI, V18, P368, DOI 10.18433/J3BK5T; Shi LL, 2011, LIFE SCI, V88, P521, DOI 10.1016/j.lfs.2011.01.011; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Sun PZ, 2007, J CEREBR BLOOD F MET, V27, P1129, DOI 10.1038/sj.jcbfm.9600424; Tietze A, 2014, NMR BIOMED, V27, P163, DOI 10.1002/nbm.3048; Tu TW, 2016, ANN NEUROL, V79, P907, DOI 10.1002/ana.24641; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang JP, 2013, BRAIN BEHAV IMMUN, V34, P56, DOI 10.1016/j.bbi.2013.07.010; Wang MY, 2015, MAGN RESON MED, V74, P42, DOI 10.1002/mrm.25690; Wang WZ, 2016, MOL NEUROBIOL, V53, P4809, DOI 10.1007/s12035-015-9385-x; Wang YM, 2016, J NEUROL SCI, V368, P223, DOI 10.1016/j.jns.2016.07.010; Watts LT, 2015, J NEUROTRAUM, V32, P1001, DOI 10.1089/neu.2014.3737; Wei XE, 2012, J NEUROTRAUM, V29, P2413, DOI 10.1089/neu.2010.1510; Wu CX, 2013, NEUROSCI LETT, V546, P57, DOI 10.1016/j.neulet.2013.04.060; Yan B, 2014, BIOMED CHROMATOGR, V28, P1601, DOI 10.1002/bmc.3186; Yan K, 2015, MOL IMAGING BIOL, V17, P479, DOI 10.1007/s11307-015-0828-6; Yang J, 2017, SCI REP-UK, V7, DOI 10.1038/srep40358; Yang ZJ, 2013, J CEREBR BLOOD F MET, V33, P1612, DOI 10.1038/jcbfm.2013.117; Zhao XC, 2015, BRAIN BEHAV IMMUN, V46, P293, DOI 10.1016/j.bbi.2015.02.011; Zhou JY, 2013, J MAGN RESON IMAGING, V38, P1119, DOI 10.1002/jmri.24067; Zhou JY, 2012, TRANSL STROKE RES, V3, P76, DOI 10.1007/s12975-011-0110-4; Zhou JY, 2011, NAT MED, V17, P130, DOI 10.1038/nm.2268; Zhou JY, 2003, NAT MED, V9, P1085, DOI 10.1038/nm907	52	19	19	2	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	AUG	2017	64						344	353		10.1016/j.bbi.2017.04.019			10	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	EZ1XR	WOS:000404504600033	28455264	Green Accepted			2021-06-18	
J	Lamb, DG; Porges, EC; Lewis, GF; Williamson, JB				Lamb, Damon G.; Porges, Eric C.; Lewis, Greg F.; Williamson, John B.			Non-invasive Vagal Nerve Stimulation Effects on Hyperarousal and Autonomic State in Patients with Posttraumatic Stress Disorder and History of Mild Traumatic Brain Injury: Preliminary Evidence	FRONTIERS IN MEDICINE			English	Article						posttraumatic stress disorder; traumatic brain injury; hyperarousal; autonomic; transcutaneous vagal nerve stimulation; vagal; transcutaneous; sympathetic	HEART-RATE-VARIABILITY; PREFRONTAL CORTEX; NORADRENERGIC MODULATION; ATTENTIONAL CONTROL; EXPOSURE THERAPY; CONDITIONED FEAR; DOUBLE-BLIND; EXTINCTION; PTSD; VETERANS	Posttraumatic stress disorder (PTSD) is a reaction to trauma that results in a chronic perception of threat, precipitating mobilization of the autonomic nervous system, and may be reflected by chronic disinhibition of limbic structures. A common injury preceding PTSD in veterans is mild traumatic brain injury (mTBI). This may be due to the vulnerability of white matter in these networks and such damage may affect treatment response. We evaluated transcutaneous vagal nerve stimulation (tVNS), a non-invasive, low-risk approach that may alter the functions of the limbo-cortical and peripheral networks underlying the hyperarousal component of PTSD and thus improve patient health and well-being. In this single visit pilot study evaluating the impact of tVNS in 22 combat veterans, we used a between-subjects design in people with either PTSD with preceding mTBI or healthy controls. Participants were randomized into stimulation or sham groups and completed a posturally modulated autonomic assessment and emotionally modulated startle paradigm. The primary measures used were respiratory sinus arrhythmia (high-frequency heart rate variability) during a tilt-table procedure derived from an electrocardiogram, and skin conductance changes in response to acoustic startle while viewing emotional images (International Affective Picture System). The stimulation was well tolerated and resulted in improvements in vagal tone and moderation of autonomic response to startle, consistent with modulation of autonomic state and response to stress in this population. Our results suggest that tVNS affects systems underlying emotional dysregulation in this population and, therefore, should be further evaluated and developed as a potential treatment tool for these patients.	[Lamb, Damon G.; Williamson, John B.] Malcom Randall VAMC, Brain Rehabil Res Ctr, Gainesville, FL 32608 USA; [Lamb, Damon G.; Porges, Eric C.; Williamson, John B.] Univ Florida, Coll Med, Ctr Cognit Aging & Memory, Gainesville, FL 32611 USA; [Lamb, Damon G.; Williamson, John B.] Univ Florida, Coll Med, Dept Neurol, Ctr Neuropsychol Studies, Gainesville, FL 32611 USA; [Lamb, Damon G.; Porges, Eric C.; Williamson, John B.] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Clin & Hlth Psychol, Gainesville, FL 32611 USA; [Lewis, Greg F.] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA; [Lewis, Greg F.] Indiana Univ, Sch Informat & Comp, Intelligent Syst Engn, Bloomington, IN USA; [Lewis, Greg F.] Indiana Univ, Kinsey Inst, Bloomington, IN USA	Williamson, JB (corresponding author), Malcom Randall VAMC, Brain Rehabil Res Ctr, Gainesville, FL 32608 USA.; Williamson, JB (corresponding author), Univ Florida, Coll Med, Ctr Cognit Aging & Memory, Gainesville, FL 32611 USA.; Williamson, JB (corresponding author), Univ Florida, Coll Med, Dept Neurol, Ctr Neuropsychol Studies, Gainesville, FL 32611 USA.; Williamson, JB (corresponding author), Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Clin & Hlth Psychol, Gainesville, FL 32611 USA.	john.williamson@neurology.ufl.edu			U.S. Department of Veterans Affairs, Rehabilitation Research and Development Office, Brain Rehabilitation Research Center (BRRC) Center [B6793C]; BRRC Innovation Award [0214BRRC-17, IK2RX000707]; Center for Cognitive Aging and Memory at the University of Florida; McKnight Brain Research Foundation; University of Florida Clinical and Translational Science Institute; National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001427]; NIH/NCATS Clinical and Translational Science AwardsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000064, KL2 TR000065]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001429, UL1TR001427] Funding Source: NIH RePORTER	This work was supported by the U.S. Department of Veterans Affairs, Rehabilitation Research and Development Office, Brain Rehabilitation Research Center (BRRC) Center Grant B6793C, and BRRC Innovation Award No. 0214BRRC-17 as well as IK2RX000707 (JBW), the Center for Cognitive Aging and Memory at the University of Florida, the McKnight Brain Research Foundation, the University of Florida Clinical and Translational Science Institute, which is supported in part by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) under Award No. UL1TR001427; NIH/NCATS Clinical and Translational Science Awards Grant Nos. UL1TR000064 and KL2 TR000065 (ECP). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs, the National Institutes of Health or the University of Florida.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Ben-Menachem E, 2015, EUR J NEUROL, V22, P1260, DOI 10.1111/ene.12629; Benedek M, 2010, J NEUROSCI METH, V190, P80, DOI 10.1016/j.jneumeth.2010.04.028; Binici Z, 2011, STROKE, V42, P3196, DOI 10.1161/STROKEAHA.110.607697; Braithwaite J.J., 2015, GUIDE ANAL ELECTRODE; Bryant RA, 2008, J CONSULT CLIN PSYCH, V76, P695, DOI 10.1037/a0012616; Buffalari DM, 2007, J NEUROSCI, V27, P12358, DOI 10.1523/JNEUROSCI.2007-07.2007; Capone F, 2015, J NEURAL TRANSM, V122, P679, DOI 10.1007/s00702-014-1299-7; Clancy JA, 2014, BRAIN STIMUL, V7, P871, DOI 10.1016/j.brs.2014.07.031; Critchley HD, 2000, J PHYSIOL-LONDON, V523, P259, DOI 10.1111/j.1469-7793.2000.t01-1-00259.x; Dale LP, 2009, APPL PSYCHOPHYS BIOF, V34, P299, DOI 10.1007/s10484-009-9111-4; Davidson J, 2006, J CLIN PSYCHOPHARM, V26, P259, DOI 10.1097/01.jcp.0000222514.71390.c1; Davidson JRT, 2006, J CLIN PSYCHIAT, V67, P34; De Martino B, 2008, PSYCHOPHARMACOLOGY, V197, P127, DOI 10.1007/s00213-007-1015-5; Diamond DM, 2016, J NEUROSCI RES, V94, P437, DOI 10.1002/jnr.23684; Dietrich S, 2008, BIOMED TECH, V53, P104, DOI 10.1515/BMT.2008.022; Difede J, 2014, ANNU REV MED, V65, P319, DOI 10.1146/annurev-med-051812-145438; Fallgatter AJ, 2003, J NEURAL TRANSM, V110, P1437, DOI 10.1007/s00702-003-0087-6; Felmingham KL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103653; Foa E. B., 2009, EFFECTIVE TREATMENTS; Foa EB, 2013, PSYCHOL SCI PUBL INT, V14, P65, DOI 10.1177/1529100612468841; HARDY SGP, 1988, EXP BRAIN RES, V73, P249; Kemp AH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030777; Kotecha D, 2012, HEART, V98, P395, DOI 10.1136/heartjnl-2011-300033; Kraus T, 2013, BRAIN STIMUL, V6, P798, DOI 10.1016/j.brs.2013.01.011; Lang P. J., 2001, INT AFFECTIVE PICTUR; LANG PJ, 2001, A5 U FLOR CTR RES PS; LOEWY AD, 1991, PROG BRAIN RES, V87, P253; Magruder KM, 2016, J TRAUMA STRESS, V29, P5, DOI 10.1002/jts.22075; McEwen BS, 2003, HORM BEHAV, V43, P2, DOI 10.1016/S0018-506X(02)00024-7; Miller-Archie SA, 2014, PREV MED, V66, P34, DOI 10.1016/j.ypmed.2014.05.016; Mota N, 2016, J CLIN PSYCHIAT, V77, P348, DOI 10.4088/JCP.15m10101; Mueller D, 2010, BEHAV BRAIN RES, V208, P1, DOI 10.1016/j.bbr.2009.11.025; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Norte CE, 2013, J AFFECT DISORDERS, V150, P136, DOI 10.1016/j.jad.2012.11.039; Owens NC, 2001, BRAIN RES, V919, P221, DOI 10.1016/S0006-8993(01)03017-7; Paulus EJ, 2013, J TRAUMA STRESS, V26, P169, DOI 10.1002/jts.21785; Pena DF, 2013, BIOL PSYCHIAT, V73, P1071, DOI 10.1016/j.biopsych.2012.10.021; Pena DF, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00327; Pietrzak RH, 2010, PSYCHIAT RES, V178, P323, DOI 10.1016/j.psychres.2010.04.039; Porges SW, 2007, BIOL PSYCHOL, V74, P116, DOI 10.1016/j.biopsycho.2006.06.009; Resstel LBM, 2004, BRAIN RES, V1015, P136, DOI 10.1016/j.brainres.2004.04.065; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Santini E, 2004, J NEUROSCI, V24, P5704, DOI 10.1523/JNEUROSCI.0786-04.2004; Shah AJ, 2013, BIOL PSYCHIAT, V73, P1103, DOI 10.1016/j.biopsych.2013.01.019; Simon NM, 2008, J CLIN PSYCHIAT, V69, P400, DOI 10.4088/JCP.v69n0309; Stein MB, 2002, AM J PSYCHIAT, V159, P1777, DOI 10.1176/appi.ajp.159.10.1777; TSUJI H, 1994, CIRCULATION, V90, P878, DOI 10.1161/01.CIR.90.2.878; Umhau JC, 2002, PSYCHOPHYSIOLOGY, V39, P117, DOI 10.1017/S0048577201392016; Vaiva G, 2003, BIOL PSYCHIAT, V54, P947, DOI 10.1016/S0006-3223(03)00412-8; Verberne AJM, 1998, PROG NEUROBIOL, V54, P149, DOI 10.1016/S0301-0082(97)00056-7; White SF, 2015, NEUROIMAGE-CLIN, V7, P19, DOI 10.1016/j.nicl.2014.11.012; Williamson JB, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01571; Williamson John B, 2013, Front Neuroeng, V6, P13, DOI 10.3389/fneng.2013.00013; Williamson JB, 2010, AUTON NEUROSCI-BASIC, V156, P60, DOI 10.1016/j.autneu.2010.03.009; Zikopoulos B, 2017, J NEUROSCI, V37, P5051, DOI 10.1523/JNEUROSCI.3940-16.2017; Zohar J, 2002, J CLIN PSYCHOPHARM, V22, P190, DOI 10.1097/00004714-200204000-00013	58	19	20	0	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		2296-858X		FRONT MED-LAUSANNE	Front. Med.	JUL 31	2017	4								124	10.3389/fmed.2017.00124			9	Medicine, General & Internal	General & Internal Medicine	FC9CD	WOS:000407137600001	28824913	DOAJ Gold, Green Published			2021-06-18	
J	Lourenco, CF; Ledo, A; Gerhardt, GA; Laranjinha, J; Barbosa, RM				Lourenco, Catia F.; Ledo, Ana; Gerhardt, Greg A.; Laranjinha, Joao; Barbosa, Rui M.			Neurometabolic and electrophysiological changes during cortical spreading depolarization: multimodal approach based on a lactate-glucose dual microbiosensor arrays	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; IN-VIVO; ONLINE MICRODIALYSIS; EXTRACELLULAR GLUCOSE; MICROELECTRODE ARRAYS; MALIGNANT STROKE; DYNAMIC CHANGES; TISSUE PO2; RAT-BRAIN; DEPRESSION	Spreading depolarization (SD) is a slow propagating wave of strong depolarization of neural cells, implicated in several neuropathological conditions. The breakdown of brain homeostasis promotes significant hemodynamic and metabolic alterations, which impacts on neuronal function. In this work we aimed to develop an innovative multimodal approach, encompassing metabolic, electric and hemodynamic measurements, tailored but not limited to study SD. This was based on a novel dualbiosensor based on microelectrode arrays designed to simultaneously monitor lactate and glucose fluctuations and ongoing neuronal activity with high spatial and temporal resolution. In vitro evaluation of dual lactate-glucose microbiosensor revealed an extended linear range, high sensitivity and selectivity, fast response time and low oxygen-, temperature-and pH-dependencies. In anesthetized rats, we measured with the same array a significant drop in glucose concentration matched to a rise in lactate and concurrently with pronounced changes in the spectral profile of LFP-related currents during episodes of mechanically-evoked SD. This occurred along with the stereotypical hemodynamic response of the SD wave. Overall, this multimodal approach successfully demonstrates the capability to monitor metabolic alterations and ongoing electrical activity, thus contributing to a better understanding of the metabolic changes occurring in the brain following SD.	[Lourenco, Catia F.; Ledo, Ana; Laranjinha, Joao; Barbosa, Rui M.] Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal; [Gerhardt, Greg A.] Univ Kentucky, Ctr Microelectrode Technol, Lexington, KY 40506 USA; [Laranjinha, Joao; Barbosa, Rui M.] Univ Coimbra, Fac Pharm, Coimbra, Portugal	Lourenco, CF; Barbosa, RM (corresponding author), Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal.; Barbosa, RM (corresponding author), Univ Coimbra, Fac Pharm, Coimbra, Portugal.	cflmarques@uc.pt; rbarbosa@ff.uc.pt	Ledo, Ana/L-6016-2013; Barbosa, Rui M./U-7117-2019; Marques, Catia Lourenco/M-6634-2013	Ledo, Ana/0000-0002-7737-4241; Barbosa, Rui M./0000-0002-1604-6324; Marques, Catia Lourenco/0000-0002-0514-0198	FEDER funds through the Operational Program Competitiveness Factors - COMPETE; FCT - Foundation for Science and TechnologyPortuguese Foundation for Science and Technology [POCI-01-0145-FEDER-007440]; FCTPortuguese Foundation for Science and TechnologyEuropean Commission [SFRH/BPD/82436/2011]	This work was funded by FEDER funds through the Operational Program Competitiveness Factors - COMPETE and national funds by FCT - Foundation for Science and Technology under strategic project POCI-01-0145-FEDER-007440. C.F.L. acknowledges fellowship SFRH/BPD/82436/2011 from FCT. We acknowledge some support from Quanteon, LLC for salary of A.L.	Ayata C, 2015, PHYSIOL REV, V95, P953, DOI 10.1152/physrev.00027.2014; Balanca B, 2017, J CEREBR BLOOD F MET, V37, P1670, DOI 10.1177/0271678X16657571; Burmeister JJ, 2008, BIOSENS BIOELECTRON, V23, P1382, DOI 10.1016/j.bios.2007.12.013; Burmeister JJ, 2005, BIOSENS BIOELECTRON, V20, P1772, DOI 10.1016/j.bios.2004.07.003; Chang JC, 2010, BRAIN, V133, P996, DOI 10.1093/brain/awp338; Cornford EM, 2002, EPILEPSIA, V43, P1360, DOI 10.1046/j.1528-1157.2002.01602.x; Dienel GA, 2014, J CEREBR BLOOD F MET, V34, P1736, DOI 10.1038/jcbfm.2014.153; Disney AA, 2015, J NEUROSCI METH, V255, P29, DOI 10.1016/j.jneumeth.2015.07.009; Dreier JP, 2017, J CEREBR BLOOD F MET, V37, P1595, DOI 10.1177/0271678X16654496; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Ferreira NR, 2013, ELECTROANAL, V25, P1757, DOI 10.1002/elan.201300053; Feuerstein D, 2016, J CEREBR BLOOD F MET, V36, P1965, DOI 10.1177/0271678X15612779; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hartings JA, 2014, ANN NEUROL, V76, P681, DOI 10.1002/ana.24256; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; Hertle DN, 2016, CLIN NEUROPHYSIOL, V127, P2661, DOI 10.1016/j.clinph.2016.04.026; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Koroleva V I, 2006, Neurosci Behav Physiol, V36, P625, DOI 10.1007/s11055-006-0067-z; Kramer DR, 2016, J CLIN NEUROSCI, V24, P22, DOI 10.1016/j.jocn.2015.08.004; LAMANNA JC, 1989, METAB BRAIN DIS, V4, P225, DOI 10.1007/BF00999769; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Ledo A, 2017, ANAL CHEM, V89, P1674, DOI 10.1021/acs.analchem.6b03772; Lourenco CF, 2016, SENSOR ACTUAT B-CHEM, V237, P298, DOI 10.1016/j.snb.2016.06.083; Miele M, 1996, J NEUROSCI METH, V70, P15, DOI 10.1016/S0165-0270(96)00094-5; Murphy LJ, 1998, ANAL CHEM, V70, P2928, DOI 10.1021/ac971182r; MURR R, 1994, PFLUG ARCH EUR J PHY, V426, P348, DOI 10.1007/BF00374792; NAIR PK, 1987, STROKE, V18, P616, DOI 10.1161/01.STR.18.3.616; OGUNYEMI AO, 1995, BEHAV NEUROL, V8, P109, DOI 10.3233/BEN-1995-8206; Ostergaard L, 2015, STROKE, V46, P1392, DOI 10.1161/STROKEAHA.114.008077; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Parkin MC, 2003, TRAC-TREND ANAL CHEM, V22, P487, DOI 10.1016/S0165-9936(03)00912-9; Paxinos G, 2007, RAT BRAIN STEROTAXIC; Piilgaard H, 2009, J CEREBR BLOOD F MET, V29, P1517, DOI 10.1038/jcbfm.2009.73; Rapp PE, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00011; Rocchitta G, 2013, ANAL CHEM, V85, P10282, DOI 10.1021/ac402071w; Rogers ML, 2013, ACS CHEM NEUROSCI, V4, P799, DOI 10.1021/cn400047x; Roshchina G. Y., 2014, NEUROSCI BEHAV PHYSL, V44, P134, DOI [10.1007/s11055-014-9887-4, DOI 10.1007/S11055-014-9887-4]; SCHELLER D, 1992, NEUROSCI LETT, V135, P83, DOI 10.1016/0304-3940(92)90141-S; STAMFORD JA, 1984, BRAIN RES, V299, P289, DOI 10.1016/0006-8993(84)90710-8; Taurino I, 2013, ELECTROCHIM ACTA, V93, P72, DOI 10.1016/j.electacta.2013.01.080; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; TOMIDA S, 1989, J CEREBR BLOOD F MET, V9, P79, DOI 10.1038/jcbfm.1989.11; Vasylieva N, 2015, BIOSENS BIOELECTRON, V72, P148, DOI 10.1016/j.bios.2015.05.004; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Viggiano A, 2012, J NEUROSCI METH, V206, P1, DOI 10.1016/j.jneumeth.2012.01.013; Weltin A, 2016, ANAL BIOANAL CHEM, V408, P4503, DOI 10.1007/s00216-016-9420-4; Weltin A, 2014, IEEE SENS J, V14, P3345, DOI 10.1109/JSEN.2014.2323220; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932; Zhang H, 2009, J NEUROSCI METH, V179, P191, DOI 10.1016/j.jneumeth.2009.01.023	50	19	19	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 28	2017	7									10.1038/s41598-017-07119-6			12	Multidisciplinary Sciences	Science & Technology - Other Topics	FC1PP	WOS:000406610000015	28754993	DOAJ Gold, Green Published			2021-06-18	
J	Dati, LM; Ulrich, H; Real, CC; Feng, ZP; Sun, HS; Britto, LR				Dati, L. M.; Ulrich, H.; Real, C. C.; Feng, Z. P.; Sun, H. S.; Britto, L. R.			CARVACROL PROMOTES NEUROPROTECTION IN THE MOUSE HEMIPARKINSONIAN MODEL	NEUROSCIENCE			English	Article						carvacrol; dopamine; neuroprotection; TRP channels	PARKINSONS-DISEASE; DOPAMINERGIC-NEURONS; TRPM7 CHANNEL; ION CHANNELS; CELL-DEATH; AUTOPHAGY; ISCHEMIA; STRESS; INJURY; BRAIN	Carvacrol is a monoterpene that has been linked to neuroprotection in several animal models of neurodegeneration, including ischemia, epilepsy and traumatic neuronal injury. In this study, we investigated the effects of carvacrol (i.p.) upon the neurodegeneration induced by 6-hydroxydopamine unilateral intrastriatal injections in mice. We have also used the cylinder test to assess the behavioral effects of carvacrol in that model of Parkinson's disease, and immunoblots to evaluate the levels of caspase-3 and TRPM7, one of major targets of carvacrol. Behavioral testing revealed that carvacrol largely reduced the asymmetrical use of the forelimbs induced by unilateral 6-hydroxy-dopamine. Carvacrol dramatically reduced the loss of tyrosine hydroxylase immunostaining both in the substantia nigra and in the striatum that are typical of the model. Immunoblots for tyrosine hydroxylase confirmed this effect. Caspase-3 levels were very high after toxin injections, but carvacrol appeared to reduce them to control levels. Finally, TRPM7, observed by immunoblots, increased after 6-hydroxy-dopamine, suggesting the involvement of this cation channel in the ensuing neurodegenerative process. The present data suggest that carvacrol promotes a marked neuroprotection in the 6hydroxy-dopamine model of Parkinson's disease, possibly by its non-specific blocking effect upon TRPM7 channels. (C) 2017 IBRO. Published by Elsevier Ltd. All rights reserved.	[Dati, L. M.; Real, C. C.; Britto, L. R.] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, BR-05508900 Sao Paulo, SP, Brazil; [Ulrich, H.] Univ Sao Paulo, Inst Chem, Dept Biochem, Sao Paulo, Brazil; [Feng, Z. P.; Sun, H. S.] Univ Toronto, Fac Med, Dept Physiol, Toronto, ON, Canada; [Sun, H. S.] Univ Toronto, Fac Med, Dept Surg, Toronto, ON, Canada	Britto, LR (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, BR-05508900 Sao Paulo, SP, Brazil.	lrbritto@usp.br	Real, Caroline C/N-1674-2013; Ulrich, Henning/C-5245-2013	Real, Caroline C/0000-0001-6096-3341; Ulrich, Henning/0000-0002-2114-3815	Sao Paulo Research Foundation (FAPESP, Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/50880-4]; National Council for Scientific and Technological Development (CNPq, Brazil)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); FAPESP fellowshipsFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC) [RGPIN-2014-06471, RGPIN-2016-04574]; University of TorontoUniversity of Toronto; University of Sao Paulo; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16K08429, 26460113] Funding Source: KAKEN	This study was supported by the Sao Paulo Research Foundation (FAPESP, Project No. 2012/50880-4, Brazil) and the National Council for Scientific and Technological Development (CNPq, Brazil). L.M.D. and C.C.R. are recipients of FAPESP fellowships. This work was also supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grants to Z.P.F. (RGPIN-2014-06471) and to H.S.S. (RGPIN-2016-04574), and a University of Toronto and University of Sao Paulo Joint Call Proposal grant to H.S.S., Z.P.F. and L.R.B.	Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Chen WL, 2015, ONCOTARGET, V6, P16321, DOI 10.18632/oncotarget.3872; Chen WL, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0102-5; Dadon D, 2010, INT J BIOCHEM CELL B, V42, P1430, DOI 10.1016/j.biocel.2010.04.006; Decker AR, 2014, DEV BIOL, V386, P428, DOI 10.1016/j.ydbio.2013.11.015; Demeuse P, 2006, J GEN PHYSIOL, V127, P421, DOI 10.1085/jgp.200509410; Fleig A, 2004, TRENDS PHARMACOL SCI, V25, P633, DOI 10.1016/j.tips.2004.10.004; Fleig A, 2014, HANDB EXP PHARMACOL, V222, P521, DOI 10.1007/978-3-642-54215-2_21; Glajch KE, 2012, BEHAV BRAIN RES, V230, P309, DOI 10.1016/j.bbr.2011.12.007; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hernandes MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075532; Hotta M, 2010, J LIPID RES, V51, P132, DOI 10.1194/jlr.M900255-JLR200; Khalil A, 2017, EPILEPSIA, V58, P263, DOI 10.1111/epi.13645; Khan S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/379817; Li WT, 2015, NEUROCHEM INT, V90, P107, DOI 10.1016/j.neuint.2015.07.020; Miller BA, 2011, ADV EXP MED BIOL, V704, P531, DOI 10.1007/978-94-007-0265-3_29; Nilius B, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-218; Oh HG, 2015, BIOCHEM BIOPH RES CO, V463, P7, DOI 10.1016/j.bbrc.2015.05.007; Oz M, 2015, PHARMACOL THERAPEUT, V152, P83, DOI 10.1016/j.pharmthera.2015.05.006; Parnas M, 2009, CELL CALCIUM, V45, P300, DOI 10.1016/j.ceca.2008.11.009; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Penner R., 2007, V179, P313; Schober A, 2004, CELL TISSUE RES, V318, P215, DOI 10.1007/s00441-004-0938-y; Smith GA, 2012, BEHAV BRAIN RES, V226, P281, DOI 10.1016/j.bbr.2011.09.025; Sukumaran P, 2016, CELL CALCIUM, V60, P123, DOI 10.1016/j.ceca.2016.02.012; Sun HS, 2009, NAT NEUROSCI, V12, P1300, DOI 10.1038/nn.2395; Sun YY, 2015, CHANNELS, V9, P253, DOI 10.1080/19336950.2015.1075675; Takada Y, 2013, CURR TOP MED CHEM, V13, P322; Turlova E, 2016, MOL NEUROBIOL, V53, P595, DOI 10.1007/s12035-014-9032-y; Verma S, 2012, NEUROSCI LETT, V530, P41, DOI 10.1016/j.neulet.2012.09.044; Vink R, 2009, MAGNESIUM RES, V22, p158S; Yu HL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033584	32	19	19	1	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUL 25	2017	356						176	181		10.1016/j.neuroscience.2017.05.013			6	Neurosciences	Neurosciences & Neurology	EZ9MZ	WOS:000405055800016	28526576				2021-06-18	
J	Ljungqvist, J; Candefjord, S; Persson, M; Jonsson, L; Skoglund, T; Elae, M				Ljungqvist, Johan; Candefjord, Stefan; Persson, Mikael; Jonsson, Lars; Skoglund, Thomas; Elae, Mikael			Clinical Evaluation of a Microwave-Based Device for Detection of Traumatic Intracranial Hemorrhage	JOURNAL OF NEUROTRAUMA			English	Article						chronic subdural hematoma; intracranial hemorrhage detection; microwave technology; traumatic brain injury; triage	SUBDURAL-HEMATOMA; MAJOR TRAUMA; BRAIN-INJURY; MORTALITY; DIAGNOSIS	Traumatic brain injury (TBI) is the leading cause of death and disability among young persons. A key to improve outcome for patients with TBI is to reduce the time from injury to definitive care by achieving high triage accuracy. Microwave technology (MWT) allows for a portable device to be used in the pre-hospital setting for detection of intracranial hematomas at the scene of injury, thereby enhancing early triage and allowing for more adequate early care. MWT has previously been evaluated for medical applications including the ability to differentiate between hemorrhagic and ischemic stroke. The purpose of this study was to test whether MWT in conjunction with a diagnostic mathematical algorithm could be used as a medical screening tool to differentiate patients with traumatic intracranial hematomas, chronic subdural hematomas (cSDH), from a healthy control (HC) group. Twenty patients with cSDH and 20 HC were measured with a MWT device. The accuracy of the diagnostic algorithm was assessed using a leave-one-out analysis. At 100% sensitivity, the specificity was 75%-i.e., all hematomas were detected at the cost of 25% false positives (patients who would be overtriaged). Considering the need for methods to identify patients with intracranial hematomas in the pre-hospital setting, MWT shows promise as a tool to improve triage accuracy. Further studies are under way to evaluate MWT in patients with other intracranial hemorrhages.	[Ljungqvist, Johan; Skoglund, Thomas] Sahlgrens Univ Hosp, Dept Neurosurg, SE-41345 Gothenburg, Sweden; [Ljungqvist, Johan; Skoglund, Thomas] Univ Gothenburg, Inst Neurosci & Physiol, Dept Clin Neurosci, Sahlgrenska Acad, Gothenburg, Sweden; [Candefjord, Stefan; Persson, Mikael] Chalmers, Dept Signals & Syst, Gothenburg, Sweden; [Candefjord, Stefan; Persson, Mikael; Elae, Mikael] Sahlgrens Univ Hosp, MedTech West, Gothenburg, Sweden; [Candefjord, Stefan] SAFER Vehicle & Traff Safety Ctr Chalmers, Gothenburg, Sweden; [Jonsson, Lars] Sahlgrens Univ Hosp, Dept Neuroradiol, Gothenburg, Sweden; [Elae, Mikael] Sahlgrens Univ Hosp, Dept Clin Neurophysiol, Gothenburg, Sweden	Ljungqvist, J (corresponding author), Sahlgrens Univ Hosp, Dept Neurosurg, SE-41345 Gothenburg, Sweden.	johan.ljungqvist@vgregion.se		/0000-0001-7942-2190	Swedish Research CouncilSwedish Research CouncilEuropean Commission [921-2014-7116]; Gothenburg medical faculty [ALFGBG 542231]; Chalmers Innovation Office [V126]	The authors would like to thank Dr. Andreas Bartley and Gudrun Barrows for assisting with clinical examination and data collection. The authors would like to thank David Andtbacka and Lukas Lonnroth for assisting with CT scan assessment. This study was supported by the Swedish Research Council (proj no. 921-2014-7116), the Gothenburg medical faculty (ALFGBG 542231) and the Chalmers Innovation Office (proj no. V126).	Ashkenazi I, 2016, JAMA SURG, V151, P954, DOI 10.1001/jamasurg.2016.1742; Bonaccio M., 2016, INT J SOC ROBOT, P1, DOI DOI 10.1007/S12369-015-0335-6; Candefjord S, 2016, MED BIOL ENG COMPUT; Candefjord S, 2016, TRAFFIC INJ PREV, V17, P16, DOI 10.1080/15389588.2016.1198872; Candefjord S, 2013, IEEE ENG MED BIO, P1948, DOI 10.1109/EMBC.2013.6609909; Dehli T, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0295-3; Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y; Fhager A, 2009, IEEE ANTENN WIREL PR, V8, P1353, DOI 10.1109/LAWP.2009.2039032; Gabriel C, 1996, PHYS MED BIOL, V41, P2231, DOI 10.1088/0031-9155/41/11/001; Gabriel S, 1996, PHYS MED BIOL, V41, P2251, DOI 10.1088/0031-9155/41/11/002; Haas B, 2010, J AM COLL SURGEONS, V211, P804, DOI 10.1016/j.jamcollsurg.2010.08.014; Lecky F, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20010; Leon-Carrion J, 2010, BRAIN INJURY, V24, P1193, DOI 10.3109/02699052.2010.506636; LIN JC, 1982, P IEEE, V70, P523, DOI 10.1109/PROC.1982.12341; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mahmood Q, 2015, J ELECTROMAG ANAL AP, V7, P152, DOI [DOI 10.4236/jemaa.2015.75017, DOI 10.4236/JEMAA.2015.75017]; Meaney PM, 2013, MED PHYS, V40, DOI 10.1118/1.4820361; Mobashsher AT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152351; Mohammed BJ, 2014, IEEE T INSTRUM MEAS, V63, P117, DOI 10.1109/TIM.2013.2277562; Parker BJ, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-326; Persson M, 2014, IEEE T BIO-MED ENG, V61, P2806, DOI 10.1109/TBME.2014.2330554; Poplack SP, 2007, RADIOLOGY, V243, P350, DOI 10.1148/radiol.2432060286; Preece AW, 2016, J MED IMAGING, V3, DOI 10.1117/1.JMI.3.3.033502; Prichep LS, 2015, J NEUROTRAUM, V32, P17, DOI 10.1089/neu.2014.3365; Robertson CS, 2010, J NEUROTRAUM, V27, P1597, DOI 10.1089/neu.2010.1340; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Semenova ZB, 2016, BRAIN INJURY, V30, P18, DOI 10.3109/02699052.2014.989401; Xiang HY, 2014, AM J EMERG MED, V32, P997, DOI 10.1016/j.ajem.2014.05.038	28	19	19	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2017	34	13					2176	2182		10.1089/neu.2016.4869			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EZ2HM	WOS:000404530400456	28287909	Green Published, Bronze			2021-06-18	
J	Ma, YB; Matsuwaki, T; Yamanouchi, K; Nishihara, M				Ma, Yanbo; Matsuwaki, Takashi; Yamanouchi, Keitaro; Nishihara, Masugi			Progranulin Protects Hippocampal Neurogenesis via Suppression of Neuroinflammatory Responses Under Acute Immune Stress	MOLECULAR NEUROBIOLOGY			English	Article						Progranulin; Immune stress; Neurogenesis; Microglia; Neuroinflammation	TRAUMATIC BRAIN-INJURY; ADULT NEUROGENESIS; PROGENITOR PROLIFERATION; MICROGLIAL ACTIVATION; HUNTINGTONS-DISEASE; CELL-PROLIFERATION; ROLES; MTOR; EXPRESSION; PHENOTYPE	Immune stress is well known to suppress adult neurogenesis in the hippocampus. We have demonstrated that progranulin (PGRN) has a mitogenic effect on neurogenesis under several experimental conditions. We have also shown that PGRN suppresses excessive neuroinflammatory responses after traumatic brain injury. However, the role of PGRN in modulating neurogenesis under acute immune stress is yet to be elucidated. In the present study, we evaluated the involvement of PGRN in neurogenesis and inflammatory responses in the hippocampus using a lipopolysaccharide (LPS)-induced immune stress model. Treatment of mice with LPS significantly increased the expression of PGRN in activated microglia and decreased neurogenesis in the dentate gyrus of the hippocampus. PGRN deficiency increased CD68-immunoreactive area and exacerbated suppression of neurogenesis following LPS treatment. The expression levels of lysosomal genes including lysozyme M, macrophage expressed gene 1, and cathepsin Z were higher in PGRN-deficient than in wild-type mice, while PGRN deficiency decreased mammalian target of rapamycin (mTOR) mRNA levels, suggesting that PGRN suppresses excessive lysosomal biogenesis by promoting mTOR signaling. LPS treatment also increased the expression of proinflammatory genes such as interleukin (IL)-1 beta, tumor necrosis factor-alpha, and microsomal prostaglandin E synthase-1 (mPGES-1) in the hippocampus, and PGRN deficiency further enhanced gene expression of IL-6 and mPGES-1. These results suggest that PGRN plays a protecting role in hippocampal neurogenesis at least partially by attenuating neuroinflammatory responses during LPS-induced acute immune stress.	[Ma, Yanbo; Matsuwaki, Takashi; Yamanouchi, Keitaro; Nishihara, Masugi] Univ Tokyo, Dept Vet Physiol, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan	Nishihara, M (corresponding author), Univ Tokyo, Dept Vet Physiol, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan.	amnishi@mail.ecc.u-tokyo.ac.jp	Yamanouchi, Keitaro/R-5003-2019		JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23228004]; JSPS Postdoctoral FellowshipMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [26.04906]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17H03930] Funding Source: KAKEN	This work was partly supported by JSPS KAKENHI (Grant Number 23228004 to MN) and a JSPS Postdoctoral Fellowship for Foreign Researchers (Grant Number 26.04906 to YM).	Anacker C, 2013, P NATL ACAD SCI USA, V110, P8708, DOI 10.1073/pnas.1300886110; Asakura R, 2011, NEUROREPORT, V22, P881, DOI 10.1097/WNR.0b013e32834bf4ca; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Becker JB, 2007, J NEUROSCI, V27, P11851, DOI 10.1523/JNEUROSCI.3565-07.2007; Borsini A, 2015, TRENDS NEUROSCI, V38, P145, DOI 10.1016/j.tins.2014.12.006; Cao CY, 1996, BRAIN RES, V733, P263, DOI 10.1016/0006-8993(96)00575-6; Chen ZH, 2012, J NEUROSCI, V32, P11706, DOI 10.1523/JNEUROSCI.0730-12.2012; Chiba S, 2007, J REPROD DEVELOP, V53, P297, DOI 10.1262/jrd.18108; Christie BR, 2006, HIPPOCAMPUS, V16, P199, DOI 10.1002/hipo.20151; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; De Muynck L, 2011, J MOL NEUROSCI, V45, P549, DOI 10.1007/s12031-011-9553-z; Ehninger D, 2008, CELL TISSUE RES, V331, P243, DOI 10.1007/s00441-007-0478-3; Ek M, 2001, NATURE, V410, P430, DOI 10.1038/35068632; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Foltynie T, 2015, J CLIN INVEST, V125, P978, DOI 10.1172/JCI80822; Gil-Mohapel J, 2011, BRAIN RES, V1406, P84, DOI 10.1016/j.brainres.2011.06.040; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Gu ZH, 2013, NEURAL REGEN RES, V8, P2117, DOI 10.3969/j.issn.1673-5374.2013.23.001; Gunnar M, 2007, ANNU REV PSYCHOL, V58, P145, DOI 10.1146/annurev.psych.58.110405.085605; Harris H, 2012, NAT REV NEUROL, V8, P108, DOI 10.1038/nrneurol.2011.200; Heberle AM, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.970489; Iosif RE, 2006, J NEUROSCI, V26, P9703, DOI 10.1523/JNEUROSCI.2723-06.2006; Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020; Kleinberger G, 2013, MOL NEUROBIOL, V47, P337, DOI 10.1007/s12035-012-8380-8; Koo JW, 2008, P NATL ACAD SCI USA, V105, P751, DOI 10.1073/pnas.0708092105; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Le WD, 2001, J NEUROSCI, V21, P8447; Lehmann ML, 2013, J NEUROSCI, V33, P2961, DOI 10.1523/JNEUROSCI.3878-12.2013; Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639; Ma YB, 2013, BRAIN RES, V1508, P23, DOI 10.1016/j.brainres.2013.02.042; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; Marxreiter F, 2013, CELL MOL LIFE SCI, V70, P459, DOI 10.1007/s00018-012-1062-x; Masocha W, 2009, J NEUROIMMUNOL, V214, P78, DOI 10.1016/j.jneuroim.2009.06.022; Matsuwaki T, 2011, J REPROD DEVELOP, V57, P113, DOI 10.1262/jrd.10-116S; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Mu YL, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-85; Nedachi T, 2011, NEUROSCIENCE, V185, P106, DOI 10.1016/j.neuroscience.2011.04.037; Paxinos G., 2008, MOUSE BRAIN STEREOTA, V3rd; Puertollano Rosa, 2014, F1000Prime Rep, V6, P52, DOI 10.12703/P6-52; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; QUAN N, 1994, J NEUROIMMUNOL, V49, P125, DOI 10.1016/0165-5728(94)90188-0; Regensburger M, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/454696; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Suzuki M, 2009, J REPROD DEVELOP, V55, P351, DOI 10.1262/jrd.20249; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575; Wong EYH, 2005, EUR J NEUROSCI, V22, P785, DOI 10.1111/j.1460-9568.2005.04277.x; Yu YX, 2009, HIPPOCAMPUS, V19, P1247, DOI 10.1002/hipo.20587	56	19	20	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUL	2017	54	5					3717	3728		10.1007/s12035-016-9939-6			12	Neurosciences	Neurosciences & Neurology	EV9IQ	WOS:000402100100052	27215202				2021-06-18	
J	Silverberg, ND; Iverson, GL; Panenka, W				Silverberg, Noah D.; Iverson, Grant L.; Panenka, William			Cogniphobia in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						avoidance behavior; craniocerebral trauma; headache; neuropsychological tests; post-concussion symptoms	SYMPTOM VALIDITY TEST; RECURRENT HEADACHE; AVOIDANCE-BEHAVIOR; FEAR-AVOIDANCE; NIH TOOLBOX; PAIN; KINESIOPHOBIA; PERFORMANCE; RECOVERY; REST	Cogniphobia refers to avoidance of mental exertion out of a fear of developing or exacerbating a headache. Headaches are very common after mild traumatic brain injury (mTBI) and often become chronic. Cogniphobia is hypothesized to contribute to poor cognitive test performance and persistent disability in some patients with mTBI. Eighty patients with mTBI and posttraumatic headaches were recruited from specialty outpatient clinics. They completed a battery of questionnaires (including a cogniphobia scale) and neuropsychological tests (the National Institutes of Health Toolbox Cognition Battery and the Medical Symptom Validity Test) at 2-3 months post injury, in a cross-sectional design. Participants with more severe headaches reported higher levels of cogniphobia. Cogniphobia was associated with lower performance on memory testing (but not other cognitive tests), independent of headache severity. Participants who avoided mental exertion also tended to avoid physical activity and traumatic stress triggers. The findings provide preliminary support for the role of cogniphobia in persistent cognitive difficulties after mTBI, and suggest that cogniphobia may reflect a broader avoidant coping style.	[Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Dept Psychiat, Vancouver, BC, Canada; [Panenka, William] Univ British Columbia, British Columbia Neuropsychiat Program, Dept Psychiat, Vancouver, BC, Canada; [Silverberg, Noah D.; Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Silverberg, Noah D.] GF Strong Rehab Ctr, Rehabil Res Program, Vancouver, BC, Canada; [Iverson, Grant L.] Spaudling Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MassGen Hosp, Children Sports Concuss Program, Boston, MA USA; [Iverson, Grant L.] A Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Silverberg, ND (corresponding author), Univ British Columbia, Div Phys Med & Rehabil, Rehabil Res Program, GF Strong Rehab Ctr, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Iverson, Grant/0000-0001-7348-9570; Panenka, William/0000-0001-7143-6512	Specific Priorities Research Grant from WorkSafeBC [RS2014-SP03]; Clinician-Scientist Career Development Award from the Vancouver Coastal Health Research Institute	The authors thank research assistants Mary Ellen Johnson and Sabrina Khan as well as the clinical staff at our recruitment sites, including Kelsey Davies, Jennifer Loffree, and Grace Boutilier (GF Strong Rehab Centre); Deanna Yells, Heather MacNeil, and Rod Macdonald (Fraser Health Concussion Clinic); Denise Silva and Lesley Norris (Back in Motion); and Karilyn Lao, Wayne Tang, and Cyrus Huang (LifeMark). This study was funded by a Specific Priorities Research Grant from WorkSafeBC (#RS2014-SP03). N.D.S. receives salary support from a Clinician-Scientist Career Development Award from the Vancouver Coastal Health Research Institute.	Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blevins CA, 2015, J TRAUMA STRESS, V28, P489, DOI 10.1002/jts.22059; Brooks BL, 2016, J NEUROTRAUM, V33, P2091, DOI 10.1089/neu.2015.4301; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Casaletto KB, 2015, J INT NEUROPSYCH SOC, V21, P378, DOI 10.1017/S1355617715000351; Covassin T, 2013, BRAIN INJURY, V27, P1589, DOI 10.3109/02699052.2013.823656; Craton N, 2014, CURR SPORT MED REP, V13, P201, DOI 10.1249/JSR.0000000000000072; Gil-Gouveia R, 2015, J NEUROL, V262, P654, DOI 10.1007/s00415-014-7603-5; Green, 2004, GREENS MED SYMPTOM V; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; HURSEY KG, 1992, HEADACHE, V32, P283, DOI 10.1111/j.1526-4610.1992.hed3206283.x; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Lingsma H. F., J NEUROTRAUMA; Lucas S, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0520-1; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Lundberg M, 2011, PAIN RES TREAT, V2011, DOI 10.1155/2011/494196; Marsden KR, 2015, CURR RES CONCUSSION, V2, P17; Martelli MF, 1999, ARCH CLIN NEUROPSYCH, V14, P804, DOI 10.1016/S0887-6177(99)80356-4; Martin PR, 2014, BEHAV RES THER, V61, P1, DOI 10.1016/j.brat.2014.07.002; Martins IP, 2006, J PAIN, V7, P445, DOI 10.1016/j.jpain.2006.01.449; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Nijs J, 2013, CLIN RHEUMATOL, V32, P1121, DOI 10.1007/s10067-013-2277-4; Norton PJ, 2004, PAIN, V111, P218, DOI 10.1016/j.pain.2004.06.018; Ozen LJ, 2011, J INT NEUROPSYCH SOC, V17, P219, DOI 10.1017/S135561771000144X; Panenka WJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122746; Peres Mario F P, 2007, J Headache Pain, V8, P56, DOI 10.1007/s10194-007-0361-3; Potter S, 2012, NEUROPSYCHOL REHABIL, V22, P1, DOI 10.1080/09602011.2011.630883; Schmidt AJM, 2003, BEHAV RES THER, V41, P1243, DOI 10.1016/S0005-7967(03)00155-4; Silver JM, 2012, J NEUROL NEUROSUR PS, V83, P836, DOI 10.1136/jnnp-2011-302078; Silverberg ND, 2016, JAMA PEDIATR, V170, P946, DOI 10.1001/jamapediatrics.2016.1187; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Singhal A, 2009, ARCH CLIN NEUROPSYCH, V24, P721, DOI 10.1093/arclin/acp074; Spence M, 2005, PSYCHOL MED, V35, P583, DOI 10.1017/S0033291704003484; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Suhr J, 2012, CLIN NEUROPSYCHOL, V26, P1128, DOI 10.1080/13854046.2012.713121; Sullivan K, 2011, J HEAD TRAUMA REHAB, V26, P170, DOI 10.1097/HTR.0b013e3181e47f95; Todd D., 1998, COGNIPHOBIA SCALE C, pdomain; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; Weintraub S, 2014, J INT NEUROPSYCH SOC, V20, P567, DOI 10.1017/S1355617714000320; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020	45	19	19	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2017	34	13					2141	2146		10.1089/neu.2016.4719			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EZ2HM	WOS:000404530400452	28114873				2021-06-18	
J	Schwerin, SC; Hutchinson, EB; Radomski, KL; Ngalula, KP; Pierpaoli, CM; Juliano, SL				Schwerin, Susan C.; Hutchinson, Elizabeth B.; Radomski, Kryslaine L.; Ngalula, Kapinga P.; Pierpaoli, Carlo M.; Juliano, Sharon L.			Establishing the ferret as a gyrencephalic animal model of traumatic brain injury: Optimization of controlled cortical impact procedures	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Surgery; Behavior; Immunohistochemistry; Landmarks; Microglia; Astrocytes; MRI; Craniotomy; TBI; CCI; Temporalis; Antibiotics; Reproducibility; White matter; Cognitive; Motor; Impairment; Acute; Chronic; Inflammation	MOUSE MODEL; MRI; NEURODEGENERATION; ABNORMALITIES; INFLAMMATION; IMPAIRMENT; ESTROGEN; BEHAVIOR; DEFICIT; FEMALE	Background: Although rodent TBI studies provide valuable information regarding the effects of injury and recovery, an animal model with neuroanatomical characteristics closer to humans may provide a more meaningful basis for clinical translation. The ferret has a high white/gray matter ratio, gyrencephalic neocortex, and ventral hippocampal location. Furthermore, ferrets are amenable to behavioral training, have a body size compatible with pre-clinical MRI, and are cost-effective. New methods: We optimized the surgical procedure for controlled cortical impact (CCI) using 9 adult male ferrets. We used subject-specific brain/skull morphometric data from anatomical MRIs to overcome across-subject variability for lesion placement. We also reflected the temporalis muscle, closed the craniotomy, and used antibiotics. We then gathered MRI, behavioral, and immunohistochemical data from 6 additional animals using the optimized surgical protocol: 1 control, 3 mild, and 1 severely injured animals (surviving one week) and 1 moderately injured animal surviving sixteen weeks. Results: The optimized surgical protocol resulted in consistent injury placement. Astrocytic reactivity increased with injury severity showing progressively greater numbers of astrocytes within the white matter. The density and morphological changes of microglia amplified with injury severity or time after injury. Motor and cognitive impairments scaled with injury severity. Comparison with existing method(s): The optimized surgical methods differ from those used in the rodent, and are integral to success using a ferret model. Conclusions: We optimized ferret CCI surgery for consistent injury placement. The ferret is an excellent animal model to investigate pathophysiological and behavioral changes associated with TBI. Published by Elsevier B.V.	[Schwerin, Susan C.; Radomski, Kryslaine L.; Ngalula, Kapinga P.; Juliano, Sharon L.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd,Bldg B, Bethesda, MD 20814 USA; [Hutchinson, Elizabeth B.; Pierpaoli, Carlo M.] NICHD, NIH, 13 South Dr,Bldg 13, Bethesda, MD 20892 USA; [Juliano, Sharon L.] Uniformed Serv Univ Hlth Sci, Program Neurosci, 4301 Jones Bridge Rd,Bldg B, Bethesda, MD 20814 USA	Schwerin, SC (corresponding author), USUHS APG, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	susan.schwerin.ctr@usuhs.edu; elizabeth.hutchinson@nih.gov; kryslaine.radomski.ctr@usuhs.edu; kabaselepatricia@gmail.com; cp1a@nih.gov; sharon.juliano@usuhs.edu	Juliano, Sharon/AAO-1030-2020; Pierpaoli, Carlo/E-1672-2011	Pierpaoli, Carlo/0000-0001-8558-4428; Hutchinson, Elizabeth/0000-0002-3374-5469; Radomski, Kryslaine/0000-0001-9624-623X	Congressionally Directed Medical Research Programs CDMRPUnited States Department of Defense [W81XWH-13-2-0019, W81XWH-13-2-0018]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIAEB000089] Funding Source: NIH RePORTER	This research was supported by the Congressionally Directed Medical Research Programs CDMRP) (award numbersW81XWH-13-2-0019 and W81XWH-13-2-0018). The authors thank the Center for Neuroscience and Regenerative Medicine (CNRM) for core facility support enabling this work, specifically the translational imaging facility with Asamoah Bosomtwi and Alexandru Korotcov. The authors also thank the Laboratory of Animal Medicine staff for assistance during the surgery and care of the animals: Dennis Aguilar, Kayln Alloway, Cassie Barnett, Andrew Brown, Marla Brunell, Amanda Christy, Clayton Gerrian, Althea Jamerson, Branden Maxwell, Herlyth Pemberton, Stephen Petroski, David Smith, and Robert Wolfe. We also thank Branden Maxwell for document editing.	ATKINSON CS, 1989, STROKE, V20, P1085, DOI 10.1161/01.STR.20.8.1085; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Bakthavatchalu V, 2016, VET PATHOL, V53, P349, DOI 10.1177/0300985815623621; Ball RS, 2006, ILAR J, V47, P348, DOI 10.1093/ilar.47.4.348; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Cabot E B, 1990, J Invest Surg, V3, P177, DOI 10.3109/08941939009140347; Christensson M, 2005, NEUROREPORT, V16, P1319, DOI 10.1097/01.wnr.0000175614.93312.53; DeFelipe J, 2011, FRONT NEUROANAT, V5, DOI 10.3389/fnana.2011.00029; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dobbins HD, 2007, J NEUROSCI METH, V161, P101, DOI 10.1016/j.jneumeth.2006.10.013; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Eagle DM, 2003, BEHAV NEUROSCI, V117, P1302, DOI 10.1037/0735-7044.117.6.1302; Eakin K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090617; Empie K, 2015, INT J DEV NEUROSCI, V45, P2, DOI 10.1016/j.ijdevneu.2015.06.005; Esquenazi A., 2017, PM&R, P30030, DOI [10.1016/j.2016.12.010, DOI 10.1016/j.2016.12.010]; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feng Y, 2013, J BIOMECH, V46, P863, DOI 10.1016/j.jbiomech.2012.12.024; Fox J. G., 1988, BIOL DIFERRET; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gold JR, 2015, BEHAV NEUROSCI, V129, P473, DOI 10.1037/bne0000065; HADDAD R, 1976, DEV PSYCHOBIOL, V9, P311, DOI 10.1002/dev.420090403; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; He T, 2002, LAB ANIM-UK, V36, P86, DOI 10.1258/0023677021911795; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hutchinson EB, 2017, NEUROIMAGE, V152, P575, DOI 10.1016/j.neuroimage.2017.03.009; Hutchinson EB, 2016, SHOCK, V46, P167, DOI 10.1097/SHK.0000000000000659; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Keiser NW, 2011, CURR OPIN PULM MED, V17, P478, DOI 10.1097/MCP.0b013e32834b14c9; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kou ZH, 2015, CELL RES, V25, P1372, DOI 10.1038/cr.2015.130; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; LAWES INC, 1987, J ANAT, V154, P157; Lesniak A, 2016, NEUROPHARMACOLOGY, V101, P506, DOI 10.1016/j.neuropharm.2015.10.014; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; McLaughlin DF, 1998, SOMATOSENS MOT RES, V15, P253, DOI 10.1080/08990229870673; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Mott TF, 2012, AM FAM PHYSICIAN, V86, P1045; Munyon C, 2014, BRAIN RES, V1582, P220, DOI 10.1016/j.brainres.2014.07.036; Mychasiuk R, 2015, BEHAV BRAIN RES, V286, P285, DOI 10.1016/j.bbr.2015.03.010; Noctor SC, 1997, J COMP NEUROL, V387, P179; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Oh DY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00080; Ohsawa K, 2004, J NEUROCHEM, V88, P844, DOI 10.1046/j.1471-4159.2003.02213.x; Osier ND, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00134; Peng X, 2014, NAT BIOTECHNOL, V32, P1250, DOI 10.1038/nbt.3079; Poluch S, 2015, CEREB CORTEX, V25, P346, DOI 10.1093/cercor/bht232; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; RABE A, 1985, LAB ANIM SCI, V35, P256; Rafaels K., 2016, INT REA COUNC BIOM I; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Robbins T. W., 1993, METHODS ASSESSING AT, P13; Rodriguiz R.M., 2006, ANIMAL MODELCOGNIT; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sawada K, 2013, NEUROIMAGE, V83, P294, DOI 10.1016/j.neuroimage.2013.06.024; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Shum DHK, 2000, J CLIN EXP NEUROPSYC, V22, P25, DOI 10.1076/1380-3395(200002)22:1;1-8;FT025; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Sun X., 2014, GENETIC ENG FERRET B, V3; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; Tucker LB, 2017, J NEUROTRAUM, V34, P890, DOI 10.1089/neu.2016.4508; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Vasudevan EVL, 2014, J NEUROL PHYS THER, V38, P172, DOI 10.1097/NPT.0000000000000049; Velosky AG, 2017, BEHAV BRAIN RES, V324, P115, DOI 10.1016/j.bbr.2017.02.017; Williams G, 2009, ARCH PHYS MED REHAB, V90, P587, DOI 10.1016/j.apmr.2008.10.013; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; YUSHKEVICH PA, 2006, NEUROIMAGE; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zhou ZC, 2016, SCI REP-UK, V6, DOI 10.1038/srep23568	77	19	19	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUN 15	2017	285						82	96		10.1016/j.jneumeth.2017.05.010			15	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EY5CS	WOS:000403995400009	28499842	Green Accepted			2021-06-18	
J	Fan, KH; Ma, J; Xiao, WJ; Chen, JM; Wu, J; Ren, JD; Hou, J; Hu, YH; Gu, JW; Yu, BT				Fan, Kaihua; Ma, Jie; Xiao, Wenjing; Chen, Jingmin; Wu, Juan; Ren, Jiandong; Hou, Jun; Hu, Yonghe; Gu, Jianwen; Yu, Botao			Mangiferin attenuates blast-induced traumatic brain injury via inhibiting NLRP3 inflammasome	CHEMICO-BIOLOGICAL INTERACTIONS			English	Article						Mangiferin; Blast-induced traumatic brain injury; NLRP3; Oxidative stress; Inflammation	NF-KAPPA-B; SYSTEMIC INFLAMMATION; NALP3 INFLAMMASOME; OXIDATIVE STRESS; CEREBRAL-CORTEX; ISCHEMIC-STROKE; RAT MODEL; MANAGEMENT; PROTEIN; ACTIVATION	There is growing evidence that Mangiferin possess therapeutic benefit during neuroinflammation on various brain injury models due to its anti-inflammatory properties. It is reported that inflammatory plays a crucial role in the pathogenesis of secondary injury induced by the blast-induced traumatic brain injury (bTBI). However, the role of mangiferin in bTBI is yet to be studied. In our study, the potential effect of mangiferin in the duration of bTBI was examined first. Fortunately, the amelioration of cerebral cortex damage was found in rats suffering bTBI after mangiferin administration. Furthermore, the detail mechanism of mangiferin's beneficial actions in bTBI was also studied. The results revealed that mangiferin might alleviate brain damage in rats with bTBI by inhibiting the NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome activation, which was accompanied by mangiferin's inhibition of oxidative stress and pro-inflammatory cytokines production. Therefore, this research allows us to speculate that, for first time, NLRP3 is involved in the anti-inflammatory effect of mangiferin in the cerebral cortex, and mangiferin could be a potential therapy drug for bTBI. (C) 2017 Elsevier B.V. All rights reserved.	[Fan, Kaihua] Peoples Hosp Leshan, Dept Pharm, Leshan 614000, Sichuan, Peoples R China; [Xiao, Wenjing; Hu, Yonghe] Southwest Jiaotong Univ, Sch Mat Sci & Engn, Chengdu 610013, Sichuan, Peoples R China; [Ma, Jie; Xiao, Wenjing; Wu, Juan; Ren, Jiandong; Hou, Jun; Yu, Botao] Chengdu Mil Gen Hosp, Dept Pharm, 270 Rongdu Ave, Chengdu 610083, Sichuan, Peoples R China; [Chen, Jingmin] Chengdu Mil Gen Hosp, Dept Neurosurgery, 270 Rongdu Ave, Chengdu 610083, Sichuan, Peoples R China; [Hu, Yonghe] Chengdu Mil Gen Hosp, Dept Tradit Chinese Med, 270 Rongdu Ave, Chengdu 610083, Sichuan, Peoples R China; [Gu, Jianwen] 306 Hosp PLA, 9 Anxiang Beili, Beijing 100101, Peoples R China	Hu, YH (corresponding author), Southwest Jiaotong Univ, Sch Mat Sci & Engn, Chengdu 610013, Sichuan, Peoples R China.; Yu, BT (corresponding author), Chengdu Mil Gen Hosp, Dept Pharm, 270 Rongdu Ave, Chengdu 610083, Sichuan, Peoples R China.; Gu, JW (corresponding author), 306 Hosp PLA, 9 Anxiang Beili, Beijing 100101, Peoples R China.	huyhzyy@163.com; gujianwen5000@sina.com; baotao_yu@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81402507]; State Administration of Traditional Chinese Medicine of the General Logistics Department [10ZYZ120]; Chengdu Military General Hospital Project [2013YG-B109]	This work was supported by the National Natural Science Foundation of China (Grant No. 81402507); the State Administration of Traditional Chinese Medicine of the General Logistics Department (Grant No. 10ZYZ120); and Chengdu Military General Hospital Project (Grant No. 2013YG-B109).	BHATTACHARYA SK, 1972, J PHARM SCI-US, V61, P1838, DOI 10.1002/jps.2600611136; Biradar SM, 2012, EUR J PHARMACOL, V683, P140, DOI 10.1016/j.ejphar.2012.02.042; Bryant C, 2009, TRENDS CELL BIOL, V19, P455, DOI 10.1016/j.tcb.2009.06.002; Celtik C, 2004, BRAIN DEV-JPN, V26, P398, DOI 10.1016/j.braindev.2003.12.007; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; de Ceballos JPG, 2005, CRIT CARE, V9, P104, DOI 10.1186/cc2995; Dinarello CA, 2005, J EXP MED, V201, P1355, DOI 10.1084/jem.20050640; Dou W, 2014, INT IMMUNOPHARMACOL, V23, P170, DOI 10.1016/j.intimp.2014.08.025; Du XP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080138; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; Garrido-Suarez BB, 2014, PHARMACOL BIOCHEM BE, V124, P311, DOI 10.1016/j.pbb.2014.06.019; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Hou J, 2016, CAN J PHYSIOL PHARM, V94, P332, DOI 10.1139/cjpp-2015-0073; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li YJ, 2008, CHROMATOGRAPHIA, V67, P957, DOI 10.1365/s10337-008-0612-8; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Marquez L, 2012, EUR J NUTR, V51, P729, DOI 10.1007/s00394-011-0252-x; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Ren JD, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930894; Sanchez GM, 2003, PHYTOTHER RES, V17, P197, DOI 10.1002/ptr.921; Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xiao WJ, 2010, INT J PHARMACEUT, V393, P119, DOI 10.1016/j.ijpharm.2010.04.018; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	36	19	21	1	20	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0009-2797	1872-7786		CHEM-BIOL INTERACT	Chem.-Biol. Interact.	JUN 1	2017	271						15	23		10.1016/j.cbi.2017.04.021			9	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	EW4AL	WOS:000402444300003	28455230				2021-06-18	
J	Kennedy, E; Quinn, D; Tumilty, S; Chapple, CM				Kennedy, Ewan; Quinn, Dusty; Tumilty, Steve; Chapple, Cathy M.			Clinical characteristics and outcomes of treatment of the cervical spine in patients with persistent post-concussion symptoms: A retrospective analysis	MUSCULOSKELETAL SCIENCE AND PRACTICE			English	Article						Brain concussion; Neck; Cervicogenic; Physiotherapy	TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; NECK DISABILITY INDEX; CERVICOGENIC HEADACHE; MUSCULOSKELETAL DYSFUNCTION; FUNCTIONAL SCALE; WHIPLASH INJURY; RATING-SCALE; NUMERIC PAIN; NEW-ZEALAND	Background: Concussion is typically defined as a mild brain injury, and yet the brain is unlikely to be the only source of persistent post-concussion symptoms. Concurrent injury to the cervical spine in particular is acknowledged as a potential source of common persistent symptoms such as headache, dizziness and neck pain. Objectives: To describe the cervical spine findings and outcomes of treatment in a series of patients with persistent post-concussion symptoms, and describe the clinical characteristics of a cervicogenic component when it is present. Design: Retrospective chart review of a consecutive series of patients with concussion referred to a physiotherapist for cervical spine assessment. Method: Patient charts for all patients over a calendar year referred by a concussion service provider to a physiotherapist for cervical spine assessment were de-identified and transferred to the research team. Clinical data were independently extracted by two research assistants and analysed using descriptive statistics. Results/findings: Data were analysed from 46 patient charts. Those with a cervicogenic component (n = 32) were distinguished from those without a cervicogenic component (n = 14) by physical examination findings, particularly pain on manual segmental examination. Physiotherapy treatment of the cervicogenic component (n = 21) achieved improvements in function (mean increase of 3.8 in the patient-specific functional scale), and pain (mean decrease of 4.6 in the numeric pain-rating scale). Conclusions: The clinical characteristics described give preliminary support to the idea that the cervical spine may contribute to persistent post-concussion symptoms, and highlight the value of physiotherapy assessment and treatment of the cervical spine following a concussive injury. (C) 2017 Elsevier Ltd. All rights reserved.	[Kennedy, Ewan; Tumilty, Steve; Chapple, Cathy M.] Univ Otago, Sch Physiotherapy, 325 Great King St, Dunedin 9054, New Zealand; [Quinn, Dusty] Back Mot Ltd, 27-29 Albany St, Dunedin 9016, New Zealand	Kennedy, E (corresponding author), Univ Otago, Sch Physiotherapy, 325 Great King St, Dunedin 9054, New Zealand.	ewan.kennedy@otago.ac.nz	Kennedy, Ewan/Q-5803-2019	Kennedy, Ewan/0000-0002-7341-5309; Tumilty, Steve/0000-0003-2456-7055	Postdoctoral Fellowship in Orthopaedic Manual Therapy at the School of Physiotherapy, University of Otago	This research was supported by a Postdoctoral Fellowship in Orthopaedic Manual Therapy at the School of Physiotherapy, University of Otago and held by Ewan Kennedy. This Postdoctoral position is enabled by a bequest from the Alumni of the University of Otago in America, Inc.	Alexander Michael P, 2003, Pain Res Manag, V8, P19; Bogduk N, 2001, Curr Pain Headache Rep, V5, P382, DOI 10.1007/s11916-001-0029-7; Bogduk N, 2009, LANCET NEUROL, V8, P959, DOI 10.1016/S1474-4422(09)70209-1; Cleland JA, 2008, ARCH PHYS MED REHAB, V89, P69, DOI 10.1016/j.apmr.2007.08.126; Elkin BS, 2016, J ORTHOP SPORT PHYS, V46, P874, DOI 10.2519/jospt.2016.7049; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Hall T, 2004, MANUAL THER, V9, P197, DOI 10.1016/j.math.2004.04.004; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Jull G, 2007, CEPHALALGIA, V27, P793, DOI 10.1111/j.1468-2982.2007.01345.x; Jull G, 2002, SPINE, V27, P1835, DOI 10.1097/00007632-200209010-00004; Junn C, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0519-7; King D, 2014, J SCI MED SPORT, V17, P250, DOI 10.1016/j.jsams.2013.05.007; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leslie O, 2013, CLIN J SPORT MED, V23, P331, DOI 10.1097/JSM.0b013e318295bbb1; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Malmstrom EM, 2007, DISABIL REHABIL, V29, P1193, DOI 10.1080/09638280600948383; Marshall CM, 2015, PHYSICIAN SPORTSMED, V43, P274, DOI 10.1080/00913847.2015.1064301; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Nicholas P, 2012, J MAN MANIP THER, V20, P147, DOI 10.1179/2042618612Y.0000000006; Reid SA, 2008, MANUAL THER, V13, P357, DOI 10.1016/j.math.2007.03.006; Reid SA, 2015, MANUAL THER, V20, P148, DOI 10.1016/j.math.2014.08.003; Rubio-Ochoa J, 2016, MANUAL THER, V21, P35, DOI 10.1016/j.math.2015.09.008; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Sjaastad O, 1998, HEADACHE, V38, P442, DOI 10.1046/j.1526-4610.1998.3806442.x; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; TRELEAVEN J, 1994, CEPHALALGIA, V14, P273, DOI 10.1046/j.1468-2982.1994.1404273.x; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; Treleaven J, 2011, SPINE, V36, pS211, DOI 10.1097/BRS.0b013e3182387f78; Vassar M, 2013, J EDUC EVAL HEALTH P, V10, DOI 10.3352/jeehp.2013.10.12; Young IA, 2010, AM J PHYS MED REHAB, V89, P831, DOI 10.1097/PHM.0b013e3181ec98e6; Zito G, 2006, MANUAL THER, V11, P118, DOI 10.1016/j.math.2005.04.007	38	19	19	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	2468-7812			MUSCULOSKEL SCI PRAC	Musculoskelet. Sci. Pract.	JUN	2017	29						91	98		10.1016/j.msksp.2017.03.002			8	Rehabilitation	Rehabilitation	FO9WZ	WOS:000417250400021	28347935				2021-06-18	
J	Stefani, MA; Modkovski, R; Hansel, G; Zimmer, ER; Kopczynski, A; Muller, AP; Strogulski, NR; Rodolphi, MS; Carteri, RK; Schmidt, AP; Oses, JP; Smith, DH; Portela, LV				Stefani, Marco A.; Modkovski, Rafael; Hansel, Gisele; Zimmer, Eduardo R.; Kopczynski, Afonso; Muller, Alexandre P.; Strogulski, Nathan R.; Rodolphi, Marcelo S.; Carteri, Randhall K.; Schmidt, Andre P.; Oses, Jean P.; Smith, Douglas H.; Portela, Luis V.			Elevated glutamate and lactate predict brain death after severe head trauma	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article							EXCITATORY AMINO-ACIDS; NEUROTROPHIC FACTOR; INJURY; BIOMARKERS; RELEASE; GLUCOSE; MILD; BDNF; MICRODIALYSIS; RECEPTORS	Objective: Clinical neurological assessment is challenging for severe traumatic brain injury (TBI) patients in the acute setting. Waves of neurochemical abnormalities that follow TBI may serve as fluid biomarkers of neurological status. We assessed the cerebrospinal fluid (CSF) levels of glutamate, lactate, BDNF, and GDNF, to identify potential prognostic biomarkers of neurological outcome. Methods: This cross-sectional study was carried out in a total of 20 consecutive patients (mean [SD] age, 29 [13] years; M/ F, 9: 1) with severe TBI Glasgow Coma Scale <= 8 and abnormal computed tomography scan on admission. Patients were submitted to ventricular drainage and had CSF collected between 2 and 4 h after hospital admission. Patients were then stratified according to two clinical outcomes: deterioration to brain death (nonsurvival, n = 6) or survival (survival, n = 14), within 3 days after hospital admission. Received: 23 February 2017; Accepted: 31 March 2017 CSF levels of brain-derived substances were compared between nonsurvival and survival groups. Clinical and neurological parameters were also assessed. Results: Glutamate and lactate are significantly increased in nonsurvival relative to survival patients. We tested the accuracy of both biomarkers to discriminate patient outcome. Setting a cutoff of > 57.75, glutamate provides 80.0% of sensitivity and 84.62% of specificity (AUC: 0.8214, 95% CL: 54.55-98.08%; and a cutoff of > 4.65, lactate has 100% of sensitivity and 85.71% of specificity (AUC: 0.8810, 95% CL: 54.55-98.08%). BDNF and GDNF did not discriminate poor outcome. Interpretation: This early study suggests that glutamate and lactate concentrations at hospital admission accurately predict death within 3 days after severe TBI.	[Stefani, Marco A.; Modkovski, Rafael] Univ Fed Rio Grande do Sul, Lab Neuroanat, Dept Morphol Sci, Porto Alegre, RS, Brazil; [Hansel, Gisele; Zimmer, Eduardo R.; Kopczynski, Afonso; Strogulski, Nathan R.; Rodolphi, Marcelo S.; Carteri, Randhall K.; Schmidt, Andre P.; Portela, Luis V.] Univ Fed Rio Grande do Sul, Lab Neurotrauma, Dept Biochem, Postgrad Program Biochem, Porto Alegre, RS, Brazil; [Zimmer, Eduardo R.] Pontifical Catholic Univ Rio Grande Sul PUCRS, Brain Inst Rio Grande Sul BraIns, Porto Alegre, RS, Brazil; [Muller, Alexandre P.] Univ South Santa Catarina UNESC, Lab Exercise Biochem & Physiol, Criciuma, SC, Brazil; [Oses, Jean P.] Univ Catolica Pelotas, Grad Program Hlth & Behav, Pelotas, RS, Brazil; [Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Perelman Sch Med, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Dept Neurosurg, Perelman Sch Med, Philadelphia, PA 19104 USA	Portela, LV (corresponding author), Univ Fed Rio Grande do Sul, Dept Biochem, ICBS, 2600 Ramiro Barcelos St, BR-90035003 Porto Alegre, RS, Brazil.	roskaportela@gmail.com	Zimmer, Eduardo R Rigon/I-2932-2015; STEFANI, MARCO ANTONIO/C-3993-2013; Carteri, Randhall/A-9015-2017; Carteri, Randhall/AAN-9871-2021; Hansel, Gisele/A-9150-2015; Carvalho, Afonso/O-8654-2018; Oses, Jean Pierre/E-2534-2013; Portela, Luis V/I-3410-2014	Zimmer, Eduardo R Rigon/0000-0002-5349-0053; STEFANI, MARCO ANTONIO/0000-0002-4728-8764; Carteri, Randhall/0000-0003-4124-9470; Carteri, Randhall/0000-0003-4124-9470; Hansel, Gisele/0000-0001-5048-1293; 	Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [PNPD 1663]; Fundacao de Amparo a Pesquisa do Estado do Rio Grande do SulFundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [1010267]; Conselho Nacional de Desenvolvimento Cientifico e TecnologicoConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [4011645/2012-6, 5465346/2014-6]	This work was supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior PNPD 1663, Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul 1010267, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico 4011645/2012-6, 5465346/2014-6	Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Black IB, 1999, J NEUROBIOL, V41, P108, DOI 10.1002/(SICI)1097-4695(199910)41:1<108::AID-NEU14>3.0.CO;2-U; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Failla MD, 2016, NEUROREHAB NEURAL RE, V30, P83, DOI 10.1177/1545968315586465; Farrand AQ, 2015, NEUROBIOL AGING, V36, P1569, DOI 10.1016/j.neurobiolaging.2014.11.017; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kohara K, 2001, SCIENCE, V291, P2419, DOI 10.1126/science.1057415; Korley FK, 2016, J NEUROTRAUM, V33, P215, DOI 10.1089/neu.2015.3949; Koura SS, 1998, ACT NEUR S, V71, P244; Lama S, 2014, J BIOL CHEM, V289, P20200, DOI 10.1074/jbc.M114.570978; Lazaridis C, 2014, NEUROCRIT CARE, V21, P345, DOI 10.1007/s12028-014-0007-7; Moro N, 2016, BRAIN RES, V1642, P270, DOI 10.1016/j.brainres.2016.04.005; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Quintard H, 2016, J NEUROTRAUM, V33, P681, DOI 10.1089/neu.2015.4057; Robinet C, 2010, J CEREBR BLOOD F MET, V30, P286, DOI 10.1038/jcbfm.2009.208; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Schmidt AP, 2009, PHARMACOL BIOCHEM BE, V91, P549, DOI 10.1016/j.pbb.2008.09.009; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Simon D, 2016, BRAIN INJURY, V30, P23, DOI 10.3109/02699052.2015.1077993; Thelin EP, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00159; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zauner A, 1996, ACT NEUR S, V67, P40; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	39	19	21	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	JUN	2017	4	6					392	402		10.1002/acn3.416			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FB2PI	WOS:000405985300004	28589166	DOAJ Gold, Green Published			2021-06-18	
J	Wang, ZG; Luo, Y; Chen, LA; Liang, W				Wang, Zhigang; Luo, Yong; Chen, Lvan; Liang, Wu			Safety of neural stem cell transplantation in patients with severe traumatic brain injury	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						cell transplantation; traumatic brain injury; stem cell	AMYOTROPHIC-LATERAL-SCLEROSIS; SPINAL-CORD-INJURY; NEUROTROPHIC FACTORS; FUNCTIONAL RECOVERY; PRACTICAL SCALE; RATS; DIFFERENTIATE; EPIDEMIOLOGY; SCAFFOLDS; NEURONS	Neural stem cell (NSC) therapy is a promising treatment for traumatic brain injury (TBI). In addition, mesenchymal stem cells (MSCs) have been investigated for the treatment of TBI due to their functions in neural regeneration and their neurotrophic effect. In the present study, the safety, feasibility and biological effects of autologous MSC-derived NSC-like cell transplantation were investigated in 10 patients with severe TBI. All patients received intravenous or intrathecal injections of human NSC-like cells and were evaluated with physical and neurological examinations, routine laboratory tests and neuroradiological findings. The results indicated that the majority of patients experienced improved neurological function in different degrees during the follow-up period. No mortality or serious adverse events were observed in any patient subsequent to transplantation. Higher serum levels of nerve growth factor and brain-derived neurotrophic factor were detected following the transplantation, as compared with the levels prior to treatment. Overall, the present results suggest that transplantation of autologous NSC-like cells is feasible and appears to be safe for the treatment of non-acute severe TBI.	[Wang, Zhigang; Luo, Yong; Chen, Lvan; Liang, Wu] First Peoples Hosp Jingmen, Dept Neurosurg, 67 Xiangshan Rd, Jingmen 448000, Hubei, Peoples R China	Liang, W (corresponding author), First Peoples Hosp Jingmen, Dept Neurosurg, 67 Xiangshan Rd, Jingmen 448000, Hubei, Peoples R China.	360234044@qq.com			Science and Technology Bureau of Jingmen [2012YD34]	The present study was supported by the Science and Technology Bureau of Jingmen (grant no. 2012YD34).	Anbari F, 2014, NEURAL REGEN RES, V9, P919, DOI 10.4103/1673-5374.133133; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Brain Trauma F, 2008, J NEUROTRAUM, V25, P276; Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200; Chen GJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-21; Chu K, 2004, BRAIN RES, V1016, P145, DOI 10.1016/j.brainres.2004.04.038; Fujiwara Y, 2004, NEUROSCI LETT, V366, P287, DOI 10.1016/j.neulet.2004.05.080; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Glass JD, 2012, STEM CELLS, V30, P1144, DOI 10.1002/stem.1079; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Hage V., 2011, NURSE COM NURSING SP, V24, P44; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; JENNETT B, 1975, LANCET, V1, P480; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Karussis D, 2010, ARCH NEUROL-CHICAGO, V67, P1187, DOI 10.1001/archneurol.2010.248; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; Liu Y, 2014, MOL MED REP, V9, P333, DOI 10.3892/mmr.2013.1803; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Ma HY, 2011, MOL MED REP, V4, P849, DOI 10.3892/mmr.2011.510; Ma K, 2011, NEUROL RES, V33, P1083, DOI 10.1179/1743132811Y.0000000053; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Modo M, 2002, STROKE, V33, P2270, DOI 10.1161/01.STR.0000027693.50675.C5; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Stabenfeldt SE, 2011, CURR STEM CELL RES T, V6, P208; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Wang EY, 2012, J NEUROTRAUM, V29, P295, DOI 10.1089/neu.2011.2043; Yan ZJ, 2013, NEUROCHEM RES, V38, P1022, DOI 10.1007/s11064-013-1012-5	38	19	20	0	6	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	JUN	2017	13	6					3613	3618		10.3892/etm.2017.4423			6	Medicine, Research & Experimental	Research & Experimental Medicine	EU5NW	WOS:000401080000149	28588689	Green Published, Bronze			2021-06-18	
J	Hsieh, TH; Kang, JW; Lai, JH; Huang, YZ; Rotenberg, A; Chen, KY; Wang, JY; Chan, SY; Chen, SC; Chiang, YH; Peng, CW				Hsieh, Tsung-Hsun; Kang, Jing-Wei; Lai, Jing-Huei; Huang, Ying-Zu; Rotenberg, Alexander; Chen, Kai-Yun; Wang, Jia-Yi; Chan, Shu-Yen; Chen, Shih-Ching; Chiang, Yung-Hsiao; Peng, Chih-Wei			Relationship of mechanical impact magnitude to neurologic dysfunction severity in a rat traumatic brain injury model	PLOS ONE			English	Article							AXONAL INJURY; BEHAVIORAL DEFICITS; ACCELERATION MODEL; FLUID PERCUSSION; ANIMAL-MODELS; GFAP; PATHOPHYSIOLOGY; MODERATE; MOUSE; SERUM	Objective Traumatic brain injury (TBI) is a major brain injury type commonly caused by traffic accidents, falls, violence, or sports injuries. To obtain mechanistic insights about TBI, experimental animal models such as weight-drop-induced TBI in rats have been developed to mimic closed-head injury in humans. However, the relationship between the mechanical impact level and neurological severity following weight-drop-induced TBI remains uncertain. In this study, we comprehensively investigated the relationship between physical impact and graded severity at various weight-drop heights. Approach The acceleration, impact force, and displacement during the impact were accurately measured using an accelerometer, a pressure sensor, and a high-speed camera, respectively. In addition, the longitudinal changes in neurological deficits and balance function were investigated at 1, 4, and 7 days post TBI lesion. The inflammatory expression markers tested by Western blot analysis, including glial fibrillary acidic protein, beta-amyloid precursor protein, and bone marrow tyrosine kinase gene in chromosome X, in the frontal cortex, hippocampus, and corpus callosum were investigated at 1 and 7 days post-lesion. Results Gradations in impact pressure produced progressive degrees of injury severity in the neurological score and balance function. Western blot analysis demonstrated that all inflammatory expression markers were increased at 1 and 7 days post-impact injury when compared to the sham control rats. The severity of neurologic dysfunction and induction in inflammatory markers strongly correlated with the graded mechanical impact levels. Conclusions We conclude that the weight-drop-induced TBI model can produce graded brain injury and induction of neurobehavioral deficits and may have translational relevance to developing therapeutic strategies for TBI.	[Hsieh, Tsung-Hsun] Chang Gung Univ, Coll Med, Dept Phys Therapy, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Univ, Coll Med, Grad Inst Rehabil Sci, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Mem Hosp, Neurosci Res Ctr, Linkou, Taiwan; [Hsieh, Tsung-Hsun; Chen, Kai-Yun; Chiang, Yung-Hsiao] Taipei Med Univ, Grad Inst Neural Regenerat Med, Taipei, Taiwan; [Kang, Jing-Wei; Lai, Jing-Huei; Chen, Kai-Yun; Chiang, Yung-Hsiao] Taipei Med Univ, Ctr Neurotrauma & Neuroregenerat, Taipei, Taiwan; [Kang, Jing-Wei; Chan, Shu-Yen] Taipei Med Univ, Sch Med, Taipei, Taiwan; [Huang, Ying-Zu] Chang Gung Mem Hosp, Neurosci Res Ctr, Taoyuan, Taiwan; [Huang, Ying-Zu] Chang Gung Mem Hosp, Dept Neurol, Taoyuan, Taiwan; [Rotenberg, Alexander] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, Boston, MA USA; [Wang, Jia-Yi] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan; [Chen, Shih-Ching; Peng, Chih-Wei] Taipei Med Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chen, Shih-Ching; Peng, Chih-Wei] Taipei Med Univ, Sch Med, Dept Phys Med & Rehabil, Coll Med, Taipei, Taiwan; [Chiang, Yung-Hsiao] Taipei Med Univ Hosp, Dept Neurosurg, Taipei, Taiwan; [Peng, Chih-Wei] Taipei Med Univ, Sch Biomed Engn, Coll Biomed Engn, Taipei, Taiwan; [Peng, Chih-Wei] Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei, Taiwan	Peng, CW (corresponding author), Taipei Med Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.; Peng, CW (corresponding author), Taipei Med Univ, Sch Med, Dept Phys Med & Rehabil, Coll Med, Taipei, Taiwan.; Peng, CW (corresponding author), Taipei Med Univ, Sch Biomed Engn, Coll Biomed Engn, Taipei, Taiwan.; Peng, CW (corresponding author), Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei, Taiwan.	cwpeng@tmu.edu.tw	Hsieh, Tung-Hsun/AAZ-5010-2020	Hsieh, Tung-Hsun/0000-0002-1794-7941; Wang, Jia-Yi/0000-0002-9106-3351; Huang, Ying-Zu/0000-0002-8666-4013	Ministry of Science and Technology of TaiwanMinistry of Science and Technology, Taiwan [MOST103-2321-B-038-013, MOST103-2221E-038-007-MY3, MOST 103-2320-B182-033-MY2, MOST 105-2314-B-182-016]; Chang Gung Memorial HospitalChang Gung Memorial Hospital [CMRPD1F0501]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088583] Funding Source: NIH RePORTER	This study was supported by grants from the Ministry of Science and Technology of Taiwan (MOST103-2321-B-038-013 and MOST103-2221E-038-007-MY3 to C.W. Peng, MOST 103-2320-B182-033-MY2, MOST 105-2314-B-182-016 to T.H. Hsieh) and Chang Gung Memorial Hospital (CMRPD1F0501) to T.H.Hsieh.	Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Buchele F, 2016, J NEUROTRAUM, V33, P1171, DOI 10.1089/neu.2015.4001; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Ekmark-Lewen S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-44; Faul M, 2010, CENTERS FOR DISEASE; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Goddeyne C, 2015, J NEUROPHYSIOL, V113, P3268, DOI 10.1152/jn.00970.2014; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnstone VPA, 2014, J NEUROTRAUM, V31, P1881, DOI 10.1089/neu.2014.3343; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Viano DC, 2012, ANN BIOMED ENG, V40, P213, DOI 10.1007/s10439-011-0386-2; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wu JCC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039226; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yan EB, 2013, NEUROSCIENCE, V248, P17, DOI 10.1016/j.neuroscience.2013.05.045; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Yu Y.W., 2016, J NEUROTRAUMA	31	19	19	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2017	12	5							e0178186	10.1371/journal.pone.0178186			18	Multidisciplinary Sciences	Science & Technology - Other Topics	EV8VT	WOS:000402063000025	28552947	DOAJ Gold, Green Published			2021-06-18	
J	Han, K; Davis, RA; Chapman, SB; Krawczyk, DC				Han, Kihwan; Davis, Rebecca A.; Chapman, Sandra B.; Krawczyk, Daniel C.			Strategy-based reasoning training modulates cortical thickness and resting-state functional connectivity in adults with chronic traumatic brain injury	BRAIN AND BEHAVIOR			English	Article						functional connectivity; magnetic resonance imaging; morphometry; plasticity; rehabilitation; traumatic brain injury	HUMAN CEREBRAL-CORTEX; SURFACE-BASED ANALYSIS; WORKING-MEMORY; GRAY-MATTER; STRUCTURAL PLASTICITY; PHYSICAL-ACTIVITY; MOTOR CORTEX; DEFAULT MODE; HEAD MOTION; NETWORK	Introduction: Prior studies have demonstrated training-induced changes in the healthy adult brain. Yet, it remains unclear how the injured brain responds to cognitive training months-to-years after injury. Methods: Sixty individuals with chronic traumatic brain injury (TBI) were randomized into either strategy-based (N = 31) or knowledge-based (N = 29) training for 8 weeks. We measured cortical thickness and resting-state functional connectivity (rsFC) before training, immediately posttraining, and 3 months posttraining. Results: Relative to the knowledge-based training group, the cortical thickness of the strategy-based training group showed diverse temporal patterns of changes over multiple brain regions (p(vertex) < .05, p(cluster) < .05): (1) increases followed by decreases, (2) monotonic increases, and (3) monotonic decreases. However, network-based statistics (NBS) analysis of rsFC among these regions revealed that the strategy-based training group induced only monotonic increases in connectivity, relative to the knowledge-based training group (vertical bar Z vertical bar > 1.96, p(NBS) < 0.05). Complementing the rsFC results, the strategy-based training group yielded monotonic improvement in scores for the trail-making test (p < .05). Analyses of brain-behavior relationships revealed that improvement in trail-making scores were associated with training-induced changes in cortical thickness (p(vertex) < .05, p(cluster) < .05) and rsFC (p(vertex) < .05, p(cluster) < .005) within the strategy-based training group. Conclusions: These findings suggest that training-induced brain plasticity continues through chronic phases of TBI and that brain connectivity and cortical thickness may serve as markers of plasticity.	[Han, Kihwan; Davis, Rebecca A.; Chapman, Sandra B.; Krawczyk, Daniel C.] Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX USA; [Krawczyk, Daniel C.] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX USA	Han, K (corresponding author), Ctr BrainHlth, Sch Behav & Brain Sci, Dallas, TX 75234 USA.	kihwan.han98@gmail.com	Han, Kihwan/I-1984-2019	Han, Kihwan/0000-0002-4574-7306	Department of DefenseUnited States Department of Defense [W81XWH-11-2-0194, W81XWH-11-2-0195]; Meadows Foundation; Friends of BrainHealth Distinguished New Scientist Award	This work was supported by the Department of Defense (W81XWH-11-2-0194 to D.C.K. and W81XWH-11-2-0195 to S.B.C.), the Meadows Foundation to D.C.K. and S.B.C., and the Friends of BrainHealth Distinguished New Scientist Award to K.H.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Aleman-Gomez Y, 2013, J NEUROSCI, V33, P15004, DOI 10.1523/JNEUROSCI.1459-13.2013; Alonso-Ortiz E, 2015, MAGN RESON MED, V73, P70, DOI 10.1002/mrm.25198; Alosco ML, 2015, J INT NEUROPSYCH SOC, V21, P851, DOI 10.1017/S1355617715000697; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Arnemann KL, 2015, NEUROLOGY, V84, P1568, DOI 10.1212/WNL.0000000000001476; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Beck AT, 1996, BDI 2 BECK DEPRESSIO; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bernal-Rusiel JL, 2013, NEUROIMAGE, V66, P249, DOI 10.1016/j.neuroimage.2012.10.065; Bertolero MA, 2015, P NATL ACAD SCI USA, V112, pE6798, DOI 10.1073/pnas.1510619112; Best JR, 2015, J INT NEUROPSYCH SOC, V21, P745, DOI 10.1017/S1355617715000673; Bezzola L, 2011, J NEUROSCI, V31, P12444, DOI 10.1523/JNEUROSCI.1996-11.2011; Binder D., 2008, BRAIN HLTH WORKSHOP; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; BLACK JE, 1987, NEUROSCI LETT, V83, P351, DOI 10.1016/0304-3940(87)90113-3; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Butz M, 2009, BRAIN RES REV, V60, P287, DOI 10.1016/j.brainresrev.2008.12.023; Chapman SB, 2015, CEREB CORTEX, V25, P396, DOI 10.1093/cercor/bht234; Chen G, 2013, NEUROIMAGE, V73, P176, DOI 10.1016/j.neuroimage.2013.01.047; Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Giglio L, 2016, RADIOLOGY, V280, P202, DOI 10.1148/radiol.2016150710; Delis DC, 2001, D KEFS EXECUTIVE FUN; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Draganski B, 2006, J NEUROSCI, V26, P6314, DOI 10.1523/JNEUROSCI.4628-05.2006; Engvig A, 2010, NEUROIMAGE, V52, P1667, DOI 10.1016/j.neuroimage.2010.05.041; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; Fan YT, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00546; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Frieden T. R., 2015, C TRAUM BRAIN INJ US; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Goldstein G, 2010, BRAIN INJURY, V24, P625, DOI 10.3109/02699051003670882; Gratton C, 2012, J COGNITIVE NEUROSCI, V24, P1275, DOI 10.1162/jocn_a_00222; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Guerra-Carrillo B, 2014, NEUROSCIENTIST, V20, P522, DOI 10.1177/1073858414524442; Han K, 2016, J INT NEUROPSYCH SOC, V22, P263, DOI 10.1017/S1355617715001393; Han K, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00231; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hudak AM, 2012, J HEAD TRAUMA REHAB, V27, P87, DOI 10.1097/HTR.0b013e3182114efd; Hudak A, 2011, PSYCHIAT RES-NEUROIM, V191, P160, DOI 10.1016/j.pscychresns.2010.10.003; Ilg R, 2008, J NEUROSCI, V28, P4210, DOI 10.1523/JNEUROSCI.5722-07.2008; Johnstone T, 2006, HUM BRAIN MAPP, V27, P779, DOI 10.1002/hbm.20219; Jolles DD, 2013, HUM BRAIN MAPP, V34, P396, DOI 10.1002/hbm.21444; Joo JWJ, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0903-6; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kelly C, 2014, NEUROPSYCHOL REV, V24, P63, DOI 10.1007/s11065-014-9252-y; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kochunov P, 2008, HUM BRAIN MAPP, V29, P36, DOI 10.1002/hbm.20369; Kolb B, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00377; Krawczyk DC, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-29; Kuperberg GR, 2003, ARCH GEN PSYCHIAT, V60, P878, DOI 10.1001/archpsyc.60.9.878; Kwok V, 2011, P NATL ACAD SCI USA, V108, P6686, DOI 10.1073/pnas.1103217108; Landi SM, 2011, J NEUROSCI, V31, P11808, DOI 10.1523/JNEUROSCI.2253-11.2011; Laughlin SB, 2003, SCIENCE, V301, P1870, DOI 10.1126/science.1089662; Lewisa CM, 2009, P NATL ACAD SCI USA, V106, P17558, DOI 10.1073/pnas.0902455106; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Lopez KC, 2017, J NEUROTRAUM, V34, P16, DOI 10.1089/neu.2015.4323; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Mackey AP, 2013, J NEUROSCI, V33, P4796, DOI 10.1523/JNEUROSCI.4141-12.2013; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Markham JA, 2004, NEURON GLIA BIOL, V1, P351, DOI 10.1017/S1740925X05000219; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; May A, 2006, CURR OPIN NEUROL, V19, P407, DOI 10.1097/01.wco.0000236622.91495.21; May A, 2011, TRENDS COGN SCI, V15, P475, DOI 10.1016/j.tics.2011.08.002; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McEwen SC, 2015, J INT NEUROPSYCH SOC, V21, P868, DOI 10.1017/S1355617715000983; Metzler-Baddeley C, 2016, NEUROIMAGE, V130, P48, DOI 10.1016/j.neuroimage.2016.01.007; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Reiter K, 2015, J INT NEUROPSYCH SOC, V21, P757, DOI 10.1017/S135561771500079X; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Saad ZS, 2004, 2004 2ND IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: MACRO TO NANO, VOLS 1 and 2, P1510; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; Schmidt-Wilcke T, 2010, NEUROIMAGE, V51, P1234, DOI 10.1016/j.neuroimage.2010.03.042; Sehm B, 2014, NEUROBIOL AGING, V35, P232, DOI 10.1016/j.neurobiolaging.2013.06.021; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; SIREVAAG AM, 1988, DEV BRAIN RES, V43, P299, DOI 10.1016/0165-3806(88)90107-1; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Spielberg JM, 2015, BIOL PSYCHIAT, V78, P210, DOI 10.1016/j.biopsych.2015.02.013; Spitz G, 2013, BRAIN COGNITION, V83, P34, DOI 10.1016/j.bandc.2013.06.007; Tak S, 2014, NEUROIMAGE, V84, P672, DOI 10.1016/j.neuroimage.2013.09.057; Takeuchi H, 2014, HUM BRAIN MAPP, V35, P3646, DOI 10.1002/hbm.22427; Takeuchi H, 2013, CORTEX, V49, P2106, DOI 10.1016/j.cortex.2012.09.007; Takeuchi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023175; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Taubert M, 2011, NEUROIMAGE, V57, P1492, DOI 10.1016/j.neuroimage.2011.05.078; Taubert M, 2010, J NEUROSCI, V30, P11670, DOI 10.1523/JNEUROSCI.2567-10.2010; TEASDALE G, 1974, LANCET, V2, P81; Tellier A, 2009, BRAIN INJURY, V23, P879, DOI 10.1080/02699050903200555; Thaler NS, 2013, ARCH CLIN NEUROPSYCH, V28, P798, DOI 10.1093/arclin/act080; Thomas C, 2013, NEUROIMAGE, V73, P225, DOI 10.1016/j.neuroimage.2012.03.069; Thurman DJ., 1995, GUIDELINES SURVEILLA; Turken And U, 2009, BMC Med Imaging, V9, P20, DOI 10.1186/1471-2342-9-20; Valkanova V, 2014, INT PSYCHOGERIATR, V26, P891, DOI 10.1017/S1041610213002482; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varkuti B, 2013, NEUROREHAB NEURAL RE, V27, P53, DOI 10.1177/1545968312445910; Vas A, 2016, NEUROPSYCHOL REHABIL, V26, P502, DOI 10.1080/09602011.2015.1044013; Vas AK, 2011, J HEAD TRAUMA REHAB, V26, P224, DOI 10.1097/HTR.0b013e318218dd3d; Ventura-Campos N, 2013, J NEUROSCI, V33, P9295, DOI 10.1523/JNEUROSCI.4655-12.2013; Voss MW, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00032; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warren DE, 2014, P NATL ACAD SCI USA, V111, P14247, DOI 10.1073/pnas.1322173111; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2001, WECHSLER TEST ADULT; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woollett K, 2011, CURR BIOL, V21, P2109, DOI 10.1016/j.cub.2011.11.018; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zatorre RJ, 2012, NAT NEUROSCI, V15, P528, DOI 10.1038/nn.3045; Zhou IY, 2014, NEUROIMAGE, V84, P1, DOI 10.1016/j.neuroimage.2013.08.037; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	144	19	19	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	MAY	2017	7	5							e00687	10.1002/brb3.687			27	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	EY2EJ	WOS:000403780900020	28523229	DOAJ Gold, Green Published			2021-06-18	
J	Hanley, D; Prichep, LS; Bazarian, J; Huff, JS; Naunheim, R; Garrett, J; Jones, EB; Wright, DW; O'Neill, J; Badjatia, N; Gandhi, D; Curley, KC; Chiacchierini, R; O'Neil, B; Hack, DC				Hanley, Daniel; Prichep, Leslie S.; Bazarian, Jeffrey; Huff, J. Stephen; Naunheim, Rosanne; Garrett, John; Jones, Elizabeth B.; Wright, David W.; O'Neill, John; Badjatia, Neeraj; Gandhi, Dheeraj; Curley, Kenneth C.; Chiacchierini, Richard; O'Neil, Brian; Hack, Dallas C.			Emergency Department Triage of Traumatic Head Injury Using a Brain Electrical Activity Biomarker: A Multisite Prospective Observational Validation Trial	ACADEMIC EMERGENCY MEDICINE			English	Article							SPORT-RELATED CONCUSSION; COMPUTED-TOMOGRAPHY; UNITED-STATES; DECISION RULES; CT; IDENTIFICATION; PERFORMANCE; HEMATOMAS; VISITS	Objectives: A brain electrical activity biomarker for identifying traumatic brain injury (TBI) in emergency department (ED) patients presenting with high Glasgow Coma Scale (GCS) after sustaining a head injury has shown promise for objective, rapid triage. The main objective of this study was to prospectively evaluate the efficacy of an automated classification algorithm to determine the likelihood of being computed tomography (CT) positive, in high-functioning TBI patients in the acute state. Methods: Adult patients admitted to the ED for evaluation within 72 hours of sustaining a closed head injury with GCS 12 to 15 were candidates for study. A total of 720 patients (18-85 years) meeting inclusion/exclusion criteria were enrolled in this observational, prospective validation trial, at 11 U.S. EDs. GCS was 15 in 97%, with the first and third quartiles being 15 (interquartile range = 0) in the study population at the time of the evaluation. Standard clinical evaluations were conducted and 5 to 10 minutes of electroencephalogram (EEG) was acquired from frontal and frontal-temporal scalp locations. Using an a priori derived EEG-based classification algorithm developed on an independent population and applied to this validation population prospectively, the likelihood of each subject being CT+ was determined, and performance metrics were computed relative to adjudicated CT findings. Results: Sensitivity of the binary classifier (likely CT+ or CT-) was 92.3% (95% confidence interval [CI] = 87.8%-95.5%) for detection of any intracranial injury visible on CT (CT+), with specificity of 51.6% (95% CI = 48.1%-55.1%) and negative predictive value (NPV) of 96.0% (95% CI = 93.2%- 97.9%). Using ternary classification (likely CT+, equivocal, likely CT-) demonstrated enhanced sensitivity to traumatic hematomas (>= 1 mL of blood), 98.6% (95% CI = 92.6%-100.0%), and NPV of 98.2% (95% CI = 95.5%-99.5%). Conclusion: Using an EEG-based biomarker high accuracy of predicting the likelihood of being CT+ was obtained, with high NPV and sensitivity to any traumatic bleeding and to hematomas. Specificity was significantly higher than standard CT decision rules. The short time to acquire results and the ease of use in the ED environment suggests that EEG-based classifier algorithms have potential to impact triage and clinical management of head-injured patients.	[Hanley, Daniel] Johns Hopkins Med Inst, Brain Injury Outcomes, Baltimore, MD 21205 USA; [Prichep, Leslie S.] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA; [Prichep, Leslie S.] BrainScope Co Inc, Bethesda, MD 20814 USA; [Bazarian, Jeffrey] Univ Rochester, Med Ctr, Rochester, NY 14642 USA; [Huff, J. Stephen] Univ Virginia Hlth Syst, Charlottesville, VA USA; [Naunheim, Rosanne] Washington Univ, Barnes Jewish Med Ctr, St Louis, MO USA; [Garrett, John] Baylor Univ, Med Ctr, Dallas, TX USA; [Jones, Elizabeth B.] Univ Texas Houston, Mem Hermann Hosp, Houston, TX USA; [Wright, David W.] Emory Univ, Sch Med, Atlanta, GA USA; [Wright, David W.] Grady Mem Hosp, Atlanta, GA USA; [O'Neill, John] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; [Badjatia, Neeraj] Adams Cowley Shock Trauma Ctr, Baltimore, MD USA; [Gandhi, Dheeraj] Univ Maryland, Dept Radiol, Baltimore, MD 21201 USA; [Curley, Kenneth C.] Iatrikos Res & Dev Strategies LLC, Tampa, FL USA; [Curley, Kenneth C.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA; [Chiacchierini, Richard] RP Chiacchierini Consulting LLC, Gaithersburg, MD USA; [O'Neil, Brian] Detroit Receiving Hosp & Univ Hlth Ctr, Detroit, MI USA; [Hack, Dallas C.] Brain Hlth, Harpers Ferry, WV USA	Prichep, LS (corresponding author), NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA.; Prichep, LS (corresponding author), BrainScope Co Inc, Bethesda, MD 20814 USA.	leslie.prichep@nyumc.org			U.S. ArmyUnited States Department of Defense [W81XWH-14-C-1405]; BrainScope Co., Inc.; BIOS	This study was funded in part by a research contract from U.S. Army, contract W81XWH-14-C-1405, entitled, "Validation of Point-of-Care TBI Detection System for Head Injured Patients." Data acquisition for this study was supported by research grants from BrainScope Co., Inc., to the clinical sites.; JB, JSH, RN, JG, EBJ, DWW, JO, NB, and BO were all principal investigators at clinical data acquisition sites (University of Rochester Medical Center, Rochester, NY; University of Virginia Health System, Charlottesville, VA; Washington University Barnes Jewish Medical Center, St. Louis, MO; Baylor University Medical Center, Dallas, TX; University of Texas Memorial Hermann Hospital, Houston, TX; Emory University School of Medicine and Grady Memorial Hospital, Atlanta, GA; Allegheny General Hospital, Pittsburgh, PA; R Adams Cowley Shock Trauma Center, Baltimore, MD; Detroit Receiving Hospital, Detroit, MI, respectively), whose institutions received research contracts from BrainScope Company, Inc., to support subject recruitment, consenting and data acquisition. DH led the Brain Injury Outcomes (BIOS) Division of Johns Hopkins, the independent CRC for the trial. He is a member of the Medical Advisory Board of BrainScope Co., Inc., but receives no financial remuneration for this activity. DG served as an independent CT adjudicator, is associate professor and director of interventional neuroradiology at the University of Maryland, and receives salary from BIOS. LSP is employed by BrainScope as the chief scientific officer and is a professor at NYU School of Medicine. LSP holds potential financial interest through patented technology licensed by BrainScope from NYU School of Medicine. DCH currently serves as a consultant to BrainScope Co., Inc., who at the time the study was conducted was coordinator of the Brain Health/Fitness Research Program at the U.S. Army Medical Research and Materiel Command. KCC currently serves as a consultant to BrainScope Co., Inc., who at the time the study was conducted was the Neurotrauma Research Portfolio Manager for Combat Casualty Care Research Program and Defense Health Program at the U.S. Army Medical Research and Materiel Command. RPC served as the independent consulting statistician to BrainScope Co., Inc., for this study.	ACEP, 2013, BMJ QUAL SAF S; [Anonymous], 2014, MIL MED; [Anonymous], 2015, C TRAUM BRAIN INJ US; Ayaz SI, 2015, AM J EMERG MED, V33, P493, DOI 10.1016/j.ajem.2014.11.015; Hanley DF, 2013, J NEUROTRAUM, V30, P2051, DOI 10.1089/neu.2013.3062; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Kerber KA, 2010, AM J EMERG MED, V28, P1030, DOI 10.1016/j.ajem.2009.06.007; Korley FK, 2016, J HEAD TRAUMA REHAB, V31, P379, DOI 10.1097/HTR.0000000000000187; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Linton O, 2011, J AM COLL RADIOL, V8, P325, DOI 10.1016/j.jacr.2010.09.004; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; Melnick ER, 2015, JT COMM J QUAL PATIE, V41, P313, DOI 10.1016/S1553-7250(15)41041-4; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Newman-Toker DE, 2013, JAMA-J AM MED ASSOC, V310, P1237, DOI 10.1001/jama.2013.278019; O'Neil B, 2012, WEST J EMERG MED, V13, P394, DOI 10.5811/westjem.2011.12.6815; Papa L, 2012, ACAD EMERG MED, V19, P2, DOI 10.1111/j.1553-2712.2011.01247.x; Prichep LS, 2015, J NEUROTRAUM, V32, P17, DOI 10.1089/neu.2014.3365; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Prichep LS, 2012, IEEE T NEUR SYS REH, V20, P806, DOI 10.1109/TNSRE.2012.2206609; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Ro YS, 2011, ACAD EMERG MED, V18, P597, DOI 10.1111/j.1553-2712.2011.01094.x; Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tibshirani R., 1996, J R STAT SOC B	29	19	19	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	MAY	2017	24	5					617	627		10.1111/acem.13175			11	Emergency Medicine	Emergency Medicine	EU6SY	WOS:000401165800009	28177169	Bronze			2021-06-18	
J	Lu, WN; Albalawi, F; Beckel, JM; Lim, JC; Laties, AM; Mitchell, CH				Lu, Wennan; Albalawi, Farraj; Beckel, Jonathan M.; Lim, Jason C.; Laties, Alan M.; Mitchell, Claire H.			The P2X7 receptor links mechanical strain to cytokine IL-6 up-regulation and release in neurons and astrocytes	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; cytokines; IOP; mechanical strain; P2X7; retina	OPTIC-NERVE HEAD; RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; MEDIATED ATP RELEASE; INTRAOCULAR-PRESSURE; EXTRACELLULAR ATP; P2X(7) RECEPTOR; INTERLEUKIN-6 RELEASE; SUSTAINED ELEVATION; ANTERIOR-CHAMBER	Mechanical strain in neural tissues can lead to the up-regulation and release of multiple cytokines including interleukin 6 (IL-6). In the retina, the mechanosensitive release of ATP can autostimulate P2X7 receptors on both retinal ganglion cell neurons and optic nerve head astrocytes. Here, we asked whether the purinergic signaling contributed to the IL-6 response to increased intraocular pressure (IOP) invivo, and stretch or swelling invitro. Rat and mouse eyes were exposed to non-ischemic elevations in IOP to 50-60mmHg for 4h. A PCR array was used to screen cytokine changes, with quantitative (q)PCR used to confirm mRNA elevations and immunoblots used for protein levels. P2X7 antagonist Brilliant Blue G (BBG) and agonist (4-benzoyl-benzoyl)-ATP (BzATP) were injected intravitreally. ELISA was used to quantify IL-6 release from optic nerve head astrocytes or retinal ganglion cells. Receptor identity was confirmed pharmacologically and in P2X7(-/-) mice, acute elevation of IOP altered retinal expression of multiple cytokine genes. Elevation of IL-6 was greatest, with expression of IL1rn, IL24, Tnf, Csf1, and Lif also increased more than twofold, while expression of Tnfsf11, Gdf9, and Tnfsf4 were reduced. qPCR confirmed the rise in IL-6 and extracellular ATP marker ENTPD1, but not pro-apoptotic genes. Intravitreal injection of P2X7 receptor antagonist BBG prevented the pressure-dependent rise in IL-6 mRNA and protein in the rat retina, while injection of P2X7 receptor agonist BzATP was sufficient to elevate IL-6 expression. IOP elevation increased IL-6 in wild-type but not P2X7R knockout mice. Application of mechanical strain to isolated optic nerve head astrocytes increased IL-6 levels. This response was mimicked by agonist BzATP, but blocked by antagonists BBG and A839977. Stretch or BzATP led to IL-6 release from both astrocytes and isolated retinal ganglion cells. The mechanosensitive up-regulation and release of cytokine IL-6 from the retina involves the P2X7 receptor, with both astrocytes and neurons contributing to the response.	[Lu, Wennan; Albalawi, Farraj; Beckel, Jonathan M.; Lim, Jason C.; Mitchell, Claire H.] Univ Penn, Dept Anat & Cell Biol, 240 S 40th St, Philadelphia, PA 19104 USA; [Albalawi, Farraj] Univ Penn, Dept Orthodont, Philadelphia, PA 19104 USA; [Beckel, Jonathan M.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Laties, Alan M.; Mitchell, Claire H.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA; [Mitchell, Claire H.] Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	Mitchell, CH (corresponding author), Univ Penn, Dept Anat & Cell Biol, 240 S 40th St, Philadelphia, PA 19104 USA.	chm@upenn.edu	Beckel, Jonathan M./A-6758-2008	Beckel, Jonathan M./0000-0003-1390-2292	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EY015537, EY013434, EY001583, DK106115]; Jody Sack Fund; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY001583, R01EY013434, R01EY015537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K01DK106115] Funding Source: NIH RePORTER	The authors thank Jonathan Huwe for help with qPCR experiments. The authors declare that they have no competing interests. This work is supported by grants from the NIH EY015537 and EY013434 and core grant EY001583 (CHM). NIH DK106115 (JMB), Jody Sack Fund (WL). These funding bodies had no direct role in the design of the study and collection, analysis, and interpretation of data or and in writing the manuscript. The authors have no conflict of interest to declare.	Abbott CJ, 2014, INVEST OPHTH VIS SCI, V55, P674, DOI 10.1167/iovs.13-12811; Beckel JM, 2014, GLIA, V62, P1486, DOI 10.1002/glia.22695; Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Bustamante M, 2014, AM J PHYSIOL-ENDOC M, V306, pE869, DOI 10.1152/ajpendo.00450.2013; Cabrera CL, 1999, ACTA OPHTHALMOL SCAN, V77, P33, DOI 10.1034/j.1600-0420.1999.770108.x; CADMAN ED, 1994, NEUROSCI LETT, V178, P251, DOI 10.1016/0304-3940(94)90771-4; Cepurna W. O., 2008, INVEST OPHTH VIS SCI, V49, P3695; Chen KH, 1999, INVEST OPHTH VIS SCI, V40, P2627; Chidlow G, 2012, NEUROBIOL DIS, V48, P568, DOI 10.1016/j.nbd.2012.07.026; Chrysostomou V, 2013, INVEST OPHTH VIS SCI, V54, P4691, DOI 10.1167/iovs.13-12415; Codeluppi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092649; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Corriden R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3104re1; Crowston JG, 2015, EXP EYE RES, V141, P3, DOI 10.1016/j.exer.2015.03.006; Downs JC, 2008, OPTOMETRY VISION SCI, V85, P425, DOI 10.1097/OPX.0b013e31817841cb; Downs JC, 2015, EXP EYE RES, V133, P19, DOI 10.1016/j.exer.2015.02.011; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Franceschini A, 2015, FASEB J, V29, P2450, DOI 10.1096/fj.14-268714; Franke H, 2007, PURINERG SIGNAL, V3, P435, DOI 10.1007/s11302-007-9082-y; Gombault A, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00414; Guha S, 2013, FASEB J, V27, P4500, DOI 10.1096/fj.13-236166; Guo Y, 2011, INVEST OPHTH VIS SCI, V52, P1460, DOI 10.1167/iovs.10-5930; Hanley PJ, 2004, P NATL ACAD SCI USA, V101, P9479, DOI 10.1073/pnas.0400733101; Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8; Honore P, 2009, BEHAV BRAIN RES, V204, P77, DOI 10.1016/j.bbr.2009.05.018; Hu HL, 2010, EXP EYE RES, V91, P425, DOI 10.1016/j.exer.2010.06.017; Iglesias R, 2009, J NEUROSCI, V29, P7092, DOI 10.1523/JNEUROSCI.6062-08.2009; Inoue K, 2007, J INVEST DERMATOL, V127, P362, DOI 10.1038/sj.jid.5700526; Jo AO, 2015, J NEUROSCI, V35, P13525, DOI 10.1523/JNEUROSCI.1987-15.2015; Johnson EC, 2011, INVEST OPHTH VIS SCI, V52, P504, DOI 10.1167/iovs.10-5317; Kawano A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127919; Kezic JM, 2013, INVEST OPHTH VIS SCI, V54, P3028, DOI 10.1167/iovs.13-11865; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Li A, 2011, EXP EYE RES, V93, P528, DOI 10.1016/j.exer.2011.06.020; Lim J. C., 2011, INVEST OPHTH VIS SCI, V52, P5458; Lim JC, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00270; Lu W., 2011, INVEST OPHTH VIS SCI, V52, P5345; Lu W, 2007, J PHARMACOL EXP THER, V323, P157, DOI 10.1124/jpet.107.124545; Lu W, 2013, INVEST OPHTH VIS SCI, V54; Lu WN, 2015, INVEST OPHTH VIS SCI, V56, P3075, DOI 10.1167/iovs.14-15891; Mandal A, 2009, AM J PHYSIOL-CELL PH, V297, pC111, DOI 10.1152/ajpcell.00539.2008; Morrison JC, 2010, INVEST OPHTH VIS SCI, V51; Morrison JC, 2014, INVEST OPHTH VIS SCI, V55; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Praetorius HA, 2009, PURINERG SIGNAL, V5, P433, DOI 10.1007/s11302-009-9146-2; Reigada D, 2008, NEUROSCIENCE, V157, P396, DOI 10.1016/j.neuroscience.2008.08.036; Sanderson J, 2014, EXP EYE RES, V127, P270, DOI 10.1016/j.exer.2014.08.009; Sappington RM, 2006, INVEST OPHTH VIS SCI, V47, P2932, DOI 10.1167/iovs.05-1407; Satrawaha S, 2011, ARCH ORAL BIOL, V56, P1230, DOI 10.1016/j.archoralbio.2011.05.003; Shahidullah M, 2012, AM J PHYSIOL-CELL PH, V302, pC1751, DOI 10.1152/ajpcell.00010.2012; Shieh CH, 2014, GLIA, V62, P592, DOI 10.1002/glia.22628; Shigemoto-Mogami Y, 2001, J NEUROCHEM, V78, P1339, DOI 10.1046/j.1471-4159.2001.00514.x; Sigal IA, 2009, EXP EYE RES, V88, P799, DOI 10.1016/j.exer.2009.02.003; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Totan Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep03956; Wildman SS, 2003, BRIT J PHARMACOL, V140, P1177, DOI 10.1038/sj.bjp.0705544; Wilson GN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0399-0; WINSTON FK, 1989, J APPL PHYSIOL, V67, P397; Xia JS, 2012, J PHYSIOL-LONDON, V590, P2285, DOI 10.1113/jphysiol.2012.227983; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Zenkel M, 2010, AM J PATHOL, V176, P2868, DOI 10.2353/ajpath.2010.090914; Zhang M, 2010, NEUROCHEM INT, V56, P35, DOI 10.1016/j.neuint.2009.08.011; Zhang X, 2007, EXP EYE RES, V85, P637, DOI 10.1016/j.exer.2007.07.016; Zhang XL, 2006, J NEUROCHEM, V98, P566, DOI 10.1111/j.1471-4159.2006.03900.x; Zhi ZW, 2012, BIOMED OPT EXPRESS, V3, P2220, DOI 10.1364/BOE.3.002220	68	19	19	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2017	141	3					436	448		10.1111/jnc.13998			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	ES6JV	WOS:000399654500011	28244110	Green Accepted, Bronze			2021-06-18	
J	Ivanov, I; Fernandez, C; Mitsis, EM; Dickstein, DL; Wong, E; Tang, CY; Simantov, J; Bang, C; Moshier, E; Sano, M; Elder, GA; Hazlett, EA				Ivanov, Iliyan; Fernandez, Corey; Mitsis, Effie M.; Dickstein, Dara L.; Wong, Edmund; Tang, Cheuk Y.; Simantov, Jessie; Bang, Charlene; Moshier, Erin; Sano, Mary; Elder, Gregory A.; Hazlett, Erin A.			Blast exposure, White Matter integrity, and cognitive Function in iraq and afghanistan combat Veterans	FRONTIERS IN NEUROLOGY			English	Article						adult brain injury; diffusion tensor imaging; magnetic resonance imaging; cognitive function; military injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; DIFFUSION-TENSOR; POSTCONCUSSION SYMPTOMS; SERVICE MEMBERS; PTSD SYMPTOMS; MILD; ABNORMALITIES; TRACTOGRAPHY; SEQUELAE	The long-term effects of blast exposure are a major health concern for combat veterans returning from the recent conflicts in Iraq and Afghanistan. We used an optimized diffusion tensor imaging tractography algorithm to assess white matter (WM) fractional anisotropy (FA) in blast-exposed Iraq and Afghanistan veterans (n= 40) scanned on average 3.7 years after deployment/trauma exposure. Veterans diagnosed with a blast-related mild traumatic brain injury (mTBI) were compared to combat veterans with blast exposure but no TBI diagnosis. Blast exposure was associated with decreased FA in several WM tracts. However, total blast exposure did not correlate well with neuropsychological testing performance and there were no differences in FA based on mTBI diagnosis. Yet, veterans with mTBI performed worse on every neurocognitive test administered. Multiple linear regression across all blast-exposed veterans using a six-factor prediction model indicated that the amount of blast exposure accounted for 11-15% of the variability in composite FA scores such that as blast exposure increased, FA decreased. Education accounted for 10% of the variability in composite FA scores and 25-32% of FA variability in the right cingulum, such that as level of education increased, FA increased. Total blast exposure, age, and education were significant predictors of FA in the left cingulum. We did not find any effect of post-traumatic stress disorder on cognition or composite FA. In summary, our findings suggest that greater total blast exposure is a contributing factor to poor WM integrity. While FA was not associated with neurocognitive performance, we hypothesize that FA changes in the cingulum in veterans with multiple combat exposures and no head trauma prior to deployment may represent a marker of vulnerability for future deficits. Future work needs to examine this longitudinally.	[Ivanov, Iliyan; Fernandez, Corey; Mitsis, Effie M.; Bang, Charlene; Sano, Mary; Elder, Gregory A.; Hazlett, Erin A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Fernandez, Corey; Sano, Mary; Hazlett, Erin A.] James J Peters Vet Affairs Med Ctr, Res & Dev, Bronx, NY 10468 USA; [Mitsis, Effie M.; Simantov, Jessie; Bang, Charlene] James J Peters Vet Affairs Med Ctr, Rehabil Med Serv, Bronx, NY USA; [Dickstein, Dara L.] Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Dickstein, Dara L.; Hazlett, Erin A.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, Friedman Brain Inst, New York, NY 10029 USA; [Wong, Edmund; Tang, Cheuk Y.] Icahn Sch Med Mt Sinai, Dept Radiol, Translat & Mol Imaging Inst, New York, NY 10029 USA; [Simantov, Jessie] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Moshier, Erin] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Elder, Gregory A.] James J Peters Vet Affairs Med Ctr, Neurol Serv, Bronx, NY USA; [Hazlett, Erin A.] James J Peters Vet Affairs Med, Mental Illness Res Educ & Clin Ctr MIRECC VISN 2, Bronx, NY 10468 USA	Hazlett, EA (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Hazlett, EA (corresponding author), James J Peters Vet Affairs Med Ctr, Res & Dev, Bronx, NY 10468 USA.; Hazlett, EA (corresponding author), Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, Friedman Brain Inst, New York, NY 10029 USA.; Hazlett, EA (corresponding author), James J Peters Vet Affairs Med, Mental Illness Res Educ & Clin Ctr MIRECC VISN 2, Bronx, NY 10468 USA.	erin.hazlett@mssm.edu	Dickstein, Dara/AAH-6603-2020	Tang, Cheuk Ying/0000-0002-9828-0092; Fernandez, Corey/0000-0003-3901-5552	Veteran's Affairs (VA) Merit Awards [I01CX000190, I01CX000261]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138] Funding Source: NIH RePORTER	This research was funded by Veteran's Affairs (VA) Merit Awards (I01CX000190 to EMM and I01CX000261 to EH).	Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Beckmann M, 2009, J NEUROSCI, V29, P1175, DOI 10.1523/JNEUROSCI.3328-08.2009; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benedict R., 1997, BRIEF VISUOSPATIAL M; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2012, NEUROSCI LETT, V509, P1, DOI 10.1016/j.neulet.2011.12.009; Carpenter DM, 2008, NEUROREPORT, V19, P1369, DOI 10.1097/WNR.0b013e32830abc35; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; De Palma RG., 2015, BRAIN NEUROTRAUMA MO; Delis DC, 2000, CALIFORNIA VERBAL LE; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elwood RW, 1995, NEUROPSYCHOL REV, V5, P173, DOI 10.1007/BF02214761; Geary EK, 2011, J INT NEUROPSYCH SOC, V17, P709, DOI 10.1017/S1355617711000646; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Golden CJ., 2000, NEUROPSYCHOLOGICAL I; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Haran FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079595; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang H, 2004, MAGN RESON MED, V52, P559, DOI 10.1002/mrm.20147; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kamnaksh A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04809; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kucherov Y, 2012, J APPL PHYS, V112, DOI 10.1063/1.4765727; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lin YC, 2014, BRAIN TOPOGR, V27, P393, DOI 10.1007/s10548-013-0346-2; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; Mori S, 1999, J NEUROPHYSIOL, V82, P290; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nandipati Sirisha, 2012, Curr Aging Sci, V5, P131; Noble KG, 2013, DEVELOPMENTAL SCI, V16, P653, DOI 10.1111/desc.12077; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Post JB, 2012, AM J NEPHROL, V35, P120, DOI 10.1159/000334871; Rueda MR, 2005, P NATL ACAD SCI USA, V102, P14931, DOI 10.1073/pnas.0506897102; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thomas C, 2014, P NATL ACAD SCI USA, V111, P16574, DOI 10.1073/pnas.1405672111; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Troyanskaya M, 2015, MIL MED, V180, P285, DOI 10.7205/MILMED-D-14-00256; UDDO M, 1993, J PSYCHOPATHOL BEHAV, V15, P43, DOI 10.1007/BF00964322; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yeh PH, 2017, HUM BRAIN MAPP, V38, P352, DOI 10.1002/hbm.23365; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; YEHUDA R, 1995, AM J PSYCHIAT, V152, P137	73	19	19	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	APR 21	2017	8								127	10.3389/fneur.2017.00127			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	ET0UI	WOS:000399979100001	28484418	DOAJ Gold, Green Published			2021-06-18	
J	Kocher, GJ; Sharafi, S; Azenha, LF; Schmid, RA				Kocher, Gregor J.; Sharafi, Siamak; Azenha, Luis Filipe; Schmid, Ralph A.			Chest wall stabilization in ventilator-dependent traumatic flail chest patients: who benefits?	EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY			English	Article						Blunt chest trauma; Flail chest; Rib fracture; Rib and sternal fixation	SURGICAL STABILIZATION; PULMONARY CONTUSION; OPERATIVE STABILIZATION; MANAGEMENT; FIXATION; INJURIES; OUTCOMES	OBJECTIVES: Traumatic flail chest is a potentially life threatening injury, often associated with prolonged invasive mechanical ventilation and intensive care unit stay. This study evaluates the usefulness and cost-effectiveness of surgical rib stabilization in patients with flail chest resulting in ventilator dependent respiratory insufficiency. METHODS: A retrospective study on a consecutive series of patients with flail chest with the need for mechanical ventilation was performed. Effectiveness of rib fixation was evaluated in terms of predictors for prolonged ventilation, cost-effectiveness and outcome. RESULTS: A total of 61 patients underwent flail chest stabilization using a locked titanium plate fixation system between July 2010 and December 2015 at our institution. 62% (n = 38) of patients could be weaned from the ventilator within the first 72 h after surgery. Multiple linear regression analysis revealed that closed head injury, bilateral flail chest, number of stabilized ribs and severity of lung contusion were the main independent predictors for prolonged mechanical ventilation (Odds ratio (OR) 6.88; 3.25; 1.52 and 1.42) and tracheostomy (OR 9.17; 2.2; 1.76 and 0.84), respectively. Furthermore cost analysis showed that already a two day reduction in ICU stay could outweigh the cost of surgical rib fixation. CONCLUSIONS: Operative rib fixation has the potential to reduce ventilator days and ICU stay and subsequently hospital costs in selected patients with severe traumatic flail chest requiring mechanical ventilation. Especially associated closed head injury can adversely affect mechanical ventilation time. Furthermore the subgroups of patients sustaining a fall from a height and those with flail chest after cardiopulmonary re-animation seem to profit only marginally from surgical rib fixation.	[Kocher, Gregor J.; Sharafi, Siamak; Azenha, Luis Filipe; Schmid, Ralph A.] Univ Bern, Bern Univ Hosp, Div Gen Thorac Surg, Inselspital, Bern, Switzerland	Schmid, RA (corresponding author), Univ Hosp Bern, Div Gen Thorac Surg, CH-3010 Bern, Switzerland.	ralph.schmid@insel.ch		Kocher, Gregor Jan/0000-0001-6531-2919; Schmid, Ralph Alexander/0000-0003-0699-079X			AHMED Z, 1995, J THORAC CARDIOV SUR, V110, P1676, DOI 10.1016/S0022-5223(95)70030-7; Althausen PL, 2011, J ORTHOP TRAUMA, V25, P641, DOI 10.1097/BOT.0b013e318234d479; Balci Akin Eraslan, 2004, Asian Cardiovasc Thorac Ann, V12, P11; Bhatnagar A, 2012, J AM COLL SURGEONS, V215, P201, DOI 10.1016/j.jamcollsurg.2012.02.023; Bille A, 2013, GEN THORAC CARDIOVAS, V61, P345, DOI 10.1007/s11748-013-0218-4; Bottlang M, 2013, INJURY, V44, P232, DOI 10.1016/j.injury.2012.08.011; Cohn SM, 2010, WORLD J SURG, V34, P1959, DOI 10.1007/s00268-010-0599-9; de Lesquen H, 2015, INTERACT CARDIOV TH, V20, P399, DOI 10.1093/icvts/ivu397; Granetzny Andreas, 2005, Interact Cardiovasc Thorac Surg, V4, P583, DOI 10.1510/icvts.2005.111807; Karev D V, 1997, Wiad Lek, V50 Suppl 1 Pt 2, P205; Lafferty PM, 2011, J BONE JOINT SURG AM, V93A, P97, DOI 10.2106/JBJS.I.00696; Lardinois D, 2001, EUR J CARDIO-THORAC, V20, P496, DOI 10.1016/S1010-7940(01)00818-1; Leinicke JA, 2013, ANN SURG, V258, P914, DOI 10.1097/SLA.0b013e3182895bb0; Marasco SF, 2013, J AM COLL SURGEONS, V216, P924, DOI 10.1016/j.jamcollsurg.2012.12.024; Mayberry JC, 2009, AM SURGEON, V75, P389; Mouton W, 1997, THORAC CARDIOV SURG, V45, P242, DOI 10.1055/s-2007-1013735; Nirula R, 2006, AM SURGEON, V72, P307; Simon B, 2012, J TRAUMA ACUTE CARE, V73, pS351, DOI 10.1097/TA.0b013e31827019fd; Slobogean GP, 2013, J AM COLL SURGEONS, V216, P302, DOI 10.1016/j.jamcollsurg.2012.10.010; Tanaka H, 2002, J TRAUMA, V52, P727, DOI 10.1097/00005373-200204000-00020; Voggenreiter G, 1998, J AM COLL SURGEONS, V187, P130, DOI 10.1016/S1072-7515(98)00142-2	21	19	20	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1010-7940	1873-734X		EUR J CARDIO-THORAC	Eur. J. Cardio-Thorac. Surg.	APR	2017	51	4					696	701		10.1093/ejcts/ezw365			6	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	ER1NS	WOS:000398558800014	28007867	Bronze			2021-06-18	
J	Scott, JC; Harb, G; Brownlow, JA; Greene, J; Gur, RC; Ross, RJ				Scott, J. Cobb; Harb, Gerlinde; Brownlow, Janeese A.; Greene, Jennifer; Gur, Ruben C.; Ross, Richard J.			Verbal memory functioning moderates psychotherapy treatment response for PTSD-Related nightmares	BEHAVIOUR RESEARCH AND THERAPY			English	Article						Posttraumatic stress disorder; Psychotherapy; Nightmares; Insomnia; Memory; Neuropsychology; Sleep; Imagery rehearsal therapy	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; SLEEP QUALITY INDEX; COMPUTERIZED NEUROCOGNITIVE BATTERY; COGNITIVE PROCESSING THERAPY; RANDOMIZED CONTROLLED-TRIAL; PROLONGED EXPOSURE THERAPY; SEXUAL ASSAULT SURVIVORS; NEUROPSYCHOLOGICAL PERFORMANCE; IMAGERY REHEARSAL	Posttraumatic stress disorder (PTSD) is associated with cognitive deficits in attention, executive control, and memory, although few studies have investigated the relevance of cognitive difficulties for treatment outcomes. We examined whether cognitive functioning and history of traumatic brain injury (TBI) were associated with response to cognitive-behavioral therapy (CBT) for PTSD-related sleep problems. In a randomized controlled trial of Imagery Rehearsal (IR) added to components of CBT for Insomnia (IR + cCBT-I) compared to cCBT-I alone for PTSD-related recurrent nightmares, 94 U.S. veterans completed a battery of cognitive tests. TBI was assessed via structured clinical interview. Mixed-effects models examined main effects of cognitive functioning and interactions with time on primary sleep and nightmare outcomes. Significant verbal immediate memory by time interactions were found for nightmare distress, nightmare frequency, and sleep quality, even after controlling for overall cognitive performance and depression. TBI exhibited main effects on outcomes but no interactions with time. Findings indicated that individuals with lower verbal memory performance were less likely to respond to treatment across two sleep interventions. Veterans with TBI displayed greater symptoms but no altered trajectories of treatment response. Together with prior literature, findings suggest that verbal memory functioning may be important to consider in PTSD treatment implementation. Published by Elsevier Ltd.	[Scott, J. Cobb; Harb, Gerlinde; Brownlow, Janeese A.; Greene, Jennifer; Gur, Ruben C.; Ross, Richard J.] Corporal Michael J Crescenz VA Med Ctr, VISN4 Mental Illness Res Educ & Clin Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA; [Scott, J. Cobb; Brownlow, Janeese A.; Greene, Jennifer; Gur, Ruben C.; Ross, Richard J.] Univ Penn, Perelman Sch Med, Dept Psychiat, 3400 Spruce St,10 Gates, Philadelphia, PA 19104 USA	Scott, JC (corresponding author), Corporal Michael J Crescenz VA Med Ctr, MIRECC 116, 3900 Woodland Ave, Philadelphia, PA 19104 USA.	scottl@upenn.edu		Scott, J. Cobb/0000-0001-6538-9043	Department of Defense (DOD) CDMRP Award [W81XWH-08-2-0104, NCT00691626]; Department of Veterans Affairs Career Development AwardUS Department of Veterans Affairs [IK2CX000772]	This work was supported by a Department of Defense (DOD) CDMRP Award (W81XWH-08-2-0104, Clinical trial #NCT00691626) to Dr. Ross, and a Department of Veterans Affairs Career Development Award (IK2CX000772) to Dr. Scott. The authors also wish to thank Dr. Warren Bilker for statistical consultation. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors declare no conflicts of interest.	Almasy L, 2008, AM J PSYCHIAT, V165, P1185, DOI 10.1176/appi.ajp.2008.07121869; American Psychiatric Association, 2000, DIAGN STAT MAN TEXT; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; BELICKI K, 1992, J ABNORM PSYCHOL, V101, P592, DOI 10.1037/0021-843X.101.3.592; Belicki K., 1992, DREAMING, V2, P143, DOI DOI 10.1037/H0094355; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; Breslau N, 2006, ARCH GEN PSYCHIAT, V63, P1238, DOI 10.1001/archpsyc.63.11.1238; Brewin CR, 2007, MEMORY, V15, P227, DOI 10.1080/09658210701256423; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Brewin CR, 2014, PSYCHOL BULL, V140, P69, DOI 10.1037/a0033722; Brewin CR, 2005, J BEHAV THER EXP PSY, V36, P61, DOI 10.1016/j.jbtep.2004.11.006; Brownlow JA, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0587-8; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; BUYSSE DJ, 1991, SLEEP, V14, P331; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Cohen JD, 1996, PHILOS T R SOC B, V351, P1515, DOI 10.1098/rstb.1996.0138; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; Davis JJ, 2013, REHABIL PSYCHOL, V58, P36, DOI 10.1037/a0031525; Delis DC, 2000, CALIFORNIA VERBAL LE; DIKMEN S, 2009, NEUROPSYCHOLOGICAL A, P597; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Epstein, 2014, COGNITIVE BEHAV THER; Etkin A, 2015, J CLIN PSYCHIAT, V76, pE1035, DOI 10.4088/JCP.14com09752; First MB., 2002, STRUCTURED CLIN INTE; Forbes D, 2010, J TRAUMA STRESS, V23, P537, DOI 10.1002/jts.20565; Gehrman P, 2013, SLEEP, V36, P1009, DOI 10.5665/sleep.2798; Geuze E, 2009, DEPRESS ANXIETY, V26, P7, DOI 10.1002/da.20476; Gilbertson MW, 2006, J ABNORM PSYCHOL, V115, P484, DOI 10.1037/0021-843X.115.3.484; Goldman-Mellor S, 2015, SLEEP, V38, P623, DOI 10.5665/sleep.4584; Gur RC, 2001, NEUROPSYCHOPHARMACOL, V25, P766, DOI 10.1016/S0893-133X(01)00278-0; Gur RC, 2010, J NEUROSCI METH, V187, P254, DOI 10.1016/j.jneumeth.2009.11.017; Gutner CA, 2013, BEHAV RES THER, V51, P817, DOI 10.1016/j.brat.2013.09.008; Haagen JFG, 2015, CLIN PSYCHOL REV, V40, P184, DOI 10.1016/j.cpr.2015.06.008; Harb GC, 2013, J TRAUMA STRESS, V26, P570, DOI 10.1002/jts.21854; Harvey AG, 2014, PERSPECT PSYCHOL SCI, V9, P161, DOI 10.1177/1745691614521781; Jak AJ, 2015, CONTEMP CLIN TRIALS, V45, P210, DOI 10.1016/j.cct.2015.10.009; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kiluk BD, 2011, DRUG ALCOHOL DEPEN, V114, P169, DOI 10.1016/j.drugalcdep.2010.09.019; Koenen KC, 2001, BRAIN COGNITION, V45, P64, DOI 10.1006/brcg.2000.1256; Krakow B, 2001, JAMA-J AM MED ASSOC, V286, P537, DOI 10.1001/jama.286.5.537; Krakow B, 2002, J ANXIETY DISORD, V16, P175, DOI 10.1016/S0887-6185(02)00093-2; Krakow Barry, 2006, Behav Sleep Med, V4, P45, DOI 10.1207/s15402010bsm0401_4; Lane RD, 2015, BEHAV BRAIN SCI, V38, DOI 10.1017/S0140525X14000041; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; Martinez MP, 2005, SLEEP HYPN, V7, P29, DOI DOI 10.1037/T02025-000; McNally RJ, 2006, TRENDS COGN SCI, V10, P271, DOI 10.1016/j.tics.2006.04.007; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Moore TM, 2015, NEUROPSYCHOLOGY, V29, P235, DOI 10.1037/neu0000093; National Collaborating Centre for Mental Health (UK), 2005, POSTTR STRESS DIS MA; National Institute on Alcohol Abuse and Alcoholism, 2010, RETH DRINK ALC YOUR; Nijdam MJ, 2015, J CLIN PSYCHIAT, V76, pE1023, DOI 10.4088/JCP.14m09438; Parslow RA, 2007, AM J PSYCHIAT, V164, P509, DOI 10.1176/appi.ajp.164.3.509; Pascual-Leone A, 2015, BEHAV BRAIN SCI, V38, DOI 10.1017/S0140525X14000387; Patkar AA, 2004, J ADDICT DIS, V23, P109, DOI 10.1300/J069v23n02_08; Roalf DR, 2014, NEUROPSYCHOLOGY, V28, P161, DOI 10.1037/neu0000011; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Satterthwaite TD, 2013, J NEUROSCI, V33, P16249, DOI 10.1523/JNEUROSCI.2345-13.2013; Scott JC, 2015, PSYCHOL BULL, V141, P105, DOI 10.1037/a0038039; SMITH DE, 1991, ADDICT BEHAV, V16, P265, DOI 10.1016/0306-4603(91)90019-E; Swagerman SC, 2016, NEUROPSYCHOLOGY, V30, P53, DOI 10.1037/neu0000248; Teichner G, 2002, ADDICT BEHAV, V27, P751, DOI 10.1016/S0306-4603(01)00207-6; Teichner G, 2001, INT J NEUROSCI, V106, P253, DOI 10.3109/00207450109149753; Thomas ML, 2013, J CLIN EXP NEUROPSYC, V35, P225, DOI 10.1080/13803395.2012.762974; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; Vermetten E, 2003, BIOL PSYCHIAT, V54, P693, DOI 10.1016/S0006-3223(03)00634-6; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wild J, 2008, BRIT J PSYCHIAT, V193, P254, DOI 10.1192/bjp.bp.107.045922; Wolf GK, 2015, J TRAUMA STRESS, V28, P339, DOI 10.1002/jts.22029; Wolf GK, 2012, J HEAD TRAUMA REHAB, V27, P26, DOI 10.1097/HTR.0b013e31823cd01f; Wrocklage K. M., 2016, J INT NEUROPSYCH SOC, V22, P1; Yehuda R, 2004, BIOL PSYCHIAT, V55, P291, DOI 10.1016/S0006-3223(03)00641-3	77	19	19	1	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0005-7967	1873-622X		BEHAV RES THER	Behav. Res. Ther.	APR	2017	91						24	32		10.1016/j.brat.2017.01.004			9	Psychology, Clinical	Psychology	EP0JC	WOS:000397072600003	28110112	Bronze			2021-06-18	
J	Song, Y; Han, GX; Chen, L; Zhai, YZ; Dong, J; Chen, W; Li, TS; Zhu, HY				Song, Y.; Han, G. -X.; Chen, L.; Zhai, Y. -Z.; Dong, J.; Chen, W.; Li, T. -S.; Zhu, H. -Y.			The role of the hippocampus and the function of calcitonin gene-related peptide in the mechanism of traumatic brain injury accelerating fracture-healing	EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES			English	Article						Hippocampus; Fracture-healing; Traumatic brain injury; Calcitonin gene-related peptide	BLOOD-BRAIN; CEREBROSPINAL-FLUID; MOUSE MODEL; RAT; ISCHEMIA; BARRIER; IMMUNOREACTIVITY; POLYPEPTIDE; REPERFUSION; OSTEOBLASTS	OBJECTIVE: This research attempts to identify the part the hippocampus plays in accelerated fracture-healing after traumatic brain injury as well as to test functions of calcitonin gene-related peptide (CGRP) during this process. MATERIALS AND METHODS: Experiments were carried out on Male Sprague-Dawley rats that were split into four groups at random: TBI-fracture group, fracture-only group, TBI-only group, and control group. In the first week, blood specimen would be drawn from rats among the groups except those of the control group at threetime points (24, 72 and 168 hours) post-damage. These rats would be assessed from the neurological perspective based on their grades of performance in a sequence of tests 24 hours before and 12 hours after brain injury. Blood samples were also taken from the control group 24 hours before the injury, and whole brain tissues in the injured groups were harvested at 72 and 168 hours post-injury. We compared the serum CGRP concentration, the distribution of CGRP, the CGRP expression, and the expression of CGRP in the hippocampus, the expression of CGRP in the hippocampus, the expression of CGRP in the hippocampus, and the expression of CGRP in the brain by immunohistochemistry, Western blotting, RT-Of CGRP RNA expression levels. RESULTS: Neurological examinations suggested that the functions of the cerebral cortex, cerebellum, and brain stem showed significant differences pre-and post-injury (p < 0.001). ELISA analysis indicated a great density of CGRP in TBI-fracture group at different time points. Furthermore, in the TBI-fracture group, CGRP in both hippocampus and the whole brain showed a noticeable augment in RT-PCR and western blot analysis at 72 and 168 h post-injury, and only in this group, immunohistochemistry analysis indicated that CGRP was present in the hippocampus at 168 hours post-injury. CONCLUSIONS: We observed that the hippo-campus and CGRP were responsible for quick bone-healing mechanisms. We suggest a role for the hippocampus in accelerated fracture healing. CGRP expression, as determined by IHC, cannot be observed in other groups, indicating that the hippocampus may be the specific component of the brain that responds to "big stress".	[Song, Y.; Han, G. -X.; Chen, L.; Zhai, Y. -Z.; Dong, J.; Chen, W.; Li, T. -S.; Zhu, H. -Y.] Gen Hosp Chinese PLA, Dept Emergency, Beijing, Peoples R China	Zhu, HY (corresponding author), Gen Hosp Chinese PLA, Dept Emergency, Beijing, Peoples R China.	zhuhy301@aliyun.com			National Natural Science Research Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81670467]; Beijing Scientific & Technologic Supernova Supportive Project [15111000030000/XXJH2015B100]; Youth Project of National Natural fund [81400648]; Beijing Natural Science FundBeijing Natural Science Foundation [7152136]; Youth Culture Project of Chinese PLA [13QNP171]; Surface Project of Hainan Province Natural Fund [20158315]; Clinical Science Fund of PLA General Hospital [2015FC-ZHCG-2007, 2012FC-TSYS-4028]	This study was supported by the National Natural Science Research Foundation of China (No: 81670467), Beijing Scientific & Technologic Supernova Supportive Project (No: 15111000030000/XXJH2015B100), Youth Project of National Natural fund (No: 81400648), the Beijing Natural Science Fund (No: 7152136), Youth Culture Project of Chinese PLA (No: 13QNP171), Surface Project of Hainan Province Natural Fund (No: 20158315), and Clinical Science Fund of PLA General Hospital (No: 2015FC-ZHCG-2007, 2012FC-TSYS-4028).	Akopian A, 2000, PEPTIDES, V21, P559, DOI 10.1016/S0196-9781(00)00185-6; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; Arrieta-Cruz I, 2007, EXP NEUROL, V205, P449, DOI 10.1016/j.expneurol.2007.03.005; Beggs S, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-74; BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; Bucinskaite V, 1998, NEUROPEPTIDES, V32, P179, DOI 10.1016/S0143-4179(98)90035-X; Bulloch K, 1998, EXP NEUROL, V150, P195, DOI 10.1006/exnr.1997.6765; Cornish J, 1999, J BONE MINER RES, V14, P1302, DOI 10.1359/jbmr.1999.14.8.1302; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Edvinsson L, 2008, BRIT J PHARMACOL, V155, P967, DOI 10.1038/bjp.2008.346; Edvinsson Lars, 2002, ScientificWorldJournal, V2, P1484; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; Harada N, 2009, TRANSL RES, V154, P90, DOI 10.1016/j.trsl.2009.05.001; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; Liu XD, 2011, NEUROSCI LETT, V494, P10, DOI 10.1016/j.neulet.2011.02.036; Ma W, 2003, NEUROSCIENCE, V120, P677, DOI 10.1016/S0306-4522(03)00159-3; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Shih C, 1997, CLIN ORTHOP RELAT R, P335; Sobanska K, 2016, EUR REV MED PHARMACO, V20, P166; Somogyvari-Vigh A, 2000, REGUL PEPTIDES, V91, P89, DOI 10.1016/S0167-0115(00)00123-3; Sun Bao-liang, 2010, Front Biosci (Elite Ed), V2, P1502; Toth CC, 2009, J NEUROPATH EXP NEUR, V68, P326, DOI 10.1097/NEN.0b013e31819ac71b; Trinkl A, 2006, EUR J NEUROSCI, V24, P520, DOI 10.1111/j.1460-9568.2006.04920.x; Vignery A, 1996, BONE, V18, P331, DOI 10.1016/8756-3282(96)00017-8; Vrettos T, 2016, EUR REV MED PHARMACO, V20, P620; Yang CS, 2004, ANAL CHEM, V76, P4465, DOI 10.1021/ac035491v; Zhi XL, 2016, EUR REV MED PHARMACO, V20, P2156; Ziporen L, 1997, J CLIN INVEST, V100, P613, DOI 10.1172/JCI119572	31	19	20	0	7	VERDUCI PUBLISHER	ROME	VIA GREGORIO VII, ROME, 186-00165, ITALY	1128-3602			EUR REV MED PHARMACO	Eur. Rev. Med. Pharmacol. Sci.	APR	2017	21	7					1522	1531					10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	ET0CS	WOS:000399929900013	28429354				2021-06-18	
J	Tu, TM; Kolls, BJ; Soderblom, EJ; Cantillana, V; Ferrell, PD; Moseley, MA; Wang, HC; Dawson, HN; Laskowitz, DT				Tu, Tian Ming; Kolls, Brad J.; Soderblom, Erik J.; Cantillana, Viviana; Ferrell, Paul Durham; Moseley, M. Arthur; Wang, Haichen; Dawson, Hana N.; Laskowitz, Daniel T.			Apolipoprotein E mimetic peptide, CN-105, improves outcomes in ischemic stroke	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article							BLOOD-BRAIN-BARRIER; MURINE MODEL; INTRACEREBRAL HEMORRHAGE; INFLAMMATORY MECHANISMS; MICROGLIAL ACTIVATION; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; CNS RESPONSE; COG1410; INJURY	Objective: At present, the absence of a pharmacological neuroprotectant represents an important unmet clinical need in the treatment of ischemic and traumatic brain injury. Recent evidence suggests that administration of apolipoprotein E mimetic therapies represent a viable therapeutic strategy in this setting. We investigate the neuroprotective and anti-inflammatory properties of the apolipoprotein E mimetic pentapeptide, CN-105, in a microglial cell line and murine model of ischemic stroke. Methods: Ten to 13-week-old male C57/BL6 mice underwent transient middle cerebral artery occlusion and were randomly selected to receive CN-105 (0.1 mg/kg) in 100 mu L volume or vehicle via tail vein injection at various time points. Survival, motor-sensory functional outcomes using rotarod test and 4-limb wire hanging test, infarct volume assessment using 2,3,5-Triphenyltetrazolium chloride staining method, and microglial activation in the contralateral hippocampus using F4/80 immunostaining were assessed at various time points. In vitro assessment of tumor necrosis factor-alpha secretion in a microglial cell line was performed, and phosphoproteomic analysis conducted to explore early mechanistic pathways of CN-105 in ischemic stroke. Results: Mice receiving CN-105 demonstrated improved survival, improved functional outcomes, reduced infarct volume, and reduced microglial activation. CN-105 also suppressed inflammatory cytokines secretion in microglial cells in vitro. Phosphoproteomic signals suggest that CN-105 reduces proinflammatory pathways and lower oxidative stress. Interpretation: CN-105 improves functional and histological outcomes in a murine model of ischemic stroke via modulation of neuroinflammatory pathways. Recent clinical trial of this compound has demonstrated favorable pharmacokinetic and safety profile, suggesting that CN-105 represents an attractive candidate for clinical translation.	[Tu, Tian Ming; Kolls, Brad J.; Cantillana, Viviana; Wang, Haichen; Dawson, Hana N.; Laskowitz, Daniel T.] Duke Univ, Sch Med, Dept Neurol, DUMC 2900, Durham, NC 27710 USA; [Tu, Tian Ming] Natl Neurosci Inst, Dept Neurol, Tan Tock Seng Campus, Singapore, Singapore; [Soderblom, Erik J.; Moseley, M. Arthur] Duke Univ, Duke Prote Core Facil, Ctr Genom & Computat Biol, DUMC 2900, Durham, NC 27710 USA; [Ferrell, Paul Durham] Duke Univ, Sch Med, Dept Pathol, DUMC 2900, Durham, NC 27710 USA	Tu, TM (corresponding author), Duke Univ, Med Ctr, Dept Neurol, DUMC 2900, Durham, NC 27710 USA.	tu.tian.ming@singhealth.com.sg	Kolls, Brad/R-9154-2019	Tu, Tian Ming/0000-0002-7175-0357	North Carolina Biotechnology Center [2014-CFG-8004]; Ministry of Health, Singapore through the National Medical Research Council Research Training Fellowship [0012/2015]	This work was supported by a grant from the North Carolina Biotechnology Center (2014-CFG-8004) to D.T.L and by the Ministry of Health, Singapore through the National Medical Research Council Research Training Fellowship (NMRC/Fellowship/0012/2015) supporting T.M.T.	Aartsma-Rus A, 2014, JOVE-J VIS EXP, DOI 10.3791/51303; Ahmed N, 2010, LANCET NEUROL, V9, P866, DOI 10.1016/S1474-4422(10)70165-4; Amantea D, 2009, FEBS J, V276, P13, DOI 10.1111/j.1742-4658.2008.06766.x; Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Bejot Y, 2011, NEUROCHEM INT, V58, P102, DOI 10.1016/j.neuint.2010.10.019; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Braga Patricia, 2002, J Stroke Cerebrovasc Dis, V11, P15, DOI 10.1053/jscd.2002.123970; Cao F, 2016, J NEUROTRAUM, V33, P175, DOI 10.1089/neu.2015.3887; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Croy JE, 2004, BIOCHEMISTRY-US, V43, P7328, DOI 10.1021/bi036208p; Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008; Day EK, 2016, CURR OPIN BIOTECH, V40, P185, DOI 10.1016/j.copbio.2016.06.005; Duan RS, 2006, EXP NEUROL, V202, P373, DOI 10.1016/j.expneurol.2006.06.013; Fonarow GC, 2011, CIRCULATION, V123, P750, DOI 10.1161/CIRCULATIONAHA.110.974675; Fu Y, 2015, NAT REV NEUROL, V11, P524, DOI 10.1038/nrneurol.2015.144; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Grupke S, 2015, CLIN NEUROL NEUROSUR, V129, P1, DOI 10.1016/j.clineuro.2014.11.013; Gu Zhen, 2013, J Neurol Neurophysiol, V2014, P10; Guptill JT, 2016, J CLIN PHARM; Guttman M, 2010, J MOL BIOL, V398, P306, DOI 10.1016/j.jmb.2010.03.022; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hafezi-Moghadam A, 2007, AM J PHYSIOL-CELL PH, V292, pC1256, DOI 10.1152/ajpcell.00563.2005; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hanrahan F., 2016, TRANSLATIONAL RES TR; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hu JR, 1998, J NEUROCHEM, V71, P1626; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Ingley E, 2008, BBA-PROTEINS PROTEOM, V1784, P56, DOI 10.1016/j.bbapap.2007.08.012; James ML, 2009, J STROKE CEREBROVASC, V18, P144, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.012; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kim AS, 2011, CIRCULATION, V124, P314, DOI 10.1161/CIRCULATIONAHA.111.018820; Krishnamurthy K, 2016, TRANSLATIONAL RES TR; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 2012, NEUROCRIT CARE, V16, P316, DOI 10.1007/s12028-011-9641-5; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Lei BL, 2016, SCI REP-UK, V6, DOI 10.1038/srep34834; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Mace BE, 2007, NEUROL RES, V29, P243, DOI 10.1179/016164107X158974; Manocha GD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132604; Martinez-Gonzalez NA, 2006, J NEUROL NEUROSUR PS, V77, P1329, DOI 10.1136/jnnp.2006.097543; McColl BW, 2007, J CEREBR BLOOD F MET, V27, P477, DOI 10.1038/sj.jcbfm.9600361; Mesis Rachel G, 2006, Neurosurg Focus, V21, pE4; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Pocivavsek A, 2009, GLIA, V57, P444, DOI 10.1002/glia.20772; Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074; Qureshi AI, 2003, CRIT CARE MED, V31, P272, DOI 10.1097/00003246-200301000-00043; Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005; Sbarbati A, 2002, ANAT REC, V266, P118, DOI 10.1002/ar.10044; Schilling M, 2003, EXP NEUROL, V183, P25, DOI 10.1016/S0014-4886(03)00082-7; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Shichita T, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00319; Skolarus LE, 2015, STROKE, V46, P1890, DOI 10.1161/STROKEAHA.115.009163; Sutherland BA, 2012, INT J STROKE, V7, P407, DOI 10.1111/j.1747-4949.2012.00770.x; Thrift AG, 2014, INT J STROKE, V9, P6, DOI 10.1111/ijs.12245; Tong D, 2012, STROKE, V43, P1912, DOI 10.1161/STROKEAHA.111.644963; Tukhovskaya EA, 2009, J NEUROSCI RES, V87, P677, DOI 10.1002/jnr.21874; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Waetzig V, 2004, NEUROSCI LETT, V361, P64, DOI 10.1016/j.neulet.2004.02.041; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Wang H, 2013, EXP NEUROL, V241, P67, DOI 10.1016/j.expneurol.2012.11.027; Wang RH, 2014, J NEUROSCI RES, V92, P884, DOI 10.1002/jnr.23371; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wu Y, 2016, NEUROSCI LETT, V627, P92, DOI 10.1016/j.neulet.2016.05.058; Xiao WB, 2005, J IMMUNOL, V175, P6885, DOI 10.4049/jimmunol.175.10.6885; Zhang F., 2012, ANIM MODEL ACUTE NEU, V9, P93, DOI [10.1007/978-1-61779-782-8_9, DOI 10.1007/978-1-61779-782-8_9]; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193; Zlokovic BV, 2013, JAMA NEUROL, V70, P440, DOI 10.1001/jamaneurol.2013.2152	83	19	19	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	APR	2017	4	4					246	265		10.1002/acn3.399			20	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EU2JZ	WOS:000400856300003	28382306	DOAJ Gold, Green Published			2021-06-18	
J	Bellerose, J; Bernier, A; Beaudoin, C; Gravel, J; Beauchamp, MH				Bellerose, Jenny; Bernier, Annie; Beaudoin, Cindy; Gravel, Jocelyn; Beauchamp, Miriam H.			Long-Term Brain-Injury-Specific Effects Following Preschool Mild TBI: A Study of Theory of Mind	NEUROPSYCHOLOGY			English	Article						concussion; pediatric; social cognition; theory of mind; traumatic brain injury	SOCIAL-EMOTIONAL BEHAVIOR; FALSE-BELIEF; MIDDLE CHILDHOOD; NEUROCOGNITIVE OUTCOMES; INDIVIDUAL-DIFFERENCES; EXECUTIVE FUNCTIONS; HEAD-INJURY; CHILDREN; ADOLESCENTS; RECOVERY	Objective: A previous study conducted by our group found theory of mind (ToM) differences in preschool children who sustained mild traumatic brain injury (mTBI) compared with typically developing peers, 6 months postinjury. The goals of the current longitudinal study were to determine whether these findings are the result of a brain-injury-specific effect or rather a general-injury effect, to examine the long-term evolution of ToM skills following preschool mTBI, as well as to investigate the links between ToM abilities and general social functioning. Method: Seventy-two children who sustained mTBI between the ages of 18 and 60 months were evaluated 6 and 18 months postinjury on ToM tasks including desires and emotions reasoning and false belief understanding. They were compared with 58 participants who sustained an orthopedic injury (OI) and 83 typically developing children (TDC). Results: The 3 groups did not differ on demographic and baseline characteristics. The mTBI group obtained poorer scores relative to both comparison groups on the desires and emotions reasoning task, both at 6 and 18 months injury. No correlations were found between injury characteristics and ToM performance. For the mTBI group, associations were found between ToM performance and global social competence. Conclusion: These findings suggest a brain-injury-specific effect that persists in the long-term following mTBI in preschool children.	[Bellerose, Jenny; Bernier, Annie; Beaudoin, Cindy; Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, CP 6128 Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada; [Bellerose, Jenny; Beaudoin, Cindy; Gravel, Jocelyn; Beauchamp, Miriam H.] St Justine Hosp Res Ctr, Montreal, PQ, Canada	Beauchamp, MH (corresponding author), Univ Montreal, Dept Psychol, CP 6128 Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	miriam.beauchamp@umontreal.ca		Gravel, Jocelyn/0000-0001-5901-4990			Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baron-Cohen S, 2000, UNDERSTANDING OTHER, V2, P3, DOI DOI 10.1093/ACPROF:OSO/9780199692972.001.0001; Bayley N., 2005, BAYLEY SCALES INFANT, VThird; Bellerose J.S., 2011, BRAIN MAPPING NEURAL, P181; Bellerose J, 2015, J INT NEUROPSYCH SOC, V21, P483, DOI 10.1017/S1355617715000569; Benson JE, 2013, DEV PSYCHOL, V49, P1615, DOI 10.1037/a0031056; Bianco F, 2016, J EXP CHILD PSYCHOL, V149, P41, DOI 10.1016/j.jecp.2015.11.006; Blair C, 2002, AM PSYCHOL, V57, P111, DOI 10.1037//0003-066X.57.2.111; Blakemore SJ, 2004, NEUROREPORT, V15, P119, DOI 10.1097/00001756-200401190-00024; BONADIO WA, 1989, AM J DIS CHILD, V143, P1061, DOI 10.1001/archpedi.1989.02150210095025; Bonfield CM, 2013, J NEUROSURG-PEDIATR, V12, P97, DOI 10.3171/2013.5.PEDS12424; Brooks R, 2015, J EXP CHILD PSYCHOL, V130, P67, DOI 10.1016/j.jecp.2014.09.010; Brosseau-Liard P, 2015, BRIT J DEV PSYCHOL, V33, P464, DOI 10.1111/bjdp.12107; Ciurea A V, 2011, J Med Life, V4, P234; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Devine RT, 2014, CHILD DEV, V85, P1777, DOI 10.1111/cdev.12237; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Fahie CM, 2003, J APPL DEV PSYCHOL, V24, P51, DOI 10.1016/S0193-3973(03)00024-8; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hill BD, 2013, ARCH CLIN NEUROPSYCH, V28, P640, DOI 10.1093/arclin/act045; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hughes C, 1998, J CHILD PSYCHOL PSYC, V39, P981, DOI 10.1017/S0021963098003059; Hughes C, 2007, J CHILD PSYCHOL PSYC, V48, P1025, DOI 10.1111/j.1469-7610.2007.01806.x; Hughes C, 2011, J EXP CHILD PSYCHOL, V108, P96, DOI 10.1016/j.jecp.2010.07.012; Im-Bolter N, 2016, J EXP CHILD PSYCHOL, V149, P98, DOI 10.1016/j.jecp.2015.12.006; Jones DE, 2015, AM J PUBLIC HEALTH, V105, P2283, DOI 10.2105/AJPH.2015.302630; Kaldoja ML, 2015, J CHILD NEUROL, V30, P860, DOI 10.1177/0883073814544705; Kaldoja ML, 2012, BRAIN INJURY, V26, P1005, DOI 10.3109/02699052.2012.660516; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Ladd GW, 1999, ANNU REV PSYCHOL, V50, P333, DOI 10.1146/annurev.psych.50.1.333; Lagattuta KH, 2005, CHILD DEV, V76, P713, DOI 10.1111/j.1467-8624.2005.00873.x; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, BRAIN INJURY, V12, P41; Miller ScottA., 2012, THEORY MIND PRESCHOO; Mink D, 2014, INFANT BEHAV DEV, V37, P66, DOI 10.1016/j.infbeh.2013.12.001; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Noppens R, 2004, EXP TOXICOL PATHOL, V56, P113, DOI 10.1016/j.etp.2004.04.005; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; Pears KC, 2003, SOC DEV, V12, P1, DOI 10.1111/1467-9507.00219; Razza RA, 2009, J APPL DEV PSYCHOL, V30, P332, DOI 10.1016/j.appdev.2008.12.020; Repacholi BM, 1997, DEV PSYCHOL, V33, P12, DOI 10.1037/0012-1649.33.1.12; Robinson KE, 2014, J NEUROTRAUM, V31, P1835, DOI 10.1089/neu.2014.3422; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ryan NP, 2016, SOC COGN AFFECT NEUR, V11, P683, DOI 10.1093/scan/nsw007; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Sariaslan A, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002103; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Wang M. C., 2009, NEUROTRAUMA CRITICAL, P87; Wechsler, 2002, WECHSLER PRESCHOOL P; Wellman H.M., 1994, CHILDRENS EARLY UNDE, P331; Wellman HM, 2011, CHILD DEV, V82, P780, DOI 10.1111/j.1467-8624.2011.01583.x; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; Wilde Astington J., 2003, INDIVIDUAL DIFFERENC, P13; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	87	19	19	0	10	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2017	31	3					229	241		10.1037/neu0000341			13	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	EN4UY	WOS:000396003600001	28114784				2021-06-18	
J	Betancur, MI; Mason, HD; Alvarado-Velez, M; Holmes, PV; Bellamkonda, RV; Karumbaiah, L				Betancur, Martha I.; Mason, Hannah D.; Alvarado-Velez, Melissa; Holmes, Phillip V.; Bellamkonda, Ravi V.; Karumbaiah, Lohitash			Chondroitin Sulfate Glycosaminoglycan Matrices Promote Neural Stem Cell Maintenance and Neuroprotection Post-Traumatic Brain Injury	ACS BIOMATERIALS SCIENCE & ENGINEERING			English	Article						traumatic brain injury; biomaterials; neuroprotection; chondroitin sulfate glycosaminoglycan; neural stem cells; hydrogels	GROWTH-FACTORS; STEM/PROGENITOR CELLS; GLIAL SCAR; PROTEOGLYCAN; PROLIFERATION; NEUROGENESIS; BINDING; DIFFERENTIATION; REGENERATION; REGIONS	There are currently no effective treatments for moderate-to-severe traumatic brain injuries (TBIs). The paracrine functions of undifferentiated neural stem cells (NSCs) are believed to play a significant role in stimulating the repair and regeneration of injured brain tissue. We therefore hypothesized that fibroblast growth factor (FGF2) enriching chondroitin sulfate glycosaminoglycan (CS-GAG) matrices can maintain the undifferentiated state of neural stem cells (NSCs) and facilitate brain tissue repair subacutely post-TBI. Rats subjected to a controlled cortical impactor (CCI) induced TBI were intraparenchymally injected with CS-GAG matrices alone or with CS-GAG matrices containing PKH26GL labeled allogeneic NSCs. Nissl staining of brain tissue 4 weeks post-TBI demonstrated the significantly enhanced (p < 0.05) tissue protection in CS-GAG treated animals when compared to TBI only control, and NSC only treated animals. CS-GAG-NSC treated animals demonstrated significantly enhanced (p < 0.05) FGF2 retention, and maintenance of PKH26GL labeled NSCs as indicated by enhanced Soxl+ and Ki67+ cell presence over other differentiated cell types. Lastly, all treatment groups and sham controls exhibited a significantly (p < 0.05) attenuated GFAP+ reactive astrocyte presence in the lesion site when compared to TBI only controls.	[Betancur, Martha I.; Mason, Hannah D.; Karumbaiah, Lohitash] Univ Georgia, Regenerat Biosci Ctr, 425 River Rd,ADS Complex, Athens, GA 30602 USA; [Holmes, Phillip V.] Univ Georgia, Dept Psychol, 125 Baldwin St, Athens, GA 30602 USA; [Alvarado-Velez, Melissa; Bellamkonda, Ravi V.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA	Karumbaiah, L (corresponding author), Univ Georgia, Regenerat Biosci Ctr, 425 River Rd,ADS Complex, Athens, GA 30602 USA.	lohitash@uga.edu		Karumbaiah, Lohitash/0000-0001-7969-417X	University of Georgia CAES and OVPR; Georgia Institute of Technology/Emory University Regenerative Engineering and Medicine Center; University of Georgia; National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR00454]; National Institutes of Health (NIH/NCRR) - entitled 'Integrated Technology Resource for Biomedical Glycomics' [1P41RR018502-01]	This research was supported by startup funds awarded to L.K. by the University of Georgia CAES and OVPR, and in part by seed grant funding from the Georgia Institute of Technology/Emory University Regenerative Engineering and Medicine Center and The University of Georgia awarded to R.V.B. and L.K. This work is also supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR00454. The National Institutes of Health (NIH/NCRR)-funded grant entitled 'Integrated Technology Resource for Biomedical Glycomics' (Grant 1P41RR018502-01) to the Complex Carbohydrate Research Center, The University of Georgia.	Akita K, 2008, STEM CELLS, V26, P798, DOI 10.1634/stemcells.2007-0448; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gilbert RJ, 2005, MOL CELL NEUROSCI, V29, P545, DOI 10.1016/j.mcn.2005.04.006; He Z, 2015, MOL NEUROBIOL, V52, P927, DOI 10.1007/s12035-015-9244-9; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Kan LX, 2007, DEV BIOL, V310, P85, DOI 10.1016/j.ydbio.2007.07.026; Karimi-Abdolrezaee S, 2010, J NEUROSCI, V30, P1657, DOI 10.1523/JNEUROSCI.3111-09.2010; Karumbaiah L, 2015, BIOCONJUGATE CHEM, V26, P2336, DOI 10.1021/acs.bioconjchem.5b00397; Karumbaiah L, 2013, BIOMATERIALS, V34, P8061, DOI 10.1016/j.biomaterials.2013.07.016; Karumbaiah L, 2011, GLIA, V59, P981, DOI 10.1002/glia.21170; Koppe G, 1997, HISTOCHEM J, V29, P11, DOI 10.1023/A:1026408716522; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Logun MT, 2016, J MATER CHEM B, V4, P6052, DOI [10.1039/C6TB01083K, 10.1039/c6tb01083k]; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saxena T, 2013, BIOMATERIALS, V34, P4703, DOI 10.1016/j.biomaterials.2013.03.007; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sirko S, 2007, DEVELOPMENT, V134, P2727, DOI 10.1242/dev.02871; Sirko S, 2010, STEM CELLS, V28, P775, DOI 10.1002/stem.309; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; TOOLE BP, 1976, J BIOL CHEM, V251, P895; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998	40	19	20	2	12	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	2373-9878			ACS BIOMATER SCI ENG	ACS Biomater. Sci. Eng.	MAR	2017	3	3					420	430		10.1021/acsbiomaterials.6b00805			11	Materials Science, Biomaterials	Materials Science	EO0JU	WOS:000396384900021	29744379	Green Accepted			2021-06-18	
J	De Blasio, D; Fumagalli, S; Longhi, L; Orsini, F; Palmioli, A; Stravalaci, M; Vegliante, G; Zanier, ER; Bernardi, A; Gobbi, M; De Simoni, MG				De Blasio, Daiana; Fumagalli, Stefano; Longhi, Luca; Orsini, Franca; Palmioli, Alessandro; Stravalaci, Matteo; Vegliante, Gloria; Zanier, Elisa R.; Bernardi, Anna; Gobbi, Marco; De Simoni, Maria-Grazia			Pharmacological inhibition of mannose-binding lectin ameliorates neurobehavioral dysfunction following experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Inflammation; brain trauma; behavior (rodent); mannose-binding lectin inhibitor; neuroregeneration; brain recovery	ISCHEMIA-REPERFUSION INJURY; INNATE IMMUNITY; COMPLEMENT-SYSTEM; MICE BRAIN; C1-INHIBITOR; CELLS; NEUROPROTECTION; FICOLINS; THERAPY; DISEASE	Mannose-binding lectin is present in the contusion area of traumatic brain-injured patients and in that of traumatic brain-injured mice, where mannose-binding lectin-C exceeds mannose-binding lectin-A. The reduced susceptibility to traumatic brain injury of mannose-binding lectin double knock-out mice (mannose-binding lectin(-/-)) when compared to wild type mice suggests that mannose-binding lectin may be a therapeutic target following traumatic brain injury. Here, we evaluated the effects of a multivalent glycomimetic mannose-binding lectin ligand, Polyman9, following traumatic brain injury in mice. Invitro surface plasmon resonance assay indicated that Polyman9 dose-dependently inhibits the binding to immobilized mannose residues of plasma mannose-binding lectin-C selectively over that of mannose-binding lectin-A. Male C57Bl/6 mice underwent sham/controlled cortical impact traumatic brain injury and intravenous treatment with Polyman9/saline. Ex-vivo surface plasmon resonance studies confirmed that Polyman9 effectively reduces the binding of plasma mannose-binding lectin-C to immobilized mannose residues. Invivo studies up to four weeks post injury, showed that Polyman9 induces significant improvement in sensorimotor deficits (by neuroscore and beam walk), promotes neurogenesis (73% increase in doublecortin immunoreactivity), and astrogliosis (28% increase in glial fibrillary acid protein). Polyman9 administration in brain-injured mannose-binding lectin(-/-) mice had no effect on post-traumatic brain-injured functional deficits, suggestive of the specificity of its neuroprotective effects. The neurobehavioral efficacy of Polyman9 implicates mannose-binding lectin-C as a novel therapeutic target for traumatic brain injury.	[De Blasio, Daiana; Fumagalli, Stefano; Orsini, Franca; Stravalaci, Matteo; Vegliante, Gloria; Zanier, Elisa R.; Gobbi, Marco; De Simoni, Maria-Grazia] Ist Ric Farmacol Mario Negri, IRCCS, Milan, Italy; [De Blasio, Daiana; Fumagalli, Stefano] Osped Maggiore Policlin, Fdn IRCCS CaGranda, Dept Anesthesia & Crit Care Med, Milan, Italy; [Longhi, Luca] Azienda Socio Sanit Terr Papa Giovanni XXIII, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Bergamo, Italy; [Palmioli, Alessandro; Bernardi, Anna] Univ Milan, Dept Chem, Milan, Italy	De Simoni, MG (corresponding author), Mario Negri Inst Pharmacol Res, Lab Inflammat & Nervous Syst, Dept Neurosci, IRCCS, Via G La Masa 19, I-20156 Milan, Italy.	desimoni@marionegri.it	Gobbi, Marco/J-2638-2016; Stravalaci, Matteo/AAB-8963-2019; Bernardi, Anna/A-1167-2012; De Simoni, Maria Grazia/I-6021-2012; Longhi, Luca/AAF-9903-2021; Zanier, Elisa/AAA-8095-2020; Fumagalli, Stefano/I-3097-2019; Palmioli, Alessandro/A-8695-2013	Gobbi, Marco/0000-0003-1014-6225; Stravalaci, Matteo/0000-0002-5636-4204; Bernardi, Anna/0000-0002-1258-2007; De Simoni, Maria Grazia/0000-0001-6695-5297; Longhi, Luca/0000-0001-9894-8788; Palmioli, Alessandro/0000-0002-5287-1663; Zanier, Elisa/0000-0002-3011-8718; Orsini, Franca/0000-0001-7415-9936; Fumagalli, Stefano/0000-0003-3598-6263	Fondazione CariploFondazione Cariplo [2012-0590]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial support including Drs De Blasio and Fumagalli fellowship was provided by Fondazione Cariplo (grant number 2012-0590).	Bottazzi B, 2010, ANNU REV IMMUNOL, V28, P157, DOI 10.1146/annurev-immunol-030409-101305; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; De Simoni MG, 2004, AM J PATHOL, V164, P1857, DOI 10.1016/S0002-9440(10)63744-3; Endo Y, 2015, INT REV CEL MOL BIO, V316, P49, DOI 10.1016/bs.ircmb.2015.01.003; Endo Y, 2011, INT J BIOCHEM CELL B, V43, P705, DOI 10.1016/j.biocel.2011.02.003; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; Gesuete R, 2009, ANN NEUROL, V66, P332, DOI 10.1002/ana.21740; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Hansen S, 2000, J IMMUNOL, V164, P2610, DOI 10.4049/jimmunol.164.5.2610; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; Ip WKE, 2009, IMMUNOL REV, V230, P9, DOI 10.1111/j.1600-065X.2009.00789.x; KAWASAKI N, 1983, J BIOCHEM, V94, P937, DOI 10.1093/oxfordjournals.jbchem.a134437; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Lo EH, 2010, NAT MED, V16, P1205, DOI 10.1038/nm.2226; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Longhi L, 2014, CRIT CARE MED, V42, P1910, DOI 10.1097/CCM.0000000000000399; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Moriyama M, 2011, J NEUROSCI, V31, P3981, DOI 10.1523/JNEUROSCI.3617-10.2011; Mountney A, 2016, J NEUROTRAUM, V33, P567, DOI 10.1089/neu.2015.4130; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Orsini F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00380; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Storini C, 2005, NEUROBIOL DIS, V19, P10, DOI 10.1016/j.nbd.2004.11.001; Stravalaci M, 2016, J BIOMOL SCREEN, V21, P749, DOI 10.1177/1087057116637563; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Varga N, 2014, BIOMATERIALS, V35, P4175, DOI 10.1016/j.biomaterials.2014.01.014; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2010, DISCOV MED, V10, P434; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; Yongqing T, 2011, BIOCHIM BIOPHYS ACTA, V1824, P253; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; ZIPURSKY A, 1965, CAN J PHYSIOL PHARM, V43, P289, DOI 10.1139/y65-028	44	19	19	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2017	37	3					938	950		10.1177/0271678X16647397			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	EL5KQ	WOS:000394660400017	27165013	Green Published, Bronze			2021-06-18	
J	Fuller, GW; Kemp, SPT; Raftery, M				Fuller, G.; Kemp, S.; Raftery, M.			The accuracy and reproducibility of video assessment in the pitch-side management of concussion in elite rugby	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain concussion; Rugby; Video analysis; Reproducibility of results; Sensitivity and specificity	INTERRATER RELIABILITY; AGREEMENT; KAPPA	Objectives: To investigate the accuracy and reliability of side-line video review of head impact events to aid identification of concussion in elite sport. Design: Diagnostic accuracy and inter-rater agreement study. Methods: Immediate care, match day and team doctors involved in the 2015 Rugby Union World Cup viewed 20 video clips showing broadcaster's footage of head impact events occurring during elite Rugby matches. Subjects subsequently recorded whether any criteria warranting permanent removal from play or medical room head injury assessment were present. The accuracy of these ratings were compared to consensus expert opinion by calculating mean sensitivity and specificity across raters. The reproducibility of doctor's decisions was additionally assessed using raw agreement and Gwets AC1 chance corrected agreement coefficient. Results: Forty rugby medicine doctors were included in the study. Compared to the expert reference standard overall sensitivity and specificity of doctors decisions were 77.5% (95% Cl 73.1-81.5%) and 53.3% (95% CI 48.2-58.2%) respectively. Overall there was raw agreement of 67.8% (95% CI 57.9-77.7%) between doctors across all video clips. Chance corrected Gwets AC1 agreement coefficient was 0.39 (95% CI 0.17-0.62), indicating fair agreement. Conclusions: Rugby World Cup doctors' demonstrated moderate accuracy and fair reproducibility in head injury event decision making when assessing video clips of head impact events. The use of real-time video may improve the identification, decision making and management of concussion in elite sports. (C) 2016 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Fuller, G.] Univ Sheffield, Emergency Med Res Sheffield Grp, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England; [Kemp, S.] Rugby Football Union, Rugby House, Twickenham, England; [Raftery, M.] World Rugby, World Rugby House, Dublin, Ireland	Fuller, GW (corresponding author), Univ Sheffield, Emergency Med Res Sheffield Grp, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England.	g.fuller@sheffield.ac.uk		Kemp, Simon/0000-0002-3250-2713; Fuller, Gordon Ward/0000-0001-8532-3500	World Rugby; National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2015-04-005] Funding Source: researchfish	The authors would like to match day doctors, team doctors and intermediate care doctors participating in the 2015 Rugby World Cup for their assistance with the study. Funding was received by World Rugby.	Brolinson P Gunnar, 2014, Clin J Sport Med, V24, P89, DOI 10.1097/JSM.0000000000000062; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061865; Feiss JL, 2003, STAT METHODS RATES P; Fuller GW, 2015, BRIT J SPORT MED, V49, P529, DOI 10.1136/bjsports-2014-093498; Gardner AJ, 2016, INT J SPORTS MED, V37, P267, DOI 10.1055/s-0035-1565203; Gwet K, 2001, HDB INTERTATER RELIA; Gwet K, 2002, STAT METHODS INTERRA, V2, P1; Helmy A, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5748; Kottner J, 2011, J CLIN EPIDEMIOL, V64, P96, DOI 10.1016/j.jclinepi.2010.03.002; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Makdissi M, 2016, J SCI MED SPORT; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Moore IS, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115596194; NFL Head NaSC, 2015, NFL HEAD NECK SPIN C; Rugby W, 2016, MED PROTOCOLS MATCH; Rugby W, 2016, CONCUSSION MANAGEMEN; Rutjes A W S, 2007, Health Technol Assess, V11, pix; Wongpakaran N, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-61	18	19	19	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAR	2017	20	3					246	249		10.1016/j.jsams.2016.07.008			4	Sport Sciences	Sport Sciences	EQ8IF	WOS:000398327400007	27544658	Green Accepted			2021-06-18	
J	Janickova, H; Rosborough, K; Al-Onaizi, M; Kljakic, O; Guzman, MS; Gros, R; Prado, MAM; Prado, VF				Janickova, Helena; Rosborough, Kaie; Al-Onaizi, Mohammed; Kljakic, Ornela; Guzman, Monica S.; Gros, Robert; Prado, Marco A. M.; Prado, Vania F.			Deletion of the vesicular acetylcholine transporter from pedunculopontine/laterodorsal tegmental neurons modifies gait	JOURNAL OF NEUROCHEMISTRY			English	Article						acetylcholine; balance; gait; motor disease; Parkinson's disease; pedunculopontine	PROGRESSIVE SUPRANUCLEAR PALSY; M5 MUSCARINIC RECEPTORS; TRAUMATIC BRAIN-INJURY; SPINAL-CORD CONTUSION; PARKINSONS-DISEASE; CHOLINERGIC NEURONS; NUCLEUS-ACCUMBENS; MESOPONTINE TEGMENTUM; EXCITOTOXIC LESIONS; SUBTHALAMIC NUCLEUS	Postural instability and gait disturbances, common disabilities in the elderly and frequently present in Parkinson's disease (PD), have been suggested to be related to dysfunctional cholinergic signaling in the brainstem. We investigated how long-term loss of cholinergic signaling from mesopontine nuclei influence motor behaviors. We selectively eliminated the vesicular acetylcholine transporter (VAChT) in pedunculopontine and laterodorsal tegmental nuclei cholinergic neurons to generate mice with selective mesopontine cholinergic deficiency (VAChT(En1-Cre-flox/flox)). VAChT(En1-Cre-flox/flox) mice did not show any gross health or neuromuscular abnormality on metabolic cages, wire-hang and grip-force tests. Young VAChT(En1-Cre-flox/flox) mice (2-5months-old) presented motor learning/coordination deficits on the rotarod; moved slower, and had smaller steps on the catwalk, but showed no difference in locomotor activity on the open field. Old VAChT(En1-Creflox/flox) mice (13-16months-old) showed more pronounced motor learning/balance deficits on the rotarod, and more pronounced balance deficits on the catwalk. Furthermore, old mutants moved faster than controls, but with similar step length. Additionally, old VAChT-deficient mice were hyperactive. These results suggest that dysfunction of cholinergic neurons from mesopontine nuclei, which is commonly seen in PD, has causal roles in motor functions. Prevention of mesopontine cholinergic failure may help to prevent/improve postural instability and falls in PD patients.	[Janickova, Helena; Rosborough, Kaie; Al-Onaizi, Mohammed; Kljakic, Ornela; Guzman, Monica S.; Gros, Robert; Prado, Marco A. M.; Prado, Vania F.] Univ Western Ontario, Schulich Sch Med & Dent, Robarts Res Inst, London, ON N6A 5B7, Canada; [Rosborough, Kaie; Al-Onaizi, Mohammed; Kljakic, Ornela; Guzman, Monica S.; Prado, Marco A. M.; Prado, Vania F.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Anat & Cell Biol, London, ON, Canada; [Gros, Robert; Prado, Marco A. M.; Prado, Vania F.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON, Canada	Prado, MAM; Prado, VF (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Robarts Res Inst, London, ON N6A 5B7, Canada.	mprado@robarts.ca; vprado@robarts.ca	Gros, Robert/A-3010-2009; Prado, Vania Ferreira/K-7630-2013; Gros, Robert/AAV-2237-2020; Prado, Marco Antonio Maximo/K-7638-2013; Janickova, Helena/Q-7211-2017	Gros, Robert/0000-0002-3667-8011; Prado, Vania Ferreira/0000-0003-4994-6393; Gros, Robert/0000-0002-3667-8011; Prado, Marco Antonio Maximo/0000-0002-3028-5778; Janickova, Helena/0000-0003-0310-7893	Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP 126000, MOP 89919]; NSERCNatural Sciences and Engineering Research Council of Canada (NSERC) [402524-2013]; Brain Canada; Canadian Foundation for InnovationCanada Foundation for Innovation; Ontario research fund; Kuwait University; Heart and Stroke FoundationHeart & Stroke Foundation of Canada	The authors declare no competing financial interests. We thank Sanda Raulic, Jue Fan, and Matthew Cowan for animal care and technical support. Work supported by Canadian Institute of Health Research (MOP 126000 and MOP 89919), NSERC (402524-2013), Brain Canada, Canadian Foundation for Innovation, and Ontario research fund (M.A.M.P. and V.F.P.). M.A.A-O and M.S.G received support from Kuwait University and The Heart and Stroke Foundation respectively. The authors have no conflict of interest to declare.	Al-Onaizi M. A., 2016, CEREB CORTEX; Alderson HL, 2003, NEUROSCIENCE, V118, P311, DOI 10.1016/S0306-4522(03)00152-0; Baiguera C, 2012, BRAIN, V135, P2750, DOI 10.1093/brain/aws193; Balkaya M, 2013, J CEREBR BLOOD F MET, V33, P330, DOI 10.1038/jcbfm.2012.185; Bohnen NI, 2013, MOVEMENT DISORD, V28, P1492, DOI 10.1002/mds.25534; Bohnen NI, 2012, J CEREBR BLOOD F MET, V32, P1609, DOI 10.1038/jcbfm.2012.60; Bohnen NI, 2009, NEUROLOGY, V73, P256, DOI 10.1212/WNL.0b013e3181b0bd3d; Bolivar VJ, 2009, NEUROBIOL LEARN MEM, V92, P206, DOI 10.1016/j.nlm.2009.02.002; Brooks SP, 2009, NAT REV NEUROSCI, V10, P519, DOI 10.1038/nrn2652; Chung KA, 2010, NEUROLOGY, V75, P1263, DOI 10.1212/WNL.0b013e3181f6128c; Clarke NP, 1997, NEUROSCIENCE, V81, P371, DOI 10.1016/S0306-4522(97)00247-9; Clements J R, 1991, Adv Exp Med Biol, V295, P127; Cross DJ, 2015, BRAIN RES, V1618, P299, DOI 10.1016/j.brainres.2015.06.006; Cyr M, 2015, BEHAV BRAIN RES, V278, P107, DOI 10.1016/j.bbr.2014.09.021; de Castro BM, 2009, GENES BRAIN BEHAV, V8, P23, DOI 10.1111/j.1601-183X.2008.00439.x; de Castro BM, 2009, MOL CELL BIOL, V29, P5238, DOI 10.1128/MCB.00245-09; Fernandez Hubert H, 2012, Cleve Clin J Med, V79 Suppl 2, pS14, DOI 10.3949/ccjm.79.s2a.03; Forster GL, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0001.2002; Gangarossa G, 2016, NEUROBIOL DIS, V87, P69, DOI 10.1016/j.nbd.2015.12.010; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; Grabli D, 2013, J NEUROSCI, V33, P11986, DOI 10.1523/JNEUROSCI.1568-13.2013; Gray SL, 2015, JAMA INTERN MED, V175, P401, DOI 10.1001/jamainternmed.2014.7663; Guzman MS, 2013, J NEUROCHEM, V124, P658, DOI 10.1111/jnc.12128; Guzman MS, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001194; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; Hernandez-Chan NG, 2011, BEHAV BRAIN RES, V225, P482, DOI 10.1016/j.bbr.2011.08.007; HIRSCH EC, 1987, P NATL ACAD SCI USA, V84, P5976, DOI 10.1073/pnas.84.16.5976; Honey CR, 2016, CAN J NEUROL SCI, V2016, P1; INGLIS WL, 1994, NEUROSCIENCE, V62, P51, DOI 10.1016/0306-4522(94)90314-X; Jaarsma D, 1997, PROG BRAIN RES, V114, P67; JELLINGER K, 1988, J NEUROL NEUROSUR PS, V51, P540, DOI 10.1136/jnnp.51.4.540; Jia HG, 2003, BRAIN RES, V992, P205, DOI 10.1016/j.brainres.2003.08.062; Karachi C, 2010, J CLIN INVEST, V120, P2745, DOI 10.1172/JCI42642; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kimmel RA, 2000, GENE DEV, V14, P1377; Kloos AD, 2005, EXP NEUROL, V191, P251, DOI 10.1016/j.expneurol.2004.09.016; KNUTSSON E, 1972, BRAIN, V95, P475, DOI 10.1093/brain/95.3.475; Kojima J, 1997, NEUROSCI LETT, V226, P111, DOI 10.1016/S0304-3940(97)00254-1; Kolisnyk B, 2016, CEREB CORTEX; Kolisnyk B, 2013, J NEUROSCI, V33, P14908, DOI 10.1523/JNEUROSCI.1933-13.2013; Koopmans GC, 2005, J NEUROTRAUM, V22, P214, DOI 10.1089/neu.2005.22.214; Krout KE, 2002, J COMP NEUROL, V448, P53, DOI 10.1002/cne.10236; Kucinski A, 2015, BEHAV BRAIN RES, V282, P155, DOI 10.1016/j.bbr.2015.01.012; Lambert CS, 2015, BEHAV BRAIN RES, V291, P342, DOI 10.1016/j.bbr.2015.05.056; LAVOIE B, 1994, J COMP NEUROL, V344, P190, DOI 10.1002/cne.903440203; Lima RD, 2010, J NEUROCHEM, V113, P943, DOI 10.1111/j.1471-4159.2010.06657.x; Liu Y, 2013, BEHAV BRAIN RES, V257, P166, DOI 10.1016/j.bbr.2013.10.007; MacLaren DAA, 2014, EUR J NEUROSCI, V40, P3224, DOI 10.1111/ejn.12666; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Martins-Silva C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017611; Martyn AC, 2012, P NATL ACAD SCI USA, V109, P17651, DOI 10.1073/pnas.1215381109; Maskos U, 2008, BRIT J PHARMACOL, V153, pS438, DOI 10.1038/bjp.2008.5; MESULAM MM, 1983, J COMP NEUROL, V214, P170, DOI 10.1002/cne.902140206; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; Munro-Davies LE, 1999, EXP BRAIN RES, V129, P511, DOI 10.1007/s002210050921; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Oakman SA, 1999, NEUROSCIENCE, V94, P529, DOI 10.1016/S0306-4522(99)00307-3; Pahapill PA, 2000, BRAIN, V123, P1767, DOI 10.1093/brain/123.9.1767; Patel JC, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2144; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Perlman, 2000, Curr Treat Options Neurol, V2, P215, DOI 10.1007/s11940-000-0004-3; Pienaar IS, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0044-5; Plaha P, 2005, NEUROREPORT, V16, P1883, DOI 10.1097/01.wnr.0000187637.20771.a0; Prado VF, 2013, BIOCHEM J, V450, P265, DOI 10.1042/BJ20121662; Prado VF, 2006, NEURON, V51, P601, DOI 10.1016/j.neuron.2006.08.005; Prado VF, 2002, CELL MOL NEUROBIOL, V22, P565, DOI 10.1023/A:1021884319363; Sakae DY, 2015, MOL PSYCHIATR, V20, P1448, DOI 10.1038/mp.2015.104; Shoji H, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0191-9; SKINNER RD, 1984, BRAIN RES, V323, P385, DOI 10.1016/0006-8993(84)90319-6; Stefani A, 2007, BRAIN, V130, P1596, DOI 10.1093/brain/awl346; Steidl S, 2015, BEHAV BRAIN RES, V287, P82, DOI 10.1016/j.bbr.2015.02.049; Steidl S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084412; Steiniger B, 2004, BEHAV BRAIN RES, V151, P17, DOI 10.1016/j.bbr.2003.08.001; SWERDLOW NR, 1987, BRAIN RES, V412, P233, DOI 10.1016/0006-8993(87)91129-2; Thomsen M, 2011, EXP CLIN PSYCHOPHARM, V19, P321, DOI 10.1037/a0024798; Visser Jasper E., 2005, Neural Plasticity, V12, P161, DOI 10.1155/NP.2005.161; Vlamings R, 2007, NEUROSCIENCE, V148, P815, DOI 10.1016/j.neuroscience.2007.06.043; Wang HL, 2009, EUR J NEUROSCI, V29, P340, DOI 10.1111/j.1460-9568.2008.06576.x; Wang XH, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-142; Wang YG, 2008, J CEREBR BLOOD F MET, V28, P1936, DOI 10.1038/jcbfm.2008.82; Wecker L, 2013, NEUROPHARMACOLOGY, V73, P75, DOI 10.1016/j.neuropharm.2013.05.016; Wenning GK, 1999, MOVEMENT DISORD, V14, P947, DOI 10.1002/1531-8257(199911)14:6<947::AID-MDS1006>3.0.CO;2-O; Westin JE, 2012, BEHAV BRAIN RES, V226, P519, DOI 10.1016/j.bbr.2011.10.006; Whitley E, 2002, CRIT CARE, V6, P335; Wilcox RA, 2011, J NEUROL NEUROSUR PS, V82, P1256, DOI 10.1136/jnnp.2010.213462; Winn P, 2006, J NEUROL SCI, V248, P234, DOI 10.1016/j.jns.2006.05.036; WOOLF NJ, 1990, BRAIN RES, V520, P55, DOI 10.1016/0006-8993(90)91691-9; Yeomans J, 2001, LIFE SCI, V68, P2449, DOI 10.1016/S0024-3205(01)01038-4; Zervas M, 2004, NEURON, V43, P345, DOI 10.1016/j.neuron.2004.07.010; Zesiewicz TA, 2012, NEUROLOGY, V78, P545, DOI 10.1212/WNL.0b013e318247cc7a; ZWEIG RM, 1989, ANN NEUROL, V26, P41, DOI 10.1002/ana.410260106	91	19	19	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAR	2017	140	5					787	798		10.1111/jnc.13910			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EM8OX	WOS:000395571900010	27889925	Bronze			2021-06-18	
J	Lai, NS; Zhang, JQ; Qin, FY; Sheng, B; Fang, XG; Li, ZB				Lai, Nian-sheng; Zhang, Jia-qi; Qin, Fei-yun; Sheng, Bin; Fang, Xing-gen; Li, Zhen-bao			Serum microRNAs are non-invasive biomarkers for the presence and progression of subarachnoid haemorrhage	BIOSCIENCE REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; CELL CARCINOMA; CANCER; PROLIFERATION; INVASION; EXPRESSION; PATHWAY; ASSOCIATION; HIPPOCAMPUS; INHIBITION	miRNAs are important regulators of translation and have been associated with the pathogenesis of a number of cardiovascular diseases including stroke and may be possible prognostic biomarkers. The purpose of the present study was to determine the expression levels of miRNAs in the sera of subarachnoid haemorrhage (SAH) patients and to evaluate their relationships with the severity and clinical outcome of SAH. Serum samples on day 3 after the onset of SAH were subjected to microarray analysis with Exqion miRCURY (TM) LNA array and quantitative PCR analysis. Serum samples from SAH patients (n=60) and healthy controls (n=10) were subjected to quantitative PCR analysis. The severities and clinical outcomes of the SAH patients were evaluated with the WFNS grade and the Modified Rankin Scale (mRS). Three miRNAs, miR-502-5p, miR-1297 and miR-4320 were significantly up-regulated in the sera of SAH patients when compared with the healthy controls. The serum miR-502-5p and miR-1297 levels were significantly higher in the patients with severe SAH and a poor outcome than in those with mild SAH and a good outcome (P<0.05). The areas under the receiver operating characteristic (ROC) curves (AUCs) of miR-502-5p, miR-1297 and miR-4320 to distinguish the SAH patients from the healthy controls were 0.958 (P<0.001), 0.950(P<0.001) and 0.843 (P<0.001) respectively. Taken together, these results indicate that miR-502-5p and miR-1297 are potentially valuable indicators of the diagnosis, severity and prognosis of SAH, and miR-4320 was a potentially valuable indicator of the diagnosis of SAH.	[Lai, Nian-sheng; Qin, Fei-yun; Sheng, Bin; Fang, Xing-gen; Li, Zhen-bao] Wannan Med Coll, Affiliated Hosp 1, Dept Neurosurg, Wuhu City 241001, Anhui, Peoples R China; [Zhang, Jia-qi] Xinxiang Cent Hosp, Dept Neurosurg, Xinxiang City 453000, Henan, Peoples R China	Li, ZB (corresponding author), Wannan Med Coll, Affiliated Hosp 1, Dept Neurosurg, Wuhu City 241001, Anhui, Peoples R China.	zhenbaoli123@126.com			Young and Middle-Aged Natural Science Foundation of Wannan Medical College [WK2015F25]; Natural Science Foundation of AnhuiNatural Science Foundation of Anhui Province [1708085QH181]	This work was supported by the Young and Middle-Aged Natural Science Foundation of Wannan Medical College [grant number WK2015F25] and the Natural Science Foundation of Anhui [grant number 1708085QH181].	Ayer RE, 2008, ACTA NEUROCHIR SUPPL, V104, P33; Badjatia N, 2015, NEUROLOGY, V84, P680, DOI 10.1212/WNL.0000000000001259; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Chen LJ, 2015, CIRC RES, V116, P1157, DOI 10.1161/CIRCRESAHA.116.305987; Chen P, 2014, ASIAN PAC J CANCER P, V15, P9185, DOI 10.7314/APJCP.2014.15.21.9185; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Dahan D, 2014, AM J PHYSIOL-CELL PH, V307, pC1093, DOI 10.1152/ajpcell.00250.2014; Daniere F, 2015, DIAGN INTERV IMAG, V96, P677, DOI 10.1016/j.diii.2015.05.006; Helbok R, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0809-9; Ju HQ, 2016, THERANOSTICS, V6, P1160, DOI 10.7150/thno.14848; Lai NS, 2015, BRIT J CANCER, V112, P1241, DOI 10.1038/bjc.2015.91; Lai PMR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151853; Lei Q, 2015, NEURORADIOLOGY, V57, P63, DOI 10.1007/s00234-014-1435-y; Li YF, 2016, MOL MED REP, V13, P1895, DOI 10.3892/mmr.2015.4692; Liang X, 2016, BIOCHEM BIOPH RES CO, V480, P208, DOI 10.1016/j.bbrc.2016.10.029; Liu Y, 2015, INT J MOL MED, V36, P1345, DOI 10.3892/ijmm.2015.2341; Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9; Muller AH, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1341-7; Pluta RM, 2009, NEUROL RES, V31, P151, DOI 10.1179/174313209X393564; Powers CJ, 2016, PHYSIOL GENOMICS, V48, P361, DOI 10.1152/physiolgenomics.00052.2015; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Selvamani A, 2014, CLIN SCI, V127, P77, DOI 10.1042/CS20130565; Shao AW, 2014, CNS NEUROSCI THER, V20, P182, DOI 10.1111/cns.12194; Strickland ER, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00117; Stylli S. S., 2016, J NEUROSURG, V29, P1; Su XW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144724; Sun LL, 2014, ONCOL REP, V31, P2085, DOI 10.3892/or.2014.3105; Sun M, 2016, CANCER RES, V76, P6299, DOI 10.1158/0008-5472.CAN-16-0356; Triglia T, 2016, EUR J ANAESTH, V33, P662, DOI 10.1097/EJA.0000000000000494; Vijayan M, 2016, BBA-MOL BASIS DIS, V1862, P1984, DOI 10.1016/j.bbadis.2016.08.003; Vivancos J, 2014, NEUROLOGIA, V29, P353, DOI 10.1016/j.nrl.2012.07.009; Wang CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32921; Wang J., 2016, SHOCK VIB, V2016, P1, DOI DOI 10.1155/2016/9371563; Wang WX, 2015, EXP NEUROL, V265, P84, DOI 10.1016/j.expneurol.2014.12.018; Yang NQ, 2016, AM J TRANSL RES, V8, P1091; Yang SD, 2014, ASIAN PAC J CANCER P, V15, P6505, DOI 10.7314/APJCP.2014.15.16.6505; Zhang GL, 2016, CELL IMMUNOL, V302, P50, DOI 10.1016/j.cellimm.2016.01.007; Zhao YH, 2015, INT J MOL SCI, V16, P30105, DOI 10.3390/ijms161226223	38	19	19	0	3	PORTLAND PRESS LTD	LONDON	CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND	0144-8463	1573-4935		BIOSCIENCE REP	Biosci. Rep.	FEB 28	2017	37		1						BSR20160480	10.1042/BSR20160480			10	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	EM1SA	WOS:000395096100019	28115593	DOAJ Gold, Green Published			2021-06-18	
J	Gao, HB; Han, ZL; Bai, RJ; Huang, S; Ge, XT; Chen, FL; Lei, P				Gao, Huabin; Han, Zhaoli; Bai, Ruojing; Huang, Shan; Ge, Xintong; Chen, Fanglian; Lei, Ping			The accumulation of brain injury leads to severe neuropathological and neurobehavioral changes after repetitive mild traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Neurodegeneration; Neuroinflammation; Neurobehavioral	CONTROLLED CORTICAL IMPACT; CLINICAL MANAGEMENT; HEAD-INJURY; ENCEPHALOPATHY; DEFICITS; RATS; VULNERABILITY; CONCUSSION; MICROGLIA; SINGLE	Traumatic brain injury (TBI) is a major public health problem with long-term neurobehavioral sequela. The evidences have revealed that TBI is a risk factor for later development of neurodegenerative disease and both the single and repetitive brain injury can lead to the neurodegeneration. But whether the effects of accumulation play an important role in the neurodegenerative disease is still unknown. We utilized the Sprague Dawley (SD) rats to develop the animal models of repetitive mild TBI and single mild TBI in order to detect the neurobehavioral changes. The results of neurobehavioral test revealed that the repetitive mild TBI led to more severe behavioral injuries than the single TBI. There were more activated microglia cells and astrocytes in the repetitive mild TBI group than the single TBI group. In consistent with this, the levels of TNF-alpha and IL-6 were higher and the expression of IL-10 was lower in the repetitive mild TBI group compared with the single TBI group. The expression of amyloid precursor protein (APP) increased in the repetitive TBI group detected by ELISA and western blot. But the levels of total tau (Tau-5) and P-tau (ser202) seem no different between the two groups in most time point. In conclusion, repetitive mild TBI could lead to more severe neurobehavioral impairments and the effects of accumulation may be associated with the increased inflammation in the brain. (C) 2016 Elsevier B.V. All rights reserved.	[Gao, Huabin; Huang, Shan; Ge, Xintong; Chen, Fanglian; Lei, Ping] Tianjin Med Univ, Tianjin Neurol Inst, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China; [Han, Zhaoli; Bai, Ruojing; Lei, Ping] Tianjin Med Univ, Gen Hosp, Tianjin Inst Geriatr, Tianjin 300052, Peoples R China	Lei, P (corresponding author), Tianjin Med Univ, Gen Hosp, Tianjin Geriatr Inst, Dept Geriatr, Anshan Rd 154, Tianjin 300052, Peoples R China.	leiping1974@163.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471252, 81501055]; Tianjin Municipal Science and Technology Commission [13JCYBJC23700]	This work was supported by grants from the National Natural Science Foundation of China (grant nos. 81471252 and 81501055), Tianjin Municipal Science and Technology Commission natural fund Project (13JCYBJC23700).	Abisambra JF, 2014, J ALZHEIMERS DIS, V40, P495, DOI 10.3233/JAD-131019; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen X, 2010, NEUROL RES, V32, P1097, DOI 10.1179/016164110X12681290831162; Darwish H, 2012, BRAIN INJURY, V26, P1763, DOI [10.3109/02699052.2012.741452, 10.3109/02699052.2011.635362]; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Plummer S, 2016, AGING DIS, V7, P163, DOI 10.14336/AD.2015.0907; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Semple BD, 2015, NEUROBIOL DIS, V74, P263, DOI 10.1016/j.nbd.2014.12.003; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Washington P. M., 2015, EXP NEUROL; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Zhao YD, 2001, WORLD J SURG, V25, P1202; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	37	19	19	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 15	2017	1657						1	8		10.1016/j.brainres.2016.11.028			8	Neurosciences	Neurosciences & Neurology	EL9DI	WOS:000394919200001	27923640				2021-06-18	
J	Mossberg, KA; Durham, WJ; Zgaljardic, DJ; Gilkison, CR; Danesi, CP; Sheffield-Moore, M; Masel, BE; Urban, RJ				Mossberg, Kurt A.; Durham, William J.; Zgaljardic, Dennis J.; Gilkison, Charles R.; Danesi, Christopher P.; Sheffield-Moore, Melinda; Masel, Brent E.; Urban, Randall J.			Functional Changes after Recombinant Human Growth Hormone Replacement in Patients with Chronic Traumatic Brain Injury and Abnormal Growth Hormone Secretion	JOURNAL OF NEUROTRAUMA			English	Article						cognitive; growth hormone; physical; TBI	GH-DEFICIENT ADULTS; QUALITY-OF-LIFE; MULTIPLE-SCLEROSIS; AEROBIC CAPACITY; MUSCLE STRENGTH; FATIGUE; EXERCISE; THERAPY; HYPOPITUITARISM; PERFORMANCE	We explored the effects of recombinant human growth hormone (rhGH) replacement on physical and cognitive functioning in subjects with a moderate-to-severe traumatic brain injury (TBI) with abnormal growth hormone (GH) secretion. Fifteen individuals who sustained a TBI at least 12 months prior to study enrollment were identified as having abnormal GH secretion by glucagon stimulation testing (maximum GH response less than 8 ng/mL). Peak cardiorespiratory capacity, body composition, and muscle force testing were assessed at baseline and one year after rhGH replacement. Additionally, standardized neuropsychological tests that assess memory, processing speed, and cognitive flexibility, as well as self-report inventories related to depression and fatigue, were administered at baseline and 1 year after rhGH replacement. Comparison tests were performed with proper post hoc analyses. All analyses were carried out at alpha < 0.05. Peak O-2 consumption, peak oxygen pulse (estimate of cardiac stroke volume), and peak ventilation all significantly increased (p < 0.05). Maximal isometric and isokinetic force production were not altered. Skeletal muscle fatigue did not change but the perceptual rating of fatigue was reduced by similar to 25% (p = 0.06). Cognitive performance did not change significantly over time, whereas self-reported symptoms related to depression and fatigue significantly improved. The observed changes suggest that rhGH replacement has a positive impact on cardiorespiratory fitness and a positive impact on perceptual fatigue in survivors of TBI with altered GH secretion.	[Mossberg, Kurt A.; Durham, William J.; Zgaljardic, Dennis J.; Gilkison, Charles R.; Danesi, Christopher P.; Sheffield-Moore, Melinda; Masel, Brent E.; Urban, Randall J.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Zgaljardic, Dennis J.; Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA	Mossberg, KA (corresponding author), Univ Texas Med Branch, Dept Phys Therapy, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossber@utmb.edu	Sheffield-Moore, Melinda/A-9794-2016	Sheffield-Moore, Melinda/0000-0001-6579-4655	Moody Endowment; Pfizer, Inc.Pfizer; Institute for Translational Sciences at the University of Texas Medical Branch; Clinical and Translational Science Award from National Center for Advancing Translational Sciences, National Institutes of Health [UL1TR001439]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001439] Funding Source: NIH RePORTER	This work was partially funded by the generous support of the Moody Endowment and Pfizer, Inc. Recombinant growth hormone was supplied by Pfizer, Inc. This study was conducted with the support of the Institute for Translational Sciences at the University of Texas Medical Branch, supported in part by a Clinical and Translational Science Award (UL1TR001439) from the National Center for Advancing Translational Sciences, National Institutes of Health.	Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Astrand PO., 2003, TXB WORK PHYSL PHYSL, V4; BALKE B, 1959, U S Armed Forces Med J, V10, P675; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Benedict RHB, 2001, J NEUROPSYCH CLIN N, V13, P70, DOI 10.1176/appi.neuropsych.13.1.70; Bhagia V, 2010, BRAIN INJURY, V24, P560, DOI 10.3109/02699051003601705; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Conceicao FL, 2003, J ENDOCRINOL INVEST, V26, P1065, DOI 10.1007/BF03345251; Cuocolo A, 1996, EUR J NUCL MED, V23, P390, DOI 10.1007/BF01247366; Delis DC, 2000, CALIFORNIA VERBAL LE; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Gotherstrom G, 2005, CLIN ENDOCRINOL, V62, P105, DOI 10.1111/j.1365-2265.2004.02181.x; Gullestad L, 1998, GROWTH HORM IGF RES, V8, P377, DOI 10.1016/S1096-6374(98)80307-9; Hampson DB, 2001, SPORTS MED, V31, P935, DOI 10.2165/00007256-200131130-00004; Hartman ML, 2008, J CLIN ENDOCR METAB, V93, P125, DOI 10.1210/jc.2007-1430; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; Janssen YJH, 1999, J CLIN ENDOCR METAB, V84, P279, DOI 10.1210/jc.84.1.279; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Johannsson G, 1997, J CLIN ENDOCR METAB, V82, P2877, DOI 10.1210/jc.82.9.2877; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lafortuna CL, 2014, J CLIN ENDOCR METAB, V99, P1816, DOI 10.1210/jc.2013-3607; Li GL, 2008, J CLIN ENDOCR METAB, V93, P1379, DOI 10.1210/jc.2007-2021; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2008, J CLIN ENDOCR METAB, V93, P2581, DOI 10.1210/jc.2008-0368; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; NASS R, 1995, J CLIN ENDOCR METAB, V80, P552, DOI 10.1210/jc.80.2.552; Nyberg F, 2013, NAT REV ENDOCRINOL, V9, P357, DOI 10.1038/nrendo.2013.78; Nystrom Henrik C, 2005, BMC Physiol, V5, P17, DOI 10.1186/1472-6793-5-17; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Popovic V, 2005, GROWTH HORM IGF RES, V15, P177, DOI 10.1016/j.ghir.2005.02.003; Robergs R. A., 2004, AM J PHYSIOL-REG I, V56, pR502; RUTHERFORD OM, 1995, CLIN SCI, V88, P67, DOI 10.1042/cs0880067; Schnieders J, 2012, J HEAD TRAUMA REHAB, V27, P404, DOI 10.1097/HTR.0b013e3182306341; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; Short KR, 2008, J CLIN ENDOCR METAB, V93, P597, DOI 10.1210/jc.2007-1814; Thompson WR., 2010, ACSMS GUIDELINES EXE; Wechsler D., 1997, WECHSLER ADULT INTEL; WHITEHEAD HM, 1992, CLIN ENDOCRINOL, V36, P45, DOI 10.1111/j.1365-2265.1992.tb02901.x; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; WILSON J T L, 1990, Brain Injury, V4, P349; Woodhouse LJ, 2006, ENDOCR REV, V27, P287, DOI 10.1210/er.2004-0022; Woodhouse LJ, 1999, J CLIN ENDOCR METAB, V84, P4570, DOI 10.1210/jc.84.12.4570; Zgaljardic DJ, 2014, BRAIN INJURY, V28, P389, DOI 10.3109/02699052.2014.884242	55	19	19	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					845	852		10.1089/neu.2016.4552			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200011	27627580	Green Published			2021-06-18	
J	Janak, JC; Orman, JA; Soderdahl, DW; Hudak, SJ				Janak, Judson C.; Orman, Jean A.; Soderdahl, Douglas W.; Hudak, Steven J.			Epidemiology of Genitourinary Injuries among Male US Service Members Deployed to Iraq and Afghanistan: Early Findings from the Trauma Outcomes and Urogenital Health (TOUGH) Project	JOURNAL OF UROLOGY			English	Article						urogenital system; wounds and injuries; blast injuries; penis; organ transplantation	SEXUAL DYSFUNCTION; COMBAT; AMPUTATION; MANAGEMENT; IMPACT	Purpose: In this study we report the number, nature and severity of genitourinary injuries among male U.S. service members deployed to Operations Iraqi Freedom and Enduring Freedom. Materials and Methods: This retrospective cross-sectional study of the Department of Defense Trauma Registry used ICD-9-CM codes to identify service members with genitourinary injuries, and used Abbreviated Injury Scale codes to determine injury severity, genitourinary organs injured and comorbid injuries. Results: From October 2001 to August 2013, 1,367 male U.S. service members sustained 1 or more genitourinary injuries. The majority of injuries involved the external genitalia (1,000, 73.2%), including the scrotum (760, 55.6%), testes (451, 33.0%), penis (423, 31%) and/or urethra (125, 9.1%). Overall more than a third of service members with genitourinary injury sustained at least 1 severe genitourinary injury (502, 36.7%). Loss of 1 or both testes was documented in 146 men, including 129 (9.4%) unilateral orchiectomies and 17 (1.2%) bilateral orchiectomies. Common comorbid injuries included traumatic brain injury (549, 40.2%), pelvic fracture (341, 25.0%), colorectal injury (297, 21.7%) and lower extremity amputations (387, 28.7%). Conclusions: An unprecedented number of U.S. service members sustained genitourinary injury while deployed to Operation Iraqi Freedom/Operation Enduring Freedom. Further study is needed to describe the long-term impact of genitourinary injury and determine the potential need for novel treatments to improve sexual, urinary and/or reproductive function among service members with severe genital injury.	[Janak, Judson C.; Orman, Jean A.] JBSA, US Army Inst Surg Res, Ft Sam Houston, TX USA; [Soderdahl, Douglas W.; Hudak, Steven J.] JBSA, San Antonio Mil Med Ctr, Ft Sam Houston, TX USA	Hudak, SJ (corresponding author), JBSA, San Antonio Mil Med Ctr, Dept Surg, Urol Clin, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	Steven.J.Hudak2.mil@mail.mil					Banti M, 2016, J TRAUMA ACUTE CARE, V80, P131, DOI 10.1097/TA.0000000000000864; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Cosgrove DJ, 2002, UROLOGY, V60, P881, DOI 10.1016/S0090-4295(02)01899-X; Davendra M Sharma, 2013, J R Army Med Corps, V159 Suppl 1, pi1; Doukas WC, 2013, J BONE JOINT SURG AM, V95A, P138, DOI 10.2106/JBJS.K.00734; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Feltman R, 2014, WASHINGTON POST; Ficke JR, 2012, J TRAUMA ACUTE CARE, V73, pS520, DOI 10.1097/TA.0b013e31827559da; Fleming Mark, 2012, J Surg Orthop Adv, V21, P32; Frappell-Cooke W, 2013, J ROY ARMY MED CORPS, V159, P52, DOI 10.1136/jramc-2013-000028; Grady D, 2015, NY TIMES; Han JS, 2013, J MENS HEALTH, V10, P124, DOI 10.1089/jomh.2013.1504; Harvey-Kelly KF, 2011, J UROLOGY, V185, P2027, DOI 10.1016/j.juro.2011.01.076; Holcomb JB, 2006, J TRAUMA, V60, P397, DOI 10.1097/01.ta.0000203581.75241.f1; Hudak SJ, 2005, UROLOGY, V65, P1041, DOI 10.1016/j.urology.2004.11.031; Kime P, 2016, MILITARY TIMES  0131; Kime P, 2016, ARMY TIMES; Melcer T, 2010, MIL MED, V175, P147, DOI 10.7205/MILMED-D-09-00120; Nicol MN, 2016, DAILY MAIL; Paquette EL, 2007, J UROLOGY, V177, P2196, DOI 10.1016/j.juro.2007.01.132; Penn-Barwell JG, 2014, INJURY, V45, P1105, DOI 10.1016/j.injury.2014.01.025; Rees PM, 2007, LANCET, V369, P512, DOI 10.1016/S0140-6736(07)60238-4; Schmidt Michael S., 2016, NY TIMES; Serkin FB, 2010, J TRAUMA, V69, pS175, DOI 10.1097/TA.0b013e3181e45cd1; Sharma DM, 2013, J ROY ARMY MED CORPS, V159, P57, DOI 10.1136/jramc-2013-000029; Sharma DM, 2013, J ROY ARMY MED CORPS, V159, P18, DOI 10.1136/jramc-2013-000023; Sorensen MD, 2008, J TRAUMA, V65, P1045, DOI 10.1097/TA.0b013e3181896192; Wilcox Sherrie L, 2015, GENITOURINARY TRAUMA; Williamson GM, 1996, J SEX RES, V33, P221, DOI 10.1080/00224499609551838	29	19	19	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5347	1527-3792		J UROLOGY	J. Urol.	FEB	2017	197	2					414	419		10.1016/j.juro.2016.08.005			6	Urology & Nephrology	Urology & Nephrology	EH8YT	WOS:000392059300059	27506692				2021-06-18	
J	Sheridan, DC; Newgard, CD; Selden, NR; Jafri, MA; Hansen, ML				Sheridan, David C.; Newgard, Craig D.; Selden, Nathan R.; Jafri, Mubeen A.; Hansen, Matthew L.			QuickBrain MRI for the detection of acute pediatric traumatic brain injury	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						trauma; imaging; child	COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; CHILDREN; HEMORRHAGE; CANCER; CT	OBJECTIVE The current gold-standard imaging modality for pediatric traumatic brain injury (TB1) is CT, but it confers risks associated with ionizing radiation. QuickBrain MRI (qbMRI) is a rapid brain MRI protocol that has been studied in the setting of hydrocephalus, but its ability to detect traumatic injuries is unknown. METHODS The authors performed a retrospective cohort study of pediatric patients with TBI who were undergoing evaluation at a single Level I trauma center between February 2010 and December 2013. Patients who underwent CT imaging of the head and qbMRI during their acute hospitalization were included. Images were reviewed independently by 2 neuroradiology fellows blinded to patient identifiers. Image review consisted of identifying traumatic mass lesions and their intracranial compartment and the presence or absence of midline shift. CT imaging was used as the reference against which qbMRI was measured. RESULTS A total of 54 patients met the inclusion criteria; the median patient age was 3.24 years, 65% were male, and 74% were noted to have a Glasgow Coma Scale score of 14 or greater. The sensitivity and specificity of qbMRI to detect any lesion were 85% (95% Cl 73%-93%) and 100% (95% Cl 61%-100%), respectively; the sensitivity increased to 100% (95% CI 89%-100%) for clinically important TB's as previously defined. The mean interval between CT and qbMRI was 27.5 hours, and approximately half of the images were obtained within 12 hours. CONCLUSIONS In this retrospective pilot study, qbMRI demonstrated reasonable sensitivity and specificity for detecting a lesion or injury seen with neuroimaging (radiographic TBI) and clinically important acute pediatric TBI.	[Sheridan, David C.; Newgard, Craig D.; Hansen, Matthew L.] Oregon Hlth & Sci Univ, Ctr Policy & Res Emergency Med, Dept Emergency Med, Portland, OR 97201 USA; [Selden, Nathan R.] Oregon Hlth & Sci Univ, Div Pediat Neurosurg, Dept Neurol Surg, Portland, OR 97201 USA; [Jafri, Mubeen A.] Oregon Hlth & Sci Univ, Div Pediat Surg, Dept Surg, Portland, OR 97201 USA	Sheridan, DC (corresponding author), Oregon Hlth & Sci Univ, Dept Emergency Med, 707 SW Gaines Rd,Mail Code CDRC W, Portland, OR 97239 USA.	sheridda@ohsu.edu					Berdahl CT, 2013, ANN EMERG MED, V62, P486, DOI 10.1016/j.annemergmed.2013.02.018; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Choi SJ, 2014, PEDIATR EMERG CARE, V30, P479, DOI 10.1097/PEC.0000000000000165; Cohen AR, 2015, AM J EMERG MED, V33, P887, DOI 10.1016/j.ajem.2015.03.052; Copenhaver BR, 2009, NEUROLOGY, V72, P1576, DOI 10.1212/WNL.0b013e3181a411df; Di Leva A, 2015, J NEUROSURG, V123, P1463, DOI 10.3171/2015.1.JNS142349; Donnelly LF, 2001, AM J ROENTGENOL, V176, P303, DOI 10.2214/ajr.176.2.1760303; Hahn B, 2013, PEDIATR EMERG CARE, V29, P822, DOI 10.1097/PEC.0b013e3182983d5d; Holmes JF, 2011, ANN EMERG MED, V58, P315, DOI 10.1016/j.annemergmed.2011.03.060; Iskandar BJ, 2004, J NEUROSURG, V101, P147, DOI 10.3171/ped.2004.101.2.0147; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lee Bruce, 2005, NeuroRx, V2, P372; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Missios S, 2008, J NEUROS-PEDIATR, V2, P438, DOI 10.3171/PED.2008.2.12.438; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Roguski M, 2015, J NEUROSURG-PEDIATR, V15, P529, DOI 10.3171/2014.10.PEDS14128; Romanova AL, 2014, J STROKE CEREBROVASC, V23, P2036, DOI 10.1016/j.jstrokecerebrovasdis.2014.03.005; Smitherman E, 2016, J NEUROTRAUM, V33, P35, DOI 10.1089/neu.2014.3801; Thompson EM, 2014, J NEUROSURG-PEDIATR, V13, P636, DOI 10.3171/2014.2.PEDS13567; Yue EL, 2015, J NEUROSURG-PEDIATR, V15, P420, DOI 10.3171/2014.9.PEDS14207	21	19	19	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	FEB	2017	19	2					259	264		10.3171/2016.7.PEDS16204			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	EJ3CM	WOS:000393089000016	27885947	Bronze			2021-06-18	
J	Zaccaria, L; Tharakan, SJ; Altermatt, S				Zaccaria, Laura; Tharakan, Sasha Job; Altermatt, Stefan			Hydroxyapatite ceramic implants for cranioplasty in children: a single-center experience	CHILDS NERVOUS SYSTEM			English	Article						Pediatric; Hydroxyapatite; Cranioplasty; Hounsfield unit; Osteointegration	TRAUMATIC BRAIN-INJURY; AUTOLOGOUS BONE FLAP; DECOMPRESSIVE CRANIECTOMY; CRANIAL REPAIR; COMPLICATIONS; PROSTHESES; DEFECT; OLD	Purpose The use of hydroxyapatite ceramic (HAC) implants for the treatment of skull defects in pediatric patients started 2010 at our institution. Ceramic implants facilitate osteoblast migration and therefore optimize osteointegration with the host bone. The purpose of this study is to report a single-center experience with this treatment modality. Methods A retrospective review of all patients from July 2010 through June 2014 undergoing a cranioplasty using hydroxyapatite ceramic implant and managed at a single institution was performed. Indication for cranioplasty, the hospital course, and follow-up were reviewed. Bone density was measured in Hounsfield Units (HU) and osteointegration was calculated using Mimics Software (R) (Mimics Innovation Suite v17.0 Medical, Materialize, Leuven, Belgium). Results Over the 4-year period, six patients met criteria for the study. Five patients had an osteointegration of nearly 100%. One patient had an incomplete osteointegration with a total bone-implant contact area of 69%. The mean bone density was 2800 HU (2300-3000 HU). Bone density alone is estimated to have a Hounsfield value between 400 and 2000 HU depending on the body region and bone quality. There were no major complications, and the patients were highly satisfied with the esthetical result. Conclusion Hydroxyapatite ceramic implants for cranioplasty in pediatric patients are a good choice for different indications. The implants show excellent osteointegration and esthetical results.	[Zaccaria, Laura] Univ Childrens Hosp, Dept Pediat Surg, Bern, Switzerland; [Tharakan, Sasha Job; Altermatt, Stefan] Univ Childrens Hosp Zurich, Dept Pediat Surg, Steinwiesstr 75, CH-8032 Zurich, Switzerland	Altermatt, S (corresponding author), Univ Childrens Hosp Zurich, Dept Pediat Surg, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	stefan.altermatt@kispi.uzh.ch					Agner C, 2003, MINIM INVAS NEUROSUR, V46, P186; Appelboom G, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.8.FOCUS11177; Bibb R, 2015, MED MODELLING APPL A, P8; Brevi BC, 2010, J PEDIATR SURG, V45, pE17, DOI 10.1016/j.jpedsurg.2010.01.011; Chen TM, 2002, ANN PEDIAT SURG, V49; D'Urso PS, 2000, BRIT J PLAST SURG, V53, P200, DOI 10.1054/bjps.1999.3268; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Della Puppa A, 2010, ACTA NEUROCHIR, V152, P155, DOI 10.1007/s00701-009-0374-6; Di Rienzo A., 2012, SURG NEOROLOGY INT, V3, P161; El Ghoul W, 2014, BR J NEUROSURG EARLY, P1; Eppley BL, 2005, J CRANIOFAC SURG, V16, P140, DOI 10.1097/00001665-200501000-00028; Frassanito P, 2015, ACTA NEUROCHIR, V157, P115, DOI 10.1007/s00701-014-2254-y; Frassanito P, 2013, CLIN NEUROL NEUROSUR, V115, P1496, DOI 10.1016/j.clineuro.2012.11.032; Frassanito P, 2012, ACTA NEUROCHIR, V154, P927, DOI 10.1007/s00701-011-1253-5; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Lee SC, 2009, J CLIN NEUROSCI, V16, P56, DOI 10.1016/j.jocn.2008.04.001; Lemee JM, 2013, NEUROCHIRURGIE, V59, P60, DOI 10.1016/j.neuchi.2012.10.138; Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701-014-2021-0; Martini L, 2012, PLAST RECONSTR SURG, V129, p625E, DOI 10.1097/PRS.0b013e318244220d; Pechmann A, 2015, NEUROPEDIATRICS, V46, P5, DOI 10.1055/s-0034-1393707; Perlyn CA, 2005, PLAST RECONSTR SURG, V115, P1129, DOI 10.1097/01.PRS.0000156217.33683.2B; Rocque BG, 2013, J NEUROSURG-PEDIATR, V12, P120, DOI 10.3171/2013.4.PEDS12605; Shah AM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13561; Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9; Staffa G, 2012, J CRANIO MAXILL SURG, V40, pE65, DOI 10.1016/j.jcms.2011.04.014; Stefini Roberto, 2013, Surg Neurol Int, V4, P12, DOI 10.4103/2152-7806.106290; Wehrli LA, 2012, EUR J PEDIATR SURG, V22, P479, DOI 10.1055/s-0032-1313349; Zins JE, 2007, PLAST RECONSTR SURG, V120, P1332, DOI 10.1097/01.prs.0000279557.29134.cd	28	19	20	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	FEB	2017	33	2					343	348		10.1007/s00381-016-3327-4			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	EO7XT	WOS:000396904100022	28013335				2021-06-18	
J	Surguchov, A; Surgucheva, I; Sharma, M; Sharma, R; Singh, V				Surguchov, Andrei; Surgucheva, Irina; Sharma, Mukut; Sharma, Ram; Singh, Vikas			Pore-Forming Proteins as Mediators of Novel Epigenetic Mechanism of Epilepsy	FRONTIERS IN NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; ALPHA-SYNUCLEIN EXPRESSION; PARKINSONS-DISEASE; DNA METHYLATION; ION CHANNELS; ALZHEIMERS-DISEASE; STEFIN-B; EPILEPTOGENESIS; GENETICS	Epilepsy is a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures. In the last two decades, numerous gene defects underlying different forms of epilepsy have been identified with most of these genes encoding ion channel proteins. Despite these developments, the etiology of majority of non-familial epilepsies has no known associated genetic mutations and cannot be explained by defects in identified ion channels alone. We hypothesize that de novo formation of ion channels by naturally unfolded proteins (NUPs) increases neuronal excitability. Altered ionic homeostasis may initiate/contribute to cellular cascades related to epileptogenesis in susceptible individuals. Here, we consider two small proteins, namely, alpha-synuclein and stefin B, as prototypical candidates to illustrate the underlying mechanism(s). Previous work points to an association between epilepsy and a-synuclein or stefin B, but the mechanism(s) underlying such association remains elusive. We review the evidence to link the structure-function of these proteins with disease processes. Epigenetic mechanisms unrelated to altered DNA sequence(s) that may affect epileptogenesis include transcriptional or posttranscriptional regulation. Such epigenetic mechanisms or their combination(s) enhance the levels of these proteins and as a result the ability to form annular structures, which upon incorporation into membrane form novel ion channels and disturb intracellular ion homeostasis. Alternative epigenetic mechanisms may change amyloidogenic proteins by posttranslational modifications, thereby increasing their propensity to form channels. Further research elucidating the details about the formation of ion channels through these mechanisms and their role in epileptogenesis may define new molecular targets and guide the development of new drug targets.	[Surguchov, Andrei; Surgucheva, Irina; Singh, Vikas] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA; [Sharma, Mukut; Sharma, Ram; Singh, Vikas] Kansas City Vet Adm, Med Ctr, Kansas City, KS USA; [Sharma, Mukut] Midwest Biomed Res Fdn, Kansas City, MO USA	Surguchov, A (corresponding author), Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA.	asurguchov@kumc.edu			VA Merit ReviewUS Department of Veterans Affairs [1I01BX000361]; Glaucoma Foundation [QB42308]; Midwest Biomedical Research Foundation (MBRF); KC VA Medical Research Center, Kansas City, MO, USA	Some of the work by AS and IS cited in this manuscript was conducted at the Kansas City VA Medical Center, Kansas City, MO, USA, with support from VA Merit Review grants 1I01BX000361 and the Glaucoma Foundation grant QB42308. MS is supported, in part, by the Midwest Biomedical Research Foundation (MBRF), KC VA Medical Research Center, Kansas City, MO, USA, and as co-investigator for NIDDK 1RO1 DK107490.	Anderluh G, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00085; Appel-Cresswell S, 2013, MOVEMENT DISORD, V28, P811, DOI 10.1002/mds.25421; Aranda S, 2016, MOL CELL BIOL, V36, P2432, DOI 10.1128/MCB.00328-16; Boison D, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00026; Born HA, 2015, NEUROSCIENCE, V286, P251, DOI 10.1016/j.neuroscience.2014.11.051; Butterfield SM, 2010, ANGEW CHEM INT EDIT, V49, P5628, DOI 10.1002/anie.200906670; Costa C, 2016, NEUROBIOL AGING, V48, P161, DOI 10.1016/j.neurobiolaging.2016.08.025; Cunliffe VT, 2015, SEIZURE-EUR J EPILEP, V24, P44, DOI 10.1016/j.seizure.2014.09.018; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Doxakis E, 2010, J BIOL CHEM, V285, P12726, DOI 10.1074/jbc.M109.086827; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; England MJ, 2012, EPILEPSY SPECTRUM PR, P19; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Ghanizadeh A, 2015, IRAN J CHILD NEUROL, V9, P99; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Graves TD, 2006, QJM-INT J MED, V99, P201, DOI 10.1093/qjmed/hcl021; Henshall DC, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a022731; Hildebrand MS, 2013, J MED GENET, V50, P271, DOI 10.1136/jmedgenet-2012-101448; Hirose S, 2002, BRAIN DEV-JPN, V24, P211, DOI 10.1016/S0387-7604(02)00056-6; Hoffman-Zacharska D, 2013, PARKINSONISM RELAT D, V19, P1057, DOI 10.1016/j.parkreldis.2013.07.011; Horiuchi H, 2005, GENET TEST, V9, P328, DOI 10.1089/gte.2005.9.328; Hu R, 2015, SEIZURE-EUR J EPILEP, V27, P6, DOI 10.1016/j.seizure.2015.02.007; Jevnikar Z, 2009, ATLAS GENET CYTOGENE, V13, P406, DOI [10.4267/2042/44486, DOI 10.4267/2042/44486]; Jowaed A, 2010, J NEUROSCI, V30, P6355, DOI 10.1523/JNEUROSCI.6119-09.2010; Kagan BL, 2010, ADV EXP MED BIOL, V677, P150; Kobow K, 2013, ACTA NEUROPATHOL, V126, P741, DOI 10.1007/s00401-013-1168-8; Kobow K, 2012, EPILEPSIA, V53, P11, DOI 10.1111/epi.12031; Kobow K, 2009, J NEUROPATH EXP NEUR, V68, P356, DOI 10.1097/NEN.0b013e31819ba737; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lashuel HA, 2006, Q REV BIOPHYS, V39, P167, DOI 10.1017/S0033583506004422; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lesage S, 2013, ANN NEUROL, V73, P459, DOI 10.1002/ana.23894; Li AQ, 2010, BRAIN PATHOL, V20, P1077, DOI 10.1111/j.1750-3639.2010.00414.x; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Loscher W, 2010, EPILEPSIA, V51, P89, DOI 10.1111/j.1528-1167.2009.02183.x; Lubin FD, 2012, EPILEPSY CURR, V12, P105, DOI 10.5698/1535-7511-12.3.105; Lundberg J, 2009, NEUROSCI LETT, V457, P8, DOI 10.1016/j.neulet.2009.03.105; Matsumoto L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015522; McCormack AL, 2009, CURR PROTEIN PEPT SC, V10, P476, DOI 10.2174/138920309789351912; Meldrum B, 2007, EPILEPSIA, V48, P33, DOI 10.1111/j.1528-1167.2007.01343.x; Meldrum BS, 2007, NEUROTHERAPEUTICS, V4, P18, DOI 10.1016/j.nurt.2006.11.010; Miller-Delaney SFC, 2015, BRAIN, V138, P616, DOI 10.1093/brain/awu373; Mulley JC, 2003, CURR OPIN NEUROL, V16, P171, DOI 10.1097/00019052-200304000-00009; Munishkina LA, 2004, J MOL RECOGNIT, V17, P456, DOI 10.1002/jmr.699; Myers CT, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0214-7; Nicita F, 2012, SEIZURE-EUR J EPILEP, V21, P3, DOI 10.1016/j.seizure.2011.08.007; Oliveras-Salva M, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-44; Pandolfo M, 2011, SEMIN NEUROL, V31, P506, DOI 10.1055/s-0031-1299789; Poduri A, 2011, CURR OPIN GENET DEV, V21, P325, DOI 10.1016/j.gde.2011.01.005; Polajnar M, 2014, BBA-MOL CELL RES, V1843, P2089, DOI 10.1016/j.bbamcr.2014.05.018; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Puschmann A, 2009, PARKINSONISM RELAT D, V15, P390, DOI 10.1016/j.parkreldis.2008.08.002; Qureshi IA, 2010, NEUROBIOL DIS, V39, P53, DOI 10.1016/j.nbd.2010.02.005; Rabzelj S, 2008, FEBS J, V275, P2455, DOI 10.1111/j.1742-4658.2008.06390.x; Rivenbark AG, 2009, FRONT BIOSCI-LANDMRK, V14, P453, DOI 10.2741/3254; Ross CA, 2005, NAT REV MOL CELL BIO, V6, P891, DOI 10.1038/nrm1742; Rostovtseva TK, 2015, J BIOL CHEM, V290, P18467, DOI 10.1074/jbc.M115.641746; Ruzza P, 2014, ACS CHEM NEUROSCI, V5, P30, DOI 10.1021/cn400149k; Salahuddin P, 2016, EUR J MED CHEM, V114, P41, DOI 10.1016/j.ejmech.2016.02.065; Sima XT, 2014, MOL MED REP, V9, P1242, DOI 10.3892/mmr.2014.1977; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Soto C., 2013, J NEUROL TRANSL NEUR, V1, P1010; Staley K, 2015, NAT NEUROSCI, V18, P367, DOI 10.1038/nn.3947; Steinlein OK, 2004, NAT REV NEUROSCI, V5, P400, DOI 10.1038/nrn1388; Striano P, 2016, PHARMACOL RES, V107, P426, DOI 10.1016/j.phrs.2016.04.006; Surguchov A, 2008, INT REV CEL MOL BIO, V270, P225, DOI 10.1016/S1937-6448(08)01406-8; Surguchov A, 2015, INT REV CEL MOL BIO, V320, P103, DOI 10.1016/bs.ircmb.2015.07.007; Uversky VN, 2003, J BIOMOL STRUCT DYN, V21, P211, DOI 10.1080/07391102.2003.10506918; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Waszkielewicz AM, 2013, CURR MED CHEM, V20, P1241; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Williams-Karnesky RL, 2013, J CLIN INVEST, V123, P3552, DOI 10.1172/JCI65636; Yang JW, 2006, AMINO ACIDS, V30, P477, DOI 10.1007/s00726-005-0281-y; Zakharov SD, 2007, BIOCHEMISTRY-US, V46, P14369, DOI 10.1021/bi701275p; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang ZY, 2007, NEUROSCI LETT, V429, P1, DOI 10.1016/j.neulet.2007.09.061; Zhu Q, 2012, J MOL NEUROSCI, V46, P420, DOI 10.1007/s12031-011-9602-7	82	19	19	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JAN 18	2017	8								3	10.3389/fneur.2017.00003			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EH9HE	WOS:000392081600001	28149289	DOAJ Gold, Green Published			2021-06-18	
J	MacManus, DB; Pierrat, B; Murphy, JG; Gilchrist, MD				MacManus, David B.; Pierrat, Baptiste; Murphy, Jeremiah G.; Gilchrist, Michael D.			A viscoelastic analysis of the P56 mouse brain under large-deformation dynamic indentation	ACTA BIOMATERIALIA			English	Article						Traumatic brain injury; Prony; Dynamic modulus; Damping ratio; neo-Hookean	MECHANICAL CHARACTERIZATION; IN-VIVO; TISSUE; HEAD; SHEAR; EPIDEMIOLOGY; VALIDATION; MODELS	The brain is a complex organ made up of many different functional and structural regions consisting of different types of cells such as neurons and glia, as well as complex anatomical geometries. It is hypothesized that the different regions of the brain exhibit significantly different mechanical properties which may be attributed to the diversity of cells within individual brain regions. The regional viscoelastic properties of P56 mouse brain tissue, up to 70 mu m displacement, are presented and discussed in the context of traumatic brain injury, particularly how the different regions of the brain respond to mechanical loads. Force-relaxation data obtained from micro-indentation measurements were fit to both linear and quasi-linear viscoelastic models to determine the time and frequency domain viscoelastic response of the pons, cortex, medulla oblongata, cerebellum, and thalamus. The damping ratio of each region was also determined. Each region was found to have a unique mechanical response to the applied displacement, with the pons and thalamus exhibiting the largest and smallest force-response, respectively. All brain regions appear to have an optimal frequency for the dissipation of energies which lies between 1 and 10 Hz. Statement of significance We present the first mechanical characterization of the viscoelastic response for different regions of mouse brain. Force-relaxation tests are performed under large strain dynamic micro-indentation, and viscoelastic models are used subsequently, providing time-dependent mechanical properties of brain tissue under loading conditions comparable to what is experienced in TBI. The unique mechanical properties of different brain regions are highlighted, with substantial variations in the viscoelastic properties and damping ratio of each region. Cortex and pons were the stiffest regions, while the thalamus and medulla were most compliant. The cerebellum and thalamus had highest damping ratio values and those of the medulla were lowest. The reported material parameters can be implemented into finite element computer models of the mouse to investigate the effects of trauma on individual brain regions. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[MacManus, David B.; Pierrat, Baptiste; Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland; [Murphy, Jeremiah G.] Dublin City Univ, Dept Mech & Mfg Engn, Dublin, Ireland	Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland.	david.mac-manus@ucdconnect.ie; baptiste.pierrat@emse.fr; jeremiah.murphy@dcu.ie; michael.gilchrist@ucd.ie		MacManus, David/0000-0003-2959-698X; Pierrat, Baptiste/0000-0001-8064-8496	Science Foundation IrelandScience Foundation IrelandEuropean Commission [12/IP/1732]	This work was supported by Science Foundation Ireland (Grant No. 12/IP/1732).	Antona-Makoshi J., 2012, IRCOBI C, P441; Atkin R. J., 2005, INTRO THEORY ELASTIC, P79; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; Bernick K.B., 2010, 27 ARM SCI C ASC ORL; Bilston L.E., 2016, STRUCTURE BASED MECH, P1, DOI [10.1007/978-1-4899-7630-7, DOI 10.1007/978-1-4899-7630-7]; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Chen FQ, 2015, ANN BIOMED ENG, V43, P2903, DOI 10.1007/s10439-015-1350-3; Cullen DK, 2007, BRAIN RES, V1158, P103, DOI 10.1016/j.brainres.2007.04.070; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Elkin BS, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025386; Elkin BS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004494; England M. A., 1996, COLOUR ATLAS BRAIN S, P10; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferrer I, 2007, J NEUROPATH EXP NEUR, V66, P35, DOI 10.1097/nen.0b013e31802c3e7d; Finan JD, 2012, ANN BIOMED ENG, V40, P70, DOI 10.1007/s10439-011-0394-2; Fountoulakis M, 2001, EXP NEUROL, V167, P86, DOI 10.1006/exnr.2000.7529; Gilchrist MD, 2003, KEY ENG MATER, V245-2, P417, DOI 10.4028/www.scientific.net/KEM.245-246.417; Giordano C, 2014, J BIOMECH, V47, P1052, DOI 10.1016/j.jbiomech.2013.12.036; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hoshizaki T.B., 2014, NEUROSURGERY, V75; Howard MA, 1999, IEEE T BIO-MED ENG, V46, P891, DOI 10.1109/10.771205; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Jiang Y, 2015, BIOMECH MODEL MECHAN, V14, P1119, DOI 10.1007/s10237-015-0658-0; Jin X, 2013, J BIOMECH, V46, P2795, DOI 10.1016/j.jbiomech.2013.09.001; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Libertiaux V, 2011, J MECH BEHAV BIOMED, V4, P1177, DOI 10.1016/j.jmbbm.2011.03.028; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; MacManus DB, 2015, J BIOMECH, V48, P3213, DOI 10.1016/j.jbiomech.2015.06.028; MacManus DB, 2016, SCI REP-UK, V6, DOI 10.1038/srep21569; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Menard H.P., 2008, DYNAMIC MECH ANAL PR, P151; Pervin F, 2011, NEUROIMAGE, V54, pS98, DOI 10.1016/j.neuroimage.2010.03.077; PHARR GM, 1992, J MATER RES, V7, P613, DOI 10.1557/JMR.1992.0613; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Puso MA, 1998, J BIOMECH ENG-T ASME, V120, P62, DOI 10.1115/1.2834308; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Urbanczyk CA, 2015, ULTRASOUND MED BIOL, V41, P713, DOI 10.1016/j.ultrasmedbio.2014.10.019; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Wang TW, 2009, ACTA BIOMATER, V5, P2371, DOI 10.1016/j.actbio.2009.03.033; Willinger R, 1999, CR ACAD SCI II B, V327, P125, DOI 10.1016/S1287-4620(99)80021-0; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang J, 2011, J BIOMECH, V44, P1909, DOI 10.1016/j.jbiomech.2011.04.034; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang MG, 2014, J APPL MECH-T ASME, V81, DOI 10.1115/1.4027973	50	19	20	0	20	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	JAN 15	2017	48						309	318		10.1016/j.actbio.2016.10.029			10	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	EJ5GY	WOS:000393247000026	27777117				2021-06-18	
J	Asken, BM; Snyder, AR; Smith, MS; Zaremski, JL; Bauer, RM				Asken, Breton M.; Snyder, Aliyah R.; Smith, M. Seth; Zaremski, Jason L.; Bauer, Russell M.			Concussion-like symptom reporting in non-concussed adolescent athletes	CLINICAL NEUROPSYCHOLOGIST			English	Article						Brain injury; high school; biopsychosocial; adolescent; sport-related concussion	MILD HEAD-INJURY; POSTCONCUSSION SYNDROME; BASE RATES; SPORT; DISORDER; PARTICIPATION; BENEFITS; CRITERIA; STRESS; REST	Objective: The primary goals of this study were (1) to report rates of concussion-like symptoms in healthy adolescent student athletes assessed using the Sport Concussion Assessment Tool, 3rd edition (SCAT3) at baseline, (2) to examine rates of psychiatric diagnoses in this population, and (3) to evaluate effects of baseline symptoms on SCAT3 cognitive and balance performance. Methods: 349 adolescent student athletes (245 male) were administered the SCAT3 during pre-participation physical examinations. We described the prevalence rate of student athletes meeting criteria for International Classification of Diseases, 10th revision, post-concussional syndrome (ICD-10 PCS) diagnosis at baseline, and evaluated associations between symptom reporting and demographic/medical history factors using chi-square tests. Rates of self-reported psychiatric diagnosis were compared to general population estimates with one-sample binomial tests. We also compared SCAT3 cognitive and balance performance between adolescents with and without baseline ICD-10 PCS symptoms. Results: Overall, 20.3% of participants met ICD-10 PCS criteria at baseline. Rates were similar across sexes and age groups. We found no statistical association with medical history factors. The proportion of student athletes reporting a history of psychiatric diagnosis (5.2%) was significantly lower than general population estimates (14.0%; p<.001), and this effect was consistent across sexes and age groups. SCAT3 cognitive and balance performance did not differ based on baseline symptom reporting. Conclusions: Healthy adolescent student athletes frequently report concussion-like symptoms at baseline. Clinicians should factor pre-injury symptomatology and medical history into concussion management when determining symptom etiology throughout the course of recovery.	[Asken, Breton M.; Snyder, Aliyah R.; Bauer, Russell M.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32611 USA; [Smith, M. Seth; Zaremski, Jason L.] Univ Florida, Dept Orthopaed & Rehabil, Gainesville, FL USA	Asken, BM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32611 USA.	basken8@phhp.ufl.edu	Snyder, Aliyah/AAT-6250-2020	Asken, Breton/0000-0001-8419-142X; Snyder, Aliyah/0000-0003-1185-7424			American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; [Anonymous], 1992, ICD 10 CLASS MENT BE; Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; CHAN CS, 1988, PERCEPT MOTOR SKILL, V66, P875, DOI 10.2466/pms.1988.66.3.875; Daniels E, 2006, SEX ROLES, V55, P875, DOI 10.1007/s11199-006-9138-4; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Edmed SL, 2012, APPL NEUROPSYCH-ADUL, V19, P164, DOI 10.1080/09084282.2011.643961; ENGEL GL, 1980, AM J PSYCHIAT, V137, P535; Fainaru S, 2013, YOUTH FOOTBALL PARTI; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Findlay LC, 2008, CAN J BEHAV SCI, V40, P153, DOI 10.1037/0008-400X.40.3.153; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; IBM Corp, 2019, IBM SPSS STAT WIND V; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Joyce AS, 2015, MED SCI SPORT EXER, V47, P1119, DOI 10.1249/MSS.0000000000000534; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McLeod TCV, 2012, J ATHL TRAINING, V47, P221; Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Steptoe A, 1996, LANCET, V347, P1789, DOI 10.1016/S0140-6736(96)91616-5; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	49	19	19	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	1					138	153		10.1080/13854046.2016.1246672			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	EK2VR	WOS:000393785300008	27758158				2021-06-18	
J	Haller, CS; Delhumeau, C; De Pretto, M; Schumacher, R; Pielmaier, L; Rebetez, MML; Haller, G; Walder, B				Haller, Chiara S.; Delhumeau, Cecile; De Pretto, Michael; Schumacher, Rahel; Pielmaier, Laura; Rebetez, Marie My Lien; Haller, Guy; Walder, Bernhard			Trajectory of disability and quality-of-life in non-geriatric and geriatric survivors after severe traumatic brain injury	BRAIN INJURY			English	Article						Head injury; elderly; functional outcome; health-related quality-of-life; recovery	GLASGOW OUTCOME SCALE; SEVERE HEAD-INJURY; OLDER-ADULTS; INPATIENT REHABILITATION; NATIONAL INSTITUTE; MODEL SYSTEMS; HEALTH SURVEY; COHORT; MULTICENTER; PREDICTORS	Objective: The objective was to investigate disability and health-related quality-of-life (HRQoL) 3, 6 and 12 months after traumatic brain injury (TBI) in non-geriatric (<= 65 years) and geriatric patients (> 65 years). Methods: Patients >= 16 years who sustained a severe TBI (Abbreviated Injury Scale of the head region > 3) were included in this prospective, multi-centre study. Outcome measures were Glasgow Outcome Scale Extended (GOSE; disability), SF-12 (HRQoL). Mixed linear model analyses were performed. Results: Three hundred and fifty-one patients (median age = 50 years; interquartile range (IQR) = 27-67) were included; 73.2% were male and 27.6% were geriatric patients. Median GOSE at 3, 6 and 12 months was 5 (IQR = 3-7), 6 (IQR = 4-8) and 7 (IQR = 5-8); this increase (slope(time) = 0.22, p < 0.0001) was age dependent (slope(age*time) = -0.06, p = 0.003). Median SF-12 physical component scale score at 3, 6 and 12 months was 42.1 (IQR = 33.6-50.7), 46.6 (IQR = 37.4-53.9) and 50.4 (IQR = 392-55.1); this increase (slopetime = 1.52, p < 0.0001) was not age dependent (slope(age*time) = -0.30, p = 0.083). SF-12 mental component scale scores were unchanged. Conclusions: Disability decreased and HRQoL improved after TBI between 3-12 months. In geriatric patients this improvement was relevant for HRQoL only.	[Haller, Chiara S.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA; [Haller, Chiara S.] Massachusetts Mental Hlth Ctr, Div Publ Psychiat, Boston, MA 02115 USA; [Delhumeau, Cecile; De Pretto, Michael; Haller, Guy; Walder, Bernhard] Univ Hosp Geneva HUG, Div Anaesthesiol, Geneva, Switzerland; [Schumacher, Rahel] Univ Hosp Bern, Inselspital, Dept Neurol, Div Cognit & Restorat Neurol, Bern, Switzerland; [Schumacher, Rahel] Univ Bern, Bern, Switzerland; [Pielmaier, Laura] Psychiat Serv Aargau, Windisch, Switzerland; [Rebetez, Marie My Lien] Univ Geneva, Dept Clin Psychol, Geneva, Switzerland; [Haller, Guy] Univ Hosp Geneva HUG, Div Clin Epidemiol, Geneva, Switzerland	Walder, B (corresponding author), Univ Hosp Geneva, Dept APSI, Div Anaesthesiol, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland.	bernhard.walder@hcuge.ch		Schumacher, Rahel/0000-0001-7500-7491; De Pretto, Michael/0000-0003-4176-4798	Bangerter-Rhyner-Foundation; Swiss Accident Insurance Foundation	The authors report no conflicts of interest. This study was funded by the Bangerter-Rhyner-Foundation and the Swiss Accident Insurance Foundation. The funding sources had no role in the study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all data. He was also responsible for the final decision-making which eventually lead to the submission of the present material for publication.	Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Andruszkow H, 2013, PATIENT SAF SURG, V7, DOI 10.1186/1754-9493-7-32; Bayen E, 2013, J HEAD TRAUMA REHAB, V28, P408, DOI 10.1097/HTR.0b013e31825413cf; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; Cadotte DW, 2011, J NEUROSURG, V114, P1502, DOI 10.3171/2010.12.JNS10808; Chan V, 2013, CAN J AGING, V32, P278, DOI 10.1017/S0714980813000317; Copay AG, 2008, SPINE J, V8, P968, DOI 10.1016/j.spinee.2007.11.006; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889; Eapen Blessen C, 2015, Semin Neurol, V35, pe1, DOI 10.1055/s-0035-1549094; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Garthe E, 1999, J TRAUMA, V47, P309, DOI 10.1097/00005373-199908000-00016; Gelman A., 2007, DATA ANAL USING REGR; Graham JE, 2010, ARCH PHYS MED REHAB, V91, P43, DOI 10.1016/j.apmr.2009.09.017; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Heyland DK, 2015, INTENS CARE MED, V41, P1911, DOI 10.1007/s00134-015-4028-2; Hu XB, 2012, BRAIN INJURY, V26, P183, DOI 10.3109/02699052.2011.648707; Klein AM, 2013, J NEUROTRAUM, V30, P1476, DOI 10.1089/neu.2012.2735; Krellman JW, 2014, ARCH PHYS MED REHAB, V95, P633, DOI 10.1016/j.apmr.2013.10.016; Ladermann A, 2008, KNEE, V15, P206, DOI 10.1016/j.knee.2008.01.010; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lees KR, 2012, STROKE, V43, P1163, DOI 10.1161/STROKEAHA.111.641423; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McIntyre A, 2013, NEUROREHABILITATION, V32, P409, DOI 10.3233/NRE-130862; McIntyre A, 2013, BRAIN INJURY, V27, P31, DOI 10.3109/02699052.2012.700086; Mosconi P, 2011, PATIENT, V4, P55, DOI 10.2165/11535550-000000000-00000; Oppenheim-Gluckman H., 2003, Annales de Readaptation et de Medecine Physique, V46, P41, DOI 10.1016/S0168-6054(02)00352-5; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Pielmaier L, 2011, BRAIN INJURY, V25, P259, DOI 10.3109/02699052.2010.542429; Prang KH, 2012, BRAIN INJURY, V26, P1611, DOI 10.3109/02699052.2012.698790; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P579, DOI 10.1016/j.apmr.2012.08.197; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Rabe-Hesketh S., 2008, MULTILEVEL LONGITUDI; Sasse N, 2013, J HEAD TRAUMA REHAB, V28, P464, DOI 10.1097/HTR.0b013e318263977d; Scheid R, 2010, DTSCH ARZTEBL INT, V107, P199, DOI 10.3238/arztebl.2010.0199; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Siponkoski ST, 2013, J REHABIL MED, V45, P835, DOI 10.2340/16501977-1189; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Svedbom A, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657-014-0187-y; Swanenburg J, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.13976; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tillou A, 2014, JAMA SURG, V149, P83, DOI 10.1001/jamasurg.2013.4244; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; von Elm E, 2008, SWISS MED WKLY, V138, P327, DOI 2008/23/smw-12025; Walder B, 2013, J NEUROTRAUM, V30, P1934, DOI 10.1089/neu.2013.2955; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	55	19	19	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	3					319	328		10.1080/02699052.2016.1255777			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EQ3WY	WOS:000398005900006	28112980				2021-06-18	
J	Kirkwood, MW; Peterson, RL; Baker, DA; Connery, AK				Kirkwood, Michael W.; Peterson, Robin L.; Baker, David A.; Connery, Amy K.			Parent satisfaction with neuropsychological consultation after pediatric mild traumatic brain injury	CHILD NEUROPSYCHOLOGY			English	Article						Neuropsychological assessment; patient satisfaction; consumer satisfaction; concussion; pediatrics	POST-CONCUSSION SYMPTOMS; POSTCONCUSSION SYNDROME; SUBOPTIMAL EFFORT; CHILDREN; PATIENT; PERCEPTIONS; CARE; ADOLESCENTS; PREDICTORS; EXPERIENCE	Few studies have focused on consumer satisfaction following neuropsychological evaluation. We sought to examine parent satisfaction with neuropsychological consultation following a mild traumatic brain injury (TBI) in school-age children. We surveyed 71 parents of 8-to 17-year-olds participating in a prospective longitudinal study examining neuropsychological consultation as an intervention for persistent postconcussive symptoms. Children had sustained injuries between 2 and 12 months prior to enrollment. Neuropsychological consultation occurred on average 5 months post-injury. Parent satisfaction data were collected via telephone approximately 4 months after the neuropsychological consultation. The vast majority of parents were quite satisfied with the service (e.g., 94% overall satisfaction rate; 96% rated the service as good or excellent). Satisfaction rates were associated positively with time since injury and negatively with parental education. No other child, parent, or provider variable correlated with satisfaction. The results add to the relatively sparse literature on parent satisfaction with neuropsychological evaluation. A pressing future need in pediatric neuropsychology is to examine the satisfaction of other consumers of the service, including healthcare personnel, educators, and the child patients themselves.	Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA; Childrens Hosp Colorado, Aurora, CO USA	Kirkwood, MW (corresponding author), Childrens Hosp Colorado, Dept Rehabil Med, 13123 E 16th Ave, Aurora, CO 80045 USA.	michael.kirkwood@childrenscolorado.org			Children's Hospital Colorado Research Institute	The work was supported by the Children's Hospital Colorado Research Institute.	Araujo GC, 2014, CLIN NEUROPSYCHOL, V28, P786, DOI 10.1080/13854046.2014.896415; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; BENNETTLEVY J, 1994, CLIN NEUROPSYCHOL, V8, P219, DOI 10.1080/13854049408401559; Bleich SN, 2009, B WORLD HEALTH ORGAN, V87, P271, DOI 10.2471/BLT.07.050401; Bodin D, 2007, CLIN NEUROPSYCHOL, V21, P884, DOI 10.1080/13854040600888784; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Centers for Medicaid and Medicaid Services, 2012, HOSP CONS ASS HEALTH; Dillman DA, 2009, SOC SCI RES, V38, P3, DOI 10.1016/j.ssresearch.2008.03.007; Farmer J E, 1998, Appl Neuropsychol, V5, P194, DOI 10.1207/s15324826an0504_4; Fenton JJ, 2012, ARCH INTERN MED, V172, P405, DOI 10.1001/archinternmed.2011.1662; HALL JA, 1990, SOC SCI MED, V30, P811, DOI 10.1016/0277-9536(90)90205-7; Hilsabeck RC, 2014, ARCH CLIN NEUROPSYCH, V29, P131, DOI 10.1093/arclin/act084; King SM, 1996, DEV MED CHILD NEUROL, V38, P757, DOI 10.1111/j.1469-8749.1996.tb15110.x; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2016, J PEDIATR-US, V169, P244, DOI 10.1016/j.jpeds.2015.10.014; Kirkwood MW, 2014, PEDIATRICS, V133, P643, DOI 10.1542/peds.2013-3195; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Larsen D L, 1979, Eval Program Plann, V2, P197, DOI 10.1016/0149-7189(79)90094-6; Nygren-de Boussard Catharina, 2014, Arch Phys Med Rehabil, V95, pS257, DOI 10.1016/j.apmr.2013.10.009; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Peterson RL, 2015, J NEUROPSYCH CLIN N, V27, P280, DOI 10.1176/appi.neuropsych.14120373; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Shirley Eric D, 2013, J Bone Joint Surg Am, V95, pe69, DOI 10.2106/JBJS.L.01048; Sweet JJ, 2011, CLIN NEUROPSYCHOL, V25, P12, DOI 10.1080/13854046.2010.544165; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Temple RO, 2006, ARCH CLIN NEUROPSYCH, V21, P371, DOI 10.1016/j.acn.2006.05.002; Tremont G, 2002, CLIN NEUROPSYCHOL, V16, P551, DOI 10.1076/clin.16.4.551.13902; Wechsler D., 2011, WECHSLER ABBREVIATED; Westervelt HJ, 2007, CLIN NEUROPSYCHOL, V21, P263, DOI 10.1080/13854040500519745; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082	32	19	19	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.		2017	23	3					273	283		10.1080/09297049.2015.1130219			11	Clinical Neurology	Neurosciences & Neurology	EO6YY	WOS:000396839600002	26739699				2021-06-18	
J	Marin, JR; Weaver, MD; Mannix, RC				Marin, Jennifer R.; Weaver, Matthew D.; Mannix, Rebekah C.			Burden of USA hospital charges for traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; charges; nationwide emergency department sample	EMERGENCY-DEPARTMENT VISITS; HEALTH-CARE; ECONOMIC BURDEN; UNITED-STATES; HEAD-INJURY; OUTCOMES; COST; MANAGEMENT; BLUNT	Objectives: This study sought to estimate charges associated with USA hospital visits for traumatic brain injury (TBI), compare charges from 2006-2010 and evaluate factors associated with higher charges. Methods: The Nationwide Emergency Department Sample database, 2006-2010, was used to estimate charges for emergency department visits and inpatient hospital stays associated with TBI and trends in charges over time were compared. Multivariable linear regression was used to evaluate factors associated with visit charges. Results: In 2010, there were $21.4 billion (95% confidence interval (CI) = $17.7-$25.2 billion) in charges for TBI-related admissions, an increase of 22% from 2006. Charges for ED visits resulting in discharge or transfer were $8.2 billion (95% CI = $7.4-$8.9 billion), an increase of 94% from 2006. The proportion of charges for TBI-related visits was disproportionately higher than the proportion of visits for TBI across all years of the study (p < 0.001). Patient age and gender, West region, trauma, centre status, non-paediatric hospital designation, metropolitan location and hospital ownership were independently associated with higher charges. Conclusions: There was a substantial charge burden from TBI-related hospital visits and charges increased disproportionately to visit volume. There are patient and hospital factors independently associated with higher charges. These findings, as well as methods to, reduce the charge burden and charge disparities, deserve further study.	[Marin, Jennifer R.] Univ Pittsburgh, Sch Med, Dept Pediat, 4401 Penn Ave,AOB Suite 2400, Pittsburgh, PA 15224 USA; [Marin, Jennifer R.] Univ Pittsburgh, Sch Med, Dept Emergency Med, 4401 Penn Ave,AOB Suite 2400, Pittsburgh, PA 15224 USA; [Weaver, Matthew D.] Harvard Med Sch, Dept Med, Div Sleep Med, Boston, MA USA; [Mannix, Rebekah C.] Childrens Hosp Boston, Div Emergency Med, Boston, MA USA	Marin, JR (corresponding author), Univ Pittsburgh, Sch Med, Dept Pediat, 4401 Penn Ave,AOB Suite 2400, Pittsburgh, PA 15224 USA.; Marin, JR (corresponding author), Univ Pittsburgh, Sch Med, Dept Emergency Med, 4401 Penn Ave,AOB Suite 2400, Pittsburgh, PA 15224 USA.	jennifer.marin@chp.edu	Mannix, Rebekah/AAD-8702-2020	Marin, Jennifer/0000-0003-3090-664X	National Institutes of Health, National Heart Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K12HL109068]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K12HL109068] Funding Source: NIH RePORTER	The first author received grant support from the National Institutes of Health, National Heart Lung and Blood Institute (K12HL109068). The first author has consulted in the last 12 months for SmartAnalyst, Inc, for research relating to traumatic brain injury. The remaining authors report no conflicts of interest.	Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Clark DE OT, 2010, ICDPIC STATA MODULE; Coronado VG, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P84; Davis KL, 2007, J TRAUMA, V62, P622, DOI 10.1097/TA.0b013e318031afe3; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fisher ES, 2003, PERSPECT BIOL MED, V46, P69, DOI 10.1353/pbm.2003.0004; Gaynor M, 2003, RAND J ECON, V34, P764, DOI 10.2307/1593787; Hsia RY, 2008, ANN EMERG MED, V51, P265, DOI 10.1016/j.annemergmed.2007.08.009; Hsia RY, 2014, ANN EMERG MED, V64, P120, DOI 10.1016/j.annemergmed.2014.03.006; Hsia RY, 2012, ARCH INTERN MED, V172, P818, DOI 10.1001/archinternmed.2012.1173; Huber-Wagner S, 2009, LANCET, V373, P1455, DOI 10.1016/S0140-6736(09)60232-4; Ingram DD, 2014, VITAL HLTH STAT, V2, P1; Kayani NA, 2009, PUBLIC HEALTH REP, V124, P551, DOI 10.1177/003335490912400412; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Larson DB, 2011, RADIOLOGY, V259, P793, DOI 10.1148/radiol.11101939; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Melnick G, 2007, J HEALTH ECON, V26, P400, DOI 10.1016/j.jhealeco.2006.10.002; Obirieze AC, 2012, J TRAUMA ACUTE CARE, V73, P516, DOI 10.1097/TA.0b013e31825132a0; Rochette LM, 2009, J SAFETY RES, V40, P353, DOI 10.1016/j.jsr.2009.08.003; Rubin DB., 1987, MULTIPLE IMPUTATION; Salim A, 2006, ARCH SURG-CHICAGO, V141, P468, DOI 10.1001/archsurg.141.5.468; Sears JM, 2014, INJURY, V45, P16, DOI 10.1016/j.injury.2012.12.024; Stocchetti N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0887-8; Thompson HJ, 2012, J NEUROTRAUM, V29, P1864, DOI 10.1089/neu.2011.2284; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Yong PL., 2010, HEALTHCARE IMPERATIV; Zwanziger J, 2006, HEALTH AFFAIR, V25, P197, DOI 10.1377/hlthaff.25.1.197	35	19	19	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	1					24	31		10.1080/02699052.2016.1217351			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EJ5KT	WOS:000393257600004	27830939	Green Accepted			2021-06-18	
J	Stanley, IH; Joiner, TE; Bryan, CJ				Stanley, Ian H.; Joiner, Thomas E.; Bryan, Craig J.			Mild traumatic brain injury and suicide risk among a clinical sample of deployed military personnel: Evidence for a serial mediation model of anger and depression	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						TBI; Suicide; Suicidality; Anger; Depression	NEUROPSYCHOLOGICAL ASSESSMENT METRICS; BEHAVIORS QUESTIONNAIRE; VETERANS; TBI; POPULATION; PREVALENCE; MANAGEMENT; SYMPTOMS; IDEATION; HEALTH	Research has demonstrated a robust link between traumatic brain injuries (TBIs) and suicide risk. Yet, few studies have investigated factors that account for this link. Utilizing a clinical sample of deployed military personnel, this study aimed to examine a serial meditation model of anger and depression in the association of mild TBI and suicide risk. A total of 149 military service members referred for evaluation/treatment of a suspected head injury at a military hospital participated in the present study (92.6% male; M-age = 27.9y). Self-report measures included the Suicidal Behaviors Questionnaire Revised (SBQ-R), Automated Neuropsychological Assessment Metrics (ANAM) anger and depression subscales, and Behavioral Health Measure-20 depression subscale. A current mild TBI diagnosis was confirmed by a licensed clinical psychologist/physician. Overall, 84.6% (126/149) of participants met diagnostic criteria for a current mild TB]. Bootstrapped serial mediation analyses indicated that the association of mild TBI and suicide risk is serially mediated by anger and depression symptoms (bias-corrected 95% confidence interval [CI] for the indirect effect = 0.044, 0.576). An alternate serial mediation model in which depression symptoms precede anger was not statistically significant (bias-corrected 95% Cl for the indirect effect = -0.405, 0.050). Among a clinical sample of military personnel, increased anger and depression statistically mediated the association of mild TBI and suicide risk, and anger appears to precede depression in this pathway. Findings suggest that therapeutically targeting anger may serve to thwart the trajectory to suicide risk among military personnel who experience a mild TBI. Future research should investigate this conjecture within a prospective design to establish temporality. (C) 2016 Elsevier Ltd. All rights reserved.	[Stanley, Ian H.; Joiner, Thomas E.] Florida State Univ, Dept Psychol, 1107 West Call St, Tallahassee, FL 32306 USA; [Bryan, Craig J.] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA; [Bryan, Craig J.] Natl Ctr Vet Studies, Salt Lake City, UT USA	Stanley, IH (corresponding author), Florida State Univ, Dept Psychol, 1107 West Call St, Tallahassee, FL 32306 USA.	stanley@psy.fsu.edu		Bryan, Craig/0000-0002-9714-0733	Military Suicide Research Consortium; Office of the Assistant Secretary of Defense for Health Affairs [W81XWH-10-2-0181]	This research was supported in part by the Military Suicide Research Consortium, an effort supported by the Office of the Assistant Secretary of Defense for Health Affairs under Award No. (W81XWH-10-2-0181). Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Military Suicide Research Consortium or the Department of Defense.	Aboulafia-Brakha T., 2015, J HEAD TRAUMA REHABI, V1; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Bahraini NH, 2013, BRAIN IMPAIR, V14, P92, DOI 10.1017/BrImp.2013.11; Bailie JM, 2015, J HEAD TRAUMA REHAB, V30, P12, DOI 10.1097/HTR.0000000000000024; Batterham PJ, 2015, PSYCHOL ASSESSMENT, V27, P501, DOI 10.1037/pas0000053; Blount T. H., 2010, ASS BEHAV COGNITIVE; Brenner LA, 2015, ARCH PHYS MED REHAB, V96, P1411, DOI 10.1016/j.apmr.2015.04.010; Brenner LA, 2013, J HEAD TRAUMA REHAB, V28, P21, DOI 10.1097/HTR.0b013e31827df0b5; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Cavanagh JTO, 2003, PSYCHOL MED, V33, P395, DOI 10.1017/S0033291702006943; Centers for Disease Control and Prevention, 2016, LEAD CAUS DEATH REP; Chu C, 2015, J CLIN PSYCHOL, V71, P1186, DOI 10.1002/jclp.22210; COTTON CR, 1995, DEATH STUD, V19, P391, DOI 10.1080/07481189508252740; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; Defense Suicide Prevention Office, 2014, FISC YEAR 2013 ANN R; Department of Veterans Affairs & Department of Defense, 2016, VA DOD CLIN PRACT GU; FAVA M, 1993, AM J PSYCHIAT, V150, P1158; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gradus JL, 2015, J TRAUMA STRESS, V28, P361, DOI 10.1002/jts.22021; Gutierrez PM, 2008, ARCH SUICIDE RES, V12, P336, DOI 10.1080/13811110802324961; Hawkins KA, 2013, J NERV MENT DIS, V201, P959, DOI 10.1097/NMD.0000000000000041; Hayes A.F., 2018, INTRO MEDIATION MODE, V2nd ed.; Hoge CW, 2012, JAMA-J AM MED ASSOC, V308, P671, DOI 10.1001/jama.2012.9955; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Johnson DR, 2008, ARCH CLIN NEUROPSYCH, V23, P73, DOI 10.1016/j.acn.2007.10.001; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Joiner TE, 2016, PSYCHIATRY, V79, P107, DOI 10.1080/00332747.2016.1142800; Kemp J., 2013, SUICIDE DATA REPORT; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; Klonsky ED, 2016, ANNU REV CLIN PSYCHO, V12, P307, DOI 10.1146/annurev-clinpsy-021815-093204; Koh KB, 2002, J CLIN PSYCHIAT, V63, P486, DOI 10.4088/JCP.v63n0604; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kopta SM, 2002, PSYCHOTHER RES, V12, P413, DOI 10.1093/ptr/12.4.413; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Luutonen S, 2007, NORD J PSYCHIAT, V61, P246, DOI 10.1080/08039480701414890; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; MINKOFF K, 1973, AM J PSYCHIAT, V130, P455; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Osman A, 2001, ASSESSMENT, V8, P443, DOI 10.1177/107319110100800409; Potegal M, 2010, INTERNATIONAL HANDBOOK OF ANGER, P3, DOI 10.1007/978-0-387-89676-2_1; Ramchand R, 2011, WAR PREVENTING SUICI; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Ribeiro JD, 2011, J PERS ASSESS, V93, P597, DOI 10.1080/00223891.2011.608758; Rudd MD, 2006, ASSESSMENT MANAGEMEN; Skopp Nancy A, 2012, MSMR, V19, P7; Sours C, 2015, BRAIN IMAGING BEHAV, V9, P190, DOI 10.1007/s11682-014-9295-y; Stefan A., 2016, ANN PHYS REHABIL MED; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; U.S. Department of Health and Human Services, 2012, NAT STRAT SUIC PREV; VANORDEN KA, 2010, Patent No. 117575; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Walker AJ, 2010, BRAIN INJURY, V24, P517, DOI 10.3109/02699051003601721	59	19	19	0	26	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	JAN	2017	84						161	168		10.1016/j.jpsychires.2016.10.004			8	Psychiatry	Psychiatry	EG0OW	WOS:000390733100020	27743528	Bronze			2021-06-18	
J	Tang, CH; Shan, YD; Hu, YL; Fang, ZJ; Tong, Y; Chen, MD; Wei, XJ; Fu, XJ; Xu, XL				Tang, Chonghui; Shan, Yudong; Hu, Yilan; Fang, Zhanjian; Tong, Yun; Chen, Mengdan; Wei, Xiaojie; Fu, Xiaojun; Xu, Xinlong			FGF2 Attenuates Neural Cell Death via Suppressing Autophagy after Rat Mild Traumatic Brain Injury	STEM CELLS INTERNATIONAL			English	Article							FIBROBLAST-GROWTH-FACTOR; UBIQUITINATED PROTEIN ACCUMULATION; SUBARACHNOID HEMORRHAGE; MITOCHONDRIAL PATHWAY; FUNCTIONAL RECOVERY; CLINICAL-TRIAL; MICE; APOPTOSIS; CONTRIBUTES; NEUROGENESIS	Traumatic brain injury (TBI) can lead to physical and cognitive deficits, which are caused by the secondary injury process. Effective pharmacotherapies for TBI patients are still lacking. Fibroblast growth factor-2 (FGF2) is an important neurotrophic factor that can stimulate neurogenesis and angiogenesis and has been shown to have neuroprotective effects after brain insults. Previous studies indicated that FGF2's neuroprotective effects might be related to its function of regulating autophagy. The present study investigated FGF2's beneficial effects in the early stage of rat mild TBI and the underlying mechanisms. One hundred and forty-four rats were used for creating controlled cortical impact (CCI) models to simulate the pathological damage after TBI. Our results indicated that pretreatment of FGF2 played a neuroprotective role in the early stage of rat mild TBI through alleviating brain edema, reducing neurological deficits, preventing tissue loss, and increasing the number of surviving neurons in injured cortex and the ipsilateral hippocampus. FGF2 could also protect cells from various forms of death such as apoptosis or necrosis through inhibition of autophagy. Finally, autophagy activator rapamycin could abolish the protective effects of FGF2. This study extended our understanding of FGF2's neuroprotective effects and shed lights on the pharmacological therapy after TBI.	[Tang, Chonghui; Shan, Yudong; Hu, Yilan; Fang, Zhanjian; Tong, Yun; Chen, Mengdan; Wei, Xiaojie; Fu, Xiaojun; Xu, Xinlong] Wenzhou Med Univ, Affiliated Cixi Hosp, Dept Neurosurg, 999 Nanerhuandong Rd, Ningbo 315300, Zhejiang, Peoples R China	Xu, XL (corresponding author), Wenzhou Med Univ, Affiliated Cixi Hosp, Dept Neurosurg, 999 Nanerhuandong Rd, Ningbo 315300, Zhejiang, Peoples R China.	xuxinlong2001@126.com			Natural Science Foundation of Ningbo City [2015A610192]; Science and Technology Plan Projects of Cixi City [CN2015022]	This study was supported by the Natural Science Foundation of Ningbo City (2015A610192) and Science and Technology Plan Projects of Cixi City (CN2015022).	Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Feng CC, 2012, INT J PHARMACEUT, V423, P226, DOI 10.1016/j.ijpharm.2011.12.008; Feng Y, 2017, CELL MOL NEUROBIOL, V37, P155, DOI 10.1007/s10571-016-0356-1; Grishchuk Y, 2011, AUTOPHAGY, V7, P1115, DOI 10.4161/auto.7.10.16608; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Huang B, 2012, NEUROBIOL DIS, V46, P204, DOI 10.1016/j.nbd.2012.01.008; Jing CH, 2012, NEUROSCIENCE, V213, P144, DOI 10.1016/j.neuroscience.2012.03.055; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Katsouri L, 2015, NEUROBIOL AGING, V36, P821, DOI 10.1016/j.neurobiolaging.2014.10.004; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lin X, 2011, INT J BIOL SCI, V7, P1114, DOI 10.7150/ijbs.7.1114; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Mellergard P, 2010, BRIT J NEUROSURG, V24, P261, DOI 10.3109/02688690903521605; Menon DK, 2015, NAT REV NEUROL, V11, P71, DOI 10.1038/nrneurol.2014.261; Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001; Ogane K, 2002, NEUROL RES, V24, P365, DOI 10.1179/016164102101200159; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Shetty AK, 2005, GLIA, V51, P173, DOI 10.1002/glia.20187; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Thau-Zuchman O, 2012, J MOL NEUROSCI, V47, P166, DOI 10.1007/s12031-012-9706-8; Wang ZG, 2016, MOL NEUROBIOL, V53, P7298, DOI 10.1007/s12035-015-9583-6; Wang ZG, 2015, SCI REP-UK, V5, DOI 10.1038/srep09287; Wang ZG, 2012, TOXICOL LETT, V212, P137, DOI 10.1016/j.toxlet.2012.05.006; Weickert CS, 2005, NEUROSCIENCE, V131, P219, DOI 10.1016/j.neuroscience.2004.09.070; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wirawan E, 2012, CELL RES, V22, P43, DOI 10.1038/cr.2011.152; Woodbury ME, 2014, J NEUROIMMUNE PHARM, V9, P92, DOI 10.1007/s11481-013-9501-5; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Ye LB, 2016, NEUROTHERAPEUTICS, V13, P844, DOI 10.1007/s13311-016-0437-3; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Zhang HY, 2013, MOL NEUROBIOL, V48, P452, DOI 10.1007/s12035-013-8432-8; Zhang J, 2012, AUTOPHAGY, V8, P690, DOI 10.4161/auto.19290; Zhao M., 2015, MOL MED REPORTS, V13	52	19	20	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1687-966X	1687-9678		STEM CELLS INT	Stem Cells Int.		2017	2017								2923182	10.1155/2017/2923182			14	Cell & Tissue Engineering	Cell Biology	FK0GU	WOS:000413159100001	29181034	DOAJ Gold, Green Published			2021-06-18	
J	Wu, Y; Wang, JY; Shi, YJ; Pu, HJ; Leak, RK; Liou, AKF; Badylak, SF; Liu, ZX; Zhang, J; Chen, J; Chen, L				Wu, Yun; Wang, Jiayin; Shi, Yejie; Pu, Hongjian; Leak, Rehana K.; Liou, Anthony K. F.; Badylak, Stephen F.; Liu, Zhixiong; Zhang, Jun; Chen, Jun; Chen, Ling			Implantation of Brain-Derived Extracellular Matrix Enhances Neurological Recovery after Traumatic Brain Injury	CELL TRANSPLANTATION			English	Article						astrogliosis; microglia; neurobehavioral function; neurodegeneration; white matter injury; concussion	MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; WHITE-MATTER; NERVOUS-SYSTEM; BIOLOGIC SCAFFOLDS; CEREBRAL-ISCHEMIA; PROGENITOR CELLS; MOUSE MODEL; STEM-CELLS; STROKE; RATS	Scaffolds composed of extracellular matrix (ECM) are being investigated for their ability to facilitate brain tissue remodeling and repair following injury. The present study tested the hypothesis that the implantation of brain-derived ECM would attenuate experimental traumatic brain injury (TBI) and explored potential underlying mechanisms. TBI was induced in mice by a controlled cortical impact (CCI). ECM was isolated from normal porcine brain tissue by decellularization methods, prepared as a hydrogel, and injected into the ipsilesional corpus callosum and striatum 1 h after CCI. Lesion volume and neurological function were evaluated up to 35 d after TBI. Immunohistochemistry was performed to assess post-TBI white matter integrity, reactive astrogliosis, and microglial activation. We found that ECM treatment reduced lesion volume and improved neuro-behavioral function. ECM-treated mice showed less post-TBI neurodegeneration in the hippocampus and less white matter injury than control, vehicle-treated mice. Furthermore, ECM ameliorated TBI-induced gliosis and microglial pro-inflammatory responses, thereby providing a favorable microenvironment for tissue repair. Our study indicates that brain ECM hydrogel implantation improved the brain microenvironment that facilitates post-TBI tissue recovery. Brain ECM offers excellent biocompatibility and holds potential as a therapeutic agent for TBI, alone or in combination with other treatments.	[Wu, Yun; Liu, Zhixiong] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China; [Wu, Yun; Shi, Yejie; Pu, Hongjian; Liou, Anthony K. F.; Chen, Jun] Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, S507 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA; [Wu, Yun; Shi, Yejie; Pu, Hongjian; Liou, Anthony K. F.; Chen, Jun] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Wang, Jiayin] Capital Med Univ, Xuanwu Hosp, Dept Gynecol & Obstet, Beijing, Peoples R China; [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA; [Badylak, Stephen F.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Zhang, Jun; Chen, Ling] Gen Hosp PLA, Dept Neurosurg, 28 Fuxing Rd, Beijing 100853, Peoples R China	Chen, J (corresponding author), Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, S507 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA.; Chen, L (corresponding author), Gen Hosp PLA, Dept Neurosurg, 28 Fuxing Rd, Beijing 100853, Peoples R China.	chenj2@upmc.edu; chen_ling301@163.com	Leak, Rehana K/I-2607-2019; Shi, Yejie/C-2355-2018; Pu, Hongjian/AAW-3322-2020	Leak, Rehana K/0000-0003-2817-7417; Shi, Yejie/0000-0001-7502-9201; 	U. S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045048, NS095671]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30970939, 81272804, 81301066, 81271365]; Beijing Natural Science FoundationBeijing Natural Science Foundation [7132046]; Beijing Nova ProgramBeijing Municipal Science & Technology Commission [XX2013019]; VA Senior Research Career Scientist Award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS095029, R01NS095671, R01NS045048] Funding Source: NIH RePORTER	author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This project was supported by the U. S. National Institutes of Health grants NS045048, NS095671, and NS095029 (to J.C.), National Natural Science Foundation of China grants (#30970939 and # 81272804 to L.C., #81301066 to J.W., and #81271365 to J.Z.), Beijing Natural Science Foundation (#7132046 to J.W.), and Beijing Nova Program (# XX2013019 to J.W.). J.C. is also supported by the VA Senior Research Career Scientist Award. The authors are indebted to Pat Strickler for excellent administrative support.	Agrawal V, 2011, TISSUE ENG PT A, V17, P2435, DOI [10.1089/ten.tea.2011.0036, 10.1089/ten.TEA.2011.0036]; An CR, 2014, PROG NEUROBIOL, V115, P6, DOI 10.1016/j.pneurobio.2013.12.002; Badylak SF, 2005, J SURG RES, V128, P87, DOI 10.1016/j.jss.2005.03.002; Badylak SF, 2008, TISSUE ENG PT A, V14, P1835, DOI 10.1089/ten.tea.2007.0264; Badylak SF, 2012, LANCET, V379, P943, DOI 10.1016/S0140-6736(12)60073-7; Barros CS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005108; Bible E, 2012, BIOMATERIALS, V33, P2858, DOI 10.1016/j.biomaterials.2011.12.033; Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904; Brown BN, 2012, BIOMATERIALS, V33, P3792, DOI 10.1016/j.biomaterials.2012.02.034; Crapo PM, 2014, TISSUE ENG PT A, V20, P313, DOI [10.1089/ten.tea.2013.0186, 10.1089/ten.TEA.2013.0186]; Crapo PM, 2012, BIOMATERIALS, V33, P3539, DOI 10.1016/j.biomaterials.2012.01.044; Desmond DW, 2002, CEREBROVASC DIS, V13, P53, DOI 10.1159/000049151; Dutta S, 2013, CNS NEUROSCI THER, V19, P5, DOI 10.1111/cns.12027; Gan Y, 2012, ANTIOXID REDOX SIGN, V17, P719, DOI 10.1089/ars.2011.4298; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Ho PW, 2005, STROKE, V36, P2742, DOI 10.1161/01.STR.0000189748.52500.a7; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Liu FT, 2014, CNS NEUROSCI THER, V20, P778, DOI 10.1111/cns.12258; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Medberry CJ, 2013, BIOMATERIALS, V34, P1033, DOI 10.1016/j.biomaterials.2012.10.062; Mifsud G, 2014, CNS NEUROSCI THER, V20, P603, DOI 10.1111/cns.12263; Reing JE, 2009, TISSUE ENG PT A, V15, P605, DOI 10.1089/ten.tea.2007.0425; Robinson KA, 2005, CIRCULATION, V112, pI135, DOI 10.1161/CIRCULATIONAHA.104.525436; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Shi H, 2015, EXP NEUROL, V272, P17, DOI 10.1016/j.expneurol.2015.03.017; Stetler RA, 2008, J NEUROSCI, V28, P13038, DOI 10.1523/JNEUROSCI.4407-08.2008; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Wang JY, 2013, CNS NEUROL DISORD-DR, V12, P413, DOI 10.2174/1871527311312030014; Wang JY, 2014, NEUROBIOL DIS, V68, P91, DOI 10.1016/j.nbd.2014.04.014; Wood JD, 2005, JAVMA-J AM VET MED A, V226, P1095, DOI 10.2460/javma.2005.226.1095; Yan T, 2014, CNS NEUROSCI THER, V20, P935, DOI 10.1111/cns.12307; Zantop T, 2006, J ORTHOP RES, V24, P1299, DOI 10.1002/jor.20071; Zhao YH, 2013, CNS NEUROSCI THER, V19, P67, DOI 10.1111/cns.12040	39	19	19	1	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2017	26	7					1224	1234		10.1177/0963689717714090			11	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	EZ4GO	WOS:000404671800010	28933217	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Bennett, TD; Dixon, RR; Kartchner, C; DeWitt, PE; Sierra, Y; Ladell, D; Kempe, A; Runyan, DK; Dean, JM; Keenan, HT				Bennett, Tellen D.; Dixon, Rebecca R.; Kartchner, Cory; DeWitt, Peter E.; Sierra, Yamila; Ladell, Diane; Kempe, Allison; Runyan, Desmond K.; Dean, J. Michael; Keenan, Heather T.			Functional Status Scale in Children With Traumatic Brain Injury: A Prospective Cohort Study	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						brain injuries; craniocerebral trauma; critical care outcomes; patient outcome assessment; pediatrics	PEDIATRIC INTENSIVE-CARE; PERFORMANCE CATEGORY; RISK STRATIFICATION; OUTCOME SCALE; PREDICTION; MORTALITY; ILLNESS; SCORES; UNIT	Objectives: In children with traumatic brain injury, 1) to describe the hospital discharge functional outcome and change from baseline function using the Functional Status Scale and 2) to determine any associations between discharge Functional Status Scale and age, injury mechanism, neurologic examination, imaging, and other predictors of outcome. Design: Prospective observational cohort study, May 2013 to November 2015. Setting: Two U.S. children's hospitals designated as American College of Surgeons level 1 pediatric trauma centers. Patients: Children less than 18 years old admitted to an ICU with acute traumatic brain injury and either a surgical or critical care intervention within the first 24 hours or in-hospital mortality. Interventions: None. Measurements and Main Results: The primary outcome was hospital discharge Functional Status Scale. Most, 133 of 196 (68%), had severe traumatic brain injury (admission Glasgow Coma Scale, 3-8). Overall hospital mortality was 14%; 20% among those with severe traumatic brain injury. Hospital discharge Functional Status Scale had an inverse relationship with Glasgow Coma Scale: for each increase in admission Glasgow Coma Scale by 1, the discharge Functional Status Scale decreased by 0.5 (95% CI, 0.7-0.3). Baseline Functional Status Scale was collected at one site (n = 75). At that site, nearly all (61/62) of the survivors had normal or near-normal (<= 7) preinjury Functional Status Scale. More than one-third, 23 of 62 (37%), of survivors had new morbidity at hospital discharge (increase in Functional Status Scale, >= 3). Among children with severe traumatic brain injury who had baseline Functional Status Scale collected, 21 of 41 survivors (51%) had new morbidity at hospital discharge. The mean change in Functional Status Scale from baseline to hospital discharge was 3.9 +/- 4.9 overall and 5.2 +/- 5.4 in children with severe traumatic brain injury. Conclusions: More than one-third of survivors, and approximately half of survivors with severe traumatic brain injury, will have new morbidity. Hospital discharge Functional Status Scale, change from baseline Functional Status Scale, and new morbidity acquisition can be used as outcome measures for hospital-based care process improvement initiatives and interventional studies of children with traumatic brain injury.	[Bennett, Tellen D.] Univ Colorado, Sch Med, Dept Pediat, Pediat Crit Care Sect, Aurora, CO 80045 USA; [Bennett, Tellen D.; Sierra, Yamila; Ladell, Diane; Kempe, Allison] Childrens Hosp Colorado, Aurora, CO 80045 USA; [Bennett, Tellen D.; Kempe, Allison] Univ Colorado, Sch Med, Adult & Child Consortium Hlth Outcomes Res & Deli, Aurora, CO 80045 USA; [Dixon, Rebecca R.; Dean, J. Michael; Keenan, Heather T.] Univ Utah, Sch Med, Dept Pediat, Div Pediat Crit Care, Salt Lake City, UT USA; [Kartchner, Cory] Primary Childrens Med Ctr, Salt Lake City, UT USA; [DeWitt, Peter E.] Univ Colorado Denver, Dept Bioinformat & Biostat, Aurora, CO USA; [Runyan, Desmond K.] Univ Colorado, Sch Med, Kempe Ctr, Dept Pediat, Aurora, CO USA	Bennett, TD (corresponding author), Univ Colorado, Sch Med, Dept Pediat, Pediat Crit Care Sect, Aurora, CO 80045 USA.; Bennett, TD (corresponding author), Childrens Hosp Colorado, Aurora, CO 80045 USA.; Bennett, TD (corresponding author), Univ Colorado, Sch Med, Adult & Child Consortium Hlth Outcomes Res & Deli, Aurora, CO 80045 USA.	tell.bennett@ucdenver.edu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029; DeWitt, Peter/0000-0002-6391-0795; Bennett, Tellen/0000-0003-1483-4236	Eunice Kennedy Shriver National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074620]; National Center for Research Resources (Colorado Clinical and Translational Sciences Institute grant) [UL1 TR001082]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH funds from the Collaborative Pediatric Clinical Research Network (CPCCRN); federal government for research (NICHD, CDC); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074620] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001082] Funding Source: NIH RePORTER	Supported, in part, by the Eunice Kennedy Shriver National Institute for Child Health and Human Development (grant number: K23HD074620 to Dr. Bennett) and the National Center for Research Resources (Colorado Clinical and Translational Sciences Institute grant number: UL1 TR001082).; Dr. Bennet received support for article research from the National Institutes of Health (NIH). His institution received funding from NICHD and from National Center for Research Resources. Dr. Dixon disclosed other support: she works for the University of Utah Division of Pediatric Critical Care Medicine; this Division receives NIH funding to be the Data Coordinating Center for the Collaborative Pediatric Critical Care Research Network [CPCCRN], which developed the Functional Status Scale [FSS]. She has not personally received any payments or support from this relationship with the NIH. Dr. Kartchner disclosed other support: all funding was received through the lead author, Tellen Bennett, MD. He has given full disclosure). Drs. Sierra and Ladel's institution received funding from NIH funds from the Collaborative Pediatric Clinical Research Network (CPCCRN) projects for salary and travel reimbursement. CPCCRN developed the FSS that this paper discusses. Dr. Kempe's institution received funding from the NIH. Dr. Keenan's institution received funding: she receives grant funding from the federal government for research (NICHD, CDC). Her institution received funding from the NICHD as a K23 award (Dr. Bennett) for this work. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Bennett TD, 2015, PEDIATR CRIT CARE ME, V16, P377, DOI 10.1097/PCC.0000000000000380; Bone MF, 2014, PEDIATR CRIT CARE ME, V15, P640, DOI 10.1097/PCC.0000000000000199; Choong K, 2015, PEDIATR CRIT CARE ME, V16, P310, DOI 10.1097/PCC.0000000000000362; Chun KA, 2010, J NEUROTRAUM, V27, P325, DOI 10.1089/neu.2009.1115; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; Frieden T, 2014, C TRAUM BRAIN INJU U; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Liesemer K, 2014, PEDIATR CRIT CARE ME, V15, P554, DOI 10.1097/PCC.0000000000000150; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Namachivayam P, 2010, PEDIATR CRIT CARE ME, V11, P549, DOI 10.1097/PCC.0b013e3181ce7427; Pollack MM, 2015, CRIT CARE MED, V43, P1699, DOI 10.1097/CCM.0000000000001081; Pollack MM, 2014, PEDIATR CRIT CARE ME, V15, P821, DOI 10.1097/PCC.0000000000000250; Pollack MM, 2014, JAMA PEDIATR, V168, P671, DOI 10.1001/jamapediatrics.2013.5316; Pollack MM, 2009, PEDIATRICS, V124, pE18, DOI 10.1542/peds.2008-1987; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Slonim AD, 2010, PEDIATRICS, V125, P1208, DOI 10.1542/peds.2009-1451; Tasker RC, 2014, PEDIATR CRIT CARE ME, V15, P569, DOI 10.1097/PCC.0000000000000164; Tufte E. R., 2001, VISUAL DISPLAY QUANT	24	19	19	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	DEC	2016	17	12					1147	1156		10.1097/PCC.0000000000000934			10	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	EF2FA	WOS:000390138900010	27753754	Green Accepted			2021-06-18	
J	Chen, SL; Phang, I; Zoumprouli, A; Papadopoulos, MC; Saadoun, S				Chen, Suliang; Phang, Isaac; Zoumprouli, Argyro; Papadopoulos, Marios C.; Saadoun, Samira			Metabolic profile of injured human spinal cord determined using surface microdialysis	JOURNAL OF NEUROCHEMISTRY			English	Article						critical care unit; human; Kohonen self-organizing maps; microdialysis; prognosis; spinal cord injury	TRAUMATIC BRAIN-INJURY; PRESSURE EVALUATION; INTRASPINAL PRESSURE; PERFUSION-PRESSURE	The management of patients having traumatic spinal cord injury would benefit from understanding and monitoring of spinal cord metabolic states. We hypothesized that the metabolism of the injured spinal cord could be visualized using Kohonen self-organizing maps. Sixteen patients with acute, severe spinal cord injuries were studied. Starting within 72h of the injury, and for up to a week, we monitored the injury site hourly for tissue glucose, lactate, pyruvate, glutamate, and glycerol using microdialysis as well as intraspinal pressure and spinal cord perfusion pressure. A Kohonen map, which is an unsupervised, self-organizing topology-preserving neural network, was used to analyze 3366h of monitoring data. We first visualized the different spinal cord metabolic states. Our data show that the injured cord assumes one or more of four metabolic states. On the basis of their metabolite profiles, we termed these states near-normal, ischemic, hypermetabolic, and distal. We then visualized how patients' intraspinal pressure and spinal cord perfusion pressure affect spinal cord metabolism. This revealed that for more than 60% of the time, spinal cord metabolism is patient-specific; periods of high intraspinal pressure or low perfusion pressure are not associated with specific spinal cord metabolic patterns. Finally, we determined relationships between spinal cord metabolism and neurological status. Patients with complete deficits have shorter periods of near-normal spinal cord metabolic states (74% vs. 58 +/- 12%, p<0.01, mean +/- standard error) and more variable injury site metabolic responses (metabolism spread in 70 +/- 11 vs. 40 +/- 6 hexagons, p<0.05), compared with patients who have incomplete neurological deficits. We conclude that Kohonen maps allow us to visualize the metabolic responses of the injured spinal cord and may thus aid us in treating patients with acute spinal cord injuries.	[Chen, Suliang; Phang, Isaac; Papadopoulos, Marios C.; Saadoun, Samira] St Georges Univ London, Acad Neurosurg Unit, London, England; [Zoumprouli, Argyro] St George Hosp, Neurointens Care, London, England	Saadoun, S (corresponding author), St Georges Univ London, Room 1-234 Jenner Wing, London SW17 0RE, England.	ssaadoun@sgul.ac.uk		Saadoun, Samira/0000-0002-5480-5678; Papadopoulos, Marios/0000-0001-9174-4176; Zoumprouli, Argyro/0000-0003-0890-690X	Wings for Life Spinal Cord Research Foundation; Neurosciences Research Foundation (Fletcher Fund); London Deanery	We thank St. George's Hospital, King's College Hospital and Hurstwood Park Neurological Centre neurosurgical departments helped recruit patients. The anesthetic, neuro-intensive care and operating theater staff at St. George's Hospital helped with data collection. The study was funded by Wings for Life Spinal Cord Research Foundation, Neurosciences Research Foundation (Fletcher Fund), and the London Deanery. The authors have no conflict of interest to declare.	Awad BI, 2015, WORLD NEUROSURG, V83, P120, DOI 10.1016/j.wneu.2013.01.042; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Cozzens JW, 2013, NEUROSURGERY, V72, P2, DOI 10.1227/NEU.0b013e3182772981; Cripps RA, 2011, SPINAL CORD, V49, P493, DOI 10.1038/sc.2010.146; Fehlings MG, 2010, SPINE, V35, pS166, DOI 10.1097/BRS.0b013e3181f386f6; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Kohonen T, 2013, NEURAL NETWORKS, V37, P52, DOI 10.1016/j.neunet.2012.09.018; Nelson DW, 2004, CRIT CARE MED, V32, P2428, DOI 10.1097/01.CCM.0000147688.08813.9C; Phang I, 2016, ANN NEUROL, V80, P522, DOI 10.1002/ana.24750; Phang I, 2016, J NEUROSURG-SPINE, V25, P398, DOI 10.3171/2016.1.SPINE151317; Phang I, 2015, J NEUROTRAUM, V32, P865, DOI 10.1089/neu.2014.3668; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028; Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038	14	19	19	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	2016	139	5					700	705		10.1111/jnc.13854			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	ED8QA	WOS:000389134800003	27664973	Green Accepted			2021-06-18	
J	Di Iorgi, N; Morana, G; Allegri, AEM; Napoli, F; Gastaldi, R; Calcagno, A; Patti, G; Loche, S; Maghnie, M				Di Iorgi, Natascia; Morana, Giovanni; Allegri, Anna Elsa Maria; Napoli, Flavia; Gastaldi, Roberto; Calcagno, Annalisa; Patti, Giuseppa; Loche, Sandro; Maghnie, Mohamad			Classical and non-classical causes of GH deficiency in the paediatric age	BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article						hypopituitarism; GHD; MRI; pituitary stalk; anterior pituitary; ectopic posterior pituitary	GROWTH-HORMONE DEFICIENCY; PITUITARY-STALK INTERRUPTION; ECTOPIC POSTERIOR PITUITARY; CENTRAL DIABETES-INSIPIDUS; TRAUMATIC BRAIN-INJURY; SEPTO-OPTIC DYSPLASIA; INTERNAL CAROTID-ARTERY; FOLLOW-UP; EMPTY SELLA; IMAGING ABNORMALITIES	Growth hormone deficiency (GHD) may result from a failure of hypothalamic GHRH production or release, from congenital disorders of pituitary development, or from central nervous system insults including tumors, surgery, trauma, radiation or infiltration from inflammatory diseases. Idiopathic, isolated GHD is the most common sporadic form of hypopituitarism. GHD may also occur in combination with other pituitary hormone deficiencies, and is often referred to as hypopituitarism, combined pituitary hormone deficiency (CPHD), multiple pituitary hormone deficiency (MPHD) or panhypopituitarism. Children without any identifiable cause of their GHD are commonly labeled as having idiopathic hypopituitarism. MRI imaging is the technique of choice in the diagnosis of children with hypopituitarism. Marked differences in MRI pituitary gland morphology suggest different etiologies of GHD and different prognoses. Pituitary stalk agenesis and ectopic posterior pituitary (EPP) are specific markers of permanent GHD, and patients with these MRI findings show a different clinical and endocrine outcome compared to those with normal pituitary anatomy or hypoplastic pituitary alone. Furthermore, the classic triad of ectopic posterior pituitary gland, pituitary stalk hypoplasia/agenesis, and anterior pituitary gland hypoplasia is generally associated with permanent GHD. T2 DRIVE images aid in the identification of pituitary stalk without the use of contrast medium administration. Future developments in imaging techniques will undoubtedly reveal additional insights. Mutations in a number of genes encoding transcription factors - such as HESX1, SOX2, SOX3, LHX3, LHX4, PROP1, POUlF1, PITX, GLI3, GLI2, OTX2, ARNT2, IGSF1, FGF8, FGFR1, PROKR2, PROK2, CHD7, WDR11, NFKB2, PAX6, TCF7L1, IFT72, GPR161 and CDON - have been associated with pituitary dysfunction and abnormal pituitary gland development; the correlation of genetic mutations to endocrine and MRI phenotypes has improved our knowledge of pituitary development and management of patients with hypopituitarism, both in terms of possible genetic counseling, and of early diagnosis of evolving anterior pituitary hormone deficiencies. (C) 2016 Elsevier Ltd. All rights reserved.	[Di Iorgi, Natascia; Allegri, Anna Elsa Maria; Napoli, Flavia; Gastaldi, Roberto; Calcagno, Annalisa; Patti, Giuseppa; Maghnie, Mohamad] Univ Genoa, Ist Giannina Gaslini, Dept Pediat, Genoa, Italy; [Morana, Giovanni] Ist Giannina Gaslini, Neuroradiol Unit, Genoa, Italy; [Loche, Sandro] Osped Pediat Microcitem A Cao, SSD Endocrinol Pediat, Cagliari, Italy; [Di Iorgi, Natascia; Allegri, Anna Elsa Maria; Napoli, Flavia; Gastaldi, Roberto; Calcagno, Annalisa; Patti, Giuseppa; Maghnie, Mohamad] Univ Genoa, Ist Giannina Gaslini, Dept Endocrine Unit, Genoa, Italy	Maghnie, M (corresponding author), IRCCS Giannina Gaslini, Dept Pediat, Largo Gerolamo Gaslini 5, I-16147 Genoa, Italy.	mohamadmaghnie@gaslini.org	patti, giusi/AAB-4362-2021; Di Iorgi, Natascia/AAB-8486-2021; Allegri, Anna Elsa Maria/AAB-5750-2021; Napoli, Flavia/AAA-7624-2020; Morana, Giovanni/J-6134-2018; GASTALDI, ROBERTO/AAB-4584-2020; CALCAGNO, ANNALISA/AAA-8142-2020	patti, giusi/0000-0002-6217-1919; Di Iorgi, Natascia/0000-0002-4492-4585; Allegri, Anna Elsa Maria/0000-0002-5927-049X; Morana, Giovanni/0000-0001-8707-5969; GASTALDI, ROBERTO/0000-0002-2157-1158			ADAN L, 1994, J CLIN ENDOCR METAB, V78, P353, DOI 10.1210/jc.78.2.353; Akcay A, 2013, EUR J MED GENET, V56, P445, DOI 10.1016/j.ejmg.2013.06.006; Alatzoglou KS, 2014, ENDOCR REV, V35, P376, DOI 10.1210/er.2013-1067; Arends NJT, 2002, CLIN ENDOCRINOL, V57, P719, DOI 10.1046/j.1365-2265.2002.01605.x; Argente J, 2014, EMBO MOL MED, V6, P299, DOI 10.1002/emmm.201303573; ARGYROPOULOU M, 1992, J PEDIATR-US, V120, P886, DOI 10.1016/S0022-3476(05)81955-9; Asakura Yumi, 2015, Clin Pediatr Endocrinol, V24, P27, DOI 10.1297/cpe.24.27; Bancalari RE, 2012, ENDOCR DEV, V23, P1, DOI 10.1159/000341733; BAO XL, 1992, CHINESE MED J-PEKING, V105, P401; Barnes N, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00101; Bas F, 2006, J PEDIATR ENDOCR MET, V19, P535; Bashamboo A, 2016, J CLIN ENDOCR METAB, V101, P12, DOI 10.1210/jc.2015-2995; Bensing S, 2007, P NATL ACAD SCI USA, V104, P949, DOI 10.1073/pnas.0610070104; Bonneville F, 2006, RADIOGRAPHICS, V26, P93, DOI 10.1148/rg.261055045; CACCIARI E, 1994, J CLIN ENDOCR METAB, V78, P767, DOI 10.1210/jc.78.3.767; Casano-Sancho P, 2013, CLIN ENDOCRINOL, V79, P853, DOI 10.1111/cen.12237; Castinetti F, 2016, EUR J ENDOCRINOL, V174, pR239, DOI 10.1530/EJE-15-1095; Caturegli P, 2005, ENDOCR REV, V26, P599, DOI 10.1210/er.2004-0011; Cervantes Luisa F, 2006, Radiology, V241, P936, DOI 10.1148/radiol.2413032060; Chemaitilly W, 2015, J CLIN ONCOL, V33, P492, DOI 10.1200/JCO.2014.56.7933; Chen S, 1999, J CLIN ENDOCR METAB, V84, P2408, DOI 10.1210/jc.84.7.2408; Chernov MF, 2009, J NEURO-ONCOL, V91, P191, DOI 10.1007/s11060-008-9698-y; Child CJ, 2016, EUR J ENDOCRINOL, V15, P1203; Clayton PE, 2005, EUR J ENDOCRINOL, V152, P165, DOI 10.1530/eje.1.01829; Clement SC, 2014, PEDIATR BLOOD CANCER, V61, P2285, DOI 10.1002/pbc.25176; Correa FA, 2015, ENDOCR CONNECT, V4, P100, DOI 10.1530/EC-15-0015; Coutant R, 2001, J CLIN ENDOCR METAB, V86, P4649, DOI 10.1210/jc.86.10.4649; COX TD, 1991, RADIOLOGY, V179, P721, DOI 10.1148/radiology.179.3.2027981; Darzy Ken H., 2009, V15, P1, DOI 10.1159/000207607; De Bellis A, 2012, J CLIN ENDOCR METAB, V97, P3684, DOI 10.1210/jc.2012-2269; De Bellis A, 2006, J CLIN ENDOCR METAB, V91, P2484, DOI 10.1210/jc.2006-0040; De Bellis A, 2016, EUR J ENDOCRINOL, V174, P381, DOI 10.1530/EJE-15-0766; de Graaff LCG, 2008, CLIN ENDOCRINOL, V69, P112, DOI 10.1111/j.1365-2265.2007.03167.x; De Luca F, 1992, ACTA PAEDIATR, V85, P1167; Deal C, 2013, HORM RES PAEDIAT, V79, P283, DOI 10.1159/000350829; Degnan AJ, 2011, AM J NEURORADIOL, V32, P1986, DOI 10.3174/ajnr.A2404; Demaerel P, 2008, NEURORADIOLOGY, V50, P85, DOI 10.1007/s00234-007-0323-0; Demurger F, 2015, EUR J HUM GENET, V23, P92, DOI 10.1038/ejhg.2014.62; di Iorgi N, 2007, J CLIN ENDOCR METAB, V92, P3875, DOI 10.1210/jc.2007-1081; Di Iorgi N, 2015, CLIN ENDOCRINOL, V83, P449, DOI 10.1111/cen.12769; Di Iorgi N, 2015, BEST PRACT RES CL EN, V29, P415, DOI 10.1016/j.beem.2015.04.013; Di Iorgi N, 2014, J CLIN ENDOCR METAB, V99, P1264, DOI 10.1210/jc.2013-3724; Di Iorgi N, 2012, ENDOCR DEV, V23, P16, DOI 10.1159/000341736; Di Iorgi N, 2012, HORM RES PAEDIAT, V77, P69, DOI 10.1159/000336333; DIETRICH RB, 1995, AM J NEURORADIOL, V16, P1413; Dupuis-Girod S, 2001, J PEDIATR-US, V138, P129, DOI 10.1067/mpd.2001.109200; Eldevik OP, 1996, AM J NEURORADIOL, V17, P1427; ELSTER AD, 1990, RADIOLOGY, V174, P681, DOI 10.1148/radiology.174.3.2305049; ELSTER AD, 1993, RADIOLOGY, V187, P1; Fink AM, 2005, J CLIN ENDOCR METAB, V90, P3274, DOI 10.1210/jc.2004-1558; Franca MM, 2010, J CLIN ENDOCR METAB, V95, pE384, DOI 10.1210/jc.2010-1050; FUJITA K, 1992, EUR J PEDIATR, V151, P266, DOI 10.1007/BF02072226; Gabbay LB, 2014, ARQ NEURO-PSIQUIAT, V72, P548, DOI 10.1590/0004-282X20140063; Gan HW, 2015, J CLIN ENDOCR METAB, V100, P3787, DOI 10.1210/jc.2015-2028; Gaston-Massuet C, 2016, P NATL ACAD SCI USA, V113, pE548, DOI 10.1073/pnas.1503346113; Genovese E, 1997, PEDIATR RADIOL, V27, P48, DOI 10.1007/s002470050062; Gleeson H, 2008, EUR J ENDOCRINOL, V159, pS95, DOI 10.1530/EJE-08-0400; Gleeson HK, 2004, ENDOCR-RELAT CANCER, V11, P589, DOI 10.1677/erc.1.00779; Gregory LC, 2015, J CLIN ENDOCR METAB, V100, P2158, DOI 10.1210/jc.2014-4484; Gregory LC, 2015, CLIN ENDOCRINOL, V82, P728, DOI 10.1111/cen.12637; Gregory LC, 2013, J CLIN ENDOCR METAB, V98, pE737, DOI 10.1210/jc.2012-3467; Halasz Z, 2008, J ENDOCRINOL INVEST, V31, P74, DOI 10.1007/BF03345570; Hamilton J, 1998, AM J MED GENET, V80, P128, DOI 10.1002/(SICI)1096-8628(19981102)80:2<128::AID-AJMG7>3.0.CO;2-C; Hasi-Zogaj M, 2015, AM J MED GENET C, V169, P251, DOI 10.1002/ajmg.c.31445; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Hopper N, 2006, J PEDIATR ENDOCR MET, V19, P325; Iorgi ND, 2012, CLIN ENDOCRINOL, V76, P161, DOI 10.1111/j.1365-2265.2011.04238.x; Joustra SD, 2016, J CLIN ENDOCR METAB, V101, P1627, DOI 10.1210/jc.2015-3880; Kalra AA, 2011, J CHILD NEUROL, V26, P87, DOI 10.1177/0883073810373278; Karaca E, 2015, J CLIN ENDOCR METAB, V100, pE140, DOI 10.1210/jc.2014-1984; Kaulfers AMD, 2010, J PEDIATR-US, V157, P894, DOI 10.1016/j.jpeds.2010.07.004; KIKUCHI K, 1988, J CLIN ENDOCR METAB, V67, P817, DOI 10.1210/jcem-67-4-817; Kjellin IB, 1999, PEDIATR RADIOL, V29, P586, DOI 10.1007/s002470050654; LACEY KA, 1974, LANCET, V1, P42; LARIZZA D, 1993, EUR J PEDIATR, V152, P424, DOI 10.1007/BF01955903; LARIZZA D, 1990, J MED GENET, V27, P53, DOI 10.1136/jmg.27.1.53; Leger J, 2005, J CLIN ENDOCR METAB, V90, P650, DOI 10.1210/jc.2004-1274; Lenz Anne M, 2012, Pediatr Endocrinol Rev, V9, P710; LINDSAY R, 1994, J PEDIATR-US, V125, P29, DOI 10.1016/S0022-3476(94)70117-2; Lubinsky MS, 1997, AM J MED GENET, V69, P235, DOI 10.1002/(SICI)1096-8628(19970331)69:3<235::AID-AJMG4>3.3.CO;2-5; Lucas-Herald AK, 2015, J CLIN ENDOCR METAB, V100, P1221, DOI 10.1210/jc.2014-3852; Maghnie M, 1999, J CLIN ENDOCR METAB, V84, P1324, DOI 10.1210/jc.84.4.1324; MAGHNIE M, 1994, RADIOLOGY, V193, P493, DOI 10.1148/radiology.193.2.7972767; Maghnie M, 1998, J CLIN ENDOCR METAB, V83, P3089, DOI 10.1210/jc.83.9.3089; Maghnie M, 2000, NEW ENGL J MED, V343, P998, DOI 10.1056/NEJM200010053431403; Maghnie M, 1998, EUR J ENDOCRINOL, V139, P635, DOI 10.1530/eje.0.1390635; Maghnie M, 2005, EUR J ENDOCRINOL, V152, P589, DOI 10.1530/eje.1.01873; Maghnie M, 2004, J ENDOCRINOL INVEST, V27, P496, DOI 10.1007/BF03345298; Maghnie M, 2004, J CLIN ENDOCR METAB, V89, P1891, DOI 10.1210/jc.2003-031608; MAGHNIE M, 1993, EUR J PEDIATR, V152, P175, DOI 10.1007/BF02072501; Maghnie M, 1996, CLIN ENDOCRINOL, V45, P281, DOI 10.1046/j.1365-2265.1996.00789.x; Maghnie M, 2002, J CLIN ENDOCR METAB, V87, P2740, DOI 10.1210/jc.87.6.2740; MAGHNIE M, 1991, J CLIN ENDOCR METAB, V73, P79, DOI 10.1210/jcem-73-1-79; MAGHNIE M, 1990, PEDIATR RADIOL, V20, P229, DOI 10.1007/BF02019654; Maghnie M, 2006, J CLIN ENDOCR METAB, V91, P2900, DOI 10.1210/jc.2006-0050; Maghnie M, 2013, EUR J ENDOCRINOL, V168, P211, DOI 10.1530/EJE-12-0801; Marziali S, 2004, PEDIATR RADIOL, V34, P547, DOI 10.1007/s00247-004-1208-6; McCabe MJ, 2013, J CLIN ENDOCR METAB, V98, pE547, DOI 10.1210/jc.2012-3067; McCabe MJ, 2011, J CLIN ENDOCR METAB, V96, pE1709, DOI 10.1210/jc.2011-0454; McMahon CL, 2001, TERATOLOGY, V64, P83, DOI 10.1002/tera.1049; Mehta A, 2009, CLIN ENDOCRINOL, V71, P376, DOI 10.1111/j.1365-2265.2009.03572.x; Melo C, 2013, GENE, V529, P186, DOI 10.1016/j.gene.2013.07.031; Merchant TE, 2011, J CLIN ONCOL, V29, P4776, DOI 10.1200/JCO.2011.37.9453; Migliaretti G, 2006, J ENDOCRINOL INVEST, V29, P438, DOI 10.1007/BF03344127; Morana G, 2010, ENDOCRIN DEV, V17, P160, DOI 10.1159/000262537; Muller HL, 2014, ENDOCR REV, V35, P513, DOI 10.1210/er.2013-1115; Murray PG, 2008, CLIN ENDOCRINOL, V69, P597, DOI 10.1111/j.1365-2265.2008.03236.x; Murray PG, 2009, CLIN ENDOCRINOL, V71, P215, DOI 10.1111/j.1365-2265.2009.03554.x; Murray PG, 2005, J PEDIATR ENDOCR MET, V18, P471; Netchine I, 2000, NAT GENET, V25, P182, DOI 10.1038/76041; Oguz KK, 2003, EUR RADIOL, V13, P1056, DOI 10.1007/s00330-002-1580-2; Orrico A, 2002, EUR J NEUROL, V9, P679, DOI 10.1046/j.1468-1331.2002.00473.x; Pampanini V, 2015, HORM RES PAEDIAT, V84, P323, DOI 10.1159/000439590; Parano E, 2000, NEUROPEDIATRICS, V31, P325, DOI 10.1055/s-2000-12957; PARKIN JM, 1974, ARCH DIS CHILD, V49, P904, DOI 10.1136/adc.49.11.904; Patat O, 2013, MOL SYNDROMOL, V4, P302, DOI 10.1159/000353727; Petryk A, 2015, J CLIN ENDOCR METAB, V100, P803, DOI 10.1210/jc.2014-4357; Pfaeffle RW, 2008, J CLIN ENDOCR METAB, V93, P1062, DOI 10.1210/jc.2007-1525; Pfaeffle RW, 2007, J CLIN ENDOCR METAB, V92, P1909, DOI 10.1210/jc.2006-2177; PHILLIPS JA, 1994, J CLIN ENDOCR METAB, V78, P11, DOI 10.1210/jc.78.1.11; Pinto G, 1997, J CLIN ENDOCR METAB, V82, P3450, DOI 10.1210/jc.82.10.3450; Poretti A, 2013, PEDIATR RADIOL, V43, P28, DOI 10.1007/s00247-012-2428-9; Quentien MH, 2012, J CLIN ENDOCR METAB, V97, pE121, DOI 10.1210/jc.2011-0407; Quigley Charmian A, 2013, Int J Pediatr Endocrinol, V2013, P6, DOI 10.1186/1687-9856-2013-6; Reifschneider K, 2015, J CLIN MED, V4, P1536, DOI 10.3390/jcm4081536; Reynaud R, 2012, J CLIN ENDOCR METAB, V97, pE1068, DOI 10.1210/jc.2011-3056; Righini A, 2009, AM J NEURORADIOL, V30, P1014, DOI 10.3174/ajnr.A1481; RONA RJ, 1977, ARCH DIS CHILD, V52, P197, DOI 10.1136/adc.52.3.197; Rossi A, 2006, J PEDIATR ENDOCR MET, V19, P299; Rossi A, 2010, PEDIATR RADIOL, V40, P999, DOI 10.1007/s00247-010-1613-y; Secco A, 2011, EUR J ENDOCRINOL, V165, P411, DOI 10.1530/EJE-11-0437; Secco A, 2009, J CLIN ENDOCR METAB, V94, P4251, DOI 10.1210/jc.2009-0779; Secco A, 2009, J CLIN ENDOCR METAB, V94, P4195, DOI 10.1210/jc.2009-0602; Sergouniotis PI, 2015, J HUM GENET, V60, P199, DOI 10.1038/jhg.2014.122; SIEGEL SF, 1995, EUR J ENDOCRINOL, V133, P87, DOI 10.1530/eje.0.1330087; Sobrier ML, 2006, J CLIN ENDOCR METAB, V91, P4528, DOI 10.1210/jc.2006-0426; Stagi S, 2015, BMC ENDOCR DISORD, V15, DOI 10.1186/s12902-015-0037-y; SURTEES R, 1987, HORM RES, V28, P5, DOI 10.1159/000180918; Takagi M, 2015, EUR J ENDOCRINOL, V172, DOI 10.1530/EJE-14-0255; Takano K, 1999, AM J NEURORADIOL, V20, P312; Tanriverdi F, 2015, ENDOCR REV, V36, P305, DOI 10.1210/er.2014-1065; Thomas M, 2004, EUR J ENDOCRINOL, V151, P67, DOI 10.1530/eje.0.1510067; Tortori-Donati P, 2005, PEDIAT NEURORADIOLOG, P855; TRIULZI F, 1994, PEDIATRICS, V93, P409; Tsunoda A, 1997, AM J NEURORADIOL, V18, P551; Turton JPG, 2005, J CLIN ENDOCR METAB, V90, P4762, DOI 10.1210/jc.2005-0570; Vega RM, 2015, CANCER-AM CANCER SOC, V121, P1694, DOI 10.1002/cncr.29209; VIMPANI GV, 1977, BRIT MED J, V2, P427, DOI 10.1136/bmj.2.6084.427; Vincent A, 2014, J MED GENET, V51, P797, DOI 10.1136/jmedgenet-2014-102620; Voutetakis A, 2004, J CLIN ENDOCR METAB, V89, P2200, DOI 10.1210/jc.2003-031765; Wang YJ, 2010, CHILD NERV SYST, V26, P1773, DOI 10.1007/s00381-010-1247-2; Webb EA, 2013, BRAIN, V136, P3096, DOI 10.1093/brain/awt218; Werther GA, 1996, J PEDIATR-US, V128, pS47, DOI 10.1016/S0022-3476(96)70011-2; Williamson KA, 2014, EUR J MED GENET, V57, P369, DOI 10.1016/j.ejmg.2014.05.002; Wit JM, 2016, EUR J ENDOCRINOL, V174, pR145, DOI 10.1530/EJE-15-0937; Xu H, 2015, BIOMED RES INT, pExpression; Yamamoto M, 2011, J CLIN INVEST, V121, P113, DOI 10.1172/JCI44073; Zenaty D, 2003, CLIN ENDOCRINOL, V58, P647; Zygmunt-Gorska A, 2009, J PEDIATR ENDOCR MET, V22, P653	159	19	19	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1521-690X	1532-1908		BEST PRACT RES CL EN	Best Pract. Res. Clin. Endoc. Metab.	DEC	2016	30	6					705	736		10.1016/j.beem.2016.11.008			32	Endocrinology & Metabolism	Endocrinology & Metabolism	EG5LE	WOS:000391084500004	27974186				2021-06-18	
J	Epstein, DJ; Legarreta, M; Bueler, E; King, J; McGlade, E; Yurgelun-Todd, D				Epstein, Daniel J.; Legarreta, Margaret; Bueler, Elliot; King, Jace; McGlade, Erin; Yurgelun-Todd, Deborah			Orbitofrontal cortical thinning and aggression in mild traumatic brain injury patients	BRAIN AND BEHAVIOR			English	Article						aggression; mild traumatic brain injury; morphometry; orbitofrontal cortex	VOXEL-BASED MORPHOMETRY; PREFRONTAL CORTEX; HEAD-INJURY; PREVALENCE; DISORDERS; RELIABILITY; DEPRESSION; VALIDITY; PERSONALITY; POPULATION	Introduction: Although mild traumatic brain injury (mTBI) comprises 80% of all TBI, the morphological examination of the orbitofrontal cortex (OFC) in relation to clinical symptoms such as aggression, anxiety and depression in a strictly mTBI sample has never before been performed. Objectives: The primary objective of the study was to determine if mTBI patients would show morphological differences in the OFC and if the morphology of this region would relate to clinical symptoms. Methods: Using structural images acquired in a 3T MRI machine, the cortical thickness and cortical volume (corrected for total brain volume) of the OFC was collected for healthy control (N = 27) subjects and chronic mTBI (N = 55) patients at least one year post injury. Also, during clinical interviews, measures quantifying the severity of clinical symptoms, including aggression, anxiety, and depression, were collected. Results: MTBI subjects displayed increased aggression, anxiety, and depression, and anxiety and depression measures showed a relationship with the number of mTBI in which the subject lost consciousness. The cortical thickness of the right lateral OFC displayed evidence of thinning in the mTBI group; however, after correction for multiple comparisons, this difference was no longer significant. Clinical measures were not significantly related with OFC morphometry. Conclusion: This study found increased aggression, anxiety, and depression, in the mTBI group as well as evidence of cortical thinning in the right lateral OFC. The association between clinical symptoms and the number of mTBI with loss of consciousness suggests the number and severity of mTBI may influence clinical symptoms long after injury. Future studies examining other brain regions involved in the production and regulation of affective processes and inclusion of subjects with well-characterized mood disorders could further elucidate the relationship between mTBI, brain morphology, and clinical symptoms.	[Epstein, Daniel J.; King, Jace; Yurgelun-Todd, Deborah] Univ Utah, Interdept Program Neurosci, Salt Lake City, UT 84112 USA; [Epstein, Daniel J.; Legarreta, Margaret; Bueler, Elliot; King, Jace; McGlade, Erin; Yurgelun-Todd, Deborah] Cognit Neuroimaging Lab, Salt Lake City, UT USA; [Epstein, Daniel J.; Legarreta, Margaret; Bueler, Elliot; McGlade, Erin; Yurgelun-Todd, Deborah] Salt Lake City Rocky Mt MIRECC, Salt Lake City, UT USA; [McGlade, Erin; Yurgelun-Todd, Deborah] Univ Utah, Dept Psychiat, Salt Lake City, UT USA	Epstein, DJ (corresponding author), Univ Utah, Interdept Program Neurosci, Salt Lake City, UT 84112 USA.	Daniel.Epstein@utah.edu	McGlade, Erin C/K-1157-2016	McGlade, Erin C/0000-0003-2234-1984; King, Jace/0000-0002-0206-0475	Veterans Health AdministrationUS Department of Veterans Affairs [5I01CX000253-02]; Veterans AffairsUS Department of Veterans Affairs [I01CX000253] Funding Source: NIH RePORTER	Veterans Health Administration - Merit Review Grant, (Grant / Award Number: '5I01CX000253-02')	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arciniegas DB, 2014, PSYCHIAT CLIN N AM, V37, P31, DOI 10.1016/j.psc.2013.12.001; Barbas H, 2007, J ANAT, V211, P237, DOI 10.1111/j.1469-7580.2007.00777.x; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI 10.1089/neu.2008-0849; Blair RJR, 2001, J NEUROL NEUROSUR PS, V71, P727, DOI 10.1136/jnnp.71.6.727; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Cady EB, 1996, MAGN RESON MED, V36, P878, DOI 10.1002/mrm.1910360610; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cavada C, 2000, CEREB CORTEX, V10, P220, DOI 10.1093/cercor/10.3.220; Cirino PT, 2002, ASSESSMENT, V9, P145, DOI 10.1177/10791102009002005; Colantonio A, 2014, J CORRECT HEALTH CAR, V20, P271, DOI 10.1177/1078345814541529; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Depue BE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/691505; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dougherty DD, 2004, ARCH GEN PSYCHIAT, V61, P795, DOI 10.1001/archpsyc.61.8.795; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308; Farrer TJ, 2013, CHILD NEUROPSYCHOL, V19, P225, DOI 10.1080/09297049.2011.647901; Farrer TJ, 2012, TRAUMA VIOLENCE ABUS, V13, P77, DOI 10.1177/1524838012440338; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Felde AB, 2006, BRAIN INJURY, V20, P41, DOI 10.1080/02699050500309718; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; First MB., 2002, STRUCTURED CLIN INTE; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gansler DA, 2009, PSYCHIAT RES-NEUROIM, V171, P145, DOI 10.1016/j.pscychresns.2008.03.007; Gerevich J, 2007, INT J METH PSYCH RES, V16, P124, DOI 10.1002/mpr.221; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Greve KW, 2001, BRAIN INJURY, V15, P255; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Harlow JM, 1848, BOSTON MED SURG J, V39, P389, DOI DOI 10.1056/NEJM184812130392001; Harris JA, 1997, BEHAV RES THER, V35, P1047, DOI 10.1016/S0005-7967(97)00064-8; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Hoptman MJ, 2014, AM J PSYCHIAT, V171, P939, DOI 10.1176/appi.ajp.2014.13111553; Hudak A, 2011, PSYCHIAT RES-NEUROIM, V191, P160, DOI 10.1016/j.pscychresns.2010.10.003; Huebner T, 2008, J AM ACAD CHILD PSY, V47, P540, DOI 10.1097/CHI.0b013e3181676545; IBM Corp, 2011, IBM SPSS Statistics for Windows, Version 20.0; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kahnt T, 2012, J NEUROSCI, V32, P6240, DOI 10.1523/JNEUROSCI.0257-12.2012; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kierans AS, 2014, NEUROLOGY, V82, P521, DOI 10.1212/WNL.0000000000000105; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kuhn S, 2010, BIOL PSYCHIAT, V68, P1061, DOI 10.1016/j.biopsych.2010.08.004; Kuperberg GR, 2003, ARCH GEN PSYCHIAT, V60, P878, DOI 10.1001/archpsyc.60.9.878; Liu CH, 2014, NEUROSCIENCE, V262, P190, DOI 10.1016/j.neuroscience.2013.12.058; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MAIER W, 1988, J AFFECT DISORDERS, V14, P61, DOI 10.1016/0165-0327(88)90072-9; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Miczek KA, 2007, J NEUROSCI, V27, P11803, DOI 10.1523/JNEUROSCI.3500-07.2007; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Ochsner KN, 2002, J COGNITIVE NEUROSCI, V14, P1215, DOI 10.1162/089892902760807212; Ochsner KN, 2004, NEUROIMAGE, V23, P483, DOI 10.1016/j.neuroimage.2004.06.030; Ongur D, 2000, CEREB CORTEX, V10, P206, DOI 10.1093/cercor/10.3.206; Panksepp J, 2004, REV INT PSYCHOL SOC, V17, P37, DOI DOI 10.1016/J.BRAINRES.2004.07.076; Pardini M, 2011, NEUROLOGY, V76, P1038, DOI 10.1212/WNL.0b013e318211c33e; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Phan KL, 2005, BIOL PSYCHIAT, V57, P210, DOI 10.1016/j.biopsych.2004.10.030; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Raine A, 2000, ARCH GEN PSYCHIAT, V57, P119, DOI 10.1001/archpsyc.57.2.119; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rassovsky Y, 2015, J CLIN EXP NEUROPSYC, V37, P354, DOI 10.1080/13803395.2015.1015498; Ratiu P, 2004, J NEUROTRAUM, V21, P637, DOI 10.1089/089771504774129964; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Schofield PW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132558; Siever LJ, 2008, AM J PSYCHIAT, V165, P429, DOI 10.1176/appi.ajp.2008.07111774; Sivak S, 2014, BRAIN INJURY, V28, P341, DOI 10.3109/02699052.2013.865270; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Sours C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134019; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; Stikov N, 2011, NEUROIMAGE, V54, P1112, DOI 10.1016/j.neuroimage.2010.08.068; Tu PC, 2012, PSYCHIAT RES-NEUROIM, V202, P206, DOI 10.1016/j.pscychresns.2011.07.011; Underhill HR, 2011, NEUROIMAGE, V54, P2052, DOI 10.1016/j.neuroimage.2010.10.065; van Horn JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037454; van Tol MJ, 2010, ARCH GEN PSYCHIAT, V67, P1002, DOI 10.1001/archgenpsychiatry.2010.121; Vaughn MG, 2014, CRIM BEHAV MENT HEAL, V24, P188, DOI 10.1002/cbm.1900; Von Der Heide RJ, 2013, BRAIN, V136, P1692, DOI 10.1093/brain/awt094; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	84	19	19	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	DEC	2016	6	12							e00581	10.1002/brb3.581			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	EI7VL	WOS:000392712000013	28032004	DOAJ Gold, Green Published			2021-06-18	
J	Katzenberger, RJ; Ganetzky, B; Wassarman, DA				Katzenberger, Rebeccah J.; Ganetzky, Barry; Wassarman, David A.			Age and Diet Affect Genetically Separable Secondary Injuries that Cause Acute Mortality Following Traumatic Brain Injury in Drosophila	G3-GENES GENOMES GENETICS			English	Article						Drosophila Genetic Reference Panel; gene expression; hyperglycemia innate immune response; repetitive TBI; RNA-seq	IMMUNE-RESPONSE; HOST-DEFENSE; EXPRESSION; OUTCOMES; DISEASE; SYSTEM; IMPACT; GENES; MODEL; MELANOGASTER	Outcomes of traumatic brain injury (TBI) vary because of differences in primary and secondary injuries. Primary injuries occur at the time of a traumatic event, whereas secondary injuries occur later as a result of cellular and molecular events activated in the brain and other tissues by primary injuries. We used a Drosophila melanogaster TBI model to investigate secondary injuries that cause acute mortality. By analyzing mortality percentage within 24 hr of primary injuries, we previously found that age at the time of primary injuries and diet afterward affect the severity of secondary injuries. Here, we show that secondary injuries peaked in activity 1-8 hr after primary injuries. Additionally, we demonstrate that age and diet activated distinct secondary injuries in a genotype-specific manner, and that concurrent activation of age- and diet-regulated secondary injuries synergistically increased mortality. To identify genes involved in secondary injuries that cause mortality, we compared genome-wide mRNA expression profiles of uninjured and injured flies under age and diet conditions that had different mortalities. During the peak period of secondary injuries, innate immune response genes were the predominant class of genes that changed expression. Furthermore, age and diet affected the magnitude of the change in expression of some innate immune response genes, suggesting roles for these genes in inhibiting secondary injuries that cause mortality. Our results indicate that the complexity of TBI outcomes is due in part to distinct, genetically controlled, age- and diet-regulated mechanisms that promote secondary injuries and that involve a subset of innate immune response genes.	[Katzenberger, Rebeccah J.; Wassarman, David A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Genet, Madison, WI 53706 USA; [Ganetzky, Barry] Univ Wisconsin, Coll Agr & Life Sci, Dept Genet, Madison, WI 53706 USA	Ganetzky, B; Wassarman, DA (corresponding author), Univ Wisconsin, Dept Genet, Genet Biotechnol Bldg,425G Henry Mall, Madison, WI 53706 USA.	ganetzky@wisc.edu; dawassarman@wisc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS091893-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS091893] Funding Source: NIH RePORTER	We thank Grace Boekhoff-Falk, Stanislava Chtarbanova, Douglas Wassarman, and members of the Boekhoff-Falk, Ganetzky, and Wassarman laboratories for their comments that greatly improved the manuscript. We also thank Derek Pavelek in the University of Wisconsin-Madison Biotechnology Center for assistance analyzing the RNA-sequencing data. This work was supported by a grant from the National Institutes of Health (R21 NS091893-01 to B.G. and D.A.W.).	Agaisse H, 2004, IMMUNOL REV, V198, P72, DOI 10.1111/j.0105-2896.2004.0133.x; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Alluri H, 2015, METAB BRAIN DIS, V30, P1093, DOI 10.1007/s11011-015-9651-7; Ao JQ, 2007, MOL IMMUNOL, V44, P2541, DOI 10.1016/j.molimm.2006.12.024; Bailes JE, 2014, PROG NEUROL SURG, V28, P50, DOI 10.1159/000358765; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Bier E, 2012, DIS MODEL MECH, V5, P48, DOI 10.1242/dmm.000406; Bosarge PL, 2015, J TRAUMA ACUTE CARE, V79, P289, DOI 10.1097/TA.0000000000000716; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Brun S, 2006, GENES CELLS, V11, P397, DOI 10.1111/j.1365-2443.2006.00953.x; Chakrabarti S, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006089; Chakrabarti S, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004659; Chong SL, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/719476; Clemmons AW, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004876; Cohen L, 2009, J BIOL CHEM, V284, P23558, DOI 10.1074/jbc.M109.023358; Dalla Libera AL, 2011, BRAIN INJURY, V25, P365, DOI 10.3109/02699052.2011.556107; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; Dhandapani SS, 2012, J NEUROSCI RURAL PRA, V3, P131, DOI 10.4103/0976-3147.98208; Djordjevic J, 2016, CURR ALZHEIMER RES, V13, P730, DOI 10.2174/1567205013666160222110320; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Ekengren S, 2001, BIOCHEM BIOPH RES CO, V284, P998, DOI 10.1006/bbrc.2001.5067; Failla MD, 2016, NEUROREHAB NEURAL RE, V30, P83, DOI 10.1177/1545968315586465; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Ferrandon D, 2007, NAT REV IMMUNOL, V7, P862, DOI 10.1038/nri2194; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Gadani SP, 2015, NEURON, V87, P47, DOI 10.1016/j.neuron.2015.05.019; Garringer JA, 2013, J NEUROTRAUM, V30, P1415, DOI 10.1089/neu.2012.2565; Griesdale DEG, 2009, NEUROCRIT CARE, V11, P311, DOI 10.1007/s12028-009-9249-1; Hall ANB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159442; Heiman A, 2014, BRAIN BEHAV IMMUN, V42, P232, DOI 10.1016/j.bbi.2014.06.203; Hellewell SC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/356494; Hosseini Parsa, 2010, BMC Res Notes, V3, P183, DOI 10.1186/1756-0500-3-183; Hu YC, 2014, INFLAMM RES, V63, P109, DOI 10.1007/s00011-013-0677-1; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; Huang XJ, 2014, J NEUROTRAUM, V31, P346, DOI 10.1089/neu.2013.2899; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jiang HS, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-182; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Katzenberger RJ, 2015, FLY, V9, P68, DOI 10.1080/19336934.2015.1085623; Katzenberger RJ, 2015, JOVE-J VIS EXP, DOI 10.3791/52905; Katzenberger RJ, 2015, ELIFE, V4, DOI 10.7554/eLife.04790; Katzenberger RJ, 2013, P NATL ACAD SCI USA, V110, pE4152, DOI 10.1073/pnas.1316895110; Krishnamurthy K, 2016, TRANSLATIONAL RES TR; Kurata S, 2014, DEV COMP IMMUNOL, V42, P36, DOI 10.1016/j.dci.2013.06.006; Lamiable O, 2016, P NATL ACAD SCI USA, V113, P698, DOI 10.1073/pnas.1516122113; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Mackay TFC, 2012, NATURE, V482, P173, DOI 10.1038/nature10811; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mychasiuk R, 2015, NEUROBIOL DIS, V73, P1, DOI 10.1016/j.nbd.2014.09.003; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Owusu-Ansah E, 2015, ANNU REV CELL DEV BI, V31, P497, DOI 10.1146/annurev-cellbio-100814-125523; Papai G, 2011, CURR OPIN GENET DEV, V21, P219, DOI 10.1016/j.gde.2011.01.009; Petersen AJ, 2012, P NATL ACAD SCI USA, V109, pE656, DOI 10.1073/pnas.1110470109; Prins ML, 2014, J LIPID RES, V55, P2450, DOI 10.1194/jlr.R046706; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Rajan A, 2012, CELL, V151, P123, DOI 10.1016/j.cell.2012.08.019; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sperry JL, 2014, ANN SURG, V260, P698, DOI 10.1097/SLA.0000000000000918; Stec W, 2013, MOL BIOL CELL, V24, P3000, DOI 10.1091/mbc.E13-05-0275; Stocchetti N, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1318-1; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Wang HC, 2014, BRAIN INJURY, V28, P1491, DOI 10.3109/02699052.2014.943288; Wang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058838; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; White TE, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-282; Wong YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020216; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Zaidman-Remy A, 2006, IMMUNITY, V24, P463, DOI 10.1016/j.immuni.2006.02.012	80	19	20	0	11	GENETICS SOCIETY AMERICA	BETHESDA	9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA	2160-1836			G3-GENES GENOM GENET	G3-Genes Genomes Genet.	DEC	2016	6	12					4151	4166		10.1534/g3.116.036194			16	Genetics & Heredity	Genetics & Heredity	EF8PN	WOS:000390591400034	27754853	DOAJ Gold, Green Published			2021-06-18	
J	Patino, P; Parada, E; Farre-Alins, V; Molz, S; Cacabelos, R; Marco-Contelles, J; Lopez, MG; Tasca, CI; Ramos, E; Romero, A; Egea, J				Patino, Paloma; Parada, Esther; Farre-Alins, Victor; Molz, Simone; Cacabelos, Ramon; Marco-Contelles, Jose; Lopez, Manuela G.; Tasca, Carla I.; Ramos, Eva; Romero, Alejandro; Egea, Javier			Melatonin protects against oxygen and glucose deprivation by decreasing extracellular glutamate and Nox-derived ROS in rat hippocampal slices	NEUROTOXICOLOGY			English	Article						Melatonin; Cerebral ischemia; Glutamate Neurotoxicity; OGD-reoxygenation; Rat hippocampal slices	TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; CELL-DEATH; SUPEROXIDE-PRODUCTION; REACTIVE OXYGEN; NADPH OXIDASE; NEURONS; STROKE; MICE	Therapeutic interventions on pathological processes involved in the ischemic cascade, such as oxidative stress, neuroinflammation, excitotoxicity and/or apoptosis, are of urgent need for stroke treatment. Melatonin regulates a large number of physiological actions and its beneficial properties have been reported. The aim of this study was to investigate whether melatonin mediates neuroprotection in rat hippocampal slices subjected to oxygen-glucose-deprivation (OGD) and glutamate excitotoxicity. Thus, we describe here that melatonin significantly reduced the amount of lactate dehydrogenase released in the OGD-treated slices, reverted neuronal injury caused by OGD-reoxygenation in CAl and CA3 hippocampal regions, restored the reduction of GSH content of the hippocampal slices induced by OGD, and diminished the oxidative stress produced in the reoxygenation period. Furthermore, melatonin afforded maximum protection against glutamate-induced toxicity and reversed the glutamate released almost basal levels, at 10 and 30 mu M concentration, respectively. Consequently, we propose that melatonin might strongly and positively influence the outcome of brain ischemia/reperfusion. (C) 2016 Elsevier B.V. All rights reserved.	[Patino, Paloma] La Paz Univ Hosp, Paediat Unit, Paseo Castellana 261, Madrid 28046, Spain; [Parada, Esther; Farre-Alins, Victor; Lopez, Manuela G.; Egea, Javier] Hosp Univ Princesa, Inst Invest Sanitaria, Serv Farmacol Clin, Madrid, Spain; [Parada, Esther; Farre-Alins, Victor; Lopez, Manuela G.; Egea, Javier] Univ Autonoma Madrid, Inst Teofilo Hernando, C Arzobispo Morcillo 4, E-28049 Madrid, Spain; [Parada, Esther; Farre-Alins, Victor; Lopez, Manuela G.; Egea, Javier] Univ Autonoma Madrid, Dept Pharmacol, C Arzobispo Morcillo 4, E-28049 Madrid, Spain; [Farre-Alins, Victor] Contestado Univ, Sch Pharm, BR-89460000 Canoinhas, SC, Brazil; [Cacabelos, Ramon; Tasca, Carla I.] Inst CNS Disorders & Genom Med, EuroEspes Biomed Res Ctr, La Corunna 15166, Spain; [Cacabelos, Ramon] Camilo Jose Cela Univ, Chair Genom Med, Madrid, Spain; [Marco-Contelles, Jose] Inst Gen Organ Chem CSIC, Lab Med Chem, Juan Cierva 3, Madrid 28006, Spain; [Tasca, Carla I.] Univ Fed Santa Catarina, Dept Bioquim, Ctr Ciencias Biol, BR-88040900 Florianopolis, SC, Brazil; [Ramos, Eva; Romero, Alejandro] Univ Complutense Madrid, Fac Vet Med, Dept Toxicol & Pharmacol, E-28040 Madrid, Spain	Egea, J (corresponding author), Hosp Univ Princesa, Inst Invest Sanitaria, Serv Farmacol Clin, Madrid, Spain.; Romero, A (corresponding author), Univ Complutense Madrid, Fac Vet, Dept Toxicol & Farmacol, Avda Puerta de Hierro S-N, E-28040 Madrid, Spain.	manarome@ucm.es; javier.egea@inv.uam.es	Lopez, Manuela G/D-2164-2015; Romero, Alejandro/A-8282-2018; Egea, Javier/X-7281-2019; Ramos, Eva/A-8275-2018; Romero, Alejandro/N-9686-2019; Tasca, Carla Ines/AAB-8287-2019	Lopez, Manuela G/0000-0003-4461-8788; Romero, Alejandro/0000-0001-5483-4973; Egea, Javier/0000-0003-4704-3019; Romero, Alejandro/0000-0001-5483-4973; Tasca, Carla Ines/0000-0002-3414-6150; FARRE ALINS, VICTOR/0000-0002-6908-1705; RAMOS ALONSO, EVA/0000-0001-5791-0687	IS Carlos III, Programa Miguel Servet [CP14/00008]; IS Carlos III research contract under Miguel Servet Program; Spanish Ministry of Economy and Competence [SAF2015-63935-R]	This work was supported by a grant from IS Carlos III, Programa Miguel Servet (CP14/00008) and IS Carlos III research contract under Miguel Servet Program to JE. MGL has a grant from Spanish Ministry of Economy and Competence Ref. SAF2015-63935-R.	Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007; Aladag MA, 2009, NEUROCHEM RES, V34, P1935, DOI 10.1007/s11064-009-9979-7; Andersen LPH, 2016, CLIN DRUG INVEST, V36, P169, DOI 10.1007/s40261-015-0368-5; Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Buendia I, 2015, NEUROPHARMACOLOGY, V99, P187, DOI 10.1016/j.neuropharm.2015.07.014; CHIANG G L, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P643; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; Egea J, 2007, NEUROSCIENCE, V145, P866, DOI 10.1016/j.neuroscience.2006.12.036; Egea J, 2014, NEUROSCIENCE, V267, P11, DOI 10.1016/j.neuroscience.2014.02.025; Egea J, 2012, NEUROPHARMACOLOGY, V62, P1082, DOI 10.1016/j.neuropharm.2011.10.022; El-Denshary E. S., 2002, J PINEAL RES, V33, P87; FERNANDEZCHECA JC, 1990, ANAL BIOCHEM, V190, P212, DOI 10.1016/0003-2697(90)90183-A; Fiorina P, 1996, LANCET, V347, P692, DOI 10.1016/S0140-6736(96)91246-5; He Z, 2014, CELL MOL NEUROBIOL, V34, P539, DOI 10.1007/s10571-014-0037-x; Jefferies H, 2003, ANZ J SURG, V73, P517, DOI 10.1046/j.1445-1433.2003.02682.x; Juan WS, 2014, J PINEAL RES, V56, P213, DOI 10.1111/jpi.12114; Kamencic H, 2000, ANAL BIOCHEM, V286, P35, DOI 10.1006/abio.2000.4765; Kelestemur T, 2016, NEUROSCI LETT, V612, P92, DOI 10.1016/j.neulet.2015.11.043; Koh PO, 2008, J PINEAL RES, V45, P199, DOI 10.1111/j.1600-079X.2008.00577.x; Koh PO, 2008, J PINEAL RES, V44, P101, DOI 10.1111/j.1600-079X.2007.00495.x; Koh PO, 2012, J PINEAL RES, V53, P358, DOI 10.1111/j.1600-079X.2012.01005.x; Koh PO, 2012, J PINEAL RES, V52, P57, DOI 10.1111/j.1600-079X.2011.00918.x; Kumar VSS, 2014, CURR MED CHEM, V21, P2065, DOI 10.2174/0929867321666131228204246; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lezoualch F, 1996, NEUROREPORT, V7, P2071, DOI 10.1097/00001756-199609020-00003; Li HY, 2014, J PINEAL RES, V57, P110, DOI 10.1111/jpi.12148; Lipton P, 1999, PHYSIOL REV, V79, P1431; Lloyd-Jones DM, 2010, CIRCULATION, V121, P1768, DOI 10.1161/CIRCULATIONAHA.109.849166; Lorrio S, 2013, NEUROPHARMACOLOGY, V67, P403, DOI 10.1016/j.neuropharm.2012.12.001; Manev H, 1996, FASEB J, V10, P1546; Mauriz JL, 2013, J PINEAL RES, V54, P1, DOI 10.1111/j.1600-079X.2012.01014.x; Molz S, 2008, BRAIN RES, V1231, P113, DOI 10.1016/j.brainres.2008.07.009; Molz S, 2008, NEUROCHEM RES, V33, P27, DOI 10.1007/s11064-007-9402-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nishio N, 2013, NEUROSCIENCE, V247, P201, DOI 10.1016/j.neuroscience.2013.05.023; Ogden KK, 2011, TRENDS PHARMACOL SCI, V32, P726, DOI 10.1016/j.tips.2011.08.003; Parada E, 2014, J PINEAL RES, V56, P204, DOI 10.1111/jpi.12113; Perez EL, 2012, NEUROBIOL DIS, V47, P331, DOI 10.1016/j.nbd.2012.05.010; Reiter RJ, 1997, ANN NY ACAD SCI, V825, P70, DOI 10.1111/j.1749-6632.1997.tb48415.x; Romero A, 2013, CNS NEUROSCI THER, V19, P285, DOI 10.1111/cns.12073; Schousboe A, 2003, NEUROCHEM RES, V28, P347, DOI 10.1023/A:1022397704922; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Thrift AG, 2001, STROKE, V32, P1732, DOI 10.1161/01.STR.32.8.1732; Uchida K, 2004, J PINEAL RES, V37, P215, DOI 10.1111/j.1600-079X.2004.00159.x; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; Wang X, 2009, CNS NEUROSCI THER, V15, P345, DOI 10.1111/j.1755-5949.2009.00105.x; Weimar Christian, 2006, Expert Rev Neurother, V6, P185, DOI 10.1586/14737175.6.2.185; Yang Y, 2015, J PINEAL RES, V58, P61, DOI 10.1111/jpi.12193; Yuruker V, 2015, METAB BRAIN DIS, V30, P223, DOI 10.1007/s11011-014-9623-3; Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162; Zhou M, 2006, J NEUROSCI, V26, P2956, DOI 10.1523/JNEUROSCI.4299-05.2006	56	19	21	0	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	DEC	2016	57						61	68		10.1016/j.neuro.2016.09.002			8	Neurosciences; Pharmacology & Pharmacy; Toxicology	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	EE3NT	WOS:000389497000008	27620136				2021-06-18	
J	Zhao, S; Yu, A; Wang, XT; Gao, X; Chen, JH				Zhao, Shu; Yu, Alex; Wang, Xiaoting; Gao, Xiang; Chen, Jinhui			Post-Injury Treatment of 7,8-Dihydroxyflavone Promotes Neurogenesis in the Hippocampus of the Adult Mouse	JOURNAL OF NEUROTRAUMA			English	Article						brain-derived neurotrophic factor; cell survival; dendrite development; neurogenesis; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; MOLECULE TRKB AGONIST; DENTATE GYRUS; NEUROTROPHIC FACTOR; NEURONAL DIFFERENTIATION; ENHANCED NEUROGENESIS; CELL-PROLIFERATION; DENDRITIC GROWTH; IMMATURE NEURONS	Traumatic brain injury (TBI) at the moderate level of impact induces massive cell death and results in extensive dendrite degeneration in the brain, leading to persistent cognitive, sensory, and motor dysfunction. Our previous reports have shown that adult-born immature granular neurons in the dentate gyrus are the most vulnerable cell type in the hippocampus after receiving a moderate TBI with a controlled cortical impact (CCI) device. There is no effective approach to prevent immature neuron death or degeneration following TBI. Our recent study found that pretreatment of 7,8-dihydroxyflavone (DHF), a small molecule imitating brain-derived neurotrophic factor, protected immature neurons in the hippocampus from death following TBI. In the present study, we systemically treated moderate CCI-TBI mice or sham surgery mice with DHF once a day for 2 weeks via intraperitoneal injection, and then assessed the immature neurons in the hippocampus the 2nd day after the last DHF injection. We found that post-injury treatment of DHF for 2 weeks not only increased the number of adult-born immature neurons in the hippocampus, but also promoted their dendrite arborization in the injured brain following TBI. Thus, DHF may be a promising compound that can promote neurogenesis and enhance immature neuron development following TBI.	[Zhao, Shu; Wang, Xiaoting; Gao, Xiang; Chen, Jinhui] Indiana Univ, Spinal Cord & Brain Injury Res Grp, Stark Neurosci Res Inst, Dept Neurosurg, Indianapolis, IN 46204 USA; [Yu, Alex] Carmel High Sch, Indianapolis, IN USA	Chen, JH (corresponding author), Indiana Univ Sch Med, 320 W 15th St, Indianapolis, IN 46202 USA.	chen204@iupui.edu			Indiana Spinal Cord and Brain Injury Research Grants; Ralph W. and Grace M. Showalter Research Award; Indiana University; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RR025761, 1R21NS072631, R21NS075733]	This work was supported by funding from Indiana Spinal Cord and Brain Injury Research Grants, the Ralph W. and Grace M. Showalter Research Award, Indiana University Biological Research Grant, and National Institutes of Health grants RR025761, 1R21NS072631, and R21NS075733 to J. Chen.	Agrawal R, 2015, BBA-MOL BASIS DIS, V1852, P862, DOI 10.1016/j.bbadis.2015.01.018; Agrawal R, 2014, BBA-MOL BASIS DIS, V1842, P535, DOI 10.1016/j.bbadis.2013.12.004; Andero R, 2012, HIPPOCAMPUS, V22, P399, DOI 10.1002/hipo.20906; Andero R, 2011, AM J PSYCHIAT, V168, P163, DOI 10.1176/appi.ajp.2010.10030326; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Babu H, 2009, FRONT NEUROSCI-SWITZ, V3, DOI 10.3389/neuro.22.001.2009; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Carlson SW, 2014, J NEUROPATH EXP NEUR, V73, P734, DOI 10.1097/NEN.0000000000000092; Chen L, 2015, J NEUROPATH EXP NEUR, V74, P557, DOI 10.1097/NEN.0000000000000199; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Devi L, 2012, NEUROPSYCHOPHARMACOL, V37, P434, DOI 10.1038/npp.2011.191; Dijkhuizen PA, 2005, J NEUROBIOL, V62, P278, DOI 10.1002/neu.20100; Donovan MH, 2008, HIPPOCAMPUS, V18, P435, DOI 10.1002/hipo.20410; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI 10.1089/neu.2008-0744; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Horch HW, 2004, REV NEUROSCIENCE, V15, P117; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Jang SW, 2010, P NATL ACAD SCI USA, V107, P2687, DOI 10.1073/pnas.0913572107; Johnson RA, 2012, J APPL PHYSIOL, V112, P704, DOI 10.1152/japplphysiol.01361.2011; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; Liu X, 2010, J MED CHEM, V53, P8274, DOI 10.1021/jm101206p; Magavi SS, 2000, NATURE, V405, P951; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; TIMMUSK T, 1994, NEUROSCIENCE, V60, P287, DOI 10.1016/0306-4522(94)90242-9; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Yacoubian T., 2000, NAT NEUROSCI, P3; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zeng Y, 2012, J ALZHEIMERS DIS, V31, P765, DOI 10.3233/JAD-2012-120886; Zhao S., 2015, MOL NEUROBIOL; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078	61	19	20	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2016	33	22					2055	2064		10.1089/neu.2015.4036			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EC4OL	WOS:000388112300009	26715291	Green Published			2021-06-18	
J	Davis, G; Makdissi, M				Davis, Gavin; Makdissi, Michael			Use of video to facilitate sideline concussion diagnosis and management decision-making	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain concussion; Football; Clinical management; Flowchart; Video analysis	HOCKEY LEAGUE NHL; HEAD; BLOWS	Objectives: Video analysis can provide critical information to improve diagnostic accuracy and speed of clinical decision-making in potential cases of concussion. The objective of this study was to validate a hierarchical flowchart for the assessment of video signs of concussion, and to determine whether its implementation could improve the process of game day video assessment. Design: Prospective cohort study. Methods: All impacts and collisions potentially resulting in a concussion were identified during 2012 and 2013 Australian Football League (AFL) seasons. Consensus definitions were developed for clinical signs associated with concussion. A hierarchical flowchart was developed based on the reliability and validity of the video signs of concussion. Ninety videos were assessed, with 45 incidents of clinically confirmed concussion, and 45 cases where no concussion was sustained. Each video was examined using the hierarchical flowchart, and a single response was given for each video based on the highest-ranking element in the flowchart. Results: No protective action, impact seizure, motor incoordination or blank/vacant look were the highest ranked video signs in almost half of the clinically confirmed concussions, but in only 8.8% of non-concussed individuals. The presence of facial injury, clutching at the head and slow to get up were the highest ranked sign in 77.7% of non-concussed individuals. Conclusions: This study suggests that the implementation of a flowchart model could improve timely assessment of concussion, and it identifies the video signs that should trigger automatic removal from play. (C) 2016 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Davis, Gavin; Makdissi, Michael] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Heidelberg, Vic, Australia; [Davis, Gavin] Austin Hosp, Dept Neurosurg, Heidelberg, Vic, Australia; [Davis, Gavin] Cabrini Hlth, Dept Neurosurg, Malvern, Vic, Australia; [Makdissi, Michael] Federat Univ, Australian Ctr Res Injury Sport & Its Prevent ACR, Ballarat, Vic, Australia; [Makdissi, Michael] La Trobe Univ, Sch Allied Hlth, Bundoora, Vic 3086, Australia	Davis, G (corresponding author), Cabrini Med Ctr, Suite 53 Neurosurg, Malvern, Vic 3145, Australia.	gadavis@netspace.net.au					Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Gardner AJ, 2015, BRAIN INJURY, V17, P1; Hutchison MG, 2015, BRIT J SPORT MED, V49, P552, DOI 10.1136/bjsports-2013-092235; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; Koh JO, 2004, BRAIN INJURY, V18, P1287, DOI 10.1080/02699050410001719907; Koh JO, 2002, J SPORT MED PHYS FIT, V42, P348; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; Makdissi M, J SCI MED SPORT; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002	14	19	19	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	NOV	2016	19	11					898	902		10.1016/j.jsams.2016.02.005			5	Sport Sciences	Sport Sciences	ED0PK	WOS:000388544200008	27117715				2021-06-18	
J	Wang, T; Zhu, M; He, ZZ				Wang, Tao; Zhu, Mang; He, Zhong-Zheng			Low-Molecular-Weight Fucoidan Attenuates Mitochondrial Dysfunction and Improves Neurological Outcome After Traumatic Brain Injury in Aged Mice: Involvement of Sirt3	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Fucoidan; TBI; Mitochondrial dysfunction; Sirt3; Aging	OXIDATIVE STRESS; CLINICAL-TRIALS; EPIDEMIOLOGY; THERAPIES; MODEL	Traumatic brain injury (TBI) is a leading cause of death and long-term disability. Fucoidan, a sulfated polysaccharide extracted from brown algae, possesses potent anti-oxidative and anti-inflammatory effects. Considering TBI happens frequently in adults, especially in aged individuals, we herein sought to define the protective effects of low-molecular-weight fucoidan (LMWF) in the aged mice. 16- to 18-month-old mice administered with LMWF (1-50 mg/kg) or vehicle were subjected to TBI using a controlled cortical impact (CCI) model. LMWF at the doses of 10 and 50 mg/kg significantly reduced both cortical and hippocampal lesion volume. This protection was associated with reduced neuronal apoptosis, as evidenced by TUNEL staining. Importantly, LMWF was effective even when administered up to 4 h after TBI. Treatment with LMWF improved long-term neurobehavioral outcomes, including sensorimotor function, and hippocampus-associated spatial learning and memory. In addition, LMWF significantly suppressed protein carbonyl, lipid peroxidation, reactive oxygen species (ROS) generation, as well as mitochondrial dysfunction, which was evidenced by mitochondrial cytochrome c release and collapse of mitochondrial membrane potential (MMP). To evaluate the underlying molecular mechanisms, the expression of sirtuin 3 (Sirt3) was detected by RT-PCR and Western blot. The results showed that TBI significantly increased the expression of Sirt3, which was further elevated by LMWF treatment. Knockdown of Sirt3 using intracerebroventricular injection of small interfering RNA (siRNA) partially prevented the therapeutic effects of LMWF. Collectively, these findings demonstrated that LMWF exerts neuroprotection against TBI in the aged brain, which may be associated with the attenuation of mitochondrial dysfunction through Sirt3 activation.	[Wang, Tao; Zhu, Mang; He, Zhong-Zheng] Xi An Jiao Tong Univ, Dept Neurosurg, Xian Cent Hosp, Xian 710032, Shaanxi, Peoples R China	Wang, T (corresponding author), Xi An Jiao Tong Univ, Dept Neurosurg, Xian Cent Hosp, Xian 710032, Shaanxi, Peoples R China.	wangtao_zxyy@126.com					Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barker-Collo Suzanne, 2008, N Z Med J, V121, pU2903; Bause AS, 2013, EXP GERONTOL, V48, P634, DOI 10.1016/j.exger.2012.08.007; Berteau O, 2003, GLYCOBIOLOGY, V13, p29R, DOI 10.1093/glycob/cwg058; Brown K, 2013, CELL REP, V3, P319, DOI 10.1016/j.celrep.2013.01.005; Chen JJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/658925; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Chen W, 2014, NEUROCHEM INT, V68, P28, DOI 10.1016/j.neuint.2014.01.015; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dai SH, 2014, INT J MOL SCI, V15, P14591, DOI 10.3390/ijms150814591; Dai SH, 2014, INT J MOL MED, V34, P1159, DOI 10.3892/ijmm.2014.1876; Fitton JH, 2011, MAR DRUGS, V9, P1731, DOI 10.3390/md9101731; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Hofman M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/204842; Hu W, 2014, NEUROCHEM INT, V79, P57, DOI 10.1016/j.neuint.2014.10.005; Kwak JY, 2014, MAR DRUGS, V12, P851, DOI 10.3390/md12020851; Li B, 2008, MOLECULES, V13, P1671, DOI 10.3390/molecules13081671; Luyt CE, 2003, J PHARMACOL EXP THER, V305, P24, DOI 10.1124/jpet.102.046144; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; McDonnell E, 2015, TRENDS ENDOCRIN MET, V26, P486, DOI 10.1016/j.tem.2015.06.001; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Mioni G, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00269; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; Pillai VB, 2010, CARDIOVASC RES, V88, P250, DOI 10.1093/cvr/cvq250; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Veena CK, 2008, EUR J PHARMACOL, V579, P330, DOI 10.1016/j.ejphar.2007.09.044; Ye RD, 2011, NEUROPHARMACOLOGY, V61, P815, DOI 10.1016/j.neuropharm.2011.05.029; Yu XF, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/420929; Zheng SL, 2015, EXP NEUROL, V272, P160, DOI 10.1016/j.expneurol.2015.03.012	40	19	22	1	24	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	NOV	2016	36	8					1257	1268		10.1007/s10571-015-0323-2			12	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	DY5VX	WOS:000385173600004	26743530				2021-06-18	
J	Zhang, GX; Zhang, F; Zhang, T; Gu, JB; Li, CM; Sun, YW; Yu, P; Zhang, ZJ; Wang, YQ				Zhang, Gaoxiao; Zhang, Fen; Zhang, Tao; Gu, Jianbo; Li, Cuimei; Sun, Yewei; Yu, Pei; Zhang, Zaijun; Wang, Yuqiang			Tetramethylpyrazine Nitrone Improves Neurobehavioral Functions and Confers Neuroprotection on Rats with Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Neuroprotection; Oxidative stress; Apoptosis; Nrf-2; HO-1	CELL-DEATH; NEURONS; PROTEIN; STROKE; ACTIVATION; EXPRESSION; TRANSIENT; BIOMARKER; ISCHEMIA; PATHWAY	Oxidative stress is one of the major secondary injury mechanisms after traumatic brain injury (TBI). 2-[[(1,1-Dimethylethyl)oxidoimino]-methyl]-3,5,6-trimethylpyrazine (TBN), a derivative of the clinically used anti-stroke drug tetramethylpyrazine armed with a powerful free radical-scavenging nitrone moiety, has been demonstrated promising therapeutic efficacy in ischemic stroke and Parkinson's models. The present study aims to investigate the effects of TBN on behavioral function and neuroprotection in rats subjected to TBI. TBN (90 mg/kg) was administered twice daily for 7 days by intravenous injection following TBI. TBN improved neuronal behavior functions after brain injury, including rotarod test and adhesive paper removal test. Compared with the TBI model group, TBN treatment significantly protected NeuN-positive neurons, while decreased glial fibrillary acidic protein (GFAP)-positive cells. The number of 4-hydroxynonenal (4-HNE)-positive and 8-hydroxy-2'-deoxyguanosine (8-OHdG)-positive cells around the damaged area after TBI were significantly decreased in the TBN treatment group. In addition, TBN effectively reversed the altered expression of Bcl-2, Bax and caspase 3, and the down-regulation of nuclear factor erythroid-derived 2-like 2 (Nrf-2) and hemeoxygenase-1 (HO-1) proteins expression stimulated by TBI. In conclusion, TBN improves neurobehavioral functions and protects neurons against TBI. This protective effect may be achieved by anti-neuronal apoptosis, alleviating oxidative stress damage and up-regulating Nrf-2 and HO-1 expression.	[Zhang, Gaoxiao; Zhang, Fen; Zhang, Tao; Gu, Jianbo; Li, Cuimei; Sun, Yewei; Yu, Pei; Zhang, Zaijun; Wang, Yuqiang] Jinan Univ, Coll Pharm, Inst New Drug Res, Huangpu Rd, Guangzhou 510632, Guangdong, Peoples R China; [Zhang, Gaoxiao; Zhang, Fen; Zhang, Tao; Gu, Jianbo; Li, Cuimei; Sun, Yewei; Yu, Pei; Zhang, Zaijun; Wang, Yuqiang] Jinan Univ, Coll Pharm, Guangzhou Key Lab Innovat Chem Drug Res Cardiocer, Guangzhou 510632, Guangdong, Peoples R China	Zhang, ZJ (corresponding author), Jinan Univ, Coll Pharm, Inst New Drug Res, Huangpu Rd, Guangzhou 510632, Guangdong, Peoples R China.; Zhang, ZJ (corresponding author), Jinan Univ, Coll Pharm, Guangzhou Key Lab Innovat Chem Drug Res Cardiocer, Guangzhou 510632, Guangdong, Peoples R China.	zaijunzhang@163.com		Zhang, Zai-jun/0000-0002-0690-1673	Science and Technology Project of Guangdong [2015B020232011, 2013A022100030, 2016A020217013, 2015A030313317]; Key Laboratory Project of Guangzhou [151800010]	This work is supported by grants from the Science and Technology Project of Guangdong (2015B020232011 to YW, 2013A022100030 and 2016A020217013 to PY, 2015A030313317 to ZZ), and the Key Laboratory Project of Guangzhou (151800010 to YW).	Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bembea MM, 2011, PEDIATR CRIT CARE ME, V12, P572, DOI 10.1097/PCC.0b013e3181fe3ec7; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; CHAN PH, 1985, PROG BRAIN RES, V63, P227; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Emami P, 2016, J NEUROSURG, P1; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Guo BJ, 2014, BIOL PHARM BULL, V37, P274, DOI 10.1248/bpb.b13-00743; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Harish G, 2015, J NEUROCHEM, V134, P156, DOI 10.1111/jnc.13082; Johnson JA, 2008, ANN NY ACAD SCI, V1147, P61, DOI 10.1196/annals.1427.036; Lee EJ, 2005, J PINEAL RES, V38, P42, DOI 10.1111/j.1600-079X.2004.00173.x; Lian TT, 2015, INT J MOL SCI, V16, P13427, DOI 10.3390/ijms160613427; Loncarevic-Vasiljkovic N, 2016, NEUROCHEM INT, V96, P69, DOI 10.1016/j.neuint.2016.02.017; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Peterson TC, 2015, BEHAV BRAIN RES, V294, P254, DOI 10.1016/j.bbr.2015.08.007; Ren ZQ, 2012, J ETHNOPHARMACOL, V144, P555, DOI 10.1016/j.jep.2012.09.037; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Shu LF, 2016, NEUROSCI LETT, V611, P74, DOI 10.1016/j.neulet.2015.11.012; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Sun YW, 2008, BIOORGAN MED CHEM, V16, P8868, DOI 10.1016/j.bmc.2008.08.075; Sun YW, 2012, J NEUROSCI RES, V90, P1662, DOI 10.1002/jnr.23034; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yanamoto H, 1999, STROKE, V30, P2720, DOI 10.1161/01.STR.30.12.2720; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	35	19	21	0	11	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	NOV	2016	41	11					2948	2957		10.1007/s11064-016-2013-y			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EB5DG	WOS:000387393000012	27452038				2021-06-18	
J	Yu, W; Parakramaweera, R; Teng, S; Gowda, M; Sharad, Y; Thakker-Varia, S; Alder, J; Sesti, F				Yu, Wei; Parakramaweera, Randika; Teng, Shavonne; Gowda, Manasa; Sharad, Yashsavi; Thakker-Varia, Smita; Alder, Janet; Sesti, Federico			Oxidation of KCNB1 Potassium Channels Causes Neurotoxicity and Cognitive Impairment in a Mouse Model of Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						aging; dasatinib; Kv2.1; oxidative stress; ROS; Src kinases	KV2.1 K+ CHANNEL; CONTROLLED CORTICAL IMPACT; SRC KINASE-ACTIVITY; NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; HIPPOCAMPAL; RAT; EXCITABILITY; DASATINIB; ACTIVATION	The delayed rectifier potassium (K+) channel KCNB1 (Kv2.1), which conducts a major somatodendritic current in cortex and hippocampus, is known to undergo oxidation in the brain, but whether this can cause neurodegeneration and cognitive impairment is not known. Here, we used transgenic mice harboring human KCNB1 wild-type (Tg-WT) or a nonoxidable C73A mutant (Tg-C73A) in cortex and hippocampus to determine whether oxidizedKCNB1channels affect brain function. Animals were subjected to moderate traumatic brain injury (TBI), a condition characterized by extensive oxidative stress. Dasatinib, a Food and Drug Administration-approved inhibitor of Src tyrosine kinases, was used to impinge on the proapoptotic signaling pathway activated by oxidized KCNB1 channels. Thus, typical lesions of brain injury, namely, inflammation (astrocytosis), neurodegeneration, and cell death, were markedly reduced in Tg-C73A and dasatinib-treated non-Tg animals. Accordingly, Tg-C73A mice and non-Tg mice treated with dasatinib exhibited improved behavioral outcomes in motor (rotarod) and cognitive (Morris water maze) assays compared to controls. Moreover, the activity of Src kinases, along with oxidative stress, were significantly diminished in Tg-C73A brains. Together, these data demonstrate that oxidation of KCNB1 channels is a contributing mechanism to cellular and behavioral deficits in vertebrates and suggest a new therapeutic approach to TBI.	[Yu, Wei; Parakramaweera, Randika; Teng, Shavonne; Gowda, Manasa; Sharad, Yashsavi; Thakker-Varia, Smita; Alder, Janet; Sesti, Federico] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, 683 Hoes Lane West, Piscataway, NJ 08854 USA	Sesti, F (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, 683 Hoes Lane West, Piscataway, NJ 08854 USA.	federico.sesti@rutgers.edu			National Science FoundationNational Science Foundation (NSF) [1456675]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21NS096619-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS096619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG060919] Funding Source: NIH RePORTER	This work was supported by National Science Foundation Grant 1456675 and NIH Grant 1R21NS096619-01 to F.S. The thy1.2 cassette was a kind gift from Dr. Pico Caroni. We thank Drs. Madura and Chen for help with the Zeiss Axio Imager and Shuang Liu for critical reading of this manuscript. We thank Nick Scurato for helping with the genotyping.	Agarwal S, 2012, MOL CANCER THER, V11, P2183, DOI 10.1158/1535-7163.MCT-12-0552; AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Alder J, 2016, BRAIN INJURY, V30, P48, DOI 10.3109/02699052.2015.1088963; Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; BARNES CA, 1987, J COMP NEUROL, V259, P549, DOI 10.1002/cne.902590405; BARNES CA, 1994, TRENDS NEUROSCI, V17, P13, DOI 10.1016/0166-2236(94)90029-9; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Cai SQ, 2009, NAT NEUROSCI, V12, P611, DOI 10.1038/nn.2291; Cernak I, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00209; Chen YC, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00100; Chico LK, 2009, NAT REV DRUG DISCOV, V8, P892, DOI 10.1038/nrd2999; Chou JL, 2011, J PROTEOMICS, V74, P466, DOI 10.1016/j.jprot.2010.12.012; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Cotella D, 2012, J NEUROSCI, V32, P4133, DOI 10.1523/JNEUROSCI.6153-11.2012; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Dhawan G, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-117; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Domeniconi M, 2007, MOL CELL NEUROSCI, V34, P271, DOI 10.1016/j.mcn.2006.11.005; Du J, 2000, J PHYSIOL-LONDON, V522, P19, DOI 10.1111/j.1469-7793.2000.t01-2-00019.xm; Fox PD, 2013, J NEUROSCI, V33, P1259, DOI 10.1523/JNEUROSCI.3008-12.2013; Frazzini V, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.18; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hasima Noor, 2012, Int J Biochem Mol Biol, V3, P328; Hettiarachchi NT, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.529; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Hille B., 2001, IONIC CHANNELS EXCIT, V3rd; JACQUE CM, 1978, J NEUROL SCI, V35, P147, DOI 10.1016/0022-510X(78)90107-7; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Ju M, 2003, J BIOL CHEM, V278, P12769, DOI 10.1074/jbc.M212973200; Katsumata R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046185; Kobrinsky E, 2006, J BIOL CHEM, V281, P19233, DOI 10.1074/jbc.M601231200; Konig H, 2008, CANCER RES, V68, P9624, DOI 10.1158/0008-5472.CAN-08-1131; LANDFIELD PW, 1986, J NEUROPHYSIOL, V56, P797; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Lim ST, 2000, NEURON, V25, P385, DOI 10.1016/S0896-6273(00)80902-2; Liu H, 2013, MOL CELL NEUROSCI, V57, P73, DOI 10.1016/j.mcn.2013.10.008; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luo FR, 2006, CLIN CANCER RES, V12, P7180, DOI 10.1158/1078-0432.CCR-06-1112; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McEwen ML, 2005, J HISTOCHEM CYTOCHEM, V53, P809, DOI 10.1369/jhc.4A6467.2005; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McManus MJ, 2011, J NEUROSCI, V31, P15703, DOI 10.1523/JNEUROSCI.0552-11.2011; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Murakoshi H, 1999, J NEUROSCI, V19, P1728; O'Connell KMS, 2006, J NEUROSCI, V26, P9609, DOI 10.1523/JNEUROSCI.1825-06.2006; O'Connell KMS, 2010, P NATL ACAD SCI USA, V107, P12351, DOI 10.1073/pnas.1003028107; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Papatheodoropoulos C, 1996, EUR J NEUROSCI, V8, P510, DOI 10.1111/j.1460-9568.1996.tb01235.x; Patel R, 2016, BRAIN RES, V1639, P174, DOI 10.1016/j.brainres.2016.02.046; Porkka K, 2008, BLOOD, V112, P1005, DOI 10.1182/blood-2008-02-140665; Redman PT, 2007, P NATL ACAD SCI USA, V104, P3568, DOI 10.1073/pnas.0610159104; RHODES KJ, 1995, J NEUROSCI, V15, P5360; Rojas P, 2008, J NEUROSCI, V28, P757, DOI 10.1523/JNEUROSCI.3825-07.2008; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rowe RK, 2014, SLEEP, V37, P743, DOI 10.5665/sleep.3582; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sarmiere PD, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-112; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sensi SL, 2008, EXP GERONTOL, V43, P488, DOI 10.1016/j.exger.2007.10.018; Sesti Federico, 2014, World J Biol Chem, V5, P85, DOI 10.4331/wjbc.v5.i2.85; Shen QH, 2016, WORLDV EVID-BASED NU, V13, P380, DOI 10.1111/wvn.12167; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smith IF, 2005, J NEUROCHEM, V94, P1711, DOI 10.1111/j.1471-4159.2005.03332.x; Speca DJ, 2014, GENES BRAIN BEHAV, V13, P394, DOI 10.1111/gbb.12120; Thakker-Varia S, 2001, J NEUROSCI, V21, P6782; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wu XL, 2013, J BIOL CHEM, V288, P4128, DOI 10.1074/jbc.M112.440933; Yao J, 2009, P NATL ACAD SCI USA, V106, P14670, DOI 10.1073/pnas.0903563106; Zhou TT, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.119	74	19	19	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 26	2016	36	43					11084	11096		10.1523/JNEUROSCI.2273-16.2016			13	Neurosciences	Neurosciences & Neurology	EG4WX	WOS:000391045800015	27798188	Green Published, Bronze			2021-06-18	
J	Iscan, Z; Nazarova, M; Fedele, T; Blagovechtchenski, E; Nikulin, VV				Iscan, Zafer; Nazarova, Maria; Fedele, Tommaso; Blagovechtchenski, Evgeny; Nikulin, Vadim V.			Pre-stimulus Alpha Oscillations and Inter-subject Variability of Motor Evoked Potentials in Single- and Paired-Pulse TMS Paradigms	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						brain stimulation; variability; paired-pulse; motor evoked potentials; electroencephalography; oscillations	TRANSCRANIAL MAGNETIC STIMULATION; RANGE TEMPORAL CORRELATIONS; TRAUMATIC BRAIN-INJURY; INTRACORTICAL INHIBITION; EEG ALPHA; CORTICAL EXCITABILITY; CORTICOSPINAL EXCITABILITY; ACTIVITY FLUCTUATIONS; ONGOING OSCILLATIONS; BAND OSCILLATIONS	Inter- and intra-subject variability of the motor evoked potentials (MEPs) to TMS is a well-known phenomenon. Although a possible link between this variability and ongoing brain oscillations was demonstrated, the results of the studies are not consistent with each other. Exploring this topic further is important since the modulation of MEPs provides unique possibility to relate oscillatory cortical phenomena to the state of the motor cortex probed with TMS. Given that alpha oscillations were shown to reflect cortical excitability, we hypothesized that their power and variability might explain the modulation of subject-specific MEPs to single- and paired-pulse TMS (spTMS, ppTMS, respectively). Neuronal activity was recorded with multichannel electroencephalogram. We used spTMS and two ppTMS conditions: intracortical facilitation (ICE) and short interval intracortical inhibition (SICI). Spearman correlations were calculated within and across subjects between MEPs and the pre-stimulus power of alpha oscillations in low (8-10 Hz) and high (10-12 Hz) frequency bands. Coefficient of quartile variation was used to measure variability. Across-subject analysis revealed no difference in the pre-stimulus alpha power among the TMS conditions. However, the variability of high-alpha power in spTMS condition was larger than in the SICI condition. In ICF condition pre-stimulus high-alpha power variability correlated positively with MEP amplitude variability. No correlation has been observed between the pre-stimulus alpha power and MEP responses in any of the conditions. Our results show that the variability of the alpha oscillations can be more predictive of TMS effects than the commonly used power of oscillations and we provide further support for the dissociation of high and low-alpha bands in predicting responses produced by the stimulation of the motor cortex.	[Iscan, Zafer; Nazarova, Maria; Fedele, Tommaso; Blagovechtchenski, Evgeny; Nikulin, Vadim V.] Natl Res Univ, Higher Sch Econ, Ctr Cognit & Decis Making, Moscow, Russia; [Nazarova, Maria] Res Ctr Neurol, Moscow, Russia; [Fedele, Tommaso] Univ Zurich, Univ Zurich Hosp, Dept Neurosurg, Zurich, Switzerland; [Blagovechtchenski, Evgeny] St Petersburg State Univ, Inst Translat Biomed, Lab Neurosci & Mol Pharmacol, St Petersburg, Russia; [Nikulin, Vadim V.] Charite Univ Med Berlin, Dept Neurol, Neurophys Grp, Berlin, Germany	Iscan, Z (corresponding author), Natl Res Univ, Higher Sch Econ, Ctr Cognit & Decis Making, Moscow, Russia.	ziscan@hse.ru	Iscan, Zafer/G-8771-2015; Nazarova, Maria A./D-8810-2012; Nikulin, Vadim V/A-6050-2014	Iscan, Zafer/0000-0001-9832-6591; Nazarova, Maria A./0000-0001-5347-5948; Nikulin, Vadim V/0000-0001-6082-3859			Arias P, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00316; Babiloni C, 2014, CLIN NEUROPHYSIOL, V125, P1936, DOI 10.1016/j.clinph.2014.04.021; Beck S, 2009, EUR J NEUROSCI, V29, P1634, DOI 10.1111/j.1460-9568.2009.06710.x; Berger B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/936096; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Bonett DG, 2006, COMPUT STAT DATA AN, V50, P2953, DOI 10.1016/j.csda.2005.05.007; Bosl W, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-18; Brzezicka A, 2017, COGNITION EMOTION, V31, P868, DOI 10.1080/02699931.2016.1170669; Butefisch CM, 2008, NEUROREHAB NEURAL RE, V22, P4, DOI 10.1177/1545968307301769; Butefisch CM, 2005, MOVEMENT DISORD, V20, P545, DOI 10.1002/mds.20367; Cantisani A, 2015, J AFFECT DISORDERS, V188, P167, DOI 10.1016/j.jad.2015.08.018; Casarotto S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010281; Chen R, 1998, J NEUROPHYSIOL, V80, P2870; Chen R, 2004, EXP BRAIN RES, V154, P1, DOI 10.1007/s00221-003-1684-1; Chouchou F, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00402; Chung YG, 2012, NEURAL NETWORKS, V36, P46, DOI 10.1016/j.neunet.2012.08.006; Churchland MM, 2010, NAT NEUROSCI, V13, P369, DOI 10.1038/nn.2501; Conforto AB, 2012, J HEADACHE PAIN, V13, P29, DOI 10.1007/s10194-011-0379-4; Di Lazzaro V, 2006, J NEUROPHYSIOL, V96, P1765, DOI 10.1152/jn.00360.2006; Di Lazzaro V, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00018; Dugue L, 2011, J NEUROSCI, V31, P11889, DOI 10.1523/JNEUROSCI.1161-11.2011; Ellaway PH, 1998, ELECTROMYOGR MOTOR C, V109, P104, DOI 10.1016/S0924-980X(98)00007-1; Fedele T, 2016, NEUROSCIENCE, V331, P109, DOI 10.1016/j.neuroscience.2016.06.015; Ferreri F, 2011, NEUROIMAGE, V54, P90, DOI 10.1016/j.neuroimage.2010.07.056; Fleming MK, 2012, IEEE T NEUR SYS REH, V20, P617, DOI 10.1109/TNSRE.2012.2202692; da Silva AKF, 2016, ANN NONINVAS ELECTRO, V21, P223, DOI 10.1111/anec.12372; Frenkel-Toledo S, 2013, BRAIN RES, V1509, P43, DOI 10.1016/j.brainres.2013.03.004; Garrett DD, 2013, NEUROSCI BIOBEHAV R, V37, P610, DOI 10.1016/j.neubiorev.2013.02.015; Garrett DD, 2013, CEREB CORTEX, V23, P684, DOI 10.1093/cercor/bhs055; Gharabaghi A, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00122; Giambattistelli F, 2014, HUM BRAIN MAPP, V35, P1740, DOI 10.1002/hbm.22288; Goldsworthy MR, 2016, NEUROSCIENCE, V320, P205, DOI 10.1016/j.neuroscience.2016.02.012; Haegens S, 2011, P NATL ACAD SCI USA, V108, P19377, DOI 10.1073/pnas.1117190108; Hanslmayr S, 2011, BRAIN RES REV, V67, P331, DOI 10.1016/j.brainresrev.2011.04.002; Hebb MO, 2007, J NEUROTRAUM, V24, P579, DOI 10.1089/neu.2006.0146; Hermsen AM, 2016, J NEUROL SCI, V362, P209, DOI 10.1016/j.jns.2016.01.039; Hohlefeld FU, 2012, EUR J NEUROSCI, V36, P2812, DOI 10.1111/j.1460-9568.2012.08198.x; Hyvarinen A, 1999, IEEE T NEURAL NETWOR, V10, P626, DOI 10.1109/72.761722; Julkunen P, 2012, BRAIN STIMUL, V5, P526, DOI 10.1016/j.brs.2011.07.006; Jung NH, 2010, BRAIN STIMUL, V3, P87, DOI 10.1016/j.brs.2009.10.003; Karabanov A, 2016, CURR OPIN NEUROL, V29, P397, DOI 10.1097/WCO.0000000000000342; Keil J, 2014, J NEUROPHYSIOL, V111, P513, DOI 10.1152/jn.00387.2013; Klein-Flugge MC, 2013, J NEUROSCI, V33, P5564, DOI 10.1523/JNEUROSCI.2448-12.2013; Klimesch W, 1998, EVOKED POTENTIAL, V108, P123, DOI 10.1016/S0168-5597(97)00078-6; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Klimesch W, 2012, TRENDS COGN SCI, V16, P606, DOI 10.1016/j.tics.2012.10.007; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Kundu B, 2014, J NEUROPHYSIOL, V112, P1885, DOI 10.1152/jn.00390.2013; Larsson PG, 2005, CLIN NEUROPHYSIOL, V116, P2701, DOI 10.1016/j.clinph.2005.07.019; Linkenkaer-Hansen K, 2007, J NEUROSCI, V27, P13882, DOI 10.1523/JNEUROSCI.3083-07.2007; Lioumis P, 2012, TOP STROKE REHABIL, V19, P182, DOI 10.1310/tsr1902-182; Lioumis P, 2009, HUM BRAIN MAPP, V30, P1387, DOI 10.1002/hbm.20608; Maki H, 2010, CLIN NEUROPHYSIOL, V121, P492, DOI 10.1016/j.clinph.2009.11.078; Maris E, 2007, J NEUROSCI METH, V164, P177, DOI 10.1016/j.jneumeth.2007.03.024; Misic B, 2010, J NEUROPHYSIOL, V104, P2667, DOI 10.1152/jn.00648.2010; Mitchell WK, 2007, J PHYSIOL-LONDON, V583, P567, DOI 10.1113/jphysiol.2007.134031; Mizuno T, 2010, CLIN NEUROPHYSIOL, V121, P1438, DOI 10.1016/j.clinph.2010.03.025; Moore RA, 2008, INT J PSYCHOPHYSIOL, V69, P79, DOI 10.1016/j.ijpsycho.2008.03.003; Nakamura H, 1997, J PHYSIOL-LONDON, V498, P817, DOI 10.1113/jphysiol.1997.sp021905; Nenadovic V, 2008, J NEUROTRAUM, V25, P615, DOI 10.1089/neu.2007.0474; Neuper C, 2006, PROG BRAIN RES, V159, P211, DOI 10.1016/S0079-6123(06)59014-4; Oh BM, 2010, INT J NEUROSCI, V120, P512, DOI 10.3109/00207451003760114; Orth M, 2003, CLIN NEUROPHYSIOL, V114, P2362, DOI 10.1016/S1388-2457(03)00243-8; Palva JM, 2013, P NATL ACAD SCI USA, V110, P3585, DOI 10.1073/pnas.1216855110; Pellicciari MC, 2016, CLIN NEUROPHYSIOL, V127, P621, DOI 10.1016/j.clinph.2015.03.002; Pfurtscheller G, 2000, CLIN NEUROPHYSIOL, V111, P1873, DOI 10.1016/S1388-2457(00)00428-4; Pfurtscheller G, 1997, INT J PSYCHOPHYSIOL, V26, P121, DOI 10.1016/S0167-8760(97)00760-5; Poil SS, 2012, J NEUROSCI, V32, P9817, DOI 10.1523/JNEUROSCI.5990-11.2012; Premoli I, 2014, J NEUROSCI, V34, P5603, DOI 10.1523/JNEUROSCI.5089-13.2014; Ritter P, 2009, HUM BRAIN MAPP, V30, P1168, DOI 10.1002/hbm.20585; Romei V, 2008, CEREB CORTEX, V18, P2010, DOI 10.1093/cercor/bhm229; Romei V, 2010, J NEUROSCI, V30, P8692, DOI 10.1523/JNEUROSCI.0160-10.2010; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Russmann H, 2009, CLIN NEUROPHYSIOL, V120, P1204, DOI 10.1016/j.clinph.2009.04.005; Sadaghiani S, 2009, J NEUROSCI, V29, P13410, DOI 10.1523/JNEUROSCI.2592-09.2009; Samaha J, 2016, J COGNITIVE NEUROSCI, V28, P1090, DOI 10.1162/jocn_a_00955; Sanger TD, 2001, J PHYSIOL-LONDON, V530, P307, DOI 10.1111/j.1469-7793.2001.0307l.x; Sauseng P, 2009, NEUROPSYCHOLOGIA, V47, P284, DOI 10.1016/j.neuropsychologia.2008.07.021; Schlee W, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/436146; Schlogl A, 2007, CLIN NEUROPHYSIOL, V118, P98, DOI 10.1016/j.clinph.2006.09.003; Schulz H, 2014, CEREB CORTEX, V24, P1708, DOI 10.1093/cercor/bht024; Segrave RA, 2011, CLIN EEG NEUROSCI, V42, P45, DOI 10.1177/155005941104200110; Shew WL, 2013, NEUROSCIENTIST, V19, P88, DOI 10.1177/1073858412445487; Smit DJA, 2013, J NEUROSCI, V33, P11212, DOI 10.1523/JNEUROSCI.2816-12.2013; Stagg CJ, 2011, J PHYSIOL-LONDON, V589, P5845, DOI 10.1113/jphysiol.2011.216978; Strube W, 2014, BEHAV BRAIN RES, V264, P17, DOI 10.1016/j.bbr.2014.01.041; Takemi M, 2013, J NEUROPHYSIOL, V110, P1158, DOI 10.1152/jn.01092.2012; Walter A, 2012, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00087; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141; Zarkowski P, 2006, CLIN EEG NEUROSCI, V37, P247, DOI 10.1177/155005940603700316; Ziemann U, 2015, CLIN NEUROPHYSIOL, V126, P1847, DOI 10.1016/j.clinph.2014.08.028; Zoon HFA, 2013, J CLIN NEUROPHYSIOL, V30, P261, DOI 10.1097/WNP.0b013e3182933d6e; Zrenner C, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00092	94	19	21	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	OCT 7	2016	10								504	10.3389/fnhum.2016.00504			11	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	DZ5FT	WOS:000385888100001	27774060	DOAJ Gold, Green Published			2021-06-18	
J	Hill, JL; Kobori, N; Zhao, J; Rozas, NS; Hylin, MJ; Moore, AN; Dash, PK				Hill, Julia L.; Kobori, Nobuhide; Zhao, Jing; Rozas, Natalia S.; Hylin, Michael J.; Moore, Anthony N.; Dash, Pramod K.			Traumatic brain injury decreases AMP-activated protein kinase activity and pharmacological enhancement of its activity improves cognitive outcome	JOURNAL OF NEUROCHEMISTRY			English	Article						glucose metabolism; hippocampus; memory retention; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FLUID PERCUSSION INJURY; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBOSIDE; ENERGY HOMEOSTASIS; CYCLOSPORINE-A; RAT; GLUCOSE; METFORMIN; REDUCTION; METABOLISM	Prolonged metabolic suppression in the brain is a well-characterized secondary pathology of both experimental and clinical traumatic brain injury (TBI). AMP-activated kinase (AMPK) acts as a cellular energy sensor that, when activated, regulates various metabolic and catabolic pathways to decrease ATP consumption and increase ATP synthesis. As energy availability after TBI is suppressed, we questioned if increasing AMPK activity after TBI would improve cognitive outcome. TBI was delivered using the electromagnetic controlled cortical impact model on male Sprague-Dawley rats (275-300g) and C57BL/6 mice (20-25g). AMPK activity within the injured parietal cortex and ipsilateral hippocampus was inferred by western blots using phospho-specific antibodies. The consequences of acute manipulation of AMPK signaling on cognitive function were assessed using the Morris water maze task. We found that AMPK activity is decreased as a result of injury, as indicated by reduced AMPK phosphorylation and corresponding changes in the phosphorylation of its downstream targets: ribosomal protein S6 and Akt Substrate of 160kDa (AS160). Increasing AMPK activity after injury using the drugs 5-amino-1--d-ribofuranosyl-imidazole-4-carboxamide or metformin did not affect spatial learning, but significantly improved spatial memory. Taken together, our results suggest that decreased AMPK activity after TBI may contribute to the cellular energy crisis in the injured brain, and that AMPK activators may have therapeutic utility.	[Hill, Julia L.; Kobori, Nobuhide; Zhao, Jing; Rozas, Natalia S.; Hylin, Michael J.; Moore, Anthony N.; Dash, Pramod K.] McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX USA; [Hylin, Michael J.] Southern Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA	Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston UTHlth, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019	Dash, Pramod/0000-0001-6746-1002; Rozas, Natalia/0000-0003-0848-0478; Hill, Julia/0000-0003-4744-0532	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS086301, NS090935]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086301, R01NS090935, R01NS101686] Funding Source: NIH RePORTER	The authors thank Sara Orsi and Kimberly Hood for their technical help, and Dr John Redell for his critical reading of the manuscript. This work was supported by a grant from NIH (NS086301, NS090935). The authors do not have any conflicts of interest to declare.	Alessandri B, 2012, J NEUROTRAUM, V29, P2181, DOI 10.1089/neu.2011.2067; Aoyama N, 2008, BRAIN RES, V1230, P310, DOI 10.1016/j.brainres.2008.07.006; Ashabi G, 2015, METAB BRAIN DIS, V30, P747, DOI 10.1007/s11011-014-9632-2; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Blum S, 1999, J NEUROSCI, V19, P3535; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Chen KH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106554; Cheng XL, 2013, J CHROMATOGR B, V915, P64, DOI 10.1016/j.jchromb.2012.12.020; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FABIANOWSKAMAJEWSKA K, 1994, BIOCHEM PHARMACOL, V48, P897, DOI 10.1016/0006-2952(94)90360-3; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guerrieri D, 2015, ONCOTARGET, V6, P18293, DOI 10.18632/oncotarget.4715; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hattori N, 2003, J NUCL MED, V44, P1709; Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Jin XS, 2007, STRUCTURE, V15, P1285, DOI 10.1016/j.str.2007.07.017; Karagounis LG, 2009, INT J BIOCHEM CELL B, V41, P2360, DOI 10.1016/j.biocel.2009.07.004; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kokiko-Cochran ON, 2008, NEUROSCI LETT, V436, P27, DOI 10.1016/j.neulet.2008.02.046; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Li J, 2007, STROKE, V38, P2992, DOI 10.1161/STROKEAHA.107.490904; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; MARANGOS PJ, 1990, EPILEPSIA, V31, P239, DOI 10.1111/j.1528-1157.1990.tb05371.x; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Moro N, 2011, NEUROSCI LETT, V491, P158, DOI 10.1016/j.neulet.2011.01.029; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Park HG, 2011, PROG NEURO-PSYCHOPH, V35, P1933, DOI 10.1016/j.pnpbp.2011.09.008; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Rena G, 2013, DIABETOLOGIA, V56, P1898, DOI 10.1007/s00125-013-2991-0; Rousset CI, 2015, J NEUROCHEM, V133, P242, DOI 10.1111/jnc.13034; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Shang J, 2004, J BIOL CHEM, V279, P12076, DOI 10.1074/jbc.M400431200; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Treebak JT, 2006, DIABETES, V55, P2051, DOI 10.2337/db06-0175; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Weisova P, 2009, J NEUROSCI, V29, P2997, DOI 10.1523/JNEUROSCI.0354-09.2009; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Xing GQ, 2012, NEUROSCI LETT, V525, P140, DOI 10.1016/j.neulet.2012.07.055; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhao YH, 2016, STEM CELLS, V34, P1263, DOI 10.1002/stem.2310; Zhou L, 2000, Zhongguo Zhong Xi Yi Jie He Za Zhi, V20, P356	76	19	20	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2016	139	1					106	119		10.1111/jnc.13726			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DX8RT	WOS:000384657500010	27379837	Bronze, Green Accepted			2021-06-18	
J	Oldham, JR; Munkasy, BA; Evans, KM; Wikstrom, EA; Buckley, TA				Oldham, Jessie R.; Munkasy, Barry A.; Evans, Kelsey M.; Wikstrom, Erik A.; Buckley, Thomas A.			Altered dynamic postural control during gait termination following concussion	GAIT & POSTURE			English	Article						Mild traumatic brain injury; Motor control; Center of pressure displacements; Center of pressure velocities	BALANCE CONTROL; STABILITY; MANAGEMENT; INITIATION; STATEMENT; MOVEMENT; DEFICITS; SPORT	Impaired postural control is a cardinal symptom following concussion. Planned gait termination (GT) is a non-novel, dynamic task that challenges postural control in individuals with neurological deficits, and it could be an impactful measure for identifying dynamic postural control impairments following concussion. Therefore, the purpose of this study was to assess acute post-concussion dynamic postural control utilizing a planned GT task. The concussion participants (n = 19, age: 19.0 +/- 0.8 years, height: 177.0 +/- 10.1 cm, weight: 83.3 +/- 20.0 kg) completed five planned GT trials during preseason baseline testing (Baseline) and on Day 1 post-concussion (Day-1). Healthy control participants (n = 19, age: 20.4 +/- 1.2 years, height: 173.8 +/- 8.9 cm, weight: 80.2 +/- 17.6 kg) completed the same trials a week apart. The dependent variables of interest included COP displacement and velocity in the mediolateral (ML) and anteroposterior (AP) axes during the three phases (braking, transitional, stabilization) of planned GT. There were significant interactions observed in both the braking ML and transitional AP displacement (p = 0.042, p = 0.030) and velocity (p = 0.027, p = 0.030). These results suggest a conservative post concussion motor control strategy during planned GT. Further, these results support the use of dynamic postural control tasks as measures of post-concussion impairments. (C) 2016 Elsevier B.V. All rights reserved.	[Oldham, Jessie R.; Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, 541 South Coll Ave, Newark, DE 19716 USA; [Munkasy, Barry A.] Georgia Southern Univ, Sch Hlth & Kinesiol, Statesboro, GA 30460 USA; [Evans, Kelsey M.] Emory Univ, Dept Emergency Med, Sch Med, 49 Jesse Hill Jr Dr,Suite 126, Atlanta, GA 30303 USA; [Wikstrom, Erik A.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 311 Woollen Gym, Chapel Hill, NC 27599 USA	Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, 541 South Coll Ave, Newark, DE 19716 USA.	Jroldham@udel.edu; Bmunkasy@georgiasouthern.edu; Kelsey.evans@emory.edu; Wikstrom@unc.edu; Tbuckley@udel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; Wikstrom, Erik/0000-0002-7260-0502; Oldham, Jessie/0000-0003-2801-2110	National Institute of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R15NS070744-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS070744] Funding Source: NIH RePORTER	This study was supported by the National Institute of Health/National Institute of Neurological Disorders and Stroke (1R15NS070744-01A1). The funding source had no role in the study design, data collection and interpretation, or decision to submit this manuscript for publication.	Bishop M, 2006, NEUROSCI LETT, V397, P240, DOI 10.1016/j.neulet.2005.12.031; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Buckley TA, 2014, GAIT BIOMETRICS BASI, P141; Buckley TA, 2008, MOVEMENT DISORD, V23, P1274, DOI 10.1002/mds.22079; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P61, DOI 10.1016/j.jshs.2016.01.007; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Chang HA, 1999, ARCH PHYS MED REHAB, V80, P490; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Concussion in Sport Group, 2013, BRIT J SPORT MED, V47, P259; Coxon JP, 2009, J COGNITIVE NEUROSCI, V21, P1193, DOI 10.1162/jocn.2009.21081; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hass CJ, 2012, GAIT POSTURE, V35, P669, DOI 10.1016/j.gaitpost.2011.12.022; Howell D., 2015, J BIOMECH; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; Lee H., 2012, J AM CERAM SOC, P1; MASSION J, 1992, PROG NEUROBIOL, V38, P35, DOI 10.1016/0301-0082(92)90034-C; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; NORLIN R, 1981, J PEDIATR ORTHOPED, V1, P261, DOI 10.1097/01241398-198111000-00004; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Rahn C., CLIN J SPORT MED, V25; Ryckewaert G, 2014, NEUROPHYSIOL CLIN, V44, P227, DOI 10.1016/j.neucli.2014.03.004; Sparrow WA, 2005, GAIT POSTURE, V22, P362, DOI 10.1016/j.gaitpost.2004.11.005; Wang JJ, 2009, J NEURAL TRANSM, V116, P1087, DOI 10.1007/s00702-009-0269-y; Wrisley DM, 2007, ARCH PHYS MED REHAB, V88, P1049, DOI 10.1016/j.apmr.2007.05.003; Zhang S, 2014, GAIT BIOMETRICS, P191	30	19	19	1	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	SEP	2016	49						437	442		10.1016/j.gaitpost.2016.07.327			6	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	DY1MF	WOS:000384858400073	27522565	Green Accepted			2021-06-18	
J	Paterno, R; Metheny, H; Xiong, GX; Elkind, J; Cohen, AS				Paterno, Rosalia; Metheny, Hannah; Xiong, Guoxiang; Elkind, Jaclynn; Cohen, Akiva S.			Mild Traumatic Brain Injury Decreases Broadband Power in Area CA1	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; in vivo recording; theta rhythm; traumatic brain injury	FLUID PERCUSSION INJURY; GAMMA-OSCILLATIONS; FIRING RATE; HIPPOCAMPUS; INHIBITION; MEMORY; RAT; DYSFUNCTION; POTENTIALS; FREQUENCY	Cognitive impairment caused by traumatic brain injury (TBI) can lead to devastating consequences for both patients and their families. The underlying neurological basis for TBI-induced cognitive dysfunction remains unknown. However, many lines of research have implicated the hippocampus in the pathophysiology of TBI. In particular, past research has found that theta oscillations, long thought to be the electrophysiological basis of learning and memory, are decreased in the hippocampus post-TBI. Here, we recorded in vivo electrophysiological activity in the hippocampi of 16 mice, 8 of which had previously undergone a TBI. Consistent with previous data, we found that theta power in the hippocampus was decreased in TBI animals compared to sham controls; however, this effect was driven by changes in broadband power and not theta oscillations. This result suggests that broadband fluctuations in the hippocampal local field potential can be used as an electrophysiological surrogate of abnormal neurological activity post-TBI.	[Paterno, Rosalia] Hosp Univ Penn, Ctr Sleep & Circadian Neurobiol, 3400 Spruce St, Philadelphia, PA 19104 USA; [Metheny, Hannah; Xiong, Guoxiang; Elkind, Jaclynn; Cohen, Akiva S.] Childrens Hosp Philadelphia, Dept Anesthesiol, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; [Cohen, Akiva S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol, Philadelphia, PA 19104 USA	Cohen, AS (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Abramson Res Ctr, Dept Anesthesiol & Crit Care Med,Perelman Sch Med, Room 816-h,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	cohena@email.chop.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R37HD059288] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069629] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32 HL007713] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R37 HD059288] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS069629] Funding Source: Medline		Addison P, 2002, ILLUSTRATED WAVELET; Atallah BV, 2009, NEURON, V62, P566, DOI 10.1016/j.neuron.2009.04.027; Bartos M, 2007, NAT REV NEUROSCI, V8, P45, DOI 10.1038/nrn2044; BRAGIN A, 1995, J NEUROSCI, V15, P47; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; Ekstrom A, 2007, HIPPOCAMPUS, V17, P606, DOI 10.1002/hipo.20300; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; Hinman JR, 2011, J NEUROPHYSIOL, V105, P2675, DOI 10.1152/jn.00837.2010; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Johnson BN, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00435; Lee DJ, 2015, J NEUROTRAUM, V32, P1822, DOI 10.1089/neu.2014.3744; Lee DJ, 2013, J NEUROTRAUM, V30, P131, DOI 10.1089/neu.2012.2646; Manning JR, 2009, J NEUROSCI, V29, P13613, DOI 10.1523/JNEUROSCI.2041-09.2009; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Miller KJ, 2007, J NEUROSCI, V27, P2424, DOI 10.1523/JNEUROSCI.3886-06.2007; Munyon C, 2014, BRAIN RES, V1582, P220, DOI 10.1016/j.brainres.2014.07.036; Nir Y, 2007, CURR BIOL, V17, P1275, DOI 10.1016/j.cub.2007.06.066; Ray S, 2015, TRENDS COGN SCI, V19, P78, DOI 10.1016/j.tics.2014.12.002; Ray S, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000610; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Tiesinga P, 2009, NEURON, V63, P727, DOI 10.1016/j.neuron.2009.09.009; Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397; Whittington MA, 2000, INT J PSYCHOPHYSIOL, V38, P315, DOI 10.1016/S0167-8760(00)00173-2; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052	29	19	19	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2016	33	17					1645	1649		10.1089/neu.2015.4107			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DU6EH	WOS:000382306300010	26529412	Green Published			2021-06-18	
J	Ritter, AC; Wagner, AK; Szaflarski, JP; Brooks, MM; Zafonte, RD; Pugh, MJV; Fabio, A; Hammond, FM; Dreer, LE; Bushnik, T; Walker, WC; Brown, AW; Johnson-Greene, D; Shea, T; Krellman, JW; Rosenthal, JA				Ritter, Anne C.; Wagner, Amy K.; Szaflarski, Jerzy P.; Brooks, Maria M.; Zafonte, Ross D.; Pugh, Mary Jo V.; Fabio, Anthony; Hammond, Flora M.; Dreer, Laura E.; Bushnik, Tamara; Walker, William C.; Brown, Allen W.; Johnson-Greene, Doug; Shea, Timothy; Krellman, Jason W.; Rosenthal, Joseph A.			Prognostic models for predicting posttraumatic seizures during acute hospitalization, and at 1 and 2 years following traumatic brain injury	EPILEPSIA			English	Article						Epilepsy; TBI Model System; Prognostic modeling; Risk factors; Craniectomy	RISK-FACTORS; DECOMPRESSIVE CRANIECTOMY; GENETIC-VARIATION; EPILEPSY; ASSOCIATIONS; REHABILITATION; COMPLICATIONS; MECHANISMS	Objective: Posttraumatic seizures (PTS) are well-recognized acute and chronic complications of traumatic brain injury (TBI). Risk factors have been identified, but considerable variability in who develops PTS remains. Existing PTS prognostic models are not widely adopted for clinical use and do not reflect current trends in injury, diagnosis, or care. We aimed to develop and internally validate preliminary prognostic regression models to predict PTS during acute care hospitalization, and at year 1 and year 2 postinjury. Methods: Prognostic models predicting PTS during acute care hospitalization and year 1 and year 2 post-injury were developed using a recent (2011-2014) cohort from the TBI Model Systems National Database. Potential PTS predictors were selected based on previous literature and biologic plausibility. Bivariable logistic regression identified variables with a p-value < 0.20 that were used to fit initial prognostic models. Multivariable logistic regression modeling with backward-stepwise elimination was used to determine reduced prognostic models and to internally validate using 1,000 bootstrap samples. Fit statistics were calculated, correcting for overfitting (optimism). Results: The prognostic models identified sex, craniotomy, contusion load, and pre-injury limitation in learning/remembering/concentrating as significant PTS predictors during acute hospitalization. Significant predictors of PTS at year 1 were subdural hematoma (SDH), contusion load, craniotomy, craniectomy, seizure during acute hospitalization, duration of posttraumatic amnesia, preinjury mental health treatment/psychiatric hospitalization, and preinjury incarceration. Year 2 significant predictors were similar to those of year 1: SDH, intraparenchymal fragment, craniotomy, craniectomy, seizure during acute hospitalization, and preinjury incarceration. Corrected concordance (C) statistics were 0.599, 0.747, and 0.716 for acute hospitalization, year 1, and year 2 models, respectively. Significance: The prognostic model for PTS during acute hospitalization did not discriminate well. Year 1 and year 2 models showed fair to good predictive validity for PTS. Cranial surgery, although medically necessary, requires ongoing research regarding potential benefits of increased monitoring for signs of epileptogenesis, PTS prophylaxis, and/or rehabilitation/social support. Future studies should externally validate models and determine clinical utility.	[Ritter, Anne C.; Brooks, Maria M.; Fabio, Anthony] Univ Pittsburgh, Phys Med & Rehabil, Pittsburgh, PA USA; [Ritter, Anne C.; Wagner, Amy K.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Szaflarski, Jerzy P.] Univ Alabama Birmingham, Dept Neurol, Epilepsy Ctr, UAB Stn, Birmingham, AL 35294 USA; [Zafonte, Ross D.] Harvard Med Sch, Spaulding Rehabil Hosp, Boston, MA USA; [Pugh, Mary Jo V.] South Texas Vet Hlth Care Syst Polytrauma Rehabil, San Antonio, TX USA; [Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA; [Bushnik, Tamara] NYU, Sch Med, Rusk Rehabil, New York, NY USA; [Walker, William C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; [Johnson-Greene, Doug] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Shea, Timothy] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Krellman, Jason W.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Rosenthal, Joseph A.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Pugh, Mary Jo/K-5336-2019	Pugh, Mary Jo/0000-0003-4196-7763; Brooks, Maria/0000-0002-2030-7873; Fabio, Anthony/0000-0002-6808-4939; Brown, Allen W./0000-0001-7228-3351; Bushnik, Tamara/0000-0003-3328-257X	NIDILRRUnited States Department of Health & Human Services [90DP0041, 90DP0038, 90DP0036, 90DP0033]; Polytrauma Rehabilitation Center Traumatic Brain Injury Model System; Department of Veterans Affairs (VA)US Department of Veterans Affairs; NIDILRRUnited States Department of Health & Human Services	The National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) supported the collection of original data for this manuscript. The contents of this manuscript were developed under grants NIDILRR Grants 90DP0041 (AKW, ACR), NIDILRR 90DP0038 (JWK), 90DP0036 (FH), 90DP0033 (WCW), and the Polytrauma Rehabilitation Center Traumatic Brain Injury Model System (MJP). The Polytrauma Rehabilitation Center TBI Model System is a funded collaboration between the Department of Veterans Affairs (VA) and NIDILRR. NIDILRR is a Center within the Administration for Community Living (ACL), U.S. Department of Health and Human Services (HHS). The contents of this manuscript do not necessarily represent the policy of the VA, NIDILRR, ACL, or HHS, and endorsement of this content by the Federal Government should not be assumed.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Bushnik T, 2012, J HEAD TRAUMA REHAB, V27, pE36, DOI 10.1097/HTR.0b013e318273375c; Centers for Disease Control and Prevention, 2014, REP C TRAUM BRAIN IN; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020; Darrah SD, 2013, EPILEPSY RES, V103, P180, DOI 10.1016/j.eplepsyres.2012.07.006; Devinsky O, 2013, TRENDS NEUROSCI, V36, P174, DOI 10.1016/j.tins.2012.11.008; Diamond ML, 2015, EPILEPSIA, V56, P1198, DOI 10.1111/epi.13044; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Fisher RS, 2012, EPILEPSY BEHAV, V24, P304, DOI 10.1016/j.yebeh.2012.04.128; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Harrell Frank E., 2001, REGRESSION MODELING; Harrison-Felix C, 2015, J NEUROTRAUM, V32, P1893, DOI 10.1089/neu.2014.3353; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hesdorffer DC, 2012, ANN NEUROL, V72, P184, DOI 10.1002/ana.23601; Honeybul S, 2014, INJURY, V45, P1332, DOI 10.1016/j.injury.2014.03.007; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Keele NB, 2005, EPILEPSY BEHAV, V7, P325, DOI 10.1016/j.yebeh.2005.06.014; Kumlien E, 2010, SEIZURE-EUR J EPILEP, V19, P69, DOI 10.1016/j.seizure.2009.11.005; McDermott S, 2005, AM J MENT RETARD, V110, P48, DOI 10.1352/0895-8017(2005)110<48:POEIAW>2.0.CO;2; Moons KGM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b375; R Core Team, 2017, R LANG ENV STAT COMP; Ramakrishnan Vivek, 2015, Surg Neurol Int, V6, P8, DOI 10.4103/2152-7806.149613; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Ritter AC, 2016, EPILEPSIA, V57, P984, DOI 10.1111/epi.13397; Scharfman HE, 2007, CURR NEUROL NEUROSCI, V7, P348, DOI 10.1007/s11910-007-0053-z; Sills Graeme J, 2007, Epilepsy Curr, V7, P103, DOI 10.1111/j.1535-7511.2007.00189.x; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Staley K, 2015, NAT NEUROSCI, V18, P367, DOI 10.1038/nn.3947; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Walker WC, 2015, J HEAD TRAUMA REHAB, V30, P231, DOI 10.1097/HTR.0000000000000127; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; Weston J, 2015, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.00007286.PUB3; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	46	19	20	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	SEP	2016	57	9					1503	1514		10.1111/epi.13470			12	Clinical Neurology	Neurosciences & Neurology	EB8QJ	WOS:000387655600025	27430564				2021-06-18	
J	Stache, S; Howell, D; Meehan, WP				Stache, Stephen; Howell, David; Meehan, William P., III			Concussion Management Practice Patterns Among Sports Medicine Physicians	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						sport-related concussion; management; medications; neuropsychological testing; return to play	STATES HIGH-SCHOOL; UNITED-STATES; PEDIATRIC-PATIENTS	Objective:The primary purpose of this study was to examine concussion management practice patterns among sports medicine physicians in the United States.Design:Cross-sectional study using a web-based survey.Participants:Members of the American Medical Society for Sports Medicine (AMSSM).Main Outcome Measures:We distributed a questionnaire to physician members of the AMSSM assessing the current practices for evaluating and managing concussions sustained during sports. Specifically, we asked respondents about their use of management guidelines, medications, balance assessments, neuropsychological tests, and return-to-play strategies.Results:Of the 3591 members emailed, 425 (11.8%) respondents responded. Ninety-seven percent of respondents reported basing current management of sport-related concussion on a published set of criteria, with a majority (91.9%) following the guidelines provided by the Fourth International Conference on Concussion in Sport. Seventy-six percent of respondents reported using medication beyond 48 hours postinjury. Acetaminophen was reported as the most commonly administered medication, although tricyclic antidepressants and amantadine were also commonly administered. Vitamins, minerals, and dietary supplements were also reported as commonly administered. Most respondents reported using a form of neuropsychological testing (87.1%). A majority of respondents (88.6%) reported allowing athletes to return to competition after concussion only once the athlete becomes symptom free and completes a return-to-play protocol.Conclusions:Most sports medicine physicians seem to use recently developed guidelines for concussion management, regularly use medications and neuropsychological testing in management strategies, and follow established return-to-play guidelines.Clinical Relevance:Sports medicine physicians seem to have clinical expertise in the management of sport-related concussion.	[Stache, Stephen] Rothman Inst Orthopaed, Philadelphia, PA USA; [Stache, Stephen] Thomas Jefferson Univ, Dept Family & Community Med, Philadelphia, PA 19107 USA; [Howell, David; Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Dept Orthoped, Boston, MA USA; [Howell, David; Meehan, William P., III] Boston Childrens Hosp, Sports Concuss Clin, Boston, MA USA; [Howell, David; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Meehan, William P., III] Boston Childrens Hosp, Div Emergency Med, Dept Med, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA USA; Harvard Med Sch, Dept Orthoped, Boston, MA USA	Stache, S (corresponding author), 825 Old Lancaster Ave,Ste 200, Bryn Mawr, PA 19096 USA.	Stephen.stache@rothmaninstitute.com		Howell, David/0000-0002-2955-0191	National Football League Players Association	W.P.M. receives royalties from ABC-Clio publishing for the sale of his book, Kids, Sports, and Concussion: A Guide for Coaches and Parents, and royalties from Wolters Kluwer for working as an author for UpToDate. His research is funded, in part, by a grant from the National Football League Players Association and by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament. The reamining authors report no conflicts of interest.	[Anonymous], 2014, TRAUM BRAIN INJ LEG; [Anonymous], 2014, POP WARNER CONCUSSIO; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broshek DK, 2014, J CHILD NEUROL, V29, P17, DOI 10.1177/0883073812464525; Colvin JD, 2013, ARCH DIS CHILD, V98, P934, DOI 10.1136/archdischild-2012-303588; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Graham R., 2014, SPORTS RELATED CONCU; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Kinnaman KA, 2014, PEDIATR EMERG CARE, V30, P458, DOI 10.1097/PEC.0000000000000161; Kinnaman KA, 2013, ACTA PAEDIATR, V102, pE424, DOI 10.1111/apa.12315; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; Williams RM, 2014, SPORTS HEALTH, V6, P434, DOI 10.1177/1941738114545612; Zemek R, 2014, PAED CHILD HEALT-CAN, V19, P474, DOI 10.1093/pch/19.9.475	22	19	19	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2016	26	5					381	385		10.1097/JSM.0000000000000270			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	DW8LH	WOS:000383906800008	26584436				2021-06-18	
J	Vink, R				Vink, Robert			Magnesium in the CNS: recent advances and developments	MAGNESIUM RESEARCH			English	Article; Proceedings Paper	14th International Magnesium Symposium - Magnesium and Health	JUN 23-24, 2016	Rome, ITALY			magnesium; treatment; blood brain barrier; alcohol; amyloid; inflammation	TRAUMATIC BRAIN-INJURY; STEM-CELL PROLIFERATION; SPINAL-CORD-INJURY; SUBSTANCE-P; NEUROGENIC INFLAMMATION; POLYETHYLENE-GLYCOL; SULFATE; DEFICIENCY; THERAPY; NEUROPROTECTION	A potential neuroprotective role for magnesium in neurological disease has been appreciated for almost three decades, yet translation to the clinical arena has proven elusive. Accumulating experimental evidence continues to suggest that magnesium plays a critical role in a number of neurological conditions including headache, stress, alcohol/drug intoxication, acute brain injury, seizures, Parkinson's disease and Alzheimer's disease. Simple administration of a magnesium salt in these conditions has not always been therapeutically successful, with a number of studies showing poor penetration of serum magnesium across the blood brain barrier. Several studies have since demonstrated that using a carrier such as polyethylene glycol can address this, simultaneously reducing the dose of magnesium required to achieve the desired central effects while at the same time attenuating deleterious peripheral effects. Alternatively, administering a more permeable magnesium salt, such as magnesium threonate, is seen as the preferred option in more chronic neurological conditions, with positive results having been achieved in experimental models of Alzheimer's disease. Irrespective of the approach, improved central penetration of a magnesium compound that avoids peripheral side effects of high magnesium dosages is clearly a desirable outcome, and should now be investigated in animal models that accurately mimic the complex human condition.	[Vink, Robert] Univ South Australia, Sansom Inst Hlth Res, Adelaide, SA 5000, Australia	Vink, R (corresponding author), Univ South Australia, Off Pro Vice Chancellor Hlth, Adelaide, SA 5000, Australia.	Robert.Vink@unisa.edu.au	Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667			Aslanyan S, 2007, STROKE, V38, P1269, DOI 10.1161/01.STR.0000259628.94421.09; Brewer RP, 2001, CLIN NEUROPHARMACOL, V24, P341, DOI 10.1097/00002826-200111000-00005; Busingye DS, 2016, CNS NEUROSCI THER, V22, P854, DOI 10.1111/cns.12591; Chui D, 2011, MAGNESIUM CENTRAL NE, V18, P239; Corrigan F, 2016, BRIT J PHARMACOL, V173, P703, DOI 10.1111/bph.13155; Corrigan F, 2012, J NEUROCHEM, V122, P208, DOI 10.1111/j.1471-4159.2012.07761.x; Dhandapani SS, 2008, INDIAN J NEUROTRAUM, V5, P27, DOI 10.1016/S0973-0508(08)80025-1; Dibaba DT, 2014, EUR J CLIN NUTR, V68, P510, DOI 10.1038/ejcn.2014.7; Ditor DS, 2007, J NEUROSCI RES, V85, P1458, DOI 10.1002/jnr.21283; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Ema M, 1998, ALCOHOL, V15, P95, DOI 10.1016/S0741-8329(97)00102-X; FLINK EB, 1986, ALCOHOL CLIN EXP RES, V10, P590, DOI 10.1111/j.1530-0277.1986.tb05150.x; Harris JM, 2001, CLIN PHARMACOKINET, V40, P539, DOI 10.2165/00003088-200140070-00005; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Jia SS, 2016, J CELL PHYSIOL, V231, P1903, DOI 10.1002/jcp.25306; Jia SS, 2016, CELL BIOL INT, V40, P465, DOI 10.1002/cbin.10569; Kodikara S, 2007, Forensic Sci Med Pathol, V3, P283, DOI 10.1007/s12024-007-0041-2; Kramer JH, 1997, J MOL CELL CARDIOL, V29, P97, DOI 10.1006/jmcc.1996.0255; Kwon BK, 2009, J NEUROTRAUM, V26, P1379, DOI [10.1089/neu.2009.0884, 10.1089/neu.2009-0884]; Lees KR, 2004, LANCET, V363, P439; Li W, 2014, MOL BRAIN, V7, DOI 10.1186/s13041-014-0065-y; Marinov MB, 1996, J NEUROSURG, V85, P117, DOI 10.3171/jns.1996.85.1.0117; Mazur A, 2007, ARCH BIOCHEM BIOPHYS, V458, P48, DOI 10.1016/j.abb.2006.03.031; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MULLINS PGM, 1995, NEUROREPORT, V6, P1633, DOI 10.1097/00001756-199508000-00011; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Nimmo Alan J, 2009, Recent Pat CNS Drug Discov, V4, P86; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; Richardson JD, 2002, J PHARMACOL EXP THER, V302, P839, DOI 10.1124/jpet.102.032797; Saver JL, 2015, NEW ENGL J MED, V372, P528, DOI 10.1056/NEJMoa1408827; Sen AP, 2010, NEUROTHERAPEUTICS, V7, P91, DOI 10.1016/j.nurt.2009.10.014; Stippler M, 2007, J NEUROTRAUM, V24, P1347, DOI 10.1089/neu.2007.0277; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Van den Heuvel C, 2000, J NEUROTRAUM, V17, P1041, DOI 10.1089/neu.2000.17.1041; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; Vink R, 2004, J AM COLL NUTR, V23, p538S, DOI 10.1080/07315724.2004.10719398; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 2012, MAGNESIUM CENTRAL NE; Vink R, 2012, J FORENSIC SCI, V57, P979, DOI 10.1111/j.1556-4029.2012.02108.x; WEGLICKI WB, 1992, AM J PHYSIOL, V263, pR734; Westermaier T, 2003, ACTA NEUROCHIR, V145, P393, DOI 10.1007/s00701-003-0013-6	42	19	21	1	23	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	0953-1424	1952-4021		MAGNESIUM RES	Magnes. Res.	SEP	2016	29	3					95	101		10.1684/mrh.2016.0408			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	EG7NV	WOS:000391235500003	27829572				2021-06-18	
J	Bao, HJ; Yang, XF; Huang, YX; Qiu, HY; Huang, GP; Xiao, H; Kuai, JX				Bao, Haijun; Yang, Xiaofang; Huang, Yuxiu; Qiu, Haiyang; Huang, Genping; Xiao, Hua; Kuai, Jinxia			The neuroprotective effect of apelin-13 in a mouse model of intracerebral hemorrhage	NEUROSCIENCE LETTERS			English	Article						Apoptosis; Apelin-13; Intracerebral hemorrhage	ISCHEMIC REPERFUSION INJURY; FOCAL CEREBRAL-ISCHEMIA; BRAIN-BARRIER DAMAGE; TRANSIENT MODEL; RECEPTOR; EDEMA; APJ; INHIBITION; POLOXAMER-188; INFLAMMATION	Adipocytokine apelin-13 is a peptide which could reportedly protect the brain against ischemic reperfusion injury and traumatic brain injury (TBI). Whether apelin-13 has any roles to play in intracerebral hemorrhage (ICH) has not been clarified. We aimed to investigate the roles of apelin-13 in ICH and effects on ICH-induced apoptosis. Firstly, CD-1 mice were subjected to infusion of Type IV collagenase (to induce ICH) or saline (for shams) into the left striatum. ICH animals received intracerebroventricular administration of vehicle, apelin-13 (50 mu g dissolved in 5 mu l saline) immediately after ICH. The motor function and the cerebral water content (CWC) as well as blood brain barrier (BBB) disruption were measured, coupled with determination of ICH-induced neural cell death by Terminal-deoxynucleoitidyl Transferase Mediated Nick End Labeling (TUNEL). The apoptosis-associated proteins caspase-3 and Bcl-2 as well as the brain edema-associated proteins aquaporin-4 (AQP4) and MMP-9 were all assessed with western blotting. The results showed that apelin-13 decreased CWC and reduced Evans blue leakage into injured hemispheres, with the motor function significantly improved. Additionally, apelin-13 also acutely decreased the number of ICH-induced TUNEL-positive (TUNEL+) cells at 48 h after ICH. The expressions of AQP4, MMP-9, caspse-3 and Bcl-2 were all downregulated by apelin-13 at 24 h and 4811 after ICH. All these results revealed that apelin-13 attenuated brain edema and reduced cellular death by suppressing apoptosis after ICH in mice. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Bao, Haijun; Yang, Xiaofang; Huang, Yuxiu; Qiu, Haiyang; Huang, Genping; Xiao, Hua] Xuzhou Med Univ, Dept Pathol, Xuzhou, Peoples R China; [Kuai, Jinxia] Xuzhou Med Univ, Dept Forens Med, 209 Tongshan Rd, Xuzhou, Peoples R China	Kuai, JX (corresponding author), Xuzhou Med Univ, Dept Forens Med, 209 Tongshan Rd, Xuzhou, Peoples R China.	55752663@qq.com			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81302612]; Student Innovation Training Program of Jiangsu Province [201510313010Z]	The study was supported by the National Science Foundation of China (No. 81302612) and Student Innovation Training Program of Jiangsu Province (No. 201510313010Z).	Aboutaleb N, 2014, INT J PEPT RES THER, V20, P127, DOI 10.1007/s10989-013-9374-8; Bao HJ, 2015, NEUROCHEM RES, V40, P89, DOI 10.1007/s11064-014-1469-x; Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Busch R, 2015, CELL SIGNAL, V27, P1286, DOI 10.1016/j.cellsig.2015.03.011; Chang JJ, 2014, J STROKE CEREBROVASC, V23, P2498, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.005; Choe W, 2000, J NEUROVIROL, V6, pS61; Hosoya M, 2000, J BIOL CHEM, V275, P21061, DOI 10.1074/jbc.M908417199; Hwang BY, 2011, CEREBROVASC DIS, V31, P211, DOI 10.1159/000321870; Jiao H, 2013, EXP THER MED, V5, P797, DOI 10.3892/etm.2013.902; Khaksari M, 2012, J MOL NEUROSCI, V48, P201, DOI 10.1007/s12031-012-9808-3; Krafft PR, 2012, STROKE, V43, P844, DOI 10.1161/STROKEAHA.111.639989; Li M, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000736; Nicchia GP, 2004, NEUROSCIENCE, V129, P935, DOI 10.1016/j.neuroscience.2004.07.055; O'Carroll AM, 2013, J ENDOCRINOL, V219, pR13, DOI 10.1530/JOE-13-0227; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Sandal S, 2015, NEUROSCI LETT, V602, P133, DOI 10.1016/j.neulet.2015.06.059; Sawane M, 2011, AM J PATHOL, V179, P2691, DOI 10.1016/j.ajpath.2011.08.024; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang T, 2015, J MOL NEUROSCI, V55, P240, DOI 10.1007/s12031-014-0313-8; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xin Q, 2015, PEPTIDES, V63, P55, DOI 10.1016/j.peptides.2014.09.016; Yamashiro S, 2015, NEUROL MED-CHIR, V55, P819, DOI 10.2176/nmc.oa.2014-0136; Zhang MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087241	27	19	20	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 15	2016	628						219	224		10.1016/j.neulet.2016.06.046			6	Neurosciences	Neurosciences & Neurology	DT6JP	WOS:000381590800036	27343409	Bronze			2021-06-18	
J	Sprigg, N; Robson, K; Bath, P; Dineen, R; Roberts, I; Robinson, T; Roffe, C; Werring, D; Salman, RA; Pocock, S; Duley, L; England, T; Whynes, D; Ciccone, A; Laska, AC; Christensen, H; Ozturk, S; Collins, R; Bereczki, D; Egea-Guerrero, JJ; Law, ZK; Czlonkowska, A; Seiffge, D; Beredzie, M				Sprigg, Nikola; Robson, Katie; Bath, Philip; Dineen, Robert; Roberts, Ian; Robinson, Tom; Roffe, Christine; Werring, David; Salman, Rustam Al-Shahi; Pocock, Stuart; Duley, Lelia; England, Tim; Whynes, David; Ciccone, Alfonso; Laska, Ann Charlotte; Christensen, Hanne; Ozturk, Serefnur; Collins, Ronan; Bereczki, Daniel; Egea-Guerrero, Juan Jose; Law, Zhe Kang; Czlonkowska, Anna; Seiffge, David; Beredzie, Maia		Tich-2 Investigators	Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial	INTERNATIONAL JOURNAL OF STROKE			English	Article						Hyperacute intracerebral hemorrhage; tranexamic acid; randomized trial; placebo controlled	TRAUMATIC BRAIN-INJURY; SPOT SIGN SCORE; HEMATOMA EXPANSION; IDENTIFIES PATIENTS; STROKE TRIALS; HIGHEST RISK; CRASH-2	Rationale Outcome after intracerebral hemorrhage remains poor. Tranexamic acid is easy to administer, readily available, inexpensive, and effective in other hemorrhagic conditions. Aim This randomized trial aims to test the hypothesis that intravenous tranexamic acid given within 8h of spontaneous intracerebral hemorrhage reduces death or dependency. Design Phase III prospective double-blind randomized placebo-controlled trial. Participants within 8h of spontaneous intracerebral hemorrhage are randomized to receive either intravenous tranexamic acid 1g 10min bolus followed by 1g 8h infusion, or placebo. Sample size estimates A trial of 2000 participants (300 from start-up phase and 1700 from main phase) will have 90% power to detect an ordinal shift of the modified Rankin Scale with odds ratio 0.79. Study outcomes The primary outcome is death or dependency measured by ordinal shift analysis of the 7 level mRS at day 90. Secondary outcomes are neurological impairment at day 7 and disability, quality of life, cognition, and mood at day 90. Safety outcomes are death, serious adverse events, thromboembolic events, and seizures. Cost outcomes are length of stay in hospital, readmission, and institutionalization. Discussion This pragmatic trial is assessing efficacy of tranexamic acid after spontaneous intracerebral hemorrhage. Recruitment started in 2013; as of 15th January 2016 1355 participants have been enrolled, from 95 centers in seven countries. Recruitment is due to end in 2017. TICH-2 Trial is registered as ISRCTN93732214.	[Sprigg, Nikola; Robson, Katie; Bath, Philip; Dineen, Robert; Roberts, Ian; Robinson, Tom; Roffe, Christine; Werring, David; Salman, Rustam Al-Shahi; Pocock, Stuart; Duley, Lelia; England, Tim; Whynes, David; Ciccone, Alfonso; Laska, Ann Charlotte; Christensen, Hanne; Ozturk, Serefnur; Collins, Ronan; Bereczki, Daniel; Egea-Guerrero, Juan Jose; Law, Zhe Kang; Czlonkowska, Anna; Seiffge, David; Beredzie, Maia; Tich-2 Investigators] Stroke, Div Clin Neurosci, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England	Sprigg, N (corresponding author), Stroke, Div Clin Neurosci, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.	Nikola.sprigg@nottingham.ac.uk	OZTURK, SEREFNUR/AAG-4973-2019; Law, Zhe Kang/ABC-6224-2020; Roffe, Christine/AAT-5611-2020; England, Timothy J/AAD-3100-2021; Werring, David/Q-8435-2019; Seiffge, David/W-8289-2019; Dineen, Robert/S-7192-2019; Bereczki, Daniel/AAL-9886-2020; Egea-Guerrero, Juan Jose/P-5080-2014	Law, Zhe Kang/0000-0002-7900-9037; Roffe, Christine/0000-0002-5259-6649; England, Timothy J/0000-0001-5330-8584; Werring, David/0000-0003-2074-1861; Seiffge, David/0000-0003-3890-3849; Ciccone, Alfonso/0000-0002-4590-3575; Christensen, Hanne/0000-0002-7472-3194; Egea-Guerrero, Juan Jose/0000-0002-4166-313X; Czlonkowska, Anna/0000-0002-1956-1866; Robinson, Thompson/0000-0003-2144-2468; Dineen, Robert/0000-0002-9523-2546; collins, Ronan/0000-0003-0404-8266; Al-Shahi Salman, Rustam/0000-0002-2108-9222	National Institute of Health Research Health Technology Assessment (NIHR HTA), UK [11_129_109]; Swiss Heart foundation in Switzerland; British Heart FoundationBritish Heart Foundation [SP/12/2/29422] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002605] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [11/129/109] Funding Source: researchfish	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors received financial support for the research from National Institute of Health Research Health Technology Assessment (NIHR HTA project code 11_129_109), UK and Swiss Heart foundation in Switzerland.	Almandoz JED, 2010, STROKE, V41, P54, DOI 10.1161/STROKEAHA.109.565382; Almandoz JED, 2009, STROKE, V40, P2994, DOI 10.1161/STROKEAHA.109.554667; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; [Anonymous], 2011, LANCET, V377; Bath P, 2009, STROKE, V40, P888, DOI 10.1161/STROKEAHA.108.519207; Bath PMW, 2012, STROKE, V43, P1171, DOI 10.1161/STROKEAHA.111.641456; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; de Jager CA, 2003, INT J GERIATR PSYCH, V18, P318, DOI 10.1002/gps.830; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Ederies A, 2009, STROKE, V40, P1672, DOI 10.1161/STROKEAHA.108.541201; Fonville AF, 2013, STROKE, V44, P2729, DOI 10.1161/STROKEAHA.113.001493; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; HORROW JC, 1995, ANESTHESIOLOGY, V82, P383, DOI 10.1097/00000542-199502000-00009; Kazui S, 1996, STROKE, V27, P1783, DOI 10.1161/01.STR.27.10.1783; MAHONEY F I, 1965, Md State Med J, V14, P61; Meretoja A, 2014, INT J STROKE, V9, P519, DOI 10.1111/ijs.12132; OJACASTRO MF, 2008, INT J STROKE S1, V3, P197; Roos Y, 2003, STROKE, V34, P2308, DOI 10.1161/01.STR.0000089030.04120.0E; Roos YBWEM, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3958; Saghaei Mahmoud, 2011, J Med Signals Sens, V1, P55; Salman RA, 2014, STROKE, V45, P3149, DOI 10.1161/STROKEAHA.114.005786; Salman RAS, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005951.pub3; Sorimachi T, 2005, NEUROSURGERY, V57, P837, DOI 10.1227/01.NEU.0000180815.38967.57; Sprigg N, 2014, J STROKE CEREBROVASC, V23, P1312, DOI 10.1016/j.jstrokecerebrovasdis.2013.11.007; Steiner T, 2010, STROKE, V41, P402, DOI 10.1161/STROKEAHA.109.552919; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Zehtabchi S, 2014, AM J EMERG MED, V32, P1503, DOI 10.1016/j.ajem.2014.09.023; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; 2010, LANCET, V376, P23, DOI DOI 10.1016/S0140-6736(10)60835-5	30	19	19	0	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1747-4930	1747-4949		INT J STROKE	Int. J. Stroke	AUG	2016	11	6					717	723		10.1177/1747493016641960			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	DS7VJ	WOS:000380990700014	27048694	Green Accepted			2021-06-18	
J	Zenisek, R; Millis, SR; Banks, SJ; Miller, JB				Zenisek, RyAnna; Millis, Scott R.; Banks, Sarah J.; Miller, Justin B.			Prevalence of below-criterion Reliable Digit Span scores in a clinical sample of older adults	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Dementia; Malingering/symptom validity testing; Assessment; Reliable Digit Span	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; SYMPTOM VALIDITY TESTS; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; DEMENTIA; MEMORY; VALIDATION; INVALIDITY; INDICATORS; SEVERITY	Objective: The Reliable Digit Span (RDS) is a well-validated embedded indicator of performance validity. An RDS score of <= 7 is commonly referenced as indicative of invalid performance; however, few studies have examined the classification accuracy of the RDS among individuals suspected for dementia. The current study evaluated performance of the RDS in a clinical sample of 934 non-litigating individuals presenting to an outpatient memory disorders clinic for assessment of dementia. Method: The RDS was calculated for each participant in the context of a comprehensive neuropsychological assessment completed as part of routine clinical care. Score distributions were examined to establish the base rate of below criterion performance for RDS cutoffs of <= 7, <= 6, and <= 5. One-way ANOVA was used to compare performance on a cognitive screening measure and informant reports of functional independence of those falling below and above cutoffs. Results: A cutoff score of <= 7 resulted in a high prevalence of below-criterion performance (29.7%), though an RDS of <= 6 was associated with fewer below-criterion scores (12.8%) and prevalence of an RDS of <= 5 was infrequent (4.3%). Those scoring below cutoffs performed worse on cognitive measures compared with those falling above cutoffs. Conclusions: Using the RDS as a measure of performance validity among individuals presenting with a possibility of dementia increases the risk of misinterpreting genuine cognitive impairment as invalid performance when higher cutoffs are used; lower cutoffs may be useful when interpreted in conjunction with other measures of performance validity.	[Zenisek, RyAnna] Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA; [Millis, Scott R.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Banks, Sarah J.; Miller, Justin B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA	Miller, JB (corresponding author), Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA.	millerj4@ccf.org		Miller, Justin B./0000-0002-4439-6604; Banks, Sarah/0000-0001-7536-2370	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20 GM109025] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM109025] Funding Source: NIH RePORTER		An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Benedict R., 1997, BRIEF VISUOSPATIAL M; Boone, 2007, ASSESSMENT FEIGNED C; Bortnik KE, 2013, APPL NEUROPSYCH-ADUL, V20, P233, DOI 10.1080/09084282.2012.695757; Brandt J., 2001, HOPKINS VERBAL LEARN; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Calderon J, 2001, J NEUROL NEUROSUR PS, V70, P157, DOI 10.1136/jnnp.70.2.157; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DeRight J, 2015, CLIN NEUROPSYCHOL, V29, P101, DOI 10.1080/13854046.2014.989267; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox DD, 2011, CLIN NEUROPSYCHOL, V25, P488, DOI 10.1080/13854046.2011.554443; Gagnon LG, 2011, NEUROPSYCHOLOGY, V25, P226, DOI 10.1037/a0020919; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Hales R. E., 2014, AM PSYCHIAT PUBLISHI; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Johnson N, 2004, ALZ DIS ASSOC DIS, V18, P223; Kaplan E., 2001, Boston naming test; Kessels RPC, 2011, AGING CLIN EXP RES, V23, P487; Kiewel NA, 2012, CLIN NEUROPSYCHOL, V26, P965, DOI 10.1080/13854046.2012.694478; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Silk-Eglit GM, 2014, ARCH CLIN NEUROPSYCH, V29, P415, DOI 10.1093/arclin/acu028; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Vogel Sally J, 2015, Alzheimers Dement (Amst), V1, P289, DOI 10.1016/j.dadm.2015.05.002; Walter J, 2014, CLIN NEUROPSYCHOL, V28, P1197, DOI 10.1080/13854046.2014.960454; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 2009, ADV CLIN SOLUTIONS W; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Weintraub S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006171; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083	40	19	19	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2016	31	5					426	433		10.1093/arclin/acw025			8	Psychology, Clinical; Psychology	Psychology	DU0LF	WOS:000381895200005	27193362	Bronze, Green Published			2021-06-18	
J	Damianakis, T; Tough, A; Marziali, E; Dawson, DR				Damianakis, Thecla; Tough, Alicia; Marziali, Elsa; Dawson, Deirdre R.			Therapy Online: A Web-Based Video Support Group for Family Caregivers of Survivors With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; family caregiving; online intervention; support group; videoconferencing	SOCIAL SUPPORT; COPING STYLE; INTERVENTION; BURDEN; INDIVIDUALS; PREDICTORS; PROGRAM; ADULTS; NEEDS; TBI	Objective: This innovative descriptive study explores the benefits of a traumatic brain injury (TBI) caregiver support group intervention provided using videoconferencing within a password protected Web-based platform. Methods: Ten caregivers of family members with TBI were registered to a password-protected Web site (Caring for Others) that provided information about caring for a person with TBI and access to a videoconferencing support group intervention program. Where needed, caregivers were provided with computer equipment, Internet access, and training to negotiate the Web site links. Two groups of 5 caregivers of survivors of TBI participated (average age of survivor-20 years, average time since injury-4.6 years) and met online with a trained clinician weekly for 10 sessions. Using directed content analysis, transcripts of each session were coded with NVivo software. Results: The content analysis reported group process themes, therapeutic interventions used, caregiver outcomes, and the challenges for clinicians delivering a therapeutic intervention online. Conclusions: Traumatic brain injury caregivers shared similar concerns and problem-solving strategies for managing caregiving tasks. Overall, participants found the sessions helpful for managing the emotional impact of caring for a family member with TBI.	[Damianakis, Thecla] Univ Windsor, Sch Social Work, Windsor, ON, Canada; [Damianakis, Thecla; Dawson, Deirdre R.] Baycrest, Rotman Res Inst, Toronto, ON, Canada; [Tough, Alicia] Gestalt Inst Toronto, Ctr Rehabil & Hlth, Toronto, ON, Canada; [Marziali, Elsa] Univ Toronto, Fac Med, Toronto, ON, Canada; [Marziali, Elsa] Univ Toronto, Factor Inwentash Fac Social Work, Toronto, ON, Canada; [Dawson, Deirdre R.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Ste 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada; [Dawson, Deirdre R.] Univ Toronto, Rehabil Sci Inst, Toronto, ON, Canada	Dawson, DR (corresponding author), Univ Toronto, Dept Occupat Sci & Occupat Therapy, Ste 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	ddawson@research.baycrest.org	Dawson, Deirdre/I-8882-2014	Dawson, Deirdre/0000-0001-7517-6121	Bell Laboratories at the University of Toronto; Ontario Neurotrauma Foundation; Quebec Rehabilitation Research Network (ONF-REPAR)	Dr Marziali received a grant from Bell Laboratories at the University of Toronto. Dr Dawson received a grant from the Ontario Neurotrauma Foundation in collaboration with the Quebec Rehabilitation Research Network (ONF-REPAR). Ms Tough was a student in the Department of Occupational Science and Occupational Therapy, University of Toronto while this research was being carried out.	ACORN S, 1993, J ADV NURS, V18, P39, DOI 10.1046/j.1365-2648.1993.18010039.x; ACORN S, 1995, J ADV NURS, V21, P872, DOI 10.1046/j.1365-2648.1995.21050872.x; Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Albert SM, 2002, J HEAD TRAUMA REHAB, V17, P175, DOI 10.1097/00001199-200204000-00007; *AM GROUP PSYCH AS, PRACT GUID GROUP PSY; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Brauer J, 2011, OCCUP THER HEALTH CA, V25, P119, DOI 10.3109/07380577.2011.570420; Brown FL, 2013, J HEAD TRAUMA REHAB, V28, P349, DOI 10.1097/HTR.0b013e318245fed5; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Dawson DR, 2010, OCCUP THER HEALTH CA, V24, P295, DOI 10.3109/07380577.2010.514383; Dawson DR, 2006, BRAIN COGNITION, V60, P214; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Gan C, 2010, NEUROREHABILITATION, V27, P5, DOI 10.3233/NRE-2010-0577; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Hunt A, 2004, HDB CAREGIVERS FAMIL; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; Lincoln Y.S., 1985, NATURALISTIC INQUIRY, V289, P289, DOI DOI 10.1016/0147-1767(85)90062-8; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Marziali E, 2006, GERONTOLOGIST, V46, P398, DOI 10.1093/geront/46.3.398; Marziali E, 2005, FAM SOC, V86, P375, DOI 10.1606/1044-3894.3435; Marziali E, 2011, AM J ALZHEIMERS DIS, V26, P36, DOI 10.1177/1533317510387586; Marziali E, 2009, TELEMED J E-HEALTH, V15, P176, DOI 10.1089/tmj.2008.0082; McLaughlin KA, 2013, J HEAD TRAUMA REHAB, V28, P341, DOI 10.1097/HTR.0b013e31824e1d43; McReynolds Connie J., 2001, Work, V16, P57; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Sander AM, 2009, J HEAD TRAUMA REHAB, V24, P248, DOI 10.1097/HTR.0b013e3181ad593a; Sosin DM, 1996, BRAIN INJURY, V10, P47; Van Baalen B, 2007, BRAIN INJURY, V21, P925, DOI 10.1080/02699050701553197; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2006, J CONSULT CLIN PSYCH, V51, P178; Wongvatunyu S, 2008, J FAM NURS, V14, P314, DOI 10.1177/1074840708321473; Yalom I. D., 2005, THEORY PRACTICE GROU	43	19	19	1	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2016	31	4					E12	E20		10.1097/HTR.0000000000000178			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DR3FW	WOS:000379789000002	26291634				2021-06-18	
J	Lin, M; He, HJ; Schifitto, G; Zhong, JH				Lin, Mu; He, Hongjian; Schifitto, Giovanni; Zhong, Jianhui			Simulation of Changes in Diffusion Related to Different Pathologies at Cellular Level After Traumatic Brain Injury	MAGNETIC RESONANCE IN MEDICINE			English	Article						Monte Carlo simulation; DTI; TBI; demyelination; edema; axonal injury	AMYLOID PRECURSOR PROTEIN; MONTE-CARLO SIMULATIONS; AXONAL INJURY; WHITE-MATTER; WATER DIFFUSION; CORPUS-CALLOSUM; HEAD-INJURY; RESTRICTED DIFFUSION; SPINAL-CORD; MILD	Purpose: The goal of the current study was to investigate tissue pathology at the cellular level in traumatic brain injury (TBI) as revealed by Monte Carlo simulation of diffusion tensor imaging (DTI)-derived parameters and elucidate the possible sources of conflicting findings of DTI abnormalities as reported in the TBI literature. Methods: A model with three compartments separated by permeable membranes was employed to represent the diffusion environment of water molecules in brain white matter. The dynamic diffusion process was simulated with a Monte Carlo method using adjustable parameters of intra-axonal diffusivity, axon separation, glial cell volume fraction, and myelin sheath permeability. The effects of tissue pathology on DTI parameters were investigated by adjusting the parameters of the model corresponding to different stages of brain injury. Results: The results suggest that the model is appropriate and the DTI-derived parameters simulate the predominant cellular pathology after TBI. Our results further indicate that when edema is not prevalent, axial and radial diffusivity have better sensitivity to axonal injury and demyelination than other DTI parameters. Conclusion: DTI is a promising biomarker to detect and stage tissue injury after TBI. The observed inconsistencies among previous studies are likely due to scanning at different stages of tissue injury after TBI. (C) 2015 Wiley Periodicals, Inc.	[Lin, Mu; He, Hongjian; Zhong, Jianhui] Zhejiang Univ, Dept Biomed Engn, Ctr Brain Imaging Sci & Technol, Hangzhou, Zhejiang, Peoples R China; [Schifitto, Giovanni] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; [Schifitto, Giovanni; Zhong, Jianhui] Univ Rochester, Med Ctr, Dept Imaging Sci, Rochester, NY 14642 USA	Zhong, JH (corresponding author), Zhejiang Univ, Ctr Brain Imaging Sci & Technol, Hangzhou, Zhejiang, Peoples R China.	jzhong@zju.edu.cn	Zhong, Jianhui/AAE-6061-2020		National High-Tech R.D Program (863 Program) of ChinaNational High Technology Research and Development Program of China [2012AA011603, 2012AA011602]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-MH099921]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81401473]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH099921] Funding Source: NIH RePORTER	Grant sponsor: National High-Tech R.D Program (863 Program) of China; Grant numbers: 2012AA011603; 2012AA011602; Grant sponsor: National Institutes of Health; Grant number: R01-MH099921; Grant sponsor: National Natural Science Foundation of China; Grant number: 81401473.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2005, NEUROIMAGE, V27, P48, DOI 10.1016/j.neuroimage.2005.03.042; Assaf Y, 2004, MAGN RESON MED, V52, P965, DOI 10.1002/mrm.20274; Barzo P, 1997, ACT NEUR S, V70, P119; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRISMAR T, 1981, ACTA PHYSIOL SCAND, V113, P167, DOI 10.1111/j.1748-1716.1981.tb06878.x; Budde MD, 2010, P NATL ACAD SCI USA, V107, P14472, DOI 10.1073/pnas.1004841107; Choi SJ, 2005, J GERIATR PSYCH NEUR, V18, P12, DOI 10.1177/0891988704271763; Edgar JM, 2014, WHITE MATTER STRUCTU, P127; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Fieremans E, 2008, J MAGN RESON, V190, P189, DOI 10.1016/j.jmr.2007.10.014; Fieremans E, 2010, NMR BIOMED, V23, P711, DOI 10.1002/nbm.1577; Ford JC, 1997, MAGNET RESON MED, V37, P387, DOI 10.1002/mrm.1910370315; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Hall MG, 2009, IEEE T MED IMAGING, V28, P1354, DOI 10.1109/TMI.2009.2015756; Harkins KD, 2012, MAGN RESON MED, V67, P793, DOI 10.1002/mrm.23053; Hossmann K-A, 1985, BRAIN EDEMA, P367; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Ishiguri H, 1985, BRAIN EDEMA, P20; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Karger J., 1988, ADV MAGN RESON, V12, P1; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Landman BA, 2008, MAGN RESON IMAGING, V26, P790, DOI 10.1016/j.mri.2008.01.034; Latt J, 2009, NMR BIOMED, V22, P619, DOI 10.1002/nbm.1376; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nilsson M, 2010, J MAGN RESON, V206, P59, DOI 10.1016/j.jmr.2010.06.002; Nilsson M, 2012, NMR BIOMED, V25, P795, DOI 10.1002/nbm.1795; Nilsson M, 2009, MAGN RESON IMAGING, V27, P176, DOI 10.1016/j.mri.2008.06.003; Olveczky BP, 1998, BIOPHYS J, V74, P2722, DOI 10.1016/s0006-3495(98)77978-0; Peled S, 1999, MAGNET RESON MED, V42, P911; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Quirk JD, 2003, MAGNET RESON MED, V50, P493, DOI 10.1002/mrm.10565; Regan DG, 2000, EUR BIOPHYS J BIOPHY, V29, P221, DOI 10.1007/s002490000081; Regan DG, 2003, EUR BIOPHYS J BIOPHY, V31, P563, DOI 10.1007/s00249-002-0249-8; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sargon MF, 2007, INT J NEUROSCI, V117, P749, DOI 10.1080/00207450600910119; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Spatz M, 2010, ACTA NEUROCHIR SUPPL, V106, P21, DOI 10.1007/978-3-211-98811-4_3; Stanisz GJ, 1997, MAGNET RESON MED, V37, P103, DOI 10.1002/mrm.1910370115; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; SZAFER A, 1995, MAGNET RESON MED, V33, P697, DOI 10.1002/mrm.1910330516; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; VANGELDEREN P, 1994, J MAGN RESON SER B, V103, P255, DOI 10.1006/jmrb.1994.1038; VONKEYSERLINGK DG, 1984, ANAT ANZEIGER, V157, P97; Webb S, 2003, MAGNET RESON MED, V49, P638, DOI 10.1002/mrm.10411; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zhao FY, 2006, ACTA NEUROCHIR SUPPL, V96, P168	65	19	20	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	JUL	2016	76	1					290	300		10.1002/mrm.25816			11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	DY3MK	WOS:000384996900029	26256558	Green Accepted			2021-06-18	
J	Vavilis, T; Delivanoglou, N; Aggelidou, E; Stamoula, E; Mellidis, K; Kaidoglou, A; Cheva, A; Pourzitaki, C; Chatzimeletiou, K; Lazou, A; Albani, M; Kritis, A				Vavilis, Theofanis; Delivanoglou, Nikoleta; Aggelidou, Eleni; Stamoula, Eleni; Mellidis, Kyriakos; Kaidoglou, Aikaterini; Cheva, Angeliki; Pourzitaki, Chryssa; Chatzimeletiou, Katerina; Lazou, Antigone; Albani, Maria; Kritis, Aristeidis			Oxygen-Glucose Deprivation (OGD) Modulates the Unfolded Protein Response (UPR) and Inflicts Autophagy in a PC12 Hypoxia Cell Line Model	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Oxygen-glucose deprivation; Unfolded protein response; Autophagy; Glucose-regulated proteins; Hypoxia; Chaperones	ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; CHAPERONE-MEDIATED AUTOPHAGY; FOCAL CEREBRAL-ISCHEMIA; GENE-EXPRESSION; RAT MODEL; DEATH; ACTIVATION; GRP78; NEUROPROTECTION	Hypoxia is the lack of sufficient oxygenation of tissue, imposing severe stress upon cells. It is a major feature of many pathological conditions such as stroke, traumatic brain injury, cerebral hemorrhage, perinatal asphyxia and can lead to cell death due to energy depletion and increased free radical generation. The present study investigates the effect of hypoxia on the unfolded protein response of the cell (UPR), utilizing a 16-h oxygen-glucose deprivation protocol (OGD) in a PC12 cell line model. Expression of glucose-regulated protein 78 (GRP78) and glucose-regulated protein 94 (GRP94), key players of the UPR, was studied along with the expression of glucose-regulated protein 75 (GRP75), heat shock cognate 70 (HSC70), and glyceraldehyde 3-phosphate dehydrogenase, all with respect to the cell death mechanism(s). Cells subjected to OGD displayed upregulation of GRP78 and GRP94 and concurrent downregulation of GRP75. These findings were accompanied with minimal apoptotic cell death and induction of autophagy. The above observation warrants further investigation to elucidate whether autophagy acts as a pro-survival mechanism that upon severe and prolonged hypoxia acts as a concerted cell response leading to cell death. In our OGD model, hypoxia modulates UPR and induces autophagy.	[Vavilis, Theofanis; Delivanoglou, Nikoleta; Aggelidou, Eleni; Stamoula, Eleni; Albani, Maria; Kritis, Aristeidis] Aristotle Univ Thessaloniki, Fac Hlth Sci, Sch Med, Physiol Lab, Thessaloniki 54124, Greece; [Mellidis, Kyriakos; Lazou, Antigone] Aristotle Univ Thessaloniki, Sch Biol, Physiol Lab, Fac Sci, Thessaloniki 54124, Greece; [Kaidoglou, Aikaterini] Aristotle Univ Thessaloniki, Sch Med, Lab Histol Embryol & Anthropol, Fac Hlth Sci, Thessaloniki 54124, Greece; [Cheva, Angeliki] Gen Hosp Thessaloniki G Papanikolaou, Dept Pathol, Thessaloniki, Greece; [Pourzitaki, Chryssa] Aristotle Univ Thessaloniki, Pharmacol Lab, Sch Med, Fac Hlth Sci, Thessaloniki 54124, Greece; [Chatzimeletiou, Katerina] Aristotle Univ Thessaloniki, Human Reprod Unit, Sch Med, Papageorgiou Gen Hosp,Dept Obstet & Gynaecol 1, Thessaloniki 54124, Greece	Kritis, A (corresponding author), Aristotle Univ Thessaloniki, Fac Hlth Sci, Sch Med, Physiol Lab, Thessaloniki 54124, Greece.	kritis@med.auth.gr	Vavilis, Theofanis/D-1852-2016; Lazou, Antigone/L-3878-2014; Kritis, Aristeidis/AAG-7474-2019; Lazou, A./I-4511-2019	Vavilis, Theofanis/0000-0002-5658-4637; Kritis, Aristeidis/0000-0002-2067-8842; Lazou, A./0000-0002-7889-9648; CHEVA, ANGELIKI/0000-0002-5374-1772	Program for Basic Research Activity Enhancement of the Research Committee of Aristotle University [89337]; European Union/European Social Fund EPEAEK PYTHGORAS II [13]	The present work was supported by the Program for Basic Research Activity Enhancement of the Research Committee of Aristotle University (Project Number 89337), European Union/European Social Fund EPEAEK PYTHGORAS II (Project Number 13) as well as the yearly Laboratory of Physiology fund allocation. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AOKI M, 1993, J CEREBR BLOOD F MET, V13, P781, DOI 10.1038/jcbfm.1993.99; Balduini W, 2012, J MATERN-FETAL NEO M, V25, P119, DOI 10.3109/14767058.2012.663232; Balduini W, 2009, AUTOPHAGY, V5, P221, DOI 10.4161/auto.5.2.7363; Bando Y, 2003, EUR J NEUROSCI, V18, P829, DOI 10.1046/j.1460-9568.2003.02818.x; Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Burbulla LF, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.103; Calderwood SK, 2009, GERONTOLOGY, V55, P550, DOI 10.1159/000225957; Cavaliere F, 2001, NEUROCHEM INT, V38, P199, DOI 10.1016/S0197-0186(00)00087-5; Chakrabarti A, 2011, BIOTECHNOL BIOENG, V108, P2777, DOI 10.1002/bit.23282; Chatzimeletiou K, 2005, PRENATAL DIAG, V25, P919, DOI 10.1002/pd.1227; Chatzimeletiou K, 2011, FERTIL STERIL, V95, DOI 10.1016/j.fertnstert.2011.01.161; Chiu BY, 2014, CELL MOL NEUROBIOL, V34, P825, DOI 10.1007/s10571-014-0059-4; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Cui DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035324; Dohi E, 2012, NEUROCHEM INT, V60, P431, DOI 10.1016/j.neuint.2012.01.020; Ginet V, 2009, AM J PATHOL, V175, P1962, DOI 10.2353/ajpath.2009.090463; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P949, DOI 10.1097/01.WCB.0000077641.41248.EA; Hillion JA, 2005, J CEREBR BLOOD F MET, V25, P154, DOI 10.1038/sj.jcbfm.9600003; Hol EM, 2008, J MOL NEUROSCI, V34, P23, DOI 10.1007/s12031-007-0013-8; Jiang YF, 2012, NEUROSCI LETT, V516, P182, DOI 10.1016/j.neulet.2012.03.074; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kang CH, 2008, AUTOPHAGY, V4, P82, DOI 10.4161/auto.5154; Kang LH, 2013, NEUROCHEM RES, V38, P311, DOI 10.1007/s11064-012-0922-y; Kashyap MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017757; Kiffin R, 2004, MOL BIOL CELL, V15, P4829, DOI 10.1091/mbc.E04-06-0477; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Komatsu M, 2007, CELL DEATH DIFFER, V14, P887, DOI 10.1038/sj.cdd.4402120; Kostandy BB, 2012, NEUROL SCI, V33, P223, DOI 10.1007/s10072-011-0828-5; Kritis A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025950; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; MASSA SM, 1995, J NEUROSCI RES, V40, P807, DOI 10.1002/jnr.490400612; Mizushima N, 2007, AUTOPHAGY, V3, P542; Mo ZT, 2012, ACTA PHARMACOL SIN, V33, P737, DOI 10.1038/aps.2012.35; Mo ZT, 2012, CELL BIOL INT, V36, P1043, DOI 10.1042/CBI20120229; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Olender T, 2013, ISR J CHEM, V53, P185, DOI 10.1002/ijch.201200094; Outeiro Tiago Fleming, 2007, Semin Pediatr Neurol, V14, P15, DOI 10.1016/j.spen.2006.11.005; Pamenter ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051469; Papadopoulou LC, 1996, BIOCHEM PHARMACOL, V52, P713, DOI 10.1016/0006-2952(96)00349-8; Ravikumar B, 2009, J CELL SCI, V122, P1707, DOI 10.1242/jcs.031773; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Renaud J, 2014, NEUROTOX RES, V25, P110, DOI 10.1007/s12640-013-9439-7; Sabri M, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/394036; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Seki T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031232; Sheng R, 2012, AUTOPHAGY, V8, P310, DOI 10.4161/auto.18673; Sheng R, 2010, AUTOPHAGY, V6, P482, DOI 10.4161/auto.6.4.11737; Stricher F, 2013, AUTOPHAGY, V9, P1937, DOI 10.4161/auto.26448; Wang K, 2014, CHINESE MED J-PEKING, V127, P1964, DOI 10.3760/cma.j.issn.0366-6999.20120638; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Xin Q, 2014, NEUROCHEM INT, V68, P18, DOI 10.1016/j.neuint.2014.02.001; Xu F, 2012, NEUROSCI BULL, V28, P658, DOI 10.1007/s12264-012-1268-9; Yan WJ, 2011, BRAIN RES, V1402, P109, DOI 10.1016/j.brainres.2011.05.049; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; Zhu CL, 2006, J NEUROCHEM, V96, P1016, DOI 10.1111/j.1471-4159.2005.03639.x	65	19	19	0	15	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JUL	2016	36	5					701	712		10.1007/s10571-015-0250-2			12	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	DN9LP	WOS:000377401400007	26239244				2021-06-18	
J	Blumenfeld, RS; Winsell, JC; Hicks, JW; Small, SL				Blumenfeld, Robert S.; Winsell, Jessica C.; Hicks, James W.; Small, Steven L.			The Epidemiology of Sports-Related Head Injury and Concussion in Water Polo	FRONTIERS IN NEUROLOGY			English	Article						concussion; brain injury; sports-related head injury; epidemiology; survey; mild TBI; contact sports	DIAGNOSIS; SYMPTOMS	Purpose: Water polo is a sport with a high degree of physicality and aggressive play. Unlike most contact sports, epidemiological data on the incidence or prevalence of head trauma in water polo have not been gathered, reported, or made publicly available. The purpose of this study was to begin a systematic characterization of the risks of head impact and concussion in men and women who play water polo at various levels. Design: We sent an electronic survey to the 44,000+ members of USA Water Polo, asking questions about concussions, head impacts, and symptoms commonly associated with prior concussion. From over 1500 complete responses, we report summary information on the prevalence of concussions and major head impacts in water polo. Results: We found that 36% of respondents report sustaining a concussion while playing water polo, with an average of two concussions reported. The prevalence and number of concussions reported varied across positions, levels, and gender. Most strikingly, we found that goalies are at significantly higher risk for concussion, report a significantly more concussions, and appear to experience a qualitatively different type of head impact compared to other positions. Additionally, we found that competition level, gender, and field position are robust predictors of concussion risk. Conclusion: Our findings demonstrate that concussions are not uncommon in water polo players. We conclude that there is need for systematic concussion reporting in water polo and suggest that understanding the risk factors of concussion in water polo will require fully considering differences in the head impact exposure between different field positions, competition levels, sexes, and differences in exposure between competition and practice.	[Blumenfeld, Robert S.] Calif State Polytech Univ Pomona, Dept Psychol & Sociol, Pomona, CA 91768 USA; [Blumenfeld, Robert S.; Winsell, Jessica C.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA; [Hicks, James W.] Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92717 USA; [Small, Steven L.] Univ Calif Irvine, Brain Circuits Lab, Biol Sci 3, Irvine, CA USA	Small, SL (corresponding author), Univ Calif Irvine, Brain Circuits Lab, Biol Sci 3, Irvine, CA USA.	small@uci.edu		Small, Steven/0000-0002-5293-6172	University of California Irvine (UC Irvine) School of Medicine	Financial support for the study was provided by the University of California Irvine (UC Irvine) School of Medicine. Logistical support was provided by USA Water Polo, which graciously sent our survey out to its entire constituency, and by the UC Irvine Department of Intercollegiate Athletics, which has consistently provided our sports neurology program with access, advice, and hands-on assistance. Thanks to Manali Khadilkar for helping to implement the survey. Finally, we are particularly grateful to Maria Corrada-Bravo, Sc.D., who read over the manuscript and provided invaluable advice on epidemiology and biostatistics.	Bell L., 2014, SELF REPORTED CONCUS; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Harmon KG, 2012, BRIT J SPORT MED, V46, P158, DOI 10.1136/bjsports-2012-090999; Katz Douglas I, 2015, Handb Clin Neurol, V127, P131, DOI 10.1016/B978-0-444-52892-6.00009-X; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Parsons JT., 2014, 2014 15 NCAA SPORTS, V25th ed; Perez F, 2007, COMPUT SCI ENG, V9, P21, DOI 10.1109/MCSE.2007.53; Snyder AR, 2014, CLIN NEUROPSYCHOL, V28, P1091, DOI 10.1080/13854046.2014.952667	14	19	19	0	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JUN 24	2016	7								98	10.3389/fneur.2016.00098			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DP5OR	WOS:000378547400001	27445965	DOAJ Gold, Green Published			2021-06-18	
J	Wu, G; Liu, ZY				Wu, Gang; Liu, Zongying			Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Mediates Neuroprotection in Traumatic Brain Injury at Least in Part by Inactivating Microglia	MEDICAL SCIENCE MONITOR			English	Article						Brain Injuries; Microglia; NF-E2-Related Factor 2	TRANSCRIPTION FACTOR NRF2; ACTIVATION; INFLAMMATION; MICE; PROTECTION; PHENOTYPE; SYSTEM; RAT	Background: Microglial activation has been reported to be involved in traumatic brain injury (TBI). Nuclear factor erythroid 2-related factor 2 (Nrf2) plays a significant role in protecting against TBI-induced secondary brain injury. However, the exact mechanism is not clearly understood. The present study aimed to explore whether Nrf2 protects against TBI partly by regulating microglia function. Material/Methods: Microglia cells were isolated from C57BL/6 mouse brains (postnatal day 1-3). The expression of Nrf2 was suppressed by transfection with Nrf2-specific small interfering RNA (siRNA), and overexpressed by transfections with pcDNA3.1-Nrf2. The expression of Nrf2 was confirmed by real-time PCR and Western blotting. After transfection, cell viability, phagocytic ability, and the expression of pro-inflammatory cytokines (tumor necrosis factor (TNF)-alpha and interleukin (IL)-6) were determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) colorimetric assay, phagocytosis assay, and enzyme-linked immunosorbent assay (ELISA), respectively. Results: mRNA and protein expression levels of Nrf2 were significantly reduced by transfection with Nrf2-specific siRNA (both P<0.05) but were elevated by transfection with pcDNA3.1-Nrf2 (both P<0.01). The cell viability, phagocytic ability, and the expression of TNF-alpha and IL-6 were all significantly reduced by overexpression of Nrf2 but were significantly increased by silencing of Nrf2 compared with the control group. Conclusions: Our results suggest that Nrf2 protects against TBI, at least part by regulating microglia function.	[Wu, Gang] Binzhou Peoples Hosp, Dept Neurol, Binzhou, Shandong, Peoples R China; [Liu, Zongying] Peoples Hosp Pingyi Cty, Dept Clin Lab, Linyi, Shandong, Peoples R China	Wu, G (corresponding author), Binzhou Peoples Hosp, Dept Neurol, Binzhou, Shandong, Peoples R China.	wugang2425@126.com					Balu R, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0484-2; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Floden AM, 2007, J NEUROSCI METH, V164, P218, DOI 10.1016/j.jneumeth.2007.04.018; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Garden GA, 2006, J NEUROIMMUNE PHARM, V1, P127, DOI 10.1007/s11481-006-9015-5; Gehrmann J, 1996, RES VIROLOGY, V147, P79, DOI 10.1016/0923-2516(96)80220-2; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; Hubbs AF, 2007, AM J PATHOL, V170, P2068, DOI 10.2353/ajpath.2007.060898; Innamorato NG, 2008, J IMMUNOL, V181, P680, DOI 10.4049/jimmunol.181.1.680; Jacobowitz DM, 2012, BRAIN RES, V1465, P80, DOI 10.1016/j.brainres.2012.05.008; Jin W, 2009, J SURG RES, V157, P251, DOI 10.1016/j.jss.2008.08.003; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Kim J, 2010, MUTAT RES-FUND MOL M, V690, P12, DOI 10.1016/j.mrfmmm.2009.09.007; Kishimoto T, 2010, INT IMMUNOL, V22, P347, DOI 10.1093/intimm/dxq030; Koh K, 2011, J NEUROIMMUNOL, V233, P160, DOI 10.1016/j.jneuroim.2011.01.004; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kraft AD, 2006, J NEUROCHEM, V98, P1852, DOI 10.1111/j.1471-4159.2006.04019.x; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Nagamoto-Combs K, 2010, J NEUROSCI, V30, P9641, DOI 10.1523/JNEUROSCI.0828-10.2010; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Schwarzmaier SM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00358; Shah ZA, 2007, NEUROSCIENCE, V147, P53, DOI 10.1016/j.neuroscience.2007.02.066; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	35	19	19	0	4	INT SCIENTIFIC LITERATURE, INC	SMITHTOWN	361 FOREST LANE, SMITHTOWN, NY 11787 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	JUN 23	2016	22						2161	2166		10.12659/MSM.896568			6	Medicine, Research & Experimental	Research & Experimental Medicine	DQ0HS	WOS:000378880500001	27336674	Green Published			2021-06-18	
J	Song, J; Li, N; Xia, Y; Gao, Z; Zou, SF; Kong, L; Yao, YJ; Jiao, YN; Yan, YH; Li, SH; Tao, ZY; Lian, G; Yang, JX; Kang, TG				Song, Jie; Li, Na; Xia, Yang; Gao, Zhong; Zou, Sa-feng; Kong, Liang; Yao, Ying-Jia; Jiao, Ya-Nan; Yan, Yu-Hui; Li, Shao-Heng; Tao, Zhen-Yu; Lian, Guan; Yang, Jing-Xian; Kang, Ting-Guo			Arctigenin Treatment Protects against Brain Damage through an Anti-Inflammatory and Anti-Apoptotic Mechanism after Needle Insertion	FRONTIERS IN PHARMACOLOGY			English	Article						arctigenin; stab wound injury; inflammation; apoptosis; convection enhanced delivery; traumatic brain injury	TUMOR-NECROSIS-FACTOR; STEM-CELL TRANSPLANTATION; SECONDARY DAMAGE; FACTOR-ALPHA; RAT MODEL; IN-VITRO; KAPPA-B; INJURY; INFLAMMATION; DEATH	Convection enhanced delivery (CED) infuses drugs directly into brain tissue. Needle insertion is required and results in a stab wound injury (SWI). Subsequent secondary injury involves the release of inflammatory and apoptotic cytokines, which have dramatic consequences on the integrity of damaged tissue, leading to the evolution of a pericontusional-damaged area minutes to days after in the initial injury. The present study investigated the capacity for arctigenin (ARC) to prevent secondary brain injury and the determination of the underlying mechanism of action in a mouse model of SWI that mimics the process of CED. After CED, mice received a gavage of ARC from 30 min to 14 days. Neurological severity scores (NSS) and wound closure degree were assessed after the injury. Histological analysis and immunocytochemistry were used to evaluated the extent of brain damage and neuroinflammation. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was used to detect universal apoptosis. Enzyme-linked immunosorbent assays (ELISA) was used to test the inflammatory cytokines (tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-10) and lactate dehydrogenase (LDH) content. Gene levels of inflammation (TNF-alpha, IL-6, and IL-10) and apoptosis (Caspase-3, Bax and Bcl-2) were detected by reverse transcription-polymerase chain reaction (RT-PCR). Using these, we analyzed ARC's efficacy and mechanism of action. Results: ARC treatment improved neurological function by reducing brain water content and hematoma and accelerating wound closure relative to untreated mice. ARC treatment reduced the levels of TNF-alpha and IL-6 and the number of allograft inflammatory factor (IBA)- and myeloperoxidase (MPO)-positive cells and increased the levels of IL-10. ARC-treated mice had fewer TUNEL+ apoptotic neurons and activated caspase-3-positive neurons surrounding the lesion than controls, indicating increased neuronal survival. Conclusions: ARC treatment confers neuroprotection of brain tissue through anti-inflammatory and anti-apoptotic effects in a mouse model of SWI. These results suggest a new strategy for promoting neuronal survival and function after CED to improve long-term patient outcome.	[Song, Jie; Li, Na; Kong, Liang; Yao, Ying-Jia; Jiao, Ya-Nan; Yan, Yu-Hui; Li, Shao-Heng; Tao, Zhen-Yu; Lian, Guan; Yang, Jing-Xian; Kang, Ting-Guo] Liaoning Univ Tradit Chinese Med, Sch Pharm, Dalian, Peoples R China; [Xia, Yang] Univ Oxford, Dept Engn, St Cross Coll, Oxford, England; [Gao, Zhong; Zou, Sa-feng] Dalian Municipal Cent Hosp, Dept Intervent Therapy, Dept Rehabil, Dalian, Peoples R China	Yang, JX; Kang, TG (corresponding author), Liaoning Univ Tradit Chinese Med, Sch Pharm, Dalian, Peoples R China.	421151563@qq.com; ting_guo_kang@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30572336, 81173580]	This work was supported by the National Natural Science Foundation of China (grant No. 30572336 and 81173580).	Abbott NJ, 1996, MOL MED TODAY, V2, P106, DOI 10.1016/1357-4310(96)88720-X; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Banz A, 2002, J IMMUNOL, V169, P750, DOI 10.4049/jimmunol.169.2.750; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bitto A, 2012, CRIT CARE MED, V40, P945, DOI 10.1097/CCM.0b013e318236efde; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Casanova F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094919; Casanova F, 2014, J NEUROSCI METH, V237, P79, DOI 10.1016/j.jneumeth.2014.08.012; Chen JW, 2006, FREE RADICAL BIO MED, V40, P817, DOI 10.1016/j.freeradbiomed.2005.10.037; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Fan J, 2010, NEUROSCI LETT, V473, P196, DOI 10.1016/j.neulet.2010.02.045; Fan T, 2012, BIOL PHARM BULL, V35, P2004, DOI 10.1248/bpb.b12-00463; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Gao Z, 2014, J PHARMACOL SCI, V124, P54, DOI 10.1254/jphs.13144FP; Genovese T, 2008, SHOCK, V30, P231, DOI 10.1097/shk.0b013e318162d290; Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944; Green D., 2011, MEANS END APOPTOSIS; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gu Y, 2012, BIOCHEM PHARMACOL, V84, P468, DOI 10.1016/j.bcp.2012.06.002; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hirjak D, 2013, NEUROPSYCHOBIOLOGY, V68, P91, DOI 10.1159/000350999; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; Hu Y, 2013, BIOL PHARM BULL, V36, P1950, DOI 10.1248/bpb.b13-00561; Hyam SR, 2013, EUR J PHARMACOL, V708, P21, DOI 10.1016/j.ejphar.2013.01.014; Kang HS, 2008, J ETHNOPHARMACOL, V116, P305, DOI 10.1016/j.jep.2007.11.030; Kastrup A, 2008, STROKE, V39, P2385, DOI 10.1161/STROKEAHA.107.505420; Kong L, 2015, BIOL PHARM BULL, V38, P1290, DOI 10.1248/bpb.b15-00142; Kotipatruni RR, 2011, NEUROCHEM RES, V36, P2063, DOI 10.1007/s11064-011-0530-2; Kou XJ, 2011, INT IMMUNOPHARMACOL, V11, P1095, DOI 10.1016/j.intimp.2011.03.005; Kuhnel W, 2003, COLOR ATLAS CYTOLOGY; Kurapati KRV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112818; Kurapati KRV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077624; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Lee JY, 2010, BIOL PHARM BULL, V33, P1847, DOI 10.1248/bpb.33.1847; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu SJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-66; Loftspring MC, 2011, J CEREBR BLOOD F MET, V31, P1133, DOI 10.1038/jcbfm.2010.203; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Luo ZF, 2012, EURASIP J WIREL COMM, DOI 10.1186/1687-1499-2012-2; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Moxon-Emre I, 2011, J NEUROPATH EXP NEUR, V70, P218, DOI 10.1097/NEN.0b013e31820d94a5; Nicholson C, 2001, REP PROG PHYS, V64, P815, DOI 10.1088/0034-4885/64/7/202; Perrot R, 2008, MOL NEUROBIOL, V38, P27, DOI 10.1007/s12035-008-8033-0; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; SAAL JS, 1995, SPINE, V20, P1821, DOI 10.1097/00007632-199508150-00013; Salvesen GS, 2002, CELL DEATH DIFFER, V9, P3, DOI 10.1038/sj.cdd.4400963; Schmit A, 2002, EUR CYTOKINE NETW, V13, P298; Shi H, 2015, CNS NEUROSCI THER, V21, P374, DOI 10.1111/cns.12366; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Swarup V, 2008, J ANTIMICROB CHEMOTH, V61, P679, DOI 10.1093/jac/dkm503; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; THOMPSON R. F., 2000, BRAIN NEUROSCIENCE P; Tsai WJ, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-12; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; Wilson MR, 2005, AM J PHYSIOL-LUNG C, V288, pL599, DOI 10.1152/ajplung.00304.2004; Wood P., 2003, NEUROINFLAMMATION ME; Xia L, 2012, J NEUROSCI RES, V90, P1424, DOI 10.1002/jnr.22811; Xia Y, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0373-x; Yan J, 2013, CELL, V152, P304, DOI 10.1016/j.cell.2012.12.021; Yang JX, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002864; Yao WJ, 2015, AM J CHINESE MED, V43, P183, DOI 10.1142/S0192415X15500123; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhai PP, 2015, NEUROPHARMACOLOGY, V95, P1, DOI 10.1016/j.neuropharm.2015.02.026; Zhang N, 2013, INT J MOL SCI, V14, P18657, DOI 10.3390/ijms140918657; Zhang N, 2012, EUR J PHARMACOL, V697, P32, DOI 10.1016/j.ejphar.2012.10.008; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang WZ, 2015, INFLAMMATION, V38, P1406, DOI 10.1007/s10753-015-0115-3; Zhao F, 2009, J ETHNOPHARMACOL, V122, P457, DOI 10.1016/j.jep.2009.01.038; Zhao GW, 2014, J ETHNOPHARMACOL, V151, P694, DOI 10.1016/j.jep.2013.11.041; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	85	19	21	1	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	JUN 22	2016	7								182	10.3389/fphar.2016.00182			16	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DP1WV	WOS:000378281000001	27445818	DOAJ Gold, Green Published			2021-06-18	
J	Fontana, ACK; Fox, DP; Zoubroulis, A; Mortensen, OV; Raghupathi, R				Fontana, Andreia Cristina Karklin; Fox, Douglas P.; Zoubroulis, Argie; Mortensen, Ole Valente; Raghupathi, Ramesh			Neuroprotective Effects of the Glutamate Transporter Activator (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153) following Traumatic Brain Injury in the Adult Rat	JOURNAL OF NEUROTRAUMA			English	Article						EAAT2; GLT-1; glutamate uptake; MS-153; neuroprotection; traumatic brain injury	AMINO-ACID TRANSPORTER-2; ALCOHOL-PREFERRING RATS; BEHAVIORAL SENSITIZATION; EXTRACELLULAR GLUTAMATE; NUCLEUS-ACCUMBENS; NMDA RECEPTOR; UP-REGULATION; EXPRESSION; MECHANISMS; RELEASE	Traumatic brain injury (TBI) in humans and in animals leads to an acute and sustained increase in tissue glutamate concentrations within the brain, triggering glutamate-mediated excitotoxicity. Excitatory amino acid transporters (EAATs) are responsible for maintaining extracellular central nervous system glutamate concentrations below neurotoxic levels. Our results demonstrate that as early as 5min and up to 2h following brain trauma in brain-injured rats, the activity (V-max) of EAAT2 in the cortex and the hippocampus was significantly decreased, compared with sham-injured animals. The affinity for glutamate (K-M) and the expression of glutamate transporter 1 (GLT-1) and glutamate aspartate transporter (GLAST) were not altered by the injury. Administration of (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153), a GLT-1 activator, beginning immediately after injury and continuing for 24h, significantly decreased neurodegeneration, loss of microtubule-associated protein 2 and NeuN (+) immunoreactivities, and attenuated calpain activation in both the cortex and the hippocampus at 24h after the injury; the reduction in neurodegeneration remained evident up to 14 days post-injury. In synaptosomal uptake assays, MS-153 up-regulated GLT-1 activity in the naive rat brain but did not reverse the reduced activity of GLT-1 in traumatically-injured brains. This study demonstrates that administration of MS-153 in the acute post-traumatic period provides acute and long-term neuroprotection for TBI and suggests that the neuroprotective effects of MS-153 are related to mechanisms other than GLT-1 activation, such as the inhibition of voltage-gated calcium channels.	[Fontana, Andreia Cristina Karklin; Zoubroulis, Argie; Mortensen, Ole Valente] Drexel Univ, Coll Med, Dept Physiol & Pharmacol, 245 N 15th St, Philadelphia, PA 19102 USA; [Fox, Douglas P.; Raghupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19102 USA	Fontana, ACK (corresponding author), Drexel Univ, Coll Med, Dept Physiol & Pharmacol, 245 N 15th St, Philadelphia, PA 19102 USA.	andreia.mortensen@drexelmed.edu	Mortensen, Andreia/AAR-2177-2020	Mortensen, Andreia/0000-0002-4791-8746; Mortensen, Ole Valente/0000-0002-3487-8239	DUCOM [001564-002]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS065017-03]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065017] Funding Source: NIH RePORTER	The study was supported by DUCOM Tobacco Settlement grant 001564-002 to A.C.K.F. and NIH 5R01NS065017-03 to R.R.	Aal-Aaboda M, 2015, J NEUROSCI RES, V93, P930, DOI 10.1002/jnr.23554; Abekawa T, 2002, BRAIN RES, V926, P176, DOI 10.1016/S0006-8993(01)03164-X; Abekawa T, 2002, PSYCHOPHARMACOLOGY, V160, P122, DOI 10.1007/s00213-001-0958-1; Alhaddad H, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00366; Amara SG, 2002, NEUROCHEM INT, V41, P313, DOI 10.1016/S0197-0186(02)00018-9; Amin B, 2012, NEUROSCIENCE, V224, P15, DOI 10.1016/j.neuroscience.2012.07.058; Aslan A, 2009, PHARMACOL RES, V59, P120, DOI 10.1016/j.phrs.2008.10.003; Azbill RD, 2000, BRAIN RES, V871, P175, DOI 10.1016/S0006-8993(00)02430-6; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Berry JD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061177; Billups B, 1996, NATURE, V379, P171, DOI 10.1038/379171a0; Brothers HM, 2013, J NEUROIMMUNE PHARM, V8, P1098, DOI 10.1007/s11481-013-9476-2; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Castillo MR, 1998, NEUROSCIENCE, V86, P1133, DOI 10.1016/S0306-4522(98)00070-0; Cheney JA, 2000, J NEUROTRAUM, V17, P83, DOI 10.1089/neu.2000.17.83; Conrad KL, 2010, NEUROSCIENCE, V169, P182, DOI 10.1016/j.neuroscience.2010.04.056; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Cristina A, 2007, MOL PHARMACOL, V72, P1228, DOI 10.1124/mol.107.037127; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dunlop J, 2006, CURR OPIN PHARMACOL, V6, P103, DOI 10.1016/j.coph.2005.09.004; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fontana ACK, 2003, BRIT J PHARMACOL, V139, P1297, DOI 10.1038/sj.bjp.0705352; Frizzo ME, 2005, CELL MOL NEUROBIOL, V25, P913, DOI 10.1007/s10571-005-4939-5; Frizzo MES, 2001, NEUROREPORT, V12, P879, DOI 10.1097/00001756-200103260-00051; Gegelashvili G, 2000, NEUROCHEM INT, V37, P163, DOI 10.1016/S0197-0186(00)00019-X; Gonzalez-Gonzalez IM, 2008, GLIA, V56, P963, DOI 10.1002/glia.20670; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Grewer C, 2008, IUBMB LIFE, V60, P609, DOI 10.1002/iub.98; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Ikematsu K, 2002, FORENSIC SCI INT, V130, P83, DOI 10.1016/S0379-0738(02)00344-4; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Jabaudon D, 2000, P NATL ACAD SCI USA, V97, P5610, DOI 10.1073/pnas.97.10.5610; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kawazura H, 1997, JPN J PHARMACOL, V73, P317, DOI 10.1254/jjp.73.317; Kim K, 2011, J CELL PHYSIOL, V226, P2484, DOI 10.1002/jcp.22609; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Lauriat TL, 2007, MOL PSYCHIATR, V12, P1065, DOI 10.1038/sj.mp.4002065; Li XB, 2004, EUR J PHARMACOL, V505, P145, DOI 10.1016/j.ejphar.2004.10.041; Li Y, 2011, NEUROPHARMACOLOGY, V60, P1168, DOI 10.1016/j.neuropharm.2010.10.016; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; Liu SY, 2008, BIOCHEM BIOPH RES CO, V366, P520, DOI 10.1016/j.bbrc.2007.11.179; Maas AIR, 2000, CNS DRUGS, V13, P139, DOI 10.2165/00023210-200013020-00007; Maragakis NJ, 2004, ANN NEUROL, V55, P469, DOI 10.1002/ana.20003; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Minger SL, 1998, BRAIN RES, V810, P181, DOI 10.1016/S0006-8993(98)00921-4; Mu XJ, 2000, J NEUROTRAUM, V17, P773, DOI 10.1089/neu.2000.17.773; Nakagawa T, 2005, BEHAV BRAIN RES, V156, P233, DOI 10.1016/j.bbr.2004.05.029; Nakagawa T, 2001, EUR J PHARMACOL, V419, P39, DOI 10.1016/S0014-2999(01)00965-7; Nicholson KJ, 2014, J NEUROSCI RES, V92, P116, DOI 10.1002/jnr.23295; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nishida A, 2004, BIOL PHARM BULL, V27, P817, DOI 10.1248/bpb.27.817; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pan Xiang-dong, 2011, Zhejiang Da Xue Xue Bao Yi Xue Ban, V40, P522; Phillis JW, 1996, BRAIN RES, V730, P150; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramos KM, 2010, NEUROSCIENCE, V169, P1888, DOI 10.1016/j.neuroscience.2010.06.014; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Rasmussen BA, 2011, AMINO ACIDS, V40, P761, DOI 10.1007/s00726-010-0589-0; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Shimada F, 1999, EUR J PHARMACOL, V386, P263, DOI 10.1016/S0014-2999(99)00735-9; Suchak SK, 2003, J NEUROCHEM, V84, P522, DOI 10.1046/j.1471-4159.2003.01553.x; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; Uenishi H, 1999, ANN NY ACAD SCI, V890, P385, DOI 10.1111/j.1749-6632.1999.tb08018.x; Umemura K, 1996, STROKE, V27, P1624, DOI 10.1161/01.STR.27.9.1624; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vetiska S., 2014, HDB NEUROTOXICITY, P1381; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yamamoto T, 1999, ACT NEUR S, V75, P17; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	88	19	19	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2016	33	11					1073	1083		10.1089/neu.2015.4079			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DN3SU	WOS:000376984600011	26200170	Green Published			2021-06-18	
J	Skogan, AH; Egeland, J; Zeiner, P; Overgaard, KR; Oerbeck, B; Reichborn-Kjennerud, T; Aase, H				Skogan, Annette Holth; Egeland, Jens; Zeiner, Pal; Overgaard, Kristin Romvig; Oerbeck, Beate; Reichborn-Kjennerud, Ted; Aase, Heidi			Factor structure of the Behavior Rating Inventory of Executive Functions (BRIEF-P) at age three years	CHILD NEUROPSYCHOLOGY			English	Article						Executive function; BRIEF-P; Preschool; Factor analysis; Development	CONFIRMATORY FACTOR-ANALYSIS; AUTISM SPECTRUM DISORDERS; LATENT VARIABLE APPROACH; TRAUMATIC BRAIN-INJURY; PRESCHOOL-CHILDREN; INDIVIDUAL-DIFFERENCES; CRITERION VALIDITY; YOUNG-CHILDREN; FOLLOW-UP; DIMENSIONS	The preschool period is an important developmental period for the emergence of cognitive self-regulatory skills or executive functions (EF). To date, evidence regarding the structure of EF in preschool children has supported both unitary and multicomponent models. The aim of the present study was to test the factor structure of early EF as measured by the Behavior Rating Inventory of Executive Function-Preschool version (BRIEF-P). BRIEF-P consists of five subscales and three broader indexes, hypothesized to tap into different subcomponents of EF. Parent ratings of EF from a nonreferred sample of children recruited from the Norwegian Mother and Child Cohort Study (N=1134; age range 37-47months) were subjected to confirmatory factor analyses (CFA). Three theoretically derived models were assessed; the second-order three-factor model originally proposed by the BRIEF-P authors, a true first-order one-factor model and a second-order one-factor model. CFA fit statistics supported the original three-factor solution. However, the difference in fit was marginal between this model and the second-order one-factor model. A follow-up exploratory factor analysis (EFA) supported the existence of several factors underlying EF in early preschool years, with a considerable overlap with the five BRIEF-P subscales. Our results suggest that some differentiation in EF has taken place at age 3 years, which is reflected in behavior ratings. The internal consistency of the BRIEF-P five clinical subscales is supported. Subscale interrelations may, however, differ at this age from those observed in the preschool group as a whole.	[Skogan, Annette Holth; Zeiner, Pal; Overgaard, Kristin Romvig; Oerbeck, Beate] Oslo Univ Hosp, Div Mental Hlth & Addict, Pb 4959 Nydalen, N-0424 Oslo, Norway; [Egeland, Jens] Univ Oslo, Inst Psychol, Oslo, Norway; [Egeland, Jens] Vestfold Hosp Trust, Div Mental Hlth & Addict, Tonsberg, Norway; [Reichborn-Kjennerud, Ted; Aase, Heidi] Norwegian Inst Publ Hlth, Div Mental Hlth, Oslo, Norway; [Reichborn-Kjennerud, Ted] Univ Oslo, Inst Clin Med, Oslo, Norway	Skogan, AH (corresponding author), Oslo Univ Hosp, Div Mental Hlth & Addict, Pb 4959 Nydalen, N-0424 Oslo, Norway.	annette.holth.skogan@ous-hf.no			Norwegian South Eastern Health Region [2010081]; Norwegian Ministry of Health; Norwegian Health Directorate; South Eastern Health Region; G & PJ Sorensen Fund for Scientific Research; Norwegian Resource Centre for ADHD, Tourette's syndrome and Narcolepsy; Ministry of Education and Research; NIH/NIEHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [N0-ES75558]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 UO1 NS047537-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS047537] Funding Source: NIH RePORTER	The study was supported by a grant from the Norwegian South Eastern Health Region, grant no. 2010081. The study "Preschool ADHD: Early characteristics, developmental trajectories, risk and protective factors in a prospective birth cohort (The ADHD study)" from which the present data were drawn, was supported by funds and grants from the Norwegian Ministry of Health, The Norwegian Health Directorate, The South Eastern Health Region, G & PJ Sorensen Fund for Scientific Research, and from The Norwegian Resource Centre for ADHD, Tourette's syndrome and Narcolepsy. MoBa is supported by the Norwegian Ministry of Health and the Ministry of Education and Research, NIH/NIEHS (Contract no. N0-ES75558) and NIH/NINDS (Grant no. 1 UO1 NS047537-01).	Achenbach T M, 2000, Pediatr Rev, V21, P265, DOI 10.1542/pir.21-8-265; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Best JR, 2010, CHILD DEV, V81, P1641, DOI 10.1111/j.1467-8624.2010.01499.x; Bonillo A, 2012, CHILD NEUROPSYCHOL, V18, P347, DOI 10.1080/09297049.2011.613808; Byrne B., 2012, STRUCTURAL EQUATION; Byrne BM, 2005, J PERS ASSESS, V85, P17, DOI 10.1207/s15327752jpa8501_02; Carlson SA, 2005, DEV NEUROPSYCHOL, V28, P595, DOI 10.1207/s15326942dn2802_3; Carlson SM, 2001, CHILD DEV, V72, P1032, DOI 10.1111/1467-8624.00333; Delis DC, 2003, J INT NEUROPSYCH SOC, V9, P936, DOI 10.1017/S1355617703960139; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Duku E, 2014, CHILD NEUROPSYCHOL, V20, P358, DOI 10.1080/09297049.2013.796919; Egeland J, 2010, CHILD NEUROPSYCHOL, V16, P326, DOI 10.1080/09297041003601462; Egger H. L., 2004, HDB INFANT TODDLER P, P223; Egger HL, 2006, J CHILD PSYCHOL PSYC, V47, P313, DOI 10.1111/j.1469-7610.2006.01618.x; Espy KA, 1999, BRAIN COGNITION, V41, P178, DOI 10.1006/brcg.1999.1117; Espy KA, 2001, CLIN NEUROPSYCHOL, V15, P46, DOI 10.1076/clin.15.1.46.1908; Espy KA, 2011, J CHILD PSYCHOL PSYC, V52, P33, DOI 10.1111/j.1469-7610.2010.02265.x; Ezpeleta L, 2015, J ATTEN DISORD, V19, P476, DOI 10.1177/1087054712466439; Ezpeleta L, 2012, J CHILD PSYCHOL PSYC, V53, P1128, DOI 10.1111/j.1469-7610.2012.02545.x; Field A. P, 2009, DISCOVERING STAT USI; Garon N, 2008, PSYCHOL BULL, V134, P31, DOI 10.1037/0033-2909.134.1.31; Gioia G., 2002, J INT NEUROPSYCH SOC, V8, P143; Gioia G.A., 2003, BEHAV RATING INVENTO; Gioia G.A., 2002, BEHAV RATING INVENTO; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Greene N, 2011, EPIDEMIOLOGY, V22, P815, DOI 10.1097/EDE.0b013e31822939fd; Hill AL, 2006, DEV PSYCHOL, V42, P913, DOI 10.1037/0012-1649.42.5.913; Hongwanishkul D, 2005, DEV NEUROPSYCHOL, V28, P617, DOI 10.1207/s15326942dn2802_4; Hovik KT, 2017, J ATTEN DISORD, V21, P811, DOI 10.1177/1087054714550336; Hughes C, 2010, DEV NEUROPSYCHOL, V35, P20, DOI 10.1080/87565640903325691; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Isquith PK, 2004, DEV NEUROPSYCHOL, V26, P403, DOI 10.1207/s15326942dn2601_3; Lamm C, 2010, DEV NEUROPSYCHOL, V35, P156, DOI 10.1080/87565640903526512; Lee K, 2013, CHILD DEV, V84, P1933, DOI 10.1111/cdev.12096; Lehto JE, 2003, BRIT J DEV PSYCHOL, V21, P59, DOI 10.1348/026151003321164627; Magnus P, 2006, INT J EPIDEMIOL, V35, P1146, DOI 10.1093/ije/dyl170; Mahone EM, 2007, CLIN NEUROPSYCHOL, V21, P569, DOI 10.1080/13854040600762724; Marsh HW, 2004, STRUCT EQU MODELING, V11, P320, DOI 10.1207/s15328007sem1103_2; Miller MR, 2012, J COGN DEV, V13, P395, DOI 10.1080/15248372.2011.585478; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nicholas J, 2006, BRIEF P NORWEGIAN MA; Nilsen RM, 2013, PAEDIATR PERINAT EP, V27, P553, DOI 10.1111/ppe.12077; Nilsen RM, 2009, PAEDIATR PERINAT EP, V23, P597, DOI 10.1111/j.1365-3016.2009.01062.x; Overgaard KR, 2016, J ATTEN DISORD, V20, P573, DOI 10.1177/1087054712463063; Pauli-Pott U, 2011, CLIN PSYCHOL REV, V31, P626, DOI 10.1016/j.cpr.2011.02.005; Posner MI, 2012, DEV PSYCHOL, V48, P827, DOI 10.1037/a0025530; Rubia K, 2013, EUR CHILD ADOLES PSY, V22, P719, DOI 10.1007/s00787-012-0291-8; Tabachnick BG, 2007, USING MULTIVARIATE S; Teunisse JP, 2012, J CLIN EXP NEUROPSYC, V34, P714, DOI 10.1080/13803395.2012.670209; Tsujimoto S, 2008, NEUROSCIENTIST, V14, P345, DOI 10.1177/1073858408316002; van der Ven SHG, 2013, BRIT J DEV PSYCHOL, V31, P70, DOI 10.1111/j.2044-835X.2012.02079.x; Wasserman T, 2013, APPL NEUROPSYCH-CHIL, V2, P88, DOI 10.1080/21622965.2013.748394; Watkins M. W, 2002, MONTE CARLO PCA PARA; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Wichstrom L, 2012, J CHILD PSYCHOL PSYC, V53, P695, DOI 10.1111/j.1469-7610.2011.02514.x; Wiebe SA, 2011, J EXP CHILD PSYCHOL, V108, P436, DOI 10.1016/j.jecp.2010.08.008; Willoughby MT, 2010, PSYCHOL ASSESSMENT, V22, P306, DOI 10.1037/a0018708; Zelazo PD, 2003, MONOGR SOC RES CHILD, V68, P1, DOI 10.1111/j.0037-976X.2003.00261.x	62	19	22	6	42	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	MAY 18	2016	22	4					472	492		10.1080/09297049.2014.992401			21	Clinical Neurology	Neurosciences & Neurology	DD3UN	WOS:000369848600006	25573465	Green Published			2021-06-18	
J	da Costa, L; van Niftrik, CB; Crane, D; Fierstra, J; Bethune, A				da Costa, Leodante; van Niftrik, Christiaan Bas; Crane, David; Fierstra, Jorn; Bethune, Allison			Temporal Profile of cerebrovascular reactivity impairment, gray Matter Volumes, and Persistent symptoms after Mild Traumatic head injury	FRONTIERS IN NEUROLOGY			English	Article							BRAIN-INJURY; CEREBRAL AUTOREGULATION; BLOOD-FLOW; CT; SPECT; PATHOPHYSIOLOGY; METABOLISM; HISTORY; MODEL; MEG	Objective: Increased awareness around neurocognitive deficits after mild traumatic brain injury (mTBI) has progressed the search for objective, diagnostic, and monitoring tools, yet imaging biomarkers for mTBI and recovery are not established in clinical use. It has been suggested that mTBI impairs cerebrovascular reactivity (CVR) to CO2, which could be related to post-concussive syndrome (PCS). We investigate CVR evolution after mTBI using blood-oxygen-level dependent (BOLD) magnetic resonance imaging (MRI) and possible correlation with PCS. Methods: A prospective cohort of 25 mTBI patients and 18 matched controls underwent BOLD MRI CVR measurements. A subset of 19 mTBI patients underwent follow-up testing. Visits took place at a mean of 63 and 180 days after injury. Symptoms were assessed with the Sport Concussion Assessment Tool 2 (SCAT2). Symptoms, CVR and brain volume [ gray matter (GM), white matter (WM), and whole brain (WB)], age, and sex, were examined between groups and longitudinally within traumatic brain injury (TBI) patients. Results: Traumatic brain injury participants were 72% males, mean age being 42.7 years. Control participants were 61% with mean age of 38.7 years. SCAT2 scores tended to improve among those mTBI patients with follow-up visits (p = 0.07); however, they did not tend to recover to scores of the healthy controls. Brain volumes were not statistically different between groups at the first visit (WM p = 0.71; GM p = 0.36). In mTBI patients, there was a reduction in GM volume between visits 1 and 2 (p = 0.0046). Although mean CVR indexes were similar (WM p = 0.27; GM p = 0.36; and WB p = 0.35), the correlation between SCAT2 and CVR was negative in controls (WM-r = -0.59; p = 0.010; GM-r = -0.56; p = 0.016; brain-r = -0.58; p = 0.012) and weaker and positive in mTBI (brain-r = 0.4; p = 0.046; GM- r = 0.4; p = 0.048). SCAT2 correlated with GM volume (r = 0.5215, p = 0.0075) in mTBI but not in controls (r = 0.2945, p = 0.2355). Conclusion: There is a correlation between lower GM CVR indexes and lower performance on SCAT2 in patients with mTBI, which seems to be associated with more symptoms. This correlation seems to persist well beyond 120 days. mTBI may lead to a decrease in GM volume in these patients.	[da Costa, Leodante; Bethune, Allison] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Surg, Div Neurosurg, Toronto, ON, Canada; [da Costa, Leodante] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med Imaging, Toronto, ON, Canada; [van Niftrik, Christiaan Bas; Fierstra, Jorn] Univ Zurich Hosp, Div Neurosurg, CH-8091 Zurich, Switzerland; [Crane, David] Sunnybrook Res Inst, Brain Sci Program, Toronto, ON, Canada	da Costa, L (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Surg, Div Neurosurg, Toronto, ON, Canada.; da Costa, L (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med Imaging, Toronto, ON, Canada.	leo.dacosta@sunnybrook.ca		Fierstra, Jorn/0000-0001-6220-0727; van Niftrik, Christiaan/0000-0003-0930-8717			Abu-Judeh HH, 1998, J NUCL MED, V39, P1357; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson-Barnes Victoria C, 2010, Continuum (Minneap Minn), V16, P17, DOI 10.1212/01.CON.0000391450.48225.73; Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Devonshire IM, 2012, NEUROIMAGE, V59, P1997, DOI 10.1016/j.neuroimage.2011.09.050; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Fierstra J, 2013, J PHYSIOL-LONDON, V591, P5809, DOI 10.1113/jphysiol.2013.259150; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Giza CC, 2001, J ATHL TRAINING, V36, P228; Glass TF, 2001, J NEUROTRAUM, V18, P57, DOI 10.1089/089771501750055776; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; GRAY BG, 1992, J NUCL MED, V33, P52; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kastrup A, 1997, STROKE, V28, P2353, DOI 10.1161/01.STR.28.12.2353; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Maggio P, 2014, PHYSIOL REP, V2, DOI 10.1002/phy2.280; Marshall RS, 2004, CURR OPIN NEUROL, V17, P705, DOI 10.1097/00019052-200412000-00010; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Metting Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064461; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Paemeleire K, 2002, ACTA NEUROL BELG, V102, P153; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Pomschar A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055447; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; Slessarev M, 2007, J PHYSIOL-LONDON, V581, P1207, DOI 10.1113/jphysiol.2007.129395; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Thomas BP, 2013, NEUROIMAGE, V83, P505, DOI 10.1016/j.neuroimage.2013.07.005; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	55	19	19	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	MAY 11	2016	7								70	10.3389/fneur.2016.00070			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DL3JH	WOS:000375529600001	27242655	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Gilmore, CS; Camchong, J; Davenport, ND; Nelson, NW; Kardon, RH; Lim, KO; Sponheim, SR				Gilmore, Casey S.; Camchong, Jazmin; Davenport, Nicholas D.; Nelson, Nathaniel W.; Kardon, Randy H.; Lim, Kelvin O.; Sponheim, Scott R.			Deficits in Visual System Functional Connectivity after Blast-Related Mild TBI are Associated with Injury Severity and Executive Dysfunction	BRAIN AND BEHAVIOR			English	Article						blast TBI; executive function; functional connectivity; rest fMRI; TBI severity; traumatic brain injury; Visual	TRAUMATIC BRAIN-INJURY; LATERAL GENICULATE-NUCLEUS; DEPLOYED MILITARY PERSONNEL; RESTING-STATE NETWORKS; WHITE-MATTER; COGNITIVE RESERVE; OCCIPITAL CORTEX; NATIONAL-GUARD; WORKING-MEMORY; FMRI	Introduction: Approximately, 275,000 American service members deployed to Iraq or Afghanistan have sustained a mild traumatic brain injury (mTBI), with 75% of these incidents involving an explosive blast. Visual processing problems and cognitive dysfunction are common complaints following blast-related mTBI. Methods: In 127 veterans, we examined resting fMRI functional connectivity (FC) of four key nodes within the visual system: lateral geniculate nucleus (LGN), primary visual cortex (V1), lateral occipital gyrus (LO), and fusiform gyrus (FG). Regression analyses were performed (i) to obtain correlations between time-series from each seed and all voxels in the brain, and (ii) to identify brain regions in which FC variability was related to blast mTBI severity. Blast-related mTBI severity was quantified as the sum of the severity scores assigned to each of the three most significant blast-related injuries self-reported by subjects. Correlations between FC and performance on executive functioning tasks were performed across participants with available behavioral data (n = 94). Results: Greater blast mTBI severity scores were associated with lower FC between: (A) LGN seed and (i) medial frontal gyrus, (ii) lingual gyrus, and (iii) right ventral anterior nucleus of thalamus; (B) V1 seed and precuneus; (C) LO seed and middle and superior frontal gyri; (D) FG seed and (i) superior and medial frontal gyrus, and (ii) left middle frontal gyrus. Finally, lower FC between visual network regions and frontal cortical regions predicted worse performance on the WAIS digit-symbol coding task. Conclusion: These are the first published results that directly illustrate the relationship between blast-related mTBI severity, visual pathway neural networks, and executive dysfunction -results that highlight the detrimental relationship between blast-related brain injury and the integration of visual sensory input and executive processes.	[Gilmore, Casey S.; Lim, Kelvin O.] Def & Vet Brain Injury Ctr, Minneapolis, MN USA; [Gilmore, Casey S.; Davenport, Nicholas D.; Nelson, Nathaniel W.; Lim, Kelvin O.; Sponheim, Scott R.] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN USA; [Camchong, Jazmin; Davenport, Nicholas D.; Lim, Kelvin O.; Sponheim, Scott R.] Univ Minnesota, Dept Psychiat, Minneapolis, MN USA; [Nelson, Nathaniel W.] Univ St Thomas, Grad Sch Profess Psychol, Minneapolis, MN USA; [Kardon, Randy H.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA; [Kardon, Randy H.] Iowa City Vet Affairs Hlth Care Syst, Iowa City, IA USA	Gilmore, CS (corresponding author), Minneapolis Vet Affairs Hlth Care Syst, Def & Vet Brain Injury Ctr, 1 Vet Way, Minneapolis, MN 55417 USA.	casey.gilmore2@va.gov	Davenport, Nicholas/AAY-8057-2020; Sponheim, Scott/J-3857-2017; Lim, Kelvin/AAF-6833-2020	Davenport, Nicholas/0000-0002-3441-7256; Sponheim, Scott/0000-0002-2782-0856; Kardon, Randy/0000-0002-3173-7123; Lim, Kelvin/0000-0002-2390-7268	Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-08-2-0038]; Minnesota Veterans Research Institute (MVRI); Rehabilitation Research and Development Service of the VA Office of Research and Development [1I01RX000622]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000113, UL1TR000114] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000622] Funding Source: NIH RePORTER	This work was supported by grants to Scott R. Sponheim from the Congressionally Directed Medical Research Program (W81XWH-08-2-0038), the Minnesota Veterans Research Institute (MVRI), and the Rehabilitation Research and Development Service of the VA Office of Research and Development (Award Number 1I01RX000622).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Brandstack N, 2013, RADIOLOGY, V267, P231, DOI 10.1148/radiol.12112570; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Camchong J, 2014, DRUG ALCOHOL DEPEN, V139, P145, DOI 10.1016/j.drugalcdep.2014.03.024; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Caverzasi E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100274; Chafetz MD, 2004, ARCH CLIN NEUROPSYCH, V19, P555, DOI 10.1016/j.acn.2003.08.004; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Cox RW, 2012, NEUROIMAGE, V62, P743, DOI 10.1016/j.neuroimage.2011.08.056; Crowe SF, 1999, AUST PSYCHOL, V34, P204, DOI 10.1080/00050069908257455; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; De Moraes Carlos Gustavo, 2013, J Glaucoma, V22 Suppl 5, pS2, DOI 10.1097/IJG.0b013e3182934978; Debbane M, 2012, SCHIZOPHR RES, V139, P33, DOI 10.1016/j.schres.2012.05.021; Demery JA, 2010, CLIN NEUROPSYCHOL, V24, P1292, DOI 10.1080/13854046.2010.528452; DENNYBROWN D, 1945, J NEUROPATH EXP NEUR, V4, P305, DOI 10.1097/00005072-194504040-00001; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Dutca LM, 2014, INVEST OPHTH VIS SCI, V55, P8330, DOI 10.1167/iovs.14-15468; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; First MB., 2002, STRUCTURED CLIN INTE; Forkel SJ, 2014, CORTEX, V56, P73, DOI 10.1016/j.cortex.2012.09.005; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Fujita N, 2001, AM J NEURORADIOL, V22, P1719; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Golden C. J., 1978, STROOP WORD COLOR TE; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Gour N, 2011, NEUROIMAGE, V58, P687, DOI 10.1016/j.neuroimage.2011.05.090; Graner J, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00016; Grill-Spector K, 2001, VISION RES, V41, P1409, DOI 10.1016/S0042-6989(01)00073-6; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Han ZZ, 2013, BRAIN, V136, P2952, DOI 10.1093/brain/awt205; HAXBY JV, 1994, J NEUROSCI, V14, P6336; Hemphill MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022899; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holdnack J., 2001, WTAR WECHSLER TEST A; Holland JN, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/902802; HOLM S, 1979, SCAND J STAT, V6, P65; Horowitz-Kraus T, 2015, NEUROIMAGE-CLIN, V8, P619, DOI 10.1016/j.nicl.2015.06.010; Jahn K, 2004, NEUROIMAGE, V22, P1722, DOI 10.1016/j.neuroimage.2004.05.017; Jahn K, 2009, ANN NY ACAD SCI, V1164, P229, DOI 10.1111/j.1749-6632.2009.03770.x; Kardon R. H., 2013, ARVO 2013 ANN M; Kaufman A. S., 1990, ASSESSING ADOLESCENT; Kelly RE, 2010, J NEUROSCI METH, V189, P233, DOI 10.1016/j.jneumeth.2010.03.028; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kim MJ, 2003, NEUROSCIENCE, V120, P283, DOI 10.1016/S0306-4522(03)00021-6; Koyama MS, 2011, J NEUROSCI, V31, P8617, DOI 10.1523/JNEUROSCI.4865-10.2011; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kubler A, 2006, J COGNITIVE NEUROSCI, V18, P1331, DOI 10.1162/jocn.2006.18.8.1331; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Lauritzen TZ, 2009, J VISION, V9, DOI 10.1167/9.13.18; Lemke S, 2013, JAMA OPHTHALMOL, V131, P1602, DOI 10.1001/jamaophthalmol.2013.5028; Leung HC, 2002, J COGNITIVE NEUROSCI, V14, P659, DOI 10.1162/08989290260045882; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lewisa CM, 2009, P NATL ACAD SCI USA, V106, P17558, DOI 10.1073/pnas.0902455106; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Magone M. T., 2013, US NEUROL, V9, P61; Magone MT, 2014, J REHABIL RES DEV, V51, P71, DOI 10.1682/JRRD.2013.01.0008; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; Margulies DS, 2009, P NATL ACAD SCI USA, V106, P20069, DOI 10.1073/pnas.0905314106; Markett S, 2014, HUM BRAIN MAPP, V35, P1700, DOI 10.1002/hbm.22285; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Mennes M, 2011, NEUROIMAGE, V54, P2950, DOI 10.1016/j.neuroimage.2010.10.046; Mennes M, 2010, NEUROIMAGE, V50, P1690, DOI 10.1016/j.neuroimage.2010.01.002; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Moore DF, 2010, NEUROREHABILITATION, V26, P179, DOI 10.3233/NRE-2010-0553; Moussa MN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044428; Murphy PC, 1999, SCIENCE, V286, P1552, DOI 10.1126/science.286.5444.1552; Nelson NW, 2015, BRIT J PSYCHIAT, V206, P237, DOI 10.1192/bjp.bp.114.149096; Nelson NW, 2011, BRAIN INJURY, V25, P511, DOI 10.3109/02699052.2011.558040; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Patriat R, 2013, NEUROIMAGE, V78, P463, DOI 10.1016/j.neuroimage.2013.04.013; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ranganath C, 2003, NEUROPSYCHOLOGIA, V41, P378, DOI 10.1016/S0028-3932(02)00169-0; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Reineberg AE, 2015, NEUROIMAGE, V104, P69, DOI 10.1016/j.neuroimage.2014.09.045; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Ruff RM, 1999, STUD NEUROPSYCHOL DE, P315; RUSSELL EW, 1972, J CONSULT CLIN PSYCH, V39, P133, DOI 10.1037/h0033212; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; SALTHOUSE TA, 1992, J GERONTOL, V47, pP121, DOI 10.1093/geronj/47.3.P121; Sarubbo S, 2015, HUM BRAIN MAPP, V36, P3117, DOI 10.1002/hbm.22832; Sarubbo S, 2015, J ANAT, V226, P47, DOI 10.1111/joa.12254; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Schneider KA, 2004, J NEUROSCI, V24, P8975, DOI 10.1523/JNEUROSCI.2413-04.2004; Sherman SM, 2002, PHILOS T R SOC B, V357, P1695, DOI 10.1098/rstb.2002.1161; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; SPRANDEL HZ, 1995, PSYCHOEDUCATIONAL US; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P181, DOI 10.1017/S1355617710001414; Tootell RBH, 1998, P NATL ACAD SCI USA, V95, P811, DOI 10.1073/pnas.95.3.811; Van Dyke SA, 2010, MIL MED, V175, P947, DOI 10.7205/MILMED-D-10-00337; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wardlaw A, 2010, IFMBE PROC, V32, P34, DOI 10.1007/978-3-642-14998-6_9; Wechsler D, 1997, WAIS 3 ADM SCORING M; WOOSAM J, 1971, PERCEPT MOTOR SKILL, V32, P407, DOI 10.2466/pms.1971.32.2.407; Xu JH, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00200; Zelinsky DG, 2010, PM&R, V2, P852, DOI 10.1016/j.pmrj.2010.06.012; Zhang JX, 2003, NEUROIMAGE, V20, P1531, DOI 10.1016/j.neuroimage.2003.07.016; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zhu Q, 2011, J NEUROSCI, V31, P10323, DOI 10.1523/JNEUROSCI.0873-11.2011	124	19	19	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	MAY	2016	6	5							e00454	10.1002/brb3.454			19	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	DQ2FY	WOS:000379019000005	27257516	DOAJ Gold, Green Published			2021-06-18	
J	Lossi, L; Cocito, C; Alasia, S; Merighi, A				Lossi, Laura; Cocito, Carolina; Alasia, Silvia; Merighi, Adalberto			Ex vivo imaging of active caspase 3 by a FRET-based molecular probe demonstrates the cellular dynamics and localization of the protease in cerebellar granule cells and its regulation by the apoptosis-inhibiting protein survivin	MOLECULAR NEURODEGENERATION			English	Article						Neurons; Caspase 3; Survivin; Apoptosis; FRET; Biolistic transfection; Cerebellum; Organotypic cultures; Live imaging; Confocal microscopy	RESONANCE ENERGY-TRANSFER; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; NEURONAL APOPTOSIS; FLUORESCENT PEPTIDE; MAMMALIAN CNS; DEATH; ACTIVATION; MECHANISMS; IDENTIFICATION	Background: Apoptosis takes place in naturally occurring neuronal death, but also in aging, neurodegenerative disorders, and traumatic brain injuries. Caspase 3 (Casp3) is the most important effector protease in apoptosis: being inactive inside the cell, it undergoes enzymatic cleavage and - hence - activation once the apoptotic cascade is triggered. Immunological techniques with antibodies against cleaved Casp3 (cCasp3) or assays with colorimetric/fluorogenic substrates are commonly in use, but they do not allow to directly follow the dynamics of activation in alive neurons that may be committed to die. Results: By combined biolistic transfection, confocal microscopy, and fluorescence resonance energy transfer (FRET), we have implemented a methodology to dynamically monitor Casp3 activation in organotypic cerebellar slices from postnatal mice. After transfection with pSCAT3 FRET probes, we measured the ratio of the emissions of the donor/acceptor pair (ECFPem/Venus(em)) in fixed or alive cultures. In so doing, we i. discriminated the cellular compartment(s) of enzyme activation (nucleus, perikaryon, neurites); ii. demonstrated that Casp3 was constitutively active in the granule cells; iii. followed the fluctuations of ECFPem/Venusem, and its response to 25 mM KCl depolarization, or to increased intracellular Ca++ after NMDA (1 mM), kainic acid (1 mM), or A23187 (100-200 mu M). The specificity of the active pSCAT3-DEVD probe was confirmed with RNA interference and after inhibition of Casp3 with Ac-DEVD-CMK (100 mu M), as both sets of experiments brought ECFPem/Venus(em) to the values recorded with the control probe pSCAT3-DEVG. After double-transfection with pSCAT3-DEVD + pHcRed1-C1-survivin, we also showed a 44-56 % reduction of basal Casp3 activity in cells overexpressing survivin, a protein-member of the family of apoptosis inhibitors, with augmented survival (2.82 folds). Survivin-rescued cells were sensitive to 5 mM H2O2 oxidative stress but died without intervention of Casp3. Conclusions: This ex vivo FRET-based methodology provides quantitative information on the functional and histological dynamics of Casp3 activation in individual neurons at a cell level resolution. Not only it can be combined with experimental manipulation of the apoptotic machinery inside the cell, but offers several advantages over existing protocols for monitoring apoptosis in live mammalian neurons, and has potential to be transferred in vivo. Due to the pivotal role of Casp3 in apoptosis, our approach is relevant for a better comprehension of molecular neurodegeneration in the normal and pathological brain.	[Lossi, Laura; Cocito, Carolina; Alasia, Silvia; Merighi, Adalberto] Univ Turin, Dept Vet Sci, Largo Paolo Braccini 2, I-10095 Grugliasco, TO, Italy	Merighi, A (corresponding author), Univ Turin, Dept Vet Sci, Largo Paolo Braccini 2, I-10095 Grugliasco, TO, Italy.	adalberto.merighi@unito.it	Merighi, Adalberto/AAE-1308-2020	Merighi, Adalberto/0000-0002-1140-3556; Cocito, Carolina/0000-0003-2325-5244	University of Turin	We are greatly indebted to Prof. Masayuki Miura for kindly providing us with the SCAT3-DEVD and SCAT3-DEVG probes and for useful comments and suggestions about this work. We also wish to thank Dr. Rachel Altura for her kind gift of the HcRed1-C1-survivin plasmid. This work was supported by local grants from the University of Turin.	Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Alasia S., 2015, IMMUNOCYTOCHEMISTRY, P329; Alasia S, 2015, METHODS MOL BIOL, V1254, P99, DOI 10.1007/978-1-4939-2152-2_8; Altieri DC, 2010, BIOCHEM J, V430, P199, DOI 10.1042/BJ20100814; Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Altman J, 1997, DEV CEREBELLAR SYSTE; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Barnett EM, 2009, P NATL ACAD SCI USA, V106, P9391, DOI 10.1073/pnas.0812884106; Becker W, 2004, MICROSC RES TECHNIQ, V63, P58, DOI 10.1002/jemt.10421; Bickler PE, 2004, NEUROSCIENCE, V127, P673, DOI 10.1016/j.neuroscience.2004.05.035; Blatt NB, 2001, BIOORGAN MED CHEM, V9, P1371, DOI 10.1016/S0968-0896(01)00041-4; Bullok K, 2005, J MED CHEM, V48, P5404, DOI 10.1021/jm050008p; Caldas H, 2005, ONCOGENE, V24, P1994, DOI 10.1038/sj.onc.1208350; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; D'Amelio M, 2010, CELL DEATH DIFFER, V17, P1104, DOI 10.1038/cdd.2009.180; D'Amelio M, 2012, TRENDS NEUROSCI, V35, P700, DOI 10.1016/j.tins.2012.06.004; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Hamburger Viktor, 1990, NATURALLY OCCURRING, P126; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Jiang YY, 2005, J NEUROSCI, V25, P6962, DOI 10.1523/JNEUROSCI.1446-05.2005; JOHNSON EM, 1992, EXP NEUROL, V115, P163, DOI 10.1016/0014-4886(92)90242-I; Jolivel V, 2014, J MOL NEUROSCI, V54, P451, DOI 10.1007/s12031-014-0325-4; Juan TSC, 1997, GENOMICS, V40, P86, DOI 10.1006/geno.1996.4548; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Koike-Kuroda Y, 2010, TOXICOL IN VITRO, V24, P2012, DOI 10.1016/j.tiv.2010.07.022; Koushik SV, 2006, BIOPHYS J, V91, pL99, DOI 10.1529/biophysj.106.096206; Kuranaga E, 2011, DEVELOPMENT, V138, P1493, DOI 10.1242/dev.058958; Lakowicz JR, 1999, J BIOMOL SCREEN, V4, P355, DOI 10.1177/108705719900400610; Liu Y, 2012, J CONTROL RELEASE, V163, P203, DOI 10.1016/j.jconrel.2012.09.001; Lo SC, 2015, J NEUROSCI, V35, P2118, DOI 10.1523/JNEUROSCI.3280-14.2015; Lossi L, 2004, J MOL HISTOL, V35, P621; Lossi L, 2004, J NEUROBIOL, V60, P437, DOI 10.1002/neu.20032; Lossi L, 2003, PROG NEUROBIOL, V69, P287, DOI 10.1016/S0301-0082(03)00051-0; Lossi L, 2002, NEUROSCIENCE, V112, P509, DOI 10.1016/S0306-4522(02)00112-4; Lossi L., 2002, CELLULAR MOL METHODS, P235; Lossi L, 2015, METHODS MOL BIOL, V1254, P1, DOI 10.1007/978-1-4939-2152-2_1; Lossi L, 2009, DEV NEUROBIOL, V69, P855, DOI 10.1002/dneu.20744; Lossi L, 2009, PROG NEUROBIOL, V88, P221, DOI 10.1016/j.pneurobio.2009.01.002; Marzban H, 2015, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00450; Maxwell D, 2009, BIOCONJUGATE CHEM, V20, P702, DOI [10.1021/bc800516n, 10.1021/bcB00516n]; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pasti L, 1997, J NEUROSCI, V17, P7817; Pelet S, 2006, MICROSC RES TECHNIQ, V69, P861, DOI 10.1002/jemt.20361; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Smolewski P, 2011, CURR MOL MED, V11, P633, DOI 10.2174/156652411797536723; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; Takemoto K, 2003, J CELL BIOL, V160, P235, DOI 10.1083/jcb.200207111; Takemoto K, 2007, P NATL ACAD SCI USA, V104, P13367, DOI 10.1073/pnas.0702733104; Tanaka M, 2000, DEV BRAIN RES, V121, P223, DOI 10.1016/S0165-3806(00)00041-9; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verdaguer E, 2002, BRIT J PHARMACOL, V135, P1297, DOI 10.1038/sj.bjp.0704581; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Wang JY, 2014, DEV CELL, V28, P670, DOI 10.1016/j.devcel.2014.02.009; Weyer A, 2003, J NEUROSCI RES, V73, P400, DOI 10.1002/jnr.10655; Wu YX, 2006, CANCER LETT, V235, P239, DOI 10.1016/j.canlet.2005.04.036; Yamaguchi Y, 2011, J CELL BIOL, V195, P1047, DOI 10.1083/jcb.201104057; Yang JH, 2013, BIOMETALS, V26, P43, DOI 10.1007/s10534-012-9593-z; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1; Zadran S, 2012, APPL MICROBIOL BIOT, V96, P895, DOI 10.1007/s00253-012-4449-6	61	19	20	0	27	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1750-1326			MOL NEURODEGENER	Mol. Neurodegener.	APR 28	2016	11								34	10.1186/s13024-016-0101-8			20	Neurosciences	Neurosciences & Neurology	DK7LS	WOS:000375107400001	27122136	DOAJ Gold, Green Published			2021-06-18	
J	Liu, H; Rose, ME; Culver, S; Ma, XC; Dixon, CE; Graham, SH				Liu, Hao; Rose, Marie E.; Culver, Sherman; Ma, Xiecheng; Dixon, C. Edward; Graham, Steven H.			Rosiglitazone attenuates inflammation and CA3 neuronal loss following traumatic brain injury in rats	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						Traumatic brain injury; PPAR gamma; Inflammation; Rosiglitazone; Behavioral; Cell survival	SPINAL-CORD-INJURY; PPAR-GAMMA; STROKE; AGONIST; DYSFUNCTION; MECHANISMS; THERAPIES; DEFICITS; TARGET; DAMAGE	Rosiglitazone, a potent peroxisome proliferator-activated receptor (PPAR)-gamma agonist, has been shown to confer neuroprotective effects in stroke and spinal cord injury, but its role in the traumatic brain injury (TBI) is still controversial. Using a controlled cortical impact model in rats, the current study was designed to determine the effects of rosiglitazone treatment (6 mg/kg at 5 min, 6 h and 24 h post injury) upon inflammation and histological outcome at 21 d after TBI. In addition, the effects of rosiglitazone upon inflammatory cytokine transcription, vestibulomotor behavior and spatial memory function were determined at earlier time points (24 h, 1-5 d, 14-20 d post injury, respectively). Compared with the vehicle-treated group, rosiglitazone treatment suppressed production of TNF alpha at 24 h after TBI, attenuated activation of microglia/macrophages and increased survival of CA3 neurons but had no effect on lesion volume at 21 d after TBI. Rosiglitazone-treated animals had improved performance on beam balance testing, but there was no difference in spatial memory function as determined by Morris water maze. In summary, this study indicates that rosiglitazone treatment in the first 24 h after TBI has limited anti-inflammatory and neuroprotective effects in rat traumatic injury. Further study using an alternative dosage paradigm and more sensitive behavioral testing may be warranted. Published by Elsevier Inc.	[Liu, Hao; Rose, Marie E.; Culver, Sherman; Ma, Xiecheng; Dixon, C. Edward; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA; [Liu, Hao; Rose, Marie E.; Graham, Steven H.] Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15260 USA; [Culver, Sherman; Ma, Xiecheng; Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15216 USA; [Culver, Sherman; Ma, Xiecheng; Dixon, C. Edward] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15216 USA	Graham, SH (corresponding author), VA Pittsburgh Healthcare Ctr Res, Geriatr Res Educ & Clin Ctr, Off Bldg 30,Mail Code 151, Pittsburgh, PA 15240 USA.	Steven.Graham@va.gov			Veteran's Affairs Rehabilitation Research and Development Merit Review Program Award [I01RX000310]; Veterans AffairsUS Department of Veterans Affairs [I01RX000310] Funding Source: NIH RePORTER	This work was supported by the Veteran's Affairs Rehabilitation Research and Development Merit Review Program Award I01RX000310 (S.H.G.).	Allahtavakoli M, 2009, BRAIN RES, V1271, P121, DOI 10.1016/j.brainres.2009.03.040; Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341; Carta AR, 2013, CURR DRUG TARGETS, V14, P743, DOI 10.2174/1389450111314070004; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Chen YC, 2012, MOL NEUROBIOL, V46, P114, DOI 10.1007/s12035-012-8259-8; Culman J, 2007, TRENDS PHARMACOL SCI, V28, P244, DOI 10.1016/j.tips.2007.03.004; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Esposito E, 2011, EXPERT OPIN THER TAR, V15, P943, DOI 10.1517/14728222.2011.581231; Gu C, 2015, BRAIN RES, V1624, P199, DOI 10.1016/j.brainres.2015.07.025; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Liu H, 2013, BRAIN RES, V1519, P71, DOI 10.1016/j.brainres.2013.04.029; Mandrekar-Colucci S, 2013, ASN NEURO, V5, DOI 10.1042/AN20130030; Meng QQ, 2011, NEUROSCI LETT, V503, P191, DOI 10.1016/j.neulet.2011.08.033; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Pearse D, 2010, CURR OPIN INVEST DR, V11, P1207; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Semple BD, 2011, EXP NEUROL, V229, P195, DOI 10.1016/j.expneurol.2011.02.002; Shin SS, 2012, J NEUROTRAUM, V29, P843, DOI 10.1089/neu.2011.1966; Sobrado M, 2009, J NEUROSCI, V29, P3875, DOI 10.1523/JNEUROSCI.5529-08.2009; Stahel PF, 2008, PPAR RES, V2008, DOI 10.1155/2008/538141; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Ya JC, 2015, MOL MED REP, V12, P6591, DOI 10.3892/mmr.2015.4292; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074	26	19	20	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	APR 15	2016	472	4					648	655		10.1016/j.bbrc.2016.03.003			8	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	DI8LX	WOS:000373753600013	26947332				2021-06-18	
J	Ellis, MJ; McDonald, PJ; Cordingley, D; Mansouri, B; Essig, M; Ritchie, L				Ellis, Michael J.; McDonald, Patrick J.; Cordingley, Dean; Mansouri, Behzad; Essig, Marco; Ritchie, Lesley			Retirement-from-sport considerations following pediatric sports-related concussion: case illustrations and institutional approach	NEUROSURGICAL FOCUS			English	Article						concussion; traumatic brain injury; neuropsychology; neuroimaging; return to play; retirement	CHRONIC TRAUMATIC ENCEPHALOPATHY; SPINAL-CORD-INJURY; SELF-REPORTED CONCUSSIONS; ARACHNOID CYST SECONDARY; CERVICAL-SPINE; OPTIC NEUROPATHY; RADIOGRAPHIC ABNORMALITY; RECURRENT CONCUSSION; HEAD-INJURY; POSTCONCUSSION SYNDROME	The decision to advise an athlete to retire from sports following sports-related concussion ( SRC) remains a persistent challenge for physicians. In the absence of strong empirical evidence to support recommendations, clinical decision making must be individualized and should involve a multidisciplinary team of experts in concussion and traumatic brain injury. Although previous authors have advocated for a more conservative approach to these issues in child and adolescent athletes, there are few reports outlining considerations for this process among this unique population. Here, the authors use multiple case illustrations to discuss 3 subgroups of clinical considerations for sports retirement among pediatric SRC patients including the following: those with structural brain abnormalities identified on neuroimaging, those presenting with focal neurological deficits and abnormalities on physical examination, and those in whom the cumulative or prolonged effects of concussion are suspected or demonstrated. The authors' evolving multidisciplinary institutional approach to return-to-play and retirement decision making in pediatric SRC is also presented.	[Ellis, Michael J.] Univ Manitoba, Dept Surg, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Essig, Marco] Univ Manitoba, Dept Diagnost Radiol, Winnipeg, MB, Canada; [Mansouri, Behzad] Univ Manitoba, Dept Neurol & Neuroophthalmol, Winnipeg, MB, Canada; [Ritchie, Lesley] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Neurosurg Sect, Winnipeg, MB, Canada; [Ellis, Michael J.; Cordingley, Dean; Mansouri, Behzad; Essig, Marco; Ritchie, Lesley] Pan Am Concuss Program, Winnipeg, MB, Canada; [Ellis, Michael J.; McDonald, Patrick J.] Childrens Hosp, Res Inst Manitoba, 840 Sherbrook St, Winnipeg, MB R3A 1S1, Canada; [Ellis, Michael J.; McDonald, Patrick J.; Cordingley, Dean; Mansouri, Behzad; Essig, Marco; Ritchie, Lesley] Canada North Concuss Network, Winnipeg, MB, Canada; [McDonald, Patrick J.] British Columbia Childrens Hosp, Div Neurosurg, Vancouver, BC V6H 3V4, Canada; [McDonald, Patrick J.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Ellis, MJ (corresponding author), Pan Am Clin, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada.	mellis3@panamclinic.com		essig, marco/0000-0002-7964-2297			Al-Holou WN, 2010, J NEUROSURG-PEDIATR, V5, P578, DOI 10.3171/2010.2.PEDS09464; Allen CR, 2002, CLIN SPORT MED, V21, P15, DOI 10.1016/S0278-5919(03)00054-1; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; BAILES JE, 1991, NEUROSURGERY, V29, P491, DOI 10.1227/00006123-199110000-00001; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Blount JP, 2004, NEUROSURGERY, V54, P1190, DOI 10.1227/01.NEU.0000119236.08000.49; Bondurant CP, 1995, PEDIATR NEUROSURG, V23, P254, DOI 10.1159/000120968; Bosch PP, 2002, SPINE, V27, P2788, DOI 10.1097/00007632-200212150-00009; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Cantu RC, 1998, CLIN SPORT MED, V17, P137, DOI 10.1016/S0278-5919(05)70068-5; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Cantu RC, 2013, CURR SPORT MED REP, V12, P14, DOI 10.1249/JSR.0b013e31827dc1fb; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; CANTU RV, 1994, J NEUROSURG, V80, P592; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Concannon LG, 2014, CURR SPORT MED REP, V13, P365, DOI 10.1249/JSR.0000000000000098; Cook MW, 1996, ARCH OTOLARYNGOL, V122, P389; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Cress M, 2013, NEUROSURGERY, V72, P716, DOI 10.1227/NEU.0b013e318285b3a4; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058868; Davis G, 2010, BRIT J SPORT MED, V44, P1139, DOI 10.1136/bjsm.2008.048215; Davis GA, 2015, NEUROSURGERY, V76, P643, DOI 10.1227/NEU.0000000000000722; De Marco AP, 2016, J CHILD NEUROL, V31, P68, DOI 10.1177/0883073814559645; Demetriades AK, 2004, BRIT J SPORT MED, V38, DOI 10.1136/bjsm.2003.005710; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2012, ARCH CLIN NEUROPSYCH, V27, P119, DOI 10.1093/arclin/acr077; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Ellis MJ, 2016, CURR SPORT MED REP, V15, P27, DOI 10.1249/JSR.0000000000000223; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P241, DOI 10.3171/2015.1.PEDS14510; Ellis MJ, 2015, CURR SPORT MED REP, V14, P20, DOI 10.1249/JSR.0000000000000108; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; ELLIS MJ, 2014, CURR RES CONCUSSION, V1, P33; Ford RL, 2012, J AAPOS, V16, P413, DOI 10.1016/j.jaapos.2012.04.009; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gardner A, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00141; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldenberg-Cohen N, 2004, J AAPOS, V8, P20, DOI 10.1016/j.jaapos.2003.08.009; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2014, BRIT J SPORT MED, V48, P162, DOI 10.1136/bjsports-2013-092935; Kawanishi A, 1999, NEUROL MED-CHIR, V39, P231, DOI 10.2176/nmc.39.231; Kelly JP, 1997, NEUROLOGY, V48, P581; Kepler CK, 2012, CLIN SPORT MED, V31, P499, DOI 10.1016/j.csm.2012.03.005; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kestle JRW, 2003, NEUROL CLIN, V21, P883, DOI 10.1016/S0733-8619(03)00016-1; KODSI SR, 1992, AM J OPHTHALMOL, V114, P568, DOI 10.1016/S0002-9394(14)74484-8; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; MAHAPATRA AK, 1993, PEDIATR NEUROSURG, V19, P34, DOI 10.1159/000120698; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2001, BRIT J SPORT MED, V35, P380, DOI 10.1136/bjsm.35.6.380; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2015, CLIN J SPORT MED, V25, P133, DOI 10.1097/JSM.0000000000000107; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Miele Vincent J, 2006, Neurosurg Focus, V21, pE9; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Mutch WAC, 2016, J NEUROSURG, V125, P648, DOI 10.3171/2015.6.JNS15972; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; OSENBACH RK, 1992, NEUROSURGERY, V30, P385, DOI 10.1227/00006123-199203000-00012; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pang D, 2004, NEUROSURGERY, V55, P1325, DOI 10.1227/01.NEU.0000143030.85589.E6; PANG D, 1989, J TRAUMA, V29, P654, DOI 10.1097/00005373-198905000-00021; Paulus S, 2014, PHYS MED REH CLIN N, V25, P723, DOI 10.1016/j.pmr.2014.06.005; POLLACK IF, 1988, J NEUROSURG, V69, P177, DOI 10.3171/jns.1988.69.2.0177; Prabhu VC, 2002, NEUROSURGERY, V50, P195; RICHARDS BW, 1992, AM J OPHTHALMOL, V113, P489, DOI 10.1016/S0002-9394(14)74718-X; Rihn JA, 2009, SPORTS MED, V39, P697, DOI 10.2165/11315190-000000000-00000; Ritchie LJ, 2015, CURR RES CONCUSSION, V2, P8; Saigal R, 2014, WORLD NEUROSURG, V82, P485, DOI 10.1016/j.wneu.2014.06.043; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Solomon GS, 2015, BRAIN INJURY, V29, P164, DOI 10.3109/02699052.2014.965205; STEINSAPIR KD, 1994, SURV OPHTHALMOL, V38, P487, DOI 10.1016/0039-6257(94)90145-7; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Tempel ZJ, 2015, NEUROSURGERY, V77, P23, DOI 10.1227/NEU.0000000000000728; THORNDIKE A, 1952, NEW ENGL J MED, V247, P554, DOI 10.1056/NEJM195210092471504; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Torg JS, 2009, SPORTS HEALTH, V1, P376, DOI 10.1177/1941738109343161; Torg JS, 1996, J BONE JOINT SURG AM, V78A, P1308, DOI 10.2106/00004623-199609000-00003; Torg JS, 1997, PHYSICIAN SPORTSMED, V25, P60, DOI 10.3810/psm.1997.07.1487; Torg JS, 1997, J NEUROSURG, V87, P843, DOI 10.3171/jns.1997.87.6.0843; Torg JS, 1997, CLIN J SPORT MED, V7, P273, DOI 10.1097/00042752-199710000-00005; Torg JS, 1997, CLIN SPORT MED, V16, P501, DOI 10.1016/S0278-5919(05)70037-5; Tsuzuki N, 2003, NEUROSURGERY, V53, P242, DOI 10.1227/01.NEU.0000072303.16102.E1; Tubbs RS, 2011, CHILD NERV SYST, V27, P1927, DOI 10.1007/s00381-011-1457-2; WHITE AA, 1975, CLIN ORTHOP RELAT R, P85, DOI 10.1097/00003086-197506000-00011; Wippold FJ, 2008, AM J NEURORADIOL, V29, P1998; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zuckerman SL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12257	115	19	19	0	18	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	APR	2016	40	4							E8	10.3171/2016.1.FOCUS15600			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI4NL	WOS:000373476500003	27032925	Bronze			2021-06-18	
J	Ryan, NP; Catroppa, C; Beare, R; Silk, TJ; Crossley, L; Beauchamp, MH; Yeates, KO; Anderson, VA				Ryan, Nicholas P.; Catroppa, Cathy; Beare, Richard; Silk, Timothy J.; Crossley, Louise; Beauchamp, Miriam H.; Yeates, Keith Owen; Anderson, Vicki A.			Theory of mind mediates the prospective relationship between abnormal social brain network morphology and chronic behavior problems after pediatric traumatic brain injury	SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE			English	Article						childhood; brain injuries; social cognition; theory of mind; magnetic resonance imaging	SUPERIOR TEMPORAL SULCUS; YOUNG-ADULT SURVIVORS; NEURAL BASIS; EXTERNALIZING BEHAVIOR; CORPUS-CALLOSUM; CHILDREN; MODERATE; PREDICTORS; OUTCOMES; PREVALENCE	Childhood and adolescence coincide with rapid maturation and synaptic reorganization of distributed neural networks that underlie complex cognitive-affective behaviors. These regions, referred to collectively as the 'social brain network' (SBN) are commonly vulnerable to disruption from pediatric traumatic brain injury (TBI); however, the mechanisms that link morphological changes in the SBN to behavior problems in this population remain unclear. In 98 children and adolescents with mild to severe TBI, we acquired 3D T1-weighted MRIs at 2-8 weeks post-injury. For comparison, 33 typically developing controls of similar age, sex and education were scanned. All participants were assessed on measures of Theory of Mind (ToM) at 6 months post-injury and parents provided ratings of behavior problems at 24-months post-injury. Severe TBI was associated with volumetric reductions in the overall SBN package, as well as regional gray matter structural change in multiple component regions of the SBN. When compared with TD controls and children with milder injuries, the severe TBI group had significantly poorer ToM, which was associated with more frequent behavior problems and abnormal SBN morphology. Mediation analysis indicated that impaired theory of mind mediated the prospective relationship between abnormal SBN morphology and more frequent chronic behavior problems. Our findings suggest that sub-acute alterations in SBN morphology indirectly contribute to long-term behavior problems via their influence on ToM. Volumetric change in the SBN and its putative hub regions may represent useful imaging biomarkers for prediction of post-acute social cognitive impairment, which may in turn elevate risk for chronic behavior problems.	[Ryan, Nicholas P.; Catroppa, Cathy; Silk, Timothy J.; Crossley, Louise; Anderson, Vicki A.] Australian Ctr Child Neuropsychol Studies, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Ryan, Nicholas P.; Catroppa, Cathy; Anderson, Vicki A.] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki A.] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Beare, Richard] Murdoch Childrens Res Inst, Dev Imaging, Melbourne, Vic, Australia; Royal Childrens Hosp, Dept Radiol, Melbourne, Vic, Australia; Univ Melbourne, Dept Pediat, Melbourne, Vic, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, CP 6128, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Res Ctr, Montreal, PQ, Canada; [Yeates, Keith Owen] Univ Calgary, Dept Psychol, Hotchkiss, Inst Brain, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada; [Yeates, Keith Owen] Univ Calgary, Res Inst, Alberta Childrens Hosp, Calgary, AB, Canada	Ryan, NP (corresponding author), Murdoch Childrens Res Inst, Child Neuropsychol, Flemington Rd, Parkville, Vic 3052, Australia.	nicholas.ryan@mcri.edu.au	Silk, Tim/K-4295-2019; Ryan, Nicholas/K-5445-2019; Yeates, Keith/AAJ-4223-2020	Ryan, Nicholas/0000-0002-0878-8889; Yeates, Keith/0000-0001-7680-2892; Silk, Tim/0000-0002-7290-512X; Beare, Richard/0000-0002-7530-5664	Victorian Neurotrauma Initiative, Australia [CO6E1]; Victorian Government Operational Infrastructure Support Program; Australian Postgraduate AwardAustralian Government; MCRI; National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Brain Injury Recovery Seed GrantNational Health and Medical Research Council of Australia; NHMRCNational Health and Medical Research Council of Australia	This work was supported by a grant from the Victorian Neurotrauma Initiative (No. CO6E1), Australia; the Victorian Government Operational Infrastructure Support Program; an Australian Postgraduate Award, MCRI PhD scholarship, and National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Brain Injury Recovery Seed Grant to N.R.; and an NHMRC Senior Practitioner Fellowship to V.A. The funding bodies did not play a role in the design of the study, collection, analysis and interpretation of the data, or writing of the article.	Achenbach T. M., 2001, ASEBA SCH AGE FORMS; Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beauchamp MH, 2011, BRAIN INJURY, V25, P950, DOI 10.3109/02699052.2011.589791; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bernhardt BC, 2012, ANNU REV NEUROSCI, V35, P1, DOI 10.1146/annurev-neuro-062111-150536; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Boddaert N, 2004, NEUROIMAGE, V23, P364, DOI 10.1016/j.neuroimage.2004.06.016; Burnett S, 2011, NEUROSCI BIOBEHAV R, V35, P1654, DOI 10.1016/j.neubiorev.2010.10.011; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P338, DOI 10.1017/S1355617712001440; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001; Hayes A.F., 2018, INTRO MEDIATION MODE, V2nd ed.; Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360; Herbet G, 2013, CORTEX, V49, P2711, DOI 10.1016/j.cortex.2013.08.003; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Iacoboni M, 2004, NEUROIMAGE, V21, P1167, DOI 10.1016/j.neuroimage.2003.11.013; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kennedy DP, 2012, TRENDS COGN SCI, V16, P559, DOI 10.1016/j.tics.2012.09.006; Kenny D.T., 2007, NSW CRIME JUSTICE B, V107, P1; Lahnakoski JM, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00233; Lavin C., 2013, FRONT NEUROSCI-SWITZ, V7, P1; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Max JE, 2012, J AM ACAD CHILD PSY, V51, P1208, DOI 10.1016/j.jaac.2012.08.026; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2014, J HEAD TRAUMA REHAB, V29, P498, DOI 10.1097/HTR.0000000000000001; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Moore E, 2014, J HEAD TRAUMA REHAB, V29, P239, DOI 10.1097/HTR.0b013e31828f9876; Robinson KE, 2014, J NEUROTRAUM, V31, P1835, DOI 10.1089/neu.2014.3422; Ryan NP, 2015, HUM BRAIN MAPP, V36, P1677, DOI 10.1002/hbm.22729; Ryan NP, 2015, J HEAD TRAUMA REHAB, V30, P75, DOI 10.1097/HTR.0000000000000123; Ryan NP, 2015, BRAIN LANG, V142, P86, DOI 10.1016/j.bandl.2015.01.007; Ryan NP, 2015, NEUROPSYCHOLOGIA, V66, P32, DOI 10.1016/j.neuropsychologia.2014.10.040; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; Shin JE, 2015, PROG NEURO-PSYCHOPH, V58, P81, DOI 10.1016/j.pnpbp.2014.12.006; Singer T, 2009, TRENDS COGN SCI, V13, P334, DOI 10.1016/j.tics.2009.05.001; Sodian B, 2011, CHILD DEV PERSPECT, V5, P39, DOI 10.1111/j.1750-8606.2010.00152.x; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Spitz G, 2013, BRAIN COGNITION, V83, P34, DOI 10.1016/j.bandc.2013.06.007; Surian L, 2007, PSYCHOL SCI, V18, P580, DOI 10.1111/j.1467-9280.2007.01943.x; TEASDALE G, 1974, LANCET, V2, P81; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Uddin LQ, 2009, NEUROSCI BIOBEHAV R, V33, P1198, DOI 10.1016/j.neubiorev.2009.06.002; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Walter H, 2004, J COGNITIVE NEUROSCI, V16, P1854, DOI 10.1162/0898929042947838; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Wylie KP, 2010, SCHIZOPHR RES, V123, P93, DOI 10.1016/j.schres.2010.08.027; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zilbovicius M, 2006, TRENDS NEUROSCI, V29, P359, DOI 10.1016/j.tins.2006.06.004	83	19	19	1	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1749-5016	1749-5024		SOC COGN AFFECT NEUR	Soc. Cogn. Affect. Neurosci.	APR	2016	11	4					683	692		10.1093/scan/nsw007			10	Neurosciences; Psychology; Psychology, Experimental	Neurosciences & Neurology; Psychology	DJ5DT	WOS:000374227700016	26796967	Green Published, Other Gold			2021-06-18	
J	Tkachenko, N; Singh, K; Hasanaj, L; Serrano, L; Kothare, SV				Tkachenko, Nataliya; Singh, Kanwaljit; Hasanaj, Lisena; Serrano, Liliana; Kothare, Sanjeev V.			Sleep Disorders Associated With Mild Traumatic Brain Injury Using Sport Concussion Assessment Tool 3	PEDIATRIC NEUROLOGY			English	Article						TBI; sleep disorders; SCAT3; comorbidity	INTERNATIONAL-CONFERENCE; AGREEMENT STATEMENT; MANAGEMENT; DISTURBANCES; INSOMNIA	BACKGROUND: Sleep problems affect 30% to 80% of patients with mild traumatic brain injury. We assessed the prevalence of sleep disorders after mild traumatic brain injury and its correlation with other symptoms. METHODS AND MATERIALS: Individuals with mild traumatic brain injury were assessed at the New York University Concussion Center during 2013-2014 with the Sports Concussion Assessment Tool, third edition, data following mild traumatic brain injury. The relationship between sleep problems (drowsiness, difficulty falling asleep, fatigue or low energy), psychiatric symptoms (sadness, nervousness or anxiousness), headache, and dizziness were analyzed by Spearman correlation and logistic regression using moderate to severe versus none to mild categorization. RESULTS: Ninety-three patients were retrospectively considered. The most common injury causes were falls (34.4%) and motor vehicle accidents (21.5%). There was a positive correlation between dizziness, headache, psychiatric problems (sadness, anxiety, irritability), and sleep problems (fatigue, drowsiness, and difficulty falling asleep) (P < 0.001). Logistic regression showed a significant association between moderate to severe psychiatric symptoms and moderate to severe sleep symptoms (P < 0.05). Sleep symptoms became more severe with increased time interval from mild traumatic brain injury to Sport Concussion Assessment Tool 3 administration (odds ratio = 1.005, 1.006, and 1.008, P < 0.05). There was significant correlation between motor vehicle accident and drowsiness and difficulty falling asleep (P < 0.05). Medications given in the emergency department had a positive correlation with drowsiness (P < 0.05). CONCLUSIONS: Individuals who report moderate to severe headache, dizziness, and psychiatric symptoms have a higher likelihood of reporting moderate to severe sleep disorders following mild traumatic brain injury and should be counseled and initiated with early interventions. (C) 2016 Elsevier Inc. All rights reserved.	[Tkachenko, Nataliya; Kothare, Sanjeev V.] NYU, Dept Neurol, Langone Med Ctr, Sleep Ctr, New York, NY 10016 USA; [Tkachenko, Nataliya] Dnepropetrovsk State Med Acad, Dept Pediat, Dnepropetrovsk, Ukraine; [Singh, Kanwaljit] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA USA; [Hasanaj, Lisena; Serrano, Liliana] NYU, Dept Neurol, Langone Med Ctr, New York, NY 10016 USA	Kothare, SV (corresponding author), NYU, Langone Med Ctr, Sch Med, Pediat Sleep Program, 223 East 34th St, New York, NY 10016 USA.	Sanjeev.Kothare@nyumc.org		Kothare, Sanjeev/0000-0001-7849-6649			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT, 2001, J ATHL TRAINING, V36, P253; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; GUSKIEWICZ KM, 2004, AM J MED SPORTS, V6, P13; Hou LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076087; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kelly JP, 1997, NEUROLOGY, V48, P581; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; Krumholtz I, 2000, Optometry, V71, P426; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Saether R, 2011, RES DEV DISABIL, V32, P727, DOI 10.1016/j.ridd.2010.11.007; Weber M, 2013, J SLEEP DISORDERS TH, V2, P2; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	27	19	19	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	APR	2016	57						46	50		10.1016/j.pediatrneurol.2015.12.019			5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	DI5EX	WOS:000373522800010	26795630				2021-06-18	
J	Vogel, EW; Effgen, GB; Patel, TP; Meaney, DF; Bass, CR; Morrison, B				Vogel, Edward W., III; Effgen, Gwen B.; Patel, Tapan P.; Meaney, David F.; Bass, Cameron R. Dale; Morrison, Barclay, III			Isolated Primary Blast Inhibits Long-Term Potentiation in Organotypic Hippocampal Slice Cultures	JOURNAL OF NEUROTRAUMA			English	Article						brain; electrophysiology; in vitro; learning; neuron	TRAUMATIC BRAIN-INJURY; PAIRED-PULSE FACILITATION; FLUID PERCUSSION INJURY; IN-VITRO MODEL; AREA CA1; SYNAPTIC-TRANSMISSION; CELL-DEATH; RAT MODEL; MECHANISMS; CALCIUM	Over the last 13 years, traumatic brain injury (TBI) has affected over 230,000 U.S. service members through the conflicts in Iraq and Afghanistan, mostly as a result of exposure to blast events. Blast-induced TBI (bTBI) is multi-phasic, with the penetrating and inertia-driven phases having been extensively studied. The effects of primary blast injury, caused by the shockwave interacting with the brain, remain unclear. Earlier in vivo studies in mice and rats have reported mixed results for primary blast effects on behavior and memory. Using a previously developed shock tube and in vitro sample receiver, we investigated the effect of isolated primary blast on the electrophysiological function of rat organotypic hippocampal slice cultures (OHSC). We found that pure primary blast exposure inhibited long-term potentiation (LTP), the electrophysiological correlate of memory, with a threshold between 9 and 39 kPa center dot ms impulse. This deficit occurred well below a previously identified threshold for cell death (184 kPa center dot ms), supporting our previously published finding that primary blast can cause changes in brain function in the absence of cell death. Other functional measures such as spontaneous activity, network synchronization, stimulus-response curves, and paired-pulse ratios (PPRs) were less affected by primary blast exposure, as compared with LTP. This is the first study to identify a tissue-level tolerance threshold for electrophysiological changes in neuronal function to isolated primary blast.	[Vogel, Edward W., III; Effgen, Gwen B.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, 1210 Amsterdam Ave, New York, NY 10027 USA; [Patel, Tapan P.; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Bass, Cameron R. Dale] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Patel, Tapan/0000-0001-8959-6645; Meaney, David/0000-0002-0954-4122	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS088176] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088176] Funding Source: NIH RePORTER		Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Axmacher N, 2006, BRAIN RES REV, V52, P170, DOI 10.1016/j.brainresrev.2006.01.007; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Choi JH, 2006, IEEE T BIO-MED ENG, V53, P738, DOI 10.1109/TBME.2006.870239; Commins S, 1998, NEUROREPORT, V9, P4109, DOI 10.1097/00001756-199812210-00019; Compte A, 2006, NEUROSCIENCE, V139, P135, DOI 10.1016/j.neuroscience.2005.06.011; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DISCENNA PG, 1994, HIPPOCAMPUS, V4, P569, DOI 10.1002/hipo.450040506; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DVBIC, 2015, DEP DEF NUMB TRAUM B; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Fueta Y, 1998, BRAIN RES, V779, P324, DOI 10.1016/S0006-8993(97)01214-6; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Gullotti DM, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027873; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Heuschkel MO, 2002, J NEUROSCI METH, V114, P135, DOI 10.1016/S0165-0270(01)00514-3; Hu DY, 2007, NEUROBIOL LEARN MEM, V87, P372, DOI 10.1016/j.nlm.2006.10.003; Huang M., 2015, PSYCHONEUROENDOCRINO; Hue CD, 2014, J NEUROTRAUM, V31, P951, DOI 10.1089/neu.2013.3149; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; JOY RM, 1993, BRAIN RES, V604, P273, DOI 10.1016/0006-8993(93)90379-2; Kang W. H., 2015, BIOMECH MODEL MECHAN, P1; Kang WH, 2015, J NEUROTRAUM, V32, P1011, DOI 10.1089/neu.2014.3667; Kang WH, 2015, BIOMECH MODEL MECHAN, V14, P561, DOI 10.1007/s10237-014-0622-4; Keyes DC, 2005, MED RESPONSE TERRORI; Li XL, 2007, J NEUROPHYSIOL, V98, P3341, DOI 10.1152/jn.00977.2007; Li XL, 2010, BIOPHYS J, V98, P1733, DOI 10.1016/j.bpj.2010.01.013; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maugineanu DG, 2000, BRAIN RES BULL, V51, P69, DOI 10.1016/S0361-9230(99)00209-9; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Patel TP, 2015, J NEUROSCI METH, V243, P26, DOI 10.1016/j.jneumeth.2015.01.020; Patel TP, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00349; Patel TP, 2012, ANN BIOMED ENG, V40, P23, DOI 10.1007/s10439-011-0390-6; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; SCHULZ PE, 1995, J PHYSIOLOGY-PARIS, V89, P3, DOI 10.1016/0928-4257(96)80546-8; SCHULZ PE, 1994, J NEUROSCI, V14, P5325; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; STANFORD IM, 1995, EUR J PHARMACOL, V277, P229, DOI 10.1016/0014-2999(95)00083-W; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Swant J, 2006, LEARN MEMORY, V13, P161, DOI 10.1101/lm.63806; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Tsirka V, 2011, INT J PSYCHOPHYSIOL, V79, P89, DOI 10.1016/j.ijpsycho.2010.09.006; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Wallis RA, 1995, EUR J PHARMACOL, V294, P475, DOI 10.1016/0014-2999(95)00568-4; Wang XJ, 2001, TRENDS NEUROSCI, V24, P455, DOI 10.1016/S0166-2236(00)01868-3; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; WU LG, 1994, J NEUROSCI, V14, P645; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Yu Z, 2010, J NEUROPHYSIOL, V103, P499, DOI 10.1152/jn.00775.2009; Zhang BL, 2011, BRAIN RES, V1382, P165, DOI 10.1016/j.brainres.2011.01.065; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305	72	19	19	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2016	33	7					652	661		10.1089/neu.2015.4045			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DI6QK	WOS:000373624700004	26414012	Green Published			2021-06-18	
J	Haran, HP; Bressan, S; Oakley, E; Davis, GA; Anderson, V; Babl, FE				Haran, Harini P.; Bressan, Silvia; Oakley, Ed; Davis, Gavin A.; Anderson, Vicki; Babl, Franz E.			On-field management and return-to-play in sports-related concussion in children: Are children managed appropriately?	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Concussion; Traumatic brain injury; Head injury; Sport; Child; Return to play	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; RECOVERY; FOOTBALL; STATEMENT	Objectives: On-field management and return-to-play guidelines aim to ensure the identification and appropriate management of the concussed athlete. Compliance with current guidelines in many settings is unknown. We assessed whether key components of current concussion guidelines are being followed in child athletes. Design: Prospective observational study. Methods: Data were collected from children (5-18 years) presenting to a paediatric emergency department with sport-related concussion via researcher-administered surveys in the emergency department and during a follow up phone call. On hospital discharge all patients received a return to sports fact sheet based on the International Concussion in Sports Group. Results: Ninety-three had sustained a concussion (mean age 12.7 (+/- 0.27) years, 83% male). Sports played included Australian Football (47%), soccer (12%), rugby (9%) basketball (8%), other (25%). 82% participated in organised sports. Concussive signs or symptoms included loss of consciousness (41%), disorientation (36%), vomiting (23%), amnesia (30%), headache (60%). For concussive injury in organised sports (n = 76), overall 42% were not managed according to recommended guidelines: 19% were not immediately removed from play, 29% were allowed to return to play on the same day and 27% were not assessed by qualified personnel. 93% of parents and 96% of patients were unaware of concussionor return-to-play guidelines from their organisations. Overall, 72% were compliant with provided return-to-play guidelines. Conclusions: Many children with sports related-concussion are not formally assessed on-field and continue to play. On-field concussion management and return to play practices are often suboptimal. Awareness and education of coaches, teachers, parents and children need to be improved. (C) 2015 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Haran, Harini P.; Bressan, Silvia; Oakley, Ed; Babl, Franz E.] Royal Childrens Hosp Melbourne, Emergency Dept, Melbourne, Vic, Australia; [Haran, Harini P.; Bressan, Silvia; Oakley, Ed; Davis, Gavin A.; Anderson, Vicki; Babl, Franz E.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Haran, Harini P.] Monash Univ, Clayton, Vic, Australia; [Bressan, Silvia] Univ Padua, I-35100 Padua, Italy; [Oakley, Ed; Davis, Gavin A.; Anderson, Vicki; Babl, Franz E.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia	Babl, FE (corresponding author), Royal Childrens Hosp Melbourne, Emergency Dept, Melbourne, Vic, Australia.; Babl, FE (corresponding author), Murdoch Childrens Res Inst, Melbourne, Vic, Australia.; Babl, FE (corresponding author), Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia.	Franz.babl@rch.org.au			Victorian Government Infrastructure Support programme; Royal Children's Hospital Foundation, Melbourne, Australia [2014-400]	The authors declare that there are no competing interests and no grants associated with the research contained within this manuscript. We acknowledge the support of the families involved in the study, the assistance of medical and nursing staff and Ms. Amanda Williams, emergency research coordinator, Murdoch Children's Research Institute, Melbourne, Australia. This study was supported by the Victorian Government Infrastructure Support programme and the Royal Children's Hospital Foundation (2014-400), Melbourne, Australia.	AFL Research Board AFL Medical Officer's Association, GUID MAN CONC AUSTR; Australian Bureau of Statistics, 2009, 49010 AUSTR BUR STAT; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harrison EA, 2014, AM J PUBLIC HEALTH, V104, P822, DOI 10.2105/AJPH.2013.301840; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; International Rugby Board, IRB CONC GUID; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Royal Children's Hospital Melbourne Australia, HEAD INJ RET SPORT; Royal Children's Hospital Melbourne Australia, HEAD INJ GEN ADV; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; White PE, 2013, BR J SPORTS MED; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	24	19	19	0	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAR	2016	19	3					194	199		10.1016/j.jsams.2015.02.009			6	Sport Sciences	Sport Sciences	DF6DH	WOS:000371445600002	25772997	Bronze			2021-06-18	
J	Liu, H; Mao, P; Wang, J; Wang, T; Xie, CH				Liu, Hao; Mao, Ping; Wang, Jia; Wang, Tuo; Xie, Chang-Hou			Azilsartan, an angiotensin II type 1 receptor blocker, attenuates tert-butyl hydroperoxide-induced endothelial cell injury through inhibition of mitochondrial dysfunction and anti-inflammatory activity	NEUROCHEMISTRY INTERNATIONAL			English	Article						Neuroprotection; Azilsartan; eNOS; PPAR-gamma; Mitochondrial dysfunction	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; RAT CORTICAL-NEURONS; CEREBRAL-ISCHEMIA; GLUCOSE DEPRIVATION; OXIDATIVE STRESS; PROTECTS NEURONS; DOWN-REGULATION; CANDESARTAN; NEUROPROTECTION	Angiotensin II type 1 receptor (AT1-R) blockers protect against brain ischemia by mechanisms dependent on and independent of arterial blood pressure. However, the effects of AT1-R blockers on brain endothelial cell injury and detailed mechanisms remain unclear. The goal of this study is to investigate whether azilsartan, an AT1-R blocker, could attenuate oxidative injury in endothelial cells via regulating mitochondrial function and inflammatory responses. We found that treatment with azilsartan suppressed tert-butyl hydroperoxide (t-BHP)-induced oxidative damage in murine brain endothelial cells (mBECs) by increasing cell viability, decreasing lactate dehydrogenase (LDH) release and inhibiting cell apoptosis. Azilsartan significantly inhibited reactive oxygen species (ROS) generation and lipid peroxidation, but had no effect on antioxidant system. We also detected preserved mitochondrial function after azilsartan treatment, as evidenced by increased mitochondrial membrane potential (MMP), reduced cytochrome c release, preserved ATP synthesis and inhibited mitochondrial swelling. In addition, azilsartan differently regulated expression of inflammatory cytokines and increased the activation of endothelial nitric oxide synthase (eNOS). Pretreatment with eNOS inhibitor L-NIO partially prevented the azilsartan-induced regulation of cytokines and protection. Furthermore, azilsartan-induced protection in our in vitro model was shown to be associated with protein stability of peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Overall, our data suggest that the AT1-R blocker azilsartan may have therapeutic values in treating endothelial dysfunction associated neurological disorders through anti-oxidative and anti-inflammatory properties. (C) 2016 Elsevier Ltd. All rights reserved.	[Liu, Hao; Mao, Ping; Wang, Jia; Wang, Tuo; Xie, Chang-Hou] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Neurosurg, West Yanta Rd 277, Xian 710061, Shaanxi, Peoples R China	Liu, H (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Neurosurg, West Yanta Rd 277, Xian 710061, Shaanxi, Peoples R China.	liuhao_xjtu@126.com					Atochin DN, 2010, PFLUG ARCH EUR J PHY, V460, P965, DOI 10.1007/s00424-010-0867-4; Baker WL, 2011, ANN PHARMACOTHER, V45, P1506, DOI 10.1345/aph.1Q468; Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341; Brown RC, 2002, STROKE, V33, P1706, DOI 10.1161/01.STR.0000016405.06729.83; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen T, 2013, CELL SIGNAL, V25, P2863, DOI 10.1016/j.cellsig.2013.09.004; Chen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055601; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Dai SH, 2014, INT J MOL MED, V34, P1159, DOI 10.3892/ijmm.2014.1876; Di J, 2014, CELL PHYSIOL BIOCHEM, V34, P1063, DOI 10.1159/000366321; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Duchen MR, 2004, DIABETES, V53, pS96, DOI 10.2337/diabetes.53.2007.S96; Edvinsson LIH, 2011, J CEREBR BLOOD F MET, V31, P1554, DOI 10.1038/jcbfm.2011.70; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Fleming I, 2010, PFLUG ARCH EUR J PHY, V459, P793, DOI 10.1007/s00424-009-0767-7; Forstermann U, 2011, BRIT J PHARMACOL, V164, P213, DOI 10.1111/j.1476-5381.2010.01196.x; Gajkowska B, 1997, FOLIA NEUROPATHOL, V35, P171; Hawkins BT, 2015, J CEREBR BLOOD F MET, V35, P985, DOI 10.1038/jcbfm.2015.9; Horiuchi M, 2010, J RENIN-ANGIO-ALDO S, V11, P1, DOI 10.1177/1470320309347793; Iwai M, 2007, AM J HYPERTENS, V20, P579, DOI 10.1016/j.amjhyper.2006.12.010; Kajiya T, 2011, J HYPERTENS, V29, P2476, DOI 10.1097/HJH.0b013e32834c46fd; Kim EJ, 2002, BRAIN RES, V941, P1, DOI 10.1016/S0006-8993(02)02480-0; Kozak A, 2009, STROKE, V40, P1870, DOI 10.1161/STROKEAHA.108.537225; Kurtz TW, 2008, AM J HYPERTENS, V21, P852, DOI 10.1038/ajh.2008.202; Li J., 2013, NEUROPHARMACOLOGY; Li JM, 2008, STROKE, V39, P2029, DOI 10.1161/STROKEAHA.107.503458; Li X, 2014, CELL PHYSIOL BIOCHEM, V34, P1227, DOI 10.1159/000366334; Lima CF, 2007, CHEM-BIOL INTERACT, V167, P107, DOI 10.1016/j.cbi.2007.01.020; Liu H, 2008, J HYPERTENS, V26, P1435, DOI 10.1097/HJH.0b013e3283013b6e; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Luo P, 2013, FEBS J, V280, P6114, DOI 10.1111/febs.12531; Moretti A, 2015, PHARMACOL THERAPEUT, V146, P23, DOI 10.1016/j.pharmthera.2014.09.003; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Ogihara T, 2008, HYPERTENSION, V51, P393, DOI 10.1161/HYPERTENSIONAHA.107.098475; Ojima M, 2011, J PHARMACOL EXP THER, V336, P801, DOI 10.1124/jpet.110.176636; Ortiz PA, 2003, ACTA PHYSIOL SCAND, V179, P107, DOI 10.1046/j.1365-201X.2003.01207.x; Ostergren J, 2004, EXPERT OPIN PHARMACO, V5, P1589, DOI 10.1517/14656566.5.7.1589; Panahpour Hamdollah, 2014, Iranian Biomedical Journal, V18, P232, DOI 10.6091/ibj.13672.2014; Parone PA, 2013, J NEUROSCI, V33, P4657, DOI 10.1523/JNEUROSCI.1119-12.2013; Perry CM, 2012, CLIN DRUG INVEST, V32, P621, DOI 10.2165/11209600-000000000-00000; Saavedra JM, 2012, CLIN SCI, V123, P567, DOI 10.1042/CS20120078; Saavedra JM, 2006, CELL MOL NEUROBIOL, V26, P1099, DOI 10.1007/s10571-006-9009-0; Schaefer KL, 2005, CANCER RES, V65, P2251, DOI 10.1158/0008-5472.CAN-04-3037; Schrader J, 2003, STROKE, V34, P1699, DOI 10.1161/01.STR.0000075777.18006.89; Volpe M, 2012, INTEGR BLOOD PRESS C, V5, P19, DOI 10.2147/IBPC.S13784; Wang R, 2014, CELL PHYSIOL BIOCHEM, V34, P854, DOI 10.1159/000366304; Wosik K, 2007, J NEUROSCI, V27, P9032, DOI 10.1523/JNEUROSCI.2088-07.2007; Yu ZY, 2013, NEUROBIOL DIS, V56, P95, DOI 10.1016/j.nbd.2013.04.015; Zhang JS, 2014, CELL PHYSIOL BIOCHEM, V34, P1137, DOI 10.1159/000366327; Zhao XR, 2006, BRAIN RES, V1073, P460, DOI 10.1016/j.brainres.2005.12.061; Zhou YF, 2014, BRAIN RES BULL, V100, P14, DOI 10.1016/j.brainresbull.2013.10.013	55	19	20	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	MAR	2016	94						48	56		10.1016/j.neuint.2016.02.005			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DI6ZT	WOS:000373649600006	26879328				2021-06-18	
J	Sandsmark, DK; Kumar, MA; Woodward, CS; Schmitt, SE; Park, S; Lim, MM				Sandsmark, Danielle K.; Kumar, Monisha A.; Woodward, Catherine S.; Schmitt, Sarah E.; Park, Soojin; Lim, Miranda M.			Sleep Features on Continuous Electroencephalography Predict Rehabilitation Outcomes After Severe Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						seizure; continuous EEG; traumatic brain injury; rehabilitation; status epilepticus; modified Rankin Scale; sleep; electroencephalography	SEVERE HEAD-INJURY; UNITED-STATES; CLASSIFICATION; CONSCIOUSNESS; ANESTHESIA; DISORDERS; IMPACT; MEMORY; EEG	Objective: Sleep characteristics detected by electroencephalography (EEG) may be predictive of neurological recovery and rehabilitation outcomes after traumatic brain injury (TBI). We sought to determine whether sleep features were associated with greater access to rehabilitation therapies and better functional outcomes after severe TBI. Methods: We retrospectively reviewed records of patients admitted with severe TBI who underwent 24 or more hours of continuous EEG (cEEG) monitoring within 14 days of injury for sleep elements and ictal activity. Patient outcomes included discharge disposition and modified Rankin Scale (mRS). Results: A total of 64 patients underwent cEEG monitoring for a mean of 50.6 hours. Status epilepticus or electrographic seizures detected by cEEG were associated with poor outcomes (death or discharge to skilled nursing facility). Sleep characteristics were present in 19 (30%) and associated with better outcome (89% discharged to home/acute rehabilitation; P = .0002). Lack of sleep elements on cEEG correlated with a poor outcome or mRS > 4 at hospital discharge (P = .012). Of those patients who were transferred to skilled nursing/acute rehabilitation, sleep architecture on cEEG associated with a shorter inpatient hospital stay (20 days vs 27 days) and earlier participation in therapy (9.8 days vs 13.2 days postinjury). Multivariable analyses indicated that sleep features on cEEG predicted functional outcomes independent of admission Glasgow Coma Scale and ictal-interictal activity. Conclusion: The presence of sleep features in the acute period after TBI indicates earlier participation in rehabilitative therapies and a better functional recovery. By contrast, status epilepticus, other ictal activity, or absent sleep architecture may portend a worse prognosis. Whether sleep elements detected by EEG predict long-term prognosis remains to be determined.	[Sandsmark, Danielle K.; Kumar, Monisha A.] Univ Penn, Dept Neurol, 3400 Spruce St,3W Gates Bldg, Philadelphia, PA 19104 USA; [Woodward, Catherine S.] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA; [Woodward, Catherine S.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Schmitt, Sarah E.] Med Univ S Carolina, Dept Neurol, Charleston, SC USA; [Park, Soojin] Columbia Univ, Dept Neurol, New York, NY USA; [Lim, Miranda M.] Vet Affairs Portland Hlth Care Syst, Dept Med, Div Pulm & Crit Care Med, Portland, OR USA; [Lim, Miranda M.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Lim, Miranda M.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA; [Lim, Miranda M.] Oregon Inst Occupat Hlth Sci, Portland, OR USA	Sandsmark, DK (corresponding author), Univ Penn, Dept Neurol, 3400 Spruce St,3W Gates Bldg, Philadelphia, PA 19104 USA.	danielle.sandsmark@uphs.upenn.edu		Schmitt, Sarah/0000-0003-1384-9794	VA Career Development Award [IK2 BX002712]; Veterans AffairsUS Department of Veterans Affairs [IK2BX002712] Funding Source: NIH RePORTER	This material is the result of the work supported with resources and the use of facilities at the VA Portland Health Care System, the VA Career Development Award IK2 BX002712, the American Sleep Medicine Foundation, and the Portland VA Research Foundation (MML). The contents do not represent the views of the US Department of Veterans Affairs or the US Government.	Abel T, 2013, CURR BIOL, V23, pR774, DOI 10.1016/j.cub.2013.07.025; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Chan LG, 2015, J HEAD TRAUMA REHAB, V30, pE67, DOI 10.1097/HTR.0000000000000119; Cheliout-Heraut F, 2001, NEUROPHYSIOL CLIN, V31, P283, DOI 10.1016/S0987-7053(01)00270-2; Cologan V, 2013, J NEUROTRAUM, V30, P339, DOI 10.1089/neu.2012.2654; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Duclos C, 2015, AUST OCCUP THER J, V62, P2, DOI 10.1111/1440-1630.12164; EVANS BM, 1995, J NEUROL NEUROSUR PS, V59, P17, DOI 10.1136/jnnp.59.1.17; Gardani M, 2015, ARCH PHYS MED REHAB, V96, P1691, DOI 10.1016/j.apmr.2015.05.006; Gottselig JM, 2002, BRAIN, V125, P373, DOI 10.1093/brain/awf021; JENNETT B, 1976, LANCET, V1, P1031; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Koenig MA, 2013, SEMIN NEUROL, V33, P121, DOI 10.1055/s-0033-1348962; LABAR DR, 1991, ELECTROEN CLIN NEURO, V78, P325, DOI 10.1016/0013-4694(91)90094-K; Low D, 2009, J NEUROTRAUM, V26, P1177, DOI [10.1089/neu.2008.0841, 10.1089/neu.2008-0841]; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; Marshall LF, J NEUROSURG, V75, pS14; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Patel MB, 2015, J NEUROTRAUM, V32, P984, DOI 10.1089/neu.2014.3652; Schneider G, 2014, ANESTHESIOLOGY, V120, P819, DOI 10.1097/ALN.0000000000000151; Sherer M, 2008, ARCH PHYS MED REHAB, V89, P42, DOI 10.1016/j.apmr.2007.08.128; Stein Donald G, 2015, Handb Clin Neurol, V127, P433, DOI 10.1016/B978-0-444-52892-6.00028-3; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tung Avery, 2002, J Clin Monit Comput, V17, P37, DOI 10.1023/A:1015404803637; Urakami Y, 2012, CLIN EEG NEUROSCI, V43, P39, DOI 10.1177/1550059411428718; Wright DW, 2015, NEW ENGL J MED, V372, P1766, DOI 10.1056/NEJMc1503138; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	33	19	20	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2016	31	2			SI		101	107		10.1097/HTR.0000000000000217			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DH7NO	WOS:000372981100003	26959664	Green Accepted			2021-06-18	
J	Walls, MK; Race, N; Zheng, LX; Vega-Alvarez, SM; Acosta, G; Park, J; Shi, RY				Walls, Michael K.; Race, Nicholas; Zheng, Lingxing; Vega-Alvarez, Sasha M.; Acosta, Glen; Park, Jonghyuck; Shi, Riyi			Structural and biochemical abnormalities in the absence of acute deficits in mild primary blast-induced head trauma	JOURNAL OF NEUROSURGERY			English	Article						blast-induced neurotrauma; BBB disruption; oxidative stress; acrolein; 3-HPMA; traumatic brain injury; trauma	BLOOD-BRAIN-BARRIER; SPINAL-CORD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MEDIAL FOREBRAIN-BUNDLE; OXIDATIVE STRESS; ALPHA,BETA-UNSATURATED ALDEHYDES; ENDOTHELIAL DYSFUNCTION; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; VENTRAL PALLIDUM	OBJECTIVE Blast-induced neurotrauma (BINT), if not fatal, is nonetheless potentially crippling. It can produce a wide array of acute symptoms in moderate-to-severe exposures, but mild BINT (mBINT) is characterized by the distinct absence of acute clinical abnormalities. The lack of observable indications for mBINT is particularly alarming, as these injuries have been linked to severe long-term psychiatric and degenerative neurological dysfunction. Although the long-term sequelae of BINT are extensively documented, the underlying mechanisms of injury remain poorly understood, impeding the development of diagnostic and treatment strategies. The primary goal of this research was to recapitulate primary mBINT in rodents in order to facilitate well-controlled, long-term investigations of blast-induced pathological neurological sequelae and identify potential mechanisms by which ongoing damage may occur postinjury. METHODS A validated, open-ended shock tube model was used to deliver blast overpressure (150 kPa) to anesthetized rats with body shielding and head fixation, simulating the protective effects of military-grade body armor and isolating a shock wave injury from confounding systemic injury responses, head acceleration, and other elements of explosive events. Evans Blue labeled albumin was used to visualize blood-brain barrier (BBB) compromise at 4 hours postinjury. Iba1 staining was used to visualize activated microglia and infiltrating macrophages in areas of peak BBB compromise. Acrolein, a potent posttraumatic neurotoxin, was quantified in brain tissue by immunoblotting and in urine through liquid chromatography with tandem mass spectrometry at 1, 2, 3, and 5 days postinjury. Locomotor behavior, motor performance, and short-term memory were assessed with open field, rotarod, and novel object recognition (NOR) paradigms at 24 and 48 hours after the blast. RESULTS Average speed, maximum speed, and distance traveled in an open-field exploration paradigm did not show significant differences in performance between sham-injured and mBINT rats. Likewise, rats with mBINT did not exhibit deficits in maximum revolutions per minute or total run time in a rotarod paradigm. Short-term memory was also unaffected by mBINT in an NOR paradigm. Despite lacking observable motor or cognitive deficits in the acute term, blast injured rats displayed brain acrolein levels that were significantly elevated for at least 5 days, and acrolein's glutathione-reduced metabolite, 3-HPMA, was present in urine for 2 days after injury. Additionally, mBINT brain tissue demonstrated BBB damage 4 hours postinjury and colocalized neuroinflammatory changes 24 hours postinjury. CONCLUSIONS This model highlights mBINT's potential for underlying detrimental physical and biochemical alterations despite the lack of apparent acute symptoms and, by recapitulating the human condition, represents an avenue for further examining the pathophysiology of mBINT. The sustained upregulation of acrolein for days after injury suggests that acrolein may be an upstream player potentiating ongoing postinjury damage and neuroinflammation. Ultimately, continued research with this model may lead to diagnostic and treatment mechanisms capable of preventing or reducing the severity of long-term neurological dysfunction following mBINT.	[Walls, Michael K.; Zheng, Lingxing; Vega-Alvarez, Sasha M.; Acosta, Glen; Park, Jonghyuck; Shi, Riyi] Purdue Univ, Dept Basic Med Sci, Coll Vet Med, W Lafayette, IN 47907 USA; [Race, Nicholas; Zheng, Lingxing; Park, Jonghyuck; Shi, Riyi] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA	Shi, RY (corresponding author), Purdue Univ, Dept Basic Med Sci, Weldon Sch Biomed Engn, 404 S Univ St, W Lafayette, IN 47907 USA.	riyi@purdue.edu		Race, Nicholas/0000-0002-2683-1692	Indiana State Department of Health [204200]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS073636]; Indiana CTSI Collaboration in Biomedical Translational Research (CBR/CTR) Pilot Program Grant [RR025761]; NIH NCRR Shared InstrumentationUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1 S10 RR023734-01A1]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001108] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761, S10RR023734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073636] Funding Source: NIH RePORTER	This work was supported in part by the Indiana State Department of Health (Grant No. 204200 to R.S.), National Institutes of Health (Grant No. NS073636 to R.S.), and Indiana CTSI Collaboration in Biomedical Translational Research (CBR/CTR) Pilot Program Grant (Grant No. RR025761 to R.S.). Funding for the LSM710 was provided by NIH NCRR Shared Instrumentation (Grant No. 1 S10 RR023734-01A1).	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Andre E, 2008, J CLIN INVEST, V118, P2574, DOI 10.1172/JCI34886; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106; AUSTIN MC, 1990, J PHARMACOL EXP THER, V252, P1370; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Borchers Michael T, 2009, Res Rep Health Eff Inst, P5; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Centers for Disease Control, ACEP CLIN PRACT MAN; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chang JW, 1999, NEUROSCIENCE, V88, P617, DOI 10.1016/S0306-4522(98)00217-6; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Connell S., 2011, 2011 4th International Conference on Biomedical Engineering and Informatics, P969, DOI 10.1109/BMEI.2011.6098441; Davalos D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2230; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; Deumens R, 2002, EXP NEUROL, V175, P303, DOI 10.1006/exnr.2002.7891; Due MR, 2014, J NEUROCHEM, V128, P776, DOI 10.1111/jnc.12500; Eckert E, 2010, J CHROMATOGR B, V878, P2506, DOI 10.1016/j.jchromb.2009.09.003; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x; Facchinetti F, 2007, AM J RESP CELL MOL, V37, P617, DOI 10.1165/rcmb.2007-0130OC; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hamann K, 2008, J NEUROCHEM, V104, P708, DOI 10.1111/j.1471-4159.2007.05002.x; Hamann K, 2009, J NEUROCHEM, V111, P1348, DOI 10.1111/j.1471-4159.2009.06395.x; Hawkins BT, 2006, J NEUROSCI METH, V151, P262, DOI 10.1016/j.jneumeth.2005.08.006; Hui OY, 2008, J NEUROTRAUM, V25, P19, DOI 10.1089/neu.2007.0340; Ikemoto S, 2007, BRAIN RES REV, V56, P27, DOI 10.1016/j.brainresrev.2007.05.004; Jang AS, 2011, AM J RESP CELL MOL, V44, P483, DOI 10.1165/rcmb.2009-0391OC; Kirkham PA, 2003, FREE RADICAL BIO MED, V35, P697, DOI 10.1016/S0891-5849(03)00390-3; Koob AO, 2006, J NEUROSCI METH, V157, P330, DOI 10.1016/j.jneumeth.2006.04.020; Leung G, 2011, NEUROSCIENCE, V173, P150, DOI 10.1016/j.neuroscience.2010.11.018; Li YW, 2008, NAT PROTOC, V3, P1703, DOI 10.1038/nprot.2008.172; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lovell MA, 2001, NEUROBIOL AGING, V22, P187, DOI 10.1016/S0197-4580(00)00235-9; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; Maguen S, 2012, J REHABIL RES DEV, V49, P1115, DOI 10.1682/JRRD.2011.02.0015; Miller G, 2012, SCIENCE, V336, P790, DOI 10.1126/science.336.6083.790; Moretto N, 2009, AM J PHYSIOL-LUNG C, V296, pL839, DOI 10.1152/ajplung.90570.2008; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ouyang H, 2010, J NEUROTRAUM, V27, P1109, DOI 10.1089/neu.2010.1271; Park J, 2014, J NEUROCHEM, V129, P339, DOI 10.1111/jnc.12628; Park YS, 2008, ANN NY ACAD SCI, V1126, P185, DOI 10.1196/annals.1433.034; Pocernich CB, 2001, NEUROCHEM INT, V39, P141, DOI 10.1016/S0197-0186(01)00012-2; Ravikumar M, 2014, BIOMATERIALS, V35, P8049, DOI 10.1016/j.biomaterials.2014.05.084; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R., 2006, APPL NEUROL, V2, P22; Shi RY, 2011, MOL NUTR FOOD RES, V55, P1320, DOI 10.1002/mnfr.201100217; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Smith KS, 2009, BEHAV BRAIN RES, V196, P155, DOI 10.1016/j.bbr.2008.09.038; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; STEIN L, 1969, J COMP PHYSIOL PSYCH, V67, P189, DOI 10.1037/h0026767; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Tully M, 2013, INT J MOL SCI, V14, P20037, DOI 10.3390/ijms141020037; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; VandeVord PS, 2013, MEASURING INTRACRANI; Vilhardt F, 2005, INT J BIOCHEM CELL B, V37, P17, DOI 10.1016/j.biocel.2004.06.010; Wood PL, 2006, BRAIN RES, V1122, P184, DOI 10.1016/j.brainres.2006.09.003; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Zheng LX, 2013, J NEUROTRAUM, V30, P1334, DOI 10.1089/neu.2013.2888	80	19	19	0	15	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2016	124	3					675	686		10.3171/2015.1.JNS141571			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DE8VQ	WOS:000370915200012	26295915	Green Accepted			2021-06-18	
J	Guldenmund, P; Soddu, A; Baquero, K; Vanhaudenhuyse, A; Bruno, MA; Gosseries, O; Laureys, S; Gomez, F				Guldenmund, Pieter; Soddu, Andrea; Baquero, Katherine; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Gosseries, Olivia; Laureys, Steven; Gomez, Francisco			Structural brain injury in patients with disorders of consciousness: A voxel-based morphometry study	BRAIN INJURY			English	Article						Vegetative state/unresponsive wakefulness syndrome; voxel-based morphometry; structural brain injury; minimally conscious state	UNRESPONSIVE WAKEFULNESS SYNDROME; RESTING-STATE NETWORKS; DEFAULT MODE NETWORK; VEGETATIVE STATE; GRAY-MATTER; THALAMIC NUCLEI; CONNECTIVITY; MRI; NEUROPATHOLOGY; COMA	Main objective: Disorders of consciousness (DOC; encompassing coma, vegetative state/unresponsive wakefulness syndrome (VS/UWS) and minimally conscious state minus/plus (MCS-/+)) are associated with structural brain injury. The extent of this damage remains poorly understood and merits a detailed examination using novel analysis techniques. Research design/methods and procedures: This study used voxel-based morphometry (VBM) on structural magnetic resonance imaging scans of 61 patients with DOC to examine grey and white matter injury associated with DOC, time spent in DOC, aetiology and diagnosis. Main outcomes and results: DOC and time spent in DOC were found to be associated with widespread structural brain injury, although the latter did not correlate strongly with injury in the right cerebral hemisphere. Traumatic, as compared to non-traumatic aetiology, was related to more injury in the brainstem, midbrain, thalamus, hypothalamus, basal forebrain, cerebellum, and posterior corpus callosum. Potential structural differences were found between VS/UWS and MCS and between MCS- and MCS+, but need further examination. Conclusions: The findings indicate that both traumatic and non-traumatic DOC are associated with widespread structural brain injury, although differences exist that could lead to aetiology-specific treatment strategies. Furthermore, the high degree of atrophy occurring after initial brain injury prompts the development and use of neuroprotective techniques to potentially increase patients' chances of recovery.	[Guldenmund, Pieter; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Gosseries, Olivia; Laureys, Steven; Gomez, Francisco] Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, Liege, Belgium; [Guldenmund, Pieter; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Gosseries, Olivia; Laureys, Steven; Gomez, Francisco] Univ Liege, Univ Hosp Liege, Liege, Belgium; [Soddu, Andrea] Univ Western Ontario, Dept Phys & Astron, Brain & Mind Inst, London, ON, Canada; [Baquero, Katherine] Univ Nacl Colombia, Comp Imaging & Med Applicat Lab, Bogota, Colombia; [Baquero, Katherine] Univ Liege, Cyclotron Res Ctr, MoVeRe Grp, Liege, Belgium; [Vanhaudenhuyse, Audrey] Univ Liege, Univ Hosp Liege, Algol Palliat Care Dept, Liege, Belgium; [Gomez, Francisco] Cent Univ Colombia, Dept Comp Sci, Bogota, Colombia	Guldenmund, P; Laureys, S (corresponding author), Cyclotron Res Ctr, Coma Sci Grp, B30,Allee 6 Aout, B-4000 Liege, Belgium.	guldenmund@hotmail.com; steven.laureys@ulg.ac.be	Laureys, Steven/A-3349-2011; Gosseries, Olivia/AAB-6469-2020; Vanhaudenhuyse, Audrey/AAP-2455-2020; Soddu, Andrea/K-7087-2014; Laureys, Steven/AAN-2097-2021	Soddu, Andrea/0000-0001-6833-745X; Laureys, Steven/0000-0002-3096-3807; Gosseries, Olivia/0000-0001-9011-7496	Belgian National Funds for Scientific Research (Brussels, Belgium)Fonds de la Recherche Scientifique - FNRS; European Commission (Brussels, Belgium)European CommissionEuropean Commission Joint Research Centre; James McDonnell Foundation (Saint Louis, MO, USA); Mind Science Foundation (San Antonio, TX, USA); French Speaking Community Concerted Research Action (ARC, Brussels, Belgium) [06/11-340]; Fondation Medicale Reine Elisabeth (Brussels, Belgium); University of Liege (Liege, Belgium)University of Liege; University Hospital of Liege (Liege, Belgium)	This research was funded by the Belgian National Funds for Scientific Research (Brussels, Belgium), the European Commission (Brussels, Belgium), the James McDonnell Foundation (Saint Louis, MO, USA), the Mind Science Foundation (San Antonio, TX, USA), the French Speaking Community Concerted Research Action (ARC, 06/11-340, Brussels, Belgium), the Fondation Medicale Reine Elisabeth (Brussels, Belgium), the University of Liege (Liege, Belgium) and the University Hospital of Liege (Liege, Belgium). The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Braga B, 2012, RADIOL RES PRACT, V2012, DOI 10.1155/2012/481378; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Can DD, 2013, BRAIN LANG, V124, P34, DOI 10.1016/j.bandl.2012.10.007; Chu Nai-Shin, 1993, Journal of the Formosan Medical Association, V92, P697; Crone JS, 2014, NEUROIMAGE-CLIN, V4, P240, DOI 10.1016/j.nicl.2013.12.005; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Edlow BL, 2013, J NEUROPATH EXP NEUR, V72, P505, DOI 10.1097/NEN.0b013e3182945bf6; Ekmark-Lewen S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-44; Fernandez-Espejo D, 2012, ANN NEUROL, V72, P335, DOI 10.1002/ana.23635; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Fernandez-Espejo D, 2010, J NEUROTRAUM, V27, P1187, DOI 10.1089/neu.2010.1297; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giraud AL, 2004, CEREB CORTEX, V14, P247, DOI 10.1093/cercor/bhg124; Gitelman DR, 2001, NEUROIMAGE, V13, P623, DOI 10.1006/nimg.2000.0734; Goldfine AM, 2011, NEUROL CLIN, V29, P723, DOI 10.1016/j.ncl.2011.08.001; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Gosseries O, 2014, CURR PHARM DESIGN, V20, P4167; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; Guldenmund P, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/624724; Guldenmund P, 2012, ARCH ITAL BIOL, V150, P107, DOI 10.4449/aib.v150i2.1373; Guldenmund P, 2013, BRAIN CONNECT, V3, P273, DOI 10.1089/brain.2012.0117; Hattingen E, 2010, CLIN NEURORADIOL, V20, P81, DOI 10.1007/s00062-010-0009-6; Heine L, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00295; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Henley SMD, 2010, AM J NEURORADIOL, V31, P711, DOI 10.3174/ajnr.A1939; Hertz L, 2008, NEUROPHARMACOLOGY, V55, P289, DOI 10.1016/j.neuropharm.2008.05.023; Ho AK, 2004, NEUROREPORT, V15, P1061, DOI 10.1097/00001756-200404290-00026; Jellinger KA, 2013, BRAIN INJURY, V27, P917, DOI 10.3109/02699052.2013.793395; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Juengling FD, J NEUROLOGICAL SCI, V228, P179; Karas GB, 2004, NEUROIMAGE, V23, P708, DOI 10.1016/j.neuroimage.2004.07.006; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lieberman MD, 2009, SOC COGN AFFECT NEUR, V4, P423, DOI 10.1093/scan/nsp052; Lingor P, 2012, CELL TISSUE RES, V349, P289, DOI 10.1007/s00441-012-1362-3; Lull N, 2010, NEUROLOGIA, V25, P174; Lull N, 2010, BRAIN INJURY, V24, P1098, DOI 10.3109/02699052.2010.494592; Lutkenhoff ES, 2013, NEUROIMAGE-CLIN, V3, P396, DOI 10.1016/j.nicl.2013.09.010; Manjon JV, 2010, J MAGN RESON IMAGING, V31, P192, DOI 10.1002/jmri.22003; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Mikl M, 2008, MAGN RESON IMAGING, V26, P490, DOI 10.1016/j.mri.2007.08.006; Monti MM, 2012, ANNU REV CLIN PSYCHO, V8, P431, DOI 10.1146/annurev-clinpsy-032511-143050; Moreau OK, 2012, J NEUROTRAUM, V29, P81, DOI 10.1089/neu.2011.2048; Mura E, 2014, CURR PHARM DESIGN, V20, P4121; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Nugent AC, 2006, NEUROIMAGE, V30, P485, DOI 10.1016/j.neuroimage.2005.09.029; Peelle JE, 2012, NEUROIMAGE, V60, P1503, DOI 10.1016/j.neuroimage.2011.12.086; Phillips CL, 2011, NEUROIMAGE, V56, P797, DOI 10.1016/j.neuroimage.2010.05.083; Rajapakse JC, 1997, IEEE T MED IMAGING, V16, P176, DOI 10.1109/42.563663; Ripolles P, 2012, NEUROIMAGE, V60, P1296, DOI 10.1016/j.neuroimage.2012.01.094; Rosenblum WI, 2015, J NEUROPATH EXP NEUR, V74, P198, DOI 10.1097/NEN.0000000000000170; Rousseau MC, 2008, BRAIN INJURY, V22, P123, DOI 10.1080/02699050801895415; Rovegno M, 2012, MED INTENSIVA, V36, P37, DOI 10.1016/j.medin.2011.06.008; Saleh A, 2004, BRAIN, V127, P1670, DOI 10.1093/brain/awh191; Salmond CH, 2002, NEUROIMAGE, V17, P1027, DOI 10.1006/nimg.2002.1153; Sato H, 2012, AM J FOREN MED PATH, V33, P341, DOI 10.1097/PAF.0b013e318273b823; Scott SK, 2012, J COMMUN DISORD, V45, P419, DOI 10.1016/j.jcomdis.2012.06.007; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Soddu A, 2012, HUM BRAIN MAPP, V33, P778, DOI 10.1002/hbm.21249; Soderfeldt B, 1997, NEUROLOGY, V49, P82, DOI 10.1212/WNL.49.1.82; Takahashi R, 2010, AM J NEURORADIOL, V31, P1873, DOI 10.3174/ajnr.A2200; Toyama Yoshihiro, 2005, Radiat Med, V23, P309; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Vorobyev VA, 2004, COGNITIVE BRAIN RES, V20, P309, DOI 10.1016/j.cogbrainres.2004.03.011; Weibull A, 2008, NEUROIMAGE, V41, P346, DOI 10.1016/j.neuroimage.2008.02.015; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4; Willie JT, 2012, J NEUROTRAUM, V29, P1908, DOI 10.1089/neu.2012.2404	86	19	20	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB 23	2016	30	3					343	352		10.3109/02699052.2015.1118765			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DG9QM	WOS:000372418900012	26890670	Green Published			2021-06-18	
J	Chauvette, S; Soltani, S; Seigneur, J; Timofeev, I				Chauvette, Sylvain; Soltani, Sara; Seigneur, Josee; Timofeev, Igor			In vivo models of cortical acquired epilepsy	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Epilepsy; Epileptogenesis; Seizure; Trauma; Kindling; Undercut	TRAUMATIC BRAIN-INJURY; EXTRACELLULAR POTASSIUM ACTIVITY; SPIKE-WAVE COMPLEXES; PAROXYSMAL FAST RUNS; V PYRAMIDAL NEURONS; POSTTRAUMATIC EPILEPSY; NEOCORTICAL NEURONS; SEIZURE ACTIVITY; GAP-JUNCTIONS; ELECTRICAL-STIMULATION	The neocortex is the site of origin of several forms of acquired epilepsy. Here we provide a brief review of experimental models that were recently developed to study neocortical epileptogenesis as well as some major results obtained with these methods. Most of neocortical seizures appear to be nocturnal and it is known that neuronal activities reveal high levels of synchrony during slow-wave sleep. Therefore, we start the review with a description of mechanisms of neuronal synchronization and major forms of synchronized normal and pathological activities. Then, we describe three experimental models of seizures and epileptogenesis: ketamine-xylazine anesthesia as feline seizure triggered factor, cortical undercut as cortical penetrating wound model and neocortical kindling. Besides specific technical details describing these models we also provide major features of pathological brain activities recorded during epileptogenesis and seizures. The most common feature of all models of neocortical epileptogenesis is the increased duration of network silent states that up-regulates neuronal excitability and eventually leads to epilepsy. (C) 2015 Elsevier B.V. All rights reserved.	[Chauvette, Sylvain; Soltani, Sara; Seigneur, Josee; Timofeev, Igor] CRIUSMQ, Local F-6500,2601 Canardiere, Quebec City, PQ G1J2G3, Canada; [Soltani, Sara; Timofeev, Igor] Univ Laval, Dept Psychiat & Neurosci, Quebec City, PQ, Canada	Timofeev, I (corresponding author), CRIUSMQ, Local F-6500,2601 Canardiere, Quebec City, PQ G1J2G3, Canada.	igor.timofeev@fmed.ulaval.ca	Timofeev, Igor/E-8828-2012; Timofeev, Igor/AAP-7529-2021	Timofeev, Igor/0000-0002-1389-5857	CIHRCanadian Institutes of Health Research (CIHR) [MOP-325213, MOP-324941, MOP-37862, MOP-67175]; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01-NS060870, 1R01-NS059740]; NSERCNatural Sciences and Engineering Research Council of Canada (NSERC) [298475]; FRQ-S, FRQ-NT; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060870, R01NS059740] Funding Source: NIH RePORTER	In recent years, our work was supported by CIHR (MOP-325213, MOP-324941, MOP-37862 and MOP-67175), NIH-NINDS (1R01-NS060870 and 1R01-NS059740), NSERC (Grant 298475), and FRQ-S, FRQ-NT. We are thankful to Sergiu Ftomov for his excellent technical assistance.	Adami C, 2013, SCHWEIZ ARCH TIERH, V155, P569, DOI 10.1024/0036-7281/a000513; AGMON A, 1989, NEUROSCI LETT, V99, P137, DOI 10.1016/0304-3940(89)90278-4; AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; Amzica F, 2002, J NEUROSCI, V22, P1042, DOI 10.1523/JNEUROSCI.22-03-01042.2002; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Avramescu S, 2008, CELLULAR HOMEOSTATIC, P253; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Avramescu S, 2009, J NEUROTRAUM, V26, P799, DOI 10.1089/neu.2008.0739; BABA H, 1982, EPILEPSIA, V23, P663, DOI 10.1111/j.1528-1157.1982.tb05082.x; BARKAI E, 1994, J NEUROPHYSIOL, V72, P72; Bazhenov M, 2004, J NEUROPHYSIOL, V92, P1116, DOI 10.1152/jn.00529.2003; Beltramo R, 2013, NAT NEUROSCI, V16, P227, DOI 10.1038/nn.3306; Blake H, 1937, AM J PHYSIOL, V119, P692; Boucetta S, 2008, EPILEPSIA, V49, P1925, DOI 10.1111/j.1528-1167.2008.01707.x; Boucetta S, 2013, EXP NEUROL, V245, P5, DOI 10.1016/j.expneurol.2012.12.001; Carlen PL, 2000, BRAIN RES REV, V32, P235, DOI 10.1016/S0165-0173(99)00084-3; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chauvette S., 2007, MECH SPONTANEOUS ACT, P73; Chauvette S, 2012, NEURON, V75, P1105, DOI 10.1016/j.neuron.2012.08.034; Chauvette S, 2011, J NEUROSCI, V31, P14998, DOI 10.1523/JNEUROSCI.2339-11.2011; Chauvette S, 2010, CEREB CORTEX, V20, P2660, DOI 10.1093/cercor/bhq009; Chen JY, 2012, J PHYSIOL-LONDON, V590, P3987, DOI 10.1113/jphysiol.2012.227462; Christe KL, 2013, COMPARATIVE MED, V63, P445; Christensen J, 2012, EPILEPSIA, V53, P43, DOI 10.1111/j.1528-1167.2012.03612.x; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; CONTRERAS D, 1995, J NEUROSCI, V15, P604; Crochet S, 2005, EUR J NEUROSCI, V21, P1030, DOI 10.1111/j.1460-9568.2005.03932.x; Crunelli V, 2010, NAT NEUROSCI, V13, P10, DOI 10.1038/nn.2445; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; David F, 2013, J NEUROSCI, V33, P19599, DOI 10.1523/JNEUROSCI.3169-13.2013; DEFELIPE J, 1985, J COMP NEUROL, V231, P364, DOI 10.1002/cne.902310307; DeFelipe J, 1999, BRAIN, V122, P1807, DOI 10.1093/brain/122.10.1807; Derchansky M, 2006, NEUROBIOL DIS, V23, P312, DOI 10.1016/j.nbd.2006.03.014; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; Desai NS, 1999, NAT NEUROSCI, V2, P515; DICHTER MA, 1987, SCIENCE, V237, P157, DOI 10.1126/science.3037700; Dinner Dudley S., 1993, P654; Eccles J.C., 1964, PHYSL SYNAPSES; Eftekhar B, 2009, J NEUROSURG, V110, P319, DOI 10.3171/2008.4.17519; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; FREUND TF, 1983, J COMP NEUROL, V221, P263, DOI 10.1002/cne.902210303; Frohlich F, 2010, NEURON, V67, P129, DOI 10.1016/j.neuron.2010.06.005; Frohlich F, 2006, J NEUROSCI, V26, P6153, DOI 10.1523/JNEUROSCI.5509-05.2006; Frohlich Flavio, 2005, Thalamus & Related Systems, V3, P147, DOI 10.1017/S1472928807000155; FUKUSHIMA J, 1987, EPILEPSIA, V28, P651, DOI 10.1111/j.1528-1157.1987.tb03696.x; Galarreta M, 1998, NAT NEUROSCI, V1, P587, DOI 10.1038/2822; Galarreta M, 1999, NATURE, V402, P72; Galarreta M, 2001, NAT REV NEUROSCI, V2, P425, DOI 10.1038/35077566; Gibson JR, 1999, NATURE, V402, P75; GODDARD GV, 1967, NATURE, V214, P1020, DOI 10.1038/2141020a0; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; Gorji A, 2001, EPILEPSIA, V42, P1228, DOI 10.1046/j.1528-1157.2001.01301.x; Grand L, 2013, J NEUROSCI METH, V212, P237, DOI 10.1016/j.jneumeth.2012.10.008; Gray CM, 1996, SCIENCE, V274, P109, DOI 10.1126/science.274.5284.109; Grenier F, 2003, J NEUROPHYSIOL, V89, P841, DOI 10.1152/jn.00420.2002; Grenier FO, 2001, J NEUROPHYSIOL, V86, P1884; Haider B, 2006, J NEUROSCI, V26, P4535, DOI 10.1523/JNEUROSCI.5297-05.2006; Haider B, 2013, NATURE, V493, P97, DOI 10.1038/nature11665; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HEDLER L, 1981, EUR J PHARMACOL, V70, P43, DOI 10.1016/0014-2999(81)90430-1; HEINEMANN U, 1977, EXP BRAIN RES, V27, P237; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Hughes S, 2013, NAT NEUROSCI, V16, P115, DOI 10.1038/nn.3313; Hughes SW, 2002, NEURON, V33, P947, DOI 10.1016/S0896-6273(02)00623-2; JEFFERYS JGR, 1995, PHYSIOL REV, V75, P689; Jin XM, 2011, CEREB CORTEX, V21, P1094, DOI 10.1093/cercor/bhq181; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; JOY RM, 1983, PHARMACOL BIOCHEM BE, V19, P345, DOI 10.1016/0091-3057(83)90063-1; Kandratavicius L, 2014, NEUROPSYCH DIS TREAT, V10, P1693, DOI 10.2147/NDT.S50371; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; Kazemi H, 2012, INJURY, V43, P2132, DOI 10.1016/j.injury.2012.06.007; Kilman V, 2002, J NEUROSCI, V22, P1328, DOI 10.1523/JNEUROSCI.22-04-01328.2002; Kollevold T, 1976, J OSLO CITY HOSP, V26, P99; Kusmierczak M, 2015, NEUROSCIENCE, V284, P153, DOI 10.1016/j.neuroscience.2014.09.079; Lemieux M, 2014, J NEUROSCI, V34, P5689, DOI 10.1523/JNEUROSCI.1156-13.2014; LEVITON A, 1981, EPIDEMIOL REV, V3, P67, DOI 10.1093/oxfordjournals.epirev.a036240; MACDONALD JF, 1991, J PHYSIOL-LONDON, V432, P483, DOI 10.1113/jphysiol.1991.sp018396; MAJKOWSKI J, 1981, EPILEPSIA, V22, P275, DOI 10.1111/j.1528-1157.1981.tb04110.x; Markram H, 1997, J PHYSIOL-LONDON, V500, P409, DOI 10.1113/jphysiol.1997.sp022031; Massimini M, 2001, J NEUROPHYSIOL, V85, P1346; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; McCormick DA, 2001, ANNU REV PHYSIOL, V63, P815, DOI 10.1146/annurev.physiol.63.1.815; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; Meeren HKM, 2002, J NEUROSCI, V22, P1480, DOI 10.1523/JNEUROSCI.22-04-01480.2002; Midzyanovskaya IS, 2004, PHARMACOL BIOCHEM BE, V79, P83, DOI 10.1016/j.pbb.2004.06.007; MOODY WJ, 1974, EXP NEUROL, V42, P248, DOI 10.1016/0014-4886(74)90023-5; Mugnaini E, 1986, CELL JUCTIONS ASTROC; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; Nelson SB, 1998, NAT NEUROSCI, V1, P539, DOI 10.1038/2775; NICHOLAS AP, 1993, J COMP NEUROL, V328, P575, DOI 10.1002/cne.903280409; Nita D, 2007, MECH SPONTANEOUS ACT, P135; Nita DA, 2006, J NEUROPHYSIOL, V95, P902, DOI 10.1152/jn.00742.2005; Nita DA, 2008, EPILEPSIA, V49, P705, DOI 10.1111/j.1528-1167.2007.01431.x; Nita DA, 2008, EXP NEUROL, V211, P518, DOI 10.1016/j.expneurol.2008.02.028; Nita DA, 2008, EXP NEUROL, V211, P456, DOI 10.1016/j.expneurol.2008.02.010; Nita DA, 2007, CEREB CORTEX, V17, P272, DOI 10.1093/cercor/bhj145; Okamoto M, 1982, Seishin Shinkeigaku Zasshi, V84, P48; ONO K, 1981, INT J NEUROSCI, V12, P53, DOI 10.3109/00207458108990672; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; PRINCE DA, 1973, BRAIN RES, V50, P489, DOI 10.1016/0006-8993(73)90758-0; Pumain R, 1981, Adv Biochem Psychopharmacol, V29, P53; PUMAIN R, 1983, SCIENCE, V222, P177, DOI 10.1126/science.6623068; Racine R, 1975, Can J Neurol Sci, V2, P395; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P269, DOI 10.1016/0013-4694(72)90176-9; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; Rudolph M, 2007, J NEUROSCI, V27, P5280, DOI 10.1523/JNEUROSCI.4652-06.2007; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Sanchez-Vives M.V., 2007, MECH SPONTANEOUS ACT, P23; Sanchez-Vives MV, 2008, CEREB CORTEX, V18, P1179, DOI 10.1093/cercor/bhm152; Sanchez-Vives MV, 2000, NAT NEUROSCI, V3, P1027; Sayin U, 2003, J NEUROSCI, V23, P2759; Seigneur J, 2011, EPILEPSIA, V52, P132, DOI 10.1111/j.1528-1167.2010.02784.x; Sharma AV, 2010, J NEUROPHYSIOL, V104, P932, DOI 10.1152/jn.01065.2009; Sheroziya M, 2014, J NEUROSCI, V34, P8875, DOI 10.1523/JNEUROSCI.4460-13.2014; Shu YS, 2003, NATURE, V423, P288, DOI 10.1038/nature01616; Sinner B., 2008, V182, P313, DOI 10.1007/978-3-540-74806-9_15; Somjen GG, 2002, NEUROSCIENTIST, V8, P254, DOI 10.1177/1073858402008003011; Steriade M, 1998, J NEUROPHYSIOL, V79, P483; Steriade M, 1998, J NEUROPHYSIOL, V80, P1456; STERIADE M, 1994, J NEUROPHYSIOL, V72, P2051; STERIADE M, 1993, J NEUROSCI, V13, P3266; STERIADE M, 1995, J NEUROSCI, V15, P623; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; Steriade M., 2003, NEURONAL SUBSTRATES; Synowiec AS, 2013, EPILEPSY RES, V105, P183, DOI 10.1016/j.eplepsyres.2013.01.007; Szentagothai J, 1974, Neurosci Res Program Bull, V12, P305; TASKER JG, 1991, NEUROCHEM RES, V16, P251, DOI 10.1007/BF00966088; Temkin N R, 1995, New Horiz, V3, P518; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Teskey GC, 2002, CEREB CORTEX, V12, P98, DOI 10.1093/cercor/12.1.98; Teskey GC, 1999, CEREB CORTEX, V9, P675, DOI 10.1093/cercor/9.7.675; Thimm J, 2005, J BIOL CHEM, V280, P10646, DOI 10.1074/jbc.M412749200; Timofeev I, 2000, CEREB CORTEX, V10, P1185, DOI 10.1093/cercor/10.12.1185; Timofeev I, 1996, J NEUROPHYSIOL, V76, P4152; Timofeev I, 2004, J NEUROPHYSIOL, V92, P1133, DOI 10.1152/jn.00523.2003; Timofeev I, 2004, NEUROSCIENCE, V123, P299, DOI 10.1016/j.neuroscience.2003.08.051; Timofeev I, 2002, NEUROSCIENCE, V114, P1115, DOI 10.1016/S0306-4522(02)00300-7; Timofeev I, 1998, J NEUROPHYSIOL, V80, P1495; Timofeev I, 2001, P NATL ACAD SCI USA, V98, P1924, DOI 10.1073/pnas.041430398; Timofeev I., 2012, JASPERS BASIC MECH E; Timofeev I, 2014, INT REV NEUROBIOL, V114, P9, DOI 10.1016/B978-0-12-418693-4.00002-9; Timofeev I, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00154; Timofeev I, 2011, INHIBITORY SYNAPTIC PLASTICITY, P107, DOI 10.1007/978-1-4419-6978-1_8; Timofeev I, 2010, ATLAS OF EPILEPSIES, VOL 1-3, P203, DOI 10.1007/978-1-84882-128-6_27; Timofeev I, 2010, NEUROSCIENTIST, V16, P19, DOI 10.1177/1073858409333545; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Traub RD, 1996, EPILEPSIA, V37, P879, DOI 10.1111/j.1528-1157.1996.tb00042.x; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Valentine PA, 2004, CEREB CORTEX, V14, P827, DOI 10.1093/cercor/bhh041; Velazquez JLP, 2000, TRENDS NEUROSCI, V23, P68; Volgushev M, 2006, J NEUROSCI, V26, P5665, DOI 10.1523/JNEUROSCI.0279-06.2006; Volman V, 2011, J NEUROPHYSIOL, V106, P1933, DOI 10.1152/jn.00458.2011; WADA Y, 1989, JPN J PSYCHIAT NEUR, V43, P245; Watt AJ, 2000, NEURON, V26, P659, DOI 10.1016/S0896-6273(00)81202-7; Wester JC, 2012, J NEUROSCI, V32, P5454, DOI 10.1523/JNEUROSCI.5006-11.2012; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xiong WH, 2011, JOVE-J VIS EXP, DOI 10.3791/2840	172	19	19	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	FEB 15	2016	260				SI		185	201		10.1016/j.jneumeth.2015.08.030			17	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DE7QN	WOS:000370831900019	26343530	Green Accepted			2021-06-18	
J	Chung, MG; O'Brien, NF				Chung, Melissa G.; O'Brien, Nicole F.			Prevalence of Early Posttraumatic Seizures in Children With Moderate to Severe Traumatic Brain Injury Despite Levetiracetam Prophylaxis	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						antiepileptics; children; head injury; levetiracetam seizures; traumatic brain injury	ABUSIVE HEAD TRAUMA; CLINICAL PREDICTORS; UNITED-STATES; PHENYTOIN; TRIAL; PREVENTION	Objectives: To evaluate the prevalence of early seizures after levetiracetam prophylaxis in children with moderate to severe traumatic brain injury. Design: Prospective observational study. Setting: Level 1 pediatric trauma center. Patients: We enrolled 34 patients between the ages of 0-18 years with moderate to severe traumatic brain injury admitted to the PICU at a level 1 trauma center who received levetiracetam for early posttraumatic seizure prophylaxis. Measurements and Main Results: Primary outcome was the prevalence of early posttraumatic seizures that were defined as clinical seizures within 7 days of injury. In 6 of 34 patients (17%), clinical seizures developed despite levetiracetam prophylaxis. An additional two patients had nonconvulsive seizures. This prevalence is similar to that reported in the literature in this patient population who do not receive seizure prophylaxis (20-53%) and is higher than that in patients who receive phenytoin prophylaxis (2-15%). Patients with early posttraumatic seizures were younger (median age, 4 mo) (p < 0.001) and more likely to have suffered from abusive head trauma (p < 0.0004). Conclusions: Early clinical posttraumatic seizures occurred frequently in children with moderate to severe traumatic brain injury despite seizure prophylaxis with levetiracetam. Younger children and those with abusive head trauma were at increased risk of seizures. Further studies are needed to evaluate the efficacy of levetiracetam before it is routinely used for seizure prophylaxis in these children, particularly in young children and those who have suffered from abusive head trauma.	[Chung, Melissa G.; O'Brien, Nicole F.] Ohio State Univ, Dept Pediat, Nationwide Childrens Hosp, Div Crit Care Med, Columbus, OH 43210 USA; [Chung, Melissa G.] Ohio State Univ, Dept Pediat, Nationwide Childrens Hosp, Neurol Sect, Columbus, OH 43210 USA	Chung, MG (corresponding author), Neurol Sect, 700 Childrens Dr, Columbus, OH 43205 USA.						Arango JI, 2012, CHILD NERV SYST, V28, P1925, DOI 10.1007/s00381-012-1863-0; Arndt DH, 2013, EPILEPSIA, V54, P1780, DOI 10.1111/epi.12369; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Caballero G Christina, 2013, Hosp Pharm, V48, P757, DOI 10.1310/hpj4809-757; Centers for Disease Control and Prevention, 2010, WEB BAS INJ STAT QUE; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Cotton BA, 2011, J TRAUMA, V71, P375, DOI 10.1097/TA.0b013e318224d307; Goldstein JL, 2011, NEUROCRIT CARE, V15, P63, DOI 10.1007/s12028-010-9468-5; Greiner MV, 2012, CHILD NERV SYST, V28, P889, DOI 10.1007/s00381-012-1714-z; Hasbani DM, 2013, PEDIATR CRIT CARE ME, V14, P709, DOI 10.1097/PCC.0b013e3182917b83; Inaba K, 2013, J TRAUMA ACUTE CARE, V74, P766, DOI 10.1097/TA.0b013e3182826e84; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Knoblich O E, 1980, Neurosurg Rev, V3, P243, DOI 10.1007/BF01650029; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kruer RM, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.11.020; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Pearl PL, 2013, EPILEPSIA, V54, pe135, DOI 10.1111/epi.12326; POSNER JB, 1969, ARCH NEUROL-CHICAGO, V20, P388, DOI 10.1001/archneur.1969.00480100064010; Rhine T, 2012, J TRAUMA ACUTE CARE, V73, pS248, DOI 10.1097/TA.0b013e31826b0062; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Thapa A, 2010, SEIZURE-EUR J EPILEP, V19, P211, DOI 10.1016/j.seizure.2010.02.004; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016; Zafar SN, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-30	32	19	20	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	FEB	2016	17	2					150	156		10.1097/PCC.0000000000000588			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	DD1HW	WOS:000369672900007	26669640				2021-06-18	
J	Kailainathan, S; Piers, TM; Yi, JH; Choi, S; Fahey, MS; Borger, E; Gunn-Moore, FJ; O'Neill, L; Lever, M; Whitcomb, DJ; Cho, K; Allen, SJ				Kailainathan, Sumangali; Piers, Thomas M.; Yi, Jee Hyun; Choi, Seongmin; Fahey, Mark S.; Borger, Eva; Gunn-Moore, Frank J.; O'Neill, Laurie; Lever, Michael; Whitcomb, Daniel J.; Cho, Kwangwook; Allen, Shelley J.			Activation of a synapse weakening pathway by human Val66 but not Met66 pro-brain-derived neurotrophic factor (proBDNF)	PHARMACOLOGICAL RESEARCH			English	Article						Pro-brain-derived neurotrophic factor (proBDNF); Val66Met polymorphism; Long-term depression (LTD); Binding kinetics; Neurotrophin receptors; Chemical compounds studied in this article	ACTIVITY-DEPENDENT SECRETION; BASAL FOREBRAIN NEURONS; LONG-TERM DEPRESSION; ALZHEIMERS-DISEASE; SIGNALING PATHWAY; PRECURSOR BDNF; CELL-SURVIVAL; HUMAN-MEMORY; RECEPTOR; POLYMORPHISM	This study describes a fundamental functional difference between the two main polymorphisms of the pro-form of brain-derived neurotrophic factor (proBDNF), providing an explanation as to why these forms have such different age-related neurological outcomes. Healthy young carriers of the Met66 form (present in similar to 30% Caucasians) have reduced hippocampal volume and impaired hippocampal-dependent memory function, yet the same polymorphic population shows enhanced cognitive recovery after traumatic brain injury, delayed cognitive dysfunction during aging, and lower risk of late-onset Alzheimer's disease (AD) compared to those with the more common Val66 polymorphism. To examine the differences between the protein polymorphisms in structure, kinetics of binding to proBDNF receptors and in vitro function, we generated purified cleavage-resistant human variants. Intriguingly, we found no statistical differences in those characteristics. As anticipated, exogenous application of proBDNF Val66 to rat hippocampal slices dysregulated synaptic plasticity, inhibiting long-term potentiation (LTP) and facilitating long-term depression (LTD). We subsequently observed that this occurred via the glycogen synthase kinase 313 (GSK3 beta) activation pathway. However, surprisingly, we found that Met66 had no such effects on either LTP or LTD. These novel findings suggest that, unlike Val66, the Met66 variant does not facilitate synapse weakening signaling, perhaps accounting for its protective effects with aging. (C) 2015 The Authors. Published by Elsevier Ltd.	[Kailainathan, Sumangali; Piers, Thomas M.; Yi, Jee Hyun; Choi, Seongmin; Fahey, Mark S.; O'Neill, Laurie; Lever, Michael; Whitcomb, Daniel J.; Cho, Kwangwook; Allen, Shelley J.] Univ Bristol, Fac Hlth Sci, Sch Clin Sci, Henry Wellcome Labs Integrat Neurosci & Endocrino, Whitson St, Bristol BS1 3NY, Avon, England; [Piers, Thomas M.; Yi, Jee Hyun; Choi, Seongmin; O'Neill, Laurie; Lever, Michael; Whitcomb, Daniel J.; Cho, Kwangwook] Univ Bristol, Ctr Synapt Plast, Whitson St, Bristol BS1 3NY, Avon, England; [Piers, Thomas M.; Choi, Seongmin; Whitcomb, Daniel J.; Cho, Kwangwook] Chonnam Natl Univ Hosp, Biomed Res Inst, Chonnam Bristol Frontier Lab, Gwangju 501757, South Korea; [Borger, Eva; Gunn-Moore, Frank J.] Univ St Andrews, Med & Biol Sci Bldg, St Andrews KY16 9TF, Fife, Scotland; [Kailainathan, Sumangali; Allen, Shelley J.] Southmead Gen Hosp, Fac Hlth Sci, Sch Clin Sci, Learning & Res, Bristol BS10 5NB, Avon, England	Cho, K; Allen, SJ (corresponding author), Univ Bristol, Fac Hlth Sci, Sch Clin Sci, Henry Wellcome Labs Integrat Neurosci & Endocrino, Whitson St, Bristol BS1 3NY, Avon, England.; Cho, K (corresponding author), Univ Bristol, Ctr Synapt Plast, Whitson St, Bristol BS1 3NY, Avon, England.; Cho, K (corresponding author), Chonnam Natl Univ Hosp, Biomed Res Inst, Chonnam Bristol Frontier Lab, Gwangju 501757, South Korea.; Allen, SJ (corresponding author), Southmead Gen Hosp, Fac Hlth Sci, Sch Clin Sci, Learning & Res, Bristol BS10 5NB, Avon, England.	Kei.Cho@bristol.ac.uk; shelley.allen@bristol.ac.uk	Borger, Eva/H-5999-2013	Borger, Eva/0000-0003-4965-2969; Gunn-Moore, Francis James/0000-0003-3422-3387; Cho, Kwangwook/0000-0001-6724-7073; Allen, Shelley/0000-0001-7870-740X; Whitcomb, Daniel/0000-0003-2703-1643	Bristol Research into Alzheimer's and Care of the Elderly (BRACE); Sigmund Gestetner Trust Fund (University of Bristol); Alzheimer's Society; Alumni of the University of Bristol; UK Wellcome Trust-MRC Neurodegenerative Disease Initiative Programme [089703]; Korea-UK Alzheimer's Research Consortium Programme under the Korean Ministry of Health and Welfare; Bristol-Chonnam Frontier Programme under the Chonnam National University Hospital; Wolfson Research Merit AwardRoyal Society of London; Royal Society, LondonRoyal Society of London; MRC projectUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_G1000734]; Alzheimers Research UKAlzheimer&apos;s Research UK (ARUK) [ART-PG2002-3] Funding Source: researchfish; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/N001893/1] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_G1000734] Funding Source: researchfish; Alzheimer&quot;s Society [106] Funding Source: researchfish	This work has been supported by Bristol Research into Alzheimer's and Care of the Elderly (BRACE), the Sigmund Gestetner Trust Fund (University of Bristol), the Alzheimer's Society and the Alumni of the University of Bristol. K.C. and D.J.W. were supported by UK Wellcome Trust-MRC Neurodegenerative Disease Initiative Programme 089703, MRC project code MC_G1000734. J.H.Y. was supported by the Korea-UK Alzheimer's Research Consortium Programme under the Korean Ministry of Health and Welfare. T.M.P. and S.C. were supported by Bristol-Chonnam Frontier Programme under the Chonnam National University Hospital. K.C. was supported by the Wolfson Research Merit Award and Royal Society, London.	Allen SJ, 1999, BIOCHEM BIOPH RES CO, V264, P648, DOI 10.1006/bbrc.1999.1561; Anastasia A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3490; Barbey AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088733; Bath KG, 2012, NEUROPSYCHOPHARMACOL, V37, P1297, DOI 10.1038/npp.2011.318; Busceti CL, 2015, PHARMACOL RES, V99, P258, DOI 10.1016/j.phrs.2015.06.017; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Chen ZY, 2005, J NEUROSCI, V25, P6156, DOI 10.1523/JNEUROSCI.1017-05.2005; Clewes O, 2008, J NEUROCHEM, V107, P1124, DOI 10.1111/j.1471-4159.2008.05698.x; Doherty GH, 2013, NEUROBIOL AGING, V34, P226, DOI 10.1016/j.neurobiolaging.2012.08.003; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Erickson KI, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.011.2008; Fan YJ, 2008, EUR J NEUROSCI, V27, P2380, DOI 10.1111/j.1460-9568.2008.06215.x; Fayard B, 2005, J NEUROSCI RES, V80, P18, DOI 10.1002/jnr.20432; Gajewski PD, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2011.06.010; Ginsberg SD, 2006, J NEUROCHEM, V97, P475, DOI 10.1111/j.1471-4159.2006.03764.x; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; Glerup S, 2014, NEURON, V82, P1074, DOI 10.1016/j.neuron.2014.04.022; Golpich M, 2015, PHARMACOL RES, V97, P16, DOI 10.1016/j.phrs.2015.03.010; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471-4159.2007.05194.x; Hwang JJ, 2005, J BIOL CHEM, V280, P11995, DOI 10.1074/jbc.M403172200; Iqbal K, 2010, CURR ALZHEIMER RES, V7, P656, DOI 10.2174/156720510793611592; Jo J, 2011, NAT NEUROSCI, V14, P545, DOI 10.1038/nn.2785; Kimura T, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0144; Koshimizu H, 2010, NEUROSCI LETT, V473, P229, DOI 10.1016/j.neulet.2010.02.055; Koshimizu H, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-27; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Li X, 1999, GENOME INFORMATICS, V10, P30; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; Massey PV, 2007, TRENDS NEUROSCI, V30, P176, DOI 10.1016/j.tins.2007.02.005; Naylor RL, 2002, BIOCHEM BIOPH RES CO, V291, P501, DOI 10.1006/bbrc.2002.6468; Ninan I, 2010, J NEUROSCI, V30, P8866, DOI 10.1523/JNEUROSCI.1405-10.2010; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Pang PT, 2004, AGEING RES REV, V3, P407, DOI 10.1016/j.arr.2004.07.002; Peineau S, 2007, NEURON, V53, P703, DOI 10.1016/j.neuron.2007.01.029; Petryshen TL, 2010, MOL PSYCHIATR, V15, P810, DOI 10.1038/mp.2009.24; Pezawas L, 2004, J NEUROSCI, V24, P10099, DOI 10.1523/JNEUROSCI.2680-04.2004; Quistgaard EM, 2009, NAT STRUCT MOL BIOL, V16, P96, DOI 10.1038/nsmb.1543; Regan P, 2015, J NEUROSCI, V35, P4804, DOI 10.1523/JNEUROSCI.2842-14.2015; Romero Obradovic, 1997, GENOME INFORM SER WO, V8, P110; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Seidah NG, 1996, FEBS LETT, V379, P247, DOI 10.1016/0014-5793(95)01520-5; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; Sun Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035883; Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; Voineskos AN, 2011, ARCH GEN PSYCHIAT, V68, P198, DOI 10.1001/archgenpsychiatry.2010.194; Volosin M, 2006, J NEUROSCI, V26, P7756, DOI 10.1523/JNEUROSCI.1560-06.2006; Webster MJ, 2006, GENE EXPR PATTERNS, V6, P941, DOI 10.1016/j.modgep.2006.03.009; Woo NH, 2005, NAT NEUROSCI, V8, P1069, DOI 10.1038/nn1510; Yang J., 2014, CELL REP	52	19	22	0	6	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	FEB	2016	104						97	107		10.1016/j.phrs.2015.12.008			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DG1QE	WOS:000371841800010	26687096	Green Published, Other Gold			2021-06-18	
J	Morecraft, RJ; Ge, J; Stilwell-Morecraft, KS; McNeal, DW; Hynes, SM; Pizzimenti, MA; Rotella, DL; Darling, WG				Morecraft, R. J.; Ge, J.; Stilwell-Morecraft, K. S.; McNeal, D. W.; Hynes, S. M.; Pizzimenti, M. A.; Rotella, D. L.; Darling, W. G.			Frontal and frontoparietal injury differentially affect the ipsilateral corticospinal projection from the nonlesioned hemisphere in monkey (Macaca mulatta)	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						pyramidal tract; frontal lobe; parietal lobe; corticofugal; neurosurgical resection; plasticity; spinal cord; motor recovery; hand movements	PRIMARY MOTOR CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; CERVICAL-SPINAL-CORD; SELECTIVE MUSCLE ACTIVATION; TRAUMATIC BRAIN-INJURY; RHESUS-MONKEY; SUPPLEMENTARY MOTOR; STROKE PATIENTS; NONHUMAN-PRIMATES; MACAQUE MONKEY	Upper extremity hemiplegia is a common consequence of unilateral cortical stroke. Understanding the role of the unaffected cerebral hemisphere in the motor recovery process has been encouraged, in part, by the presence of ipsilateral corticospinal projections (iCSP). We examined the neuroplastic response of the iCSP from the contralesional primary motor cortex (cM1) hand/arm area to spinal levels C5-T1 after spontaneous long-term recovery from isolated frontal lobe injury and isolated frontoparietal injury. High-resolution tract tracing, stereological, and behavioral methodologies were applied. Recovery from frontal motor injury resulted in enhanced numbers of terminal labeled boutons in the iCSP from cM1 compared with controls. Increases occurred in lamina VIII and the adjacent ventral sectors of lamina VII, which are involved in axial/proximal limb sensorimotor processing. Larger frontal lobe lesions were associated with greater numbers of terminal boutons than smaller frontal lobe lesions. In contrast, frontoparietal injury blocked this response; total bouton number was similar to controls, demonstrating that disruption of somatosensory input to one hemisphere has a suppressive effect on the iCSP from the nonlesioned hemisphere. However, compared with controls, elevated bouton numbers occurred in lamina VIII, at the expense of lamina VII bouton labeling. Lamina IX boutons were also elevated in two frontoparietal lesion cases with extensive cortical injury. Because laminae VIII and IX collectively harbor axial, proximal, and distal motoneurons, therapeutic intervention targeting the ipsilateral corticospinal linkage from cM1 may promote proximal, and possibly distal, upper-limb motor recovery following frontal and frontoparietal injury. J. Comp. Neurol. 524:380-407, 2016. (c) 2015 Wiley Periodicals, Inc.	[Morecraft, R. J.; Ge, J.; Stilwell-Morecraft, K. S.; McNeal, D. W.] Univ S Dakota, Sanford Sch Med, Lab Neurol Sci, Div Basic Biomed Sci, Vermillion, SD 57069 USA; [Hynes, S. M.; Pizzimenti, M. A.; Rotella, D. L.; Darling, W. G.] Univ Iowa, Motor Control Labs, Dept Hlth & Human Physiol, Iowa City, IA 52242 USA; [Pizzimenti, M. A.] Univ Iowa, Carver Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA	Morecraft, RJ (corresponding author), Univ S Dakota, Sanford Sch Med, Lab Neurol Sci, Div Basic Biomed Sci, Vermillion, SD 57069 USA.	rmorecra@usd.edu		Pizzimenti, Marc A/0000-0002-1309-6633	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 046367]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS046367, R01NS046367] Funding Source: NIH RePORTER	Grant sponsor: National Institutes of Health; Grant number: NS 046367.	AIZAWA H, 1990, EXP BRAIN RES, V82, P219; Alagona G, 2001, STROKE, V32, P1304, DOI 10.1161/01.STR.32.6.1304; ARMAND J, 1982, PROG BRAIN RES, V57, P329, DOI 10.1016/S0079-6123(08)64136-9; Armand J, 1997, J NEUROSCI, V17, P251; Baker SN, 2015, PROG BRAIN RES, V218, P389, DOI 10.1016/bs.pbr.2014.12.010; Belhaj-Saif A, 2000, J NEUROPHYSIOL, V83, P3147; Bonin Gvon, 1947, NEOCORTEX MACACA MUL; Bradnam LV, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00184; Bradnam LV, 2010, J NEUROPHYSIOL, V104, P2594, DOI 10.1152/jn.00365.2010; Calautti C, 2007, NEUROIMAGE, V34, P322, DOI 10.1016/j.neuroimage.2006.08.026; Carey JR, 2006, RESTOR NEUROL NEUROS, V24, P191; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; Chen R, 1997, ANN NEUROL, V41, P247, DOI 10.1002/ana.410410216; CHENEY PD, 1991, PROG BRAIN RES, V87, P213; Chiken S, 2001, NEUROSCI LETT, V307, P143, DOI 10.1016/S0304-3940(01)01918-8; Darling WG, 2013, EXP BRAIN RES, V228, P9, DOI 10.1007/s00221-013-3533-1; Darling WG, 2011, J INTEGR NEUROSCI, V10, P353, DOI 10.1142/S0219635211002737; Darling WG, 2010, EXP BRAIN RES, V202, P529, DOI 10.1007/s00221-010-2157-y; Darling WG, 2009, EXP NEUROL, V220, P90, DOI 10.1016/j.expneurol.2009.07.034; Darling WG, 2006, J NEUROSCI METH, V154, P38, DOI 10.1016/j.jneumeth.2005.11.013; Davare M, 2007, CEREB CORTEX, V17, P353, DOI 10.1093/cercor/bhj152; DENNYBROWN D, 1950, J NERV MENT DIS, V112, P1; Dhamoon MS, 2012, STROKE, V43, P2180, DOI 10.1161/STROKEAHA.112.658922; Gerloff C, 1998, J PHYSIOL-LONDON, V510, P249, DOI 10.1111/j.1469-7793.1998.249bz.x; Glaser J, 2007, STEREOLOGY BIOL RES; GODSCHALK M, 1995, NEUROSCI RES, V23, P269, DOI 10.1016/0168-0102(95)00950-7; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; Guthrie L, 1918, Proc R Soc Med, V11, P21; Holstege G, 1988, Rev Oculomot Res, V2, P431; Hoyer EH, 2011, RESTOR NEUROL NEUROS, V29, P395, DOI 10.3233/RNN-2011-0611; HUNTLEY GW, 1991, J NEUROPHYSIOL, V66, P390; Jang SH, 2004, NEUROREPORT, V15, P395, DOI 10.1097/00001756-200403010-00002; Jankowska E, 2006, NEUROSCIENTIST, V12, P67, DOI 10.1177/1073858405283392; JENNY AB, 1983, J NEUROSCI, V3, P567; Johansen-Berg H, 2002, P NATL ACAD SCI USA, V99, P14518, DOI 10.1073/pnas.222536799; Kennard MA, 1940, J NEUROPHYSIOL, V3, P248; Kermadi I, 1998, SOMATOSENS MOT RES, V15, P287, DOI 10.1080/08990229870709; Kuypers H., 1981, HDB PHYSL, VVol II, P567; KUYPERS HGJ, 1970, BRAIN RES, V24, P29, DOI 10.1016/0006-8993(70)90272-6; KUYPERS HGJM, 1982, PROG BRAIN RES, V57, P381, DOI 10.1016/S0079-6123(08)64138-2; Lassek AM, 1954, PYRAMIDAL TRACT ITS, P88; Lemon RN, 2005, MUSCLE NERVE, V32, P261, DOI 10.1002/mus.20333; LEMON RN, 1993, EXP PHYSIOL, V78, P263, DOI 10.1113/expphysiol.1993.sp003686; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Lotze M, 2012, NEUROREHAB NEURAL RE, V26, P594, DOI 10.1177/1545968311427706; Lotze M, 2006, J NEUROSCI, V26, P6096, DOI 10.1523/JNEUROSCI.4564-05.2006; Martin JH, 2005, NEUROSCIENTIST, V11, P161, DOI 10.1177/1073858404270843; MATELLI M, 1985, BEHAV BRAIN RES, V18, P125, DOI 10.1016/0166-4328(85)90068-3; MATSUSHITA M, 1979, J COMP NEUROL, V184, P63, DOI 10.1002/cne.901840105; McCambridge AB, 2011, J NEUROPHYSIOL, V105, P2937, DOI 10.1152/jn.00171.2011; McNeal DW, 2010, J COMP NEUROL, V518, P586, DOI 10.1002/cne.22218; Misawa S, 2008, EUR J NEUROL, V15, P706, DOI 10.1111/j.1468-1331.2008.02168.x; MOLENAAR I, 1978, BRAIN RES, V158, P203, DOI 10.1016/0006-8993(78)90016-1; MOLENAAR I, 1974, BRAIN RES, V78, P239, DOI 10.1016/0006-8993(74)90549-6; MOLENAAR I, 1978, BRAIN RES, V152, P429, DOI 10.1016/0006-8993(78)91102-2; Montgomery LR, 2013, EXP BRAIN RES, V230, P153, DOI 10.1007/s00221-013-3639-5; Morecraft RJ, 2015, J COMP NEUROL, V523, P669, DOI 10.1002/cne.23703; Morecraft RJ, 2012, BRAIN RES BULL, V87, P457, DOI 10.1016/j.brainresbull.2011.12.005; Morecraft RJ, 2004, J COMP NEUROL, V469, P37, DOI 10.1002/cne.10980; MORECRAFT RJ, 1992, J COMP NEUROL, V322, P471, DOI 10.1002/cne.903220403; MORECRAFT RJ, 1992, J COMP NEUROL, V323, P341, DOI 10.1002/cne.903230304; Morecraft RJ, 2014, DIFFUSION MRI QUANTI, P359, DOI DOI 10.1016/B978-0-12-396460-1.00017-2; Morecraft RJ, 2007, J COMP NEUROL, V504, P149, DOI 10.1002/cne.21438; Morecraft RJ, 2007, J COMP NEUROL, V500, P134, DOI 10.1002/cne.21165; Morecraft RJ, 2013, J COMP NEUROL, V521, P4205, DOI 10.1002/cne.23410; Morishita T, 2011, BRAIN RES, V1371, P65, DOI 10.1016/j.brainres.2010.11.049; Murase N, 2004, ANN NEUROL, V55, P400, DOI 10.1002/ana.10848; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nagamoto-Combs K, 2010, J NEUROTRAUM, V27, P565, DOI 10.1089/neu.2009.0966; Netz J, 1997, BRAIN, V120, P1579, DOI 10.1093/brain/120.9.1579; NUDO RJ, 1992, J NEUROSCI, V12, P2918; PANDYA DN, 1982, J COMP NEUROL, V204, P196, DOI 10.1002/cne.902040208; Pizzimenti MA, 2007, J NEUROPHYSIOL, V98, P1015, DOI 10.1152/jn.00354.2007; Plow EB, 2015, NEUROSCIENTIST, V21, P225, DOI 10.1177/1073858414537381; Porter R., 1993, CORTICOSPINAL FUNCTI; PREUSS TM, 1991, J COMP NEUROL, V310, P429, DOI 10.1002/cne.903100402; RASMUSSEN D, 1992, STROKE, V23, P506, DOI 10.1161/01.STR.23.4.506; Rathelot JA, 2009, P NATL ACAD SCI USA, V106, P918, DOI 10.1073/pnas.0808362106; Reed AF, 1940, J COMP NEUROL, V72, P187, DOI 10.1002/cne.900720107; Riddle CN, 2010, J NEUROPHYSIOL, V103, P2821, DOI 10.1152/jn.00491.2009; Riecker A, 2010, HUM BRAIN MAPP, V31, P1017, DOI 10.1002/hbm.20914; Schaechter JD, 2002, NEUROREHAB NEURAL RE, V16, P326, DOI 10.1177/154596830201600403; Schieber Marc H, 2007, Handb Clin Neurol, V82, P15, DOI 10.1016/S0072-9752(07)80005-4; Schwerin S, 2008, EXP BRAIN RES, V185, P509, DOI 10.1007/s00221-007-1169-8; Shimizu T, 2002, BRAIN, V125, P1896, DOI 10.1093/brain/awf183; Sonde L, 2000, CLIN REHABIL, V14, P14, DOI 10.1191/026921500673534278; Soteropoulos DS, 2011, J NEUROSCI, V31, P11208, DOI 10.1523/JNEUROSCI.0257-11.2011; SPRAGUE JM, 1948, AM J ANAT, V82, P1, DOI 10.1002/aja.1000820102; STERLING PETER, 1967, BRAIN RES, V4, P16, DOI 10.1016/0006-8993(67)90145-X; STERLING PETER, 1968, BRAIN RES, V7, P419, DOI 10.1016/0006-8993(68)90008-5; Stinear CM, 2014, CURR OPIN NEUROL, V27, P624, DOI 10.1097/WCO.0000000000000153; Takei T, 2013, J NEUROSCI, V33, P8850, DOI 10.1523/JNEUROSCI.4032-12.2013; Takei T, 2010, J NEUROSCI, V30, P17041, DOI 10.1523/JNEUROSCI.4297-10.2010; TANJI J, 1988, J NEUROPHYSIOL, V60, P325; Thorsen AM, 2005, STROKE, V36, P297, DOI 10.1161/01.STR.0000152288.42701.a6; Turton A, 1996, ELECTROMYOGR MOTOR C, V101, P316, DOI 10.1016/0924-980X(96)95560-5; Uehara K, 2011, NEUROSCI LETT, V488, P22, DOI 10.1016/j.neulet.2010.10.073; Ward NS, 2007, EUR J NEUROSCI, V25, P1865, DOI 10.1111/j.1460-9568.2007.05434.x; Ward NS, 2003, BRAIN, V126, P1430, DOI 10.1093/brain/awg145; Werhahn KJ, 2003, ANN NEUROL, V54, P464, DOI 10.1002/ana.10686; West M.J., 2012, BASIC STEREOLOGY BIO; WOOLSEY CN, 1950, RES PUBL ASSOC RES N, V30, P238; Yoo K M, 1998, J Stroke Cerebrovasc Dis, V7, P344, DOI 10.1016/S1052-3057(98)80053-0; Young Brittany M, 2014, Front Neuroeng, V7, P26, DOI 10.3389/fneng.2014.00026; Zaaimi B, 2012, BRAIN, V135, P2277, DOI 10.1093/brain/aws115	105	19	19	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	FEB 1	2016	524	2					380	407		10.1002/cne.23861			28	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	CY7QV	WOS:000366604700010	26224429	Green Accepted			2021-06-18	
J	Willems, C; Fu, QL; Roose, H; Mertens, F; Cox, B; Chen, JH; Vankelecom, H				Willems, Christophe; Fu, Qiuli; Roose, Heleen; Mertens, Freya; Cox, Benoit; Chen, Jianghai; Vankelecom, Hugo			Regeneration in the Pituitary After Cell-Ablation Injury: Time-Related Aspects and Molecular Analysis	ENDOCRINOLOGY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TRAUMATIC BRAIN-INJURY; STEM-CELLS; STEM/PROGENITOR CELL; SIDE POPULATION; GLAND; DIFFERENTIATION; HORMONE; HYPOPITUITARISM; EXPRESSION	We recently showed that the mouse pituitary holds regenerative competence. Young-adult GHCre/iDTR mice, expressing diphtheria toxin (DT) receptor in GH-producing cells, regenerate the GH(+) cells, as ablated by 3-day DT treatment (3DT), up to 60% after 5 months. The pituitary's stem cells participate in this restoration process. Here, we characterized this regenerative capacity in relation to age and recovery period and started to search for underlying molecular mechanisms. Extending the recovery period (up to 19 mo) does not result in higher regeneration levels. In addition, the regenerative competence disappears at older age, coinciding with a reduction in pituitary stem cell number and fitness. Surprisingly, prolonging DT treatment of young-adult mice to 10 days (10DT) completely blocks the regeneration, although the stem cell compartment still reacts by promptly expanding, and retains in vitro stem cell functionality. To obtain a first broad view on molecular grounds underlying reparative capacity and/or failure, the stem cell-clustering side population was analyzed by whole-genome expression analysis. A number of stemness factors and components of embryonic, epithelial-mesenchymal transition, growth factor and Hippo pathways are higher expressed in the stem cell-clustering side population of the regenerating pituitary (after 3DT) when compared with the basal gland and to the nonregenerating pituitary (after 10DT). Together, the regenerative capacity of the pituitary is limited both in age-related terms and final efficacy, and appears to relyonstem cell-associated pathway activation. Dissection of the molecular profiles may eventually identify targets to induce or boost regeneration in situations of (injury-related) pituitary deficiency.	[Willems, Christophe; Fu, Qiuli; Roose, Heleen; Mertens, Freya; Cox, Benoit; Chen, Jianghai; Vankelecom, Hugo] Univ Leuven KU Leuven, Dept Dev & Regenerat, Cluster Stem Cell Biol & Embryol, Unit Stem Cell Res, B-3000 Leuven, Belgium; [Fu, Qiuli] Zhejiang Univ, Ctr Eye, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China; Key Lab Ophthalmol Zhejiang Prov, Hangzhou 310009, Zhejiang, Peoples R China; [Chen, Jianghai] Huazhong Univ Sci & Technol, Dept Hand Surg, Tongji Med Coll, Union Hosp, Wuhan 430022, Hubei, Peoples R China	Vankelecom, H (corresponding author), Katholieke Univ Leuven, Dept Dev & Regenerat, Cluster Stem Cell Biol & Embryol, Unit Stem Cell Res, Campus Gasthuisberg O&N4,Herestr 49, B-3000 Leuven, Belgium.	hugo.vankelecom@med.kuleuven.be		Cox, Benoit/0000-0002-3139-268X; Vankelecom, Hugo/0000-0002-2251-7284	KU Leuven (Research Fund, BOF)KU Leuven; Fund for Scientific Research (FWO), Flanders (Belgium)FWO; FWOFWO [2012DFG32000]; Ministry of Science and Technology of China (MOST)Ministry of Science and Technology, China [2012DFG32000]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30500248, 81300641]; Agency for Innovation by Science and Technology (IWT-Flanders, Belgium)	This work was supported by research grants from the KU Leuven (Research Fund, BOF) and from the Fund for Scientific Research (FWO), Flanders (Belgium), by a joint research grant between the FWO and the Ministry of Science and Technology of China (MOST) (2012DFG32000), and by collaborative efforts in the context of grants from the National Natural Science Foundation of China (30500248 and 81300641). Q.F. received a Selective Bilateral Agreement Scholarship (KU Leuven), F.M. and H.R. obtained a PhD Fellowship from the Agency for Innovation by Science and Technology (IWT-Flanders, Belgium), and B.C. a PhD Fellowship from the FWO.	Alexander JM, 2010, TRENDS MOL MED, V16, P426, DOI 10.1016/j.molmed.2010.06.003; Baltus GA, 2009, STEM CELLS, V27, P2175, DOI 10.1002/stem.168; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Biteau B, 2011, DEVELOPMENT, V138, P1045, DOI 10.1242/dev.056671; BOTNICK LE, 1979, BLOOD CELLS, V5, P195; Buch T, 2005, NAT METHODS, V2, P419, DOI 10.1038/NMETH762; Call MK, 2004, EXP EYE RES, V78, P297, DOI 10.1016/j.exer.2003.10.021; Chen JH, 2005, ENDOCRINOLOGY, V146, P3985, DOI 10.1210/en.2005-0185; Chen JH, 2006, MOL ENDOCRINOL, V20, P3293, DOI 10.1210/me.2006-0293; Chen JH, 2009, STEM CELLS, V27, P1182, DOI 10.1002/stem.51; Chen Xin-Ming, 2009, Front Biosci (Schol Ed), V1, P132, DOI 10.2741/s13; Coutu DL, 2011, AGING-US, V3, P920, DOI 10.18632/aging.100369; Davis SW, 2009, HORM RES, V71, P101, DOI 10.1159/000192447; De Bellis A, 2008, EUR J ENDOCRINOL, V158, P147, DOI 10.1530/EJE-07-0647; Dean CE, 1999, ENDOCRINOLOGY, V140, P1104, DOI 10.1210/en.140.3.1104; Drouin J, 2006, FRONT HORM RES, V35, P74, DOI 10.1159/000094310; Fanjul M, 2010, J HISTOCHEM CYTOCHEM, V58, P807, DOI 10.1369/jhc.2010.955807; Fauquier T, 2008, P NATL ACAD SCI USA, V105, P2907, DOI 10.1073/pnas.0707886105; Fu QL, 2012, STEM CELLS DEV, V21, P3245, DOI 10.1089/scd.2012.0290; Fu QL, 2012, ENDOCRINOLOGY, V153, P3224, DOI 10.1210/en.2012-1152; Garcia-Lavandeira M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004815; Gargett CE, 2008, MOL CELL ENDOCRINOL, V288, P22, DOI 10.1016/j.mce.2008.02.026; Geiger H, 2014, CURR OPIN IMMUNOL, V29, P86, DOI 10.1016/j.coi.2014.05.002; Gibson DJ, 2014, INVEST OPHTH VIS SCI, V55, P2062, DOI 10.1167/iovs.13-12735; Gremeaux L, 2012, STEM CELLS DEV, V21, P801, DOI 10.1089/scd.2011.0496; Hariharan N, 2015, J MOL CELL CARDIOL, V83, P32, DOI 10.1016/j.yjmcc.2015.04.008; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huggett JF, 2013, CLIN CHEM, V59, P892, DOI 10.1373/clinchem.2013.206375; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Le Tissier PR, 2012, FRONT NEUROENDOCRIN, V33, P252, DOI 10.1016/j.yfrne.2012.08.002; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Luque RM, 2007, ENDOCRINOLOGY, V148, P1946, DOI 10.1210/en.2006-1542; Luque RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015767; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mao L, 2011, CANCER RES, V71, P4314, DOI 10.1158/0008-5472.CAN-11-0051; Marshall OJ, 2004, BIOINFORMATICS, V20, P2471, DOI 10.1093/bioinformatics/bth254; Melmed S, 2010, PITUITARY; Mertens F, 2015, ENDOCR-RELAT CANCER, V22, P481, DOI 10.1530/ERC-14-0546; Mogi C, 2005, J ENDOCRINOL, V184, P41, DOI 10.1677/joe.1.05870; Ojeda L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023414; Pals K, 2006, J NEUROENDOCRINOL, V18, P203, DOI 10.1111/j.1365-2826.2005.01404.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Radisky DC, 2008, CELL STEM CELL, V2, P511, DOI 10.1016/j.stem.2008.05.007; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Riley KG, 2015, DIABETES, V64, P1284, DOI 10.2337/db14-1195; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Sierra A, 2015, CELL STEM CELL, V16, P488, DOI 10.1016/j.stem.2015.04.003; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tanriverdi F, 2015, ENDOCR REV, V36, P305, DOI 10.1210/er.2014-1065; Tanriverdi F, 2013, J NEUROTRAUM, V30, P1426, DOI 10.1089/neu.2012.2752; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; van Wijk B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044692; Vankelecom H, 2012, CURR STEM CELL RES T, V7, P36, DOI 10.2174/157488812798483467; Vankelecom H, 2010, EUR J NEUROSCI, V32, P2063, DOI 10.1111/j.1460-9568.2010.07523.x; White PM, 2012, DEV BIOL, V363, P191, DOI 10.1016/j.ydbio.2011.12.035; Willems C, 2014, REGEN MED, V9, P513, DOI [10.2217/RME.14.19, 10.2217/rme.14.19]; Yan CL, 2010, AM J PATHOL, V176, P2247, DOI 10.2353/ajpath.2010.090048; Zhu XY, 2007, PHYSIOL REV, V87, P933, DOI 10.1152/physrev.00006.2006	59	19	19	1	5	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	FEB	2016	157	2					705	721		10.1210/en.2015-1741			17	Endocrinology & Metabolism	Endocrinology & Metabolism	DD5LT	WOS:000369965900026	26653762				2021-06-18	
J	Misic, B; Dunkley, BT; Sedge, PA; Da Costa, L; Fatima, Z; Berman, MG; Doesburg, SM; McIntosh, AR; Grodecki, R; Jetly, R; Pang, EW; Taylor, MJ				Misic, Bratislav; Dunkley, Benjamin T.; Sedge, Paul A.; Da Costa, Leodante; Fatima, Zainab; Berman, Marc G.; Doesburg, Sam M.; McIntosh, Anthony R.; Grodecki, Richard; Jetly, Rakesh; Pang, Elizabeth W.; Taylor, Margot J.			Post-Traumatic Stress Constrains the Dynamic Repertoire of Neural Activity	JOURNAL OF NEUROSCIENCE			English	Article						connectivity; dynamics; MEG; network; PTSD; TBI	BRAIN SIGNAL VARIABILITY; MULTISCALE ENTROPY ANALYSIS; PSYCHOPHYSIOLOGICAL ASSESSMENT; FUNCTIONAL CONNECTIVITY; SPATIAL NAVIGATION; NEUROIMAGING DATA; HUMAN HIPPOCAMPAL; MASS MODEL; DISORDER; MEG	Post-traumatic stress disorder (PTSD) is an anxiety disorder arising from exposure to a traumatic event. Although primarily defined in terms of behavioral symptoms, the global neurophysiological effects of traumatic stress are increasingly recognized as a critical facet of the human PTSD phenotype. Here we use magnetoencephalographic recordings to investigate two aspects of information processing: inter-regional communication (measured by functional connectivity) and the dynamic range of neural activity (measured in terms of local signal variability). We find that both measures differentiate soldiers diagnosed with PTSD from soldiers without PTSD, from healthy civilians, and from civilians with mild traumatic brain injury, which is commonly comorbid with PTSD. Specifically, soldiers with PTSD display inter-regional hypersynchrony at high frequencies (80-150 Hz), as well as a concomitant decrease in signal variability. The two patterns are spatially correlated and most pronounced in a left temporal subnetwork, including the hippocampus and amygdala. We hypothesize that the observed hypersynchrony may effectively constrain the expression of local dynamics, resulting in less variable activity and a reduced dynamic repertoire. Thus, the re-experiencing phenomena and affective sequelae in combat-related PTSD may result from functional networks becoming "stuck" in configurations reflecting memories, emotions, and thoughts originating from the traumatizing experience.	[Misic, Bratislav; Taylor, Margot J.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA; [Dunkley, Benjamin T.; Doesburg, Sam M.; Pang, Elizabeth W.] Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON M5G 1X8, Canada; [Sedge, Paul A.] Canadian Forces Hlth Serv, Directorate Mental Hlth, Ottawa, ON K1K 0T2, Canada; [Da Costa, Leodante] Sunnybrook Med Ctr, Div Neurosurg, Toronto, ON M4N 3M5, Canada; [Fatima, Zainab; McIntosh, Anthony R.] Baycrest Ctr Geriatr Care, Res Inst, Toronto, ON M6A 2E1, Canada; [Berman, Marc G.] Univ Chicago, Dept Psychol, Chicago, IL 60637 USA; [Grodecki, Richard] Canadian Forces Environm Med Estab, Toronto, ON M3K 2C9, Canada; [Jetly, Rakesh] Def Res & Dev Canada, Toronto, ON N3K 2C9, Canada	Misic, B (corresponding author), Indiana Univ, Dept Psychol & Brain Sci, 1101 E 10th St, Bloomington, IN 47405 USA.	bmisic@indiana.edu		Dunkley, Ben/0000-0001-6173-1171; McIntosh, Anthony/0000-0002-1784-5662	Defense Research and Development Canada [SW7719-135182/001/TOR]; Canadian Forces Health Services; James S. McDonnell Foundation grant; Natural Sciences and Engineering Research Council of Canada postdoctoral fellowshipNatural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by Defense Research and Development Canada (contract SW7719-135182/001/TOR) and the Canadian Forces Health Services to M.J.T. and E.W.P. and a James S. McDonnell Foundation grant to A.R.M., B.M. was supported by an Natural Sciences and Engineering Research Council of Canada postdoctoral fellowship.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Attal Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059856; Balderston NL, 2013, JOVE-J VIS EXP, DOI 10.3791/50212; Bardouille T, 2008, NEUROIMAGE, V42, P323, DOI 10.1016/j.neuroimage.2008.04.176; Berman MG, 2014, NEUROIMAGE, V103, P267, DOI 10.1016/j.neuroimage.2014.09.027; Bish JP, 2004, NEUROSCI LETT, V362, P48, DOI 10.1016/j.neulet.2004.02.032; Boersma M, 2013, BRAIN CONNECT, V3, P41, DOI 10.1089/brain.2012.0127; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Brookes MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120991; Brown VM, 2014, NEUROPSYCHOPHARMACOL, V39, P351, DOI 10.1038/npp.2013.197; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Catarino A, 2011, CLIN NEUROPHYSIOL, V122, P2375, DOI 10.1016/j.clinph.2011.05.004; Cornwell BR, 2008, J NEUROSCI, V28, P5983, DOI 10.1523/JNEUROSCI.5001-07.2008; Cornwell BR, 2007, NEUROIMAGE, V37, P282, DOI 10.1016/j.neuroimage.2007.04.055; Cornwell BR, 2010, AM J PSYCHIAT, V167, P836, DOI 10.1176/appi.ajp.2009.09050614; Cornwell BR, 2008, BRAIN RES, V1244, P103, DOI 10.1016/j.brainres.2008.09.068; Costa M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021906; Costa M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.068102; David O, 2003, NEUROIMAGE, V20, P1743, DOI 10.1016/j.neuroimage.2003.07.015; Deco G, 2013, TRENDS NEUROSCI, V36, P268, DOI 10.1016/j.tins.2013.03.001; Deco G, 2009, P NATL ACAD SCI USA, V106, P10302, DOI 10.1073/pnas.0901831106; Dimitriadis SI, 2013, NEUROIMAGE, V83, P307, DOI 10.1016/j.neuroimage.2013.06.036; Dunkley BT, 2014, NEUROIMAGE-CLIN, V5, P377, DOI 10.1016/j.nicl.2014.07.017; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; Engdahl B, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/6/066005; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Felmingham K, 2010, J ABNORM PSYCHOL, V119, P241, DOI 10.1037/a0017551; Friston KJ, 1995, HUM BRAIN MAPP, V3, P56, DOI 10.1002/hbm.460030106; Garber BG, 2012, CAN J PSYCHIAT, V57, P736, DOI 10.1177/070674371205701205; Garrett DD, 2015, P NATL ACAD SCI USA, V112, P7593, DOI 10.1073/pnas.1504090112; Garrett DD, 2014, CEREB CORTEX, V24, P2931, DOI 10.1093/cercor/bht150; Garrett DD, 2013, NEUROSCI BIOBEHAV R, V37, P610, DOI 10.1016/j.neubiorev.2013.02.015; Garrett DD, 2011, J NEUROSCI, V31, P4496, DOI 10.1523/JNEUROSCI.5641-10.2011; Garrett DD, 2010, J NEUROSCI, V30, P4914, DOI 10.1523/JNEUROSCI.5166-09.2010; Georgopoulos AP, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/1/016011; Hamada Y, 2004, HIPPOCAMPUS, V14, P426, DOI 10.1002/hipo.10196; Heisz JJ, 2012, NEUROIMAGE, V63, P1384, DOI 10.1016/j.neuroimage.2012.08.018; Hung YW, 2012, NEUROIMAGE, V60, P545, DOI 10.1016/j.neuroimage.2011.12.003; Ibrahim GM, 2014, BRAIN, V137, P2690, DOI 10.1093/brain/awu214; James LM, 2013, JAMA PSYCHIAT, V70, P410, DOI 10.1001/jamapsychiatry.2013.878; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Keane TM, 1998, J CONSULT CLIN PSYCH, V66, P914, DOI 10.1037/0022-006X.66.6.914; Kirsch Peter, 2003, Neural Plasticity, V10, P291, DOI 10.1155/NP.2003.291; Kitayama N, 2006, J AFFECT DISORDERS, V90, P171, DOI 10.1016/j.jad.2005.11.006; Kitayama N, 2005, J AFFECT DISORDERS, V88, P79, DOI 10.1016/j.jad.2005.05.014; Kolassa IT, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-56; Lau TM, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-47; Luo Q, 2007, NEUROIMAGE, V34, P839, DOI 10.1016/j.neuroimage.2006.09.023; McCabe C, 2011, NEUROIMAGE, V57, P1317, DOI 10.1016/j.neuroimage.2011.05.051; McIntosh AR, 2014, CEREB CORTEX, V24, P1806, DOI 10.1093/cercor/bht030; McIntosh AR, 2013, ANNU REV PSYCHOL, V64, P499, DOI 10.1146/annurev-psych-113011-143804; McIntosh AR, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000106; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; Mills T, 2012, BRAIN TOPOGR, V25, P248, DOI 10.1007/s10548-012-0217-2; Misic B, 2015, CEREB CORTEX, V25, P2815, DOI 10.1093/cercor/bhu082; Misic B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111007; Misic B, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00090; Misic B, 2010, J NEUROPHYSIOL, V104, P2667, DOI 10.1152/jn.00648.2010; Mizuno T, 2010, CLIN NEUROPHYSIOL, V121, P1438, DOI 10.1016/j.clinph.2010.03.025; Muthukumaraswamy SD, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00138; Oizumi M, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003588; Orr SP, 2000, J AFFECT DISORDERS, V61, P225, DOI 10.1016/S0165-0327(00)00340-2; PITMAN RK, 1987, ARCH GEN PSYCHIAT, V44, P970; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Pole N, 2007, PSYCHOL BULL, V133, P725, DOI 10.1037/0033-2909.133.5.725; Quraan MA, 2011, HUM BRAIN MAPP, V32, P812, DOI 10.1002/hbm.21068; Quraan MA, 2010, NEUROIMAGE, V49, P2387, DOI 10.1016/j.neuroimage.2009.10.012; Rabinak Christine A, 2011, Front Psychiatry, V2, P62, DOI 10.3389/fpsyt.2011.00062; Raja Beharelle A, 2012, NEUROIMAGE, V60, P1528, DOI 10.1016/j.neuroimage.2012.01.037; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; Schaefer A, 2014, CURR BIOL, V24, P2314, DOI 10.1016/j.cub.2014.08.024; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.ph.55.030193.002025; Small M, 2004, PHYSICA D, V194, P283, DOI 10.1016/j.physd.2004.03.006; Tagliazucchi E, 2014, HUM BRAIN MAPP, V35, P5442, DOI 10.1002/hbm.22562; Takahashi T, 2010, NEUROIMAGE, V51, P173, DOI 10.1016/j.neuroimage.2010.02.009; Tononi G, 2012, ARCH ITAL BIOL, V150, P56, DOI 10.4449/aib.v149i5.1388; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vakorin VA, 2011, J NEUROSCI, V31, P6405, DOI 10.1523/JNEUROSCI.3153-10.2011; Vinck M, 2011, NEUROIMAGE, V55, P1548, DOI 10.1016/j.neuroimage.2011.01.055; Yang AC, 2013, NEUROBIOL AGING, V34, P428, DOI 10.1016/j.neurobiolaging.2012.05.004; Ye AX, 2014, HUM BRAIN MAPP, V35, P6049, DOI 10.1002/hbm.22604; Zavaglia M, 2008, IEEE T BIO-MED ENG, V55, P69, DOI 10.1109/TBME.2007.897814; Zhou Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046833	85	19	19	0	16	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 13	2016	36	2					419	431		10.1523/JNEUROSCI.1506-15.2016			13	Neurosciences	Neurosciences & Neurology	DB2PX	WOS:000368352600016	26758834	Bronze, Green Published			2021-06-18	
J	Alway, Y; McKay, A; Gould, KR; Johnston, L; Ponsford, J				Alway, Yvette; McKay, Adam; Gould, Kate Rachel; Johnston, Lisa; Ponsford, Jennie			FACTORS ASSOCIATED WITH POSTTRAUMATIC STRESS DISORDER FOLLOWING MODERATE TO SEVERE TRAUMATIC BRAIN INJURY: A PROSPECTIVE STUDY	DEPRESSION AND ANXIETY			English	Article						traumatic brain injury; anxiety disorder; posttraumatic stress disorder; trauma; quality of life; rehabilitation	STRUCTURED CLINICAL INTERVIEW; HEAD-INJURY; PSYCHIATRIC-DISORDERS; SELF-REPORT; PTSD; SYMPTOMS; AMNESIA; DEPRESSION; TELEPHONE; ANXIETY	Background This study prospectively examined the relationship between preinjury, injury-related, and postinjury factors and posttraumatic stress disorder (PTSD) following moderate to severe traumatic brain injury (TBI). Method Two hundred and three participants were recruited during inpatient admission following moderate to severe TBI. Participants completed an initial assessment soon after injury and were reassessed at 3, 6, and 12 months, 2, 3, 4, and 5 years postinjury. The Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-fourth edition was used to diagnose pre- and postinjury PTSD and other psychiatric disorders. The Glasgow Outcome Scale-Extended (GOSE) and the Quality of Life Inventory (QOLI) were used to evaluate functional and psychosocial outcome from 6 months postinjury.ResultsThe frequency of PTSD ranged between 0.5 and 9.4% during the 5-year period, increasing throughout the first 12 months and declining thereafter. After controlling for other predictors, shorter posttraumatic amnesia duration (odds ratio = 0.96, 95% CI = 0.92-1.00), other concurrent psychiatric disorder (odds ratio = 14.22, 95% CI = 2.68-75.38), and lower GOSE (odds ratio = 0.38, 95% CI = 0.20-0.72) and QOLI scores (odds ratio = 0.97, 95% CI = 0.95-0.97) were associated with greater odds of having injury-related PTSD.DiscussionThe results of this study indicate that while shorter posttraumatic amnesia duration is associated with PTSD, greater TBI severity does not prevent PTSD from evolving. Patients with PTSD experienced high rates of psychiatric comorbidity and poorer functional and quality of life outcomes after TBI.ConclusionThere is a need to direct clinical attention to early identification and treatment of PTSD following TBI to improve outcomes.	[Alway, Yvette; McKay, Adam; Gould, Kate Rachel; Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Alway, Yvette; McKay, Adam; Gould, Kate Rachel; Johnston, Lisa; Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Gould, Kate Rachel; Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Alway, Y (corresponding author), Monash Epworth Rehabil Res Ctr, 185-187 Hoddle St, Richmond, Vic 3121, Australia.	yvette.alway@monash.edu	McKay, Adam JD/M-6003-2017; Gould, Kate/AAA-5511-2020	McKay, Adam JD/0000-0002-0479-7681; Gould, Kate/0000-0002-3564-7408			[Anonymous], 2008, REPORT ARMY SURG GEN; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Barker-Collo S, 2013, BRAIN IMPAIR, V14, P425, DOI 10.1017/BrImp.2013.27; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Brady KT, 2000, J CLIN PSYCHIAT, V61, P22; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Bryant RA, 2011, J CLIN PSYCHIAT, V72, P233, DOI 10.4088/JCP.09r05072blu; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Chalton LD, 2009, BRAIN INJURY, V23, P77, DOI 10.1080/02699050802635273; Chung H, 2008, PSYCHOL MED, V38, P563, DOI 10.1017/S0033291707002589; Creamer M, 2001, PSYCHOL MED, V31, P1237, DOI 10.1017/S0033291701004287; Crippa JAS, 2008, PERSPECT PSYCHIATR C, V44, P241, DOI 10.1111/j.1744-6163.2008.00183.x; Feinstein A, 2002, J NEUROPSYCH CLIN N, V14, P25, DOI 10.1176/appi.neuropsych.14.1.25; First MB., 2002, STRUCTURED CLIN INTE; Frisch M.B., 1992, PSYCHOL ASSESSMENT, V4, P92, DOI [DOI 10.1037/1040-3590.4.1.92, 10.1037/1040-3590.4.1.92]; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Gill IJ, 2014, BRAIN INJURY, V28, P1, DOI 10.3109/02699052.2013.851416; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Hajebi A, 2012, COMPR PSYCHIAT, V53, P579, DOI 10.1016/j.comppsych.2011.06.001; Heron-Delaney M, 2013, INJURY, V44, P1413, DOI 10.1016/j.injury.2013.07.011; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Hidalgo RB, 2000, J CLIN PSYCHIAT, V61, P5; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Olatunji BO, 2007, CLIN PSYCHOL REV, V27, P572, DOI 10.1016/j.cpr.2007.01.015; Reid LM, 2011, J NEUROPSYCH CLIN N, V23, P454, DOI 10.1176/jnp.23.4.jnp454; Roitman P, 2013, J TRAUMA STRESS, V26, P727, DOI 10.1002/jts.21862; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; SIMON GE, 1993, J PSYCHIAT RES, V27, P247, DOI 10.1016/0022-3956(93)90035-Z; STIRATELLI R, 1984, BIOMETRICS, V40, P961, DOI 10.2307/2531147; Sumpter RE, 2006, BRAIN INJURY, V20, P93, DOI 10.1080/02699050500394090; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158	48	19	19	1	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1091-4269	1520-6394		DEPRESS ANXIETY	Depress. Anxiety	JAN	2016	33	1					19	26		10.1002/da.22396			8	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	DA3TX	WOS:000367722900002	26219232				2021-06-18	
J	Azman, KF; Zakaria, R; Aziz, CBA; Othman, Z				Azman, Khairunnuur Fairuz; Zakaria, Rahimah; Aziz, Che Badariah Abdul; Othman, Zahiruddin			Tualang Honey Attenuates Noise Stress-Induced Memory Deficits in Aged Rats	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article							NERVE GROWTH-FACTOR; RADICAL SCAVENGING ACTIVITY; TRAUMATIC BRAIN-INJURY; ANTIOXIDANT CAPACITY; COGNITIVE FUNCTION; OXIDATIVE STRESS; SPATIAL MEMORY; RECOGNITION MEMORY; MESSENGER-RNA; DNA-DAMAGE	Ageing and stress exposure may lead to memory impairment while oxidative stress is thought to be one of the underlying mechanisms involved. This study aimed to investigate the potential protective effects of Tualang honey supplementation on memory performance in aged rats exposed to noise stress. Tualang honey supplementation was given orally, 200 mg/kg body weight for 28 days. Rats in the stress group were subjected to loud noise, 100 dB(A), 4 hours daily for 14 days. All rats were subjected to novel object recognition test for evaluation of memory performance. It was observed that the rats subjected to noise stress exhibited significantly lower memory performance and higher oxidative stress as evident by elevated malondialdehyde and protein carbonyl levels and reduction of antioxidant enzymes activities compared to the nonstressed rats. Tualang honey supplementation was able to improve memory performance, decrease oxidative stress levels, increase brain-derived neurotrophic factor (BDNF) concentration, decrease acetylcholinesterase activity, and enhance neuronal proliferation in the medial prefrontal cortex (mPFC) and hippocampus. In conclusion, Tualang honey protects against memory decline due to stress exposure and/or ageing via enhancement of mPFC and hippocampal morphology possibly secondary to reduction in brain oxidative stress and/or upregulation of BDNF concentration and cholinergic system.	[Azman, Khairunnuur Fairuz; Zakaria, Rahimah; Aziz, Che Badariah Abdul] Univ Sains Malaysia, Sch Med Sci, Dept Physiol, Kota Baharu 16150, Kelantan, Malaysia; [Othman, Zahiruddin] Univ Sains Malaysia, Sch Med Sci, Dept Psychiat, Kota Baharu 16150, Kelantan, Malaysia	Zakaria, R (corresponding author), Univ Sains Malaysia, Sch Med Sci, Dept Physiol, Kota Baharu 16150, Kelantan, Malaysia.	rahimah@usm.my	Azman, Khairunnuur F/A-2041-2014; Azman, Khairunnuur/AAY-6094-2020; Zakaria, Rahimah/C-8660-2016; Othman, Zahiruddin/E-3914-2012	Azman, Khairunnuur F/0000-0003-2735-0177; Azman, Khairunnuur/0000-0003-2735-0177; Zakaria, Rahimah/0000-0002-2459-3213; Othman, Zahiruddin/0000-0002-9070-2078; Zakaria, Wan Nur Amalina/0000-0001-5709-1861; Abdul Aziz, Che Badariah/0000-0003-0102-1594	Universiti Sains MalaysiaUniversiti Sains Malaysia [304/PPSP/61313056]; School of Medical Sciences USM; Ministry of Education MalaysiaMinistry of Education, Malaysia	This project was supported by short-term grant of Universiti Sains Malaysia (304/PPSP/61313056). The financial supports from School of Medical Sciences USM and Ministry of Education Malaysia for RLKA fellowship and SLAB scholarship to Ms. Khairunnuur Fairuz Azman are gratefully acknowledged.	Abreu RV, 2011, PHARMACOL BIOCHEM BE, V99, P659, DOI 10.1016/j.pbb.2011.06.010; Adlard PA, 2004, NEUROSCIENCE, V124, P985, DOI 10.1016/j.neuroscience.2003.12.039; Al-Himyari FA, 2009, ALZHEIMERS DEMENT, V5, pP247, DOI DOI 10.1016/J.JALZ.2009.04.248; Al-Mamary M, 2002, NUTR RES, V22, P1041, DOI 10.1016/S0271-5317(02)00406-2; Al-Rahbi B., 2014, International Journal of Applied Research in Natural Products, V7, P28; Al-Rahbi B, 2014, ACTA HISTOCHEM, V116, P79, DOI 10.1016/j.acthis.2013.05.004; Al-Rahbi B, 2014, SCI WORLD J, DOI 10.1155/2014/310821; Al-Waili Noori S., 2003, Journal of Medicinal Food, V6, P135, DOI 10.1089/109662003322233549; Aljadi AM, 2004, FOOD CHEM, V85, P513, DOI 10.1016/S0308-8146(02)00596-4; Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; ARMSTRONG DM, 1993, NEUROBIOL AGING, V14, P457, DOI 10.1016/0197-4580(93)90104-J; Azman KF, 2015, NOISE HEALTH, V17, P83, DOI 10.4103/1463-1741.153388; Backman C, 1996, J NEUROSCI, V16, P5437; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Beretta G, 2007, PLANTA MED, V73, P1182, DOI 10.1055/s-2007-981598; Chen CZ, 2011, J OCCUP HEALTH, V53, P157, DOI 10.1539/joh.L10125; Cheng L, 2011, PHYSIOL BEHAV, V104, P981, DOI 10.1016/j.physbeh.2011.06.018; Chepulis LM, 2009, PHYSIOL BEHAV, V97, P359, DOI 10.1016/j.physbeh.2009.03.001; Cotman CW, 2002, NEUROBIOL AGING, V23, P809, DOI 10.1016/S0197-4580(02)00073-8; Dias CP, 2007, NEUROSCIENCE, V146, P1719, DOI 10.1016/j.neuroscience.2007.03.018; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Erejuwa OO, 2010, ANN ENDOCRINOL-PARIS, V71, P291, DOI 10.1016/j.ando.2010.03.003; Erejuwa OO, 2011, INT J MOL SCI, V12, P829, DOI 10.3390/ijms12010829; Fahnestock M, 2012, NEUROBIOL AGING, V33, P546, DOI 10.1016/j.neurobiolaging.2010.03.019; Ferreira ICFR, 2009, FOOD CHEM, V114, P1438, DOI 10.1016/j.foodchem.2008.11.028; FISCHER W, 1991, J NEUROSCI, V11, P1889; Fu Z, 2010, ENDOCRINOLOGY, V151, P3026, DOI 10.1210/en.2009-1294; Fukui K, 2001, ANN NY ACAD SCI, V928, P168; Gheldof N, 2003, J AGR FOOD CHEM, V51, P1500, DOI 10.1021/jf025897t; Gheldof N, 2002, J AGR FOOD CHEM, V50, P3050, DOI 10.1021/jf0114637; Granholm AC, 2000, EXPERT OPIN INV DRUG, V9, P685, DOI 10.1517/13543784.9.4.685; Gustilo MC, 1999, J COMP NEUROL, V405, P491, DOI 10.1002/(SICI)1096-9861(19990322)405:4<491::AID-CNE4>3.0.CO;2-N; Haider Saida, 2012, Sci Pharm, V80, P1001, DOI 10.3797/scipharm.1207-15; Hwang SL, 2009, J AGR FOOD CHEM, V57, P2576, DOI 10.1021/jf8033607; Ilhan A, 2004, CLIN CHIM ACTA, V340, P153, DOI 10.1016/j.cccn.2003.10.012; Jama JW, 1996, AM J EPIDEMIOL, V144, P275, DOI 10.1093/oxfordjournals.aje.a008922; Jhoo JH, 2004, BEHAV BRAIN RES, V155, P185, DOI 10.1016/j.bbr.2004.04.012; Kishore RK, 2011, NUTR RES, V31, P322, DOI 10.1016/j.nutres.2011.03.001; Lee JS, 2014, J ETHNOPHARMACOL, V153, P782, DOI 10.1016/j.jep.2014.03.048; Lenzi P, 2003, ENVIRON HEALTH PERSP, V111, P467, DOI 10.1289/ehp.5847; LEVIMONTALCINI R, 1987, BIOSCIENCE REP, V7, P681, DOI 10.1007/BF01116861; Lovell MA, 2007, NUCLEIC ACIDS RES, V35, P7497, DOI 10.1093/nar/gkm821; Manikandan S, 2005, BIOL PHARM BULL, V28, P2327, DOI 10.1248/bpb.28.2327; Manikandan S, 2006, NEUROSCI LETT, V399, P17, DOI 10.1016/j.neulet.2006.01.037; Marghitas LA, 2009, FOOD CHEM, V112, P863, DOI 10.1016/j.foodchem.2008.06.055; MEANEY MJ, 1995, EXP GERONTOL, V30, P229, DOI 10.1016/0531-5565(94)00065-B; Mohamed M, 2010, AFR J TRADIT COMPLEM, V7, P59; Murakami S, 2005, NEUROSCI RES, V53, P129, DOI 10.1016/j.neures.2005.06.008; Nibuya M, 1999, NEUROSCI LETT, V267, P81, DOI 10.1016/S0304-3940(99)00335-3; Othman Z, 2011, MENOPAUSE, V18, P1219, DOI 10.1097/gme.0b013e31821e2044; Ozarowski M, 2013, FITOTERAPIA, V91, P261, DOI 10.1016/j.fitote.2013.09.012; Pachauri SD, 2013, BEHAV PHARMACOL, V24, P307, DOI 10.1097/FBP.0b013e3283637a51; Perez E, 2006, J MED FOOD, V9, P510, DOI 10.1089/jmf.2006.9.510; QUIRION R, 1995, J NEUROSCI, V15, P1455; Rainey-Smith S, 2008, NEUROSCI LETT, V438, P29, DOI 10.1016/j.neulet.2008.04.056; Ravindran R, 2005, J PHARMACOL SCI, V98, P354, DOI 10.1254/jphs.FP0050127; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; Sapolsky R. M., 2002, SCI AGING KNOWLEDGE, V2002, P21; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1222; SAPOLSKY RM, 1983, EXP GERONTOL, V18, P55, DOI 10.1016/0531-5565(83)90051-7; Sharifabad M. H., 2008, IRAN J BASIC MED SCI, V11, P37; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; Srikumar R, 2006, MOL CELL BIOCHEM, V283, P67, DOI 10.1007/s11010-006-2271-0; Wang PS, 1997, J FORMOS MED ASSOC, V96, P792; WATANABE Y, 1992, BRAIN RES, V588, P341, DOI 10.1016/0006-8993(92)91597-8; Wengreen HJ, 2007, J NUTR HEALTH AGING, V11, P230; WILSON MM, 1980, BRAIN RES, V197, P433, DOI 10.1016/0006-8993(80)91128-2; WOOLF NJ, 1991, PROG NEUROBIOL, V37, P475, DOI 10.1016/0301-0082(91)90006-M; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Zaid SSM, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-82	71	19	19	0	2	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.		2016	2016								1549158	10.1155/2016/1549158			11	Cell Biology	Cell Biology	DM1AT	WOS:000376078100001	27119005	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
S	Glushakov, AV; Glushakova, OY; Dore, S; Carney, PR; Hayes, RL		Kobeissy, F; Dixon, CE; Hayes, RL; Mondello, S		Glushakov, Alexander V.; Glushakova, Olena Y.; Dore, Sylvain; Carney, Paul R.; Hayes, Ronald L.			Animal Models of Posttraumatic Seizures and Epilepsy	INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS	Methods in Molecular Biology		English	Article; Book Chapter						Posttraumatic epilepsy; Posttraumatic seizures; Epileptogenesis; Animal model; Rodents; CCI; TBI; Fluid percussion injury; Behavioral seizures; Electroencephalography (EEG)	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; FLUID PERCUSSION INJURY; ACID-INDUCED SEIZURE; ANTAGONIST IMPROVES OUTCOMES; EP1 RECEPTOR INHIBITION; TEMPORAL-LOBE EPILEPSY; PROSTAGLANDIN E-2; KAINIC ACID; RAT HIPPOCAMPUS	Posttraumatic epilepsy (PTE) is one of the most common and devastating complications of traumatic brain injury (TBI). Currently, the etiopathology and mechanisms of PTE are poorly understood and as a result, there is no effective treatment or means to prevent it. Antiepileptic drugs remain common preventive strategies in the management of TBI to control acute posttraumatic seizures and to prevent the development of PTE, although their efficacy in the latter case is disputed. Different strategies of PTE prophylaxis have been showing promise in preclinical models, but their translation to the clinic still remains elusive due in part to the variability of these models and the fact they do not recapitulate all complex pathologies associated with human TBI. TBI is a multifaceted disorder reflected in several potentially epileptogenic alterations in the brain, including mechanical neuronal and vascular damage, parenchymal and subarachnoid hemorrhage, subsequent toxicity caused by iron-rich hemoglobin breakdown products, and energy disruption resulting in secondary injuries, including excitotoxicity, gliosis, and neuroinflammation, often coexisting to a different degree. Several in vivo models have been developed to reproduce the acute TBI cascade of events, to reflect its anatomical pathologies, and to replicate neurological deficits. Although acute and chronic recurrent posttraumatic seizures are well-recognized phenomena in these models, there is only a limited number of studies focused on PTE. The most used mechanical TBI models with documented electroencephalographic and behavioral seizures with remote epileptogenesis include fluid percussion, controlled cortical impact, and weight-drop. This chapter describes the most popular models of PTE-induced TBI models, focusing on the controlled cortical impact and the fluid percussion injury models, the methods of behavioral and electroencephalogram seizure assessments, and other approaches to detect epileptogenic properties, and discusses their potential application for translational research.	[Glushakov, Alexander V.] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32611 USA; [Glushakov, Alexander V.; Dore, Sylvain] Univ Florida, Coll Med, Ctr Translat Res Neurodegenerat Dis, Gainesville, FL 32611 USA; [Glushakova, Olena Y.; Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA; [Dore, Sylvain] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL USA; [Dore, Sylvain; Carney, Paul R.] Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA; [Dore, Sylvain; Carney, Paul R.] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA; [Dore, Sylvain] Univ Florida, Dept Psychiat, Coll Med, Gainesville, FL 32611 USA; [Carney, Paul R.] Univ Florida, Dept Pediat, Coll Med, Gainesville, FL USA; [Carney, Paul R.] Univ Florida, Coll Med, Dept Biomed Engn, Gainesville, FL USA	Glushakov, AV (corresponding author), Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32611 USA.; Glushakov, AV (corresponding author), Univ Florida, Coll Med, Ctr Translat Res Neurodegenerat Dis, Gainesville, FL 32611 USA.		Dore, Sylvain/AAG-1470-2020; Glushakov, Alexander V/B-5452-2008	Glushakov, Alexander V/0000-0003-2872-8960; Dore, Sylvain/0000-0003-3771-5109	NCCIH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine [R01 AT007429] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS046400] Funding Source: Medline; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046400] Funding Source: NIH RePORTER		Abe T, 2009, J CEREBR BLOOD F MET, V29, P66, DOI 10.1038/jcbfm.2008.88; Ahmad AS, 2008, NEUROTOX RES, V14, P343, DOI 10.1007/BF03033858; Ahmad AS, 2006, TOXICOL SCI, V89, P265, DOI 10.1093/toxsci/kfj022; Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Baik EJ, 1999, BRAIN RES, V843, P118, DOI 10.1016/S0006-8993(99)01797-7; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; BERCHTOLDKANZ E, 1981, PROSTAGLANDINS, V22, P65, DOI 10.1016/0090-6980(81)90054-X; BERGER AR, 1988, NEUROLOGY, V38, P1363, DOI 10.1212/WNL.38.9.1363; Berges S, 2000, EUR NEUROL, V43, P3, DOI 10.1159/000008120; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bladin CF, 2000, ARCH NEUROL-CHICAGO, V57, P1617, DOI 10.1001/archneur.57.11.1617; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burn J, 1997, BRIT MED J, V315, P1582, DOI 10.1136/bmj.315.7122.1582; CABRAL RJ, 1976, J NEUROL NEUROSUR PS, V39, P1052, DOI 10.1136/jnnp.39.11.1052; Campbell John N, 2014, Int J Neurol Brain Disord, V1, P1; Cao R, 2006, NEUROSCI LETT, V401, P136, DOI 10.1016/j.neulet.2006.03.005; Cao W, 2009, BRIT J PHARMACOL, V158, P2005, DOI 10.1111/j.1476-5381.2009.00498.x; Cao WG, 2011, AMINO ACIDS, V40, P1151, DOI 10.1007/s00726-010-0739-4; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cavazos JE, 2004, NEUROSCIENCE, V126, P677, DOI 10.1016/j.neuroscience.2004.04.014; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chen LLK, 2014, MIL MED, V179, P492, DOI 10.7205/MILMED-D-13-00413; Chung JI, 2013, EXP NEUROL, V249, P95, DOI 10.1016/j.expneurol.2013.08.014; Claassen J, 2003, NEUROLOGY, V60, P208, DOI 10.1212/01.WNL.0000038906.71394.DE; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Desjardins P, 2003, NEUROCHEM INT, V42, P299, DOI 10.1016/S0197-0186(02)00101-8; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ferro JM, 2004, DRUG AGING, V21, P639, DOI 10.2165/00002512-200421100-00003; Fischborn SV, 2010, EPILEPSY RES, V91, P57, DOI 10.1016/j.eplepsyres.2010.06.012; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; FOLCO GC, 1977, PROSTAG OTH LIPID M, V13, P893, DOI 10.1016/0090-6980(77)90218-0; FORSTERMANN U, 1983, ARCH INT PHARMACOD T, V263, P180; FORSTERMANN U, 1983, PSYCHOPHARMACOLOGY, V80, P365, DOI 10.1007/BF00432122; FORSTERMANN U, 1984, PROSTAGLANDINS, V27, P913, DOI 10.1016/S0090-6980(84)80010-6; FORSTERMANN U, 1982, BRAIN RES, V240, P303, DOI 10.1016/0006-8993(82)90225-6; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franzblau M, 2013, MED HYPOTHESES, V81, P842, DOI 10.1016/j.mehy.2013.09.012; Frey L, 2014, NEUROL RES, V36, P26, DOI 10.1179/1743132813Y.0000000269; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Glushakov AV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113689; Glushakov AV, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-132; Glushakov AV, 2013, J NEUROTRAUM, V30, pA163; Glushakov AV, 2015, J TRAUMA CARE, V1, P1007; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Glushakova OY, 2012, TOXICOL SCI, V130, P158, DOI 10.1093/toxsci/kfs224; Golarai G, 2001, J NEUROSCI, V21, P8523; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GRANDMAISON F, 1991, ELECTROEN CLIN NEURO, V79, P264, DOI 10.1016/0013-4694(91)90121-J; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hartl R, 1997, ACT NEUR S, V70, P240; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873; Huang YH, 2015, SEIZURE-EUR J EPILEP, V25, P150, DOI 10.1016/j.seizure.2014.10.008; Hunt RF, 2012, EPILEPSY RES, V99, P167, DOI 10.1016/j.eplepsyres.2011.10.011; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Huusko N, 2014, NEUROSCIENCE, V267, P30, DOI 10.1016/j.neuroscience.2014.02.026; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Jordan KG, 2004, J CLIN NEUROPHYSIOL, V21, P341; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Kawaguchi K, 2005, BRAIN RES, V1050, P130, DOI 10.1016/j.brainres.2005.05.038; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Kazemi H, 2012, INJURY, V43, P2132, DOI 10.1016/j.injury.2012.06.007; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Khatibi NH, 2011, ACTA NEUROCHIR SUPPL, V111, P277, DOI 10.1007/978-3-7091-0693-8_46; Kim HJ, 2008, BRAIN RES, V1193, P153, DOI 10.1016/j.brainres.2007.12.017; King C, 2010, J NEUROTRAUM, V27, P1895, DOI 10.1089/neu.2009.1178; Kinirons P, 2006, SEIZURE-EUR J EPILEP, V15, P387, DOI 10.1016/j.seizure.2006.05.001; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kovacs SK, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00047; Kramer G, 2001, EPILEPSIA, V42, P55, DOI 10.1046/j.1528-1157.2001.042suppl.3055.x; Kucukkaya B, 1998, BRAIN RES, V788, P133, DOI 10.1016/S0006-8993(97)01544-8; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Lei ZG, 2012, J NEUROTRAUM, V29, P235, DOI 10.1089/neu.2010.1537; Li BC, 2014, NEUROL RES, V36, P974, DOI 10.1179/1743132813Y.0000000314; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lopez PHH, 2011, J NEUROCHEM, V116, P900, DOI 10.1111/j.1471-4159.2010.07069.x; Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x; Macolino CM, 2014, J NEUROSCI METH, V226, P139, DOI 10.1016/j.jneumeth.2014.01.008; Maganti R, 2008, EPILEPSY BEHAV, V12, P572, DOI 10.1016/j.yebeh.2007.12.002; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martynyuk Anatoly E, 2006, Recent Pat CNS Drug Discov, V1, P261, DOI 10.2174/157488906778773706; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Menon B, 2009, EPILEPSY RES, V87, P1, DOI 10.1016/j.eplepsyres.2009.08.007; Menzler K, 2011, EPILEPSIA, V52, P707, DOI 10.1111/j.1528-1167.2011.02984.x; Michelucci R, 2006, NEUROLOGY, V67, pS14, DOI 10.1212/WNL.67.12_suppl_4.S14; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; Miller G, 2011, SCIENCE, V333, P517, DOI 10.1126/science.333.6042.517; Mishra AK, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0086852, 10.1371/journal.pone.0095280]; Moezi L, 2011, EPILEPSY BEHAV, V22, P200, DOI 10.1016/j.yebeh.2011.07.002; NAFFAHMAZZACORATTI MG, 1995, NEUROCHEM INT, V27, P461, DOI 10.1016/0197-0186(95)00053-B; Nandan M, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/3/036001; Neuberger EJ, 2014, J NEUROSCI RES, V92, P1350, DOI 10.1002/jnr.23401; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; Okada K, 2001, BRAIN RES, V894, P332, DOI 10.1016/S0006-8993(01)02019-4; Oliveira MS, 2008, NEUROSCIENCE, V152, P1110, DOI 10.1016/j.neuroscience.2008.01.005; Pagni CA, 2005, ACT NEUR S, V93, P27; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pinto AN, 1996, J NEUROL, V243, P161, DOI 10.1007/BF02444009; Pitkanen A, 2014, EPILEPSY RES, V108, P653, DOI 10.1016/j.eplepsyres.2014.02.001; Privitera Michael D., 1994, Emergency Medicine Clinics of North America, V12, P1089; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Rhoney DH, 2000, NEUROLOGY, V55, P258, DOI 10.1212/WNL.55.2.258; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sanchez JC, 2006, IEEE T NEUR SYS REH, V14, P217, DOI 10.1109/TNSRE.2006.875581; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scher AI, 2011, J NEUROTRAUM, V28, P1739, DOI 10.1089/neu.2011.1982; Shimamura M, 2013, J CEREBR BLOOD F MET, V33, P1207, DOI 10.1038/jcbfm.2013.69; Silverman IE, 2002, ARCH NEUROL-CHICAGO, V59, P195, DOI 10.1001/archneur.59.2.195; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stalhammar D, 1987, Brain Inj, V1, P73, DOI 10.3109/02699058709034448; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; STEINHAUER HB, 1979, N-S ARCH PHARMACOL, V310, P53, DOI 10.1007/BF00499874; STEINHAUER HB, 1981, EUR J PHARMACOL, V69, P199, DOI 10.1016/0014-2999(81)90414-3; Stover JF, 2003, J NEUROTRAUM, V20, P315, DOI 10.1089/089771503765172273; Strauss KI, 2008, BRAIN BEHAV IMMUN, V22, P285, DOI 10.1016/j.bbi.2007.09.011; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Takemiya T, 2006, NEUROSCI RES, V56, P103, DOI 10.1016/j.neures.2006.06.003; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tomimoto H, 2000, ACTA NEUROPATHOL, V99, P26, DOI 10.1007/PL00007402; Tomimoto H, 2002, ACTA NEUROPATHOL, V104, P601, DOI 10.1007/s00401-002-0590-0; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; Torbic H, 2013, AM J HEALTH-SYST PH, V70, P759, DOI 10.2146/ajhp120203; Toscano CD, 2008, NEUROTOXICOLOGY, V29, P1114, DOI 10.1016/j.neuro.2008.08.008; Toth Z, 1997, J NEUROSCI, V17, P8106; Toti P., 2001, Journal of Submicroscopic Cytology and Pathology, V33, P245; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Turrin NP, 2004, NEUROBIOL DIS, V16, P321, DOI 10.1016/j.nbd.2004.03.010; Velioglu SK, 1999, CEPHALALGIA, V19, P797, DOI 10.1046/j.1468-2982.1999.1909797.x; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Wallis RA, 1995, EUR J PHARMACOL, V294, P475, DOI 10.1016/0014-2999(95)00568-4; Wang YP, 2014, NEUROREPORT, V25, P954, DOI 10.1097/WNR.0000000000000219; Willmore LJ, 2009, NEUROCHEM RES, V34, P688, DOI 10.1007/s11064-008-9841-3; WILLMORE LJ, 1983, BRAIN RES, V277, P393, DOI 10.1016/0006-8993(83)90954-X; WILLMORE LJ, 1991, INT J DEV NEUROSCI, V9, P175, DOI 10.1016/0736-5748(91)90009-B; WILLMORE LJ, 1981, NEUROLOGY, V31, P63, DOI 10.1212/WNL.31.1.63; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yang TH, 2010, J NEUROL SCI, V296, P1, DOI 10.1016/j.jns.2010.06.002; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Yoshikawa K, 2006, J BIOL CHEM, V281, P14663, DOI 10.1074/jbc.M511089200; Zhen GH, 2012, NEUROBIOL AGING, V33, P2215, DOI 10.1016/j.neurobiolaging.2011.09.017; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007; Zweckberger K, 2010, NEUROSCI LETT, V470, P150, DOI 10.1016/j.neulet.2009.12.075	202	19	21	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA	1064-3745	1940-6029	978-1-4939-3816-2; 978-1-4939-3814-8	METHODS MOL BIOL	Methods Mol. Biol.		2016	1462						481	519		10.1007/978-1-4939-3816-2_27	10.1007/978-1-4939-3816-2		39	Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	BH1UG	WOS:000398551500029	27604735	Green Accepted			2021-06-18	
J	Patanwala, AE; Erstad, BL; Roe, DJ; Sakles, JC				Patanwala, Asad E.; Erstad, Brian L.; Roe, Denise J.; Sakles, John C.			Succinylcholine Is Associated with Increased Mortality When Used for Rapid Sequence Intubation of Severely Brain Injured Patients in the Emergency Department	PHARMACOTHERAPY			English	Article						brain injuries; succinylcholine; intubation; neuromuscular blocking agents	CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; SEVERITY SCORE; HEAD-INJURIES; SUXAMETHONIUM; ROCURONIUM; TRAUMA	ObjectiveTo compare succinylcholine and rocuronium regarding mortality in patients with traumatic brain injury (TBI) who are intubated in the emergency department (ED). MethodsThis was a retrospective cohort study conducted in an academic ED in the United States. Adult patients with TBI who underwent rapid sequence intubation (RSI) in the ED with rocuronium or succinylcholine between October 2010 and October 2014 were included. The main outcome of interest was in-hospital mortality. Subjects were stratified based on severity of injury using head abbreviated injury scores. The high-severity group had a severe or critical head injury (score 4 or higher); the low-severity group had a less than severe head injury (score lower than 4). Main ResultsThe final study cohort included 233 patients who were underwent RSI with succinylcholine (149 patients) or rocuronium (84 patients). In patients who received rocuronium, mortality was 22% (12/54) and 23% (7/30) in the low-severity and high-severity categories, respectively (difference 1%, 95% confidence interval [CI] -18% to 20%). In patients who received succinylcholine, mortality was 14% (14/103) and 44% (20/46) in the low-severity and high-severity categories, respectively (difference 30%, 95% CI 14-46). In the multivariate analysis after adjusting for important confounders, there was no significant association between succinylcholine and mortality in the low-severity category (odds ratio [OR] 0.75, 95% CI 0.29-1.92). However, in patients in the high-severity category, succinylcholine was associated with increased mortality compared with rocuronium (OR 4.10, 95% CI 1.18-14.12). ConclusionsIn severely brain-injured patients undergoing RSI in the ED, succinylcholine was associated with increased mortality compared with rocuronium.	[Patanwala, Asad E.; Erstad, Brian L.] Univ Arizona, Dept Pharm Practice & Sci, Coll Pharm, 1295 N Martin,POB 210202, Tucson, AZ 85721 USA; [Roe, Denise J.] Univ Arizona, Dept Epidemiol & Biostat, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ 85721 USA; [Sakles, John C.] Univ Arizona, Dept Emergency Med, Coll Med, Tucson, AZ 85721 USA	Patanwala, AE (corresponding author), Univ Arizona, Dept Pharm Practice & Sci, Coll Pharm, 1295 N Martin,POB 210202, Tucson, AZ 85721 USA.	patanwala@pharmacy.arizona.edu					Amini A, 2013, AM J HEALTH-SYST PH, V70, P1513, DOI 10.2146/ajhp120673; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Brown MM, 1996, EUR J ANAESTH, V13, P474, DOI 10.1046/j.1365-2346.1996.00973.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; Healthcare Cost and Utilization Project (HCUP), 2015, HCUP NEDS DESCR DAT; Korinek JD, 2014, EUR J EMERG MED, V21, P206, DOI 10.1097/MEJ.0b013e3283606b89; KOVARIK WD, 1994, ANESTH ANALG, V78, P469; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; May N, 2012, EMERG MED J, V29, P511, DOI 10.1136/emermed-2012-201374.4; MCLESKEY CH, 1974, ANESTH ANALG, V53, P985, DOI 10.1213/00000539-197453060-00033; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Osler T, 1996, J TRAUMA, V41, P386; Patanwala AE, 2011, ACAD EMERG MED, V18, P11, DOI 10.1111/j.1553-2712.2010.00954.x; Perry JJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002788.pub2; Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209; Sandoz Inc, 2011, SUCC CHLOR INJ SOL P; Sandoz Inc, 2015, ROC BROM INJ SOL PAC; Watt JM, 2013, EMERG MED J, V30, P893, DOI 10.1136/emermed-2012-201812	20	19	19	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0277-0008	1875-9114		PHARMACOTHERAPY	Pharmacotherapy	JAN	2016	36	1					57	63		10.1002/phar.1683			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DC0XP	WOS:000368941600008	26799349				2021-06-18	
J	Ranganathan, P; Kumar, RG; Davis, K; McCullough, EH; Berga, SL; Wagner, AK				Ranganathan, Prerna; Kumar, Raj G.; Davis, Kendra; McCullough, Emily H.; Berga, Sarah L.; Wagner, Amy K.			Longitudinal sex and stress hormone profiles among reproductive age and post-menopausal women after severe TBI: A case series analysis	BRAIN INJURY			English	Article						Hypogonadism; sex hormone physiology; traumatic brain injury; cortisol; amenorrhea; luteal hormone; functional hypothalamic amenorrhea	CORTICOTROPIN-RELEASING HORMONE; TRAUMATIC BRAIN-INJURY; NEUROENDOCRINE DYSFUNCTION; HYPOTHALAMIC AMENORRHEA; CORTISOL SECRETION; HEAD TRAUMA; RESPONSES; COMA; HYPOGONADISM; DISABILITY	Primary objectives: To describe hormone profiles for pre-/post-menopausal women, to monitor time to resumption of menstruation among pre-menopausal women and to describe cortisol associated LH suppression and phasic variation in other sex hormones over time Methods and procedures: This study determined amenorrhea duration and characterized acute (days 0-7) and chronic (months 1-6) gonadotropins [luteinizing hormone and follicle stimulating hormone (LH, FSH)], sex hormones (progesterone, estradiol) and stress hormone (cortisol) profiles. Women were pre-menopausal (n = 3) or post-menopausal (n = 3). Among premenopausal women, menstrual cycle resolution and phase association (luteal/follicular) was monitored using self-report monthly reproductive history questionnaires. This study compared post-TBI hormone profiles, stratified by menopausal status, to hormone levels from seven controls and described 6- and 12-month outcomes for these women. Main outcomes and results: Consistent with functional hypothalamic amenorrhea (FHA), menstruation resumption among pre-menopausal women occurred when serum cortisol normalized to luteal phase control levels. For post-menopausal women, serum cortisol reductions corresponded with resolution of suppressed LH levels. Conclusions: The stress of TBI results in anovulation and central hypothalamic-pituitary-ovarian (HPG) axis suppression. Future work will examine acute/chronic consequences of post-TBI hypercortisolemia and associated HPG suppression, the temporal association of HPG suppression with other neuroendocrine adaptations and how HPG suppression impacts multidimensional recovery for women with TBI.	[Ranganathan, Prerna; Kumar, Raj G.; Davis, Kendra; McCullough, Emily H.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Berga, Sarah L.] Wake Forest Univ, Dept Obstet Gynecol, Winston Salem, NC 27109 USA; [Wagner, Amy K.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Wagner, AK (corresponding author), 3471 Fifth Ave,Kaufman Bldg,Suite 202, Pittsburgh, PA 15237 USA.	wagnerak@upmc.edu			University of Pittsburgh Women's Studies Faculty Research Fund [CDC: R49 CCR 323155, DOD: W81XWH-071-0701, NIDRR H133A120087]	The authors report no conflicts of interest. This work was supported by CDC: R49 CCR 323155, DOD: W81XWH-071-0701, NIDRR H133A120087, University of Pittsburgh Women's Studies Faculty Research Fund.	[Anonymous], 2013, TRAUMATIC BRAIN INJU; ARIMURA A, 1971, P SOC EXP BIOL MED, V136, P290; Ashman T, 2014, J HEAD TRAUMA REHAB, V29, P467, DOI 10.1097/HTR.0000000000000098; Barbieri RL, 2014, METHODS MOL BIOL, V1154, P145, DOI 10.1007/978-1-4939-0659-8_7; Barton DJ, 2015, J HEAD TRAUMA REHABI; BERGA SL, 1989, J CLIN ENDOCR METAB, V68, P301, DOI 10.1210/jcem-68-2-301; Berga SL, 1997, FERTIL STERIL, V67, P1024, DOI 10.1016/S0015-0282(97)81434-3; BILLER BMK, 1990, J CLIN ENDOCR METAB, V70, P311, DOI 10.1210/jcem-70-2-311; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; BOYAR RM, 1977, NEW ENGL J MED, V296, P190, DOI 10.1056/NEJM197701272960403; Bughi Stefan, 2008, Endocr Pract, V14, P437; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Caronia LM, 2011, NEW ENGL J MED, V364, P215, DOI 10.1056/NEJMoa0911064; CASPER RC, 1979, J CLIN ENDOCR METAB, V49, P406, DOI 10.1210/jcem-49-3-406; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; COOKE RS, 1995, INJURY, V26, P399, DOI 10.1016/0020-1383(95)00064-G; Fernez-Rodriguez E., 2011, FRONT ENDOCRINOL, DOI [10.3389/fendo.2011.00025, DOI 10.3389/FENDO.2011.00025, DOI 10.3389/FEND0.2011.00025]; Foy MR, 2000, CURR DIR PSYCHOL SCI, V9, P148, DOI 10.1111/1467-8721.00081; Gordon CM, 2010, NEW ENGL J MED, V363, P365, DOI 10.1056/NEJMcp0912024; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; HILLIARD J, 1971, ENDOCRINOLOGY, V88, P730, DOI 10.1210/endo-88-3-730; HOTTA M, 1986, J CLIN ENDOCR METAB, V62, P319, DOI 10.1210/jcem-62-2-319; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kassi E, 2000, ENDOTEXT; KIMURA D, 1994, CURR DIR PSYCHOL SCI, V3, P57, DOI 10.1111/1467-8721.ep10769964; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LOUCKS AB, 1989, J CLIN ENDOCR METAB, V68, P402, DOI 10.1210/jcem-68-2-402; Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639; May AK, 2008, CRIT CARE MED, V36, P62, DOI 10.1097/01.CCM.0000292015.16171.6D; Meczekalski B, 2008, GYNECOL ENDOCRINOL, V24, P4, DOI 10.1080/09513590701807381; Michopoulos V, 2013, FERTIL STERIL, V99, P2084, DOI 10.1016/j.fertnstert.2013.02.036; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REAME NE, 1985, J CLIN ENDOCR METAB, V61, P851, DOI 10.1210/jcem-61-5-851; Reynolds RM, 2010, DIABETES CARE, V33, P714, DOI 10.2337/dc09-1796; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; ROLIH CA, 1995, MED CLIN N AM, V79, P211, DOI 10.1016/S0025-7125(16)30093-1; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; SCHALLY AV, 1964, ENDOCRINOLOGY, V75, P608, DOI 10.1210/endo-75-4-608; SCHALLY AV, 1973, SCIENCE, V179, P341, DOI 10.1126/science.179.4071.341; SCHALLY AV, 1973, ENDOCRINOLOGY, V93, P893, DOI 10.1210/endo-93-4-893; Spratt DI, 2008, AM J PHYSIOL-ENDOC M, V295, pE63, DOI 10.1152/ajpendo.00472.2007; SPRATT DI, 1993, J CLIN ENDOCR METAB, V76, P1542, DOI 10.1210/jc.76.6.1542; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wagner AK, 2012, BRAIN INJURY, V26, P1226, DOI 10.3109/02699052.2012.667594; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	52	19	19	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	4					452	461		10.3109/02699052.2016.1144081			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DK1BF	WOS:000374646200010	26963638				2021-06-18	
J	Vikane, E; Hellstrom, T; Roe, C; Bautz-Holter, E; Assmus, J; Skouen, JS				Vikane, Eirik; Hellstrom, Torgeir; Roe, Cecilie; Bautz-Holter, Erik; Assmus, Jorg; Skouen, Jan Sture			Predictors for Return to Work in Subjects with Mild Traumatic Brain Injury	BEHAVIOURAL NEUROLOGY			English	Article							CONCUSSION SYMPTOMS QUESTIONNAIRE; GLASGOW OUTCOME SCALE; HEAD-INJURY; FOLLOW-UP; POSTCONCUSSION SYMPTOMS; DEPRESSION SCALE; HOSPITAL ANXIETY; PAIN; MODERATE; RELIABILITY	Objective. To predict return to work (RTW) at 12 months for patients who either were sick-listed or were at risk to be sick-listed with persistent postconcussion symptoms (PCS) at six to eight weeks after injury. Method. A prospective cohort study of 151 patients with mild traumatic brain injury (MTBI) admitted consecutively to outpatient clinics at two University Hospitals in Norway. The study was conducted as part of a randomised clinical trial. Injury characteristics were obtained from the medical records. Sick leave data from one year before to one year after MTBI were obtained from the Norwegian Labour and Welfare Service. Self-report questionnaires were used to obtain demographic and symptom profiles. Results. We observed a significant negative association between RTW at 12 months and psychological distress, global functioning, and being sick-listed at two months after MTBI, as well as having been sick-listed the last year before injury. Conclusion. Psychological distress, global functioning postinjury, and the sick leave trajectory of the subjects were negative predictors for RTW. These findings should be taken into consideration when evaluating future vocational rehabilitation models.	[Vikane, Eirik; Skouen, Jan Sture] Haukeland Hosp, Dept Phys Med & Rehabil, N-5021 Bergen, Norway; [Vikane, Eirik; Skouen, Jan Sture] Univ Bergen, Dept Global Publ Hlth & Primary Care, N-5020 Bergen, Norway; [Hellstrom, Torgeir; Roe, Cecilie; Bautz-Holter, Erik] Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0424 Oslo, Norway; [Roe, Cecilie; Bautz-Holter, Erik] Univ Oslo, Fac Med, N-0316 Oslo, Norway; [Assmus, Jorg] Haukeland Hosp, Clin Res Ctr, N-5021 Bergen, Norway	Vikane, E (corresponding author), Haukeland Hosp, Dept Phys Med & Rehabil, N-5021 Bergen, Norway.; Vikane, E (corresponding author), Univ Bergen, Dept Global Publ Hlth & Primary Care, N-5020 Bergen, Norway.	eirik.vikane@gmail.com			Norwegian Extra Foundation for Health and Rehabilitation	The first author, Eirik Vikane, was financially supported by EXTRA funds from the Norwegian Extra Foundation for Health and Rehabilitation. The authors declare that they have no potential conflict of interests to disclose.	Burke MJ, 2015, BRAIN INJURY, V29, P300, DOI 10.3109/02699052.2014.974673; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Cancelliere C, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-17; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Constantino MJ, 2011, J CLIN PSYCHOL, V67, P184, DOI 10.1002/jclp.20754; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Eid J, 1999, SCAND J PSYCHOL, V40, P101, DOI 10.1111/1467-9450.00105; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Eriksen HR, 1999, SCAND J PUBLIC HEALT, V27, P63, DOI 10.1177/14034948990270010401; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Gjesdal S, 2004, EUR J PUBLIC HEALTH, V14, P398, DOI 10.1093/eurpub/14.4.398; Guerin F, 2006, NEUROREHABILITATION, V21, P295; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Holen A, 1983, ALEXANDER L KIELLAND; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kristman VL, 2010, OPEN OCCUP HLTH SAF, V2, P1, DOI DOI 10.2174/1876216601002010001; Kvale A, 2001, NORD J PSYCHIAT, V55, P177; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lannsjo M, 2011, J REHABIL MED, V43, P997, DOI 10.2340/16501977-0875; Lavigne G, 2015, PAIN, V156, pS75, DOI 10.1097/j.pain.0000000000000111; Lundeberg T, 2001, J REHABIL MED, V33, P279; McKerral M, 2005, J REHABIL MED, V37, P61, DOI 10.1080/16501970510026647; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Salmi L Rachid, 2014, Arch Phys Med Rehabil, V95, pS95, DOI 10.1016/j.apmr.2013.10.026; Saltychev M, 2013, BRAIN INJURY, V27, P1516, DOI 10.3109/02699052.2013.831131; Soberg HL, 2011, J TRAUMA, V71, P425, DOI 10.1097/TA.0b013e3181eff54f; Stalnacke B. M., 2012, REHABIL RES PRACT, V2012; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; TEASDALE G, 1974, LANCET, V2, P81; URSIN H, 1988, EUR J APPL PHYSIOL O, V57, P282, DOI 10.1007/BF00635986; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Noordt M, 2014, OCCUP ENVIRON MED, V71, P730, DOI 10.1136/oemed-2013-101891; Vikane E, 2014, BRAIN INJURY, V28, P1374, DOI 10.3109/02699052.2014.919532; Vindholmen S, 2014, PSYCHOL RES BEHAV MA, V7, P77, DOI 10.2147/PRBM.S56013; Waljas M, 2014, J HEAD TRAUMA REHAB, V29, P443, DOI 10.1097/HTR.0000000000000002; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; WEISAETH L, 1989, ACTA PSYCHIAT SCAND, V80, P63, DOI 10.1111/j.1600-0447.1989.tb05255.x; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	53	19	19	1	2	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0953-4180	1875-8584		BEHAV NEUROL	Behav. Neurol.		2016	2016								8026414	10.1155/2016/8026414			10	Clinical Neurology	Neurosciences & Neurology	DF8AO	WOS:000371579200001	26980942	DOAJ Gold, Green Published			2021-06-18	
J	Walsh, M; Fritz, S; Hake, D; Son, M; Greve, S; Jbara, M; Chitta, S; Fritz, B; Miller, A; Bader, MK; McCollester, J; Binz, S; Liew-Spilger, A; Thomas, S; Crepinsek, A; Shariff, F; Ploplis, V; Castellino, FJ				Walsh, Mark; Fritz, Stephanie; Hake, Daniel; Son, Michael; Greve, Sarah; Jbara, Manar; Chitta, Swetha; Fritz, Braxton; Miller, Adam; Bader, Mary K.; McCollester, Jonathon; Binz, Sophia; Liew-Spilger, Alyson; Thomas, Scott; Crepinsek, Anton; Shariff, Faisal; Ploplis, Victoria; Castellino, Francis J.			Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy	CURRENT DRUG TARGETS			English	Article						Thromboelastography; point-of-care; acquired coagulopathy; blood component therapy; systemic hemostatic agents; trauma-induced coagulopathy; hemostatic resuscitation; tranexamic acid; targeted pharmacologic therapy	RECOMBINANT-FACTOR-VIIA; FRESH-FROZEN PLASMA; PROTHROMBIN COMPLEX CONCENTRATE; DAMAGE CONTROL RESUSCITATION; ACTIVATED FACTOR-VII; CONVENTIONAL COAGULATION TESTS; BRAIN-INJURY; TRANEXAMIC ACID; FIBRINOGEN CONCENTRATE; MAJOR TRAUMA	Trauma-induced coagulopathy (TIC) is a recently described condition which traditionally has been diagnosed by the common coagulation tests (CCTs) such as prothrombin time/international normalized ratio (PT/INR), activated partial thromboplastin time (aPTT), platelet count, and fibrinogen levels. The varying sensitivity and specificity of these CCTs have led trauma coagulation researchers and clinicians to use Viscoelastic Tests (VET) such as Thromboelastography (TEG) to provide Targeted Thromboelastographic Hemostatic and Adjunctive Therapy (TTHAT) in a goal directed fashion to those trauma patients in need of hemostatic resuscitation. This review describes the utility of VETs, in particular, TEG, to provide TTHAT in trauma and acquired non-trauma-induced coagulopathy.	[Walsh, Mark; Fritz, Stephanie; Hake, Daniel; Son, Michael; Greve, Sarah; Chitta, Swetha; McCollester, Jonathon; Binz, Sophia; Liew-Spilger, Alyson; Thomas, Scott; Crepinsek, Anton; Shariff, Faisal] Mem Hosp South Bend, South Bend, IN 46601 USA; [Walsh, Mark; Jbara, Manar; Binz, Sophia; Crepinsek, Anton] Indiana Univ Sch Med SB, South Bend, IN USA; E Tennessee State Univ, Dept Internal Med, Johnson City, TN 37614 USA; [Fritz, Braxton] Montgomery Ctr Family Med, Self Reg Healthcare, Greenwood, SC USA; [Miller, Adam] Mayo Clin, Dept Urol, Rochester, MN USA; [Bader, Mary K.] St Joseph Hosp Miss, Viejo, CA USA; [Ploplis, Victoria; Castellino, Francis J.] WM Keck Ctr Transgene Res, Notre Dame, IN USA	Walsh, M (corresponding author), Mem Hosp South Bend, South Bend, IN 46601 USA.	markwalshmd@gmail.com		Walsh, Mark/0000-0002-5795-1144; Shariff, Faisal/0000-0001-6934-4600	Haemonetics Corporation, Niles, IL	MW, FJC, VP received research grants from Haemonetics Corporation, Niles, IL. MW has received educational honoraria from Boehringer Ingelheim, CSL Behring.	Bartal C, 2007, J TRAUMA, V63, P725, DOI 10.1097/TA.0b013e318031ccca; Bartal C, 2009, CURR OPIN ANESTHESIO, V22, P281, DOI 10.1097/ACO.0b013e328325a6be; Batchelor JS, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000588; Bauer KA, 2015, NEW ENGL J MED, V373, P569, DOI 10.1056/NEJMe1506600; Benes J, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00062; Bochsen L, 2007, THROMB J, V5; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Bolliger D, 2012, TRANSFUS MED REV, V26, P1, DOI 10.1016/j.tmrv.2011.07.005; Branco BC, 2014, SHOCK, V41, P200, DOI 10.1097/SHK.0000000000000109; Brenni M, 2010, ACTA ANAESTH SCAND, V54, P111, DOI 10.1111/j.1399-6576.2009.02132.x; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, CURR OPIN CRIT CARE, V13, P680, DOI 10.1097/MCC.0b013e3282f1e78f; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Brooks A, 2012, TRANSFUSION, V54, P727; Brown JB, 2015, PREHOSP EMERG CARE, V19, P79, DOI 10.3109/10903127.2014.936635; Cap A, 2015, ANAESTHESIA, V70, DOI 10.1111/anae.12914; Carroll RC, 2009, TRANSL RES, V154, P34, DOI 10.1016/j.trsl.2009.04.001; Castellino FJ, 2014, J TRAUMA ACUTE CARE, V76, P1169, DOI 10.1097/TA.0000000000000216; Chapman MP, 2013, J TRAUMA ACUTE CARE, V75, P961, DOI 10.1097/TA.0b013e3182aa9c9f; Chen LQ, 2004, J THORAC CARDIOV SUR, V128, P425, DOI 10.1016/j.jtcvs.2004.02.019; Clark AD, 2004, VOX SANG, V86, P120, DOI 10.1111/j.0042-9007.2004.00393.x; Cole E, 2015, ANN SURG, V261, P390, DOI 10.1097/SLA.0000000000000717; Collyer TC, 2009, BRIT J ANAESTH, V102, P492, DOI 10.1093/bja/aep039; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Connors J, 2015, N ENGL J MED; Cotton BA, 2011, NEW ENGL J MED, V365, P2039, DOI 10.1056/NEJMc1111095; Cotton BA, 2009, J TRAUMA, V66, P41, DOI 10.1097/TA.0b013e31819313bb; Da Luz LT, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0518-9; Dager WE, 2013, CRIT CARE MED, V41, pE42, DOI 10.1097/CCM.0b013e31827caaa3; Darlington DN, 2011, J TRAUMA, V71, P1152, DOI 10.1097/TA.0b013e318215178c; Davenport R, 2011, CRIT CARE MED, V39, P2652, DOI 10.1097/CCM.0b013e3182281af5; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Davis PK, 2012, THROMB HAEMOSTASIS, V108, P586, DOI 10.1160/TH12-04-0222; DAY JENNIFER CHEESEMAN, 1996, US BUREAU CENSUS CUR, P25; de Lange NM, 2012, OBSTET GYNECOL SURV, V67, P426, DOI 10.1097/OGX.0b013e3182605861; Dias JD, 2015, ARCH PATHOL LAB MED, V139, P665, DOI 10.5858/arpa.2014-0170-OA; Dobson GP, 2015, J TRAUMA ACUTE CARE, V79, P301, DOI 10.1097/TA.0000000000000729; Duchesne JC, 2011, AM SURGEON, V77, P201; Duchesne JC, 2010, J TRAUMA, V69, P976, DOI 10.1097/TA.0b013e3181f2abc9; Dumkow LE, 2012, AM J HEALTH-SYST PH, V69, P1646, DOI 10.2146/ajhp120055; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; Dzik W, 2011, CRIT CARE, V15, P1; Dzik Walter H, 2004, Curr Hematol Rep, V3, P324; Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017; Ellis TC, 2007, BLOOD COAGUL FIBRIN, V18, P45, DOI 10.1097/MBC.0b013e3280111a8e; Enriquez L, 2009, BR J ANAESTH S1, V103, pil4; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fayed N, 2015, TRANSFUS MED HEMOTH, V42, P99, DOI 10.1159/000381733; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; Gando S, 2009, J TRAUMA, V67, P381, DOI 10.1097/TA.0b013e3181a84f63; Garber ST, 2012, J NEUROSURG, V116, P1093, DOI 10.3171/2012.2.JNS112132; Garcia D, 2005, CHEST, V127, P2049, DOI 10.1378/chest.127.6.2049; Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907; Godier A, 2012, ANESTHESIOLOGY, V116, P94, DOI 10.1097/ALN.0b013e318238c036; Gonzalez E, 2015, ANN SURG, V262; Gonzalez E, 2010, SEMIN THROMB HEMOST, V36, P723, DOI 10.1055/s-0030-1265289; Grassetto A, 2015, POINT OF CARE TESTS; Grassetto A, 2012, CRIT CARE, V16, DOI 10.1186/cc11322; Grassetto A, 2012, BLOOD COAGUL FIBRIN, V23, P551, DOI 10.1097/MBC.0b013e32835553c0; Grottke O, 2014, CRIT CARE, V18, DOI 10.1186/cc13717; Gruen RL, 2013, MED J AUSTRALIA, V199, P310, DOI 10.5694/mja13.10747; Gunter OL, 2008, J TRAUMA, V65, P527, DOI 10.1097/TA.0b013e3181826ddf; Gurbel PA, 2011, THROMB HAEMOSTASIS, V106, P248, DOI 10.1160/TH11-02-0063; Hardaway R, 1988, CARE WOUNDED VIETNAM, P139; Harr JN, 2013, SHOCK, V39, P45, DOI 10.1097/SHK.0b013e3182787122; HARTERT H, 1948, KLIN WOCHENSCHR, V26, P577, DOI 10.1007/BF01697545; HARTERT H., 1962, BIORHEOLOGY, V1, P31; Harvin JA, 2015, J TRAUMA ACUTE CARE, V78, P905, DOI 10.1097/TA.0000000000000612; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Hepner DL, 2002, J CLIN ANESTH, V14, P405, DOI 10.1016/S0952-8180(02)00373-2; Heron MP, 2008, NATL VITAL STAT REPO, V56; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Hoffman M, 2012, J THROMB HAEMOST, V10, P1478, DOI 10.1111/j.1538-7836.2012.04793.x; Hoffman M, 2007, HEMATOL ONCOL CLIN N, V21, P1, DOI 10.1016/j.hoc.2006.11.004; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Holness L, 2004, TRANSFUS MED REV, V18, P184, DOI 10.1016/j.tmrv.2004.03.004; Hunt H, 2015, THROMBOELASTOGRAPHY; Inaba K, 2010, J AM COLL SURGEONS, V211, P573, DOI 10.1016/j.jamcollsurg.2010.06.392; Inaba K, 2010, J AM COLL SURGEONS, V210, P957, DOI 10.1016/j.jamcollsurg.2010.01.031; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; James KMH, 2008, ANESTH ANALG, V107, P402, DOI 10.1213/ane.0b013e3181770b87; Jeger V, 2009, J TRAUMA, V66, P1253, DOI 10.1097/TA.0b013e31819d3caf; Johansson PI, 2010, MED HYPOTHESES, V75, P564, DOI 10.1016/j.mehy.2010.07.031; Johansson PI, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-45; Johansson Par I, 2012, J Emerg Trauma Shock, V5, P120, DOI 10.4103/0974-2700.96479; Johansson PI, 2014, BLOOD, V124, P3052, DOI 10.1182/blood-2014-05-575340; Johansson PI, 2012, CURR OPIN ANESTHESIO, V25, P235, DOI 10.1097/ACO.0b013e32834fab76; Johnson JL, 2010, ARCH SURG-CHICAGO, V145, P973, DOI 10.1001/archsurg.2010.216; Kaatz S, 2012, AM J HEMATOL, V87, pS141, DOI 10.1002/ajh.23202; Kane I, 2015, ORTHOP SURG, V7, P26, DOI 10.1111/os.12158; Kang Y, 1985, ANESTH ANALG, V64; Kashuk JL, 2010, ANN SURG, V252, P434, DOI 10.1097/SLA.0b013e3181f09191; Kashuk JL, 2010, ANN SURG, V251, P604, DOI 10.1097/SLA.0b013e3181d3599c; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; Kelsey P, 2003, BRIT J HAEMATOL, V122, P10; Kenet G, 1999, LANCET, V354, P1879, DOI 10.1016/S0140-6736(99)05155-7; Kitchens CS, 2005, J THROMB HAEMOST, V3, P2607, DOI 10.1111/j.1538-7836.2005.01552.x; Konkle BA, 2011, HEMATOL-AM SOC HEMAT, P391, DOI 10.1182/asheducation-2011.1.391; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Labrador J, 2014, J HEMATOL THROMB DIS, V2, pe105; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Levi M, 2015, J THROMB HAEMOST, V13, P1960, DOI 10.1111/jth.13126; Levrat A, 2008, BRIT J ANAESTH, V100, P792, DOI 10.1093/bja/aen083; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; MacDonald SG, 2010, SEMIN THROMB HEMOST, V36, P712, DOI 10.1055/s-0030-1265288; Madsen EH, 2010, CLIN CHEM, V56, P839, DOI 10.1373/clinchem.2009.137471; Maegele M, 2009, VOX SANG, V97, P39, DOI 10.1111/j.1423-0410.2009.01179.x; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Mamtani R, 2012, WORLD J EMERG SURG, V7, DOI 10.1186/1749-7922-7-S1-S7; Marlu R, 2012, THROMB HAEMOSTASIS, V108, P217, DOI 10.1160/TH12-03-0179; Massaro AM, 2015, NEUROCRIT CARE, V22, P45, DOI 10.1007/s12028-014-0051-3; McCurdy MT, 2015, JAMA-J AM MED ASSOC, V313, P2077, DOI 10.1001/jama.2015.4421; Mitra B, 2012, INJURY, V43, P33, DOI 10.1016/j.injury.2011.10.011; Mitra B, 2012, INJURY, V43, P1409, DOI 10.1016/j.injury.2011.01.033; Morrison JJ, 2013, JAMA SURG, V148, P218, DOI 10.1001/jamasurg.2013.764; Morrison JJ, 2012, ARCH SURG-CHICAGO, V147, P113, DOI 10.1001/archsurg.2011.287; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Naidech AM, 2009, NEUROCRIT CARE, V11, P307, DOI 10.1007/s12028-009-9219-7; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Napolitano LM, 2013, J TRAUMA ACUTE CARE, V74, P1575, DOI 10.1097/TA.0b013e318292cc54; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Neyens R, 2014, J THROMB THROMBOLYS, V37, P80, DOI 10.1007/s11239-013-0933-9; Nienaber U, 2011, INJURY, V42, P697, DOI 10.1016/j.injury.2010.12.015; Omert L, THROMBOELASTOGRAPH T; Pearson S, 2011, NEW ENGL J MED, V365, P2334, DOI 10.1056/NEJMc1112233; Perkins JG, 2009, J TRAUMA, V66, pS77, DOI 10.1097/TA.0b013e31819d8936; Plotkin AJ, 2008, J TRAUMA, V64, pS64, DOI 10.1097/TA.0b013e318160772d; Pollack Jr CV, 2015, NEW ENGL J MED, V373, P511, DOI 10.1056/NEJMoa1502000; Pusateri AE, 2013, SHOCK, V39, P121, DOI 10.1097/SHK.0b013e318280409a; Raza I, 2013, J THROMB HAEMOST, V11, P307, DOI 10.1111/jth.12078; Riskin DJ, 2009, J AM COLL SURGEONS, V209, P198, DOI 10.1016/j.jamcollsurg.2009.04.016; Rugeri L, 2007, J THROMB HAEMOST, V5, P289, DOI 10.1111/j.1538-7836.2007.02319.x; Sankarankutty A, 2012, WORLD J EMERG SURG, V7, DOI 10.1186/1749-7922-7-S1-S3; Sarani B, 2008, CRIT CARE MED, V36, P1114, DOI 10.1097/CCM.0b013e318168f89d; Sarma A, 2013, CARDIOL THER, V2, P111, DOI 10.1007/s40119-013-0016-1; Schaden E, 2013, WIEN KLIN WOCHENSCHR, V125, P156, DOI 10.1007/s00508-013-0327-1; Schaden E, 2010, BLOOD COAGUL FIBRIN, V21, P256, DOI 10.1097/MBC.0b013e328337014c; Schiele F, 2013, BLOOD, V121, P3554, DOI 10.1182/blood-2012-11-468207; Schochl H, 2011, CRIT CARE, V15, P34; Schochl H, 2012, HAMOSTASEOLOGIE, V32, P22, DOI 10.5482/ha-1178; Schochl H, 2010, NETH J CRIT CARE, V14, P23; Schochl H, 2010, ANAESTHESIA, V65, P199, DOI 10.1111/j.1365-2044.2009.06188.x; Schochl H, 2014, ANESTH ANALG, V119, P1064, DOI 10.1213/ANE.0b013e318270a6f7; Schochl H, 2013, J TRAUMA ACUTE CARE, V74, P1587, DOI 10.1097/TA.0b013e31828c3171; Schochl H, 2013, CURR OPIN ANESTHESIO, V26, P221, DOI 10.1097/ACO.0b013e32835cca92; Schochl H, 2011, CRIT CARE, V15, DOI 10.1186/cc10539; Schochl H, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-15; Schochl H, 2010, SCAND J CLIN LAB INV, V70, P453, DOI 10.3109/00365513.2010.500396; Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948; Schochl H, 2009, J TRAUMA, V67, P125, DOI 10.1097/TA.0b013e31818b2483; Schulman S, 2013, BRIT J HAEMATOL, V164, P296; Schulman S, 2012, BLOOD, V119, P3016, DOI 10.1182/blood-2011-10-378950; Segal JB, 2005, TRANSFUSION, V45, P1413, DOI 10.1111/j.1537-2995.2005.00546.x; Shakur H, 2010, TRIALS, V11; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shore-Lesserson L, 1999, ANESTH ANALG, V88, P312, DOI 10.1097/00000539-199902000-00016; Siguret V, 2013, DRUG AGING, V30, P687, DOI 10.1007/s40266-013-0101-0; Silliman CC, 2005, BLOOD, V105, P2266, DOI 10.1182/blood-2004-07-2929; Simon DI, 2009, J AM COLL CARDIOL, V54, P1447, DOI 10.1016/j.jacc.2009.07.011; SJOGREN H, 1991, ACCIDENT ANAL PREV, V23, P77, DOI 10.1016/0001-4575(91)90037-6; Solbeck S, 2014, INT J CARDIOL, V176, P794, DOI 10.1016/j.ijcard.2014.07.084; Solomon C, 2015, ANESTH ANALG, V121, P868, DOI 10.1213/ANE.0000000000000859; Solomon C, 2015, ANESTH ANALG, V121, P289, DOI 10.1213/ANE.0000000000000738; Solomon C, 2013, BLOOD TRANSFUS-ITALY, V11, P412, DOI 10.2450/2012.0043-12; Solomon C, 2011, THROMB HAEMOSTASIS, V106, P322, DOI 10.1160/TH11-03-0175; Soreide K, 2009, BRIT J SURG, V96, P697, DOI 10.1002/bjs.6643; Southworth MR, 2013, NEW ENGL J MED, V368, P1272, DOI 10.1056/NEJMp1302834; Spahn DR, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0637-3; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Spahn DR, 2012, ANESTHESIOLOGY, V116, P9, DOI 10.1097/ALN.0b013e318238c070; Spiezia L, 2008, THROMB HAEMOSTASIS, V100, P1106, DOI 10.1160/TH08-04-0243; Spinella PC, 2008, J TRAUMA, V64, P286, DOI 10.1097/TA.0b013e318162759f; Stainsby D, 2006, BRIT J HAEMATOL, V135, P634; Stein DM, 2009, J TRAUMA, V66, P63, DOI 10.1097/TA.0b013e318191bc8a; Stensballe J, 2014, CURR OPIN ANESTHESIO, V27, P212, DOI 10.1097/ACO.0000000000000051; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tapia NM, 2013, J TRAUMA ACUTE CARE, V74, P378, DOI 10.1097/TA.0b013e31827e20e0; Theusinger OM, 2015, TRANSFUS MED HEMOTH, V42, P115, DOI 10.1159/000381320; Theusinger OM, 2015, ANESTH ANALG, V120, P627, DOI 10.1213/ANE.0000000000000561; Theusinger OM, 2014, CURR OPIN CRIT CARE, V20, P646, DOI 10.1097/MCC.0000000000000152; Theusinger Oliver M, 2013, Anesthesiol Clin, V31, P55, DOI 10.1016/j.anclin.2012.10.006; Theusinger OM, 2012, CURR OPIN ANESTHESIO, V25, P59, DOI 10.1097/ACO.0b013e32834dec98; Theusinger OM, 2011, ANESTH ANALG, V113, P1003, DOI 10.1213/ANE.0b013e31822e183f; Toulon P, 2009, THROMB HAEMOSTASIS, V101, P394, DOI 10.1160/TH08-06-0383; Toy P, 2005, CRIT CARE MED, V33, P721, DOI 10.1097/01.CCM.0000159849.94750.51; Truumees E, 2012, SPINE, V37, pE863, DOI 10.1097/BRS.0b013e31824ee320; Valle EJ, 2014, J TRAUMA ACUTE CARE, V76, P1373, DOI 10.1097/TA.0000000000000242; Van PY, 2009, J TRAUMA, V66, P1509, DOI 10.1097/TA.0b013e3181a51e33; Velik-Salchner C, 2007, J THROMB HAEMOST, V5, P1019, DOI 10.1111/j.1538-7836.2007.02481.x; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Walsh M, 2014, BLOOD B; Walsh Mark, 2011, J Extra Corpor Technol, V43, P162; Warkentin TE, 2012, BLOOD, V119, P2172, DOI 10.1182/blood-2011-11-393587; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Wojcik C, 2009, INT J EMERG MED, V2, P217, DOI 10.1007/s12245-009-0125-8; Woolley T, 2013, INJURY, V44, P593, DOI 10.1016/j.injury.2012.03.018; Wychowski Maura K, 2012, Ann Pharmacother, V46, pe10, DOI 10.1345/aph.1Q747; Ziegler B, 2013, CLIN APPL THROMB-HEM, V19, P453, DOI 10.1177/1076029612458149; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	208	19	20	0	5	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1389-4501	1873-5592		CURR DRUG TARGETS	Curr. Drug Targets		2016	17	8					954	970		10.2174/1389450117666160310153211			17	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DN5OL	WOS:000377119600009	26960340	Green Published			2021-06-18	
J	Yang, L; Guo, Y; Wen, D; Yang, L; Chen, Y; Zhang, G; Fan, Z				Yang, L.; Guo, Y.; Wen, D.; Yang, L.; Chen, Y.; Zhang, G.; Fan, Z.			Bone Fracture Enhances Trauma Brain Injury	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Article							GROUP BOX 1; MOBILITY GROUP BOX-1; COGNITIVE DEFICITS; INFLAMMATION; HMGB1; MICE; DYSFUNCTION; ACTIVATION; EXPRESSION; RELEASE	Traumatic brain injury (TBI) is one of the leading causes of mortality and morbidity in young individuals worldwide. However, the understanding of TBI at secondary phase remained obscure, and more knowledge of the pathophysiology of TBI is necessary. In this study, we examined the influence of bone fracture (BF) on TBI and investigated whether blocking high mobility group 1 (HMGB1) protein, an inflammatory mediator, could be effective to alleviate TBI. We found neurological severity was significantly increased by BF at 4days post-TBI with longer removal time of adhesive tape and higher percentage of left turn in the corner test compared to TBI treatment alone. Additionally, higher brain lesion volume and severer brain oedema in TBI+BF mice supports the negative effect of BF on TBI. HMGB1 level was significantly stimulated by BF, suggesting the important role of HMGB1 in the development of secondary TBI. Notably, ablation of HMGB1 significantly reduced this negative influence of BF on TBI. These results suggest that HMGB1 can be massively induced by the systemic immune activation triggered by BF, which in turn aggravates inflammation. Blocking HMGB1 reduced the inflammatory effect of BF and therefore helps lessen the severity of secondary TBI. In conclusion, these results provided the evidence that anti-HMGB1 may be an effective and feasible method to alleviate TBI.	[Yang, L.; Chen, Y.; Zhang, G.; Fan, Z.] Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang 050000, Peoples R China; [Guo, Y.] Hebei Univ, Dept Neurosurg, Affiliated Hosp, Baoding, Peoples R China; [Wen, D.] Hebei Med Univ, Dept Forens Med, Hebei Key Lab Forens Med, Shijiazhuang 050000, Peoples R China; [Yang, L.] Hebei Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Shijiazhuang 050000, Peoples R China	Yang, L (corresponding author), Hebei Med Univ, Hosp 2, Dept Neurosurg, 215 Heping Rd, Shijiazhuang 050000, Peoples R China.	yanglijun1981@163.com			Natural Science Foundation of Hebei Province, ChinaNatural Science Foundation of Hebei Province [H2015206201]	This project is supported by Natural Science Foundation of Hebei Province, China (Grant No. H2015206201).	Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Baethmann A, 1998, Curr Opin Anaesthesiol, V11, P193, DOI 10.1097/00001503-199804000-00013; Bouet V, 2007, EXP NEUROL, V203, P555, DOI 10.1016/j.expneurol.2006.09.006; Chen D, 2013, ACTA OTORHINOLARYNGO, V33, P398; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cibelli M, 2010, ANN NEUROL, V68, P360, DOI 10.1002/ana.22082; Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Dombovy Mary L, 2011, Continuum (Minneap Minn), V17, P584, DOI 10.1212/01.CON.0000399074.07686.76; Fan J, 2007, J IMMUNOL, V178, P6573, DOI 10.4049/jimmunol.178.10.6573; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Frink M, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-49; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Kang R, 2014, GASTROENTEROLOGY, V146, P1097, DOI 10.1053/j.gastro.2013.12.015; Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; McIntosh TK, 1996, LAB INVEST, V74, P315; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Peltz ED, 2009, SHOCK, V32, P17, DOI 10.1097/SHK.0b013e3181997173; Probst C, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/136020; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schaper F, 2014, MOL MED, V20, P72, DOI 10.2119/molmed.2014.00019; Schulze J, 2013, STROKE, V44, P246, DOI 10.1161/STROKEAHA.112.676072; Shen FX, 2011, J CEREBR BLOOD F MET, V31, P2343, DOI 10.1038/jcbfm.2011.97; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Weber DJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009443; Woolbright BL, 2013, TOXICOL APPL PHARM, V273, P524, DOI 10.1016/j.taap.2013.09.023; Yanai H, 2013, P NATL ACAD SCI USA, V110, P20699, DOI 10.1073/pnas.1320808110; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	43	19	19	0	10	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	JAN	2016	83	1					26	32		10.1111/sji.12393			7	Immunology	Immunology	CZ2IF	WOS:000366927600004	26448486	Bronze			2021-06-18	
J	Broer, S; Loscher, W				Broeer, Sonja; Loescher, Wolfgang			Novel combinations of phenotypic biomarkers predict development of epilepsy in the lithium-pilocarpine model of temporal lobe epilepsy in rats	EPILEPSY & BEHAVIOR			English	Article						Seizures; Epileptogenesis; Seizure threshold; Behavior; Status epilepticus	TRANSCRANIAL MAGNETIC STIMULATION; STATUS EPILEPTICUS; BRAIN-INJURY; BEHAVIORAL ALTERATIONS; SEIZURE MODEL; EPILEPTOGENESIS; BUMETANIDE; DISCOVERY; DISEASE; DAMAGE	The discovery and validation of biomarkers in neurological and neurodegenerative diseases is an important challenge for early diagnosis of disease and for the development of therapeutics. Epilepsy is often a consequence of brain insults such as traumatic brain injury or stroke, but as yet no biomarker exists to predict the development of epilepsy in patients at risk. Given the complexity of epilepsy, it is unlikely that a single biomarker is sufficient for this purpose, but a combinatorial approach may be needed to overcome the challenge of individual variability and disease heterogeneity. The goal of the present prospective study in the lithium-pilocarpinemodel of epilepsy in rats was to determine the discriminative utility of combinations of phenotypic biomarkers by examining their ability to predict epilepsy. For this purpose, we used a recent model refinement that allows comparing rats that will or will not develop spontaneous recurrent seizures (SRS) after pilocarpine-induced status epilepticus (SE). Potential biomarkers included in our study were seizure threshold and seizure severity in response to timed i.v. infusion of pentylenetetrazole (PTZ) and behavioral alterations determined by a battery of tests during the three weeks following SE. Three months after SE, video/EEG monitoring was used to determine which rats had developed SRS. To determine whether a biomarker or combination of biomarkers performed better than chance at predicting epilepsy after SE, derived data underwent receiver operating characteristic (ROC) curve analyses. When comparing rats with and without SRS and sham controls, the best intergroup discrimination was obtained by combining all measurements, resulting in a ROC area under curve (AUC) of 0.9592 (P < 0.01), indicating an almost perfect discrimination or accuracy to predict development of SRS. These data indicate that a combinatorial biomarker approach may overcome the challenge of individual variability in the prediction of epilepsy. (C) 2015 Elsevier Inc. All rights reserved.	[Loescher, Wolfgang] Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany; Ctr Syst Neurosci, D-30559 Hannover, Germany	Loscher, W (corresponding author), Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de	Loscher, Wolfgang/G-9824-2016	Loscher, Wolfgang/0000-0002-9648-8973; Broer, Sonja/0000-0002-7969-6586	European UnionEuropean Commission [602102]; Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony (Germany)	This study was funded by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 602102 (EPITARGET) and the Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony (Germany). We thank G. Bougamra, R. Klee, Dr. V. Rankovic, J. Ostermeyer, P. Hampel, E. Kaczmarek, M. Weissing, and D. Moller for skilled technical assistance.	Atluri G, 2013, NEUROIMAGE-CLIN, V3, P123, DOI 10.1016/j.nicl.2013.07.004; Bauer PR, 2014, INT J NEURAL SYST, V24, DOI 10.1142/S0129065714300010; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Brandt C, 2006, NEUROPHARMACOLOGY, V51, P789, DOI 10.1016/j.neuropharm.2006.05.021; Brandt C, 2015, NEUROBIOL DIS, V75, P78, DOI 10.1016/j.nbd.2014.12.015; Brandt C, 2010, J NEUROSCI, V30, P8602, DOI 10.1523/JNEUROSCI.0633-10.2010; Brima T, 2013, BRAIN RES, V1507, P146, DOI 10.1016/j.brainres.2013.02.037; Broer S, 2013, NEUROSCIENCE, V252, P253, DOI 10.1016/j.neuroscience.2013.07.050; Broer S, 2012, NEUROBIOL DIS, V46, P362, DOI 10.1016/j.nbd.2012.01.017; CHERLOW DG, 1977, ARCH NEUROL-CHICAGO, V34, P527, DOI 10.1001/archneur.1977.00500210029003; Choy M, 2014, J NEUROSCI, V34, P8672, DOI 10.1523/JNEUROSCI.4806-13.2014; Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Engel J, 2013, EPILEPSIA, V54, P61, DOI 10.1111/epi.12299; Faure JB, 2013, EPILEPSIA, V54, P1203, DOI 10.1111/epi.12219; FISH DR, 1993, BRAIN, V116, P397, DOI 10.1093/brain/116.2.397; Glien M, 2001, EPILEPSY RES, V46, P111, DOI 10.1016/S0920-1211(01)00272-8; GLOOR P, 1990, BRAIN, V113, P1673, DOI 10.1093/brain/113.6.1673; Grund B, 2010, CURR OPIN HIV AIDS, V5, P473, DOI 10.1097/COH.0b013e32833ed742; Honndorf S, 2011, EPILEPSY RES, V94, P26, DOI 10.1016/j.eplepsyres.2010.12.012; Hsieh TH, 2012, J NEUROPHYSIOL, V107, P966, DOI 10.1152/jn.00690.2011; Humpel C, 2011, TRENDS BIOTECHNOL, V29, P26, DOI 10.1016/j.tibtech.2010.09.007; Immonen R, 2013, J NEUROTRAUM, V30, P1305, DOI 10.1089/neu.2012.2815; Kandratavicius L, 2014, NEUROPSYCH DIS TREAT, V10, P1693, DOI 10.2147/NDT.S50371; Kanner AM, 2014, NEUROTHERAPEUTICS, V11, P358, DOI 10.1007/s13311-014-0271-4; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kimiskidis VK, 2014, CURR OPIN NEUROL, V27, P236, DOI 10.1097/WCO.0000000000000071; Kucker S, 2010, NEUROBIOL DIS, V37, P661, DOI 10.1016/j.nbd.2009.12.002; Langer M, 2011, EPILEPSY RES, V96, P207, DOI 10.1016/j.eplepsyres.2011.06.005; Loscher W, 2013, NAT REV DRUG DISCOV, V12, P757, DOI 10.1038/nrd4126; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Loscher W, 2009, EUR J PHARMACOL, V610, P1, DOI 10.1016/j.ejphar.2009.03.025; Mishra AK, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0086852, 10.1371/journal.pone.0095280]; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Pitkanen A, 2012, JASPERS BASIC MECH E, P1; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P231, DOI 10.1007/s13311-014-0257-2; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; POLLACK GM, 1985, J PHARMACOL METHOD, V13, P135, DOI 10.1016/0160-5402(85)90057-9; Rattka M, 2013, EPILEPSY RES, V103, P135, DOI 10.1016/j.eplepsyres.2012.09.015; Rattka M, 2012, EUR J NEUROSCI, V36, P2505, DOI 10.1111/j.1460-9568.2012.08143.x; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Rice AC, 1998, EPILEPSIA, V39, P1148, DOI 10.1111/j.1528-1157.1998.tb01305.x; Rosen C, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-20; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; SO N, 1989, ANN NEUROL, V25, P423, DOI 10.1002/ana.410250502; Soreide K, 2009, J CLIN PATHOL, V62, P1, DOI 10.1136/jcp.2008.061010; Tollner K, 2014, ANN NEUROL, V75, P550, DOI 10.1002/ana.24124; Valdes PA, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3646916; White HS, 2014, NEUROTHERAPEUTICS, V11, P373, DOI 10.1007/s13311-013-0250-1	50	19	19	2	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	DEC	2015	53						98	107		10.1016/j.yebeh.2015.09.028			10	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	CY3RS	WOS:000366328200017	26539702				2021-06-18	
J	Kadow, BT; Tyagi, P; Chermansky, CJ				Kadow, Brian T.; Tyagi, Pradeep; Chermansky, Christopher J.			Neurogenic Causes of Detrusor Underactivity	CURRENT BLADDER DYSFUNCTION REPORTS			English	Article						Detrusor underactivity; Underactive bladder; Neurogenic bladder; Urinary retention		Detrusor underactivity (DU) is a poorly understood dysfunction of the lower urinary tract which arises from multiple etiologies. Symptoms of DU are non-specific, and a pressure-flow urodynamic study is necessary to differentiate DU from other conditions such as overactive bladder (OAB) or bladder outlet obstruction (BOO). The prevalence of DU ranges from 10 to 48 %, and DU is most prevalent in elderly males. The pathophysiology underlying DU can be from both neurogenic and non-neurogenic causes. In this article, we review the neurogenic causes of detrusor underactivity, including diabetic bladder dysfunction, spinal cord injury, multiple sclerosis, Parkinson's disease, cerebrovascular accident, traumatic brain injury, and Fowler's syndrome. As knowledge about the underlying causes of DU advances, there have been several potential therapeutic approaches proposed to help those who suffer from this condition.	[Kadow, Brian T.; Tyagi, Pradeep; Chermansky, Christopher J.] Univ Pittsburgh, Dept Urol, Med Ctr, 300 Halket St,Suite 4710, Pittsburgh, PA 15213 USA	Chermansky, CJ (corresponding author), Univ Pittsburgh, Dept Urol, Med Ctr, 300 Halket St,Suite 4710, Pittsburgh, PA 15213 USA.	chermanskycj2@upmc.edu			NIH/NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK093424]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P01DK093424] Funding Source: NIH RePORTER	This study received support provided in part from NIH/NIDDK grant DK093424.	Abarbanel J, 2007, UROLOGY, V69, P436, DOI 10.1016/j.urology.2006.11.019; Abrams P, 1999, BJU INT, V84, P14; Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; Aizawa N, 2012, NEUROUROL URODYNAM, V31, P148, DOI 10.1002/nau.21212; Araki I, 2000, J UROLOGY, V164, P1640, DOI 10.1016/S0022-5347(05)67048-6; Araki I, 2003, J UROLOGY, V169, P1384, DOI 10.1097/01.ju.0000049644.27713.c8; Arrellano-Valdez F, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-549; Badri AV, 2014, CURR UROL REP, V15, DOI 10.1007/s11934-014-0435-0; Blackett H, 2009, PARKINSONISM RELAT D, V15, P81, DOI 10.1016/j.parkreldis.2007.10.016; Bougas Dimitrios A., 2004, International Urology and Nephrology, V36, P507, DOI 10.1007/s11255-004-0847-8; BRINDLEY GS, 1977, J NEUROL NEUROSUR PS, V40, P358, DOI 10.1136/jnnp.40.4.358; BRINDLEY GS, 1982, PARAPLEGIA, V20, P365, DOI 10.1038/sc.1982.65; Burney TL, 1996, J UROLOGY, V156, P1748, DOI 10.1016/S0022-5347(01)65498-3; Campeau Lysanne, 2011, Curr Urol Rep, V12, P396, DOI 10.1007/s11934-011-0219-8; Cardenas DD, 2014, SPINAL CORD, V52, P70, DOI 10.1038/sc.2013.137; Chancellor MB, 2008, UROLOGY, V72, P966, DOI 10.1016/j.urology.2008.04.041; Chapple CR, 2015, EUR UROL, V68, P351, DOI 10.1016/j.eururo.2015.02.030; Cho HJ, 2015, ANN NEUROL, V77, P726, DOI 10.1002/ana.24379; Chua K, 2003, BRAIN INJURY, V17, P469, DOI 10.1080/02699050210154268; Corcos J, 2013, CUAJ-CAN UROL ASSOC, V7, pS181, DOI 10.5489/cuaj.1618; Cruz CD, 2015, ADV DRUG DELIVER REV, V82-83, P153, DOI 10.1016/j.addr.2014.11.007; DasGupta R, 2003, DRUGS, V63, P153, DOI 10.2165/00003495-200363020-00003; Dmitrieva N, 2002, J NEUROSCI, V22, P7147; Drake MJ, 2014, NAT REV UROL, V11, P454, DOI 10.1038/nrurol.2014.156; Ersoz M, 2005, CEREBROVASC DIS, V20, P395, DOI 10.1159/000088670; Fedele D, 2005, NAT CLIN PRACT UROL, V2, P282, DOI 10.1038/ncpuro0211; FOWLER CJ, 1985, BRIT J UROL, V57, P67, DOI 10.1111/j.1464-410X.1985.tb08988.x; FOWLER CJ, 1988, BRIT MED J, V297, P1436, DOI 10.1136/bmj.297.6661.1436; Frias B, 2015, J NEUROSCI, V35, P2146, DOI 10.1523/JNEUROSCI.0373-14.2015; FRIMODTMOLLER C, 1978, DAN MED BULL, V25, P49; Giannantoni A, 2011, ARCH PHYS MED REHAB, V92, P1134, DOI 10.1016/j.apmr.2011.02.013; Hinson JL, 1996, UROL CLIN N AM, V23, P475, DOI 10.1016/S0094-0143(05)70326-8; Jeong SJ, 2012, KOREAN J UROL, V53, P342, DOI 10.4111/kju.2012.53.5.342; Kim TG, 2015, ANN REHABIL MED-ARM, V39, P262, DOI 10.5535/arm.2015.39.2.262; Kong KH, 2000, ARCH PHYS MED REHAB, V81, P1464, DOI 10.1053/apmr.2000.9630; Krishnamoorthy S, 2009, INDIAN J UROL, V25, P407, DOI 10.4103/0970-1591.56186; Kulakli F, 2014, BRAIN INJURY, V28, P323, DOI 10.3109/02699052.2013.865268; Kuo Hann-Chorng, 2010, Rev Urol, V12, pe69; LAPIDES J, 1972, Journal of Urology, V107, P458; Levanovich PE, 2015, INT UROL NEPHROL, V47, P465, DOI 10.1007/s11255-015-0924-1; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LIM CS, 1995, WORLD J UROL, V13, P34; Litwiller SE, 1999, J UROLOGY, V161, P743, DOI 10.1016/S0022-5347(01)61760-9; Liu CW, 2010, SPINAL CORD, V48, P319, DOI 10.1038/sc.2009.132; Liu Z, 2015, INT UROL NEPHROL, V47, P751, DOI 10.1007/s11255-015-0951-y; MAGGI CA, 1988, BRAIN RES, V449, P61, DOI 10.1016/0006-8993(88)91024-4; Manack A, 2011, NEUROUROL URODYNAM, V30, P395, DOI 10.1002/nau.21003; Miyazato Minoru, 2013, Rev Urol, V15, P11; Moody BJ, 2014, NEUROUROL URODYNAM, V33, P1159, DOI 10.1002/nau.22470; Nirmal J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102644; Oelke M, 2015, NEUROL URODYN; Osman NI, 2014, NAT REV UROL, V11, P639, DOI 10.1038/nrurol.2014.286; Pataky Z, 2013, EXP CLIN ENDOCR DIAB, V121, P20, DOI 10.1055/s-0032-1329957; Pezet S, 2006, ANNU REV NEUROSCI, V29, P507, DOI 10.1146/annurev.neuro.29.051605.112929; Ransmayr GN, 2008, NEUROLOGY, V70, P299, DOI 10.1212/01.wnl.0000296826.61499.26; Ren J, 2015, NEUROUROL URODYN; Roth B, 2009, J UROLOGY, V181, P2209, DOI 10.1016/j.juro.2009.01.049; Sasaki K, 2004, DIABETES, V53, P2723, DOI 10.2337/diabetes.53.10.2723; Sasaki K, 2003, UROL CLIN N AM, V30, P1, DOI 10.1016/S0094-0143(02)00116-7; SCHAFER W, 1995, WORLD J UROL, V13, P47; Sievert KD, 2010, ANN NEUROL, V67, P74, DOI 10.1002/ana.21814; Smith PP, 2014, INT UROL NEPHROL, V46, pS35, DOI 10.1007/s11255-014-0809-8; Smith PP, 2010, NEUROUROL URODYNAM, V29, P408, DOI 10.1002/nau.20765; Song QX, 2014, NAT REV UROL, V11, P579, DOI 10.1038/nrurol.2014.244; STASKIN DS, 1988, J UROLOGY, V140, P117, DOI 10.1016/S0022-5347(17)41501-1; Vizzard MA, 2006, PROG BRAIN RES, V152, P97, DOI 10.1016/S0079-6123(05)52007-7; Witsell DL, 2012, HEAD NECK-J SCI SPEC, V34, P1136, DOI 10.1002/hed.21894; Wu ZZ, 2009, J BIOL CHEM, V284, P36453, DOI 10.1074/jbc.M109.075523; Yoshimura N, 2005, BJU INT, V95, P733, DOI 10.1111/j.1464-410X.2005.05392.x; Yu Z, 2015, UROL INT; Yum KS, 2013, EUR NEUROL, V70, P291, DOI 10.1159/000352040	71	19	19	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7212	1931-7220		CURR BLADDER DYSFUNC	Curr. Bladder Dysfunct. Rep.	DEC	2015	10	4					325	331		10.1007/s11884-015-0331-6			7	Urology & Nephrology	Urology & Nephrology	V5Z9B	WOS:000420091000003	26715948	Green Accepted			2021-06-18	
J	Roberts, RA; Aschner, M; Calligaro, D; Guilarte, TR; Hanig, JP; Herr, DW; Hudzik, TJ; Jeromin, A; Kallman, MJ; Liachenko, S; Lynch, JJ; Miller, DB; Moser, VC; O'Callaghan, JP; Slikker, W; Paule, MG				Roberts, Ruth A.; Aschner, Michael; Calligaro, David; Guilarte, Tomas R.; Hanig, Joseph P.; Herr, David W.; Hudzik, Thomas J.; Jeromin, Andreas; Kallman, Mary J.; Liachenko, Serguei; Lynch, James J., III; Miller, Diane B.; Moser, Virginia C.; O'Callaghan, James P.; Slikker, William, Jr.; Paule, Merle G.			Translational Biomarkers of Neurotoxicity: A Health and Environmental Sciences Institute Perspective on the Way Forward	TOXICOLOGICAL SCIENCES			English	Article						neurotoxicity; biomarker; imaging; CSF; neurotoxicity	CEREBROSPINAL-FLUID BIOMARKERS; TRAUMATIC BRAIN-INJURY; C-TERMINAL HYDROLASE-L1; 18 KDA TSPO; TRIMETHYLTIN; NEURODEGENERATION; CORRELATE	Neurotoxicity has been linked to a number of common drugs and chemicals, yet efficient and accurate methods to detect it are lacking. There is a need for more sensitive and specific biomarkers of neurotoxicity that can help diagnose and predict neurotoxicity that are relevant across animal models and translational from nonclinical to clinical data. Fluid-based biomarkers such as those found in serum, plasma, urine, and cerebrospinal fluid (CSF) have great potential due to the relative ease of sampling compared with tissues. Increasing evidence supports the potential utility of fluid-based biomarkers of neurotoxicity such as microRNAs, F-2-isoprostanes, translocator protein, glial fibrillary acidic protein, ubiquitin C-terminal hydrolase L1, myelin basic protein, microtubule-associated protein-2, and total tau. However, some of these biomarkers such as those in CSF require invasive sampling or are specific to one disease such as Alzheimer's, while others require further validation. Additionally, neuroimaging methodologies, including magnetic resonance imaging, magnetic resonance spectroscopy, and positron emission tomography, may also serve as potential biomarkers and have several advantages including being minimally invasive. The development of biomarkers of neurotoxicity is a goal shared by scientists across academia, government, and industry and is an ideal topic to be addressed via the Health and Environmental Sciences Institute (HESI) framework which provides a forum to collaborate on key challenging scientific topics. Here we utilize the HESI framework to propose a consensus on the relative potential of currently described biomarkers of neurotoxicity to assess utility of the selected biomarkers using a nonclinical model.	[Roberts, Ruth A.] ApconiX, BioHub Alderley Pk, Macclesfield SK10 4TG, Cheshire, England; [Aschner, Michael] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; [Calligaro, David] Eli Lilly & Co, Div Eli Lilly & Co, Pharmacol Toxicol Res Lilly Res Labs, Lilly Corp Ctr, Indianapolis, IN 46285 USA; [Guilarte, Tomas R.] Columbia Univ, New York, NY 10032 USA; [Hanig, Joseph P.] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA; [Herr, David W.; Moser, Virginia C.] US EPA, NHEERL, Toxicol Assessment Div, Res Triangle Pk, NC 27711 USA; [Hudzik, Thomas J.] AbbVie Inc, N Chicago, IL 60064 USA; [Jeromin, Andreas; Lynch, James J., III] Quanterix Inc, Lexington, MA 02421 USA; [Kallman, Mary J.] Covance Inc, Indianapolis, IN 46214 USA; [Liachenko, Serguei; Slikker, William, Jr.] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; [Miller, Diane B.; O'Callaghan, James P.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA; [Paule, Merle G.] US FDA, Natl Ctr Toxicol Res, Div Neurotoxicol, Jefferson, AR 72079 USA	Roberts, RA (corresponding author), ApconiX, BioHub Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.	ruth.roberts@apconix.com			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES009089] Funding Source: NIH RePORTER; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30 ES009089] Funding Source: Medline		Auffray C, 2009, GENOME MED, V1, DOI 10.1186/gm2; BACHMANN MO, 1993, OCCUP MED-OXFORD, V43, P149, DOI 10.1093/occmed/43.3.149; BALABAN CD, 1988, NEUROSCIENCE, V26, P337, DOI 10.1016/0306-4522(88)90150-9; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Belogurov AA, 2008, J IMMUNOL, V180, P1258, DOI 10.4049/jimmunol.180.2.1258; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Blennow K, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006221; Bolon B, 2013, TOXICOL PATHOL, V41, P1028, DOI 10.1177/0192623312474865; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Cook D, 2014, NAT REV DRUG DISCOV, V13, P419, DOI 10.1038/nrd4309; Donnan G A, 1986, Clin Exp Neurol, V22, P155; Dopp E, 2012, J TOXICOL-US, V2012, DOI 10.1155/2012/358484; Ferris MJ, 2008, NEUROSCI BIOBEHAV R, V32, P883, DOI 10.1016/j.neubiorev.2008.01.004; FOWLE JR, 1992, ENVIRON HEALTH PERSP, V98, P235, DOI 10.2307/3431277; Gouzoulis-Mayfrank Euphrosyne, 2009, Dialogues Clin Neurosci, V11, P305; Guo D, 2013, STROKE, V44, P1739, DOI 10.1161/STROKEAHA.111.000835; Hanig J, 2014, REGUL TOXICOL PHARM, V70, P641, DOI 10.1016/j.yrtph.2014.09.010; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; Keifer Matthew C, 2007, J Agromedicine, V12, P17, DOI 10.1300/J096v12n01_03; Koh W, 2014, P NATL ACAD SCI USA, V111, P7361, DOI 10.1073/pnas.1405528111; Kreisl WC, 2013, J CEREBR BLOOD F MET, V33, P53, DOI 10.1038/jcbfm.2012.131; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liachenko S, 2015, TOXICOL SCI, V146, P183, DOI 10.1093/toxsci/kfv083; Liu H, 2014, NEUROTOX RES, V26, P179, DOI 10.1007/s12640-014-9461-4; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; MCMILLAN DE, 1986, NEUROTOXICOL TERATOL, V8, P499; Milne GL, 2006, ANTIOXID REDOX SIGN, V8, P1379, DOI 10.1089/ars.2006.8.1379; Miodovnik A, 2011, MT SINAI J MED, V78, P58, DOI 10.1002/msj.20237; Mondello S, 2012, BRAIN INJURY, V26, P1629, DOI 10.3109/02699052.2012.700083; Moser VC, 1996, J TOXICOL ENV HEALTH, V47, P567, DOI 10.1080/009841096161546; O'CALLAGHAN J P, 1991, Biomedical and Environmental Sciences, V4, P197; O'Callaghan James P, 2005, Expert Opin Drug Saf, V4, P433, DOI 10.1517/14740338.4.3.433; O'Callaghan JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102003; Ogata K, 2015, TOXICOL PATHOL, V43, P198, DOI 10.1177/0192623314530533; Perrin RJ, 2009, NATURE, V461, P916, DOI 10.1038/nature08538; Pogge A, 2004, NEUROTOXICOLOGY, V25, P525, DOI 10.1016/j.neuro.2003.10.007; Poste G, 2011, NATURE, V469, P156, DOI 10.1038/469156a; Pritt ML, 2014, TOXICOL SCI, V141, P398, DOI 10.1093/toxsci/kfu136; Rosen C, 2013, CURR OPIN PSYCHIATR, V26, P276, DOI 10.1097/YCO.0b013e32835f6747; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Sadiq S, 2012, J TOXICOL-US, V2012, DOI 10.1155/2012/132671; Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454; Spencer P, 2000, EXPT CLIN NEUROTOXIC; Stephenson E, 2014, NAT REV NEUROL, V10, P459, DOI 10.1038/nrneurol.2014.118; Teunissen CE, 2012, MULT SCLER J, V18, P552, DOI 10.1177/1352458512443092; Tumani H, 2009, NEUROBIOL DIS, V35, P117, DOI 10.1016/j.nbd.2009.04.010; US Environmental Protection Agency. (EPA), 1998, GUID NEUR RISK ASS, V63; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wan HI, 2012, BIOMARK MED, V6, P119, DOI [10.2217/BMM.11.98, 10.2217/bmm.11.98]; Zhang X, 2013, J APPL TOXICOL, V33, P861, DOI 10.1002/jat.2857	53	19	20	1	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1096-6080	1096-0929		TOXICOL SCI	Toxicol. Sci.	DEC	2015	148	2					332	340		10.1093/toxsci/kfv188			9	Toxicology	Toxicology	CZ6FB	WOS:000367195500001	26609132	Green Published			2021-06-18	
J	Han, K; Chapman, SB; Krawczyk, DC				Han, Kihwan; Chapman, Sandra B.; Krawczyk, Daniel C.			Altered amygdala connectivity in individuals with chronic traumatic brain injury and comorbid depressive symptoms	FRONTIERS IN NEUROLOGY			English	Article						TBI; depression; functional connectivity; fMRI; amygdala; resting-state; BDI; beck depression inventory-II	INTRINSIC FUNCTIONAL CONNECTIVITY; TREATMENT-RESISTANT DEPRESSION; POSTTRAUMATIC-STRESS-DISORDER; GLOBAL SIGNAL REGRESSION; IMPAIRED SELF-AWARENESS; MAJOR DEPRESSION; INVENTORY-II; PSYCHIATRIC-DISORDERS; NETWORK DYSFUNCTION; DEFAULT MODE	Depression is one of the most common psychiatric conditions in individuals with chronic traumatic brain injury (TBI). Though depression has detrimental effects in TBI and network dysfunction is a "hallmark" of TBI and depression, there have not been any prior investigations of connectivity-based neuroimaging biomarkers for comorbid depression in TBI. We utilized resting-state functional magnetic resonance imaging to identify altered amygdala connectivity in individuals with chronic TBI (8 years post injury on average) exhibiting comorbid depressive symptoms (N = 31), relative to chronic TBI individuals having minimal depressive symptoms (N = 23). Connectivity analysis of these participant sub-groups revealed that the TBI-plus-depressive symptoms group showed relative increases in amygdala connectivity primarily in the regions that are part of the salience, somatomotor, dorsal attention, and visual networks (p), < 0.01, Pihiswi < 0.025). Relative increases in amygdala connectivity in the TBI-plus-depressive symptoms group were also observed within areas of the limbic cortical mood regulating circuit (the left dorsomedial and right dorsolateral prefrontal cortices and thalamus) and the brainstem. Further analysis revealed that spatially dissociable patterns of correlation between amygdala connectivity and symptom severity according to subtypes (Cognitive and Affective) of depressive symptoms (p(voxel) < 0.01, p(duster) < 0.025). Taken together, these results suggest that amygdala connectivity may be a potentially effective neuroimaging biomarker for comorbid depressive symptoms in chronic TBI.	[Han, Kihwan; Chapman, Sandra B.; Krawczyk, Daniel C.] Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX 75230 USA; [Krawczyk, Daniel C.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA	Han, K (corresponding author), Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX 75230 USA.	kihwan.han@utdallas.edu	Han, Kihwan/I-1984-2019	Han, Kihwan/0000-0002-4574-7306	Department of Defense CDMRP grantsUnited States Department of Defense [W81XWH-11-2-0194, W81XWH-11-2-0195]; Meadows Foundation	We would like to thank all study participants and their families that supported this study. Our thanks also go to Mr. kVeikei Yu and Mr. Michael Holloway for the acquisition of MRI scans, Ms. Tiffani Jantz, Mr. David Martinez and Ms. Jellena Rakic for the acquisition of neuropsychological test scores and Mr. Barry Rodgers for his assistance with the analysis of neuropsychological test scores. Lastly, we would like to thank Dr. Ian Robertson and Dr. Vas Asha for their helpful suggestions. This work has been supported by Department of Defense CDMRP grants W81XWH-11-2-0194 to DCK and W81XWH-11-2-0195 to SRC and a grant from the Meadows Foundation to DCK and SBC.	Adolphs R, 2008, CURR OPIN NEUROBIOL, V18, P166, DOI 10.1016/j.conb.2008.06.006; Alalade E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020035; AMARAL DG, 1992, EXP BRAIN RES, V88, P375, DOI 10.1007/BF02259113; Anand A, 2005, BIOL PSYCHIAT, V57, P1079, DOI 10.1016/j.biopsych.2005.02.021; APPLEGATE CD, 1983, PHYSIOL BEHAV, V31, P353, DOI 10.1016/0031-9384(83)90201-9; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Beck AT, 1996, BDI 2 BECK DEPRESSIO; Bilek E, 2013, J NEUROSCI, V33, P7050, DOI 10.1523/JNEUROSCI.3081-12.2013; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Buckley TC, 2001, J SUBST ABUSE TREAT, V20, P197, DOI 10.1016/S0740-5472(00)00169-0; Buckner RL, 2011, J NEUROPHYSIOL, V106, P2322, DOI 10.1152/jn.00339.2011; Cao H, 2014, NEUROIMAGE, V84, P888, DOI 10.1016/j.neuroimage.2013.09.013; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen CH, 2008, NEUROPSYCHOPHARMACOL, V33, P1909, DOI 10.1038/sj.npp.1301593; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; CLARK DC, 1983, J NERV MENT DIS, V171, P705, DOI 10.1097/00005053-198312000-00001; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Cordova-Palomera A, 2015, HUM BRAIN MAPP, V36, P3761, DOI 10.1002/hbm.22876; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; de Pasquale F, 2013, NEUROIMAGE, V69, P51, DOI 10.1016/j.neuroimage.2012.11.051; Deb S, 1999, AM J PSYCHIAT, V156, P374; Delis DC, 2001, D KEFS EXECUTIVE FUN; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Dutta A, 2014, PSYCHIAT RES-NEUROIM, V224, P139, DOI 10.1016/j.pscychresns.2014.10.003; Elliott R, 1997, PSYCHOL MED, V27, P931, DOI 10.1017/S0033291797005187; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fox MD, 2006, NAT NEUROSCI, V9, P23, DOI 10.1038/nn1616; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; Goldberg D, 2011, WORLD PSYCHIATRY, V10, P226; Gotts SJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00356; Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020; Guo WB, 2011, PROG NEURO-PSYCHOPH, V35, P1297, DOI 10.1016/j.pnpbp.2011.02.006; Guo WB, 2013, PROG NEURO-PSYCHOPH, V46, P13, DOI 10.1016/j.pnpbp.2013.06.009; Guo WB, 2013, PROG NEURO-PSYCHOPH, V44, P51, DOI 10.1016/j.pnpbp.2013.01.010; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Hamilton JP, 2013, NEUROBIOL DIS, V52, P4, DOI 10.1016/j.nbd.2012.01.015; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Han K, 2011, J MAGN RESON IMAGING, V34, P1480, DOI 10.1002/jmri.22823; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Harro J, 2001, BRAIN RES REV, V38, P79, DOI 10.1016/S0165-0173(01)00082-0; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Hsu M, 2005, SCIENCE, V310, P1680, DOI 10.1126/science.1115327; Hu X, 2015, MOVEMENT DISORD, V30, P238, DOI 10.1002/mds.26087; Hudak A, 2011, PSYCHIAT RES-NEUROIM, V191, P160, DOI 10.1016/j.pscychresns.2010.10.003; Jo HJ, 2013, J APPL MATH, DOI 10.1155/2013/935154; Johansen-Berg H, 2008, CEREB CORTEX, V18, P1374, DOI 10.1093/cercor/bhm167; Johnstone T, 2006, HUM BRAIN MAPP, V27, P779, DOI 10.1002/hbm.20219; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kaiser RH, 2015, JAMA PSYCHIAT, V72, P603, DOI 10.1001/jamapsychiatry.2015.0071; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Krawczyk DC, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-29; Lancaster JL, 2007, HUM BRAIN MAPP, V28, P1194, DOI 10.1002/hbm.20345; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liu ZF, 2010, PSYCHIAT RES-NEUROIM, V182, P211, DOI 10.1016/j.pscychresns.2010.03.004; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Lui S, 2011, AM J PSYCHIAT, V168, P642, DOI 10.1176/appi.ajp.2010.10101419; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Maller JJ, 2014, BEHAV BRAIN RES, V271, P147, DOI 10.1016/j.bbr.2014.05.047; Maller JJ, 2014, HUM BRAIN MAPP, V35, P227, DOI 10.1002/hbm.22171; Manoliu A, 2014, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00930; Matthews SC, 2008, J AFFECT DISORDERS, V111, P13, DOI 10.1016/j.jad.2008.05.022; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mayberg HS, 2009, J CLIN INVEST, V119, P717, DOI 10.1172/JCI38454; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nichols T, 2005, NEUROIMAGE, V25, P653, DOI 10.1016/j.neuroimage.2004.12.005; Northoff G, 2011, NEUROSCI BIOBEHAV R, V35, P1929, DOI 10.1016/j.neubiorev.2010.12.007; Ochsner KN, 2009, PSYCHOL SCI, V20, P1322, DOI 10.1111/j.1467-9280.2009.02459.x; Ongur D, 2003, J COMP NEUROL, V460, P425, DOI 10.1002/cne.10609; Palmer GA, 2014, MIL MED, V179, P879, DOI 10.7205/MILMED-D-14-00048; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Peng DH, 2011, CHINESE MED J-PEKING, V124, P369, DOI 10.3760/cma.j.issn.0366-6999.2011.03.009; Pessoa L, 2010, NAT REV NEUROSCI, V11, P773, DOI 10.1038/nrn2920; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Price JL, 2012, TRENDS COGN SCI, V16, P61, DOI 10.1016/j.tics.2011.12.011; Price JL, 2010, NEUROPSYCHOPHARMACOL, V35, P192, DOI 10.1038/npp.2009.104; Rabinak Christine A, 2011, Front Psychiatry, V2, P62, DOI 10.3389/fpsyt.2011.00062; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ramasubbu R, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00017; Rao V, 2012, J NEUROPSYCH CLIN N, V24, P309, DOI 10.1176/appi.neuropsych.11080188; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P231, DOI 10.1176/appi.neuropsych.22.2.231; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Reiman EM, 1997, AM J PSYCHIAT, V154, P918; Romero K, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00158; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Roy AK, 2009, NEUROIMAGE, V45, P614, DOI 10.1016/j.neuroimage.2008.11.030; Saad ZS, 2013, BRAIN CONNECT, V3, P339, DOI 10.1089/brain.2013.0156; Saad ZS, 2012, BRAIN CONNECT, V2, P25, DOI 10.1089/brain.2012.0080; Sagaspe P, 2011, NEUROIMAGE, V55, P1825, DOI 10.1016/j.neuroimage.2011.01.027; Sakaki M, 2013, J COGNITIVE NEUROSCI, V25, P1206, DOI 10.1162/jocn_a_00392; Sander D, 2003, REV NEUROSCIENCE, V14, P303, DOI 10.1515/REVNEURO.2003.14.4.303; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; Schmahmann JD, 2010, NEUROPSYCHOL REV, V20, P236, DOI 10.1007/s11065-010-9142-x; Schonberger M, 2011, BRAIN INJURY, V25, P543, DOI 10.3109/02699052.2011.565013; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sheline YI, 2010, P NATL ACAD SCI USA, V107, P11020, DOI 10.1073/pnas.1000446107; Siegert RJ, 2009, J INT NEUROPSYCH SOC, V15, P142, DOI 10.1017/S1355617708090048; Siegle GJ, 2002, BIOL PSYCHIAT, V51, P693, DOI 10.1016/S0006-3223(02)01314-8; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sripada C, 2014, NEUROIMAGE, V89, P110, DOI 10.1016/j.neuroimage.2013.11.006; Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069; Stoodley CJ, 2012, CEREBELLUM, V11, P352, DOI 10.1007/s12311-011-0260-7; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Tahmasian M, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00639; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Taylor JG, 2005, NEURAL NETWORKS, V18, P353, DOI 10.1016/j.neunet.2005.03.005; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ., 1995, GUIDELINES SURVEILLA; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Van Essen DC, 2005, NEUROIMAGE, V28, P635, DOI 10.1016/j.neuroimage.2005.06.058; Van Essen DC, 2001, J AM MED INFORM ASSN, V8, P443, DOI 10.1136/jamia.2001.0080443; Vanheule S, 2008, ASSESSMENT, V15, P177, DOI 10.1177/1073191107311261; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Veer IM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00041; Vincent JL, 2008, J NEUROPHYSIOL, V100, P3328, DOI 10.1152/jn.90355.2008; Vuilleumier P, 2005, TRENDS COGN SCI, V9, P585, DOI 10.1016/j.tics.2005.10.011; Wang L, 2012, J AFFECT DISORDERS, V142, P6, DOI 10.1016/j.jad.2012.04.013; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 2008, WECHSLER MEMORY SCAL, V3; Wei MB, 2015, J AFFECT DISORDERS, V174, P527, DOI 10.1016/j.jad.2014.12.020; Whalen PJ, 1998, CURR DIR PSYCHOL SCI, V7, P177, DOI 10.1111/1467-8721.ep10836912; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Zeng LL, 2012, BRAIN, V135, P1498, DOI 10.1093/brain/aws059; Zhang XC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085241	159	19	21	0	20	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	NOV 4	2015	6								231	10.3389/fneur.2015.00231			22	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CV3LR	WOS:000364161200001	26581959	DOAJ Gold, Green Published			2021-06-18	
J	Chin, LMK; Chan, L; Woolstenhulme, JG; Christensen, EJ; Shenouda, CN; Keyser, RE				Chin, Lisa M. K.; Chan, Leighton; Woolstenhulme, Joshua G.; Christensen, Eric J.; Shenouda, Christian N.; Keyser, Randall E.			Improved Cardiorespiratory Fitness With Aerobic Exercise Training in Individuals With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						endurance training; exercise tolerance; fatigue; physical activity; (V)over dotO(2)	FATIGUE SEVERITY SCALE; PHYSICAL-ACTIVITY; ANAEROBIC THRESHOLD; MULTIPLE-SCLEROSIS; SLEEP DISTURBANCE; CAPACITY; ADULTS; EPIDEMIOLOGY; INTENSITY; HEALTH	Objective: To examine cardiorespiratory fitness in individuals with traumatic brain injury (TBI), before and following participation in a supervised 12-week aerobic exercise training program. Methods: Ten subjects with nonpenetrating TBI (TBI severity: mild, 50%; moderate, 40%; severe, 10%; time since injury [mean +/- SD]: 6.6 +/- 6.8 years) performed exercise training on a treadmill 3 times a week for 30 minutes at vigorous intensity (70%-80% of heart rate reserve). All subjects completed a cardiopulmonary exercise test, with pulmonary gas exchange measured and a questionnaire related to fatigue (Fatigue Severity Scale) at baseline and following exercise training. Results: After training, increases (P <.01) in peak oxygen consumption ((V)over dotO(2); + 3.1 +/- 2.4 mL/min/kg), time to volitional fatigue (+ 1.4 +/- 0.8 minutes), and peak work rate (+ 59 +/- 43 W) were observed. At the anaerobic threshold, (V)over dotO(2) (+ 3.6 +/- 2.1 mL/kg/min), treadmill time (+ 1.8 +/- 1.1 minutes), and work rate (+ 37 +/- 39 W) were higher (P <.01) following exercise training. Subjects also reported significantly lower (P <.05) Fatigue Severity Scale composite scores (-0.9 +/- 1.3) following exercise training. Conclusion: These findings suggest that individuals with TBI may benefit from participation in vigorous aerobic exercise training with improved cardiorespiratory fitness and diminished fatigue.	[Chin, Lisa M. K.; Woolstenhulme, Joshua G.; Keyser, Randall E.] George Mason Univ, Dept Rehabil Sci, 4400 Univ Dr, Fairfax, VA 22030 USA; [Chin, Lisa M. K.; Chan, Leighton; Woolstenhulme, Joshua G.; Christensen, Eric J.; Keyser, Randall E.] NIH, Dept Rehabil Med, Ctr Clin, Bethesda, MD 20892 USA; [Chan, Leighton; Shenouda, Christian N.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA	Chin, LMK (corresponding author), George Mason Univ, Dept Rehabil Sci, 4400 Univ Dr, Fairfax, VA 22030 USA.	lchin2@gmu.edu	Chin, Lisa MK/O-4706-2014	Chin, Lisa MK/0000-0002-0178-739X	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G192HI-H]; National Institutes of Health Clinical Center (Rehabilitation Medicine Department Intramural Funds)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This study was supported by the Center for Neuroscience and Regenerative Medicine (G192HI-H) and the National Institutes of Health Clinical Center (Rehabilitation Medicine Department Intramural Funds). The authors thank Bart Drinkard and Anne Quinn for their assistance with the exercise training sessions and data collection. They also thank Beth Kvochak for initial recruitment efforts.	Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12; Amonette WE, 2013, J HEAD TRAUMA REHAB, V28, pE13, DOI 10.1097/HTR.0b013e31826463a1; Baquet G, 2003, SPORTS MED, V33, P1127, DOI 10.2165/00007256-200333150-00004; Bartlo P, 2007, J CARDIOPULM REHABIL, V27, P368, DOI 10.1097/01.HCR.0000300263.07764.4a; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Bhambhani Y, 2005, ARCH PHYS MED REHAB, V86, P268, DOI 10.1016/j.apmr.2004.04.022; BLUMENTHAL JA, 1989, J GERONTOL, V44, pM147, DOI 10.1093/geronj/44.5.M147; Borg E, 2006, SCAND J MED SCI SPOR, V16, P57, DOI 10.1111/j.1600-0838.2005.00448.x; Borg E., 2001, P 17 ANN M INT SOC P, P298; Boule NG, 2003, DIABETOLOGIA, V46, P1071, DOI 10.1007/s00125-003-1160-2; Cantor JB, 2013, NEUROREHABILITATION, V32, P875, DOI 10.3233/NRE-130912; CHEN MK, 1986, PREV MED, V15, P74, DOI 10.1016/0091-7435(86)90037-X; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DAVIS JA, 1985, MED SCI SPORT EXER, V17, P6; Driver S, 2004, BRAIN INJURY, V18, P847, DOI 10.1080/02699050410001671856; Driver S, 2012, DISABIL HEALTH J, V5, P117, DOI 10.1016/j.dhjo.2011.11.002; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI 10.1249/mss.0b013e3180616b27; Hassett LM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006123.pub2; Hassett LM, 2011, BRAIN INJURY, V25, P698, DOI 10.3109/02699052.2011.579934; Hootman JM, 2002, MED SCI SPORT EXER, V34, P838, DOI 10.1097/00005768-200205000-00017; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kennedy-Armbruster C, 2013, MIL MED, V178, P1358, DOI 10.7205/MILMED-D-13-00186; Krupp L.B., 2003, FATIGUE, V1st; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lange G, 2005, ISS CLIN COGN NEUROP, P301; Latimer-Cheung AE, 2013, ARCH PHYS MED REHAB, V94, P1800, DOI 10.1016/j.apmr.2013.04.020; Lee IM, 2000, AM J EPIDEMIOL, V151, P293, DOI 10.1093/oxfordjournals.aje.a010205; Linke SE, 2011, ANN BEHAV MED, V42, P197, DOI 10.1007/s12160-011-9279-8; Londeree BR, 1997, MED SCI SPORT EXER, V29, P837, DOI 10.1097/00005768-199706000-00016; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; MCINNIS KJ, 1992, AM J CARDIOL, V69, P84, DOI 10.1016/0002-9149(92)90680-W; McNeely ML, 2006, CAN MED ASSOC J, V175, P34, DOI 10.1503/cmaj.051073; Milani RV, 2006, MAYO CLIN PROC, V81, P1603, DOI 10.4065/81.12.1603; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; Mossberg KA, 2010, J HEAD TRAUMA REHAB, V25, P173, DOI 10.1097/HTR.0b013e3181dc98ff; Mulligan HF, 2012, ADAPT PHYS ACT Q, V29, P243, DOI 10.1123/apaq.29.3.243; Murphy MH, 2009, SPORTS MED, V39, P29, DOI 10.2165/00007256-200939010-00003; Myers J, 2002, NEW ENGL J MED, V346, P793, DOI 10.1056/NEJMoa011858; Neuberger G.B., 2003, ARTHRITIS RHEUM, V49, pS175, DOI [DOI 10.1002/art.11405, 10.1002/art.11405, DOI 10.1002/ART.11405]; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pang MYC, 2006, CLIN REHABIL, V20, P97, DOI 10.1191/0269215506cr926oa; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Reavenall S, 2010, INT J THER REHABIL, V17, P360, DOI 10.12968/ijtr.2010.17.7.48893; REYBROUCK T, 1986, INT J SPORTS MED, V7, P26, DOI 10.1055/s-2008-1025730; Swain DP, 2002, MED SCI SPORT EXER, V34, P152, DOI 10.1097/00005768-200201000-00023; Thompson W., 2009, ACSMS GUIDELINES EXE, V8th; US Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; VAGO P, 1987, INT J SPORTS MED, V8, P190, DOI 10.1055/s-2008-1025654; Valko PO, 2008, SLEEP, V31, P1601, DOI 10.1093/sleep/31.11.1601; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; WASSERMAN K, 1984, AM REV RESPIR DIS, V129, pS35, DOI 10.1164/arrd.1984.129.2P2.S35; Wasserman K, 2005, PRINCIPLES EXERCISE; WENGER HA, 1986, SPORTS MED, V3, P346, DOI 10.2165/00007256-198603050-00004; Wolman RL, 1994, CLIN REHABIL, V8, P253; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	67	19	22	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					382	390		10.1097/HTR.0000000000000062			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300010	24901330	Green Accepted			2021-06-18	
J	Donders, J; Oh, YI; Gable, J				Donders, Jacobus; Oh, Ye In; Gable, Jessica			Self- and Informant Ratings of Executive Functioning After Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						executive functioning; mild traumatic brain injury; outcomes; risk factors	CARD SORTING TEST; COGNITIVE RESERVE; DIAGNOSIS THREAT; HEAD-INJURY; SYMPTOMS; VALIDITY; INDIVIDUALS; PERFORMANCE; CHILDREN; ADULTS	Objective: To determine correlates of self-and informant reports on a standardized rating of executive functioning in persons with mild traumatic brain injury. Setting: Outpatient clinic at a rehabilitation hospital. Participants: One hundred referred persons whomet criteria formild traumatic brain injury (ie, time to follow commands < 30 minutes, posttraumatic amnesia < 24 hours, and Glasgow Coma Scale score > 12). Design: Retrospective case series review. Main Measures: Participants and informants completed the Behavior Rating Inventory of Executive FunctionAdult Version (BRIEF-A) during outpatient neuropsychological evaluations within 30 to 360 days postinjury. Results: Participant and informant BRIEF-A ratings were strongly correlated, but participants rated themselves as worse than informants did. Regression analysis revealed that higher levels of education and presence of intracranial neuroimaging findings were associated with better BRIEF-A ratings whereas worse BRIEF-A ratings were associated with longer time since injury and prior psychiatric treatment. BRIEF-A ratings were not correlated with laboratory measures of executive functioning. Conclusions: Subjective perceptions of executive dysfunction during the first year after mild TBI are driven primarily by premorbid factors and do not reflect acquired cerebral impairment.	[Donders, Jacobus] Mary Free Bed Rehabil Hosp, Grand Rapids, MI 49503 USA; [Oh, Ye In] Calvin Coll, Grand Rapids, MI 49506 USA; [Gable, Jessica] Hope Coll, Holland, MI 49423 USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Anderson PJ, 2010, STUD NEUROPSYCHOL NE, P3; Banos J, 2010, PRINCIPLES PRACTICE, P329; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Culbertson WC, 2005, TOWER LONDON DREXEL; Deepika A, 2013, J HEAD TRAUMA REHAB, V28, P442, DOI 10.1097/HTR.0b013e31825e19e5; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Demery JA, 2010, CLIN NEUROPSYCHOL, V24, P1292, DOI 10.1080/13854046.2010.528452; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Fox J., 1991, REGRESSION DIAGNOSTI; Garcia-Molina A, 2012, BRAIN INJURY, V26, P864, DOI 10.3109/02699052.2012.655362; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Halari R, 2006, SCHIZOPHRENIA BULL, V32, P751, DOI 10.1093/schbul/sbl002; Heaton R., 1993, WISCONSIN CARD SORTI; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Krishnan M, 2012, CLIN NEUROPSYCHOL, V26, P951, DOI 10.1080/13854046.2012.708166; Lahr Denise, 2007, Cogn Neuropsychiatry, V12, P25, DOI 10.1080/13546800600714791; Larrabee GJ, 2013, BEHAV SCI LAW, V31, P686, DOI 10.1002/bsl.2087; Levi Y, 2013, J INT NEUROPSYCH SOC, V19, P664, DOI 10.1017/S1355617713000192; Lovstad M, 2012, BRAIN INJURY, V26, P1586, DOI 10.3109/02699052.2012.698787; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Merrick EE, 2003, CLIN NEUROPSYCHOL, V17, P153, DOI 10.1076/clin.17.2.153.16512; Millis SR, 2003, CHILD NEUROPSYCHOL, V9, P221, DOI 10.1076/chin.9.3.221.16455; Murphy KR, 2004, STAT POWER ANAL; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P132, DOI 10.1080/13803390902858874; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Roth R, BEHAV RATING INVENTO; Sakamoto M, 2013, J NEUROVIROL, V19, P442, DOI 10.1007/s13365-013-0196-4; Sesma HW, 2010, PEDIATRICS, V121, pS1686; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Solsnes AE, 2014, J INT NEUROPSYCH SOC, V20, P506, DOI 10.1017/S1355617714000332; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh TN, 1996, TEST MEMORY MALINGER; Trontel HG, 2013, J CLIN EXP NEUROPSYC, V35, P960, DOI 10.1080/13803395.2013.844770; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Wilson KR, 2011, REHABIL PSYCHOL, V56, P100, DOI 10.1037/a0023446	44	19	19	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					E30	E39		10.1097/HTR.0000000000000120			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300004	25699624				2021-06-18	
J	Narad, ME; Minich, N; Taylor, HG; Kirkwood, MW; Brown, TM; Stancin, T; Wade, SL				Narad, Megan E.; Minich, Nori; Taylor, H. Gerry; Kirkwood, Michael W.; Brown, Tanya M.; Stancin, Terry; Wade, Shari L.			Effects of a Web-Based Intervention on Family Functioning Following Pediatric Traumatic Brain Injury	JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS			English	Article						traumatic brain injury; adolescents; family functioning; problem solving	BEHAVIOR PROBLEMS; PARENTAL DISTRESS; ASSESSMENT DEVICE; HEAD-INJURY; CHILDREN; ADOLESCENTS; PREDICTORS; OUTCOMES; ADAPTATION; CHILDHOOD	Objective:Investigate effectiveness of an online Counselor-Assisted Problem-Solving (CAPS) intervention on family functioning after traumatic brain injury.Methods:Participants were randomized to CAPS (n = 65) or Internet resource comparison (IRC; n = 67). CAPS is a counselor-assisted web-based program. IRC was given access to online resources. Outcomes were examined at 6, 12, and 18 months after baseline. Injury severity, age, and socioeconomic status were examined as moderators.Results:A main effect of time was noted for teen-reported conflict and parent-reported problem solving. CAPS had decreased parent-reported conflict and a reduction in parental effective communication. Effects were specific to subsets of the sample.Conclusion:CAPS, a family-based problem-solving intervention designed to address problem behaviors, had modest effects on some aspects of family functioning compared with IRC. Effects were generally limited to subsets of the families and were not evident across all follow-up assessments.	[Narad, Megan E.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil & Behav Med & Clin Psychol, Cincinnati, OH 45229 USA; [Minich, Nori; Taylor, H. Gerry] Case Western Reserve Univ, Div Dev & Behav Pediat & Pediat, Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Aurora, CO USA; [Brown, Tanya M.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA; [Stancin, Terry] Case Western Reserve Univ, Dept Pediat, Div Pediat Psychol, MetroHlth Med Ctr, Cleveland, OH 44106 USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil & Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Narad, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil & Behav Med & Clin Psychol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	megan.narad@cchmc.org	Stancin, Terry/L-7993-2019		NIH from the National Institutes of Mental Health [R01-MH073764]; Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; National Institute of Disability and Rehabilitation Research, Department of Education [H133G050239]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	Supported in part by (1) NIH grant R01-MH073764 from the National Institutes of Mental Health, (2) a grant from the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program, and (3) grant H133G050239 from the National Institute of Disability and Rehabilitation Research, Department of Education. This material does not necessarily represent the policy of these agencies, or is the material necessarily endorsed by the Federal Government.	Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Gan C, 2010, BRAIN INJURY, V24, P651, DOI 10.3109/02699051003692142; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Kurowski BG, 2014, JAMA PEDIATR, V168, P523, DOI 10.1001/jamapediatrics.2013.5070; Lorenz FO, 2001, ANN M NAT COUNC FAM; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Melby J., 1998, IOWA FAMILY INTERACT; Melby JN, 2003, J SOC PERS RELAT, V20, P171, DOI 10.1177/02654075030202003; Micklewright JL, 2012, J INT NEUROPSYCH SOC, V18, P343, DOI 10.1017/S1355617711001792; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; NEZU AM, 1986, J CONSULT CLIN PSYCH, V54, P196, DOI 10.1037/0022-006X.54.2.196; Pericall MTL, 2014, DEV MED CHILD NEUROL, V56, P19, DOI 10.1111/dmcn.12237; Raj SP, 2014, J PEDIATR PSYCHOL, V39, P84, DOI 10.1093/jpepsy/jst075; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2014, J HEAD TRAUMA REHAB, V29, P198, DOI 10.1097/HTR.0b013e31828f9fe8; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	28	19	19	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0196-206X	1536-7312		J DEV BEHAV PEDIATR	J. Dev. Behav. Pediatr.	NOV-DEC	2015	36	9					700	707		10.1097/DBP.0000000000000208			8	Behavioral Sciences; Psychology, Developmental; Pediatrics	Behavioral Sciences; Psychology; Pediatrics	CV7YX	WOS:000364494500006	26461100	Green Accepted			2021-06-18	
J	Piao, C; Ranaivo, HR; Rusie, A; Wadhwani, N; Koh, S; Wainwright, MS				Piao, Chunshu; Ranaivo, Hantamalala Ralay; Rusie, Allison; Wadhwani, Nitin; Koh, Sookyong; Wainwright, Mark S.			Thrombin decreases expression of the glutamate transporter GLAST and inhibits glutamate uptake in primary cortical astrocytes via the Rho kinase pathway	EXPERIMENTAL NEUROLOGY			English	Article						Protease; Glutamate transporter; Kinases; Blood-brain barrier	BLOOD-BRAIN-BARRIER; PROTEASE-ACTIVATED RECEPTORS; TEMPORAL-LOBE; CULTURED ASTROCYTES; INJURY; SEIZURES; NEUROPROTECTION; HIPPOCAMPUS; EPILEPSY; CELLS	Astrocyte glutamate transporters GLAST and GLT1 play a key role in regulating neuronal excitation and their levels are altered in patients with epilepsy, and after traumatic brain injury. The mechanisms which regulate their expression are not well understood. We tested the hypothesis that exposure of astrocytes to high levels of thrombin, as may occur after a compromise of the blood-brain barrier, would reduce astrocyte glutamate transporter levels. In isolated rat cortical astrocytes we examined the effects of thrombin on the expression and function of glutamate transporters, and the signaling pathways involved in these responses by using Western blotting and selective inhibitors. Thrombin induced a selective decrease in the expression of GLAST but not GLT1, with a corresponding decrease in the capacity of astrocytes to take up glutamate. Activation of the thrombin receptor PAR-1 with an activating peptide induced a similar decrease in the expression of GLAST and compromise of glutamate uptake. The downregulation of GLAST induced by thrombin was mediated by the mitogen activated protein kinases p38 MAPK, ERK and JNK, but inhibition of these kinases did not prevent the decrease in glutamate uptake induced by thrombin. In contrast, inhibition of the Rho kinase pathway using the specific inhibitor, Y27632, suppressed both the decrease in the expression of GLAST and the decrease in glutamate uptake induced by thrombin. In hippocampal astrocyte cultures, thrombin caused a decrease in both GLAST and GLT1. In tissue resected from brains of children with intractable epilepsy, we found a decrease in the integrity of the blood-brain barrier along with a reduction in immunoreactivity for both transporters which was associated with an increase in cleaved thrombin and reactive astrogliosis. The in vitro results suggest a specific mechanism by which thrombin may lead to a compromise of astrocyte function and enhanced synaptic excitability after the blood-brain barrier is compromised. The human in vivo results provide indirect support evidence linking the compromise of the blood-brain barrier to thrombin-induced reduction in glutamate transporter expression and an increase in neuronal excitation. (C) 2015 Elsevier Inc All rights reserved.	[Piao, Chunshu; Ranaivo, Hantamalala Ralay; Rusie, Allison; Koh, Sookyong; Wainwright, Mark S.] Northwestern Univ, Dept Pediat, Div Neurol, Feinberg Sch Med, Chicago, IL 60611 USA; [Wainwright, Mark S.] Northwestern Univ, Dept Pediat, Div Crit Care, Feinberg Sch Med, Chicago, IL 60611 USA; [Piao, Chunshu; Ranaivo, Hantamalala Ralay; Rusie, Allison; Wainwright, Mark S.] Northwestern Univ, Dept Pediat, Ruth D & Ken M Davee Pediat Neurocrit Care Progra, Feinberg Sch Med, Chicago, IL 60611 USA; [Wadhwani, Nitin] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA	Wainwright, MS (corresponding author), Ann & Robert H Lurie Childrens Hosp Chicago, Div Neurol, 225 E Chicago Ave,Mailstop 51, Chicago, IL 60611 USA.	m-wainwright@northwestern.edu		Wainwright, Mark/0000-0002-4736-7462	Lyndsey Whittingham Foundation; Ruth D. & Ken M. Davee Pediatric Neurocritical Care Program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073768] Funding Source: NIH RePORTER	This work was supported by the Lyndsey Whittingham Foundation and by the Ruth D. & Ken M. Davee Pediatric Neurocritical Care Program. The authors thank Bradley Scher for technical assistance.	Abbott NJ, 2012, EPILEPSIA, V53, P1, DOI 10.1111/j.1528-1167.2012.03696.x; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abe K, 2003, NEUROSCI RES, V45, P25, DOI 10.1016/S0168-0102(02)00190-6; Aburima A, 2013, BLOOD, V122, P3533, DOI 10.1182/blood-2013-03-487850; Anderson CM, 2000, GLIA, V32, P1; Barzo P, 1997, ACT NEUR S, V70, P243; Beart PM, 2007, BRIT J PHARMACOL, V150, P5, DOI 10.1038/sj.bjp.0706949; Choi MS, 2008, BRAIN RES BULL, V76, P368, DOI 10.1016/j.brainresbull.2008.02.031; Chrzaszcz M, 2010, J NEUROTRAUM, V27, P1283, DOI 10.1089/neu.2009.1227; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Donovan FM, 1997, J NEUROSCI, V17, P5316; Fang QH, 2006, AM J RESP CELL MOL, V35, P714, DOI 10.1165/rcmb.2005-0026OC; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Greenberg DL, 2003, BIOCHEMISTRY-US, V42, P702, DOI 10.1021/bi027100x; Gupta RK, 2013, BIOGERONTOLOGY, V14, P531, DOI 10.1007/s10522-013-9459-y; Huynh THV, 2012, J MED CHEM, V55, P5403, DOI 10.1021/jm300345z; Isaeva E, 2012, ANN NEUROL, V72, P192, DOI 10.1002/ana.23587; Koo BH, 2009, J BIOL CHEM, V284, P23375, DOI 10.1074/jbc.M109.036848; Koyama Y, 1996, GLIA, V16, P342, DOI 10.1002/(SICI)1098-1136(199604)16:4<342::AID-GLIA6>3.0.CO;2-1; KOYAMA Y, 1994, NEUROSCIENCE, V61, P1007, DOI 10.1016/0306-4522(94)90420-0; Lau CL, 2011, BRIT J PHARMACOL, V163, P533, DOI 10.1111/j.1476-5381.2011.01259.x; Lee CJ, 2007, J PHYSIOL-LONDON, V581, P1057, DOI 10.1113/jphysiol.2007.130377; Lee KR, 1997, J NEUROSURG, V87, P73, DOI 10.3171/jns.1997.87.1.0073; Lin CC, 2011, EUR J PHARMACOL, V672, P180, DOI 10.1016/j.ejphar.2011.10.005; Luo W, 2007, BRAIN RES REV, V56, P331, DOI 10.1016/j.brainresrev.2007.08.002; Maggio N, 2008, J NEUROSCI, V28, P732, DOI 10.1523/JNEUROSCI.3665-07.2008; Maggio N, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00019; Maggio N, 2013, NEUROBIOL DIS, V50, P171, DOI 10.1016/j.nbd.2012.10.017; Mahajan VB, 2000, P NATL ACAD SCI USA, V97, P12062, DOI 10.1073/pnas.97.22.12062; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Meli R, 2001, J NEUROCHEM, V79, P556, DOI 10.1046/j.1471-4159.2001.00617.x; Namekata K, 2008, MOL CELL BIOL, V28, P3273, DOI 10.1128/MCB.02159-07; Perez-Dominguez M, 2014, NEUROCHEM RES, V39, P1219, DOI 10.1007/s11064-014-1300-8; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Proper EA, 2002, BRAIN, V125, P32, DOI 10.1093/brain/awf001; Ranaivo HR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-68; Ranaivo HR, 2010, EXP NEUROL, V226, P310, DOI 10.1016/j.expneurol.2010.09.005; Ranaivo HR, 2010, BRAIN RES, V1313, P222, DOI 10.1016/j.brainres.2009.11.063; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Razafimanjato H, 2010, NEUROTOXICOLOGY, V31, P475, DOI 10.1016/j.neuro.2010.06.003; Robel S, 2015, J NEUROSCI, V35, P3330, DOI 10.1523/JNEUROSCI.1574-14.2015; Rohatgi T, 2004, NEUROSCIENTIST, V10, P501, DOI 10.1177/1073858404269955; Rose EM, 2009, J NEUROSCI, V29, P8143, DOI 10.1523/JNEUROSCI.1081-09.2009; Rossignol P, 2004, EXP CELL RES, V299, P279, DOI 10.1016/j.yexcr.2004.05.034; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rozyczka J, 2004, BRAIN PATHOL, V14, P406; Sarac S, 2009, APMIS, V117, P291, DOI 10.1111/j.1600-0463.2009.02443.x; Shikamoto Y, 1999, FEBS LETT, V463, P387, DOI 10.1016/S0014-5793(99)01657-9; Striggow F, 2001, EUR J NEUROSCI, V14, P595, DOI 10.1046/j.0953-816x.2001.01676.x; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Tomkins O, 2007, NEUROBIOL DIS, V25, P367, DOI 10.1016/j.nbd.2006.10.006; Ulu MO, 2010, ACTA NEUROCHIR, V152, P845, DOI 10.1007/s00701-009-0548-2; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; van Vliet EA, 2014, NEUROSCIENCE, V277, P455, DOI 10.1016/j.neuroscience.2014.07.030; Vazquez-Juarez E, 2009, J NEUROCHEM, V111, P1398, DOI 10.1111/j.1471-4159.2009.06418.x; Wang XK, 2003, J PHARMACOL EXP THER, V304, P172, DOI 10.1124/jpet.102.040246	62	19	20	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2015	273						288	300		10.1016/j.expneurol.2015.09.009			13	Neurosciences	Neurosciences & Neurology	CW7BB	WOS:000365151800027	26391563				2021-06-18	
J	Sawyer, K; Bell, KR; Ehde, DM; Temkin, N; Dikmen, S; Williams, RM; Dillworth, T; Hoffman, JM				Sawyer, Kathryn; Bell, Kathleen R.; Ehde, Dawn M.; Temkin, Nancy; Dikmen, Sureyya; Williams, Rhonda M.; Dillworth, Tiara; Hoffman, Jeanne M.			Longitudinal Study of Headache Trajectories in the Year After Mild Traumatic Brain Injury: Relation to Posttraumatic Stress Disorder Symptoms	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Headache; Rehabilitation; Stress disorders; post-traumatic	CHRONIC PAIN; US SOLDIERS; VETERANS; PTSD; DEPRESSION; DIAGNOSIS; SEVERITY; MODERATE; HEALTH	Objective: To examine headache trajectories among persons with mild traumatic brain injury (MTBI) in the year after injury and the relation of headache trajectory to posttraumatic stress disorder (PTSD) at 1 year postinjury. Design: Prospective, longitudinal study. Setting: Participants were recruited through a university medical center and participated in follow-up assessments by telephone. Participants: Prospectively enrolled individuals (N=212) within 1 week of MTBI who were hospitalized for observation or other system injuries. Participants were assessed at baseline and 3, 6, and 12 months postinjury. Interventions: Not applicable. Main Outcome Measures: Participants rated average headache pain intensity using the 0 to 10 numerical rating scale at each assessment period. The PTSD Checklist-Civilian Version was completed at 12 months postinjury. Results: Latent class growth analysis produced a 4-trajectory group model, with groups labeled resolved, worsening, improving, and chronic. Multivariate regression modeling revealed that younger age and premorbid headache correlated with membership in the worse trajectory groups (worsening and chronic; P<.001). Univariate regression revealed a significant association between PTSD and membership in the worse trajectory groups (P<.001). Conclusions: Headache is common in the year after MTBI, with younger people, persons who previously had headaches, and persons with PTSD more likely to report chronic or worsening headache. Further research is needed to examine whether PTSD symptoms exacerbate headaches or whether problematic headache symptoms exacerbate PTSD. (C) 2015 by the American Congress of Rehabilitation Medicine	[Sawyer, Kathryn; Ehde, Dawn M.; Temkin, Nancy; Dikmen, Sureyya; Williams, Rhonda M.; Dillworth, Tiara; Hoffman, Jeanne M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Bell, Kathleen R.] Univ Texas SW Med Ctr Dallas, Dept Phys Med & Rehabil, Dallas, TX 75390 USA; [Temkin, Nancy; Dikmen, Sureyya] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Williams, Rhonda M.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA	Sawyer, K (corresponding author), Univ Washington, Sch Med, Box 359612, Seattle, WA 98195 USA.	kasawyer@uw.edu	Ehde, Dawn/K-1883-2016	Bell, Kathleen/0000-0002-0928-2046; Ehde, Dawn/0000-0002-9555-2347	Department of Education, National Institute on Disability and Rehabilitation Research [H133G090022]; Department of Defense Congressionally Directed Medical Research ProgramsUnited States Department of Defense [W81XWH-12-2-0109]	Supported by the Department of Education, National Institute on Disability and Rehabilitation Research (grant no. H133G090022) and Department of Defense Congressionally Directed Medical Research Programs (grant no. W81XWH-12-2-0109).	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kozminski M, 2010, J AM OSTEOPATH ASSOC, V110, P514; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M., 2008, MILD TRAUMATIC BRAIN, P85; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NAGIN DS, 1993, CRIMINOLOGY, V31, P327, DOI 10.1111/j.1745-9125.1993.tb01133.x; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; RESICK PA, 1992, J CONSULT CLIN PSYCH, V60, P748, DOI 10.1037/0022-006X.60.5.748; Rosenthal JF, 2013, HEADACHE, V53, P1564, DOI 10.1111/head.12200; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Scioli-Salter ER, 2015, CLIN J PAIN, V31, P363, DOI 10.1097/AJP.0000000000000115; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158	32	19	19	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2015	96	11					2000	2006		10.1016/j.apmr.2015.07.006			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DB1YX	WOS:000368306600009	26220236				2021-06-18	
J	Sun, LH; Perakyla, J; Polvivaara, M; Ohman, J; Peltola, J; Lehtimaki, K; Huhtala, H; Hartikainen, KM				Sun, Lihua; Perakyla, Jani; Polvivaara, Markus; Ohman, Juha; Peltola, Jukka; Lehtimaki, Kai; Huhtala, Heini; Hartikainen, Kaisa M.			Human anterior thalamic nuclei are involved in emotion-attention interaction	NEUROPSYCHOLOGIA			English	Article						Deep brain stimulation; Anterior thalamic nuclei; EEG; Emotion; Attention; Epilepsy	TRAUMATIC BRAIN-INJURY; CINGULATE CORTEX; ORBITOFRONTAL CORTEX; INTEGRATIVE THEORY; PREFRONTAL CORTEX; NEURAL MECHANISMS; COGNITIVE CONTROL; STIMULI COMPETE; EPILEPSY; FEAR	Patients treated with deep brain stimulation (DBS) provide an opportunity to study affective processes in humans with "lesion on demand" at key nodes in the limbic circuitries, such as at the anterior thalamic nuclei (ANT). ANT has been suggested to play a role in emotional control with its connection to the orbitofrontal cortex and the anterior cingulate cortex. However, direct evidence for its role in emotional function in human subjects is lacking. Reported side effects of ANT-DBS in the treatment of refractory epilepsy include depression related symptoms. In line with these mood-related clinical side effects, we have previously reported that stimulating the anterior thalamus increased emotional interference in a visual attention task as indicated by prolonged reaction times due to threat-related emotional distractors. We used event-related potentials to investigate potential attentional mechanism behind this behavioural observation. We hypothesized that ANT-DBS leads to greater attention capture by threat-related distractors. We tested this hypothesis using centro-parietal N2-P3 peak-to-peak amplitude as a measure of allocated attentional resources. Six epileptic patients treated with deep brain stimulation at ANT participated in the study. Electroencephalography was recorded while the patients performed a computer based Executive-Reaction Time test with threat-related emotional distractors. During the task, either ANT or a thalamic control location was stimulated, or the stimulation was turned off. Stimulation of ANT was associated with increased centro-parietal N2-P3 amplitude and increased reaction time in the context of threat-related emotional distractors. We conclude that high frequency electric stimulation of ANT leads to greater attentional capture by emotional stimuli. This is the first study to provide direct evidence from human subjects with on-line electric manipulation of ANT for its role in emotion-attention interaction. (C) 2015 The Authors. Published by Elsevier Ltd.	[Sun, Lihua; Perakyla, Jani; Polvivaara, Markus; Hartikainen, Kaisa M.] Tampere Univ Hosp, Behav Neurol Res Unit, FI-33520 Tampere, Finland; [Ohman, Juha; Peltola, Jukka; Lehtimaki, Kai; Hartikainen, Kaisa M.] Tampere Univ Hosp, Dept Neurosci & Rehabil, FI-33520 Tampere, Finland; [Huhtala, Heini] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland	Hartikainen, KM (corresponding author), Tampere Univ Hosp, Behav Neurol Res Unit, Finn Medi 6-7,POB 2000, FI-33520 Tampere, Finland.	kaisa.hartikainen@uta.fi		Sun, Lihua/0000-0002-9931-9497; Hartikainen, Kaisa/0000-0001-7278-9635; Ohman, Juha/0000-0002-6592-1367	Academy of FinlandAcademy of FinlandEuropean Commission; Competitive Research Fund of Pirkanmaa Hospital District	This research was supported by the Academy of Finland and the Competitive Research Fund of Pirkanmaa Hospital District.	Arend I, 2015, NEUROPSYCHOLOGY, V29, P191, DOI 10.1037/neu0000139; Barcelo F, 2009, FRONT NEUROSCI-SWITZ, V3, P6, DOI 10.3389/neuro.01.010.2009; Behrmann M, 2004, CURR OPIN NEUROBIOL, V14, P212, DOI 10.1016/j.conb.2004.03.012; Bishop SJ, 2008, ANN NY ACAD SCI, V1129, P141, DOI 10.1196/annals.1417.016; Bockova M., 2014, BRAIN TOPOGR; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Chao LL, 1998, J COGNITIVE NEUROSCI, V10, P167, DOI 10.1162/089892998562636; Child ND, 2013, NEUROLOGY, V81, P1869, DOI 10.1212/01.wnl.0000436078.95856.56; Daffner KR, 1998, NEUROREPORT, V9, P787, DOI 10.1097/00001756-199803300-00004; Dalgleish T, 2004, NAT REV NEUROSCI, V5, P583, DOI 10.1038/nrn1432; Lanna MED, 2012, J NEUROL SCI, V322, P176, DOI 10.1016/j.jns.2012.08.004; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; Fisher R, 2010, EPILEPSIA, V51, P899, DOI 10.1111/j.1528-1167.2010.02536.x; Hartikainen KM, 2007, NEUROREPORT, V18, P1929, DOI 10.1097/WNR.0b013e3282f1ca18; Hartikainen KM, 2014, J CLIN EXP NEUROPSYC, V36, P540, DOI 10.1080/13803395.2014.913554; Hartikainen KM, 2012, J CLIN EXP NEUROPSYC, V34, P588, DOI 10.1080/13803395.2012.666231; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hartikainen KM, 2010, NEUROREPORT, V21, P344, DOI 10.1097/WNR.0b013e328336eeb3; Hartikainen KM, 2000, NEUROPSYCHOLOGIA, V38, P1576, DOI 10.1016/S0028-3932(00)00072-5; Jaeger A, 2012, COGN AFFECT BEHAV NE, V12, P748, DOI 10.3758/s13415-012-0110-1; Kayser J, 1997, PSYCHOPHYSIOLOGY, V34, P414, DOI 10.1111/j.1469-8986.1997.tb02385.x; LeDoux JE, 2012, PROG BRAIN RES, V195, P431, DOI 10.1016/B978-0-444-53860-4.00021-0; Leppanen JM, 2006, CURR OPIN PSYCHIATR, V19, P34, DOI 10.1097/01.yco.0000191500.46411.00; MACLEAN PD, 1949, PSYCHOSOM MED, V11, P338, DOI 10.1097/00006842-194911000-00003; Maki-Marttunen V, 2015, J NEUROTRAUM, V32, P272, DOI 10.1089/neu.2014.3557; Maki-Marttunen V, 2014, NEUROREPORT, V25, P1038, DOI 10.1097/WNR.0000000000000223; Maratos EJ, 2000, NEUROPSYCHOLOGIA, V38, P1452, DOI 10.1016/S0028-3932(00)00061-0; Marchand A, 2014, BRAIN STRUCT FUNCT, V219, P1575, DOI 10.1007/s00429-013-0586-7; Matthews G, 2000, BEHAV MODIF, V24, P69, DOI 10.1177/0145445500241004; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Moddel G, 2012, NERVENARZT, V83, P1001, DOI 10.1007/s00115-012-3572-z; Montgomery E, 2010, DEEP BRAIN STIMULATI; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; Ohman A, 2001, J EXP PSYCHOL GEN, V130, P466, DOI 10.1037/0096-3445.130.3.466; Okon-Singer H, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00058; Papez J. W., 1937, J NEUROPSYCHIATRY CL, V79, P217; Patel Salil H, 2005, Int J Med Sci, V2, P147; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Pessoa L, 2012, EMOTION, V12, P192, DOI 10.1037/a0024109; Petersen SE, 2012, ANNU REV NEUROSCI, V35, P73, DOI 10.1146/annurev-neuro-062111-150525; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Rule RR, 2002, COGN AFFECT BEHAV NE, V2, P264, DOI 10.3758/CABN.2.3.264; Schaltenbrand G, 1998, ATLAS STEREOTAXY HUM; Sen F., 2005, NEUROANATOMY, V4, P10; Shenhav A, 2013, NEURON, V79, P217, DOI 10.1016/j.neuron.2013.07.007; Shimamura AP, 2000, PSYCHOBIOLOGY, V28, P207; Spinks R, 2002, NEUROIMAGE, V17, P631, DOI 10.1006/nimg.2002.1185; Takebayashi S, 2007, EPILEPSIA, V48, P348, DOI 10.1111/j.1528-1167.2006.00948.x; van Groen T, 1999, BRAIN RES REV, V30, P1, DOI 10.1016/S0165-0173(99)00006-5; Vuilleumier P, 2001, NEUROREPORT, V12, P1119, DOI 10.1097/00001756-200105080-00014; Ward R, 2007, NEUROPSYCHOLOGIA, V45, P1973, DOI 10.1016/j.neuropsychologia.2006.09.017; Xiao D., 2002, Thalamus & Related Systems, V2, P21, DOI 10.1016/S1472-9288(02)00031-6	53	19	19	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	NOV	2015	78						88	94		10.1016/j.neuropsychologia.2015.10.001			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	CW5RH	WOS:000365053800010	26440152	Green Published, Other Gold			2021-06-18	
J	Mastro-Martinez, I; Perez-Suarez, E; Melen, G; Gonzalez-Murillo, A; Casco, F; Lozano-Carbonero, N; Gutierrez-Fernandez, M; Diez-Tejedor, E; Casado-Flores, J; Ramirez-Orellana, M; Serrano-Gonzalez, A				Mastro-Martinez, Ignacio; Perez-Suarez, Esther; Melen, Gustavo; Gonzalez-Murillo, Africa; Casco, Fernando; Lozano-Carbonero, Nieves; Gutierrez-Fernandez, Maria; Diez-Tejedor, Exuperio; Casado-Flores, Juan; Ramirez-Orellana, Manuel; Serrano-Gonzalez, Ana			Effects of local administration of allogenic adipose tissue-derived mesenchymal stem cells on functional recovery in experimental traumatic brain injury	BRAIN INJURY			English	Article						Animal model; cell therapy; neurogenesis; children; MSCs (mesenchymal stem cells); pediatric intensive care medicine; TBI (traumatic brain injury)	FOCAL CEREBRAL-ISCHEMIA; BONE-MARROW; PROGENITOR CELLS; TRANSPLANTATION; ADULT; THERAPY; OPPORTUNITIES; REPLACEMENT; MECHANISMS; VOLUME	Objective: Traumatic brain injury (TBI) is the leading cause of mortality and morbidity in paediatric patients after the first year of life. The aim of this study was to evaluate effects of locally administered allogeneic mesenchymal stem cells (MSC), in the acute period after a TBI.Methodology: MSC were isolated from peritoneal fat of healthy rats, expanded in vitro and labelled with the green fluorescent protein. Rats were placed in one of three experimental groups: (1) Control: TBI, (2) IP-Control: TBI+local saline and (3) IP-Treat: TBI+2x10(5) MSC 24 hours after receiving a moderate, unilateral, controlled cortical impact. Motor and cognitive behavioural tests were performed to evaluate functional recovery. Histological examination and immunohistochemistry were used to identify cell distribution.Main results: Improved performance was found on motor tests in the MSC-treated group compared to control groups. MSC were found in the perilesional area and their number decreased with time after transplantation. MSC treatment increased the cell density in the hippocampus (CA3 pyramidal cells and granule cells in the dentate gyrus) and enhanced neurogenesis in this area.Conclusion: MSC cell therapy resulted in better recovery of motor function compared with the control group. This cellular therapy might be considered for patients suffering from TBI.	[Mastro-Martinez, Ignacio; Perez-Suarez, Esther; Casado-Flores, Juan; Serrano-Gonzalez, Ana] Hosp Nino Jesus, Pediat Intens Crit Care, Madrid 28009, Spain; [Melen, Gustavo; Gonzalez-Murillo, Africa; Casco, Fernando; Lozano-Carbonero, Nieves; Ramirez-Orellana, Manuel] Hosp Nino Jesus, Inst Invest Sanitaria Princesa, Madrid 28009, Spain; [Gutierrez-Fernandez, Maria; Diez-Tejedor, Exuperio] Univ Autonoma Madrid, Dept Neurol, La Paz Univ Hosp, Neurosci Area IdiPAZ,Hlth Res Inst, Madrid, Spain; [Gutierrez-Fernandez, Maria; Diez-Tejedor, Exuperio] Univ Autonoma Madrid, Stroke Ctr, Neurosci & Cerebrovasc Res Lab, Neurosci Area IdiPAZ,Hlth Res Inst, Madrid, Spain	Mastro-Martinez, I (corresponding author), Hosp Nino Jesus, Pediat Intens Crit Care, Av Menendez Pelayo 65, Madrid 28009, Spain.	ignacio.mastro@salud.madrid.org	Mastro-Martinez, Ignacio/N-3555-2019; Ramirez, Manuel/H-7710-2015; Gonzalez, Africa/M-3426-2014	Mastro-Martinez, Ignacio/0000-0001-6812-1608; Ramirez, Manuel/0000-0003-0332-6973; Gonzalez, Africa/0000-0001-7747-1204	Fundacion Mutua MadrilenaInstituto de Salud Carlos III; Fundacion ACS	This study was supported by grants from Fundacion Mutua Madrilena and Fundacion ACS. The funding played no role in the design of the study, collection, analysis and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication. The authors alone are responsible for the content and writing of the paper.	Aboody K, 2011, NEURON, V70, P597, DOI 10.1016/j.neuron.2011.05.007; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Bochev I, 2008, CELL BIOL INT, V32, P384, DOI 10.1016/j.cellbi.2007.12.007; Bonilla C, 2009, BRAIN INJURY, V23, P760, DOI 10.1080/02699050903133970; Brunt KR, 2012, CAN J PHYSIOL PHARM, V90, P327, DOI [10.1139/Y2012-007, 10.1139/y2012-007]; Cao Qi-lin, 2008, V438, P361, DOI 10.1007/978-1-59745-133-8_28; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; De Feo D, 2012, CURR OPIN NEUROL, V25, P322, DOI 10.1097/WCO.0b013e328352ec45; de Girolamo L, 2013, CURR PHARM DESIGN, V19, P2459, DOI 10.2174/1381612811319130015; de Lecinana MA, 2006, J NEUROL SCI, V247, P121, DOI 10.1016/j.jns.2006.03.022; Ertas G, 2012, SCI WORLD J, DOI 10.1100/2012/105698; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gutierrez-Fernandez M, 2011, NEUROSCIENCE, V175, P394, DOI 10.1016/j.neuroscience.2010.11.054; Gutierrez-Fernandez M, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt159; Gutierrez-Fernandez M, 2013, DISCOV MED, V16, P37; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Jain KK, 2009, MOL BIOTECHNOL, V42, P367, DOI 10.1007/s12033-009-9166-8; Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Kochanek PM, 2010, DEV NEUROSCI-BASEL, V32, P335, DOI 10.1159/000323016; Komotar RJ, 2007, NAT PROTOC, V2, P2345, DOI 10.1038/nprot.2007.359; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mackay KB, 1996, NEURODEGENERATION, V5, P319, DOI 10.1006/neur.1996.0043; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mahmood A, 2007, NEUROSURGERY, V61, P206, DOI 10.1227/01.neu.0000279914.37559.de; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Michalczyk K, 2005, HISTOL HISTOPATHOL, V20, P665, DOI 10.14670/HH-20.665; Mori K, 2005, J CEREBR BLOOD F MET, V25, P887, DOI 10.1038/sj.jcbfm.9600083; Ozen I, 2012, CLIN TRANSL MED, V1, DOI 10.1186/2001-1326-1-30; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Persons DA, 1998, NAT MED, V4, P1201, DOI 10.1038/2704; Ribeiro A, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt336; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Richardson RM, 2006, ACTA NEUROCHIR, V148, P773, DOI 10.1007/s00701-006-0778-5; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Rovegno M, 2012, MED INTENSIVA, V36, P37, DOI 10.1016/j.medin.2011.06.008; Sughrue ME, 2006, J NEUROSCI METH, V151, P83, DOI 10.1016/j.jneumeth.2005.04.023; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Walker PA, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/369578; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wang S, 2013, BRAIN RES, V1532, P76, DOI 10.1016/j.brainres.2013.08.001; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2010, DISCOV MED, V10, P434; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Xue S, 2010, NEUROSCI LETT, V473, P186, DOI 10.1016/j.neulet.2010.02.035	54	19	23	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT 15	2015	29	12					1497	1510		10.3109/02699052.2015.1053525			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CV7CO	WOS:000364430200015	26287760				2021-06-18	
J	Thiagarajan, P; Ciuffreda, KJ				Thiagarajan, Preethi; Ciuffreda, Kenneth J.			Pupillary responses to light in chronic non-blast-induced mTBI	BRAIN INJURY			English	Article						Mild traumatic brain injury; parasympathetic system; pupillary dynamics; pupillary light reaction; sympathetic system	TRAUMATIC BRAIN-INJURY; PATHOPHYSIOLOGY	Purpose: To evaluate objectively and quantitatively human pupillary responses to a light stimulus under photopic conditions in individuals with non-blast-induced, chronic, mild traumatic brain injury (mTBI).Methods: Seventeen individuals with chronic, non-blast-induced mTBI and 15 visually-normal (VN) controls were tested (aged 21-45 years). Pupillary responsivity to a brief step-input light stimulus was assessed objectively in each eye for 5 seconds using the Neuroptics PLR-200 monocular, hand-held pupillometer with its pre-set and automated eight parameter analysis.Results: Five of the eight parameters assessed were significantly reduced (p0.05) in the mTBI group as compared to the VN control group: maximum (or peak) constriction velocity, average constriction velocity, average dilation velocity, maximum diameter and amplitude of constriction. The remaining three parameters were similar in each group (p>0.05): constriction latency, 75% dilation recovery time and minimum diameter.Conclusions: The slowed dilation dynamics and reduced maximum pupillary diameter in mTBI suggest deficiency primarily of the sympathetic control system. The reduced peak velocities and related amplitudes suggest subtle parasympathetic involvement.	[Thiagarajan, Preethi; Ciuffreda, Kenneth J.] SUNY State Coll Optometry, Dept Biol & Vis Sci, New York, NY 10036 USA	Ciuffreda, KJ (corresponding author), SUNY State Coll Optometry, Dept Biol & Vis Sci, 33 West 42nd St, New York, NY 10036 USA.	kciuffreda@sunyopt.edu			SUNY College of Optometry's Schnurmacher Institute for Vision Research	This project was funded by the SUNY College of Optometry's Schnurmacher Institute for Vision Research. The authors report non conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Adoni Andea, 2007, J Trauma Nurs, V14, P191; Birch D., 2003, ADLERS PHYSL EYE, P586; Bitsios R, 1996, AGE AGEING, V25, P432; Bradley JC, 2010, J CATARACT REFR SURG, V36, P277, DOI 10.1016/j.jcrs.2009.09.025; Bremner FD, 2012, INVEST OPHTH VIS SCI, V53, P7343, DOI 10.1167/iovs.12-10881; Capo-Aponte JE, 2013, J SPINE S, VS4, DOI [10.4172/2165-7939.S4-004., DOI 10.4172/2165-7939.S4-004]; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Ciuffreda KJ, 2014, MIL MED, V179, P1212, DOI 10.7205/MILMED-D-14-00059; Ciuffreda KJ., 2006, ACCOMMODATION PUPIL, V6th ed, P93, DOI DOI 10.1016/B978-0-7506-7524-6.50009-0; ELLIS CJK, 1981, BRIT J OPHTHALMOL, V65, P754, DOI 10.1136/bjo.65.11.754; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Han M H Esther, 2008, Optometry, V79, P252, DOI 10.1016/j.optm.2008.01.001; Kardon R, 1995, Curr Opin Ophthalmol, V6, P20, DOI 10.1097/00055735-199512000-00004; Kardon R, 2003, ADLERS PHYSL EYE, P713; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Loewenfeld IE, 1999, PUPIL ANATOMY PHYSL; Lopez NE, 2012, J TRAUMA ACUTE CARE, V72, P1562, DOI 10.1097/TA.0b013e3182569875; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Pearson BC, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.036731; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; Stapert S, 2006, BRAIN INJURY, V20, P161, DOI 10.1080/02699050500442949; Stark L., 1968, NEUROLOGICAL CONTROL, P160; Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205; VA/DoD, 2009, CLIN PRACT GUID MAN; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zinn KM, 1972, THE PUPIL	27	19	20	1	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT 15	2015	29	12					1420	1425		10.3109/02699052.2015.1045029			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CV7CO	WOS:000364430200004	26182230				2021-06-18	
J	Dardiotis, E; Paterakis, K; Siokas, V; Tsivgoulis, G; Dardioti, M; Grigoriadis, S; Simeonidou, C; Komnos, A; Kapsalaki, E; Fountas, K; Hadjigeorgiou, GM				Dardiotis, Efthimios; Paterakis, Konstantinos; Siokas, Vasileios; Tsivgoulis, Georgios; Dardioti, Maria; Grigoriadis, Savas; Simeonidou, Constantina; Komnos, Apostolos; Kapsalaki, Eftychia; Fountas, Kostas; Hadjigeorgiou, Georgios M.			Effect of angiotensin-converting enzyme tag single nucleotide polymorphisms on the outcome of patients with traumatic brain injury	PHARMACOGENETICS AND GENOMICS			English	Article						angiotensin-converting enzyme; polymorphism; tag single nucleotide polymorphisms; traumatic brain injury	CEREBRAL-BLOOD-FLOW; GENETIC ASSOCIATION; SUBSTANCE-P; ACE; AUTOREGULATION; NEUROTRAUMA; DEFICITS; DAMAGE; EDEMA	BackgroundGenetic variants appear to influence, at least to some degree, the extent of brain injury and the clinical outcome of patients who have sustained a traumatic brain injury (TBI). Angiotensin-converting enzyme (ACE) is a zinc metallopeptidase that is implicated in the regulation of blood pressure and cerebral circulation. ACE gene polymorphisms were found to regulate serum ACE enzyme activity.ObjectiveThe present study aimed to investigate possible influence of ACE gene region variants on patients' outcome after TBI.Patients and methodsIn total, 363 TBI patients prospectively enrolled in the study were genotyped for five tag single nucleotide polymorphisms (SNPs) across the ACE gene. Using logistic regression analyses, tag SNPs and their constructed haplotypes were tested for associations with 6-month Glasgow Outcome Scale scores, after adjustment for age, sex, Glasgow Coma Scale scores at admission, and the presence of a hemorrhagic event in the initial computed tomography scan.ResultsSignificant effects on TBI outcome were found for three neighboring tag SNPs in the codominant (genotypic) model of inheritance [rs4461142: odds ratio (OR) 0.26, 95% confidence interval (CI) 0.12-0.57, P=0.0001; rs7221780: OR 2.67, 95% CI 1.25-5.72, P=0.0003; and rs8066276: OR 3.82, 95% CI 1.80-8.13, P=0.0002; for the heterozygous variants compared with the common alleles]. None of the constructed common tag SNPs haplotypes was associated with TBI outcome.ConclusionThe present study provides evidence of the possible influence of genetic variations in a specific region of the ACE gene on the outcome of TBI patients. This association may have pharmacogenetic implications in identifying those TBI patients who may benefit from ACE inhibition.	[Dardiotis, Efthimios; Siokas, Vasileios; Dardioti, Maria; Hadjigeorgiou, Georgios M.] Univ Thessaly, Univ Hosp Larissa, Fac Med, Lab Neurogenet,Dept Neurol, Larisa 41100, Greece; [Paterakis, Konstantinos; Fountas, Kostas] Univ Thessaly, Univ Hosp Larissa, Fac Med, Dept Neurosurg, Larisa 41100, Greece; [Komnos, Apostolos] Gen Hosp Larissa, Intens Care Unit, Larisa, Greece; [Kapsalaki, Eftychia] Univ Thessaly, Sch Med, Dept Radiol, Larisa, Greece; [Tsivgoulis, Georgios] Univ Athens, Sch Med, Attikon Univ Hosp, Dept Neurol 2, GR-11527 Athens, Greece; [Grigoriadis, Savas] Hippokrat Univ Hosp, Dept Neurosurg 2, Thessaloniki, Greece; [Simeonidou, Constantina] Aristotle Univ Thessaloniki, Dept Physiol, GR-54006 Thessaloniki, Greece; [Tsivgoulis, Georgios] St Annes Univ Hosp, Int Clin Res Ctr, Brno, Czech Republic	Hadjigeorgiou, GM (corresponding author), Univ Thessaly, Univ Hosp Larissa, Fac Med, Lab Neurogenet,Dept Neurol, Mezourlo Hill, Larisa 41100, Greece.	gmhadji@med.uth.gr	Tsivgoulis, Georgios/AAD-5360-2020; Tsivgoulis, Georgios/AAD-7467-2019; Paterakis, Konstantinos/AAH-4554-2019	Tsivgoulis, Georgios/0000-0002-0640-3797; Dardiotis, Efthimios/0000-0003-2957-641X	Research Committee of the University of Thessaly, Greece [2845]	This study was supported in part by a research grant from the Research Committee of the University of Thessaly, Greece (code: 2845).	Ariza M, 2006, J NEUROPSYCH CLIN N, V18, P39, DOI 10.1176/appi.neuropsych.18.1.39; Baranov D, 2003, ANESTHESIOLOGY, V99, P1118, DOI 10.1097/00000542-200311000-00018; Carter KW, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-557; Carter KW, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-60; Dardiotis E, 2006, SURG NEUROL, V66, P334, DOI 10.1016/j.surneu.2006.05.042; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; Dardiotis E, 2012, CURR OPIN PSYCHIATR, V25, P231, DOI 10.1097/YCO.0b013e3283523c0e; Dardiotis E, 2011, PHARMACOGENET GENOM, V21, P136, DOI 10.1097/FPC.0b013e328343ab15; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; DEMOLIS P, 1993, J CARDIOVASC PHARM, V22, P373, DOI 10.1097/00005344-199309000-00005; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Friedman A, 2014, EXPERT REV NEUROTHER, V14, P1365, DOI 10.1586/14737175.2014.972945; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Harford-Wright E, 2010, NEUROSCI LETT, V481, P26, DOI 10.1016/j.neulet.2010.06.044; Lettre G, 2007, GENET EPIDEMIOL, V31, P358, DOI 10.1002/gepi.20217; Li ZQ, 2009, CELL RES, V19, P519, DOI 10.1038/cr.2009.33; Maas Andrew I R, 2015, Handb Clin Neurol, V128, P455, DOI 10.1016/B978-0-444-63521-1.00029-7; Namsolleck P, 2013, NEUROBIOL DIS, V51, P177, DOI 10.1016/j.nbd.2012.11.008; Oba R, 2005, EUR J NEUROSCI, V21, P733, DOI 10.1111/j.1460-9568.2005.03912.x; Panahpour H, 2014, CLIN EXP PHARMACOL P, V41, P220, DOI 10.1111/1440-1681.12210; Sayed-Tabatabaei FA, 2006, CIRC RES, V98, P1123, DOI 10.1161/01.RES.0000223145.74217.e7; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; YOKOSAWA H, 1983, BIOCHEM BIOPH RES CO, V116, P735, DOI 10.1016/0006-291X(83)90586-7; Zhu XF, 2000, AM J HUM GENET, V67, P1144	28	19	19	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1744-6872	1744-6880		PHARMACOGENET GENOM	Pharmacogenet. Genomics	OCT	2015	25	10					485	490		10.1097/FPC.0000000000000161			6	Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy	Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy	CR6SB	WOS:000361476500002	26181640				2021-06-18	
J	Ki, HJ; Lee, HJ; Lee, HJ; Yi, JS; Yang, JH; Lee, IW				Ki, Hee Jong; Lee, Hyung-Jin; Lee, Hong-Jae; Yi, Jin-Seok; Yang, Ji-Ho; Lee, Il-Woo			The Risk Factors for Hydrocephalus and Subdural Hygroma after Decompressive Craniectomy in Head Injured Patients	JOURNAL OF KOREAN NEUROSURGICAL SOCIETY			English	Article						Decompressive craniectomy; Hydrocephalus; Subdural hygroma	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC HYDROCEPHALUS; COMMUNICATING HYDROCEPHALUS; SURGICAL COMPLICATIONS; EFFUSION	Objective : The present study aims to investigate 1) the risk factors for hydrocephalus and subdural hygroma (SDG) occurring after decompressive craniectomy (DC), and 2) the association between the type of SDG and hydrocephalus. Methods : We retrospectively reviewed the clinical and radiological features of 92 patients who underwent DC procedures after severe head injuries. The risk factors for developing post-traumatic hydrocephalus (PTH) and SDG were analyzed. Types of SDGs were classified according to location and their relationship with hydrocephalus was investigated. Results : Ultimately, 26.09% (24/92) of these patients developed PTH. In the univariate analyses, hydrocephalus was statically associated with large bone flap diameter, large craniectomy area, bilateral craniectomy, intraventricular hemorrhage, contralateral or interhemisheric SDGs, and delayed cranioplasty. However, in the multivariate analysis, only large craniectomy area (adjusted OR=4.66; p=0.0239) and contralateral SDG (adjusted OR=6.62; p=0.0105) were significant independent risk factors for developing hydrocephalus after DC. The incidence of overall SDGs after DC was 55.43% (51/92). Subgroup analysis results were separated by SDG types. Statistically significant associations between hydrocephalus were found in multivariate analysis in the contralateral (adjusted OR=5.58; p=0.0074) and interhemispheric (adjusted OR=17.63; p=0.0113) types. Conclusion : For patients who are subjected to DC following severe head trauma, hydrocephalus is associated with a large craniectomy area and contralateral SDG. For SDGs after DC that occur on the interhemispherical or controlateral side of the craniectomy, careful follow-up monitoring for the potential progression into hydrocephalus is needed.	[Ki, Hee Jong; Lee, Hyung-Jin; Lee, Hong-Jae; Yi, Jin-Seok; Yang, Ji-Ho; Lee, Il-Woo] Catholic Univ Korea, Coll Med, Daejeon St Marys Hosp, Dept Neurosurg, Taejon 34943, South Korea	Lee, HJ (corresponding author), Catholic Univ Korea, Coll Med, Daejeon St Marys Hosp, Dept Neurosurg, 64 Daeheung Ro, Taejon 34943, South Korea.	hyungjin@catholic.ac.kr					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Cho BR, 2012, KOREAN J NEUROTRAUMA, V8, P110; Choi I, 2008, J KOREAN NEUROSURG S, V43, P227, DOI 10.3340/jkns.2008.43.5.227; da Costa DG, 1941, ARCH SURG-CHICAGO, V43, P559, DOI 10.1001/archsurg.1941.01210160020003; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; FOLTZ EL, 1956, J NEUROSURG, V13, P546, DOI 10.3171/jns.1956.13.6.0546; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2014, INJURY, V45, P1332, DOI 10.1016/j.injury.2014.03.007; Honeybul S, 2012, J NEUROTRAUM, V29, P1872, DOI 10.1089/neu.2012.2356; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Huh PW, 2006, J NEUROSURG, V105, P65, DOI 10.3171/jns.2006.105.1.65; Jeon SW, 2011, J KOREAN NEUROSURG S, V49, P355, DOI 10.3340/jkns.2011.49.6.355; Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132; Kilincer C, 2005, CLIN NEUROL NEUROSUR, V107, P412, DOI 10.1016/j.clineuro.2004.09.018; Lee KS, 1998, BRAIN INJURY, V12, P595, DOI 10.1080/026990598122359; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Murata Keiji, 1993, Neurologia Medico-Chirurgica, V33, P691, DOI 10.2176/nmc.33.691; OHNO K, 1987, J NEUROL NEUROSUR PS, V50, P1694, DOI 10.1136/jnnp.50.12.1694; Rahme R, 2010, NEUROSURGERY, V67, P675, DOI 10.1227/01.NEU.0000383142.10103.0B; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Su TM, 2011, J TRAUMA, V71, P833, DOI 10.1097/TA.0b013e31821b092a; VANNESTE J, 1992, ARCH NEUROL-CHICAGO, V49, P366, DOI 10.1001/archneur.1992.00530280046021; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	29	19	26	0	4	KOREAN NEUROSURGICAL SOC	SEOUL	BLDG B, #402, 27, CHILPAE-RO, JUNG-GU, SEOUL, 04511, SOUTH KOREA	2005-3711	1598-7876		J KOREAN NEUROSURG S	J. Korean. Neurosurg. Soc.	SEP	2015	58	3					254	261		10.3340/jkns.2015.58.3.254			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CX2BU	WOS:000365500700014	26539270	DOAJ Gold, Green Published			2021-06-18	
J	Pozzi, M; Conti, V; Locatelli, F; Galbiati, S; Radice, S; Citerio, G; Clementi, E; Strazzer, S				Pozzi, Marco; Conti, Valentino; Locatelli, Federica; Galbiati, Sara; Radice, Sonia; Citerio, Giuseppe; Clementi, Emilio; Strazzer, Sandra			Paroxysmal Sympathetic Hyperactivity in Pediatric Rehabilitation: Clinical Factors and Acute Pharmacological Management	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						dysautonomia; drug therapy; paroxysmal sympathetic hyperactivity; rehabilitation; pediatric	TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; DYSAUTONOMIA; SPECTRUM	Objective: Paroxysmal sympathetic hyperactivity (PSH) is widely described as occurring during intensive care, but in a number of patients it may last longer into the rehabilitation phase. Furthermore, drug therapy has been based on isolated observations. In this study, our aims are to describe a group of 26 pediatric rehabilitation patients with PSH and to quantify the effect of several drugs used to suppress PSH episodes. Setting: Neurorehabilitation unit of IRCCS Eugenio Medea, Bosisio Parini (LC), Italy. Participants: A total of 407 pediatric patients with postacute acquired brain injury, 26 of which had PSH. Design: Retrospective cohort study. Main Measures: Descriptive demographic and clinical data. Odds ratios quantification of the efficacy of drug therapies administered acutely to suppress PSH episodes. Results: PSH was associated with a longer duration of coma and a greater incidence of death. When administered acutely to suppress PSH episodes, the best drugs were clonazepam, hydroxyzine, and delorazepam, while analgesic drugs showed little efficacy. Conclusions: PSH, whether causative or not, is associated with a worse long-term course in rehabilitation. Clinical management of PSH may be helped by a number of acutely administered drug therapies.	[Pozzi, Marco; Locatelli, Federica; Galbiati, Sara; Clementi, Emilio; Strazzer, Sandra] Sci Inst IRCCS Eugenio Medea, Bosisio Parini, Lecco, Italy; [Conti, Valentino] Reg Ctr Pharmacovigilance Lombardy, Milan, Italy; [Radice, Sonia] Univ Milan, Luigi Sacco Univ Hosp, Dept Biomed & Clin Sci L Sacco, Clin Pharmacol Unit, Milan, Italy; [Citerio, Giuseppe] AO San Gerardo, Neuroreanimat, Monza, Italy; [Clementi, Emilio] Univ Milan, Luigi Sacco Univ Hosp, Dept Biomed & Clin Sci L Sacco, Unit Clin Pharmacol,CNR Inst Neurosci, Milan, Italy	Strazzer, S (corresponding author), IRCCS Eugenio Medea, Inst Sci, UO Gravi Cerebrolesioni Acquisite NR3, I-23842 Bosisio Parini, Lecco, Italy.	sandra.strazzer@bp.lnf.it	Pozzi, Marco/Z-2684-2019; Pozzi, Marco/J-7915-2016; Citerio, Giuseppe/B-1839-2015; Galbiati, Sara/AAA-7115-2020; Strazzer, Sandra/AAH-5712-2019; FEDERICA, LOCATELLI/AAA-5601-2020	Pozzi, Marco/0000-0002-3800-5697; Pozzi, Marco/0000-0002-3800-5697; Citerio, Giuseppe/0000-0002-5374-3161; Galbiati, Sara/0000-0001-6810-359X; Strazzer, Sandra/0000-0001-8414-6565; FEDERICA, LOCATELLI/0000-0002-8243-5483	Agenzia Italiana del Farmaco (AIFA); Regione Lombardia (MEAP Project, Monitoraggio degli Eventi Avversi in Pediatria)Regione Lombardia; Italian Ministry of Health (Ricerca Corrente)Ministry of Health, Italy	The financial support by Agenzia Italiana del Farmaco (AIFA) and Regione Lombardia (MEAP Project, Monitoraggio degli Eventi Avversi in Pediatria, to E.C.) and by the Italian Ministry of Health (Ricerca Corrente 2014, to E.C. and S.S.) is gratefully acknowledged. The funding public institutions had no role in any part of the work.	Altamura AC, 2013, EXPERT OPIN DRUG MET, V9, P423, DOI 10.1517/17425255.2013.759209; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Choi HA, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0370-3; Dolce G, 2008, J NEUROTRAUM, DOI [10.1089/neu.2008.0536, DOI 10.1089/NEU.2008.0536, 10.1089/neu.2008.0536.]; Estraneo A, 2013, NEUROLOGY, V80, P464, DOI 10.1212/WNL.0b013e31827f0f31; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Fernandez-Ortega JF, 2012, J NEUROTRAUM, V29, P1364, DOI 10.1089/neu.2011.2033; Greer DM, 2008, STROKE, V39, P3029, DOI 10.1161/STROKEAHA.108.521583; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; Hinson HE, 2012, CURR OPIN CRIT CARE, V18, P139, DOI 10.1097/MCC.0b013e3283513290; Kirk KA, 2012, DEV MED CHILD NEUROL, V54, P759, DOI 10.1111/j.1469-8749.2012.04322.x; Koike H, 2013, J NEUROL NEUROSUR PS, V84, P98, DOI 10.1136/jnnp-2012-302833; Kwasnica C, 2008, ARCH PHYS MED REHAB, V89, pS15, DOI 10.1016/j.apmr.2007.12.006; Lemke DM, 2007, CRIT CARE NURSE, V27, P30; Lv LQ, 2011, J TRAUMA, V71, P538, DOI 10.1097/TA.0b013e31820ebee1; Morgan AS, 1999, J HEAD TRAUMA REHAB, V14, P454, DOI 10.1097/00001199-199910000-00006; Norcliffe-Kaufmann L, 2012, AUTON NEUROSCI-BASIC, V172, P26, DOI 10.1016/j.autneu.2012.10.012; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Perkes IE, 2011, BRAIN INJURY, V25, P925, DOI 10.3109/02699052.2011.589797; Pignolo L, 2012, J REHABIL MED, V44, P502, DOI 10.2340/16501977-0981; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Wenning GK, 2013, LANCET NEUROL, V12, P264, DOI 10.1016/S1474-4422(12)70327-7	29	19	19	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2015	30	5					357	363		10.1097/HTR.0000000000000084			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DD0JE	WOS:000369605400013	25310291				2021-06-18	
J	Sours, C; George, E; Zhuo, JC; Roys, S; Gullapalli, R				Sours, Chandler; George, Elijah O.; Zhuo, Jiachen; Roys, Steven; Gullapalli, Rao P.			Hyper-connectivity of the thalamus during early stages following mild traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild traumatic brain injury; Resting state functional connectivity; Thalamus; H-1 magnetic resonance spectroscopy	DEFAULT-MODE NETWORK; MAGNETIC-RESONANCE-SPECTROSCOPY; STATE FUNCTIONAL CONNECTIVITY; PROTON MR SPECTROSCOPY; RECEPTOR SUBUNITS; CORTEX; CONCUSSION; INTEGRITY; SYMPTOMS; DYSFUNCTION	The thalamo-cortical resting state functional connectivity of seven sub-thalamic regions were examined in a prospectively recruited population of 77 acute mild TBI (mTBI) patients within the first 10 days (mean 6 +/- 3 days) of injury and 35 neurologically intact control subjects using the Oxford thalamic connectivity atlas. Neuropsychological assessments were conducted using the Automated Neuropsychological Assessment Metrics (ANAM). A subset of participants received a magentic resonance spectroscopy (MRS) exam to determine metabolite concentrations in the thalamus and the posterior cingulate cortex. Results show that patients performed worse than the control group on various subtests of ANAM and the weighted throughput score, suggesting reduced cognitive performance at this early stage of injury. Both voxel and region of interest based analysis of the resting state fMRI data demonstrated that acute mTBI patients have increased functional connectivity between the various sub-thalamic regions and cortical regions associated with sensory processing and the default mode network (DMN). In addition, a significant reduction in NAA/Cr was observed in the thalamus in the mTBI patients. Furthermore, an increase in Cho/Cr ratio specific to mTBI patients with self-reported sensory symptoms was observed compared to those without self-reported sensory symptoms. These results provide novel insights into the neural mechanisms of the brain state related to internal rumination and arousal, which have implications for new interventions for mTBI patients with persistent symptoms. Furthermore, an understanding of heightened sensitivity to sensory related inputs during early stages of injury may facilitate enhanced prediction of safe return to work.	[Sours, Chandler; George, Elijah O.; Zhuo, Jiachen; Roys, Steven; Gullapalli, Rao P.] Univ Maryland, Sch Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA; [Sours, Chandler; George, Elijah O.; Zhuo, Jiachen; Roys, Steven; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [George, Elijah O.; Gullapalli, Rao P.] Univ Maryland, Dept Bioengn, College Pk, MD 20740 USA	Gullapalli, R (corresponding author), Univ Maryland, Sch Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA.	rgullapalli@umm.edu			Department of DefenseUnited States Department of Defense [W81XWH-08-1-0725, W81XWH-12-1-0098]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR019214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS081984, R03NS088014] Funding Source: NIH RePORTER	The authors would like to thank Joshua Betz, Jacqueline Janowich, Teodora Stoica and Joseph Rosenberg for their help with patient recruitment, Dr. Robert Kane for providing access to ANAM, and and George Makris for his help with acquiring and processing the data. Support for this work was in part provided by the Department of Defense (W81XWH-08-1-0725 & W81XWH-12-1-0098 to RPG).	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Bey T, 2009, WEST J EMERG MED, V10, P6; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Callard F, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00321; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; DAVIE CA, 1993, LANCET, V341, P630, DOI 10.1016/0140-6736(93)90390-3; Di X, 2014, PEERJ, V2, DOI 10.7717/peerj.367; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Drexel M, 2015, NEUROPHARMACOLOGY, V88, P122, DOI 10.1016/j.neuropharm.2014.08.023; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Galarreta M, 2001, NAT REV NEUROSCI, V2, P425, DOI 10.1038/35077566; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; George EO, 2014, J NEUROTRAUM, V31, P1018, DOI 10.1089/neu.2013.3224; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Grossman Elan J, 2010, Top Magn Reson Imaging, V21, P379, DOI 10.1097/RMR.0b013e31823e65b8; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hattingen E, 2009, BRAIN, V132, P3285, DOI 10.1093/brain/awp293; He J.H., 2014, ACTA NEUROL SCAND; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Huusko N, 2014, NEUROSCIENCE, V267, P30, DOI 10.1016/j.neuroscience.2014.02.026; Inglese M, 2003, MAGNET RESON MED, V50, P190, DOI 10.1002/mrm.10481; Iraji A., 2014, J NEUROTRAUMA; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kapogiannis D, 2013, NEUROIMAGE, V64, P112, DOI 10.1016/j.neuroimage.2012.09.029; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Kucyi A, 2014, J NEUROSCI, V34, P3969, DOI 10.1523/JNEUROSCI.5055-13.2014; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Laouchedi M, 2014, J NEURORADIOL, V10, P1016; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lynall ME, 2010, J NEUROSCI, V30, P9477, DOI 10.1523/JNEUROSCI.0333-10.2010; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; Mathias JL, 2014, J NEUROTRAUM, V31, P658, DOI 10.1089/neu.2013.3160; Mayer A., 2013, J NEUROTRAUMA; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McCrea M., 2000, STANDARDIZED ASSESSM; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reich S, 2005, VALIDATION ANAM TEST; Robinson M. E., 2014, HUM BRAIN MAPP; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Sours C, 2014, BRAIN IMAGING BEHAV; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Stokum J., 2014, BRAIN INJUR IN PRESS; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wang X, 2014, NEUROSCIENCE, V278, P291, DOI 10.1016/j.neuroscience.2014.08.006; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; Yin Y, 2011, BRAIN RES, V1411, P98, DOI 10.1016/j.brainres.2011.07.016; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhou Y., 2013, J MAGN RESON IMAGING; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	88	19	19	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2015	9	3					550	563		10.1007/s11682-015-9424-2			14	Neuroimaging	Neurosciences & Neurology	CR8LQ	WOS:000361604300015	26153468	Green Accepted			2021-06-18	
J	Cross, DJ; Garwin, GG; Cline, MM; Richards, TL; Yarnykh, V; Mourad, PD; Ho, RJY; Minoshima, S				Cross, Donna J.; Garwin, Gregory G.; Cline, Marcella M.; Richards, Todd L.; Yarnykh, Vasily; Mourad, Pierre D.; Ho, Rodney J. Y.; Minoshima, Satoshi			Paclitaxel improves outcome from traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; MR imaging; Microtubule stabilization; Neurological function	ALZHEIMERS-DISEASE; HEAD-INJURY; AXONAL INJURY; ENCEPHALOPATHY; MICROTUBULES; TAXOL; PATHOLOGY; RISK; IRAQ	Pharmacologic interventions for traumatic brain injury (TBI) hold promise to improve outcome. The purpose of this study was to determine if the microtubule stabilizing therapeutic paclitaxel used for more than 20 years in chemotherapy would improve outcome after TBI. We assessed neurological outcome in mice that received direct application of paclitaxel to brain injury from controlled cortical impact (CCI). Magnetic resonance imaging was used to assess injury-related morphological changes. Catwalk Gait analysis showed significant improvement in the paclitaxel group on a variety of parameters compared to the saline group. MRI analysis revealed that paclitaxel treatment resulted in significantly reduced edema volume at site-of-injury (11.92+/-3.0 and 8.86+/-2.2 mm(3) for saline vs. paclitaxel respectively, as determined by T2-weighted analysis; p <= 0.05), and significantly increased myelin tissue preservation (9.45+/-0.4 vs. 8.95+/-0.3, p <= 0.05). Our findings indicate that paclitaxel treatment resulted in improvement of neurological outcome and MR imaging biomarkers of injury. These results could have a significant impact on therapeutic developments to treat traumatic brain injury. (C) 2015 Elsevier B.V. All rights reserved.	[Cross, Donna J.; Garwin, Gregory G.; Cline, Marcella M.; Richards, Todd L.; Yarnykh, Vasily] Univ Washington, Dept Radiol, Seattle, WA 98195 USA; [Mourad, Pierre D.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Ho, Rodney J. Y.] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA; [Minoshima, Satoshi] Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA	Cross, DJ (corresponding author), Univ Washington, Dept Radiol, 1959 NE Pacific St, Seattle, WA 98195 USA.	dcross@uw.edu	Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasiliy/N-7635-2014	Yarnykh, Vasily/0000-0002-1583-8979; Cross, Donna/0000-0003-1918-2214; Cline, Marcella/0000-0002-9590-3725; Minoshima, Satoshi/0000-0002-0043-3047	Institute for Translational Health Sciences [UL1TR000423]; UW; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000423] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [UM1AI120176] Funding Source: NIH RePORTER	Support for this research was provided by the Institute for Translational Health Sciences pilot project grant opportunity (UL1TR000423) and the UW. Center on Human Development and Disability animal imaging and animal behavioral cores The authors would like to acknowledge Nathalie Martin and Abigail McClintic for their assistance with this project.	Adlard PA, 2000, ACTA NEUROPATHOL, V100, P183, DOI 10.1007/s004019900160; Alberts B, 1994, MOL BIOL CELL; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; Barten DM, 2012, J NEUROSCI, V32, P7137, DOI 10.1523/JNEUROSCI.0188-12.2012; Brunden KR, 2011, PHARMACOL RES, V63, P341, DOI 10.1016/j.phrs.2010.12.002; Carlson K, 2011, CLIN BREAST CANCER, V11, P73, DOI 10.1016/j.clbc.2011.03.006; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Diaz JF, 2003, J BIOL CHEM, V278, P8407, DOI 10.1074/jbc.M211163200; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldstein L.E., 2012, SCI TRANSL MED, V4; Gornstein E, 2014, NEUROPHARMACOLOGY, V76, P175, DOI 10.1016/j.neuropharm.2013.08.016; Hellal F, 2011, SCIENCE, V331, P928, DOI 10.1126/science.1201148; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kharatishvili I, 2009, EXP NEUROL, V217, P154, DOI 10.1016/j.expneurol.2009.01.026; Lou K, 2014, J MED CHEM, V57, P6116, DOI 10.1021/jm5005623; Lunn KF, 1997, J NEUROSCI, V17, P4921; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Michaelis ML, 2002, J MOL NEUROSCI, V19, P289, DOI 10.1385/JMN:19:3:289; Mountney A, 2013, J NEUROSCI METH, V212, P1, DOI 10.1016/j.jneumeth.2012.08.025; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Petrie EC, 2009, ARCH NEUROL-CHICAGO, V66, P632, DOI 10.1001/archneurol.2009.59; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Roberts G, 1969, BRAIN DAMAGE BOXERS; Si DW, 2014, EXP THER MED, V8, P1010, DOI 10.3892/etm.2014.1840; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Underhil HR, 2009, NEUROIMAGE, V47, P1568, DOI 10.1016/j.neuroimage.2009.05.075; Underhill HR, 2011, NEUROIMAGE, V54, P2052, DOI 10.1016/j.neuroimage.2010.10.065; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Yarnykh VL, 2012, MAGN RESON MED, V68, P166, DOI 10.1002/mrm.23224; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174/1568009033333754	44	19	20	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 27	2015	1618						299	308		10.1016/j.brainres.2015.06.006			10	Neurosciences	Neurosciences & Neurology	CP5XB	WOS:000359957600030	26086366	Green Accepted			2021-06-18	
J	Lin, C; He, HQ; Li, Z; Liu, YL; Chao, HL; Ji, J; Liu, N				Lin, Chao; He, Hongquan; Li, Zheng; Liu, Yinglong; Chao, Honglu; Ji, Jing; Liu, Ning			Efficacy of progesterone for moderate to severe traumatic brain injury: a meta-analysis of randomized clinical trials	SCIENTIFIC REPORTS			English	Article							NEUROPROTECTION; RECOVERY	Progesterone has been shown to have neuroprotective effects in multiple animal models of brain injury, whereas the efficacy and safety in patients with traumatic brain injury (TBI) remains contentious. Here, a total of seven randomized controlled trials (RCTs) with 2492 participants were included to perform this meta-analysis. Compared with placebo, there was no significant decrease to be found in the rate of death or vegetative state for patients with acute TBI (RR = 0.88, 95% CI = 0.70, 1.09, p = 0.24). Furthermore, progesterone was not associated with good recovery in comparison with placebo (RR = 1.00, 95% CI = 0.88, 1.14, p = 0.95). Together, our study suggested that progesterone did not improve outcomes over placebo in the treatment of acute TBI.	[Lin, Chao; Li, Zheng; Liu, Yinglong; Chao, Honglu; Ji, Jing; Liu, Ning] Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [He, Hongquan] Gaochun Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China	Ji, J (corresponding author), Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	jijing@njmu.edu.cn; liuning_0853@163.com		Liu, Ning/0000-0001-7895-1285	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471269 (BA14)]	This study was supported by grants from the National Natural Science Foundation of China ( No. 81471269 (BA14)).	Aminmansour Bahram, 2012, Adv Biomed Res, V1, P58, DOI 10.4103/2277-9175.100176; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Ma JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub3; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Mustafa AG, 2013, NEUROSCIENCES, V18, P222; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Shakeri M, 2013, CLIN NEUROL NEUROSUR, V115, P2019, DOI 10.1016/j.clineuro.2013.06.013; Si DW, 2013, NEUROSCI LETT, V553, P18, DOI 10.1016/j.neulet.2013.07.052; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xiao Guo-min, 2007, Zhonghua Wai Ke Za Zhi, V45, P106; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	32	19	19	1	11	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	2045-2322			SCI REP-UK	Sci Rep	AUG 25	2015	5								13442	10.1038/srep13442			7	Multidisciplinary Sciences	Science & Technology - Other Topics	CP6ZY	WOS:000360038200002	26304556	DOAJ Gold, Green Published			2021-06-18	
J	Merritt, VC; Meyer, JE; Arnett, PA				Merritt, Victoria C.; Meyer, Jessica E.; Arnett, Peter A.			A novel approach to classifying postconcussion symptoms: The application of a new framework to the Post-Concussion Symptom Scale	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Sports-related concussion; Postconcussion symptoms; Collegiate athletes	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; NEUROCOGNITIVE PERFORMANCE; HIGH-SCHOOL; SEX-DIFFERENCES; RECOVERY; RETURN; PLAY; STABILITY; SEVERITY	Introduction: Self-report measures such as the Post-Concussion Symptom Scale (PCSS) are frequently used during baseline and postconcussion testing to evaluate athletes' symptom profiles. However, the common approach of evaluating the total symptom score and/or symptom clusters may not allow for a complete understanding of the nature of athletes' symptom reporting patterns. The primary objective of this study was to apply three global indices of distress variables, derived from the Symptom Checklist-90-Revised (SCL-90-R) framework, to the PCSS at baseline and postconcussion. We aimed to evaluate the utility of these symptom indices in relation to four PCSS symptom clusters and the total PCSS symptom score. Method: Participants included college athletes evaluated at baseline (N = 846) and postconcussion (N = 86). Athletes underwent neuropsychological testing at both time points, including completion of the PCSS and a paper/pencil and computerized test battery. Eight symptom indices were derived from the PCSS, and a postconcussion neurocognitive composite score was calculated. Results: Results showed that there were significant mean increases from baseline to postconcussion on four of the eight symptom indices evaluated. Furthermore, a significant proportion of athletes showed no change from baseline to postconcussion when evaluating the total symptom score, but showed at least a one standard deviation increase in symptom reporting from baseline to postconcussion when evaluating at least one other symptom index (i.e., a global index of distress or symptom cluster). Finally, the three global indices of distress variables, two of the four symptom clusters, and the total symptom score significantly predicted a postconcussion neurocognitive composite score, such that greater postconcussion symptoms were associated with lower postconcussion neurocognitive performance. Conclusions: These findings suggest that, in addition to evaluating the postconcussion total symptom score, there may be value in examining more specific symptom indices such as the global indices of distress variables and symptom clusters.	[Merritt, Victoria C.; Meyer, Jessica E.; Arnett, Peter A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA	Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vca106@psu.edu		Merritt, Victoria/0000-0001-5683-4168	Penn State Sports Medicine	The authors have no conflicts of interest to report. No formal grant funding was obtained for this project; however, we would like to thank Penn State Sports Medicine and Wayne Sebastianelli for their ongoing support of our concussion program.	Barth JT, 1989, MILD HEAD INJURY SPO; Benedict R., 1997, BRIEF VISUOSPATIAL M; Brandt J., 2001, HOPKINS VERBAL LEARN; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cegalis J.A., 1994, VIGIL W CONTINUOUS P; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Derogatis L.R., 1994, SCL 90 R ADM SCORING, V3rd; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P81, DOI 10.1017/S1355617713001288; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; IBM Corp, 2010, IBM SPSS STAT WIND V; ImPACT Applications Inc., 2012, IMPACT TEST TECHN MA; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR., 2000, IMPACT IMMEDIATE POS; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Pardini D., 2004, BR J SPORTS MED, V38, P661; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Smith A., 1991, SYMBOL DIGIT MODALIT; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Wechsler D, 1997, WAIS 3 ADM SCORING M	51	19	19	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG 9	2015	37	7					764	775		10.1080/13803395.2015.1060950			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CQ1ZS	WOS:000360399700008	26241079				2021-06-18	
J	Gardner, EC				Gardner, Elizabeth C.			Head, Face, and Eye Injuries in Collegiate Women's Field Hockey	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head; eye; and face injuries; women's field hockey; collegiate	SURVEILLANCE SYSTEM; LACROSSE; SPORT	Background: While there is concern regarding head, face, and eye injuries in field hockey, prompting some to recommend the use of protective equipment such as goggles and helmets, little has been written about their incidence and mechanism of injury in the modern game of field hockey. The elucidation of this information will better inform the development of maximally effective injury prevention schemes to protect the athlete while maintaining the integrity of the game. Purpose: To determine the incidence and epidemiology of head, face, and eye injuries in United States collegiate women's field hockey players from 2004-2005 to 2008-2009. Study Design: Descriptive epidemiological study. Methods: All head, face, and eye injuries reported to the National Collegiate Athletic Association Injury Surveillance System for collegiate women's field hockey athletes from the 2004-2005 through 2008-2009 seasons were analyzed. Data regarding the event type, injury mechanism, body part injured, type of injury, outcome, and time lost were reviewed. The weighted injury incidence per 1000 athlete-exposures (AEs) was calculated using the exposure data set for the same years; 95% CIs were calculated based on a normal approximation to the Poisson distribution. Results: There were 150 reported traumatic injuries during this time period, with a weighted occurrence of 1587.3 injuries. The overall incidence of head, face, and eye injuries in collegiate women's field hockey was 0.94 per 1000 AEs (95% CI, 0.86-1.19). Injuries to the head or face, other than the mouth, nose, and eye, accounted for 75.3% of these injuries. The incidence of eye injuries was 0.07 per 1000 AEs (95% CI, 0.03-0.12); nose injuries occurred at a rate of 0.10 per 1000 AEs (95% CI, 0.05-0.15). The rate of traumatic dental injuries was 0.06 per 1000 AEs (95% CI, 0.04-0.14). Contact with an apparatus caused 72.9% of all injuries; specifically, contact with an elevated ball accounted for 47.9% of all injuries, and contact with an elevated stick caused 21.7% of all injuries. While the majority of players suffering a head, face, or eye injury were able to return to sport that season (90.0%), the remaining athletes suffered season-ending injuries (10%). Concussions accounted for 42.8% of all head, face, and eye injuries reported (0.40 per 1000 AEs; 95% CI, 0.32-0.53). Conclusion: Head, face, and eye injuries occur regularly in women's field hockey. This description of the injury profile and mechanisms of injury may be used to design appropriate injury prevention schemes for the sport.	Yale Univ, Sch Med, Dept Orthopaed Surg & Rehabil, New Haven, CT 06519 USA	Gardner, EC (corresponding author), Yale Univ, Sch Med, Dept Orthopaed Surg & Rehabil, 800 Howard Ave,1st Floor, New Haven, CT 06519 USA.	elizabeth.gardner@yale.edu			NCAA	The author has declared the following potential conflict of interest or source of funding: The National Collegiate Athletic Association (NCAA) Injury Surveillance System data were provided by the Datalys Center for Sports Injury Research and Prevention. The Injury Surveillance System was funded by the NCAA. The content of this article is solely the responsibility of the author and does not necessarily represent the official view of the Datalys Center or the NCAA.	[Anonymous], 1996, Pediatrics, V98, P311; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Datalys Center Inc, 2012, NCAA 2004 05 2008 09; Dick R, 2007, J ATHL TRAINING, V42, P211; Dick R, 2007, J ATHL TRAINING, V42, P173; Echlin PS, 2005, BRIT J SPORT MED, V39, P254, DOI 10.1136/bjsm.2004.013128; ELLIOTT AJ, 1984, BRIT MED J, V289, P21, DOI 10.1136/bmj.289.6436.21-a; Hendrickson CD, 2008, CLIN J SPORT MED, V18, P399, DOI 10.1097/JSM.0b013e318188b89d; International Hockey Federation, MEMB NAT FED; JONES NP, 1994, BRIT J SPORT MED, V28, P272, DOI 10.1136/bjsm.28.4.272; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Knapik JJ, 2007, SPORTS MED, V37, P117, DOI 10.2165/00007256-200737020-00003; Kucera KL, 2011, J ATHL TRAINING, V46, P489; Lincoln AE, 2012, AM J SPORT MED, V40, P611, DOI 10.1177/0363546511428873; Murtaugh K, 2001, MED SCI SPORT EXER, V33, P201; National Center for Catastrophic Sport Injury Research, 24 NAT CTR CAT SPORT; National Collegiate Athletic Association, FIELD HOCK RUL MOD 2; Schwarz A, 2011, NY TIMES, pB13; Smith C, NEW JERSEY SCH DISTR; Stoner LJ, 1993, ASTM STP, V2, P183; Washington RL, 2004, PEDIATRICS, V113, P619; Webster DA, 1999, MED SCI SPORT EXER, V31, P938, DOI 10.1097/00005768-199907000-00004; WILDE GJS, 1986, RISK ANAL, V6, P95, DOI 10.1111/j.1539-6924.1986.tb00197.x; Yard EE, 2006, J ATHL TRAINING, V41, P441	24	19	19	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	AUG	2015	43	8					2027	2034		10.1177/0363546515588175			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CO1DF	WOS:000358892400031	26093006				2021-06-18	
J	Ji, SB; Zhao, W				Ji, Songbai; Zhao, Wei			A Pre-computed Brain Response Atlas for Instantaneous Strain Estimation in Contact Sports	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Sports concussion; Rotational acceleration; Pre-computation; Dartmouth Head Injury Model	HEAD IMPACT EXPOSURE; HIGH-SCHOOL; WHITE-MATTER; CONCUSSION DIAGNOSIS; AXONAL DAMAGE; FOOTBALL; ACCELERATION; MODEL; PREDICTORS; GENERATION	Finite element models of the human head play an important role in investigating the mechanisms of traumatic brain injury, including sports concussion. A critical limitation, however, is that they incur a substantial computational cost to simulate even a single impact. Therefore, current simulation schemes significantly hamper brain injury studies based on model-estimated tissue-level responses. In this study, we present a pre-computed brain response atlas (pcBRA) to substantially increase the simulation efficiency in estimating brain strains using isolated rotational acceleration impulses parameterized with four independent variables (peak magnitude and duration, and rotational axis azimuth and elevation angles) with values determined from on-field measurements. Using randomly generated testing datasets, the partially established pcBRA achieved a 100% success rate in interpolation based on element-wise differences in accumulated peak strain () according to a "double-10%" criterion or average regional in generic regions and the corpus callosum. A similar performance was maintained in extrapolation. The pcBRA performance was further successfully validated against directly simulated responses from two independently measured typical real-world rotational profiles. The computational cost to estimate element-wise whole-brain or regional was 6 s and < 0.01 s, respectively, vs. 50 min directly simulating a 40 ms impulse. These findings suggest the pcBRA could substantially increase the throughput in impact simulation without significant loss of accuracy from the estimation itself and, thus, its potential to accelerate the exploration of the mechanisms of sports concussion in general. If successful, the pcBRA may also become a diagnostic adjunct in conjunction with sensors that measure head impact kinematics on the field to objectively monitor and identify tissue-level brain trauma in real-time for "return-to-play" decision-making on the sideline.	[Ji, Songbai; Zhao, Wei] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Ji, Songbai] Geisel Sch Med Dartmouth, Dept Surg & Orthopaed Surg, Hanover, NH 03755 USA	Ji, SB (corresponding author), Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Hanover, NH 03755 USA.	Songbai.Ji@Dartmouth.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS078607]; Dartmouth Hitchcock Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS088781, R21NS078607] Funding Source: NIH RePORTER	This work was sponsored, in part, by the NIH Grant R21 NS078607 and the Dartmouth Hitchcock Foundation.	Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dumpuri P, 2007, MED IMAGE ANAL, V11, P128, DOI 10.1016/j.media.2006.11.002; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; HAKOPIAN H, 1982, SIAM J NUMER ANAL, V19, P510, DOI 10.1137/0719033; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Holbourn AHS, 1943, LANCET, V2, P438; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Ji SB, 2011, FINITE ELEM ANAL DES, V47, P1178, DOI 10.1016/j.finel.2011.05.007; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; King A. I, 2003, IS HEAD INJURY CAUSE; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Loader C., 1999, LOCAL REGRESSION LIK; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morrison B, 2011, STUD MECHANOBIOL TIS, V3, P247, DOI 10.1007/8415_2011_79; Nahum A. M., 1977, 770922 SAE; Newman J A, 2000, Stapp Car Crash J, V44, P215; Newman JA., 1986, GEN ACCELERATION MOD; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A, 2012, J BIOMECH, V45, P679, DOI 10.1016/j.jbiomech.2011.12.005; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Talavage TM, 2013, J NEUROTRAUM, V30, P1; Trosseille X, 1992, DEV FEM HUMAN HEAD A; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Yang KH, 2011, STUD MECHANOBIOL TIS, V3, P69, DOI 10.1007/8415_2010_62; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang L., 2004, J BIOMECH ENG, V126; Zhao W, 2015, BIOMECH MODEL MECHAN, V14, P753, DOI 10.1007/s10237-014-0634-0	59	19	20	0	7	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	AUG	2015	43	8					1877	1895		10.1007/s10439-014-1193-3			19	Engineering, Biomedical	Engineering	CN2KM	WOS:000358249800015	25449149	Green Accepted			2021-06-18	
J	Wang, YC; Cui, Y; Cui, JZ; Sun, LQ; Cui, CM; Zhang, HA; Zhu, HX; Li, R; Tian, YX; Gao, JL				Wang, Yong-Chao; Cui, Ying; Cui, Jian-Zhong; Sun, Li-Qian; Cui, Chang-Meng; Zhang, Hong-Ao; Zhu, Hui-Xing; Li, Ran; Tian, Yan-Xia; Gao, Jun-Ling			Neuroprotective effects of brilliant blue G on the brain following traumatic brain injury in rats	MOLECULAR MEDICINE REPORTS			English	Article						brilliant blue G; P2X7; neuroprotection; traumatic brain injury; rats	PROTEIN-KINASE-C; SPINAL-CORD-INJURY; INTERLEUKIN-1 RECEPTOR ANTAGONIST; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; P2X(7) RECEPTORS; INFLAMMATORY RESPONSE; IMPROVES RECOVERY; EXTRACELLULAR ATP; MICROGLIAL CELLS	The P2X7 inhibitor, brilliant blue G (BBG), has been reported as a neuroprotective drug against a variety of disorders, including neuropathic pain and brain ischemia. Currently, no studies have examined the potential for BBG to provide neuroprotection in animal models of TBI. The aim of the present study was to investigate the neuroprotective effect of BBG on TBI and to determine the underlying mechanisms. The rats were subjected to a diffuse cortical impact injury caused by a modified weight-drop device, and then divided randomly into three groups: the sham-operated, BBG treatment and vehicle groups. In the BBG treatment group, 50 mg/kg brilliant blue G (BBG; 100% pure), a highly specific and clinically useful P2X7 antagonist, was administered via the tail vein 15 min prior to or up to 8 h following TBI. The co-localization of NeuN and protein kinase C gamma (PKC gamma) was followed with immunofluorescent staining. The expression of P2X7, PKC. and inflammatory cytokines was identified by western blot analysis. Wet-dry weight method was used to evaluate brain edema, and motor function outcome was examined using the neurological severity score. The present study demonstrated that the administration of BBG attenuated TBI-induced cerebral edema and the associated motor deficits. Following trauma, BBG treatment significantly reduced the levels of PKC. and interleukin-1 beta in the cortex. The results provide in vivo evidence that BBG exerted neuroprotective effects by attenuating brain edema and improving neurological functions via reducing PKC. and interleukin-1 beta levels following TBI.	[Wang, Yong-Chao; Zhang, Hong-Ao; Zhu, Hui-Xing; Li, Ran; Tian, Yan-Xia; Gao, Jun-Ling] Hebei United Univ, Dept Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Cui, Ying; Cui, Jian-Zhong; Sun, Li-Qian] Tangshan Workers Hosp, Dept Surg, Tangshan 063000, Hebei, Peoples R China; [Cui, Jian-Zhong; Cui, Chang-Meng] Hebei Med Univ, Dept Surg, Shijiazhuang 050017, Hebei, Peoples R China	Gao, JL (corresponding author), Hebei United Univ, Dept Basic Med Sci, Tangshan 063000, Hebei, Peoples R China.	junlinggao666@163.com			Natural Science Foundation of Hebei, Hebei, China [H2012401071, H2014105079]	This study was supported by grants from the Natural Science Foundation of Hebei, Hebei, China (grant nos. H2012401071 and NO. H2014105079).	Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; HUANG FL, 1988, J NEUROSCI, V8, P4734; Iwashita A, 2007, J PHARMACOL EXP THER, V320, P1087, DOI 10.1124/jpet.106.115758; Jiang LH, 2000, MOL PHARMACOL, V58, P82; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; KARPIAK SE, 1990, CRIT REV NEUROBIOL, V5, P221; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Le Feuvre R, 2002, EUR J PHARMACOL, V447, P261, DOI 10.1016/S0014-2999(02)01848-4; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matsumoto S, 2008, NEUROCHEM RES, V33, P2302, DOI 10.1007/s11064-008-9727-4; NISHIZUKA Y, 1995, FASEB J, V9, P484; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Ohno S, 1997, PROTEIN KINASE C, P178; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; SAITO N, 1988, J NEUROSCI, V8, P369; Sanz JM, 2000, J IMMUNOL, V164, P4893, DOI 10.4049/jimmunol.164.9.4893; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Sperlagh B, 2006, PROG NEUROBIOL, V78, P327, DOI 10.1016/j.pneurobio.2006.03.007; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Takenouchi T, 2009, CRIT REV IMMUNOL, V29, P335, DOI 10.1615/CritRevImmunol.v29.i4.40; TANAKA C, 1992, NEUROCHEM INT, V21, P499, DOI 10.1016/0197-0186(92)90081-2; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa	47	19	19	0	9	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	AUG	2015	12	2					2149	2154		10.3892/mmr.2015.3607			6	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CN8GR	WOS:000358678600075	25873133	Bronze			2021-06-18	
J	Yuan, YM; Zhu, F; Pu, YY; Wang, D; Huang, AJ; Hu, X; Qin, SY; Sun, X; Su, ZD; He, C				Yuan, Yimin; Zhu, Feng; Pu, Yingyan; Wang, Dan; Huang, Aijun; Hu, Xin; Qin, Shangyao; Sun, Xiu; Su, Zhida; He, Cheng			Neuroprotective effects of nitidine against traumatic CNS injury via inhibiting microglia activation	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Nitidine; Microglia; Traumatic brain injury; Spinal cord injury; Neuroprotection	SPINAL-CORD-INJURY; OLFACTORY ENSHEATHING CELLS; NF-KAPPA-B; REACTIVE MICROGLIA; K+ CHANNEL; EXPRESSION; RECOVERY; PATHWAY; NEUROTOXICITY; KCNN4/KCA3.1	Glial cell response to injury has been well documented in the pathogenesis after traumatic brain injury (TBI) and spinal cord injury (SCI). Although microglia, the resident macrophages in the central nervous system (CNS), are responsible for clearing debris and toxic substances, excessive activation of these cells will lead to exacerbated secondary damage by releasing a variety of inflammatory and cytotoxic mediators and ultimately influence the subsequent repair after CNS injury. In fact, inhibition of microgliosis represents a therapeutic strategy for CNS trauma. We here showed that nitidine, a benzophenanthridine alkaloid, restricted reactive microgliosis and promoted CNS repair after traumatic injury. Nitidine was shown to prevent cultured microglia from LPS-induced reactive activation by regulation of ERK and NF-kappa B signaling pathway. Furthermore, the nitidine-mediated inhibition of microgliosis was also shown in injured brain and spinal cord, which significantly increased neuronal survival and decreased neural tissue damage after injury. Importantly, behavioral analysis revealed that nitidine-treated mice with SCI had improved functional recovery as assessed by Basso Mouse Scale and swimming test. Together, these findings indicated that nitidine increased CNS tissue sparing and improved functional recovery by attenuating reactive microgliosis, suggestive of the potential therapeutic benefit for CNS injury. (C) 2015 Elsevier Inc. All rights reserved.	[Su, Zhida] Second Mil Med Univ, Minist Educ, Inst Neurosci, Shanghai, Peoples R China; Second Mil Med Univ, Minist Educ, Key Lab Mol Neurobiol, Shanghai, Peoples R China	Su, ZD (corresponding author), Second Mil Med Univ, Minist Educ, Inst Neurosci, Shanghai, Peoples R China.	suzhida@smmu.edu.cn; chenghe@smmu.edu.cn	Su, Zhida/G-6094-2015	Hu, Xin/0000-0002-3253-6024	National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81271352, 31171124, 31130024, 31301210]; National Key Basic Research ProgramNational Basic Research Program of China [2011CB504401]; Foundation for Military Medicine [CWS11J042]	This work was supported by the National Natural Science Foundation (81271352, 31171124, 31130024, 31301210), National Key Basic Research Program (2011CB504401), and Foundation for Military Medicine (CWS11J042).	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bouhy D, 2011, J NEUROSCI, V31, P16298, DOI 10.1523/JNEUROSCI.0047-11.2011; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Cao L, 2013, NEUROSCI BULL, V29, P189, DOI 10.1007/s12264-013-1324-0; Chen J, 2012, MOL CANCER THER, V11, P277, DOI 10.1158/1535-7163.MCT-11-0648; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Hu J, 2006, CHEM BIODIVERS, V3, P990, DOI 10.1002/cbdv.200690108; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Iwasaki H, 2010, CANCER CHEMOTH PHARM, V65, P719, DOI 10.1007/s00280-009-1077-7; Jones LL, 2002, J NEUROSCI, V22, P4611, DOI 10.1523/JNEUROSCI.22-11-04611.2002; Kaminska B, 2009, ANAT REC, V292, P1902, DOI 10.1002/ar.21047; Kaushal V, 2007, J NEUROSCI, V27, P234, DOI 10.1523/JNEUROSCI.3593-06.2007; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Koistinaho M, 2002, GLIA, V40, P175, DOI 10.1002/glia.10151; Kozlowski C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031814; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lemmon VP, 2014, J NEUROTRAUM, V31, P1354, DOI 10.1089/neu.2014.3400; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Neumann H, 2001, GLIA, V36, P191, DOI 10.1002/glia.1108; Plemel JR, 2008, J NEUROTRAUM, V25, P350, DOI 10.1089/neu.2007.0426; Rohl C, 2007, BRAIN RES, V1129, P43, DOI 10.1016/j.brainres.2006.10.057; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stirling DP, 2009, J NEUROSCI, V29, P753, DOI 10.1523/JNEUROSCI.4918-08.2009; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Su ZD, 2007, J CELL SCI, V120, P1877, DOI 10.1242/jcs.03448; Su ZD, 2013, GLIA, V61, P490, DOI 10.1002/glia.22450; Su ZD, 2010, GLIA, V58, P901, DOI 10.1002/glia.20972; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Tamashiro TT, 2012, JOVE-J VIS EXP, DOI 10.3791/3814; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Wang ZQ, 2012, J ETHNOPHARMACOL, V144, P145, DOI 10.1016/j.jep.2012.08.041; Wasserman JK, 2008, EXP NEUROL, V214, P266, DOI 10.1016/j.expneurol.2008.08.010; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Yuan YM, 2013, NEUROSCI BULL, V29, P421, DOI 10.1007/s12264-013-1358-3; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4; Zhang SC, 1999, ACTA NEUROPATHOL, V97, P393, DOI 10.1007/s004010051003	54	19	20	3	26	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	AUG	2015	48						287	300		10.1016/j.bbi.2015.04.008			14	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	CN5HP	WOS:000358460700030	25900440				2021-06-18	
J	Lazarus, C; Soheilypour, M; Mofrad, MRK				Lazarus, Carole; Soheilypour, Mohammad; Mofrad, Mohammad R. K.			Torsional Behavior of Axonal Microtubule Bundles	BIOPHYSICAL JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; FLEXURAL RIGIDITY; TRANSPORT; DENDRITES; MECHANICS; FILAMENTS; NETWORKS; NEURONS; LENGTH; MODEL	Axonal microtubule (MT) bundles crosslinked by microtubule-associated protein (MAP) tau are responsible for vital biological functions such as maintaining mechanical integrity and shape of the axon as well as facilitating axonal transport. Breaking and twisting of MTs have been previously observed in damaged undulated axons. Such breaking and twisting of MTs is suggested to cause axonal swellings that lead to axonal degeneration, which is known as "diffuse axonal injury". In particular, overstretching and torsion of axons can potentially damage the axonal cytoskeleton. Following our previous studies on mechanical response of axonal MT bundles under uniaxial tension and compression, this work seeks to characterize the mechanical behavior of MT bundles under pure torsion as well as a combination of torsional and tensile loads using a coarse-grained computational model. In the case of pure torsion, a competition between MAP tau tensile and MT bending energies is observed. After three turns, a transition occurs in the mechanical behavior of the bundle that is characterized by its diameter shrinkage. Furthermore, crosslink spacing is shown to considerably influence the mechanical response, with larger MAP tau spacing resulting in a higher rate of turns. Therefore, MAP tau crosslinking of MT filaments protects the bundle from excessive deformation. Simultaneous application of torsion and tension on MT bundles is shown to accelerate bundle failure, compared to pure tension experiments. MAP tau proteins fail in clusters of 10-100 elements located at the discontinuities or the ends of MT filaments. This failure occurs in a stepwise fashion, implying gradual accumulation of elastic tensile energy in crosslinks followed by rupture. Failure of large groups of interconnecting MAP tau proteins leads to detachment of MT filaments from the bundle near discontinuities. This study highlights the importance of torsional loading in axonal damage after traumatic brain injury.	[Lazarus, Carole; Soheilypour, Mohammad; Mofrad, Mohammad R. K.] Univ Calif Berkeley, Dept Bioengn, Mol Cell Biomech Lab, Berkeley, CA 94720 USA; [Lazarus, Carole; Soheilypour, Mohammad; Mofrad, Mohammad R. K.] Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA	Mofrad, MRK (corresponding author), Univ Calif Berkeley, Dept Bioengn, Mol Cell Biomech Lab, Berkeley, CA 94720 USA.	mofrad@berkeley.edu	/R-6010-2019	/0000-0001-7004-4859	National Science Foundation through a CAREER awardNational Science Foundation (NSF) [CBET-0955291]	Financial support was provided by the National Science Foundation through a CAREER award (CBET-0955291).	Bathe M, 2008, BIOPHYS J, V94, P2955, DOI 10.1529/biophysj.107.119743; Blundell JR, 2009, MACROMOLECULES, V42, P5388, DOI 10.1021/ma9004633; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; BRADY ST, 1984, J CELL BIOL, V99, P1716, DOI 10.1083/jcb.99.5.1716; Cheminiak P, 2010, EUR PHYS J E, V31, P215, DOI 10.1140/epje/i2010-10562-x; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; Cotter C. J., 2004, COMPUTATIONAL NANOTE; FADIC R, 1985, J COMP NEUROL, V236, P258, DOI 10.1002/cne.902360209; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Guzik BW, 2004, CURR OPIN CELL BIOL, V16, P443, DOI 10.1016/j.ceb.2004.06.002; He XS, 2000, J NEUROSURG, V93, P626, DOI 10.3171/jns.2000.93.4.0626; Huang A, 2009, FUTURE MED CHEM, V1, P467, DOI 10.4155/FMC.09.40; Ivancevic VG, 2009, COGN NEURODYNAMICS, V3, P281, DOI 10.1007/s11571-008-9070-0; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kikumoto M, 2006, BIOPHYS J, V90, P1687, DOI 10.1529/biophysj.104.055483; Kim T, 2009, EXP MECH, V49, P91, DOI 10.1007/s11340-007-9091-3; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lees-Haley PR, 2003, ARCH CLIN NEUROPSYCH, V18, P585; Li C, 2006, BIOCHEM BIOPH RES CO, V349, P1145, DOI 10.1016/j.bbrc.2006.08.153; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Mofrad MRK, 2009, ANNU REV FLUID MECH, V41, P433, DOI 10.1146/annurev.fluid.010908.165236; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; PALAY SL, 1968, J CELL BIOL, V38, P193, DOI 10.1083/jcb.38.1.193; Parikh S, 2007, INT ANESTHESIOL CLIN, V45, P119, DOI 10.1097/AIA.0b013e318078cfe7; Paszkowska E, 2010, POL J RADIOL, V75, P13; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Peter SJ, 2012, BIOPHYS J, V102, P749, DOI 10.1016/j.bpj.2011.11.4024; Reeves A, 2004, DISORDERS NERVOUS SY; Rodney D, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.108004; Rosenberg KJ, 2008, P NATL ACAD SCI USA, V105, P7445, DOI 10.1073/pnas.0802036105; Soheilypour M, 2015, BIOPHYS J, V108, P1718, DOI 10.1016/j.bpj.2015.01.030; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Thibault L. E., 1990, P IRCOBI C BIOM IMP; Vable M., 2009, MECH MAT; Wang HC, 2010, J CLIN NEUROSCI, V17, P157, DOI 10.1016/j.jocn.2009.07.099; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yasuda R, 1996, J MOL BIOL, V263, P227, DOI 10.1006/jmbi.1996.0571; Yi LJ, 2008, J APPL PHYS, V103, DOI 10.1063/1.2930882; YU WQ, 1994, J NEUROSCI, V14, P2818; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	45	19	19	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0006-3495	1542-0086		BIOPHYS J	Biophys. J.	JUL 21	2015	109	2					231	239		10.1016/j.bpj.2015.06.029			9	Biophysics	Biophysics	CN3GE	WOS:000358312800007	26200859	Bronze, Green Published			2021-06-18	
J	Kerr, ZY; Littleton, AC; Cox, LM; DeFreese, JD; Varangis, E; Lynall, RC; Schmidt, JD; Marshall, SW; Guskiewicz, KM				Kerr, Zachary Y.; Littleton, Ashley C.; Cox, Leah M.; DeFreese, J. D.; Varangis, Eleanna; Lynall, Robert C.; Schmidt, Julianne D.; Marshall, Stephen W.; Guskiewicz, Kevin M.			Estimating Contact Exposure in Football Using the Head Impact Exposure Estimate	JOURNAL OF NEUROTRAUMA			English	Article						subconcussive impacts; traumatic brain injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; RECURRENT CONCUSSION; NCAA CONCUSSION; LEAGUE PLAYER; RISK; SYMPTOMS; ASSOCIATION; DEPRESSION; DISEASE; INJURY	Over the past decade, there has been significant debate regarding the effect of cumulative subconcussive head impacts on short and long-term neurological impairment. This debate remains unresolved, because valid epidemiological estimates of athletes' total contact exposure are lacking. We present a measure to estimate the total hours of contact exposure in football over the majority of an athlete's lifespan. Through a structured oral interview, former football players provided information related to primary position played and participation in games and practice contacts during the pre-season, regular season, and post-season of each year of their high school, college, and professional football careers. Spring football for college was also included. We calculated contact exposure estimates for 64 former football players (n=32 college football only, n=32 professional and college football). The head impact exposure estimate (HIEE) discriminated between individuals who stopped after college football, and individuals who played professional football (p<0.001). The HIEE measure was independent of concussion history (p=0.82). Estimating total hours of contact exposure may allow for the detection of differences between individuals with variation in subconcussive impacts, regardless of concussion history. This measure is valuable for the surveillance of subconcussive impacts and their associated potential negative effects.	[Kerr, Zachary Y.] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN 46202 USA; [Kerr, Zachary Y.; Littleton, Ashley C.; Lynall, Robert C.; Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Kerr, Zachary Y.; Cox, Leah M.; DeFreese, J. D.; Varangis, Eleanna; Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Ctr Study Retired Athletes, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Varangis, Eleanna] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA; [Kerr, Zachary Y.; Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Injury Prevent Ctr, Chapel Hill, NC USA; [Schmidt, Julianne D.] Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA	Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org	Lynall, Robert/M-2888-2014	Lynall, Robert/0000-0002-0785-6640; Littleton, Ashley/0000-0001-6188-1284; Varangis, Eleanna/0000-0002-2688-2297; Kerr, Zachary/0000-0003-1423-1259; Guskiewicz, Kevin/0000-0002-8682-2130	National Football League Charities and National Football League Players' Association; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE002479]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE002479] Funding Source: NIH RePORTER	Funding/Support was provided by the National Football League Charities and National Football League Players' Association. Stephen W. Marshall is partly supported by grant R49CE002479 from the Centers for Disease Control and Prevention. Kevin Guskiewicz is a member of the NFL Head Neck and Spine Committee and the NFL Players' Association's Mackey-White Committee.	Broglio J., 2011, J BIOMECH, V44, P2673; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dick R, 2007, J ATHL TRAINING, V42, P221; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Piland SG, 2003, J ATHL TRAINING, V38, P104; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Sadek JR, 2004, NEUROPSYCHOLOGY, V18, P692, DOI 10.1037/0894-4105.18.4.692; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; USA Football, 2010, US FOOTB OV	25	19	19	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2015	32	14					1083	1089		10.1089/neu.2014.3666			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0TB	WOS:000363965000007	25603189	Green Published			2021-06-18	
J	Haring, RS; Canner, JK; Asemota, AO; George, BP; Selvarajah, S; Haider, AH; Schneider, EB				Haring, R. Sterling; Canner, Joseph K.; Asemota, Anthony O.; George, Benjamin P.; Selvarajah, Shalini; Haider, Adil H.; Schneider, Eric B.			Trends in incidence and severity of sports-related traumatic brain injury (TBI) in the emergency department, 2006-2011	BRAIN INJURY			English	Article						Emergency department; epidemiology; sport; TBI		Objective: To characterize and identify trends in sports-related traumatic brain injury (TBI) emergency department (ED) visits from 2006-2011. Methods: This study reviewed data on sports-related TBI among individuals under age 65 from the Nationwide Emergency Department Sample from 2006-2011. Visits were stratified by age, sex, injury severity, payer status and other criteria. Variations in incidence. and severity were examined both between groups and over time. Odds of inpatient admission were calculated using regression modelling. Results: Over the period examined, 489 572 sports-related TBI ED visits were reported. The majority (62.2%) of these visits occurred among males under the age of 18. The average head Abbreviated Injury Severity score among these individuals was 1.93 (95% CI = 1.93-1.94) and tended to be lowest among those in middle school and high school age groups; these were also less likely to be admitted. The absolute annual number of visits grew 65.9% from 2006 until 2011, with the majority of this growth occurring among children under age 15. Hospitalization rates dropped 35.6% over the same period. Conclusion: Changes in year-over-year presentation rates vs. hospitalization rates among young athletes suggest that players, coaches and parents may be more aware of sports-related TBI and have developed lower thresholds for seeking medical attention.	[Haring, R. Sterling] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Haring, R. Sterling] Lake Erie Coll Osteopath Med, Bradenton, FL USA; [Haring, R. Sterling; Canner, Joseph K.; Asemota, Anthony O.; George, Benjamin P.; Selvarajah, Shalini; Schneider, Eric B.] Johns Hopkins Univ, CSTOR, Baltimore, MD USA; [Asemota, Anthony O.] Johns Hopkins Univ, Dept Neurol & Neurosurg, Baltimore, MD USA; [George, Benjamin P.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Haider, Adil H.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA	Haring, RS (corresponding author), 600 N Wolfe St,Blalock 618, Baltimore, MD 21287 USA.	sharing1@jhu.edu	Meijer, Anna/K-5118-2016		Patient Centered Outcomes Research Institute, the American College of SurgeonsPatient-Centered Outcomes Research Institute - PCORI; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS); World Health Organization, Geneva, SwitzerlandWorld Health Organization; Karolinska Institutet, Stockholm, Sweden; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112] Funding Source: NIH RePORTER	R. Sterling Haring, MPH: No competing interests exist. Joseph K. Canner, MHS: No competing interests exist. Anthony O. Asemota, MBBS, MPH: No competing interests exist. Benjamin P. George, MPH: No competing interests exist. Shalini Selvarajah, MD, MPH: No competing interests exist. Adil H. Haider, MD, MPH: receives funding from the Patient Centered Outcomes Research Institute, the American College of Surgeons and the National Institute of General Medical Sciences. Eric B. Schneider, PhD: has pending patents regarding CNS trauma, is a member of Bergeim, LLC, receives consulting fees from the World Health Organization, Geneva, Switzerland and Karolinska Institutet, Stockholm, Sweden. This research was not funded. The authors report no conflicts of interest.	CDC Injury Center, 2013, HEADS CONC YOUTH SPO; Centers for Disease Control and Prevention, TRAUMATIC BRAIN INJU; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Esquivel A, 2013, SPORTS HEALTH, V5, P258, DOI 10.1177/1941738113476850; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Haut ER, 2012, JAMA-J AM MED ASSOC, V307, P2589, DOI 10.1001/jama.2012.6626; MACKENZIE EJ, 1985, MED CARE, V23, P823, DOI 10.1097/00005650-198506000-00008; National Federation of State High School Associations, 2014, CONC SPORTS 2 0; Redding R., 2013, TARGETING CROWN OF H; US Census Bureau DID, POP EST	10	19	20	0	4	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2015	29	7-8					989	992		10.3109/02699052.2015.1033014			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CO0BJ	WOS:000358814800027	25962926				2021-06-18	
J	Sabir, M; Gaudreault, PO; Freyburger, M; Massart, R; Blanchet-Cohen, A; Jaber, M; Gosselin, N; Mongrain, V				Sabir, Meriem; Gaudreault, Pierre-Olivier; Freyburger, Marlene; Massart, Renaud; Blanchet-Cohen, Alexis; Jaber, Manar; Gosselin, Nadia; Mongrain, Valerie			Impact of traumatic brain injury on sleep structure, electrocorticographic activity and transcriptome in mice	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Closed-head injury; Sleep architecture; Recovery sleep; EEG spectral analysis; Transcriptome; Cerebral cortex; Hippocampus; Plasticity genes; Clock genes; Chemokines	CLOSED-HEAD INJURY; DIFFUSE AXONAL INJURY; MICROGLIAL ACTIVATION; OXIDATIVE DAMAGE; MILD; EXPRESSION; DEPRIVATION; MODEL; HOMEOSTASIS; DISTURBANCE	Traumatic brain injury (TBI), including mild TBI (mTBI), is importantly associated with vigilance and sleep complaints. Because sleep is required for learning, plasticity and recovery, we here evaluated the bidirectional relationship between mTBI and sleep with two specific objectives: (1) Test that mTBI rapidly impairs sleep-wake architecture and the dynamics of the electrophysiological marker of sleep homeostasis (i.e., non-rapid eye movement sleep delta (1-4 Hz) activity); (2) evaluate the impact of sleep loss following mTBI on the expression of plasticity markers that have been linked to sleep homeostasis and on genome-wide gene expression. A closed-head injury model was used to perform a 48 h electrocorticographic (ECoG) recording in mice submitted to mTBI or Sham surgery. mTBI was found to immediately decrease the capacity to sustain long bouts of wakefulness as well as the amplitude of the time course of ECoG delta activity during wakefulness. Significant changes in ECoG spectral activity during wakefulness, non-rapid eye movement and rapid eye movement sleep were observed mainly on the second recorded day. A second experiment was performed to measure gene expression in the cerebral cortex and hippocampus after a mTBI followed either by two consecutive days of 6 h sleep deprivation (SD) or of undisturbed behavior (quantitative PCR and next-generation sequencing). mTBI modified the expression of genes involved in immunity, inflammation and glial function (e.g., chemokines, glial markers) and SD changed that of genes linked to circadian rhythms, synaptic activity/neuronal plasticity, neuroprotection and cell death and survival. SD appeared to affect gene expression in the cerebral cortex more importantly after mTBI than Sham surgery including that of the astrocytic marker Gfap, which was proposed as a marker of clinical outcome after TBI. Interestingly, SD impacted the hippocampal expression of the plasticity elements Arc and EfnA3 only after mTBI. Overall, our findings reveal alterations in spectral signature across all vigilance states in the first days after mTBI, and show that sleep loss post-mTBI reprograms the transcriptome in a brain area-specific manner and in a way that could be deleterious to brain recovery. (C) 2015 Elsevier Inc. All rights reserved.	[Sabir, Meriem; Gaudreault, Pierre-Olivier; Freyburger, Marlene; Jaber, Manar; Gosselin, Nadia; Mongrain, Valerie] Hop Sacre Coeur, Ctr Adv Res Sleep Med, Montreal, PQ H4J 1C5, Canada; [Sabir, Meriem; Gaudreault, Pierre-Olivier; Freyburger, Marlene; Jaber, Manar; Gosselin, Nadia; Mongrain, Valerie] Hop Sacre Coeur, Res Ctr, Montreal, PQ H4J 1C5, Canada; [Sabir, Meriem] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada; [Gaudreault, Pierre-Olivier; Gosselin, Nadia] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Freyburger, Marlene; Mongrain, Valerie] Univ Montreal, Dept Neurosci, Montreal, PQ H3C 3J7, Canada; [Massart, Renaud] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; [Blanchet-Cohen, Alexis] Inst Rech Clin Montreal, Bioinformat, Montreal, PQ H2W 1R7, Canada	Mongrain, V (corresponding author), Hop Sacre Coeur, Res Ctr, Ctr Adv Res Sleep Med, 5400 Gouin West Blvd, Montreal, PQ H4J 1C5, Canada.	valerie.mongrain@umontreal.ca	Mongrain, Valerie/A-3931-2012	Massart, Renaud/0000-0002-1631-1853	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [CBI-127051]; Research Center of the Hopital du Sacre-Coeur de Montreal; Fonds de la Recherche du Quebec - SanteFonds de la Recherche en Sante du Quebec [22210, 24742]	The authors thank Odile Neyret and Gaetan Tremblay for help with sequencing, Eric Beaumont for help regarding the brain injury, Peter Meerlo for critical discussion of the data, Catherine Duclos and Erika Belanger-Nelson for critical review of the manuscript, and Erika Belanger-Nelson, Michele Houde, Janine El Helou, Adeline Rachalski and Chloe Provost for help with SD and animal handling. This study was supported by a grant from the Canadian Institutes of Health Research (CBI-127051), start-up funds from the Research Center of the Hopital du Sacre-Coeur de Montreal, and salary awards from the Fonds de la Recherche du Quebec - Sante (22210, 24742).	Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Amzica F, 2000, ACTA NEUROBIOL EXP, V60, P229; Anders S, 2014, HTSEQ PYTHON FRAMEWO; Andrews S, 2014, FASTQC QUALITY CONTR; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bellesi M, 2013, J NEUROSCI, V33, P14288, DOI 10.1523/JNEUROSCI.5102-12.2013; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Borbely A A, 1982, Hum Neurobiol, V1, P195; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Colak T, 2012, INJURY, V43, P1264, DOI 10.1016/j.injury.2012.01.021; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; Curie T, 2013, SLEEP, V36, P311, DOI 10.5665/sleep.2440; Deister C, 2006, J NEURAL ENG, V3, P172, DOI 10.1088/1741-2560/3/2/011; Diekelmann S, 2010, NAT REV NEUROSCI, V11, P114, DOI 10.1038/nrn2762; Duclos C, 2014, PATHOL BIOL, V62, P252, DOI 10.1016/j.patbio.2014.05.014; Duclos C, 2014, NEUROREHAB NEURAL RE, V28, P472, DOI 10.1177/1545968313517756; El Helou J, 2013, P NATL ACAD SCI USA, V110, P9974, DOI 10.1073/pnas.1221381110; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Eroglu B, 2014, J NEUROCHEM, V130, P626, DOI 10.1111/jnc.12781; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FRANKEN P, 1991, AM J PHYSIOL, V261, pR198; Franken P, 2001, J NEUROSCI, V21, P2610, DOI 10.1523/JNEUROSCI.21-08-02610.2001; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Halassa MM, 2009, NEURON, V61, P213, DOI 10.1016/j.neuron.2008.11.024; Hanell A, 2012, J NEUROTRAUM, V29, P2660, DOI 10.1089/neu.2012.2376; Hazra A., 2014, J NEUROSCI RES; He Y, 2009, SCIENCE, V325, P866, DOI 10.1126/science.1174443; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hou LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076087; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huber R, 2007, SLEEP, V30, P129, DOI 10.1093/sleep/30.2.129; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Junghans D, 2004, DEVELOPMENT, V131, P4425, DOI 10.1242/dev.01313; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Krueger JM, 2011, PROG BRAIN RES, V193, P39, DOI 10.1016/B978-0-444-53839-0.00003-X; Krueger JM, 2008, NAT REV NEUROSCI, V9, P910, DOI 10.1038/nrn2521; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Leemburg S, 2010, P NATL ACAD SCI USA, V107, P15939, DOI 10.1073/pnas.1002570107; Lerman BJ, 2012, BRAIN BEHAV, V2, P563, DOI 10.1002/brb3.75; Lim MM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007092; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.116; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Maret S, 2007, P NATL ACAD SCI USA, V104, P20090, DOI 10.1073/pnas.0710131104; Martinez-Vargas M, 2006, NEUROSCI LETT, V400, P21, DOI 10.1016/j.neulet.2006.02.010; Martinez-Vargas M, 2012, NEUROSCI LETT, V529, P118, DOI 10.1016/j.neulet.2012.09.037; Massart R, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.120; McAllister TW, 2012, J NEUROTRAUM, V29, P1111, DOI 10.1089/neu.2011.1930; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Meerlo P, 2009, SLEEP MED REV, V13, P187, DOI 10.1016/j.smrv.2008.07.004; Mirabelli-Badenier M, 2011, THROMB HAEMOSTASIS, V105, P409, DOI 10.1160/TH10-10-0662; Mitsui S, 2001, GENE DEV, V15, P995, DOI 10.1101/gad.873501; Moller-Levet CS, 2013, P NATL ACAD SCI USA, V110, pE1132, DOI 10.1073/pnas.1217154110; Mongrain V, 2013, GENETIC BASIS OF SLEEP AND SLEEP DISORDERS, P147; Mongrain V, 2010, SLEEP, V33, P1147, DOI 10.1093/sleep/33.9.1147; Murai KK, 2011, GLIA, V59, P1567, DOI 10.1002/glia.21226; Nelson AB, 2010, SLEEP, V33, P1659, DOI 10.1093/sleep/33.12.1659; Ohlmann KK, 2009, AAOHN J, V57, P381, DOI 10.3928/08910162-20090817-02; Oliveros JC, 2007, VENNY INTERACTIVE TO; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Pellegrino R, 2014, SLEEP, V37, P1327, DOI 10.5665/sleep.3924; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Ramesh G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/480739; Rao V, 2011, J NEUROPSYCH CLIN N, V23, P201, DOI 10.1176/appi.neuropsych.23.2.201; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Rowe RK, 2014, BRAIN INJURY, V28, P504, DOI 10.3109/02699052.2014.888768; Rowe SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066955; Schiehser D. M., 2014, J HEAD TRAU IN PRESS; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Theus MH, 2010, STEM CELLS, V28, P1231, DOI 10.1002/stem.449; Vyazovskiy VV, 2011, NATURE, V472, P443, DOI 10.1038/nature10009; Willie JT, 2012, J NEUROTRAUM, V29, P1908, DOI 10.1089/neu.2012.2404; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Ziegler G, 2009, BBA-MOL BASIS DIS, V1792, P1198, DOI 10.1016/j.bbadis.2009.10.003	97	19	20	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	JUL	2015	47				SI		118	130		10.1016/j.bbi.2014.12.023			13	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	CL8NM	WOS:000357231400014	25576803				2021-06-18	
J	Sonmez, A; Sayin, O; Gurgen, SG; Calisir, M				Sonmez, Atac; Sayin, Oya; Gurgen, Seren Gulsen; Calisir, Meryem			Neuroprotective effects of MK-801 against traumatic brain injury in immature rats	NEUROSCIENCE LETTERS			English	Article						Immature rats; Traumatic brain injury; MK-801; Hippocampus; BDNF; NGF; NMDAR; Cognition	D-ASPARTATE RECEPTORS; EXCITOTOXICITY; HIPPOCAMPUS; MECHANISMS; MODEL; ACID	Traumatic brain injury (TBI) is a major health problem in pediatric ages and also has major social, economic, and emotional outcomes, with diverse sequelae in many spheres of everyday life. We aimed to investigate the effect of MK-801, a competitive NMDA receptor antagonist, on hippocampal damage and behavioral deficits on 10-day-old rat pups subjected to contusion injury. The aims of the present study were to determine: (i) the short term effects of MK-801 on hippocampal BDNF, NGF and NMDA receptor immunoreactivity and neuron density in hippocampus (ii) long term effects of MK-801 on cognitive dysfunction following TBI in the immature rats. MK-801, was injected intraperitoneally at the doses of 1 mg/kg of body weight immediately after induction of traumatic injury. Hippocampal damage was examined by cresyl violet staining, BDNF, NGF and NMDAR receptor immunohistochemistry on P10 day and behavioral alterations were evaluated using elevated plus maze and novel object recognition tests two months after the trauma. Histopathological and immunohistochemical evaluations showed that treatment with a single dose of 1 mg/kg MK-801 (i.p.) significantly ameliorated the trauma induced hippocampal neuron loss and decreased BDNF, NGF and NMDAR expressions in CA1, CA3 and DG hippocampal brain regions. Additionally, treatment with MK-801 ameliorated anxiety and hippocampus dependent memory of animals subjected to trauma. These results show that acute treatment of MK-801 has a neuroprotective role against trauma induced hippocampal neuron loss and associated cognitive impairment in immature rats. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Sonmez, Atac] Dokuz Eylul Univ, Fac Med, Dept Physiol, TR-35340 Izmir, Turkey; [Sayin, Oya] Dokuz Eylul Univ, Fac Med, Res Lab, TR-35340 Izmir, Turkey; [Gurgen, Seren Gulsen] Celal Bayar Univ, Fac Med, Dept Histol & Embriyol, Manisa, Turkey; [Calisir, Meryem] Dokuz Eylul Univ, Lab Anim Sci, Hlth Sci Inst, TR-35340 Izmir, Turkey	Sonmez, A (corresponding author), Dokuz Eylul Univ, Fac Med, Dept Physiol, TR-35340 Izmir, Turkey.	atac.sonmez@deu.edu.tr	sayin, oya/O-9614-2019; sayin, oya/O-9541-2019	sayin, oya/0000-0003-0879-9091; Calisir, Meryem/0000-0002-9890-8943			Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Cassol OJ, 2011, J NEUROIMMUNOL, V230, P48, DOI 10.1016/j.jneuroim.2010.08.026; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Gurgen SG, 2013, NUTRITION, V29, P777, DOI 10.1016/j.nut.2012.11.004; Han RZ, 2009, NEUROSCI BULL, V25, P367, DOI 10.1007/s12264-009-0608-x; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Phillips LL, 1997, J NEUROSCI RES, V49, P197; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	27	19	19	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 15	2015	597						137	142		10.1016/j.neulet.2015.05.001			6	Neurosciences	Neurosciences & Neurology	CK4HY	WOS:000356186100025	25943283				2021-06-18	
J	Sweeney, TE; Salles, A; Harris, OA; Spain, DA; Staudenmayer, KL				Sweeney, Timothy E.; Salles, Arghavan; Harris, Odette A.; Spain, David A.; Staudenmayer, Kristan L.			Prediction of neurosurgical intervention after mild traumatic brain injury using the national trauma data bank	WORLD JOURNAL OF EMERGENCY SURGERY			English	Article						Traumatic brain injury; National trauma data bank; Neurosurgery	INTRACRANIAL HEMORRHAGE; ADULT PATIENTS; ADMISSION	Introduction: Patients with mild traumatic brain injury (TBI) as defined by an admission Glasgow Coma Score (GCS) of 14-15 often do not require neurosurgical interventions, but which patients will go on to require neurosurgical care has been difficult to predict. We hypothesized that injury patterns would be associated with need for eventual neurosurgical intervention in mild TBI. Methods: The National Trauma Databank (2007-2012) was queried for patients with blunt injury and a diagnosis of TBI with an emergency department GCS of 14-15. Patients were stratified by age and injury type. Multiple logistic regression for neurosurgical intervention was run with patient demographics, physiologic variables, and injury diagnoses as dependent variables. Results: The study included 50,496 patients, with an overall 8.8 % rate of neurosurgical intervention. Neurosurgical intervention rates varied markedly according to injury type, and were only correlated with age for patients with epidural and subdural hemorrhage. In multiple logistic regression, TBI diagnoses were predictive of need for neurosurgical interventions; moreover, after controlling for injury type and severity score, age was not significantly associated with requiring neurosurgical intervention. Conclusions: We found that in mild TBI, injury pattern is associated with eventual need for neurosurgical intervention. Patients with cerebral contusion or subarachnoid hemorrhage are much less likely to require neurosurgical intervention, and the effects of age are not significant after controlling for other patient factors. Prospective studies should validate this finding so that treatment guidelines can be updated to better allocate ICU resources.	[Sweeney, Timothy E.; Salles, Arghavan; Spain, David A.; Staudenmayer, Kristan L.] Stanford Univ, Med Ctr, Dept Surg, Stanford, CA 94305 USA; [Harris, Odette A.] Stanford Univ, Med Ctr, Dept Neurosurg, Stanford, CA 94305 USA	Sweeney, TE (corresponding author), Stanford Univ, Med Ctr, Dept Surg, 300 Pasteur Dr, Stanford, CA 94305 USA.	tes17@stanford.edu; kristans@stanford.edu		Sweeney, Timothy/0000-0002-3596-1093	NLM training grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [2T15LM007033]; Stanford Department of Surgery	TES was supported by NLM training grant 2T15LM007033 and the Stanford Department of Surgery. We would like to thank Jay Bhattacharya and Eran BenDavid for helpful comments, and Lakshika Tennakoon for data preparation. The NTDB remains the full and exclusive copyrighted property of the American College of Surgeons. The American College of Surgeons is not responsible for any claims arising from works based on the original Data, Text, Tables, or Figures.	Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Hukkelhoven CWPM, 2005, INTENS CARE MED, V31, P799, DOI 10.1007/s00134-005-2628-y; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Nishijima DK, 2014, ANN EMERG MED, V63, P448, DOI 10.1016/j.annemergmed.2013.11.003; Nishijima DK, 2013, ANN EMERG MED, V61, P509, DOI 10.1016/j.annemergmed.2012.08.024; Nishijima DK, 2012, INJURY, V43, P1827, DOI 10.1016/j.injury.2011.07.020; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Ratcliff JJ, 2014, AM J EMERG MED, V32, P844, DOI 10.1016/j.ajem.2014.04.003; Seddighi AS, 2013, BRAIN INJURY, V27, P1666, DOI 10.3109/02699052.2013.830333; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tong WS, 2011, NEURORADIOLOGY, V53, P305, DOI 10.1007/s00234-010-0659-8; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092	18	19	20	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1749-7922			WORLD J EMERG SURG	World J. Emerg. Surg.	JUN 6	2015	10								23	10.1186/s13017-015-0017-6			7	Emergency Medicine; Surgery	Emergency Medicine; Surgery	CK4UR	WOS:000356219300001	26060506	DOAJ Gold, Green Published			2021-06-18	
J	Bernhard, M; Hossfeld, B; Bein, B; Bottiger, BW; Bohn, A; Fischer, M; Grasner, JT; Hinkelbein, J; Kill, C; Lott, C; Popp, E; Roessler, M; Schaumberg, A; Wenzel, V				Bernhard, Michael; Hossfeld, Bjoern; Bein, Berthold; Boettiger, Bernd W.; Bohn, Andreas; Fischer, Matthias; Graesner, Jan-Thorsten; Hinkelbein, Jochen; Kill, Clemens; Lott, Carsten; Popp, Erik; Roessler, Markus; Schaumberg, Alin; Wenzel, Volker			Policy Recommendation: Prehospital Emergency Anesthesia in Adults	ANASTHESIOLOGIE & INTENSIVMEDIZIN			German	Article						Guideline; Emergency Medicine; Emergency Anaesthesia; Management; Complications	RAPID-SEQUENCE INTUBATION; TRAUMATIC BRAIN-INJURY; AIRWAY-MANAGEMENT; TRACHEAL INTUBATION; SUCCESS RATES; ADRENAL INSUFFICIENCY; VIDEO LARYNGOSCOPES; ETOMIDATE; MULTICENTER; GUIDELINES	Inducing anaesthesia outside the hospital is an important therapeutic intervention in emergency medicine and much more difficult to accomplish than inside the hospital. Its primary goals include hypnosis, and analgesia and it enables airway management to achieve mechanical ventilation and adequate oxygenation. Secondary goals of emergency anaesthesia include amnesia, anxiolysis, reduced oxygen consumption and work of breathing, and thus protection of vital organs and avoidance of secondary myocardial injury or cerebral injuries. Factors specific to the individual patient, the site of intervention and the operator need to be considered prior to prehospital induction of anaesthesia. The rapid sequence induction procedure comprises basic monitoring, pre-oxygenation, standardised preparation of drugs and equipment, administration of drugs, removal of the cervical collar and manual in-line stabilisation during an intubation attempt (if needed), intubation and confirmation of endotracheal intubation, Every spontaneously breathing emergency patient should receive pre-oxygenation at a rate of 12-15 I oxygen per minute for at least 3-4 minutes, using a tight-sealing face mask or a demand valve. The standardised preparation process includes preparation and labelling drugs/syringes, checking the bag-valve mask, preparing the endotracheal tube with a stylet and blocking syringe, as well as having a stethoscope and material to secure the tube at hand, as well as alternative airway devices. It also includes immediate access to alternative means of airway management, as well as a suction unit, ventilator and monitoring devices including capnography. Basic monitoring in prehospital emergency anaesthesia includes ECG equipment, an automatic/manual blood pressure cuff and pulse oximetry. Continuous capnography is used without exception to confirm ventilation, detect possible disconnections/dislocations, and indirectly monitor haemodynamics. Prior to induction of prehospital emergency anaesthesia, two peripheral IV catheters should be placed, if possible.	[Bernhard, Michael] Univ Klinikum Leipzig AoR, Zentrale Notaufnahme, D-04103 Leipzig, Germany; [Hossfeld, Bjoern] Bundeswehrkrankenhaus Ulm, Klin Anasthesiol & Intens Med, Ulm, Germany; [Bein, Berthold] Asklepios Klin St Georg, Klin Anasthesiol & Operat Intens Med, Hamburg, Germany; [Boettiger, Bernd W.; Hinkelbein, Jochen] Univ Klinikum Koln AoR, Klin Anasthesiol & Operat Intens Med, Cologne, Germany; [Bohn, Andreas] Feuerwehr Munster, Munster, Germany; [Fischer, Matthias] ALB FILS KLINIKEN GmbH, Klin Eichert, Klin Anasthesiol & Operat Intens Med, Goppingen, Germany; [Graesner, Jan-Thorsten] Christian Albrechts Univ Kiel Klinikum, Klin Anasthesiol & Operat Intens Med, Kiel, Germany; [Kill, Clemens] Univ Klinikum Giessen & Marburg, Zentrum Notfallmed, Standort Marburg, Germany; [Lott, Carsten] Univ Med Mainz, Anasthesiol Klin, Mainz, Germany; [Popp, Erik] Univ Klinikum Heidelberg, Sekt Notfallmed, Anasthesiol Klin, Heidelberg, Germany; [Roessler, Markus] Univ Med Gottingen, Zentrum Anasthesiol Rettungs & Intens Med, Anasthesiol Klin, Gottingen, Germany; [Schaumberg, Alin] Univ Klinikum Giessen & Marburg, Klin Anasthesiol & Operat Intens Med, Standort Giessen, Germany; [Wenzel, Volker] Med Univ Innsbruck, Univ Klin Anasthesie & Intens Med, A-6020 Innsbruck, Austria	Bernhard, M (corresponding author), Univ Klinikum Leipzig AoR, Zentrale Notaufnahme, Liebigstr 26, D-04103 Leipzig, Germany.	Michael.Bernhard@medizin.uni-leipzig.de	Hinkelbein, Jochen/AAA-8801-2021; Roessler, Markus Soeren/I-7834-2013				Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; [Anonymous], 2009, ANASTH INTENSIVMED, V50, pS489; Barnard EBG, RAPID SEQUENCE INDUC, DOI [10.1136/emermed-2014-203740, DOI 10.1136/EMERMED-2014-203740]; Benumof JL, 1997, ANESTHESIOLOGY, V87, P979, DOI 10.1097/00000542-199710000-00034; Bergen Joseph M., 1997, Journal of Emergency Medicine, V15, P221, DOI 10.1016/S0736-4679(96)00350-2; Bernhard M, 2006, ANAESTHESIST, V55, P1157, DOI 10.1007/s00101-006-1106-4; Bernhard M, 2014, ANAESTHESIST, V63, P589, DOI 10.1007/s00101-014-2348-1; Bernhard M, 2011, NOTFALL RETTUNGSMED, V14, P554, DOI 10.1007/s10049-010-1402-z; Bernhard M, 2010, ANASTH INTENSIVMED, V51, pS615; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS7, DOI DOI 10.1089/NEU.2007.9995; Braun P, 2010, CURR OPIN ANESTHESIO, V23, P500, DOI 10.1097/ACO.0b013e32833bc135; Breckwoldt J, 2012, RESUSCITATION, V83, P434, DOI 10.1016/j.resuscitation.2011.10.011; Bretschneider I, 2011, NOTARZT, V27, P270, DOI 10.1055/s-0031-1276960; Cavus E, 2011, EMERG MED J, V28, P650, DOI 10.1136/emj.2010.098707; Chan CM, 2012, CRIT CARE MED, V40, P2945, DOI 10.1097/CCM.0b013e31825fec26; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Christ M., 2010, Intensivmedizin und Notfallmedizin, V47, P83, DOI 10.1007/s00390-009-0140-2; Connor CW, 2014, ANESTH ANALG, V118, P419, DOI 10.1213/ANE.0000000000000012; Cook T, 2012, CURR OPIN ANESTHESIO, V25, P461, DOI 10.1097/ACO.0b013e32835528b1; Cotton BA, 2008, ARCH SURG-CHICAGO, V143, P62, DOI 10.1001/archsurg.143.1.62; Cowan GM, 2012, EMERG MED J, V29, P136, DOI 10.1136/emj.2010.105304; Easby J, 2004, J TRAUMA, V6, P217; Edlow JA, 2014, LANCET, V384, P2064, DOI 10.1016/S0140-6736(13)62184-4; Eich C, 2009, RESUSCITATION, V80, P1371, DOI 10.1016/j.resuscitation.2009.09.004; El-Orbany M, 2010, ANESTH ANALG, V110, P1318, DOI 10.1213/ANE.0b013e3181d5ae47; ELBEHEIRY H, 1995, CAN J ANAESTH, V42, P875, DOI 10.1007/BF03011034; Genzwurker HV, 2010, ANASTH INTENSIVMED, V51, P202; Grasner JT, 2007, NOTFALLMEDIZIN UP2DA, V2, P197; Gries A, 2006, ANAESTHESIST, V55, P1080, DOI 10.1007/s00101-006-1051-2; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Hasler RM, 2012, RESUSCITATION, V83, P476, DOI 10.1016/j.resuscitation.2011.10.018; Hedenstierna G, 2005, INTENS CARE MED, V31, P1327, DOI 10.1007/s00134-005-2761-7; Helm M, 2006, BRIT J ANAESTH, V96, P67, DOI 10.1093/bja/aei275; Helm M, 2013, ACTA ANAESTH SCAND, V57, P199, DOI 10.1111/aas.12032; Helm M, 2010, ANAESTHESIST, V59, P896, DOI 10.1007/s00101-010-1759-x; Helm M, 2005, BEST PRACT RES-CLIN, V19, P623, DOI 10.1016/j.bpa.2005.06.002; Henderson JJ, 2004, ANAESTHESIA, V59, P675, DOI 10.1111/j.1365-2044.2004.03831.x; Herff H, 2009, ANESTH ANALG, V109, P303, DOI 10.1213/ane.0b013e3181ad8a1e; Heuer JF, 2012, ANAESTH INTENS CARE, V40, P120, DOI 10.1177/0310057X1204000113; Hossfeld B, 2011, NOTFALL RETTUNGSMED, V14, P15, DOI 10.1007/s10049-010-1355-2; Hossfeld B, 2011, NOTFALL RETTUNGSMED, V14, P10, DOI 10.1007/s10049-010-1354-3; HUG CC, 1993, ANESTH ANALG, V77, pS21; Jabre P, 2009, LANCET, V374, P293, DOI 10.1016/S0140-6736(09)60949-1; Jacoby J, 2006, ANN EMERG MED, V47, P525, DOI 10.1016/j.annemergmed.2005.12.009; Kheterpal S, 2013, ANESTHESIOLOGY, V119, P1360, DOI 10.1097/ALN.0000435832.39353.20; Koenig SJ, 2014, J INTENSIVE CARE MED; Kuhnigk H, 2007, NARKOSE NOTFALLMEDIZ; Liccardi G, 2009, CURR MED RES OPIN, V25, P1621, DOI 10.1185/03007990903010474; Lockey D, AAGBI SAFETY GUIDE P; Lossius HM, 2012, CRIT CARE, V16, DOI 10.1186/cc11189; Luxen J, 2014, ANAESTHESIST, V63, P331, DOI 10.1007/s00101-014-2303-1; Mayglothling J, 2012, J TRAUMA ACUTE CARE, V73, pS333, DOI 10.1097/TA.0b013e31827018a5; Messelken M, 2010, DTSCH ARZTEBL INT, V107, P523, DOI 10.3238/arztebl.2010.0523; MOULTON C, 1994, LANCET, V343, P1261, DOI 10.1016/S0140-6736(94)92155-5; MRUGALLA H, 2003, NOTFALL RETTUNGSMED, V6, P233; Neumayr A, 2014, NOTFALL RETTUNGSMED, V17, P25, DOI 10.1007/s10049-013-1816-5; Newton A, 2008, J TRAUMA, V64, P487, DOI 10.1097/TA.0b013e31802e7476; Niven AS, 2013, CURR OPIN CRIT CARE, V19, P9, DOI 10.1097/MCC.0b013e32835c6014; Paal P, 2010, RESUSCITATION, V81, P148, DOI 10.1016/j.resuscitation.2009.10.023; Patanwala AE, 2014, ACAD EMERG MED, V21, P87, DOI 10.1111/acem.12292; Pehbock D, 2010, ANESTHESIOLOGY, V113, P593, DOI 10.1097/ALN.0b013e3181e73f07; Perry JJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002788.pub2; Reinhart K, 2010, ANAESTHESIST, V59, P347, DOI 10.1007/s00101-010-1719-5; Rortgen D, 2011, ANAESTHESIST, V60, P312, DOI 10.1007/s00101-010-1812-9; Rognas L, 2014, EUR J EMERG MED, V21, P418, DOI 10.1097/MEJ.0000000000000103; Rognas L, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-58; Sakles JC, 2013, ACAD EMERG MED, V20, P71, DOI 10.1111/acem.12055; Schlechtriemen T, 2004, NOTFALL RETTUNGSMED, V7, P231; Schmidt J, 2007, ANASTH INTENSIVMED, V48, pS88; Sefrin P, 2014, NOTARZT, V30, P73, DOI 10.1055/s-0034-1369910; Sitzwohl C, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5943; Sorensen MK, 2012, BRIT J ANAESTH, V108, P682, DOI 10.1093/bja/aer503; Steinmann D, 2009, ANAESTHESIST, V58, P695, DOI 10.1007/s00101-009-1548-6; Stollings JL, 2014, ANN PHARMACOTHER, V48, P62, DOI 10.1177/1060028013510488; Swanson Eric R, 2004, Prehosp Emerg Care, V8, P273; Thierbach A, 2004, ANAESTHESIST, V53, P543, DOI 10.1007/s00101-004-0679-z; Timmermann A, 2012, ANASTH INTENSIVMED, V53, P294; Timmermann A, 2009, ANAESTHESIST, V58, P663, DOI 10.1007/s00101-009-1570-8; van den Heuvel I, 2013, CURR OPIN ANESTHESIO, V26, P404, DOI 10.1097/ACO.0b013e328362a84c; VANDERWALT J, 1995, PAEDIATR ANAESTH, V5, P257; Voelckel WG, 2004, ANAESTHESIST, V53, P1151, DOI 10.1007/s00101-004-0771-4; von Goedecke A, 2007, ANESTH ANALG, V104, P481, DOI 10.1213/01.ane.0000255964.86086.63; Weingart SD, 2012, ANN EMERG MED, V59, P165, DOI 10.1016/j.annemergmed.2011.10.002; Weller D, 2006, AKTUEL NEUROL, V33, pP532; Werdan K, 2011, KARDIOLOGE, V5, P166, DOI 10.1007/s12181-011-0349-8; Wetsch WA, 2013, EUR J ANAESTH, V30, P537, DOI 10.1097/EJA.0b013e3283614119; Wetsch WA, 2011, EUR J ANAESTH, V28, P849, DOI 10.1097/EJA.0b013e32834c7c7f; Wilbur K, 2001, CJEM, V3, P302; Zollinger A, 2012, DIE ANAESTHESIOLOGIE	89	19	21	0	8	AKTIV DRUCK & VERLAG GMBH	EBELSBACH	AN DER LOHWIESE 36, EBELSBACH, 97500, GERMANY	0170-5334	1439-0256		ANASTH INTENSIVMED	Anasthesiol. Intensivmed.	JUN	2015	56						317	335					19	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	CM7BY	WOS:000357846600012					2021-06-18	
J	Christensen, J				Christensen, Jakob			The Epidemiology of Posttraumatic Epilepsy	SEMINARS IN NEUROLOGY			English	Article						traumatic brain injury; seizures; epilepsy; posttraumatic; epidemiology	TRAUMATIC BRAIN-INJURY; ACUTE SYMPTOMATIC SEIZURE; RISK-FACTORS; HEAD-INJURY; MULTICENTER; DEFINITION; PREVENTION; ADULTS; TRIAL; ILAE	Traumatic brain injury is an important contributor to morbidity and mortality, and results in reduced quality of life and lifespan: An estimated 1.7 million traumatic brain injuries occur annually in the United States alone. Traumatic brain injury carries an increased risk of epilepsy that correlates with the severity of the brain injury. Posttraumatic epilepsy accounts for less than 10% of epilepsy, but traumatic brain injury is one of only a few potentially preventable causes of epilepsy. Despite several well-controlled human studies, there is no current preventive treatment available for humans. Therefore, primary prevention is the only proven way to prevent posttraumatic epilepsy.	Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus C, Denmark	Christensen, J (corresponding author), Aarhus Univ Hosp, Dept Neurol, Norrebrogade 44, DK-8000 Aarhus C, Denmark.	Jakob@farm.au.dk		Christensen, Jakob/0000-0002-9385-6435			Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Beghi E, 2010, EPILEPSIA, V51, P671, DOI 10.1111/j.1528-1167.2009.02285.x; Centers for Disease Control and Prevention, 2012, TRAUMATIC BRAIN INJU; Chen LLK, 2014, MIL MED, V179, P492, DOI 10.7205/MILMED-D-13-00413; Christensen J, 2012, EPILEPSIA, V53, P43, DOI 10.1111/j.1528-1167.2012.03612.x; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Emanuelson I, 2009, BRAIN INJURY, V23, P612, DOI 10.1080/02699050902973913; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Hakimian S, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11329; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hesdorffer DC, 2009, EPILEPSIA, V50, P1102, DOI 10.1111/j.1528-1167.2008.01945.x; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; McGuire SA, 2012, AVIAT SPACE ENVIR MD, V83, P140, DOI 10.3357/ASEM.3104.2012; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Schmidt D, 2014, NEUROTHERAPEUTICS, V11, P401, DOI 10.1007/s13311-013-0252-z; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Thurman DJ, 2011, EPILEPSIA, V52, P2, DOI 10.1111/j.1528-1167.2011.03121.x; Wang HQ, 2013, EPILEPSY RES, V107, P272, DOI 10.1016/j.eplepsyres.2013.10.006; Zhao YQ, 2012, SEIZURE-EUR J EPILEP, V21, P322, DOI 10.1016/j.seizure.2012.02.007	32	19	26	0	2	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	JUN	2015	35	3					218	222		10.1055/s-0035-1552923			5	Clinical Neurology	Neurosciences & Neurology	CK1YU	WOS:000356006700006	26060901	Bronze			2021-06-18	
J	Tse, KM; Tan, LB; Lee, SJ; Lim, SP; Lee, HP				Tse, Kwong Ming; Tan, Long Bin; Lee, Shu Jin; Lim, Siak Piang; Lee, Heow Pueh			Investigation of the relationship between facial injuries and traumatic brain injuries using a realistic subject-specific finite element head model	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Finite element; Concomitant injury; Facial trauma; Traumatic brain injury (TBI); Blunt impacts	INTRACRANIAL-PRESSURE; DYNAMIC-RESPONSE; TOLERANCE LIMITS; FE MODEL; FRACTURES; IMPACT; BONE; VALIDATION; DEFORMATION; MECHANISMS	In spite of anatomic proximity of the facial skeleton and cranium, there is lack of information in the literature regarding the relationship between facial and brain injuries. This study aims to correlate brain injuries with facial injuries using finite element method (FEM). Nine common impact scenarios of facial injuries are simulated with their individual stress wave propagation paths in the facial skeleton and the intracranial brain. Fractures of cranio-facial bones and intracranial injuries are evaluated based on the tolerance limits of the biomechanical parameters. General trend of maximum intracranial biomechanical parameters found in nasal bone and zygomaticomaxillary impacts indicates that severity of brain injury is highly associated with the proximity of location of impact to the brain. It is hypothesized that the midface is capable of absorbing considerable energy and protecting the brain from impact. The nasal cartilages dissipate the impact energy in the form of large scale deformation and fracture, with the vomer-ethmoid diverging stress to the "crumpling zone" of air-filled sphenoid and ethmoidal sinuses; in its most natural manner, the face protects the brain. This numerical study hopes to provide surgeons some insight in what possible brain injuries to be expected in various scenarios of facial trauma and to help in better diagnosis of unsuspected brain injury, thereby resulting in decreasing the morbidity and mortality associated with facial trauma. (C) 2015 Elsevier Ltd. All rights reserved.	[Tse, Kwong Ming; Tan, Long Bin; Lim, Siak Piang; Lee, Heow Pueh] Natl Univ Singapore, Dept Mech Engn, Singapore 117576, Singapore; [Lee, Shu Jin] Natl Univ Hlth Syst, Div Plast Reconstruct & Aesthet Surg, Singapore 119074, Singapore; [Lee, Heow Pueh] Natl Univ Singapore, Suzhou Res Inst, Suzhou 215123, Jiangsu, Peoples R China	Tse, KM (corresponding author), Natl Univ Singapore, Dept Mech Engn, 9 Engn Dr 1, Singapore 117576, Singapore.	tsekm.research@yahoo.com; mpeleehp@nus.edu.sg	Lee, Heow Pueh/I-7834-2014; Tse, Kwong Ming/D-8669-2011	Lee, Heow Pueh/0000-0002-4380-3888; Tse, Kwong Ming/0000-0002-8170-0775; Tan, Long Bin/0000-0002-3897-7365	Swiss-based CMF Clinical Priority Program of the AO Foundation [C-09-2L]	The authors would like to acknowledge the support by a grant from the Swiss-based CMF Clinical Priority Program of the AO Foundation under the project no. C-09-2L.	ABAQUS, 2013, AB AN US MAN; Al-Bsharat AS, 2000, COMPUTATIONAL ANAL B; Anderson RWG, 1999, P INT IRCOBI C BIOM, P107; Autuori B, 2006, IEEE T BIO-MED ENG, V53, P1225, DOI 10.1109/TBME.2006.872812; Bar-Kochba E, 2012, SIMULIA COMM C SCC P, P10; Baumgartner D, 2005, SOLID MECH APPL, V124, P195; Baumgartner D, 2005, EUR J COMPUT MECH, V14, P421; CHANG CJ, 1994, J TRAUMA, V37, P807, DOI 10.1097/00005373-199411000-00017; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Cormier J., 2011, J BIOMECH ENG, V133; Cormier JM, 2009, EPIDEMIOLOGY BIOMECH; Cormier Joseph, 2010, Ann Adv Automot Med, V54, P3; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; DiMasi F., 1991, 13 INT TECHN C EXP S; Doblare M, 2004, ENG FRACT MECH, V71, P1809, DOI 10.1016/j.engfracmech.2003.08.003; Fournier E., 2000, IRCOBI INT RES COUNC, V2000, P223; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Grellmann W, 2006, J BIOMED MATER RES A, V78A, P168, DOI 10.1002/jbm.a.30625; GWYN PP, 1971, PLAST RECONSTR SURG, V47, P225, DOI 10.1097/00006534-197103000-00004; Hardt N, 2010, CRANIOFACIAL TRAUMA: DIAGNOSIS AND MANAGEMENT, P31, DOI 10.1007/978-3-540-33041-7_3; HARDY CH, 1973, J APPL MECH-T ASME, V40, P838, DOI 10.1115/1.3423172; HARRISON DH, 1979, BRIT J PLAST SURG, V32, P57, DOI 10.1016/0007-1226(79)90063-8; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HAYTER JP, 1991, BRIT J ORAL MAX SURG, V29, P370, DOI 10.1016/0266-4356(91)90003-N; Ho J, 2009, INT J CRASHWORTHINES, V14, P555, DOI 10.1080/13588260902895708; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Kang HS, 1997, P STAPP CAR CRASH J, V41, P329; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; Khalighi Sigaroudi S. A., 2012, J DENT SHIRAZ, V13, P18; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; Lee SJ, 2010, LARYNGOSCOPE, V120, P1931, DOI 10.1002/lary.21072; LIM LH, 1993, BRIT J PLAST SURG, V46, P635, DOI 10.1016/0007-1226(93)90191-D; LUCE EA, 1979, PLAST RECONSTR SURG, V63, P26, DOI 10.1097/00006534-197901000-00005; Mansfield R. T., 1995, PEDIAT TRANSPORT MED, P285; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Martin RCG, 2002, AM SURGEON, V68, P477; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; Miller R.T., 1998, STAPP CAR CRASH J, P155; Nahum A. M., 1977, P 21 STAPP CAR CRASH, P339; NICKELL RE, 1974, J ENG IND-T ASME, V96, P490, DOI 10.1115/1.3438355; Oberascher G, 1993, Eur Arch Otorhinolaryngol Suppl, V1, P347; Pappachan B, 2006, J ORAL MAXIL SURG, V64, P1023, DOI 10.1016/j.joms.2006.03.021; Payan Y, 1998, LECT NOTES COMPUT SC, V1496, P688; Pietruszczak S, 1999, J BIOMECH, V32, P1071, DOI 10.1016/S0021-9290(99)00096-2; Ruan J. S., 1994, IMPACT BIOMECHANICS; Ruan J. S., 1997, J TRAFFIC MED, V25, P33; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Saladin K. S., 2007, HUMAN ANATOMY, P414; Schaller A, 2012, INT J ORAL MAX SURG, V41, P66, DOI 10.1016/j.ijom.2011.09.004; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Stalnaker R.L., 1969, MECH PROPERTIES HEAD; Stranc M F, 1979, Ann Plast Surg, V2, P468, DOI 10.1097/00000637-197906000-00004; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; TANNE K, 1989, AM J ORTHOD DENTOFAC, V95, P200, DOI 10.1016/0889-5406(89)90050-4; Tse KM, 2014, INT J NUMER METH BIO, V30, P397, DOI 10.1002/cnm.2609; Turquier F, 1996, STAPP CAR C, VP-30, P283; Wanyura H., 2011, J STOMA, V64, P411; Ward C. C., 1980, P 24 STAPP CAR CRASH, P347; WARD CC, 1975, P 19 STAPP CAR CRASH, P641; Weller MD, 2006, TRAUMA, V8, P21, DOI 10.1191/1460408606ta355oa; Westreich RW, 2007, ARCH FACIAL PLAST S, V9, P264, DOI 10.1001/archfaci.9.4.264; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029; Zandi M., 2012, ORAL MAXILLOFAC SURG, P1; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhou C., 1995, P STAPP CAR CRASH J, P121	72	19	20	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	JUN	2015	79						13	32		10.1016/j.aap.2015.03.012			20	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	CJ2ZF	WOS:000355352500002	25795050				2021-06-18	
J	Vartiainen, MV; Holm, A; Peltonen, K; Luoto, TM; Iverson, GL; Hokkanen, L				Vartiainen, M. V.; Holm, A.; Peltonen, K.; Luoto, T. M.; Iverson, G. L.; Hokkanen, L.			King-Devick test normative reference values for professional male ice hockey players	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						sport; concussion; head injury; measurement; neurology	VISUAL SCREENING TOOL; CONCUSSION; UTILITY	The King-Devick (K-D) test, a measure of processing speed, visual tracking, and saccadic eye movements, has shown promise as a supplemental screening test following concussion. However, limited normative data for this test have been published.The K-D test was administered to 185 professional ice hockey players as a preseason baseline test in seasons 2012-2013 and 2013-2014. Their average age was 23.8 years (median=22.0 years, range=16-40 years). The average K-D score was 40.0s (SD=6.1s, range=24.0-65.7s). K-D test performance showed no association with age, education, or the number of self-reported previous concussions in this sample. The association between trials 1 and 2 of the K-D test was good (ICC=0.92, Pearson=0.93). Normative values of the K-D test for professional male ice hockey players are reported. K-D test performance did not vary by age, education, or concussion history in this study.	[Vartiainen, M. V.; Peltonen, K.; Hokkanen, L.] Univ Helsinki, Inst Behav Sci, Div Cognit Psychol & Neuropsychol, SF-00100 Helsinki, Finland; [Holm, A.] Satakunta Cent Hosp, Dept Clin Neurophysiol, Pori, Finland; [Luoto, T. M.] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere, Finland; [Iverson, G. L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, G. L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, G. L.] Red Sox Fdn, Boston, MA USA; [Iverson, G. L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, G. L.] Massachusetts Gen Hosp, Sport Concuss Clin, Boston, MA 02114 USA	Vartiainen, MV (corresponding author), Univ Helsinki, Inst Behav Sci, Div Cognit Psychol & Neuropsychol, Raisalantie 24, SF-00100 Helsinki, Finland.	m.vartiainen@kolumbus.fi	Luoto, Teemu/W-6468-2018	Luoto, Teemu/0000-0002-7329-3284; Hokkanen, Laura/0000-0001-8342-9248; Iverson, Grant/0000-0001-7348-9570			Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Putukian M, 2013, BRIT J SPORT MED, V47, P285, DOI 10.1136/bjsports-2013-092158; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015	11	19	19	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	JUN	2015	25	3					e327	e330		10.1111/sms.12307			4	Sport Sciences	Sport Sciences	CI2ID	WOS:000354568800014	25138698				2021-06-18	
J	Baker, FA; Rickard, N; Tamplin, J; Roddy, C				Baker, Felicity Anne; Rickard, Nikki; Tamplin, Jeanette; Roddy, Chantal			Flow and meaningfulness as mechanisms of change in self-concept and well-being following a songwriting intervention for people in the early phase of neurorehabilitation	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						songwriting; self-concept clarity; spinal cord injuries; acquired brain injury; depression and anxiety disorders; well-being; flow theory	PATIENT HEALTH QUESTIONNAIRE-9; GENERALIZED ANXIETY DISORDER; TRAUMATIC BRAIN-INJURY; NEGATIVE AFFECT; SATISFACTION; VALIDITY; MUSIC; LIFE; INDIVIDUALS; VALIDATION	Anecdotal evidence suggests that songwriting assists people with spinal cord injury (SCI) or acquired brain injury (ABI) to explore threats to self-concept, yet studies that explore the mechanisms of change have not been reported. In a pilot study, we explored the correlations between changes in self-concept and well-being, with mechanisms of flow and meaningfulness of songwriting. Five people with ABI (all male) and 5 SCI (4 males, 1 female) (mean age 38.90 years, SD = 13.21), with an average 3 months post-injury, participated in a 12-session songwriting program that targeted examination of self-concept. Measures of self-concept, depression, anxiety, emotion regulation, affect, satisfaction with life, and flourishing were collected pre-, mid-, and post-intervention, and compared with repeated measures of flow and meaningfulness of songwriting. Medium effects were found for changes in self-concept (d = 0.557) and depression (d = 0.682) and approached a medium effect for negative affect (d = 0.491). Improvements in self-concept over time were associated with decreases in depression (r(p) = -0.874, n = 9, p < 0.01), anxiety (r(p) = -0.866, n = 9, p < 0.01), and negative affect (r(p) = -0.694, n = 10, p < 0.05), and an increase in flourishing (r(p) = +0.866, n = 9, p < 0.01) and positive affect (r(p) = +0.731, n = 10, p < 0.05). Strong experiences of flow were not positively correlated with positive changes to self-concept and well-being, whereas deriving high levels of meaning were associated with increased negative affect (r(p) = +0.68 p < 0.05), increased anxiety (r(p) = +0.74, p < 0.05), and reduced emotional suppression (r(p) = -0.58, p < 0.05). These findings show that the targeted songwriting intervention appears to be positively associated with enhanced well-being outcomes. However, the findings also suggest that people who find the songwriting process has strong meaning for them might be more likely to start accepting their emotions and as a result experience an increase in anxiety and depression, although full, mediated regression analyses with larger sample sizes are required to explore this further. Acknowledging their changed circumstances may nonetheless assist people with SCI and ABI to grieve their losses and facilitate the building of a healthy post-injured self-concept. We propose that there may be other mechanisms more critical in facilitating the positive changes in self-concept and well-being than flow and meaning, such as the role of story-telling and the impact of music in facilitating the consolidation of self-concept explorations in memory.	[Baker, Felicity Anne; Tamplin, Jeanette] Univ Melbourne, Melbourne, Vic, Australia; [Rickard, Nikki; Roddy, Chantal] Monash Univ, Melbourne, Vic 3004, Australia	Baker, FA (corresponding author), Univ Melbourne, Melbourne, Vic, Australia.	felicity.baker@unimelb.edu.au	Roddy, Chantal/Q-1558-2017; Tamplin, Jeanette/AAR-2855-2021	Roddy, Chantal/0000-0001-5220-9226; Tamplin, Jeanette/0000-0002-3623-033X			Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Baker F, 2005, J MUSIC THER, V42, P111, DOI 10.1093/jmt/42.2.111; Baker F., 2005, SONGWRITING METHODS, P116; Baker F, 2004, BRIT J MUSIC THERAPY, V2, P55; Baker F., 2005, AUSTR J MUSIC THERAP, V16, P25; Baker F., 2005, BRAIN IMPAIR, V6, P205, DOI [10.1375/brim.2005.6.3.205, DOI 10.1375/BRIM.2005.6.3.205]; Baker FA, 2015, THERAPEUTIC SONGWRITING: DEVELOPMENTS IN THEORY, METHODS, AND PRACTICE, P1, DOI 10.1057/9781137499233; Baker F, 2008, NORD J MUSIC THER, V17, P105, DOI 10.1080/08098130809478203; Baker FA, 2013, MUSIC SCI, V17, P131, DOI 10.1177/1029864913476287; Baker FA, 2014, ARTS HEALTH, V6, P143, DOI 10.1080/17533015.2013.808254; Bombardier CH, 2012, ARCH PHYS MED REHAB, V93, P1838, DOI 10.1016/j.apmr.2012.04.019; Cahill L, 1996, CURR OPIN NEUROBIOL, V6, P237, DOI 10.1016/S0959-4388(96)80078-X; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Crawford JR, 2004, BRIT J CLIN PSYCHOL, V43, P245, DOI 10.1348/0144665031752934; Csikszentmihalyi M., 2008, FLOW PSYCHOL OPTIMAL; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Diener E, 2010, SOC INDIC RES, V97, P143, DOI 10.1007/s11205-009-9493-y; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Feinstein D., 2008, PERSONAL MYTHOLOGY U; Fitts W.H., 1996, TENNESSEE SELF CONCE, V2nd ed; Fortmann AL, 2013, SPINAL CORD, V51, P482, DOI 10.1038/sc.2012.172; Gana K., 2012, PSYCHOL EMOTIONS ACT; Gross JJ, 2003, J PERS SOC PSYCHOL, V85, P348, DOI 10.1037/0022-3514.85.2.348; Habermas T, 2000, PSYCHOL BULL, V126, P748, DOI 10.1037//0033-2909.126.5.748; Hinkebein J. H., 2007, COPING CHRONIC ILLNE, P389, DOI DOI 10.1007/978-0-387-48670-3_18; Janata P, 2009, CEREB CORTEX, V19, P2579, DOI 10.1093/cercor/bhp008; Judde S, 2010, NEUROBIOL LEARN MEM, V94, P13, DOI 10.1016/j.nlm.2010.03.002; Juengst SB, 2014, REHABIL PSYCHOL, V59, P242, DOI 10.1037/a0036294; Kelly A, 2013, NEUROPSYCHOL REHABIL, V23, P563, DOI 10.1080/09602011.2013.795903; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lennon A, 2014, BRAIN INJURY, V28, P27, DOI 10.3109/02699052.2013.848378; Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093; MacKinnon NJ, 2010, SELF, IDENTITY, AND SOCIAL INSTITUTIONS, P1, DOI 10.1057/9780230108493; MARKUS H, 1986, AM PSYCHOL, V41, P954, DOI 10.1037/0003-066X.41.9.954; Martin AJ, 2008, MOTIV EMOTION, V32, P141, DOI 10.1007/s11031-008-9094-0; Melka SE, 2011, J CLIN PSYCHOL, V67, P1283, DOI 10.1002/jclp.20836; Menon V, 2005, NEUROIMAGE, V28, P175, DOI 10.1016/j.neuroimage.2005.05.053; Obodaru O, 2012, ACAD MANAGE REV, V37, P34, DOI 10.5465/amr.2009.0358; Pavot W, 2009, SOC INDIC RES SER, V39, P101, DOI 10.1007/978-90-481-2354-4_5; Salimpoor VN, 2013, PSYCHOL AESTHET CREA, V7, P62, DOI 10.1037/a0031819; Salter JE, 2013, SPINAL CORD, V51, P252, DOI 10.1038/sc.2012.105; Schultz R, 2013, BRAIN IMPAIR, V14, P450, DOI 10.1017/BrImp.2013.24; Seligman ME., 2011, FLOURISHING; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Tamplin J., 2006, NORD J MUSIC THER, V15, P177, DOI [10.1080/08098130609478164, DOI 10.1080/08098130609478164]; Tamplin J, 2016, NORD J MUSIC THER, V25, P111, DOI 10.1080/08098131.2015.1011208; Tamplin J, 2013, NEUROREHABILITATION, V32, P929, DOI 10.3233/NRE-130916; Tamplin J, 2013, ARCH PHYS MED REHAB, V94, P426, DOI 10.1016/j.apmr.2012.10.006; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; White D., 2014, THESIS CORNELL U NEW	52	19	19	1	36	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAY 26	2015	9								299	10.3389/fnhum.2015.00299			10	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	CK2VM	WOS:000356072100001	26082702	DOAJ Gold, Green Published			2021-06-18	
J	Bramley, H; Heverley, S; Lewis, MM; Kong, L; Rivera, R; Silvis, M				Bramley, Harry; Heverley, Steven; Lewis, Mechelle M.; Kong, Lan; Rivera, Rowena; Silvis, Matthew			Demographics and Treatment of Adolescent Posttraumatic Headache in a Regional Concussion Clinic	PEDIATRIC NEUROLOGY			English	Article						mild traumatic brain injury; concussion; headache; treatment; amitriptyline	TRAUMATIC BRAIN-INJURY; 4TH INTERNATIONAL-CONFERENCE; STATES HIGH-SCHOOL; SEX-DIFFERENCES; MINOR HEAD; SYMPTOM EXPECTATION; CONSENSUS STATEMENT; GENDER-DIFFERENCES; FOOTBALL PLAYERS; RISK-FACTOR	OBJECTIVE: Mild traumatic brain injury affects over one million pediatric patients annually. Minimal data and no guidelines exist regarding treatment of posttraumatic headache (PTH). The current study investigated treatment and outcomes in patients with posttraumatic headache. METHODS: Medical records of all patients (age 13-18 years of age) seen at a regional concussion program from 2006 to 2011 were reviewed. Statistical analysis using SAS 9.2 was conducted to determine the effectiveness of treatment as well as the association of gender, concussion history, and football participation on the duration of posttraumatic headache. RESULTS: Four hundred subjects met the inclusion criteria. Females were more likely to report posttraumatic headache than males (90% vs. 79%, P = 0.004), more likely to be prescribed amitriptyline (24% vs. 13%, P = 0.004), and had a significantly longer recovery time (median, 80 days versus 34 days, P < 0.001). Seventeen percent of subjects were prescribed amitriptyline for treatment of posttraumatic headache, of which 82% reported a beneficial effect. There was no difference in the percentage of posttraumatic headache or recovery time in football players versus other male athletes from other sport mechanisms. CONCLUSION: Females are more likely to report posttraumatic headache than males and also take longer to recover. Amitriptyline appears to be well-tolerated and an effective treatment strategy for patients with posttraumatic headache. Among pediatric patients evaluated in a concussion clinic, there is no difference in the proportion of football players reporting headaches compared with male players of other sports.	[Bramley, Harry; Lewis, Mechelle M.; Kong, Lan; Rivera, Rowena; Silvis, Matthew] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA; [Heverley, Steven] Tan & Garcia Pediat, Harrisburg, PA USA	Bramley, H (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Pediat, Mail Code H085,500 Univ Dr, Hershey, PA 17033 USA.	hbramley@hmc.psu.edu					Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Barlow KM, 2014, J CHILD NEUROL; Bekkelund SI, 2003, HEADACHE, V43, P59, DOI 10.1046/j.1526-4610.2003.03010.x; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Bettucci D, 1998, ITAL J NEUROL SCI, V19, P20, DOI 10.1007/BF03028807; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Esposito G, 1996, J NUCL MED, V37, P559; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P254, DOI 10.1016/S0303-8467(01)00161-5; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gladstone J, 2009, HEADACHE, V49, P1097, DOI 10.1111/j.1526-4610.2009.01461.x; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heyer GL, 2014, PEDIATR NEUROL, V51, P489, DOI 10.1016/j.pediatrneurol.2014.07.001; Kinart CM, 2002, HEADACHE, V42, P620, DOI 10.1046/j.1526-4610.2002.02149.x; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton RB, 2004, JAMA-J AM MED ASSOC, V291, P493, DOI 10.1001/jama.291.4.493; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Montgomery SA, 1997, ANN NY ACAD SCI, V836, P329, DOI 10.1111/j.1749-6632.1997.tb52368.x; Moore RA, 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD008242.PUB2; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Scher AI, 2014, CEPHALALGIA, V34, P83, DOI 10.1177/0333102413499644; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Silberstein SD, 2006, TRENDS PHARMACOL SCI, V27, P410, DOI 10.1016/j.tips.2006.06.003; Thanacoody H K Ruben, 2005, Toxicol Rev, V24, P205, DOI 10.2165/00139709-200524030-00013; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x	48	19	20	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	MAY	2015	52	5					493	498		10.1016/j.pediatrneurol.2015.01.008			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CG9BL	WOS:000353609300003	25728223				2021-06-18	
J	Fahlstedt, M; Depreitere, B; Halldin, P; Sloten, JV; Kleiven, S				Fahlstedt, Madelen; Depreitere, Bart; Halldin, Peter; Sloten, Jos Vander; Kleiven, Svein			Correlation between Injury Pattern and Finite Element Analysis in Biomechanical Reconstructions of Traumatic Brain Injuries	JOURNAL OF BIOMECHANICS			English	Article						Head injuries; Accident reconstructions; Image correlation; Bicycle accidents; FEA	HEMORRHAGE; PROGRESSION; THRESHOLD	At present, Finite Element (FE) analyses are often used as a tool to better understand the mechanisms of head injury. Previously, these models have been compared to cadaver experiments, with the next step under development being accident reconstructions. Thus far, the main focus has been on deriving an injury threshold and little effort has been put into correlating the documented injury location with the response displayed by the FE model. Therefore, the purpose of this study was to introduce a novel image correlation method that compares the response of the FE model with medical images. The injuries shown on the medical images were compared to the strain pattern in the FE model and evaluated by two indices; the Overlap Index (OI) and the Location Index (LI). As the name suggests, OI measures the area which indicates both injury in the medical images and high strain values in the FE images. LI evaluates the difference in center of mass in the medical and FE images. A perfect match would give an OI and LI equal to 1. This method was applied to three bicycle accident reconstructions. The reconstructions gave an average OI between 0.01 and 0.19 for the three cases and between 039 and 0.88 for LI. Performing injury reconstructions are a challenge as the information from the accidents often is uncertain. The suggested method evaluates the response in an objective way which can be used in future injury reconstruction studies. (C) 2015 Elsevier Ltd. All rights reserved.	[Fahlstedt, Madelen; Halldin, Peter; Kleiven, Svein] KTH Royal Inst Technol, Sch Technol & Hlth, Neuron Engn, S-14152 Huddinge, Sweden; [Depreitere, Bart] Katholieke Univ Leuven, Expt Neurosurg & Neuroanat, Leuven, Belgium; [Sloten, Jos Vander] Katholieke Univ Leuven, Biomech, Leuven, Belgium	Fahlstedt, M (corresponding author), KTH Royal Inst Technol, Sch Technol & Hlth, Neuron Engn, Alfred Nobels Alle 10, S-14152 Huddinge, Sweden.	madelen.fahlstedt@sth.kth.se	Depreitere, Bart/AAA-9846-2020	Depreitere, Bart/0000-0002-7458-0648	Lansforsakringarnas Cooperation Research Fund [P1/14]	This study was partly financed by Lansforsakringarnas Cooperation Research Fund (Grant no. P1/14). The authors would also like to thank Katrien Baeck for her assistance in gathering and retrieving the information on the accident data and medical images.	Anderson R.W.G., 1999, P INT RES COUNC BIOM; Baeck K., 2013, THESIS KU LEUVEN LEU; Bourdet N, 2012, P I MECH ENG P-J SPO, V226, P282, DOI 10.1177/1754337112442326; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Derler S, 2012, TRIBOL LETT, V45, P1, DOI 10.1007/s11249-011-9854-y; Dokko Y., 2003, P ENH SAF VEH ESV C; Doorly M.C., 2007, THESIS U COLL DUBLIN; Fahlstedt M., 2012, P INT RES COUNC BIOM; Gennarelli T, 1987, P 31 STAPP CAR CRASH; Hardy W N, 2001, Stapp Car Crash J, V45, P1; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Mao HJ, 2011, INT J NUMER METH BIO, V27, P357, DOI 10.1002/cnm.1403; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Nahum A. M., 1977, P 21 STAPP CAR CRASH; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Post A, 2015, NEUROSURGERY, V76, P81, DOI 10.1227/NEU.0000000000000554; Takhounts EG, 2008, STAPP CAR C, V52, P1; Trosseille X., 1992, P 36 STAPP CAR CRASH; Verschueren P., 2009, THESIS KU LEUVEN LEU; Viola P, 1997, INT J COMPUT VISION, V24, P137, DOI 10.1023/A:1007958904918; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	26	19	21	0	16	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	MAY 1	2015	48	7					1331	1335		10.1016/j.jbiomech.2015.02.057			5	Biophysics; Engineering, Biomedical	Biophysics; Engineering	CH0ZP	WOS:000353751200014	25817473				2021-06-18	
J	He, XH; Lakkaraju, SK; Hanscom, M; Zhao, ZR; Wu, JF; Stoica, B; MacKerell, AD; Faden, AI; Xue, FT				He, Xinhua; Lakkaraju, Sirish K.; Hanscom, Marie; Zhao, Zaorui; Wu, Junfang; Stoica, Bogdan; MacKerell, Alexander D., Jr.; Faden, Alan I.; Xue, Fengtian			Acyl-2-aminobenzimidazoles: A novel class of neuroprotective agents targeting mGluR5	BIOORGANIC & MEDICINAL CHEMISTRY			English	Article						Traumatic brain injury; Metabotropic glutamate receptor; Neuroprotection; Computer-aided drug design; Positive allosteric modulator	POSITIVE ALLOSTERIC MODULATORS; TRAUMATIC BRAIN INJURY; SPINAL-CORD-INJURY; MOLECULAR-DYNAMICS; MACROMOLECULAR ENERGY; SITE-IDENTIFICATION; IMMUNE FUNCTION; IN-VIVO; DISCOVERY; ACTIVATION	Positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 5 (mGluR5) are promising therapeutic agents for treating traumatic brain injury (TBI). Using computational and medicinal methods, the structure-activity relationship of a class of acyl-2-aminobenzimidazoles (1-26) is reported. The new compounds are designed based on the chemical structure of 3,3'-difluorobenzaldazine (DFB), a known mGluR5 PAM. Ligand design and prediction of binding affinities of the new compounds have been performed using the site identification by ligand competitive saturation (SILCS) method. Binding affinities of the compounds to the transmembrane domain of mGluR5 have been evaluated using nitric oxide (NO) production assay, while the safety of the compounds is tested. One new compound found in this study, compound 22, showed promising activity with an IC50 value of 6.4 mu M, which is similar to 20 fold more potent than that of DFB. Compound 22 represents a new lead for possible development as a treatment for TBI and related neurodegenerative conditions. (C) 2015 Elsevier Ltd. All rights reserved.	[He, Xinhua; Lakkaraju, Sirish K.; MacKerell, Alexander D., Jr.; Xue, Fengtian] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Hanscom, Marie; Zhao, Zaorui; Wu, Junfang; Stoica, Bogdan; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Hanscom, Marie; Zhao, Zaorui; Wu, Junfang; Stoica, Bogdan; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA	Xue, FT (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 Penn St, Baltimore, MD 21201 USA.	fxue@rx.umaryland.edu	STOICA, BOGDAN/H-9782-2013; MacKerell, Alex/AAA-2560-2020; MacKerell, Alex/Y-2469-2019	STOICA, BOGDAN/0000-0002-2501-6434; MacKerell, Alex/0000-0001-8287-6804; Faden, Alan I./0000-0003-0128-2348; Hanscom, Marie/0000-0001-8308-135X; Lakkaraju, Sirish Kaushik/0000-0003-1553-5780; He, Xinhua/0000-0001-7826-2973	UMB Pilot & Exploratory Interdisciplinary Research (IDR); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA107331]; United States and Maryland Industrial Partnerships Award [5212]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA107331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R43GM109635] Funding Source: NIH RePORTER	This work was supported by the UMB Pilot & Exploratory Interdisciplinary Research (IDR), NIH grant CA107331 United States and Maryland Industrial Partnerships Award 5212. The authors acknowledge computer time and resources from the Computer Aided Drug Design (CADD) Center at the University of Maryland, Baltimore.	Allen M.P., 1989, PHYS TODAY, V42, P105, DOI [DOI 10.1063/1.2810937, 10.1063/1.2810937]; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Byrnes KR, 2006, GLIA, V53, P420, DOI 10.1002/glia.20295; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Biase A, 2005, PHYSIOL GENOMICS, V22, P368, DOI 10.1152/physiolgenomics.00081.2005; DURELL SR, 1994, J PHYS CHEM-US, V98, P2198, DOI 10.1021/j100059a038; Engers DW, 2009, CHEMMEDCHEM, V4, P505, DOI 10.1002/cmdc.200800357; FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Gebicke-Haerter PJ, 2005, J NEUROSCI RES, V81, P327, DOI 10.1002/jnr.20479; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guvench O, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000435; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; Jo S, 2009, BIOPHYS J, V97, P50, DOI 10.1016/j.bpj.2009.04.013; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Lakkaraju S. K., 2014, J CHEM THEORY COMPUT, P10; Lee JH, 2006, HETEROCYCLES, V70, P571; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; LEVITT M, 1969, J MOL BIOL, V46, P269, DOI 10.1016/0022-2836(69)90421-5; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Malherbe P, 2003, MOL PHARMACOL, V64, P823, DOI 10.1124/mol.64.4.823; NOSE S, 1984, MOL PHYS, V52, P255, DOI 10.1080/00268978400101201; O'Brien JA, 2004, J PHARMACOL EXP THER, V309, P568, DOI 10.1124/jpet.103.061747; O'Brien JA, 2003, MOL PHARMACOL, V64, P731, DOI 10.1124/mol.64.3.731; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693; Pearlman DA, 2001, J MED CHEM, V44, P3417, DOI 10.1021/jm0100279; Pilyugin VS, 2004, RUSS J GEN CHEM+, V74, P738, DOI 10.1023/B:RUGC.0000039088.87053.eb; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Powers JP, 2006, BIOORG MED CHEM LETT, V16, P2842, DOI 10.1016/j.bmcl.2006.03.020; Raman EP, 2013, J CHEM INF MODEL, V53, P3384, DOI 10.1021/ci4005628; Raman EP, 2011, J CHEM INF MODEL, V51, P877, DOI 10.1021/ci100462t; Ritzen A, 2009, BIOORG MED CHEM LETT, V19, P3275, DOI 10.1016/j.bmcl.2009.04.095; Rodriguez AL, 2010, MOL PHARMACOL, V78, P1105, DOI 10.1124/mol.110.067207; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sharma S, 2009, J MED CHEM, V52, P4103, DOI 10.1021/jm900654c; Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606; Shim J., 2013, J PHYS CHEM B; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367; Vilhardt F, 2005, INT J BIOCHEM CELL B, V37, P17, DOI 10.1016/j.biocel.2004.06.010; Wu HX, 2014, SCIENCE, V344, P58, DOI 10.1126/science.1249489; Xue FT, 2014, CNS NEUROL DISORD-DR, V13, P558, DOI 10.2174/18715273113126660199; Zhao ZJ, 2007, BIOORG MED CHEM LETT, V17, P1386, DOI 10.1016/j.bmcl.2006.11.081	57	19	19	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0968-0896	1464-3391		BIOORGAN MED CHEM	Bioorg. Med. Chem.	MAY 1	2015	23	9					2211	2220		10.1016/j.bmc.2015.02.054			10	Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, Organic	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry	CF6WZ	WOS:000352698700031	25801156	Green Accepted			2021-06-18	
J	Kerr, ZY; Hayden, R; Dompier, TP; Cohen, R				Kerr, Zachary Y.; Hayden, Ross; Dompier, Thomas P.; Cohen, Randy			Association of Equipment Worn and Concussion Injury Rates in National Collegiate Athletic Association Football Practices 2004-2005 to 2008-2009 Academic Years	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						epidemiology; injury prevention; scrimmages; traumatic brain injury	SURVEILLANCE SYSTEM; RECURRENT CONCUSSION; NCAA CONCUSSION; PLAYERS; EPIDEMIOLOGY; DEPRESSION; STATEMENT; RISK	Background: The epidemiology of football-related concussions has been extensively examined. However, although football players experience more at-risk exposure time during practices than competitions, there is a dearth of literature examining the nature of the activities or equipment worn during practice. In particular, varying levels of equipment worn during practices may place players at varying levels of risk for concussion. Purpose: To describe the epidemiology of NCAA men's football concussions that occurred during practices from the 2004-2005 to 2008-2009 academic years by amount of equipment worn. Study Design: Descriptive epidemiology study. Methods: Men's collegiate football data from the National Collegiate Athletic Association Injury Surveillance System (NCAA ISS) during the 5-year study period were analyzed. Injury rates and injury rate ratios (RRs) were reported with 95% confidence intervals. Results: During the study period, 795 concussions were reported during practices, resulting in an injury rate of 0.39 per 1000 athlete-exposures (AEs) (95% CI, 0.36-0.42). Among NCAA divisions, Division III had the highest concussion rate (0.54/1000 AEs), followed by Division I (0.34/1000 AEs) and Division II (0.24/1000 AEs) (all P values for RRs comparing divisions <.001). Most concussions in practice occurred when players were fully padded (69.9%), followed by wearing shells (23.5%) and helmets only (1.9%). The practice concussion rate was higher in fully padded practices (0.66/1000 AEs) compared with practices when shells were worn (0.33/1000 AEs; RR = 1.99 [95% CI, 1.69-2.35]; P < .001) and practices when only helmets were worn (0.03/1000 AEs; RR = 22.39 [95% CI, 13.41-37.39]; P < .001). The practice concussion rate of the preseason (0.76/1000 AEs) was higher than that of the regular season (0.18/1000 AEs; RR = 4.14 [95% CI, 3.55-4.83]; P < .001) and that of postseason (0.25/1000 AEs; RR = 3.02 [95% CI, 1.95-4.67]; P < .001). The types of practice with the highest concussion rate were scrimmages (1.55/1000 AEs). Although only 3 concussions were sustained during scrimmage practices in which players wore shells, the concussion rate (2.84/1000 AEs) was higher than all other reported rates. Conclusion: Practice concussion rates are highest during fully padded practices, preseason practices, and scrimmages, suggesting that the nature, focus, and intensity of football practices affect concussion risk. In addition, coaching staff should continue to closely monitor player safety during scrimmages. Meanwhile, future surveillance should examine whether removing scrimmages, particularly those that are not fully padded, will meaningfully reduce the incidence and rate of concussions.	[Kerr, Zachary Y.; Hayden, Ross; Dompier, Thomas P.; Cohen, Randy] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN USA	Kerr, ZY (corresponding author), 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org		Kerr, Zachary/0000-0003-1423-1259	The National Collegiate Athletic Association (NCAA) Injury Surveillance Program data were provided by the Datalys Center for Sports Injury Research and Prevention; NCAA	One or more of the authors has declared the following potential conflict of interest or source of funding: The National Collegiate Athletic Association (NCAA) Injury Surveillance Program data were provided by the Datalys Center for Sports Injury Research and Prevention. The Injury Surveillance Program was funded by the NCAA. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NCAA.	Dick R, 2007, J ATHL TRAINING, V42, P221; Dick R, 2007, J ATHL TRAINING, V42, P173; Dick RW, 1997, AM SOC TEST MATER, V1305, P9, DOI 10.1520/STP11767S; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; ESPN, 2014, PAC 12 LIM CONT PRAC; ESPN, 2014, IVY LEAG LIM FULL CO; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heck JF, 2004, J ATHL TRAINING, V39, P101; Kerr Zachary Y, 2014, Inj Epidemiol, V1, P28; Kerr ZY, 2014, PEDIATRICS, V134, P489, DOI 10.1542/peds.2014-0770; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Kucera KL, 2011, J ATHL TRAINING, V46, P489; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mueller FO, 2012, ANN SURVEY FOOTBALL; National Collegiate Athletic Association, FOOTB PRACT GUID	23	19	19	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2015	43	5					1134	1141		10.1177/0363546515570622			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CH4CV	WOS:000353980000019	25931501				2021-06-18	
J	Shamloo, A; Manuchehrfar, F; Rafii-Tabar, H				Shamloo, Amir; Manuchehrfar, Farid; Rafii-Tabar, Hashem			A viscoelastic model for axonal microtubule rupture	JOURNAL OF BIOMECHANICS			English	Article						Axon; Microtubule; Rupture; Standard Linear Solid; Viscoelastic	HEAD-INJURY; DYNAMIC INSTABILITY; BRAIN-INJURY; BREAKING	Axon is an important part of the neuronal cells and axonal microtubules are bundles in axons. In axons, microtubules are coated with microtubule-associated protein tau, a natively unfolded filamentous protein in the central nervous system. These proteins are responsible for cross-linking axonal microtubule bundles. Through complimentary dimerization with other tau proteins, bridges are formed between nearby microtubules creating bundles. Formation of bundles of microtubules causes their transverse reinforcement and has been shown to enhance their ability to bear compressive loads. Though microtubules are conventionally regarded as bearing compressive loads, in certain circumstances during traumatic brain injuries, they are placed in tension. In our model, microtubule bundles were formed from a large number of discrete masses. We employed Standard Linear Solid model (SLS), a viscoelastic model, to computationally simulate microtubules. In this study, we investigated the dynamic responses of two dimensional axonal microtubules under suddenly applied end forces by implementing discrete masses connected to their neighboring masses with a Standard Linear Solid unit. We also investigated the effect of the applied force rate and magnitude on the deformation of bundles. Under tension, a microtubule fiber may rupture as a result of a sudden force. Using the developed model, we could predict the critical regions of the axonal microtubule bundles in the presence of varying end forces. We finally analyzed the nature of microtubular failure under varying mechanical stresses. (C) 2015 Elsevier Ltd. All rights reserved.	[Shamloo, Amir; Manuchehrfar, Farid] Sharif Univ Technol, Sch Mech Engn, CEEC, Tehran, Iran; [Shamloo, Amir; Rafii-Tabar, Hashem] Inst Res Fundamental Sci, Tehran, Iran	Shamloo, A (corresponding author), Sharif Univ Technol, Sch Mech Engn, CEEC, POB 11155-9567, Tehran, Iran.	shamloo@sharif.edu		, amir/0000-0002-0131-0567			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Buxton GA, 2010, PROG NEUROBIOL, V92, P478, DOI 10.1016/j.pneurobio.2010.08.003; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.biophys.21.1.145; FADIC R, 1985, J COMP NEUROL, V236, P258, DOI 10.1002/cne.902360209; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FLYVBJERG H, 1994, PHYS REV LETT, V73, P2372, DOI 10.1103/PhysRevLett.73.2372; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kilinc D, 2009, COMPUT METH PROG BIO, V95, P62, DOI 10.1016/j.cmpb.2009.01.002; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Peter SJ, 2012, BIOPHYS J, V102, P749, DOI 10.1016/j.bpj.2011.11.4024; Sanjith S, 2011, INDIAN J NEUROTRAUM, V8, P71, DOI 10.1016/S0973-0508(11)80003-1; Shahinnejad A, 2013, PROCEDIA ENGINEER, V59, P16, DOI 10.1016/j.proeng.2013.05.088; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Teixeira CA, 2014, NEUROBIOL DIS, V66, P92, DOI 10.1016/j.nbd.2014.02.012; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; YU WQ, 1994, J NEUROSCI, V14, P2818	26	19	19	2	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	MAY 1	2015	48	7					1241	1247		10.1016/j.jbiomech.2015.03.007			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	CH0ZP	WOS:000353751200002	25835789				2021-06-18	
J	Dong, GC; Kuan, CY; Subramaniam, S; Zhao, JY; Sivasubramaniam, S; Chang, HY; Lin, FH				Dong, Guo-Chung; Kuan, Che-Yung; Subramaniam, Sadhasivam; Zhao, Jiong-Yao; Sivasubramaniam, Savitha; Chang, Hwan-You; Lin, Feng-Huei			A potent inhibition of oxidative stress induced gene expression in neural cells by sustained ferulic acid release from chitosan based hydrogel	MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS			English	Article						TBI; Secondary brain injury; Hydrogel; Ferulic acid; Oxidative stress; Neuro-2a cells	TRAUMATIC BRAIN-INJURY; ANTIOXIDANT ENZYMES; COMPOSITE	Traumatic brain injury (TBI) is an extremely cataclysmic neurological disorder and the inhibition of oxidative stress following TBI could effectively protect the brain from further impairments. An injectable thermosensitive chitosan/gelatin/beta-Glycerol phosphate (C/G/GP) hydrogel for the controlled release of the phenolic antioxidant ferulic acid (FA) to inhibit the neurological oxidative stress was demonstrated. The C/G/GP hydrogel ensures an excellent clinical expediency with a gelation temperature of 32.6 degrees C and gelation time of 75.58 s. In-vitro cytotoxicity assays of C/G/GP hydrogel and FA have revealed an excellent biocompatibility with the Neuro-2a cells. 500 mu M of FA was considered to be an effective concentration to reduce the oxidative stress in Neuro-2a cells. TUNEL staining images evidenced that the H2O2 induced DNA fragmentation was comprehensively controlled after FA treatment. The mRNA gene expression profiles markedly authenticate the neuroprotectivity of FA by down-regulating ROS, inflammatory and apoptosis related markers. The outcomes of this study suggest that, C/G/GP hydrogel carrying ferulic acid could effectively protect further secondary traumatic brain injury associated impairments. (C) 2015 Elsevier B.V. All rights reserved.	[Dong, Guo-Chung; Kuan, Che-Yung; Subramaniam, Sadhasivam; Zhao, Jiong-Yao; Lin, Feng-Huei] Natl Hlth Res Inst, Inst Biomed Engn & Nanomed, Zhunan, Miaoli County, Taiwan; [Kuan, Che-Yung] Natl Chung Hsing Univ, Program Tissue Engn & Regenerat Med, Taichung 40227, Taiwan; [Zhao, Jiong-Yao; Chang, Hwan-You] Natl Tsing Hua Univ, Inst Mol Med, Hsinchu, Taiwan; [Lin, Feng-Huei] Natl Taiwan Univ, Inst Biomed Engn, Taipei 10764, Taiwan; [Sivasubramaniam, Savitha] Sree Sastha Inst Engn & Technol, Dept Biotechnol, Madras, Tamil Nadu, India	Lin, FH (corresponding author), Natl Taiwan Univ, Inst Biomed Engn, Taipei 10764, Taiwan.	double@ntu.edu.tw	Sadhasivam, Subramaniam/AAF-4545-2019; Dong, Guo-Chung/E-3950-2010	Dong, Guo-Chung/0000-0003-1159-1718			Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019; Cheng CY, 2008, BRAIN RES, V1209, P136, DOI 10.1016/j.brainres.2008.02.090; Cheng YH, 2011, PROCESS BIOCHEM, V46, P1670, DOI 10.1016/j.procbio.2011.05.017; Cheng YH, 2011, BIOMATERIALS, V32, P6953, DOI 10.1016/j.biomaterials.2011.03.065; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GRAF E, 1992, FREE RADICAL BIO MED, V13, P435, DOI 10.1016/0891-5849(92)90184-I; Hong Y, 2007, ACTA BIOMATER, V3, P23, DOI 10.1016/j.actbio.2006.06.007; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Li XY, 2012, INT J PHARMACEUT, V437, P110, DOI 10.1016/j.ijpharm.2012.08.001; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manickam DS, 2012, J CONTROL RELEASE, V162, P636, DOI 10.1016/j.jconrel.2012.07.044; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Nakata R, 2014, MAT SCI ENG C-MATER, V41, P59, DOI 10.1016/j.msec.2014.04.016; O'Connell KM, 2013, BIOL RES NURS, V15, P253, DOI 10.1177/1099800411431823; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Picone P, 2013, BIOL BULL-US, V224, P18, DOI 10.1086/BBLv224n1p18; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wang H, 2003, J NEUROCHEM, V87, P1527, DOI 10.1046/j.1471-4159.2003.02123.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	25	19	20	0	47	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0928-4931	1873-0191		MAT SCI ENG C-MATER	Mater. Sci. Eng. C-Mater. Biol. Appl.	APR 1	2015	49						691	699		10.1016/j.msec.2015.01.030			9	Materials Science, Biomaterials	Materials Science	CC6YE	WOS:000350514100079	25686998				2021-06-18	
J	Zygourakis, CC; Kahn, JG				Zygourakis, Corinna C.; Kahn, James G.			Cost-Effectiveness Research in Neurosurgery	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Cost-effectiveness; Cost-utility; QALY; Neurosurgery; Spine surgery	LUMBAR INTERBODY FUSION; INTERVENTION CLINICAL ARTICLE; ANTERIOR CERVICAL DISKECTOMY; ADJACENT-SEGMENT DISEASE; TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; UTILITY ANALYSIS; STEREOTACTIC RADIOSURGERY; SUBARACHNOID HEMORRHAGE; INTRACRANIAL ANEURYSMS	Cost and value are increasingly important components of health care discussions. Despite a plethora of cost and cost-effectiveness analyses in many areas of medicine, there has been little of this type of research for neurosurgical procedures. This scarcity is vexing because this specialty represents one of the most expensive areas in medicine. This article discusses the general principles of cost-effectiveness analyses and reviews the cost- and cost-effectiveness-related research to date in neurosurgical subspecialties. The need for standardization of cost and cost-effectiveness measurement and reporting within neurosurgery is highlighted and a set of metrics for this purpose is defined.	[Zygourakis, Corinna C.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Kahn, James G.] Univ Calif San Francisco, Global Hlth Econ Consortium, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94118 USA	Zygourakis, CC (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Room 779M, San Francisco, CA 94143 USA.	zygourakisc@neurosurg.ucsf.edu					Adogwa O, 2013, J NEUROSURG-SPINE, V18, P147, DOI 10.3171/2012.11.SPINE12226; Adogwa O, 2012, J NEUROSURG-SPINE, V16, P141, DOI 10.3171/2011.9.SPINE11419; Adogwa O, 2012, J NEUROSURG-SPINE, V16, P135, DOI 10.3171/2011.9.SPINE11308; Adogwa O, 2011, J NEUROSURG-SPINE, V15, P138, DOI 10.3171/2011.3.SPINE10562; Al-Khouja LT, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.4.FOCUS1449; Alali AS, 2014, CRIT CARE MED, V42, P2235, DOI 10.1097/CCM.0000000000000500; Alvin MD, 2014, J SPINAL DISORD TECH; [Anonymous], COST EFFECTIVENESS T; Arts MP, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-122; Banerjee R, 2008, J NEUROSURG, V108, P1220, DOI 10.3171/JNS/2008/108/6/1220; Bowen James M, 2012, Ont Health Technol Assess Ser, V12, P1; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Brill Steven, 2013, Time, V181, P16; Brown DA, 2014, SPINE, V39, pE902, DOI 10.1097/BRS.0000000000000395; Burnett MG, 2010, J NEUROSURG-SPINE, V13, P39, DOI 10.3171/2010.3.SPINE09552; Cho DY, 2006, NEUROSURGERY, V58, P866, DOI 10.1227/01.NEU.0000209892.42585.9B; Vuong DA, 2013, CLIN NEUROL NEUROSUR, V115, P276, DOI 10.1016/j.clineuro.2012.05.005; Vuong DA, 2012, WORLD NEUROSURG, V77, P321, DOI 10.1016/j.wneu.2011.05.050; Fehlings MG, 2014, SPINE, V39, P1265, DOI [10.1097/BRS.0000000000000390, 10.1097/BRS.0000000000000525]; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; Fransen P, 2012, ACTA NEUROL BELG, V112, P245, DOI 10.1007/s13760-012-0095-0; Furlan JC, 2012, NEURO-ONCOLOGY, V14, P631, DOI 10.1093/neuonc/nos062; Greving JP, 2009, NEUROLOGY, V73, P258, DOI 10.1212/01.wnl.0b013e3181a2a4ea; Ho KM, 2011, J TRAUMA, V71, P1637, DOI 10.1097/TA.0b013e31823a08f1; Hofmeijer J, 2013, STROKE, V44, P2923, DOI 10.1161/STROKEAHA.113.002445; Hoh BL, 2010, STROKE, V41, P337, DOI 10.1161/STROKEAHA.109.569269; Holmes MW, 2013, ARCH DIS CHILD, V98, P939, DOI 10.1136/archdischild-2012-302820; Horsman John, 2003, Health Qual Life Outcomes, V1, P54, DOI 10.1186/1477-7525-1-54; Jabbarli R, 2014, NEURORADIOLOGY, V56, P817, DOI 10.1007/s00234-014-1406-3; Jethwa PR, 2013, NEUROSURGERY, V72, P511, DOI 10.1227/NEU.0b013e318282a578; KING JT, 1995, J NEUROSURG, V83, P403, DOI 10.3171/jns.1995.83.3.0403; King JT, 1997, J NEUROSURG, V87, P20, DOI 10.3171/jns.1997.87.1.0020; Koffijberg H, 2011, J NEUROL NEUROSUR PS, V82, P718, DOI 10.1136/jnnp.2009.185660; Lee WY, 2009, J CLIN NEUROSCI, V16, P630, DOI 10.1016/j.jocn.2008.06.021; Lester SC, 2014, CANCER-AM CANCER SOC, V120, P433, DOI 10.1002/cncr.28422; Long DM, 2003, NEUROSURGERY, V52, P1056, DOI 10.1227/01.NEU.0000057745.48813.93; Makary M, 2011, J MAGN RESON IMAGING, V34, P1022, DOI 10.1002/jmri.22739; Malmivaara K, 2012, EUR J NEUROL, V19, P1455, DOI 10.1111/j.1468-1331.2012.03744.x; Malmivaara K, 2011, EUR J NEUROL, V18, P656, DOI 10.1111/j.1468-1331.2010.03294.x; Marko NF, 2012, J NEUROSURG, V117, P522, DOI 10.3171/2012.4.JNS11739; Martino J, 2013, ACTA NEUROCHIR, V155, P41, DOI 10.1007/s00701-012-1541-8; Maud A, 2009, J NEUROSURG, V110, P880, DOI 10.3171/2008.8.JNS0858; McCarthy IM, 2014, SPINE J, V14, P2326, DOI 10.1016/j.spinee.2014.01.032; Mehta M, 1997, INT J RADIAT ONCOL, V39, P445, DOI 10.1016/S0360-3016(97)00071-0; Mendez I, 2001, CAN J NEUROL SCI, V28, P61; Mukherjee D, 2013, J CLIN NEUROSCI, V20, P57, DOI 10.1016/j.jocn.2012.05.014; Ney JP, 2013, J CLIN NEUROPHYSIOL, V30, P280, DOI 10.1097/WNP.0b013e3182933d8f; Nussbaum ES, 1996, NEUROSURGERY, V38, P237, DOI 10.1097/00006123-199602000-00001; Overdevest GM, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-57; Papatheofanis FJ, 2009, NEUROSURGERY, V64, pA73, DOI 10.1227/01.NEU.0000341205.37067.DE; Parker SL, 2011, MINIM INVAS NEUROSUR, V54, P33, DOI 10.1055/s-0030-1269904; Parker SL, 2014, WORLD NEUROSURG, V82, P230, DOI 10.1016/j.wneu.2013.01.041; Parker SL, 2013, J SPINAL DISORD TECH, V26, P42, DOI 10.1097/BSD.0b013e318232313d; Parker SL, 2012, NEUROSURGERY, V71, P1149, DOI 10.1227/NEU.0b013e318271ebde; Parker SL, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.09.013; PICKARD JD, 1990, BRIT MED J, V301, P629, DOI 10.1136/bmj.301.6753.629; Pollock BE, 2005, CLIN J PAIN, V21, P317, DOI 10.1097/01.ajp.0000125267.40304.57; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Rasanen P, 2006, J NEUROSURG-SPINE, V5, P204, DOI 10.3171/spi.2006.5.3.204; Ray WZ, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.4.FOCUS1289; Sanborn MR, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.2.FOCUS121; Sivakanthan S, 2014, NEUROSURGERY, V75, P220, DOI 10.1227/NEU.0000000000000430; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Sonig A, 2012, NEUROSURG FOCUS, V33, pE3, DOI DOI 10.3171/2012.7.F0CUS12193; Sulaiman WAR, 2014, OCHSNER J, V14, P32; Tan SS, 2011, J NEURO-ONCOL, V101, P237, DOI 10.1007/s11060-010-0243-4; Terran J, 2014, OCHSNER J, V14, P14; Tosteson ANA, 2008, SPINE, V33, P2108, DOI 10.1097/BRS.0b013e318182e390; Tosteson ANA, 2008, ANN INTERN MED, V149, P845, DOI 10.7326/0003-4819-149-12-200812160-00003; Tumeh John W, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P153, DOI 10.1586/14737167.5.2.153; Tumialan LM, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09305; Undabeitia J, 2011, NEUROCIRUGIA, V22, P535, DOI 10.4321/S1130-14732011000600006; vanRoijen L, 1997, ACTA NEUROCHIR, V139, P942, DOI 10.1007/BF01411303; Virk SS, 2014, J SPINAL DISORD TECH; Vogel TW, 2014, J NEUROSURG-PEDIATR, V13, P324, DOI 10.3171/2013.12.PEDS13320; Warf BC, 2011, J NEUROSURG-PEDIATR, V8, P509, DOI 10.3171/2011.8.PEDS11163; Wellis G, 2003, ACTA NEUROCHIR, V145, P249, DOI 10.1007/s00701-003-0007-4; Whitmore RG, 2012, J NEUROSURG, V116, P1106, DOI 10.3171/2012.1.JNS11962; Whitmore RG, 2012, NEUROSURGERY, V70, P860, DOI 10.1227/NEU.0b013e3182367272; Widjaja E, 2011, EPILEPSY RES, V94, P61, DOI 10.1016/j.eplepsyres.2011.01.005; World Health Organization, 2003, INTRODUCTION TO DRUG; Zhen Jing-Ran, 2008, Zhonghua Fu Chan Ke Za Zhi, V43, P257; Zhu XL, 2014, WORLD NEUROSURG; Zygourakis C, SURGERY IS MORE COST; Zygourakis CC, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.8.FOCUS14435	85	19	19	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	APR	2015	26	2					189	+		10.1016/j.nec.2014.11.008			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CF4KU	WOS:000352518800007	25771274				2021-06-18	
J	Jackson, JC; Mitchell, N; Hopkins, RO				Jackson, James C.; Mitchell, Nathaniel; Hopkins, Ramona O.			Cognitive Functioning, Mental Health, and Quality of Life in ICU Survivors: An Overview	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Cognitive impairments; Critical illness; Critical care outcomes; Psychiatric disorders; Quality of life	INTENSIVE-CARE-UNIT; POSTTRAUMATIC-STRESS-DISORDER; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; TRAUMATIC BRAIN INJURY; CRITICAL ILLNESS; RISK-FACTORS; DELIRIUM; OUTCOMES; MEMORY	Critical illness can and often does lead to significant cognitive impairment and to the development of psychological disorders. These conditions are persistent and, although they improve with time, often fail to completely abate. Although the functional correlates of cognitive and psychological morbidity (depression, anxiety, and posttraumatic stress disorder) have been studied, they may include poor quality of life, inability to return to work or to work at previously established levels, and inability to function effectively in emotional and interpersonal domains. The potential etiologies of cognitive impairment and psychological morbidity in ICU survivors are particularly poorly understood and may vary widely across patients. Potential contributors may include the potentially toxic effects of sedatives and narcotics, delirium, hypoxia, glucose dysregulation, metabolic derangements, and inflammation. Patients with preexisting vulnerabilities, including predisposing genetic factors, and frail elderly populations may be at particular risk for emergence of acceleration of conditions such as mild cognitive impairment.	[Jackson, James C.] Vanderbilt Univ, Med Ctr, Sch Med, Ctr Hlth Serv Res, Nashville, TN 37232 USA; [Jackson, James C.] VA Tennessee Valley Hlth Syst VA TVHS, Murfreesboro, TN 37129 USA; [Mitchell, Nathaniel] Spalding Univ, Dept Psychol, Louisville, KY 40203 USA; [Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] Brigham Young Univ, Neurosci Ctr, Provo, UT 84602 USA; [Hopkins, Ramona O.] Intermt Med Ctr, Dept Med, Pulm & Crit Care Div, Murray, UT USA	Jackson, JC (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Ctr Hlth Serv Res, 6th Floor MCE Suite 6100, Nashville, TN 37232 USA.	james.c.jackson@vanderbilt.edu					ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; Angus DC, 2003, INTENS CARE MED, V29, P368, DOI 10.1007/s00134-002-1624-8; [Anonymous], 1988, LANCET, V2, P349; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Brewin CR, 2001, BEHAV RES THER, V39, P373, DOI 10.1016/S0005-7967(00)00087-5; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Capuzzo M, 2005, Minerva Anestesiol, V71, P167; Capuzzo M, 2004, CRIT CARE, V8, pR48, DOI 10.1186/cc2416; Cheung AM, 2006, AM J RESP CRIT CARE, V174, P538, DOI 10.1164/rccm.200505-693OC; Combes A, 2003, CRIT CARE MED, V31, P1373, DOI 10.1097/01.CCM.0000065188.87029.C3; Dowdy DW, 2008, CRIT CARE MED, V36, P2726, DOI 10.1097/CCM.0b013e31818781f5; Dowdy DW, 2009, CRIT CARE MED, V37, P1702, DOI 10.1097/CCM.0b013e31819fea55; Dowdy DW, 2005, INTENS CARE MED, V31, P611, DOI 10.1007/s00134-005-2592-6; Eikelenboom P, 1999, DEMENT GERIATR COGN, V10, P319, DOI 10.1159/000017162; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Ely EW, 2001, SEMIN RESP CRIT CARE, V22, P115, DOI 10.1055/s-2001-13826; Fong TG, 2006, J GERONTOL A-BIOL, V61, P1294, DOI 10.1093/gerona/61.12.1294; Foreman M, 2004, PRIM PSYCHIAT, V11, P46; Galanakis P, 2001, INT J GERIATR PSYCH, V16, P349, DOI 10.1002/gps.327; Girard TD, 2006, DURATION DELIRIUM PA, pA739; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Heyland DK, 2000, CRIT CARE MED, V28, P3599, DOI 10.1097/00003246-200011000-00006; Hopkins RO, 2006, CURR OPIN CRIT CARE, V12, P388, DOI 10.1097/01.ccx.0000244115.24000.f5; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 2005, CURR OPIN CRIT CARE, V11, P369, DOI 10.1097/01.ccx.0000166399.88635.a5; Hopkins RO, 2004, J INT NEUROPSYCH SOC, V10, P1005, DOI 10.1017/S135561770410711X; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Hopkins RO, 2005, P AM THORAC SOC, V2, pA36; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; Jackson JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5707; Jackson JC, 2004, NEUROPSYCHOL REV, V14, P87, DOI 10.1023/B:NERV.0000028080.39602.17; Jackson JC, 2004, INTENS CARE MED, V30, P2009, DOI 10.1007/s00134-004-2422-2; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; Jones C, 2003, CRIT CARE MED, V31, P2456, DOI 10.1097/01.CCM.0000089938.56725.33; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Jones C, 2000, MEMORY, V8, P81; Kapfhammer HP, 2004, AM J PSYCHIAT, V161, P45, DOI 10.1176/appi.ajp.161.1.45; KATON W, 1990, Journal of Clinical Psychiatry, V51, P3; Katz IR, 1996, AM J GERIAT PSYCHIAT, V4, P1, DOI 10.1097/00019442-199624410-00001; Klein E, 2003, CAN J PSYCHIAT, V48, P28; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; Lyketsos CG, 2005, AM J GERIAT PSYCHIAT, V13, P656, DOI 10.1176/appi.ajgp.13.8.656; MacLullich AMJ, 2009, INT REV PSYCHIATR, V21, P30, DOI 10.1080/09540260802675031; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Meagher DJ, 2001, BMJ-BRIT MED J, V322, P144, DOI 10.1136/bmj.322.7279.144; MOODY DM, 1990, AM J NEURORADIOL, V11, P431; Nelson BJ, 2000, CRIT CARE MED, V28, P3626, DOI 10.1097/00003246-200011000-00013; OKEEFE ST, 1994, BRIT J ANAESTH, V73, P673, DOI 10.1093/bja/73.5.673; Orme J, 2003, AM J RESP CRIT CARE, V167, P690, DOI 10.1164/rccm.200206-542OC; Pandharipande P, 2005, CURR OPIN CRIT CARE, V11, P360; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Parkin AJ, 1999, CURR BIOL, V9, pR582, DOI 10.1016/S0960-9822(99)80378-9; Pollack MH, 1996, AM J PSYCHIAT, V153, P110; Pomara N, 2005, ARCH GEN PSYCHIAT, V62, P209, DOI 10.1001/archpsyc.62.2.209; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; Schillerstrom JE, 2005, PSYCHOSOMATICS, V46, P411, DOI 10.1176/appi.psy.46.5.411; Schillerstrom JE, 2005, PSYCHOSOMATICS, V46, P508, DOI 10.1176/appi.psy.46.6.508; Sessler CN, 2001, CHEST, V120, P1390, DOI 10.1378/chest.120.4.1390; Silverstone PH, 1996, J NERV MENT DIS, V184, P43, DOI 10.1097/00005053-199601000-00008; Silverstone PH, 1996, CAN J PSYCHIAT, V41, P67, DOI 10.1177/070674379604100202; Skodol A E, 1999, Semin Clin Neuropsychiatry, V4, P64; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; Starr JM, 1996, J AM GERIATR SOC, V44, P411, DOI 10.1111/j.1532-5415.1996.tb06412.x; STARR JM, 1994, DRUG SAFETY, V11, P310, DOI 10.2165/00002018-199411050-00003; STRAIN JJ, 1981, PSYCHIAT CLIN N AM, V4, P333, DOI 10.1016/0165-1781(81)90035-4; SUCHYTA MR, 2004, AM J RESP CRIT CARE, V169, pA18; Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; Teunissen CE, 2003, J NEUROIMMUNOL, V134, P142, DOI 10.1016/S0165-5728(02)00398-3; Toshima MT, 1992, J CARDIOPULM REHABIL, V12, P261; Trzepacz P T, 2000, Semin Clin Neuropsychiatry, V5, P132; Uldall KK, 2000, AIDS PATIENT CARE ST, V14, P95, DOI 10.1089/108729100318037; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Weinert CR, 1997, AM J RESP CRIT CARE, V156, P1120, DOI 10.1164/ajrccm.156.4.9611047; Yaffe K, 2003, NEUROLOGY, V61, P76, DOI 10.1212/01.WNL.0000073620.42047.D7	85	19	21	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	MAR	2015	38	1					91	104		10.1016/j.psc.2014.11.002			14	Psychiatry	Psychiatry	CE4MM	WOS:000351804700007	25725571				2021-06-18	
J	Jenson, D; Unnikrishnan, VU				Jenson, Daniel; Unnikrishnan, Vinu U.			Energy dissipation of nanocomposite based helmets for blast-induced traumatic brain injury mitigation	COMPOSITE STRUCTURES			English	Article						Blast-induced traumatic brain injury; Multiscale analysis; Mathematical homogenization; Molecular dynamics		Injuries caused to the head by ballistic shock waves during blast impacts are not well understood. It has been postulated that traumatic brain injury (TBI) can be caused when the blast wave causes the kinetic energy and the pressure in the main blood vessels to oscillate rapidly and travel to the brain thereby damaging the axonal fibers and neurons or with the direct wave transmission to the head. In the direct wave transmission, the severity of blast wave impact can be reduced by ballistic helmets. The ballistic helmets currently used in the military have been designed to provide protection against penetrating ballistic projectiles and their effectiveness against blast shock wave has not been thoroughly understood. This research would focus on developing a multiscale computational model of blast impact response of high-performance nanocomposite materials for the helmet, followed by estimation of blast energy transfer to the tissues in the human head. Such a combined atomistic-computational model of ballistic response of nanocomposites, coupled with a human morphology-specific computational model is necessary to study the mechanics of blast impact on human head. (C) 2014 Elsevier Ltd. All rights reserved.	[Jenson, Daniel; Unnikrishnan, Vinu U.] Univ Alabama, Dept Aerosp Engn & Mech, Tuscaloosa, AL 35487 USA	Unnikrishnan, VU (corresponding author), Univ Alabama, Dept Aerosp Engn & Mech, Tuscaloosa, AL 35487 USA.	vunnikrishnan@ua.edu			University of Alabama	The second author would like to acknowledge the faculty start up funds and the Research Grants Committee 2014-seed Grants from The University of Alabama.	Ackerman MJ, D LIB MAGAZINE, V1; Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; BRENNER DW, 1990, PHYS REV B, V42, P9458, DOI 10.1103/PhysRevB.42.9458; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chandra N, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.094101; Che JW, 1999, NANOTECHNOLOGY, V10, P263, DOI 10.1088/0957-4484/10/3/307; Collins PG, 2000, SCI AM, V283, P62, DOI 10.1038/scientificamerican1200-62; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Cullis Ian G, 2010, INT J PRESS VESSELS, V87, P493; Dewey JM, 2010, INT S MIL ASP BLAST; Edmund Baker Wilfred, 1973, EXPLOSIONS AIR; Elias Randjbaran, 2014, SCI WORLD J, V24, P7; Ganpule S, 2012, COMPUT METHOD BIOMEC, V15, P1233, DOI 10.1080/10255842.2011.597353; Gilbert RP, 2013, COMPUT MATH APPL, V66, P943, DOI 10.1016/j.camwa.2013.06.022; Griebel M, 2004, COMPUT METHOD APPL M, V193, P1773, DOI 10.1016/j.cma.2003.12.025; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jason AM, 2010, THESIS; Kleiven S, 2002, TRAFFIC INJ PREV, V3, P303, DOI DOI 10.1080/15389580214633; Kulkarni SG, 2013, COMPOS STRUCT, V101, P313, DOI 10.1016/j.compstruct.2013.02.014; Mellor Adrian J, 2012, J CRIT CARE, V27; Meo M, 2006, COMPOS SCI TECHNOL, V66, P1597, DOI 10.1016/j.compscitech.2005.11.015; MORI T, 1973, ACTA METALL MATER, V21, P571, DOI 10.1016/0001-6160(73)90064-3; Mylvaganam K, 2004, J PHYS CHEM B, V108, P15009, DOI 10.1021/jp048061x; Namilae S, 2004, CHEM PHYS LETT, V387, P247, DOI 10.1016/j.cplett.2004.01.104; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ostraich B, 2011, SHOCK WAVES, V21, P101, DOI 10.1007/s00193-011-0300-8; QU JM, 1993, MECH MATER, V14, P269, DOI 10.1016/0167-6636(93)90082-3; Reddy JN, 2008, INTRO CONTINUUM MECH; Sainsbury T, 2010, CHEM MATER, V22, P2164, DOI 10.1021/cm902987k; Sears A, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.235406; Stuart SJ, 2000, J CHEM PHYS, V112, P6472, DOI 10.1063/1.481208; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Tan KT, 2014, INT J IMPACT ENG, V64, P20, DOI 10.1016/j.ijimpeng.2013.09.003; Taraghi I, 2014, MATER DESIGN, V53, P152, DOI 10.1016/j.matdes.2013.06.051; Unnikrishnan GU, 2007, J BIOMECH ENG-T ASME, V129, P315, DOI 10.1115/1.2720908; Unnikrishnan GU, 2012, INT J NUMER METH BIO, V28, P229, DOI 10.1002/cnm.1462; Vonach M, 2012, PHYSIOL MEAS, V33, P801, DOI 10.1088/0967-3334/33/5/801; Wang X, 2013, J MECH BEHAV BIOMED, V20, P126, DOI 10.1016/j.jmbbm.2013.01.007	39	19	20	1	32	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0263-8223	1879-1085		COMPOS STRUCT	Compos. Struct.	MAR	2015	121						211	216		10.1016/j.compstruct.2014.08.028			6	Mechanics; Materials Science, Composites	Mechanics; Materials Science	AZ2TP	WOS:000348085500020					2021-06-18	
J	Nelson, NW; Anderson, CR; Thuras, P; Kehle-Forbes, SM; Arbisi, PA; Erbes, CR; Polusny, MA				Nelson, Nathaniel W.; Anderson, Carolyn R.; Thuras, Paul; Kehle-Forbes, Shannon M.; Arbisi, Paul A.; Erbes, Christopher R.; Polusny, Melissa A.			Factors associated with inconsistency in self-reported mild traumatic brain injury over time among military personnel in Iraq	BRITISH JOURNAL OF PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; COMBAT-RELATED CONCUSSION; NEUROPSYCHOLOGICAL OUTCOMES; OEF/OIF VETERANS; SYMPTOMS; SOLDIERS; DEPLOYMENT; AFGHANISTAN; CONSISTENCY; CONTEXT	Background Estimates of the prevalence of mild traumatic brain injury (mTBI) among military personnel and combat veterans rely almost exclusively on retrospective self-reports; however, reliability of these reports has received little attention. Aims To examine the consistency of reporting of mTBI over time and identify factors associated with inconsistent reporting. Method A longitudinal cohort of 948 US National Guard Soldiers deployed to Iraq completed self-report questionnaire screening for mTBI and psychological symptoms while in-theatre 1 month before returning home (time 1, T-1) and 1 year later (time 2, T-2). Results Most respondents (n = 811, 85.5%) were consistent in their reporting of mTBI across time. Among those who were inconsistent in their reports (n = 137, 14.5%), the majority denied mTBI at T-1 and affirmed mTBI at T-2 (n = 123, 89.8%). Respondents rarely endorsed mTBI in-theatre and later denied mTBI (n = 1 4, 10.2% of those with inconsistent reports). Post-deployment post-traumatic stress symptoms and non-specific physical complaints were significantly associated with inconsistent report of mTBI. Conclusions Military service members' self-reports of mTBI are generally consistent over time; however, inconsistency in retrospective self-reporting of mTBI status is associated with current posttraumatic stress symptoms and non-specific physical health complaints.	[Nelson, Nathaniel W.] Univ St Thomas, Grad Sch Profess Psychol, Minneapolis, MN 55403 USA; [Nelson, Nathaniel W.; Anderson, Carolyn R.; Thuras, Paul; Kehle-Forbes, Shannon M.; Arbisi, Paul A.; Erbes, Christopher R.; Polusny, Melissa A.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA; [Thuras, Paul; Kehle-Forbes, Shannon M.; Arbisi, Paul A.; Erbes, Christopher R.; Polusny, Melissa A.] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA; [Kehle-Forbes, Shannon M.; Polusny, Melissa A.] Ctr Chron Dis Outcomes Res, Minneapolis, MN USA	Nelson, NW (corresponding author), Univ St Thomas, MOH 217,1000 LaSalle Ave, Minneapolis, MN 55403 USA.		Polusny, Melissa/X-8158-2019; Polusny, Melissa Anderson/N-8112-2014	Polusny, Melissa/0000-0002-4932-305X; Polusny, Melissa Anderson/0000-0002-4932-305X	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (Quality Enhancement Research Initiative Rapid Response) [08-252]; resources and facilities of the Minneapolis VA Health Care System; VA Health Services Research & Development Career Development Award	This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (Quality Enhancement Research Initiative Rapid Response Project 08-252) and the resources and facilities of the Minneapolis VA Health Care System The views expressed in this manuscript are those of the authors and do not reflect the official policy or position of the Department of Veterans Affairs, the Department of Defense or the US Government S.M.K -F is supported by a VA Health Services Research & Development Career Development Award.	Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2012, ARCH PHYS MED REHAB, V93, P1234, DOI 10.1016/j.apmr.2012.03.003; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bush S. S., 2013, MILD TRAUMATIC BRAIN, P381; Clauw DJ, 2003, J OCCUP ENVIRON MED, V45, P1040, DOI 10.1097/01.jom.0000091693.43121.2f; David AC, 2010, J TRAUMA STRESS, V23, P599, DOI 10.1002/jts.20566; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Engelhard IM, 2008, MEMORY, V16, P3, DOI 10.1080/09658210701334022; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; General Accounting Office, 2008, GAO08276; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Heir T, 2009, BRIT J PSYCHIAT, V194, P510, DOI 10.1192/bjp.bp.108.056580; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jones N, 2014, BRAIN INJURY, V28, P896, DOI 10.3109/02699052.2014.888479; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Maestas KL, 2011, REHABIL PSYCHOL, V56, P366, DOI 10.1037/a0025447; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; Nelson NW, 2011, CLIN NEUROPSYCHOL, V25, P716, DOI 10.1080/13854046.2011.579174; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Panayiotou A, 2010, J CLIN EXP NEUROPSYC, V32, P463, DOI 10.1080/13803390903164371; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Terrio HP, 2011, REHABIL PSYCHOL, V56, P26, DOI 10.1037/a0022685; Van Dyke SA, 2010, MIL MED, V175, P947, DOI 10.7205/MILMED-D-10-00337; Vanderploeg RD, 2013, J HEAD TRAUMA REHAB, V28, P211, DOI 10.1097/HTR.0b013e31828b50db; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Veterans Affairs/Department of Defense, 2009, VA DOD CLIN PRACT GU; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wessely S, 2003, BRIT J PSYCHIAT, V183, P314, DOI 10.1192/bjp.183.4.314	39	19	19	0	7	ROYAL COLLEGE OF PSYCHIATRISTS	LONDON	BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND	0007-1250	1472-1465		BRIT J PSYCHIAT	Br. J. Psychiatry	MAR	2015	206	3					237	244		10.1192/bjp.bp.114.149096			8	Psychiatry	Psychiatry	CE0FC	WOS:000351478900010	25614533	Bronze			2021-06-18	
J	Yu, TS; Kim, A; Kernie, SG				Yu, Tzong-Shiue; Kim, Ahleum; Kernie, Steven G.			Donepezil Rescues Spatial Learning and Memory Deficits following Traumatic Brain Injury Independent of Its Effects on Neurogenesis	PLOS ONE			English	Article							ADULT HIPPOCAMPAL NEUROGENESIS; GROWTH-FACTOR-I; PATTERN SEPARATION; MICE; RATS	Traumatic brain injury (TBI) is ubiquitous and effective treatments for it remain supportive largely due to uncertainty over how endogenous repair occurs. Recently, we demonstrated that hippocampal injury-induced neurogenesis is one mechanism underlying endogenous repair following TBI. Donepezil is associated with increased hippocampal neurogenesis and has long been known to improve certain aspects of cognition following many types of brain injury through unknown mechanisms. By coupling donepezil therapy with temporally regulated ablation of injury-induced neurogenesis using nestin-HSV transgenic mice, we investigated whether the pro-cognitive effects of donepezil following injury might occur through increasing neurogenesis. We demonstrate that donepezil itself enhances neurogenesis and improves cognitive function following TBI, even when injury-induced neurogenesis was inhibited. This suggests that the therapeutic effects of donepezil in TBI occur separately from its effects on neurogenesis.	[Kernie, Steven G.] Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY 10032 USA	Kernie, SG (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pediat, 3959 Broadway,CHN 10-24, New York, NY 10032 USA.	sk3516@columbia.edu	Kernie, Steven/AAT-9912-2020	Yu, Tzong-Shiue/0000-0003-4277-6213; Kernie, Steven/0000-0003-1371-0549	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS083077]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS083077] Funding Source: NIH RePORTER	National Institutes of Health R21 NS083077, SK, TY, AK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akers KG, 2014, SCIENCE, V344, P598, DOI 10.1126/science.1248903; Ballesteros J, 2008, J HEAD TRAUMA REHAB, V23, P171, DOI 10.1097/01.HTR.0000319935.99837.96; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bruel-Jungerman E, 2011, BEHAV BRAIN RES, V221, P379, DOI 10.1016/j.bbr.2011.01.021; Creer DJ, 2010, P NATL ACAD SCI USA, V107, P2367, DOI 10.1073/pnas.0911725107; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dou JT, 2005, LEARN MEMORY, V12, P646, DOI 10.1101/lm.88005; Itou Y, 2011, HIPPOCAMPUS, V21, P446, DOI 10.1002/hipo.20761; Kaneko N, 2006, GENES CELLS, V11, P1145, DOI 10.1111/j.1365-2443.2006.01010.x; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kotani S, 2008, CHEM-BIOL INTERACT, V175, P227, DOI 10.1016/j.cbi.2008.04.004; Miles DK, 2008, HIPPOCAMPUS, V18, P793, DOI 10.1002/hipo.20439; Narimatsu N, 2009, J PHARMACOL EXP THER, V330, P2, DOI 10.1124/jpet.108.147280; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Shaw KE, 2013, J NEUROTRAUM, V30, P557, DOI 10.1089/neu.2012.2782; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Sonntag WE, 2005, AGEING RES REV, V4, P195, DOI 10.1016/j.arr.2005.02.001; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008	21	19	19	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2015	10	2							e0118793	10.1371/journal.pone.0118793			13	Multidisciplinary Sciences	Science & Technology - Other Topics	CC2IM	WOS:000350168700100	25714524	DOAJ Gold, Green Published			2021-06-18	
J	Krieg, SM; Sonanini, S; Plesnila, N; Trabold, R				Krieg, Sandro M.; Sonanini, Sebastian; Plesnila, Nikolaus; Trabold, Raimund			Effect of Small Molecule Vasopressin V-1a and V-2 Receptor Antagonists on Brain Edema Formation and Secondary Brain Damage following Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; traumatic brain injury; CBF; arginine vasopressin	EXPERIMENTAL SUBARACHNOID HEMORRHAGE; PLASMA ARGININE-VASOPRESSIN; CONTROLLED CORTICAL IMPACT; RAT-BRAIN; STROKE PATIENTS; WATER; PERMEABILITY; ASTROCYTES; EXPRESSION; MECHANISM	The attenuation of brain edema is a major therapeutic target after traumatic brain injury (TBI). Vasopressin (AVP) is well known to play a major role in the regulation of brain water content and vasoendothelial functions and to be involved in brain edema formation. Therefore, the aim of the current study was to analyze the antiedematous efficacy of a clinically relevant, nonpeptidic AVP V-1a and V-2 receptor antagonists. C57Bl6 mice were subjected to controlled cortical impact (CCI) and V-1a or V-2 receptors were inhibited by using the highly selective antagonists SR-49059 or SR-121463A either by systemic (intraperitoneal, IP) or intracerebroventricular (ICV) application. After 24 h, brain edema, intracranial pressure (ICP), and contusion volume were assessed. Systemically applied AVP receptor antagonists could not reduce secondary lesion growth. In contrast, ICV administration of AVP V-1a receptor antagonist decreased brain edema formation by 68%, diminished post-traumatic increase of ICP by 46%, and reduced secondary contusion expansion by 43% 24 h after CCI. The ICV inhibition of V-2 receptors resulted in significant reduction of post-traumatic brain edema by 41% 24 h after CCI, but failed to show further influence on ICP and lesion growth. Hence, centrally applied vasopressin V-1a receptor antagonists may be used to reduce brain edema formation after TBI.	[Krieg, Sandro M.; Sonanini, Sebastian; Plesnila, Nikolaus; Trabold, Raimund] Univ Munich, Univ Munich Med Ctr Grosshadern, Lab Expt Neurosurg, Munich, Germany; [Plesnila, Nikolaus] Univ Munich, Univ Munich Med Ctr Grosshadern, Inst Stroke & Dementia Res, Munich, Germany; [Plesnila, Nikolaus; Trabold, Raimund] Univ Munich, Univ Munich Med Ctr Grosshadern, Dept Neurosurg, Munich, Germany	Plesnila, N (corresponding author), Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany.	nikolaus.plesnila@med.uni-muenchen.de	Krieg, Sandro M./W-2389-2019; Plesnila, Nikolaus/T-7522-2019; Krieg, Sandro M. M/L-8902-2016	Krieg, Sandro M./0000-0003-4050-1531; Krieg, Sandro M. M/0000-0003-4050-1531	Program for Research and Medical Education (Forderprogramm fur Forschung und Lehre) of the Faculty of Medicine, Ludwig-Maximilians-University, Munich	This study was supported by grants of the Program for Research and Medical Education (Forderprogramm fur Forschung und Lehre) of the Faculty of Medicine, Ludwig-Maximilians-University, Munich. The authors thank Sanofi Aventis and Dr. Serradeil-Le Gal for providing SR-49059 and SR-121463A.	Armstead WM, 2001, BRAIN RES, V910, P19, DOI 10.1016/S0006-8993(01)02716-0; Barreca T, 2001, CEREBROVASC DIS, V11, P113, DOI 10.1159/000047622; Bemana I, 1999, NEUROSURGERY, V44, P148, DOI 10.1097/00006123-199901000-00091; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; BRINTON RE, 1984, P NATL ACAD SCI-BIOL, V81, P7248, DOI 10.1073/pnas.81.22.7248; Brouard R, 1998, ADV EXP MED BIOL, V449, P455; BUIJS RM, 1980, J HISTOCHEM CYTOCHEM, V28, P357, DOI 10.1177/28.4.6989899; CHEN Y, 1992, CAN J PHYSIOL PHARM, V70, pS367, DOI 10.1139/y92-285; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DELBIGIO MR, 1990, ACT NEUR S, V51, P14; DICKINSON LD, 1992, J CEREBR BLOOD F MET, V12, P681, DOI 10.1038/jcbfm.1992.93; DOCZI T, 1984, NEUROSURGERY, V14, P436, DOI 10.1227/00006123-198404000-00008; DOCZI T, 1982, NEUROSURGERY, V11, P402; FARACI FM, 1990, AM J PHYSIOL, V258, pR94; FARACI FM, 1988, AM J PHYSIOL, V255, pH70; Fernandez N, 2001, BRIT J PHARMACOL, V132, P1837, DOI 10.1038/sj.bjp.0704034; Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z; Hertz L, 2000, AM J PHYSIOL-ENDOC M, V278, pE1175; Hockel K, 2012, STROKE, V43, P227, DOI 10.1161/STROKEAHA.111.626168; Huang WD, 2008, J ENDOCRINOL INVEST, V31, P996, DOI 10.1007/BF03345638; JOYNT RJ, 1981, ANN NEUROL, V9, P182, DOI 10.1002/ana.410090212; KATO Y, 1995, DIFFERENTIATION, V59, P163, DOI 10.1046/j.1432-0436.1995.5930163.x; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; LIU XF, 1991, CHINESE MED J-PEKING, V104, P480; LOLAIT SJ, 1995, P NATL ACAD SCI USA, V92, P6783, DOI 10.1073/pnas.92.15.6783; Manaenko A, 2011, NEUROCHEM INT, V58, P542, DOI 10.1016/j.neuint.2011.01.018; MATHER HM, 1981, J NEUROL NEUROSUR PS, V44, P216, DOI 10.1136/jnnp.44.3.216; NAGAO S, 1994, ACTA NEUROCHIR, P502; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; OSTROWSKI NL, 1994, ENDOCRINOLOGY, V135, P1511, DOI 10.1210/en.135.4.1511; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; Pearl GS, 1998, CLIN LAB MED, V18, P39; RAICHLE ME, 1978, BRAIN RES, V143, P191, DOI 10.1016/0006-8993(78)90766-7; RIPHAGEN CL, 1986, FASEB J, V45, P2318; ROSENBERG GA, 1986, AM J PHYSIOL, V251, pF485; ROSENBERG GA, 1992, STROKE, V23, P1767, DOI 10.1161/01.STR.23.12.1767; Serradeil-Le Gal C, 2002, J PHARMACOL EXP THER, V300, P1122; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; SerradeilLeGal C, 1996, J CLIN INVEST, V98, P2729, DOI 10.1172/JCI119098; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; Xu Miao, 2007, Chin J Traumatol, V10, P90; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	47	19	20	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2015	32	4					221	227		10.1089/neu.2013.3274			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CB0KN	WOS:000349314900002	25111427	Green Published			2021-06-18	
